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Preface
It is an incontrovertible fact that anesthesiology is the
practice of medicine. Therefore, anesthesiologists must
be fluent in the theories and techniques of preoperative
medical assessment, intraoperative cardiopulmonary life
support, and postoperative critical care intervention.
Anesthesiology is the synthesis of the basic medical 
sciences, including anatomy, physiology, biochemistry,
pharmacology, and epidemiology; and is a bridge that
spans the disciplines of medicine and all its subspecial-
ties, surgery, and obstetrics. The making of an anesthesi-
ologist is therefore the culmination of premedical and
medical schooling, a four-year intense postgraduate 
clinical residency program, and possibly thereafter a 
subspecialized fellowship. Most importantly, there then
follows a lifetime commitment to learning and further
honing of technical skills.
It is likely that no person will ever trust anyone else
to the extent that they trust their anesthesiologist. The
patient undergoing surgery will depend on the anesthe-
siologist for safety and comfort during a time when their
body is subjected to extreme stress. It is a remarkable
fact that most patients accept the risks of anesthesia
without questions, are incognizant of the fact that they
will fully be on “life support” for the duration of their
operation, and most do not remember the experience or
even the name of their anesthesiologist. That the public
at large can have such trust and high expectations from
medical professionals who will only be transiently
involved in their care is a testament to the training, pro-
fessionalism, and skill of anesthesiologists as well as a
reflection of the many technological advances in medical
science which have made modern anesthesiology a safer
experience.
In order for the anesthesiologist to provide the level
of medical care that will result in the best outcome for
the patient, the anesthesiologist must be comfortable in
the role of a “perioperative physician.” That physician
who cares for patients as they undergo the stress of 
surgery is best positioned to understand the preopera-
tive and postoperative issues. Every preoperative patient
requires that the anesthesiologist perform a careful and
detailed assessment of their medical condition including
coexisting illnesses, physical limitations, and their gen-
eral fitness for anesthesia and surgery. It is a seldom-
voiced tacit understanding among anesthesiologists that
each and every patient who undergoes elective surgery
becomes critically ill, albeit perhaps only for a limited
time period. Of course, those patients who come to the
operating room in the setting of severe trauma, over-
whelming organ dysfunction due to illness, or patients
who present with severe comorbidities for emergency
surgery are de facto critically ill and are likely to remain
so for some time postoperatively. There was once a time
when patients could be deemed “too sick for surgery.”
However, this adage is seldom employed today and anes-
thesiologists, surgeons, as well as patients and their fam-
ilies in weighing the risks against the potential benefits
often determine that the short and intense stress of 
surgery compares favorably to the alternative. Patients
come to the operating room in septic shock for the con-
trol of their septic source, following an acute myocardial
infarction for emergency coronary revascularization, in
multiple organ failure and end-stage liver disease for liver
transplantation, and after massive trauma; each patient’s
condition can be further complicated by systemic dis-
eases such as chronic lung disease, severe athero-
sclerotic coronary and vascular disease, renal failure,
diabetes mellitus, malnutrition, and others. Therefore,
anesthesiology is unique in that there is no other spe-
cialty of medicine where every single patient encounter
requires both knowledge and application of advanced
life-support skills. All these patient groups will require
elements of mechanical ventilation, sedation and 
analgesia, neuromuscular blockade, intravascular volume
replacement, management of electrolytes, hemo-
dynamic support and monitoring, monitoring of and
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replacement of blood and coagulation factors, as well as
related monitoring and interventions directed at mini-
mizing secondary injuries.
It is because anesthesiology is also the practice of
critical care medicine that this textbook summarizes for
anesthesiologists the state-of-the-art and the standard of
care for the management of critically ill patients.
It is incumbent on anesthesiologists to understand and
apply the principles of critical care medicine that are
relevant to the management of intraoperative patients as
well as their continued postoperative care. We recog-
nize that not all anesthesiologists will participate in the
care of patients in the intensive care unit. However, all
anesthesiologists will use critical care principles in the
operating room. Therefore, new advances in modes of
mechanical ventilation, new understanding regarding
optimization of oxygen delivery to tissues, new perspec-
tives on the evaluation and management of severe
comorbidities, as well as preparedness for emerging
threats such as biological and chemical terrorism are
matters of interest to all anesthesiologists. Finally, for
those physicians who also practice in the intensive care
unit, this book is intended to highlight established
principles, evolving standards of care, and new
opportunities to provide excellence in patient care.
Peter J. Papadakos, M.D.
James E. Szalados, M.D.
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Conclusion
Sepsis, the inflammatory response to infection, is
perhaps the most common disease encountered by the
critical care physician, complicating some 30 to 40% of
intensive care unit (ICU) admissions and accounting for
considerable morbidity and mortality. The exact inci-
dence of sepsis is difficult to determine because of dif-
ferences in definitions and populations. An international
study across eight countries involving 14,364 ICU patients
reported that there were 3034 infectious episodes giving
a crude incidence of infections of 21.1%. Interestingly,
one-fifth of these infections did not fit into any of the def-
inition categories proposed by the ACCP/SCCM classifi-
cation, which has been widely used in studies of sepsis.
The mortality rate in patients with repeated infectious
episodes was 53.6% compared to 16.9% in non-infected
patients. A recent study, the Sepsis Occurrence in
Acutely Ill Patients (SOAP), involving 3147 patients in
24 European countries, reported that 37.4% of patients
were infected at some point during their ICU stay.
Interestingly, the occurrence of sepsis ranged from 17.5 to
72.5% between countries. Importantly, the incidence of
sepsis seems to be increasing with one study reporting
an annual increase of 8.7% in the USA, from 82.7 cases
per 100,000 population in 1979 to 240.4 per 100,000
population in 2000. Thus, although the risk of death per
individual case may be falling, overall mortality rates are
increasing as the size of the problem increases. This
chapter briefly considers some of the basic features and
the latest developments in this critically important field
of sepsis in terms of diagnosis, pathophysiology, and
management.
DEFINITION AND DIAGNOSIS
For many years definitions of sepsis have relied on
those proposed by the ACCP/SCCM consensus confer-
ence published back in 1992. This conference intro-
duced the systemic inflammatory response syndrome
(SIRS) concept, whereby a patient was said to have SIRS
if they met two or more of the following conditions:
temperature greater than 38°C or less than 36°C, tachy-
cardia, tachypnea, white blood cell count greater than
12,000 cells/mm3 or less than 4000 cells/mm3. Sepsis was
then defined as infection plus SIRS, severe sepsis as sep-
sis plus organ dysfunction, and septic shock as severe
sepsis with hypotension despite adequate fluid resusci-
tation and evidence of perfusion abnormalities. However,
the SIRS criteria are very sensitive, and are met by most
ICU patients and many general ward patients, making
them of little practical value in identifying the patient
with sepsis.
Recently, a sepsis definitions conference involving
29 physicians from Europe and North America was held
in Washington, DC, to improve and standardize defini-
tions in the field of sepsis. The conference participants
agreed with the 1992 definitions in that sepsis should be
defined as infection plus signs of systemic inflammation,
but felt that the SIRS criteria were too non-specific and
proposed rather a much longer list of possible signs of
sepsis (Table 1-1). Unfortunately, as yet, no individual
sign is specific for sepsis and clinical diagnosis relies on
the combined presence of several signs and symptoms that
together confirm the likelihood of sepsis as the diagnosis.
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Definitions of severe sepsis and septic shock remained
unchanged from the 1992 publication.
In addition to discussing problems of definition, the par-
ticipants at the Washington conference also developed a
new system to characterize and stage patients with sepsis,
to enable patients to be stratified according to their base-
line risk of an adverse outcome and their potential to
respond to therapy. Such systems are used widely in other
areas of medicine, the prototypical system perhaps being
the tumor/nodes/metastases (TNM) staging system for
malignant tumors developed by Pierre Denoix in the
1940s. The PIRO system stratifies patients according to
their Predisposing conditions, the nature and extent of the
Insult, the nature and magnitude of the host Response, and
the degree of concomitant Organ dysfunction (Table 1-2).
Predisposing conditions – As with any disease
process, there are certain conditions that predispose a
patient to developing sepsis. These include individual
characteristics, such as age, presence of chronic disease
processes (e.g., cancer), chronic administration of certain
medications (e.g., immunodepressant drugs), history of
alcohol abuse, etc., which may influence a patient’s
response to infection and/or suggest which therapies
may be most appropriate in that patient. Recent attention
has focused on genetic polymorphisms that may influ-
ence a patient’s susceptibility to develop sepsis or affect
their outcome if they do develop it. Various potential
genetic factors have already been elucidated.
A polymorphism of the tumor necrosis factor alpha
(TNF-α) gene, the TNF-2 allele, is associated with increased
serum levels of TNF and a greater risk of mortality from
septic shock. A polymorphism within the intron 2 of
the interleukin-1 receptor antagonist (IL-1ra) gene
(IL-1RN*2) has been associated with reduced IL-1ra
production and increased mortality rates. Similarly poly-
morphisms of the Toll-like receptor 4 (TLR4) and
mannose-binding lectin (MBL) genes that seem to
increase susceptibility to sepsis have also been identified.
Gender may also influence susceptibility to and outcome
from sepsis. Clearly, this is an area of ongoing research
and the complex interaction of these predisposing fac-
tors requires more research to determine which carry
most weight and how knowledge of increased risks can
be translated into improved clinical outcomes.
Insult – The insult in sepsis is infection and specific
characteristics of the infection that will influence the
patient’s immune response to that infection and likely
outcome and response to treatment include the site of
infection (e.g., urinary tract versus respiratory versus intra-
abdominal), the specific organism (e.g., Gram-positive
versus Gram-negative), the size of the inoculum, the sus-
ceptibility of the organism to antimicrobial agents, and
the severity of the infection.
Response – The host response to sepsis can be
assessed according to the presence or absence of various
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Table 1-1 Diagnostic Criteria for Sepsis
Infection, documented or suspected, and some of the following:
General variables
Fever or hypothermia
Tachycardia
Tachypnea
Significant edema or unexplained positive fluid balance
Inflammatory variables
Leukocytosis or leukopenia
Increased plasma C-reactive protein (CPR), procalcitonin (PCT) 
or interleukin-6 (IL-6) levels
Hemodynamic alterations
Arterial hypotension
Hyperkinetic state (high cardiac index – high SvO2)
Decreased capillary refill or mottling
Hyperlactatemia
Organ dysfunction variables
Arterial hypoxemia
Creatinine increase or acute oliguria
Altered mental status
Thrombocytopenia – coagulation abnormalities
Hyperbilirubinemia
Ileus
Hyperglycemia in the absence of diabetes
Table 1-2 The PIRO System
Clinical Laboratory
P: predisposition Age, alcoholism, chronic diseases, steroid or Genetic factors
immunosuppressive therapy, gender, etc.
I: insult Site (urinary tract, lungs, abdomen, etc.) Bacteriology, assay of microbial products 
(lipopolysaccharide, mannan, bacterial DNA, etc.)
R: response Temperature, heart rate, respiratory rate, White blood cell count, blood lactate, C-reactive 
arterial pressure, etc. protein, procalcitonin, etc.
O: organ dysfunction Arterial pressure, urine output, Glasgow coma PaO2/FIO2, creatinine, bilirubin, platelet count, etc.
scale, etc.
signs and symptoms and to the degree of elevation of,
for example, white cell count, C-reactive protein, pro-
calcitonin, etc. Importantly, initial suggestions that sep-
sis was simply an uncontrolled inflammatory response
and could be treated by blocking or removing any or sev-
eral of the inflammatory cytokines have been supplanted
by the realization that the inflammatory response is a
normal and necessary response to infection, and inter-
rupting that response at any point may do more harm
than good. Indeed, the early hyperinflammatory phase of
sepsis is soon replaced by a hypoinflammatory state.
Each individual will mount a different response pattern
depending on various factors including those outlined in
the predisposing factors and insult sections above, and
patients who die from sepsis often have a prolonged
hypoimmune stage (Figure 1-1). This differentiation is
important in therapeutic terms, as anti-inflammatory
therapies may be harmful if given to a patient who is
already in the hypoinflammatory phase; such a patient
may benefit rather from a pro-inflammatory therapy to
boost their immune system.
Organ dysfunction – Organ dysfunction can be mea-
sured using scores such as the sequential organ failure
assessment (SOFA; Table 1-3). This system uses parameters
that are routinely available in all ICUs to assess the
degree of dysfunction for six organ systems, respiratory,
cardiovascular, renal, coagulation, neurologic, and hepatic,
with a scale of 0 (no dysfunction) to 4 for each organ.
Importantly, organ dysfunction can be recorded for each
organ separately or a composite score can be calculated.
Thus with repeated scores, a dynamic picture of the effects
of sepsis on individual or global organ dysfunction can be
developed and followed. Sequential assessment of SOFA
during the first few days of ICU admission has been shown
to be a good indicator of prognosis, with an increase in
SOFA score during the first 48 hours in the ICU predicting
a mortality rate of at least 50%.
The PIRO system is newly developed and each item
requires weighting and validation in septic patients.
However, one could envisage patients receiving a PIRO
stage, e.g., P2I2R1O3, which would help determine prog-
nosis and direct treatment. This is an important advance
in this field and, in addition to characterizing individual
patients, will facilitate comparison of patient popula-
tions for clinical trial purposes, and help focus clinical
research. Importantly, as new developments are made in
gene mapping, or new markers of disease presence and
severity are identified, the relevant component of the
PIRO system would need to be modified accordingly.
PATHOPHYSIOLOGY
Inflammatory Mediators
The pathophysiology of sepsis is complex and
although huge advances have been made, many facets
remain unclear; indeed, while each new discovery pro-
vides new understanding, it also reveals new intricacies
requiring further clarification. Essentially, the sepsis
response is initiated directly by an invading organism, 
or by particular products or features of the organism,
such as endotoxin (Gram-negative), peptidoglycan, 
and lipotiechoic acid (Gram-positive). These microbial
products stimulate endothelial damage, the release of
cytokines, the generation of complement, the activation
of coagulation, and a range of other effects, both directly
and via so-called mediators of sepsis. The activities and
identities of many of the mediators of sepsis have been
widely studied, but many features of the response remain
unclear. Initiation occurs as microbial components are
recognized by soluble or cell-bound pattern recognition
molecules or receptors, such as CD14 and TLRs. For
Gram-negative organisms, endotoxin (lipopolysaccharide,
LPS) binds to a specific LPS-binding protein (LPB) in 
the plasma, which carries the LPS to a macrophage mem-
brane receptor, CD14. The LPS/CD14 complex then
interacts with a signal-transducing receptor in the mem-
brane, TLR4, and MD-2. Activation of TLR4 induces the
transcription of inflammatory and immune response genes
via a nuclear factor-κB (NF-κB)-mediated mechanism,
resulting in the release of cytokines. Pro-inflammatory
cytokine release then attracts further macrophages and
monocytes and the cycle repeats. The LPS/LBP complex
can also bind to a soluble CD14 receptor present in the
serum that promotes LPS binding to endothelial cells,
again via TLRs. For Gram-positive and fungal organisms,
the sequence is probably similar with cell-wall compo-
nents such as lipoteichoic acid or peptidoglycan binding
to CD14, which then binds to TLR2, again stimulating
cytokine release. Bacterial components can also act directly
to stimulate the coagulation (see below) and complement
Sepsis: The Systemic Inflammatory Response 5
Hyper-reactivity
Normal
baseline level
Hypo-reactivity
Adequate
response
Degree of
activation
TimeInsult
Figure 1-1 Graph shows prolonged hypoimmune stage
response.
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systems; the overall host response is thus a complex
interaction between multiple factors.
Pro-inflammatory Cytokines
Cytokines are produced by a variety of cell types
under normal and pathological conditions, and have sys-
temic and local effects. They are commonly divided into
pro- or anti-inflammatory cytokines although some may
have both effects at different times or on different cells
or tissues. Some of the key pro-inflammatory cytokines
are TNF and IL-1, -6, and -8.
The TNF family is primarily involved in the regulation
of cell proliferation and apoptosis, but TNF-α also recruits
and activates neutrophils, macrophages, and lympho-
cytes, and stimulates the release of other pro-inflammatory
cytokines and acute-phase proteins. TNF-α exerts its
actions by binding to two distinct TNF receptors (TNFR1
and TNFR2). TNFR1 stimulation leads to classic TNF
effects, while TNFR2 stimulation facilitates binding of
TNF-α to the TNFR1 receptor.
IL-1 includes two related proteins, IL-1α and IL-1β,
which activate the same receptors and thus have similar
biological actions. The spectrum of activity of IL-1 is sim-
ilar to that of TNF-α, although it generally produces less
severe effects; these two cytokines work synergistically
to give a greater effect than stimulation of either alone.
IL-6 is released largely under the influence of TNF-α
and IL-1, and is involved in stimulating the release of
acute-phase proteins, such as C-reactive protein (CRP),
by the liver. It also induces B-cell growth and T-cell dif-
ferentiation, and has been implicated in the myocardial
depression seen in septic shock. IL-6 levels correlate
more closely than other cytokines with the severity and
outcome of septic shock.
IL-8 is released predominantly on stimulation by TNF-α
and IL-1. Its major role is as a chemokine, i.e., it recruits
inflammatory cells to the site of injury. It promotes recruit-
ment and activation of leukocytes, upregulates expression
of adhesion molecules, and enhances degranulation.
Anti-inflammatory Cytokines
Anti-inflammatory cytokines are released alongside
the pro-inflammatory cytokines to modulate the inflam-
matory response. IL-10 is synthesized by monocytes,
macrophages, T cells and B cells. IL-10 inhibits the
release of TNF, IL-1, and IL-6, and suppresses monocyte
procoagulant activity. Soluble TNF receptors are present
in septic patients and bind to TNF, thus acting to limit
TNF activity. IL-1 receptor antagonist (IL-1ra) is a com-
petitive inhibitor of the IL-1 receptor and is produced by
sepsis-activated monocytes and polymorphonuclear cells.
Other Mediators
Many other sepsis mediators are involved in the prop-
agation or control of the septic response; some of the
key agents are platelet activating factor (PAF), interferon
(IFN)-γ, IL-4, macrophage inhibitory factor, high mobility
group (HMG) proteins, transforming growth factor
(TGF)-β, arachidonic acid metabolites, reactive oxygen
species, nitric oxide, and cell adhesion molecules.
Coagulation and Inflammation
One of the key concepts that has changed our view,
and indeed management, of sepsis is new understanding
of the interaction of inflammation, coagulation, and 
fibrinolysis. The imbalance in hemostatic mechanisms
may manifest as disseminated intravascular coagulopathy
(DIC) and microvascular thrombosis and could be a key
factor in the development of organ dysfunction, ultimately
leading to multiple organ failure and death.
Essentially, the cycle starts with early endothelial
damage initiated both directly by endotoxins and other
infectious products, and indirectly by the initial compo-
nents of the inflammatory response to the invading
microorganism, including TNF-α and IL-1. Subendothelial
structures are exposed and collagenases are released.
Exposed tissue factor triggers the extrinsic coagulation
cascade and accelerates the production of thrombin. At
the same time, the endothelial damage further exacerbates
inflammation, with neutrophil activation, neutrophil–
endothelial cell adhesion, and continued elaboration of
inflammatory cytokines, which in turn produce more
endothelial damage, compromising microvascular func-
tion. Endogenous modulators of homeostasis, such as
protein C and antithrombin, are consumed as the body
attempts to return to a normal functional state. Under nor-
mal conditions, the endothelial surface proteins, throm-
bomodulin and endothelial protein C receptor (EPCR),
activate protein C and its modulating effects; however,
in sepsis the endothelial damage impairs this function of
thrombomodulin and EPCR, thereby contributing to the
loss of control. In addition to activated coagulation, fibri-
nolysis is suppressed, with increased levels of two of the
key inhibitors of fibrinolysis: plasminogen activator
inhibitor 1 (PAI-1) and thrombin activatable fibrinolysis
inhibitor (TAFI). There is thus a cascade of inflammation
and coagulopathy that drives the sepsis response, lead-
ing to multiple organ failure and death for many patients.
MANAGEMENT OF SEPSIS
Hemodynamic Stabilization
The basic management of sepsis involves appropriate
and rapid antimicrobial therapy, surgical removal of any
infectious nidus, and hemodynamic stabilization follow-
ing the VIP (ventilate, infuse, pump) principles. The opti-
mal hemodynamic management of septic shock has been
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the subject of some debate, in particular regarding the
choice of fluid and vasoactive agents. Patients with sep-
tic shock can be successfully resuscitated with crystal-
loid or colloid, and when crystalloids and colloids are
titrated to the same level of filling pressure they restore
tissue perfusion to the same degree. However, because
of their propensity for leakage into the extravascular
space, to achieve the same effect approximately three
times greater volume of crystalloid is required than col-
loid, and slightly longer infusion periods may be necessary
to achieve comparable hemodynamic endpoints. The
choice of fluid is probably less important than the quan-
tity given, with cardiac output and systemic oxygen deliv-
ery increasing in proportion to the degree of intravascular
volume expansion achieved. Repeated fluid challenges, in
which a predefined amount of fluid is infused over a set
time and the chosen clinical endpoints and pressure safety
limits monitored, can be conducted to assess the ade-
quacy of fluid resuscitation (Table 1-4).
Colloid solutions are much more expensive than crys-
talloid solutions, even when taking into account the
reduced volumes required. Crystalloids are often regarded
as first-line fluids for the hemodynamically stable patient
and colloids are administered in addition to rather than
in lieu of crystalloids. However, when the patient is
hemodynamically compromised many clinicians prefer
colloids. With several recent studies suggesting that 
new generation hydroxyethyl starches may reduce the
inflammatory response and directly improve tissue oxy-
genation, the precise choice of fluid may become more
important; however, further study is needed to confirm
these observations.
The choice of vasoactive agent similarly has been the
subject of some debate, with a keen search to determine
which agent, if any, has direct beneficial effects on the
microcirculation. However, there remains no evidence
in favor of one agent or another, with dopamine and nor-
epinephrine both valid choices as first-line agents.
One of the key features of hemodynamic stabilization
in septic patients is that it should be done early. Early
goal-directed therapy in patients with severe sepsis 
and septic shock improves mortality rates compared to
standard therapy.
Immunomodulating Therapy
The recognition of the important interaction between
the coagulation system and the inflammatory response
outlined above led to the development of the first
immunomodulating therapy to be shown to reduce mor-
tality in patients with severe sepsis. A recombinant form
of activated protein C, known as drotrecogin-alfa (acti-
vated), given at a dose of 24 μg/kg/hour for 96 hours
improves organ dysfunction and decreases mortality in
patients with severe sepsis and septic shock. The mech-
anisms of action of this drug are still uncertain, but com-
bine anticoagulant properties and direct effects on the
inflammatory response. Activated protein C can reduce
LPS-induced TNF release, inhibit leukocyte adhesion,
decrease leukocyte activation, inhibit NF-κB formation,
and inhibit induction of inducible nitric oxide synthase
(iNOS), all key factors in the systemic inflammatory
response to sepsis. Activated protein C also has anti-
apoptotic effects. As expected, drotrecogin alfa (acti-
vated) administration is associated with an increase in
the risk of bleeding, although this is mostly associated
with use of invasive procedures. It is therefore con-
traindicated in patients with active internal bleeding,
recent hemorrhagic stroke, intracranial or intraspinal
surgery, severe head trauma, presence of an epidural
catheter, intracranial neoplasm, or evidence of cerebral
herniation (Table 1-5). Care should be taken in other
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Table 1-4 Clinical Example of Fluid Challenge
Strategy Patient with Arterial Hypotension (MAP 65 mmHg, CVP 12 mmHg)
Select type of fluid Ringer’s lactate
Select rate of infusion 1000 ml/30 min
Select clinical end-points MAP 75 mmHg
Select pressure safety limits CVP 15 mmHg
Results Baseline Fluid Challenge Fluid Challenge Fluid Challenge
MAP 65 70 75 65
CVP 12 14 15 OR 15
Urine output 0 20 20 0
Skin Mottled OK OK Mottled
Action Continue Stop Stop
groups of patients at high risk of bleeding, and infusion
should be interrupted for surgery or invasive inter-
ventions. Although costly, its cost-effectiveness ratio
compares well with other widely used healthcare
strategies.
Another strategy that has been shown to be beneficial
in patients with septic shock is the administration of
moderate doses of corticosteroids. In patients with septic
shock the adrenal response may be insufficient, and in
such patients moderate doses of corticosteroids (50 mg
IV hydrocortisone every 6 hours) have been shown to
improve survival rates. Similarly, septic shock is associ-
ated with a relative deficiency of vasopressin and admin-
istration of low doses of vasopressin may be beneficial
although this has yet to undergo randomized clinical trials,
and thus cannot be recommended for routine use.
CONCLUSION
Severe sepsis and septic shock are common causes of
morbidity and mortality, and their incidence is increasing.
Improved understanding of the pathophysiology of the
sepsis response, in particular regarding the interaction
between inflammation and coagulation, has seen a major
advance in the treatment options with the development
of drotrecogin alfa (activated). Importantly, as other
effective immunomodulatory strategies become available,
strategies to characterize the patient with sepsis, such as
the PIRO system, will become increasingly important to
help determine which therapy or therapies should be
given to which patient and when.
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Hypoxemia
Hypoxemia: Management
Hypercapnia
Hypercapnia: Management
Summary
Respiratory failure is a condition in which the respi-
ratory system fails in one or both of its gas-exchanging
functions (oxygenation of or carbon dioxide removal
from mixed venous blood). Thus, respiratory failure is a
syndrome rather than a specific disease.
Respiratory failure may be acute or chronic. Acute 
respiratory failure is associated with life-threatening alter-
ations in arterial blood gases and acid–base status whereas
chronic respiratory failure is a more indolent process. This
chapter focuses on acute respiratory failure.
Respiratory failure may be divided into two broad cat-
egories: hypoxemic (type 1) and hypercapnic (type 2).
Hypoxemic respiratory failure is defined as an arterial
PO2 less than 55 mmHg when the fraction of inspired air
(FIO2) is 0.60 or greater. Hypercapnic respiratory failure
is defined as an arterial PCO2 greater than 45 mmHg.
Disorders that initially cause hypoxemia may be compli-
cated by respiratory pump failure and hypercapnia
(Table 2-1). Conversely, diseases that produce respiratory
pump failure are frequently complicated by hypoxemia
due to secondary pulmonary parenchymal processes
(e.g., pneumonia) or vascular disorders (e.g., pulmonary
embolism).
HYPOXEMIA
Hypoxemia may be broadly divided into four major
categories:
1. Ventilation/perfusion (V
.
/Q
.
) mismatch
2. Shunt
3. Diffusion limitation
4. Hypoventilation and low FIO2
These will now be addressed individually in reverse
order.
Hypoventilation and low FIO2 are rare causes of
hypoxemia in the intensive care unit (ICU). One should
suspect hypoventilation as the cause of hypoxemia in
patients with elevated PaCO2. Oversedation or hyper-
carbic respiratory failure are common causes of this
condition. Low FIO2 should not be a cause of this condi-
tion in the ICU unless there is an inadvertent oxygen 
disconnection. Hypoventilation and low FIO2 may be
separated from the other causes of hypoxemia in that
they are the only ones associated with a normal alveolar-
arterial (A-a) PO2 gradient (Table 2-2).
The A-a PO2 gradient represents the difference
between alveolar and arterial PO2. The A-a PO2 gradient
may be calculated from the following equation: A-a PO2
gradient = FIO2(PBPH2O) − (PaCO2/R) − PaO2, where FIO2
is the fraction of inspired O2, PB is the barometric pres-
sure, PH2O is the partial pressure of water, and R is the
respiratory quotient. The A-a PO2 gradient is normally
less than 10 mmHg on room air. In adults over the age of
65, normal values may extend up to 25 mmHg.
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Table 2-1 Common Causes of Hypoxemia 
and Hypercapnia
Hypoxemia Hypercapnia
Pneumonia Muscle weakness
Acute respiratory distress syndrome Increased CO2 production
Congestive heart failure Airway obstruction
Pulmonary embolism Narcotic overdose
An example of the usefulness of calculating an A-a PO2
gradient is demonstrated by this case. A 21-year-old patient
is admitted from the emergency department (ED) with a
drug (narcotic) overdose. On presentation to the ED the
patient’s respiratory rate is 4 breaths per minute. Initial ABG
is pH 7.1, PaCO2 = 80 mmHg, PaO2 = 40 mmHg, O2 sat =
70%. The patient is intubated and transferred to the ICU.
The A-a PO2 gradient calculated from the equation above is:
A-a PO2 gradient = 0.21(747 − 47) − (80/0.8) − 40 = 147 − 100 − 40
= 7 (i.e., ≤10 on room air)
The normal A-a PO2 gradient supports the fact that
this patient’s hypoxemia is due solely to hypoventilation
and that no other cause of hypoxemia, such as pneumo-
nia, needs to be implicated. The normal A-a PO2 gradient
separates this category of hypoxemia from the other
three categories.
Diffusion limitation is a very rare cause of hypoxemia
in the ICU. The alveolar capillary unit has about 1 second
in which to exchange carbon dioxide for oxygen. This
normally occurs within the first 0.3 seconds. This leaves
approximately 0.7 seconds as a buffer. This protects
against hypoxemia during exercise (which increases 
cardiac output and hence decreases available time for
gas exchange) and/or to overcome diseases which cause
diffusion limitation. Except for severe end-stage lung dis-
ease (e.g., fibrosis, emphysema), this is a very rare occur-
rence and, hence, a very rare cause of acute hypoxemia.
Diffusion limitation, in general, is something that is handled
by the pulmonary specialist over a long period of time..
V/
.
Q mismatch is the most common cause of hypox-
emia. With reference to hypoxemia, only perfusion with
reduced or absent ventilation leads to hypoxemia.
Ventilation without perfusion is simply deadspace venti-
lation and by itself does not lead to hypoxemia. If severe,
it may lead to CO2 retention.
To understand this completely, one needs to call to
mind the following equations:
.
VE =
.
VD +
.
VA
PaCO2 = k ×
.
VCO2/
.
VA
where
.
VE equals total minute ventilation, 
.
VD equals dead-
space minute ventilation, 
.
VA equals alveolar minute ven-
tilation, and 
.
VCO2 equals CO2 production. Normally 
.
VD
and 
.
VA represent 30% and 70% respectively of total ven-
tilation. Also, as k is a constant and 
.
VCO2 can generally be
considered constant, PaCO2 is inversely proportional to.
VA (i.e., PaCO2 ~ 1/
.
VA). This will become important to
understand when adjusting ventilator settings.
When assessing hypoxemia it is important to under-
stand the normal physiology of the lung (Figure 2-1A).
The pulmonary artery is the only artery in the body that
delivers unoxygenated blood. A normal blood gas
obtained from the pulmonary artery is pH 7.35/PCO2 =
45 mmHg/PO2 = 40 mmHg/O2 sat = 75%. The alveolar PO2
is approximately 110 mmHg (obtained from the alveolar-
arterial gas equation), and alveolar PCO2 is 40 mmHg. 
A perfectly matched alveolar capillary unit will produce
pulmonary venous blood with a pH of 7.4/PCO2 =
40 mmHg/PO2 = 110 mmHg, and O2 sat = 100%. However,
a “normal” arterial blood gas obtained peripherally will
yield something like: pH = 7.4/PaCO2 = 40 mmHg/PaO2 =
95 mmHg/O2 sat = 98%. The difference between the pul-
monary venous blood and the arterial blood gas is due to
anatomic shunt. Approximately 2% of venous return
from the systemic circulation is returned to the left side
of the circulation without going through the pulmonary
circulation. Two major contributors to this shunt are the
bronchial circulation and the thebesian veins of the
heart. A combination of 98% of pulmonary venous blood
and 2% anatomic shunt (systemic venous) blood yields
the “normal” peripheral ABG..
V/
.
Q mismatch leads to hypoxemia when perfused
alveolar units have reduced oxygen levels in the alveolar
space due to reduced ventilation. This reduced ventila-
tion is generally due to some obstruction (bronchiolar
edema or mucus related to infection, bronchospasm sec-
ondary to asthma, etc.).
.
V/
.
Q mismatch, however, may be
overcome with additional FIO2 (Figure 2-1B). Shunt is
simply the extreme of
.
V/
.
Q mismatch where there is no
ventilation but perfusion persists. (Remember ventila-
tion without perfusion is deadspace ventilation.) Shunt
will not be overcome by additional FIO2 (Figure 2-1C).
HYPOXEMIA: MANAGEMENT
Quite simply there are two major ways to improve
oxygenation: (i) increase FIO2 and (ii) increase mean air-
way pressure.
Increasing FIO2 is simple and can only be done one
way. Increasing mean airway pressure can be done by a
multitude of ways. Increasing mean airway pressure
improves oxygenation by recruiting partially or fully col-
lapsed alveoli, thus better matching ventilation to perfu-
sion and reducing shunt. Mean airway pressure may be
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Table 2-2 Type 1 Respiratory Failure Mechanisms,
Responsiveness to Supplemental O2, 
and Presence of A-a Gradient
Responds Increased 
Mechanism to Added O2 A-a PO2 Gradient
Decreased FIO2 Yes No
Hypoventilation Yes No
Shunt No Yes
V/Q Mismatch Yes Yes
Diffusion Limitation Yes Yes
Acute Respiratory Failure 13
A
B
C
Figure 2-1 Physiology of oxygenation in the lung under normal circumstances (A), during V/Q
mismatch (B), and shunt (C). See text for details. (Adapted from Apostolakos MJ: The critically ill
patient: overview of respiratory failure and oxygen delivery. In Apostolakos MJ, Papadakos PJ, 
editors: The Intensive Care Manual, New York: McGraw-Hill, 2001, pp 1–13.)
increased either invasively or non-invasively. Non-invasive
means include the use of continuous positive airway pres-
sure ventilation (CPAP). CPAP utilizes a tightfitted nasal
or naso-oral mask (to reduce leaks). The CPAP machine
provides a continuous pressure to the airway to assist 
in recruiting alveoli and improving oxygenation. Usual
starting pressures are 3–8 cmH2O and may be titrated to
10–15 cmH2O to improve oxygenation. Issues of comfort
limit the pressure that can be used. Contraindications to
the use of CPAP include poor mental status or patients
with increased risk of aspiration (such as those patients
with ileus or bowel obstruction).
Another way to increase mean airway pressure is
through invasive mechanical ventilation which utilizes
an endotracheal tube. The easiest way to increase mean
airway pressure for a patient on invasive mechanical
ventilation is to increase positive end expiratory pres-
sure (PEEP). This is the back pressure that the ventilator
provides during the exhalation phase to prevent alveolar
collapse. Inverse ratio ventilation (IRV) is another
maneuver that increases mean airway pressure by
increasing the normal inspiratory/expiratory ratio from
1:2 to 1:1 or 2:1. This change keeps the positive pressure
in the chest for longer periods of time. Some believe that
this technique simply adds to the PEEP by not allowing
enough time for exhalation. This has led to the term
“sneaky PEEP” being used in reference to IRV. High-
frequency JET ventilation and oscillating ventilation are
“high tech” ways of increasing mean airway pressure
and oxygenation. Two less commonly used ways to
improve oxygenation, prone positioning and inhaled
nitric oxide, work by improving
.
V/
.
Q matching.
HYPERCAPNIA
Besides oxygenation, the other major function of the
respiratory system is ventilation (CO2 removal). At a con-
stant rate of CO2 production (
.
VCO2), PaCO2 is deter-
mined by the level of alveolar ventilation. The relationship
between alveolar ventilation, rate of CO2 production,
and PaCO2 is:
.
VA = K ×
.
VCO2/PaCO2
where
.
VA = alveolar minute ventilation, K = a con-
stant, and
.
VCO2 = rate of CO2 production. When
.
VCO2
is constant a patient’s PaCO2 will be inversely propor-
tional to
.
VA in a linear fashion.
One also needs to remember that 
.
VE =
.
VD +
.
VA, where.
VE = total minute ventilation, 
.
VD = deadspace minute venti-
lation, and 
.
VA = alveolar minute ventilation. Normally
deadspace ventilation represents approximately 30% of
total ventilation. This, however, can increase in certain
conditions such as chronic obstructive pulmonary dis-
ease (COPD) or acute respiratory distress syndrome
(ARDS). At times, deadspace ventilation may approach
70% or more of total ventilation. If this occurs, the rela-
tive amount of alveolar ventilation is reduced and total
ventilation must be increased if PCO2 is to be maintained
constant. When this demand cannot be met, hyper-
capnia ensues. Abnormalities of the airways or alveoli 
as described above increase the demand as well as
increased metabolic rate or elevated respiratory quotient
(
.
VCO2/
.
VO2) (Table 2-1).
The other side of the supply/demand equation that
can lead to hypercapnia is when the supply side is
adversely affected. The supply side is made up of the
neuromuscular system. Normally the respiratory system
can sustain approximately half of the maximum volun-
tary ventilation (MVV). This is called the maximal sus-
tainable ventilation (MSV). A 70-kg adult under basal
conditions has a minute ventilation of approximately
6 l/min, MSV of 80 l/min, and MVV of 160 l/min. When
certain conditions intervene (Table 2-1) the body’s abil-
ity to supply increases in ventilation are compromised
and therefore hypercapnia can ensue. This may lead to
respiratory failure.
Abnormalities of the central nervous system, peripheral
nervous system, chest wall, airways, or alveoli can all lead
to hypercapnic respiratory failure. Narcotic overdose,
meningoencephalitis, vascular abnormalities, or strokes
affecting medullary control centers can lead to hypoventi-
lation and subsequently to hypercapnic respiratory failure.
A wide variety of disorders that affect peripheral
nerves, neuromuscular junction, and chest wall are asso-
ciated with weakness and ineffective ventilation and
thus with hypercapnic respiratory failure. Guillain-Barré
syndrome, myasthenia gravis, polymyositis, muscular
dystrophies, and metabolic disorders are the most com-
mon neuromuscular causes of hypercapnic respiratory
failure.
Primary disorders of the chest wall constitute another
important category of neuromuscular respiratory failure.
These conditions include severe kyphoscoliosis, flail
chest, extensive thoracoplasty, morbid obesity, and mas-
sive abdominal distention secondary to distended loops
of bowel or ascites. These conditions place respiratory
muscles at mechanical disadvantage and tidal volume
drops. Despite increases in respiratory rate, alveolar ven-
tilation drops and hypercapnia ensues.
Obstructed airways are another common cause of
hypercapnia. Causes of obstruction include aspirated
foreign objects, tracheal tumor, COPD, and asthma. The
airway narrowing leads to greater transthoracic pres-
sure gradient required for inspiratory flow. The resistive
component of the work of breathing is increased, and
the increase is associated with increased oxygen con-
sumption. In addition tidal volume falls and deadspace
ventilation increases. Respiratory muscle fatigue and
hypercapnia develops.
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HYPERCAPNIA: MANAGEMENT
When hypercapnia occurs ventilatory demand out-
strips supply. Therefore choices of treatment are in two
categories: augment ventilatory capacity (supply) or
decrease workload (demand).
If airway obstruction is an issue such as it is in COPD
or asthma, bronchodilators (e.g., beta agonists), anti-
inflammatories (e.g., steroids), and secretion elimination
are effective in decreasing airway resistance and hence
the workload. Thus, demand on ventilation is reduced.
Correcting electrolyte disturbances (e.g., hypokalemia,
hypocalcemia, hypomagnesemia, and hypophosphatemia)
may improve respiratory pump function and thus augment
ventilatory supply. Improving nutritional parameters can
have similar effects.
If the above fails, augmentation of the patient’s spon-
taneous ventilation can be achieved by either invasive or
non-invasive techniques. Non-invasive ventilation includes
bi-level positive airway pressure (BiPAP). Nasal or naso-
oral masks may be used. Settings include inspiratory
pressures (generally 8–15 cmH2O) and expiratory pres-
sures (generally 3–8 cmH2O). Inspiratory pressures 
augment alveolar ventilation and thus this pressure is
adjusted upward to increase tidal volumes and reduce
PCO2 levels. Expiratory pressures are adjusted to opti-
mize oxygenation. Contraindications to BiPAP are the
same as CPAP above. The use of this form of ventilation
has resulted in a reduced need for invasive ventilation,
more rapid stabilization of gas exchange and vital signs,
and a decrease in hospital mortality.
Invasive mechanical ventilation is reserved for patients
who cannot tolerate or who do not improve with non-
invasive ventilation. Increasing respiratory rate and/or
tidal volumes on the mechanical ventilator will increase
alveolar minute ventilation and thus reduce PCO2.
SUMMARY
Acute respiratory failure is divided into type 1 hypox-
emic respiratory failure and type 2 hypercapnic respira-
tory failure. Type 1 hypoxemic respiratory failure is
subdivided into four major categories that have unique
characteristics with respect to the presence of A-a PO2
gradient and response to supplemental oxygen. Type 2
hypercapnic respiratory failure occurs when ventilatory
supply is outstripped by demand.
Treatment of respiratory failure focuses on reversing
the underlying cause of respiratory failure. Barring that,
supportive measures incude increasing FIO2 and mean
airway pressure to improve oxygenation and the use of
BiPAP or invasive ventilation to reduce PCO2.
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CLINICAL CAVEAT
Non-invasive Ventilation in Acute
Respiratory Failure
● Reduces need for invasive ventilation.
● Stabilizes gas exchange and vital signs.
● Decreases hospital mortality.
CURRENT CONTROVERSY
Non-invasive Ventilation
● Characterization of which patients may benefit from
non-invasive forms of ventilation remains unclear.
● The question as to which patients are not candidates
for non-invasive ventilation is controversial.
CASE STUDY
A 72-year-old white female with history of COPD
and coronary artery disease is one day status post an
uneventful open cholecystectomy. Pain control is an
issue despite escalating doses of narcotics. During the
evening shift the patient is found “gurgling” in bed, 
O2 saturation is 50% on room air, and the patient is
only responsive to painful stimuli with groaning. 
An arterial blood gas is checked with the following
results on room air: pH = 7.18, PCO2 = 65, PO2 = 32,
O2 saturation = 52%.
QUESTIONS
1. What is the A-a PO2 gradient?
2. Is the cause of the respiratory failure simply
narcotic overdose or is there a superimposed cause
of hypoxemia such as pneumonia?
3. How can this respiratory failure be managed?
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MONITORING STANDARDS OF CARE
The intensive care unit (ICU) is defined by the inten-
sity of monitoring (technology and personnel) and the
aggressiveness of diagnostic and therapeutic interven-
tions aimed at optimizing patient care and outcome.
Teamwork facilitates the complex care processes,
increases the level of vigilance, and provides multiple
tiers of backup for safety. Since all ICU patients are
inherently unstable with respect to dysfunctional organ
system status, the typical feedback loop of monitoring
and evaluation, through therapeutic intervention, and
then back to re-evaluation is extremely tight.
The most important potential complication of patient
monitoring is that of erroneous decisions based on inade-
quate or flawed data. Monitors are only as useful as the 
people who operate them and interpret the data.
Whenever the data do not reconcile with the clinical pic-
ture, they must be questioned. For this reason, physicians
must closely and personally participate in all aspects of data
collection and be completely familiar with all monitoring
protocols, tools, and data presentation. It is a fallacy to
believe that the role of the physician can be separated from
moment-to-moment bedside patient care in the ICU.
Therefore, reliable information is vital to effective
clinical decision-making. In the critically ill patient
immediately actionable information frequently deter-
mines their survival. The greater the complexity of any
individual ICU patient, the greater is the need for data.
In order for a monitor to have both utility and effec-
tiveness, it must be (1) capable of detecting a physiolog-
ically useful signal, (2) capable of responding rapidly to
physiologic changes, (3) able to process the data and dis-
play it in such a way that the user can rapidly interpret
it, and, preferably, (4) able to track trends. Therefore,
monitors must provide valid information: information
that accurately represents the state of the patient; and
monitors must provide reliable information: data that 
are precise and reproducible. Monitors must also be
equipped with alarm systems which should never be
disabled; and, whenever possible, alarm systems should
be redundant and also should be graduated so that prob-
lems trigger more than one alarm and increase rapidly in
intensity of warning. The level of monitoring must be
commensurate with the patient’s severity of illness and
underlying organ dysfunction. More importantly, skilled,
alert, and prepared staff must be ready to respond imme-
diately to the alarms.
It is generally accepted that critically ill patients must
receive continuous monitoring. However, monitoring
standards for ICU patients have not yet been universally
codified, as they have by the American Society of
Anesthesiologists for intraoperative patient monitoring.
The typical physiologic monitors in the ICU include 
continuous electrocardiography (ECG), pulse oximetry,
apnea/respiratory rate, urine output, and blood pressure.
Respiratory rate can be easily obtained from modern ECG
monitoring which should be configured to detect apnea,
especially in patients receiving sedation, or in patients
who are mechanically ventilated. Hourly urine output 
is a standard of care for all patients at risk of shock. A 
minimally acceptable urine output of 0.5 cm3/kg/hour 
suggests, but does not guarantee, that renal perfusion is
adequate. Blood pressure monitoring should occur at an
interval that accounts for a patient’s potential for decom-
pensation, recent trends, and therapeutic regimen. Invasive
and noninvasive monitoring of cardiovascular status is thus
a backbone to the delivery of critical care.
More complicated patients who receive additional
levels of critical care may require general or organ-
specific monitors; these may include, for example, capnog-
raphy (monitoring of end tidal CO2 concentrations),
peripheral nerve stimulation (monitoring of the level of
neuromuscular blockade), intracranial pressure monitor-
ing, or abdominal compartment pressure monitoring.
Additionally, ICU patients who are mechanically ven-
tilated require ventilator monitoring such as spirometry,
and most ICU patients receive aggressive biochemical
monitoring by frequent blood sampling as indicated by
their condition.
ELECTROCARDIOGRAPHY
Basic telemetry requires continuous ECG monitoring
of heart rate and rhythm. The choice of the lead that is
monitored during ECG determines diagnostic sensitivity.
Since the electrical axis of lead II runs parallel to the
atria, lead II accentuates P wave morphology changes
and also enhances the diagnosis of dysrhythmias and
inferior wall, or right ventricular, ischemia. V5 at the
level of the fifth intercostal space in the left axillary line
is especially useful for the detection of lateral wall, or
left ventricular, ischemia. Whenever only one lead is dis-
played, the choice of lead depends upon clinical history
and an index of suspicion.
ST–T wave changes cannot be reliably detected on
telemetry; both false positive and false negative errors
are possible. A 12-lead ECG should be performed to 
verify any suspected changes.
PULSE OXIMETRY
The importance of pulse oximetry is that it is inex-
pensive, easy to use, reliable, and it has been definitively
shown to increase greatly patient safety; therefore, pulse
oximetry must be used for every critically ill patient.
Pulse oximetry estimates the saturation of arterial blood
by using changes in light absorption and reflectance
from vascular beds. Oximetry is based on the principle
of reflectance spectrophotometry whereby light passed
through a solution is differentially absorbed based on
solute concentration, solute characteristics, the path
length of transmitted light, and solution-specific extinction
coefficients. For a solution containing hemoglobin (Hb),
the relative concentrations of oxyhemoglobin and
deoxyhemoglobin can be determined because the hemo-
globin moieties differ in their absorption coefficients to
red and infrared light; this technology is based on the
Beer–Lambert law. Specifically, oxyhemoglobin absorbs
more infrared light (990 nm) than does deoxyhemoglo-
bin, which instead absorbs more red light (660 nm) and
thus visually appears blue or cyanotic (Figure 3-1). When
changes in light absorption during arterial pulsation are
compared as a ratio using microprocessor technology,
both plethysmographic and oxygen saturation (SpO2)
data are derived. The value for oxygen saturation is dis-
played by the pulse oximeter is correctly referred to as
the SpO2 in order to differentiate it from the SaO2 which
is obtained from blood gas analysis.
Mathematically, the determination of functional SpO2
is represented by the following equation:
where SpO2 is the saturation of hemoglobin with oxygen
as measured by pulse oximetry, HbO2 is the oxyhemo-
globin concentration of blood, and HBO2 + Hb is the total
hemoglobin concentration of blood. Mathematically, the
determination of fractional saturation is represented by
the following equation:
Based on the oxyhemoglobin dissociation curve, an
SpO2 of 90% reliably corresponds to an arterial or partial
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Figure 3-1 Hemoglobin extinction curves. Extinction coeffi-
cient plotted as a function of the absorption spectral wavelength
of transmitted light is shown for four hemoglobin species. Points
at which two species of hemoglobin have the same extinction
coefficient are known as isobestic points. For example, at 805 nm
the extinction coefficients for oxyhemoglobin and reduced hemoglo-
bin are the same. Met-Hb, methemoglobin; Oxy-Hb, oxyhemoglobin;
Deoxy-Hb, deoxyhemoglobin; Carboxy-Hb, carboxyhemoglobin. See
text for details.
pressure of oxygen (PaO2) of 60 torr (or mmHg); and an
SpO2 of 75% corresponds to a PaO2 of 40 torr. The SpO2
as displayed by most pulse oximeters in clinical use can be
expected to be within 2% of the value for oxyhemoglobin
concentration of blood determined using a co-oximeter.
Therefore, there is an approximately 2% error associated
with pulse oximetry measurements. Anemia, as long as
the hematocrit is above 15%, does not interfere with the
accuracy of pulse oximetry. Clinically detectable cyanosis
generally occurs at an SpO2 of 80%, which correlates with
a deoxyhemoglobin concentration of 5 g-%. However, the
reliability of most pulse oximeters in clinical use deteri-
orates very rapidly when the saturation value is < 75%.
Therefore, there is very little physiologic meaning
attached to clinical documentation of saturations signifi-
cantly below 75%.
SpO2 values that are obtained in the absence of a
plethysmographic waveform are unreliable – the heart
rate by the oximeter must correlate with the heart rate
as displayed by the ECG. Therefore, the use of pulse
oximetry is limited in patients with severe peripheral
vasoconstriction, since there is frequently inadequate
peripheral perfusion to obtain a reliable plethysmographic
waveform. In the setting of profound peripheral vaso-
constriction, alternative sites for measurement of pulse
oximetry are available such as the earlobe, tongue, or
cheek. Additionally, warming the extremity is frequently
effective. Pulse oximeters are also prone to failure under
some ambient light conditions as well as in the presence
of certain colors of fingernail polish (e.g., dark blue).
Finally, pulse oximeters may be unreliable during periods
of tachycardia and other arrhythmias. New technology,
by MasimoR for example, allows computer-assisted extrac-
tion of pulse oximeter signals from ambient noise and
increases reliability and accuracy.
Since carboxyhemoglobin and oxyhemoglobin both
absorb light at identical frequencies, 660 nm, pulse
oximeters that compare only two wavelengths of light
will provide falsely high readings of SpO2 in patients
with carbon monoxide poisoning. In these cases, a 
co-oximeter is necessary to determine SpO2 accurately
(Figure 3-1). On the other hand, met-hemoglobin
absorbs light and red and infrared wavelengths with 
the same absorption coefficient; this results in a 1:1
absorption ratio which then corresponds to an SpO2
reading of 85%. Met-hemoglobinemia causes falsely low
saturations when the actual arterial saturation is >85%
and causes falsely elevated SpO2 readings when the
actual arterial saturation is <85%. Met-hemoglobinemia
occurs in patients with severe septic shock due to
increased nitric oxide production and it is also common
following excessive topical administration of benzocaine
spray.
The use of pulse oximetry to determine the saturation
of mixed venous blood return from the brain, known as
jugular venous bulb oximetry, is used as an indicator of
global oxygen kinetics in the brain. A fiber-optic catheter
containing fiber-optic sensors is passed retrograde via
the jugular vein to the point of the jugular venous bulb
where it continuously measures the saturation of ambi-
ent blood. When the saturation of blood falls, there is
increased oxygen utilization in the brain and the data
can be used to estimate the cerebral oxygen extraction
ratio. This technology is commonly employed in neuro-
surgical and trauma ICUs to guide therapy.
CAPNOGRAPHY
Capnography and capnometery refer to the monitor-
ing of CO2 concentration in exhaled gases. Capnometery
refers to the determination of a simple numerical value
for CO2 concentration in expired gas. Capnography pro-
vides exhaled CO2 concentrations as a continuous wave-
form display in addition to a numerical value for end-tidal
CO2 (ETCO2) concentration. Reliable CO2 determination
in exhaled gas generally requires a closed ventilator 
circuit. However, the use of capnography as a general
monitor of respiration, e.g., during sedation when a patient
is receiving oxygen by nasal cannulae, is widely accepted
and encouraged as long as the associated limitations are
understood. The concentration of CO2 in exhaled gas is
measured using either an infrared analyzer or by mass
spectrometry. The infrared analyzer determines CO2
concentration using infrared light absorption and is
more readily available, less costly, and allows for real-
time sampling. The mass spectrometer is more complex
and costly, is not portable, but is more accurate. Since
capnography provides significantly more information, it
has displaced capnometery as a standard for CO2 monitor-
ing. Capnography thus allows for (1) real-time assessment 
of the adequacy of alveolar ventilation, (2) an indirect
assessment of pulmonary perfusion, (3) early detection of
ventilator malfunction or systems disconnections, and 
(4) waveform analysis that correlates with conditions
such as bronchospasm. CO2 detection in expired gases is
essential to document correct endotracheal tube place-
ment following endotracheal intubation. Ordinarily, single-
breath detection devices are used for this purpose;
however, under some circumstances (such as ambient air
insufflation into the stomach, or recent consumption of
carbonated beverages) single-breath detection is mislead-
ing. Note that while continuous capnography can reliably
detect esophageal intubation or verify airway intubation,
it cannot detect endobronchial intubation.
The early return of CO2 in expired gases during resus-
citation from cardiac arrest correlates with outcome.
Additionally, patients who are receiving sedation with-
out a secure airway may become apneic for prolonged
periods of time during which pulse oximetry values do
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not show hypoxemia; therefore, exhaled CO2 monitor-
ing should be considered in all patients prone to apnea.
When ETCO2 values are used in conjunction with 
arterial PaCO2 estimation of the deadspace ventilation
fraction is also possible. The deadspace to tidal volume
ratio can be calculated from the Bohr equation:
where PaCO2 is the partial pressure of CO2 in arte-
rial blood and PECO2 is the partial pressure of CO2 in
expired gas.
Note that ETCO2 is not in itself an accurate indicator
of PaCO2. However, once an individual patient’s ETCO2
to PaCO2 has been determined, under relatively stable
physiologic conditions, the relationship should be rela-
tively constant and therefore ETCO2 can be used as a
substitute for arterial blood gas monitoring to assess the
adequacy of ventilation. In most patients the normal
arterial–ETCO2 gradient is 2–5 torr.
NONINVASIVE BLOOD 
PRESSURE MONITORING
Arterial blood pressure can be measured using auscul-
tation (the Riva-Rocci method) whereby a compressed
artery is auscultated using a stethoscope and the turbu-
lent flow within the blood vessel walls causes character-
istic Korotkoff sounds. Korotkoff sounds cannot be heard
during the range of cuff deflation between systolic and
diastolic pressures; this is known as the “auscultatory gap.”
Typically, a sphygmomanometer is used to inflate a cuff
to a set pressure and then slowly deflate the cuff while
ausculating for Korotkoff sounds. Visual–auscultatory
correlation of the sounds with the pressure in the cuff
(manometry) allows bedside determination of systolic and
diastolic pressures. Although auscultated blood pressure
measure is now relatively seldom used, it plays a very
important role in the rapid verification of blood pressures
when automated methods fail.
Noninvasive blood pressure (NIBP) measurements are
more typically obtained using automated cuffs which rely
on the oscillometric technique. The DINAMAP (device
for indirect noninvasive automatic mean arterial blood
pressure) is the most commonly used NIBP system. The
oscillometric technique for determining blood pressure
either uses two cuffs placed in series, one includes the
artery proximally, while the other detects the onset of
pulsations; or, as in the DINAMAP system, a single cuff is
alternately rapidly inflated and deflated. Oscillometry
actually measures mean arterial pressure, MAP, which
corresponds to the point of maximal cuff deflation.
Despite its common usage, noninvasive oscillometric
blood pressure measurements are relatively inaccurate
measures of diastolic blood pressure. Also, oscillometric
blood pressure measurement is very difficult to use in
patients with arrhythmias or severe bradycardia.
Furthermore, blood pressure measurements which rely
on cuff bladders are subject to error based on relative
cuff-arm sizing, the conical anatomy of obese extremi-
ties, and alterations in the blood volume of the ipsilateral
extremity induced by repeated cuff inflation. Generally,
a cuff that is 20% wider than the diameter of the limb
must be used to obtain reliable noninvasive cuff blood
pressures, and this is not always feasible. Blood pres-
sures measured by automated cuffs are most reliable
with respect to systolic blood pressure and MAP,
whereas invasively obtained blood pressures are more
reliable with respect to MAP as well as the diastolic
blood pressure.
Doppler measurements of blood pressure are usually
obtained as an adjunct to sphygmomanometry during
profound hypotension or to auscultate specifically 
flow properties within an artery. The Doppler principle
creates a sound wave by applying electrical potential to
a crystal. When the sound wave passes through tissue
and encounters a moving object, such as blood, the 
frequency of the reflected sound is altered in a manner
proportionate to the velocity of the reflecting material.
Therefore, “hissing” arterial pressures can be easily 
differentiated from venous “hums.” Additionally, amplifi-
cation of the Doppler signal allows the determination 
of flow which cannot be otherwise auscultated during
periods of hypotension.
GENERAL PROCEDURAL PRINCIPLES
Each year in the USA more than 150 million intravas-
cular devices such as peripheral venous catheters, arterial
catheters, dialysis catheters, and central venous catheters
(CVCs) are inserted. Of these, more than 5 million are
CVCs. Therefore, these statistics underscore the depend-
ence of modern inpatient medical care on intravenous
access.
Credentialing
Procedural credentialing is generally accepted to be
specialty- as well as institution-specific. Providers who
are not credentialed to perform a procedure independ-
ently must be supervised. The level of supervision of
non-credentialed providers that is typically required is
“immediately available,” a legal term which is commonly
interpreted to mean that the supervisor is gowned,
gloved, and ready to assume redirection or the full com-
pletion of the procedure at an instant’s notice. The super-
vising or teaching physician assumes full responsibility
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for all and any complications. There is a presumption that
providers credentialed to perform independently a pro-
cedure be able to recognize and treat or obtain immedi-
ate back-up in treating the more common complications
associated with the procedure.
Justification
No critically ill patient should be without secure and
functional intravenous access. Intravenous access is
required for the therapeutic administration of medica-
tions, fluids, blood or blood products, and for diagnostic
monitoring. On the other hand, arterial blood pressure
monitoring is indicated for specific reasons in unstable
patients. Every invasive procedure has an associated
risk–benefit analysis associated with its use. Therefore,
justification requires that the potential benefit to the
patient be weighed against the short- and long-term risks
to the patient. Risk–benefit analysis is not the same as
cost–benefit analysis which has no role in emergency
procedural justification. The justification or indication for
a given intervention or procedure should be documented
in the patient chart together with the procedural consent.
Preparation
Prior to considering any elective invasive procedure,
the provider must be intimately acquainted with the
patient’s anatomy and physiology. Anatomic considera-
tions include any lesions at or near the proposed opera-
tive site, prior surgery, or positioning contraindications.
For example, CVCs should not be placed near sites of
active infection, adjacent to arterial reconstructions, 
or near prior hardware placement. Physiologic considera-
tions might include pre-existing coagulopathy, or cardiac
conduction abnormalities such as a left bundle branch
block (LBBB). Where there is a pre-existing coagulopathy,
such as in the setting of active anticoagulant therapy, liver
disease, uremia, or thrombocytopenia, vessels that can
easily be compressed with external pressure (internal
jugular, femoral) should be chosen for access over those
that cannot be externally controlled if a hemorrhage
occurs (subclavian). Additionally, since irritation of the
right heart by catheter, or by the guide wire during place-
ment, can precipitate right-sided conduction abnormali-
ties and complete heart block or asystole, temporary
pacing may be required in patients with LBBB.
Informed Consent
Patients and/or their surrogate decision-makers have the
right to consent to or refuse treatment. Treatment without
consent may represent assault and/or battery. Informed
consent has two components: first, an explanation of
the risks, benefits, and alternatives to the proposed pro-
cedures; and second, clear acceptance or denial of per-
mission by a decision-maker after careful consideration.
Patients who have received psychoactive medications,
have an organic brain syndrome, or are confused due to
their underlying disease cannot give their valid informed
consent and they are considered to lack capacity. In
such situations the healthcare proxy or surrogate decision-
maker must give their consent on behalf of the patient,
expressing the patient’s wishes as they understand them
to be. Even so, medical providers must be careful to
avoid the use of jargon and technical language that may
not be clearly understood during the consent process; a
clear concise presentation decreases the possibility of
misunderstanding and confusion. Consent must always
be documented in writing. The documentation of 
consent may be limited to a brief note in the patient
chart relating the informed consent discussions, the
issues considered, and the outcome or decision and
plan. However, a simple signed standard consent form
placed within the body of the chart is traditionally
acceptable, but less adequate. Frequently, during the
care of unstable patients in the ICU, time pressures in
the setting of life-threatening illness, non-communicative
patients, or unavailability of proxy decision-makers, limit
practitioners’ ability to obtain informed consent and
‘implied consent’ may temporarily suffice. In such
instances, the inability to obtain consent should be doc-
umented. In some instances, consent may be obtained
by telephone, these versions of verbal consents should
always be verified and witnessed, and similarly docu-
mented in the record.
Analgesia and Sedation
Patient comfort during procedures is important for
both humanistic as well as practical purposes. A history
of allergies or reactions should be determined prior to
administering any medication. Local anesthesia or sys-
temic analgesia and/or anxiolysis may be appropriate.
When local anesthesia is used it may be used copiously
as long as it does not distort the surrounding anatomy.
Note that 10 cm3 of 2% plain lidocaine that is inadver-
tently administered intravenously will have minimal 
cardiovascular effects under normal circumstances.
Infiltration with local anesthesia must involve both
superficial and deep structures; however, the majority of
pain receptors will be in the subcutaneous tissues.
Lidocaine 1–2% is typically used for infiltration. In some
instances epinephrine in a concentration of 1:100,000 or
1:200,000 may be used to decrease cutaneous bleeding.
However, local anesthetics containing epinephrine 
must never be injected in the proximity of arteries, 
especially end-arteries, because of the risk of vasospasm
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and distal ischemia. Therefore, providers must person-
ally verify that the local anesthetic used for radial arterial
line placement does not contain epinephrine.
In critically ill patients sedation needs to be considered
carefully; in particular, bolus dosing of sedatives can pre-
cipitate hemodynamic compromise because all sedatives
decrease autonomic tone. Bolus doses are more likely
than infusions to result in high plasma concentrations and
resulting side effects. In those patients who are maintain-
ing cardiovascular homeostasis through an endogenous
catecholamine release, even small doses of systemic
sedation may acutely cause significant cardiovascular
depression. Procedural sedation with fentanyl alone or
small doses of intravenous etomidate are likely to provide
the most sedation with the least hemodynamic compro-
mise. Dexmetomidine provides hypnosis and analgesia
but does not suppress respirations and only minimally
alters cardiovascular status and is an excellent alternative.
Patient immobility during delicate procedures is important
for technical efficiency as well as for patient safety.
Sterile Technique
Sterile technique is fundamental to procedural medi-
cine. The components of sterile technique are hand-
washing, sterile attire (gowns, gloves, mask, hat), sterile
field containment, and recognition of breaches in sterile
technique. The importance of handwashing in the ICU
cannot be over-emphasized. The cost of using sterile
technique is minimal compared to the cost of iatrogenic
infection. In the ICU all invasive procedures should be
performed using sterile technique, as opposed to simpler
aseptic techniques, because of the propensity of ICUs
to harbor ubiquitous pathogenic organisms. In most
instances a breach in sterile technique is easier to correct
by re-gloving, for example, than to have to address an
infectious complication later.
Procedural Positioning
Central veins must be cannulated with the patient in
at least 15 degree Trendelenburg (head-down) position
because when veins are open to air above the level of
the phlebostatic axis (the level of the right atrium) there
is an increased risk for venous air entrainment and
venous air embolism (VAE). The Trendelenburg position
during CVC placement both decreases the incidence of
VAE and also facilitates line placement because of
venous engorgement.
The risk of VAE is especially great in those patients
who are hypovolemic, breathing spontaneously, and
generating significant intrathoracic pressure, or when
large-bore catheters are used. When the intrathoracic
pressure is negative relative to atmospheric pressure and
the catheter is open, air can be entrained at the rate of
100 cm3 per second and is capable of producing a fatal
air embolus within one second in an adult. The air that
enters the central venous system will pass through the
right heart and cause an acute right ventricular outflow
tract obstruction. Smaller amounts of air may pass
through a patent foramen ovale, and precipitate a stroke
in patients with this abnormality. The Trendelenburg
position is also indicated for every removal of indwelling
vascular catheters for the same reasons; central catheters
must never be removed while the patient is in the
upright or sitting position.
Infectious Complications
Implanted foreign bodies are especially predisposed
to bacterial infection. More than 200,000 nosocomial
bloodstream infections occur each year in the USA, with
most of these being related to intravascular access devices.
The case-fatality rate of catheter-related sepsis ranges from
14 to 19%. The mortality rate for Streptococcus aureus-
related sepsis alone is 8.2%. Infected foreign bodies 
cannot be sterilized and must be removed. Indwelling
vascular cannulae have been shown to develop a thin
biofilm coating shortly after intravascular insertion. The
biofilm is composed of thrombin and fibrin which serves
as a nidus for microthrombus formation and clot propa-
gation, as well as for bacterial colonization. Therefore,
increasingly, catheters are impregnated with heparin,
antibiotics, or both to decrease the microfilm coating
and minimize the possibility of catheter colonization or
infection.
Catheters may be infected hematogenously during
septicemia or episodes of bacteremia. Typically, follow-
ing hematogenous colonization or infection, bacterial
cultures reveal enteric organisms such as enterococ-
cus or Enterobacter; pulmonary organisms such as
Pseudomonas, S. pneumoniae, or Haemophilus; or
genitourinary organisms such as E. coli or Proteus.
Fungal catheter colonization is increasingly common in
ICU patients but very difficult to detect on routine blood
and catheter cultures.
Most catheters are infected by cutaneous organisms
which translocate through the catheter insertion tract.
These organisms, such as S. epidermidis and S. aureus
are the most common organisms isolated from catheter
tip cultures. Catheters intended for long-term use are
usually tunneled subcutaneously prior to intravenous
insertion, a technique that decreases the incidence of
infection from cutaneous sources.
The gut motor hypothesis proposes that bacterial
translocation occurs across the intestinal mucosal barrier
during periods of splanchnic hypoperfusion, as occurs
during shock. Bacteria have been identified in the 
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submucosal lymphatics and venous plexus of patients
with splanchic ischemia. In addition to being a potential 
secondary source for systemic inflammation, re-initiation,
or propagation (the second hit hypothesis), the gut is a
potential source of enteric organisms and sepsis.
The rate of catheter infection increases at 1–2% per
day after the first 72 hours. The number of manipulations
of the closed infusion-catheter system may be a more
important determinant of infection than the duration 
of catheterization. Erythema or exudate at the insertion
site requires immediate line removal. Signs of vasculitis
are even more ominous. Patients who are immune-
compromised such as those with hematologic malignan-
cies, malnutrition, or diabetes are especially vulnerable
to iatrogenic line infections. Indwelling catheters must
be monitored daily for evidence of infection.
Additionally, the placement of indwelling catheters
should be minimized in patients with prostheses such as
cardiac valves or orthopedic hardware. Routine catheter
changes are not recommended since the incremental
risk of infection from breaches of sterile technique dur-
ing insertion may equal or surpass the risk of infection
from an already indwelling catheter. Femoral venous cen-
tral lines should be avoided in trauma patients because of
the high risk of distal venous thrombosis. Additionally,
whenever possible, total parenteral nutrition should not
be infused through femoral venous catheters because of
the significantly increased incidence of line infection.
Differentiation between catheter tip infection and
catheter tip colonization is important for optimal anti-
biotic management. Catheter-related sepsis is diagnosed
when the same organism is simultaneously isolated from
the tip of the catheter and from blood cultures. Catheter
colonization occurs when organisms are isolated from the
catheter only. Both the diagnosis and optimal treatment of
catheter sepsis are controversial and antibiotic therapy is
based on local antibiograms and local epidemiologic data.
Semiquantitative cultures of catheter tips provide a
guide to differentiating between catheter sepsis and
catheter colonization, the latter requiring therapy less
intensely and less often. Catheter infection is confirmed
when there are greater than 15 colony-forming units
(cfu) in semiquantitative culture analysis or more then
100 cfu/ml in quantitative culture analysis from catheter
tips (Table 3-1).
Where the catheter is either infected or colonized, in
the absence of catheter-related sepsis, a simple catheter
change over a guide wire is appropriate unless there is
otherwise evidence of infection at the insertion site.
However, whenever possible, catheter change over guide
wires in the setting of suspected catheter-related infec-
tion should be avoided. Other related infectious syn-
dromes related to intravenous catheters include phlebitis
and pocket infections (infected fluid in a subcutaneous
pocket surrounding an implanted vascular device).
Septic thrombosis refers to the development of an
infected clot which may present as phlebitis, abscess,
periodic drainage, or a pseudoaneurysm.
Each episode of catheter sepsis will typically increase
the cost of a hospitalization by at least US$15,000–
US$20,000 based on the additional hospital days, anti-
biotic therapy, and additional monitoring blood work.
Where the catheter infection is due to especially danger-
ous organisms such as a resistant S. aureus or entero-
coccus, not only is the cost of hospitalization higher but the
associated morbidity and mortality are also concomitantly
significantly increased.
Wound and Dressing Care
Evidence demonstrates that wound and dressing care
subsequent to procedures is a key element in the pre-
vention of infectious complications. Pooled or dried
blood on or around the catheter insertion site is an obvi-
ous nidus for bacterial colonization; dressings should not
be applied over blood if it is at all possible. Intravenous
catheters are at significantly higher risk of infection than
are arterial catheters, possibly because the higher PaO2
of arterial blood deters bacterial growth. The type of
dressing used and the frequency with which it is
changed is also related to the infection rate. The use of
bacteriocidal creams and ointments over the insertion
site is no longer favored because these preparations can
macerate the skin and increase the risk of local infection.
Latex Allergy
The ubiquitous use of latex gloves over the past
20–30 years has resulted in increased prevalence of sensi-
tization to latex in both patients and healthcare providers.
In the general population the incidence of latex allergy
is estimated to be approximately 1%, and in healthcare
providers it is thought to be at least 10%; however, in
patients who are chronically institutionalized the incidence
can range from 28 to 67%. Inhalation of latex particles
within the cornstarch dust that coats many latex gloves
is the most common and significant route of exposure.
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Table 3-1 Differentiating Between Catheter 
Sepsis and Catheter Infection
Catheter Tip 
Blood Culture Colony Count Interpretation
Positive >15 cfu Catheter sepsis
<15 cfu Catheter hematogenously
seeded
Negative >15 cfu Catheter infection
<15 cfu Catheter position
Percutaneous exposure to latex is unlikely to trigger a sys-
temic anaphylactic reaction, but such an adverse reaction
should be recognized and treated immediately. Therefore,
a high index of suspicion is important. In patients with a
history of latex allergy or where there is a high proba-
bility of prior subsidization, alternatives to latex barriers
and tourniquets should be used. The treatment of any
allergic reaction includes rapid initiation of intravascular
volume resuscitation, airway support, epinephrine,
inhaled bronchodilators, systemic steroids, an intravenous
antihistamine such as diphenhydramine, and an H-2 antag-
onist such as ranitidine.
Needlestick Injuries
Barriers such as gloves, masks, eye shields, and gowns
that are used during “sterile technique” also protect the
operator from percutaneous exposure to body fluids.
However, obviously sharp objects will penetrate most of
these barriers, and, since vascular access cannot presently
be performed without sharp cannulae, providers must use
special precautions in the use and disposal of sharp
objects. At least 20 different pathogens have been con-
clusively shown to be transmitted by needlestick injuries.
These include HIV, human T cell lymphotropic virus
(HTLV), hepatitis, Creutzfeldt–Jakob, and cytomegalovirus
(CMV). The risk of transmission of HIV infection is esti-
mated to be approximately 0.4% per single percutaneous
exposure to body fluids from an HIV-infected patient.
However, it is unethical for healthcare providers to
decline to perform necessary procedures on patients
infected with HIV or hepatitis.
The provider who is performing the procedure is
responsible for the proper disposal of all contaminated
objects. The premise behind the use of “universal precau-
tions” is that any patient may be an unrecognized carrier of
latent infection. Although the risk of transmission of blood-
borne pathogens through percutaneous exposure or by
needlestick injury is relatively low, the implications for
healthcare workers are potentially devastating. Inadvertent
needlestick injuries are thought to occur in as many as 80%
of cases of inexperienced practitioners performing inva-
sive procedures. However, it is estimated that less than
25% of injuries are documented. Documentation of inad-
vertent exposure to infectious agents is important for the
management of occupational health risks, early initiation
of appropriate treatment, and support for future disability.
The CDC has guidelines regarding testing and prophylaxis
following inadvertent needlestick injury. Hospital policies
should also be consulted and followed.
Radiologic Verification
Vascular catheters are typically constructed of polymers
such as polyurethane, polytetrafluoroethylene (Teflon),
polyethylene, or siliconized polypropylene. Most catheters
in common use are made radio-opaque by impregnation
with barium or tungsten salts to facilitate their intravascu-
lar localization by radiography. Typically, radiographic
confirmation is used to verify the positioning of centrally
placed venous catheters, endotracheal tubes, and feeding
and nasogastric tubes.
Although the radiation exposure from portable x-ray
machines is greater than that of fixed x-ray machines,
the beam is less concentrated, there is significantly
greater scatter of radiation, and therefore the total or
focused exposure may be less significant. The scatter of
radiation from portable x-ray machines increases expo-
nentially at distances of greater than 6 ft from the source.
However, radiographs are routinely performed in ICUs
and therefore providers receive potentially higher levels
of cumulative exposure than staff outside the ICU. When
indicated, maintaining a safe distance, lead shielding, or
dosimeter monitoring may be considered. When there is
a possibility of pregnancy in either the patient or the
provider, appropriate lead shielding is encouraged.
Malposition of CVCs occurs in as many as 15% of cases,
even when inserted by experienced clinicians. Therefore,
a chest radiograph is indicated to check for catheter
positioning as well as to rule out complications. Catheters
placed via the internal jugular (IJ) approach are statisti-
cally less likely to be malpositioned than those placed by
the subclavian route. Examples of malpositioned CVCs
are those that are placed arterially or subcutaneously,
within the cardiac chambers, or subclavian lines that
inadvertently pass retrograde into the internal jugular vein.
ICU radiographs for central line placement are usually
AP films. Since upright expiratory films decrease relative
lung volume, they are most useful to exclude a small
pneumothorax. Pneumothorax is air within the pleural
space. A pneumothorax is not always located at the lung
apex and this is especially true when supine chest x-rays
are used. A pneumothorax may not be immediately evi-
dent following pleural injury and may take 24–48 hours
to become sufficiently large as to be clearly visualized.
The size of a pneumothorax will develop much more
rapidly when pleural injury occurs in patients receiving
positive pressure ventilation. When there are clinical
signs of a significant pneumothorax, or tension pneu-
mothorax, occurring in the setting of clinical index of sus-
picion, the diagnosis should never await chest x-ray
confirmation prior to treatment. The emergency treatment
for tension pneumothorax is the insertion of a large-bore
catheter, such as a 16- or 14-gauge IV, into the second
intercostal space, above the rib, in the anterior midclavic-
ular line. Thereafter, following evacuation of the tension, a
tube thoracostomy can be placed semi-electively.
The CVC tip should lie within the superior vena cava.
When the catheter tip is in a subclavian vein, the risk of
thrombus formation or vessel occlusion is increased.
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Furthermore, when the catheter tip is within the right
atrium, or within the cardiac silhouette on the chest radio-
graph, there is increased risk of right atrial perforation and
cardiac tamponade and arrhythmias. In some instances,
usually following left subclavian catheterization, a catheter
tip will be seen to abut the wall of the superior vena cava.
A catheter tip left in this position can erode and perforate
the vena cava causing death by acute hemothorax.
Catheters and Thrombosis
Stasis predisposes to coagulation. By definition, the
blood flow in cannulated vessels is diminished because
of the decreased effective luminal size. Therefore, intra-
vascular catheters must be flushed regularly with sterile
fluids or anticoagulant solution to maintain catheter and
luminal patency. Typically, pressure transducers infuse a
flushing solution at the rate of 3 cm3/hour. Although
dilute heparin (100 units/ml) has been used ubiquitously
to prevent the clotting of catheters, frequent or repeated
exposure to heparin may precipitate heparin-induced
thrombocytopenia (HIT), or heparin-associated thrombo-
cytopenia (HAT), through platelet sensitization. HIT is 
a devastating complication and practitioners should have
a high index of suspicion for HIT when the platelet
count acutely drops following heparin exposure.
Furthermore, the incidence of HIT in the general popu-
lation is increasing rapidly as more patients are sensi-
tized to heparin and are returning for repeat episodes 
of medical care.
An acceptable alternative to heparin is the use of
sodium citrate in catheter flushes. Since citrate binds cal-
cium, it prevents completion of the coagulation cascade.
Sodium citrate is the anticoagulant used to prevent clotting
of banked blood. The key advantage of sodium citrate is
that it does not produce HIT. Furthermore, the negligible
amount of citrate does not usually contribute to the
development of metabolic alkalosis.
Patients with underlying malignancies tend to be
hypercoagulable at baseline and therefore are at increased
risk for catheter-related thrombosis. Thrombosis of the
subclavian vein should be considered whenever there is
unilateral upper extremity edema which may be related
to an indwelling vascular catheter.
Polytetrafluoroethylene (Teflon) catheters are signifi-
cantly less thrombogenic than are catheters made of
polypropylene, polyvinyl chloride, or polyethylene.
Therefore, the choice of catheter material may also 
influence complication rates.
ARTERIAL CANNULATION
Percutaneous arterial cannulation is most often per-
formed for the purpose of continuous monitoring of
blood pressure. Continuous beat-to-beat blood pressure
monitoring is essential in patients with rapidly changing
hemodynamic status and patients receiving rapidly acting
cardiovascular agents. Under some circumstances, such
as extreme obesity, arterial blood pressure monitoring
may necessarily and appropriately take the place of non-
invasive pressure monitoring. Arterial cannulation is also
indicated when there is a need for frequent blood bio-
chemical analyses, especially arterial blood gas analysis.
It is generally accepted that if a patient will require more
than six arterial punctures over their admission, conven-
ience and safety favor an indwelling cannula.
The primary sites for arterial cannulation for blood
pressure monitoring are the radial artery, the femoral
artery, and the dorsalis pedis artery. However, the radial
artery is the most common site for percutaneous arterial
cannulation because it is superficial, technically easy to
access, and is well collateralized. The ulnar artery is a
dominant artery to the hand in up to 90% of patients.
Under some circumstances the axillary artery may also be
used as an alternative. However, the risk of thrombotic
or air embolic stroke during flushing of the catheter is
significantly greater with axillary artery lines because 
the tip of the cannula is very close to the carotid artery.
End-arteries are never cannulated, since in the absence
of collateral flow tissue distal to the end-artery will
become ischemic. Surgical arterial cutdown should be
used only in extreme circumstances because of the need
for distal ligation and the high incidence of thrombosis
and infection.
The Allen test is used to evaluate collateral flow to the
hand when the radial artery is occluded; it is therefore a
test for the patency of the ulnar artery. Under normal 
circumstances blanching following release of the ulnar
artery during the Allen test should resolve in approxi-
mately 7–10 seconds. Although universally recommended,
the Allen test does not have any proven validity.
Insertion technique is an important determination of
complications. Typically, a 20-gauge catheter is inserted
using the Seldinger technique under aseptic, and prefer-
ably sterile, conditions. Repeated attempts to cannulate
the artery may cause vasospasm, laceration, or thrombo-
sis and even permanent occlusion. Arterial occlusion has
been documented in up to 25% of arterial cannulations
and the occlusion may be permanent in up to 3% of
these cases. Ischemic necrosis of the digits is extremely
rare, but since the thumb is at risk, closed monitoring of
distal perfusion is important. Therefore, arterial cannula-
tion is not a benign procedure. Pre-existing arterial dis-
ease may be a risk factor for distal ischemia. Due to the
right-handed dominance of the majority of patients, the
left hand may be the preferred site for radial cannulation
if the patient’s “handedness” is unknown. It is estimated
that the critical wrist circumference to safely accommo-
date a 20-gauge radial arterial catheter is 15 cm; smaller
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wrists require smaller catheters. Raynaud’s disease is 
a special contraindication to instrumentation of distal
arteries.
The dorsalis pedis artery is especially useful for mon-
itoring when the upper extremities are inaccessible due
to patient position, infection or burns, or trauma. The
dorsalis pedis artery has a relatively higher incidence of
thrombotic occlusion than does the radial artery.
Additionally, the cannulation of arteries, the dorsalis
pedis artery especially, should be carefully considered 
in patients with diabetes or severe peripheral vascular 
disease. Since the arterial branch points distal to a dorsalis
pedis arterial cannula are inevitably close to the point of
cannulation, systolic amplification of the arterial wave-
form is of more significant concern.
Inexperienced operators commonly find arterial can-
nulation challenging (Figure 3-2). The following techni-
cal considerations may be helpful: (1) the artery is
generally very superficial and usually lies 0.5 cm or less
from the skin; (2) the artery can be more easily pinned
when the angle of approach is more acute, such as
45–60°; (3) at the point of entry into the lumen of the
artery and the subsequent “flashback” of blood, usually
only the steel tip of the cannula is within the artery, and
premature withdrawal of the steel needle will result in a
failed attempt because the plastic catheter cannot be
forced through the relatively thick arterial wall; and 
(4) immediately following the “flashback” the angle of
approach must be dropped to 30° or less so that the plastic
catheter can enter the lumen without the steel needle pass-
ing through the posterior wall. Initial attempts at cannula-
tion should be made distally, since iatrogenic vasospasm
may preclude subsequent attempts more distally.
The reliability of the arterial blood pressure readings
obtained via indwelling catheters depends on a large
number of variables. Catheter “whip” will overestimate
the systolic pressure. When blood flow velocity is rela-
tively high, as in patients with low arterial compliance,
reflected pressure waves return in diffuse with the 
systolic component of the next pressure waves. This
produces an increase in the systolic pressure, catheter
“whip,” and a decrease in a diastolic pressure. Such systolic
amplification is common in ICU patients. Over-damping
and under-damping will alter the arterial waveform as
well as provide erroneous blood pressure values. The
transducer, which should be placed at the level of the
phlebostastic axis, the right atrium, will erroneously pro-
vide higher blood pressure values if the transducer is
placed too low, and it will provide erroneously low
blood pressures if it is vertically higher than the patient.
Since the numerical values obtained by transduction
reflect pressure data that have been converted into 
electrical signals for monitoring, calibration prior to 
use is essential. The accuracy of pressures obtained 
via transducer systems also depends upon calibration
and zeroing, and positioning with respect to the 
phlebostatic axis.
The shape of the arterial waveform can also provide
clues regarding hemodynamic states. For example, the rate
of upstroke may correlate with cardiac contractility; the
rate of downstroke may correlate with peripheral vascular
resistance; and exaggerated variations in waveform ampli-
tude size with respirations may indicate hypovolemia.
As the arterial pressure waveform moves distally away
from the aorta, the systolic pressure increases and the
diastolic pressure decreases; the mean pressure remains
relatively constant. Furthermore, amplification of the
systolic pressure reading is common in patients with
“stiff” arteries. Moreover, distortion of waveforms via
under-damping of a resonant system can produce falsely
elevated systolic blood pressure readings. Damping
refers to the tendency of a waveform to die down.
MAP is directly related to the cardiac output (CO) and
the total peripheral resistance: MAP = CO × TPR, where
TPR or systemic resistance represents left ventricular
afterload, mainly as reflected in arteriolar tone. Therefore,
reliance on blood pressure alone is extremely dangerous
when patients are clinically in shock (Figure 3-3). Notice
that the MAP remains constant while the CO decreases
and the TPR increases, or the MAP remains constant
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Figure 3-2 The technique of radial artery cannulation. (A) The
wrist is dorsiflexed but not overly hyper-extended (which may
compromise radial artery flow and increase the difficulty of can-
nulation). The initial angle of approach is 45°. Following “flash-
back” the angle is immediately dropped to 30° prior to advancing
the catheter or the guide wire. (B) The steel cannula enters the
thick wall of the artery before the plastic catheter does. Further
advancement of the catheter at 45° will pierce the posterior wall
of the artery. Advancement of the guide wire at 45° may be difficult
and cause “kinking.” When the catheter is dropped to 30° with
gentle advancement so as to place the guide wire and the plastic
catheter comfortably within the arterial lumen the technique is
almost always successful.
while the TPR drops and CO increases. In both the 
scenarios global tissue perfusion can be severely com-
promised in the face of a normal MAP.
The mean arterial blood pressure can be determined
electronically by integrating the area under the arterial
pressure waveform and dividing by the duration of the
cardiac cycle; MAP can also be estimated as diastolic
pressure is one-third of the pulse pressure. Mean arterial
blood pressure is the driving pressure for peripheral
blood flow and a key determinant of tissue perfusion
(Box 3-1). The MAP represents the standing pressure 
in the arterial circuit, “averaging” the phasic nature of
systolic and diastolic variations. Mathematically it is
given by:
Pulse pressure is the difference between the systolic
and diastolic pressures and reflects both cardiac stroke vol-
ume and vascular compliance. Pulse pressure narrowing,
less than 30 torr, is associated with tachycardia, constric-
tive pericarditis, pleural effusions, and aortic stenosis.
Widening of the pulse pressure is associated with aortic
regurgitation, patent ductus arteriosus, arteriovenous
shunting, coarctation of the aorta, and thyrotoxicosis.
Normally, there is little or no variation in the amplitude
of arterial waves. However, respiratory variation, usually a
decrease in the amplitude of arterial waves with inspira-
tion (pulsus alternans), correlates well with hypovolemia.
When arterial catheters are flushed manually after
sampling, heparinized fluid is infused into the artery
under high pressure (250–300 torr). During flushing, the
area supplied by the artery is frequently observed to
blanch visibly. However, there is also retrograde flow of
flush solution and with continued flushing, saline, air
bubbles, and debris can be flushed into the central arte-
rial circulation. This is an important consideration with
axillary arterial catheters but can be significant even
with radial or femoral arterial lines. Flushing of arterial
catheters is an extremely important consideration in
pediatric patients both with respect to flush volume as
well as the possibility of cerebral embolization.
The presence of an indwelling arterial catheter is inde-
pendently correlated with the frequency of blood work
drawn from any one particular patient. Therefore, arterial
catheters correlate with the cost of ICU care. Biochemical
laboratory analyses are frequently most easily drawn from
arterial catheters. Routine monitoring of blood chemistries
may phlebotomize an adult ICU patient at the rate of one
unit of packed red blood cells per week. Whenever possi-
ble adult ICU patients should have all their blood work
drawn in pediatric tubes. Arterial cannulation should be
avoided for blood sampling purposes alone and the use of
venous blood gases coupled with pulse oximetry should
be used to monitor oxygenation and ventilation status.
Finally, arterial catheters must be clearly labeled to mini-
mize the possibility that vasoconstrictive substances be
inadvertently injected or infused.
CENTRAL VENOUS CANNULATION
Overview
CVCs are essential for the management of critically ill
patients. A large variety of catheters are available for
venous access and the choice of catheter must be based
on its intended purpose. CVCs are used for the infusion
of vasoactive substances, intravascular volume replace-
ment, total parenteral nutrition (TPN), hemodialysis, and
hemodynamic monitoring. CVCs are routinely placed in
many clinical settings; however, they are probably more
frequent in operating rooms and ICUs. Large-bore single-
lumen catheters are best suited for rapid infusion of fluid,
whereas multi-lumen catheters are important when
multiple infusions of a potentially incompatible nature
must be administered simultaneously. It is estimated that at
least 8–12% of hospitalized patients receive percutaneous
central venous cannulation.
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The fallacy of blood pressure
Pressure = Flow x Resistance
Blood pressure = Cardiac output x Systemic resistance
Preload
Afterload
Contractility
Heart rate
Central sympathetic
 outflow
Adrenergic release
Alpha-1 receptors
Facilitators
   Glucocorticoids
   Vasopressin
BP =   CO x   TPR
Figure 3-3 The fallacy of blood pressure. See text for details.
Box 3-1 Examples Where MAP Reflects
Driving Pressure for Perfusion
1. Cerebral Perfusion Pressure:
CPP = MAP − ICP
(ICP is the intracranial pressure)
2. Coronary Perfusion Pressure:
CPP = MAP − LVEDP
(LVEDP is the left ventricular end-diastolic pressure)
MAP = mean arterial blood pressure.
Vasoactive drugs should always be infused via secure
CVCs since inadvertent infiltration of vasoactive 
substances subcutaneously or into deep tissue spaces
will cause vasospasm, severe tissue necrosis, and even
loss of limb or limb function. The insertion of catheters
into central veins, because of their larger size and more
rapid vascular flow, is also indicated for the administration
of hyperosmotic substances such as for chemotherapy or
TPN. Hyperosmotic substances irritate small vessels and
predispose to thrombophlebitis (venous inflammation)
and phlebothrombosis (intravascular clotting).
Peripherally inserted central catheters (PICC lines)
are increasingly used for intravenous access in hospitals.
PICC lines are long catheters that are used for the basilic
or cephalic vein at the antecubital fossa. Generally, the
basilic vein (medial) is preferred because it follows 
a straighter course into the thorax and is less likely to 
have venous valvular obstruction (Figure 3-4). PICC lines
have lower nosocomial infection rates than do other
short-term CVCs. Therefore, PICC lines have important
advantages in those instances where the need for central
access is based on medication infusions, TPN, or even
intravenous therapy in the home care setting. PICC lines
do retain their favorable comparison to other CVCs with
respect to the incidence of venous thrombosis. PICC
lines are completely inadequate for monitoring or for
acute intravascular volume expansion.
However, the maximum fluid infusion rate is deter-
mined by the size of the catheter and not by the size of the
vein that is cannulated. For example, the maximum flow
rate through a 9-French introducer sheath is approxi-
mately 247 cm3/minute, through 14-gauge peripheral IV
the maximum flow rate is 195 cm3/minute, and through
the 16-gauge port of a typical triple-lumen catheter the
maximum flow rate is only 54 cm3/minute. In reality, the
most important limitation of flow rate through a 9-French
introducer is the diameter and length of the IV tubing and
not the catheter itself. The Advanced Cardiac Life Support
protocol of the American Heart Association advocates
venous cannulation of the antecubital veins for cardiac
resuscitation as the preferred IV access site.
The rate of flow through a cylinder such as a catheter
or tube is described mathematically by the Poiseuille–
Hagen formula which states that flow is directly propor-
tional to the fourth power of the radius and inversely
proportional to the length of the catheter and the 
viscosity of the fluid. This formula is expressed as:
where Q is the rate of flow, r is the internal radius of the
catheter, η is the viscosity of the fluid or gas flowing
through the catheter or tube, and L is the catheter
length. Therefore, for the purpose of rapid infusion 
of volume, because of length considerations, a short
peripheral catheter is a better choice than an identical
gauge longer centrally inserted catheter such as a PICC
line. Alternatively, a large-bore CVC such as an 8.5 or 9 Fr
percutaneous introducer sheath, which is both of short
length and of large gauge, is the access of choice for
rapid intravascular volume expansion. Furthermore, the
relationship also makes it clear that viscous fluids such
as packed red blood cells will infuse more rapidly if
diluted with a crystalloid to decrease viscosity. Of note,
packed red blood cells transfused through catheters of
20-gauge or smaller, especially when transfused under
pressure, are extremely likely to hemolyze on infusion.
Additional considerations regarding catheter size are
related to other specific indications for catheter place-
ment. An introducer sheath is necessary for a pulmonary
artery catheter placement, and a different type of intro-
ducer is required for passage of a temporary transvenous
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Basilic vein
Cephalic vein
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Figure 3-4 The vascular anatomy of the arm and forearm. The
cephalic vein runs medial to the basilica vein in the arm. The radial
and ulnar arteries together provide the blood supply to the hand
via the palmar arches.
pacemaker wire. Hemodialysis catheters are typically
large-bore catheters that have two ports to facilitate
high-volume flow during hemodialysis.
Central venous lines directly administer fluid and med-
ications to the right heart. Catheterization of the femoral
vein is not technically central venous cannulation
because it infuses fluid and medications into the inferior
vena cava, which is far removed from the right heart.
Additionally, femoral venous access during cardiac arrest
and external thoracic compressions is notoriously ineffec-
tive for the delivery of vasoactive substances to the heart.
Moreover, in trauma patients infusion of substances
through a femoral venous catheter may be ineffective in
the setting of inferior vena cava disruption or hepatic
trauma. Finally, central venous pressure (CVP) cannot be
reliably measured via a femoral venous catheter.
Cannulation of the external jugular (EJ) vein is not
considered an appropriate approach for CVC placement
in ICU patients because the vein is technically difficult 
to catheterize and therefore does not represent secure
access, venous valves prevent successful catheter pas-
sage in most instances, and the catheter often does not
pass into the thorax past the level of the clavicle. Venous
valves are also prone to injury during EJ cannulation.
Catheters sizes are expressed in either gauge or
French units which are measures of external diameter.
The largest catheter diameters are those with the small-
est gauge designation but with the largest French size.
Mathematically, French size is defined as the outside
catheter diameter in millimeters multiplied by three.
Central Venous Catheter Placement
Procedure
CVCs are typically placed using the Seldinger tech-
nique, which refers to a “catheter-over-guide wire”
method that is typical to vascular access and other inva-
sive procedures. Typically, the guide wire has both a
straight tip, and a flexible “J-wire” tip which is inserted
intravascularly to prevent vascular injury.
Cannulation of the central circulation, which typically
refers to the great veins within the thorax, is usually
accomplished via the internal jugular (IJ) or subclavian
vein (SV) approaches (Figure 3-5).
The IJ vein can be cannulated via at least three differ-
ent approaches: (1) the anterior approach, anterior to
the lateral belly of the sternocleidomastoid muscle
(SCM); (2) the posterior approach, posterior to the lat-
eral belly of the SCM; and (3) a supraclavicular approach
at the midpoint of the anterior triangle immediately
above the clavicle. The two heads of the SCM and the
clavicle form the three sides of triangle which contains
IJ vein, the carotid artery, and the vagus nerve. In almost
any patient, except the extremely obese or edematous,
the IJ vein can be located using a 25-gauge “finder” 
needle. The IJ runs deep to the lateral or posterior head
of the SCM in a direction parallel to a line drawn
between the mastoid process and the ipsilateral nipple
when the neck is turned slightly (30°) to the opposite
side. The large introducer needle should never be used
for initial localization. If a paresthesia is obtained in an
awake patient, the needle is injuring the cervical seg-
ment of the brachial plexus and needle location is too far
posterior. The carotid artery runs close and medial to the IJ.
Moreover, “cutting-tip” needles should never be reposi-
tioned subcutaneously because of the risk of lacerating
vital structures; successive attempts requiring redirec-
tion of the needle tip must always be initiated at the
level of the skin. Recently, the use of bedside ultrasound
technology such as the Site-RiteR can help better locate
the IJ vein, decrease the incidence of pneumothorax and
arterial puncture, and also improve patient comfort.
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Figure 3-5 Approaches to central
venous access: (1) the anterior approach
to the IJ vein in the high to mid-anterior
triangle of the neck; (2) the supraclavic-
ular approach; (3) the common entry
point into the subclavian vein; (4) the
posterior approach to the IJ vein. See
text for details. Note that the carotid
artery runs medial to the IJ vein. Also
note that the cupula of the lung extends
approximately 2.5 cm above the clavicle
into the neck.
However, such bedside ultrasound technology is rarely
available in emergencies and therefore practitioners
should be able to place reliably CVCs without the aid of
such a device. When the possibility of a carotid arterial
puncture is suspected, the needle or catheter should
either be transduced, or blood should be drawn for a
comparison in color to an arterial sample. Acute embolic
cerebrovascular accidents (CVAs) have been reported
with a single carotid puncture with a 25-gauge finder
needle. Acute CVAs are rare, however, and every
attempt must be made to ascertain venous location prior
to passing subsequently the larger-bore catheters via the
Seldinger technique. CVC kits usually contain both a soft
plastic catheter and a larger steel needle, either of which
can be used to pass the J-wire. The catheter may be more
appropriate for the IJ approach, since it can be inserted
with minimal trauma and is more easily secured prior to
guide wire placement. On the other hand, the catheter
will bend and kink under the clavicle and therefore only
the steel needle should be used for the subclavian
approach. Following insertion of the guide wire, with
the J-tip leading, the introducer needle or catheter is
withdrawn and a dilator is inserted. A scalpel is used to
cut the skin at the insertion site and facilitate passage of
the dilator and, ultimately, the catheter. The smaller the
cut, the smaller the chance of lacerating the EJ vein, or
cutting into the IJ vein. The scalpel tip should always be
aimed laterally so that the chance of carotid puncture
with the scalpel tip is minimized. If the dilator does not
pass easily, it must not be forced since the possibility of
lacerating a thin-walled vein exists. Thereafter, the CVC
should be passed to an appropriate depth.
The SV is most often cannulated via an infraclavicular
approach. Supraclavicular approaches are only more
likely to cause a pneumothorax when attempted by inex-
perienced operators. The SV begins at the outer aspect of
the first rib as a continuation of the axillary vein, passes
anterior to the scalenus anterior muscle and its insertion
point on the first rib, then passes caudally and anteriorly
to join the IJ to form the brachial cephalic trunk. As the
SV passes over the first rib, it is anterior to the subclavian
artery and brachial plexus and only separated from 
them by the thin scalenus anterior muscle. In general, in
order to access the SV, the insertion site should be at least
2 cm in and inferior to the clavicle in order to optimize
the angle approach and minimize the possibility of passing
inferior to the vein. A frequent choice for initial needle
placement is at the level of the clavicular notch, the point
at which the clavicle turns posteriorly. The clavicular
notch lies at the junction of the outer one-third and the
medial two-thirds of the clavicle. This point also generally
coincides with the insertion point of the SCM on the
clavicle. The direction in which the needle is pointed is
directly toward the sternal notch. The left SV is anatom-
ically preferable to the right SV for pulmonary artery
catheter insertion because the acute angulation from the
right subclavian vein makes PAC passage into the right
atrium technically more difficult.
Typically, the CVC should be passed to a depth of
15–16 cm via the right IJ approach, 13–15 cm via the
right subclavian approach, 15–16 cm via the left sub-
clavian approach, and 16–17 cm via the left IJ approach.
Radiographic verification is used to confirm proper
catheter tip location and to exclude pneumothorax or
hemothorax. Data suggest that the incidence of pneu-
mothorax is not different between the IJ and subclavian
approaches. The tip of the pleura, the cupula of the 
lung, extends approximately 2.5–3 cm above the clavicle
into the anterior triangle. Therefore, lower approaches,
especially when the needle is misdirected posteriorly,
may puncture the pleura. However, inadvertent arterial
cannulation is slightly more likely with the anterior IJ
approach, because the carotid artery runs immediately
medial to the IJ vein higher in the neck. The left-sided IJ
approach carries an increased risk for thoracic duct
injury, since the duct is anatomically located underneath
the left IJ vein.
The femoral vein runs medial to the femoral artery
within the femoral sheath. The femoral vein is a direct
continuation of the popliteal vein and becomes the
external iliac vein at the level of the inguinal ligament.
The femoral vein is cannulated inferior to the inguinal
ligament, and is usually located 1–2 cm medial to the 
palpated femoral artery pulsation.
Central Venous Pressure Monitoring
Vascular accesses are also used for monitoring pur-
poses, and CVCs allow for the measurement of venous
pressure within the thorax. Preload is defined by the 
volume of blood in the cardiac ventricle just prior to
contraction and represents the sum of venous filling and
residual volume following the previous contraction. CVP
correlates with jugular venous distention and jugular
venous pulsation on bedside clinical examination. The
CVP, like the arterial waveform, must be measured at 
the level of the right atrium, or the phlebostatic axis. The
phlebostatic axis is defined as the only point within 
the cardiovascular system where intravascular pressure
reaches zero.
A typical CVP waveform consists of three positive
deflections (a, c, v waves) and two descents (x and y)
(Figure 3-6). The a wave represents the increasing
venous pressure generated by each atrial contraction. The
c wave is generated when the tricuspid valve is displaced
into the right atrium during initial ventricular contraction.
The v wave is produced by the increasing atrial pressure
which occurs when venous return continues despite 
closure of the tricuspid valve. The x descent is the rapid
decrease in CVP which corresponds to the period of
Vascular Access and Hemodynamic Monitoring 29
ventricular ejection. The y descent occurs when the 
tricuspid valve opens at the end of ventricular contrac-
tion and blood again enters the ventricle. The impor-
tance of these waveforms is in their correlation with
pathophysiologic processes. An absence of the a wave 
is characteristic of atrial fibrillation, where the x descent
is also often absent. Amplified, or “cannon,” a waves
occur in the presence of mitral stenosis. Finally, both 
the x and y descents are frequently exaggerated in the
presence of constrictive pericarditis whereas cardiac
tamponade magnifies the x descent and abolishes the 
y descent.
PULMONARY ARTERY CATHETERIZATION
Shock is defined as a state of diminished tissue perfu-
sion, where tissue blood flow is inadequate to meet the
substrate (oxygen) needs of metabolizing tissues. The
longer a patient is in shock, the more likely it is that
the patient will die.
The importance of cardiac output determination in
critically ill patients is reflected in the formula for oxygen
delivery:
DO2 = ([Hb] × SpO2 × 1.34) × (PaO2 × 0.0031) × CI
In a simplified form, DO2 = CaO2 × CI, the product of
arterial oxygen content and cardiac output. From this
formula it is clear that cardiac index and the hemoglobin
concentration and saturation are the key determinants of
global systemic oxygen delivery (Figure 3-7).
The determinants of cardiac output are preload, after-
load, contractility, and heart rate. The ventricular func-
tion curve shows that cardiac performance increases
almost linearly with increasing preload to a point, after
which it levels off and may actually be impaired – a point
of “fluid overload” (Figure 3-8).
Therefore, hypovolemic shock reflects a low cardiac
output state which can be treated with intravascular vol-
ume expansion. Since oxygen delivery is most effectively
improved by increasing cardiac output, clinical strategies to
monitor and improve cardiac output must be implemented.
Therefore, hemodynamic monitoring is necessary to
determine the pathophysiologic basis of the shock state.
Hypovolemic shock is treated by improving venous
return, CVP, pulmonary capillary wedge pressure (PCWP),
and cardiac preload. Cardiogenic shock is treated by
optimizing, often decreasing, cardiac preload to prevent
ventricular overdistention and through the use of inotropic
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Figure 3-6 Correlation of CVP waveform monitoring with the
electrocardiogram. See text for details.
Systemic oxygen delivery
DO2 = Arterial oxygen content x Total systemic blood flow
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Figure 3-7 The determinants of oxygen delivery, DO2.
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Figure 3-8 A “family” of left ventricular function curves. Cardiac
function is dependent upon preload. Indices of cardiac function
including cardiac output, ejection fraction, stroke volume, or left
ventricular stroke work index. Indices of preload include CVP,
PCWP, LVEDP, and LVEDV. Curve I represents a “normal” cardiac
function curve whereby serial increases in preload generate pro-
gressive improvement in cardiac function to a point. Curve II 
represents cardiac failure. Curve III represents a hyperdynamic
ventricle. In order to move from curve II to I to III, an inotrope can
be administered. In order to move from left to right, from a point
of relative excessive preload to a more “normal” ventricular filling
pressure, a diuretic or vasodilator can be administered.
therapy to improve contractility. Where pharmacologic
intervention does not improve cardiac output in cardio-
genic shock, intra-aortic counter pulsation may be neces-
sary. Obstructive shock, such as in cardiac tamponade, 
is treated by relieving the obstruction via pericardio-
centesis, or surgical intervention, whereas pulmonary
embolism requires thrombolytic therapy or urgent sur-
gery (Trendelenburg procedure). Preload must be main-
tained at an elevated level during cardiac tamponade,
whereas the load elevation is dangerous where there is
embolic right ventricular outflow tract obstruction and
in these cases inotropes are important adjunctive ther-
apy to prevent acute right heart failure. Finally, distribu-
tive shock states, such as sepsis or anaphylaxis, respond
well to fluid therapy, inotropic support, and etiology-
specific adjunctive pharmacotherapy. Since the various
shock states differ in terms of their effect on hemody-
namic variables, cardiovascular monitoring is frequently
necessary. The clinician’s ability to utilize, understand,
and act upon hemodynamic data is an important deter-
minant of patient survival. Alternatively, ventricular
function is correlated inversely with afterload and there-
fore afterload reduction in either the pulmonary or sys-
temic circuits improves cardiac output (Figure 3-9).
Right heart catheterization using a pulmonary artery
catheter (PAC or Swan-Ganz catheter) is used to guide
volume resuscitation and vasoactive therapy in critically
ill patients. The PAC is a long thin catheter, inserted via
a larger bore central line, an “introducer,” and is advanced
through the central veins and the right cardiac chambers
into the pulmonary outflow tract (Figure 3-10). Since the
placement of the catheter is flow-directed, advancement
of the catheter with each beat facilitates passage. Only
rarely is fluoroscopic assistance necessary, but it should
be considered if a recent transvenous pacer has been
placed, if selective right or left pulmonary artery
catheterization is necessary, or unusual cardiac anatomy
exists. If the catheter is advanced without a common
evidence of waveform progression (Figure 3-11), then it
should be suspected that the catheter is either coiling
within the cardiac chambers or has passed into the infe-
rior vena cava. When the catheter tip is in the distal pul-
monary outflow tract, inflation of the balloon at the tip of
the PAC occludes blood flow past the catheter tip. At this
point the catheter tip is considered to be in the “wedged”
position. “Pseudo-wedging” may occur if the catheter
becomes entrapped underneath the pulmonary valve, 
trabeculae, or between pampering muscles. A pulmonary
artery tip that is in a pseudo-wedged position reveals a
flattened waveform, which appears almost identical to a
catheter tip that is in a true “wedge” position. However,
whereas a normal wedge tracing occurs after the tip of
the catheter has passed through the pulmonary artery, a
pseudo-wedge tracing is typically encountered out of
sequence, often before the catheter tip has passed
through the right ventricle and the pulmonary artery. 
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Figure 3-9 The relationship between cardiac function and
afterload. Curve III represents a normal ventricular response to
increasing afterload. Following an initial period of compensation,
there is progressive decrease in left ventricular performance.
Curve II represents a failing ventricle or it can also represent a nor-
mal right ventricular curve. Curve I represents a failed ventricle.
Decreasing afterload improves cardiac performance.
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Figure 3-10 A schematic view of the anatomy of pulmonary
catheterization.
Figure 3-11 Sequential waveform changes during advancement
of the pulmonary artery catheter from the superior vena cava (SVC)
through the right atrium (RA), to the right ventricle (RV), into the
pulmonary artery (PA), and finally into the “wedge position”
(PCWP). Note that catheter migration from the RV into the PA is
heralded by a change in diastolic pressure.
A pseudo-wedge tracing also resembles an “over-
wedged” catheter tip with an elevated pressure reading.
Since there is no blood flow past the tip of the PAC, the 
pressure transducer at the tip of the catheter distal to the
balloon will transduce pressure from a theoretically
static column of blood extending from that particular
pulmonary arteriole through to the left atrium. During dias-
tole, when the mitral valve is open, the pressure transduced
by the PAC tip may approximate the left ventricular end-
diastolic pressure (LVEDP). Therefore, the measured pres-
sure is known as the pulmonary artery occlusion pressure
(PAOP), or, more commonly, the PCWP.
The information obtained through the use of a PAC is
complex and includes differential cardiac chamber pres-
sure information, transduced waveforms, measures of
cardiac output, and the oximetry-derived saturation of
venous blood.
The PAC directly measures right heart pressures, ther-
modilution, right heart cardiac output, and mixed venous
oxygen saturation. The utility of the PAC is that it allows
for bedside construction of serial ventricular function
(“Starling”) curves. The ventricular function curve relates
indices of cardiac function as dependent variables to
indices of estimated preload.
Derived indices of cardiac function include CO, cardiac
index (CI), stroke volume (SV), ejection fraction (EF), 
or ventricular stroke work index. Measured indices 
of estimated preload include CVP or PAOP or PCWP. The
cardiac index is the cardiac output divided by the body
surface area: CI = CO/BSA; the units are l/minute/m2.
It is important to realize that in physiologic terms,
preload is actually a volume, which causes stretching of
cardiac sarcomeres to various points of contractility.
More accurately, preload is a wall tension that results
from the LVEDV, which causes myofibril stretch.
Optimal pre-contraction sarcomere length is 2.2 times
the resting sarcomere length. When the sarcomeres are
stretched beyond 3.0 times their resting length, they are
overstretched and cardiac contractility is impaired; this
may account for the negative slope of the ventricular
function curve during volume overload. However, it is
very difficult to obtain clinically accurate bedside 
measurements of ventricular volumes. Therefore, pres-
sures are measured and these pressures are used to 
estimate preload. Pressure and volume are related 
mathematically through compliance (C = ΔV/ΔP). Where
preload acutely exceeds the ability of cardiac contractil-
ity to move the blood forward, the excessive preload
precipitates signs and symptoms of heart failure.
However, the causes of pulmonary edema are many. 
The CVP measures right-sided cardiac pressures, and 
the PCWP extrapolates LVEDP by measuring the back
pressure at the point of right heart pulmonary capillaries
via a catheter lodged in the right heart. Therefore, 
volume is estimated from pressure measurements 
without accounting for compliance. Furthermore, the
assumption that the PCWP is directly related to LVEDP 
is flawed since pressures are measured across the pul-
monary circuit, the left atrium, and the left ventricle.
CVP ∝ RVEDP ∝ PCWP ∝ LAP ∝ LVEDP ∝ LVEDV
Contractility can be improved using inotropic 
agents. Examples of inotropic agents include β-1 agonists
such as epinephrine, dopamine, or dobutamine; 
phosphodiesterase-III inhibitors such as milrinone; or
more general inotropes such as digoxin or calcium. When
contractility is improved, the cardiac function at any given
level of preload is increased.
Tachycardia is often seen in hypovolemic states in
physiologic effort to maintain cardiac output, a response
mediated by endogenous catecholamine release. Also, 
β-1 agonists have chronotropic action in addition to their
inotropic effects. Tachycardia may not be desirable
because it increases myocardial oxygen demand and
consumption and also may compromise cardiac output
due to a rate-related impairment of diastolic ventricular
filling. Patients with either fixed coronary obstruction or
those with dynamic left ventricular outflow tract obstruc-
tion do not tolerate tachycardia well. Additionally, patients
who are receiving beta-blocker therapy may not mani-
fest a compensatory tachycardia in hypovolemic states;
these patients will instead retain a controlled slower heart
rate and the only sign of hypovolemia may be progressive
hypotension.
Cardiac output was at one time determined using indi-
cator dye methods (Fick principle) or manual thermo-
dilution measurements using iced saline. Most catheters
currently in use have instead a heater-coil which allows
continuous automated cardiac output determination
without the variability introduced by manual injections.
The principle of thermodilution remains founded on a
temperature gradient between the heater-coil and a
more distally placed temperature sensor. The greater the
cardiac output, the faster the blood flow around the
catheter, and the less and more transient the change in
blood temperature (Figure 3-12).
It is important to realize that the SVR is not measured
but is calculated. Additionally, it is calculated using the
cardiac output, to which the SVR is inversely related by
the formula SVR = [(MAP − CVP)/CO] × 80. The term
“SVR” is frequently and erroneously used to refer to the
total peripheral resistance (TPR) in the vascular circuit,
which is related to a quantity different from the calcu-
lated SVR. Moreover, SVR does not in itself describe
“afterload” which is a more specific term referring to the
impedance to forward cardiac output.
Complications that are relatively unique to PAC use
include catheter knotting and pulmonary artery rupture.
The inadvertent knotting of a PAC occurs when the
catheter does not pass easily through the cardiac 
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chambers and instead redundant catheter is entangled
upon itself. Knotted catheters must be removed by inva-
sive radiology techniques. Pulmonary artery rupture is
probably the most feared complication of pulmonary
artery catheterization and may result from either patient-
specific pathology or operator error, or both. Pulmonary
artery rupture has an overall incidence of less than 1%
but is relatively more common in patients with pulmonary
hypertension. Other factors associated with increased inci-
dence of pulmonary artery rupture include age greater
than 60 years, female gender, hypothermia, anticoagula-
tion, catheter tip location >5 cm lateral to the medi-
astinum, frequent wedge pressure determinations, and
mitral valve disease. Patients with pre-existing left bun-
dle branch block may develop complete heart block as
the catheter tip passes through the right ventricular wall
and stimulates the right bundle branch system. In these
cases, the immediate availability of transcutaneous 
pacing should be considered. However, most catheter-
related arrhythmias are transient.
A PAC may, under normal circumstances, migrate dis-
tally into smaller pulmonary artery segments with contin-
ued normal pulmonary blood flow. When the balloon tips
of these catheters are subsequently inflated, there is ini-
tially a typical “over-wedging” waveform indicative of
excessive balloon pressures. If balloon inflation is inadver-
tently continued under these circumstances, iatrogenic
rupture of the pulmonary artery is likely. Acute hemoptysis
is the usual presenting sign of a pulmonary artery rupture.
Generally accepted recommendations include leaving the
catheter in place to tamponade bleeding, placing the
patient with the affected side down, and emergent cardio-
thoracic consultation. Under usual circumstances, a pul-
monary artery catheter will preferentially float into the
right lung. Placement of a double-lumen endotracheal tube
to allow for independent ventilation may also be necessary.
Pulmonary infarction is also a frequently unrecognized
complication of PAC use whereby either an uninflated
catheter tip migrates into a distal pulmonary artery and
occludes blood flow or when the PAC is intermittently left
inflated after determination of PCWP. Pulmonary infarc-
tion does not typically occur in the absence of lapses in
appropriate patient monitoring. A PAC waveform that is
persistently in wedge position should be a signal which
triggers repositioning of the PAC, or simply deflation of the
balloon, before a segment of lung becomes ischemic.
Subsequent infarction of a watershed segment around the
tip of a PAC may appear on subsequent chest radiography.
Infarcted lung areas can later become hemorrhagic.
Ventilation–perfusion zones within the lung may be
described in terms of West zones, which describe the
relationship between alveolar pressure (PA), pulmonary
capillary pressure (PC), and mean pulmonary artery pres-
sure (Pa) (Figure 3-13). PC resembles pulmonary venous
pressure (Pv), which numerically approximates left atrial
pressure PLA. Due to gravitational effects, dependent lung
zones receive better perfusion, whereas non-dependent
lung zones receive less perfusion and relatively more
ventilation. Thus, alveolar pressure (PA) exceeds both
capillary (PC) and arteriolar (Pa) pressures in zone I, and
pulmonary arteriolar pressure (Pa) exceeds alveolar
pressure (PA) and capillary pressure (PC) in zone III. The
influence of vascular pressure in dependent lung zones
helps explain the development of pulmonary edema dur-
ing failing contractility or acute hypervolemia. Since the
pulmonary artery catheter is placed blindly, blood flow
normally places the PAC tip in either zone II or, more
likely, zone III of the lung. It is when the catheter tip is
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Figure 3-12 Thermodilution cardiac output. The rate of change
in temperature as a function of time correlates mathematically
with ambient blood flow and therefore cardiac output.
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Figure 3-13 West zones of the lung. West zones depict rela-
tionships between ventilation and perfusion in different areas of
the lung. Dependent lung zones receive more perfusion and 
non-dependent lung zones receive more ventilation. PA, alveolar
pressure; Pa, pulmonary arterial pressure; PC, pulmonary capillary
(or pulmonary venous) pressure.
within zone III that the reliability of the PCWP is greatest.
Only in zone III is there a constant, uninterrupted column
of blood between the catheter tip, through the pulmonary
capillary circuit, through to the left heart. However, zone
distributions change with patient positioning changes.
Zone III is gravitationally defined so that it is in the
dependent lung, for whatever position in which the
patient is placed. Note that lung zones cannot be actu-
ally determined by chest radiography and catheter tip
positioning is instead determined physiologically.
Zone I is especially vulnerable to high airway pres-
sures. When positive end-expiratory pressure (PEEP) is
applied then there is a greater likelihood that the PCWP
will be falsely elevated by the airway pressures when the
catheter tip is in zone I. Since many patients who have
required PAC placement in the past have also required
mechanical ventilation with higher airway pressure 
and PEEP, the PCWP may have inadvertently been mis-
interpreted. The relationship between PEEP and PCEP 
is not linear but can be estimated by:
PCWP = PCWPM − 0.5(PEEP − 10)
where PCWPM is the PCWP measured at any level 
of PEEP.
In order for the PAC to provide meaningful measure-
ments of PCWP, the PCWP must always be measured at
end-expiration in the respiratory cycle. Intrathoracic
pressure variations differ between spontaneously breath-
ing and mechanically ventilated patients (Figure 3-14).
The saturation of the blood within the pulmonary
capillaries, immediately prior to reoxygenation in the
alveolar capillaries, is known as the mixed venous oxy-
gen saturation SVO2. Since the diffusion of oxygen from
oxyhemoglobin into the tissues follows a concentration
gradient, tissues with greater metabolic rates utilize
more oxygen and blood flowing from these tissues is
more “desaturated.” Additionally, blood that is flowing at
lower rates, as in low cardiac output states, is more likely
to be “desaturated.” Therefore, the oxyhemoglobin 
saturation of “desaturated” blood accurately reflects the
combined effects of peripheral tissue extraction and 
cardiac output (flow).
Normally, peripheral oxygen consumption, or uptake,
is independent of oxygen delivery. Peripheral oxygen
extraction is linearly related to oxygen delivery.
The oxygen extraction ratio, O2 ER, is a calculation 
that determines global oxygen utilization based on the 
difference between the oxygen that is delivered to tissues
in the oxygen concentration in mixed venous blood:
O2 ER = VO2/DO2
The pulmonary artery catheter has recently fallen into
disfavor. Outcome studies are ambivalent regarding the
benefit of the PAC in critically ill patients. Perhaps an
important response to the skepticism is that repeated
studies demonstrate that many clinical practitioners
have a flawed or incomplete understanding of the physi-
ology and the assumptions involved in PAC placement
and data interpretation. Furthermore, practitioners fre-
quently treat absolute numbers such as the wedge pres-
sure or the CVP in isolation from the cardiac output, and
in isolation of the rest of the clinical picture. The key
assumptions, that right heart function and compliance,
that the catheter tip is reliably placed within lung zone
II or III, that transpulmonary pressures are linearly
related to the PCWP, and that left-sided volumes can be
reliably estimated by using right-sided pressures, must be
accounted for within the global clinical context.
Situations where the PCWP is likely to be significantly
greater than LVEDP include mitral stenosis, pulmonary
venous instruction or hypertension, left atrial myxoma,
or elevated pulmonary alveolar pressure. Situations
where the PCWP is likely to be significantly less than
LVEDP include instances of diminished left ventricular
compliance (infarction, ischemia, chronic left ventricu-
lar failure) or aortic insufficiency. A classic finding with
the PAC occurs with cardiac tamponade where there is
“equalization of pressures” and the CVP, mean PA pres-
sure, and PCWP all become equal.
Where oxygen delivery (DO2) is decreased past the
point at which metabolically active tissues can compensate,
oxygen uptake (VO2) decreases linearly in proportion to
DO2. When tissues become hypoxic, and VO2 falls, oxygen
metabolism changes from oxidative phosphorylation 
to anaerobic glycolysis. Anaerobic glycolysis is a signifi-
cantly less effective metabolic pathway and produces
substantially less ATP per molecule of oxygen; lactate
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Figure 3-14 Determination of wedge pressure (PCWP). PCWP
is determined at the end expiration. However, in spontaneously
ventilating patients end expiration corresponds with positive
intrathoracic pressure and therefore PCWP is measured at the end
of a plateau. In patients receiving positive pressure ventilation end
expiration corresponds with negative intrathoracic pressure, prior
to the next breath, and is measured at the end of a “valley.”
and acid production are by-products of tissue hypoxia
(Figure 3-15).
Serum lactate and serum base excess are therefore
important indicators of global tissue hypoxia in the set-
ting of shock (Figure 3-16). Since the peripheral oxygen
extraction is elevated in the setting of diminished delivery,
the saturation of blood returning to the lungs is profoundly
diminished.
NONINVASIVE HEMODYNAMIC
MONITORING
Despite its alleged drawbacks, invasive thermodilution
is still the reference method for clinical determination of
CO in critically ill patients. A large number of noninvasive
hemodynamic monitors are available and marketed for
intraoperative or ICU use. The three primary technological
approaches are (1) pulsed esophageal Doppler ultrasound,
(2) partial CO2 re-breathing using the Fick principle, and
(3) thoracic bioimpedance. All methods that derive
stroke volume from the blood flow velocity, Fick data, or
relative amplitude of the bioimpedance signal rely on
empirical data to calibrate the algorithms. These algo-
rithms are not perfect and provide misleading inform-
ation in critical pathophysiologic states. Additionally,
where there is an inability to actually view the waveforms
provided by the noninvasive device, there is no way of
ensuring that adequate or appropriate waveforms are
being analyzed. The simplicity of the PAC cannot be
approximated by these newer noninvasive techniques.
Esophageal ultrasound technology is based on aortic
blood flow velocity which helps determine both cardiac
output and afterload. The advantage of the ultrasound-
based technology is that it does not depend on an esti-
mation of CVP. Disadvantages include difficulty and
variability in probe positioning, difficulty in placement
in awake patients, and difficulty in obtaining reliable
data regarding cardiac preload. Thoracic bioimpedance
is based on the principal that changes in thoracic blood
volume alter the thoracic resistance to an electrical 
current. When bioimpedance changes are correlated
with ventricular depolarization, stroke volume can be
continuously and relatively reliably determined. Generally,
four pairs of electrocardiographic electrodes pulse
microcurrents across the thorax and sense the changes in
resistance or conduction. A primary limitation of bioim-
pedance technology is that it also cannot independently
determine cardiac filling pressures. In fact, cardiac func-
tion parameters determined using bioimpedance devices
require an independent estimation of CVP. Therefore, inva-
sive monitoring is either required, or the clinician must
make a numerical approximation based on judgment.
ECHOCARDIOGRAPHY
Increasingly, echocardiography is available as a bed-
side monitoring device. Anesthesiologists are trained in
the use of transesophageal echocardiography (TEE) in
the operating room and this is a skill that can easily be
transferred to the ICU. Experience in the use of TEE is
especially important when other invasive hemodynamic
monitoring, such as the PAC, is impossible, impractical,
or likely to be unreliable.
Ultrasound waves are generated during electrical
stimulation of piezoelectric crystals. The sound waves
differentially penetrate tissues of varying density and
allow the localization and visualization of these densities.
Additionally, echocardiographic monitoring is now almost
universally equipped with Doppler ultrasound which is
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Figure 3-15 The classic DO2–VO2 relationship. Progressive
decrease in oxygen delivery is compensated for by local tissue reg-
ulation and cellular oxygen kinetics. However, when DO2 reaches
a critical point, the curve’s inflection point, cellular dysoxia occurs
and there is progressive accumulation of cellular lactate and hydro-
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Figure 3-16 The relationship between tissue PO2 and serum
lactate. Serum lactate is a biochemical marker for anaerobic glycoly-
sis and tissue dysoxia. It is a global marker rather than a tissue-specific
or organ-specific indicator.
extremely useful to image blood flow. In perioperative
liver transplantation patients TEE can also easily image
hepatic blood flow and serve as a useful adjunct to clin-
ical and laboratory data regarding graft patency.
TEE is extremely useful in the direct visualization of
cardiac chamber size and dynamic contractility. In
patients with hypovolemia the end-systolic volume
(ESV) and the end-diastolic volume (EDV) can be easily
visualized with TEE to guide diagnosis and therapy. In
hypovolemia the left ventricle contracts down upon
itself almost completely. Computer-assisted TEE imaging
allows for reliable determination of cardiac ejection frac-
tion by comparison of EDV and ESV. However, the deter-
mination of cardiac ejection fraction based on chamber
size comparisons alone is unreliable if there are associ-
ated valvular abnormalities or intracardiac shunts.
In patients with impaired contractility dynamic imag-
ing will clearly reveal areas of wall motion abnormality,
segmental wall motion defects (SWMAs). The SWMA will
correlate with the anatomic distribution of ischemia and
frequently will demonstrate reversibility with therapy.
Since SWMAs are much earlier and more sensitive indi-
cators of cardiac ischemia than are either the PAC or the
ECG, TEE is an important clinical monitor.
TEE can also help visualize anatomic abnormalities
such as valvular abnormalities and function, tumor or
clot within the cardiac chambers, or aortic pathology.
Pulsed Doppler ultrasound is especially useful when
examining cardiac valves to look for valvular gradient
abnormalities, prosthetic valve dysfunction or perivalvu-
lar leak, regurgitant ejection fraction, and pulmonary
blood flow; this is known as color-flow mapping. When
Doppler technology is combined with rapid ejection of
agitated saline or agitated albumin the microbubbles 
can help delineate intracardiac shunting; which may be
more sensitive than Doppler technology alone. TEE can
also help visualize valvular endocarditis lesions. Pulsed
Doppler evaluation of aortic blood flow velocity is an
important adjunctive evaluation of cardiac function.
Important limitations regarding the use of TEE in ICU
patients include a secure airway, coagulopathy, hiatal
hernia, esophageal variceal disease, or recent esophago-
gastric surgery.
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Conclusion
Significant advances in medicine, like other fields of
science, are the products of multiple individual discov-
eries, usually by many different people, often over many
years. Furthermore, pivotal advances, those that alter
the very way we look at a particular issue, occur only
very rarely given the thousands of individual investiga-
tors who contribute to the collective literature of 
science and medicine. These paradigm shifts are often
met with great resistance in part because they require
us to unlearn the old way as much as they require us to
learn something new. When it was first reported that
peptic ulcer disease was due to H. pylori infection, the
scientific community reacted slowly and then with
skepticism.
Little more than 20 years ago Peter Stewart published
his revolutionary physical chemical analysis of acid–base
physiology. Stewart’s approach to acid–base was praised
by some and criticized by others, but mostly it was
ignored. Indeed, there has been very little interest in this
approach until quite recently. It would seem that the 
disinterest was due mainly to the fact that the approach,
while conceptually simple and elegant, is operationally
complicated and unwieldy. Most clinicians feel quite
comfortable with the traditional approach to acid–base
physiology and few can be easily convinced that
“re-learning” this area is worthwhile. However, for
patients in the intensive care unit (ICU), extreme
derangements in physiology are common and traditional
methods are often inadequate to explain the severe
acid–base disorders present in some of these patients.
Although the Stewart approach is based on the same
physical chemical principles on which more traditional
approaches are based, this new approach is vastly dif-
ferent. The most important difference is that, in this
view of the biological universe, hydrogen ions and
bicarbonate ions are not independent variables but are
instead determined by other factors. Changes in pH are
not the result of the generation or removal of these ions
per se, but rather are the result of changes in other
variables. In this universe, it is the Earth rather than the
Sun that moves.
The Stewart approach has now been found very
robust in a wide variety of patient types and experimen-
tal conditions. Recently, it has been shown that quanti-
tatively this approach is compatible with the more
traditional approaches; the difference lies in the under-
standing of the mechanisms involved. The observation
that metabolic acidosis is associated with a decrease in
plasma bicarbonate and base excess remains valid.
However, the implication that these changes cause the
acidosis is not. Some might argue that such a conceptual
change makes little difference. If one can measure the
size and origin (respiratory vs. metabolic) of a change in
acid–base status, does the average clinician really need
to understand how it occurs? Of course, this was the
same argument facing Galileo when he insisted that the
Earth was not the center of the universe. Even without
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Copernicus’s theory it was still quite possible to “under-
stand” the universe and it is very unlikely that the life of
the average person living in those times was altered 
in any way by this new knowledge. The argument 
obviously evaporates when considered in these terms.
The understanding that bicarbonate (HCO3−) and hydro-
gen ions (H+) are not at the center of the acid–base 
universe produces as violent a change in our concepts 
of physiology as did Copernicus change our concepts of
astronomy.
At this point, the authors of this chapter find it intel-
lectually impossible to continue to teach conventional
acid–base physiology.
In this chapter we explain the fundamental aspects of
the Stewart approach, review the implications for clini-
cal medicine, particularly in the ICU, and consider some
of the more practical aspects of acid–base management
from this perspective.
HISTORICAL BACKGROUND OF THE
ACID–BASE PHYSIOLOGY DEBATE
In the late 1800s Arrhenius, a Swedish physicist, deve-
loped two chemical concepts important to acid–base
physiology. The first was a new approach to the dissoci-
ation of chemical salts into electrolytes; for this work
Arrhenius almost failed his doctorate but was later
awarded a Nobel prize. The second concept was a new
definition of an acid: a substance that when added to a
solution increases the hydrogen ion concentration. The
next important development was the work of a Boston
physician, Henderson, in the early 1900s. From in vitro
work, Henderson rewrote the law of mass action equa-
tion to describe the role of weak acids in maintaining
“neutrality regulation in the animal organism.” The
“Henderson” equation applies particularly to bicarbonate
and carbonic acid:
where k is a constant.
Over the next 20 years several developments came
from Denmark. A new definition of an acid was devel-
oped by Brønsted: an acid is a substance that donates
hydrogen ions in solution. Brønsted noted that an
Englishman, Lowry, had developed a similar definition.
This became the Brønsted–Lowry definition, still the
dominant definition of an acid. The operative and sci-
entific superiority in the biological field of this later
definition of acid over Arrhenius’s concept is neither
obvious nor proven.
Sorensen, a chemist, made two further major contri-
butions. First he developed the concept of taking the
negative logarithm to the base ten of the hydrogen ion
concentration, which he called pH. Second he called
chemicals that reduced pH changes in solutions “buffers”
after the springs on the end of railway carriages.
Hasselbalch, a physician-farmer, combined Sorensen’s
work with Henderson’s to produce the Henderson–
Hasselbalch equation:
Whether concepts like “buffers” and the continued
use of a logarithmic scale for changes in hydrogen ion
activity serve modern medicine well remains doubtful.
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CURRENT CONTROVERSY
What is an acid? The definition of an acid is just
that: a definition. It cannot be proved to be false or
true. All that one can do is to see how, from an
operative point of view, such a definition is internally
consistent and able to fit into all observations that are
made empirically. Which definition dominates at a
particular time in history is not the product of science
alone but also the product of the spirit of the times,
politics, influence, and other non-scientific factors. If
we add hydrochloric acid to saline, does the pH fall
because we add the hydrogen ions of the acid or
because the chloride lowers the strong ion difference
or both? Is hydrochloric acid an acid because it donates
hydrogen ions or because it increases the
concentration of hydrogen ions in the solution?
CURRENT CONTROVERSY
What is a buffer? Why use pH? The same issues
related to the definition of an acid pertain to the
definition  of a buffer. Sodium lactate is a “buffer” in
conventional acid–base physiology. However, if enough
sodium lactate is given fast enough, hyperlactatemia
occurs and the base excess falls. Is this because lactate
is not transformed into CO2 (conventional explanation)
by the liver or because the SID has decreased due to
the rapid infusion of a solution with a SID of 0 (Stewart
explanation)? It is not possible to tell. Equally, is the
use of pH helpful to clinicians to appreciate changes in
acid–base balance more than the actual hydrogen ion
activity in nmol/l? We doubt it. In our opinion, the use
of pH in modern medicine appears unnecessary and
potentially misleading.
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Over the next 50 years acid–base physiology centered
on the Henderson–Hasselbalch equation. The partial
pressure of carbon dioxide was substituted for carbonic
acid. The non-volatile, or metabolic, component was
interpreted as being due to the body controlling plasma
bicarbonate concentration. One difficulty in clinical appli-
cation was that changes in bicarbonate had to be inter-
preted while allowing for changes in the partial pressure
of carbon dioxide. To deal with this problem, Schwartz
and Relman, Boston physicians, produced “rules of
thumb.” The rules of thumb were equations to deter-
mine whether the simultaneous changes in bicarbonate
and carbon dioxide were a single process, such as meta-
bolic acidosis with compensation, or mixed processes.
In the 1960s Siggard-Anderson, a Danish physician,
introduced “base excess” as a measure of the metabolic
acid–base status. Using base excess did not require cal-
culating the rules of thumb. Base excess assumes a par-
tial pressure of carbon dioxide of 40 mmHg and includes
the plasma bicarbonate concentration in the calculation.
The subsequent controversy between Boston and
Copenhagen over the merits of the rules of thumb ver-
sus base excess was known as the “Great Transatlantic
Debate.” It continues to this day.
In the late 1970s and early 1980s, in several papers
and a book, Peter Stewart, a Canadian-American physiol-
ogist working at Brown University, introduced a new
approach to acid–base physiology and disorders. While
using the partial pressure of carbon dioxide, Stewart
used two other variables, the strong ion difference and
the total weak acid concentration, instead of bicarbonate.
Stewart based his work on several chemical principles,
particularly electroneutrality, conservation of mass, and
dissociation of electrolytes. Unfortunately for the ongoing
debate, Stewart died in 1993.
The main principles of Stewart’s approach are that
there are three important independent factors control-
ling the acid–base status of a physiological solution: the
partial pressure of carbon dioxide, the strong ion differ-
ence, and the total weak acid concentration. The role of
carbon dioxide, controlled by the lungs, is similar to that
in the Henderson–Hasselbalch approach. Strong ions are
ions that are completely dissociated in solution. The
most important strong ions are sodium, potassium, and
chloride. The important factor is the difference between
the strong ions rather than the absolute concentrations
of the ions. As the strong ion difference falls the hydro-
gen ion concentration increases. Lactate is treated as a
strong ion because with a pKa of 3.4 it is almost com-
pletely dissociated at a pH of 7.40. The most important
weak acids in plasma are albumin and, to a lesser extent,
phosphate. Stewart emphasized that the three independ-
ent factors must be considered simultaneously. These inde-
pendent factors will control dependent factors including
bicarbonate, hydroxyl ions, and hydrogen ions. The source
of hydrogen ions in the Stewart approach is the dissoci-
ation of water molecules. Important underlying factors
are the temperature-dependent dissociation constants of
weak acids, including carbonic acid, and the dissociation
constant of water.
For several reasons Stewart’s work provoked, and
continues to provoke, strong adverse reaction from those
committed to the Henderson–Hasselbalch approach.
First, he rejected bicarbonate as a vital controlling factor.
Second, he emphasized the vital role of strong ions; he
saw hydrochloric acid as acidifying not because it has
hydrogen ions but because it has strong anions, chloride,
without strong cations. Third, he rejected the notion of
buffers, and instead talked of weak acids. Fourth, he
rejected pH in favor of a return to hydrogen ion concen-
tration. Last, he returned to the acid definition of
Arrhenius: a substance that when added to a solution
increases the hydrogen ion concentration. This defini-
tion accommodates both carbon dioxide and strong
anions.
Many groups have continued Stewart’s work: in clini-
cal work (particularly critical care), in exercise physiol-
ogy, and in veterinary work.
FUNDAMENTAL PRINCIPLES OF
HYDROGEN ION REGULATION
Before we examine this area it is first necessary to
review the basic principles of H+ regulation. Large living
organisms seek to maintain plasma pH within strict toler-
ance limits. In fact, the free H+ concentration is maintained
within the nmol/l range (36–43 nmol/l). By contrast,
most other ions are regulated in the mmol/l range. One
reason H+ concentration is so closely regulated is that
CLINICAL CAVEAT
What is the source of hydrogen ions? The source of
hydrogen ions is plasma water not “acid” generation by
cells. One liter of water contains approximately 55 ×
6.022 × 1023 hydrogen ions. The quantity of hydrogen
ions that is released from water depends on the
independent variables described by Stewart. Normally,
at 25°C, one in 1014 molecules of water is dissociated.
To put it another way, in a solution of distilled water,
not all of the water is water. Some of it is dissociated
into hydroxyl ions and hydrogen ions. The glass
electrode measures free hydrogen ions and, of course,
ignores free hydroxyl ions. The more water is
dissociated, the greater the amount of free hydrogen
ions and the lower the pH.
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these ions have very high charge densities and conse-
quently very large electric fields. Furthermore, the
strength of H+ bonds (ubiquitous in biologic systems) is
very sensitive to local H+ concentration. Biochemical
reactions as well as interactions of hormones and drugs
with plasma proteins and cell surface receptors are also
influenced by changes in H+ concentration. In addition,
fluctuations in intracellular H+ concentration have major
effects on cellular performance presumably by altering
protein charge, thereby affecting structure and enzy-
matic function. Obviously then, in order to understand
how the body regulates plasma H+ concentration, we
must first understand the physicochemical determinants
of H+ concentration.
Biochemistry of Aqueous Solutions
Virtually all solutions in human biology contain water
and aqueous solutions provide a virtually inexhaustible
source of H+. In these solutions, H+ concentration is
determined by the dissociation of water into H+ and OH−
ions. In other words, changes in H+ concentration occur
not as a result of how much H+ is added or removed but
as a consequence of water dissociation. The factors that
determine the dissociation of water are the laws of phys-
ical chemistry. Two in particular apply here, electroneu-
trality (which dictates that, in aqueous solutions, the
sum of all positively charged ions must equal the sum of
all negatively charged ions) and conservation of mass
(which means that the amount of a substance remains
constant unless it is added or generated, or removed or
destroyed). In pure water, according to the principle of
electroneutrality, the concentration of H+ must always
equal the concentration of OH−. In more complex solu-
tions we have to consider other determinants of water
dissociation, but still the source of H+ remains water.
Fortunately, even in a solution as complex as blood
plasma, the determinants of H+ concentration can be
reduced to three. If we know the value of these three
determinants, the H+ concentration can be predicted
under any conditions. These three determinants are the
strong ion difference (SID), pCO2, and total weak acid
concentration (ATOT).
Strong Ion Difference, pCO2, and Total
Weak Acid Concentration
The SID is the net charge balance of all strong ions
present, where a “strong” ion is one that is completely
(or near-completely) dissociated. For practical purposes
this means (Na+ + K+ + Ca2+ + Mg2+) − (Cl− + lactate−).
This is often referred to as the “apparent” SID (SIDa) with
the understanding that some “unmeasured” ions might
also be present. In healthy humans this value is 40–42
mEq/l, although it is often quite different in critically
ill patients. Of note, neither H+ nor HCO3− is a strong ion.
The pCO2 is an independent variable assuming that the
system is open (i.e., ventilation is present). Finally, the
weak acids (A−), which are mostly proteins and phos-
phates, contribute the remaining charges to satisfy the
principle of electroneutrality. A−, however, is not an
independent variable because it changes with alterations
in SID and pCO2. ATOT (AH + A−) is the third independent
variable because its value is not determined by any
other. The essence of the Stewart approach (and indeed
what is revolutionary) is the understanding that only
these three variables are important. Neither H+ nor
HCO3− can change unless one or more of these three
variables change. The principle of conservation of mass
makes this point more than semantics. Strong ions can-
not be created or destroyed to satisfy electroneutrality
but H+ ions are generated or consumed by changes in
water dissociation. Hence, in order to understand how
the body regulates pH we need only ask how it regulates
these three independent variables (SID, pCO2, and ATOT).
CLINICAL APPLICATIONS
This “new” approach changes nothing about the mea-
surement or classification of acid–base disorders. All of the
careful observations that have been made over the years
are no less valid under this approach. What does change
is the interpretation of these observations. The Sun still
sets in the west and rises in the east, but now it is the
Earth that moves.
Quantification of Acid–Base Disorders
While the understanding of how an acid–base dis-
order occurs is now quite different, it is important to
emphasize that not only does the traditional approach to
quantifying an acid–base disorder still “work,” but that
it is entirely complementary to this physical chemical
analysis. In fact the standard base excess (SBE) can be
used to quantify the amount of change in SID that has
occurred from baseline. The SBE can be thought of as
the amount of change in the SID that is required in order
to restore the pH to 7.40, given a PCO2 of 40 mmHg (a
negative SBE refers to the amount the SID must increase).
This is because the SID is essentially equal to the buffer
base of Singer and Hastings and base excess (BE) quanti-
fies the change in buffer base. SBE is superior to BE
because the former has been “standardized” to account
for the difference between CO2 equilibration in vitro
compared to in vivo. Although SBE is not strictly com-
parable to the change in SID because it deals with whole
blood as opposed to plasma, the two are generally close
enough for most clinical circumstances. Thus, SBE pro-
vides an estimate of the amount of strong anion that
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needs to be removed or strong cation added in order 
to normalize the pH. For example, in order to change
the SBE from −20 to −10 mEq/l by adding NaHCO3, the
serum Na+ concentration would need to be increased by
10 mEq/l.
Recently, Schlichtig and co-workers described the
changes in SBE that occur with acute and chronic disor-
ders of PaCO2. The SBE does not change with acute
changes in PaCO2. During chronic respiratory acidosis
or alkalosis the change in the SBE is equal to 0.4 ×
(PaCO2 − 40). Similarly, the expected change in PaCO2
for a given abnormality in SBE is as follows: for acidosis
the decrease in PaCO2 is equal to the change in SBE; for
alkalosis the increase in PaCO2 is equal to 0.6 × SBE.
Chloride: The “Forgotten Electrolyte”
One of the most important implications of the Stewart
analysis is the role of chloride in acid–base homeostasis.
If the body is to alter the SID, its primary tools are Na+
and Cl−. An increase in Na+ relative to Cl− (or a decrease
in Cl− relative to Na+) increases the SID and hence the
pH. The opposite effects, a decrease in the SID and a fall
in the pH, occur when Na+ and Cl− concentrations move
closer together. Since Na+ concentration is tightly regu-
lated by the body to control tonicity, Cl− emerges as the
body’s foremost tool for adjusting the SID and hence the
plasma pH. Furthermore, acid–base abnormalities are
frequently the result of disorders in chloride homeosta-
sis. For example, a common form of metabolic alkalosis
seen in the ICU is caused by the loss of gastric secre-
tions. The loss of HCl from the stomach results in a
hypochloremic metabolic alkalosis sometimes severe
enough to require therapy. Of course this is the loss of
H+, but H+ is also lost with every molecule of water
removed from the body. Moreover, gastric secretions
may reach a pH of 1.0, or a H+ concentration of 108 nmol/l.
If one liter of gastric fluid is lost, this would mean that
108 nmol (0.1 mol!) of H+ would be removed. If one con-
siders that plasma H+ concentration is 40 nmol/l (or 4 ×
10−8 mol/l), and if the majority of body fluids are at or
near this concentration, one sees that the amount of total
body free H+ is only about 1.6 × 10−7 mol. If physiology
were just simple accounting, a patient with a 200 ml
emesis would entirely deplete the H+ stores of the body
and die of severe alkalemia in minutes. Of course this is
not what happens and in reality the H+ concentration
decreases by a much smaller amount. The reason it
decreases at all is because the plasma SID is increased and
this is because Cl− (a strong anion) is lost without loss of
a strong cation. This increased SID forces a decrease in
the amount of water dissociation and hence a decrease in
the plasma H+ concentration. When H+ is “lost” as water
rather than HCl, there is virtually no change in the SID
and hence no change in the plasma H+ concentration.
Next, consider the treatment for a hypochloremic meta-
bolic alkalosis. Aside from preventing further Cl− loss,
the therapy is to give back Cl−. Saline works in this
regard because even though one is giving equal amounts
of Na+ and Cl−, the plasma Cl− concentration is always
much lower than the plasma Na+ concentration and thus
Cl− increases more than Na+ when large amounts of
saline are administered. KCl works better for this indica-
tion because, with a metabolic alkalosis, much of the K+
goes intracellular leaving much of the Cl− in the plasma
to decrease the SID.
From the example above, one can easily understand
not only how administration of 0.9% saline can correct a
hypochloremic metabolic alkalosis but also how massive
amounts would lead to a decreased plasma SID and thus
a hyperchloremic metabolic acidosis. This particular
issue has been the focus of two recent studies, one in
animals with experimental sepsis the other in humans
undergoing surgery.
In the first study we administered E. coli endotoxin to
dogs and then volume resuscitated with 0.9% saline.
Over a 3 hour period, each animal received an average
of 1.8 liters of saline and the pH decreased from 7.32 to
7.11 (p < 0.01) while CO2 and lactate were unchanged.
Using the SID it was possible to calculate the amount of
acidosis that was attributable to saline. Although the
serum Na+ concentration did not change, the serum Cl−
concentration increased by almost 10 mmol/l. It was
concluded that saline alone was responsible for 42% of
the total acid load experienced by these animals. In the
second study, Scheingraber and colleagues randomized
patients undergoing major gynecologic surgery to
receive either 0.9% saline or lactated Ringer’s solution.
Patients receiving saline exhibited a decrease in their
arterial pH from 7.41 to 7.28 while no change occurred
in the lactated Ringer’s group. These investigators also
used the SID to calculate the expected change in pH
with saline and found that the acidosis was entirely
explained by chloride administration.
Although dilutional acidosis was first described over
40 years ago, it has more recently been likened to Lewis
CURRENT CONTROVERSY
What is the cause of so-called dilutional acidosis?
The conventional view of this phenomenon is that the
“buffers” are diluted by the administration of fluids.
The Stewart explanation is simple. If one adds solutions
with a SID of 0, the SID of plasma will fall and water
will be more dissociated with a greater release of
hydrogen ions.
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Carroll’s Cheshire cat in that it is more imaginary than
real. In healthy animals large doses of NaCl have been
demonstrated to produce only a minor hyperchloremic
acidosis. These studies have been interpreted to show
that if dilutional acidosis occurs it is only in the extreme
case and even then it is only mild. This line of reasoning
cannot be applied to many critically ill patients for two
reasons. First, large-volume resuscitation is commonly
required in patients with sepsis and trauma. These
patients may receive crystalloid infusions of 5–10 times
their plasma volumes in a single day. The second prob-
lem with this line of reasoning is that it fails to consider
the fact that critically ill patients are frequently not in
normal acid–base balance to begin with. These patients
may have lactic acidosis or renal insufficiency.
Furthermore, critically ill patients might not be able to
compensate normally by increasing ventilation and may
have abnormal buffer capacity owing to hypoalbumin-
emia. In patients, as well as in animals with experimental
sepsis, dilutional acidosis does occur and can produce
significant acid–base derangements.
The clinical implication for management of patients in
the ICU is that when large volumes of fluid are used for
resuscitation they should be more physiologic than saline.
CLINICAL CAVEAT
How can one avoid “dilutional” acidosis? Dilutional
acidosis can be avoided by administering “balanced
solutions” which have a SID close to the normal SID of
plasma. Lactate Ringer’s solution is such a fluid. It is
important to realize that if large amounts of this fluid
are given to critically ill patients, hyperlactemia might
be induced. Such hyperlactemia is usually mild to
moderate and should not be misunderstood as a sign of
clinical deterioration.
anion gap (AG), which is a measure of missing charge,
does not change. However, when other anions are pres-
ent, the AG increases. Unfortunately, the accuracy of the
AG is questionable in certain clinical situations, particu-
larly in critically ill patients who are frequently hypoalbu-
minemic and acidotic. This has prompted some authors to
adjust the “normal range” for the AG by the patient’s
albumin or even phosphate concentration. Each g/dl of
albumin has a charge of 2.8 mEq/l at pH 7.4 (2.3 mEq/l at
7.0 and 3.0 mEq/l at 7.6) and each mg/dl of phosphate has
a charge of 0.59 mEq/l at pH 7.4 (0.55 mEq/l at 7.0 and
0.61 mEq/l at 7.6). Except in cases of abnormal parapro-
teins, globulin does not contribute to the AG. Thus a con-
venient way to estimate the “normal range” of the AG for
a given patient is by use of the following formula:
“Normal” AG = 2(albumin g/dl) + 0.5(phosphate mg/dl)
Or for international units:
“Normal” AG = 0.2(albumin g/l) + 1.5(phosphate mmol/l)
Figge et al. have shown that in the majority of criti-
cally ill patients the “normal” AG can be estimated by
using 2.5 times the albumin concentration in g/dl (or
0.25 for albumin in g/l). However, if the serum phos-
phate concentration is significantly abnormal this esti-
mate will be inaccurate.
The etiology of anions other than Cl− varies depend-
ing on the population studied. Ketones, organic acids
accumulating in renal failure, and toxins are important
causes in appropriate patient groups. In critically ill
patients lactate is a particularly important cause. Lactate
is a strong ion by virtue of the fact that at pH within the
physiologic range, it is almost completely dissociated (i.e.,
the pK of lactate is 3.9; at a pH of 7.4, 3162 ions are disso-
ciated for every one that is not). Because the body can pro-
duce and dispose of lactate rapidly, it functions as one of
the most dynamic components of the SID. Lactate there-
fore can produce significant acidemia. However, often crit-
ically ill patients have hyperlactatemia that is much greater
than the amount of acidosis seen. Physical chemistry 
also allows us to understand how hyperlactatemia may
exist without metabolic acidosis. First, acid is not being
One alternative is lactated Ringer’s solution. This fluid
contains a more physiologic difference between Na+ and
Cl− and thus the SID is closer to normal (roughly 28 mEq/l
compared to saline which has an SID of 0 mEq/l). Of course
this assumes that the lactate in lactated Ringer’s is metabo-
lized, which may take several minutes. Until the lactate is
removed the effect of lactated Ringer’s is identical to saline
since one strong anion (i.e., lactate) is as good as another
(i.e., Cl−). Therefore, massive doses of sodium lactate, for
example given as replacement fluid for hemofiltration, may
transiently result in acidosis as the SID decreases.
Other Anions
When the SID decreases, metabolic acidosis ensues.
When this occurs as a result of increased Cl−, the
CLINICAL CAVEAT
With regards albumin and the anion gap, the anion
gap must always be adjusted for the effect of
hypoalbuminemia. In a critically ill patient with an
albumin of 1.5 g/dl a normal unadjusted anion gap can
coexist with a lactate of 6 mmol/l!
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“generated” apart from lactate such as through “unreversed
ATP hydrolysis” as some have suggested. Phosphate is a
weak acid and does not contribute substantially to meta-
bolic acidosis even under extreme circumstances.
Furthermore, the H+ concentration is not determined by
how much H+ is produced or removed from the plasma but
rather by changes in one of the three independent variables
(SID, pCO2, or ATOT). Virtually anywhere in the body, pH is
above 6.0 and lactate behaves as a strong ion. Its generation
will then decrease the SID and result in increased water dis-
sociation and thus increased H+ concentration.
How then might the plasma lactate concentration be
increased and the H+ concentration not? There are two
possible answers. First, if lactate is added to the plasma,
not as lactic acid but rather as the salt of a strong acid
(i.e., sodium lactate), there will be little change in the
SID. This is because a strong cation (Na+) is being added
along with a strong anion. In fact, as lactate is then
removed by metabolism, the remaining Na+ will increase
the SID resulting in metabolic alkalosis. Hence it would
be possible to give enough lactate to increase the plasma
lactate concentration without any change in H+ con-
centration. However, the amount of exogenous lactate
required would be very large. This is because normal
metabolism results in the turnover of approximately
1500–4500 mmol of lactic acid per day. Thus, only very
large amounts of lactate infused rapidly will result in
appreciable increases in the plasma lactate concentra-
tion. In this setting, a mild acidosis may occur until the
lactate is metabolized (usually within several minutes).
Levraut et al. infused 1 mmol/kg of lactate over 15 minutes
in 10 patients with acute renal failure on continuous renal
replacement therapy. Their mean plasma lactate con-
centration increased from 1.4 to 4.8 mmol/l after the
infusion but normalized rapidly. Under such conditions
it is possible (if transiently) to produce hyperlactatemia
without acidemia. Unfortunately, these authors do not
report the acid–base status of their patients. However, in
another recent study, Morgera et al. showed that lactate-
based hemofiltration resulted in increased plasma 
HCO3− concentration and pH as well as hyperlactatemia.
A more important mechanism whereby hyperlactatemia
exists without acidemia (or with less acidemia than
expected) is where the SID is corrected by the elimina-
tion of another strong anion from the plasma. This was
demonstrated by Madias et al. In the setting of sustained
lactic acidosis induced by lactic acid infusion, these
investigators found that Cl− moves out of the plasma
space to normalize pH. Under these conditions hyper-
lactatemia may persist but BE may be normalized by
compensatory mechanisms to restore the SID.
The meaning of hyperlactatemia is very different
depending on the patient population being considered.
Healthy humans can achieve plasma lactate concentra-
tions with exercise in excess of 25 mmol/l without any
long-term sequelae. By contrast, hyperlactatemia in the
critically ill is an important predictor of mortality. One of
the major controversies associated with hyperlactatemia
and associated acidosis or indeed acidemia concerns its
treatment.
Treatment of Acidosis and/or Acidemia
Whether induced by the accumulation of the lactate
anion or by the accumulation of other anions (chloride,
ketones, exogenous acids, acids associated with renal
failure), severe acidosis may be associated with inade-
quate physiological compensation and lead to acidemia.
Although it is agreed by all that treatment of such
acidemia/acidosis should first and foremost involve cor-
rection of its cause, it is controversial whether some or all
of these patients should also receive alkalinizing solutions
such as sodium bicarbonate. The biologic rationale for
administering sodium bicarbonate rests on three major
considerations: (1) a low pH impairs myocardial contrac-
tility, (2) IV sodium bicarbonate can increase pH, and
(3) any adverse effects of sodium bicarbonate are out-
weighed by its benefits. However, concerning point
(1), evidence that a low pH decreases myocardial con-
tractility is mostly based on data from isolated animal
heart muscle preparations. In whole-animal preparations
the effects of acidosis on contractility are much more dif-
ficult to document. In humans data from patients with
permissive hypercapnia or with diabetic ketoacidosis sup-
port the view that there is marked tolerance to a low pH
without major adverse effects. Furthermore, there is a
body of data to suggest that acidosis may protect cells
from anoxia, chemical hypoxia, and reperfusion injury.
With regard to point (2), clinical studies show that the
effect of up to 2 mmol/kg of sodium bicarbonate on pH is
small with increments in the range 0.05–0.014 in humans.
In addition, sodium bicarbonate fails to predictably
increase intracellular pH and often appears to induce a
decrease instead. Changes in blood pH may also decrease
oxygen delivery to tissues by changing the dissociation
curve of hemoglobin. Thus the efficacy of sodium bicar-
bonate in lowering pH where it matters is unclear. The
hemodynamic effects of IV sodium bicarbonate have been
studied in humans. They were indistinguishable from
those of an equivalent amount of sodium delivered as
saline. In uncontrolled studies of patients with diabetic
ketoacidosis no benefits could be seen and delayed 
clearance of ketones and lactate were documented.
Bicarbonate also lowers ionized calcium concentrations
and PaO2 in animals and non-acidemic patients with con-
gestive cardiac failure. Thus the safety of IV bicarbonate
remains untested. Other alkalinizing preparations exist:
1. Carbicarb (equimolar mixture of sodium carbonate
and sodium bicarbonate)
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2. Dichloroacetate (an agent that stimulates pyruvate
dehydrogenase and lowers lactate levels)
3. Tris-hydroxymethyl aminomethane (THAM)
Carbicarb has also undergone limited studies in
humans and its role is unclear. Dichloroacetate has been
tested in a large randomized controlled trial in patients
with lactic acidosis. In this trial it was found efficacious
in lowering lactate levels and increasing bicarbonate
concentration and pH. However, it did not achieve any
changes in hemodynamics or clinical outcomes. THAM
appears to improve contractility in isolated rabbit heart
preparations. However, no controlled studies are avail-
able to support its use in humans with acidemia and the
side effects of hyperkalemia, hypoglycemia, extravasation-
related tissue necrosis, and neonatal hepatic necrosis
demand great caution in its utilization.
Other Mechanisms of Lactic Acidosis
Although lactic acidosis is associated with major physio-
logical stress in all patients and with shock in most, some
particular situations occur where neither may be at work.
A unique situation that requires separate discussion is that
of the patient receiving artificial kidney support.
The Artificial Kidney and Lactate
The use of the artificial kidney also has a clinically sig-
nificant impact on lactate balance and on plasma lactate
concentrations. This impact may derive from lactate
removal as well as lactate administration. Lactate clear-
ance during intermittent hemodialysis or intermittent
hemofiltration has not been formally studied but is likely
to be similar to that of other small molecules given the
molecular weight of lactate. Assuming a small molecular
clearance of 200 ml/minute, lactate clearance during
dialysis would reach approximately 20% of endogenous
clearance. The impact of such clearance on lactate lev-
els, however, has not been studied. Lactate has not been
traditionally used as a buffer for intermittent hemodialy-
sis, and therefore there is little specific information on
the use of lactate-buffered dialysate on lactate levels and
acid–base balance in dialysis patients.
When intermittent hemofiltration is used, however, and
lactate-based replacement fluid is administered at high
rates (approximately 200 mmol/hour), a significant
increase in plasma lactate levels can be easily demon-
strated. Although the clinical significance of such increases
in lactate levels is unknown, this iatrogenic phenomenon
needs to be appreciated in order to avoid misdiagnosis.
Also, the magnitude of this phenomenon (average peak
increase of 3 mmol/l at 3 hours) needs to be understood
to separate it from other factors, which may simultane-
ously be operative in determining the patient’s lactate
levels.
A similar phenomenon has been described during
continuous renal replacement therapy (CRRT), but the
increment in lactate levels was less due to the lower rate
of lactate administration. However, it is important to
note that increments in lactate levels in patients on
CRRT are not simply dependent on the rate of lactate
administration but also on the body’s ability to handle a
given lactate load. Thus, the administration of up to
200 mmol/hour of lactate may lead to modest changes in
lactate levels and pH. However, the administration of the
same amount or even less in a patient with pre-treatment
lactate intolerance (liver failure, severe septic shock) will
induce a dramatic increase in lactate concentration and
a profound acidosis. Under such circumstances, lactate-
buffered replacement solutions should be avoided.
Furthermore, in patients with lactic acidosis and acute
renal failure receiving CRRT, the administration of
bicarbonate-based replacement fluids is an effective way
of avoiding any exacerbation of hyperlactatemia and of
restoring acid–base homeostasis. Some investigators
have suggested that lactate removal during CRRT may
lower plasma lactate levels and participate in the cor-
rection of acidosis seen during bicarbonate-based CRRT.
In response to this hypothesis, Levraut and colleagues
conducted a careful analysis of lactate clearance during
CRRT and compared it to endogenous clearance. They
found that the median endogenous lactate clearance 
was 1379 ml/minute, while the median filter lactate
clearance was 24.2 ml/minute. Thus, CRRT-based lactate
clearance accounted for <3% of total lactate removal.
It may appear surprising that increases in plasma lac-
tate concentration of up to 8 mmol/l would not induce
a pronounced degree of acidification. It should do so by
increasing the concentration of anions in plasma and
CURRENT CONTROVERSY
The administration of IV sodium bicarbonate in
patients with acidemia remains one of the most passion-
laden areas of anesthetic and critical care practice. Like
other similar areas of controversy, the intensity of
opinion is inversely proportional to the quality and
amount of evidence available. There are insufficient data
to support the use of IV sodium bicarbonate in patients
with acidemia. There are also insufficient data to
proscribe the use of sodium bicarbonate in these
patients. If a decision is made to administer IV sodium
bicarbonate, we recommend that it should occur with
close hemodynamic and biochemical monitoring and
that the agent be administered in the presence of a
physician.
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thus decreasing the SID and its effect on the dissociation
of plasma water into hydrogen ion. In fact some prelim-
inary observations suggest that several complex events
occur during the onset of such rapid iatrogenic hyper-
lactatemia. In particular, a marked decrease in chloride
appears to occur despite the administration of chloride-
rich replacement fluid. This change in chloride is likely
to be secondary to a shift into cells similar to that seen in
venous blood when the CO2 rises (Hamburger shift).
Such a shift in chloride rapidly attenuates the impact of
hyperlactatemia on pH and prevents the development of
a progressive and sustained acidemia.
Finally, it must be emphasized that the view of lactate as
representative of so-called “anaerobic glycolysis” is not
supported by the data available. The hyperlactatemia of
septic shock, for example, appears most likely secondary
to accelerated glycolytic flux, where glucose breakdown
into pyruvate is proceeding faster than pyruvate can be
channeled into the citric acid cycle via acetyl coenzyme A.
It is important to note that not all anions appearing in the
blood of the critically ill can be explained. The SID can be
used to detect unexplained anions because the apparent
SID (SIDa) calculated from the measurable ions should be
equal to the effective SID (SIDe) derived from the remain-
ing charges attributable to CO2 and A−. If a difference exists
between the SIDa and SIDe, then unmeasured anions must
be present. This difference has been termed the strong ion
gap (SIG) to distinguish it from the AG. Unlike the AG, the
SIG is normally zero and does not change with changes in
pH or albumin concentration as does the AG. However, it
should be noted that this “gap” need not be filled by
strong ions. Weak acids may also play a role.
In recent years unmeasured anions have been reported
in the blood of patients with sepsis and liver disease. These
anions may be the source of much of the unexplained 
acidosis seen in patients with critical illness. The presence
of unexplained anions in the blood of both patients with
sepsis and liver disease was investigated further in an ani-
mal model of sepsis using endotoxemia. In this study it was
found that during control conditions the liver cleared
unmeasured anions from the circulation (mean flux
−0.34 mEq/minute). With early endotoxemia, however,
the liver switched to release of anions (0.12 mEq/minute,
p < 0.005). These data suggest that the liver has a role in
systemic acid–base balance by way of regulating anion
fluxes apart from metabolism of lactate.
EFFECTS OF PLASMA PROTEINS
Considerable controversy has developed over the
past decade as to how to classify acid–base derange-
ments occurring as a result of abnormalities in the weak
acids, ATOT. A sudden decrease in ATOT produces alkalo-
sis while an increase is acidifying. Some have advocated
a third classification for this effect, perhaps termed 
“proteinaceous acidosis or alkalosis,” to be added to
“metabolic” (SID) and “respiratory” (pCO2). Others have
strenuously objected. The debate may actually prove
moot in light of more recent evidence. When the SID of
critically ill patients was compared to SBE the intercept
for SBE = 0 was found to be 30–35 mEq/l rather than
40–42 mEq/l as for healthy individuals. Thus, in these
critically ill patients, many of whom had a decreased
ATOT secondary to hypoalbuminemia, the SID was
reduced even when there was no apparent acid–base
disorder. The reason for this is obvious from a physical
chemical perspective. As a patient’s albumin decreases
so does ATOT and thus A−. This decrease in weak acid has
a slightly alkalinizing effect. The body could adapt to this
change by retaining CO2 but it appears to reserve this
adaptation for changes in SID. Instead, the body adapts
to a decreased ATOT by decreasing the SID. While one
might be tempted classify this adaptation as a mixed
acid–base disorder, a hypoalbuminemic alkalosis with a
compensatory metabolic acidosis, it does not appear to
be a disorder at all. Indeed, a patient who failed to
reduce their SID in response to a decreased ATOT should
be considered to have a metabolic alkalosis as conse-
quence of failed renal homeostatic mechanisms (e.g.,
secondary to hypovolemia), not a proteinacious alkalosis
secondary to hypoalbuminemia. The findings of Wilkes
in critically ill patients and Wooten in mathematical
simulations appear to support this assertion. Both
authors have demonstrated that the “set point” for the
SID to achieve a normal pH given a normal pCO2
changes with changes in ATOT. Furthermore, although
the loss of weak acid from the plasma space is an 
alkalinizing process, there is no evidence that the body
regulates ATOT to maintain acid–base balance and there is
CURRENT CONTROVERSY
What is the meaning of hyperlactatemia? There is no
evidence to indicate that hyperlactatemia is due to
anaerobic glycolysis in critically ill patients and much
evidence to suggest that it occurs in the setting of full
intracellular oxygenation and in the presence of
elevated levels of pyruvate. As fast glycolysis occurs in
the liver and glucose is the preferred fuel of stress, it
appears likely that peripheral lactate generation allows
rapid fuel supply for glycolysis (lactate from muscle to
liver, in liver to pyruvate for gluconeogenesis (Cori
cycle), then glucose use for energy generation: the
lactate shuttle). Alternatively, glucose breakdown is so
fast under stress that pyruvate is generated faster than
it can be taken up by mitochondria, and thus it
becomes lactate and is recycled.
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no evidence that clinicians should treat hypoalbumin-
emia as an acid–base disorder.
CONCLUSION
In order to understand the causes of the acid–base
derangements, many of which are common in the ICU,
we need only look at three independent variables (SID,
pCO2, and ATOT). Metabolic acidemia results from a
decrease in the plasma SID usually brought about by the
addition of strong anions (lactate, Cl−, other “unknown”
anions). Conversely, metabolic alkalemia occurs when
the plasma SID is increased either as a result of the addition
of strong cations without strong anions (e.g., NaHCO3) or
by the removal of strong anions without strong cations
(e.g., gastric suctioning).
This “new” understanding has considerable impact on
how we think about gastric suction alkalosis, dilutional aci-
dosis, and lactic acidosis as well as how we approach the
treatment of these disorders. Our understanding of many
other medical conditions (e.g., renal tubular acidosis)
relies on a paradigm of acid–base regulation that is incon-
sistent with established physical chemistry principles. 
In this “post-Copernican” era, we will need to rethink
our-approach to these areas in the light of this fact.
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CASE STUDY
A 77-year-old man has cardiopulmonary bypass
(CPB). On admission to the ICU he has a pH of 7.24,
CO2 of 47, bicarbonate of 19 mmol/l, and BE of −7 mEq/l.
He is receiving a low-dose epinephrine infusion at
3 μg/minute for a poor cardiac output following
separation from the pump. His urea and electrolytes
show a sodium of 140 mmol/l, chloride of 110 mmol/l,
potassium of 6 mmol/l, and urea of 6 mmol/l (BUN of
16.5 mg/dl). His anion gap is 11 (normal). Does this
man have a lactic acidosis? What acid–base disorders
does this man have? A normal anion gap would suggest
that this man does not have a lactic acidosis. However,
the anion gap is not corrected for the serum albumin.
This man had a crystalloid pump prime, which was
saline based. He now has iatrogenic hyperchloremia
with a low SID which is responsible for a degree of
acidosis. The acidemia might have contributed to
hyperkalemia which will have an alkalinizing effect on
the SID. But he is also likely to have dilutional
hypoalbuminemia, which would cause an alkalosis.
When measured, the albumin concentration was in fact
1.5 g/dl. Thus the normal anion gap (assuming a normal
phosphate) should actually be about 4.5–5 mEq/l.
The fact that it is 11 mEq/l indicates that there are
approximately 6–7 mEq/l of unmeasured anions, which
of course could be due to lactate. The lactate was
indeed measured. It was 6.3 mmol/l. This man had
iatrogenic hyperchloremic acidosis, iatrogenic
hypoalbuminemic alkalosis, a mild hyperkalemic
alkalosis, a mild respiratory acidosis, and a moderate
lactic acidosis. No obvious cause for his lactic acidosis
was found. Epinephrine was suspected as being
responsible for it. His epinephrine was changed to
milrinone. Within 6 hours his lactate level was down
to 2.3 mmol/l and his cardiac index was preserved at
2.4 l/m2/minute.
47
CHAPTER
5 MetabolicDerangementsCARLOS J. LOPEZ III, M.D.JUDIT SZOLNOKI, M.D.
Sodium Derangements
Hyponatremia
Hypernatremia
Potassium Derangements
Hypokalemia
Hyperkalemia
Calcium Derangements
Hypocalcemia
Hypercalcemia
Magnesium Derangements
Hypomagnesemia
Hypermagnesemia
Phosphorus
Hypophosphatemia
Hyperphosphatemia
Thermal Derangements
Hyperthermia
Heat Stroke
Drug-Induced Hyperthermias
Malignant Hyperthermia
Neuroleptic Malignant Syndrome
Serotonin Syndrome
Sympathomimetic Poisoning Syndrome
Anticholinergic Syndrome
Hypothermia
Perioperative Hypothermia
Summary
Metabolic derangements can present with mild 
alterations in signs and symptoms or as life-threatening 
situations. Rapid recognition and understanding of the
physiology involved allows a more directed approach to
their management. In this chapter we review some com-
mon abnormalities in electrolyte homeostasis and briefly
explore derangements in temperature regulation.
SODIUM DERANGEMENTS
Hyponatremia
Hyponatremia is defined as a [Na+] < 135 mEq/l.
Symptoms and signs are a factor of sodium concentra-
tion and rapidity of onset. They typically begin to occur
at levels <130 mEq/l, primarily with neurologic symp-
toms such as headache, lethargy, and confusion. The
more severe symptoms such as stupor, seizures, and
coma generally do not occur until [Na+] < 120 mEq/l.
The biggest danger is the brain edema that occurs from
movement of water from the extracellular fluid (ECF) to
the intracellular fluid (ICF) compartments. The rapidity
at which hyponatremia occurs will also play a role in
development of the clinical picture. Patients with
chronic hyponatremia will often be asymptomatic in
spite of having remarkably low levels. There are dangers
to an overly rapid correction of hyponatremia.
Approaches to treating the hyponatremic patient must
be tempered by the level, associated symptoms, and
chronicity.
Causes of hyponatremia can be described by the osmo-
lality of the ECF. The osmolality is the solute or particle
concentration of a fluid. Box 5-1 presents the osmolality
calculation for plasma.
The differential diagnosis includes (1) hypo-osmolar
hyponatremia, (2) normo-osmolar hyponatremia, and
(3) hyperosmolar hyponatremia.
Hypo-osmolar hyponatremia is the most common.
In general it is caused by either sodium loss or primary
water gain. Because the ECF volume reflects total body
sodium, the volume status of the patient is used
to further subdivide hypo-osmolar hyponatremia into
decreased, normal, and increased ECF volume.
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Decreased ECF volume is due to renal or extrarenal
losses of sodium such as sodium wasting nephropathies,
hypoaldosteronism, diuretics, and vomiting. These
losses are often replaced with hypotonic fluids. The
decreased arterial volume can also contribute by stimu-
lating thirst and vasopressin release and impairing the
ability of the kidneys to excrete a dilute urine. Diuretics
and vomiting can also result in a large potassium loss
which through transcellular ion exchange causes further
hyponatremia. A UNa+ > 20 mmol/l in the face of a
hyponatremic, hypovolemic state suggests a renal cause,
while UNa+ < 10 mmol/l is consistent with extrarenal
losses.
Normal ECF volume can present with SIADH which 
is the most common cause of normovolemic hypo-
natremia. It is associated with an impaired excretion of
renal free water due to nonphysiologic release of antidi-
uretic hormone (ADH) or vasopressin. Malignant tumors,
pulmonary diseases, central nervous system (CNS) dis-
orders, and drugs are causes of SIADH. It is characterized
by (1) hypo-osmotic, hyponatremia, (2) euvolemia,
(3) no renal, adrenal thyroid dysfunction, or diuretic
use, (4) UNa+ > 20 mmol/l, and (5) a less than maximally
dilute urine UOSM > 300 mOsm/l. These patients are
treated with water restriction, democycline, and treat-
ment of underlying disorders. Other causes not related
to SIADH are glucocorticoid deficiency, hypothyroidism,
chronic renal failure, drugs, and primary polydipsia.
Increased ECF volume tends to have an increased
total body sodium, but there is a much larger increase in
total body water. It is usually a consequence of condi-
tions associated with edema, congestive heart failure
(CHF), cirrhosis, nephrotic syndrome, and acute renal
failure. These conditions result in a decrease in arterial
blood volume, which leads to increased thirst and vaso-
pressin levels. Diagnosis is made by a UNa+ ≤ 20 mmol/l
for CHF and cirrhosis, and UNa+ > 20 mmol/l for acute
renal failure.
Normo-osmolar hyponatremia is commonly due
to a pseudohyponatremia resulting from hyperlipidemia
and hyperproteinemia. Plasma is composed of water and
nonaqueous plasma proteins and lipid. If proteins or
lipids are elevated, the sodium concentration measured
is less than its true concentration. These patients have
both a normal plasma sodium and plasma osmolality.
Elevations in solutes other than sodium, like glucose and
mannitol, can also result in a similar picture.
Hyperosmolar hyponatremia is usually due to
increases in nonsodium solutes that remain mostly in the
ECF. Hyperglycemia and mannitol use are common
causes of this condition. The sodium in hyperglycemia is
corrected by adding 1.6 mmol/l to the sodium for every
100 mg/dl rise in glucose. Other solutes such as ethanol,
methanol, and ethylene glycol which occur from intoxi-
cations may also be implicated.
Treatment of hyponatremia depends on the sodium
concentration, symptoms, and the ECF volume status.
Mild asymptomatic hyponatremia requires no treatment.
Patients with underlying chronic hyponatremia that
have mild symptoms are treated gently with the goal of
returning sodium levels to 125 mEq/l. Those patients
with stupor, seizures, and coma, however, are treated
aggressively with 3% NS in order to reach a sodium goal
of 125–130 mEq/l. This must not be done too rapidly
because of the risk of an osmotic demyelination syn-
drome called central pontine demyelination (CPM).
These patients may develop flaccid paralysis, dysarthria,
and dysphagia. The diagnosis is confirmed by magnetic
resonance imaging (MRI). To avoid this one does not
correct sodium at greater than 0.5 mEq/l/hour and one
corrects to a sodium of 125–130 mEq/l. Mild sympto-
matic hyponatremia is treated with NS and occasionally
3% NS, while avoiding too rapid a correction. Patients
with normal ECF volume may have pseudohyponatremia
and not require treatment. Those with mild symptoms
are treated with furosemide diuresis or isotonic saline.
CLINICAL CAVEAT
Hyponatremia
Hypo-osmolar: most common – sodium loss or primary
water gain
● Decreased ECF – nephropathies, hypoaldosteronism,
diuretics, and vomiting
● Normal ECF – SIADH, steroids, hypothyroidism,
CRF, drugs, and primary polydipsia
● Increased ECF – CHF, cirrhosis, nephritic syndrome,
and ARF
Normo-osmolar: most commonly pseudohyponatremia
● Hyperlipidemia and hyperproteinemia
Hyperosmolar: excess nonsodium solutes
● Hyperglycemia and mannitol
Box 5-1 Calculation of Osmolality
Osmolality = 2[Na+] + glucose/18 + BUN/2.8, where normal = 282 − 292 mOsm/KG.
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In patients with increased ECF volume, fluid restriction
and hypertonic saline are useful. Fluid restriction is 
particularly useful in patients with SIADH, renal failure,
or primary polydipsia.
Hypernatremia
Hypernatremia is defined as a [Na+] > 145 mEq/l.
Symptoms and signs are typically seen with levels > 150
mEq/l. Neurologically these patients may present at first
with neuromuscular irritability, ataxia, lethargy and
progress to confusion, coma, and seizures as the sodium
approaches 180 mEq/l. They may complain of increased
thirst and have evidence of hypovolemia. They may have
evidence of decreased urinary concentrating ability,
renal insufficiency, and occasionally progress to acute
renal failure.
Hypernatremia is typically caused by either a water
loss or a primary sodium gain. Hypernatremia due to
water losses is due to either renal or nonrenal causes.
Renal losses are the most common and are either from
diabetes insipidus or osmotic diuresis. Nonrenal losses
are from the gastrointestinal (GI) tract and from insensi-
ble losses. Hypernatremia due to sodium gain occurs
much less frequently. Hypertonic saline, sodium bicar-
bonate, and iatrogenic causes of sodium administration
account for the majority of these patients. Less com-
monly hypernatremia can occur because of a decreased
ability to take in PO fluids. Infants, patients with an
altered mental status, and intubated patients may
develop hypernatremia.
The treatment of hypernatremia requires the assess-
ment of water deficit and ECF volume status. Box 5-2
presents the calculation for water deficit. Although use-
ful in initiating therapy, this assessment tends to under-
estimate the free water loss in those patients with
hypotonic fluid losses. Half the deficit is replaced over
the first 24 hours and the remainder over the next 24–48
hours. Overly rapid correction of [Na+], however, can
result in seizures, coma, and brain edema. Therefore a
reasonable goal should be to limit the decline in [Na+] to
1–2 mEq/l/hour.
The specific therapy will depend on ECF volume 
status. Hypovolemic patients should be treated first with
volume resuscitation using NS. The hypernatremia can
subsequently be corrected with hypotonic fluid admin-
istration either PO or intravenously. Euvolemic patients
are treated with hypotonic fluids to replace water
deficits. This group also includes those with DI. Specific
treatment using DDAVP along with water deficit replace-
ment is used for central DI. In nephrogenic DI the 
concentrating defect may be reversed by removing the
offending drug, restricting sodium and water intake, and
administering thiazides. This strategy results in increased
fluid reabsorption in the proximal tubules by decreasing
ECF volume. Hypervolemic patients are sodium over-
loaded. They respond to increasing sodium excretion
with loop diuretics and replacement of water deficit
with hypotonic fluids.
POTASSIUM DERANGEMENTS
Potassium is the major intracellular cation. While 
normal plasma potassium is 3.5–5.0 mEq/l, normal intra-
cellular concentration is 150 mEq/l. The concentration
gradient between ICF and ECF is kept fairly constant.
Since the ICF volume is much greater than ECF volume,
the vast majority of potassium stores are intracellular.
Therefore plasma potassium is a poor indicator of total
potassium stores. Potassium concentrations are main-
tained by the Na-K-ATPase pump, which actively trans-
ports potassium into the cell and sodium out of the cell.
It is the quantitative passive diffusion of potassium out of
the cell that helps establish a resting membrane poten-
tial and generates action potentials. Therefore keeping
potassium concentrations within normal range is impor-
tant for the proper functioning of skeletal and smooth
muscle, and for CNS function.
Hypokalemia
Symptoms and signs include myalgias, fatigue, ileus,
constipation, and weakness which can progress to paralysis
in severe cases. EKG changes with T-wave flattening,
Box 5-2 Calculation of Free Water Deficit
Free water deficit (liters) = (TBW) × [(plasma [Na+] − 140)/140], where TBW = 0.6 × BW in kilograms.
CLINICAL CAVEAT
Potassium
● An intracellular cation – serum levels do not reflect
stores
● Requires repeated dosing to correct low levels
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U waves, ST-segment depression; and cardiac arrhyth-
mias such as APCs, PVCs, ventricular tachycardia, and
ventricular fibrillation can occur. Severe hypokalemia can
also result in decreased renal concentrating activity with
polyuria and development of alkalosis.
Hypokalemia results from either a shift of potassium
into the cells or by potassium depletion. The shifts can
occur due to the increased activity of Na-K-ATPase pump
by β-agonists, insulin, carbohydrate loading, or by alkalo-
sis which causes a potassium–hydrogen exchange across
the cellular membrane. Potassium depletion is due pre-
dominantly to renal losses but extrarenal losses can
occur. Renal losses have UK+ > 30 mEq/l. They can be cat-
egorized on the basis of their acid–base status. They can
have a serum bicarbonate less than 24 mEq/l such as in
patients with renal tubular acidosis type I (distal) and
type II (proximal). Others with metabolic acidosis
include patients with diarrhea, chronic laxative abuse,
and diabetic ketoacidosis (DKA). Patients with serum
bicarbonate greater than 24 mEq/l can be differentiated
by their urine [Cl+] levels. For those with [Cl+] > 10 mEq/l
the etiology may be due to diuretics, hyperaldosteronism,
steroids, and low magnesium levels. Cases with [Cl+]
< 10 mEq/l are caused by vomiting, nasogastric suction-
ing, and hyperventilation. Extrarenal causes of potassium
depletion include diarrhea, villous adenoma, vasoactive
intestinal peptide tumors, chronic laxative abuse, and
profuse sweating. Inadequate intake of potassium by
itself is rarely a cause of hypokalemia because the kidneys
can effectively reduce potassium excretion.
The treatment depends on the potassium level and
the clinical picture. Although a serum potassium level
greater than 3.5 mEq/l is considered normal, one aims
for a level of 4.0 mEq/l in the critically ill patient. A [K+]
of 3.0 mEq/l in a patient with a normal acid–base status
correlates with a 200–400 mEq deficit. For nonlife-
threatening hypokalemia oral KCl is given at 10–40 mEq
PO qd to bid depending on the level. In patients who are
critically ill or who are not eating, KCl IV at 10 mEq/l
peripherally or 20 mEq/l centrally is administered at a
rate no more than 10–20 mEq/hour to avoid hyper-
kalemic complications. If more rapid replacement is
required because of very low plasma levels and signs of
hypokalemia, continuous EKG monitoring and frequent
[K+] checks should be used. One should avoid glucose-
containing solutions, insulin, β-agonists, and other agents
that may shift potassium intracellularly. The underlying
cause of hypokalemia should be diagnosed and treated.
Potassium-sparing diuretics should be considered for
those with continuing losses.
Hyperkalemia
Hyperkalemia is typically defined as a [K+] > 5.0 mEq/l,
although patients are generally asymptomatic at
[K+] < 6.0 mEq/l. EKG changes and cardiac arrhythmias
account for the most severe presentations. When the
plasma potassium is above 6.0 mEq/l the patient’s EKG
begins to show tall narrow T waves, blunted P waves,
prolonged PR intervals, which progress until the P wave
disappears and eventually QRS widening and cardiac
asystole. Neuromuscular symptoms and signs can occur
at plasma levels of [K+] around 7.0 mEq/l, with proximal
muscle weakness, flaccid paralysis, and even respiratory
failure occurring in severe cases.
Hyperkalemia can result from pseudohyperkalemia
due to hemolysis during venipuncture, prolonged
tourniquet use, and marked leukocytosis. Hyperkalemia
can also occur due to redistribution of potassium from
ICF to ECF and increased total body potassium stores.
Redistribution of potassium is seen in acidosis, hypo-
insulinemia, and digoxin toxicity. Destruction of cellular
membranes due to rhabdomyolysis and hemolysis also
results in the release of potassium into the ECF. Reduced
renal excretion and exogenous administration account
for the rest of the causes. Reduced renal excretion occurs
in severe renal failure with a GFR less than 10 ml/min,
adrenal insufficiency, potassium-sparing diuretics,
angiotensin-converting enzyme (ACE) inhibitors, and
nonsteroidal anti-inflammatory drugs (NSAIDs). These
patients have a reduced urine [K+] < 30 mEq/l.
Exogenous causes include diets rich in potassium, iatro-
genic administration and blood transfusions. These
patients have urine [K+] > 30 mEq/l.
Treatment depends on the level. Removal of all
exogenous causes is the first step in mild hyperkalemia.
Kayexelate (polystyrene sulfonate), a cation-exchange
resin, removes potassium through the GI tract and is
given as 30 g in 100 cm3 20% sorbitol every 3 to 4 hours
orally or 50 g in 200 cm3 20% sorbitol as a retention
enema. Lasix by enhancing renal excretion is also useful.
Life-threatening cases, however, require more aggressive
therapy. Treatment to minimize membrane repolariza-
tion, to decrease quickly plasma potassium levels, and to
decrease total body stores needs to be instituted. Calcium
gluconate 10% at 10 cm3 over 3 minutes is given to antag-
onize membrane hyperexcitability. Glucose as 50 cm3
D50 and regular insulin at 10 units is given to promote
an intracellular shift of potassium. This effect lasts
approximately 15 to 30 minutes and can be repeated.
DRUG INTERACTIONS
Exogenous Potassium
● Examine closely medication list for exogenous
sources of potassium
● Do not forget diet as a contributor
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Sodium bicarbonate by alkalinizing the plasma will also
cause a transcellular shift and is given either as one
50 cm3 ampule over 5 minutes and repeated in 10 minutes
as needed, or as a drip by placing 3 ampules in 1 liter of
D5W. Patients with chronic renal failure respond poorly
to this intervention. Nebulized albuterol at 2.5 mg can
also be used and lasts approximately 2 to 4 hours. Care
in patients with tachycardia needs to be observed.
Decrease in potassium stores, however, does not occur
unless kayexelate and lasix are used. Hemodialysis
which removes 70–150mEq of potassium is usually
reserved for very severe cases which are complicated by
unresponsiveness to treatment, volume overload, and
acidosis.
CALCIUM DERANGEMENTS
Normal total serum calcium in plasma is 8.5–
10.2 mg/dl, while normal ionized calcium is 4.8–7.2 mg/dl
or 1.1–1.3 mmol/l. Ionized calcium is the physiologically
active form of calcium. The total serum calcium as com-
monly measured is not. Therefore ionized calcium should
be measured instead. Total serum calcium is dependent
on albumin level, acid–base status, and chelators. A low
total serum calcium, which commonly occurs in critically
ill patients due to a low albumin, is generally associated
with a normal ionized calcium level. These patients may
not truly be hypocalcemic. If ionized calcium cannot be
measured, the total serum calcium is often adjusted
upward by 0.8 mg/dl for every 1 mg/dl decrease in albu-
min below 4.0 mg/dl. Calcium is responsible for normal
neuromuscular function and bone formation. Alterations
in calcium levels will affect normal muscle, cardiac, res-
piratory, neurologic, and psychiatric function.
Hypocalcemia
Manifestations of hypocalcemia include neuromuscular
excitability such as paresthesia, cramps, hyperreflexia,
spasms, tetany, and Chvostek’s and Trousseau’s signs;
cardiovascular signs such as peripheral vasodilatation,
hypotension, ventricular tachycardia, and prolonged QT
interval; respiratory signs including laryngospasm and
apnea; and psychiatric presentations with anxiety, irri-
tability, and depression.
The causes of hypocalcemia are varied. Decreased
parathyroid hormone (PTH) secretion due to hypoparathy-
roidism, hypomagnesemia, hypermagnesemia, or surgi-
cal damage can result in hypocalcemia. Hypocalcemia
will occur 24–36 hours postoperatively following sur-
gery on the parathyroid glands and on the thyroid gland
if all four parathyroid glands are removed. Alkalosis
which results in increased calcium binding to albumin
can cause a precipitous fall in plasma calcium. Massive
blood transfusions, especially in patients with hepatic
and renal failure where citrate clearance is reduced, can
develop hemodynamically significant hypocalcemia due
to the chelation effect of citrate. Other causes include
reduced intestinal absorption of calcium from vitamin D
deficiency, renal insufficiency, hyperphosphatemia, and
liver disease; drugs such as lasix and aminoglycosides;
sepsis; and pancreatitis.
Aggressive treatment should be limited to ionized
calcium levels below 0.8 mmol/l or to symptomatic
patients. Replacement should be initiated with 1 amp IV
calcium chloride and continued with an IV infusion to
keep the level between 0.8 and 1.0 mmol/l. A drip at
1 mg/kg/hour can be used to keep levels replaced as cal-
cium diffuses into tissues and is eliminated in the urine.
Special attention needs to be given to certain conditions.
For instance rhabdomyolysis and tumor lysis syndrome
can result in a hyperphosphatemic hypocalcemia.
Treating these patients with calcium may cause calcium
precipitation, which can lead to organ injury. These
patients are treated by lowering phosphorus levels. This
can be accomplished with phosphorus binders, dialysis,
and diuresis. Severe hypomagnesemia can inhibit PTH
production and action. Replacement of magnesium gen-
erally corrects the ionized calcium level by stimulating
PTH secretion.
Hypercalcemia
The signs and symptoms of hypercalcemia are often
described by the constellation of symptoms referred to
as “bones, stones, psychic moans, and abdominal groans.”
The symptoms and signs include weakness, hypotonia,
CLINICAL CAVEAT
Calcium
● Ionized calcium is a more accurate measure of
calcium homeostasis
● Ionized calcium is the physiologically active form of
calcium
● Ionized calcium is affected by albumin level,
acid–base status, and chelators
DRUG INTERACTIONS
Calcium
● Rhabdomyolysis and tumor lysis syndrome can
result in hyperphosphatemic hypocalcemia
● Treatment with calcium may cause calcium
precipitation with organ injury
● Treat by lowering phosphorus with phosphorus
binders, dialysis, and diuresis
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hyporeflexia, and seizures; confusion, psychosis, and
coma; anorexia, vomiting, and constipation; polyuria
and nephrocalcinosis; fractures, osteopenia, and ectopic
calcification; hypovolemia and hypotension; and QT
shortening, cardiac arrhythmias, and heart block. Causes
of hypercalcemia include primary hyperparathyroidism,
the most common cause in outpatient setting. However,
malignancies such as squamous cell cancer of the lung,
head and neck tumors, metastatic disease from breast
cancer, multiple myeloma, and lymphoma are the most
common in hospitalized patients. Other etiologies
include sarcoidosis, hyperthyroidism, immobilization,
thiazide diuretics, aluminum intoxification in renal fail-
ure patients, and vitamin A and D intoxication.
Hypercalcemia is defined as a [Ca+] > 1.3 mmol/l, or
serum calcium level > 10.5 mg/dl. Patients are asympto-
matic or with mild symptoms until the serum calcium
levels are above 11.5 mg/dl. Moderate symptoms then
occur with the more severe presentations occurring at
levels of greater than 13 mg/dl. Management requires
efforts to lower directly the calcium and treatment of 
the underlying disease. Drugs that may elevate calcium
levels are removed. Normal saline at 250–500 cm3/hour
is given to correct volume depletion, dilute the ionized
calcium, and inhibit calcium reabsorption by increasing
sodium excretion by the kidneys. After volume replace-
ment is complete, a loop diuretic such as furosemide
40–100 mg IV every 2 hours is given to further enhance
calcium excretion. Calcitonin, 4–8 IU/kg IM or SC q12
hours × 2, inhibits bone resorption and increases calcium
excretion. It is most effective in patients with increased
bone resorption. It begins to lower calcium within 2 hours,
with a peak effect at 6 to 10 hours. Due to tachyphylaxis
it lasts only a few days. An added benefit appears to be
its potent analgesic activity in patients with bone metas-
tasis. It is associated with allergic reactions and skin test-
ing should be done before its use. Pamidronate, a
biphosphonate, is used at 60 mg IV over 4 hours for mild
cases of hypercalcemia and 90 mg IV over 24 hours
for severe cases. Bone resorption is decreased because
of its inhibitory effect on osteoclasts. Another biphos-
phonate, etidronate disodium, 7.5 mg/kg over 4 hours
for 3–7 days, is also useful. Its use is limited because of
diarrhea and nephrotoxicity. Mithramycin (Plicamycin),
25 μg/kg over 6 hours, is a cytotoxic agent that inhibits
bone resorption. Due to its side effects of thrombo-
cytopenia, coagulopathy, and hepatic and renal failure it
is rarely used.
Hydrocortisone, 200–300 mg qd for 3 days, lowers
plasma calcium by lowering cytokine release, inhibiting
intestinal reabsorption, and increasing urinary calcium
excretion. It is particularly effective in patients with lym-
phatic malignancies, multiple myeloma, granulomas, and
vitamin D intoxication. Hyperparathyroidism and other
tumors causing metastasis rarely respond. Phosphorus
administration with Neutraphos at 0.5–1.0 g bid to qid
may be useful because it inhibits calcium absorption and
increases calcium deposition in bone. Use should be lim-
ited to patients with low phosphate levels because of the
potential for soft tissue calcification. Dialysis can be
done as a last resort prior to surgery. In patients with
hyperparathyroidism due to an adenoma or hyperplastic
thyroid tissue surgical removal is undertaken. Malignancies
may require chemotherapy, radiation therapy, and surgery.
MAGNESIUM DERANGEMENTS
Magnesium is important for neuromuscular function,
cardiac conduction, and many metabolic pathways. The
physiologically active form of magnesium is ionized and
normal levels are generally expressed as 1.6–2.6 mEq/l.
In the critically ill patient, however, the goal for
replacement is 2.0 mEq/l. Only 1% of total magnesium
stores are in the ECF, the majority is in bone, muscles,
and cells. Serum magnesium levels are therefore a poor
reflection of total body stores.
Hypomagnesemia
Hypomagnesemia can present with neurologic mani-
festations such as parathesias, fasciculations, spasms,
tetany, hyperreflexia, and seizures; cardiac signs such as
APCs, PVCs, prolonged PR and QT intervals, atrial fibril-
lation, SVTs, and ventricular arrhythmias including 
torsades de pointes; CNS symptoms such as confusion,
ataxia, and coma; and metabolic abnormalities such 
as refractory hypokalemia and hypocalcemia. Digoxin
toxicity is exacerbated by hypomagnesemia.
CLINICAL CAVEAT
Hypercalcemia
● “Bones, stones, psychic moans, and abdominal
groans”
● Hyperparathyroidism most common cause in
outpatient setting
● Malignancies most common cause in hospitalized
patients
CLINICAL CAVEAT
Magnesium
● Serum magnesium is a poor indicator of total body
stores
● Optimal level in critically ill patients is 2.0 mEq/l
● Check [Mg+] and [K+] in the critically ill patient with
arrhythmias
● Consider digoxin toxicity with arrhythmias
Etiologies are decreased intestinal absorption or
increased renal excretion. Malabsorption, malnutrition,
alcoholism, diarrhea, and gastric aspiration are common
for decreased absorption. Renal losses result from
osmotic diuresis, hypercalcemia, aminoglycosides,
amphotericin B, and cyclosporin.
Treatment depends on the level and clinical signs.
Because magnesium is essentially only eliminated by the
kidneys, replacement in patients with renal insufficiency
is done carefully. Chronic or mild hypomagnesemia is
treated with magnesium oxide, 400 mg PO qid to bid.
Magnesium sulfate IV is used in critically ill patients with
symptoms or low levels. One gram of magnesium sulfate
is approximately 4 mmol or 8.0 mEq of elemental mag-
nesium. Generally 2 g are given over 1 hour and repeated
several times depending on the level. Severe hypomag-
nesemia with serum levels less than 1.0 mEq/l can be
treated with magnesium sulfate, 2 g IV over 30 minutes,
followed by 6 g in 250 cm3 NS over 6 hours. In life-
threatening hypomagnesemia with seizures and arrhyth-
mias, 2 g IV over 2 minutes is given, and followed with
6 g in 250 cm3 NS infused over 3 hours. These patients
will require further aggressive replacement over the
next several days due to the large body deficits.
Hypermagnesemia
The manifestations of hypermagnesemia occur when
serum magnesium is greater than 4 mEq/l. Neurologic
and cardiac dysfunction predominates. Weakness, lethargy,
and paralysis can occur, with progressive areflexia often
present as the magnesium concentration increases.
Cardiac signs include hypotension, bradycardia, pro-
longed PR, QRS, and QT, complete heart block, and
asystole. The loss of tendon reflexes occurs as the 
level approaches 6 mEq/l, with respiratory paralysis at
12–15 mEq/l, then cardiac block and subsequently car-
diac arrest at levels above 15 mEq/l.
The causes are few, because any excess magnesium is
rapidly excreted by the kidneys. Acute renal insuffi-
ciency or renal failure especially when combined with
magnesium-containing antacids, laxatives, and IV mag-
nesium is the most common cause of hypermagnesemia.
It can occur with the large amounts of exogenous mag-
nesium used in patients with pre-eclampsia and eclamp-
sia. Patients with rhabdomyolysis and hemolysis can also
develop hypermagnesemia.
Treatment involves eliminating exogenous adminis-
tration, antagonizing the chemical–electrical effects, and
removing magnesium from the body. Calcium gluconate
10%, 10–20 cm3 IV (1–2 g) over 10 minutes, temporarily
antagonizes the effects. If renal function is not impaired
severely and the patient makes urine, excretion of
magnesium can be enhanced by providing 2 g of calcium
gluconate 10% in 1 liter NS at 150–200 cm3/hour.
Elimination of magnesium may require hemodialysis in
patients with acute renal failure. Supportive care with
mechanical ventilation or temporary pacemaker may be
needed.
PHOSPHORUS
Phosphorus is important for cellular energy metabo-
lism, the maintenance of acid–base balance, and bone
formation. It is difficult to assess exactly the ion concen-
tration and so it is measured in mg/dl with a normal
range of 2.5–4.5 mg/dl. Bone accounts for 85% of total
body stores, followed by cells with 14% and ECF at 1%.
Serum phosphorus levels like potassium and magnesium
are poor indicators of total deficit.
Hypophosphatemia
Symptoms and signs do not usually present unless 
the level is less than 1.0 mg/dl. There can be muscular,
respiratory, cardiac, neurologic, hematologic, and bone
involvement. Patients may complain of weakness;
develop impaired diaphragmatic function, and respiratory
and cardiac failure; progress to rhabdomyolysis; manifest
confusion, stupor, and seizures; show hemolysis and
thrombocytopenia; and develop osteomalacia and rickets.
Hypophosphatemia results from decreased intestinal
absorption, increased urinary excretion, and redistribu-
tion into the intracellular space. Decreased absorption
is seen in malabsorption, malnutrition, starvation, and
administration of phosphate binders. Increased urinary
excretion can result from hyperparathyroidism, diuretics,
polyuric phase of ATN, postobstructive diuresis, DKA,
RTAs, and renal transplantation. Redistribution occurs
with glucose, insulin, β-agonists, respiratory alkalosis,
alcohol withdrawal, and recovery phase of starvation.
Patients with aggressive overfeeding poststarvation, alco-
hol abuse and withdrawal, hyperalimentation, DKA, and
burns are at high risk for very low phosphate levels of
less than 1.0 mg/dl.
Treatment depends on the level and clinical picture.
Mild hypophosphatemia, in healthy patients tolerating
PO, can be replaced with Neutraphos, 250–500 mg PO
q 6 hours. In moderate hypophosphatemia, 1.0–2.0 mg/dl,
elemental phosphate 0.08–0.16 mmol/kg in 100 NS IV
over 6 hours can be used safely. Elemental phosphate
comes as potassium phosphate which contains 3 mmol
PO4 with 4.4 mEq potassium per cm3, and sodium phos-
phate which is 3 mmol PO4 with 4 mEq sodium per cm3.
Severe hypophosphatemia is treated aggressively with
elemental phosphate, 0.16–0.25 mmol/kg over 4–8 hours.
Continued phosphate replacement will be required for
several days due to depleted phosphate stores. Hypo-
magnesemia and hypokalemia often occur concurrently
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and must be addressed. Extreme care should be taken in
treating patients with DKA, as the level often improves
significantly with treatment of acidosis.
Hyperphosphatemia
Patients are generally asymptomatic until the level is
>5.0 mg/dl. The clinical picture is due to hypocalcemia
and ectopic calcification. Ectopic calcification occurs as
the calcium × phosphorus product goes over 60. Heart
block is a life-threatening complication for which one
should monitor.
A common etiology is renal failure, but it also occurs
due to cellular damage caused by trauma, acidosis, 
rhabdomyolysis, and tumor lysis syndrome. Hypopara-
thyroidism and exogenous phosphate syndrome are also
frequently implicated as causes of hyperphosphatemia.
Management requires eliminating the cause; restrict-
ing dietary phosphate; increasing urinary excretion with
normal saline and acetazolamide, 500 mg q 6 hours; and
increasing GI losses with phosphate binders such as alu-
minum hydroxide, 30–45 cm3 q 6 hours. Patients with
renal failure or ectopic calcification will benefit from
dialysis. Associated hypocalcemia may also need to be
treated, but care must be taken to keep the calcium ×
phosphorus product less than 60.
THERMAL DERANGEMENTS
Maintaining a normal body temperature despite 
environmental variations creates a stable milieu for the
hundreds of heat-sensitive enzymes to function and to
maintain homeostasis within normal ranges. There exists
a 24-hour circadian temperature rhythm with a morning
nadir and an afternoon peak that can be as much as
0.5–1°C. In ovulating women there is an additional
increase in the baseline body temperature of approxi-
mately 0.5°C in the second half of the menstruating
cycle. Other physiologic states that can affect baseline
temperatures are postprandial state, pregnancy, and age.
HYPERTHERMIA
Hyperthermia describes the state when body temper-
ature is above normal. Normothermia is generally
accepted to exist between 36 and 37.5°C measured at
the body surface. When an elevated body temperature
exists because of a change that occurs in the thermoreg-
ulatory center at the anterior hypothalamus we talk about
fever. Substances that cause fever are called pyrogens.
Pyrogens can be further divided to endogenous and
exogenous pyrogens.
When the elevation in the body temperature occurs
without alteration in the hypothalamic set point we talk
about hyperthermia. In this case the underlying process
is either excessive heat production or inadequate heat
dissipation or both. Hyperthermic syndromes include
heat stroke and endocrinopathies, which are described
elsewhere, and the drug-induced hyperthermias. The
drug-induced hyperthermias are malignant hyperther-
mia, neuroleptic malignant syndrome, serotonin syn-
drome, sympathomimetic poisoning syndrome, and
anticholinergic syndrome.
Heat Stroke
Heat stroke is an acute breakdown of the body’s ther-
moregulatory mechanism in warm environments result-
ing in severe hyperthermia with core temperatures
>40°C. There are actually two forms of heat stroke.
Exertional heat stroke occurs typically in young individ-
uals who engage in strenuous physical activity for a 
prolonged period in a hot environment, while classic
nonexertional heat stroke occurs in sedentary elderly
individuals, in persons who are chronically ill, and in the
very young. This latter form is more prevalent during
environmental heat waves. Both types are associated
with high morbidity and mortality especially when diag-
nosis is delayed.
Increased heat production, impaired heat loss, and
decreased ability to sweat effectively are important in
the pathogenesis of the syndrome. High-risk groups include
the elderly, patients with schizophrenia, Parkinson’s dis-
ease, alcoholics, and paraplegics and quadriplegics. The
pathophysiology involves muscle degeneration and
necrosis resulting in rhabdomyolysis; increased cardiac
output, with decreased systemic vascular resistance;
direct thermal injury to brain and spinal cord resulting in
edema and hemorrhage; acute renal failure due to dehy-
dration and myoglobinuria; hepatic necrosis leading to
death; coagulopathy; and multiple electrolyte abnormal-
ities. The diagnostic criteria include a compatible 
history, core temperature >40°C, anhidrosis, elevated
creatine kinase level, and depressed mental status.
Treatment with aggressive cooling is initiated by
using evaporative cooling techniques such as wetting
skin, cool water spray, and electric fans; direct careful
external cooling by ice packs or cold water immer-
sion; and occasionally when very severe hyperthermia
is present by performing gastric lavage or peritoneal
lavage with iced saline, or even hemodialysis. Aggressive
hemodynamic monitoring and supportive care is insti-
tuted in an intensive care unit (ICU). Hypotension is
common and is treated with warm IV fluids initially.
Dopaminergic and alpha agents should be avoided
because they may enhance vasoconstriction and instead
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isoproterenol should be used if needed. Seizures are
common and are treated with benzodiazepines. Liver
failure and DIC may occur and are poor prognosticators.
DRUG-INDUCED HYPERTHERMIAS
Malignant Hyperthermia
Malignant hyperthermia (MH) is a life-threatening
emergency with very high mortality rate if left undiag-
nosed. It has an autosomal dominant hereditary basis
with reduced penetrance. Its prevalence is estimated to
be 1 in 15,000 children and 1 in 50,000–100,000 adults
treated with anesthetics. The suspected derangement is
related to abnormal ryanodine receptors on the T tubules
of the striated muscles. To date more than 20 different
mutations of the ryanodine receptor have been reported
worldwide.
In individuals susceptible to develop MH an increased
and exaggerated calcium response exists to volatile 
anesthetics and succinylcholine (triggering agents)
which leads to increased muscle metabolism, rigidity,
rhabdomyolysis, hyperthermia, and metabolic and respi-
ratory acidosis, and eventually cardiovascular collapse
develops rapidly if prompt treatment is delayed. This
abnormal metabolic response does not necessarily occur
after each exposure to the triggering agents.
Although the syndrome’s name carries the hyperther-
mia term, the elevated body temperature tends to be a
relatively late sign preceded by increased carbon dioxide
production and tachycardia. Prevention is based upon
previous anesthetic and family history, but one needs to
keep in mind that negative history for both of those does
not exclude the future possibility of an MH event. The
gold standard treatment consists of immediate cessation
of any triggering agent still in use, hyperventilation with
100% oxygen, intravenous Dantrolene sodium, and
intense supportive measures. Dantrolene is given at
2.5 mg/kg IV bolus q15 minutes up to a total dose of
10 mg/kg. A maintenance dose is continued at 1–2 mg/kg
PO for 3 days. Intense supportive measures include close
hemodynamic and acid–base balance monitoring,
mechanical ventilation to correct respiratory acidosis,
forced diuresis with alkalinization of the urine to prevent
renal damage secondary to myoglobinuria, and cooling
the patient. Getting in contact with the North American
MH Group and the MH Association of the US provides
not only up-to-date information for the practitioner but
supplies data for these organizations for epidemiologic
purposes. Definitive diagnosis of MH can be established
on the results of caffeine-halothane contracture testing
of fresh muscle biopsy samples taken from the sus-
pected individual.
Neuroleptic Malignant Syndrome
Neuroleptic malignant syndrome (NMS) is a poten-
tially life-threatening idiosyncratic reaction, resulting
from the blockade of central dopamine receptors.
Although the blockade may cause a disruption of the
thermoregulatory role of the hypothalamus, it is the
generalized muscle activity and rigidity that are thought
to be the main contributors to the hyperthermia.
Antipsychotic agents, especially Haldol, are generally
implicated. A history of rapid upward titration or depot
preparations is common. Other associated predisposing
factors are a prior episode of NMS, organic brain syn-
drome, psychomotor agitation, and dehydration.
Although there are no widely accepted criteria for
diagnosing NMS, there is a characteristic presentation.
Most patients present within 30 days of initiating ther-
apy. The initial presentation is of a psychiatric patient
with an altered mental status, who is found to have fever
and muscle rigidity. The constellation of signs and symp-
toms typically develop over 24 to 72 hours. Hyperthermia
which is not universal can range between 38 and 42°C.
Patients develop a generalized “lead-pipe” muscle rigid-
ity which may result in involvement of the chest wall
muscles. Motor abnormalities that are typical of parkin-
sonian-type extrapyradimal reactions occur. Autonomic
instability with hypotension, hypertension, diaphoresis,
CURRENT CONTROVERSY
Cooling Blankets
Traditionally cooling is initiated with cooling
blankets; however, aside from inefficiency these
blankets may cause localized areas of hypothermic
injury. Evaporative cooling techniques using misted
cool water spray with fans are more effective.
CLINICAL CAVEAT
Malignant Hyperthermia
● Autosomal dominant distribution with reduced
penetrance
● Triggering agents are succinylcholine and inhalation
agents
● Multiple exposures may occur before clinical
presentation
● Tachycardia and increased CO2 production occur
before hyperthermia
● Rapid recognition is crucial
● Treatment requires immediate Dantrolene and
supportive care
● MH hotline number 1-800-MH-HYPER (800-644-9737)
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bladder and bowel incontinence, and nausea and vomiting
are frequently seen. Laboratory tests are generally non-
specific and reflect organ involvement. Elevations in cre-
atine kinase due to rhabdomyolysis from hyperthermia
and muscle rigidity, elevations in blood urea nitrogen
and creatinine due to pre-renal azotemia and myo-
globinuria, leukocytosis from the stress response, and
multiple electrolyte and acid–base abnormalities are 
frequently seen.
Treatment includes discontinuation of the neurolep-
tic agent. General measures to lower body temperature
such as removal of excess clothing and cool water spray
with air circulation should start immediately. In mild
cases supportive care may be sufficient. In moderate to
severe NMS aggressive monitoring and support in an ICU
setting is necessary. Dantrolene which reduces thermo-
genesis by reducing muscle contraction is given at
1.0–2.5 mg/kg IV q6 hours until a dose of 100–300
mg/day PO can be given. Neuromuscular blockade may
be useful initially to reduce the metabolic rate and 
muscle contraction. Specific drug therapy to lower core
temperature and reduce extrapyramidal side effects is
initiated. Dopamine agonists such as bromocryptine,
amantadine, and levo-carbidopa combination are recom-
mended. Bromocryptine 5–20 mg/day given in divided
doses has been shown to decrease the course of NMS. It
is continued at 2.5 mg PO tid for 1 week or longer
depending on the rate of elimination of the offending
drug. Recurrence can occur if dopamine agonists are
prematurely discontinued. Mean recovery time is
approximately 9 days.
Serotonin Syndrome
Serotonin syndrome results from increased central
serotonin receptor activity which produces a clinical
picture of encephalopathy, neuromuscular hyperactivity,
and autonomic dysfunction. Initially described in associ-
ation with monoamine oxidase inhibitors, serotonin
uptake inhibitors are more commonly implicated reflect-
ing their increased use. It typically occurs from the use
of two or more drugs with serotonergic activity, or
from the overdose of a single agent. Increased serotonin
synthesis from L-tryptophan; decreased metabolism of
serotonin due to MAOIs; serotonin receptor agonists
busripone, lithium, LSD; increased serotonin release
caused by amphetamines, amphetamine derivatives, and
cocaine; nonselective serotonin reuptake inhibitors like
TCAs, cocaine, amphetamines, meperidine, dextro-
methorphan, and selective inhibitors such as sertaline,
fluoxetine, and nefazodone are all mechanisms that can
interact to cause a serotonin overload.
Signs and symptoms are acute, within 24 hours of a
precipitating event. Altered sensorium with hyperactivity,
agitation, delirium, and occasionally seizures occur.
Neuromuscular irritability is reflected mostly in the
lower extremities with tremors, myoclonus, and muscle
rigidity. The autonomic instability is characterized by
diaphoresis, dilated reactive pupils, labile blood pres-
sure, arrhythmias, and vomiting. Hyperthermia is com-
mon and can reach 40°C. Laboratory abnormalities are
minimal and nonspecific, but in severe cases leukocyto-
sis, metabolic acidosis, renal failure, rhabdomyolysis,
and DIC may occur.
Treatment includes immediate withdrawal of the
offending drug, aggressive supportive care and monitor-
ing in an ICU, rapid cooling, and the use of benzodi-
azepines for the treatment of neuromuscular irritability.
The serotonin antagonist cyproheptadine, at 4–8 mg
repeated every 4 hours to a total daily dose of 32 mg, 
has been reported to shorten the course of serotonin
syndrome. Methysergide, another nonspecific serotonin
receptor blocker, has had mixed results. Fatalities do
occur, but recovery is expected in most patients.
Sympathomimetic Poisoning Syndrome
Sympathomimetic poisoning syndrome results from
an increase central sympathetic activity due to both ther-
apeutic and recreational drugs. Over the counter cold
remedies, appetite suppressants, and frequently abused
drugs such as cocaine, amphetamines, LSD, and PCP are
known causes. Increased ambient temperature is an
associated predisposing factor.
Patients are usually referred to the emergency depart-
ment because they are delirious, agitated, and combat-
ive. Tremors, hyperreflexia, rigidity, and occasionally
seizures occur. On physical examination patients are
diaphoretic with dilated but reactive pupils, and are
hypertensive and tachycardic. Hyperthermia as a marker
of moderate to severe poisoning is associated with many
complications involving organ damage. Rhabdomyolysis,
acute renal failure, metabolic acidosis, DIC, and liver fail-
ure similar to the other drug-induced hyperthermias may
occur. The diagnosis is suggested in those patients with
previous drug use and confirmed by a positive toxicol-
ogy screen.
Treatment requires aggressive cooling including pos-
sibly neuromuscular blockade and benzodiazepines to
treat delirium, agitation, and seizures. Nitroprusside or
labetolol may be needed to treat the hypertensive mani-
festations of the syndrome. Aggressive monitoring and
supportive care, including mechanical ventilation, may
be needed for several days.
Anticholinergic Syndrome
Anticholinergic syndrome results from the blockade
of central and peripheral muscarinic receptors. Many
drugs including over the counter medications and some
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plants are known to precipitate this syndrome.
Medications such as atropine, scopolamine, belladonna
extracts, TCAs, oxybutynin, antihistamines including
diphenhydramine and meclizine, phenothiazines,
antiparkinsonian agents, and the antiarrhythmics quini-
dine, procanamide, and dispyramide can be causes of
the syndrome.
Presentation is usually due to an altered fluctuating
mental status. Patients can manifest a depressed senso-
rium including unresponsiveness and even coma, or an
agitated, hyperactive, delirious state which may result in
seizures. Dry mouth, dry skin, blurry vision with dilated
unreactive or slightly reactive pupils, hypoactive bowel
sounds, and hyperthermia characterize the syndrome.
The hyperthermia is only seen in a quarter of patients,
and can be mild to severe.
Treatment is mostly supportive. Aggressive cooling
and monitoring are necessary. Physostigmine, an acetyl-
cholinesterase inhibitor that increases the concentration
of acetylcholine and overcomes the muscarinic block, is
sometimes used. Physostigmine, however, is associated
with serious adverse effects such as bradycardia, asys-
tole, salivation, bronchorrhea, and seizures. Therefore it
is reserved for severe cases presenting with seizures,
severe delirium, cardiovascular collapse, or life-threaten-
ing hyperthermia in the absence of sweating.
Physostigmine 1–4 mg IV is given slowly while monitor-
ing the heart rate. The effect is quick, but lasts less than
60 minutes. The dose may need to be repeated.
HYPOTHERMIA
Hypothermia is characterized by a core body temper-
ature < 35°C. It can be classified as mild hypothermia,
32–35°C; moderate hypothermia, 30–32°C, and severe,
< 32°C. Predisposing factors are advanced age, exposure
to cold, drug use (especially alcohol), trauma, CNS dys-
function, SCI, endocrine dysfunction, and iatrogenic
causes. Signs and symptoms are characterized by a
depressed level of consciousness. Mental status can
range from stuporous or confused at temperatures
< 35°C to coma when the temperature is < 27°C. Other
physiologic affects of hypothermia include cardiac dys-
function with decreased cardiac output, bradycardia and
cardiac irritability at < 33°C, ventricular fibrillation at
< 28°C, and hypotension at < 25°C; hematologic abnor-
malities with coagulopathy, and decreased oxygen deliv-
ery; and endocrine dysfunction with decreased insulin
release and insulin resistance.
Treatment with rewarming is initiated at 2°C/hour
depending on the degree of hypothermia. Mild exposure
requires passive external warming with blankets, cloth-
ing, and warm IV fluids. Moderate exposure requires
active rewarming with hot blankets, circulating warm air
blankets, and immersion in warm baths. Severe
hypothermia requires active core rewarming with
humidified warmed oxygen, gastric lavage, peritoneal or
pleural lavage, and may include cardiopulmonary
bypass. Cardiac medications are typically not effective.
However, bretrylium for arrhythmias and dopamine for
ionotropic support have been shown to be effective.
Electrical defibrillation may be ineffective until the core
temperature is >30°C. Although hypothermic patients
may be brought into the emergency department without
a blood pressure or rhythm, they cannot be pronounced
dead until they are at 37°C.
PERIOPERATIVE HYPOTHERMIA
Anesthesia and surgery commonly cause substantial
thermal perturbations. Hypothermia, the typical alter-
ation, results from a combination of anesthetic-induced
impairment of thermoregulatory control, a cool operat-
ing room environment, and factors unique to surgery
that promote excessive heat loss. Hypothermia develops
with a characteristic pattern. An initial decrease of the
core temperature by 1–1.5°C over the first hour is fol-
lowed by a slower linear decrease, which finally leads to
a plateau phase during which the temperature remains
constant. Data suggest much more hypothermia results
from altered distribution of body heat rather than from a
systemic imbalance between metabolic heat production
and heat loss.
Since intra- and postoperative hypothermia carries
many disadvantages (including increased blood loss sec-
ondary to impaired coagulation and reduced platelet
function, myocardial ischemia secondary to the
increased oxygen consumption associated with shiver-
ing, decreased drug metabolism, and of course patient
discomfort), all patients should be protected from it.
Patients especially susceptible to hypothermia are those
in extremes of age.
In neurosurgical procedures, however, mild systemic
hypothermia carries the advantage of cerebral protec-
tion due to decreased cerebral metabolic rate. This 
neuroprotective effect of decreased body temperature
also seems to be useful at the initial resuscitation phase
in closed head injured trauma patients as long as the
degree of hypothermia does not jeopardize other vital
functions.
SUMMARY
Metabolic abnormalities are extremely common in
the critically ill patient. Maintaining electrolytes at nor-
mal levels is important for the proper functioning of the
electrochemical reactions of the body. Failure to do so
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CASE STUDY
An 18-year-old male is admitted to the ICU early
Monday morning after being brought to the ER because
of delirium, tremors and high fever. According to his
girlfriend who called 911, he had returned late Sunday
evening after attending a weekend concert with his
friends. He is agitated, confused, hallucinating,
tremulous, and notably hot to touch. On exam, his
blood pressure is 199/115, heart rate 160 and regular,
respiratory rate 30–40, and his temperature is 40°C.
Since arrival to the ER 4 hours before, he has made 10 cc
of dark colored urine, and his lab work has returned
with a K 6.9 meq/l, HCO3 12 meq/l, BUN 65 mg/dl,
creatinine 2.6 mg/dl and a PO4 of 9.9 mg/dl.
QUESTIONS
1. What further information would you like from his
girlfriend?
2. What is your differential diagnosis?
3. How would you explain the signs and symptoms?
4. What is your initial treatment plan?
5. What are the potential pitfalls during treatment?
will result in abnormalities in neuromuscular, cardiac,
and metabolic pathways. For instance, calcium and
phosphorus which are very closely interrelated are
important in neuromuscular function, cellular metabo-
lism, maintenance of acid–base balance, and bone for-
mation. A poor understanding of this relationship may
result in the inappropriate replacement of calcium in the
hyperphosphatemic, hypocalcemia patient, rather than
the correct treatment with phosphate binders and cause
calcium precipitation with organ injury. Similarly
hypothermia and hyperthermia require an appreciation
of the interrelationship between the physiology and the
pharmacologic actions of both recreational and thera-
peutic drugs. Recognizing the syndrome, avoiding inad-
vertent interactions, selecting medications to counter
the deleterious effects, and aggressive supportive care
are essential for proper care.
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Physiologically, intravenous fluid administration
serves two purposes: (1) to replete or maintain intravas-
cular fluid volume and (2) to maintain or replete free
water, electrolyte, blood component, or protein con-
centration derangements. Ultimately, the purpose of
fluid volume administration is to maintain cardiac pre-
load and cardiac output, oxygen delivery, and tissue 
perfusion to maintain cellular homeostasis.
Intravascular volume is essential to maintain cardiac
filling volume. Diastolic tension and cardiac sarcomere
“stretch” imposes a preload which directly affects the
development of muscular tension in the ventricular
chambers. Preload, measured directly as end-diastolic
volume or indirectly as end-diastolic pressure, then
determines cardiac function, measured as cardiac output
or ejection fraction (Figure 6-1). Cardiac output is a key
determinant of tissue and organ perfusion. Diminished
organ perfusion is associated with decreased oxygen and
nutrient delivery, removal of metabolic by-products, and
in the case of the kidneys decreased filtration pressure
and waste elimination in urine output. Tissue hypoper-
fusion, and even transient ischemia, triggers metabolic
alterations such as a shift from oxidative phosphoryla-
tion to anaerobic glycolysis with ensuing lactate and
hydrogen ion production, and alterations in cellular
water, sodium, and calcium flux. Cellular metabolic
alterations are the trigger for activation of the cellular
and humoral inflammatory response which perpetuates
the cycle of ischemia, cell death, tissue necrosis, and
systemic inflammatory response.
The electrolytes, water, and protein content of body
fluids are regulated within a narrow range; however 
Figure 6-1 Starling curves.
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physiologic and pathophysiologic processes result in con-
tinual transformation, redistribution, and loss of the vari-
ous components. Under normal circumstances nutritional
intake replenishes losses; the result is that the “homeosta-
tic milieu” in which cells and tissues function is constant.
Tissue perfusion with a nutrient-rich and electrolyte-bal-
anced fluid to deliver fuel and extract waste is the basic
function of body fluid.
NORMAL BODY FLUID AND
ELECTROLYTE COMPOSITION (TABLE 6-1)
Fluid Compartments
Total body water is distributed across semipermeable
membranes into fluid compartments as outlined in
Figure 6-2.
For an average adult male, body weight is comprised
of 60% water, 7% minerals, 18% protein, and 15% fat.
Females have a slightly increased body fat content and 
a correspondingly decreased water content of 50%.
Extracellular fluid (ECF) comprises one-third of total
body water and of body weight. The ECF is divided
between blood volume (8% body weight), plasma (5%
body weight), and interstitial fluid (ISF; 15% body
weight). Intracellular fluid (ICF) comprises two-thirds of
total body water and about 40% of body weight.
PEARLS
● Total body water = 0.6 × wt (kg) in males; and
0.5 × wt (kg) in females
● Serum osmolarity = (2 × [Na]) + [glucose]/18 +
[BUN]/2.8. Normal serum osmolarity =
290 mOsm/kg H2O.
● The fractional excretion of sodium (FEN) is
extremely useful in the management of oliguria
(FENa = [NaUrine/NaSerum]/[CrUrine/CrSerum]). A FENa of
less than 1% is an excellent indicator of prerenal
oliguria in the absence of diuretic therapy, renal
failure, or osmotic load.
● The Starling–Landis equation (transcapillary fluid flux)
is: F = k[(PH − PISF) − δ (COPV − COPISF)], where k is the
ultrafiltration coefficient of fluid; PH is the intravascular
hydrostatic pressure; PISF is the hydrostatic pressure of
intravascular fluid; δ is the reflection coefficient; COPV
is the intravascular oncotic pressure; and COPISF is the
oncotic pressure of the interstitial fluid.
PEARLS
● Hypovolemia is decreased effective intravascular
volume. Cardiac signs of hypovolemia are decreased
preload (low CVP, pulmonary artery occlusion
pressure, or diminished end-systolic ventricular
chamber volumes on echocardiography),
tachycardia, and decreased cardiac output (oliguria,
vasoconstriction, acidosis, lactate accumulation, and
altered mental status).
● The Starling curve depicts the effect of incremental
changes in preload on cardiac function. See Figure 6-1.
● Decreased oxygen delivery to tissues resulting from
diminished cardiac output defines the state known
as “shock.”
● Empiric therapy based on the clinical presentation
may suffice; however, if there is no response or a
continued deterioration, then invasive monitoring is
necessary to determine intravascular volume and
cardiac output, and to guide resuscitation.
Table 6-1 Average Electrolyte Content and Daily Volumes of Body Fluids and Secretions
Adult Volume
Fluid Na (mEq/l) K (mEq/l) H (mEq/l) Cl (mEq/l) HCO3 (mEq/l) (ml/day)
Saliva 60 20 0 15 50 1500
Gastric 20-120 15 60 130 0 2500
Pancreatic 140 5 0 70 70 1000
Biliary 140 5 0 140 44 600
Ileostomy 120 20 0 100 40 3000
Diarrhea 100 20 0 100 40 –
Figure 6-2 Distribution of body water.
Total body water: TBW
60% body weight
42 L
Intracellular fluid: ICF
40% body weight
2/3 body water
28 L
Extracellular fluid: ECF
20% body weight
1/3 body water
14 L
Interstitial fluid: ISF
15% body weight
75% ECF
10.5 L
Plasma volume: PV
5% body weight
25% ECF
3.5 L
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Electrolyte Distribution
Osmotic pressure is the tendency of fluid to equili-
brate across membranes to maintain equivalent solute
concentrations (Box 6-1).
Hydrostatic pressure forces water and electrolytes
from the intravascular into the interstitial space.
Hydrostatic pressure is greatest at the arteriolar end of
capillaries. Oncotic pressure, due mainly to serum albu-
min concentration, draws this ISF into the intravascular
space. Oncotic pressure exerts its greater influence at
the venular end of the tissue capillary beds.
Normal body fluid losses (urine, stool, tears) are from
ISF space. A constant flux between the intravascular,
interstitial, and intracellular spaces exists and normally is
at equilibrium. Thus, when there is volume loss all fluid
compartments will be affected.
FLUID AND ELECTROLYTE LOSS AND
REDISTRIBUTION IN PATHOLOGIC
STATES
Acute volume depletion represents almost exclusively
ECF loss. A 2% body weight loss represents 10% ECF loss
and results in thirst and oliguria. A 4% body weight loss
represents 20% ECF loss and results in tachycardia and
postural hypotension. A 6% body weight loss represents
30% ECF loss and results in shock and acute tubular
necrosis. Laboratory values suggestive of dehydration
(prerenal oliguria) include a serum BUN/creatinine ratio
> 20, a urine specific gravity ≥ 1.020, urine sodium
< 20 mEq/l, a urine osmolarity > 500 mOsm/l, and a frac-
tional excretion of sodium (FENa) < 1%.
Fluid balance is represented as interval and cumula-
tive intake/output (I/O). Positive fluid balances occur
when I > O and typically represent third space fluid
sequestration, persistent vasodilation, or compromised
elimination (renal failure).
I/O balances represented on intensive care unit (ICU)
flowsheets do not include insensible losses (sweat, stool,
respiratory evaporation, etc.). Insensible losses are nor-
mally approximately 1–1.5 l/day in adults but can be
much greater in pathologic conditions such as loss of
epithelial integrity (i.e., burns), fever, unhumidified res-
piratory gases, and diarrhea. I/O balances, as they appear
on the ICU flow sheet, generally also fail to account for
the differences in crystalloid, colloid, or blood component
volumes infused; this is important because the relative
contributions of these different fluids to volume expan-
sion varies significantly.
Box 6-1 Definitions
● Cations are positively charged ions such as sodium
and potassium. Anions are negatively charged ions
such as chloride and bicarbonate.
● The mole is a standard unit of measurement defined as
the gram-molecular weight of a substance consisting
of 6 × 1023 molecules.
● The electrical equivalent is one mole of an ionized
substance divided by its equivalence. The
milliequivalent (mEq) is 1/1000 of 1 equivalent.
● The osmole (Osm) is the molecular weight of a
substance in grams divided by the number of
particles liberated in solution.
● Osmolarity pressure refers to the concentration of
osmotically active particles (osmolarity; mOsm/l) in
a solution. When solute concentrations differ across
a semipermeable membrane the resulting tendency
of a fluid to equalize the concentrations is the
osmotic pressure. The differing solute concentration
is also expressed as tonicity.
● Oncotic pressure, or colloid osmotic pressure
(COP), is the pressure required to prevent net fluid
movement between two solutions separated by a
semipermeable membrane when there is net
difference of colloid concentrations between them.
PEARLS
● The initial approach to shock is restoration of
circulating volume, cardiac output, and oxygen-
carrying capacity.
● Cardiac output can be adversely affected by
decreased preload, decreased cardiac contractility,
or increased afterload.
● Hypovolemia has a dual adverse effect on cardiac
output: a low preload decreases cardiac output as
per the Starling curve, and compensatory
vasoconstriction increases afterload and impedes
cardiac output.
● Intravascular volume must always be corrected
before diuretics are used in the treatment of
oliguria. The use of diuretics in the ICU should
always be questioned.
● It is easier to treat congestive heart failure, even
pulmonary edema, than it is to treat renal failure.
● Optimum care of the patient is data driven. First
there is a question: if it cannot be answered with
the data at hand then there is a manifest need for
more information. The ICU is an information-rich
environment: there is examination, testing, analysis,
and monitoring, all of which assist in decision-
making. This feedback loop must be very tight in
the ICU. Information gathering seldom occurs only
once a day.
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Plasma volume is the first ECF space. The normal 
ISF space is the second ECF space. A pathologically
expanded ISF space is a third ECF space, increased pri-
marily at the expense of plasma volume referred to as a
“third space” loss. Tissue edema is one type of third space
fluid loss. Third space losses can constitute tremendous
plasma volume loss: 1 mm of diffuse peritoneal edema 
in an adult represents approximately 20 liters of fluid.
Failure to replace lost intravascular fluid results in dimin-
ished cardiac output and tissue perfusion, and ischemic
tissue injury. Third space losses occur in the setting of
injury and inflammation and do not equilibrate with
other fluid compartments. Third space fluid cannot be
mobilized and removed by changing the volume of other
fluid compartments. Third space fluid mobilizes sponta-
neously when inflammation subsides and the fluid
moves from the abnormal interstitial compartment to
the plasma volume.
Electrolyte Deficit and Excess
Glucose
Blood or serum glucose levels must be closely moni-
tored in critically ill patients since both hyperglycemia
and hypoglycemia have important therapeutic ramifica-
tions. Sources of glucose include endogenous synthetic
processes, such as gluconeogenesis and glycogenolysis,
and exogenous sources, such as enteral or parenteral
nutrition and intravenous fluids. It is important to realize
that glucose is present in intravenous fluids either to cre-
ate a fluid which is isotonic for safe intravascular adminis-
tration (without precipitating hemolysis), or with the
specific intent of glucose administration. Glucose admin-
istered intravenously is rapidly metabolized and the fluid
in which it was contained then becomes hypotonic and
behaves as “free water.” Thus, dextrose-containing solu-
tions such as D5W represent a major source of free water
and should not be administered to patients with head
injury or after recent neurosurgery where there is a risk
for the development of cerebral edema, or in those patients
with pre-existing hyponatremia. The administration of
intravenous glucose does not have any measurable “pro-
tein-sparing effect” in catabolic states. Furthermore, the
metabolism of glucose will typically result in some level of
hypokalemia as glucose and potassium are co-transported
into cells.
Hypoglycemia
Glucose is an important metabolic substrate.
Hypoglycemia should be considered as a potential cause of
any acute deterioration, such as mental status change or
cardiac arrest, in critically ill patients. Hypoglycemia is an
important cause of agitation, somnolence, or seizures.
Early symptoms of hypoglycemia include tremulousness,
diaphoresis, palpitations, and nausea; however, profound
hypoglycemia can precipitate a myocardial infarction or
encephalopathy. Tissues may be starved for glucose either
due to absolute hypoglycemia (low serum glucose levels),
or relative cellular hypoglycemia (insulin resistance, defec-
tive glycolysis or oxidative phosphorylation). Patients at
risk for fasting hypoglycemia include those with depleted
glycogen stores or impaired glycogenolysis, such as
patients with malnutrition, cirrhosis, renal failure, alco-
holic ketoacidosis, or patients with inborn errors of metab-
olism. Medications that can lead to hypoglycemia include
ethanol, oral hypoglycemic agents, insulin, pentamidine,
moxifloxacin, salicylates, haloperidol, and trimethoprim-
sulfamethoxazole. Hypoglycemia of endocrine origin is
seen with glucocorticoid deficiency, hypopituitarism, and
glycogen storage diseases.
Hyperglycemia
Hyperglycemia is most often seen in the setting of dia-
betes, insulin resistance, diabetic ketoacidosis, or nonke-
totic hyperosmolar states. Hyperglycemia may also result
from overfeeding, stress, or medications. Patients with
renal failure typically have insulin resistance and hyper-
glycemia. Hyperglycemia in critically ill patients has been
shown to increase morbidity due to hospital-acquired infec-
tions, and also increase overall mortality. Relative insulin
resistance occurs in the setting of glucocorticoid or cate-
cholamine administration. Hyperglycemia causes a relative
hyperosmolar state and can thereby precipitate an osmotic
diuresis, which can lead to dehydration and electrolyte
imbalances (hypokalemia, hypernatremia) due to diuresis
of a very dilute urine. Hyperglycemia has also been shown
to detrimentally affect neurologic outcome after cardiac
arrest, presumably by increasing the level of intraneural 
lactic acidosis in the setting of cerebral ischemia. Thus,
insulin is an important adjunct therapy for most critically 
ill patients and is most appropriately administered intra-
venously, especially in instances where there is peripheral
edema or anasarca which impairs the absorption of sub-
cutaneous insulin.
Sodium and Water
A minimal urine output of 500 cm3/24° is required for
solute excretion in a normal adult. In the adult ICU
patient, oliguria is defined as a urine output of < 0.5 cm3/
kg/hour over two consecutive hours. Adult maintenance
CLINICAL CAVEAT
Infusion of Free Water
Free water should never be infused in patients with
head injury or those undergoing neurosurgery because
it exacerbates cerebral edema. Normal saline is the
fluid of choice in these patients.
fluid requirements are approximately 2500 ml/day under
normal conditions. Serial body weight and daily
intake/output measurements are important to follow
total body water status. Normal plasma or serum sodium
concentration ranges from 135 to 145 mEq/l. Serum
osmolarity (mOsm/kg) = total solute (mOsm)/ total body
water (kg). Sodium is the main determinant of plasma
(serum) osmolarity. The disorders of sodium balance are
summarized in Tables 6-2 and 6-3.
Hypernatremia
Symptoms of hypernatremia include lethargy, irri-
tability, seizures, and coma. The in-hospital mortality
associated with severe hypernatremia exceeds 50%. The
diagnosis of hypernatremia relies on the measurement of
urine sodium and/or osmolarity.
Hypernatremia (plasma sodium > 145 mEq/l) may be
a result either of hypertonic fluid gain (sodium infusion),
or more commonly a relative free water deficit. The differ-
ential diagnosis and treatment of hypernatremia depends
on the estimated total body sodium (Table 6-2). Thirst
occurs when serum sodium rises by 3–4 mEq/l. Calculated
water deficit = 0.6(M) or 0.5(F) × Wt(kg) × ([Na+] −
140/140) or water deficit = 0.6(M) or 0.5(F) × Wt(kg) ×
[plasma Na+/140 − 1] × 10. Males (M) have slightly
higher total body water content than do females (F).
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Table 6-3 A Diagnostic and Therapeutic Approach to Hyponatremia
Excess of Total Body Sodium
Deficit of Total Body Water and Excess Total Body Water [Minimal ECF and Water [Significant 
Sodium [ECF Depletion] Excess] ECF Volume Excess]
Extrarenal loss Renal loss Glucocorticoid Nephrotic syndrome, Renal failure
deficiency, cirrhosis, heart failure 
hypothyroidism, (natriuretic 
SIADH peptide deficit)
Vomiting, Diuresis, nephritis,
diarrhea, renal tubular acidosis,
third space ketosis, osmotic 
losses, burns diuresis
Urine Urine Na+ > 20 mmol/l Urine Na+ > 20 mmol/l Urine Na+ < 10 mmol/l Urine Na+ > 20 mmol/l
Na+ < 10 mmol/l
Isotonic saline Water restriction Water restriction
CLINICAL CAVEAT
Correction of Hypernatremia
● Hypernatremia that is corrected too rapidly may
result in acute cerebral edema.
● Urine osmolality less than that of plasma suggests
central (antidiuretic hormone (ADH)-deficient) or
nephrogenic (ADH-resistant) diabetes insipidus.
● Urine sodium is low in the setting of water loss and
high with salt ingestion.
● The water restriction test is helpful in hypernatremic
states to diagnose central diabetes insipidus: water
intake is stopped to stimulate ADH release; if no
response occurs then 1-deamino-8-D-arginine
vasopressin (DDAVP) is administered. If the urine
osmolality rises the patient has central diabetes
insipidus.
Table 6-2 A Diagnostic and Therapeutic Approach to Hypernatremia
Increased Total Body Na+
Low Total Body Na+ [Na+ and H2O Loss] Normal Total Body Na+ [H2O Loss Only] [Exogenous Na+ Load]
Extrarenal loss Renal loss Extrarenal loss Renal loss Cushing’s syndrome,
hyperaldosteronism
Perspiration Osmotic diuresis Insensible losses Diabetes insipidus NaHCO3−; NaCl dialysis
(respiratory, skin)
Hypertonic urine Iso- or hypertonic Hypertonic urine Variable urine Iso- or hypertonic urine
urine tonicity
Urine Na+ < 10 mEq/l Urine Na+ > 20 mEq/l Variable urine Na+ Variable urine Na+ Urine Na+ mEq/l
Hypertonic saline Water replacement Diuretics + water
Hyponatremia
The assessment of volume status is essential to the
diagnosis. If the measured plasma osmolality is elevated
with respect to the calculated value, the diagnosis is
pseudohyponatremia. Hyponatremia in the setting of a
low urine sodium or high urine osmolality (>100
mOsm/kg) suggests defective urinary dilution, whereas
lower urine sodium or osmolality suggest polydipsia.
Equations that calculate excess body water are not
reliable. Hyponatremia is classified based on esti-
mated volume status and on urine sodium or osmolarity
(Table 6-3). Pseudohyponatremia occurs in the setting 
of severe hyperlipidemia, hyperproteinemia, or hyper-
glycemia. Hyperglycemia does not cause hyponatremia
until the plasma glucose exceeds 300 mg/dl. Sodium
concentration decreases by approximately 1.6 mEq/l for
every 100 mg/dl rise in serum glucose or change in
sodium = 0.016 × (glucose − 100). Hyponatremia is char-
acterized clinically by central nervous system (CNS)
changes such as nausea and vomiting, disorientation,
seizures, coma, and respiratory arrest. SIADH is under-
recognized in hospitalized patients. SIADH is a cause of
isovolemic hypotonic hyponatremia and is associated
with stress, drugs, tumors, or CNS and pulmonary 
infections. The rate of change of serum sodium may be
more important clinically than the absolute value.
Hypertonic (1.8 or 3%) saline is indicated for the treat-
ment of severe symptoms of hyponatremia. Intravenous
medication formulation and enteral free water load
should be considered when treating hyponatremia. Free
water restriction is a first-line therapy in hypervolemic
hyponatremia.
In the setting of hypervolemia, a hypo-osmolar serum
and a urine sodium less than 10 mmol/l is usually associ-
ated with congestive heart failure, nephritic syndrome,
hypothyroidism, malnutrition, and hypoalbuminemia,
cirrhosis, or pregnancy. In the setting of hypovolemia, a
hypo-osmolar serum is associated with gastrointestinal
(GI) losses or pancreatitis, burns, or diaphoresis if the
urine sodium is less than 20 mmol/l; and with renal dis-
ease (nonoliguric renal failure, renal tubular acidosis,
interstitial nephritis), diuretic use, or cerebral salt wast-
ing if the urine sodium is greater than 20 mmol/l.
Volume status is measured clinically: heart rate, jugular
venous distention, edema, central venous pressure
(CVP), pulmonary capillary wedge pressure (PCWP),
orthostasis, or pulse pressure. Adrenal insufficiency
presents as hyperkalemia, hyponatremia, acidosis, and
perhaps fever and leukocytosis.
Potassium
Hyperkalemia
Normal plasma or serum potassium concentration
ranges from 3.5 to 5.5 mEq/l. Body potassium stores are
primarily intracellular and total body potassium is
approximately 50 mEq/kg or 3500 mEq in a 70 kg person.
Of this total, 2% (70 mEq) are found in the ECF.
Hypokalemia (<3.5 mEq/l) signals total body depletion of
potassium stores, a deficit of approximately 250–300 mEq
in a 70 kg adult. This deficit must be replaced gradually.
Hyperkalemia in the face of acidosis signals a significant
total body potassium deficit. Untreated hypokalemia can
be expected to worsen as the pH rises. Acidosis pro-
motes an efflux of potassium from the ICF compartment.
Sources of hyperkalemia include renal failure, hypo-
adrenocorticalism (Addison’s syndrome), hemolysis, rhab-
domyolysis, potassium supplements, and medications
such as penicillin-K, heparin, aldosterone antagonists,
ACE inhibitors, and succinylcholine. Pseudohyperkalemia
may result from leukocytosis (>100,000/mm3) or elevated
platelet count (>600,000/mm3).
Hyperkalemia causes tall peaked T waves, widened QRS,
and wide PR. These patients should be carefully monitored.
PEARLS
● Whenever any laboratory value is inconsistent with
the clinical picture it must be treated as suspect and
reconfirmed immediately if the situation allows it.
● The diagnosis of the etiology of hyponatremia
depends on an accurate determination of fluid 
status.
● The rate of correction of hyponatremia should be as
slow as is safe given the patient’s symptoms.
● Hypernatremia is usually due to a free water deficit
and can be corrected by free water administration,
enterally or intravenously.
● Rarely, hypernatremia is due to diabetes insipidus
and may require treatment with antidiuretic
hormone (ADH).
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CLINICAL CAVEAT
Correction of Hyponatremia
● The rate of serum sodium increase during the correc-
tion of hyponatremia should not exceed 0.5–2
mEq/l/hour (12–20 mEq/l) in the first 24 hours; and
0.3–0.5 mEq/l/hour thereafter. In extreme emergen-
cies a maximum of 20 mEq/l/day may be tolerated
but has significant associated risks which should not
outweigh benefits.
● Hyponatremia corrected too rapidly can produce
central pontine myelinolysis (osmotic demyelination)
syndrome which is an irreversible CNS injury related
to both rate and degree of Na+ correction. Imaging
studies may not be positive for up to weeks.
Hypokalemia
Hypokalemia is defined as a serum potassium concen-
tration of less than 3.5 mEq/l and is due to either intracel-
lular potassium shift or total body potassium depletion
(renal losses with diuresis, diarrhea). Urine potassium can
help guide diagnosis. If urine potassium is less than 20
mmol/l one should consider inadequate intake, diarrhea,
biliary loss, or diuresis. If the urine potassium is greater
than 20 mmol/l in a normotensive patient one should con-
sider renal tubular acidosis, diabetic ketoacidosis. If the
urine potassium is greater than 20 mmol/l in a hyperten-
sive patient one should consider malignant hypertension
or renal artery stenosis if the plasma renin activity is ele-
vated; otherwise one should consider mineralocorticoid
use or Cushing’s syndrome. Clinical manifestations of
hypokalemia include muscle weakness, cardiac arrhyth-
mias, cardiac U waves, flattened and inverted T waves,
ileus, paresthesias, and prolongation of the QT interval.
Severe hypokalemia can precipitate rhabdomyolysis.
Hypokalemia will also increase renal ammonia production
and worsen hepatic encephalopathy. Magnesium deple-
tion impairs potassium reabsorption across the renal
tubules; therefore effective treatment of hypokalemia is
difficult in the setting of magnesium depletion.
Chloride
Gastric secretions are a primary source of loss pro-
ducing hypochloremic metabolic alkalosis. (See section
on acid–base physiology below). Exogenous chloride
and renal failure are the primary causes of hyper-
chloremic metabolic acidosis.
Magnesium
Since magnesium is primarily intracellular, serum mag-
nesium levels can be normal while total body magnesium
is severely depleted. Magnesium is a cofactor for many
enzymatic reactions and therefore plays an important role
in ATP mediated processes (N+–K+ ATPase) such as elec-
trical membrane potentials, neurotransmitter release,
and smooth muscle contraction. Magnesium deficiency
predisposes to arrhythmias especially those arising from
QT and PR interval prolongation; and intravenous mag-
nesium is the treatment for torsades de pointes.
Magnesium deficiency may also manifest as vertigo,
dysarthria, psychosis, weakness, tremor, paresthesias, and
seizures. Magnesium deficiency is extremely common
and under-recognized. Losses are from the GI and renal
systems. Predisposing conditions include chronic alcohol
abuse, secretory diarrhea, diabetes mellitus, myocardial
infarction, and drug therapy (furosemide, aminoglyco-
sides, amphotericin, pentamidine, cyclosporine, digitalis).
Gentamicin induces magnesuria. Alcoholics are particu-
larly likely to have magnesium depletion. In addition, mag-
nesium is a cofactor for thiamine action. There are no
specific clinical manifestations of magnesium deficiency.
However, reactive CNS magnesium deficiency can
mimic a cerebrovascular accident (ataxia, dysarthria,
seizures, obtundaton, and spasms).
Magnesium has also been used as an adjunct bron-
chodilator in status asthmaticus. Magnesium accumula-
tion occurs in patients with impaired renal function and
CLINICAL CAVEAT
Magnesium Repletion
● Magnesium repletion can be accomplished using
enteral or intravenous supplementation. Magnesium
sulfate delivers 8 mEq/g and may be given intra-
venously over minutes to hours. A typical dose in a
70 kg adult with moderate magnesium depletion
would be in the range 2–4 g IV. Magnesium oxide
delivers 20 mEq, 10 mmol, or 241 mg of elemental
magnesium per 400 mg tablet.
● Magnesium is administered in obstetric patients in
large doses for severe eclampsia and pre-eclampsia
where the dose is titrated to diminished deep ten-
don reflexes (DTRs). DTRs are abolished above
serum levels of 4 mEq/l; somnolence accompanies
levels of 7 mEq/l; and heart block and paralysis is
likely at levels of 10 mEq/l or greater.
CLINICAL CAVEAT
Treatment of Hypokalemia
● Potassium repletion can be accomplished using
enteric or intravenous supplementation. Intravenous
potassium repletion should never exceed 40 mEq/hour
in adults and administration of more than 10 mEq/hour
should be performed with telemetry monitoring.
● The average increase in serum potassium is
0.25 mmol/l per 20 mmol infused.
CLINICAL CAVEAT
Treatment of Hyperkalemia
● Plasma or serum hyperkalemia can be reduced by
promoting alkalosis (hyperventilation, exogenous
bicarbonate), or increasing intracellular glucose by
the administration of glucose (0.5–1.0 g/kg) and
insulin (0.1 unit regular insulin/kg); beta2-agonist
(albuterol); maneuvers that move potassium from the
ECF to the ICF compartment. Ten percent calcium glu-
conate 50 mg/kg IV or 10% calcium chloride
10 mg/kg IV transiently antagonize the effects of
hyperkalemia at excitable membranes.
● Sodium polystyrene sulfonate in 20% sorbitol by mouth,
NG tube, or enema removes approximately 1 mEq/g
of K+, but simultaneously adds approximately 1.7 mEq
of Na+/g.
● Hyperkalemia decreases the transmembrane electrical
potential and will arrest the heart in diastole. Intravenous
calcium administration preserves cardiac contractility
and transiently antagonizes symptomatic hyperkalemia.
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supplementation should be with great care in these
patients. Hypermagnesemia also occurs with adrenal
insufficiency, hyperparathyroidism, and lithium intoxi-
cation. Clinical effects of hypermagnesemia include
diminished neuromuscular function and paralysis,
vasodilation and hypotension, bradycardia, heart block,
respiratory depression, and coma. Hemolysis releases
magnesium from lysed erythrocytes.
Calcium
Calcium is the most abundant electrolyte in the
human body but 99% is bound in bone. Calcium is
mainly distributed in ECF where 50% is bound to plasma
proteins. Albumin accounts for 80% of calcium binding
in plasma. Some 5–10% is chelated to sulfates and phos-
phates. Calcium is important to blood clot formation,
excitation–contraction coupling, neurotransmission,
enzyme function, cell division and motility, and wound
healing. Only unbound, or ionized, plasma calcium is
physiologically active.
Normal total serum calcium ranges from 8.0 to 10.2
mg/dl or 2.2 to 2.5 mmol/l; and normal serum ionized
calcium ranges from 4.0 to 4.6 mg/dl or 1.0 to 1.5 mmol/l.
Hypocalcemia
Calcium must be corrected for plasma albumin levels.
Corrected total Ca = measured total Ca + 0.8 × (4.0 −
albumin). The key clinical manifestations of hypo-
calcemia are enhanced neuromuscular excitability and
reduced muscle contractility. Hypocalcemia is associ-
ated with decreased parathormone (PTH) levels follow-
ing parathyroidectomy, tumor, or hemochromatosis.
Pseudohyoparathyroidism is end-organ unresponsive-
ness to PTH and is often nephrogenic. Vitamin D defi-
ciency due to inadequate dietary intake is rare. However,
vitamin D deficiency due to malabsorption, hepatobil-
iary disease, renal disease, and alcoholism is a relatively
common cause of hypocalcemia. Classic but insensitive
clinical signs of hypocalcemia are Chvostek’s (facial
hyperreflexia) and Trousseau’s (carpopedal spasm)
signs. Ionized hypocalcemia (<1.0 mmol/l) occurs in 
the setting of alkalosis, magnesium depletion, renal
insufficiency, and sepsis, and with the use of medi-
cations such as aminoglycosides, estrogen, dilantin, 
theophylline, and heparin. Hypocalcemia is refractory to
calcium administration in the presence of concomitant
hypomagnesemia.
Ionized calcium levels can decrease rapidly in the
presence of pancreatitis, where fat necrosis binds cal-
cium in a process of saponification; and following mas-
sive red cell transfusion where the anticoagulant citrate
in transfused red blood cells binds plasma ionized cal-
cium (especially with coexisting liver disease which
impairs citrate metabolism). Calcium is administered
intravenously as either 10% (100 mg/ml calcium salt) cal-
cium chloride (0.1–0.2 ml/kg) or 10% calcium gluconate
(0.5–1.0 ml/kg). However, calcium chloride contains
three times as much elemental calcium (1.36 mEq/ml) as
calcium gluconate (0.46 mEq/ml). Ten milliliter amps
contain 272 mg compared to 90 mg of elemental cal-
cium, respectively. Intravenous calcium administration
can precipitate ventricular arrhythmias in patients receiv-
ing digoxin because calcium antagonizes potassium at
the cardiac muscle membrane. Calcium supplementa-
tion should be avoided in digoxin toxicity.
Hypercalcemia
Hypercalcemia (>10.5 mmol/l) or ionized hypercal-
cemia (>1.3 mmol/l) is relatively rare, most commonly
due to hyperparathyroidism, sarcoidosis, milk-alkali syn-
drome, vitamin A or D intoxication, malignancy, thyro-
toxicosis, or drugs (lithium, tamoxifen, thiazides).
Hypercalcemia produces an osmotic diuresis resulting in
symptoms of polyuria and polydipsia. Clinical manifesta-
tions of hypercalcemia are nonspecific and include ileus,
pancreatitis, nephrocalcinosis, confusion, and coma.
Electrocardiographic effects of hypercalcemia include
PR prolongation, QRS widening, ST shortening, and flat-
tened T waves. Management of hypercalcemia is with
saline infusion and diuretics to maintain a brisk diuresis.
Severe or symptomatic hypercalemia can be managed
with calcitonin IM/SQ; hydrocortisone; pamidronate IV;
and mithramycin or plicamycin IV. Calcium salts are
deposited in tissues when a critical calcium–phosphate
product is reached (>60). Administration of either salt in
the presence of high concentrations of the other must
be carried out with caution.
Phosphate
Phosphate is the most abundant intracellular anion
and is essential for energy storage and transport (ATP,
cAMP, cGTP, CPK, etc.). Normal dietary phosphate
accounts for 1 g/day. Most body phosphorus is in the
bony skeleton; the rest is bound in phospholipids and
phosphoproteins. The remaining 15% exists as inorganic
phosphorus which is primarily intracellular, mainly as
high-energy phosphates. Normal serum phosphate
ranges from 2.5 mg/dl (0.8 mmol/l) to 4.5 mg/dl (1.4
mmol/dl). Phosphorus is filtered at the glomerulus and
reabsorbed in the proximal tubules, regulated by 
PTH and vitamin D. Hypophosphatemia (<3 mg/dl) is
CLINICAL CAVEAT
Treatment of Elevated Magnesium
● Neuromuscular and cardiac toxicity from hyper-
magnesemia can be treated emergently but tran-
siently with calcium, 100–200 mg slow IV push.
● Forced diuresis will decrease serum magnesium in
patients with intact renal function.
● Magnesium can be removed by dialysis
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common in hypermetabolic states (diabetic ketoacidosis,
alcohol withdrawal, refeeding syndrome, trauma, etc.).
However, even severe hypophosphatemia is usually
clinically silent. Phosphate depletion can also occur with
medications such as aluminum- or calcium-containing
antacids, sucralfate, diuretics, androgens, salicylates,
aminoglycoside and acetaminophen toxicity, and cisplatin
therapy. Clinical manifestations of hypophosphatemia
may become evident with stress and include acute skele-
tal myopathy, respiratory muscle dysfunction, cardiomy-
opathy, decreased platelet adhesion and prolonged
bleeding time, phagocytic impairment, and hemolysis.
Hyperphosphatemia (>4.5 mg/dl) is common in renal
failure and widespread tissue or cell lysis syndrome
(tumor lysis, rhabdomyolysis). Calcium acetate, sucral-
fate, or hemodialysis will lower serum phosphate.
ACID–BASE PHYSIOLOGY
In general, mild acidosis is better tolerated physiologi-
cally than alkalosis, because of improved oxygen kinetics
in the setting of acidosis. With the exception of the
pulmonary vasculature, all vascular beds vasodilate in
response to acidosis. Acidosis causes pulmonary vaso-
constriction and bronchodilation. Acidosis increases
catecholamine release but severe acidosis impairs cate-
cholamine responsiveness. Proper arterial blood collection
technique is essential. If the specimen is not placed on 
ice PaCO2 rises 3–10 mmHg/hour with a concomitant fall
in pH. Pseudohypoxemia and pseudoacidosis can occur
when increased oxygen consumption and CO2 production
occurs in the sample due to active metabolism in the set-
ting of temperature, leukocytosis (>105/mm3), or throm-
bocytosis (>106/mm3). Pseudohypocarbia and false oxygen
PaO2 can occur in the setting of trapped air bubbles. Air
bubbles can increase PO2 by >25 mmHg, but are unlikely
to affect PCO2. The oxygen saturation of a blood gas spec-
imen is not measured but calculated from the PaO2 using a
normogram. The body temperature should be recorded at
the time of ABG collection. Gas solubility decreases with
warming and “temperature correction” of PaO2 and PCO2
may be necessary. Venous blood gases have a higher PCO2
and lower PO2 than arterial blood. Venous blood gases may
be adequate indicators of acid–base and, when used with
oximetry, approximate arterial blood gases. In the ICU the
number of blood gas analyses correlates with the presence
or absence of an arterial cannula. Normal arterial pH varies
from 5.35 to 7.45. A pH less than 7.35 is a relative acidosis,
whereas a pH greater than 7.45 is a relative alkalosis.
Acidosis
Metabolic acidosis represents excess unbuffered H+
ion concentration. Metabolic acidosis is usually partially
compensated by hyperventilation and a relative respira-
tory alkalosis. Bicarbonate is not measured during blood
gas analysis; it is calculated from the pH and PCO2 using
a normogram derived from the Henderson–Hasselbach
equation. Directed automated determination of HCO3−
(PCO2) is standard with electrolyte panels using the
sequential multichannel analyzer (SMA). The bicarbonate
(carbonic acid) buffer is quantitatively the most important
plasma buffering system. In metabolic acidosis bicarbonate
is consumed and depleted. Bicarbonate compensation
occurs over 24–38 hours. Below a pH of 7.15 the con-
formation of catecholamine receptors is altered and
there is a decreased responsiveness to endogenous and
exogenous catecholamines. Acidemia also decreases
conduction in excitable tissues. Hyperkalemia in acido-
sis increases cardiac depression and arrhythmias.
Acidosis in the setting of excessive lactate production
(Type A) usually occurs in the setting of anaerobic gly-
colysis in shock. Excess lactate production suggests an
imbalance in oxygen delivery and extraction (DO2 < VO2).
Type B lactic acidosis is differentiated into subtypes:
B1 is due to underlying diseases such as liver disease,
malignancy, pheochromocytoma, and, most importantly,
thiamine deficiency; B2 is associated with medications
or toxins such as biguanides, ethanol, methanol, salicylates,
acetaminophen, or propylene glycol; B3 occurs with
inborn errors of metabolism such as glucose-6-phosphate
dehydrogenase deficiency, pyruvate dehydrogenase
deficiency, or fructose-1,6-diphosphatase deficiency. 
The anion gap is given by (Na+ + K+) − (HCO3− + Cl−).
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CLINICAL CAVEAT
Treatment of Hypophosphatemia
● Intravenous replacement therapy for hypophos-
phatemia is with either sodium (4.0 mEq/l Na) or
potassium (4.3 mEq/l K) phosphate. A dose of
0.02–0.04 mmol/kg (15–30 mmol in a 70 kg patient)
over 1–4 hours is a typical starting dose. Phosphate
replacement should be slow and cautious in patients
with renal failure.
● Enteral phosphate replacement with Neutra-Phos or
K-Phos is an alternative.
PEARLS
● A decrease in plasma albumin affects primarily
protein-bound calcium. Measured serum calcium is
low in hypoalbuminemia but the physiologically
active ionized calcium fragment may be unaffected.
● Calcium chelates phosphorus; caution must be used
when administering either when the concentration
of the other is high.
Normal anion gap is 15 mEq/l. K+ is sometimes omitted
and changes the normal value of the anion gap to 12 mEq/l.
Anion gap acidotic states are due to excess lactate, 
salicylate intoxication, renal failure, penicillins, diabetic
ketoacidosis, or methanol, ethylene glycol, or paralde-
hyde intoxication. Decreased serum unmeasured cations
such as potassium, calcium, and magnesium will increase
the anion gap. Increased unmeasured anions such as phos-
phate and sulfate will increase the anion gap. Bicarbonate
loss is most often due to renal failure (renal tubular acid-
osis), diarrhea, hypersecretory states, or cholestyramine.
Lost bicarbonate will be compensated by Cl− reabsorption
to maintain electrical neutrality (Box 6-2).
Patients with chronic respiratory acidosis who
acutely receive mechanical ventilatory support are at
risk of developing a relative state of acute metabolic aci-
dosis, whereby the artificially imposed hyperventilation
impairs the ability of their kidneys to retain bicarbonate.
Thus, over-ventilation is a common iatrogenic cause of
failure to wean from mechanical ventilation. Acute
hyperventilation of patients with chronic respiratory fail-
ure will delay weaning because chronically retained
HCO3− will be rapidly lost, and during weaning increased
PCO2 (which may be unavoidable because of abnormal
respiratory mechanics) will cause an acutely uncompen-
sated acidosis. Respiratory acidosis is usually well tolerated
to a pH ≥ 7.25. Respiratory acid–base physiology is 
covered in Chapter 4. Bicarbonate administration may 
be used to correct metabolic acidosis. A pitfall of bicar-
bonate administration is the development of acute
hypernatremia.
Alkalosis
Metabolic alkalosis is usually due to chloride loss
(vomiting, nasogastric suction, cystic fibrosis, villous
adenomas, post-hypercapneic alkalosis) or acute intra-
vascular volume loss (volume contraction) which is
accompanied by hyperaldosteronism. Chloride replace-
ment (NaCl, HCl) will correct metabolic acidosis due to
chloride loss. Urine chloride is a diagnostic aid: low urine
chloride (<15 mEq/l) is seen in vomiting, nasogastric
suction, acute diuresis, post-hypercapnic syndrome, and
alkali loading; high urine chloride (>20 mEq/l) is seen
with mineralocorticoid excess, alkali loading, chronic
diuresis, hypokalemia, and Bartter’s syndrome.
Metabolic alkalosis resistant to chloride replacement is
frequently due to hyperaldosteronism, hyperreninism,
severe potassium depletion, refeeding alkalosis,
hypoparathyroidism, licorice ingestion, 11- or 17-adrenal
hydroxylase deficiency, or Cushing’s syndrome. It
should be aggressively treated. Alkalosis causes bron-
choconstriction, coronary artery vasoconstriction, and
can cause shifts in potassium intracellularly which can
affect cardiac pacemaker cells and lead to arrhythmias.
Alkalosis also decreases ionized calcium levels and
affects cardiac contractility. Hyperkalemia can precipitate
intracellular acidosis in the renal tubules, which results
in bicarbonate retention and metabolic alkalosis.
CRYSTALLOIDS
Crystalloids are electrolytes dissolved in sterile water.
Normal saline (NS) is 0.9% saline. It is not electrically
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CLINICAL CAVEAT
Treatment of Alkalosis
● Acetazolamide is useful in those patients who have
excess total body water but are alkalotic.
Acetazolamide is a diuteric that inhibits carbonic
anhydrase and leads to HCO3− (and K+) loss.
● HCO3− excess = 0.5 × Wt (kg) × (HCO3− observed −
HCO3− desired).
● Normal hydrochloric acid (HCl) is used to treat
severe metabolic alkalosis; 0.1 or 0.2 N HCl has
100 mEq/l hydrogen and chloride ions.
PEARLS
● pH, PaO2, PaCO2, and saturation are measured.
HCO3− is calculated. CO2 is measured.
● An acute increase in PCO2 of 10 mmHg will
decrease pH by 0.05 unit.
● An acute decrease in PCO2 of 10 mmHg will
increase pH by 0.1 unit.
● An acute increase in PCO2 of 10 mmHg will be
buffered by 1 mEq/l increase in HCO3−.
● An acute decrease in PCO2 of 10 mmHg will be
buffered by a 2.5 mEq/l decrease in HCO3−.
● A chronic increase in PCO2 of 10 mmHg will be
buffered by a 2.5–3.5 mEq/l increase in HCO3−.
● A chronic decrease in PCO2 of 10 mmHg will be
buffered by a 5 mEq/l decrease in HCO3−.
Box 6-2 Acidosis Treatment
Identification and directed treatment of the
underlying cause of metabolic acidosis is essential.
TRIS (Tromethamine, THAM) is an intravenous
buffer solution with a buffering capacity of 1 mEq/ml
at a concentration of 36 g/l. The advantage of THAM is
a relatively low sodium load, which is beneficial in the
setting of acidosis and pre-existing hypernatremia or
sodium overload.
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Box 6-3 Starling–Landis Equation
The Starling–Landis equation defines transcapillary fluid
flux:
F = k[(PH − PISF) − δ (COPV − COPISF)]
where k is the ultrafiltration coefficient of fluid; PH is
the intravascular hydrostatic pressure; PISF is the
hydrostatic pressure of intravascular fluid; δ is the
reflection coefficient; COPV is the intravascular oncotic
pressure; and COPISF is the oncotic pressure of the
interstitial fluid.
normal (1 gEq/l). NS is termed “normal” because it is iso-
tonic (actually slightly hypertonic at 308 mOsm/l) with
human ECF.
NS is acidic and unbuffered. Accumulation of chloride
with NS administration results in hyperchloremic meta-
bolic acidosis. Lactated Ringer’s solution, or Hartman’s
solution, is a balanced-salt solution with a composition
closely approximating human ECF. Under normal condi-
tions the infused lactate is extracted (primarily in the
liver) and converted to bicarbonate and water. Solutions
containing dextrose, acetate, or lactate (RL, D5W,
D51/2NS, D51/4NS, Normosol, etc.) add to free water
load. Free water is contraindicated in head injury patients
and hyponatremia. Hypertonic saline (1.8%, 3%, or 5%)
expands intravascular volume transiently primarily
through its osmotic effects, drawing fluid from the inter-
stitial and intracellular spaces (Table 6-4).
COLLOIDS
Colloids maintain or increase oncotic pressure (COP).
Normal plasma COP is 25–30 mmHg. COP cannot be
inferred from plasma protein concentrations – it must be
measured. Albumin accounts for most of the COP of
plasma. However, albumin also accounts for binding of
electrolytes, drugs, and other molecules, free radical
scavenging, toxin binding, and inhibition of platelet
aggregation. If plasma COP remains above 20 mmHg it is
likely that plasma albumin concentration, in itself, is of
no significance in transmembrane fluid flux (Box 6-3).
In the absence of pathologic capillary leak syndrome,
edema is favored by increased intravascular hydrostatic
pressure, increased interstitial oncotic pressure, or
decreased intravascular oncotic pressure. Tissue edema
increases the diffusion distance for oxygen and can lead
to widespread relative cellular hypoxia.
Volume for volume, colloids increase threefold the
effect of crystalloids on preload. In the setting of inflam-
mation “capillary leak” may allow colloids to leak from
the vascular to the ISF space, diminishing volume expan-
sion and contributing to “third space” losses and diffuse
edema. The intravascular half-life of colloids depends on
elimination and metabolism, molecular size, and the
presence of capillary leak. Six percent Hetastarch in 0.9
normal saline (HespanR) is implicated in coagulopathy
(alteration of platelet rheology and adhesion) at volumes
exceeding 1.5 liters in a 70 kg patient and in hyper-
chloremic acidosis due to the chloride load inherent in
saline. Six percent Hetastarch in Ringer’s lactate
(HextendR) is not presently implicated in either coagu-
lopathy or hyperchloremic acidosis (Table 6-5).
BLOOD AND BLOOD PRODUCTS
Red Cell Transfusion
Anemia is frequently diagnosed in hospitalized patients,
especially those with critical illness. Whereas acute ane-
mia, most commonly due to blood loss, may be life-threat-
ening, anemia of gradual onset is usually well-tolerated 
due to cardiovascular compensation (increased cardiac
output). Causes of anemia which are often overlooked
include hemodilution, phlebotomy, or drug-induced
hemolysis. The primary function of red blood cell transfu-
sion is to maintain oxygen carrying capacity. Red blood
cell transfusion should never be used solely for intravascu-
lar volume expansion. Although the transfusion of red
blood cells to maintain an arbitary hematocrit level has
been a mainstay of ICU therapy, the practice of routine red
blood cell transfusion is being increasingly challenged.
Transfusions have been shown to impair immune func-
tion, to increase the risk of nosocomial infectious compli-
cations, and also to promote the spread of tumor emboli
during cancer surgery. Moreover, critically ill patients are
at risk of erythropoietin deficiency. Therefore, alternatives
to transfusion such as therapeutic erythropoietin supple-
mentation, vitamin and mineral supplementation, and
appropriate caloric intake are important adjuncts in both
acute and chronic care.
Patients at risk for hemorrhage should have at least
one catheter placed into a large vein. The Poisseuille–
Hagen formula defines flow through catheters. Flow is
faster with short, wide-bore catheters, and with fluids of
low viscosity. As much as 750 cm3 of acute blood loss
can be tolerated without hemodynamic derangements in
a typical adult. The first sign of acute hemorrhage is a
narrowing of pulse pressure which occurs with a Class
II (750–1000 cm3) hemorrhage. Tachycardia does not
occur until late in Class II hemorrhage. Patients with 
cardiomyopathy, medications that decrease or limit heart
rate (beta-blockers, calcium channel blockers, digitalis),
or patients with dysautonomia due to diabetes mellitus
may not show tachycardia despite severe hypovolemia.
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The optimal hematocrit in ICU patients has not been
well defined. A hematocrit as low as 21% is often
well tolerated. Cardiac output increases in anemia to
maintain oxygen delivery (DO2). Where increased car-
diac output is not possible (cardiomyopathy) or poten-
tially detrimental (myocardial ischemia) a hematocrit
closer to 30% may be better. Patients with severe COPD
often have hematocrits of 45–50% prior to admission to
compensate for chronic hypoxemia. These patients may
need hematocrits closer to their normal values to wean
successfully from mechanical ventilation. The typical
ICU patient loses the equivalent of approximately 1 unit
of packed red blood cells (PRBCs)/week to diagnostic
phlebotomy. Where possible, phlebotomy should be
limited and blood collected in pediatric phlebotomy
tubes. Blood conservation strategies may decrease the
need for transfusions significantly, especially in chronic
ICU patients. Empiric transfusion triggers should be
avoided. Risk and benefit must be considered. Informed
consent should be obtained and documented for all
transfusions whenever possible. At higher hematocrits,
blood viscosity increases and may decrease cardiac out-
put and impair microcapillary blood flow. Whole blood
is no longer available unless it is an autologous donation.
Red blood cells are stored in a CPD solution (citrate,
phosphate, dextrose). Citrate metabolism can contribute
to metabolic alkalosis; citrate accumulation binds cal-
cium and can contribute to hypocalcemia. PRBCs are
used to restore oxygen-carrying capacity. Each unit of
PRBCs will increase the plasma hemoglobin by about 1%
and the hematocrit by 3%. There is no rate limit on the
transfusion of blood or blood products. The rate is
determined by the clinical situation and the patient’s
physiology. Normal erythrocyte destruction in banked
blood causes banked blood to progressively increase in
potassium content. The K+ in PRBCs stored longer than
three weeks can approximate 20 mEq/l. Transfusion of
PRBCs through intravenous catheters smaller than 18 gauge
will lead to increasing levels of mechanical hemolysis
the smaller the catheter size.
Leukocyte-poor PRBCs are indicated for patients who
have had prior white cell or leukoagglutinin reactions, or
who are at risk for graft versus host (GVH) reactions. In
immunosuppressed patients at high risk for GVH, the
blood is usually also irradiated to further decrease the
number of viable leukocytes. The hematocrit of trans-
fused red blood cells ranges from 60 to 80%. Transfusion
flow can be increased by diluting PRBCs with 0.9 NS,
which decreases viscosity. Ringer’s lactate contains cal-
cium and should not be mixed with PRBCs since it can
precipitate thrombosis in vitro. Transfusion of PRBCs in
D5W, an iso-osmotic but hypotonic solution, will cause
red cell lysis.
Complications of transfusion are of major concern to
the public. TRALI is transfusion-related acute lung injury
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Table 6-5 Electrolyte Composition and Characteristics of Typical Colloid Solutions
Na Cl Lactate  Albumin  Dextran HES COP 
Solution (mEq/l) (mEq/l) (mEq/l) (g/l) (g/l) (g/l) pH (mmHg) Osm
Albumin 5% 154 154 0 50 0 0 6.6 20 290
Albumin 25% 154 154 0 250 0 0 6.9 100 310
HES
HespanR 154 154 0 0 0 60 310
HextendR* 130 109 28 0 0 60 310
Pentastarch
Dextran 40
Water 0 0 0 0 100 0 6.7 68 320
NS 154 154 0 0 100 0 6.7 68 320
Dextran 70 154 154 0 0 60 0 6.3 70 320
* Hextend also contains K+ 4 mEq/l; and Ca2+ 3 mEq/l.
PEARLS
● Oxygen delivery is the product of arterial oxygen
content and cardiac output: DO2 = CaO2 × CO.
● Arterial oxygen content includes the oxygen bound
to hemoglobin and the oxygen dissolved in blood:
CaO2 = ([Hg] × Sat × 1.34) + (PaO2 × 0.0031).
● Note that dissolved arterial oxygen, which is based
in the PaO2, is negligible.
● The Pouiseille–Hagen formula defines flow in
catheters: resistance = (8 μl/πr4).
● Flow = 1/R.
● Flow is inversely proportional to catheter length.
Flow is directly proportional to radius to the fourth
power; hence small increases in catheter diameter
increase flow significantly.
● A short peripheral IV will have better flow dynamics
than a long central line (triple lumen or PICC).
and is a pulmonary manifestation of systemic inflamma-
tion in the setting of large-volume transfusions.
Infectious complications of transfusion persist despite
testing and include transmission of HIV, hepatitis A–E,
cytomegalovirus (CMV), West Nile virus, and prions.
Transfusions must be administered through filters which
filter microaggregates of fibrin, platelets, and cells rang-
ing in size from 20 to 170 μm. Hypothermia can compli-
cate rapid infusion of unwarmed PRBCs stored at 4°C.
Acute hemolytic reactions have an incidence of 1/6000
and are fatal in about 1/100,000 transfusions. The most
common cause of transfusion reaction is clerical error
and therefore autologous blood is not significantly safer
than homologous blood transfusion. Acute hemolytic
transfusion reactions are usually due to ABO erythrocyte
surface antigen incompatibility between donor and recip-
ient red cells. Acute hemolytic transfusion reactions are
potentially life threatening. Morbidity is related to the vol-
ume of cells infused. Recipient blood should be exam-
ined for xanthochromia and free hemoglobin. A positive
direct Coomb’s test confirms a hemolytic reaction; how-
ever, a false negative direct Coomb’s test is seen when the
majority of donor cells are already lysed. Serum LDH is
usually elevated and serum haptoglobin decreased.
Platelet Transfusion
Thrombocytopenia is variably defined as a platelet
count less than 100,000–150,000/mm3. In the absence
of risk factors, platelet counts as low as 5000/mm3 may
be tolerated without bleeding. Platelet counts below
5000/mm3 are associated with a high risk of sponta-
neous hemorrhage. Platelet counts ≥ 50,000/mm3 are
sufficient to provide hemostasis for surgical procedures,
assuming the platelets are functional (absence of uremia,
NSAID, or aspirin therapy). Causes of thrombocytopenia
include sepsis, disseminated intravascular coagulation,
thrombotic thrombocytopenic purpura, and heparin-
associated thrombocytopenia (HAT). Thrombocytopenia
may be the earliest hematologic abnormality in sepsis.
Dilutional thrombocytopenia can occur with large fluid
volume or multiple packed cell infusions. The major
complication of HAT is thrombosis, not bleeding.
Platelet dysfunction is most commonly due to renal
insufficiency, cardiopulmonary bypass, or medications.
Platelets are stored at room temperature. Hypothermia
interferes with platelet thromboxane synthesis and clot-
ting. Platelets are normally pooled from multiple donors,
increasing the potential for infectious complications.
Each unit of platelets transfused is expected to increase
the platelet count by 5000–10,000/mm3, unless destruc-
tion or sequestration is ongoing. Platelets are usually
administered as six-packs, which raise the platelet count
by 25,000–50,000/mm3. ABO compatible platelets are
less likely to form antiplatelet antibodies and therefore
survive longer post-transfusion. Platelets do not contain
Rh antigens. DDAVP (Desmopressin) 0.3–0.4 μg/kg tran-
siently improves platelet function in the setting of von
Willebrand’s disease, uremia, aspirin ingestion, or post-
cardiopulmonary bypass.
Fresh Frozen Plasma
Fresh frozen plasma (FFP) contains antithrombin III
and can be used to treat heparin resistance. A corollary
is that FFP can increase the anticoagulant effect of
heparin. The main indication for FFP is the rapid rever-
sal of coumadin-induced anticoagulation, replacement of
vitamin K-dependent coagulation factors (cirrhosis). FFP
is indicated for replacement of factors II, V, VII, VIII, IX,
X, XI, and XIII, and von Willebrand’s factor. Each milli-
liter of transfused plasma contains only about 1 unit of
each factor, necessitating large volumes of plasma for
effective factor replacement. Allergic reactions to FFP
are common because of platelets and leukocytes. FFP
should be compatible with the recipient’s red blood
cells, but need not be compatible with the recipient’s
plasma. FFP is not indicated for volume expansion and
should not be used as a colloid substitute.
Cryoprecipitate
Cryoprecipitate is a plasma concentrate pooled from
multiple donors and contains primarily factor VIII and
fibrinogen. A unit of cryoprecipitate contains about 100
units of factor VIII and 250 mg of fibrinogen. A typical
dose of cryoprecipitate is 8–10 units, which increases
factor VIII levels by an average of 2%. A thromboelasto-
graph is a useful guide to platelet, FFP, or cryoprecipi-
tate replacement.
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Summary
Fueled by evidence-based medicine, the pharmaco-
logic and nonpharmacologic approaches to the manage-
ment of arrhythmias have significantly evolved over the
last two decades. The perioperative and critical care
physician must be cognizant of the diagnosis and man-
agement of arrhythmias in the perioperative period and
critical illness. The optimal management of arrhythmias
in the perioperative period and critical illness requires
knowledge of the basic cardiac electrophysiology,
underlying medical problems, risk factors precipitating
arrhythmias, pharmacology of antiarrhythmic drugs, as
well as drug interactions between anti-arrhythmic drugs
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and drugs used in anesthesia and intensive care. In addi-
tion, the perioperative and critical care physician should
be familiar with implantable devices used in the treat-
ment of arrhythmias. This review summarizes recent
advances in our understanding of arrhythmia mecha-
nisms and management.
ELECTROPHYSIOLOGIC MECHANISMS 
OF ARRHYTHMIA
Knowledge of the cardiac action potential is a pre-
requisite for a better understanding of the pathophysio-
logic mechanisms underlying arrhythmia formation.
The cardiac action potential represents the rapid flux
of ions across the cardiomyocytes producing a wave-
front of excitation. An electrocardiogram (ECG) is a
recording of the electrical activity of the heart from sur-
face electrodes. Figure 7-1 summarizes the action poten-
tial and ECG. The ventricular cell at baseline maintains a
resting potential of −80 to −90 mV (polarized state) as a
result of a high level of potassium conductance across
the cell membrane. The action potential is divided into
four phases depending upon the channel activation and
changes in membrane potential. Phase 0 is the result of
activation of fast sodium channels producing an over-
shoot in membrane potential, phase 1 results from the
transient outward potassium currents and results in a
slight fall in membrane potential, phase 2 (plateau)
results from a balance of inward (sodium and calcium)
and outward (potassium) currents, phase 3 results from
the delayed activation of potassium channels, and in
some pacemaker cells (sinoatrial and atrioventricular)
phase 4 results in slow spontaneous depolarization lead-
ing to another action potential. This explains the auto-
maticity of the pacemaker cells. Phases 0 to 2 represent
depolarization and phase 3 repolarization of the car-
diac myocyes. The ECG records the electrical activity of
the heart that triggers heart muscle to contract (Figure 7-2).
The sinoatrial (S-A) node signals the beginning of the 
cardiac cycle with the P wave on the ECG due to atrial
depolarization. Atrial repolarization is usually too small
in amplitude to be detected on the ECG. Next, the elec-
trical impulse travels through the atrioventricular (A-V)
node to reach the ventricular muscle cells. The QRS
complex represents ventricular depolarization, and the
ST-T complex represents ventricular repolarization. The
J point is the junction between the end of the QRS com-
plex and the beginning of the ST segment. The rapid
upstroke (phase 0) of the action potential corresponds
to the onset of QRS. The plateau (phase 2) corresponds
to the isoelectric ST segment, and active repolarization
(phase 3) to the beginning of the T wave.
There are three fundamental electrophysiologic
mechanisms that are responsible for arrhythmia formation.
Reentry
Reentry is the most common mechanism underlying
arrhythmia formation. Three conditions must be met for
the reentry mechanism to result in an arrhythmia: the
presence of a central area of inexcitable tissue separat-
ing two pathways for conduction, unidirectional block
in one of the two pathways, and slow conduction per-
mitting delay and recovery of excitability in the previ-
ously blocked area. Pathologic substrate, as in the tissue
surrounding an infarct zone, or altered milieu, as in func-
tional alterations in conduction secondary to electrolyte
disturbance, or ischemia can predispose to reentry-
induced arrhythmia.
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Figure 7-1 Phases of ventricular action potential and ECG.
Phase 0, overshoot is caused by rapid inward Na current; Phase 1,
transient potassium efflux; phase 2 (plateau), slow inward Ca cur-
rent; phase 3 (repolarization), outward K current; phase 4, resting
potential maintained by Na–K–ATPase pump. Specialized conduc-
tion system tissue has spontaneous depolarization during phase 4.
EAD, early after-depolarization; DAD, delayed after-depolarization.
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Figure 7-2 ECG cardiac cycle. ARP, absolute refractory period;
RRP, relative refractory period; J, J-point.
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Abnormal Automaticity
Abnormal automaticity refers to the development of
slow, spontaneous phase 4 depolarization in the cells
that otherwise do not exhibit automatic pacemaker
activity. Under certain conditions ventricular myocytes
may develop a “leakage current” during phase 4, result-
ing in impulse formation. Abnormal automaticity causes
repetitive depolarization at rates faster than that found in
normally automatic tissues, resulting in overdrive sup-
pression of the S-A node. Ischemic and diseased cardiac
tissue is susceptible to arrhythmias due to abnormal
automaticity, especially under increased sympathetic
activity and metabolic disturbances.
Triggered Activity
Triggered activity refers to abnormal impulse forma-
tion from after-depolarizations. Early or delayed after-
depolarizations are oscillations of membrane potential
occurring during or immediately after repolarization.
The early after-depolarization appears to be related to
delayed reactivation of ion channels that carry inward
depolarizing currents. These channels are responsible
for the plateau phase of the action potential (phase 3).
With prolonged duration of the action potential, these
channels may reopen, resulting in a net inward flow of
ions. Once early after-depolarization reaches a sufficient
threshold, abnormal impulse propagation is triggered.
Certain conditions are associated with prolonged action
potential (a prolonged QT interval), such as bradycardia,
certain antiarrhythmic drugs (quinine, procainamide,
and sotalol), and electrolyte disturbances, such as
hypokalemia, hypocalcemia, and hypomagnesemia.
Torsades de pointes is an example of triggered arrhyth-
mia due to early after-depolarization. Delayed after-
depolarization results from increased intracellular calcium
levels. Catecholamines, ischemia, and digitalis-induced
arrhythmias are examples of triggered arrhythmias due
to delayed after-depolarization. The common finding
among these causes is intracellular calcium overload.
RISK FACTORS FOR ARRHYTHMIAS IN
ANESTHESIA AND CRITICAL ILLNESS
Anesthesia and critical illness are associated with sig-
nificant perturbations that, in a susceptible patient, can
precipitate cardiac arrhythmias. The risk of developing
atrial fibrillation increases substantially with age.
Arrhythmia formation is multifactorial. In the periopera-
tive period the interaction between structural heart 
disease, altered milieu, and drugs often leads to the for-
mation of arrhythmias (Box 7-1). Table 7-1 summarizes
the triad of risk factors for arrhythmias. In addition, the
type of surgery (cardiac vs. noncardiac) carries specific
risk for certain types of arrhythmias. For example, atrial
fibrillation is more common following cardiac surgery.
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Table 7-1 Risk Triad for Arrhythmias
1. Structural Heart Disease 2. Altered Milieu 3. Drugs
Coronary artery disease Metabolic disturbances Catecholamines
Valvular heart disease Electrolyte abnormalities Volatile anesthetics
Congenital heart disease Hyperkalemia QT interval-prolonging drugs
Cardiomyopathy Hypokalemia Beta-blocker withdrawal
Sick sinus syndrome Hypomagnesemia
Long QT interval syndromes Hypocalcemia
Wolff–Parkinson–White syndrome Acid–base imbalance
Severe acidemia or alkalemia
Myocardial ischemia, CAD, hypotension, 
hypoxia
Neurohumoral stress response, hypoxia, 
hypercarbia, laryngoscopy and intubation 
pain, systemic inflammatory response, 
hypovolemia and fluid overload
Miscellaneous intravascular and intracardiac 
catheters, device malfunction and 
microshock
Box 7-1 Risk Factors for Arrhythmias
Structural heart disease, altered milieu, and drugs
represent the triad of risk factors for arrhythmias.
Structural Heart Disease
Perioperative arrhythmias are more likely to occur in
the presence of structural heart disease. Patients with
chronic coronary artery disease (ischemia and infarction)
have areas of normal, slow, or absent conduction inter-
acting with nonuniform myocardial refractoriness.
Valvular heart disease can be associated with myocardial
fiber stretch (increased volume or wall stress). Cardio-
myopathies of various etiologies, such as hypertrophic,
dilated, infiltrative, or due to metabolic disorders (uremia,
diabetes), usually lead to ventricular arrhythmias. Other
examples of structural heart disease associated with
increased risk of arrhythmia include congenital heart
disease, sick sinus syndrome, long QT interval syndrome,
and Wolff–Parkinson–White syndrome.
Altered Milieu
Anesthesia, perioperative period, and critical illness
with its associated metabolic, ischemic, and neuro-
humoral stressors produce altered milieu surrounding
cardiomyocytes and result in changes in refractoriness
or conduction of impulses. Thus, in the patient with
underlying structural heart disease, altered milieu can
precipitate cardiac arrhythmias.
Metabolic Disturbances
Specific electrolyte abnormalities, such as potassium,
magnesium, and calcium, are well known to produce
arrhythmias.
Potassium
Hypokalemia hyperpolarizes the resting membrane
potential to a more negative value, and may cause slow-
ing of conduction. In addition, hypokalemia decreases
potassium conductance producing delayed repolarization
and early after-depolarization (enhanced automaticity).
Hyperkalemia increases the permeability to potassium
and shifts the resting membrane potential to a less negative
value. This results in shortening of the action potential 
and suppressed automaticity, and slowing of conduction.
QRS is markedly widened with severe hyperkalemia.
Therefore, treatment of hyperkalemia demands immediate
attention.
Calcium
Hypocalcemia causes prolongation of QT interval and
may result in early after-depolarization and triggered
arrhythmias, e.g., Torsade de pointes. Hypercalcemia
produces shortening of QT interval and usually does not
produce triggered arrhythmias.
Magnesium
Hypomagnesemia is also associated with prolongation
of QT interval and torsades de pointes. Hypermagne-
semia can lead to slowing of A-V nodal and ventricular
conduction. Conditions associated with hypomagnes-
emia include cachexia and malnutrition, critical illness,
cardiopulmonary bypass, hemodialysis, alcoholism, can-
cer and chemotherapy, and potassium-wasting diuretics.
It is important to emphasize that magnesium, calcium,
and potassium deficits often coexist and that magnesium
repletion must be undertaken at the same time as reple-
tion of potassium and calcium.
Acid–Base Imbalance
Acid–base homeostasis plays a critical role in tissue and
organ performance. Management of arrhythmias in the
presence of serious acid–base disorders demands precise
diagnosis and treatment of the underlying disease. Severe
acidemia can cause sensitization of the myocardium to
reentrant arrhythmias and reduction in threshold for 
ventricular fibrillation. Severe alkalemia can sensitize the
myocardium to refractory supraventricular and ventric-
ular arrhythmias. Severe acid–base disorders are also asso-
ciated with electrolyte abnormalities. Hyperkalemia is not
uncommon with severe acidemia. Hypokalemia and
hypocalcemia are frequently seen with severe alkalemia.
Ischemia
Myocardial ischemia in the perioperative period and
critical illness can occur as a consequence of underlying
coronary artery disease or from hemodynamic and
hypoxic stress. Electrophysiologic effects of myocardial
ischemia include partial depolarization of the resting
membrane potential resulting in inactivation of fast
sodium channels and slowing of conduction, increased
intracellular calcium load, elevation of extracellular
potassium, and prolongation of refractoriness. Ischemia-
induced arrhythmias are mediated by abnormal auto-
maticity, triggered activity, and reentry.
Neurohumoral Stressors
In addition to the above, many events in anesthesia and
critical illness can invoke the neurohumoral stress response
and precipitate arrhythmias. The result is increased sympa-
thetic activity and catecholamine response. Examples of
these events include hypoxia and hypercarbia, laryn-
goscopy and tracheal intubation, hypovolemia and fluid
overload, pain, and systemic inflammatory response.
Miscellaneous
Diagnostic and therapeutic interventions involving
intravascular and intracardiac catheters, device malfunc-
tion, or microschock can also predispose to mechani-
cally induced arrhythmias.
Drugs
A multitude of drugs used in anesthesia and critical
illness have effects on cardiac electrophysiology and can
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cause arrhythmias either by themselves or acting in con-
cert with the two risk factors discussed above (structural
heart disease and altered milieu).
Catecholamines
Through stimulation of β-adrenergic receptors,
endogenous (sympathetic activation) or exogenous cate-
cholamines can result in enhanced automaticity or trig-
gered activity. Reentry may also be facilitated in the
presence of ischemia.
Volatile Anesthetics
There is increasing evidence that volatile anesthetics
have potent electrophysiologic influences on arrhythmias
due to both altered impulse initiation and conduction.
Depression of inward Ca2+ currents by the volatile anes-
thetics contributes to largely antiarrhythmic actions on
mechanisms generating abnormal impulses as a result
of intracellular Ca2+ “overload” resulting from cate-
cholamine exposure, digitalis intoxication, and ischemia.
On the other hand, the actions of volatile anesthetics in
combination with catecholamines depressing conduc-
tion and altering refractoriness of the myocardium may
potentially facilitate the induction of reentrant arrhyth-
mias. The adverse interaction between volatile anesthet-
ics and catecholamines remains a clinically relevant
problem.
QT Interval-Prolonging Drugs
Prolongation of QT interval on the ECG can predis-
pose to a potentially lethal arrhythmia known as torsades
de pointes. QT interval-prolonging drugs have been
implicated in torsades de pointes. Some patients have
genetic predisposition for QT prolongation and manifest
with overt QT prolongation only with exposure to QT-
prolonging drugs. The presence of the triad of factors in
association with QT interval-prolonging drugs can result
in torsades de pointes. Table 7-2 lists commonly used QT
interval-prolonging drugs. It is also very important to
understand drug interactions between cardiac and
noncardiac QT interval-prolonging drugs. These inter-
actions can be pharmacodynamic (both drugs affect 
cardiac electrophysiology), pharmacokinetic (one drug
affects clearance of the other), or mixed in nature.
Therefore, combination of QT interval-prolonging drugs
should be avoided.
Drug Withdrawal
Beta-blockers are commonly used in the prophylaxis
and treatment of arrhythmias in the high-risk patient.
Beta-blocker withdrawal has been associated with post-
operative supraventricular arrhythmias. A state of increased
catecholamine effect occurs because of chronic β-blocker
associated up-regulation (higher density) of β-adrenergic
receptors.
CLASSIFICATION, DIAGNOSIS, AND
MANAGEMENT OF ARRHYTHMIAS
Cardiac arrhythmias may be simply classified as
(1) those resulting in cardiac arrest, (2) bradyarrhythmias,
(3) ventricular arrhythmias, and (4) supraventricular
arrhythmias. This classification places an emphasis on
the urgency of diagnosis and management. Table 7-3
summarizes the classification of cardiac arrhythmias.
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Table 7-2 QT Interval-Prolonging Drugs
Antiarrhythmics Amiodarone, Disopyramide, Ibutilide,
Dofitilide, Procainamide, Quinidine,
Sotalol
Antipsychotics Thioridazine, Pimozide, Ziprasidone,
Haloperidol, Risperidone
Anti-infectives Erythromycin, Clarithromycin,
Pentamidine, Sparfloxacin
Antiemetics Droperidol
Antifungals Ketoconazole, fluconazole, itraconazole
Others Cisapride, Bepridil
Table 7-3 Classification of Cardiac Arrhythmias
Cardiac Arrhythmia Examples
Cardiac arrest Ventricular fibrillation
arrhythmias Pulseless ventricular tachycardia
Pulseless electrical activity (PEA)
Asystole
Supraventricular Paroxysmal supraventricular tachycardia
arrhythmias A-V nodal reentry tachycardia (AVNRT)
Atrioventricular reentry tachycardia
(AVRT)
Intraatrial reentry tachycardia
Automatic atrial tachycardia
A-V junctional tachycardia
Atrial fibrillation/atrial flutter
Multifocal atrial tachycardia
Wolff–Parkinson–White syndrome
Ventricular Nonsustained ventricular tachycardia
arrhythmias Sustained ventricular tachycardia
Monomorphic
Polymorphic (Torsades de pointes)
Ventricular fibrillation
Bradyarrhythmias Sinus bradycardia
First-degree heart block
Second-degree heart block
Type I (Mobitz I – Wanckebach)
Type II (Mobitz II – non-Wanckebach)
Third-degree heart block
(A-V dissociation)
General Approach to the Diagnosis and
Management of Arrhythmias
Basic Principles
The following basic principles must be followed in
managing arrhythmias.
Treat the patient and not the ECG. One must first
decide if the arrhythmia is real or an artifact and whether
the arrhythmia is sufficient to account for the patient’s
symptoms and signs. A simply detached ECG lead can
display as asystole on the cardiac monitor. Similarly, shiv-
ering can be associated with ECG artifacts, which can 
be misinterpreted as ventricular or supraventricular
arrhythmias.
Establish the urgency of treatment. Clinical assess-
ment of the patient will establish the urgency of treat-
ment. Clinical assessment includes assessment of
responsiveness (or lack of) and a quick ABCD survey.
A defibrillator and help must be summoned for all unre-
sponsive patients. The ABCD survey consists of assess-
ment of Airway by opening the airway using head
tilt–chin lift or jaw-thrust maneuver for effective sponta-
neous breathing; Breathing by securing and confirming
airway device in an apneic patient and assuring oxy-
genation and ventilation; Circulation by checking for a
pulse and blood pressure, evaluation of peripheral per-
fusion, presence of myocardial ischemia and congestive
heart failure, and initiation of CPR in the pulseless
patient or defibrillation of identified ventricular fibrilla-
tion using a defibrillator; and Differential Diagnosis and
treatment of reversible causes, such as hypoventilation,
hypoxia, hypovolemia, metabolic disorders, etc.
Establish hemodynamic stability. Following the
initial ABCD survey and treatment, the goal must always
be to establish hemodynamic stability. Slowing the ven-
tricular response in the case of tachyarrhythmia or
increase in ventricular rate in bradyarrhythmia, or main-
taining adequate blood pressure using fluids or vaso-
active agents may achieve this goal.
Specific antiarrhythmic therapy. Next, antiarrhyth-
mic therapy is initiated based on arrhythmia diagnosis
and specifically targeted against the subcellular units.
The goal is to prevent recurrence of hemodynamic insta-
bility. Knowledge of ventricular function is also helpful
in the choice of antiarrhythmic therapy.
Restoration of sinus rhythm. Restoration of sinus
rhythm is always desirable, but may not be achievable
under specific circumstances, such as a heightened state
of sympathetic activity.
Prevention of complications. In patients in whom
sinus rhythm cannot be achieved, measures must be
taken to prevent complications related to specific
arrhythmia, e.g., thromboembolic complications due to
atrial fibrillation.
Approach to Arrhythmia Diagnosis
A 12-lead ECG must be obtained for complete inter-
pretation of arrhythmia. In the absence of a 12-lead ECG,
a long rhythm strip of a lead in which P waves are visible
is preferred. Mere observation of ECG rhythm on the
monitor may be misleading. A systemic approach to ECG
diagnosis of arrhythmia includes the following.
Rate and regularity of rhythm. The rate of normal
sinus rhythm in adults is between 60 and 100
beats/minute. Sinus tachycardia usually occurs at a rate
between 100 and 180 beats/minute. The definition of
clinically significant bradycardia or tachycardia must be
individualized. Atrial tachycardia and A-V nodal reentrant
usually present with rates from 140 to 220 beats/minute.
Rates between 240 and 320 are most likely to represent
atrial flutter. PP and RR cycles, and relation of P wave to
QRS will suggest regularity of rhythm.
Location of P waves. Leads II, III, aVF, or V1 are best
used to ascertain P waves. If no P waves are present and
RR intervals are irregular, the rhythm is most likely atrial
fibrillation. A narrow QRS complex tachycardia without
discernible P waves is most likely caused by A-V nodal
reentry. When the atria and ventricles are controlled by
independent pacemaker foci with similar rates, P waves
appear to “march in and out” of the QRS complex. This
is termed isorhythmic A-V dissociation. P waves of two
or more morphologies are characteristic of multifocal
atrial tachycardia.
Relationship between P waves and QRS complexes.
If there are more P waves than QRS complexes, then
A-V block is present. If there are more QRS complexes
than P waves, the rhythm is junctional or ventricular in
origin.
QRS morphology. A narrow QRS complex (<0.12 ms)
indicates supraventricular arrhythmia. A wide QRS com-
plex (>0.12 ms) can be present with either ventricular
tachycardia or supraventricular tachycardia with aber-
rant ventricular conduction.
Treatment of Specific Arrhythmias
Antiarrhythmic drug classification and agents are
summarized in Table 7-4.
Cardiac Arrest Arrhythmias
Early defibrillation, CPR, airway management, and
advanced cardiac life support are essential for neuro-
logic outcome in patients after cardiac arrest.
Ventricular Fibrillation and Pulseless Ventricular
Tachycardia
Pathophysiology. There are areas of normal
myocardium alternating with areas of ischemic, injured,
or infarcted myocardium, leading to chaotic pattern of
ventricular depolarization.
78 CRITICAL CARE: THE REQUISITES IN ANESTHESIOLOGY
ECG criteria (Figure 7-3). There are no recognizable
P, QRS, or T waves. The rate is difficult to determine.
The rhythm is indeterminate with patterns of upstrokes
and downstrokes. Ventricular fibrillation (VF) can be fine
(amplitude 1 to 5 mm) or coarse (amplitude 10 to 15 mm).
Clinical features. The patient becomes unconscious
without pulse. Respirations become agonal and apnea
quickly ensues. This can result in sudden death.
Etiology. Common etiologies of VF/pulseless ventric-
ular tachycardia (VT) include acute myocardial infarction
leading to areas of ischemic myocardium, untreated VT,
primary or secondary QT interval prolongation, PVCs
with R on T phenomenon, electrocution, and hypoxemia.
Therapy. Early defibrillation (asynchronous DC coun-
tershock) is the hallmark of treatment. Time to defibril-
lation is the most important determinant of survival from
cardiac arrest. Probability of successful resuscitation
declines by 2% to 10% per minute from the onset of
symptoms. In this respect the use of automatic external
defibrillators (AEDs) has gained popularity in a variety
of settings, public and healthcare alike. After a sequence
of three rapid defibrillation shocks (200, 220, 360 J),
pharmacologic therapy is considered. Current pharma-
cologic therapy consists of intravenous epinephrine 1 mg
every 3 to 5 minutes as an adrenergic stimulant to
improve perfusion pressure of vital organs. Vasopressin,
administered as 40 units intravenous push single dose,
may be used as an alternative to epinephrine and is
associated with less risk of postresuscitation tachy-
arrhythmias. Amiodarone (300 mg intravenous push) is
considered next to prevent refibrillation after a shock
causes defibrillation. If VF/VT recurs, administration of a
second dose of Amiodarone 150 mg IV should be con-
sidered, with a maximum cumulative dose of 2.2 g over
24 hours. Lidocaine and procainamide are considered of
indeterminate class benefit for persistent VF/VT.
Correction of hypomagnesemia and acidosis is consid-
ered using magnesium and sodium bicarbonate in pro-
longed arrest situations.
Pulseless Electrical Activity
Pathophysiology. In this condition there is electrical
activity in the form of cardiac conduction impulses, but
this fails to produce myocardial contraction or ejection.
ECG criteria (Figure 7-4). There is organized electrical
activity with narrow (QRS < 0.10 ms) or wide (> 0.10 ms)
waves, and at a fast or slow heart rate.
Clinical features. Clinical manifestations are the same
as those of pulseless VT/VF.
Etiologies. Common causes of pulseless electrical
activity are often reversible and can be grouped under
“five H’s”: hypovolemia, hypoxia, acidosis (increased
hydrogen ion), hyperkalemia/hypokalemia, hypothermia;
and “five T’s”: tablets (drug overdose, ingestions),
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Table 7-4 Classification of Antiarrhythmic Agents Based on Receptor Targets
Receptor Target ECG Changes (Class) Drugs
Na and K channels QRS and QT prolongation (IA) Procainamide,
Amiodarone,
disopyramide,
quinidine
Na channels QRS prolongation (IB) Lidocaine,
phenytoin,
mexiletine
Beta-receptors PR prolongation (II) Esmolol,
Amiodarone,
propranolol,
atenolol,
labetolol, sodalol
K channels QT prolongation (III) Bretylium,
ibutilide, sotalol,
dofetilide
Ca channels PR prolongation (IV) Verapamil,
deltiazem,
Amiodarone
Figure 7-3 Ventricular fibrillation.
tamponade (cardiac), tension pneumothorax, thrombus
(coronary), thromboembolism (pulmonary).
Therapy. Identification and treatment of reversible
causes is the mainstay of therapy. After establishment of
airway, ventilation, and basic CPR, intravenous epineph-
rine 1 mg or atropine 1 mg can be administered if heart
rate is < 60 beats per minute.
Asystole
Pathophysiology. It usually represents a terminal
rhythm.
ECG criteria (Figure 7-5). Classically asystole pres-
ents as a flat line. Asystole can be verified by checking
the lead and cable connection, increasing monitor gain,
and changing leads. There is no ventricular activity or at
a rate of <6 beats per minute. Occasionally P waves are
seen, but without R waves.
Clinical features. It presents as cardiac arrest with no
pulse or blood pressure, and agonal respirations.
Etiology. Usually indicates end of life. Reversible
causes such as the five H’s and five T’s should be sought
and corrected. Asystole can also be seen after massive
electrical shock or postdefibrillatory shock.
Therapy. After establishment of an airway, ventilation,
and basic CPR, intravenous epinephrine 1 mg (every 3 to
5 minutes) and atropine 1 mg (total 2 mg) is adminis-
tered. If considered, transcutaneous pacing is performed
immediately. With respect to hospital admissions and
discharge, a recent study found vasopressin (40 U) to be
superior to epinephrine in patients with asystole.
Supraventricular Arrhythmias
Atrial Fibrillation/Atrial Flutter
Atrial fibrillation (AF) occurs in 0.5–1% of the general
population, especially in patients older than 60 years.
In postcardiac surgery patients AF is more frequent
(10–65%). The frequency of AF in noncardiac surgery
patients falls between the above two groups (2–10%).
AF is the most common arrhythmia in the surgical inten-
sive care unit (cardiac and noncardiac). Five independ-
ent risk factors were identified in a recent study of AF in
surgical intensive care units. These were advanced age,
withdrawal of calcium channel blockers, blunt thoracic
trauma, shock, and use of a pulmonary artery catheter.
Pathophysiology. AF is an example of reentry tachy-
arrhythmia. In AF the atria contract in a chaotic fashion
and impulses travel in a random pathway through the
atria. The multiple wavelet theory is most common in
explaining the erratic electrical conduction occurring in
most AF. Alterations in the atrial electrophysiologic con-
ditions, such as decreased repolarization time, decreased
refractory periods, and variable refractory dispersion,
are favorable conditions to stimulate and maintain AF.
These conditions promote development of multiple
reentry circuits that perpetuate throughout the atria 
and allow AF to sustain. Atrial flutter involves impulses
traveling in a circular course around the atria.
ECG criteria (Figure 7-6). The classic pattern of AF is
an irregular rhythm with varying RR interval. P wave and
PR interval is not defined. In atrial flutter a “sawtooth”
pattern is classic. Unlike AF, ECG rhythm and ventricular
response is regular in atrial flutter with 2 to 1 or 3 to 1
ratio depending upon A-V node conduction block.
Clinical features. Signs and symptoms depend upon
the rate of ventricular response, with dyspnea, chest pain,
acute pulmonary edema, congestive heart failure, and
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Figure 7-5 Asystole. Figure 7-6 Atrial fibrillation (A) and atrial flutter (B).
A
B
Figure 7-4 Pulseless electrical activity (PEA). Organized
rhythm without detectable pulse.
altered consciousness often occurring with rapid ven-
tricular response. Loss of “atrial kick” may result in a
drop in cardiac output and blood pressure in patients
with ventricular hypertrophy and aortic stenosis.
Etiology. Common etiologies of atrial flutter/fibrilla-
tion include hypoxia (acute pulmonary embolism,
chronic obstructive pulmonary disease), enlargement of
atria (mitral or tricuspid valve disease, fluid overload),
acute coronary syndromes, hyperthyroidism, and drugs
such as digoxin and quinidine.
Therapy. The goals of AF/atrial flutter management
are hemodynamic stabilization, restoration and mainte-
nance of sinus rhythm, and prevention of thrombo-
embolism. The therapeutic decisions are based on four
factors: hemodynamic stability, cardiac function, presence
of pre-excitation on ECG, and duration (two days or more).
Cardioversion
Electrical or pharmacologic cardioversion must be
considered in patients with AF that presents with rapid
ventricular rate with hemodynamic compromise. Early
cardioversion increases both the success of cardio-
version and reduces the rate of recurrence, as well as the
need for anticoagulation. Current guidelines state that
patients with AF of less than 2 days’ duration can be
cardioverted without anticoagulation. Direct current
cardioversion usually is performed under sedation to
minimize patient discomfort. Adequate oxygenation
and ventilation must be ensured during the procedure.
A standard defibrillator is used to deliver a synchronized
shock at energies ranging from 100 to 300 J. The shock
electrode position can be either anterior–anterior (right
sternal border and left lateral chest wall) or anterior–
posterior (precordial and interscapular). Atrial flutter
requires a lower energy for cardioversion. Newer defib-
rillators with energy delivered in the form of biphasic
waveforms require less energy and provide greater suc-
cess with cardioversion. Several drugs, including ibutilide,
Amiodarone, procainamide, flecainide and propafenone,
have been used in the pharmacologic cardioversion of
AF or atrial flutter. The caveats in the pharmacologic
cardioversion of AF include avoiding multiple QT-
prolonging drugs, close watch for torsades de pointes,
and administration of magnesium.
Rate Control
For patients with AF or atrial flutter who present
with rapid ventricular rate and stable condition, rate
control can be achieved using pharmacologic means.
The rate-controlling drugs are A-V nodal blockers, which
act by slowing down the rate. These include beta-blockers,
calcium channel blockers, and digoxin. These drugs
should be avoided in patients with AF in association with
Wolff–Parkinson–White (WPW) syndrome. Pharmacologic
agents used for heart rate control in AF are shown in
Table 7-5.
Anticoagulation
Patients with AF lasting longer than two days or of
unknown or intermittent duration should be anticoagu-
lated with a therapeutic international normalized ratio
(INR) of 2–3 for at least 2–3 weeks before and after
cardioversion. Screening for left atrial thrombus by
echocardiography is an acceptable alternative to routine
pre-cardioversion anticoagulation. The risk of thrombo-
embolic complications is higher in patients older than 
65 years, with valvular heart disease, history of congestive
heart failure, enlarged atrium, left ventricular dysfunction,
and myocardial infarction.
Wolff–Parkinson–White Syndrome
Pathophysiology. A prototypical pre-excitation syn-
drome, WPW syndrome consists of an extra electrical
connection (accessory pathway) between the atria and
the ventricles that allows the atrial impulse to bypass the
A-V node. The majority of arrhythmias associated with
WPW syndrome are reciprocating tachycardias which
may be narrow complex or wide complex.
ECG criteria (Figure 7-7). When the accessory path-
ways conduct impulses in an antegrade direction, there
is a fusion of activation of the ventricles by the bypass
tract and the A-V nodal His-Purkinje system. This is rep-
resented on the ECG by a short PR interval (<120 ms) and
slurring of the initial component of the QRS complex
(delta wave) giving it a widened appearance (>120 ms).
Secondary ST-T wave changes generally are directed
opposite to the major delta and QRS vector.
Clinical features. Patients with WPW syndrome may
remain completely asymptomatic. Tachycardia may present
as palpitation, dyspnea, chest pain, or congestive heart fail-
ure (CHF). Hereditary and male predisposition is common.
Etiology. The accessory pathway in WPW syndrome
is a congenital malformation.
Therapy. Treatment of WPW syndrome is based on
the presence of hemodynamic instability, cardiac func-
tion impairment, or duration of AF with WPW syndrome.
AF with rapid ventricular response is the life-threatening
arrhythmia in the patient with WPW syndrome and
should be treated with electric cardioversion. In the
patient with a normal heart the choice of antiarrhythmic
drugs include Amiodarone, flecainide, procainamide,
propafenone, or sotalol. In the patient with impaired car-
diac function cardioversion or Amiodarone can be used.
Anticoagulation is required for AF with WPW syndrome
lasting more than two days.
CLINICAL CAVEAT
In pharmacologic cardioversion of atrial fibrillation/
atrial flutter: avoid multiple QT-prolonging drugs,
watch for torsades de pointes, and give magnesium.
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Multifocal Atrial Tachycardia
Pathophysiology. Mutifocal atrial tachycardia (MAT)
results from areas of increased automaticity arising irreg-
ularly and rapidly in different areas of the atrium.
ECG criteria (Figure 7-8A). Heart rate typically ranges
from 120 to 130 beats/minute. The rhythm is usually
irregular. There are three or more different morpholo-
gies of P waves and PR interval is variable. QRS complex
is usually narrow.
Etiology. The common causes of MAT include
chronic obstructive pulmonary disease (COPD), digoxin
toxicity, and acute coronary syndrome.
Therapy. Adenosine or vagal stimulation may be help-
ful if ECG diagnosis is unclear. In patients with preserved
heart function, beta-blockers can be used. In patients
at risk for wheezing (COPD, asthma) or in patients with
impaired heart function, calcium channel blockers
(diltiazem) and Amiodarone are effective. Direct current
cardioversion is not effective in the treatment of MAT.
Paroxysmal Supraventricular Tachycardia
Pathophysiology. Paroxysmal supraventricular tachy-
cardia (PSVT) is another example of reentry-mediated
tachyarrhythmia. In patients with PSVT impulses arise
and perpetuate repeatedly in the A-V node because of
areas of unidirectional block in the Purkinje fibers.
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Table 7-5 Pharmacologic Agents for Heart Rate Control in Atrial Fibrillation
Loading 
Drug Dose Infusion Onset Side Effects Comment
Diltiazem 0.25 mg/kg IV 5–15 mg/hour 2–7 minutes Hypotension, May be considered in
over 5–10 minutes heart block patients with low EF
Esmolol 0.5 mg/kg IV 0.05–0.2 mg/kg/ 2 minutes Hypotension, Caution in patients with
over 5–10 minutes minute heart block, asthma, low EF
bradycardia, CHF
Metoprolol 2.5–5 mg IV Not 5 minutes Hypotension, Well tolerated in patients
bolus over  recommended heart block, with normal EF and
2 minutes; repeat wheezing, no history of asthma or
up to 4 doses bradycardia, CHF COPD
Propranolol 0.15 mg/kg Not 5 minutes Hypotension, Avoid in patients with
recommended heart block, low EF and COPD
bradycardia, 
CHF, wheezing
Verapamil 0.075–0.15 mg/kg Not 3–5 minutes Hypotension, Negative inotrope
IV over recommended heart block, CHF
5 minutes
Digoxin 0.25 mg IV Not 2 hours Digitalis toxicity, May be considered in
every 2 hours, recommended. heart block, patients with low EF
total 1 mg Maintenance bradycardia
dose: 0.125–
0.25 mg daily
CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease.
Figure 7-8 (A) Onset of supraventricular tachycardia (arrow).
(B) Mutlifocal atrial tachycardia (MAT). Arrows indicate multiple
P wave morphologies.
Figure 7-7 Wolff–Parkinson–White (WPW) syndrome. Arrows
indicate delta waves.
A
B
ECG criteria (Figure 7-8B). The heart rate varies
between 150 and 250 beats/minute and the rhythm is
regular. P waves are absent or buried in T waves. QRS
complex is usually narrow.
Clinical features. Palpitation, anxiety, low exercise
tolerance, dyspnea, and light-headedness are common
presenting features of PSVT.
Etiology. Many patients with PSVT have accessory
conduction pathway. Factors that are known to precipi-
tate PSVT include caffeine, hypoxia, smoking, stress,
anxiety, and sleep deprivation.
Therapy. Vagal maneuver or adenosine may help 
differentiate between PSVT and AF. DC cardioversion
should be considered in the hemodynamically unstable
patient. The patient with preserved ventricular function
will tolerate A-V nodal blockade using beta-blockers, cal-
cium channel blockers, procainamide, or digoxin. In the
patient with impaired ventricular function Amiodarone,
diltiazem, or digoxin may be a better choice.
Junctional Tachycardia
Pathophysiology. This is an example of tachyarrythmia
as a result of enhanced automatic impulse formation in
the A-V node. Both antegrade and retrograde transmis-
sion of impulses occur.
ECG criteria. The rhythm is regular at a rate of
100–180 beats/minute. P waves are usually absent or
inverted. QRS complexes are narrow in the absence of
ventricular conduction delay.
Clinical features. CHF may occur as a result of loss of
sinus (atrial) “kick.” Symptoms of unstable tachycardia,
dyspnea, chest pain, or light-headedness may occur.
Etiology. Acute coronary syndrome or digoxin toxicity
are common causes of junctional tachycardia.
Therapy. DC cardioversion is usually not recom-
mended. Beta-blockers, calcium channel blockers, or
Amiodarone have been used with success.
Ventricular Arrhythmias
Ventricular arrhythmias are classified as benign or
malignant based upon duration, absence or presence of
hemodynamic consequences, or significant structural
heart disease. Premature ventricular contractions (PVCs)
and nonsustained ventricular tachycardia rarely require
therapy in the absence of symptoms or structural heart
disease.
Stable Monomorphic Ventricular Tachycardia
Pathophysiology. Sustained monomorphic VT is a
reentry rhythm most commonly occurring after myo-
cardial infarction or in the setting of cardiomyopathy.
The area of injured myocardium serves as the source of
ectopic impulses and the impulse conduction is slowed
around this area, resulting in repetitive depolarizations.
ECG criteria (Figure 7-9A). Ventricular rate is typi-
cally 120–250 beats/minute, and the rhythm is regular
without atrial activity. QRS complexes are wide and
“bizarre” (>0.12 ms). The presence of three or more
PVCs qualifies as VT. If the duration is <30 seconds, it is
nonsustained VT.
Clinical features. Monomorphic VT can be asympto-
matic. Symptoms of decreased cardiac output, such as
orthostasis, hypotension, or syncope, are present. If left
untreated it can deteriorate into VF or unstable VT.
Etiology. Acute myocardial ischemia or infarction, occur-
rence of PVC during the relative refractory period (R-on-T
phenomenon), cardiomyopathy, or QT interval-prolonging
drugs are some of the causes of monomorphic VT.
Therapy. In patients with normal ventricular function,
drugs like procainamide, lidocaine, sotatol, or amiodarone
can be used. Lidocaine, amiodarone, or DC cardio-
version are recommended in patients with impaired ven-
tricular function. Electrolyte abnormalities (hypokalemia
and hypomagnesemia) must be corrected.
Polymorphic Ventricular Tachycardia
Pathophysiology. Polymorphic VT also results from
reentry phenomenon, with multiple areas of ventricle
serving as the source of ectopic impulse formation.
ECG criteria (Figure 7-9B). The ventricular rate is
typically 120–250 beats/minute, and the rhythm is regular.
P waves and PR interval are not seen. QRS complexes
show marked variation and inconsistency. QT interval
is classically prolonged in patients with Torsades de
pointes.
Clinical features. The majority of patients show
symptoms of decreased cardiac output. It tends to dete-
riorate rapidly into VF.
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Figure 7-9 (A) Monomorphic ventricular tachycardia.
(B) Polymorphic ventricular tachycardia (torsades de pointes).
A
B
Etiology. Myocardial ischemia and QT interval-
prolonging drugs are common causes of polymorphic VT.
Therapy. In patients with normal QT interval, focus
should be to treat ischemia and correct electrolyte
abnormalities. Patients with normal heart tolerate well
beta-blockers, lidocaine, procainamide, or sotalol. In the
presence of impaired heart function, DC cardioversion
or Amiodarone should be considered. In patients with
prolonged QT interval and torsades de pointes, the ther-
apeutic options include administration of magnesium,
overdrive pacing, isoproterenol, phenytoin, or lidocaine.
At the same time, cardiac ischemia and electrolyte
abnormalities should be treated.
Bradyarrhythmias
Bradyarrhythmias are not uncommon in critical care
settings and can be either an incidental finding or repre-
sent a potentially life-threatening problem. Sinus brady-
cardia (heart rate < 60 beats/minute) rarely requires
treatment. Atropine or transcutaneous pacing may be
used to treat symptomatic sinus bradycardia mediated by
vagal stimulation. In addition to the oxygen, catecholamine
infusions, such as dopamine, isoproterenol, or epineph-
rine, can be used as chronotropic agents (Box 7-2).
First-Degree Heart Block
Pathophysiology. In first-degree heart block each
atrial impulse is successfully conducted to the ventricle
but with a delay at the A-V node.
ECG criteria (Figure 7-10). Each P wave is followed by
a QRS but with fixed and prolonged PR interval (>210 ms).
QRS complex is most commonly narrow when the block
occurs at the level of the A-V node. However, first-
degree A-V block with a bundle-branch block and wide
QRS represents delayed conduction in the infranodal
conduction system.
Clinical features. First-degree heart block is usually
asymptomatic at rest. Symptoms usually occur with the
degree of bradycardia.
Etiology. The most common drugs associated with
first-degree heart block include beta-blockers, calcium
channel blockers, digoxin, clonidine, and amiodarone.
Stimulation of vasovagal reflex (syncope), autonomic
instability, and inferior wall myocardial infarction due to
involvement of right coronary circulation are commonly
associated with first-degree heart block.
Therapy. In addition to oxygen, atropine, transcuta-
neous pacing, and catecholamine infusion may be used
to treat symptomatic first-degree heart block.
Second-Degree Heart Block
Pathophysiology. Only some atrial impulses are con-
ducted successfully in all types of second-degree heart
block. In Mobitz type I (Wenkebach) block the site of
block is at the level of the A-V node. However, in Mobitz
type II block the site of the block is below the A-V node.
ECG criteria (Figure 7-10). The atrial rate is usually
60–100 beats/minute. The ventricular rate is slower than
the atrial rate. In Mobitz type I block the PR interval pro-
gressively lengthens followed by absent QRS complex
(“dropped beat”). The QRS is narrow (<0.120 ms).
Mobitz type II block occurs without prolongation of the
PR interval and the level of block is usually infranodal.
Etiology. A-V nodal blocking medications and vagal
stimulation are common causes of second-degree heart
block. Right coronary-associated infarction is commonly
associated with Mobitz type I block and left coronary is
associated infarction with Mobitz type II block.
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Box 7-2 Common Causes of Bradycardia
Medications, electrolyte disturbances, and increased
vagal tone are the most common causes of bradycardia
in the critical care setting.
Figure 7-10 Heart blocks. (A) First-degree block (prolonged
PR interval). (B) Second-degree, Mobitz type 1 (Wenkebach).
(C) Second-degree type 2. (D) Third-degree (complete) heart
block.
A
B
C
D
Clinical features. Hypotension, shock, CHF, and 
syncope are seen with second-degree heart block.
Therapy. In addition to oxygen, atropine, and trans-
cutaneous pacing, transvenous pacing is required with
Mobitz type II block. Catecholamine infusions may be
needed to treat hypotension.
Third-Degree Heart Block
Pathophysiology. No atrial impulses are conducted to
the ventricles resulting in complete A-V dissociation. The
level of block can be either in the A-V node or infranodal.
ECG criteria (Figure 7-10). Both atrial and ventricular
rhythm are regular, but dissociated (independent). There
is no relationship between P wave and R wave. QRS com-
plex may be narrow (<0.10 s) or wide (>0.10 s) depending
upon whether the block is above or below the A-V node.
Clinical features. Clinical manifestations are related
to the heart rate. Bradycardia-related symptoms include
chest pain, dyspnea, CHF, hypotension, and shock.
Etiology. Acute coronary syndrome involving branches
of the left coronary artery (left anterior descending) or
right coronary artery (inferior MI) can result in third-
degree heart block.
Therapy. Medical therapy is only used until pacing
can be initiated. Atropine and isoproterenol are the most
commonly used medications and work by increasing the
activity of the sinus node and improving block within
the A-V node.
MANAGEMENT OF IMPLANTABLE
CARDIAC DEVICES
Pacemakers and implantable cardioverter defib-
rillators (ICDs) are commonly utilized by cardio-
electrophysiologists in the management of cardiac
arrhythmias. Pacemakers are the mainstay of therapy for
clinically symptomatic bradyarrhythmias. Temporary
pacemakers are utilized for emergency treatment of
patients with symptomatic bradycardia where arrhyth-
mia is transient and reversible or as a bridge to a perma-
nent pacemaker. ICDs are increasingly used in patients
with known history of ventricular arrhythmias or those
at high risk for ventricular arrhythmias. Perioperative
and critical care practitioners must be cognizant of
implantable cardiac devices and their management in
the perioperative period and intensive care unit.
Pacemakers
General indications for cardiac pacing include symp-
tomatic bradycardia due to sinus node dysfunction, A-V
conduction abnormalities, cardiomyopathy, autonomic
nervous system disorders, and as an adjunct in the treat-
ment of AF.
Transcutaneous Pacing
Indications for transcutaneous pacing (TCP) include
hemodynamically unstable bradycardia unresponsive to
atropine, bradycardia with escape rhythm, cardiac arrest
victims with profound bradycardia or PEA due to drug
overdose, acidosis, or electrolyte abnormalities, and over-
drive pacing of refractory tachycardia. TCP is achieved
by direct stimulation of the myocardium using a single
pair of electrodes (Zoll pads) placed anterior–posterior
or sternal-apex on the chest wall. Electrical capture is
characterized by wide QRS complex (resembling a PVC)
with T wave opposite to the polarity of QRS complex.
The hemodynamic response to pacing is assessed by
motoring pulse, blood pressure, and return of con-
sciousness. Advantages of TCP include convenience and
speed, and no need for fluoroscopy. However, there are
several limitations of TCP including pain with impulse
delivery, skeletal muscle and diaphragm stimulation, fail-
ure to recognize the noncapture of pacing impulse or
underlying VF, and skin burns with improper or pro-
longed pacing. Analgesia and sedation should be consid-
ered once the patient is hemodynamically stable.
Transvenous Pacing
Currently, transvenous pacing (TVP) is the method of
choice for temporary pacing. TVP can be achieved by
inserting a balloon-tipped pacing catheter into the right
ventricle via a central vein, preferably the right internal
jugular vein, or by passing a pacing wire via a central
vein or a pulmonary artery catheter. Special pacing wires
are also available for atrial pacing. Advantages of TVP
include patient comfort, and relative ease, speed, and
safety of insertion by skilled personnel. Potential com-
plications of TVP include infection, bleeding, pneumo-
thorax, perforation of cardiac chamber, ventricular
ectopy/tachycardia, and pulmonary thromboembolism.
Permanent Pacemaker
Insertion of a permanent pacemaker (PPM) is consid-
ered for persistent, nonreversible symptomatic brady-
cardia. General indications for a PPM are mentioned
above. A PPM is placed transvenously, preferably via the
left subclavian vein. The PPM consists of a pulse genera-
tor and a lead system. The pulse generator contains a
lithium battery, a silicon semiconductor chip, and elec-
tronic circuitry. Pacemaker leads can be unipolar or
bipolar depending upon the presence of one or both
electrodes within the heart. In a unipolar system the tip
of the electrode is negatively charged (cathode) and the
surface of the generator is positively charged (anode).
For pacing to occur, the surface of the pulse generator
must maintain contact with tissue. A bipolar lead houses
both electrodes within the heart, the cathode being at the
tip and the anode about 1–2 cm proximal to the tip of the
electrode. The bipolar lead system is more commonly
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used and provides several advantages over unipolar
leads. They are less susceptible to interference by electro-
magnetic current and skeletal myopotential, thereby
there is less risk of inhibition by extraneous signals.
A dual-chamber PPM (A-V) with rate-adaptive features
allows preservation of A-V synchrony and “atrial kick,”
and an increase in the heart rate in response to exercise.
Implantable Cardioverter Defibrillator
Indications for an ICD are rapidly expanding. The ICD
is indicated in patients with a known history of ventricular
arrhythmias or those at high risk for ventricular arrhyth-
mias, e.g., post-MI left ventricular ejection fraction (LV-EF)
of 30–40% and inducible sustained ventricular tachycardia,
LV-EF < 30% and QRS duration >120 ms, and patients with
hereditary arrhythmias such as long-QT syndrome and the
Brugada syndrome. The ICD consists of a generator, which
houses a microprocessor, complex electronic circuitry,
lithium battery and capacitor, and defibrillator electrodes.
The maximal output from an ICD is about 30 J (45 J in
“high-energy” devices), whereas external defibrillators
deliver a maximal output of 360 J. Modern ICDs are also
capable of functioning as pacemakers.
Clinical Management
In order to care safely for a patient with an
implantable cardiac device in the perioperative and crit-
ical care setting, careful attention must be given to the
following considerations.
Assessment of the Device
The routine history must include questions pertaining
to the presence of an implanted cardiac device, its type,
manufacturer, and model, and indication for insertion.
A detailed cardiac history must be obtained. The patient’s
old medical record or wallet card may provide informa-
tion about the type of the device as well as details on
intrinsic rhythm, programming mode, and the rate. An
ECG may be helpful to determine the type of pacemaker
(atrial, ventricular, or dual chamber) and if the patient is
completely dependent on the pacemaker. ECG must be
obtained without applying a magnet on the device, as
some ICDs may be permanently deactivated with magnet
placement. A roentgenogram of the chest can identify if
the pacemaker is single chamber vs. dual chamber, and
with unipolar or bipolar leads. An ICD generator is usually
larger than a pacemaker generator. Whenever feasible, a
competent authority must interrogate the PPM or ICD and
a copy of this report placed in the patient’s chart.
Perioperative Care of the Patient
As a rule, a means of providing backup pacing or
defibrillation must be immediately available.
An example of a perioperative guide for patients with
PPMs or ICDs is shown in Figure 7-11.
Use of a Magnet
Contrary to the traditional belief, application of a
magnet does not “turn-off” a PPM, but it allows the
pacemaker circuitry to be switched to asynchronous
mode and reveal remaining battery life and pacing
threshold safety factors. At the same time, not all pace-
makers switch to asynchronous mode when a magnet is
placed on the generator. However, the response of an
ICD to an externally applied magnet is different. ICDs
will be prevented from delivering a shock when a mag-
net is placed over the generator for 20–30 seconds
(Guidant devices signal a beeping tone). Placing the
magnet over the generator again for 20–30 seconds can
reactivate Guidant devices. The ICDs of other manufac-
turers will remain inactive as long as an external magnet
remains over the generator. If the magnet is removed,
the ICD becomes active. The pacemaker function of ICD
generators is not affected by application of a magnet.
When in doubt, one must contact the manufacturer to
find each device’s response to a magnet.
Monitoring
In addition to basic monitoring, a five-lead ECG sys-
tem is helpful in analyzing the rhythm during periods of
interference from cautery. A pulse oximeter or arterial
catheter provides monitoring of beat-to-beat mechanical
activity of the heart and ensures perfusion during 
periods of interference. If present, minute ventilation
rate responsiveness is turned off before surgery.
Electrocautery
Electrocoagulation (repeated bursts of current) and
electrocutting (sustained current) are commonly used
during surgical procedures. Electrosurgical units (ESUs)
may be unipolar or bipolar. With a unipolar ESU, current
is passed over a large area before it is returned to the
pad. However, a bipolar ESU allows limited dispersion of
current due to housing of both cathode and anode
within the tip of cautery. Therefore, most pacemaker-
related complications are likely to occur with unipolar
and cutting systems. When using the unipolar system,
short bursts are recommended. The cautery pad should
be in full contact with the patient’s skin and placed as
close as possible to the site of surgery and as far as pos-
sible from the generator. Potential adverse consequences
of cautery device interference include bradycardia, asys-
tole, tachyarrhythmia, and unintended delivery of shock,
impaired cardiac output, and endocardial injury.
Effect of Drugs, Metabolic, and Electrolyte
Imbalance
Common metabolic and electrolyte abnormalities such
as acidosis, alkalosis, myocardial ischemia, hyperkalemia,
and severe hyperglycemia may result in an increase in
pacing threshold and failure to pace. Many antiarrhyth-
mic drugs may potentially increase pacing threshold.
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Figure 7-11 An example of a patient care guide for PPM or ICD. (Courtesy of Department of
Anesthesiology, University of Rochester.)
1
"DEVICE" = pacemaker or ICD (Internal Cardioverter Defibrillator). ICDs defibrillate but may also have pacing capabilities.
2MANUFACTURER CONTACTS: MEDTRONIC: 800-462-7775 or 800-551-5544 (after hours page rep at 800-MEDTRONIC): GUIDANT: 800-
CARDIAC (medical records); ST JUDE: 888-756-2763 x 5802 (7-5 PST, after hours page rep at 800-PACE-ICD)
3EPS = Electrophysiology service of cardiology
4Proper care includes device assessment or interrogation at least once a year.
5CONSULTATION = Consultation with either the patient's cardiologist, the manufacturer of the device, or the EPS service
6ELECTROCAUTERY: You can minimize electrocautery impact on device function in most patients. Bipolar electrocautery is safest. Unipolar
electrocautery is safest when short burst (<1 sec) and distant from the device and its leads (not abdominal or thoracic). Other electromagnetic
sources (e.g. MRI, lithotripsy, ECT) can affect devices. The return pad (sometimes called grounding although it is not) should be placed furthest from
the device and its leads.
7
 MAGNET placement over a pacer results in an asynchronous pacing rate of 80-100 and is usually tolerated unless patient requires optimal pacing
(e.g. atrial synchronization) for adequate hemodynamics. Electrocautery may reprogram a pacer to other rhythm which is usually safe. MAGNET on
an ICD disables defibrillating capability (sometimes indicated by a tone of 20-30 sec) as long as the magnet is over the device. ICDs with pacing
function do not have their pacing function disabled by a magnet, but can have their pacing function inhibited by electrocautery. Majority of patients
are not pacer dependent; pacer dependent patients paced with an ICD may require consultation and reprogramming of their ICD pacing function if
electrocautry will interfere with ICD pacing.
8Beep-o-gram indicates that defibrillating capability will be disabled after 30 sec of exposure to magnetic field. Reprogramming will be necessary to
restore this function. Guidant beep may require stethoscope to be heard. No beep or beep-o-gram = consult recommended.
9Some patients may not tolerate asynchronous pacing (e.g. they require AV synchrony to optimize atrial "kick")
10All patients should have their devices interrogated after surgery.
AEMERGENT PROCEDURE: No time for consultation, perform quick check of 1) current rhythm, 2) pacer type & function, 3) effect of magnet,
4) minimize electrocautery, 5) consider preparing alternate means of pacing &/or defibrillating.                          Updated12 9 02
(Copyright pending Peter L Bailey, MD)
Perioperative care guide for patients with pacemakers or ICDs
Begin here: Device1
type & indication
Known (emergent
procedureA see below)
No
Yes
Patient's MD
manufacturer2,
EPS3, or CXR
No Yes
Device care4 &
function good
Surgery will be
on or near device
or leads
No Yes
Consultation5
recommendedYes
Electrocautery6
during surgery will
interfere with
device or adequate
rhythm?
No
Consultation5
recommended if device
not evaluated within 12
months or if findings
indicate device
malfunction or
discharge
Pacer effect (EKG),
patient response
and BP with magnet
placed is good9
Yes
No
First document known response to
magnet then place magnet7 on
device and observe EKG & clinical
response
ICD response
to magnet
"Beep-o-gram"
(beep with QRS)8
remove magnet
immediately
Solid tone
or silence
Consultation
recommended
ProceedA5, 10
Myopotentials resulting from skeletal muscle fascicula-
tions secondary to succinylcholine may result in failure
to pace due to pacemaker oversensing, especially of a
unipolar system.
External Defibrillation
External synchronized cardioversion or defibrillation
may potentially damage pacemaker circuitry and result
in increased pacing threshold. Therefore, before elective
cardioversion the pacemaker threshold must be increased
and the pacemaker appropriately reprogrammed after
shocks have been delivered. Minimally effective energy
output is selected and paddles are positioned such that
current is delivered perpendicular to the pacing system.
Special Circumstances
Magnetic resonance imaging (MRI) is known to cause
serious derangements in pacemaker activity and should
be avoided in pacemaker patients. When administered
asynchronously, shock waves and electrical interference
during lithotripsy can inhibit pacemaker output.
Therefore, shock waves are synchronized with the QRS.
The rate-responsive feature of the pacemaker and anti-
tachycardia feature of the ICD must be deactivated dur-
ing lithotripsy. Radiation therapy may potentially
damage the silicon processor chip of the pacemaker.
Cardiopulmonary resuscitation can be safely performed
in patients with ICDs.
SUMMARY
There have been tremendous advances in the diagnosis
and management of arrhythmias over the last two decades.
Optimal management of cardiac arrhythmias requires a
basic understanding of cardiac electrophysiology and
pharmacology of antiarrhythmic drugs. Perioperative
period and critical illness present with unique meta-
bolic, ischemic, and neurohumoral stressors that can
result in arrhythmia formation. The basic approaches
to arrhythmia management include airway support, cor-
rect diagnosis, establishing urgency of treatment and
hemodynamic stability, and prevention of complica-
tions. It is important to remember that antiarrhythmic
drugs can also be proarrhythmogenic. PPMs and ICDs
require unique considerations. Using care guides for
patients with PPMs or ICDs and a means of providing
backup pacing or defibrillation will ensure safe patient care.
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Summary
Hemodynamic resuscitation, management, and stabiliza-
tion of medical, surgical, and trauma patients is a primary
therapeutic indication for admission to the intensive care
unit (ICU), and often involves the administration of vasoac-
tive drugs. The term “vasoactive drugs” encompasses two
major classes of compounds, vasopressors and vasodilators.
The vasopressors include primarily the parenteral cate-
cholamines, while the vasodilator class includes drugs from
diverse pharmacologic categories that demonstrate variable
effects on global hemodynamics. This chapter reviews the
pharmacologic and clinical properties of vasoactive drugs
commonly used in the critical care setting for the acute man-
agement of hemodynamic alterations in the adult patient.
VASOPRESSORS
Depending upon the underlying etiology and patient
characteristics, the management of shock states involves
three general therapeutic modalities: volume resuscita-
tion, vasopressor therapy, and inotropic therapy. The
most common indication for the administration of vaso-
pressor agents in the critical care setting is septic shock
refractory to adequate volume resuscitation, and there-
fore most of the literature has focused on the use of
these agents for this indication. Other potential indica-
tions for vasopressors include the treatment of vasodilatory
shock following cardiopulmonary bypass, anaphylaxis,
vascular surgery (e.g., carotid endarterectomy), drug
overdoses (e.g., tricyclic antidepressants), and spinal
cord trauma. In the neurosurgical and trauma ICU vaso-
pressors are often used to manipulate mean arterial pres-
sure in an attempt to promote cerebral perfusion in
patients with an elevated intracranial pressure.
Catecholamines
The most widely used class of drugs for vasopressor
support is the parenterally available catecholamines. The
four agents available for this indication are dopamine,
norepinephrine, epinephrine, and phenylephrine.
Although these drugs are grouped together as direct-
acting catecholamines, their pharmacology is quite diverse
and the pharmacodynamic response leading to an
increase in mean arterial pressure (MAP) differs between
agents (see Table 8 -1). Although these differences in
pharmacology are appreciated and may have an impor-
tant impact on the appropriate clinical use of these
agents, there is a paucity of information from controlled
clinical trials concerning the relative merits of one drug
versus another in the treatment of common shock states.
Due to this lack of well controlled data, the updated Practice
Parameters for Hemodynamic Support of Sepsis in Adult
Patients published by the Society of Critical Care
Medicine (SCCM) in 2004 based the recommendations
on relatively low level scientific evidence (Levels C 
and D). Although there is on-going debate, there is cur-
rently inadequate evidence to declare definitively a drug
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of choice among the available agents for the treatment 
of common shock states. Therefore, a complete under-
standing of the differences in pharmacology, pharmaco-
dynamics, and safety among the available agents, and 
a discussion of the limited comparative data that are
available, will permit the critical care clinician to make
the best decision concerning the use of intravenous 
catecholamines.
Dopamine
The effects of dopamine (DA) are dose-dependent,
although it should be appreciated that there is consider-
able overlap in the dose ranges for the effects of the
drug. At low doses (<5 μg/kg/minute) DA has predomi-
nantly nonspecific agonist activity at DA1 and DA2
dopamine receptors, resulting in vasodilatation of renal,
mesenteric, and coronary vessels, and inhibition of
sodium reuptake by proximal tubular cells leading to a
potent naturesis. This dose range has been referred to as
“renal dose dopamine” with the expectation that the
Table 8-1 Hemodynamic Response to
Catecholamines During Septic Shock
MAP CI HR SVR
Dopamine +++ +++ ++ 0/+
Norepinephrine +++ 0/+ + +++
Epinephrine +++ +++ ++ +
Phenylephrine +++ 0/+ 0/+ +++
MAP, mean arterial pressure; CI, cardiac index; HR, heart rate; SVR, systemic
vascular resistance.
CURRENT CONTROVERSY
Low-Dose Dopamine
● Traditional teaching: low-dose dopamine (LDD) has
beneficial effects on renal blood flow and
glomerular filtration rate in critically ill patients.
● Current evidence:
● No evidence that LDD prevents the development
of acute renal failure (ARF) in high-risk ICU
patients.
● No evidence that LDD has a beneficial effect on
established ARF.
● The increase in urine output with LDD is
secondary to DA-induced naturesis, which may
contribute to or mask hypovolemia.
● LDD may have important noncardiovascular
adverse effects secondary to alterations in the
neurohormonal response to critical illness.
● Conclusion: the evidence does not support a role
for LDD in the routine management of ICU patients.
increase in renal blood flow, glomerular filtration rate
(GFR), and urine output will have beneficial effects on
renal function in critically ill patients. The data from clin-
ical trials over the past decade have generally concluded
that low-dose DA does not result in beneficial effects on
renal function in critically ill patients and may have some
detrimental effects, and therefore its routine use for this
indication has fallen into disfavor among most experts.
At slightly higher doses (5–10 μg/kg/minute) the
β1-adrenergic effects of DA are more prominent resulting
in a positive inotropic and chronotropic effect. DA also
has indirect pharmacologic activity resulting in the
release of endogenous norepinephrine from sympa-
thetic nerve terminals, which may also contribute to its
inotropic and vasopressor effects. At doses exceeding
10 μg/kg/minute α1-adrenergic effects become increas-
ingly important leading to arterial vasoconstriction con-
tributing to an increase in blood pressure. Similar to the
other catecholamines, DA has a rapid onset of effect and
short duration of action allowing careful titration of the
infusion rate to clinical response. There is little further
improvement in hemodynamic parameters when the DA
dose exceeds 20–25 μg/kg/minute; however, the risk of
tachyarrhythmias and other cardiovascular adverse
effects does increase. Unlike other direct-acting cate-
cholamines, DA does appear to have a ceiling effect, and
doses above 20–25 μg/kg/minute are not recommended.
An alternative agent should be used if a patient fails to
respond to maximal doses of DA despite adequate fluid
resuscitation. In addition, tachyphylaxis to the effects of
DA has been reported, and if a patient requires prolonged
vasopressor support, a direct-acting catecholamine may
need to be substituted to maintain response.
Although relatively high-dose DA (10–20 mg/kg/minute)
is commonly employed as a “vasopressor” in the manage-
ment of refractory septic shock, the predominant hemo-
dynamic response leading to improvement in blood
pressure is an increase in left ventricular stroke volume
and a modest increase in heart rate, with minimal effect
on systemic vascular resistance. In most studies central
venous, pulmonary, and pulmonary artery occlusion pres-
sures and systemic and pulmonary resistance were
unchanged. The evidence from clinical evaluations in sep-
sis therefore indicates that the predominant hemodynamic
effect of DA is due to its cardiac inotropic effects, with
arterial vasoconstriction being quantitatively unimportant.
DA increases cardiac contractility and heart rate when
used for the treatment of common shock states. This
contributes to left ventricular stroke work and myo-
cardial oxygen demand, which may lead to the develop-
ment of myocardial ischemia in patients with underlying
coronary artery disease. However, improvements in dias-
tolic blood pressure and subsequent coronary perfusion
may offset the increased oxygen demand. Patients with
a history of cardiovascular disease or evidence of on-going
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cardiac ischemia should be closely monitored or alterna-
tive vasopressors should be considered.
The most common reported adverse effects of DA are
related to its cardiovascular effects and include sinus
tachycardia, arrhythmias, cardiac ischemia, and a risk of
excessive peripheral vasoconstriction leading to tissue
necrosis. Extravasation of DA at the injection site can
cause local tissue necrosis and sloughing. The drug may
also have adverse effects on pulmonary gas exchange.
DA has been consistently shown to increase pulmonary
shunt fraction, which may lead to a worsening of oxy-
genation in some patients. However, an increase in mixed
venous oxygen saturation secondary to effects on cardiac
output may offset the increased shunt fraction minimizing
effects on arterial PaO2. The drug may also inhibit the cen-
trally mediated ventilatory response to hypercarbia.
With an increased emphasis in recent years on the
effects of vasopressors on regional perfusion as a marker
of comparative efficacy and safety, several investigators
have evaluated the effects of DA on splanchnic perfusion
and oxygen utilization with mixed results. The use of
low-dose DA in combination with fluids and norepi-
nephrine in patients with septic shock has been associ-
ated with variable effects on splanchnic perfusion.
Splanchnic blood flow, O2 delivery (DO2), and O2 con-
sumption (VO2) were increased in patients with a nor-
mal splanchnic DO2 at baseline, but not in patients with
an increased splanchnic DO2. Despite increases in O2
delivery and consumption, there was no change in gas-
tric intramucosal pH (pHi) or hepatic vein lactate con-
centrations raising concerns about the relevance of the
observed increases in DO2 and VO2 or the possibility of
a direct metabolic effect of DA. In a randomized study
comparing norepinephrine and DA in septic shock, the
group randomized to DA experienced a significant
reduction of gastric pHi despite improvement in global
DO2 and VO2, suggesting that DA may increase splanch-
nic oxygen debt due to increased splanchnic oxygen
utilization. Other investigators have found no important
effects on splanchnic blood flow. The importance these
variable effects on regional perfusion may have on clini-
cal outcome is unknown and requires additional study.
An under-appreciated potential risk of DA in critically
ill patients relates to its effects on anterior pituitary func-
tion. DA profoundly suppresses prolactin, thyroid-
stimulating hormone (TSH), and luteinizing hormone
(LH) secretion from the anterior pituitary. Prolonged
hypoprolactinemia in critically ill patients receiving DA
induces an impairment of the T-lymphocyte proliferative
response, which may increase susceptibility to infectious
complications. DA induces or aggravates the low-T3 syn-
drome of critical illness due to direct inhibition of TSH
secretion. DA attenuates pulsatile growth hormone
secretion, and prolonged infusions are associated with
low insulin-like growth factor-I, without influencing
cortisol or insulin secretion. These effects may con-
tribute to the catabolic response of critical illness and
interfere with protein anabolism. In addition, DA has
been associated with suppression of dehydroepiandros-
terone sulfate serum concentrations, an androgenic 
hormone with immune stimulatory effects. Lastly, DA
aggravates the pituitary blunting of LH pulse amplitude
observed in critically ill patients and may also decrease
pulse frequency leading to iatrogenic suppression of the
gonadal axis which delays the recovery of testosterone
secretion in men. This may contribute to negative nitro-
gen balance, delayed anabolic response, and immune
suppression. An appreciation of the complex effects DA
may have on neuroendocrine response, and the increas-
ing recognition of the importance of endocrine responses
on outcome of critically ill patients raises several concerns
about the routine use of DA for hemodynamic support in
the ICU.
In summary, DA effectively improves MAP in patients
with refractory septic shock primarily by increasing
cardiac index. In the SCCM Practice Parameters updated
in 2004 DA is recommended as a first line vasopressor for
septic shock. In the absence of definitive data concern-
ing the drug of choice for the management of refractory
septic shock, DA remains a reasonable treatment alter-
native. For other indications for vasopressor therapy
where the primary objective is to increase peripheral vas-
cular resistance, DA should not be considered the first-
line agent.
Norepinephrine
Over the past decade there has been a renewed inter-
est in the use of norepinephrine (NE) for the treatment
of common shock states, especially hyperdynamic septic
shock. At pharmacologic doses used for the treatment of
shock, NE has a predominant agonist effect at α1-adrenergic
receptors, with a lesser effect at β1-receptors, and rela-
tively little effect at β2-receptors. The typical hemody-
namic response to NE is an increase in diastolic, systolic,
and pulse pressures, no change to a slight reduction in
cardiac output, marked increases in peripheral vascular
resistance, and a reduction in heart rate with an increase
in left ventricular stroke volume. NE has minimal effects
on measures of preload and pulmonary vascular resist-
ance. In the setting of septic shock the major contribu-
tion to the increase in MAP is vasoconstriction with
a rise in vascular resistance, while the β1 agonist effect
appears to result in maintenance of cardiac output.
Unlike DA, NE behaves as a vasoconstrictor in the treat-
ment of septic shock. Although sinus tachycardia and
other tachyarrhythmias may be seen, especially at higher
doses, it is usually less frequent than what is observed at
equally effective doses of DA.
Due to early observations of renal failure, bowel
ischemia, metabolic acidosis, and severe peripheral
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vasoconstriction with tissue necrosis when NE was
administered to patients with shock, for many years the
drug was relegated to a second- or third-line role in the
management of septic shock and was only used when
the patient failed to respond to other agents. This has
been referred to as a “pharmacologic extreme unction”
and NE picked up the nickname “leave-em-dead,” a play
on the original trade name Levophed. Many textbooks
still recommend maximal doses of 10–12 μg/minute in
the treatment of adult patients with shock, primarily
based upon these fears of potent vasoconstriction.
Multiple studies over the past 10–15 years have
clearly demonstrated that NE can be safely used in the
hemodynamic management of septic shock provided the
patient has been adequately fluid resuscitated. The doses
used in these trials have been higher by several orders of
magnitude than the prior arbitrarily chosen maximal
doses. Mean doses have been 0.2–1.3 μg/kg/minute,
with doses as high as 3.3 μg/kg/minute being used.
Despite these high doses, improvement in GFR, urine
output, and renal blood flow have been reported, and
patients have not experienced worsening of metabolic
acidosis or complications from severe peripheral vaso-
constriction. The primary difference between the cur-
rent and historical experiences with NE appears to be
the careful attention to adequate fluid resuscitation in
the recent clinical reports, although there are no con-
trolled data supporting this assumption.
In the setting of septic shock, high doses of NE are often
required probably due to α-receptor downregulation and
possibly other factors that reduce vascular smooth muscle
response to catecholamines. For patients receiving NE for
the treatment of shock or hypotension due to other
causes, much lower NE infusion rates are typically
required. NE should be started at rates of 0.03
–0.05 μg/kg/minute (2–5 μg/minute in adults) and titrated
to the desired hemodynamic response. In the management
of septic shock the dose should be titrated to the goal MAP
rather than a derived parameter like systemic vascular
resistance. There is no apparent reason to dictate a maxi-
mal dose of NE in the treatment of septic shock provided
the patient’s intravascular volume status is adequately
maintained and the patient has not developed intolerable
adverse events (see later discussion of vasopressin in sep-
tic shock). Doses greater than ~3 μg/kg/minute have not
been previously reported. All patients receiving intra-
venous infusions of NE should have their blood pressure
and heart rate continuously monitored.
Several studies have evaluated the impact of NE, either
alone or in combination with low-dose dobutamine, on
measures of regional perfusion and oxygen utilization.
Although the results have been somewhat variable, the
overall conclusions are that if cardiac output is maintained,
splanchnic perfusion and oxygen utilization are main-
tained or improved in patients with sepsis. Serum lactate
concentrations are usually maintained or improved fol-
lowing the initiation of NE, and, as mentioned above,
renal blood flow and renal function are improved in
patients that have an adequate hemodynamic response
to NE. Since all of the regional perfusion data come from
patients with septic shock, it is possible that patients
with hypotension due to other causes may experience
decreases in renal and mesenteric blood flow similar to
what has been observed in healthy volunteer studies,
presumably due to a generalized vasoconstriction observed
with NE.
Increases in afterload, combined with an increase in
contractility and possibly heart rate, increase left ven-
tricular stroke work and may precipitate myocardial
ischemia and infarction. Like all catecholamines, NE
should be cautiously administered to patients with
known coronary artery disease or evidence of myocar-
dial ischemia.
Other common adverse effects of NE are predictable
extensions of its cardiovascular effects and include
tachycardia, other tachyarrhythmias, marked increases
in blood pressure, and severe peripheral vasoconstric-
tion with tissue necrosis. Ensuring the patient has an
adequate intravascular volume can minimize the risk of
tachyarrhythmias and peripheral vasoconstriction. NE
has fewer “hormonal” effects than epinephrine, but at
high doses may cause hyperglycemia. Extravasation at
the site of injection may cause local tissue necrosis and
sloughing.
NE has emerged as a drug of choice for the manage-
ment of refractory septic shock in the opinion of many
experts. Recent clinical experience and published
reports have dispelled many of the myths and fears sur-
rounding the use of this drug; however, a strong bias
against the routine use of NE persists in the minds and
practices of many critical care practitioners. If NE is
going to be used for the treatment of severe septic
shock, it should be used early in combination with
aggressive volume resuscitation and inotropic support as
indicated, and not reserved as a second-line or late salvage
therapy.
Epinephrine
Epinephrine (EPI) has potent agonist effects at both
α- and β-adrenergic receptors. Due to its complex phar-
macologic effects, the overall hemodynamic response to
an infusion of EPI is dose-dependent. At relatively low
doses, the β-receptor-mediated effects predominate lead-
ing to an increase in cardiac output due to an increased
stroke volume and heart rate, and a reduction in afterload.
The net vasodilation and reduction in afterload is prima-
rily due to stimulation of β2-receptors, which are pre-
dominantly present on the resistance arterioles of
skeletal muscle. The overall effects on MAP at low dose
are variable and dependent upon the patient’s baseline
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hemodynamic state and the net effects on cardiac output
and vascular resistance.
At higher infusion rates typically administered for the
treatment of shock or hypotension, the balance shifts
towards increased α-adrenergic effects leading to vaso-
constriction and increased peripheral resistance. Cardiac
effects will include an increase in heart rate and con-
tractility. Cardiac output is typically increased, but may
vary depending upon the effects on afterload. Due to the
nature of the distribution of α- and β2-receptors through-
out the vasculature, the local effects of EPI on vascular
tone and blood flow will depend upon the tissue.
Vasoconstriction may predominate in the arterioles and
precapillary sphincters of many tissues and organs includ-
ing the parenchymous organs such as the kidney, liver, and
lungs, the gut, cutaneous structures, and mucus mem-
branes. A reduction in vascular resistance of the skeletal
muscle vasculature is usually observed with the higher
doses of EPI since the powerful β2-receptor-mediated
effects are only partially countered by α1-receptor-mediated
vasoconstriction. Understanding these variable local
effects of EPI may explain the observed differences in
regional perfusion and oxygen utilization between EPI
and NE despite both agents being titrated to achieve a
similar target MAP during the treatment of septic shock.
EPI effectively raises MAP in patients with septic
shock that is refractory to volume resuscitation. The
hemodynamic responses leading to the increase in MAP
are an increase in cardiac output due primarily to increased
stroke volume, combined with modest increases in vascu-
lar resistance and heart rate. Similar to DA, the predomi-
nant effect in septic shock is the increase in cardiac
output. The increase in contractility and heart rate
increases left ventricular stroke work and may precipi-
tate cardiac ischemia and infarction.
Although EPI has shown consistent effects on improv-
ing global DO2 and VO2 in most clinical reports of patients
being treated for refractory septic shock, recent studies
have indicated that these global effects may not predict
regional oxygen utilization. EPI has been shown to
decrease splanchnic blood flow, increase arterial, venous,
and hepatic venous lactate concentrations, and decrease
pHi, especially in the first 12 to 24 hours of treatment. The
importance of these regional effects on clinical outcome
have not been evaluated; however, since the overall goal
of resuscitation is to improve tissue perfusion and oxy-
gen utilization these observations have raised significant
concerns relative to the role of EPI in the treatment of
refractory septic shock.
The most common adverse effects of EPI are pre-
dictable and similar to other catecholamines. These
include tachycardia, other tachyarrhythmias, cardiac
ischemia, excessive increases in blood pressure, and
severe peripheral vasoconstriction. Reductions in renal
blood flow appear to be more pronounced with EPI than
with other vasopressors. EPI also has important meta-
bolic adverse effects. Hyperglycemia secondary to inhi-
bition of insulin secretion, enhanced secretion of
glucagon, inhibition of glucose uptake by skeletal muscle
cells, and stimulation of glycogenolysis are commonly
observed. EPI also stimulates K+ uptake into cells due to
activation of β2-receptors. The resulting hypokalemia is
often exacerbated by treatment of EPI-induced hyper-
glycemia with insulin. EPI increases triglyceride lipase
activity, which increases the breakdown of triglycerides
to free fatty acids and glycerol, increases circulating con-
centrations of free fatty acids, and has a significant calori-
genic effect. Although some of these metabolic effects
may be seen with high doses of NE, they are much more
common during infusions of EPI.
In summary, EPI effectively increases MAP during the
treatment of common shock states, but recent evidence
suggesting that EPI may have more adverse effects on
regional perfusion and metabolism have led to recom-
mendations that EPI not be considered a drug of choice
for the treatment of refractory septic shock. EPI has
been commonly recommended for anaphylactic shock
due to its combined effects on cardiovascular, pulmonary,
and inflammatory systems during allergic responses. In
most common shock states EPI is not considered a drug
of choice and is often reserved as a second-line agent for
patients failing to respond to NE or DA.
Phenylephrine
Despite several decades of clinical use for the treat-
ment of shock, there is relatively little published data on
the use of phenylephrine (PHE) and essentially no com-
parative studies with other catecholamines. PHE is a rel-
atively selective α1-adrenergic receptor agonist, although
at high concentrations it may also stimulate β-receptors.
When administered to patients with septic shock follow-
ing fluid resuscitation there is typically an increase in
MAP primarily due to peripheral vasoconstriction, an
increase in stroke volume index, a small to no reduction
in heart rate, and maintenance of cardiac output. The
increase in stroke volume suggests a positive inotropic
response to PHE, which may be due to stimulation of
α-receptors present on the myocardium or some inher-
ent β-adrenergic activity of PHE at the doses being used
for septic shock. Unlike other catecholamines, heart
rate typically remains relatively unchanged or decreased
with the use of PHE as a vasopressor. In fact, sinus
bradycardia and slowed atrioventricular (AV) nodal
conduction may result from reflex vagal responses,
although this is more likely in normotensive patients
receiving PHE.
Limited data evaluating the effects of PHE on global
oxygen utilization and regional perfusion during the
treatment of septic patients indicate that DO2 and VO2
are maintained or increased, arterial lactate concentrations
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are decreased or unchanged, and urine output increases.
There is no comparative data with other catecholamines
for these parameters. In the treatment of sepsis and
refractory septic shock PHE is usually initiated at a dose
of 0.5 μg/kg/minute and titrated to goal MAP. The
reported dose range has been 0.11–9.9 μg/kg/minute,
which similar to NE is considerably higher than the
traditionally quoted maximum dose of 200 μg/minute
for adult patients. These higher doses have been well
tolerated provided the patient is adequately volume
resuscitated, suggesting that arbitrary maximum doses
for PHE are not appropriate in the management of septic
shock. For the treatment of hypotension secondary to
causes other than sepsis, or for elevation of MAP in 
normotensive patients (e.g., head trauma), a much lower
dose is typically required.
Adverse effects of PHE are predicted by its pharma-
cology and include excessive increases in blood pres-
sure, severe peripheral vasoconstriction, bradycardia,
cardiac ischemia, and local skin necrosis with extravasa-
tion at the injection site. The risk of adverse events
appears to be reduced by ensuring the patient’s intravas-
cular volume status is optimized and maintained. PHE
may be advantageous in patients with baseline tachy-
cardia, intolerance to other catecholamines secondary to
excessive increases in heart rate, or coexisting chronic
or acute atrial fibrillation. Compared to other agents, the
role of PHE in the management of common shock states
requires further comparative studies.
Choice of Catecholamine
Most of the literature and discussions on the choice of
catecholamine therapy have focused on the treatment of
hyperdynamic septic shock. There are no comparative clin-
ical trials with patient outcome or survival as a primary or
secondary endpoint. All of the comparative trials have
relied upon various surrogate endpoints. Early trials looked
primarily at differences in global hemodynamic responses,
which were later followed by studies that included global
DO2 and VO2 as primary endpoints or as components of a
composite endpoint. As it became evident that these global
surrogate endpoints were not predictive of survival, more
recent studies have focused on measures of regional perfu-
sion and oxygen utilization, most commonly focused on the
splanchnic circulation. This attention to the splanchnic cir-
culation has occurred for several reasons. First, it is thought
that inadequate splanchnic perfusion and compromise of
gastrointestinal mucosal integrity may play a central role in
the pathogenesis of multiple organ failure in the setting of
sepsis and septic shock. Secondly, due to the countercur-
rent flow in the splanchnic microcirculation the gut has a
higher critical DO2 than other organs and therefore may be
more sensitive to changes in DO2 and VO2. Lastly, the gut is
generally more easily accessible than other major organ sys-
tems, and therefore lends itself to study using relatively non-
invasive means in the critical care setting. It is important to
remember that despite the widespread attention to the
effects of catecholamine therapy on splanchnic perfusion
and metabolism there is no current evidence that differ-
ences in these intermediate endpoints translate directly into
differences in clinical outcomes.
Table 8-2 summarizes the comparative studies that have
evaluated catecholamine treatments in the management of
patients with hyperdynamic septic shock. The overall
trend in these comparative studies is that NE with or
without concomitant dobutamine is superior to DA and
EPI when evaluating either achievement of hemodynamic
and oxygen transport goals, or effects on regional per-
fusion and oxygenation. There are no comparative studies
involving PHE. Two recent reviews on the treatment of
hyperdynamic septic shock have recommended NE as
the drug of choice when vasopressor therapy is indi-
cated (see Dellinger and Ruokonen et al. in Selected
Reading), and the SCCM Practice Parameters consider NE
CLINICAL CAVEAT
Catecholamine Safety
The safe use of catecholamines for the treatment of
hypotension is improved by:
● Ensuring the patient is adequately fluid resuscitated
based upon subtle clinical evidence of intravascular
volume overload; PAOP = 14–18 mmHg; or CVP =
8–14 mmHg.
● Using the lowest effective dose for the shortest
possible length of time – frequent and ongoing dose
titration.
● Adding inotropic support (dobutamine) to NE or PHE
with reduced cardiac output (CI < 3.0 l/minute/m2).
CURRENT CONTROVERSY
Norepinephrine is Drug of Choice for Septic
Shock
● Surrogate endpoints of regional perfusion more
consistently improved by NE compared to DA or EPI.
● Minimal tachycardia compared to DA and EPI.
● No alterations in neurohormonal response, unlike DA.
● More consistent achievement of global
hemodynamic goals compared to DA.
● Contrary to traditional teaching, NE improves
cardiac output, renal blood flow, and urine output
in refractory septic shock.
● Potential survival advantage compared to other
vasopressor choices.
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a first line agent. Dobutamine should be added if the 
cardiac index is < 3.0 l/minute/m2. Although there are no
randomized, prospective trials evaluating the effects of the
choice of catecholamine therapy on outcome, a recently
published prospective, observational, cohort study of 97
adult patients with septic shock concluded that NE was
significantly associated with a lower overall hospital mor-
tality rate than high-dose DA or EPI. Based upon these lim-
ited data, NE appears to be the vasopressor of choice for
hyperdynamic septic shock at the current time.
The choice of vasopressor for other indications
besides septic shock is less clear. If the primary desired
effect is an increase in vascular resistance, then NE or
PHE are preferred over DA or EPI. If the patient has
baseline tachycardia, is at high risk for tachycardia, or is
intolerant of other catecholamines due to tachycardia,
then PHE may be considered. Due to the potential meta-
bolic adverse effects and the risk of decreased organ per-
fusion, EPI should not be considered as a first-line
vasopressor.
Vasopressin
Recent evidence suggests that low-dose vasopressin
may have a role in the hemodynamic support of hyper-
dynamic septic shock and possibly other causes of
vasodilatory shock which are resistant or relatively
refractory to catecholamines. Patients with septic shock
have significantly lower plasma vasopressin concentra-
tions than patients with cardiogenic shock, possibly due
to exhaustion of neurohypophyseal stores during pro-
longed hypotension, blunting of baroreflex-mediated
stimulation of vasopressin release, and increased catabo-
lism of circulating vasopressin. The administration of
vasopressin at a rate of 0.01–0.04 Units/minute results 
in rapid and significant improvements in MAP, often
allowing significant dosage reductions for concomitant
catecholamines required for hemodynamic support.
Although the initial studies are encouraging, the reports
to date have involved relatively small numbers of
patients, inadequate comparisons with conventional
therapy, and inadequate safety assessments to justify 
recommendations for the routine use of vasopressin for
septic shock, especially as a first-line agent. Vasopressin
should be considered experimental and unproven until
ongoing, large controlled studies are completed. Most
clinicians recommend that the addition of vasopressin
be reserved for patients that are refractory to or requir-
ing high doses of catecholamines. This conservative
approach is supported by the recent report of ischemic
skin lesions developing in 30.2% of patients receiving
vasopressin for catecholamine-resistant vasodilatory
shock. Patients with pre-existing peripheral artery dis-
ease and septic shock appear to be at greatest risk for
ischemic lesions.
If vasopressin is used for hemodynamic support of
refractory vasodilatory shock, the dose should be limited
to 0.01–0.04 Units/minute. Infusion rates greater than
0.04 Units/minute do not appear to increase the effec-
tiveness, and may increase the risk of adverse events
including myocardial and splanchnic ischemia. Once
vasopressin is started the existing catecholamine infu-
sion should be adjusted to the lowest dose necessary to
maintain the desired MAP. The patient should be closely
monitored for signs and symptoms of ischemic compli-
cations including myocardial ischemia and necrotic skin
or mucus membrane lesions.
VASODILATORS
The most common indications for the use of par-
enterally administered vasodilators in the critical care
setting include hypertensive crisis, cardiac ischemia,
acute postoperative hypertension, cardiogenic shock,
acute aortic dissection, and control of hypertension in a
patient unable to take oral medications. Less common
indications include pheochromocytoma and drug over-
doses involving sympathomimetic agents or cocaine.
The agents used for the acute management of MAP come
from multiple pharmacologic categories including
direct-acting vasodilators, nitrates, β-adrenergic antago-
nists, calcium channel blockers, angiotensin-converting
enzyme inhibitors, and dopamine agonists. From the
perspective of pharmacologic effects, the vasodilators
can be divided into agents that have predominant effects
on the arterial circulation, venous circulation, or mixed
DRUG INTERACTIONS
Catecholamines
May potentiate pressor or cardiac effects of
catecholamines:
● Tricyclic antidepressants.
● Antihistamines (e.g., diphenhydramine,
tripelennamine, dexchlorpheniramine).
● Ergot alkaloids.
● MAO inhibitors (? clinical significance).
● Oxytocic drugs.
● Nonselective β-blockers (“unopposed
α1-stimulation”).
May antagonize pressor or cardiac response:
● β-Blockers (decreased inotropic and chronotropic
response).
● Haloperidol, phenothiazines (α1-blocking effects).
May increase risk of cardiac arrhythmias:
● General anesthetics (halogenated hydrocarbons and
cyclopropane).
● Digoxin.
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vasodilator activity (see Table 8-3). This chapter limits
discussion to the vasodilators that are commonly admin-
istered intravenously in the ICU setting, and does not
include orally administered drugs or agents of a more
historical significance such as trimethaphan camsylate
and diazoxide. Most prospective clinical trials compar-
ing vasodilators for common indications, like hyperten-
sive crises and acute postoperative hypertension, have
not demonstrated important differences in efficacy or
safety. Therefore, there is no clear agent of choice
among the vasodilators for most indications, and the
choice of an agent for the management of the individual
patient is dictated by a thorough knowledge of the dif-
ferences between agents, intensity of hemodynamic mon-
itoring available, and individual patient characteristics.
Sodium Nitroprusside
Sodium nitroprusside (SNP) is a direct-acting, potent
nitrovasodilator that affects both the venous and arterial
vasculature. It is metabolized by the vascular endothe-
lium to nitric oxide leading to vasodilation via the guanyl
cyclase–cyclic-GMP pathway. This nitric oxide genera-
tion pathway is different than that of nitroglycerin,
accounting for differences in hemodynamic effects and
lack of tolerance. The advantages of SNP are its quick
onset, short duration of action, minimal effects on heart
rate, and no detrimental effects on cardiac function. It is
considered the gold standard to which other parenteral
antihypertensive agents are compared. Due to its short
duration of action, SNP is administered by continuous
infusion with the dose titrated to the desired hemo-
dynamic response.
The hemodynamic effects of SNP include a reduction
in peripheral resistance, MAP, pulmonary vascular resist-
ance, and preload, with a maintenance or increase in
cardiac output and stroke volume. Mild to moderate
increases in heart rate (10–15%) commonly occur, but
there is generally an improvement in myocardial oxygen
balance provided excessive reductions in MAP are not
achieved.
SNP is a highly effective vasodilator for most
indications in the ICU. The usual starting dose is
0.25–0.5 μg/kg/minute with the dose increased by
0.5–1 μg/kg/minute every 5–10 minutes to achieve the
desired response. For the treatment of decompensated
heart failure, a lower starting dose of 0.125 μg/kg/minute
is used with the dose adjusted every 5–10 minutes to
achieve an improvement in stroke volume without
precipitating hypotension or tachycardia. Although the
maximum recommended dose is 10 μg/kg/minute, the
dose should not exceed 5 μg/kg/minute for more than a
few minutes to reduce the risk of acute cyanide toxicity. As
a general rule, the lowest effective dose of SNP should be
used for the shortest possible time. The most common 
reason for treatment failure with SNP is the development
of adverse effects.
The most common or most concerning adverse
events with SNP are hypotension, tachycardia, myo-
cardial ischemia, cyanide and thiocyanate toxicity, and
worsening of hypoxemia secondary to a reversal of
hypoxic pulmonary vasoconstriction. Due to its potent
and labile reduction in blood pressure, SNP should only
be used in a well-monitored environment with continu-
ous monitoring of blood pressure, preferably using an
arterial catheter. Myocardial ischemia may occur sec-
ondary to excessive reductions in blood pressure with a
loss of coronary perfusion pressure, reflex tachycardia
with a resulting increase in myocardial oxygen demand,
or a redistribution of coronary blood flow away from
areas of ischemia (“coronary steal” syndrome). In the set-
ting of documented or suspected myocardial ischemia,
alternative agents are preferred.
One molecule of SNP is metabolized, by combining
with hemoglobin, to produce one molecule of cyan-
methemoglobin and four cyanide radicals. Cyanide radi-
cals are detoxified by reacting with thiosulfate to form
thiocyanate, which is then eliminated in the urine with
a half-life of about 3 days. The detoxification of cyanide
radicals is rate-limited by the availability of sulfur donors,
especially thiosulfate, cystine, and cysteine. When
cyanide production exceeds this capacity, excess
cyanide can be buffered by combination with methemo-
globin. Therefore, in a 70 kg patient with a normal red
blood cell mass and methemoglobin level, cyanide accu-
mulation will become significant after 2–2.5 hours of
receiving SNP at a rate of 5 μg/kg/minute. In acutely ill
patients the onset of cyanide accumulation and toxicity
may occur earlier and at lower doses of SNP due to
decreases in red blood cell mass and potential depletion
of sulfur donors.
The signs and symptoms of acute cyanide toxicity
include progressive central nervous system dysfunction
with headache, anxiety, confusion, lethargy, and coma;
cardiovascular instability with cardiac ischemia, dysrhyth-
mias, AV block, and cardiovascular collapse; and changes
Table 8-3 Predominant Site of Activity for
Commonly Used Vasodilators
Venous Mixed Arterial
Vasodilators Vasodilators Vasodilators
Nitroglycerin Sodium nitroprusside Hydralazine
Enalaprilat Labetalol
Nesiritide Nicardipine
Fenoldopam
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in oxygenation and pH with venous hyperoxemia and
lactic acidosis. Other manifestations may include nausea,
vomiting, abdominal pain, increased salivation, and
tachyphylaxis to the effects of SNP. The accumulation of
cyanide and resulting toxicity can be prevented by
co-administering sodium thiosulfate, typically in a 10:1
ratio in the same infusion. Sodium thiosulfate provides
the necessary substrate to detoxify cyanide, does not inter-
fere with the antihypertensive effects of SNP, and is
inexpensive. Although this may increase thiocyanate
accumulation and the risk of thiocyanate toxicity, this
should not be a concern with short-term administration
of SNP, and the adverse effects of thiocyanate are much
less concerning than cyanide toxicity.
CLINICAL CAVEAT
Sodium Nitroprusside – Preventing
Cyanide Toxicity
● Do not exceed infusion rates of 5 μg/kg/minute for
more than a few minutes.
● Avoid prolonged infusions (>2 hours) using doses
greater than 2.5 μg/kg/minute.
● Use alternative agents when high does of sodium
nitroprusside are required.
● Add sodium thiosulfate injection (10:1 ratio) to
infusions of sodium nitroprusside.
● Remain vigilant for common signs and symptoms of
cyanide toxicity – mental status changes, venous
hyperoxemia, lactic acidosis.
All institutions using sodium nitroprusside should
have a cyanide antidote kit readily available.
enzymatic reaction releases nitric oxide, leading to
vasodilation via the guanyl cyclase–cyclic-GMP pathway.
NTG exerts its anti-ischemic and antihypertensive effects
primarily through marked relaxation of the veins, result-
ing in decreased ventricular preload and increased
venous capacitance. Although venodilation with result-
ing reduction in preload is the predominant anti-ischemic
effect, NTG may also cause coronary vasodilation, reverse
coronary vasospasm, improve myocardial collateral per-
fusion, and improve the epicardial to endocardial blood
flow ratio. At higher doses, NTG also causes arterial
vasodilation leading to a reduction in afterload. NTG is
the vasodilator of choice for the management of cardiac
ischemia, or for reducing MAP in a patient with underly-
ing cardiac ischemia. NTG may also be used for rapid
reduction of preload for patients with left ventricular dys-
function or cardiogenic shock who fail to respond to
diuretics. However, the drug should be administered cau-
tiously since excessive reductions in preload may lead to
a reduction in cardiac output.
NTG is usually initiated at 5–10 μg/minute (0.075–
0.15 μg/kg/minute) with the dose increased by 5–10 μg/
minute every 3–5 minutes to achieve the desired clinical
response. Like SNP, NTG has a rapid onset and short
duration of action making it attractive for the manage-
ment of acute elevations in blood pressure or cardiac
ischemia in the ICU. Close monitoring of blood pressure
and heart rate during the initiation and titration of the
NTG infusion is recommended; however, invasive moni-
toring is not necessary.
Tolerance to the vasodilatory effects of NTG develops
within 48–72 hours of starting an infusion. The develop-
ment of tolerance is postulated to be secondary to
baroreceptor- and hormonally mediated compensatory
mechanisms evoked in response to reductions in arterial
pressure, and from depletion of tissue sulfhydryl donors
necessary for the metabolism of nitrates to nitric oxide.
The most common side effects associated with NTG
infusions are headache, hypotension, and reflex tachy-
cardia. The free nitrite ion can react with hemoglobin to
produce methemoglobinemia, which is of greatest con-
cern with prolonged, high-dose infusions. When severe,
methemoglobinemia can cause pseudocyanosis, tissue
hypoxia, and death. Patients with critical aortic stenosis
are preload-dependent and may tolerate NTG poorly;
therefore NTG should be avoided or used very cau-
tiously in these patients. NTG has less effect on hypoxic
pulmonary vasoconstriction than SNP, and therefore
may be better tolerated by the patient with hypoxemia.
Hydralazine
Hydralazine is a direct-acting arteriolar vasodilator lead-
ing to a reduction in systemic vascular resistance (SVR),
with no effect on venous or epicardial coronary arteries.
SNP can result in the reversal of pulmonary hypoxic
vasoconstriction and worsen ventilation:perfusion match-
ing leading to increased hypoxemia. Potent vasodilators
like SNP should be used cautiously in patients with com-
promised oxygenation due to chronic lung disease, acute
respiratory distress syndrome, or severe pneumonia.
Nitroprusside may also cause an abrupt increase in intra-
cranial pressure (ICP) in patients with an elevated ICP
and should be avoided in these patients. Abrupt discon-
tinuation of SNP infusions carries a risk of rebound
hypertension, and therefore should be tapered off
slowly whenever possible.
Nitroglycerin
Nitroglycerin (NTG) is denitrated in vascular smooth
muscle cells, releasing a free nitrite ion. A second
Following intravenous administration, hydralazine
reduces MAP, systolic and diastolic blood pressures, and
increases heart rate, cardiac output, and myocardial con-
tractility. An observed increase in sympathetic activity is
predominantly a result of baroreceptor-mediated reflex,
as well as a drug-induced release of NE from sympathetic
nerve terminals. Hydralazine also directly increases car-
diac contractility. Due to the effects on heart rate and
contractility, no increase in epicardial blood flow, and
the potential for “coronary steal” syndrome, hydralazine
has negative effects on myocardial oxygen balance and
may precipitate acute cardiac ischemia and infarction.
The initial dose of hydralazine should be 5–10 mg IV
over 2 minutes, with additional doses used as needed.
Single IV doses should not exceed 20 mg, and the dose
is usually repeated every 6 hours due to its long duration
of action. Intravenous hydralazine is contraindicated in
patients with known coronary artery disease or evidence
of cardiac ischemia, and should be used with caution
in patients greater than 40 years of age. Although
IV hydralazine has been widely used for many years in
the treatment of hypertension and heart failure in the
ICU, the drug should not be considered a first-line agent
due to its potential for adverse effects, long duration of
action, and the availability of safer options for achieving
short-term hemodynamic goals.
Labetalol
Labetalol is a racemic mixture of four diastereomers
that all have unique effects at α1- and β-adrenergic recep-
tors, with a net effect of nonselective β-receptor and
α1-receptor antagonism. The drug also demonstrates
some β2-receptor agonism, which may contribute to
vasodilatation, and inhibition of the neuronal uptake of
NE (a cocaine-like effect). Following intravenous admin-
istration, the potency for β-receptor blockade is about
five to ten times that for α1-receptor blockade. Labetalol
is an attractive option for the management of acute
hypertension since it potentially combines vasodilata-
tion secondary to α1-receptor antagonism, reversing the
increases in afterload observed during common hyper-
tensive syndromes, with β-receptor blockade to prevent
reflex tachycardia. In the setting of acute aortic dissec-
tion, labetalol lowers MAP, decreases left ventricular
contractility, and therefore the aortic wall is exposed to
reduced shear forces, meeting the primary objectives of
medical management for this condition.
A reduction in SVR is not universally observed with
labetalol therapy. Hemodynamic studies of labetalol for
acute postoperative hypertension have shown that the
predominant effect of the drug is a reduction in systolic
and mean arterial pressure, heart rate, and cardiac output,
with no significant change in SVR. Right ventricular
filling pressures remained unchanged or were slightly
increased. This suggests that in some clinical settings the
predominant effect on MAP is secondary to the non-
selective β-blockade effects on the heart; however, the
α1-receptor antagonism appears to prevent an increase
in SVR that is commonly observed following the admin-
istration of purely nonselective β-receptor antagonists.
Differences in hemodynamic response may be due to dif-
ferences in the severity of hypertension, or to the dose
or method of administration of the drug.
Labetalol reduces indicators of myocardial oxygen
demand while maintaining or improving indicators of
myocardial oxygen supply. This apparent beneficial effect
on myocardial metabolism may make labetalol a preferred
agent in the setting of suspected or documented myocar-
dial ischemia. In addition, labetalol does not affect ICP or
cerebral blood flow, and is therefore an effective and
safe agent for the control of blood pressure for neuro-
surgery and neurotrauma patients.
Onset of effect is within minutes following intra-
venous administration with peak effects observed within
5–10 minutes following a single intravenous injection.
The drug has a long duration of action with an elimina-
tion half-life of up to 8 hours. Labetalol has been admin-
istered as individual bolus doses, by continuous infusion,
or as a combination of bolus and infusion therapy for the
management of acute hypertension. An initial dose of
10–20 mg administered over 2 minutes can be followed
by increased doses of 20–80 mg every 10 minutes, until
the desired blood pressure goal is achieved. The patient
can receive subsequent bolus doses of labetalol if
needed to maintain blood pressure within the desired
range. Alternatively, the drug may be infused at a rate
of 0.5–4 mg/minute until the goal blood pressure is
achieved, and then should be stopped due to the long
duration of action. Supplemental bolus doses of 10–20 mg
may be given every 10 minutes during the early period of
the infusion to achieve more rapid control of blood 
pressure. Blood pressure should be carefully monitored 
during dose titration; however, invasive monitoring is
generally not required. The US FDA approved maximum
dose is 300 mg over 24 hours; however, higher doses
have been well tolerated provided the patient is properly
monitored.
All of the usual precautions and contraindications for
the use of a nonselective β-blocker should be observed.
Patients with impaired left ventricular function, defined
as an ejection fraction <40% or a cardiac index
<2.5 l/minute/m2, should receive alternative agents for
the treatment of acute hypertension. In addition,
patients with bronchospastic lung disease, impaired 
cardiac conduction, or resting bradycardia should not
receive intravenous labetalol. The most common adverse
effects associated with labetalol are hypotension, which
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can be precipitous, bradycardia, cardiac conduction
delays, left ventricular dysfunction, bronchospasm, and
rare skin rashes.
Nicardipine
Intravenous nicardipine, a dihydropyridine class cal-
cium channel blocker, is the most widely studied cal-
cium channel blocker for the treatment of hypertensive
crises and acute postoperative hypertension. Like other
dihydropyridines, nicardipine is relatively selective for
vascular smooth muscle with little effect on cardiac con-
duction or inotropic activity in vivo. Therefore, the pre-
dominant hemodynamic effect of nicardipine is arterial
vasodilation leading to a reduction in vascular resistance
and MAP. There are typically small increases in cardiac
output and heart rate with variable effects on preload.
Nicardipine has beneficial effects on myocardial metab-
olism with increases in coronary blood flow and time to
the development of angina or ECG evidence of ischemia
during exercise.
Nicardipine has been shown to effectively lower
blood pressure in multiple clinical trials involving
patients with severe hypertension or postoperative
hypertension. It has been found to be equally effective
as SNP and NTG, and superior to placebo, with overall
response rates of 86–98%. Compared to SNP, IV nicardi-
pine demonstrated more consistent control of MAP
necessitating fewer dose adjustments, and in some trials
a shorter time to therapeutic response and fewer
adverse effects necessitating discontinuation of the drug.
The shorter time to therapeutic response and higher dis-
continuation rates may have been due to protocol design
rather than true differences in efficacy or safety.
The recommended regimen for IV nicardipine is an ini-
tial infusion of 5 mg/hour with increases of 2.5 mg/hour
every 15 minutes to a maximum of 15 mg/hour or until
target MAP is achieved. The infusion should then be
decreased to a maintenance rate of 3 mg/hour and
adjusted by 1 to 2.5 mg/hour every 15 minutes to main-
tain target blood pressure. The controlled trials involving
patients with acute postoperative hypertension started
the infusion at 10 mg/hour, with increases of 2.5 mg/hour
every 5 minutes to a maximum of 15 mg/hour or until tar-
get blood pressure was achieved. A similar maintenance
infusion regimen was used. For acute postoperative
hypertension the mean time to therapeutic response
was approximately 10–15 minutes, and the time to offset
of clinical effect after discontinuation of the infusion was
approximately 15–20 minutes. Due to differences in dose
titration, the mean time to therapeutic response in the
severe hypertension trials was approximately 60 minutes.
The recommendation for a loading infusion followed by
a reduced dose maintenance infusion may create an
opportunity for medication errors. Therefore, the clinical
staff administering IV nicardipine should be properly
instructed about the use of this drug, and orders should
clearly indicate the need to reduce the infusion rate
once blood pressure goals are achieved.
Adverse events have been reported in 7–38% of
patients participating in controlled clinical trials of IV
nicardipine. These were generally mild and transient,
less common than with SNP, and usually did not require
discontinuation of the drug. The most common adverse
effects were headache, hypotension, sinus tachycardia,
and nausea and vomiting.
Fenoldopam
Fenoldopam is a selective dopamine-1 (DA1) receptor
agonist approved for the short-term treatment of severe
hypertension. The stimulation of vascular DA1 receptors
results in relaxation of vascular smooth muscle via 
a cyclic-AMP-dependent pathway. DA1 receptors are 
distributed throughout most arterial beds, but are pres-
ent in highest density in renal and splanchnic arteries.
Stimulation of DA1 receptors present on renal tubular
cells produces a naturesis and increased urine flow 
rate. The naturetic effect may be augmented by an
increase in renal blood flow and GFR associated with
fenoldopam.
The predominant hemodynamic effect of fenoldopam
is a reduction in SVR with decreases in MAP and systolic
and diastolic blood pressure. Heart rate, cardiac output,
and left ventricular stroke volumes are increased, and
there is no significant effect on preload. Unlike SNP,
fenoldopam does not significantly increase pulmonary
shunt fraction.
Fenoldopam has been shown to be equivalent to SNP
for the treatment of severe hypertension with a similar
overall response rate and time to response. For the treat-
ment of postoperative hypertension, fenoldopam has
been shown to be superior to placebo and equivalent to
SNP and IV nifedipine. The drug should be initiated at a
rate of 0.1 μg/kg/minute, then titrated by increments 
of 0.05–0.1 μg/kg/minute at 15–20 minute intervals to
achieve the goal blood pressure. The maximum recom-
mended infusion rate is 1.6 μg/kg/minute. The mean
time to therapeutic goal was 28 minutes in a placebo-
controlled trial, and 70% of cardiac surgery patients 
had achieved goal blood pressure by 30 minutes after the
start of treatment with fenoldopam. The time to thera-
peutic response may have been affected by the protocol
design and rate of titration of the infusion. Due to its short
half-life of approximately 5–10 minutes the effects of
fenoldopam dissipate relatively quickly after cessation of
an infusion, with about a 50% loss of effect by 15 minutes
without evidence of rebound hypertension.
The effects of fenoldopam on renal blood flow and
glomerular filtration pose a theoretical advantage for
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fenoldopam in the treatment of severe hypertension
associated with compromised renal function. However,
there are no clinical data to support the supposition that
fenoldopam will improve the outcome of renal function
when compared to other vasodilators. The most com-
mon adverse effects with fenoldopam are hypotension,
tachycardia, headache, flushing, dizziness, and brady-
cardia. Fenoldopam increases intraocular pressure, and
therefore should be avoided in patients with glaucoma
or high intraocular pressure. Due to its potent naturetic
effects, intravascular volume depletion may occur and
urine output will not be a reliable clinical indicator of
hypovolemia. Lastly, fenoldopam has been reported to
cause changes in T-wave morphology on the surface
ECG; however, these changes do not appear to repre-
sent myocardial ischemia. The major disadvantage of
fenoldopam when compared to other therapeutic
options is the high acquisition cost of this agent; how-
ever, the recent loss of patent protection for this com-
pound is likely to lead to significant price erosion.
Enalaprilat
Enalaprilat is the only intravenous angiotensin convert-
ing enzyme inhibitor (ACEI) approved for clinical use, and
has been evaluated for the treatment of severe hyper-
tension, acute left ventricular failure, and perioperative
hypertension. Enalaprilat is the active metabolite of the
oral prodrug enalapril. ACEIs inhibit the enzyme respon-
sible for the conversion of angiotensin I to angiotensin II,
and the metabolism of bradykinin to its inactive form.
The resultant pharmacodynamic effects include vaso-
dilation, decreased sympathetic response, renal efferent
arteriolar vasodilation, and decreased sodium retention.
Bradykinin may also contribute to systemic vasodilation.
Hemodynamic effects include reductions in MAP, sys-
tolic and diastolic blood pressure, and preload, with a
variable effect on cardiac output. Reflex tachycardia is
not observed, and arterial oxygenation is not affected.
Intravenous enalaprilat has been shown to effectively
lower blood pressure in small studies involving patients
with moderate to severe hypertension. The maximal
decrease in blood pressure is usually observed within
30 minutes, and the duration of response has been vari-
able depending upon the size of the dose administered.
Intravenous enalaprilat has also been evaluated in a ran-
domized, controlled trial for patients with hypertension
following intracranial neurosurgery. Compared to the
control group, enalaprilat effectively lowered blood
pressure, with an average onset of approximately
15 minutes. The duration of response exceeded 4 hours
in this study. The effect was primarily due to a reduction
in vascular resistance with no significant change in car-
diac output. There was a slight reduction in myocardial
perfusion pressure, which may be of some concern in
patients with evidence of myocardial ischemia.
Patients with congestive heart failure (CHF) adminis-
tered intravenous enalaprilat experience a reduction in
blood pressure, SVR, preload, and heart rate, with an
increase in stroke volume. These effects are similar to what
has been observed following oral administration of an ACEI.
The initial adult dose of IV enalaprilat should be
0.625–1.25 mg, administered over 5 minutes. The dose
can be repeated after 20–30 minutes if the patient has an
inadequate response. The effective dose is typically
repeated every 6 hours, and may be continued until the
patient is able to transition to oral therapy. Since
enalaprilat is cleared by the kidneys, the dose should be
reduced in the setting of significant renal insufficiency.
The potential adverse effects from ACEI therapy
include hypotension, which may be prolonged, acute
decreases in renal function, hyperkalemia, and rare cases
of angioedema. Patients with intravascular volume
depletion are at greatest risk for hypotension and acute
renal insufficiency, so careful attention should be paid to
volume status. Bilateral renal artery stenosis or severe
renal dysfunction are considered relative contraindica-
tions to treatment with ACEIs. The long duration of
action of enalaprilat, while potentially advantageous
from the perspective of dose frequency, may be a disad-
vantage if the patient experiences significant hypoten-
sion. For the treatment of severe hypertension in the
critical care setting, enalaprilat should be considered a
second-line agent.
Nesiritide
Nesiritide is a recombinant B-type naturetic peptide
(BNP) approved for the management of acute, decom-
pensated heart failure, and represents the first thera-
peutic advance in the treatment of severe CHF in over
10 years. Administration of nesiritide causes both arterial
and venous vasodilation with a reduction in preload
(pulmonary artery occlusion pressure (PAOP) and right
atrial pressure) and SVR, with an increase in stroke vol-
ume and cardiac index. The peptide also has naturetic
effects with increases in urinary sodium excretion and
urine output, and may be associated with increases
in GFR. Plasma aldosterone concentrations are also
decreased following the administration of nesiritide.
Nesiritide is indicated for hospitalized patients with
decompensated heart failure with signs and symptoms of
volume overload over the past 72 hours. If a pulmonary
artery catheter is inserted, the PAOP should be greater
than 18 mmHg. Patients with a history of significant
valvular stenosis; hypertrophic, restrictive, or obstructive
cardiomyopathy; constrictive pericarditis; primary pul-
monary hypertension; biopsy-proven active myocarditis;
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or complex congenital heart disease were excluded
from clinical trials and should not receive this drug until
studies demonstrating safety in these conditions
becomes available. In addition, patients receiving intra-
venous vasodilators (e.g., NTG, milrinone, amrinone, or
nitroprusside), or patients with a systolic blood pressure
consistently less than 90 mmHg, cardiogenic shock, or
intravascular volume depletion are not candidates for
nesiritide therapy.
Nesiritide has been compared to standard therapy
(most commonly dobutamine and diuretics) and intra-
venous NTG in patients with decompensated heart
failure. Global clinical status, dyspnea, and fatigue were
improved by both standard therapy and nesiritide with-
out significant differences between the groups. There is
a suggestion from post hoc analysis of the data that long-
term clinical outcomes were better in the nesiritide
groups, but effects on long-term morbidity and mortality
need to be further evaluated in larger properly designed
clinical trials. Dobutamine was associated with a signifi-
cant increase in cardiac ectopy, episodes of nonsus-
tained ventricular tachycardia, and heart rate, while
these endpoints were unchanged or decreased with
nesiritide. Compared to NTG, nesiritide led to greater
short-term reductions in preload and afterload, and
greater increases in cardiac output. Measures of global
clinical status and dyspnea were similar between the
two groups; however, there were fewer adverse effects
with nesiritide.
The recommended dose for nesiritide is an initial
bolus dose of 2 μg/kg over 1 minute followed by an infu-
sion of 0.01 μg/kg/minute. Time to onset of action is
approximately 15 minutes, and the offset of effect is rel-
atively rapid with an elimination half-life of 18 minutes.
If the patient experiences hypotension or a systolic pres-
sure <85 mmHg, the infusion should be stopped. It can
be restarted at 50% of the previous dose once the sys-
tolic blood pressure is >90 mmHg. The infusion can be
increased every 3 hours provided the systolic blood
pressure is >100 mmHg and the PAOP is >20 mmHg
(if available). The dose is titrated by administering a
bolus dose of 1 μg/kg over 1 minute and increasing the
infusion by 0.005 μg/kg/minute. The maximum infusion
rate is 0.03 μg/kg/minute.
Nesiritide has been well tolerated with the most com-
mon adverse effects being hypotension and nausea.
Despite beneficial effects on hemodynamic response,
improvement in symptoms, and the novelty of its phar-
macologic effects in heart failure, there is a need for clin-
ical outcomes and economic data to justify the routine
use of this expensive agent in the management of decom-
pensated heart failure. Until these data become available,
nesiritide should be considered a second-line agent
reserved for patients refractory to traditional therapy.
Choice of Vasodilator Therapy
Table 8-4 summarizes some of the characteristics of
the intravenously administered vasodilators. As men-
tioned above, there are no large controlled trials that sup-
port the use of one vasodilator over another for any of
the common indications. Most of the small comparative
trials demonstrate comparable efficacy with small differ-
ences in the incidence of adverse effects. Therefore the
choice of a vasodilator is typically a bedside decision
based upon the desired hemodynamic response, knowl-
edge of the pharmacologic properties of the available
options, clinical presentation of the patient, intensity of
hemodynamic monitoring available, and clinician expe-
rience. There are, however, some general clinical
caveats, which can be considered in the choice of a
vasodilator.
For patients with evidence of cardiac ischemia or at
high risk for developing cardiac ischemia, NTG,
labetalol, and nicardipine are good choices while
hydralazine is contraindicated. In the setting of acute left
ventricular dysfunction, NTG, SNP, enalaprilat, and
nicardipine are all reasonable choices; however,
labetalol should generally be avoided. For patients with
traumatic brain injury or other causes of an elevated ICP,
labetalol is considered the vasodilator of choice and SNP
and NTG should be avoided. Limited data suggest that
nicardipine and enalaprilat may be safe alternatives to
labetalol for patients with an elevated ICP. In the setting of
acute aortic dissection, labetalol or SNP with β-blockade
are considered the treatments of choice. Agents that
may significantly increase aortic shear forces, like
hydralazine, should be avoided. Fenoldopam may have
some theoretical benefit in patients with severe hyper-
tension and acute renal dysfunction although this is
unproven and questioned by recent studies showing no
renal protective effects of fenoldopam in other clinical
settings. The place of relatively new or less well-studied
agents like enalaprilat, fenoldopam, and nesiritide is 
currently uncertain.
SUMMARY
As reviewed in this chapter, there are many vasoac-
tive drugs available for the acute management of hemo-
dynamic response in the ICU, and despite many decades
of experience there is still no clear-cut, definitive evi-
dence of the superiority of any one agent for common
clinical indications. Therefore, it is imperative that criti-
cal care practitioners have a thorough knowledge of the
actions and adverse effects of these drugs, remain current
with evolving clinical evidence relating to the optimal
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use of vasoactive drugs, and not be inappropriately
committed to their traditional approaches to therapy
when new evidence from well-designed trials emerges
to the contrary. While some questions relating to the use
of vasoactive drugs are currently being addressed in
large, multicenter trials, considerably more large studies
focused on meaningful clinical outcomes are needed in
this area of critical care pharmacotherapy.
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The comprehensive evaluation of nutritional status
includes intake analysis, physical and anthropometric
examination, laboratory examination, and radiology.
Patient history is taken and physical examination is per-
formed to identify the mechanisms underlying the occur-
rence of depletion or over-nutrition, such as inadequate
intake or absorption, impeded utilization, and increasing
nutrient loss.
Anthropometric examination provides information
on the reserves of muscle mass and fat mass which
describe the reserves of energy and protein mass.
Normal examinations include body weight, body height,
skin fold thickness, and the circumference of various
body organs.
Energy balance can be determined by comparing
direct energy with that obtained indirectly with
calorimetry, or calculating the need using the Harris
Benedict formula, which is compared with intake.
Nitrogen balance can be determined by the balance
between nitrogen intake from protein and nitrogen of
urine urea (NUU), calculated by accommodating urine
for 24 hours.
Visceral protein status is determined by albumin and
transferin serum level. However, not all conditions cor-
relate with nutritional status that affects albumin and
transferin serum. Both these visceral proteins have a
long half-life.
Retinol binding protein, transthretin, thyroxin binding
prealbumin (TBPA), fibronectin, and somatomedin C
can be used as nutrition markers during enteral nutrition
in the critically ill. Visceral protein status can also be
determined by an immune function test, such as total
leukocyte count and skin hypersensitivity; however, the
interpretation should be made carefully in patients with
infection.
Somatic protein status can be determined by creati-
nine height index, because creatinine is released from
muscle tissue at relatively constant speed, and so the
amount of urine creatinine is proportional to muscle
tissue. 3-Methyl histidine (3-MH) secretion through urine
is another alternative for measuring somatic protein
status. 3-MH is a metabolic result from muscles, and thus
its value can be used to identify turnover from the muscle
which is proportional to somatic protein reserves.
The nutrition risk index (NRI) takes into account body
mass variation and serum albumin. NRI < 83.5 indicates
severely malnourished patients for whom nutritional
support is required.
ENERGY AND MACRONUTRIENTS 
USED IN NUTRITION
Energy
The energy expenditure of most hospitalized patients
is often lower than values obtained from classic equations
and textbook tables. The vast majority of patients, includ-
ing those in the intensive care unit (ICU), have energy
expenditures that do not exceed 2000 kcal/day.
The main objective is achieving a positive or zero
nitrogen balance via hypercaloric support during the
acute metabolic phase and preserving function, limiting
major depletion of lean body mass by starting nutritional
support at an early stage, but with limited amounts of
energy substrates. Partial (under) feeding is acceptable
during the hypermetabolic phase, while increased
energy intakes may be useful in the recovery or anabolic
phase of illness when tissue rebuilding is possible.
Overfeeding should be avoided since it may be associated
with major complications and side effects.
Carbohydrates
Glucose represents the major circulating carbohy-
drate fuel. Glucose may be used by most cells of the
body, including the central and peripheral nervous sys-
tem, as well as by blood cells and the ground substance
of healing tissues. In resting patients consumption of 
glucose by the brain represents an important component
of energy expenditure.
Glucose is stored as glycogen in the liver and skeletal
muscles. The hepatic reserves are limited and exhausted
after 24–36 hours of fasting. Glycogen in muscle is not
available for utilization outside these cells. When hepatic
reserves of glycogen are exhausted, glucose is produced
via gluconeogenesis from amino acids (mainly alanine),
glycerol, and lactate.
Glucose oxidation is associated with a higher produc-
tion of CO2, as shown by a higher respiratory quotient
(RQ) for glucose than for long-chain fatty acids.
A large part of the glucose is recycled after anaerobic
glycolysis into lactate (at the site of trauma, infection, 
or in cancer cells) which is then used for hepatic gluco-
neogenesis. That part of the glucose intake that is 
not immediately used as energy substrate is stored as
glycogen in the liver and adipose tissues. Large glucose
loads in hypermetabolic patients could result in hepatic
accumulation of both glycogen and fat, and can be 
associated with severe dysfunction of the liver. 
The important insulin response to high glucose infusions
markedly inhibits lipolysis and the mobilization of 
fatty acids from adipose stores as well as proteolysis 
and mobilization of amino acids from skeletal muscles.
These effects prevent the mobilization of essential 
or conditionally essential substrates (e.g., glutamine,
essential fatty acids, vitamins, and micronutrients) for
maintaining key organ function. Despite elevated glucose
turnover in conditions of stress, oxidative metabolism is
not increased in the same proportion. Therefore, the
maximal recommended infusion rate is 5 mg/kg/minute
in adult patients.
Lipids
Lipids can be provided in enteral nutrition or as intra-
venous lipid emulsions. The major steps in lipid emulsion
metabolism are hydrolysis of triglycerides, exchange of
neutral lipids with endogenous cholesterol, and uptake
of remnant particles. Each of these steps is largely influ-
enced by the composition of the triglyceride and the
phospholipid constituents.
Infusion of lipid calories allows a reduction of carbo-
hydrate intake and a substantially decreased incidence
and severity of side effects induced by high glucose
loads. Apart from the advantages of balancing energy
intake between carbohydrate and lipids, it is also impor-
tant to consider the composition of fat intake with respect
to the proportion of saturated, monounsaturated, and
polyunsaturated fats and the ratio between omega-6 and
omega-3 essential fatty acids and antioxidant content.
Lipid intake may account for 30–50% of nonprotein calo-
ries, depending on the individual patient’s tolerance to
both carbohydrate and lipids. Lipid emulsions should not
be given to those with marked hypertriglyceridemia.
During the first days of lipid emulsion supply, particu-
larly in stressed patients, the prescribed lipid load should
be infused as slowly as possible, e.g., at a rate lower than
0.1 g/kg/hour with LCT and lower than 0.15 g/kg/hour
with a mixed MCT/LCT emulsion. Plasma triglyceride
levels should be monitored during this initial period and
the infusion rate adjusted to measured values.
Amino Acids
Amino acids are subjected within the body to a series
of metabolic reactions. Part of the free amino acid pool
is incorporated into tissue proteins. Because of protein
breakdown, these amino acids return to the free pool
after a variable period of time and thus become available
for reutilization for protein synthesis or for catabolism.
Some of the free amino acid pool undergoes catabolic
reactions. This process leads to the loss of the carbon
skeleton as CO2 or deposition as glycogen and fat while
the nitrogen is eliminated as urea.
Finally some free amino acids are used for synthesis 
of new nitrogen-containing compounds, such as purine
bases, creatine, epinephrine, etc. In general, these are
subsequently degraded without return of end products to
the free amino acid pool. The nonessential amino acids
are made in the body using amino groups derived from
other amino acids and carbon skeletons, formed by reac-
tions common to intermediary metabolism.
The protein requirement for an average young adult is
0.75 g of protein/kg of body weight. This again presup-
poses a high proportion of first-class protein and an 
adequate energy supply.
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During acute illness and convalescence intakes of
1.2–1.5 g/kg are desirable and have proved beneficial. In
some diseases protein intake must be controlled, e.g.,
acute liver failure when the intake has to be restricted in
order to avoid hepatic coma and uremia, during which
the capacity to excrete nitrogenous end products is 
limited. In the dietary management of uremia, an intake
of 0.5 g protein/kg allows the patient to resist inter-
current infections better than for an earlier recommen-
dation of 0.25 g/kg.
ENTERAL NUTRITION
Enteral nutrition is the preferred method of nutri-
tional support in the critically ill with an intact function-
ing gastrointestinal tract. In general, enteral nutrition
should be started within 48 hours of ICU admission with
an aim of stimulating gut function and trophicity. There
is some evidence that this goal can be attained with only
minimal amounts of enteral nutrition.
Optimal timing of the onset of enteral nutrition is
crucial. Unnecessary delay due to regurgitation caused
by decreased gastroduodenal motility may prolong nega-
tive nitrogen balance.
The amounts of enteral nutrition are based on nutri-
tional assessment, energy requirements, patient history,
and medical condition. In patients with severe catabolic
illness and/or poorly functioning gut, parenteral nutrition
should be started concomitantly, in order to meet protein
and energy requirements and minimize excessive muscle
wasting. In patients with persistent gastroparesis and
intolerance to gastric feeding despite adequate prokinetic
treatment, endoscopic placement of a nasoduodenal tube
should be the next step, while nasojejunal tubes should
be used only as a last resort, since they are technically the
most difficult to place, and do not protect from aspiration
or duodenogastric reflux.
Percutaneous gastronomy has become a preferable
route when long-term (≥4–6 weeks) enteral nutrition
support is required. Although the risk of aspiration is
decreased when the latter is administered in the
jejunum, airway protective measures such as inclination
of the torso 30° above the horizontal plane, endotra-
cheal intubation, or tracheostomy should be considered.
The most comfortable tubes for patients are silicone
or polyurethane small-diameter (6–12 F) tubes, the
length of which depends on the location of feeding.
When higher viscosity solutions such as fiber-enriched
solutions are used, administration through smaller diam-
eter tubes might be more difficult unless a constant infu-
sion pump is applied. Since gastric aspiration is often
required in ICU patients, it is preferable to use the latter
in the early period of an ICU stay, and to switch to the
smaller feeding tubes if enteral nutrition is well tolerated
and expected to last for more than 10 days. After place-
ment of the nasoenteric tube, an abdominal x-ray should
be performed to verify its proper placement.
Hospital kitchen-prepared feeding solutions can
cause numerous potential complications, such as nutri-
tionally unbalanced solutions, water and electrolyte dis-
orders, diarrhea, and severe nosocomial infection due to
bacterial contamination. These problems have led to the
development of standardized, industrially prepared feed-
ing solutions. The most commonly used feeding solution
is the iso-osmotic solution (±300 mOsm/l).
Standard feeding solutions are polymeric, being made
up of substrates similar to those found in normal feeds.
Recent studies suggest that polymeric solutions should
be considered as the first line of enteral nutrition, while
semi-elemental solutions should be considered in
patients with severe small bowel disease or extensive
intestinal resection.
Adding fibers to enteral feeding solutions is benefi-
cial, as insoluble fibers (cellulose, lignin) absorb water,
which leads to the improved regulation of intestinal 
transit and reduced incidence of diarrhea. Soluble fibers
(pectin, gums, mucilages) are degraded into short-chain
fatty acids, which enhance water and electrolyte absorp-
tion, and provide nutrition for colonicyte.
Enteral nutrition can be administered by gravity or
with a constant delivery pump. The former is simple and
cheaper, but less precise than the pump technique, and
may cause accidental bolus administration, which
increases the risk of gastroesophageal reflux and 
bronchoaspiration. Improved tolerance and a reduced
incidence of diarrhea have been documented with 
continuous compared to bolus feeding.
Critically ill patients very often present with delayed
gastric emptying and impaired gastroduodenal motility,
which often cause incomplete delivery of the prescribed
daily feed. Measuring gastric residuals by aspiration is
often used as a monitoring tool.
An arbitrary value above which enteral nutrition is
usually given at a slower rate or discontinued is 150 ml
and may lead to underfeeding. Prokinetic drugs may be
administered to help to lessen the gastric residuals.
Diarrhea is a frequent problem in ICU patients receiv-
ing enteral nutrition, and has often been associated with
the osmolarity. Most standard polymeric industrial feeds
have osmolarity of ≤380 mOsm/kg. There are many fac-
tors that determine the etiology of diarrhea in enterally
fed patients, among which are factors related to the
nutrition itself, antibiotics and other medications,
Clostridium difficile colitis, hypoalbuminemia, sepsis,
and fever.
Mild symptoms of intolerance are managed with
observation by physical examination at the time of onset
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and within 6 hours, with the current rate of feeding
being maintained. For moderate distention, tube feeds
are stopped and the patient is assessed for evidence of
small bowel obstruction. If distention remains mod-
erate, an elemental formula is begun. Moderate diarrhea
(3–4 times/shift) is managed by maintaining the current
feeding rate and repeating the examination in 6 hours.
Severe distention is managed by stopping all tube feeds,
increasing IV fluid administration, and evaluating the
possibility of nonocclusive bowel necrosis. For severe
diarrhea, tube feeds are reduced by 50%, antidiarrheal
medications are added, and the patient is evaluated for
possible Clostridium difficile infection. Vomiting is
managed by ensuring adequate gastric decompression
and decreasing the infusion rate by half. High nasogas-
tric output is treated by verifying postpyloric placement
of the tube and checking the nasogastric aspirate.
PARENTERAL NUTRITION 
AND PERIOPERATIVE NUTRITION
Currently, total parenteral nutrition is used in a wide
variety of patients when the enteral route cannot be
used. Parenteral nutrition in the ICU is also being used
commonly together with enteral nutrition.
Parenteral nutrition may be achieved using a periph-
eral venous catheter, but it is difficult to administer ade-
quate caloric, protein, and electrolytes, and thus central
venous access should be used. In the absence of a pre-
existing line, either the subclavian or internal jugular site
is preferred. The former has lower infection risk and
dressing care is easier, while the risk of pneumothorax
or subclavian artery puncture is higher, both complica-
tions having potentially devastating effects in unstable
ICU patients. In severely ill ICU patients a central venous
line must be used solely for the purpose of parenteral
nutrition.
Subcutaneously tunneled catheters should be reserved
for long-term parenteral support (>3–4 weeks), such as
in bone marrow transplantation associated with multiple
intensive intravenous therapy.
A recent meta-analysis of perioperative feeding con-
cluded that there was no benefit, and indeed possible
harm, from the routine use of short periods of postoper-
ative parenteral nutrition. There appeared to be some
benefit when this was given perioperatively to patients
with severe antecedent malnutrition.
Malnutrition in surgical patients is associated with
delayed wound healing and increased risk of morbidity
and mortality. The main goals of perioperative nutrition
are to reduce the incidence of postoperative complica-
tions, the length of postoperative hospitalization, and
operative mortality. An additional goal is to decrease the
effects of disease and surgery-related malnutrition on body
composition, organ function, and subsequent patient per-
formance. Available trials concluded that the routine use
of perioperative parenteral nutrition in unselected surgi-
cal patients was unjustified, but might be helpful in high-
risk patients.
Approximately 40% of candidates to general and vas-
cular surgery present with malnutrition. Postoperative
outcome influenced by malnutrition may occur in major
surgery and particularly in elderly patients. The severity
of postoperative complications is related to the degree
of preoperative malnutrition. Malnutrition most often
reflects the severity of underlying disease and the occur-
rence of underlying disease complications.
Among anthropometric parameters, body weight loss
is the most useful. A weight loss ≥20% clearly indicates
poor postoperative outcome, while a weight loss ≥10%
within a six-month period or a weight loss ≥5 kg during
the three preoperative months indicates higher inci-
dence of major postoperative complications.
Protein malnutrition is the best predictor of compli-
cations both in surgical and nonsurgical patients. Among
15 tested variables, it was shown that serum albumin
<35 g/l, transferrin <1.74 g/l, and prealbumin <0.12 g/l
had the highest predictive values of postoperative 
complications.
Nutrient metabolism during surgery depends on pre-
operative patient condition and surgery-induced meta-
bolic changes. In normal subjects endocrine and metabolic
adaptation will tolerate prolonged starvation without
compromising survival. After 2 to 3 days of starvation, glu-
cose needs are mainly satisfied by gluconeogenesis from
amino acids released by protein degradation (approxi-
mately 75 g of protein/day, i.e., 300 g of muscle). Then,
an increase in fat utilization and ketogenesis are associ-
ated with a decrease in gluconeogenesis, and proteolysis
falls at 20 to 30 g/day. Surgical stress markedly impairs
those adaptations and increases protein loss. Thus, toler-
ance to starvation depends on preoperative nutritional
status, length of perioperative starvation, and intensity of
aggression. Preoperative feeding can be altered by under-
lying disease, hospitalization, and preoperative investiga-
tions. In non-malnourished patients, during elective and
noncomplicated surgery, starvation of 7 to 14 days will
not affect the outcome.
Major surgery induces a systemic inflammatory
response of varying intensity. Mobilization of fuel stores
and gluconeogenesis are stimulated by the release of cat-
echolamines, cortisol, glucagons, and growth hormone,
as well as by insulin resistance. Interleukin-1 (IL-1) and
tumor necrosis factor (TNF) are responsible for an
increase in muscle protein catabolism and a decrease in
protein synthesis, while IL-6 is responsible for acute-
phase protein synthesis in the liver.
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Endocrine changes in stress conditions are characterized
by a downregulation of hypothalamus–pituitary–thyroid
axis and low plasma T3 concentrations. Cytokines suppress
prealbumin synthesis reducing retinol-binding protein.
The subsequent release of increased amounts of thyroxine
and retinol in free form strengthens the effect of cyto-
kines. Thyroxine-binding globulin, corticosteroid-binding 
globulin, and IGF-binding protein-3 degradation allow the
occurrence of peak endocrine and mitogenic influences
at the site of inflammation. This mechanism is associated
with hyperthermia, weight loss, and hypoalbuminemia.
Increased protein catabolism and hypermetabolism vary
with stress intensity and are responsible for a decreased
response to nutritional support. The prolongation of
such metabolic state results in severe protein depletion.
Enteral nutrition, using polymeric nutritive mixtures,
is usually given through a nasogastric tube or by perendo-
scopic gastrostomy when long-term refeeding is
expected. The association of enteral and parenteral
nutrition is often necessary to achieve nutritional goals
in the early postoperative period.
In malnourished patients preoperative nutrition
should be given for 7 to 10 days. Longer preoperative
nutrition support would increase the risk of nosocomial
infection. Postoperative nutritional support should not 
be less than 7 days. In order to avoid overfeeding, it is 
recommended to ensure energy support equivalent to
energy expenditure. Daily needs vary from 20 kcal/kg/day
in non-malnourished patients to 35 kcal/kg/day in 
malnourished or severely stressed patients. Fat should
not exceed 30% of nonprotein energy supply. Standard
fat emulsions are usually given. Medium-chain triglyc-
erides are well tolerated and may be useful in selected
circumstances. According to the severity of the stress,
nitrogen support should vary from 0.25 g/kg/day to 
0.35 g/kg/day. No benefit is demonstrated for nutri-
tional support higher than 0.35 g/kg/day. In severely ill
patients glutamine-enriched parenteral nutrition can be
proposed.
NUTRITION IN TRAUMA
Trauma patients are prone to develop acute protein
malnutrition because of persistent hypermetabolism,
which compromises the immune response and increases
the risk of late MOF-associated nosocomial infection.
Early administration of exogenous substrates to meet the
increased metabolic demands would prevent or slow the
development of acute protein malnutrition and improve
patient outcome.
Although difficult for centers without experience,
total enteral nutrition (TEN) is preferred over total par-
enteral nutrition (TPN) because it is safer, less expen-
sive, and more convenient. Substrates delivered enterally
appear to be better utilized and do not produce the
hyperglycemia associated with TPN.
TEN prevents gut mucosal atrophy, attenuates the stress
response, maintains immunocompetence, and preserves
gut flora. In addition, to prevent acute protein malnutri-
tion, early TEN with immune-enhancing diets also promote
normal gut function and enhance systemic immune
responses, thereby preventing nosocomial infections.
To achieve adequate amounts of early TEN, it is best
delivered into the proximal small intestine. Enteral 
feeding access should be obtained at the time of initial
laparotomy. If the patient undergoes an abbreviated
laparotomy, the needle catheter jejunostomy (NCJ) can
be placed during a subsequent operation while for those
who do not undergo immediate laparotomy, the enteral
nutrition can be delivered through a nasojejunal (NJ)
tube for the first 24 hours after injury. A few patients
may have contraindication to upper gastrointestinal
endoscopy. In such patients a jejunostomy tube can be
easily placed laparoscopically.
Immune-enhancing diets (IEDs) are indicated for
patients with major torso trauma and who are at known
risk for septic complications and MOF. Usage is limited
up to 10 days, after which polymeric, high-protein for-
mulas are used. Polymeric high-protein formulas are for
patients who do not meet the criteria for IEDs, who have
normal gut digestive and absorptive capacity, and are
believed to have increased nitrogen requirements.
Elemental formulas are given to those who are intolerant
to polymeric formulas or who have not received enteral
nutrition for the first week postinjury. Renal failure 
formulas (concentrated, reduced electrolyte) are for
those who need intermittent hemodialysis.
Intolerance indicators of TEN are vomiting, abdominal
distention or cramping/tenderness, diarrhea, high naso-
gastric tube output, and contraindications of specific
medications. If enteral access is delayed or hemodynamic
status prevents early enteral nutrition, early TPN is not
indicated unless the patient is severely malnourished.
Routine TPN may be associated with worse outcomes
than no nutrition in patients with normal to moderate
malnutrition.
For various reasons, trauma patients are at high risk
for acute renal failure (ARF). This can be treated with
CVVH/CVVHD, which allow TPN with high fluid vol-
umes and high protein loads to be used. Alternatively
standard isotonic, normal electrolyte solutions are used
in enteral nutrition support initially (Box 9-1).
NUTRITION IN ACUTE 
RESPIRATORY FAILURE
Patients with trauma, burns, sepsis, acute respiratory
distress syndrome (ARDS), and multiple organ dysfunction
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syndromes (MODS) present a hypermetabolic and cata-
bolic state leading to extensive endogenous protein
breakdown and major loss of muscle mass, including 
respiratory muscles. As a result, these patients are prone
to respiratory muscle fatigue and/or failure, leading to
unsuccessful weaning from a ventilator. In chronic
obstructive pulmonary disease (COPD) with patients
requiring mechanical ventilation, the weaning process
can be extremely difficult due to the additive effects 
of chronic malnutrition, increased work of breathing,
increased load on inspiratory muscles, hypoxia, and
hypercapnia.
The association between respiratory failure and 
metabolic disturbances are complex and three groups of
patients can be individualized. In the first group, the
nutritional depletion is the result of COPD and the nutri-
tional status is important to the patient’s prognosis. The
second group consists of acutely ill patients, with acquired
malnutrition, among other factors (hypophosphatemia,
hypocalcemia, hypomagnesemia, postsurgery pain, etc.),
which could cause ventilator dependency or weaning
difficulties. In the last group, an inadequate nutritional
support containing too high calorie intakes might delay
the weaning process.
Infection or inflammatory status is probably the most
common feature of patients with respiratory failure
and/or need for mechanical ventilation. It is now well
recognized that acute or chronic inflammation results 
in a marked loss of lean body mass with nutritional con-
sequences. Bronchial infection is known as the major
cause of acute respiratory failure in COPD. Therefore,
denutrition in these patients is the consequence of both
pre-existing nutritional depletion and acute insult.
Severe pneumonia due to bacteremia or virus infection
is a very catabolic illness in which a prolonged venti-
latory support is often associated with a significant 
denutrition.
A significant proportion of patients with chronic pul-
monary diseases are malnourished and this nutritional
depletion contributes to the deterioration of clinical 
status and prognosis. The most severe nutritional deficits
are observed in patients requiring mechanical ventila-
tion. Nutritional depletion is predominant in patients
with “pink puffer type” emphysema compared to those
with “blue bloater type” chronic bronchitis. Muscle
wasting is responsible for decreasing respiratory muscle
function, which is significantly related to the patient’s
outcome as an independent parameter. Malnutrition and
loss of body weight is the result of chronic negative
energy balance related to decreased nutritional intakes,
increased energy expenditure, or both. In most COPD
patients, nutrient intake is largely adequate to meet their
needs. Increased energy expenditure has been found 
in underweight COPD patients compared to those with
normal weight or to underweight non-COPD patients.
This finding may be attributed to the increased work of
breathing due to obstructive disease and emphysema,
which rises further during respiratory failure episodes.
During acute episodes of respiratory tract infection, energy
expenditure could further rise due to increased work of
breathing. In addition, there is a decrease in nutritional
intakes and intestinal absorption as a result of hypoxia
and inflammatory status. In COPD patients, TNF was sig-
nificantly higher in undernourished compared to obese
patients. Prolonged hypermetabolism with a high level
of protein catabolism will lead to severe consequences
involving several organs and functions.
One of the key factors in prolonged ventilator depend-
ency is respiratory muscle function. Although the under-
lying disease may have been controlled, weaning from the
ventilator may cause tachypnea, rapid shallow breathing,
and alterations in blood gases indicating insufficient
spontaneous breathing, especially in patients with severe
or prolonged hypermetabolic phase. Such impairment in
respiratory muscle function is often the consequence of
the severe skeletal muscle protein breakdown during the
acute phase further amplified by muscle atrophy due to
prolonged immobilization and the use of muscle relaxants.
Acute myopathy or neuromyopathy can occur following
the prolonged use of muscle relaxants, either alone or in
association with corticosteroids. The impact of muscle
loss on respiratory muscles, particularly the diaphragm,
should not be ignored. The loss of diaphragmatic fat
related to malnutrition is proportional to the atrophy of
the nonrespiratory muscles.
The ability to maintain spontaneous breathing depends
on three factors: the level of central respiratory drive,
the capacity of the respiratory muscle pump, and the
workload on the respiratory muscles. Other factors such
as interstitial edema, reduced lung compliance, bron-
choconstriction, left ventricular failure, hyperinflation,
intrinsic positive end-expiratory pressure, and additional
load due to endotracheal and ventilator circuit factors
are often encountered in patients recovering from
hypermetabolic conditions. All these factors participate
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Box 9-1 Enteral Nutrition
Enteral nutrition can be started with a rate of 
10–15 cm3/hour of full-strength formula and advanced
by 15 cm3/hour every 12 hours in the absence of mod-
erate or severe intolerance symptoms until the rate of 
60 cm3/hour is reached. The rate is maintained for 
24 hours and then advanced by 15 cm3/hour every 
12 hours. Early positive energy balance is not necessary
and the initial goal could be lowered whenever neces-
sary and only advanced to the patient-specific goal after
24 hours.
in the increased load on respiratory muscles and there-
fore may worsen the weaning difficulties. Central respi-
ratory drive is often elevated in patients during weaning
trials. Therefore, the combination of increased load and
central drive leads to a rise in the work of breathing
when ventilatory support is withdrawn. The increased
work of breathing can lead to fatigue of the respiratory
muscles weakened by the prolonged catabolic phase.
Since the risk of nosocomial pneumonia increases by
approximately 1–3% per day of mechanical ventilation,
prolonged ventilator dependency can cause further mus-
cle loss through hypermetabolic septic episodes and the
ultimate chances of successful weaning become slimmer
with each new episode.
Weaning difficulties are also often encountered in
COPD patients with acute exacerbation. Pre-existing
under-nutrition with the loss of diaphragmatic mass and
strength adds to the problems described above. In these
patients, inspiratory muscle workload is increased while
the diaphragm is placed in adverse working conditions.
The result is an increased work of breathing and muscle
fatigue. This situation is worsened during weaning from
the ventilator, due to the fact that the workload of the
respiratory muscles increases.
NUTRITION IN SEPTIC PATIENTS
In septic patients the judicious use of substrate admin-
istration minimizes metabolic complications and over-
feeding must be avoided.
The total energy expenditure (TEE) over the first
week is approximately 25 kcal/kg/day but during the
second week TEE can increase significantly.
Indirect calorimetry may currently be the best way to
determine calorie needs and can provide improved
knowledge on the proportion and quantity of substrates
that should be used in septic patients.
Endogenous glucose production in sepsis is approxi-
mately 2.5 mg/kg/minute while exogenous glucose
administration of 4–8 mg/kg/minute does not inhibit this
process. It does, however, affect the respiratory quotient.
Because of this, glucose should not be administered faster
than 4 mg/kg/minute and should represent 50–60%
of total calorie requirements or 60–70% of nonprotein
calories. Overfeeding produces hypertriglyceridemia,
hyperglycemia with potential hyperosmolar syndrome,
osmotic diuresis, dehydration, increased CO2 produc-
tion (which can aggravate respiratory insufficiency and
prolong ventilator dependency), hepatic steatosis, and
cholestasis.
Hyperglycemia can glycosylate immunoglobulins and
complement factors, and alter the respiratory burst of
neutrophils and alveolar macrophage. It can also inhibit
adhesions, chemotaxis, phagocytosis, and antimicrobial
function of neutrophils and monocytes. Finally, and
probably most importantly, hyperglycemia can induce
oxidative stress. The general belief is that glucose levels
should not exceed 220 mg%. However, a recent ran-
domized study in a surgical ICU which also included sep-
tic patients showed a greater clinical benefit if the blood
glucose could be maintained between 80 and 110 mg%
with continuous drip of insulin.
Fat is efficiently used when it provides 25–30% of the
total calorie requirement and 30–40% of nonprotein
calories. A mixed fuel source reduces carbohydrate needs,
improves glucose control, and reduces insulin needs.
Excessive fat (ω - 6) administration, however, results in
neutrophil and lymphocyte dysfunction, blockades the
mononuclear phagocytic system, induces hypoxemia due
to ventilation-perfusion disorders and alveolocapillary
membrane injury, induces hepatic steatosis, and increases
PGE2 synthesis.
Fat composition in nutrition is important, since it is an
essential compound of cellular membrane phospholipids.
The proportion of polyunsaturated fatty acids (PUFA) of
omega-6 and omega-3 series is responsible for membrane
fluidity, ionic channel flow, activity of membrane recep-
tors, and the mechanisms in cellular signal response.
Both omega-3 and omega-6 compete for the same meta-
bolic pathways. The omega-6 is a precursor of arachi-
donic acid from which eicosanoids -2 and leukotrienes-4
are synthesized. These products have intense inflamma-
tory and immunosuppressive activity. The omega-3 is a
precursor of docosahexaenoic (DHA) and eicosapenta-
enoic (EPA), which are synthesized to prostaglandins,
thromboxanes -3, and leukotrienes -5. These cause
inflammatory reaction and are less immunosuppressive.
The exact proportion of essential fatty acids has not
been defined. Usage of physiologic mixtures of long- and
medium-chain triglycerides as well as omega-3 is currently
under investigation.
During the catabolic state, muscular and visceral pro-
teins are used as energy substrates in the muscle and for
hepatic gluconeogenesis (alanine and glutamine) in the
synthesis of acute-phase protein reactants. Protein needs
exceed the normal requirement of 1 g/kg/protein/day and
should be administered at 1.2 g/kg/day. Greater amounts
of protein do not improve nitrogen balance but they
increase blood urea. The quantity of protein should con-
stitute 15–20% of total calories and be provided in a non-
protein calorie/nitrogen ratio of 80:1 to 110:1.
Branched-chain amino acids (BCAAs) are precursors
of glutamine in skeletal muscle. In a study of septic
patients given parenteral nutrition with 45% BCAAs,
some positive benefits in mortality were noted with a
highly branched-chain formula. Additional benefits have
been noted through some nutritional parameters. The
use of branched-chain amino acids in septic patients,
however, still remains controversial.
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Immunonutrition in Sepsis
This is covered in the section on immunonutrition.
NUTRITION IN ACUTE RENAL FAILURE
A negative nitrogen balance frequently characterizes
ARF, and sometimes severe hypercatabolism can occur.
Many factors are involved, such as endocrine abnormali-
ties, metabolic acidosis, imbalance between protease and
antiprotease, excessive cytokine activity (TNF, IL-1, IL-6),
immobilization, and clinical conditions. Those factors
can greatly affect the clinical course of the disease, e.g.,
entailing further accumulation of urea and other uremic
toxins; promoting mineral and electrolyte problems
(hyperkalemia, hyperphosphatemia); producing lean
body mass depletion.
ARF per se is not generally associated with increased
energy expenditure, which is lower than in patients
affected by other acute conditions. However, coexisting
acute traumatic conditions do increase resting energy
expenditure (e.g., in sepsis the increase is approximately
30%). Generally, it suggests a higher energy intake in
patients with higher urea nitrogen level and worse nitrogen
balance, but energy supplies of more than 40 kcal/kg/day
are seldom used and potentially dangerous. In most cases
it does not exceed 1.3 basal energy expenditures, although
it may reach 1.5–1.7 in some cases. To avoid the risk of
overfeeding, calorie administration should be calculated
on dry weight estimation.
The presence of reduced glucose tolerance and insulin
resistance caused by acute uremia, acidosis, or increased
gluconeogenesis needs careful monitoring of blood
glucose levels and possible uses of insulin in glucose
solutions for attaining euglycemic levels.
The utilization of exogenous lipids has decreased, while
the utilization of medium-chain triglycerides does not
offer more advantages than long-chain triglycerides.
Lipid intake should be limited to 20–25% of total energy.
However, lipids are very important because of the low
osmolarity, source of energy, less CO2 production, and
essential fatty acids.
The total quantity of nitrogen to be administered to
ARF patients depends on many factors mainly related to
clinical conditions (degree of catabolism), renal dysfunc-
tion, delivery route of nutrients, and whether replacement
therapy has been instituted.
The utilization of amino acids for protein synthesis
might be impossible until uremia is controlled. Large
quantities of glucose and amino acids during the “ebb
phase” (first 48 hours after trauma) might increase renal
oxygen consumption, and aggravate tubular damage and
renal dysfunction. Patients with nonoliguric ARF are less
catabolic; if they receive conservative therapy and are
able to continue oral feeding, nitrogen provision should
not exceed 0.55–0.6 g/kg/day of proteins of high bio-
logical value. Patients with anorexia and nausea who
have a functional digestive tract may be given TEN, with
a similar nitrogen intake. Protein intake gradually
increases up to 0.8 g/kg/day if BUN levels are below
36 mmol/l; 0.6–1.0 g/kg/day of protein or essential amino
acids (EAAs) and nonessential amino acids (NEAAs) has
also been suggested. In ARF, NEAAs histidine, arginine,
tyrosine, serine, and cysteine become indispensable,
while others such as phenylalanine and methionine may
accumulate. If more than 0.4–4.5 g/kg/day of amino
acids are infused, NEAAs, and in particular those from
the urea cycle (arginine, ornitine, or citrulline), must
also be given. The use of EAAs alone must be avoided, as
the occurrence of important amino acid imbalance could
have severe clinical consequences.
Severely catabolic patients usually receive some sort
of replacement therapy (hemodialysis, hemofiltration).
This allows administration of a higher quantity of nitro-
gen, as well as a freer supply of fluid and electrolytes.
Patients with such conditions are hardly able to feed
themselves adequately by mouth and may therefore
receive enteral nutrition or, more often, TPN or combined
enteral nutrition and parenteral nutrition, because of the
impaired gastrointestinal motility, vomiting, or diarrhea.
Protein and/or amino acids are given 1.0–1.5 g/kg/day,
depending on the severity. This will result in better
nitrogen balance, but it may promote nitrogen waste
products. Protein/amino acid intake is higher (up to
1.5–2.5 g/kg/day) in more severe ARF patients treated
with CVVH, CVVHD, CVVHDF, which have greater
weekly urea clearances. In acute hypercatabolic patients,
with superimposed ARF, positive nitrogen balance is
achieved only if nitrogen intake is higher than 1 g/kg/day.
Replacement therapy also produces a considerable loss
of amino acids and/or protein with dialysate, especially
with high-flux dialysers. This loss should be integrated by
artificial nutrition, so an additional amount of protein or
amino acids is recommended. The amino acid solutions
are delivered parenterally and contain both EAAs and
NEAAs; the optimal ratio has not yet been established
and can range from 2:1 to 4:1.
NUTRITION IN ACUTE PANCREATITIS
Most patients with acute pancreatitis have a mild dis-
ease with mortality rate below 1%. Almost all of these
patients can be managed with standard supportive mea-
sures that do not need special nutritional treatment;
most will resume a normal diet within 3–7 days.
During acute pancreatitis, specific and nonspecific
metabolic changes occur. Under the influence of inflam-
matory mediators and pain, the basal metabolic rate may
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increase leading to higher energy consumption. If acute
pancreatitis is complicated by sepsis, many patients are
in a hypermetabolic state with an increase of resting
energy expenditure (REE).
Gastric and duodenal perfusion of enteral diets is a
powerful stimulant of exocrine pancreatic secretion,
whereas jejunal administration induces minimal pancre-
atic secretion. Lipid, protein, and carbohydrate metabolism
seems to be altered in acute pancreatitis. There is no
evidence that infusion of exogenous fat could develop
pancreatitis.
In severe acute pancreatitis, protein catabolism is
increased. Parenteral administration of amino acids does
not stimulate the exocrine pancreas directly, but through
the stimulation of gastric acid. On the other hand, the
anatomic site of protein and amino acid administration
determines the degree and extent of pancreatic stimu-
lation during enteral nutrition. Elemental diets are
regarded as the most beneficial diets for patients with
pancreatitis.
Glucose metabolism in acute pancreatitis is deter-
mined by an increase in energy demand. There is an
increase of endogenous gluconeogenesis in patients
with acute pancreatitis as the metabolic response to
severe inflammation. Intravenous administration of high
doses of glucose carries the risk of hyperglycemia, as the
insulin response is often impaired. The insulin resistance
can be corrected only in part by exogenous insulin
administration.
Parenteral nutrition in acute pancreatitis is useful as
an adjunct in patients’ nutritional maintenance. A reduc-
tion in mortality has been claimed with improved nutri-
tional status, especially in patients with moderate or
severe acute pancreatitis. Patients with acute pancreati-
tis who receive parenteral nutrition have shown an
increased rate of catheter-related sepsis and metabolic
disturbances such as hyperglycemia. However, both
catheter-related sepsis and hyperglycemia are often the
consequence of overfeeding rather than of the mode of
nutritional support.
The reduction in the ingestion of food together with
an increased demand in patients with severe pancreatitis
often results in negative energy balance with the potential
development of malnutrition. Patients with severe acute
pancreatitis are hypermetabolic, have a nonsuppressible
gluconeogenesis despite sufficient calorie intake, an
increased ureagenesis, and an accentuated net protein
catabolism which can go up to 40 g of nitrogen/day.
In severely ill patients neither hypercaloric nor
isocaloric nutritional support can prevent protein catab-
olism. In contrast, both enhance the metabolic burden
as measured by energy expenditure, thermogenesis,
urea production rate, and glucose and lactate levels.
Therefore, a hypocaloric energy supply of ~15–20 kcal/
kg/day is more suitable during the early catabolic stage
of nonsurgical patients with MOF. The goal of 1.2–1.5 g/
kg/day of protein intake is optimal for most patients
with acute pancreatitis. If an MOF syndrome compli-
cates the course of the disease, the calorie and protein
requirements have to be adapted; lower protein loads of
~1.2 g/kg/day should be given to patients with renal or
hepatic failure.
It is important to deliver the caloric need by the
enteral route. Enteral feeding is possible but prescribed
intakes of nutrients are frequently not achieved.
Nasojejunal tubes are feasible and desirable in the man-
agement of patients with acute pancreatitis but their
placement is sometimes difficult without endoscopic
help. There is some evidence that enteral feeding may
improve disease severity and clinical outcome in
patients with severe disease. The presence of complica-
tions (pancreatic ascites, fistula formation, or fluid col-
lection) is not a contraindication to enteral feeding.
Oral refeeding can be started when pain is controlled
and the pancreatic enzymes return to normal. Patients
are re-fed with small amounts of carbohydrate–protein
diet; the number of calories is gradually increased with
careful supplementation of fat over a period of 3–6 days.
If the enteral supply is inadequate, then the rest
should be given by the parenteral route. When enteral
nutrition is impossible, TPN should be started.
IMMUNONUTRITION IN THE 
INTENSIVE CARE UNIT
Immune system changes/depression is a complicated
factor in ICU patients. Recently, data from various experi-
ments demonstrated the beneficial effects of immuno-
nutrition supplementation to enhance or modulate the
immune status in various group of specific patients, i.e.,
surgical, burn, and ARDS patients. Such nutrients include
n-3 fatty acid, glutamine, arginine, and nucleotides. Many
clinical trials have shown risk of infection, length of 
hospital stay, and medical cost are reduced by enriched
nutritional support with immunonutrition. Nevertheless,
this administration is not appropriate for every ICU
patient; patients with severe sepsis, shock, and organ 
failure may actually be harmed.
N-3 Fatty Acid
Fatty acids are components of cell membranes, and
influence cell functions and biological responses.
Following stress, injury, or sepsis the demands of fatty
acids are increased. N-3 fatty acid is an essential fatty
acid, which is often found to be deficient in hospitalized
patients. Although n-3 fatty acid is much needed, the
ratio of n-3/n-6 fatty acid still has not been clarified,
especially in the critically ill. Mechanisms by which 
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n-3 and n-6 fatty acid may exert effects on the immune
system are regulation of gene expression, signal trans-
duction pathways, action of antioxidant enzymes, and
production of eicosanoids and cytokines.
Glutamine
In the human body glutamine plays an important phys-
iologic role in energy production, interorgan nitrogen
and carbon transport, nucleotide synthesis, renal ammo-
niagenesis, glycogen synthesis, regulation of protein
synthesis, and replication of cells. Glutamine is a NEAA in
healthy people, but in catabolic patients, such as those
suffering stress, injury, and sepsis, it becomes essential.
Several studies proved that plasma glutamine declines in
catabolic patients. Studies using stable isotopes in the
critically ill demonstrate systemic demand of glutamine
with large fluxes of glutamine from skeletal muscle.
They show that the nutrient flow of glutamine is from
muscle, where it is synthesized, and released to the tissues
and not from the gut to the tissues. The human gut
extracts 50–85% of enteral glutamine.
There is controversy as to the question of giving glut-
amine parenterally or enterally. Studies in experimental
animals proved that gut villous height and thickness
increased after appropriate doses of enteral glutamine.
In other studies, enteral diets containing glutamine
decreased bacterial translocation across the intestine.
On the other hand, a randomized study with parenteral
glutamine improved several clinical outcomes up to
6 months after administration.
The recommended dose of glutamine for less stressed
patients is 12–15 g/day and for critically ill patients is
>20 g/day up to 30 g/day. Recently, glutamine has
become available as a dipeptide and enriched in certain
solutions.
Arginine
Arginine is a semi-essential amino acid. In the body
arginine participates in the urea cycle and the citric acid
cycle, and stimulates the secretion of anabolic hormone.
Arginine is also a precursor for polyamine synthesis and
a nitrogen source for nitric oxide synthesis. This latter
function is important; nitric oxide plays a role in hyper-
tension, myocardial dysfunction, inflammation, cell
death, and protection against oxidative damage. Enteral
nutrition enriched with arginine leads to T-lymphocyte
stimulation in critically ill patients. Doses of 15 g/day
intravenous and 17–24 g/day of enteral arginine are ade-
quate for improving immune system and wound healing.
In ICU studies an amount between 16 and 19 g/day had
a beneficial outcome. If the dose is too large it can
induce lysine deficiency and could be harmful. Very high
nitric oxide levels, produced from arginine, may mediate
many of the effects of septic shock including vascular,
myocardial, and hemodynamic instability.
Nucleotides
Nucleotides (purines and pyrimidines) are synthe-
sized either de novo or salvaged from RNA turnover. If
protein intake is adequate, the main source of nucleotide
production is from de novo synthesis. Sufficient
nucleotides promote restoration of intestinal function
and immune status. The absence of nucleotides can
cause loss of T-helper lymphocytes and suppression of
IL-2 production.
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The majority of infections in the critically ill are asso-
ciated with medical devices including the urinary
catheter, the mechanical ventilator, and the central
venous catheter. More than five million central venous
catheters are utilized in the USA each year. These devices
are associated with an infection rate of 3–8% with a con-
comitant attributable mortality of up to 35%. Bloodstream
infections (BSIs) are up to seven times more frequent in
the critically ill. Nationally, the central line-associated BSI
rate averages from 2.9 per 1000 catheter days in cardio-
thoracic intensive care units to 10.6 per 1000 in the
neonatal population. Approximately 80,000 central line-
associated BSIs occur every year in the intensive care unit
(ICU) in the USA. If entire hospital populations are
assessed, approximately 250,000 central line-associated
BSIs occur annually. These infections incur a significant
cost to patient care not only in terms of potential mor-
bidity and mortality but also in financial terms. The esti-
mated costs are in excess of $25,000 per infection with a
total annual cost from $300 million to more than $2 bil-
lion. With the improved understanding of the pathogen-
esis of catheter-related infections and the implementation
of several strategies, the incidence of catheter-related
infections can be reduced, thereby reducing the ultimate
burden on the cost of patient care in terms of morbidity,
mortality, and financial cost.
PATHOGENESIS
Catheter-related infection results from the interaction
of the host, the catheter, and the microbial pathogen.
The individual properties of the microbial pathogen are
probably the most important in terms of the pathogenesis
of catheter-related infections. An intimate understanding
of these characteristics can potentially allow the modifi-
cation of catheters to circumvent microbial adherence,
thereby preventing infection. The interaction with the
host cannot be ignored; with an emphasis toward opti-
mizing the treatment of comorbidites and underlying 
illnesses to minimize immunosuppression, clinicians can
optimize nutrition and ultimately augment immunity
toward specific pathogens.
Central line-associated BSI begins with catheter colo-
nization by the pathogen, although this may not neces-
sarily lead to bacteremia. Extraluminal colonization is
linked to the skin flora at the specific insertion site when
the pathogen begins to adhere to and colonize the sub-
cutaneous segments. This type of colonization can also
occur by the hematogenous spread of a pathogen to an
intravascular catheter tip from distant sites of infection
where bacterial transmigration has occurred. Equally
important is the intraluminal colonization that can
potentially occur through catheter hubs, connections,
and infusate, as these are accessed many times a day in
the critically ill for blood draws and medications.
The development of thrombi associated with central
venous catheters has been linked to the development of
device-associated BSIs. Thrombus formation at the insertion
site, along the subcutaneous segment, at the catheter tip,
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or intraluminally is likely a key event in microbial adher-
ence and subsequent colonization that dramatically
increases the risk of infection. The thrombus serves as
both an excellent substrate for bacterial adherence and
a medium for bacterial growth. Thrombus formation can
be affected by the composition of the catheter material,
the extent of damage to the vascular endothelium at the
insertion site, and hematologic factors in the host affecting
coagulation.
CLINICAL FACTORS
The patient’s primary underlying disease and associated
comorbidities play a potential role in the development of
nosocomial infections, including catheter-related BSIs
(see Box 10-1). An ICU admission alone increases this
risk, as do interventions such as mechanical ventilation
and invasive hemodynamic monitoring. A direct correla-
tion is most notable in neutropenic patients, neonates,
and in patients with severe burns, malignancies, and the
presence of shock during the course of their ICU admis-
sion. Total parenteral nutrition has also been shown to
increase the risk of catheter-related bacteremia. The risk
of device-associated infection may be increased with
the presence of additional nosocomial infections includ-
ing active urinary tract infections, lower respiratory
infections and colonizations, and intra-abdominal
infections.
MICROBIOLOGY
In the USA the most common organisms associated
with hospital-acquired BSI are coagulase-negative staphy-
lococci (37%; see Box 10-2). Staphylococcus aureus and
Enterococcus spp. each account for approximately 
13% of these infections. Gram-negative bacilli (including
Escherichia coli (2%) and the Enterobacteriaceae
Klebsiella pneumoniae (3%), Pseudomonas aeruginosa
(4%), and Enterobacter spp. (5%)) account for 14% of
catheter-related BSIs. Candida spp. are responsible for
8% of hospital-acquired BSIs.
The antimicrobial resistance patterns of these
pathogens are continually evolving. Data from the
National Nosocomial Infections Surveillance System indi-
cate that 57% of the S. aureus isolates from ICU patients
are resistant to methicillin. A full 89% of the coagulase-
negative staphylococci are now resistant to methicillin.
Over 27% of the enterococcal isolates are resistant to
vancomycin. P. aeruginosa isolates in the ICU appear
increasingly resistant to multiple antibiotics including
imipenem (22%), quinolones (32%), and third-generation
cephalosporins (30%). Other surveillance data indicate
that 10% of the C. albicans isolates are now resistant to
fluconazole. In addition, nearly half of the fungal isolates
were non-C. albicans species which tend toward exhibit-
ing resistance to multiple antifungals. While the national
trends are alarming, ICU-specific antibiograms should be
utilized to best guide empiric antimicrobial therapy in
the treatment of catheter-related BSIs.
STRATEGIES FOR PREVENTION OF
CATHETER-RELATED INFECTIONS
No single factor is reliably responsible for the devel-
opment of BSIs associated with central venous catheters.
Ultimately, there is an intimate relationship among many
variables that can be potentially utilized for developing
strategies to minimize or prevent catheter-associated
BSIs (see Box 10-3).
CATHETER INSERTION SITE
The site at which a central venous catheter is placed
can influence the subsequent risk of device-associated BSI.
Box 10-1 Risk Factors for 
Catheter-Related Infections
Malignancy
Neutropenia
Patients receiving immunosuppression therapy
Use of parenteral nutrition
ICU admission
Mechanical ventilation
Use of multilumen catheters
Development of shock
The presence of additional nosocomial infections
Severe burns
Neonates
Box 10-2 Most Likely Pathogens 
in Central Line-Associated
Infections
COAGULASE-NEGATIVE STAPHYLOCOCCI
Staphylococcus aureus
Enterococcus spp.
Enterobacter spp.
Pseudomonas aeruginosa
Klebsiella pneumoniae
Escherichia coli
Candida spp.
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It should be noted that no randomized trials have ade-
quately assessed how variable placement sites affect the
risk of infection. The potential relationship between
catheter location and risk of infection can perhaps best
be approached by ultimately understanding the patho-
genesis of the infection. The bacterial colonization at any
given site may ultimately play a role in providing the ini-
tial inoculum leading to infection. Not only does the bac-
terial colonization differ with each insertion site, but the
potential for cross colonization and/or contamination
with other bacterial sources (such as tracheal secretions,
urine, and stool) also varies with the insertion site. There
is some observational evidence that the internal jugular
site may be associated with increased risk of infection
when compared to the subclavian or femoral sites. In
addition, the femoral site may be associated with
increased catheter colonization potentially leading to
BSI. The risk of deep vein thrombosis increases with the
use of the femoral site versus the subclavian or internal
jugular site. The development of thrombosis is a con-
tributing factor to the development of BSI. These obser-
vations lead some authorities to recommend the
subclavian site as the preferred site of venous access 
in the critically ill. The ultimate clinical decision may
best be approached by weighing the potential for infec-
tion, the duration of access, and the potential for
mechanical complications associated with each specific
insertion site.
SITE PREPARATION
Intrinsic to the process of any catheter insertion is the
ultimate decontamination of the skin at the insertion site.
Microbial colonization of the skin has been shown to be
greatly influenced by the choice of the insertion site. For
instance, the density of transient microflora appears to
be greatest at the base of the neck when compared to
the upper chest. Given the importance of the cutaneous
microbial flora in the ultimate pathogenesis of catheter-
related BSIs, the reduction of this microbial load at the
insertion site can reduce the incidence of device-related
infection. For years a povidone-iodine solution has been
the standard skin antiseptic for catheter insertion. Several
studies have shown that chlorhexidine reduces the inci-
dence of microbial colonization when compared to other
preparations including povidone-iodine and alcohol.
Chlorhexidine has potent and broad-spectrum antimi-
crobial activity which persists on the skin surface even
after a single application. It has been shown that the
preparation of arterial and central venous sites with 2%
chlorhexidine gluconate lowers catheter-related BSIs
when compared to 10% povidone-iodine or 70% alcohol
preparations. Additionally, a meta-analysis comparing
chlorhexidine with povidone-iodine for vascular catheter
site care revealed that skin sites prepared with chlorhex-
idine reduced the risk of infection by 49%. The majority
of evidence now suggests that a 2% chlorhexidine solution
is the agent of choice for skin preparation. Chlorhexidine
has also been incorporated into a sponge for use as a
catheter site dressing and has subsequently been shown
to reduce the risk of catheter colonization and catheter-
related BSI. If chlorhexidine is unavailable, tincture of
iodine has been shown to be superior to povidone-iodine
as a cutaneous antiseptic. The process of defatting the
skin with acetone has not been shown to be of any value
in the reduction of catheter-related BSIs.
ASEPTIC TECHNIQUE
The insertion of any medical device necessitates the
adherence to good hand hygiene combined with proper
aseptic technique. Hand hygiene can be achieved with
either an antimicrobial soap and water or a waterless
alcohol-based product. The insertion of short peripheral
catheters can be accomplished aseptically with non-
sterile gloves and a no touch technique. Central venous
catheter insertion requires more stringent aseptic tech-
nique with full barrier precautions including cap, mask,
long-sleeved sterile gown, sterile gloves, and a large ster-
ile drape. Maintaining maximal barrier precautions during
central venous catheter insertion has repeatedly been
shown to reduce the incidence of catheter-related BSIs
when compared to standard precautions. These precau-
tions have not been well studied with regards peripherally
inserted central venous catheters or midline catheters, 
but are nonetheless a prudent practice. One study
showed that the use of full barrier precautions during
Box 10-3 Strategies to Prevent 
Catheter-Related Infections
Education and training of personnel in catheter care
and insertion
Use of specialized IV teams
Hand hygiene
Maintain strict aseptic techniques when manipulating
the catheter
Use maximum sterile barrier precautions
Disinfect and clean the insertion site with 
chlorhexidine
Use sterile dressing at the insertion site and replace
when soiled
Consider subclavian insertion site if possible
Remove unnecessary catheters as soon as possible
Replace administration sets, caps, hubs every 72 hours
Consider use of antibiotic-coated catheters in high-risk
patients
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the insertion of arterial catheters did not prevent arterial
catheter colonization or infection.
CATHETER SITE DRESSING
Gauze or transparent semipermeable polyurethane
dressings can both be utilized as there is no substantial
clinical difference in the incidence or rate of catheter
site colonization or phlebitis. The risk of development of
catheter-related BSI when using gauze dressings has
been compared to the use of transparent dressings with
no difference in the risk of infection. As a result, the
dressing used can be a matter of preference. Transparent
dressings require less frequent changes and allow for the
direct examination of the insertion site, but can also trap
moisture and fluid collections, which could contribute
to increased microbial colonization. Transparent dress-
ings may be preferred in the presence of open wounds
or tracheostomy near the insertion site.
The efficacy of the additional application of various
antibiotic and antiseptic ointments to central venous
catheter insertion sites is not clear. Studies have been
carried out on the application of a povidone-iodine oint-
ment to the insertion sites of subclavian hemodialysis
catheters, which demonstrated a reduction in the inci-
dence of catheter tip colonization, exit site infection,
and associated BSIs. However, several randomized studies
of the prophylactic use of povidone-iodine ointment
applied to the insertion sites of short-term central venous
catheters are indeterminate. In addition, there is some
evidence that the use of some antibiotic ointments at
insertion sites may increase the rates of catheter colo-
nization by Candida spp., lead to the development of
antibiotic resistance, and potentially compromise the
integrity of the central venous catheter.
SYSTEMIC ANTIBIOTIC PROPHYLAXIS
The parenteral use of either vancomycin or teicoplanin
during central venous catheter insertion does not reduce
the incidence of subsequent BSI; in fact, one study
revealed a higher incidence of BSI in the prophylaxis
groups. Antibiotic solutions have also been utilized by
flushing and filling the lumen of the catheter and leaving
the solution to dwell as an “antibiotic lock” technique.
Such prophylaxis has been shown to benefit neutropenic
patients with long-term catheters. In addition, antibiotics
such as vancomycin have been added to flush solutions,
total parenteral solutions, and dialysate in attempts to
reduce the incidence of BSIs. While some studies have
revealed efficacy, the use of vancomycin has been shown
to be an independent risk factor for the development
of vancomycin-resistant enterococci. Prolonged use of
vancomycin may lead to the development of sub-
populations of S. aureus with intermediate or reduced
vancomycin sensitivity.
ANTICOAGULATION
The development of thrombin and fibrin deposits on
central venous catheters can promote microbial adher-
ence and is associated with catheter-related BSI.
Although a meta-analysis has revealed that the routine
use of prophylactic heparin reduced the risk of catheter-
related central venous thrombosis, there appears to be
no significant difference in the risk of development of
catheter-related BSI. Warfarin has also been evaluated:
while it reduces the incidence of catheter thrombus it
does not reduce the incidence of catheter-related BSI.
IMPREGNATION OF CATHETER WITH
ANTIBIOTICS AND ANTISEPTICS
Catheters coated with antimicrobial and antiseptic
agents are now widely available. The use of these catheters
can decrease the risk of developing catheter-related BSI.
Catheters externally coated with chlorhexidine and 
silver sulfadiazine have been demonstrated in several
studies to reduce the risk of catheter-related BSI when
compared to uncoated catheters. The antimicrobial
activity of these impregnated catheters decreases over
time and the risk reduction is realized in the first 14 days.
Although expensive, the cost reduction achieved in 
preventing a catheter-related BSI translates to net cost
savings especially when used in high-risk patient groups
such as burn patients and surgical ICU patients. It should
be noted that patient allergy and medication sensitivity
need to be taken into consideration as anaphylaxis has
been reported with the use of these catheters.
Central venous catheters coated with minocycline and
rifampin are also available. The use of these catheters is
also associated with lower rates of catheter-related BSIs.
The antimicrobial activity of this coating persists longer
than the first-generation chlorhexidine/silver sulfadiazine
catheters with a beneficial effect after day 6. The use of
these antibiotics raises the potential issue of the devel-
opment of minocycline and rifampin resistance among
the pathogens responsible for catheter-related BSI.
Further study on the development of catheter coat-
ings is ongoing. Catheters have been developed using
ionic metals including platinum and silver, as well as
coatings that extend the release of chlorhexidine and 
silver sulfadiazine. The efficacy of these catheters is not
well known. Ionic silver has also been incorporated 
into a subcutaneous cuff to act as a mechanical barrier
while providing antimicrobial activity against migrating
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pathogens along the subcutaneous portion of catheters.
This strategy has failed to show a risk reduction in the
development of catheter-related BSIs.
CATHETER CARE
Catheter access and use can be modified to help
reduce the incidence of catheter infections. Excessive
manipulation of catheters increases the risk of infection.
Catheter ports and hubs require disinfection prior to use.
In addition, the tubing and access hubs should be changed
every 48–72 hours. Well-trained staff that adheres to
strict aseptic principles can reduce the incidence of
catheter infection. Institutions that utilize specialized IV
teams can also reduce the infection rate. In addition, the
reduction of nurse-to-patient ratios increases the risk of
catheter infection. Routine replacement of central
venous catheters does not reduce the infection rate. The
use of guidewires to exchange catheters remains con-
troversial. Several studies have shown trends toward
increased colonization and infection, but these trends 
do not appear to be statistically significant. Therefore,
guidewire exchange can probably safely be used, espe-
cially where access is difficult and the risks of insertion
at a new site are thought to be high. Catheters should be
removed as soon as they are no longer needed to elimi-
nate a potential source of infection.
DIAGNOSIS
The diagnosis of catheter-related BSI cannot be made on
clinical findings alone. Fever, leukocytosis, insertion site
inflammation, and BSI alone are all unreliable in ultimately
diagnosing catheter-related BSIs. Paired blood cultures
(one from the catheter and one from a peripheral source)
should be obtained when a catheter-related BSI is
suspected. Negative cultures have been shown to have a
high negative predictive value. When catheter removal is
not desired, paired quantitative cultures can be obtained.
If the colony count of a culture obtained from the catheter
is 5–10 times greater than the colony count obtained from
a peripheral sample, a catheter-related BSI is likely. One
can also exploit the differential time to positive culture for
blood sampled from the catheter and from the periphery
to aid in the diagnosis of catheter-related infections. When
blood cultured from the device has a positive result two
hours before peripheral cultures, a diagnosis of device
infection can be made with a sensitivity and specificity 
similar to that of quantitative blood cultures.
Samples of intravascular devices can also be cultured
to aid in the diagnosis of catheter-related infection.
Differences in the culture methods, the portion of 
the catheter cultured, and the source of the catheter
infection ultimately affect the sensitivity of the diagnos-
tic method used. In general, semiquantitative and quan-
titative culture methods are thought to be the most
reliable in the identification of catheter-related infection.
Semiquantitative cultures are obtained by cutting open
the desired portion of the catheter and rolling the device
onto a culture medium. Quantitative cultures are obtained
by either sonicating or vortexing the catheter sample in
a broth and subsequently culturing the sample. A semi-
quantitative catheter culture with a yield of ≥15 cfu
(colony forming units) or a quantitative yield of ≥100 cfu
is considered indicative of a device-related infection.
There is no definitive evidence to favor the culture of
the catheter tip or the subcutaneous segment in the diag-
nosis of catheter-related infection. The increasing use of
antiseptic- and antibiotic-coated catheters may affect the
usefulness of these culture methods. Rapid diagnostic tech-
niques such as the acridine orange stain may be useful
diagnostic modalities in the future.
MANAGEMENT
Determining the etiology of fevers in the critically ill
can be challenging. Once the central venous device is
suspected, paired blood cultures (one peripheral and
one central) should be obtained. Blood cultures from an
arterial line could be used if peripheral blood cannot be
obtained. However, a positive culture from the arterial
line may indicate an infected arterial line. In the seri-
ously ill or septic patient empiric antibiotic therapy
should be instituted utilizing ICU-specific antibiograms.
If no other source of fever is identified and the central
line remains suspect, the line should be removed and
cultured. A central line can then be inserted at a new site
or exchanged over a wire provided that the insertion site
does not appear to be infected. If both blood and device
cultures are negative one must search elsewhere for the
source of fever. If the blood cultures are negative and
the catheter culture is positive, the clinician should con-
sider a short course of antimicrobial therapy, follow
closely for signs of ongoing infection, and repeat the blood
cultures when necessary. If both blood and catheter cul-
tures are positive, the catheter should be removed and
the antimicrobial treatment is guided by the etiologic
organism. Infusates such as total parenteral nutrition
should also be cultured if contamination is expected.
Unfortunately there are few good data on the dura-
tion of antimicrobial therapy. In general S. aureus,
Candida spp., and Gram-negative bacilli are treated for
10–14 days. Coagulase-negative Staphylococcus spp. can be
treated for a shorter course of 3–7 days. Some clinicians
approach coagulase-negative staphylococcus line infec-
tions with catheter removal only and no antimicrobial
therapy. Persistent fevers and bacteremia despite
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catheter removal and appropriate antimicrobial therapy
should raise the suspicion of entities such as bacterial
endocarditis, septic thrombophlebitis, or other distant
microbial metastasis. In these cases prolonged antimi-
crobial therapy for 4–8 weeks is indicated.
THE FUTURE
Future strategies aimed at preventing catheter-related
BSIs will most certainly exploit both properties of the
host and pathogen. The catheter design itself is con-
stantly evolving to minimize bacterial adherence and 
colonization as well as thrombus formation with the
ultimate goal of reducing associated BSI. Increasing abil-
ities to affect the immunomodulation of the critically ill
may one day allow the clinician to minimize the devel-
opment of nosocomial infections. However, the impor-
tance of hand hygiene, maintenance of strict aseptic
techniques, and continuing education and training of
staff remain the cornerstones in preventing catheter-
related infections in the critically ill.
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In publications from the late 1980s approximately half
of the patients in intensive care units (ICUs) described
their period of mechanical ventilation as unpleasant and
stressful, and that their time requiring mechanical venti-
lation was associated with fear, agony, and panic. Some
publications have suggested an association between the
administration of large quantities of sedation and the devel-
opment of post-traumatic stress disorders and memory
problems while others have not found that association.
In the past 5 years ICUs throughout the world have
adopted the goal of maintaining an optimal level of 
comfort and safety for patients. The use and better under-
standing of newer sedatives and analgesics has given crit-
ical care practitioners the ability to titrate specific agents
for different patient types allowing patients to be com-
fortable throughout their stay in the ICU.
As the customized care of patients continues to evolve,
a common language is mandated for the titration and use
of sedative agents. With this language also comes the
development of protocols and guidelines to better use
these drugs and to maximize each drug’s unique phar-
macodynamic profile for individual patients. No longer
is it necessary to be trapped by the all-or-none effect of
very long-acting compounds that depress respiration and
prolong ICU stays.
AGITATION AND ANXIETY EVALUATION
There is no consensus as to what level of sedation is
optimal for patients in the ICU; most likely the optimal
level of sedation will vary according to patients’ under-
lying mental and physical problems, along with the
needed level sedation for patient safety. Agitation and
anxiety are common in ICU patients of all ages, occur-
ring at least once in most patients admitted to any ICU.
Agitation can be caused by multiple factors such as
extreme anxiety, delirium, adverse drug effects, and
pain. Failure to provide adequate pain control is a signif-
icant factor in the development of agitation in critically
ill patients. In most practices inadequate pain manage-
ment is often a result of the dosing of opioids at sub-
optimal levels; this is because of concerns about respira-
tory depression and the development of dependence.
124 CRITICAL CARE: THE REQUISITES IN ANESTHESIOLOGY
Hypoxemia has long been associated with agitation,
despite the routine use of continuous plethmography. It is
crucial for ICUs to monitor the oxygen levels in all patients.
A partial pressure of oxygen (pO2) of <60 mmHg (or 
oxygen saturation <90%) can contribute to agitation.
Hypotension and transient myocardial ischemia can also
lead to agitation.
One of the most common problems confronting the
critical care physician is a patient’s withdrawal from
alcohol or other agents, including cocaine, opioids, and
benzodiazepines.
In the ICU another common cause of agitation is 
ventilator dyssynchronization. This is frequently due to
poorly set ventilator modes that delay in responding to
patient’s efforts and needs during spontaneous breathing.
However, this problem is becoming less common due to
computer-controlled ventilators and the use of graphic
displays to titrate ventilation. Patients who undergo short-
or long-term intubation also develop agitation because of
the stimulus of the endotracheal tube itself. Patients who
are alert and intubated can also become frustrated by the
inability to communicate with staff and family and
descend into a cycle of continued agitation. This along
with the sounds, monitors, and continuous stimuli of the
ICU itself can contribute to further agitation.
The consequences of numerous drug reactions,
drug–drug interactions, and drug withdrawal all increase
the incidence of agitation in the modern ICU (Table 11-1).
The occurrence of undesirable drug interactions should
always be considered when multiple agents are being
used for pain, anxiety, infection, and cardiac disturbances.
Even after the withdrawal of a pharmacologic compound
suspected of increasing agitation, it may take several days
for the drug and metabolites to clear a patient’s system
before a positive response can be seen.
The differential diagnosis of agitation begins with a
review of the patient’s current disease process, mechanism
of injury, laboratory values, baseline medications, and a
review of their past medical history. Only after this rapid
evaluation can the process move toward proper treatment
for agitation.
EVALUATION AND TITRATION 
OF SEDATIVE AGENTS
The disease state complexity of ICU patients typically
demonstrates a rapidly changing spectrum of hemo-
dynamic states, so the requirements to treat agitation
fluctuate over time. Bedside clinicians must frequently
reassess and redefine the goals of therapy. Tools and
scales to monitor agitation in the ICU should be simple
to apply, yet describe clearly graded changes between
sedation levels to allow titration of both pharmacologic
and nonpharmacologic interventions.
There are large numbers of scales and tools for evalua-
tion described in the literature. Many of these evaluate the
level of consciousness with described responses to inter-
ventions. There is no gold standard scale, but most ICUs
use modification of those described in the literature. The
development of customized unit-based scales, protocols,
and guidelines is highly important for promoting their
acceptance by all members of the health care team.
SEDATION SCALE(S)
The most commonly used sedation scale is the
Ramsey sedation scale which identifies six levels of
sedation ranging from severe agitation to deep coma
(Table 11-2). Despite its frequent use the Ramsey scale
has some shortcomings when applied at the bedside of
Table 11-1 Medications Associated with Agitation 
in the Intensive Care Unit
ANTIBIOTICS
Acyclovir
Amphotericin B
Cephalosporins
Ciprofloxin
Ketoconazole
Penicillin
Rifampin
ANTICONVULSANTS
Phenobarbital
Dilantin
MISCELLANEOUS
Theophylline
Hydroxycine
Ketamine
NSAIDs
CARDIAC DRUGS
Captopril
Clonidine
Digoxin
Dopamine
Labetalol
Nifedipine
Quinidine
CORTICOSTEROIDS
Dexamethasone
Methyl prednisone
NARCOTIC ANALGESICS
Codeine
Mereprine
Morphine sulfate
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patients with complex problems. For example, a patient
who appears to be asleep with a sluggish response to
glabellar tap (Ramsey 5) may also be restless and anxious
(Ramsey 1). The Ramsey scale is simple, however, and is
widely used in many ICUs.
The Riker Sedation–Agitation Scale (SAS) was the
first scale formally tested and developed for reliability in
the ICU (Table 11-3). The SAS identifies seven symmetri-
cal levels ranging from dangerous agitation to deep seda-
tion. This scale provides a detailed description of a
patient’s behavior, allowing the bedside physician to
adjust properly medications between agitation levels.
Table 11-2 Ramsey Scale for Assessing 
Sedation Levels
Level Response/Description
1 Patient awake and anxious, agitated, and/or restless
2 Patient awake and cooperative, accepting ventilation, 
oriented, and tranquil
3 Patient wake; responds to commands only
4 Patient asleep; brisk response to light glabellar tap 
or loud auditory stimuli
5 Patient asleep; sluggish response to light glabellar 
tap or loud auditory stimulus but does respond to 
painful stimulus
6 Patient asleep; no response to light glabellar tap or loud 
auditory stimulus
Hansen-Flaschen J, Cowen J, Polomano RC: Beyond the Ramsay scale: need
for a validated measure of sedating drug efficacy in the intensive care unit.
Crit Care Med 22(5):732–733, 1994.
Table 11-3 Riker Sedation–Agitation Scale
Score Diagnosis Description
7 Dangerous Pulls at endotracheal tube; tries to
agitation remove catheters; climbs over 
bed rails; strikes at staff
6 Very agitated Does not calm, despite frequent 
verbal reminding of limits; 
requires physical restraints; 
bites endotracheal tube
5 Agitated Calm; awakens easily; follows commands
4 Calm and Difficult to arouse; awakens to verbal 
cooperative stimuli or gentle asking but drifts off 
again; follows simple commands
3 Sedated Arouses to physical stimuli but does not 
communicate or follow commands; 
may move spontaneously
2 Very sedated
1 Unable to Minimal or no response to noxious 
arouse stimuli; does not communicate or 
follow commands
Riker RR, Picard JT, Fraser GL: Prospective evaluation of the Sedation–Agitation
Scale for adult critically ill patients. Crit Care Med 27(7):1325–1329, 1999.
Table 11-4 Motor Activity Assessment Scale
Score Description Definition
0 Unresponsive Does not move with noxious stimulus
1 Responsive only Opens eyes or raises eyebrows or
to noxious turns head toward stimulus or
stimuli moves limbs with noxious stimulus
2 Responsive to Opens eyes or raises eyebrows or
touch or name turns head toward stimulus or
moves limbs when touched or
name is loudly spoken
3 Calm and Does not require external stimulus to 
cooperative elicit movement and adjusts sheets 
or clothes purposefully and follows 
commands
4 Restless and Does not require external stimulus to 
cooperative elicit movement and picks at sheets
or clothes or uncovers self and
follows commands
5 Agitated Does not require external stimulus to 
elicit movement and attempts to 
sit up or moves limbs out of bed 
and does not consistently follow 
commands
6 Dangerously Does not require external stimulus to 
agitated; elicit movement and pulls at tubes 
uncooperative or catheters or thrashes side to side 
or strikes at staff or tries to climb 
out of bed and does not calm down 
when asked
Devlin JW, Boleski G, Mlynarek M et al: Motor Activity Assessment Scale: a valid
and reliable sedation scale for use with mechanically ventilated patients in an
adult surgical intensive care unit. Crit Care Med 27(7):1271–1275, 1999.
The Motor Activity Assessment Scale (MAAS) is
similar in structure to the SAS because it also uses the
patients’ behavior to describe the different levels of 
agitation. The MAAS identifies seven levels, ranging from
unresponsive to dangerously agitated (Table 11-4).
Ely and colleagues developed a new assessment tool,
Confusion Assessment Method for the ICU (CAM-
ICU), which has been well validated in the critically ill
patient with delirium. It is used in combination with the
Glasgow coma scale for highly complex agitated patients.
The CAM-ICU is simple to apply at the bedside and has
been found to have a high level of reliability, sensitivity,
and specificity.
Current research is hoping that real-time computer
base monitors of brain function will remove human 
variability in the evaluation of a patient with agitation.
One such monitor popular in the operating room is the
Bispectal index (BIS). This objective monitor is espe-
cially helpful for the deeply sedated patient receiving
neuromuscular blockade. By incorporating several 
electroencephalograms, the BIS monitor provides a 
discrete value from 1000 (completely wake) to <60
126 CRITICAL CARE: THE REQUISITES IN ANESTHESIOLOGY
(deep sedation) to <40 (deep hypnotic state or barbitu-
rate coma). Although the technique has been shown to
be useful in the operating room, it has not been studied
to any great extent in the ICU.
ESTABLISHING AND IMPLEMENTING
SEDATION GUIDELINES AND PROTOCOLS
One of the most important goals for any ICU is the
development of protocols and guidelines for pain med-
ication and sedative drugs. The development of such
protocols requires multidisciplinary input and should be
unit specific. All staff, including physicians and nurses,
need to agree on which monitoring scales and tools to
use and then ensure that these scales are used. It is
important for staff to agree on documentation and
assessment frequency, predefined end points of therapy,
and evaluation of patient outcomes. Using these types of
protocols and documenting their use in daily practice
can foster communication between disciplines and
shifts. Another important aspect of sedation guideline
development is consultation with hospital pharmacists.
Pharmacists can provide guidelines and educational
input regarding specific pharmacodynamic profiles of
individual agents. Participation of such professionals on
rounds and as members of the ICU team can only
improve the quality of care for complex cases. Each 
hospital should develop guidelines that foster current
pharmacologic and pharmacokinetic recommendations
that are supported by national standards.
REVIEW OF COMMON AGENTS 
USED IN SEDATION
All physicians have experienced and intuitively
understand anxiety and pain. Analgesics and sedatives
are the mainstay of supportive care in the ICU. Over the
past few years several novel highly titratable agents have
been introduced that have greatly enhanced patient
care. The pharmacology of several of these widely used
agents is reviewed (Table 11-5).
OPIOIDS
Opioids are the primary agents used for analgesia in
the ICU. Traditionally they have been administered orally,
intramuscularly, or intravenously; but more recently
epidural, intrathecal, transdermal, and transmucosal
delivery systems have been developed. Most opioids are
lipid soluble and produce analgesia through their agonist
effects on opiate receptors in the central nervous system
(CNS) and peripheral nervous system. At low doses 
opioids provide analgesia but not anxiolysis, whereas at
higher doses they act as sedatives. All the opioids share
therapeutic properties but vary in potency and pharmaco-
kinetics.
Even though opioids can be given via several routes,
the intravenous (i.v.) method is the most common.
When given in the intravenous form, in therapeutic
doses, opioids cloud the sensorium but do not possess
amnestic properties.
The removal of pain greatly affects the need for seda-
tion and other therapies. Unrelieved pain evokes power-
ful stress responses, characterized by tachycardia,
increased myocardial oxygen consumption, hypercoagu-
lability, immunosuppression, and persistent catabolism.
Effective analgesia has been shown to diminish pulmonary
complications in postoperative patients.
Comparative trials of opioids have not been per-
formed in critically ill patients. The selection of specific
agents depends on the pharmacology and potential for
CLINICAL CAVEAT
Protocol in the Intensive Care Unit
● Hospital- and unit-driven sedation/analgesic protocols
improve patient care, decrease time on mechanical
ventilation, and decrease hospital cost.
● Specific protocols should be supported by national
standards.
Table 11-5 Pharmacokinetics and Pharmacodynamics of Opioid Agents
Lipid Half-life Onset of Peak Effect Duration of
Drug Solubility (hours) Action (minutes) (minutes) Action (hours)
Morphine Low 2–3 5 20–30 2–7
Fentanyl High 4–10 1–2 5–15 0.5–1
Meperidine Moderate 5–10 5 20–60 2–4
Hydromorphone Low 2–3 10–15 15–30 2–4
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adverse events. For opioids desirable attributes include
rapid onset, ease of titration, lack of accumulation of
metabolites, and low cost.
Morphine Sulfate
Morphine sulfate, the prototypical opioid, is the pre-
ferred opioid analgesic in patients with stable hemo-
dynamics. Morphine has a rapid initial redistribution phase
of 1–1.5 minutes and an initial half-life of 10–20 minutes;
the terminal elimination half-life is between 2 and 4.5 hours.
Morphine has a lower lipid solubility which results in a
slower onset of action when compared to fentanyl. This
is important in that morphine slowly penetrates the
blood–brain barrier. The liver primarily metabolizes mor-
phine; however, the kidney eliminates approximately
40% of the drug. The major metabolite of morphine
(morphine-6-glucuronide) is excreted in the urine and
may accumulate in patients with renal failure. The opiate
activity of the metabolite is several times greater than
that of morphine and its accumulation in patients with
renal failure has been reported to prolong narcosis.
Morphine also induces the release of histamine, increasing
the likelihood of causing hypotension secondary to vaso-
dilation. The faster the rate of administration, the more 
pronounced the hypotension seen. Finally morphine can
also slow the heart rate, by its stimulation of the vagus
nerve and its depressant effects on the sinoatrial node.
Despite its side effects, morphine is still very useful in
the management of ICU patients.
Fentanyl
Fentanyl has the most rapid onset and shortest dura-
tion of the opioids. Fentanyl citrate is a synthetic narcotic
analgesic that is 50 to 100 times more potent than mor-
phine, it is highly lipid soluble, and has rapid onset of action
because it quickly crosses the blood–brain barrier. Fentanyl
onset of action is within 30 seconds, and its peak effect 
is within 5–15 minutes. The liver metabolizes fentanyl.
Fentanyl has no active metabolites. Fentanyl is not asso-
ciated with histamine release and so it infrequently
causes hypotension. Fentanyl, however, can cause
bradycardia and decrease sympathic tone; these in turn
can cause hypotension. Because of its rare hemodynamic
side effects, it is an ideal drug for patients in the ICU.
Fentanyl should be administered by continuous infu-
sion for sustained effect because of its short duration of
action. Because of these characteristics, fentanyl has
become one of the most widely used agents in the ICU.
Caution should be used when fentanyl is administered at
high doses for prolonged periods of time. Prolonged
effects can be seen, because large amounts of the drug
accumulate in the fatty tissues and then have to be
metabolized in the liver. In these situations the terminal
half-life of the drug can be as long as 16 hours.
Remifentanil
Remifentanil (Ultiva, Abbot), a newer agent, has not
been widely studied in ICU patients. The drug has a very
short half-life and may be best used in patients needing
serial examinations or neurologic evaluation. Remifentanil
is an ultrashort-acting narcotic that penetrates the blood–
brain barrier within 1 minute, and its blood concentration
decreases 50% by 6 minutes after a one-minute infusion.
Because of its shortened duration of action, it requires
continuous infusion for pain management. The novel
aspect of remifentanil is its rapid hydrolysis by circulat-
ing and tissue nonspecific esterases (the beta-adrenergic
blocker esmolol is metabolized by similar enzymes).
There does not appear to be a cumulative effect seen with
long infusions and organ dysfunction does not appear to
alter the metabolism of the drug. Side effects of remifen-
tanil include respiratory depression, hypotension, brady-
cardia, and skeletal hypertonus; this can make bag mask
ventilation difficult or impossible. The administration of
propofol or a paralytic agent prior to its administration
can attenuate the skeletal rigidity seen with the drug.
CLINICAL CAVEAT
Opioid and Pain Control
● Historically pain control has been poorly managed.
● Most physicians overestimate the risk of narcotic
addiction in postoperative patients.
● Unrelieved pain evokes powerful stress responses.
● Unrelieved pain can result in pneumonia and
atelectasis resulting from respiratory splinting, which
decreases tidal volume, vital capacity, and functional
residual capacity.
● Patient-controlled analgesia (PCA) produces adequate
pain control and at the response of patients’ needs.
CLINICAL CAVEAT
Opioid Reversal
● Narcan (naloxone hydrochloride) is an opioid
antagonist.
● Narcan can prevent or reverse the effects of opioids.
● Narcan challenge test: inject 0.2 mg Narcan and
observe for 30 seconds.
● Onset of action is usually within 2 minutes.
● Opioid dependence patients can have acute
withdrawal if given Narcan.
● Smaller doses of 400 μg (dilute 9 cm3 saline with
1 mg of Narcan) can help reverse the effects of
the opioid but prevent abrupt withdrawal.
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Meperidine
Meperidine was once a standard drug used for pain
control, but is no longer recommended for repetitive
use, it has an active metabolite that causes neurotoxicity
(apprehension, tremors, delirium, and seizures), and
may interact with antidepressants, along with its well-
documented contraindication with monoamine oxida-
tive inhibitors (MAOIs) and is best avoided in patients
taking selective serotonin reuptake inhibitors.
Meperidine should not be used in the ICU due to risks
from multiple interactions with other medication.
OPIOID ADVERSE EFFECTS
Certain adverse effects from opioid analgesics occur
frequently in ICU patients. Of greatest concern is the res-
piratory, hemodynamic, CNS, and gastrointestinal effects.
Respiratory depression is a concern in spontaneously
breathing patients or in those receiving ventilatory sup-
port. Other common side effects include pruritus, urinary
retention, and bradycardia. Opioids may also increase
intracranial pressure in traumatic brain injury patients
although the data are inconsistent and the clinical signif-
icance is unknown.
NONOPIOID ANALGESICS
The nonopioid analgesics include salicylates, aceta-
minophen, and other nonsteroidal anti-inflammatory
drugs (NSAIDs). The uses of nonopioid agents are
increasing in the ICU. The nociceptive stimuli caused 
by chemical as well as mechanical stimuli release
prostaglandins and leukotrienes leading to inflammation
and sensitization of nociceptors, resulting in hyperalgesia
that is characterized by a decrease in the pain threshold.
The pain signal could be at the site of injury or the pain
signal could also be amplified or modified in the spinal
cord as a result of the action of prostaglandins. The
NSAIDs provide analgesia via the nonselective competi-
tive inhibition of cyclooxygenase, a critical enzyme in
the inflammatory cascade. NSAIDs have many positive
attributes, including reducing opioid requirements, but
they also have many adverse effects. Unwanted effects
include an increased incidence of gastrointestinal 
bleeding (secondary to platelets inhibition) and renal
dysfunction. NSAIDs neither cause respiratory depression
nor decrease level of consciousness. They also have no
effect on intestinal and bile duct motility and thus com-
pared with opioids they are less likely to cause nausea,
vomiting, and ileus. Due to concerns of increased car-
diovascular risks COX2 agents have been withdrawn
from use.
BENZODIAZEPINES
Benzodiazepines are the most widely used sedative
drugs in medicine. They are sedative and hypnotic but not
analgesic agents that block the acquisition and encoding
of new information and potentially unpleasant experience
(anterograde amnesia) but do not induce retrograde
amnesia. They have an opioid sparing effect by moderating
the anticipatory pain response. Benzodiazepines vary 
in their potency, onset, duration of action, uptake, and
absence of active metabolites. The two predominant
mechanisms of action of benzodiazepines involve activity
at the gamma-aminobutyric acid (GABA) receptors. The
potentiation of GABA-mediated transmission by benzo-
diazepines is responsible for the somnolent, anxiolytic,
and anticonvulsant actions, whereas the amnestic prop-
erty seems to correlate with GABA agonist activity in the
limbic cortex.
Metabolism of benzodiazepines occurs in the liver,
where they are extensively cleared. The effects of these
drugs may be prolonged in critically ill patients.
Accumulation of the parent drug or active metabolite
may produce inadvertent and prolonged oversedation,
as is seen in the elderly. It is therefore paramount that
these drugs are titrated carefully and used in low doses
or patients will be somnolent for several days after stop-
ping the infusion.
Benzodiazepines should be titrated to a predefined
end point, often using a series of loading (bolus) doses.
Hemodynamically unstable patients may experience
hypotension with initial sedation. Maintenance of seda-
tion with intermittent or “as needed” doses of diazepam,
lorazepam, or midazolam may be adequate to accomplish
the goal of sedation secondary to the relative half-life of
these drugs.
CLINICAL CAVEAT
Meperidine
● No longer recommended for use in ICU patients.
● Meperidine should not been given by the
subcutaneous route; evidence that chemical
irritation and necrosis may result.
● Meperidine is contraindicated in patients 
who are receiving monoamine oxidative inhibitors
or those who have received such agents within 
14 days.
● Therapeutic doses of meperidine have
inconsistently precipitated unpredictable,
severe, and occasionally fatal reaction.
● The mechanism of this reaction is unclear.
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The new clinical practice guidelines of the Society of
Critical Care Medicine (SCCM) currently recommend
lorazepam for sedation in most patients either by inter-
mittent intravenous dosing or continuous infusion.
Lorazepam, an intermediate-acting benzodiazepine, is
less lipophilic than diazepam and thus has less poten-
tial for accumulation. Lorazepam is associated with a 
stable hemodynamic profile even when opioids are con-
currently administered. Lorazepam has no active metabo-
lites and its metabolism is less affected by advanced age
or liver dysfunction when compared with midazolam.
Lorazepam should, however, be used with caution:
propylene glycol toxicity marked by acidosis and renal
failure has occurred with high cumulative doses or pro-
longed infusion of the drug.
Midazolam
The other commonly used benzodiazepine is midazo-
lam, used initially in the operating room and now widely
accepted in the ICU. Midazolam is a slow-acting water-
soluble benzodiazepine that is transformed to lipophilic
compounds in the blood. Midazolam exhibits dose-
related hypnotic, anxiolytic, amnestic, and anticonvul-
sant actions. The drug produces dose-related respiratory
depression and larger doses may cause hypotension and
vasodilation. Midazolam is metabolized in the liver to 
an active compound that is less potent and more tran-
sient than the parent compound. The new SCCM guide-
lines recommend midazolam for short-term use and
rapid sedation of actively agitated patients. Midazolam
produces unpredictable awakening and prolonged extu-
bation times when infusions continue for longer than 
48 to 72 hours.
Paradoxical agitation has been observed when using
benzodiazepines: this may be the result of drug-induced
amnesia or disorientation. The effect of these drugs can
be reversed with a benzodiazepine receptors antagonist,
flumazenil (Romazicon, Roche). However, the routine
use of flumazenil is not recommended after prolonged
benzodiazepine therapy because there is a risk of induc-
ing withdrawal symptoms and increasing myocardial
oxygen consumption, which can occur even with small
doses.
Propofol
Propofol, 2,6-diisopropylphenol, is formulated as a 1%
aqueous emulsion, containing 10% soybean oil, 2.25%
glycerol, and 1.2% egg phosphatide. Although the mech-
anism of action of propofol is still not completely under-
stood, the drug appears to activate the GABA receptors
within the CNS. Propofol has a rapid onset of action,
within 1 to 2 minutes after a single intravenous dose, and
a short duration of action, only 10 to 15 minutes when
discontinued. This short duration of action is due to its
rapid penetration into the CNS and subsequent redistri-
bution. Therefore, in the ICU propofol is used by con-
tinuous infusion. Propofol has no analgesic activity but
has some antiemetic properties. The clearance of propo-
fol cannot be explained by hepatic clearance alone;
there appear to be extrahepatic sites of elimination. 
The clearance of propofol is rapid even after prolonged
infusions, but accumulation of the drug in lipid stores
can result in prolonged sedation.
Propofol alters the sensorium at an extremely rapid
rate and in a dose-dependent manner, from light seda-
tion to general anesthesia, making it a highly useful drug.
Propofol is a respiratory depressant. Propofol also pro-
phylactically attenuates induced bronchoconstriction
but does not affect resting airway tone. The most com-
monly seen side effect of propofol, especially when it 
is given as a bolus, is hypotension. Propofol causes
hypotension by reducing systemic vascular resistance
and causing myocardial depression. These effects are
attenuated in hypovolemic patients. Propofol decreases
cerebral metabolism resulting in a decline in cerebral per-
fusion pressure. It has interesting effects on neurophysi-
ology, causing disinhibition, dystonic or choreiform
movements. Other side effects include phlebitis, hyper-
lipidemia, and pancreatitis.
CLINICAL CAVEAT
Lorazepam
● Sedative of choice.
● Prolonged use has been associated with acidosis 
and renal failure caused by accumulation of
propylene glycol.
CLINICAL CAVEAT
Flumazenil
● Romazicon (flumazenil) is a benzodiazepine
receptor antagonist.
● Doses of 0.1 to 0.2 mg produce partial antagonism
and 0.4 to 1 mg complete reversal.
● Repeat doses of 0.5 mg at one-minute intervals to 
a maximum cumulative dose of 3–5 mg.
● Onset of reversal is usually evident within 
1 to 2 minutes.
● The use of Romazicon has been associated with 
the occurrence of seizures; this is most frequent 
in patients who have been on long-term
benzodiazepines or in overdose cases where
patients are showing signs of serious cyclic
antidepressant overdose.
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One of the most important benefits associated with
propofol is a decrease in weaning time from mechanical
ventilation. A large Spanish study, using a cost-of-care
approach, evaluated the impact of prolonged sedation 
of critically ill patients with midazolam or propofol, and
weaning time from mechanical ventilation. Although
both drugs provided equivalent sedation, the administra-
tion of propofol was associated with a shorter weaning
time than midazolam resulting in a favorable economic
profile. Due to its rapid wake-up time, propofol is con-
sidered the fundamental drug in many fast-track surgical
procedures.
Within one year of its introduction in the USA, clusters
of infections in surgical patients treated with propofol
were reported. The majority of cases were due to con-
tamination of the drug from poor aseptic techniques.
This contamination resulted in the inclusion of an additive,
ethylenediaminetetraacetic acid (EDTA), to help retard
growth of microorganisms. EDTA at low concentrations
has no effect on the physical or chemical stability of the
emulsion compound. In the years following the intro-
duction of the EDTA-containing formulations the inci-
dence of fevers and infections were reduced to zero.
EDTA is a chelator of various ions, including calcium.
In a randomized multicenter trial, patients were treated
with either the original propofol formulation or the for-
mulation with EDTA. The EDTA-containing formulation
had no effect on calcium or magnesium hemostasis,
renal function, or sedative efficacy.
One of the interesting aspects of propofol with EDTA
is it ability to modulate the system inflammatory response.
In a study of surgical ICU patients, those receiving
propofol with EDTA had significantly lower mortality
rates at 7 days and 28 days compared to patients receiv-
ing the original formulation. This potential positive effect
of propofol with EDTA may be related to the ability of
EDTA to bind and increase the excretion of zinc; this, in
turn, may diminish the inflammatory response to stress
by decreasing the release of cytokines involved in 
inflammation and the generation of free radicals and
other oxidases.
In the USA a generic formulation of propofol is avail-
able. The major difference with the generic product is
the presence of sodium metabisulfite (0.025%) as a pre-
servative. As a result of this additive, it carries an FDA
warning about its use in patients sensitive to sulfite com-
pounds and therefore should not be used in this group
of patients. Thus it is highly important for clinical staff to
know which propofol formulation is being used in their
facility.
The use of propofol is not currently recommended
for pediatric patients, due to reports of metabolic aci-
dosis with accompanying lipemic serum, bradyarrhyth-
mias, and fatal myocardial failure with excessively high
doses; however, it should be noted that these occurred
in highly complex patients with a high mortality index.
The SCCM guidelines recommend propofol as the
agent of choice for rapid awakening and early extuba-
tion. Since propofol is formulated as a lipid emulsion,
triglyceride concentrations should be monitored after
two days of infusion. Also, the total caloric intake should
be adjusted because the lipid emulsion adds calories to
the nutritional prescription.
Haloperidol
Haloperidol, a butyrophenone neuroleptic drug, is
the agent of choice for treatment of delirium in critically
ill patients. Patients treated with haloperidol generally
seem to be calmer and are better able to respond appro-
priately to commands. Haloperidol does not cause major
respiratory depression.
The adverse effects associated with haloperidol
include occasional hypotension resulting from the alpha
blocking properties of the drug. Although rare with
intravenous use, haloperidol may cause extrapyramidal
effects such as drowsiness, lethargy and fixed stare rigidity
and akathisia. A highly dangerous side effect is neuroleptic
malignant syndrome (NMS) which has a mortality rate of
up to 30%. NMS may develop slowly over 24 to 72 hours
and can last up to 10 days after discontinuation of the drug.
Ketamine
Ketamine, a phencyclidine derivative, is unique
among the intravenous agents in that it causes analgesia
as well as amnesia. The drug does not necessarily cause
CLINICAL CAVEAT
Side Effects of Haloperidol
● Neuroleptic malignant syndrome (NMS) can 
develop over 24 to 72 hours after administration 
of haloperidol.
● NMS is characterized by hyperthermia,
hypertonicity, and tachycardia.
● TX: discontinue the drug, fluid resuscitation, 
cooling techniques, and intravenous dantrolene
sodium, 2 mg/kg every 5 minutes to maximum 
dose of 10 mg/kg.
● Cardiac arrhythmias can occur. Most worrisome 
is torsade de pointes (polymorphic ventricular
tachycardia).
● Total daily doses should remain less than 50 mg.
● Monitoring QT interval is recommended.
● For corrected QT intervals exceeding 
480 milliseconds the drug should be stopped.
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a loss of consciousness, but patients lose their aware-
ness; this unique anesthetic condition is described as a
“dissociative state.” This is caused by electrophysiologic
inhibition of the thalamocortical pathways and stimula-
tion of the limbic system.
Ketamine and a benzodiazepine are frequently used for
sedation in pediatric patients. In the ICU ketamine can be
given before airway intubation in hypovolemic patients,
dressing changes, laceration repair, abscess incision and
drainage, and orthopedic manipulations. Ketamine can be
given orally, rectally, intramuscularly, or intravenously.
This drug is a racemic mixture, which is marketed in three
concentrations so care is needed to avoid dosage error. The
dose of ketamine is 0.5–1 mg/kg. Ketamine has an elimina-
tion half-life of 3 hours. Ketamine has no adverse effects on
hepatic and renal function. The effects of a single injection
of ketamine generally last less than 30 minutes, although
coadministration of other drugs may prolong the effects.
There are well-described side effects of ketamine.
General anesthesia with ketamine is characterized by 
a hyperdynamic circulatory response (tachycardia and
increased blood pressure) caused by directly simulat-
ing the autonomic nervous system to release cate-
cholamines and steroids. Despite this side effect, protec-
tive airway reflexes (coughing) and minute ventilation are
maintained.
Although ketamine is a direct myocardial depressant,
this drug inhibits reuptake of catecholamines and pro-
duces mild to moderate increases in blood pressure,
heart rate, and cardiac output. These cardiostimulatory
effects could be detrimental in patients with underlying
cardiovascular disease.
Ketamine is useful in patients with airway disease in
that it attenuates neurally induced bronchoconstriction.
It also has a small direct effect on smooth muscle activa-
tion; however, it is unclear whether it can be utilized to
improve asthma attacks.
During emergence from ketamine, patients may 
have vivid dreams (both pleasant and unpleasant) and
hallucinations.
Etomidate
Etomidate is a nonbarbiturate, carboxylated, imidazole-
containing compound. Etomidate is a hypnotic agent,
commonly used to induce general anesthesia in the
operating suite. It can also be used to facilitate rapid-
sequence endotracheal intubation in the ICU. It is gen-
erally used in conjunction with neuromuscular blocking
agents. For induction of anesthesia, the initial dose is
0.2–0.6 mg/kg over 1 minute. This drug, however, should
not be given as an infusion. It is a favored drug because
of its few cardiovascular side effects. Adverse effects are
rare. Of particular importance are its neuromuscular and
skeletal muscle side effects, which include myoclonus
(33%) and transient skeletal movements including
uncontrolled eye movements; both effects are transient.
Dexmedetomidine
Dexmedetomidine (Precedex, Abbot) is a newly
approved selective α-2-adrenergic receptor agonist.
It exhibits sympatholytic sedative and analgesics effects
and is eight times more potent for the α-receptor than
clonidine. Dexmedetomidine has been approved for short-
term (24 hours) sedation and analgesia in the intensive care
setting. Because of its short-term effects, dexmedetomidine
is a highly promising therapy for ICU patients.
Dexmedetomidine works by presynaptic activation of
the α-2-adrenoreceptor thereby inhibiting the release of
norepinephrine and terminating the propagation of pain
signals. It also affects postsynaptic activity resulting in a
decrease in blood pressure and heart rate. Together
these two effects can produce sedation, anxiolysis, and
analgesia. Dexmedetomidine has several advantages for
use as a sedative in the ICU. Because the drug does not
cause respiratory depression, a patient can be extubated
without prior discontinuation. This property also makes it
ideal for patients being weaned from mechanical ventila-
tion. The drug provides great flexibility. Since dexmedeto-
midine also lowers the requirement for narcotics it can
decrease opioid effects. Because elimination is primarily
hepatic, dexmedetomidine dosing should be lowered in
patients with hepatic dysfunction. Also, inappropriate use
of dexmedetomidine may induce or aggravate cardiac
conduction defects. Dexmedetomidine should not be
used in hypovolemic or bradycardic patients or in patients
with low cardiac output or heart conduction blocks.
Dexmedetomidine is a promising agent with multiple
actions that reduce analgesic and other sedative require-
ments and produce a cooperatively sedate patient. 
It may open a whole new arena in the sedation of 
extubated patients who have high levels of anxiety.
Dexmedetomidine needs to be further studied to deter-
mine its role in the ICU.
CLINICAL CAVEAT
Warning for Etomidate
● Etomidate inhibits 11-β-hydroxylase, an enzyme
important in adrenal steroid production.
● A single induction dose blocks the normal 
stress-induced increase in adrenal cortical production
for 4–8 hours and up to 24 hours in the elderly.
● Continuous infusions of etomidate are not
recommended.
● Blunts the patient’s ability to respond to stress.
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INTRODUCTION TO MUSCLE RELAXANTS
Neuromuscular blocking agents (NMBAs) have the
most fascinating history among the drugs used in anesthe-
siology and intensive care. Aborigines of South America
used curare for centuries to hunt before Claude Bernard
showed in 1850 that these drugs act peripherally, blocking
conduction where motor nerves meet the muscle.
NMBAs are indeed a double-edged sword. They can
be lifesaving in critical situations, such as airway man-
agement and respiratory failure, but they also can cause
serious complications. NMBAs are divided by their chem-
ical structure; by their duration of action – ultrashort,
short, intermediate, and long acting; and by the type of
block – depolarizing and nondepolarizing.
Neuromuscular blocking agents are utilized for many
reasons (Box 11-1). Long-term use is not recommended
and short-term use is considered less than two days. Few
complications have been reported with administration for
less than that time period. There are many complications
associated with NMBAs including anaphylaxis and hyper-
kalemia associated with succinylcholine administration in
selected patients with medical conditions like burns, muscle
trauma, chronic renal disease, and long-term immobility.
Risk factors for prolonged weakness include vecuro-
nium in female patients who have renal failure, high-dose
steroids, more than two days’ duration of relaxant admin-
istration, and administration of high doses of NMBAs.
There appears to be several etiologies to the persistent
weakness. One theory is that the persistent weakness
may be due to muscle paralysis from NMBA metabolites.
Vecuronium has an active metabolite, 3-desacetyl vecuro-
nium, which persist particularly in women patients with
renal failure. Pancuronium also forms active metabolites;
therefore these drugs should not chronically be adminis-
tered to patients who are in renal failure.
Another finding is in patients on corticosteroids who
receive long-term muscle relaxants. They appear to
develop a myopathic syndrome characterized by flaccid
paralysis, increased creatine kinase (CK), and myonecrosis;
these patients recover after many months. Plasma CK con-
centration appears to increase when the myopathy devel-
ops; therefore serum CK should be monitored in patients
on corticosteroids and receiving muscle relaxants. All mus-
cle relaxants have been associated with these syndromes.
A motor neuropathy has been reported after the
administration of vecuronium or atracurium. The neuro-
pathy affects all extremities and is associated with absent
tendon reflexes. This syndrome also takes months to
resolve. Another syndrome consisting of persistent
motor weakness but with preservation of sensory sensa-
tions has been reported in patients receiving pancuro-
nium and vecuronium. These patients do not have normal
neuromuscular transmission and their symptoms also
take months to resolve.
Patients can become tolerant to the effects of the
NMBAs. This tolerance can develop in the first 48 hours.
Tolerance appears to be due to the upregulation of
acetylcholine receptors. Monitoring patients receiving
NMBAs is critical. There are many ways to achieve this,
but electrical stimulation is commonly used. Single twitch,
tetany, and train-of-four (TOF) stimulation tests are com-
monly used. The most commonly used method of moni-
toring for appropriate muscle relaxation is the TOF
responses. It is important to note that the TOF monitor-
ing of patients does not ensure that persistent weakness
will not occur. Table 11-6 lists commonly used muscle
relaxants and their associated side effects.
Depolarizing Drugs
Succinylcholine
Succinylcholine is unique among the NMBAs. It is the
only depolarizing drug in clinical use. Succinylcholine has
the fastest onset of action and shortest duration of
action. Succinylcholine binds to the nicotinic receptors
mimicking the action of acetylcholine, this causing
depolarization across the post-junctional membrane.
CLINICAL CAVEAT
Train-of-Four Monitoring
● The most commonly used nerve/muscle
combination for monitoring train-of-four (TOF) 
is ulnar nerve/adductor pollicis and facial
nerve/orbicularis oculi.
● A sequence of four supramaximal stimuli with a
frequency of 15–40 mA (four stimuli 0.5 seconds
apart) is needed.
● Goal is keeping TOF at 2 out of 4.
● Combining clinical monitoring with the use of 
nerve stimulator is recommended in order to
optimize patient care and minimize complications.
Box 11-1 Possible Indications for
Neuromuscular Blocking Agents
Airway management
Decrease chest wall and/or pulmonary compliance 
(acute respiratory distress syndrome)
Respiratory asynchrony with mechanical ventilation
Elevated airway pressures
Muscular rigidity, such as in tetanus and status epilepticus
Control of intracranial hypertension
Minimizing metabolic demands and oxygen consumption
Severe agitation not controlled by sedatives
Maintenance of delicate surgical grafts until stable
Facilitation of certain procedures
Current Practices in Intensive Care Unit Sedation 133
The main indication for use in the critically ill is rapid air-
way management. However, it is also associated with
many cardiovascular side effects.
Nondepolarizing Agents
Pancuronium
Pancuronium, one of the original NMBAs used in the
ICU, is a long-acting, nondepolarizing compound that is
effective after a bolus dose of 0.06 to 0.08 mg/kg for up
to 90 minutes. It can be given as a bolus or continuous
infusion. Pancuronium is vagolytic, which limits its use
in patients who cannot tolerate an increase in heart rate.
In patients with renal failure or cirrhosis pancuronium’s
neuromuscular blocking effects are prolonged by the
increased metabolite 3-hydroxypancuronium.
Vecuronium
Vecuronium is an intermediate-acting NMBA that is
a structural analog of pancuronium but is not vagolytic.
It also can be given via bolus or continuous infusion. The
bolus dose of 0.08 to 0.10 mg/kg produces effects within
3 minutes. Its neuromuscular blocking effects last
approximately 30 minutes. A continuous infusion can be
used at doses of 1–2 μg/kg/minute. Vecuronium also has
an active metabolite, 3-desacetylvecuronium, which can
accumulate in patients with hepatic dysfunction. Also,
up to 35% is renally excreted and dose adjustment 
and careful monitoring is needed in renal insufficient
patients. Vecuronium is associated with acute quadri-
paretic myopathy syndrome (AQMS).
Rocuronium
Rocuronium is a newer nondepolarizing NMBA with a
monoquaternary steroidal chemistry. It has intermediate
duration of action and very rapid onset. When rocuronium
is given as a bolus of 0.1–0.6 mg/kg, blockade occurs
within 2 minutes. Continuous infusions, if needed, are usu-
ally started at 10 μg/kg/minute. Rocuronium is not affected
by patients with renal failure and has little prolonged
action in patients with liver dysfunction.
Atracurium
Atracurium is an intermediate-acting NMBA with 
minimal cardiovascular side effects but is associated
with histamine release at higher doses. It is inactivated in
plasma by ester hydrolysis and by Hoffmann elimination
so renal and hepatic dysfunction does not affect the
duration of blockade.
Cisatracurium
Cisatracurium, an isomer of atracurium, is an intermedi-
ate-acting benzylisoquinolinium NMBA that is increasingly
used in lieu of atracurium. It produces few cardiovascular
effects and has fewer tendencies to release histamine and
mast cell degranulation. Bolus doses are with 0.1–0.2 mg/kg
with a duration of action of 25 minutes. Infusion rates
should be started at 2.0–3.0 μg/kg/minute. Cisatracurium is
also eliminated by ester hydrolysis and by Hoffmann elimi-
nation so patients with renal or hepatic dysfunction do not
have a prolonged duration of blockade.
Complications of Neuromuscular 
Blocking Agents
Multiple complications have been associated with the
use of NMBAs, and the ICU physician should be familiar
CLINICAL CAVEAT
Succinylcholine
● Reported cases of acute rhabdomyolysis with
hyperkalemia followed by dysrhythmias, cardiac
arrest, and death after the administration of
succinylcholine in children. These children were
subsequently found to have skeletal muscle myopathy,
frequently Duchenne’s muscular dystrophy.
● Relatively contraindicated in children and patients
with burns, skeletal muscle injury, history of
malignant hyperthermia, and renal failure because 
of the risk of hyperkalemia (the risk in these
patients may last as long as 7 to 10 days).
Table 11-6 Muscle Relaxant Properties
Drug Initial Dose (mg/kg) Duration (minutes) Advantages Complications
Pancuronium 0.07–0.1 Long acting; 6–120 Inexpensive Tachycardia; accumulation in renal failure
Vecuronium 0.1 30–45 CVS stability Active metabolite; accumulation in renal 
and hepatic insufficiency
Atracurium 0.5 30–45 Reliable recovery Slow onset; no active metabolite
Rocuronium 0.6–1.2 30–90 Rapid onset None
Cisatracurium 0.1–0.2 30–90 Reliable recovery Slow onset
Succinylcholine 0.6–1 Ultrashort; 5–10 Fast onset and Hyperkalemia dysrhythmia
fast recovery
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with their common side effects. There are many drug
interactions with NMBAs that can prolong the neuro-
muscular blockade. Antibiotics such as neomycin, strepto-
mycin, lincomycin, and tetracycline all have prolonged
the effects of NMBAs. Electrolytes play an important role;
hypermagnesemia, hypokalemia, hypocalcemia, and
lithium all prolong neuromuscular blockade. Also, patients
who are paralyzed are at risk for keratitis and corneal
abrasions. The routine administration of ophthalmic 
ointment or drops is recommended. There is an increased
risk for deep venous thrombosis and the most notable
side effect is AQMS. AQMS is a serious complication of
NMBAs, which significantly prolongs ICU and hospital
stay. This is one of the reasons that NMBAs should be
used with caution and only in experienced hands.
On examination, the paralyzed patient has significant
motor deficits in the upper and lower extremities, along
with depressed deep tendon reflexes. Sensory function
and ocular muscle function are usually preserved. On elec-
tromyography (EMG), there are low-amplitude compound
motor action potential and muscle fibrillations. Modest CK
and lactate dehydrogenase increases are observed. This
syndrome can be seen in patients receiving prolonged
NMBAs for greater than 48 hours or with concomitant use
of corticosteroids. Muscle biopsy shows Type II muscle
fiber atrophy with vacuolization, disordered sarcomeric
architecture, and extensive loss of myosin.
CONCLUSION
Critically ill patients frequently experience anxiety
and pain and occasionally experience severe agitation.
These factors have a significant effects on a patient’s
sense of well-being, and perhaps equally important, on
patient outcomes. Health care providers are responsible
for maintaining a stress-free and comfortable environment
to minimize these perceptions. The most important
aspect of ICU sedation is an understanding of the drugs
used and their specific advantages and disadvantages.
Each drug is ideal for a specific use. It is crucial for the
clinician to develop guidelines and pathways for the use
of these drugs within a specific environment. Newer
drugs certainly will become available and more is being
learnt about some of the new drugs and specific protocols
that grade effect are being developed.
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Summary
In the general population hypertension is present in
one in four adults in the USA. Among certain subgroups
of the population, such as blacks and the elderly, the
prevalence of hypertension is even higher. The impor-
tance of hypertension lies in its widespread effect on an
individual’s health including the potential for causing
stroke, myocardial infarction, renal failure, congestive
heart failure, progressive atherosclerosis, and dementia.
More recently isolated systolic hypertension has been
identified as a significant risk factor among the elderly
for cardiovascular events. Both the duration and level of
hypertension have a determining effect on outcome
from cardiovascular disease in combination with other
risk factors. There is no question that the treatment of
hypertension reduces the risk of stroke and coronary
artery disease as well as congestive heart failure.
Importantly, it is also known that only 54% of patients
with hypertension receive treatment and overall only
28% are adequately treated.
EVALUATION
The Joint National Committee on Prevention,
Detection, Evaluation and Treatment of High Blood
Pressure has classified hypertension as follows. High
normal: 130–139 systolic, 85–59 diastolic; stage 1:
140–159 systolic or 90–99 diastolic; stage 2: 160–179
systolic or 100–109 diastolic; stage 3: >180 systolic or >110
diastolic. Blood pressure measurements should be accu-
rate and should also be confirmed on at least three 
different occasions. So-called white coat hypertension
can be excluded by obtaining ambulatory or at-home blood
pressure monitoring. The latter is present in up to 20%
of patients with elevated blood pressure but it may be 
a precursor of sustained hypertension and certainly 
warrants continued surveillance.
In addition to a history and physical examination, 
routine testing should include urinalysis, complete
blood count, creatinine and urea, potassium, and 12-lead
electrocardiography. Severe or resistant hypertension or
clinical or laboratory findings indicative of underlying
disease such as that originating in the kidney or adrenal
gland should be further investigated. In 90% of patients
the diagnosis is one of essential idiopathic hypertension.
=
PATHOGENESIS
In the majority of patients the cause of hypertension is
unknown. Where no definable cause can be identified
patients are said to have primary essential idiopathic hyper-
tension. There are many systems involved in the regulation
of blood pressure and the relations among these are also
complex. Therefore it has been difficult to identify one 
single factor that is primarily responsible. While many 
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different abnormalities have been described in the hyper-
tensive patient, none has clearly been identified as primary.
With the growth of new knowledge about hypertension 
in the last 20 years there has been some blurring between
primary and secondary forms of hypertension.
Animal and population studies suggest that there is a
genetic component although its influence is likely to vary
among different patients. The genetic factor interacts 
with a number of environmental factors including salt
intake, obesity, occupation, and family size and crowding.
Overall these result in abnormal activity of the sympa-
thetic nervous system. In the normal person changes in
blood pressure are compensated by adaptive changes in
activation of beta-adrenergic receptors and by secretion of
renin by the juxtaglomerular apparatus of the kidney.
Thus falls in blood pressure are accompanied by compen-
satory increases in heart rate, stroke volume, and systemic
vascular resistance to maintain normal blood pressure.
In patients with hypertension, by contrast, there are 
maladaptive compensatory mechanisms and therefore
patients thus affected tend to exist in a chronic vasocon-
strictive state. The kidney also contributes significantly to
the development of hypertension. Normally the kidney
secretes renin in response to hypertension-induced beta-
adrenergic stimulation. In turn renin promotes the 
conversion of angiotensinogen to angiotensin I and
angiotensin II. Angiotensin II increases blood pressure by
causing vasoconstriction and by stimulating the release of
aldosterone from the zona glomerulosa of the adrenal
cortex. Aldosterone causes retention of sodium.
The course of hypertension is modified by a multi-
tude of factors including race, gender, cholesterol,
smoking, diabetes, and weight. The younger a patient is
when hypertension is first diagnosed the greater the
reduction in life expectancy. In the USA blacks have
more than four times the morbidity associated with
hypertension. At all ages and in both races females with
hypertension fare better than males. Atherosclerosis is
contributed to by many factors and so it is not surprising
that the effect of hypertension on outcome may be
enhanced by certain other conditions. Thus the proba-
bility of developing a morbid cardiovascular event with
a given blood pressure will vary by many times.
Hypertensive patients will develop further increases in
blood pressure with time. From actuarial data and from
the era prior to treatment it is clear that hypertension
will significantly shorten life due presumably to the pro-
gression of the atherosclerotic process.
SECONDARY HYPERTENSION
Secondary hypertension accounts for 4–5% of all
cases of hypertension. The major causes of secondary
hypertension are renal or endocrine. Renal disease may
cause hypertension either by an inability to excrete
sodium and water, or by elaborating excess renin. In the
former retention of sodium will result in an increased
circulating volume leading to an increase in blood
pressure. In the latter high levels of renin produce high
levels of the vasoconstrictors angiotensin II and aldos-
terone. Another separate entity, renovascular hyperten-
sion, is due to atherosclerosis or fibrous dysplasia of one
or both of the main arteries supplying the kidney. The
resulting poor renal blood flow stimulates the secretion
of higher levels of renin by the affected kidney. Patients
known or suspected to have renovascular hypertension
should not receive angiotensin converting enzyme
(ACE) inhibitors as these may precipitate acute renal
failure.
The major endocrine causes of hypertension are
hyperaldosteronism, Cushing’s syndrome, and pheochro-
mocytoma. Together these three causes account for 1%
of all cases of hypertension. For example, patients with
hypertension with profound hypokalemia in the absence
of diuretics should be considered to have hyperaldo-
steronism. Cushing’s syndrome should be suspected in
those with a combination of truncal obesity, muscle
weakness, and glucose intolerance.
Pheochromocytoma is characterized by diaphoresis
and paroxysmal hypertension or orthostatic hypoten-
sion. The diagnosis is confirmed by showing increased
presence of epinephrine and norepinephrine or their
metabolites in a 24-hour urine sample. Other secondary
causes include hypercalcemia, acromegaly, oral contra-
ceptives, and coarctation of the aorta.
EFFECTS OF HYPERTENSION
The importance of hypertension lies in its deleterious
effects on end organ function. The adverse effects of
hypertension on the heart include changes in diastolic
relaxation, impairment of coronary blood flow, progression
of coronary artery disease, left ventricular hypertrophy,
ventricular ectopy and sudden death, and congestive
CLINICAL CAVEAT
Angiotensin Converting Enzyme Inhibitors 
and Renal Stenosis
Patients known or suspected to have renovascular
hypertension should not receive ACE inhibitors as they
may precipitate acute renal failure.
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heart failure. The earliest change in the heart associated
with hypertension appears to be loss of diastolic relax-
ation and the first manifestation of this abnormality is the
sudden appearance of apparent cardiac failure often in
the setting of stress or exercise.
Impairment of coronary blood flow reserve will mani-
fest as angina in the absence of coronary artery disease.
Thallium perfusion defects can be shown in those affected
with hypertension and ambulatory recording has shown
ischemia even in the absence of left ventricular hyper-
trophy. Animal studies of hypertension have shown that
below certain regulatory thresholds the myocardium is
at increased risk of subendocardial ischemia. In hyper-
tensive patients blood pressure that would not be con-
sidered abnormally low in normotensive patients may lead
to significant subendocardial ischemia and subsequent
myocardial infarction. Treatment with antihypertensive
therapy may reverse left ventricular hypertrophy. Patients
with hypertensive cardiomyopathy are at increased risk of
sudden death.
EFFECTS OF HYPERTENSION 
ON THE BRAIN
There is little question about the role of hypertension
in the genesis of stroke. Conversely lowering blood pres-
sure protects against cerebrovascular events. Strokes may
be either hemorrhagic or ischemic in origin. The under-
lying pathological change is damage to the cerebral blood
vessel wall. For example, high blood pressure induces
damage to the vascular endothelium that in turn leads to
thrombus formation and vessel narrowing. Hypertension
also predisposes to hemorrhage as weakening of the wall
occurs over time.
EFFECTS OF HYPERTENSION 
ON THE KIDNEY
Chronic hypertension induces permanent damage in
the kidney characterized by atherosclerosis of afferent
and efferent arterioles and glomerular tufts. Over time
there is loss of glomeruli resulting in gradual deteriora-
tion in overall function as well as reserve. In addition,
the autoregulatory curve is set higher so that lower levels
of blood pressure are not well tolerated and may even
produce acute renal failure.
ANESTHESIA AND HYPERTENSION
The two questions that have dominated this subject
over the years are the following. Should antihypertensive
medications be continued right up to and including the
day of surgery? When should surgery be canceled in the
hypertensive patient? Extensive studies performed in the
past have demonstrated that hemodynamic stability in
hypertensive patients is superior when antihypertensive
therapy is continued into the operative period. Nowadays
it is standard practice to continue antihypertensive therapy
throughout the perioperative period. There are convincing
data that the perioperative use of antihypertensive med-
ication in those with known hypertension and in those
with newly discovered hypertension results in signifi-
cantly less ischemia in the postoperative period. This
effect does not appear to be related primarily to better
control of blood pressure so much as improved control
of heart rate.
Patients with hypertension on the day of surgery
should not have their surgery cancelled. In general, unless
patients have diastolic blood pressure of >110 mmHg
or hypertension is associated with evidence of compro-
mised end organ function, elective surgery should 
proceed. In the case of emergency surgery blood pressure
should be brought under control as soon as is practically
possible and in any case blood pressure control can be
continued in the operating room while surgery is pro-
ceeding. While it is well recognized that hypertension is
a risk factor for poorer outcome there are no clear guide-
lines on when it is appropriate to intervene. Hypertension
is just one of many factors that can determine outcome
and so its presence and the amount of control that
should be exercised cannot be considered in isolation.
Interestingly, studies on hypertension have shown that
the use of an antihypertensive such as atenolol when
compared with a diuretic results in less ischemia that is
clearly associated with tachycardia rather than changes
in blood pressure.
In those patients with hypertension and diabetes the
occurrence of hypotension or hypertension alternating
with hypotension may increase the risk of postoperative
renal failure. As was mentioned above, longstanding
hypertension results in progressive loss of nephrons 
and therefore loss of functional reserve. In addition the
autoregulatory mechanism operates at a higher level.
These patients therefore cannot tolerate low blood
pressure. These patients warrant close monitoring with
an invasive blood pressure line. Similarly they have less
coronary reserve, even in the absence of left ventricular
hypertrophy.
The two most stressful periods in anesthesia are
induction and extubation. These are the times when
exaggerated responses are likely to be seen and precau-
tions should be taken appropriately. Many drugs have
been used. The preoperative use of atenolol will help as
will intravenous lidocaine to blunt normal reflexes to
laryngoscopy and intubation. The introduction of the
ultra-short-acting intravenous beta1-blocker esmolol has
proved useful for rapid control of blood pressure and
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heart rate during the periods of induction, intubation,
and extubation. One should also consider whether anes-
thesia can be accomplished without the need for endo-
tracheal intubation; for example, the laryngeal mask
airway does not stimulate as much hypertension or
tachycardia when it is used. Many surgical procedures
may be performed with regional anesthesia such as
epidural or spinal techniques.
Special considerations attend those patients with aor-
tic or cerebral aneurysm, as close blood pressure control
is crucial to a favorable outcome. The control of blood
pressure here is essential to prevent exacerbating the
injured vessel or even causing outright rupture; on the
other hand, too strict a control of blood pressure may
result in ischemic hypotension.
Patients should be at ease preoperatively and should
receive a mild sedative such as midazolam. As diuretics
may render patients hypovolemic, these should proba-
bly be omitted on the day of surgery. The intensity of
blood pressure monitoring should be decided after due
consideration of the presence of comorbid disease, the
type and duration of surgery, and the expected need for
postoperative intensive care.
Before intervening with blood pressure control one
should ensure that depth of anesthesia is appropriate,
that adequate analgesia has been given, and that both
hypercarbia and hypoxia have been excluded.
TREATMENT
Nitrates
These are time-honored drugs for control of intra-
operative hypertension. These drugs work by increasing
nitric oxide and thus causing smooth muscle relaxation.
Thus they are direct-acting vasorelaxants. Nitroglycerin
mainly works on the venous side and therefore is not as
useful for control of high blood pressure. Sodium nitro-
prusside (SNP) works on both the venous and arterial
sides of the circulation. One advantage of SNP is that it has
rapid onset and offset. There are numerous side effects
including profound hypotension, metabolic acidosis,
tachyphylaxis, reflex tachycardia, cyanide toxicity, and
thiocyanate accumulation in the presence of renal failure.
Hydralazine is another direct-acting vasodilator. One
must be aware of the possibility of reflex tachycardia.
Alpha2-Adrenergic Agonists
These drugs have their greatest action at the central
receptors and do so by decreasing sympathetic outflow.
Clonidine is the best-known drug in this group. One may
see unexpected falls in blood pressure with this drug as
well as profound bradycardia. More recently dexmetomi-
dine has been introduced but it has not been formally
tested as an antihypertensive. The biggest drawback
with clonidine is that it may cause rebound hypertension
when withdrawn.
Beta1-Adrenergic Antagonists
These are well tolerated and are recommended as
first-line treatment. They act by blocking beta1-receptors
in the heart, decreasing heart rate and force of contrac-
tion, thereby causing a fall in cardiac output. As well as
controlling blood pressure they are most valuable at
slowing heart rate and thus avoiding the risk of ischemia
associated with tachycardia. Both selective and non-
selective beta1-antagonists are available. In patients with
significant bronchial disease it may be better to use a
selective beta1-antagonist. They should be used cau-
tiously in patients with congestive heart failure as they
depress myocardial function. The introduction of the
short-acting agent esmolol has allowed more rapid con-
trol of blood pressure and tachycardia in the operating
room. It also seems to be well tolerated by patients
affected by bronchial smooth muscle disease.
Labetolol is useful for acute therapy of severe hyper-
tension. It has both alpha- and beta-blocking activity and
thus it brings about a concurrent decrease in contraction
and vasodilatation. It is available for intravenous use.
Alpha1-adrenergic antagonists such as phentolamine
and phenoxybenzamine are reserved for preoperative
treatment of those patients with pheochromoctyoma.
Calcium Channel Blockers
These drugs – nicardipine, nefedipine, diltiazem, and
verapamil – act by blocking the influx of calcium through
calcium channels in smooth muscle and myocytes. As with
beta1-blockers they cause a decrease in the force of con-
traction of the heart and also peripheral vasorelaxation.
DRUG INTERACTION
The preoperative use of a beta-blocker such as
atenolol when combined with a spinal anesthetic can
lead to profound bradycardia and possible cardiac
asystole.
CLINICAL CAVEAT
Before using antihypertensive therapy intraoperatively,
one should ensure that anesthesia and analgesia are
effective and that there is no hypoxia or hypercarbia.
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Nifedipine is the most potent vasodilator and it should
probably not be used in the recovery room for control of
postoperative hypertension as it may produce profound
falls in blood pressure that result in stroke or myocardial
ischemia.
Angiotensin Converting Enzyme Inhibitors
These drugs achieve their effect by inhibiting the con-
version of angiotensinogen to angiotensin II thus limit-
ing the constrictor effect of this compound on blood
vessels and its ability to release aldosterone. They have
many side effects including hypotension especially in
patients who are hypovolemic. These agents are generally
used in those patients who are unable to tolerate a beta1-
blocker. The only ACE inhibitor available for use in the
USA as an intravenous preparation is enalaprilit.
ACE also causes the breakdown of bradykinin, a
potent vasodilator. Bradykinin increases the presence of
dilatory prostaglandins in tissues. Thus treatment with
indomethacin reduces the effectiveness of these drugs.
The hemodynamic actions of ACE inhibitors are unique.
They depend on the level of renin. Blood pressure reduc-
tion depends on the level of initial renin. In those patients
with normal or low levels of renin the response is more
muted than in those with high levels. The initial response
to ACE inhibitors is exaggerated in those with volume
depletion; however, this excessive hypotension can be
counteracted with an infusion of normal saline.
The use of ACE inhibitors is beneficial in those with
diabetes as they provide some protection against decline
in renal function and in those patients with heart failure
ACE inhibitors have been shown to prolong life
expectancy.
More recently angiotensin inhibitors such as losartin
have been introduced. Whether these should be discon-
tinued prior to surgery is controversial but if the patient
is well hydrated there should not be a problem.
Diuretics
A whole host of diuretic agents are used for treating
hypertension. They include thiazides, loop diuretics, and
the potassium-sparing diuretic spironolactone. These
control blood pressure by decreasing the volume of the
circulation. They are often used as sole agents and as
first-line treatment; when blood pressure becomes resist-
ant to treatment these drugs are frequently combined
with other agents such as beta1-blockers or calcium
antagonists. Diuretics have many metabolic side effects
and preoperative preparation should include testing for
changes in electrolytes and renal function.
HYPERTENSIVE CRISIS
This is defined as diastolic blood pressure > 130 mmHg.
Malignant hypertension is marked by an increase in
blood pressure with papilledema and presence of exu-
dates in the optic fundus. Other signs and symptoms
may include severe headache, vomiting, pulmonary
edema, and visual disturbances. Only about 1% of hyper-
tensive patients progress to the malignant phase. It can
occur in either essential or secondary hypertension. This
is a medical emergency and requires immediate treat-
ment. These patients should be admitted to an intensive
care unit (ICU) where close monitoring can be done
preferably with a direct arterial pressure line. The aim of
treatment is to lower blood pressure towards but not
below 90 mmHg. Causes of hypertensive crises may be
neurological, cardiovascular, or renal. The goal is to
avoid rapid changes in blood pressure especially in the
setting of acute stroke as this may precipitate ischemia.
The main cardiovascular event associated with hyper-
tensive crisis is a dissecting thoracic aneurysm. Therapy
should be aimed at decreasing blood pressure to 
100 mmHg. The combination of SNP and a beta-blocker
works well for this critical disease until definitive surgi-
cal correction can be achieved.
Renal causes include renal artery stenosis and
parenchymal disease. In affected patients a pulmonary
artery catheter should be used in order to assess the 
circulation with reasonable accuracy and avoid the risk
of pulmonary edema.
Other causes of hypertensive crises are preeclampsia,
recreational drug use, pheochromocytoma, and hyper-
autonomic syndromes such as tetanus.
SUMMARY
Hypertension is present in one-quarter to one-third of
patients presenting for surgery. Therefore it is a disease
that is commonly encountered in the perioperative setting.
Many of these patients do not have adequate treatment
of hypertension and therefore are likely to require some
form of antihypertensive therapy while undergoing anes-
thesia and surgery. Unless confirmed blood pressure is
very high (diastolic > 110 mmHg) or there is clear evidence
of end organ compromise (e.g., myocardial ischemia) in
association with high blood pressure surgery should not
CURRENT CONTROVERSY
The use of sublingual nifedipine for the treatment of
postoperative hypertension may cause sudden severe
falls in blood pressure.
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be postponed. Patients on antihypertensive medication
should continue with their usual medication right through
the perioperative period. Those patients with newly
diagnosed hypertension may best benefit from a beta1-
antagonist over the course of their surgical procedure.
There are many different antihypertensive medications
available from which to choose and choice should be
based on consideration of the individual patient, known
side effects of medication, and goals of therapy. Certain
conditions demand close and frequent monitoring 
of blood pressure in order to minimize morbidity.
Hypertension is only one of many factors that determine
surgical and anesthesia outcomes. It should be recog-
nized that overtreatment of hypertension may be as
detrimental as undertreatment.
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CASE STUDY
A 55-year-old male presents for elective cystoscopy
and transurethral resection of bladder tumor. He weighs
120 kg, he is 6 ft tall, has hypertension, diabetes, asthma,
and a “bad back.” He had two similar procedures done
twice within the past year without any anesthetic or
surgical problems. His usual medication includes
glipizide, serevent inhaler, lisinipril, nifedipine, and
ibuprofen. He confirms that he took all his medication
as requested by his interviewer when he had his
preoperative visit three weeks before. His blood
pressure is 210/115 mmHg in the preoperative area.
QUESTIONS
1. What should the first action be on finishing an
interview with this patient?
2. Are there any additional tests that should 
be done?
3. Should surgery be cancelled? If so, why?
4. If this patient presented emergently, what are the
options (a) for treating the blood pressure and (b)
for performing anesthesia safely?
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Future Perspectives
Despite advances made in the area of risk stratifica-
tion, risk reduction, and therapy, myocardial ischemia
and infarction remain major sources of perioperative
morbidity and mortality in patients presenting for non-
cardiac surgery. Each year an estimated 50,000 of these
patients sustain a perioperative myocardial infarct and
over one million will suffer some cardiac-related compli-
cation; all at an estimated cost of over $20 billion per
year. It appears that patients with known coronary
artery disease and patients with identifiable risk factors
for coronary artery disease have a similar incidence of
adverse advents; thus a comprehensive approach to 
prevention and treatment seems warranted.
PATHOPHYSIOLOGY
Myocardial ischemia and infarction occur when
myocardial oxygen demand outweighs supply; in other
words, there is too little pressure to perfuse normal
coronaries (prolonged systemic hypotension), or blood
flow is inadequate due to blockages/spasm in the coro-
nary arteries, or shortened time for perfusion from a
rapid heart rate (Box 13-1).
Clinically this imbalance manifests in a myriad of ways:
from “silent” – the patient experiences no pain – to crush-
ing substernal chest or arm pain; from symptoms of nausea,
vomiting, diaphoresis to electrocardiographic changes and
arrhythmias; from mild shortness of breath to pulmonary
edema and severe hemodynamic instability (Box 13-2).
Thus vigilance, a high index of suspicion, and early
therapeutic interventions are required to minimize or pre-
vent cell death. While high-grade stenoses and coronary
plaques (with or without plaque rupture) are known to be
associated with myocardial ischemia, more recent work
has focused on hypercoagulable states and the inflamma-
tory cascade as key components in the process leading to
myocardial ischemia and infarction (Box 13-3).
RISK FACTORS AND RISK
STRATIFICATION
Beyond a comprehensive history and physical examina-
tion, a thorough cardiac risk assessment has become an
integral part of the preoperative evaluation of patients pre-
senting for noncardiac surgery. These range from general
criteria – age, gender, family history, life style choices (activ-
ity level, smoking, drug and alcohol consumption), work
and family stressors, to more specific areas such as comor-
bid disease states – diabetes, renal insufficiency – and type
of surgery – major, minor, elective, or emergent (Box 13-4).
In an attempt to synthesize the results of numerous
studies that have examined risk factors and to present an
evidence-based approach to therapeutic interventions,
the American College of Cardiology (ACC) and the
American Heart Association (AHA) published a set of
guidelines for preoperative evaluation of patients under-
going noncardiac surgery in 1996. These guidelines were
revised in 2000, and represent the most comprehensive
step-wise approach to date; they are the guidelines most
commonly used in preoperative centers across the USA.
By combining clinical predictors with a patient’s func-
tional capacity and surgical risk, these guidelines provide
a decision tree, outlining which patient warrants further
cardiac testing preoperatively (Figure 13-1). The only
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patients who seem to benefit from undergoing either
coronary artery bypass grafting or percutaneous trans-
luminal coronary angioplasty (PTCA) preoperatively are
those in whom these procedures would have been indi-
cated independently of the scheduled noncardiac surgery.
Timing of such an intervention also makes a difference; a
higher rate of complications, including stent thrombosis
and severe bleeding, resulted when patients had their
planned surgical procedure within two weeks of PTCA or
stent placement. Adequate time must be given for the
healing process and for a full course of aspirin/clopidogrel
therapy to be complete; current recommendations are to
wait at least two weeks, but preferably four weeks before
proceeding with noncardiac surgery.
PREOPERATIVE PREPARATION
While there seems to be general agreement on the
preparation of patients presenting for cardiac surgery –
most of their usual medications are continued through
the day of surgery, including heparin and nitrate infu-
sions in urgent/emergent cases – variation exists in the
perioperative care of the patient coming for noncardiac
surgery (Box 13-5).
Many institutions prescribe antihypertensives, antiangi-
nals, and lipid-lowering agents right through the day of
surgery. Instructions to discontinue any aspirinor aspirin-
related products up to two weeks and nonsteroidal anti-
inflammatory agents for at least three days prior to surgery
remain routine in most centers; however, there is no clear
evidence that the approach is valid (Box 13-6).
Patients who have been on a regimen but omitted to
take their cardiac medications on the morning of surgery
should receive them either orally with a sip of water, 
or intravenously prior to the surgical procedure. There 
is good evidence that perioperative beta-blockade
improves outcome beyond the immediate postoperative
period. With the advent of more sensitive monitoring
capabilities and results stemming from multicenter 
trials such as the McSPI group, target heart rates of
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Box 13-1 Factors Contributing to
Myocardial Oxygen Demand
● Preload
● Afterload/myocardial wall tension
● Heart rate
● Contractility
Box 13-2 Signs and Symptoms 
of Myocardial Ischemia
● “Silent” – no pain
● Pain or pressure – substernal or radiating to arms
and neck
● Nausea and vomiting
● Diaphoresis
● Shortness of breath – pulmonary edema
● ECG changes – arrhythmias
● Hypotension – cardiovascular collapse
Box 13-3 Factors Contributing to
Diminished Myocardial Supply
● Coronary stenosis due to atherosclerotic disease
● Coronary steal phenomenon
● Coronary vasospasm
● Acute plaque rupture
● Hypercoagulable states
● Inflammatory cascade
Box 13-4 Factors Associated with
Perioperative Myocardial
Ischemia
● Age > 65
● Male gender
● Type-A personality
● Family history of coronary artery disease
● Low activity level
● Smoking
● Drug (cocaine) and alcohol abuse
● Uncontrolled hypertension
● Hypercholesterolemia/hyperlipidemia
● Diabetes mellitus
● Renal insufficiency
● Obesity
● Known coronary artery disease, prior myocardial
ischemia, angina
● Congestive heart failure
● Abnormal ECG/arrhythmias
● Significant valvular disease
● Emergency surgery
● Pain/anxiety
Figure 13-1 Stepwise approach to preoperative cardiac assessment. The steps are discussed in the text. *Subsequent care may include
cancellation or delay of surgery, coronary revascularization followed by noncardiac surgery, or intensified care. 
(Reprinted from Eagle KA, Berger PB, Calkins H et al: ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac
surgery – executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
(Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Anesth Analg 94:1052–1064,
2002.)
Myocardial Ischemia and Infarction in the Perioperative Period 145
Step 1
Step 2
Step 3
Step 4
Need for
noncardiac surgery
Urgent or
elective
surgery
Coronary revascularization
within 5 yr?
No
Recent coronary
evaluation
No
Emergency
surgery
Operating
room
Postoperative risk
stratification and
risk factor management
No
Yes Recurrent
symptoms
or signs?
Yes
Yes Recent coronary angiogram
or stress test? 
Favorable result and
no change in  symptoms
Operating
room
Unfavorable result or
change in symptomsClinical
predictors
Step 5
Major clinical
predictors** Intermediate clinicalpredictors   
Minor or no
clinical predictors   
Consider delay
or cancel noncardiac
surgery
Medical management
and risk factor
modification
Consider coronary
angiography
Subsequent care
dictated by findings and
treatment results
Go to step 6 Go to step 7
Major clinical predictors**
   Unstable coronary syndromes
   Decompensated CHF
   Significant arrhythmias
   Severe valvular disease
Step 6
Step 8
Clinical predictors
Functional capacity
Surgical risk
Noninvasive testing
Invasive testing
Poor
(<4 METs)
Moderate or
excellent
(>4 METs)
High surgical
risk procedure
Intermediate
surgical risk
procedure
Low surgical
risk procedure
Noninvasive testing Low risk Operating
room
Postoperative risk
stratification and risk
factor reductionHigh risk
Consider coronary
angiography
Subsequent care*
dictated by findings
and treatment results
Intermediate clinical predictors   
Intermediate clinical predictors
   Mild angina pectoris
   Prior MI
   Compensated or prior CHF
   Diabetes mellitus
   Renal insufficiency
Step 7
Step 8
Clinical predictors
Functional capacity
Surgical risk
Noninvasive testing
Invasive testing
Poor
(<4 METs)
Moderate or
excellent
(>4 METs)
High surgical
risk procedure
Intermediate or low
surgical risk
procedure
Noninvasive testing Low risk Operating
room
Postoperative risk
stratification and risk
factor reductionHigh risk
Consider coronary
angiography
Subsequent care*
dictated by findings
and treatment results
Minor or no clinical predictors
Minor clinical predictors
   Advanced age
   Abnormal ECG
   Rhythm other than sinus
   Low functional capacity
   History of stroke
   Uncontrolled systemic hypertension
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50–60 beats per minute are now recommended in high-
risk patients.
Beta-adrenergic blockers remain the mainstay of
therapy. However, alpha-2 agonists such as clonidine
and more recently dexmedetomidine are gaining favor as
agents; these drugs not only reduce the sympathetic
stress response, but also have sedative and adjunctive
analgesic properties.
All patients regardless of the type of surgery should
receive anxiolysis. In addition to calming patients, sedatives
such as benzodiazepines and analgesics such as morphine
and fentanyl are the most commonly employed agents.
Whether or not to use invasive monitoring in these
patients will depend largely on the proposed procedure
and the patient’s functional status. The threshold for
placing an arterial line should be relatively low and is
surely indicated once ischemia is suspected. Central
venous monitoring is less helpful to look at absolute 
numbers, but good for following trends and useful for
administration of vasoactive drugs. Where available
transesophageal echo is preferred as a more sensitive
monitor of cardiac function. This is common practice in
patients presenting for cardiac surgery in larger centers.
Practices vary significantly regarding use of pulmonary
artery catheters. In academic centers in patients under-
going major noncardiac surgery, the pulmonary artery
catheter is still frequently used. It is most helpful in man-
aging a patient’s volume status postoperatively; ironically,
if a patient does well, the catheter is discontinued on the
first postoperative day, thereby losing whatever benefit
one might have gained from following pressures on day
three when most mobilization of fluids occurs. There are
recent data to suggest that “who” monitors the patient
may be of greater importance than with what: high-risk
patients receiving postoperative care by dedicated, spe-
cialty trained intensivists appear to have better outcomes.
Despite a host of studies trying to show the benefit of
regional over general, there is no one single best anesthetic
technique. Therefore choice of anesthesia should take into
account the type of procedure, patient’s condition, and
the anesthesiologist’s experience. Using epidural analgesia
adjunctively intraoperatively and postoperatively blunts
the sympathetic response and provides optimal pain relief,
thus reducing one of the major perioperative stress factors.
DIAGNOSIS OF MYOCARDIAL ISCHEMIA
In the absence of left bundle branch block, a properly
calibrated, five-lead electrocardiogram (ECG) is still the
gold standard for detecting myocardial ischemia in the
operating room. Leads II and V5 are displayed for best
rhythm and ischemia detection, respectively. A change
in the ST segment of greater than 0.1 mV usually down
sloping is considered diagnostic of ischemia. Monitors
equipped with ST segment trending and analyses have
made it much easier to follow and document such changes.
Unfortunately there are still many factors in an operating
room that may limit the effectiveness of ECG detection
of ischemia: interference from electrocautery, a signal
that is highly filtered, and leads placed to accommodate
the surgical field not the specificity of the equipment.
That is why such a change if observed must be correlated
with the overall clinical picture and not used in isolation to
direct therapy. We know now that ECG changes can be 
a relatively late sign in the progression of myocardial
ischemia to infarction. Only through the more intensive
use of echocardiography, specifically transesophageal
echocardiography (TEE), have we learned how much later
ECG changes appear in the early stages of diminished
blood flow. Though not all wall motion abnormalities are
caused by ischemia, once defined, ischemia-related
regional wall motion abnormalities can be seen up to four
times more often than ECG changes and are far more sen-
sitive in the detection of myocardial ischemia than ECG.
The fine points of TEE interpretation, especially concerning
the septum, require skill and a lot of experience; it also
Box 13-5 Medications to be Continued
● Antihypertensives
● Beta-blockers
● Calcium channel blockers
● Angiotensin enzyme converting inhibitors
● Antianginals
● Oral agents
● Nitropatch and infusions
● Lipid-lowering agents/statins
● Antiglycemics
● Oral intermediate acting
● Subcutaneous short and intermediate acting
● Analgesics
● Nonaspirin-containing agents
● Narcotics
Box 13-6 Medications to be Considered
Case by Case
● Diuretics
● Nitropatch and infusions
● Nonsteroidal anti-inflammatory drugs
● Antiplatelet agents
● Aspirin, clopidogrel
● Thrombin inhibitors
● Heparin, low molecular weight heparin
● Hirudin
● Antiglycemics
● Long-acting oral and subcutaneous preparations
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requires considerable resources and as such is not as widely
applicable as a routine intraoperative diagnostic tool.
However, we have learned through the combined use of
TEE and PA catheters how poorly pulmonary artery pres-
sures correlate with a patient’s true volume status.
Furthermore regional ischemia can easily occur without an
increase in pulmonary artery or wedge pressures. Thus, 
an invasive monitor previously considered essential in
patients at high risk for cardiac events (the pulmonary
artery catheter) has fallen out of favor. Furthermore, errors
in data gathering and interpretation have led some to
believe that therapies misguided by PA catheter readings
may cause more harm than good.
Finally, documentation of a myocardial infarction still
relies on 12-lead ECGs and blood testing for CK MB
isoenzymes and troponin levels. No monitor can replace
vigilance and sound clinical judgment (Box 13-7).
TREATMENT OF MYOCARDIAL ISCHEMIA
The goals of therapy are essentially the same, start
with the ABCs: whether treating a patient with a recent
MI +/– intervention presenting for an emergent proce-
dure, or a high-risk patient for elective surgery, or a
patient who develops signs and symptoms of myocardial
ischemia postoperatively (Box 13-8).
Ensure airway, oxygenation, and ventilation are ade-
quate; assess heart rate and blood pressure and treat to
minimize myocardial oxygen demand while maintaining
supply and coronary perfusion pressure; evaluate sympa-
thetic response, is the patient in pain, anxious, is there an
iatrogenic component, a reaction to a medication admin-
istered? While the overall goals are the same, the thera-
peutic options vary with the timing of the ischemic event
within the perioperative period. Cooling or allowing a
patient’s temperature to drift with the purpose of
Box 13-7 Monitors for Detection 
of Myocardial Ischemia
● Physical markers
● Angina or anginal equivalent in patients under
MAC or regional anesthesia
● Hemodynamic instability
● Diaphoresis
● Technical markers
● Five-lead ECG with ST segment trending and analysis
● Pulmonary artery catheter
● Transesophageal echocardiography
● Chemical markers
● CK MBs isoenzymes
● Troponins
Box 13-8 Treatment of Myocardial
Ischemia
● Determine etiology
● Ensure adequate oxygenation/ventilation
● Improve supply/demand balance
● Control heart rate
● Maintain coronary perfusion pressure
● Augment coronary vasodilation
● Treat pain, anxiety
● Document 12-lead ECG
● Send blood for CK MB isoenzymes and/or troponins
● Consider use of aspirin
● If severe and persistent, consider cardiac cath lab
intervention – time is of the essence!
decreasing oxygen demand and minimizing cell damage
may be an option in the anesthetized patient, especially
in cardiac surgery, but it is not applicable in the awake
state as shivering would have the opposite effect.
Preoperative Angina
Preoperative therapy is designed to optimize a patient’s
condition prior to the surgical procedure. This includes
effective pain control; for example, for patients with hip
fractures who received epidural analgesia immediately in
the emergency room to manage their perioperative pain,
there was a dramatic decrease in preoperative cardiac
events, including myocardial ischemia, infarction, and 
congestive heart failure compared with patients who
received the usual regimen of intramuscular meperidine.
Continuation or initiation of beta-adrenergic blockade is
recommended and now widely accepted. With the devel-
opment of newer, more selective agents they are increas-
ingly being employed in patients in whom they were
previously thought to be contraindicated – in cases of
depressed left ventricular function and reactive airway dis-
ease. Although there is controversy over whether calcium
channel blockers, antianginals, and angiotensin converting
enzyme (ACE) inhibitors contribute to or exacerbate intra-
operative hypotension, it is common practice to continue
them throughout the perioperative period. With the addi-
tional beneficial effect that lipid-lowering agents/statins
have on stabilizing plaques and decreasing C-reactive pro-
tein, their importance in preventive therapy is bound to
increase and their administration should not be inter-
rupted perioperatively. Finally, consideration should be
given to continuing aspirin therapy in patients who are
deemed at high risk for myocardial ischemia. Those who
are not on aspirin, following discussion with the surgeon,
may receive one ECASA immediately preoperatively or as
soon as feasible (but within 48 hours) postoperatively. 
On rare occasion a patient who is not a candidate for
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cardiac revascularization or who requires an urgent non-
cardiac surgical procedure may warrant preoperative
placement of an intra-aortic balloon pump in addition to
optimizing medical therapy.
Intraoperative Myocardial Ischemia
Infusing nitroglycerin as prophylaxis intraoperatively
has no evidence to support it; however, many practi-
tioners believe in its effect and administer it routinely in
high-risk patients. Others use it as a first-line agent when
myocardial ischemia is detected. Identifying the etiology
for the ischemia is key to successful therapy. Any inter-
vention should only be employed after ensuring adequacy
of anesthetic depth/management and hemodynamic pro-
file. Control of heart rate with a selective beta-adrenergic
blocking agent is imperative. If hypotension is due to
volume or blood loss, blood pressure should be aug-
mented with a vasoconstrictor such as phenylephrine
while fluid or blood is being replaced. The controversy
over the optimal hematocrit for a healthy patient in gen-
eral and for the cardiac patient in particular persists; at
this point clinical judgment about the risk/benefit ratio
of a transfusion for the individual patient must guide
transfusion therapy. If possible, coronary perfusion
should be enhanced with nitroglycerin; if despite all
therapies ischemic changes persist, the surgical proce-
dure should be finished as quickly and safely as possible.
Unless contraindicated, the administration of an anti-
inflammatory/antiplatelet agent like aspirin or thrombin
inhibitor like heparin is strongly encouraged. If ischemia
persists despite all of these therapies, consultation with
an interventional cardiologist for possible transfer from
the operating room directly to the cardiac catheteriza-
tion laboratory should be considered.
Postoperative Myocardial Ischemia
The focus of much anesthesia-based literature has
been on preoperative and intraoperative myocardial
ischemia. The fact that nearly half of all patients who
experience perioperative myocardial ischemia do so in
the postoperative period reminds us that our responsi-
bility to protect a high-risk patient does not end in the
recovery room with the end of surgery. Thus the same
considerations mentioned above should be given to
patients who develop signs and symptoms of myocardial
ischemia postoperatively in the post anesthesia recovery
unit (PACU) or on the ward. Unfortunately, postoperative
ischemia is frequently asymptomatic; therefore during
the early postoperative period these patients continue to
be at very high risk of myocardial ischemia, infarction, or
even sudden death. When ischemia is detected and does
not readily respond to anti-ischemic therapies such as
oxygen, nitrates, morphine, and beta-blockers urgent
cardiologic consultation for potential intervention using
TPA or angioplasty/stenting is indicated.
Recent studies looking at the effects of postoperative
aspirin administration (in the cardiac surgical popula-
tion) or use of beta-blockers for at least seven days post-
operatively have shown promising results in terms of
improved outcome.
Ideally any patient who suffers a perioperative event
should undergo cardiac evaluation and further risk strat-
ification prior to discharge.
FUTURE PERSPECTIVES
With the advent of the electronic age and enhanced
opportunity to perform large multicenter randomized
controlled trials, some of the current controversies
about appropriate monitoring and therapies for peri-
operative myocardial ischemia and infarction may be
answered in the near future. Whether to transfuse or
hemodilute, whether to keep patients cool or normo-
thermic are all questions still being debated and investi-
gated; until further evidence is available individual 
CURRENT CONTROVERSY
● Continuation of aspirin in the perioperative period
● Pulmonary artery catheters do more harm than good
● Optimal hematocrit for patients at risk of myocardial
ischemia
● Mild hypo- or normothermia for patients with
myocardial ischemia
CLINICAL CAVEAT
● Continuation of aspirin in the perioperative period
may increase bleeding
● Beta-adrenergic blockers may cause bronchospasm
● Beta-adrenergic blockers may cause significant
bradycardia
● Alpha-2 agonists may cause bradycardia and
hypotension
● ACE inhibitors may contribute to or exacerbate
intraoperative hypotension
● Therapy with nitrates may contribute to intraoperative
hypotension
DRUG INTERACTIONS
● Beta-adrenergic blockers may potentiate narcotic-
induced bradycardia
● Alpha-2 agonists may potentiate anesthetic-related
bradycardia and hypotension
● Angiotensin enzyme inhibitors may potentiate
anesthetic-related hypotension
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and institutional practice will vary. Dealing with the 
possibility of increased intraoperative bleeding as a
result of continuation of aspirin therapy may turn out to
be a small price to pay for the benefit of increased pro-
tection: not only the myocardium, but as a recent study
of patients undergoing cardiac surgery suggested, also 
a multitude of perioperative complications, including
stroke and renal failure. “Triple A” therapy with aspirin,
atenolol, and alpha-adrenergic agonists may well
become the optimum of care in this category of high-risk
patients, and quantification of C-reactive protein levels
may become part of routine preoperative blood testing
to further evaluate patients at risk. Unfortunately despite
our best care and therapies, a certain percentage of
patients still go on to suffer perioperative events, for rea-
sons still obscure. The goal remains to try to reduce mor-
bidity and mortality to the best of our ability given our
current state of knowledge. Over time we will improve
the overall outcome of patients at risk and those who
sustain a perioperative myocardial infarction.
CASE STUDY
A 63-year-old white male (77 kg, 70 in) presented
for posterior C4–5, C5–6 facetectomies. He had
experienced right arm weakness when trying to lift
wood and now was unable to lift his right arm, but
denied any pain. His blood pressure was 120/80, heart
rate 62, sinus. Past medical history was significant for
hypertension, high cholesterol, a 30-pack yr smoking
history and daily alcohol intake. He denied any
symptoms of chest pain or shortness of breath.
His medications included Atenolol, HCTZ, Zocor, Elavil,
and Prilosec. He was allergic to codeine. Only past
surgical history was a tonsillectomy as a child.
Preoperative studies showed a hematocrit of 46, a 
BUN of 28, and creatinine of 1.5; ECG: NSR, LAD, IMI,
without significant change from 5 months prior.
He received midazolam 2 mg in the preoperative
area, was brought to the operating room and induced
on the stretcher using fentanyl 50 μg, propofol 150 mg,
and rocuronium 50 mg. He was easily intubated and
the first postinduction blood pressure of 84 systolic
was treated with 5 mg of ephedrine with good effect.
He was then positioned prone in Mayfield tongs and
shortly after incision his blood pressure dropped again.
At this time significant ST elevations were noted in
lead II on the ECG. The hypotension was treated with
phenylephrine and the ST segments normalized.
QUESTIONS
1. At what point would you consider aborting the
procedure? Only if it happened again?
2. Should this patient receive aspirin in the PACU?
3. Should you check CK MBs/troponin levels? In the
operating room or in the PACU?
4. How should this patient’s risk be stratified
postoperatively?
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Management of Adult Patients with Congenital 
Heart Defects Requiring Critical Care and Anesthesia
Medical advances and refinement of surgical tech-
niques have resulted in the survival of many children with
congenital heart disease (CHD) to adulthood. However,
for many adults with CHD further surgical interventions
are necessary and the medical treatment and follow up are
often life long. These patients may be assigned to different
treatment categories such as a surgically cured group
(e.g., an atrial septal defect repair), a surgically corrected
group (anatomical correction with possible further sur-
gery), or a surgically palliated group. There is also an
“inoperable” group with conditions deemed inoperable
except for organ transplantation and a medical group
with no clinical indication for cardiac surgery.
Approximately 6–8% of CHD patients surviving to
adulthood require hospitalization annually. Therefore, an
increasing number of intensivists may be asked to care
for these patients. This review is directed at the critical
care specialists who will participate in their care.
CLASSIFICATION OF CONGENITAL
HEART DEFECTS
Congenital heart defects can be classified as cyanotic,
acyanotic, or obstructive (Table 14-1).
Acyanotic Heart Defects
Ventricular Septal Defect
Ventricular septal defect (VSD) is the most common
congenital heart defect accounting for 25% of congenital
heart lesions.
A small VSD, with a pulmonary/systolic flow ratio of
less than 1.4, produces only a modest left-to-right shunt.
Chest x-ray and ECG is usually normal as the left ventricle
is not enlarged and there is no pulmonary hypertension.
Clinical course is usually benign and the majority of
these defects close spontaneously.
A moderate VSD results in a left-to-right shunt sufficient
to produce significant pulmonary flow with a pulmonary/
systemic flow ratio between 1.4 and 2.2. This flow will
produce volume overload and enlargement of the left
ventricle and left atrium.
These changes are even more pronounced with a
large VSD which sometimes results in systemic pressure
in the right ventricle. The pulmonary/systemic flow ratio is
higher than 2.2. An infant with a large VSD and resulting
severe pulmonary flow will eventually develop pulmonary
vascular obstructive disease and chronic severe pulmonary
hypertension (Eisenmenger’s disease). Cyanosis will
develop as the shunt reverses from left-to-right to right-to-
left. Fixed high pulmonary vascular resistance precludes
cardiac surgical correction.
A substantial percentage of VSDs undergo sponta-
neous regression in size or complete closure over time.
Small VSDs have a higher risk of endocarditis but the life
expectancy is normal. Moderate VSDs are unusual in the
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adult but may occur if the defect is partially obstructed
by a prolapsing leaflet of the aortic valve. Indications for
surgical VSD closure include a pulmonary/systemic flow
ratio higher than 2, pulmonary systolic pressure higher
than 50 mmHg, and a progressive deterioration of ven-
tricular function. Although this is a low-risk operation at
any age, some of today’s adults may have undergone
surgery during an era when myocardial preservation and
surgical techniques were not as good. Therefore, they
may have some residual ventricular dysfunction, arrhyth-
mias, and heart block. Aortic regurgitation may be present
due to a prolapse of an aortic cusp or as a result of a suture
placed through one of the aortic cusps during closure of
a perimembranous VSD. Late ventricular arrhythmias 
and sudden cardiac death is a potential risk in patients
repaired late in life. Heart block requiring pacemaker
insertion may be seen occasionally, but is very rare.
Subacute bacterial endocarditis (SBE) antibiotic pro-
phylaxis is recommended for 6 months following VSD 
closure and then is not necessary unless there is a residual
defect.
Atrial Septal Defect
Atrial septal defect (ASD) accounts for about 7% of 
all cardiac anomalies. There are several types of ASD: 
primum, secundum, and sinus venosus. The primum
defects (endocardial cushion defects) occur as large
openings in the inferior atrial septum and often involve
the mitral and tricuspid valves. Surgery carries slight risk
of acquired heart block. Mitral valve rarely requires
repair or replacement. The secundum defects, which are
the most common ASD, occur in the center portion of
the interatrial septum. Mitral valve prolapse is present in
about 30% of patients. Sinus venosus defects are located
at the posterosuperior atrial border adjacent to the 
superior vena cava. They are often associated with partial
anomalous venous connection.
Unrepaired ASD allows asymptomatic survival to
adulthood, but the death rate is about 6% over the age
of 40 years. Conditions that cause reduced left ventricu-
lar compliance during late adulthood (natural aging, sys-
temic hypertension, or ischemic cardiomyopathy) will
increase the left-to-right shunt through the ASD and the
majority of patients over 60 years of age are sympto-
matic. Adult patients may develop moderate pulmonary
hypertension, right ventricular overload, and late right
heart failure (usually over the age of 40). The incidence
of atrial fibrillation or flutter increases progressively after
the age of 30.
Because of the preferential streaming of inferior vena
caval flow towards the secundum ASD, uncorrected
patients are at risk of paradoxical emboli from lower
extremity thrombophlebitis or any other source.
Incidents of air embolism into the left atrium have been
reported with increases in intrathoracic pressure during
a Valsalva maneuver or with high levels of positive end-
expiratory pressure (PEEP).
Early closure of an ASD is recommended and there is
no difference in survival between age- and sex-matched
controls when surgery is carried out before the age of 24.
Patients have an option of surgical or device closure.
Early and intermediate outcome is excellent after device
closure. Long-term outcome is unknown.
Supraventricular arrhythmias may persist after surgery
in older patients. Atrial fibrillation may occur in about
30% of patients older than 40 years. Sick sinus syndrome
may develop occasionally after the repair of a sinus 
venosus defect. A permanent pacemaker may be required
for patients with sick sinus syndrome and symptomatic
bradycardia.
SBE prophylaxis should be continued in patients with
primum defects because of abnormalities of the mitral
valve. The prophylaxis is not necessary for secundum and
sinus venosus defects beyond 6 months after surgery.
Patent Ductus Arteriosus
Most patients with patent ductus arteriosus (PDA) are
asymptomatic. When the magnitude of the left-to-right
shunt is large, there may be evidence of left ventricular
hypertrophy and increased pulmonary flow. A large PDA
is rarely seen as a primary lesion in adults, but an occa-
sional patient with a moderate-sized PDA may present in
middle age in heart failure.
Adults with PDA and pulmonary vascular obstructive
disease may have varying degrees of right-to-left shunt-
ing and symptoms related to pulmonary hypertension.
A large PDA is rare in adults but pulmonary hyper-
tension is common and may not reverse with closure of
the defect. Patients are symptomatic from dyspnea or
palpitations.
It is generally recommended that a small or moderate
PDA be closed by interventional catheterization techniques
(coil closure). Surgical closure is reserved for the PDA
too large for device closure. Postoperative complications
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Table 14-1 Classification of Congenital 
Heart Defects
ACYANOTIC (LEFT-TO-RIGHT SHUNT)
Ventricular septal defect
Atrial septal defect
Patent ductus arteriosus
CYANOTIC (RIGHT-TO-LEFT SHUNT)
Tetralogy of Fallot
Transposition of great arteries
Tricuspid atresia/single ventricle
OBSTRUCTIVE
Pulmonary stenosis
Coarctation of the aorta
may include recurrent laryngeal or phrenic nerve damage
and thoracic duct damage. Residual ductal shunts may be
encountered in patients who have had coil embolization
procedures. If a small residual shunt remains, SBE pro-
phylaxis is recommended, but when a PDA is eliminated
SBE is not needed.
Cyanotic Heart Defects
Tetralogy of Fallot
This is a most common cyanotic lesion encountered
in adults. Approximately 25% of unoperated patients 
will survive to adolescence but only 3% survive to the
age of 40.
Tetralogy of Fallot (TOF) consists of the obstruction
of the right ventricular outflow tract, VSD, right ventric-
ular hypertrophy, and an aorta that overrides the pul-
monary outflow tract. The clinical manifestations of TOF
depend on the degree of stenosis of the right ventricular
outflow tract and are due to right-to-left intracardiac
shunts with reduced pulmonary outflow and arterial
hypoxemia. About 35% of children with TOF develop
hypercyanotic attacks or “tetralogy (tet) spells.” They are
due to a spasm of the infundibular cardiac muscle caus-
ing sudden reduction in pulmonary blood flow leading to
severe hypoxemia, hypercapnia, and acidosis.
Surgical repair of TOF consists of closure of the VSD
and enlargement of the right ventricular outflow tract.
The majority of present-day adults who underwent a sur-
gical TOF correction had the repair performed through
a right ventriculotomy which may cause arrhythmias,
decreased right ventricular function, and late right ven-
tricular failure. Recently, the surgical technique has been
changed and surgeons are using a transatrial approach.
Before the era of modern cardiac surgery, palliative
procedures designed to increase pulmonary blood flow
had been developed. They include Blalock–Taussig,
Waterstone, and Potts shunts.
The Blalock–Taussig shunt consists of an anastomosis
between the subclavian artery and ipsilateral pulmonary
artery. The incidence of pulmonary hypertension is min-
imized with this shunt; however, complications include
thrombosis of the shunt and the development of sub-
clavian steal syndrome. A modified Blalock procedure
employs a synthetic graft between the vessels and 
preserves the continuity of the subclavian artery.
The Waterstone shunt is a direct anastomosis
between the ascending aorta and the right pulmonary
artery. As the proper sizing of the anastomosis is difficult,
an excessive pulmonary flow may lead to pulmonary
hypertension.
The Potts shunt is a direct anastomosis between the
descending thoracic aorta and the left pulmonary artery.
This operation has been abandoned because of the
resulting pulmonary hypertension and congestive heart
failure.
The patient with a corrected TOF should be acyanotic
and should not have any residual VSD. Pulmonary insuf-
ficiency is often present postoperatively but is usually
well tolerated by patients. Only some patients develop
significant pulmonary and tricuspid insufficiency with
severe right ventricular dilatation and dysfunction.
The long-term prognosis for patients with repaired
TOF is excellent, with nearly 90% survival at 30 years.
Late sudden death due to ventricular arrhythmias is a
recognized sequela of TOF repair with an overall preva-
lence of 3–6%. A sustained monomorphic ventricular
tachycardia could be induced by programmed stimula-
tion in 15–30% of patients and half had frequent and
complex ECG. Sinus node dysfunction and intra-atrial
re-entrant tachycardia occurred in 20–30% of patients with
repaired TOF. In patients who have developed sustained
ventricular tachycardia treatment options include anti-
arrhythmic drug therapy, map-guided ablation, surgery,
and an implantable defibrillator.
Transposition of the Great Arteries
Transposition of the great arteries (TGA) results from
failure of the truncus arteriosus to spiral. As a result, the
aorta arises from the right ventricle and the pulmonary
artery arises from the left ventricle. Complete TGA is a
common congenital heart lesion accounting for about
7% of all congenital cardiac defects. To survive a patient
with TGA must have communications between the left
and right heart to allow mixing of the blood. Early 
survival at birth is possible when prostaglandin E1 is
used to maintain ductal patency or a Rashkind balloon
septostomy is performed to allow mixing. Patients with
TGA never reach adulthood without having corrective
surgery. The majority of patients who reach adulthood
have undergone Mustard or Senning atrial switch proce-
dures that create discordant atrioventricular connections
in the presence of the preexisting discordant ventriculo-
arterial connections. In the Mustard procedure the atrial
septum is excised and a baffle made of native peri-
cardium or synthetic material is used to redirect pul-
monary and systemic venous blood. Systemic venous
blood is routed to the left ventricle, which is connected
to the pulmonary artery. Pulmonary venous blood is
routed to the right ventricle, which is connected to the
aorta. Baffle obstruction is one of the late complications
after the Mustard procedure and may occur within
months or a few years after the original operation. It has
to be considered in any patient with otherwise unex-
plained peripheral edema, ascites, hepatomegaly, or pul-
monary symptoms. However, late cardiac arrhythmias
are the major problem after atrial switch procedures.
Twenty percent of neonates have abnormal sinus node
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function or junctional rhythm when discharged from the
hospital after atrial switch procedures. An increasing
number of these patients gradually develop signs of sick
sinus syndrome over the years. About 20% of these
patients have had a pacemaker inserted because of
severe bradyarrhythmias. Rapid atrial flutter and ventric-
ular tachyarrhythmias are responsible for late sudden
death in these patients. However, the majority of patient
deaths are due to right ventricular dysfunction when the
right ventricle, which becomes a systemic chamber, fails
when subjected to abnormal afterload or preload.
Over the past ten years atrial switch operations have
been replaced by the arterial switch operation (Jatene
procedure). The arterial switch operation results in
anatomic correction of the discordant ventriculoarterial
connections. In this procedure the great arteries are tran-
sected distal to their respective valves and reconnected
to their anatomically correct ventricles. A successful
primary arterial switch must be performed within the
first 10 days of life. The major issue in those patients
who survive to adulthood is the status of the transferred
coronary arteries; however, the incidence of coronary
insufficiency is low. Supravalvular pulmonary stenosis is
probably the most common complication of the arterial
switch procedure. In contrast to the atrial switch proce-
dures, electrophysiologic abnormalities are uncommon
after the arterial switch procedure.
Tricuspid Atresia/Single Ventricle
Tricuspid atresia is characterized by a small right 
ventricle, a large left ventricle, tricuspid valve agenesis,
and markedly reduced pulmonary blood flow. Therefore,
it is a unique form of single ventricle, a term used to
describe a group of CHDs in which there is abnormal
development of both chambers, resulting in a single
functioning ventricular chamber. All the blood from the
right atrium is diverted across an atrial septal defect into
the left atrium, mixes with oxygenated blood, and enters
the left ventricle for ejection into the systemic circulation.
Survival is possible if there is pulmonary flow through a
ventricular septal defect or patent ductus arteriosus. To
correct tricuspid atresia, the original Fontan operation
was performed. Pulmonary flow was achieved by a right
atrial to pulmonary artery connection. However, this
direct connection leads to marked right atrial enlarge-
ment and the development of arrhythmias. The operation
has undergone several modifications aimed at reducing
the incidence of atrial arrhythmias. In one of the modifi-
cations inferior and superior vena caval blood flow is
directed to the pulmonary arteries. Some surgeons have
further modified this procedure by using an extracardiac
conduit to connect the inferior vena cava to the pul-
monary arteries. Therefore, patients who underwent
Fontan procedures have circulation in series without the
ventricle driving the pulmonary flow and their survival
depends on low pulmonary vascular resistance, low left
ventricular filling pressure, and adequately high central
venous pressure. Hypoxemia, hypercarbia, metabolic
acidosis, high positive airway pressure, and hypovolemia
may be detrimental in these patients.
Obstructive Heart Defects
Pulmonary Stenosis
Pulmonary stenosis accounts for as many as 8–10% of
all congenital heart defects. It can be valvular (most com-
mon), supravalvular, or subpulmonary. Valvular pulmonary
stenosis is often associated with a probe-patent foramen
ovale and atrial septal defect.
Clinical manifestations will depend on the degree of
obstruction to ejection of the right ventricle. Mild to
moderate degrees of stenosis are often asymptomatic.
Severe stenosis (gradient greater than 80 mmHg) causes
right ventricular hypertrophy and failure. The surgical
management of severe pulmonary stenosis with intact
intraventricular septum has changed over the years from
closed (no cardiopulmonary bypass) to open valvotomy
(on bypass), and in the past few years balloon pul-
monary valvulotomy became the preferred treatment
method. However, if balloon pulmonary valvulotomy is
ineffective in reducing the gradient, open valvotomy
may be performed. Adult patients after these procedures
are usually asymptomatic. Occasionally, an adult may
require pulmonary valve replacement as a result of sig-
nificant valvular obstruction and calcifications.
Coarctation of the Aorta
Coarctation is a discrete narrowing of the aorta either
proximal to the ductus arteriosus (preductal, infantile)
or distal to the left subclavian artery (postductal, adult).
Infants with preductal coarctation of the aorta often
have associated defects including patent ductus arterio-
sus, ventricular septal defect, and bicuspid aortic valve.
They usually develop severe congestive heart failure as a
result of this defect. After infancy coarctation is rarely
associated with significant symptoms and is often diag-
nosed during routine physical examination when sys-
tolic murmur is detected in the second space at the left
sternal border. Upper extremity hypertension and
reduced pressure in the lower extremities is present. In
older patients coarctation usually presents as an isolated
lesion. Complications of unoperated coarctation include
left ventricular hypertrophy and heart failure, cerebral
hemorrhage or thrombosis, rupture of the aorta, and
necrotizing arteritis. Surgical corrections include the
removal of the coarcted region and end-to-end anasto-
mosis, subclavian artery flap procedure, or patch angio-
plasty. The prognosis after repair of isolated coarctation
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is very good; however, complications include restenosis,
late hypertension, and aneurysmal dilatation of the aorta.
NONCARDIAC COMPLICATIONS 
OF CONGENITAL HEART DISEASE
Pulmonary Complications
Dynamic lung compliance is decreased in patients
with increased pulmonary blood flow (left-to-right
shunt) and is unchanged in patients with decreased pul-
monary blood flow. The mechanism for this change is
not clear. However, it is possible that the increase in pul-
monary artery pressure may result in an increase in the
tension of the walls of the pulmonary vascular system.
This “stiffer” vasculature may then oppose pulmonary
expansion resulting in decreased lung compliance, which
in turn increases the work of breathing. Enlarged pul-
monary vessels may compress bronchi or cause a con-
gestion and swelling of the bronchial wall, an increase in
small airway resistance, chronic atelectasis, pneumonia,
or focal emphysema. The likely site of compression by
the enlarged left pulmonary artery is the left mainstem
and upper lobe bronchi and the right middle lobe
bronchus may be compressed by the right lower lobe
pulmonary artery. An enlarged pulmonary artery can
also compress the recurrent laryngeal nerve.
Patients with high pulmonary blood flow secondary
to a large VSD or ASD, if not treated, will develop a pul-
monary arteriolar injury secondary to sheer stress, leading
to muscular hypertrophy, intimal proliferation, and oblit-
eration of arterioles. As the vascular disease progresses
and the pulmonary vascular resistance approaches sys-
temic resistance, a right-to-left shunt develops, and the
patient becomes cyanotic and polycythemic. This patho-
physiologic sequence is described as Eisenmenger’s 
syndrome. The presence of this syndrome precludes sur-
gical correction of the defects, as pulmonary resistance
is irreversibly elevated. These patients may have upper
lobe pulmonary artery thrombosis and hemoptysis in
end-stage disease.
Patients with CHD have blunted responses to hypox-
emia but normal ventilatory response to hypercarbia. The
oxygen–hemoglobin dissociation curve is normal or slightly
right shifted. In cyanotic patients arterial pCO2 is underes-
timated by capnometry (end-tidal pCO2). In these patients
even moderate hypercarbia and hypoxemia will increase
pulmonary vascular resistance and right-to-left shunting.
Chronic pleural effusions are fairly common in adult
patients who have had a Fontan procedure.
Neurologic Complications
Major neurologic complications of CHD include 
brain abscesses and paradoxical cerebral embolization.
Paradoxical emboli originating in the lower part of the
body in poorly mobile or postoperative adult patients
might reach the brain in cyanotic patients with a right-
to-left shunt or during a reversal of the shunt in patients
with left-to-right shunt. The emboli may also originate
from the intravenous lines and especially during place-
ment and use of central venous and Swan-Ganz
catheters. Air filters should be used in all venous lines in
patients with CHD. Hyperviscosity and reduction in
cerebral blood flow in patients with very high hemato-
crits may also play a role in increasing the risk of cere-
brovascular accidents in patients with CHD.
Patients with atrial fibrillation after late closure of an
ASD have a high risk of TIA or stroke and may be anti-
coagulated for the first six postoperative months.
Anticoagulation may be later discontinued, if patients
remain arrhythmia-free.
Adults with cyanotic CHD have a decreased risk of
thrombotic intracranial events but a higher risk of
intracranial bleeding. A cerebral hemorrhage can occur
in patients with a history of aortic coarctation repair
even if blood pressure is not elevated.
Patients who have already undergone successful cor-
rection or palliation of CHD may have residual neuro-
logic deficits related to the preoperative pathology as
well as to intraoperative (e.g., hypothermic circulatory
arrest) or postoperative events. These significant symp-
tomatic hyperviscosity neurologic sequelae may include
seizures, dyskinesia, hypotonia, or choreoathetosis.
Patients with CHD may have an injury of the recur-
rent laryngeal nerve from prior surgery or compression
by the pulmonary artery. They may also have diaphrag-
matic paresis or paralysis secondary to phrenic nerve
injury.
Hematologic Complications
Patients with cyanotic CHD are usually polycythemic
or erythrocytotic (an increase only in red cell number).
Polycythemia is an adaptive response to chronic hypox-
emia. Hypoxia triggers the release of erythropoietin by
the kidneys. Erythropoietin stimulates bone marrow pro-
duction of red cells and causes an increase in the circu-
lating blood volume. As the hematocrit increases, there
is a marked increase in viscosity. The increased viscosity
and erythrocytosis is associated with the risk thrombosis
in children under the age of 5 years, especially when
they are febrile or dehydrated. Due to high hematocrits
and limited pulmonary and systemic blood flows some
patients will complain of fatigue, faintness, headache,
dizziness, blurred vision or diplopia, myalgias and mus-
cle weakness, paresthesias of fingers, toes and lips, and
depressed mentation. Isovolemic phlebotomies are indi-
cated in these patients based more on the development
of significant symptoms of hyperviscosity rather than for
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a given hematocrit. Dehydration must be first ruled out
before any decision to phlebotomize is made.
Patients with current or even corrected cyanotic heart
disease have a higher incidence of bilirubin gallstones
and billiary colic.
About 20% of patients with CHD, both cyanotic and
acyanotic, have a variety of hemostatic abnormalities.
They include platelet dysfunction, thrombocytopenia,
hypofibrinogenemia, fibrinolysis, and abnormalities of
the intrinsic and extrinsic coagulation systems with defi-
ciencies of specific clotting factors. Patients may be very
symptomatic with complaints of easy bruising, epistaxis,
or excessive menstrual bleeding.
Prothrombin and partial thromboplastin time may be
prolonged. The risk of spontaneous bleeding is low but
the risk of excessive perioperative bleeding is fairly high,
especially in patients who are maintained on platelet
inhibitors (aspirin) due to their vascular anastomoses
from Goretex (e.g., modified Blalock–Taussig anastomosis).
Moreover, excessive bleeding may be caused by an
increased tissue vascularity in cyanotic patients, increased
venous pressure, and collateral vessels in obstructive
defects (e.g., coarctation).
Renal Complications
Patients with CHD have a variety of renal abnormali-
ties. They may be related to renal hypoperfusion
hypoxia and hyperviscosity. These patients usually have
high plasma uric levels, due to low fractional uric acid
excretion rather than to urate overproduction.
Hyperuricemia in CHD patients may be a marker of
abnormal intrarenal hemodynamics, as the enhanced
uric acid reabsorption is a result of renal hypoperfusion
and high filtration fraction.
Glomerular enlargement and alteration in the
glomerular capillary basement membrane have been
described in patients with CHD and appear to be a result
of hypoxia at an early age. These changes are associated
with benign proteinuria and contribute to the higher
incidence of nephrotic syndrome in these patients.
Renal plasma flow is reduced in patients with cyanotic
and acyanotic lesions and is due to the changes in the
outer cortical flow. Successful surgical correction of
CHD may not result in a return of the renal plasma flow
to normal.
MANAGEMENT OF ADULT PATIENTS
WITH CONGENITAL HEART DEFECTS
REQUIRING CRITICAL CARE AND
ANESTHESIA
Evaluation of patients with known CHD should be
directed toward obtaining a complete description of
anatomy of the defect and a description of all previous
surgical procedures and detection of possible residual
defects, sequelae, or late complications. For example, a
history of continued postoperative hypoxemia indicates
inadequate palliation and the existence of residual
abnormalities. However, distinguishing between cardiac
and pulmonary causes of hypoxemia may be extremely
difficult.
A minimal workup should include a thorough clinical
assessment, ECG, chest x-ray, and transthoracic (TTE) or
transesophageal echocardiographic (TEE) examination.
TTE and TEE may help to prove the existence of the
lesion or residual shunt, better define its location, and
rule out chamber enlargement, baffle obstruction, valvu-
lar insufficiency, or ventricular outflow obstruction.
Confirmed existence of an intracardiac shunt has 
several implications in the acute management of the 
critically ill or anesthetized patient.
Left-to-right shunts will result in pulmonary vascular
overperfusion; however, initially ventilation and gas
exchange are usually unaffected. These patients may
have a history of pulmonary banding to control the pul-
monary flow. In unrepaired patients one may expect
marked pulmonary hypertension. The presence of pul-
monary hypertension can be inferred from the marked
right ventricular hypertrophy on the ECG and prominent
main pulmonary artery on the chest x-ray. It can be 
confirmed either noninvasively by Doppler echocardio-
graphy or by Swan-Ganz catheterization. However,
placement of a flow-directed catheter may be very diffi-
cult due to the flow through the intracardiac shunt. Left
atrial pressure may be elevated due to increased pul-
monary venous return. Increased volume workload may
cause reduced myocardial contractility. These patients
might require treatment with intravenous pulmonary
vasodilators (e.g., milrinone, prostaglandin E1) as well as
the use of inhaled nitric oxide (NO). Some patients are
at risk of pulmonary hypertensive crisis, which is easier
to prevent than to reverse. Therefore, not only are
vasodilators needed but patients should be hyperventi-
lated (PaCO2 = 25−30) and well sedated (fentanyl and
propofol infusions).
As discussed above, enlargement of pulmonary ves-
sels may result in extrinsic compression of the airways
or congestion of the bronchial wall and an increase in
small airway resistance as well as alveolar edema. An
increased resistance to airflow combined with non-
compliant lungs will increase the inspiratory pressure
needed for adequate positive-pressure ventilation.
Anesthetics that may induce myocardial depression
should be avoided. The uptake of inhaled anesthetic
agents and therefore their cardiodepressive effects may
be increased.
Right-to-left shunts will result in low PaO2, only min-
imally improved by increasing the FIO2. The ventilatory
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support and gas exchange will be less efficient.
Capnometry (end-tidal pCO2 measurements) will under-
estimate the arterial pCO2 due to the large physiologic
dead space. As the pulmonary flow is decreased manage-
ment should be centered on the prevention of further
reduction in flow. Therefore, excessive positive inspira-
tory pressure should be avoided and PEEP maintained at
the lowest possible level. Adequate intravascular volume
and ventricular function should be maintained.
Patients with right-to-left shunts are at high risk of 
systemic emboli from lower extremity thrombophlebitis
and venous air embolism. They are also at risk of overdose
with intravenous drugs. However, if inhalational anesthetics
are used during anesthesia, one may expect a delayed uptake
of inhaled agents.
Polycythemia may be present in cyanotic patients and
should be carefully controlled either with phlebotomy
or hemodilution, but the hematocrit should not be taken
below 50. Despite the dangers of polycythemia, these
patients are very dependent on high hematocrit to ensure
adequate oxygen transport.
Obstructive defects will result in fixed stroke volume
and dependence on heart rate to compensate for changes
in metabolic demand and peripheral vascular resistance.
Left or right ventricular hypertrophy and congestive heart
failure will develop without corrective surgery. Therefore,
optimal myocardial perfusion should be maintained in
those patients by increasing the duration of diastole and the
diastolic pressure. Tachycardia, which shortens diastole,
should be avoided. Blood pressure should be maintained
with pressors and volume.
Management of arrhythmias secondary to repaired,
unrepaired, or palliated CHD may be extremely difficult.
History of early postoperative arrhythmias is associated
with a greater risk for development arrhythmias late in
life. The spectrum of clinical consequences of arrhyth-
mia in adults with CHD ranges from clinically occult
arrhythmia to sudden death. Atrial arrhythmias are most
common and are usually due to intra-atrial re-entrant
tachycardia that may respond to class 1A and class 3
antiarrhythmic drugs. Automatic antitachycardia pacing
has also been of value in some patients. Patients with
unrepaired heart disease or residual obstructive lesions
are more prone to atrial fibrillation. Sinus rhythm is
hemodynamically preferred in CHD; therefore, cardio-
version, antiarrhythmic drugs (e.g., amiodarone), and
atrial pacing should be used to treat or prevent estab-
lishment of atrial fibrillation.
Gradual loss of sinus rhythm occurs after the Mustard,
Senning, and all varieties of Fontan procedures.
Interventricular conduction abnormalities, particularly
right bundle branch block, are very common after 
surgery for CHD. Cardiac pacing in adults with CHD
presents a variety of challenges. Anatomical abnormali-
ties and shunting may not allow endocardial lead place-
ment and require transthoracic pacing.
Ventricular arrhythmias are reported in about 2% of
patients with repaired TOF. Although patients with
Mustard, Senning, and Fontan experience atrial tachy-
cardias, they are not prone to ventricular tachycardias.
Class 1C and class 3 antiarrhythmic drugs should be used
to suppress symptomatic ventricular arrhythmias.
Automatic implantable cardioverter and defibrillator
therapy is feasible in many patients with CHD.
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The incidence of pneumonia is increasing. The exact
annual incidence of pneumonia is difficult to determine
because it is not a notifiable disease. The incidence
varies with geography, population demographics,
comorbid conditions, and the severity of the flu season.
There are approximately 4 million cases of community-
acquired pneumonia and at least 300,000 cases of hospi-
tal-acquired pneumonia reported annually. Pneumonia
accounts for the largest mortality of any common infec-
tious disease. Pneumonia ranks in the top seven among
the major leading causes of death in adults in the USA.
It is the fourth leading cause of death in the US elderly
population. A large variety of organisms cause pneumonia
(Table 15-1). The important complications of pneumonia
include abscess formation, pleural effusion and empyema
formation, bacteremia and sepsis, septic shock, acute 
respiratory distress syndrome (ARDS), meningitis, endo-
carditis, and multiple organ dysfunction or failure.
The rapid initiation of broad-spectrum empirical
antibiotic therapy correlates with long-term morbidity
and mortality from pneumonia. The earlier the specific
infectious agent is appropriately treated the better the
outcome is likely to be.
The Centers for Disease Control (CDC) defines pneu-
monia to be present when the chest radiograph reveals
a new or progressive infiltrate, pleural effusion, or cavi-
tation, and any one of the following: (1) a change in
the character, quantity, or consistency of the sputum,
(2) the pathogen is isolated from the lower respiratory
tract, by cultures, or by lung biopsy, (3) a virus or viral
antigen is isolated in respiratory secretions, (4) a diag-
nostic serum IgM antibody titer or a fourfold rise in IgG
antibody titers can be demonstrated in paired serum
samples, (5) histologic evidence of pneumonia can be
demonstrated in tissue biopsy. Note that these general
criteria do not include sputum Gram stain or culture.
Pneumonia treatment is simplified by numerous
guidelines which are described below. The standard of
medical care for the management of pneumonia has
evolved considerably over the last decade based on large
multicenter outcome studies. The present evidence-based
CLINICAL CAVEAT
Treatment of Serious Infection
Serious infection should be treated as a medical
emergency and antibiotics must be initiated as soon as
possible; there should be no delay in obtaining cultures
or awaiting culture and sensitivity data.
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approach is based on best-practice data regarding diag-
nosis, risk stratification, and antibiotic management
protocols. However, evolving patterns of antibiotic
resistance, emerging pathogens, and new antibiotics
require continual reassessment of existing guidelines.
There is also sufficient variability between hospitals to
require individualization of therapy based on local or
institutional antibiogram data.
There is a clear genetic component to the risk of
pneumonia and sepsis. Genetic polymorphism for mole-
cules important in antigen recognition and binding such
as mannose-binding lectin, CD-14, and toll-like receptors
as well as for inflammatory mediators such as tumor
necrosis factor, the interleukin-1 family, interleukin-10,
and angiotensin converting enzyme are likely to have
pharmacologic significance.
There are a great many noninfectious diseases that
cause febrile pneumonitis and mimic pneumonia. These
include eosinophilic pneumonia, interstitial lung disease
associated with connective tissue disorders or vasculitis
or pulmonary airway disease, neoplasms, sarcoidosis,
ARDS, exposure to inhaled gases or toxins, radiation pneu-
monitis, cytotoxin therapy, and pulmonary infarction.
Noncytotoxic pharmacologic agents which can mimic
a pneumonia include antimicrobial agents, phenytoin,
amiodarone, and narcotics. Aspiration pneumonitis,
Mendelson’s syndrome, occurs following aspiration of
acidic gastric content and may present the lobar infiltrate
progressing to a generalized pneumonitis (Figure 15-1).
Antibiotic therapy is not indicated in the initial treatment
of aspiration pneumonitis.
The general typical presentation of a pneumonia is
that of a systemic inflammatory response syndrome
(SIRS) with evidence of a widened arteriolar-alveolar
oxygen diffusion gradient. History and physical exami-
nation and microbiologic or serologic studies help con-
firm the diagnosis.
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Table 15-1 Pneumonia Pathogens
TYPICAL PATHOGENS
Gram-positive cocci: Streptococcus pneumoniae, Staphylococcus
aureus and VISA, GISA, and VRSA, Enterococcus faecalis,
Enterobacter faecium and VRE/VREF
Gram-positive bacilli: Bacillus anthracis, Corynebacterium
diphtheriae
Gram-negative diplococci: Moraxella catarralis
Gram-negative bacilli: Haemophilus influenzae, Klebsiella
pneumoniae, Pseudomonas aeruginosa,
Proteus mirabilis, Proteus morgagnii, Serratia marcescens,
Enterobacteriaceae
ATYPICAL PATHOGENS
Legionella pneumophilia (Legionnaire’s disease)
Mycoplasma pneumoniae (“walking pneumonia”)
Chlamydia pneumonia (previously “TWAR” agent)
Coxiella burnettii (Q fever)
Francisella tularensis (tularemia)
Bacillus anthracis (anthrax)
Yersinia pestis (pneumonic plague)
Mycoplasma tuberculosis (tuberculosis)
M. avium-intracellulare
Chlamydia psittaci (psittacosis or “parrot fever”)
Pneumocystis carinii (PCP)
VIRUSES
Influenza A, B, others
Parainfluenza 1, 2, 3
Respiratory syncytial virus (RSV)
Epstein–Barr virus (EBV)
Hantavirus
Herpes virus (HSV I and II)
Varicella zoster
Respiratory syncytial virus
Cytomegalovirus (CMV)
SARS
MYCOSES
Cryptococcus
Histoplasmosis
Coccidiomycosis
Blastomycosis
Aspergillus spp.
Candida spp.
Figure 15-1 Aspiration pneumonitis. There is pseudolobar
consolidation of the right upper and left lung fields. The
accentuated interstitial markings with early alveolar changes
reflect evolving local inflammation. Notably, the distribution of
early aspiration pneumonitis findings depends on the patient’s
position at the time of aspiration and need not be localized to
lower lung fields.
RISK FACTORS FOR AND MECHANISMS
OF PNEUMONIA DEVELOPMENT
The risk factors that determine the virulence and
severity of pneumonia are related to both pathogen and
host characteristics. Characteristics of the pathogen
include the organism, its resistance characteristics, its
virulence, and the dose of the inoculum. Host factors
are commonly divided into alterations of mucosal
integrity or impaired immunity. Mucosal integrity can 
be compromised by epithelial injury (“viral priming”),
mechanical injury such as endotracheal tubes or repeti-
tive mucosal trauma resulting from vigorous tracheal
suctioning, chemical injury from aspiration of gastric
contents, tobacco abuse, and malnutrition. Impaired
host immunity may be due to systemic immunosuppres-
sion due to infection, malignancy, malnutrition, liver or
renal failure, diabetes mellitus; or the exposure to
immunosuppressant agents such as steroids, chemother-
apeutic agents, toxins, or pharmaceuticals with immuno-
suppressant side effects. Notably, blood transfusions
have been demonstrated to suppress systemic immunity
and to increase the risk of nosocomial infections including
pneumonia.
The lung is the body organ with the largest epithelial
surface area in continuous contact with the external
environment and therefore it is vulnerable. An area of
approximately 70 m2 participates in gas exchange and is
continually exposed to airborne inorganic and organic
particles, as well as microorganisms. Pulmonary infec-
tion can be caused by inhalation of aerosolized inocu-
late, aspiration of secretions or particulate matter,
hematogenous spread, or direct inoculation. The most
common mechanism of pneumonia development is by
contamination of the naso-oropharynx or upper airway,
and subsequent aspiration of infected secretions into the
distal respiratory tree. In otherwise healthy patients,
pharyngeal secretions have a bacterial concentration of
approximately 1010 organisms/ml. Therefore, aspiration
of exceedingly small volumes (<0.1 ml) introduces
a high-titer bacterial inoculum into the respiratory tract.
In patients with incapacitating or coexisting disease,
decreased salivary flow, decreased cough reflexes, or
poor oral hygiene (such as occurs in intubated and
mechanically ventilated patients) the bacterial, viral, and
fungal load of pharyngeal secretions is both greater
and more virulent, and therefore a significant risk factor
to the development of pneumonia.
Patients with chronic or acute sinusitis and postnasal
drip are at risk for the aspiration of contaminated
nasopharyngeal secretions. Rarely, in patients with pha-
ryngeal pouches or esophageal (Zenker’s) diverticuli,
sequestered secretions and food particles may be aspi-
rated during sleep.
One of the causes of contamination of the lung with
organisms is the ventilator. The ventilator circuit regu-
larly develops stagnant water as condensate which
becomes rapidly colonized with pathogenic bacteria.
If this water is inadvertently washed into the endotracheal
tube, pneumonia results. Patients who undergo elective
surgical tracheostomy must have their oropharynx well
suctioned and preferably also decontaminated prior to
deflation of the endotracheal tube cuff. A large number
of ventilator-associated pneumonias inadvertently result
from aspiration of pooled oropharyngeal secretions
during the tracheostomy procedure.
Epithelial damage predisposes to successful pathogen
colonization and the development of an infective nidus.
Such epithelial injury can be caused by chronic or acute
lung diseases such as environmental toxins, tobacco
abuse, genetic predisposition such as alpha-1 antitrypsin
deficiency, or chronic aspiration syndromes. Notably,
mucociliary clearance is diminished in smokers and prior
infections with Mycoplasma pneumoniae, viruses, and
Haemophilus influenza have been shown to both
destroy cilia and impair ciliary function. Additionally, the
SIRS alters epithelial structure and function.
The presence of the endotracheal tube has been
demonstrated in itself to inhibit synchronized ciliary
motility. Therefore mucociliary clearance is impaired in
intubated patients. Cytologic studies demonstrate struc-
tural changes in epithelial glycoprotein binding charac-
teristics, mucus production, ciliary function, surfactant
protein composition and concentration, and extracellu-
lar enzymatic profiles during severe systemic illness and
which are thought to provide a critical initial link to bac-
terial adhesion, colonization, and infection. Fibronectin
is an epithelial coating found on normal mucosa which
prevents Gram-negative pathogens from adhering to res-
piratory epithelium. Loss of fibronectin facilitates bacte-
rial pneumonia development after viral infections, for
example. Hematogenous seeding of the lung from other
infected sites is another possibility for the development
of pneumonia. Infected prostheses, intravascular devices,
CLINICAL CAVEAT
Aspiration
● Aspiration of oropharyngeal secretions is especially
common in patients with depressed levels of
consciousness due to intoxication, sedation, or
central nervous system dysfunction.
● Disorders of deglutition due to neuromuscular
disorders, gastroesophageal reflux, esophageal
dysmotility, or prolonged nasogastric intubation also
predispose to the aspiration of pooled secretions.
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or endocarditis and even possibly bacterial translocation
from the lumen of ischemic abdominal viscus are poten-
tial sources of secondary or metastatic infection. Tumors
compromise tissue integrity and suppress immunity.
Tumors both predispose to colonization and local inva-
sion but also are an important cause of postobstructive
inspissation of mucus and secretions.
There is also a hypothesis whereby bacteria are
thought to translocate from the gut lumen into the sur-
rounding venous and lymphatic plexuses and induce
generalized inflammation or bacteremia and this has been
termed the “gut motor hypothesis.”
DIAGNOSIS OF PNEUMONIA
Radiologic Diagnosis of Pneumonia
The chest radiograph is the mainstay of radiologic
diagnosis and follow-up of pneumonia. The radiologic
picture may lag behind the clinical condition. Inter-
observer variability remains a limitation to radiologic
diagnosis. The radiologic appearance of hospital- and
ventilator-acquired pneumonias is difficult to distinguish
from atelectasis. However, serial radiographs may reveal
atelectasis to resolve more rapidly. It is widely believed
but unproven that a patient’s hydration status affects 
the radiologic appearance of an underlying pneumonia.
Therefore, the contention that a chest radiograph of a dehy-
drated patient is less likely to reveal a pneumonia-related
infiltrate is an unreliable although attractive hypothesis.
Radiologic infiltrates may be more difficult to identify
in patients with hyperexpanded lung fields (COPD),
fibrosis and scars, atelectasis, and pulmonary edema.
The radiologic appearance of pneumonia has tradition-
ally resulted in a general classification based on appear-
ance and distribution. Alveolar consolidation may occur
as a result of inflammatory edema in alveolar segments.
When the consolidation involves the entire lobe, it is called
lobar pneumonia. Characteristics of lobar pneumonia
include air bronchograms, volume loss, and mediastinal
shift toward the side of consolidation. Consolidated pneu-
monias frequently occur with S. pneumoniae and
Klebsiella pneumoniae (Figure 15-2). Air bronchograms
demonstrate an air–soft tissue interface; they are espe-
cially helpful in the indirect delineation of consolidation
posterior to the heart in the left hemithorax.
Bronchopneumonia, or lobular pneumonia, involves
an inflammatory response primarily at the site of the
bronchi and surrounding parenchyma tissue. Broncho-
pneumonia is usually seen as segmental or patchy infil-
trates consistent with partial segmental consolidation.
Consolidation is more likely to be locally segmental and
involvement of the parenchyma more patchy with
bronchopneumonia than with lobar pneumonia.
Bronchopneumonia is especially common when a pneu-
monic process is superimposed on underlying chronic
bronchitis or bronchiectasis. Bronchopneumonias are
commonly seen with H. influenzae, S. aureus, and
C. pneumoniae (Figure 15-3).
Interstitial pneumonias, also known as peribroncho-
vascular infiltrates, typically appear as reticular or
reticulonodular patterns reflecting inflammation primar-
ily localized to the interstitial tissue. Interstitial promi-
nence resembles the early stages of pulmonary edema
and is also associated with noninfectious causes of inter-
stitial lung disease which must be included in the differ-
ential diagnosis. This interstitial picture is especially
common with M. pneumoniae, P. carinii, other atypical
organisms, and viruses. The radiologic appearance of
Mycoplasma pneumonia is a unilateral or bilateral lobar
or segmental infiltrate that shows a patchy or confluent
air space disease. More severe cases reveal a diffuse
bilateral reticulonodular pattern in both lung fields
(Figure 15-4).
Nodular infiltrates are typically well-defined focal
lesions greater than 1 cm2 on chest radiographs. Nodular
infiltrates may be abscesses, fungal or tuberculous
granulomas, malignancy, Wegener’s granulomatosis, or
the necrotic vascular lesions that accompany severe
P. aeruginosa infection. Nodular infiltrates may suggest
histoplasmosis or tuberculosis. Cavitation is often asso-
ciated with staphylococcal pneumonia or infection with
Aspergillus. There is no good correlation between the
radiologic appearance and the causative pathogen.
Pneumonia may be accompanied by pleural fluid col-
lections known as parapneumonic infiltrates (Figure 15-5).
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Figure 15-2 Lobar pneumonia. Pneumococcal pneumonia.
Anterior segment of the right upper lobe is densely consolidated
but there is little, if any, mediastinal shift. No effusion is present.
These may resolve or progress to organized empyemas
which may be generalized or loculated.
Nonradiologic Diagnosis of Pneumonia
Direct microscopic examination of the Gram-stained
sputum has major diagnostic value. The Gram stain is
inexpensive, easily available, and has the advantage of
immediacy. The sputum Gram stain can help guide anti-
biotic therapy based on the prevalence of Gram-positive or
Gram-negative organisms. The false negative rate for spu-
tum cultures obtained by expectoration is greater than
50%. The quality of sputum is determined by the pres-
ence of epithelial cells which indicate oropharyngeal
contamination. The presence of >25 squamous epithelial
cells per low-power field (×100) is indicative of speci-
men contamination with oropharyngeal secretions. The
presence of one or more macrophages indicates that the
sputum sample has been obtained from the lower respi-
ratory tract. The presence of elastin fibers in a sputum
sample smear prepared with 40% potassium hydroxide
indicates that the specimen has been obtained from the
lower respiratory tract and also indicates the presence of
a necrotizing pulmonary process. The presence of ≥25
neutrophils per low-power field indicates infection such
as pneumonia or tracheobronchitis. Sputum is plated on
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Figure 15-3 Bilateral bronchopneumonia. Radiograph reveals
bilateral confluent infiltrates in pulmonary lobules (lobular
pneumonia). The inflammation involves the terminal respiratory
bronchioles.
Figure 15-4 Mycoplasma pneumonia. Bilateral lower lobe
infiltrates with prominent interstitial markings. The classic
radiographic interstitial of “atypical pneumonia” process reveals
accentuated reticular markings within the lung parenchyma as
well as septal (Kerly A and B) lines. Air bronchograms are clearly
visible bilaterally indicating lung consolidation which accentuates
the air–tissue interface. There is no hilar prominence.
Figure 15-5 Right pleural effusion. There is a characteristic
fluid meniscus on the right and there is evidence of some aeration
within the right lower lobe. The underlying pneumonia is not
apparent in this view but could be defined in a lateral decubitus
view after the surrounding fluid layers away from the pulmonary
tissue.
culture media to determine innoculum density (colony
forming units or cfu), definitive identification of colony
types, and antibiotic susceptibility profiles.
Fever in the critically ill patient is a nonspecific sign
of inflammation and does not always reflect the presence
of underlying infection. Also, elevated liver function tests
may occur with any infection and reflect a nonspecific
finding but is often associated with Legionella, tuber-
culosis, Mycoplasma, Q fever, tularemia, and psittacosis.
Serologic testing is one of the most important diag-
nostic modalities to identify organisms that are not easily
cultured (Table 15-2).
CLASSIFICATION AND TREATMENT OF
PNEUMONIA
Community-Acquired Pneumonia
Community-acquired pneumonia (CAP) accounts for
10% of all medical intensive care unit (ICU) admissions.
Approximately 50% of ICU patients with CAP will
require mechanical ventilation. The incidence of CAP is
approximately 12 cases per 1000 adults per year in
the USA, accounting for almost one million hospital
admissions per year. The cost of treating CAP exceeds
$10 billion per year in the USA. Although approximately
three-quarters of patients with CAP are successfully man-
aged as outpatients, those that require hospitalization
account disproportionately for pneumonia-related
health care costs. Since the cost of inpatient manage-
ment of pneumonia exceeds the cost of outpatient care
by at least a factor of 15, it is estimated that 90% of the
total costs of treating CAP are hospital-related. The mean
duration of hospitalization for CAP is 9 days, which
includes both routine hospitalization as well as intensive
care stay. The average mortality from CAP averages 40%.
When CAP is complicated by ARDS, which occurs in
approximately 5% of patients with CAP, the mortality
rate approaches 70%.
Risk factors for CAP include chronic respiratory or
cardiac disease, institutionalization, advanced age, and
alcoholism. Additionally, dysphagia and sedation increase
the risk for both aspiration and nonaspiration pneumonia
in the elderly population. Risk factors for mortality from
CAP include multi-lobar infiltrates, positive blood cul-
tures, rapidly progressive infiltrates, polymicrobial infec-
tion, hypoalbuminemia, renal insufficiency, respiratory
failure, serious comorbidities or advanced age, immuno-
suppression, altered mental status or coma, and prolonged
mechanical ventilation.
Prevention may be an important strategy to reduce the
impact of CAP, especially in vulnerable populations such
as the elderly. Tobacco and alcohol abuse cessation pro-
grams may improve pulmonary function, mucus clearance,
and decrease the risk of aspiration. Nutritional status is an
under-recognized risk factor for pneumonia development.
Additionally, the use of a polyvalent pneumococcal vaccine
and annual influenza vaccinations many controversially
decrease hospitalization, complications, and death.
Typical Community-Acquired Pneumonias
Streptococcal pneumonia is the single most impor-
tant cause of CAP but may also be responsible for a
significant number of hospital-acquired pneumonias.
S. pneumoniae case mortality approaches 40%. Among
patients admitted to the ICU with pneumococcal pneu-
monia with bacteremia, the case mortality rate approaches
80%. Penicillin-resistant S. pneumoniae (PRSP) is the
result of configurational changes in penicillin-binding
protein structure; the strain was identified in 1967 and
its rate of isolation now approaches 40%. S. pneumoniae
has also evolved resistance to macrolides, clindamycin,
and streptogramins.
Some patients with prior medical problems are more
at risk for specific organisms. H. influenzae and
K. pneumoniae are especially common isolates from
pneumonias in alcoholic patients. Patients with chronic
CLINICAL CAVEAT
Sputum Cultures
Sputum cultures that are obtained after the initiation
of empiric antibiotic therapy will yield a lower
incidence of true positives but a greater incidence of
false negatives.
162 CRITICAL CARE: THE REQUISITES IN ANESTHESIOLOGY
Table 15-2 Serologic Testing for Pneumonia
Diagnosis
S. pneumoniae Serum, urine, or sputum counter-
immunoelectrophoresis
Latex agglutination
Coagglutination
Enzyme immunoassay
Legionella spp. Urine or sputum direct fluorescent antigen
detection test (DFA)
Sputum polymerase chain reaction test
Sputum indirect immunofluorescence
antibody
Serum enzyme immunoassay
Chlamydia Serum polymerase chain reaction
Serum complement fixation
Serum micro immunofluorescence
Serum enzyme immunoassay
Mycoplasma Serum immunoglobulin IgM
(“cold agglutinin”)
Serum polymerase chain reaction
Serum complement fixation
Coxiella Serum indirect immunofluorescence
bronchitis are likely to present with H. influenzae or
M. catarrhalis. Patients who have undergone splenec-
tomy are at special risk for infection with encapsulated
organisms such as pneumococcus.
Empiric initial antibiotic therapy for CAP must pro-
vide effect of coverage for S. pneumoniae; agents that
also cover Legionella and Mycoplasma should be con-
sidered. Antibiotics of choice are ceftriaxone or cefo-
taxime with the addition of either a macrolide (e.g.,
azithromycin) or a fluoroquinolone.
Fine et al. have used both clinical investigation and
meta-analysis to identify and quantify the effect of risk
factors on mortality. The Fine criteria are described in
Table 15-3. The Fine Prediction Rule is an algorithmic
application of the Fine criteria to determine the optimal
point of care (Table 15-4).
Blood cultures have low yield and are not recom-
mended in the workup of uncomplicated CAP. On the
other hand, in severe CAP, especially pneumococcal in
origin, bacteremia is an important predictor of mortality.
The Infectious Disease Society of America (IDSA) and
the American Thoracic Society (ATS) have promulgated
guidelines for the treatment of CAP (Table 15-5).
Atypical Community-Acquired Pneumonias
The term “atypical pneumonia” was originally used to
describe a clinical syndrome of pneumonia which dif-
fered clinically and radiologically from typical pneumo-
coccal pneumonia. Since atypical pathogens were more
difficult to identify on Gram stain and cultures, and the
term “atypical pneumonia” was coined. The atypical
pneumonias can cause serious clinical syndromes with
high morbidity and mortality and frequently require
ICU care. Presently, the diagnostic tests for atypical
pathogens include polymerase chain reaction, comple-
ment fixation, microimmunofluorescence, and enzyme
immunoassay (for C. pneumoniae and M. pneumoniae);
others include the serum IgM antibody (“cold agglu-
tinin”) for Mycoplasma, and direct fluorescent antibody
(DFA) and indirect immunofluorescence antibody test
(for Legionella spp.). The most established of these 
techniques is complement fixation which is relatively
uncomplicated but has low sensitivity. The fluorescence
techniques determine antibody titer in diluted serum
samples but are subjective and costly. Enzyme-linked
immunosorbent assays (ELISA) to not require dilution
and because the results are measured in optical density
(OD) units there is less subjectivity. Urinary antigen test-
ing for Legionella pneumophilia serogroup 1 is a non-
serologic test which becomes positive only after a few
days of illness and may require a second test during the
convalescent phase of illness to confirm the diagnosis, if
such confirmation is necessary.
The type of environment may play an important role in
the organisms to which the patient is exposed. Patients
who are immunocompromised, who live in shelters, or
who are incarcerated are at especially high risk for infec-
tion with Mycobacterium tuberculosis. Hunters and 
CLINICAL CAVEAT
Presentation of Atypical Pneumonia
The hallmark presentation of atypical pneumonia is
a nonproductive cough.
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Table 15-3 Point Scoring System Reflecting Risk in
Community-Acquired Pneumonia (after
Fine MJ et al, 1997)
Attribute Points
AGE
Male Age (years)
Female Age (years) − 10
ADMISSION FROM A NURSING FACILITY 10
COMORBID ILLNESSES
Neoplastic disease 30
Liver disease 20
Congestive heart failure 10
Cerebral vascular disease 10
Renal disease 10
PHYSICAL EXAMINATION FINDINGS
Altered mental status 20
Respiratory rate ≥ 30 bpm 20
Systolic blood pressure ≤ 90 mmHg 20
Temperature ≤ 35°C or ≥ 40°C 15
Pulse rate ≥ 125 bpm 10
LABORATORY AND RADIOLOGIC FINDINGS
Arterial blood pH ≤ 7.35 30
Blood urea nitrogen ≥ 30 mg/dl 20
Sodium ≤ 130 mEq/l 20
Glucose ≥ 250 mg/dl 10
Hematocrit ≤ 30% 10
PaO2 < 60 mmHg or oxygen saturation < 90% 10
Pleural effusion 10
Table 15-4 Fine Prediction Rule for Risk and
Treatment Site in Community-Acquired
Pneumonia (after Fine MJ et al, 1997)
Total Point Risk Mortality Recommended 
Score Class Rate (%) Treatment Site
I 0.1 Outpatient
≤ 70 II 0.6 Outpatient
71–90 III 0.9–2.8 Probably outpatient
91–130 IV 8.2–9.3 Inpatient
>130 V 27–29.2 Inpatient
people who work outdoors may be exposed to Francisella
tularensis and develop tularemia, or Yesinia pestis, plague
(see Chapter 33). Keepers of birds may contract psitta-
cosis caused by Chlamydia psittaci. Inhalational anthrax
occurs in wool sorters and tanners. However, Bacillus
anthracis, a Gram-positive spore-forming bacillus, has also
recently surfaced as a biological terror agent in the USA.
Inhalational anthrax results in a hemorrhagic necrotic
pneumonitis evolving 2–43 days following exposure.
Lymphadenitis, pleuritis, and mediastinitis, however, are
likely to predominate over pneumonitis. Fluoroquinolones
are the drug of choice since tetracycline and penicillin-
resistant strains have been isolated. Exposure to meat,
especially from ungulates, is a risk for Coxiella burnetii
pneumonia (Q fever) (see Chapter 33).
Viral Pneumonia
Viral pneumonias typically occur in the setting of an
outbreak and occur predominantly in the winter and
early spring. Patients at risk for viral pneumonias include
those with underlying heart disease, chronic pulmonary
disease, and pregnancy. Pulmonary infiltrates can occur
in 20% of young adults with varicella but a frank pneu-
monia presentation is rare and is more suggestive of a
bacterial superinfection (Figure 15-6). Herpetic pneu-
monias occur with high frequency in postoperative 
cardiac and transplant patients. The true incidence is
probably under-recognized. The route of infection is
probably the aspiration of saliva contaminated by the virus.
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Table 15-5 IDSA and ATS Guidelines for Empiric Treatment of Community-Acquired Pneumonia
Patient Class IDSA ATS
1. OUTPATIENTS (ORAL)
a. Nonsevere pneumonia; no underlying Macrolide or doxycycline or fluoroquinolone Advanced macrolide
cardiopulmonary disease
b. Nonsevere pneumonia; underlying Beta-lactam plus macrolide or
cardiopulmonary disease and/or risk doxycycline; or fluoroquinolone
factors for DRSP alone
2. INPATIENTS (IV THERAPY)
a. Nonsevere pneumonia; no underlying Beta-lactam plus macrolide or Azithromycin or fluoroquinolone
cardiopulmonary disease doxycycline; or fluoroquinolone alone
b. Nonsevere pneumonia; underlying Beta-lactam plus Azithromycin or
cardiopulmonary disease and/or risk doxycycline; or fluoroquinolone alone
factors for DRSP or enteric gram-negatives
3. ICU PATIENTS (IV THERAPY)
a. Severe pneumonia; no risk of Beta-lactam plus macrolide or Beta-lactam plus azithromycin or
P. aeruginosa fluoroquinolone fluoroquinolone
b. Severe pneumonia; risk of Antipseudomonal beta-lactam plus
P. aeruginosa fluoroquinolone
IDSA, Infectious Disease Society of America; ATS, American Thoracic Society.
Figure 15-6 Influenzal viral pneumonia. There is evidence of
consolidation in the right middle and lower lobes in the setting
of pneumonia with positive viral titers.
The clinical picture is usually limited to hypoxia and dys-
pnea. The virus may be isolated in culture. Treatment is
with antiviral agents such as acyclovir.
Pulmonary Hantavirus syndrome with the Sin
Nombre virus was identified in 1993 in the American
Southwest and is acquired through exposure to the deer
mouse, its excrement, or contaminated dust; however,
the disease has been reported throughout the USA. The
syndrome is characterized by a nonspecific 3–6-day pro-
drome followed by hypoxemia and a sepsis syndrome.
Although the clinical picture suggests a pneumonia, the
microscopic picture is more consistent with pulmonary
capillary leak syndrome such as occurs in ARDS. The
case fatality rate for Hantavirus pulmonary syndrome is
50% or more.
Over the last two years there has been a growing
concern over large-scale epidemics of viral pneumonias.
The one with the greatest impact, severe acute respira-
tory syndrome (SARS), is a coronavirus infection that
causes pneumonia and severe ARDS. It was first recog-
nized in Southeast Asia in November 2002 from where it
spread to other countries. Repeat epidemic episodes are
likely. The SARS mortality rate worldwide is approxi-
mately 10.5%; the ICU admission rate ranged from 20%
to 38%; over 60% of ICU patients require mechanical
ventilatory support. The mortality rate of SARS patients
admitted to the ICU ranges from 5% to 67%.
Emerging diseases are likely to become more of a
global threat as viruses increasingly jump species and
mutate rapidly.
Fungal Pneumonia
Fungal pneumonias represent a subset of CAPs caused
by endemic fungi such as Histoplasma capsulatum,
Blastomyces dermatitidis, and Coccidioides immitis.
However, fungal pneumonias also represent opportunis-
tic infections in immunocompromised populations and
are likely very important but largely under-diagnosed
pathogens in nosocomial and especially ventilator-
associated pneumonias. Histoplasma is found in soil
contaminated with bird and bat excreta. Histoplasmosis
is the most common systemic mycosis in the USA and is
characteristically found in the Ohio and Mississippi river
valleys. Although an estimated 500,000 people develop
histoplasmosis in the USA annually, less than 1% develop
a clinically symptomatic disease. In immunocompetent
individuals with intact T-cell function, infection is usu-
ally subclinical and self-limited. In those patients who
develop symptomatic histoplasmosis, the presentation is
usually that of a flu-like syndrome with a nonproductive
cough and pleuritic chest pain. Less than 5% of infected
individuals develop rheumatologic syndromes such as
pericarditis and arthralgias or inflammatory granuloma-
tous mediastinitis. In patients with impaired immunologic
function or patients who have received a high inoculum
exposure, such as construction or agricultural workers,
there may be an acute overwhelming pulmonary histo-
plasmosis characterized by profound hypoxemia and dif-
fuse bilateral pulmonary infiltrates. Rare complications
of histoplasmosis include chronic upper lobe cavitary
pneumonic disease, fibrosing mediastinitis, and progres-
sive disseminated histoplasmosis. Definitive diagnosis
usually requires immunodiagnostic testing which is not
definitive, or periodic acid Schiff staining. Treatment is
either with itraconazole or amphotericin B; the con-
comitant systemic corticosteroid therapy should be con-
sidered (Figure 15-7).
Blastomyces is also found in moist soil rich with
decaying organic material. Blastomycosis is endemic
along the Mississippi and Ohio river basins as well as the
Great Lakes. Approximately 75% of infected patients
have isolated lung involvement and the remaining 25%
develop a disseminated lymphohematogenous disease
involving primarily the skin, bone, and genitourinary
system. Pulmonary blastomycosis develops approximately
six weeks after exposure and presents as a flu-like syn-
drome with a productive mucopurulent sputum. Chest
radiographs reveal nonspecific diffuse reticulonodular
infiltrates. Chronic common blastomycosis is similar to
tuberculosis and is accompanied by night sweats, weight
loss, and productive cough, and may progress to cavitary
disease. Blastomycosis can be diagnosed by PAS or
silver staining of sputum. Ketoconazole, itraconazole, or
fluconazole are the mainstay therapies (Figure 15-8).
Coccidioides is found in semiarid desert soil.
Coccidiomycosis is endemic in the southwestern USA
and approximately 100,000 new cases occur annually in
the Sonoran Desert and the Central (San Joaquin) Valley
of California. Approximately 40% of infected individuals
develop clinically evident disease in one to three weeks
following exposure. The disease is typically a self-limited
flu-like pneumonitis characterized by nonproductive
CLINICAL CAVEAT
SARS
● The most common clinical symptoms and signs of
SARS are fever, cough, dyspnea, myalgias, and
malaise.
● Common laboratory abnormalities include mild
leukopenia, lymphopenia, and increased aspartate
transaminase, alanine transaminase, lactic
dehydrogenase, and creatine kinase.
● The chest radiograph pattern ranges from focal
infiltrates to diffuse airspace disease. The risk of
mortality increases with advanced age,
comorbidities, a high lactic dehydrogenase, or a
high neutrophil count at admission.
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cough and pleuritic chest pain. Rheumatologic compli-
cations occur in about 20% of patients. Radiographic
findings are typically patchy or nodular infiltrates which
may coalesce to mimic those of other CAPs. Some 20%
of patients develop pleural effusions and hilar adenopathy.
About 5% of patients develop chronic pulmonary cavi-
ties or nodules which are considered a hallmark of
coccidiomycosis. Immunocompromised patients are at
especially high risk for disseminated disease which is
manifested by plaques and papules, pustules, and
chronic granulomatous meningitis. Serologic testing 
to IgM using precipitin or similar testing, complement 
fixation of IgG, or skin tests are commonly employed
diagnostic modalities. Treatment is with ketoconazole,
fluconazole, or amphotericin B (Figure 15-9).
Nosocomial Pneumonia
The definition of a nosocomial pneumonia is one that
starts at least 48 hours after hospital admission.
Nosocomial pneumonia or hospital-acquired pneumonia
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Figure 15-7 Histoplasmosis pneumonia. Characteristic large
paratracheal and hilar adenopathy with calcifications. Old calcified
foci are present in the peripheral lung fields. Infiltrates are patchy
and poorly defined.
Figure 15-8 Blastomycosis pneumonia. Left mid-lung field
density extending outwards from the left hilum demonstrates
the focal alveolar infiltrates characteristic of approximately 75%
of cases.
Figure 15-9 Coccidiomycosis. A patient from the San Joaquin
Valley of California. Chest radiograph shows hilar prominence
indicative of both adenopathy and a focal coin-lesion type of
reaction in the mid-upper lung fields (coccidiomas).
is the main cause of nosocomial mortality; 60% of all
nosocomial infections that result in death are due to
nosocomial pneumonias.
In patients who are hospitalized for stroke, the devel-
opment of pneumonia increases the 30-day risk of death
threefold. The development of a nosocomial pneumonia
increases the length of hospital stay by an average of
6–7 days; and the cost of treating a hospital-acquired
pneumonia ranges from $5000 for patients treated
on wards to $20,000–$40,000 per case of ventilator-
associated pneumonia treated in ICUs.
Drug-resistant pathogens increasingly account for
both community- and hospital-acquired pneumonia. The
need for infectious disease (ID) services consultation is
subjective and provider-specific. In institutions with
restricted antibiotic formularies it may be necessary to
obtain ID approval for the use of specific antibiotics;
such approval is not synonymous with a formal ID con-
sultation. An ID consultation might be considered in
high-risk circumstances such as immunosuppressed
patients, patients with complicated histories of frequent
infections or the risk of pathogen resistance is high, and
in situations where patients’ conditions worsen despite
aggressive antibiotic therapy.
Nosocomial pneumonias are often divided into hospital-
acquired pneumonias (HAPs) which are nosocomial
pneumonias that develop in patients who are not
mechanically ventilated either on the wards or in the
ICU; and ventilator-associated pneumonias (VAPs) which
occur in those patients who are receiving mechanical
ventilation. VAP usually refers to patients in the ICU; but
VAPs may occur also in those patients who are receiving
chronic mechanical ventilation outside the ICU.
Hospital-Acquired Pneumonia
HAP has an incidence of 0.5–1.0% of hospital admis-
sions. Pneumonia is the second most common cause of,
and accounts for up to 20% of, bacteremia and sepsis in
hospitalized patients. Risk factors include advanced age,
malnutrition, obesity, impaired immunity, depressed
level of consciousness, and prior surgery. HAP due to
anaerobes should be considered primarily in the setting
of recent abdominal surgery, anaerobic infection, or
suspected aspiration. Patients who are admitted with
pneumonia from the community but come from an insti-
tutionalized setting or who have been recently hospital-
ized are treated as though they have HAP.
“Severe HAP” is defined based on admission to the ICU,
respiratory failure based on the need for an FIO2 > 35%
to maintain SpO2 > 90% or the need for mechanical ven-
tilation, rapid radiologic progression of lung infiltrate, or
evidence of severe sepsis with hypotension and/or end-
organ dysfunction.
The core pathogens for HAP are S. aureus, S. pneu-
moniae, and the enteric Gram-negative bacilli (EGNB).
The treatment of early-onset HAP must provide coverage
against the core pathogens. The recommended regimens
for the treatment of HAP include ceftriaxone, cefuroxime,
or cefotaxime ± a macrolide. However, antimicrobial
resistance is developing rapidly. Monotherapy with a
fourth-generation cephalosporin may be cost-effective
therapy for HAP. HAP S. aureus pneumonia due to
methicillin-/oxacillin-resistant S. aureus (MRSA/ORSA)
strains will likely require vancomycin or linezolid
(Zyvox) for effective therapy.
Legionella or opportunistic Aspergillus should be sus-
pected as a HAP in the setting of the administration of high-
dose steroids or the new onset or worsening of pulmonary
symptoms in hospitalized patients. Endemic Aspergillus
infections have been recently related to hospital construc-
tion and renovation where immunocompromised or criti-
cally ill patients have been exposed to construction dust.
Ventilator-Associated Pneumonia
A nosocomial pneumonia that develops at least 48
hours after the initiation of mechanical ventilation is
known as a VAP. Nosocomial pneumonia accrues an
approximate 25% of adult ICU patients, at an incidence
of 21 times greater than that of non-ICU patients.
Approximately 17% of nosocomial pneumonias occur in
the 1% of hospitalized patients who received mechanical
ventilation. VAP has an incidence of 3–20% in patients
receiving short-term mechanical ventilation. The cumu-
lative incidence of VAP increases with the number of
ventilator days. Statistically, the incremental risk of
developing VAP during mechanical ventilation ranges
from 1% to 3% per day.
CLINICAL CAVEAT
Nosocomial Pneumonia
● Clinical diagnosis is a relatively poor indicator of
nosocomial pneumonia and chest radiography is
also nonspecific.
● Empiric therapy for nosocomial pneumonia must
provide adequate coverage against the core
organisms responsible for the majority of
nosocomial pneumonias in any given institution.
● Antibiograms that compile statistics regarding
antibiotic efficacy profiles for pathogens in any
given institution must also be consulted.
● Strategies to decrease the incidence of nosocomial
pneumonia include the use of routine infection-
control practices, vigorous handwashing and
decontamination of equipment by hospital staff,
nutritional assessment and support, and the isolation
of patients with resistant respiratory pathogens.
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Important risk factors for VAP include emergency
surgery, intubation, recumbent positioning, oral pharyn-
geal secretions, pre-existing cardiopulmonary or neuro-
logic disease, severity of illness, and tracheostomy. The
duration of mechanical ventilation and the administra-
tion of systemic glucocorticoids independently predict
risk of VAP. Patients who require emergency intubation,
emergent re-intubation, or receive a tracheostomy are at
higher risk of developing VAP. Occult VAP is a common
cause of failure to wean from mechanical ventilation.
Endotracheal tubes predispose to pneumonia formation
because they bypass the normal filtering mechanisms in
the upper airways and provide a direct conduit for the
aspiration of pathogens into the lower respiratory tree,
they have been shown to impair mucociliary clearance
and epithelial ciliary function, they rapidly develop a
contaminated biofilm which is then mechanically intro-
duced distally routine suctioning, and the endotracheal
tube cuff interferes with deglutition and also promotes
the pooling of oral pharyngeal secretions above the
endotracheal tube cuff. The high-volume low-pressure
endotracheal tube cuffs used in clinical practice do not
completely occlude the upper airway and therefore do
not prevent either gross aspiration syndromes or
microaspiration of oral pharyngeal secretions.
VAP, similar to any other nosocomial infection, must
be managed especially aggressively in those patients
who have implanted foreign bodies such as vascular
graft material, arthroplasties, and pacemakers and defib-
rillators. The virulence of nosocomial pathogens and the
potential for immunologic compromise in inpatients
makes hematogenous seeding of foreign bodies espe-
cially likely and thereafter very difficult to treat.
VAP is also further characterized based on the time of
onset of pneumonia. Early-onset VAP occurs within the
first 96 hours of initiation of mechanical ventilation and
is most commonly attributable to antibiotic-sensitive
organisms such as S. aureus, H. influenzae, S. pneumo-
niae, and EGNB (Table 15-6). Late-onset VAP is pneu-
monia which is diagnosed 96 hours or more after the
initiation of mechanical ventilation and is typically
caused by MRSA, ORSA, P. aeruginosa, Enterobacter spp.,
or Acinetobacter spp. These organisms are more likely
to be resistant and to contribute to morbidity and mor-
tality. Therefore, the key core pathogens in VAP are gen-
erally P. aeruginosa, S. pneumoniae, Acinetobacter spp.,
S. aureus, and EGNB.
VAP is polymicrobial approximately 50% of the time.
Empiric antibiotic therapy for VAP must account for
both aggressive combination therapy based on an anti-
biogram specific to the ICU, as well as criteria for the
duration of therapy. As microbiological data become
available, usually within 48 hours, the empiric therapy
should be tapered or modified accordingly. A key
dilemma in the diagnosis of VAP is the differentiation
between endotracheal tube colonization, airway colo-
nization, bronchitis, and true pneumonia. Colonization
can be defined as the persistence of microorganisms at
an anatomic site without evidence of host response or
local invasion. The differentiation between pneumonia
and colonization is especially difficult when the diag-
nosis is based on nonquantitative cultures obtained by
simple endotracheal tube suctioning. A variety of micro-
organisms normally colonize the upper respiratory tract
and these include Viridans streptococci, Streptococcus
pyogenes, Neisseria spp., Moraxella, Corynebacterium,
Lactobacillus, and Candida spp.
S. aureus is an extremely common cause of community-
and hospital-acquired pneumonia. However, in hospitals
its endemic rate of colonization is so high as to make
it an almost ubiquitous hospital pathogen. MRSA and ORSA
account for 70–80% of hospital isolates of S. aureus.
Resistance is a function of both an altered penicillin and
binding protein which confers beta-lactam resistance, as
well as target modification which confers macrolides
and possibly fluoroquinolone resistance. Vancomycin
has become the mainstay therapy for S. aureus, but the
emergence of vancomycin-resistant S. aureus (VRSA)
and vancomycin (glycopeptide) intermediate-sensitive
S. aureus (VISA or GISA) increasingly requires complex
therapy with agents such as Quinupristin/dafopristin
(Synercid) or Linezolid.
Gram-negative pathogens account for approximately
60% of clinical laboratory isolates in patients with 
nosocomial pneumonia. The enterobacteriaceae species
that are most commonly seen include K. pneumoniae,
Proteus spp., Serratia spp., Citrobacter spp., and
Escherichia spp. These agents have been resistant to
beta-lactams through the production of bata-lactamases;
however, extended-spectrum beta-lactamases (ESBL)
and beta-lactamases resistant to beta-lactamase inhibitors
(inhibitor-resistant TEM-derived beta lactamases) have
become significant. Vancomycin-resistant enterococcus
(VRE or VREF) is increasingly prevalent. Both Enterococcus
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Table 15-6 Nosocomial Pathogens: Adapted from
NNIS Data 1992–1999
Pathogen Percentage
Staphylococcus aureus 18.1
Pseudomonas aeruginosa 17.0
Enterobacter spp. 11.2
Klebsiella pneumoniae 7.2
Candida albicans 4.7
Escherichia coli 4.3
Haemophilus influenzae 4.3
Enterococcus spp. 1.7
All others 31.4
faecium and E. faecalis are becoming serious threats.
However, the former is vastly more common than the
latter at the present time. Linezolid and Synercid are
important antibiotics against this class of organism.
Vancomycin resistance in Enterococcus and
Staphylococcus is a reflection of its overuse. It is esti-
mated that 60–65% of vancomycin use is inappropriate.
Pseudomonas aeruginosa is an extremely common
pathogen for HAP and VAP with a higher mortality rate
than most other Gram-negative bacilli. Plasmid-mediated
resistance is rapid. Pseudomonas pneumonia increases
ICU mortality by a factor of 2.6–6.4. In patients who have
P. aeruginosa or acinetobacter infections, crude ICU
mortality exceeds 70%.
Fungal pneumonias are both under-diagnosed and
under-treated in critically ill patients. Mycotic infection
is known to occur in the presence of adjunctive anti-
biotic therapy, immunosuppression, and severe illness.
Unfortunately, fungal infection is more likely be a post-
mortem diagnosis than a clinical one. A key limitation is
the inability to culture rapidly specimens containing fun-
gal pathogens and perform sensitivity testing on isolates.
The development of antifungal agents with decreased
systemic toxicity has facilitated the treatment of
mycoses in critically ill patients. Specific criteria for 
initiation and discontinuation of systemic fungal agents
remain controversial.
There is no gold standard method for the diagnosis of
VAP. Studies have repeatedly been unable to demon-
strate with statistical significance the clear value of any
technique over any other. However, a number of diag-
nostic modalities are used in practice: endotracheal tube
aspirates (ETA); bronchoscope-directed protected brush-
ings (BDPB); protected brush specimen (PBS); broncho-
scopic bronchoalveolar lavage (BBAL); and blind BAL or
QTL which are quantitative tracheal lavage techniques.
Endotracheal tube aspirates are the most commonly per-
formed method of culturing respiratory secretions. Since
endotracheal tube aspirates culture both contaminants
and colonization as well as infectious pneumonia, the
use of semiquantitative cultures and the determination
of sputum neutrophil count can greatly increase their
sensitivity. Bronchoscopy is an important adjunct to the
diagnosis of VAP, giving direct visualization of the
airways which can reveal inflammation, mucus, and mucus
plugging. A protected brush specimen can be obtained
either blindly or with a bronchoscope. The protected
brush is designed to reduce false positive cultures which
are due to contamination from upper airway secretions
and may represent only tracheobronchitis rather than
true pneumonia. The protected brush is housed within a
closed cannula. When the cannula is passed into the distal
airways, the brush is advanced through the occluding
plug of the cannula and is exposed directly to distal res-
piratory secretions. Structures are retracted into the can-
nula and removed for plating and culture. Quantitative
cultures revealing colony growth ≥103 colony forming
units (cfu)/ml are considered positive and correspond to
a bacterial density of 105–106 cfu/ml in undiluted respi-
ratory secretions.
Bronchoalveolar lavage is performed through a bron-
choscope by washing a specific lung segment with iso-
tonic saline and collecting the effluent directly through
the bronchoscope suction for culture. When the BAL is
performed using a wedged catheter tip, which isolates
the lung segment during lavage, the technique is known
as a protected BAL. A minimum lavage volume of approx-
imately 120 ml is recommended for adequate sampling;
when smaller volumes of saline (10–50 ml) are used, the
technique is called a mini-BAL. A threshold of 104 cfu/ml
is considered positive for pneumonia when the BAL is
used but this corresponds to the same bacterial titer in
undiluted respiratory secretions as a protected brush.
The sensitivity and specificity of BAL is considered to
range from 70% to 100%. Open lung biopsy is the most
definitive diagnostic procedure for histopathologic diag-
nosis of pneumonia in immunocompromised hosts.
CURRENT CONTROVERSY
Treatment of Ventilator-Associated Pneumonia
The risk of undertreatment is increased morbidity
and mortality. The risk of overtreatment includes the
development of resistant strains of bacteria, the
significant cost of continued surveillance cultures,
medications, consultations, drug level monitoring, and
the increased potential for medication errors.
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KEY POINTS
Ventilator-Associated Pneumonia
● The single best predictor of mortality in patients
with VAP is the resolution of pulmonary shunting as
measured by the pAO2/ FIO2 ratio.
● Successful prevention of VAP is a clearly more cost-
effective strategy then surveillance and treatment.
● The avoidance of patient cross-contamination by
vigorous handwashing is probably the most
important precaution that health care workers can
take to prevent spread of pneumonia and other
infections in hospitals. Universal precautions should
be considered universally.
● The use of endotracheal tubes designed to permit
continuous removal of pooled subglottic secretions
has been proven to decrease the incidence of VAP.


Pleural or parapneumonic effusions are associated
with up to 50% of bacterial pneumonias. These effusions
can be free or loculated and may either resolve or develop
into empyema. These effusions should be drained
immediately if there is radiologic evidence of an air–fluid
level. Parapneumonic effusions should be evaluated by
paracentesis for Gram stain and culture, pH, LDH, protein,
and glucose in order to differentiate between trans-
udative and exudative fluid. Grossly purulent fluid should
be drained.
The clinical pulmonary infections score (CPIS) has
utility in both detecting the onset of VAP and also deter-
mining the sufficiency and adequacy of treatment. The
CPIS also correlates with 28-day mortality. The diagnosis of
pneumonia is generally based upon variations of the CPIS
originally developed by Pugin et al. in 1990 (Table 15-7).
The CPIS has a specificity (85–95%) similar to that of
bronchoscopic diagnosis of pneumonia. The key param-
eters include temperature, quantity of secretions, leuko-
cyte count, chest radiographic findings, hypoxemia, and
BAL Gram stain and culture. A CPIS of >6 indicates infec-
tious pneumonia with a sensitivity of 93% and specificity
of 100%. Therefore, a CPIS of >6 almost excludes
acute lung injury, pulmonary edema, or atelectasis as the
etiology of a pulmonary infiltrate.
Pneumonia in Patients with Compromised
Immune Status
The causes of pneumonia in the immunocompro-
mised host include all pathogens listed above and extend
to opportunistic pathogens. Other causes of pulmonary
infection in immunocompromised patients include
Mycobacterium tuberculosis and M. avium-intracellulare,
Cryptococcus, Toxoplasma, and cytomegalovirus. Many
of these infections also involve other organs such as the
brain and the eye (Figures 15-10 and 15-11). Pneumonia
in immunocompromised patients presents atypically.
Dyspnea, hypoxemia, nonproductive cough, and a gen-
eralized radiographic infiltrate frequently constitute the
presenting picture. Such patients may be hypothermic
rather than febrile, and may have a leukopenia rather
than leukocytosis. The responsible pathogen may be
isolated in only 40% of immunocompromised patients.
The early evolution of systemic sepsis in this population
makes rapid diagnosis and intervention extremely
important.
Pneumocystis carinii (PCP) is a protozoan pneumonia
which is common in HIV-infected patients. The pneumonia
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Table 15-7 Clinical Pulmonary Infection Score (CPIS) or Pugin Score
Variable Range Points
Temperature (°C) ≥36.5 and ≤38.4 0
≥38.5 and ≤38.9 1
≥39.0 and ≤36.0 2
Leukocytes/mm3 ≥4000 and ≤11,000 0
≤4000 and ≥11,000 1
Secretions <14 + volume of tracheal secretions 0
≥14 + volume of tracheal secretions 1
Purulent secretions 1
PAO2/FIO2 (mmHg) >240 0
≤240 2
Chest radiograph No infiltrate 0
Diffuse/patchy infiltrate 1
Localized infiltrate 2
Semiquantitative tracheal aspirate cultures <1 pathogenic bacteria or no growth 0
≥1 pathogenic bacteria 1
Same organism as gram stain 1+ add 1
Modified from Pugin J, Auckenthaler R, Mili N et al: Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic
“blind” bronchoalveolar lavage fluid. Am Rev Respir Dis 143:1121–1129, 1991.
KEY POINTS—Cont’d
● Patient positioning in semi-recumbent rather than
supine position decreases the incidence of VAP.
The elevation of the head of the patient’s bed can
decrease the risk of aspiration.
● More controversial strategies include stress ulcer
prophylaxis, selective digestive decontamination,
aggressive oral and dental care, and frequent
changes of ventilator circuits and filters.
● Potential future developments include the use of
bioactive and drug-impregnated biomaterials for
endotracheal tube construction.


can be rapidly progressive and lethal. The classic
“ground glass” appearance on chest radiographs is non-
specific and may represent early ARDS. The initial anti-
biotic choice for PCP is trimethoprim-sulfamethoxazole
(TMP-SMX) and co-administration of steroids must be
considered. The initial response to therapy is frequently
a clinical deterioration which may require intubation
and mechanical ventilation. Treatment with TMP-SMX is
considered to have failed if a favorable response is not
apparent within three to five days. The second-line agent
is intravenous pentamidine. Pentamidine is associated
with significant side effects which include QTc prolonga-
tion, torsades de points, renal insufficiency and pancreatitis,
neutropenia, as well as hyper- and hypoglycemia (Figures
15-12 and 15-13).
ADJUNCTIVE AND SUPPORTIVE
THERAPEUTIC STRATEGIES
Fluid Resuscitation
In all patients with severe infective processes, sup-
portive therapy is necessary to prevent secondary injury
and the development of complications. Fluid resuscita-
tion is a basic tenet of managing infection. Many patients
are unable to “drink plenty of fluids” and therefore require
intravenous hydration. Both systemic infection and
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Figure 15-10 Miliary tuberculosis. Fine nodular lesions are
apparent in bilateral lung fields.
Figure 15-11 Cryptococcus pneumonia. Bilateral infiltrates
with small thin-walled areas of cavitation. Radiographically,
cryptococcus mimics nonspecific pneumonitis and presentation
can vary from cavitations, miliary lesions, to larger infiltrates.
Late-stage cryptococcus can be mistaken for pneumocystis, or
lymphoreticular malignancy, and it also resembles ARDS.
Figure 15-12 Early Pneumocystis carinii pneumonia. No
radiographic pattern is pathognomonic and the early appearance
is that of an “atypical” pneumonia.
systemic inflammatory response produce early periph-
eral vasodilatation and capillary leak which result in
diminished intravascular fluid volume. Since increased
stroke volume is usually not possible in such patients,
the decreased intravascular volume is initially compen-
sated for by tachycardia to maintain cardiac output and
oxygen delivery to tissues. In patients who are unable to
mount a compensatory tachycardia (diabetes, myo-
cardial pump dysfunction, beta-blocker therapy, etc.)
there are early signs of diminished peripheral perfusion
and shock. In the setting of prolonged under-resuscitation,
the inflammatory cascade is activated, regional hypo-
perfusion results, and acidosis and elevated serum lactate,
acute renal failure due to acute tubular necrosis from
regional underperfusion results, and the patient becomes
progressively more difficult to resuscitate later.
Vasopressors should not be used as the mainstay of
therapy for sepsis. Although vasopressors may be used
to temporize while fluid resuscitation is ongoing, the
substitution of vasopressors for fluid results in progres-
sive tissue ischemia and organ failure. The development
of progressive hypoxemia with intravascular volume
therapy does not necessarily mean intravascular fluid
overload – it is also consistent with a worsening of the
pneumonia or the interval development of ARDS.
There are no data to support the use of colloid over
crystalloid for intravascular volume resuscitation.
However, emerging data may suggest that judicious use
of colloids may help maintain intravascular oncotic
pressure and decrease edema formation. Intravascular
volume replacement therapy should be titrated to urine
output, signs of improvement in organ perfusion (men-
tal status, cyanosis resolution, etc.), serum lactate and
acid–base balance, central venous filling or other pre-
load measure correlated with cardiac output, or echo-
cardiographic determination of end systolic volume and
cardiac performance. A history of poor cardiac function,
congestive heart failure, or pulmonary edema are not
contraindications to intravascular volume replacement.
Nutritional Support
Patients with severe infection are highly catabolic and
nutritional support should be instituted immediately, if
possible. Many patients with pneumonia are already
nutritionally depleted on initial presentation, and base-
line nutritional status (pre-albumin, transferrin) should
be documented. Daily calorie counts and serial nutri-
tional indices may be required to ensure adequacy of
nutritional support. Unless there is a definite contraindi-
cation to enteric feeding, it is the route of choice for
nutritional support. Nutritional depletion has been shown
to increase bacterial adherence to the airways, reduce
alveolar macrophage function, impair neutrophil and
macrophage recruitment, decrease levels of circulating
complement factors, and reduce levels of airway IgA.
Pharmacologic Treatment
Antibiotic Principles
The ability of an antibiotic to exert its pharmacologic
effect is related to penetration into infected tissue and
achievement of adequate tissue concentrations.
Inappropriate treatment of pneumonia is most often due
to either nonsusceptibility or resistance of the pathogen
to the chosen antibiotic regimen. Inappropriate initial
antibiotic selection can range from 27% to 73% and has
a dramatic impact on outcome measured by length of
stay, multiple organ dysfunction syndrome, and mortality.
Antibiotics that have good penetration into respiratory
secretions that is not dependent on localized inflam-
mation include the quinolones, azithromycin, clari-
thromycin, tetracycline, clindamycin, and TMP-SMX.
Antibiotics that have impaired penetration into respira-
tory secretions and/or are dependent on inflammation for
concentration within lung tissue include aminoglycosides
and the beta-lactams (penicillins, cephalosporins, and 
carbapenems). Aminoglycosides have poor pulmonary
penetration, and especially do not penetrate well into 
respiratory secretions. Therefore aminoglycosides should
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Figure 15-13 Late-stage Pneumocystis carinii pneumonia.
Upright anteroposterior (AP) view. Widespread bilateral interstitial
and alveolar infiltrates resembling ARDS. Interstitial markings
result in a “honeycomb” appearance. An endotracheal tube is
present.
not be used as monotherapy for Gram-negative pneumo-
nias. Azithromycin has replaced erythromycin in clinical
practice because erythromycin has side effects of both QTc
prolongation as well as enteric prokinesis which causes
cramping discomfort. Fluoroquinolones are also associated
with QTc prolongation, especially at higher doses.
Pathogen susceptibilities are often reported in terms
of the minimum inhibitory concentration (MIC); the
agent of choice will therefore depend on the MIC, guide-
lines and restrictions, and cost. Optimal pharmacologic
action of antibiotics is that for which every concentration-
dependent mechanism of action occurs when Cmax/MIC
is greater than 10.
In any patient who has failed to respond clinically
after 48–72 hours of antimicrobial therapy, the thera-
peutic strategy must be reevaluated. Generally, this will
require further workup including revaluation of culture
and sensitivity data, consideration of superinfection,
reconsideration of drug dosing or route of administration,
and consideration of an alternative diagnosis. Evaluation
of the patient’s immunologic status may also be necessary.
Other routes of antibiotic therapy may be important
in the care of ICU patients. Inhaled antibiotic therapy
is probably underutilized. Inhaled antibiotics should be
considered for severe HAP and in the treatment of refrac-
tory pneumonia in populations such as patients with
cystic fibrosis.
Mechanisms of antimicrobial resistance include target-
mediated resistance, enzymatic inactivation, cell mem-
brane permeability alterations, and active expulsion of
antibiotics from bacterial cells. Target-mediated resist-
ance is a result of alterations in the number or affinity of
antimicrobial binding sites within bacteria. Enzymatic
inactivation results from the production of bacterial
enzymes often carried by plasmids, which degrade
antibiotic agents. Beta-lactamase production is the most
common form of enzymatic resistance. Cell membrane
permeability changes cause decreased antimicrobial
uptake into bacterial cells. The promotion of active
reflux of antibiotic out of bacterial cells is an energy-
dependent mechanism which is carried on by plasmids
and the creation of molecules known as transposons.
The rotation of first-line antibiotics of choice has been
demonstrated to decrease the rate of evolution of
pathogen resistance. Therefore, the choice of antibiotic
should also be made in accordance with the preferred
antibiotic in any particular cycle at any particular hospital.
Nonantibiotic Adjunctive Pharmacologic Therapy
In rare cases the use of immunomodulatory agents
such as granulocyte colony-stimulating factor (GCSF) may
need to be considered to enhance host polymorpho-
nuclear leukocyte (PMN) response.
Bronchodilators are a very important adjunctive ther-
apy in those patients with reactive airway disease who
develop a superimposed respiratory tract infection.
Since airway infection can predispose some patients to
bronchospasm and thereby interfere with their ability to
cough and clear secretions, bronchodilator therapy is
beneficial in this population. Patients who use bron-
chodilator therapy regularly prior to admission may
require an increase in the dose or frequency. Nonsteroidal
bronchodilators can be either beta-2 agonists such as
albuterol or anticholinergic such as Atrovent. The beta-2
sympathomimetics can still precipitate tachycardia.
Lev-albuterol is a selective isomer with significantly 
less cardiac activity and possibly also a longer effective
half-life.
Steroids are important bronchodilators in patients
with underlying chronic obstructive pulmonary disease
(COPD) or severe reactive airway disease. Methylpred-
nisolone is the intravenous steroid bronchodilator of
choice; prednisone is administered enterally. Patients for
whom steroids have been chronically prescribed prior to
admission require supplemental “stress doses” to avoid
adrenal insufficiency in the setting of infectious stress.
Mucolytic agents and expectorants may have a role
when mucus clearance is difficult in the setting of
dehydration or inspissated mucus is difficult for the
patient to clear. N-acetylcysteine, recombinant DNase,
and guaifenesin are prototypic mucolytic agents. N-
acetylcysteine can precipitate bronchospasm and should
be administered concomitantly with bronchodilators.
Humidification of inspired gases is important when
the endotracheal tube bypasses the normal humidifi-
cation and filtering systems of the upper airways.
Humidification is important to avoid dry mucosal sur-
faces in patients with inflamed upper airways and
humidification can improve expectoration of lower air-
way secretions. On the other hand, humidification sys-
tems must be carefully monitored for contamination
with hypophilic organisms such as Pseudomonas and
Legionella.
Stress ulcer prophylaxis must be considered in any
hospitalized or critically ill patient exposed to metabolic
stress; stress ulcer prophylaxis has been shown to
decrease the incidence of gastrointestinal bleeding as a
standard of care. The hypothesis that increasing gastric
pH with stress ulcer prophylaxis increases incidence of
nosocomial pneumonia due to aspiration of colonized
gastric contents is no longer favored. Commonly used
agents include proton pump inhibitors such as panto-
prazole or others; H2 blockers such as famotidine; or
barrier agents such as sucralfate.
The use of oral care agents such as topical Mycostatin
liquid may be beneficial because it focuses attention
on oral care and the potential for bacterial and fungal
overgrowth in the oral pharynx of integrated patients
who have decreased salivary production and clearance.
Also, oral care agents may have an antiseptic effect
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which decreases bacterial colonization. Patients who
develop perioral or intraoral herpetic vesicles should
have topical antiviral agents such as acyclovir applied.
Although pulmonary arteriolar vasodilators such as
prostacyclin (PGI2) and nitric oxide have been used in
the management of severe cases of pneumonia, the use of
these costly agents remains controversial and there is
variability in their effectiveness. Hypoxic pulmonary
vasoconstriction (HPV) is an adaptive response whereby
a reflex vasoconstriction in the arteriolar supply to
inflamed or diseased alveoli which have low alveolar oxy-
gen concentrations results in minimization of pulmonary
shunt fraction. Therefore, pulmonary arteriolar vasodila-
tors which inhibit the HPV response are likely to increase
blood supply to diseased hypoxic alveoli and actually
increase shunt fraction and systemic hypoxemia.
GENERAL PRINCIPLES OF CHEST
RADIOGRAPH INTERPRETATION
The portable anterior-posterior (AP) chest radiograph
is the most commonly obtained radiologic study in the
ICU. Although the critical care practitioner cannot be
expected to render a complete final radiologic reading,
it is incumbent on intensivists to be able reliably and
independently to render preliminary interpretations
which address specific questions regarding patients’
clinical conditions. The chest radiograph is also key in
the evaluation of a patient’s response to therapy. The
critical care notes should reflect independent readings
as well as later confirmations or variations seen by
radiologists.
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KEY POINTS
Radiologic Interpretations
(a) Technique:
(i) Anterior-posterior versus posterior-anterior versus lateral. Lateral decubitus films are sometimes obtained to
determine fluid layering.
(ii) Upright or supine. Upright films are necessary to better delineate pleural effusions and pneumothorax in and air 
under the diaphragm.
(iii) Penetration: assessed objectively by comparison of lung fields and bony structures. Over penetration will
emphasize the denser bony structures and obliterate subtle findings within the lung parenchyma.
(iv) Rotation: relates to the patient’s position on the radiographic plate. Rotation is best assessed by looking at
clavicular symmetry.
(b) Hardware:
(i) Endotracheal tube: should be midway between the clavicles and the carina within the trachea. It is important to
note that the endotracheal tube will move approximately 2.5 cm in or out of the trachea with extension and
flexion of the neck, respectively.
(ii) Nasogastric and feeding tubes: must be followed within the esophagus into the stomach or small bowel. Tubes
that enter the trachea will often pass through one mainstem bronchus.
(iii) Tube thoracostomy: mention is usually made of the position of the tube, the intra- or extrathoracic placement of
a last collecting hole of the chest tube, and resolution of the liquid or air collection which the tube was intended
to treat.
(iv) Other hardware: tracheostomy tubes, pacemakers, implantable cardiac defibrillation wires, intra-aortic balloon
pump tips, prosthetic cardiac valves, evidence of vascular prostheses and stents, sternal wires, surgical clips,
orthopedic prostheses, and airway stents. The mention of other foreign bodies, especially in trauma cases, is
particularly important.
(c) Bony structures:
(i) Fractures and dislocations of the clavicles, sternum, scapula, ribs, and vertebrae.
(ii) Hyperostosis, osteopenia, or potential bony involvement of surrounding tumor or infection.
(d) Cardiovascular silhouette:
(i) The AP portable radiograph is an unreliable indicator of cardiomegaly.
(ii) The cardiac silhouette.
(iii) The thoracic aorta. Special mention should be made of calcifications within the thoracic aorta and dilatation of
the thoracic aorta.
(iv) The pulmonary vasculature. Hilar accentuation. Pulmonary arterioles seen end-on are usually apparent and
present as small opaque circles in the hilar regions and are normal findings. Evidence of vascular prominence,
interstitial prominence, or alveolar flooding consistent with stages of congestive heart failure and pulmonary
edema, respectively, must be noted.


SELECTED READING
American Thoracic Society: Hospital-acquired pneumonia in
adults: diagnosis, assessment of severity, initial antimicro-
bial therapy, and preventative strategies. A consensus
statement. Am J Respir Crit Care Med 153:1711–1725,
1995.
Bartlett JG, Brieman RF, Mandell LA, File TM; Infectious
Diseases Society of America: Community acquired pneu-
monia in adults: guidelines for management. CID
26:811–838, 1998.
Colice GL, Curtis A, Deslauriers J et al: Medical and surgical
treatment of parapneumonic effusions: an evidence-based
guideline. Chest 118:1158–1171, 2000.
Fine MJ, Stone RA, Lave JR et al: Implementation of an
evidence-based guideline to reduce duration of intravenous
antibiotic therapy and length of stay for patients hospital-
ized with community-acquired pneumonia: a randomized
controlled trial. Am J Med 115:343–351, 2003.
Katzan IL, Cebul RD, Husak SH et al: The effect of pneumonia
on mortality among patients hospitalized for acute stroke.
Neurology 60:620–625, 2003.
Kirtland SH, Corley DE, Winterbauer RH et al: The diagnosis of
ventilator-associated pneumonia. a comparison of histo-
logic, microbiologic, and clinical criteria. Chest 112:
445–457, 1997.
Luczycki S, Papadakos PJ, Szalados JE : Ventilator-associated
pneumonia: pathophysiology, diagnosis, and treatment.
Crit Care Shock 2:72–87, 2002.
Manocha S, Walley KR, Russell JA: Severe acute respiratory
distress syndrome (SARS): a critical care perspective. Crit
Care Med 31:2684–2692, 2003.
Masur H, Kaplan JE, Holmes KK; US Public Health Service;
Infectious Diseases Society of America: Guidelines for
preventing opportunistic infections among HIV-infected
persons – 2002. Recommendations of the US Public Health
Service and the Infectious Diseases Society of America.
Ann Intern Med 137:435–478, 2002.
Niederman MS, Mandell LA, Anzueto A et al; American
Thoracic Society: Guidelines for the management of adults
with community-acquired pneumonia. Diagnosis, assess-
ment of severity, antimicrobial therapy, and prevention.
Am J Respir Crit Care Med 163:1730–1754, 2001.
Ost DE, Hall CS, Joseph G et al: Decision analysis and diagnostic
strategies in ventilator-associated pneumonia. Am J Resp
Crit Care Med 168:1060–1067, 2003.
Pugin J: Clinical signs and scores for the diagnosis of ventilator-
associated pneumonia. Minerva Anesthesiol 68:261–265,
2002.
Pugin J, Auckenthaler R, Mili N et al: Diagnosis of ventilator-
associated pneumonia by bacteriologic analysis of bron-
choscopic and nonbronchoscopic “blind” bronchoalveolar
lavage fluid. Am Rev Respir Dis 143:1121–1129, 1991.
Rex JH, Walsh TM, Sobel JD et al: Practice guidelines for the
treatment of candidiasis. CID 30:662–78, 2000.
Wunderink RG, Waterer GW: Genetics of sepsis and pneumonia.
Curr Opin Crit Care 9:384–389, 2003.
Pneumonia in Adults 175
KEY POINTS—Cont’d
(v) The cardiovascular silhouette and trachea, taken together, are good indicators of mediastinal shift in the setting
of consolidation (mediastinal shift toward the side of consolidation) and abnormal collections of air or fluid
(mediastinal shift away from the side of the collection).
(vi) The hilum: reflects both adenopathy as well as pulmonary vasculature and peribronchial tissue.
(e) Lung fields:
(i) Expansion, hyperinflation, bullae, inspiratory effort, or atelectasis.
(ii) Infiltrates, consolidation, cavitation, masses.
(iii) Air bronchograms.
(iv) Pleural collections.
(f ) Diaphragm and surrounding abdominal tissue:
(i) Air under the diaphragm is indicative of either a recent abdominal intervention such as recent surgery,
paracentesis, or hysteroscopy; or it is a sign of a surgical emergency.
(ii) A large gastric air bubble may require a nasogastric tube.
(iii) Ileus may be apparent but is nonspecific and is an indirect incidental finding on a chest radiograph.


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Conclusions
Acute lung injury (ALI) and acute respiratory distress
syndrome (ARDS) remain two of the most common 
conditions evaluated in the intensive care unit (ICU). 
ALI and ARDS are commonly encountered in the ICU
and are associated with increased mortality, morbidity,
and cost of care. ARDS is often seen in conjunction with
multiple organ failure. The overall hospital mortality rate
is between 20% and 50%. This wide range of mortality
illustrates that there is a lack of understanding of the exact
etiology and management of these conditions and further
improvements and investigations into these conditions
are needed. The exact incidence and prevalence of ALI
and ARDS are unknown at present. Current reports put
the number somewhere in the range of 150,000 cases 
in the USA or an estimated incidence of 75 cases per
100,000 population.
An American–European consensus conference has
recently defined ALI and ARDS in an attempt to remove
confusion related to terminology. This common language
will allow investigators to evaluate and treat the same
disorders and will greatly decrease confusion in the 
literature. Many investigators consider ALI and ARDS to
represent a manifestation of a systemic disorder that arises
from exaggerated proinflammatory pathways, culminat-
ing in the production of diffuse damage to the capillary
endothelial cell and/or the alveolar epithelial barriers. 
In an attempt to improve outcomes in patients with 
ALI and ARDS, clinicians have used both local and
systemic therapies to improve survival (Box 16-1).
RISK FACTORS
It has been recognized that ALI and ARDS may arise in
association with a number of different clinical conditions.
In reviewing the causes, sepsis continues to be the most
commonly encountered factor: approximately 5–40% of
septic patients develop ARDS. Shock, pneumonia, and
the systemic inflammatory response syndrome (SIRS) are
the most common risk factors. Other frequently encoun-
tered risk factors include multiple transfusions, aspiration
injury, near drowning, pancreatitis, trauma, and many
others. These clinical risk factors are synergistic, and
when more than one of the clinical risk factors is present,
the likelihood of ARDS is greater than the sum of the col-
lective risk factors. Another major risk factor that has only
recently come to light is the improper use of mechanical
ventilation. Certain ventilator settings may lead to the
development of ARDS. This so-called ventilator-induced
lung injury (VILI) is highly important in that it may be
preventable (Box 16-2).
CLINICAL MANIFESTATIONS
The initial clinical presentation may vary, primarily
reflective of the underlying disease process and the 
overall condition of the patient. However, when ARDS
becomes apparent the patient notes a significant distress
associated with dyspnea and tachypnea and an increased
work of breathing. Hypoxia is noted on the pulse oximeter
or on the arterial blood gas (ABG).
The hallmark of ARDS is the presence of hypoxemia
despite the administration of high concentrations of
inspired oxygen, evidence of increasing shunt fraction, 
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a decrease in compliance, and an increase in dead space
ventilation. A chest radiograph in both ALI and ARDS
shows the presence of diffuse bilateral pulmonary infil-
trates. Chest computed tomography has been very help-
ful in elucidating that the injury is not homogeneous and
has predominance in the dependent portions of the lung.
The precipitating injury need not directly involve the
pulmonary system but can be triggered by other insults.
For classification we separate the causes into pulmonary
and extrapulmonary. There is some evidence that there
is a difference in the mortality and morbidity based on
whether the cause is pulmonary or extrapulmonary. The
treatment may also be different (Box 16-3).
It is important to remember that ALI and ARDS is a
clinical syndrome, and the diagnosis is made clinically
using the consensus conference definition as a guide 
and not on a single radiograph, ABG measurement, or
laboratory tests.
PATHOLOGIC MANIFESTATIONS
Alveolar type I cells compose the major gas exchange
surface of the alveolus and are integral to the mainte-
nance of the permeability barrier function of the alveo-
lar membrane. Type II pneumocytes are the progenitors
of type I cells and are responsible for surfactant produc-
tion and homeostasis. During ALI and ARDS there is dam-
age to the capillary endothelial and alveolar epithelial
cells. This leads to cellular injury and alteration of the
normal barrier function results in a permeable defect
that gives way to flooding of the alveoli with protein-rich
fluid and inflammatory cells. This results in the alteration
of pulmonary mechanics, physiology, and gas exchange.
One of the most important changes is alteration of
alveolar surfactant that results directly from the damage
to the type II pneumocytes and from the inactivation
and dilution of alveolar surfactant from the protein and
fluid that may enter into the alveolar space. Surfactant
dysfunction can lead to atelectasis and a further reduc-
tion in pulmonary compliance (resulting in bilateral
chest infiltrates and disturbances in gas exchange).
Pathophysiology
The complex pathophysiologic process that culmi-
nates in the production of ALI and ARDS involves a deli-
cate balance between the body’s proinflammatory and
anti-inflammatory responses to the inciting clinical
event. This complex balance may also be genetically
mediated in that some patients will release higher levels
of cytokines when challenged by a stimulus. This cellu-
lar mediation is under active investigation and may be an
avenue of therapy in the future (Box 16-4).
Box 16-1 American–European
Consensus Conference
Definition of ALI and ARDS
Acute lung injury
● Acute onset of respiratory failure
● Bilateral chest infiltrates on chest x-ray
● Absence of elevated left heart pressure, no evidence
of heart failure (pulmonary artery occlusion
pressure (PAOP) < 18 mmHg)
● PaO2/FIO2 < 300 mmHg
Acute respiratory distress syndrome
● Acute onset of respiratory failure
● Bilateral chest infiltrates on chest x-ray
● Absence of elevated left heart pressure, no evidence
of heart failure (PAOP < 18 mmHg)
● PaO2/FIO2 < 200 mmHg
Box 16-2 Common Risk Factors 
for ARDS
● Sepsis and SIRS
● Pneumonia
● Prolonged hypotension and shock
● Trauma (long-bone fractures, lung contusion, 
fat embolism)
● Pancreatitis
● Near drowning
● Multiple emergency blood product transfusions
● Disseminated intravascular coagulation (DIC)
● Burn injury
● Postcardiopulmonary bypass
Box 16-3 Common Pulmonary and
Extrapulmonary Causes of ARDS
Direct pulmonary causes
● Pneumonia
● Acid aspiration
● Inhalation lung injury
● Chest trauma
● Near drowning
Extrapulmonary causes
● Sepsis, SIRS
● Shock, hypotension
● Pancreatitis
● Trauma
● Massive transfusion therapy
● Burns
● Postcardiopulmonary bypass
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MANAGEMENT
The mainstay of management of patients with ALI and
ARDS has been predominantly one of support. Although
hypoxemia is the key feature of ARDS, mortality is pre-
dominantly due to multiple organ failure (MOF) and
sepsis. The high mortality rates in patients with this
condition have prompted active investigation into the
physiologic processes involved in the production and
propagation of the injury. Initial attention most be
directed toward the underlying clinical condition.
If there is an active infection then antimicrobial agents
should be started and hemodynamic support provided.
Hypotension and anemia should be corrected. The cor-
nerstone still is the provision of good mechanical venti-
latory support. Recent data from several clinical trials
report significant survival benefit from a lung protective
ventilatory support protocol.
Use of nonprotective ventilatory support strategies
may have a role in a persistent proinflammatory response
and the development of multiple organ dysfunction 
syndromes (MODS) and/or MOF. The cyclic opening and
closing of alveoli in nonrecruited lung adds to the surfac-
tant dysfunction. This may add to the loss of compartmen-
talization of the lung and transmigration of cytokines and
infectious agents into and out of the lung. This in turn
may lead to further complications and a poor outcome.
Ventilator-Induced Lung Injury
Over the last few years there has been a growing con-
cern that the ventilatory support strategy in the manage-
ment of patients with ALI and ARDS may augment the
lung injury and impair the healing process. The Acute
Respiratory Distress Syndrome Network (ARDS-NET) has
been in the forefront of investigating aspects of mechan-
ical ventilation. One very important finding was that 
in patients with ALI/ARDS mechanical ventilation with
lower tidal volumes (5–7ml/kg) than those traditionally
used (10–12 ml/kg) resulted in decreased mortality and
increased the number of days without ventilator use.
Several other ongoing investigations have evaluated
other aspects of mechanical ventilation and how they affect
the lung. Investigators have found that cytokines and
vasoactive substances are released with nonphysiologic-
based modes of ventilation.
Open Lung Strategy
The repetitive recruitment/derecruitment of distal 
airways and alveoli has been shown to produce many
physiologic affects. It cannot only produce shear forces
secondary to large changes in pressure (ΔP) since the set
tidal volume may be too high when given to a lung with
atelectasis and decreased volume (functional residual
capacity, FRC) but also can activate various mediators to
be released that affect not only the lung but may trigger
systemic effects and lead to MODS. These closed alveolar
beds may also affect surfactant and produce more atelec-
tasis and loss of barrier function. Therefore it is important
for the clinician to recruit lung at the onset of mechanical
ventilation and prevent it throughout mechanical venti-
latory support.
Open Lung Concept
The law of Laplace links the pressure at the alveolar
level to the surface tension and radius. In healthy indi-
viduals surfactant minimizes the surface forces and thus
ensures alveolar stability at all alveolar sizes. During lung
injury, all lungs present with some level of surfactant
dysfunction, the degree of dysfunction determining the
amount of pressure needed to expand the alveoli from a
state of small radius (volume) to large radius (volume).
It can further be derived from these laws that the pres-
sure necessary to keep alveoli expanded is small at a
high FRC, since FRC is directly correlated to the amount 
of open lung units and their size. If we apply a peak 
pressure (PIP) of 40–60 cmH2O for ten breaths and then
splint the lung open with either elevated positive 
Box 16-4 Potential Mediators of ALI
● Polymorphonuclear leukocytes (PMLs)
● Leukotrienes
● Cytokines (interleukins 1, 2, 6, 8, 15; tumor necrosis
factor (TNF); granulocyte colony-stimulating factor
(GCSF))
● Platelet-activating factor (PAF)
● Toxic oxygen metabolites
● Endorphins
● CD-14
● Plasminogen activator inhibitor
● Vasoactive neuropeptides
● Histamine and serotonin
● Tissue macrophages and monocytes
● And many others currently under investigation
CLINICAL CAVEAT
Ventilatory Management of ALI and ARDS
Start with a lung recruitment maneuver, use tidal
volumes of 5–7 ml/kg, use a pressure control mode, and
support the recruited alveoli with proper levels of PEEP.
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end-expiratory pressure (PEEP) or inverse ratio ventila-
tion, we will stabilize the alveoli at a better position in the
pressure/volume curve (Box 16-5). (See also Chapter 17.)
Experimental Therapies
In the 1990s a plethora of clinical trials were con-
ducted to evaluate a host of “antimediators” that have
targeted the potential proinflammatory compounds that
can be identified in the blood or the lung in ARDS
patients. However, to date there has not been major 
success for these compounds. However, many more
compounds are under investigation.
Antioxidant therapy has also been under investigation.
The agents vitamins C and E, procysteine, β-carotene, and
N-acetylcysteine have been used in several ARDS trials. No
survival benefit was found with any of these compounds.
As regards inhalation of nitric oxide (NO), several
pilot studies showed a degree of success with this agent.
Two large multicenter trials, however, did not show any
benefit in survival with NO, but did show increases in
oxygenation in the short term. Several centers still use
this agent as a bridge therapy in critically ill patients.
Positioning is an important adjunct therapy; patients
with ARDS may improve their oxygenation abnormality
when they are placed in the prone position. This
improvement is marked in patients with ARDS triggered
from primary lung injury and may not be as marked in
patients with ARDS triggered from a distal focus (non
lung). Although placing the patient in the prone position
results in improvement of oxygenation, it is important to
remember that there are potential complications that
result from this position. To date no randomized con-
trolled trials have demonstrated an improvement in
mortality associated with the prone position.
An old therapy that has resurfaced in the treatment of
ARDS is the use of corticosteroids. Several reports have
shown improvement in the repair phase of ARDS (fibro-
proliferative phase) with the use of steroids. This hypoth-
esis is currently under evaluation by the NIH-sponsored
ARDS-NET.
Since many of the problems associated with ALI/ARDS
are triggered by injury to the surfactant system, there is
now great interest in surfactant replacement therapy.
The use of surfactant has been life saving in neonates so
there may be a reason to use it in adults. Several ongoing
studies are currently underway to evaluate several differ-
ent surfactant preparations. This is a highly interesting
avenue of investigation and may hold some promise in
that this therapy is physiologically based.
CONCLUSIONS
ALI/ARDS continues to be a major problem in the ICU
and generates a high level of mortality. It is important for
the clinician to understand the underlying pathophysiol-
ogy to develop treatment protocols in the management
of these patients. Improvement in our understanding of
mechanical ventilation may play an important role in
decreasing mortality and time on mechanical ventilation.
Lung recruitment and the prevention of VILI are at the
forefront of treatment for this condition.
There are currently many investigations into the triggers
of this condition and how they can be controlled. These
investigations not only will generate new treatments but
will also add to our understanding of the physiology of
the lung.
Box 16-5 Lung Opening Procedure (LOP)
● Set ventilator in pressure control mode
● Recruit with PIP of 40–60 cmH2O (higher may be
necessary with more injured lungs) for 10 breaths
● Splint the lung with PEEP set to the infection point
(usually 10–15 cmH2O)
● Adjust PIP down to lowest PIP to deliver 5–7 ml/kg
tidal volume
● Titrate ventilator PIP and PEEP to give the smallest
change in pressure (ΔP)
CASE STUDY
ARDS in a Patient with Pneumonia
A 67-year-old presents to the ICU in respiratory
distress, oxygen saturation of 85, and respiratory rate
of 40. Due to the increased work of breathing the patient
is electively intubated. A chest film shows bilateral
infiltrates, ABG shows a PaO2 of 67 on a FIO2 of 100%.
The patient had a five-day history of flu-like syndrome
at home and developed a fever and chills prior to
coming to the hospital. The patient’s medical history is
only positive for hypertension under good control with
a β-blocker. The patient had traveled to Hong Kong the
previous week. The patient was placed on pressure
control mode and a LOP was done with a PIP of
60 cmH2O for 10 breaths, and then the PIP was reduced
to a pressure to generate tidal volumes of 6 ml/kg after
the PEEP was set to 12 cmH2O. The FIO2 was rapidly
titrated down. The patient grows out a staph species
from the sputum and was started on Gram-positive
antibiotic coverage, and was SARS negative. Over three
days the patient stabilized and was weaned off the
ventilator using a pressure support wean. The patient
was extubated on day four but did require a BIPAP
mask for 24 hours to decrease work of breathing. On
day five the patient was transferred to a general ward
and was discharged home on day eight in no distress.
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Conclusions
Mechanical ventilation is the most common mode of
life support in both the operating theatre and in the
modern intensive care unit (ICU). It is present in all
types of critical care units from postoperative units, sur-
gical ICUs, trauma ICUs, medical ICUs, burn units, wean-
ing centers, and neurologic/neurosurgical ICUs. Positive
pressure mechanical ventilation became a standard tech-
nique for mechanical ventilation during the polio epi-
demic of the 1950s. As more and more complex patients
survive resuscitation and are admitted to ICUs the level
of ventilation required becomes more complex. Rapid
and proper titration of mechanical ventilation plays an
important role in many aspects of patient care. While the
use of mechanical ventilation to treat acute or chronic
respiratory failure has historically been important, inter-
active and noninvasive modes of ventilation are allowing
more therapeutic options for many more types of
patients and forms of respiratory failure. Advances in
ventilator technology with the introduction of computer
control and feedback coupled with improved monitoring
tools and a growing understanding of respiratory physi-
ology have led to an explosion in our ability to care for
patients. One of the most important advances is a grow-
ing knowledge of how the ventilator affects both normal
and abnormal physiology. We have gained an under-
standing that mechanical ventilation plays an important
role in the modulation of the inflammatory system and
the release of cytokines and other vosoactive substances.
Anesthesiologists have added considerably to the 
literature of mechanical ventilation with their ability to
see the effect of mechanical ventilation from the operat-
ing theatre to the postoperative unit especially during
extensive surgical procedures.
This experience has allowed us to better understand
the physiology of patients on ventilators and affect
changes in their therapy.
Mechanical ventilation can also affect metabolism and
with the delivery of oxygen both in healthy and unstable
patients we can affect increases in oxygen delivery to
organ systems and help in the regulation of the acid–base
status. It can allow us to provide proper levels of pain
control and sedation. Mechanical ventilation is therefore
central in rational, effective, safe, and compassionate
management.
INDICATIONS
Perhaps the most frequent application of mechanical
ventilation is as a supportive therapy for respiratory 
failure. Respiratory failure is commonly classified into
acute or chronic and these classes are then subdivided
into inadequate oxygenation, inadequate ventilation, or
both (Table 17-1).
The most important parameter to start mechanical
ventilation is close observation of the patient and the
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evaluation of the work of breathing. It does not require
any equipment but does require a degree of clinical
experience.
The range of acceptable blood gas values can vary
widely, depending on the disease process causing respi-
ratory failure and age. However, institution of mechanical
ventilation is usually indicated before the development of
laboratory values that demand immediate intubation and
mechanical ventilation. The decision both to initiate and
to discontinue mechanical ventilation is therefore a clin-
ical judgment, made on the basis of careful evaluation of
the patient and consideration of blood gas and metabolic
abnormalities.
A general rule of thumb can be used to evaluate labora-
tory data, a PaO2 < 60 mmHg (oxygen saturation <90%) on
maximal oxygen supplementation, progressively increas-
ing PaCO2 values, and an acute respiratory acidosis with
pH values below 7.25. Also other data such as worsening
arrhythmias, hemodynamic instability, and decay 
in mental status all can suggest the need for mechanical
ventilation and may stave off clinical deterioration.
Respiratory parameters that may act as a guide are respira-
tory rate above 30, tidal volume below 4 ml/kg, and a vital
capacity below 15 ml/kg with subjective respiratory 
distress, which all suggest a need for respiratory support
(Table 17-2).
MANIPULATION OF PaCO2
In many situations mechanical ventilation is instituted
in the absence of respiratory failure. The use of positive
pressure ventilation to induce hypocarbia for the pur-
pose of decreasing intercranial pressure (ICP) is a com-
mon therapy. This technique is useful both in neurologic
and neurosurgical patients. Hyperventilation for the
acute control of increased ICP is still the only emergent
technique for patients at risk for herniation. It is however
not useful after the acute phase.
PATIENTS REQUIRING SEDATION
In many surgical patients mechanical ventilation is
required for postoperative care secondary to large fluid
shifts, unstable vital signs, and a marked metabolic aci-
dosis (lactate levels > 5). Patients in need of interaortic
balloon pumping or the use of ventricular assist devices
postcardiac surgery require sedation and mechanical
ventilation. Massive trauma patients with unstable frac-
tures, closed head injuries, or who require management
of an open abdomen will need sedation titrated and 
ventilatory management secondary to these agents. Burn
patients are another group who due to large amounts of
narcotics and complex wound care may need several
days of mechanical ventilation.
Table 17-1 Classification of Acute 
Respiratory Failure
Failure of oxygenation (hypoxemia)
Pneumonia
Hydrostatic pulmonary edema
Exacerbation of asthma
Pulmonary embolus
Failure of ventilation (hypercapnia)
Hypoventilation
Reduced respiratory drive
Drug intoxication
Head trauma, cerebral vascular accident
Impaired respiratory pump function
Respiratory muscle fatigue
Neuromuscular disease
Chest wall trauma/deformity
Increased dead space
Emphysema
Pulmonary embolus
Cystic fibrosis
Increased CO2 production
Increased work of breathing (any cause)
Fever
Excessive carbohydrate intake
CLINICAL CAVEAT
Indication for Ventilator Support
Even with perfect blood gases, if a patient is working
hard they will need a level of ventilatory support.
CLINICAL CAVEAT
Heavy Sedation
If it is believed a patient will need heavy sedation or
large dosages of narcotics it is best to electively intubate
and mechanically ventilate them.
Table 17-2 Clinical Parameters Associated 
with Respiratory Failure
Respiratory Respiratory
Parameter Usual Range Failure
Respiratory rate (breaths/minute) 12–25 >30
Vital capacity (ml/kg) 30–70 <15
Tidal volume (ml/kg) 5–8 <3–4
Oxygenation, PaO2 (mmHg) 75–100 <60
Ventilation, PaCO2 (mmHg) 35–45 >55 (see text)
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A large group of patients in all ICU environments
needing a large amount of sedation that may cause res-
piratory depression are patients with complex histories
of psychiatric disorders or patients that are withdrawing
from drugs and alcohol. These patients may harm them-
selves and others if not acutely medicated.
BASIC MODES OF MECHANICAL
VENTILATION
As ventilator technology has progressed, the ways of
delivering positive pressure ventilation have proliferated.
In daily practice, however, four basic modes of positive
pressure ventilation are most commonly used. These
modes can be classified on the basis of how they are trig-
gered to deliver a breath, whether these breaths are tar-
geted to a set volume or pressure, and how the ventilator
cycles from inspiration to expiration (Table 17-3).
CONTROLLED MECHANICAL
VENTILATION
Controlled mechanical ventilation (CMV) is the most
common mode of ventilation in the patient under gen-
eral anesthesia in the operating theater. It is an excellent
starting block for the understanding of mechanical ven-
tilatory parameters. CMV or volume control (VC) was
the first volume-targeted mode. It is a pure “control”
mode; that is, the minute ventilation (VE) is completely
governed by the machine (VE = tidal volume (TV) × res-
piratory rate). The physician sets the respiratory rate,
TV, inspiratory flow rate, ratio of inspiratory to expira-
tory time (I:E), positive end-expiratory pressure (PEEP),
and the level of inspired oxygen (FIO2). In VC, the
patient is unable to trigger the ventilator to deliver addi-
tional breaths. This works well with patients under gen-
eral anesthesia, unresponsive, or heavily sedated, but not
for conscious patients, whose respiratory efforts are not
sensed by the ventilator, which leads to patient discomfort
and increased work of breathing. As a result, this mode has
been largely abandoned outside of the operating theatre.
ASSIST-CONTROL VENTILATION
This mode is similar to VC mode except that the ven-
tilator senses respiratory efforts by the patient. As in VC,
the physician sets a respiratory rate, TV, flow rate, I:E
ratio, FIO2, and PEEP. Breaths are delivered automatically,
regardless of the patient effort (“control”). In assist-
control (AC), however, the ventilator detects the
patient’s effort and responds by delivering a breath iden-
tical to the controlled one (“assist”). The patient can
therefore breathe faster than the back-up rate, but all
breaths have the same tidal volume, flow rate, and inspi-
ratory time. Hence AC mode allows better synchrony
between patient and ventilator than VC mode, while still
providing baseline minute ventilation. A better descrip-
tive and accurate name for this mode is “volume-targeted
assist-control ventilation.”
Like all modes of mechanical ventilation, AC has sev-
eral disadvantages. If the back-up respiratory rate is set
too far below the patient’s spontaneous rate, exhalation
time progressively decreases, since the inspiratory time
is fixed by the back-up rate and flow rate. In the extreme
example, this may results in inadequate time for exhala-
tion. As a result, lung volume remains above functional
residual capacity (FRC), and a process called dynamic
hyperventilation occurs. This increased lung volume is
associated with elevation in the alveolar pressure at end-
exhalation, or “auto-PEEP.” Another problem occurs when
patients with high minute ventilation requirements make
persistent efforts while a breath is being delivered. If this
effort is strong enough, the patient may trigger the ven-
tilator again, a phenomenon known as “breath stacking.”
This can cause wide swings in airway pressure and
Table 17-3 Mechanical Functions in Positive Pressure Ventilators
Mode Initiation Limit Cycle
VOLUME PRESET
Controlled mechanical ventilation Time Volume Volume/time
Assist-control ventilation Pressure Volume Volume/time
Intermittent mandatory ventilation Time Volume Volume/time
Synchronized intermittent mandatory ventilation Time/pressure Volume Volume/time
PRESSURE PRESET
Pressure-support ventilation Pressure Pressure Flow
Pressure-control ventilation Time Pressure Time
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increase both the risk of barotrauma or biotrauma
(ventilator-associated lung injury). Finally, in volume-
targeted modes, the inspiratory rate is fixed. Many
acutely ill patients strive for high inspiratory flow rates.
If ventilator-delivered airflow is below patient demand,
the work of breathing increases as the patient makes
further futile efforts to augment inspiratory flow.
INTERMITTENT MANDATORY
VENTILATION
In the early 1970s a new mode of partial ventilatory
support, intermittent mandatory ventilation (IMV), was
developed to facilitate weaning, the transition from
mechanical support to normal spontaneous breathing.
This mode has become very popular in the USA as a
support mode.
The IMV mode delivers positive pressure mechanical
breaths at a preset rate and allows spontaneous, unas-
sisted breaths between mechanical breaths. It is time ini-
tiated, volume limited, and cycled by volume or time to
provide mechanical breaths. To assist any spontaneous
ventilation between mechanical breaths the ventilator
has a secondary source of gas flow. This utilizes continu-
ous gas flow within the circuit or has a demand valve that
opens to allow gas to flow from a reservoir. Continuous
gas flow at a rate greater than peak inspiratory flow rate
imparts no additional work of breathing to the patient
and requires a great volume of fresh gas flow to be used.
The demand valve system, although more efficient in the
conservation of fresh gas flow, imparts a significant work
of breathing.
SYNCHRONIZED INTERMITTENT
MANDATORY VENTILATION
Like AC mode, synchronized intermittent mandatory
ventilation (SIMV) is also a volume-targeted mode and
provides a guaranteed VE. For the mandatory breaths,
tidal volume and respiratory rate are chosen, guarantee-
ing baseline minute ventilation. The practitioner also
sets FIO2, PEEP, and flow rate as with other modes. SIMV
is similar to IMV with the addition of computer control
to synchronize mechanical breaths with spontaneous
efforts to reduce the likelihood of breath stacking. If a
sufficient effort occurs shortly before the mandatory
breath is delivered (a time interval known as the “syn-
chronization period”) a breath identical to the manda-
tory breath is delivered. If a patient effort occurs outside
this synchronization period, the airway pressure, flow
rate, and tidal volume are purely patient-generated, and
the ventilator provides no assistance. While this reduces
the likelihood of air trapping and breath stacking, it can
increase the work of breathing. An interesting factor is if
the mandatory respiratory rate is less than approximately
80% of the patient’s actual rate, the high level of work
expended during the spontaneous breaths will also be
expended during the mandatory breaths. This is based
due to the physiology of the respiratory center in the
brain, which has a lag time and is unable to alter its output
on a breath-to-breath basis. So if high neurologic output is
required for a significant percentage of breaths, that same
output will be given for all breaths including the artificial
breaths delivered by the ventilator. Therefore, attempting
to “exercise” the respiratory muscles by setting the SIMV
rate at half of the patient’s spontaneous rate is counter-
productive, because it simply increases the work of
breathing and results in respiratory muscle fatigue and
may result in weaning failure (Box 17-1).
SIMV is the most commonly used mode of mechanical
ventilation for uncomplicated patients who require only
short periods of support. The pure use of volume-cycled
ventilation may not be ideal for long-term support and in
patients with complex problems such as acute respira-
tory distress syndrome (ARDS). In weaning this mode
should be married to pressure-support ventilation,
which is discussed later.
Box 17-1 Synchronized Intermittent
Mandatory Ventilation
● Volume-controlled mode in which operator sets TV,
flow rate, and respiratory rate.
● Mandatory breaths are positive pressure breaths that
provide full ventilatory assistance and deliver the 
set TV; the patient does not control TV during
mandatory breaths.
● Mandatory breaths are either time-triggered or 
synchronized to patient triggering.
● Spontaneous breaths are allowable between 
mandatory breaths, but patients receive no positive
pressure assistance during spontaneous breaths.
● Provides preset ventilatory backup to guarantee 
minimum VE.
CLINICAL CAVEAT
The Work of Breathing
The most important factor that leads to proper
patient–ventilator synchronization is properly
supporting the patient’s spontaneous breathing. 
Proper support leads to decreased work of breathing.
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PRESSURE-CONTROL VENTILATION
A more accurate name for pressure-control ventilation
(PCV) mode is “pressure-targeted assist-control ventila-
tion.” The mode is similar to AC mode described above,
except that a defined inspiratory pressure (IP) is set,
instead of a tidal volume. This allows absolute control over
peak pressure source. Pressure control is a more natural
form of artificial ventilation in that it mimics the natural
way we breathe. The basic setting are similar to AC: res-
piratory rate, I:E ratio, FIO2, PEEP, and trigger sensitivity.
Inspiratory flow rate is not fixed in PCV. It varies with
IP, inspiratory time, respiratory mechanics, and patient
effort. This can be advantageous, because flow rate
increases with patient effort, unlike the volume-targeted
modes, in which flow rate is fixed. Therefore patients
with high-ventilation requirements may feel more com-
fortable on PCV, because they can regulate and increase
flow as needed. This variable flow rate has another
potential advantage: the flow pattern changes as respira-
tory system compliance decreases as inflation proceeds
and compliance decreases. The major down side of this
mode is that if compliance changes the TV delivered are
variable. Therefore TV changes and can be either too
high or too low to meet patient demands. To combat this
newer more complex ventilators have created an ability
to maintain set TV in pressure-control mode.
PRESSURE SUPPORT
Pressure support ventilation (PSV) is a pressure-trig-
gered mode in which the patient’s inspiratory effort is
supported by a preset inspiratory pressure (in the usual
range 5–15 cmH2O). Inspiration is initiated by the
patient and is terminated when the flow falls below a
specific level. In this mode the patient determines the
respiratory rate, inspiratory time, and TV. Unlike the pre-
vious modes PSV assists only breaths initiated by the
patient. Therefore, patients with unstable respiratory
function or respiratory drive may not be adequately ven-
tilated with pressure support alone. Patients who are
heavily medicated with narcotics and sedatives may not
benefit from this mode alone.
In theory since the patient controls the rate, length,
depth, and flow profile of each breath, it has been
claimed that PSV is more comfortable than other modes
of ventilation. Even at low levels, PSV improves the effi-
ciency of spontaneous respiratory rate, more efficient
muscle activity, and less oxygen consumption.
PSV may be used solely to overcome the work of
breathing imposed by the endotracheal tube and ventila-
tor circuit (specific values vary from machine to machine
but a range is 8–10 cmH2O). If a patient is doing well at
a low level of PSV it may be predictive that the patient
will do well with extubation. PSV is used in combination
with other modes to provide patient comfort, decrease
work of breathing, and affect weaning outcome.
NEW MODES OF VENTILATION
In recent years more complex ventilators have been
introduced to better support a growing number of
patients with complex lung mechanics. With the addi-
tion of microcomputers and feedback loops in ICU 
ventilators they are better able to control and support
respiratory parameters that were manually adjusted only
a few short years ago. It is hoped that this technology
will aid in the management of patients and also reduce
ventilator-induced lung injury (VILI). Some of these
modes build on the basic modes of pressure control and
assist control by providing technologic advances that
correct the limitations that they have historically had.
Pressure-Regulated Volume Control
Pressure-regulated volume control (PRVC) is a mode
that is a combination of decelerating flow of pressure
control with volume guarantee. This mode allows for
nearly continuous monitoring of lung mechanics.
Inspiratory pressure is regulated to a value based on the
volume–pressure calculation of the previous breath
compared with the preset target volume. As compliance
changes, the pressure is regulated to the lowest possible
limit as long as the target pressure is reached.
Pressure-Controlled Inverse Ratio
Ventilation
To prevent gas trapping, at least as much time is
allowed for exhalation as for inhalation; however, for
certain patients, gas exchange may improve markedly
when the ratio is extended to values greater than 1:1.
This mode is usually only used in patients with severe
respiratory failure, hypoxemia, and ARDS. Pressure-
controlled inverse ratio ventilation (PCIRV) is currently
CLINICAL CAVEAT
Pressure Support
Most patients on artificial mechanical ventilation
will need the addition of pressure support to provide
patient comfort and aid in weaning. Pressure support 
is also used to counteract the resistance of endotracheal
tubes and decrease the work of breathing in spontaneous
breaths.
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used as a technique of last resort but may have a role in
the earliest phase of lung failure when lungs are most
recruitable. It may be important to decrease cyclic open-
ing and closing of alveolar units and play a role in lung
protection by keeping recruited alveoli open, thereby
decreasing shear forces.
Airway Pressure-Release Ventilation 
and Biphasic Airway Pressure
Airway pressure-release ventilation (APRV) and biphasic
airway pressure (BiPAP) can be thought of as variants 
of IRV intended for use with spontaneously breathing
patients. BiPAP is widely used to support patients with
sleep apnea and also used with success in patients prone
to atelectasis. It has been found useful in trauma patients
with multiple broken ribs from developing pneumonia.
This mechanism is used to provide added ventilatory
support for patients who need continuous positive air-
way pressure (CPAP) for oxygenation but cannot provide
adequate ventilatory drive without machine assistance.
Both APRV and BiPAP allow ventilatory efforts around
CPAP. It allows for depressurization of the system, either
partially or completely, for short periods at a set frequency.
After this release, fresh gas enters until pressure equals the
set upper limit. BiPAP differs from APRV in that it allows
for an option to have the patient breathe for extended
periods of time spontaneously at either level of pressure.
As with IRV, these modes may generate sustained
higher mean airway pressure, which may exert traction.
The efficacy of pressure-release cycles depends on the
duration of the release, the mechanical properties of the
chest, the level to which airway pressure is allowed to
fall, and the cycling frequency between the two pressure
baselines.
A problem with these systems is that as ventilatory
support increases; mean airway pressure falls decreasing
some of the oxygen-exchange advantages of the higher
CPAP levels. This mode may not be useful for patients
with significant airflow obstruction or greatly reduced
lung compliance.
Jet Ventilation, High Frequency
The goal of high-frequency ventilation (HFV) is to
effect oxygenation and ventilation at relatively low peak
pressure, thereby minimizing trauma due to higher inspi-
ratory pressure and volume. Tidal volumes that approxi-
mate to or are less than anatomic dead space may be
used. Distinct types of HFV include high-frequency jet
ventilation (HFJV) and high-frequency oscillation (HFO).
In general, sedation analgesia and neuromuscular block-
ade are maintained during the use of these modes to pre-
vent spontaneous breathing and maximize the efficiency
of these techniques.
HFO is currently the most used in the ICU. HFO 
can recruit lung units by employing mean airway pres-
sures equal to or greater than conventional ventilation
without exposing the lung to comparably high peak 
pressures. HFO has been associated with decreased inci-
dence of barotrauma in patients requiring high levels of
support. Despite enormous interest these modes have
not replaced more conventional modes of ventilation
(Box 17-2).
HOW TO SET THE VENTILATOR
The way one initially sets the ventilator will play an
important role in patient care and will affect patient
physiology. There is much evidence that the mode and
style of artificial ventilation will affect not only patient
comfort but also time of support. The settings may pro-
duce volume and pressure trauma if improper levels of
tidal volume and pressure are set. There is growing evi-
dence that the initial tidal volume can affect morbidity
and mortality. Atelectasis and alveolar collapse can affect
levels of surfactant in the lung and also be important in
the release of cytokines and the transmigration of bacte-
ria both into and out of the lung. So a rational approach
must be taken when treating patients with respiratory
failure who are admitted to the ICU (Box 17-3).
The use of ventilator graphic displays has greatly
improved monitoring of  lung function. These flow vol-
ume loops give us the ability to evaluate lung compliance,
set levels of PEEP, evaluate I:E ratios, and titrate ventilator
support with clear end points.
Box 17-2 Mode of Ventilation
The mode of ventilation used should be
individualized to specific patient’s needs. The primary
goal should be to recruit lung affected by atelectasis
and prevent further collapse.
Box 17-3 Basic Ventilator Settings
● Set the FIO2 to 100%
● Set a tidal volume of 5–7 ml/kg
● Set a rate of 14
● Use a pressure-control mode
● Set the PEEP to 10 cmH2O or best PEEP if one has
pressure/volume graphics
● Get an arterial blood gas on these settings after 
15 minutes and adjust oxygen and rate as needed.
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Traditional approaches to mechanical ventilation used
tidal volumes of 10–15 ml/kg body weight. Since 2000 a
large multicenter trial, the Acute Respiratory Syndrome
Network, has challenged this common practice. The find-
ings showed that patients fared better when placed on
normal physiologic tidal volumes of 5–7 ml/kg body
weight. This so-called low tidal volume ventilation again
points out that even the basic concepts of mechanical
ventilation need to be studied.
It is best to start to place the patient on a FIO2 of 100%
on arrival to the ICU as a baseline to evaluate the patient’s
lung physiology. The level of hypoxia can also be evalu-
ated at this time. The level of shunt can also be rapidly
evaluated at this level of oxygen. This data will also allow
the practitioner to decide if lung recruitment is necessary.
The use of PEEP to allow recruited alveolar beds to remain
open can also be elucidated from the baseline arterial
blood gas that is used on this concentration of oxygen.
TITRATION OF POSITIVE 
END-EXPIRATORY PRESSURE
PEEP refers to pressure in the airway at the end of
expiration that exceeds atmospheric pressure. The term
is applicable to patients receiving mechanical ventilation.
For spontaneously breathing subjects, the term CPAP is
used when inspiratory and expiratory portions of the 
circuit are pressurized above atmospheric pressure.
PEEP is used mainly to stabilize lung units and improve
oxygenation in patients with hypoxia and replicate normal
lung physiology (Box 17-4).
PEEP can be titrated best through the use of the
pressure–volume curve using inflection points. The ideal
point is between the lower and upper inflection where
lung compliance is maximal. Airway pressures below the
lower inflection point are associated with low compli-
ance, alveolar collapse, and atelectasis. At airway pres-
sures above the upper inflection point, compliance also
decreases, the limit of lung distention is approached,
and the risk of barotrauma is high but oxygenation is
best. A good strategy for optimized mechanical ventila-
tion and PEEP is to select a PEEP level just above the
lower inflection point, and maintain plateau airway pres-
sures below the upper inflection point (Figure 17-1).
There is no evidence that PEEP levels below or equal
to 10 cmH2O will affect ICP in patients with head injury.
In patients with both acute lung injury and closed head
injury PEEP is titrated to maximize both oxygenation and
ICP pressure (Box 17-5).
One should monitor for auto-PEEP, or intrinsic PEEP,
which is due to inadequate time for lung emptying in the
setting of increased airway resistance and expiratory
flow limitation.
Adverse effects, especially in volume-targeted modes,
include increased work of breathing, risk of barotrauma
or volutrauma, and hemodynamic compromise. Auto-
PEEP should be monitored closely; the newer generation
of ventilators can provide automated assessment of auto-
PEEP (Box 17-6).
LUNG RECRUITMENT
Every effort should be made to ensure that there is no
atelectasis present in patients on artificial ventilation.
CLINICAL CAVEAT
Tidal Volume
The ventilator should be set with normal
physiologic tidal volumes of 5–7 ml/kg versus the
traditional 10–15 ml/kg.
Box 17-4 Key Effects of Positive 
End-Expiratory Pressure
BENEFICIAL:
● Usually improves oxygenation
● Stabilizes lung units
● Minimizes potential for ventilator-induced lung injury
ADVERSE:
● May worsen gas exchange
● Decreases preload thereby decreasing cardiac output
in patients with low intervascular volume
● Interferes with assessment of hemodynamic pressures
Figure 17-1 Calculation of inflection point.
The use of an open-lung strategy will not only improve
oxygenation but also may also decrease the levels of
cytokines and prevent the loss of surfactant. There is 
evidence that this strategy also prevents the transmigra-
tion of both cytokines and infectious agents across the
lung. This lung recruitment should be applied to all
patients no matter what mode of ventilation is applied
(Figure 17-2).
CONCLUSIONS
The management of mechanical ventilation is no
longer a hit-or-miss procedure but a therapy, which has
physiological end points along with the basic goals of
oxygenation and removal of carbon dioxide. Which ven-
tilator settings are chosen from the outset will have a
great impact on patient management. Proper settings
will allow for improved oxygenation on the lowest FIO2
with the least atelectasis. Proper titration will decrease
biotrauma and may affect cytokine levels thereby affect-
ing other organs. The proper settings will allow for the
patient to be rapidly weaned from the ventilator. The
physician should work with the respiratory therapists in
the ICU to manage the patient in an ongoing manner.
This is because a patient’s condition is ever changing and
may need adjustments throughout the day. The therapist
is also specially trained to manage the ever-advancing
technology of modern ICU ventilators.
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Box 17-5 Key Indications for Positive
End-Expiratory Pressure
● Acute lung injury and acute respiratory distress 
syndrome.
● Cardiogenic pulmonary edema.
● Atelectasis associated with severe hypoxemia.
● Other forms of severe hypoxemic respiratory failure.
Box 17-6 Treatment Strategies for
Minimizing Auto-Positive 
End-Expiratory Pressure in
Volume-Targeted Ventilation
● Aggressive bronchodilator therapy.
● Pain control, sedation; consider selective use of 
neuromuscular blockade.
● Minimize I:E; e.g., increase expiratory time and 
inspiratory flow rate, reduce tidal volume, reduce
respiratory rate.
● In selected cases, judicious application of (extrinsic)
PEEP will counter intrinsic PEEP and decrease the
work of breathing (asthma, chronic obstructive 
pulmonary disease).
● In some selected patients with severe lung injury
auto-PEEP can be used to advantage especially
patients where the strategy of PCIRV is used.
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Figure 17-2 Physiologic behavior of the alveolus. The pressure
(P)–volume (V) relation is displayed on X–Y axes. The status of the
bronchoalveolar unit is shown on the right-hand side. The arrows
show the direction from closed (bottom) to open (top). The ideal
alveolar status is IV or III.
CASE STUDY
Management of a Patient with Multiple Trauma
A 25-year-old man involved in a high-speed head-on
collision presents to the emergency room with acute
respiratory distress and abdominal pain. The patient
was intubated with in-line traction. Trauma evaluation
showed a right femur deformity, chest deformity, and
abdominal rebound. An emergent x-ray showed multiple
rib fractures bilaterally, a right femur fracture, and no
evidence of a spinal injury. A CT scan showed atelectasis
and a pulmonary contusion, and a grade II liver injury.
The initial blood gas on a FIO2 of 100% was a PaO2 of
64 and PaCO2 of 38. The patient was placed on pressure
control after a lung-opening procedure (LOP) with an
opening pressure of 60 cmH2O for ten breaths. The
pressure control was titrated to generate a tidal volume
of 6 ml/kg, a ventilatory rate of 14, and the initial PEEP
was set at 10 cmH2O. The repeat arterial blood gas was
now a PaO2 of 475 and a PaCO2 of 34. The FIO2 was
lowered to 50% and the rate decreased to 12. An epidural
catheter was placed for pain management and the
patient tolerated operative management of the fracture
on hospital day two without a problem. The patient
was weaned using pressure support over the course of
five days and was extubated without a problem. He
was transferred to general surgical ward on day six.
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Summary
A significant proportion of patients admitted to inten-
sive care units (ICUs) undergo intubation with mechanical
ventilation. The majority of such patients are extubated
quite readily. However, as many as 20% of mechanically
ventilated patients will fail their first attempt at weaning.
More than 40% of the time on mechanical ventilation is
spent trying to wean the patient from the ventilator. The
causes of prolonged ventilator dependency are listed in
Table 18-1. As mechanical ventilation is associated with
a host of complications, every effort should be made to dis-
continue mechanical ventilation as soon as the patient can
resume and sustain spontaneous ventilation. However,
choosing the appropriate time for discontinuation of
mechanical ventilation may prove difficult. If chosen too
early, severe cardiopulmonary decompensation may fur-
ther delay extubation. If chosen too late, the patient
remains at risk for ventilator-associated complications such
as pneumonia. Various clinical and laboratory factors used
to evaluate respiratory capacity have been used as predic-
tive factors in weaning. These are utilized in an attempt to
optimize weaning. This chapter reviews the causes of
weaning failure and an approach to liberating patients
from mechanical ventilation.
PATHOPHYSIOLOGY OF 
WEANING FAILURE
Weaning from mechanical ventilation depends on 
the strength of the respiratory muscles, the load applied 
to the muscles, and the central drive to breathe.
Respiratory failure may occur from any of these. For
example, Guillain-Barré syndrome can lead to muscle
weakness, acute bronchospasm to increased respiratory
load, and a narcotic overdose to a decreased central
drive. All of these may lead to respiratory failure. The 
factors of strength, load, and drive constantly interact.
Disorders may occur in isolation or in concert.
The relationship between respiratory load and muscle
strength can be viewed as a balance. If muscle strength
is too weak or load is too heavy, muscular contraction
cannot be maintained and the muscles acutely fail. 
This is termed fatigue. The dominant feature of the
pathophysiology of weaning failure is high levels of load
relative to the strength of the respiratory muscles. For
those who fail, as the weaning progresses, load increases
as compared to those who succeed with the weaning
trial. Almost always the drive to breathe is high in such
cases.
APPROACH TO WEANING FROM
MECHANICAL VENTILATION
The first step in weaning a patient from mechanical
ventilation is identifying and treating the process that
caused the patient to go on the ventilator in the first
place (Table 18-2). Common causes of respiratory failure
leading to mechanical ventilation include pneumonia,
sepsis, congestive heart failure, status epilepticus, and
major surgery. Major effort should be directed to reverse
this underlying process while ventilating the patient in a
nontoxic manner. It should be remembered that mechan-
ical ventilation is a supportive but not a therapeutic
endeavor.
Common problems found in weaning patients
include fluid overload, altered mental status, acid–base
changes, and electrolyte disturbances. These need to be
corrected if weaning is to be successful.
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Volume overload is common following treatment for
systemic inflammation in patients with severe infection
and major surgery. This extra volume leads to chest wall
edema and pulmonary edema with resultant reduction in
functional residual capacity and alveolar collapse. This
leads to ventilation/perfusion mismatch and shunting
with resultant hypoxemia and a need for increased posi-
tive end-expiratory pressure (PEEP) to keep alveoli open.
Generally, fluid is mobilized quite readily once the sys-
temic inflammation has been controlled; however, at
times diuretics are required to mobilize this extra fluid.
The etiology of altered mental status in mechanically
ventilated patients is often multifactorial. Causes of
altered mental status include pain, anxiety, and delirium,
as well as toxic/metabolic processes. Oversedation with
longer-acting sedatives has been associated with longer
time on mechanical ventilation. Many institutions have
developed guidelines to assist with sedative administra-
tion in mechanically ventilated patients in an attempt to
limit this possibility. Successful guidelines utilize a seda-
tion score (e.g., Ramsay scale) to direct bedside care-
givers to the goal of sedation and have automatic
reductions in sedation dosage (or hold orders) to limit
oversedation.
For otherwise stable weaning patients, their pH
should be normal (7.35–7.45). Acute illness and the ther-
apy of such can lead to alteration of pH, but this should
correct with the treatment of the underlying condition.
However, patients with chronic hypercapnia require
special mention. Minute ventilation delivered by the ven-
tilator should be adjusted to maintain the patient’s usual
arterial carbon dioxide level. If a patient with chronic
hypercapnia is lowered to the normal range during
mechanical ventilation, renal compensation by excretion
of bicarbonate occurs and pH normalizes. Subsequently,
when the patient resumes spontaneous breathing arterial
carbon dioxide tension increases and acute respiratory
acidosis may occur because the reduced bicarbonate
stores are inadequate for buffering.
Electrolyte disturbances can also adversely affect
weaning. Most notably hypocalcemia, hypophosphatemia,
and hypomagnesemia have been associated with weak-
ness, which can limit weaning. These disturbances must
be corrected prior to weaning attempts.
Malnutrition is particularly common in ventilator-
dependent patients. This has a variety of detrimental
effects on the respiratory system. On the other hand,
nutritional repletion has been shown to increase muscle
mass and decrease fatigability of nonrespiratory muscles.
Malnutrition produces a decrease in the ventilatory
response to hypoxia, a reduction in muscle mass, and a
loss of muscle strength and endurance. Host defense
compromise related to nutritional depletion may con-
tribute to pneumonia. For malnourished, critically ill
patients, nutritional supplementation has been shown to
increase patient inspiratory force. Several retrospective
studies suggest that appropriate nutritional support may
facilitate weaning. Controlled study is required to
address fully the role of nutritional support in facilitation
of weaning from mechanical ventilation.
Before weaning trials, airway secretions should be
suctioned and bronchodilators administered. Beneficial
effects of bronchodilators delivered via a spacer device
have been noted in patients being weaned from mechan-
ical ventilation regardless of whether the patient had
preexisting chronic airway obstruction.
Psychological considerations are also extremely
important in achieving a successful weaning outcome.
Informing the patient of the weaning plan may decrease
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Table 18-1 Causes of Ventilatory Dependency
Hypoxemic respiratory failure
Impaired pulmonary gas exchange
Nonpulmonary shunt
Decreased oxygen content of venous blood
Hypoventilation
Respiratory muscle pump failure
Decreased neuromuscular capacity
Increased respiratory pump load
Psychological factors
Anxiety
Depression
Motivation
Modified from Tobin MJ: Weaning patients from mechanical ventilation.
How to avoid difficulty. Postgrad Med 89:171–178, 1991.
Table 18-2 Steps in Managing Patients Who
Have Difficulty Weaning from
Mechanical Ventilation
Determine cause of ventilatory dependency
Rectify correctable problems
Pulmonary gas exchange
Fluid balance
Mental status
Acid–base status
Electrolyte disturbance
Use team approach
Utilize weaning protocol
Utilize daily trials of spontaneous breathing
Consider psychological factors
Optimize posture
Optimize pulmonary care
Ensure adequate nutritional support
Optimize general patient care
Provide ambulation
Modified from Tobin MJ: Weaning patients from mechanical ventilation.
How to avoid difficulty. Postgrad Med 89:171–178, 1991.
patient stress. The presence of a team member providing
assurance and explanation during a trial of spontaneous
breathing or a decrease in the level of mechanical venti-
lator support may be valuable. If patients are alert, they
should be informed of progress. Environmental stimula-
tion such as the use of a television, radio, or books
should be provided. Sleep should be ensured because
deprivation causes impairment of the respiratory control
system in addition to general discomfort.
Optimal patient posture during weaning from
mechanical ventilation varies according to the underly-
ing pathophysiology. Patients with intercostal muscle
weakness resulting from low cervical spinal cord lesions
show an increase in lung volumes on changing from the
upright to the supine posture. Supine posture forces
abdominal contents upward displacing the diaphragm
cephalad. The diaphragm can then contract downward
across a longer distance increasing the volume of gas
moved. Conversely, patients with diaphragmatic paraly-
sis do better in the upright position. Vital capacity falls
by 50% when these patients are supine. The displace-
ment of the paralyzed diaphragm cephalad leads to a
decreased functional residual capacity (FRC) and places
the ancillary muscles of respiration at a mechanical
disadvantage.
Ventilator settings during periods of mechanical ven-
tilation may affect progress with subsequent weaning
trials. A major purpose of mechanical ventilation between
weaning trials is to provide rest for the respiratory mus-
cles. With most modes of ventilation (assist-control,
synchronized intermittent mandatory ventilation (SIMV),
and pressure support ventilation (PSV)) inspiratory
muscles do not stop contracting once the ventilator has
been triggered. Thus, the inspiratory muscles are not
simply “resting.” Adjustment of the ventilator settings is
necessary to minimize respiratory work. Even when
optimally adjusted, patients may still perform a consid-
erable portion of the work of inflation during assisted
ventilation.
PREDICTIVE CRITERIA OF
WEANING OUTCOME
Conventional criteria for readiness to wean are rela-
tively easy to measure but their specificity and sensitiv-
ity are relatively poor. These include vital capacity (VC),
tidal volume (TV), minute ventilation (MV), maximum
voluntary ventilation, respiratory frequency, and maxi-
mal inspiratory pressure.
VC is the greatest volume of gas that a patient is able
to exhale in taking a maximum inspiration from residual
volume. TV is that volume of gas moved during a normal
respiratory cycle. The threshold values for these two
parameters predictive of weaning remain controversial
but are of the order of 5–8 ml/kg for TV and 10–15 ml/kg
for VC. Measurement of VC is relatively difficult because
it depends on considerable cooperation from the
patient. Given the large degree variability in VC, it is not
surprising that some studies have shown that VC often
failed to predict weaning outcome with a high degree of
accuracy. Although slightly better, using a TV cutoff of 
4 ml/kg, the positive predictive value was 0.67 and 
negative predictive value was 0.85, left significant room
for improvement.
In a resting, healthy adult MV is about 6 l/minute.
Maximum voluntary ventilation (MVV) is the volume of
air that can be inhaled and exhaled with maximum effort
over one minute. Normal values for MVV range from 
50 to 250 l/minute. The relationship between resting 
MV and MVV indicates the proportion of the patient’s
ventilatory capacity required to maintain a certain level
of PaCO2 and also indicates the reserve available for fur-
ther respiratory demands. The combination of a MV of
<10 l/minute and the ability to double this value during an
MVV maneuver was associated with the ability to wean
successfully. However, both of these tests are associated
with significant false positive and false negative rates.
Furthermore, the MVV can be difficult to obtain in the
critically ill patient, as they may be unable to cooperate.
One simple assessment of respiratory muscle function
can be made by measuring muscle strength. Respiratory
muscle strength can be measured at the patient’s bedside
by recording the maximal inspiratory pressure (MIP) by
means of an aneroid manometer. Maximum static inspi-
ratory pressures for healthy young men and women are
approximately −120 cmH2O and −90 cmH2O, respectively.
Maximal inspiratory efforts may be performed easily in
uncooperative intubated patients by using a one-way valve
connected to the manometer, which allows the patient to
exhale freely but forces the patient to inhale against the
manometer. A MIP < −30 cmH2O is associated with suc-
cessful extubation but a MIP > −20 cmH2O is associated
with the inability to maintain spontaneous breathing.
Studies have shown these values to have a better nega-
tive predictive value than positive predictive value.
Several more recent predictive criteria of weaning
outcome have been described. These include measure-
ments of transdiaphragmatic pressure, airway occlusion
pressure, gastric intramural pH (pHi), and several inte-
grative indices. However, these techniques all share in
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CURRENT CONTROVERSY
Criteria for Readiness to Wean
The best criterion for readiness to wean from
mechanical ventilation remains controversial.
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common the requirement for specialized equipment, 
difficulty of measurement, or complicated equations,
which make bedside utility poor.
One exception to the above is the rapid shallow
breathing index described by Tobin and Yang. They had
found that MV is well maintained in patients who fail a
weaning trial, but its components TV and respiratory
frequency are combined in a manner that results in inef-
ficient gas exchange. In general, patients who fail wean-
ing trials drop their TVs and increase their respiratory
rates. Yang and Tobin have shown that the rapid shallow
breathing index as reflected by frequency (breaths/
minute)/tidal volume (liters) is the most accurate predictor
of weaning outcome. Using a threshold of <105, the
frequency (f)/tidal volume (VT) ratio had a positive predic-
tive value of 0.78 and a negative predictive value of 0.95.
The advantages of the f/VT ratio as a weaning predic-
tor are that it is easy to measure and not dependent on
patient cooperation or effort. The f/VT ratio was evalu-
ated while patients were spontaneously breathing
through the endotracheal tube. A bedside spirometer
was used to measure VT. The predictive value of this
index may be lower if measured while patients are on
the ventilator with either continuous positive airway
pressure (CPAP) or pressure support.
WITHDRAWAL OF MECHANICAL
VENTILATION
Withdrawal of mechanical ventilation is considered
when the underlying process responsible for the acute
respiratory failure is improving or resolved, the patient 
is in good clinical condition, and gas exchange is ade-
quate (e.g., PaO2 ≥ 60 mmHg with FIO2 ≤ 0.50 and PEEP
≤ 7.5 cmH2O).
Several clinical parameters discussed above have
been used to predict weaning outcome so that the pres-
ence of favorable weaning parameters supports the deci-
sion to undertake a weaning attempt. This is a trial of
spontaneous ventilation prior to extubation. Usually,
such a trial is conducted by disconnecting the patient
from the ventilator and observing respiratory rate, pres-
ence or absence of abdominal paradox, activity of acces-
sory inspiratory muscles, level of consciousness, and
monitoring oxygen saturation by pulse oximetry while
the patient breathes spontaneously.
Spontaneous breathing trials have been described
using a simple T-tube or low-level pressure support (PS)
or CPAP at levels ≤7 cmH2O. The T-tube is simply the
endotracheal tube connected to flow by oxygen. PS or
CPAP are used to reduce the workload imposed on the
respiratory muscles and compensates for the extra work
of breathing imposed by the endotracheal tube and the
ventilator inspiratory valve and circuit. Trial length varies
from 30 minutes to 2 hours. Intolerance is judged by
tachycardia or bradycardia (>20% increase or decrease
from baseline), tachypnea (>35 breaths/minute), hypox-
emia (<90% saturated), hypertension (>180 mmHg sys-
tolic), hypotension (<90 mmHg systolic), and/or subjective
shortness of breath (anxiety, diaphoresis, agitation).
Despite selecting the patients able to undergo a trial
of spontaneous breathing according to weaning criteria
and monitoring them during the trial looking for intoler-
ance, it is common for marginal patients to require 
reintubation within 48 hours of extubation. The frequency
of extubation failure as defined by reintubation within 
48 hours of extubation varies from 4% to 19%. The spon-
taneous breathing trial evaluates respiratory mechanical
function in the presence of an artificial airway. Patients
with altered mental status, recurrent aspiration, or copious
secretions may achieve ventilator independence but
require continued airway protection. Thus, the decision to
extubate a patient requires, in addition to a successful spon-
taneous breathing trial, sufficient level of consciousness
and adequate clearance of secretions.
MODES OF MECHANICAL 
VENTILATION DURING WEANING
Much has been written regarding the mode of
mechanical ventilation to be used during weaning.
There remain three methods in widespread use: pro-
gressive T-piece trials, intermittent mandatory ventila-
tion (IMV), and PSV. At this point no standardized
approach to wean patients from mechanical ventilation
has been developed, and the choice of technique varies
with the physician.
Recent studies suggest that IMV weaning prolongs
time on the ventilator. This is likely due to the fact that the
physician slowly decreases the IMV rate over time. By the
time the IMV rate is slowed to the point where a sponta-
neous breathing trial is performed, valuable time is lost.
Results with the use of PS trials have been variable.
Those studies with well-defined protocols and rapid
reduction of PS to lead to spontaneous breathing trials
show equivalence to daily T-piece trials.
Daily T-piece trials have consistently been superior to
IMV weaning and at least equivalent to PS weaning in
CURRENT CONTROVERSY
Weaning Mode
The optimal mode of mechanical ventilation used
during weaning is controversial but IMV weaning
appears to slow the process.
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several large studies. Twice or more times daily T-piece
trials have not been shown to be more advantageous
than daily trials. They may actually be harmful in that
they may lead to fatigue.
Several recent studies have shown that protocol-
directed weaning by nurses or respiratory care practi-
tioners is superior to independent physician-directed
weaning. This is likely due to the fact that providers are
easily distracted by more acute patients and “stable”
weaning patients may not undergo their daily trial of spon-
taneous breathing unless it is under protocol direction.
CLINICAL CAVEAT
Weaning from Mechanical Ventilation
● Use team approach
● Utilize weaning protocol
● Perform daily trials of spontaneous breathing once
patients have reached oxygenation criteria to 
extubate (FIO2 ≤ 50% and PEEP ≤ 7.5 cmH2O).
CASE STUDY
A 65-year-old male was admitted to the MICU 5 days
ago with streptococcal pneumonia, septic shock, and
respiratory failure. He was aggressively treated with
antibiotics, intravenous fluids (>15 liters crystalloid),
levophed, activated protein-C, and mechanical
ventilation. Initially he required FIO2 > 80% and 
PEEP > 12 cmH2O due to acute lung injury from the
pneumonia and sepsis. Over the next 48 hours his
blood pressure stabilized allowing levophed and
intravenous fluids to be discontinued. By day 3 the
patient began auto-diuresing and FIO2 and PEEP were
reduced. The patient had a history of mild chronic
obstructive pulmonary disease but no cardiac disease.
On day 5 the patient remains 5 liters over his admission
weight. His current vent settings are: 
IMV rate, 8; tidal volume, 500 ml: pressure support, 
10 cmH2O (resulting in spontaneous tidal volumes of
450 ml); PEEP, 7 cmH2O; and FIO2, 40%. His arterial
blood gas is pH = 7.37, PCO2 = 41, and PO2 = 110. 
He is comfortable and breathing at a total respiratory
rate of 14.
QUESTIONS
1. Is this patient ready to wean?
2. If yes, how would you proceed?
3. If the patient fails a trial of spontaneous breathing,
what factor(s) would need to be reassessed and/or
treated to optimize the patient for the next trial of
spontaneous breathing?
SUMMARY
A preferred approach to weaning patients from
mechanical ventilation involves a team approach of all
caregivers (nurses, respiratory therapists, physical thera-
pists, nutritionists, and physicians) in a protocol-driven
fashion giving authority to the front-line staff to wean
the patient as tolerated by the protocol. The protocol
generally leads rapidly to a daily trial of spontaneous
breathing (T-piece or PS) in any ventilated patient who
meets the criteria. If the patient passes the spontaneous
breathing trial, the patient is extubated. Failures of 
extubation are reassessed and reversible factors are
addressed and a subsequent spontaneous breathing trial
is undertaken when the patient is ready (usually daily).
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The term “stroke” includes every clinical condition
characterized by alterations in the cerebral circulation.
According to these alterations stroke may be classified as
ischemic or hemorrhagic. Ischemic stroke accounts for
about 85% of strokes and is most commonly caused 
by atherothrombotic brain infarction (61%) or cerebral
embolism (24%). The mortality from ischemic stroke is
7.6% within 30 days. Hemorrhagic stroke represents
about 15% of strokes and includes intraparenchymal and
subarachnoid hemorrhages. The mortality from hemor-
rhagic stroke is 37.5% within 30 days (Box 19-1).
Every year in the USA about 600,000 people suffer a
stroke; among these about 500,000 are first attacks and
100,000 are recurrent attacks. In 1998 stroke was the
cause of 158,448 deaths in the USA, accounting for about
1 of every 14.8 deaths. Among these deaths, 47% occur
out of hospital. According to these data and when con-
sidered separately from other cardiovascular diseases,
stroke ranks as the third leading cause of death, behind
heart diseases and cancer. At all ages more women than
men die of stroke. In 1998 among the deaths from stroke,
38.6% were men and 61.4% were women. About
4,500,000 stroke survivors are alive today in USA and
many of these survivors have serious, long-term disability;
in fact while 50–70% of stroke survivors regain func-
tional independence, 15–30% are permanently disabled
with high social costs. Risk factors for stroke include age
above 65 years old and black race. A multidisciplinary
approach to stroke involving neurologists, neurosurgeons,
internists, and intensivists gives the best results.
This chapter reviews the pathophysiology and the
intensive management of stroke.
ISCHEMIC STROKE
Definition and Pathophysiology
Ischemic stroke is defined as a clinical condition charac-
terized by ischemic alterations in the cerebral circulation.
According to the clinical pattern ischemic cerebrovascular
disease may be classified as transient ischemic attack (TIA),
progressing stroke, or stabilized stroke (Box 19-2).
Different clinical presentations and localizations of
cerebral lesions may identify several subtypes of
ischemic stroke with different outcome and recurrence
probability. Classification based on clinical, radiological,
and Doppler scanning findings has been recently
proposed (Box 19-3).
Ischemic strokes deriving from the occlusion of large
arteries are caused by atherosclerosis of the carotid artery
or the vertebrobasilar artery. The atherosclerotic occlusion
of small perforating branches results in small ischemic
areas termed “lacunae”: if they involve functional areas,
clinical signs will occur. A global reduction in cerebral
blood flow deriving from severe hypotension or cardiac
arrest may cause watershed infarctions involving the
most distal areas of the parenchyma perfused by cerebral
arteries.
Anterior Circulation Ischemia
The vessel most involved in the anterior circulation
ischemia of the brain is the middle cerebral artery or its
branches; however, also the occlusion of the anterior
cerebral artery may result in symptoms of anterior circu-
lation ischemia. The clinical pattern of anterior circula-
tion ischemia depends on the size and the site of the
ischemic area. This area may be represented by the
whole territory perfused by a cerebral artery, or by
smaller areas (lacunar infarctions), or by the more distal
areas (watershed infarctions) (Box 19-4).
When the occlusion involves just the superior
branches of the middle cerebral artery, hemiparesis and
hemisensory loss involving only the inferior limb are
associated with motor aphasia or neglect syndrome. The
occlusion of the inferior branches of the middle cerebral
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Box 19-1 Classification of Stroke
● Ischemic stroke
● Hemorrhagic stroke
● Intraparenchymal hemorrhage
● Subarachnoid hemorrhage
Box 19-2 Classification of
Cerebrovascular Disease
● Transient ischemic attack (TIA) includes
neurological dysfunctions secondary to
cerebrovascular disease lasting less than 24 hours
● Progressing stroke includes neurological
dysfunctions secondary to cerebrovascular disease
that worsen in a period of hours (anterior circula-
tion impairment) or days (posterior circulation 
impairment)
● Stabilized stroke includes a clinical state that
remains stable for at least 24 hours (anterior circula-
tion impairment) or 72 hours (posterior circulation
impairment)
Box 19-3 Classification of Ischemic Stroke
● Atherosclerosis of large-calibre vessels (caused by
embolism or thrombosis)
● Cardiac embolism
● Small vessel occlusion (lacunae)
● Stroke deriving from other causes (arterial dissection,
coagulopathy, arterial–arterial embolism, venous
occlusion, etc.)
● Stroke deriving from unknown cause
Box 19-4 Results of Ischemia
Ischemia of the whole territory perfused by the
middle cerebral artery results in:
● Contralateral hemiplegia
● Contralateral hemisensory loss
● Conjugated deviation of the eyes toward the 
injured side
● Homonymous hemianopia
● Global aphasia if the stroke involves the dominant
hemisphere
● Neglect syndrome if it involves the nondominant
hemisphere
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artery results in mild and transient motor and sensitive
symptoms while hemianopia may be associated with
sensorial aphasia (dominant hemisphere involvement)
or confusion (nondominant hemisphere involvement).
The occlusion of small branches may result in small
ischemic areas and minimal clinical signs.
Anterior circulation ischemia may rarely derive from
the occlusion of the anterior cerebral artery. If this is the
case, paresis and sensory loss will involve the contralat-
eral inferior limb with a minimal involvement of the eyes.
Lacunar infarctions of lenticulostriate arteries results
in the ischemia of the internal capsule with a pure motor
stroke or hemiparesis associated with ataxia or dysarthria.
These clinical signs often derive also from ischemic
lesions in the brain stem.
Watershed infarctions occurring in the areas between
the territory of the middle cerebral artery and the terri-
tory of the anterior cerebral artery cause hyposthenia in
the contralateral inferior limb associated with a milder
hyposthenia of the superior limb and no involvement of
the eyes. Motor aphasia in the case of dominant hemi-
sphere involvement or mood alterations in the case of non-
dominant hemisphere involvement may occur. Watershed
infarctions involving the territories between the areas
dependent on the middle cerebral artery and posterior
cerebral artery result in the homolateral loss of the visual
field associated with sensorial aphasia (dominant hemi-
sphere) or unilateral neglect syndrome and agnosia (non-
dominant hemisphere). Subcortical watershed infarctions
involve the cerebral white matter between the deep and
superficial perforating branches of the middle cerebral
artery and cause paresis and sensory loss of the face and
the superior limb.
Vertebrobasilar Ischemia
The clinical pattern deriving from vertebrobasilar
ischemia is characterized by the slow and progressive
development of symptoms often related to the involvement
of the cranial nerves. Headache and dizziness are common.
If ischemia involves the reticular activating system sudden
alterations of consciousness and coma may occur.
The occlusion of the posterior-inferior cerebellar
artery results in the Wallenberg syndrome (Box 19-5).
Embolic events may cause cerebellar infarctions
resulting in cerebellar edema that may progress to the
compression of the fourth ventricle with obstructive
hydrocephalus and herniation of the posterior fossa con-
tent which is a neurosurgical emergency that needs the
placement of a ventricular drain tube or the perform-
ance of decompressive craniotomy.
Lacunar strokes may result in a pure sensitive stroke
(thalamic involvement) or a pure motor stroke (pontin
involvement). Pontin lesions may also result in ataxic
hemiparesis. A peculiar clinical pattern is the locked in
syndrome caused by the occlusion of the major branch
of the basilar artery resulting in pontin ischemia without
mesencephalic involvement. Locked in syndrome is
characterized by the at least partial persistence of con-
sciousness associated with the impairment of every motor
activity except eye movement. Vertebral artery dissec-
tion and subclavian artery steal syndrome may precipitate
symptoms of vertebrobasilar ischemia. The dissection of
the vertebral artery usually is traumatic and has good out-
come with anticoagulant therapy. The subclavian artery
steal syndrome is caused by a stenosis in the subclavian
artery, proximal to the vertebral artery. Symptoms
related to vertebrobasilar ischemia may develop during
physical activity involving the superior limbs. These symp-
toms are usually transient, but surgical or endovascular
treatment of the stenosis may be necessary.
Prehospital and Emergency Room Care
The early phase of nontraumatic brain injury may be
associated with the impairment of vital functions that
makes patients with stroke critical. Large infarctions 
in the territory of the middle cerebral artery and vertebro-
basilar circulation as well as stroke-related seizures may
compromise airway patency and ventilation. These situ-
ations are often associated with loss of protective
reflexes and pulmonary inhalation. In small infarctions
ventilation impairment is usually less severe. In any case,
prehospital and emergency room care should always
begin with an assessment of airway patency and ventila-
tion. Severe heart failure is rarely precipitated by
ischemic stroke, while heart diseases may be the cause
of stroke because of arrhythmias or acute myocardial
infarction. Systemic arterial pressure usually increases in
the first hours after ischemic stroke, but usually this
increase is transient. Large strokes are associated with
cerebral edema that causes intracranial hypertension and
mass effect resulting in brain shift and brain herniation.
Patients with stroke are at high risk of seizures that may
be difficult to treat. Hyperglycemia is a usual finding in
Box 19-5 Wallenberg Syndrome
This syndrome includes:
● Homolateral Horner’s syndrome (enophthalmus,
miosis, ptosis)
● Homolateral loss of face sensibility to pain and heat
● Contralateral hemisensory loss
● Dizziness
● Nystagmus
● Eye deviation
● Dysphagia
● Dysphonia
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nontraumatic brain injury and is associated with poor
outcome, and therefore it should be avoided (Box 19-6).
Airway Management
Orotracheal intubation and ventilation support should
be considered when airway patency or ventilation are in
doubt. There are several indications for tracheal intuba-
tion in patients with stroke.
Patients who do not need tracheal intubation often
have a decreased PaO2 and therefore supplemental oxygen
should be given also in spontaneous breathing patients.
A nasogastric tube should be placed to decrease the risk
of inhalation. Many patients with nontraumatic brain
injury are confused and show psychomotor agitation
that may require sedative drugs. Imaging examination
sometimes requires deep sedation. Any time a sedative
drug is used in a brain-injured patient its respiratory
effects should be carefully monitored using clinical
examination and arterial oxygen saturation monitoring.
The use of these drugs may make tracheal intubation
necessary to achieve the complete control of airways and
ventilation. An appropriate control of volemia is manda-
tory even if a severe cardiovascular failure associated
with ischemic stroke is usually confined to cases of cardio-
genic stroke, arrhythmias, and concomitant myocardial
infarction. A central venous catheter and a urinary
catheter are necessary to address fluid management.
Systemic Blood Pressure Control
The incidence of systemic hypertension in patients
with stroke is 70%. Antihypertensive therapy should be
used only if the systolic blood pressure is above 220 mmHg
or the diastolic blood pressure is above 120 mmHg.
If stroke is associated with acute myocardial infarction,
aortic dissection, or aortic aneurysms, antihypertensive
treatment should be initiated even at lower pressure
values. Strict blood pressure control is also mandatory if
thrombolytic treatment is used. It is commonly accepted
that an acute reduction in systemic blood pressure
results in a sudden reduction in cerebral blood flow that
may worsen the damage to ischemic penumbra that is
the area closed to the necrotic tissue. This reduction in
cerebral blood flow may occur also at high values of sys-
temic pressure especially in patients with chronic hyper-
tension that is associated with a shift of the autoregulation
of cerebral blood flow to higher values of perfusion pres-
sure. Autoregulation is also abnormal with a pressure-
dependent cerebral flow in the injured and perilesional
areas. An optimal systemic blood pressure that would
ensure an appropriate cerebral perfusion pressure and
cerebral blood flow is far from being set. According to
general agreement systolic arterial blood pressure
should always be above 150–160 mmHg.
Beta-blockers
Labetalol is a blocker of both beta receptors and apha-1
receptors. The action on the latter receptors causes vaso-
dilatation that is not associated with tachycardia because
of the block of beta receptors. Boluses of 0.05–0.5 mg/kg
cause a reduction in arterial blood pressure lasting a few
minutes within 5–10 minutes. A continuous intravenous
infusion at a dose of 0.5–2 mg/kg/hour can also be used.
Asthma, acute heart failure, bradycardia, and conduction
abnormalities contraindicate the use of beta-blockers.
Alpha-2 Agonists
Clonidine is an alpha-2 agonist drug that acts centrally
inhibiting the neurons of the bulbar vasomotor center.
This causes diffuse vasodilatation of resistance and capac-
itance vessels and a reduction in heart rate and cardiac
output. Clonidine is a short-acting drug if used in a single
Box 19-6 Prehospital and Emergency
Room Care After Ischemic
Stroke
● Airway management
● Systemic blood pressure control
● Intracranial pressure management
● Diagnostic workup
CLINICAL CAVEAT
Indications for tracheal intubation after stroke:
● PaO2 < 50–60 mmHg
● PacO2 > 50–60 mmHg
● Vital capacity < 500–800 ml
● Signs of respiratory fatigue (respiratory 
rate > 30 breaths/minute, dyspnoea, respiratory
acidosis, use of the accessory respiratory muscles)
● Significant alterations of consciousness
● Inhalation risk
● Impairment of airway patency
CLINICAL CAVEAT
Antihypertensive drugs in patients with stroke:
● Beta-blockers
● Alpha-2 agonists
● Nitrates
● Calcium antagonists
● Alpha-1 inhibitors
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dose of 0.075 mg. Sedation and xerostomia are collateral
effects of clonidine.
Nitrates
Nitroglycerine induces vasodilatation mediated by
nitric oxide pathways. The short effect of this drug allows
an intravenous continuous infusion at a dose of 5–10 μg/
minute. Nitroprussate is a venous and arterial vasodilator
used intravenously at a dose of 0.5–10 μg/kg/minute. 
It is usually not used in brain-injured patients because it
causes cerebral vasodilatation associated with a depressed
response to CO2.
Calcium Antagonists
Nifedipine is a calcium antagonist that may be used
sublingually at a dose of 10 mg.
Alpha-1 Inhibitors
Urapidil is an alpha-blocker that produces prevalently
arterial vasodilatation associated with a minor venous
vasodilatation without significant changes in heart rate
and cardiac output. Urapidil can be used in boluses of
12.5 mg or by continuous intravenous infusion.
Even if hypotension decreases cerebral perfusion pres-
sure and cerebral blood flow and may worsen ischemic
injuries, severe hypertension when uncontrolled increases
perilesional cerebral edema and poses at high risk for the
hemorrhagic progression of stroke especially in patients
treated with anticoagulants that are contraindicated if
hypertension is uncontrolled.
Intracranial Pressure Management
Intracranial hypertension should be promptly identified
and treated because it may result in dramatic consequences
such as brain herniations. The treatment of intracranial
hypertension includes invasive monitoring of arterial 
blood pressure and intracranial pressure and should be per-
formed in an intensive care unit (ICU) (Box 19-7).
Sedation and analgesia are useful to prevent sudden
increases in intracranial pressure because they reduce
the adrenergic discharge associated with pain and they
control the psychomotor agitation.
Appropriate head position with a head-up tilt of
20–30° without lateral deviations of the head improves
venous return through jugular veins and it is considered
a basic step in intracranial hypertension treatment.
Indeed an increase in venous return from the brain is
associated with a reduction in cerebral perfusion pres-
sure when head tilt is applied. The reduction in cerebral
perfusion pressure may induce the vasodilatation of
cerebral vessels resulting in further intracranial hyper-
tension. A head-up tilt of 30° has become a good practice
of general intensive care also for the prevention of noso-
comial pneumonia. It should be associated with a care-
ful management of systemic arterial blood pressure to
prevent cerebral hypoperfusion.
The most popular osmotic diuretic is mannitol,
which inhibits water and sodium absorption in the 
kidney resulting in osmotic diuresis. Mannitol induces an
osmotic gap between the intravascular compartment
and the brain parenchyma resulting in a movement of
water from the extravascular compartment into cerebral
capillaries with a reduction in intracranial hypertension.
The blood–brain barrier must be intact for these effects
to occur. Mannitol acts also as plasma expander reduc-
ing hematocrit and viscosity. These effects improve cere-
bral blood flow and cerebral oxygen delivery. Moreover,
mannitol has also antioxidant properties that may result
in a neuroprotective effect. When used in continuous
intravenous infusion it may alter the blood–brain barrier.
This alteration may allow mannitol to exit into the
extravascular compartment worsening cerebral edema.
Plasmatic osmolarity should be below 320 mosm/l when
mannitol is used because of the risk of tubular necrosis.
Therefore mannitol can be used for the treatment of 
an unequivocal intracranial hypertension at a dose of
0.25–1 g/kg. This regimen produces effects lasting 
6–8 hours within 2 minutes. Euvolemia, serum osmolarity
below 320 mosm/l, diuresis, and renal function 
monitoring should always be ensured when mannitol is
used. Furosemide may exaggerate the collateral effects
of mannitol and should not be used in intracranial 
hypertension. Tris-hydroxymetil aminomethane (THAM)
increases pH resulting in a decrease in intracranial
hypertension. A dose of 60 mmol administered in 45 min-
utes decreases intracranial pressure within 15 minutes.
Provided there is a careful monitoring of blood pH,
THAM can be used with a continuous intravenous infu-
sion of 3 mmol/hour.
Hyperventilation increases pH, reducing PaCO2. 
A decreased PaCO2 causes cerebral vasoconstriction
with a reduction of both intracranial hypertension 
Box 19-7 Methods for the Control of
Intracranial Hypertension
● Sedation
● Analgesia
● Appropriate head position
● Osmotic diuretics
● Tris-hydroxymetil aminomethane (THAM)
● Hyperventilation
● Muscle relaxation
● Barbiturates
● Hypothermia
● Decompressive craniotomy
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and cerebral blood flow. Hyperventilation produces
transient effects because a readjustment in brain pH
occurs after 24 hours. Moreover, the effects of hyper-
ventilation depend on the cerebral vessel response to
CO2 that may be altered in patients with stroke resulting
in cerebral hypoperfusion of perilesional areas. Because
the transient effect of hyperventilation on intracranial
hypertension sacrifices cerebral blood flow, the benefits
resulting from hyperventilation may be limited. In any
case, PaCO2 should be maintained between 35 and 
40 mmHg because higher values exacerbate intracranial
hypertension.
Barbiturates and propofol can induce a pharmaco-
logic coma with the electroencephalographic features of
burst suppression. This produces a profound reduction
in cerebral metabolism and in cerebral blood flow because
of cerebral autoregulation resulting in a decreased
intracranial pressure. Careful hemodynamic monitoring
should be used when barbiturates or propofol are used
at high doses because of the cardiovascular effect of
these drugs.
Hypothermia shows neuroprotective effects because
it decreases cerebral metabolism. Hypothermia reduces
also the alterations of the blood–brain barrier after cere-
bral ischemia decreasing cerebral edema and intracranial
hypertension. Unequivocal outcome benefits from 
the use of hypothermia in patients with stroke are still
lacking.
Decompressive craniotomy has shown experimental
effectiveness in large cerebral infarctions. It should be
considered when every other treatment has failed but
neurologic impairment is not already irreversible.
Diagnostic Workup
The role of diagnostic workup in the management of
nontraumatic brain injury is very important to choose
the appropriate treatment. The use of specific therapy
such as thrombolytic therapy increases further the impor-
tance of early diagnostic workup. Among neuroimaging
techniques, computed tomography (CT) scanning is the
first choice in patients with stroke and it should be per-
formed as soon as possible. Initially CT scanning should
identify or exclude the presence of intracranial hemor-
rhages or nonvascular lesions (neoplastic tissue). CT
scanning is then important to identify the location and
extension of the neurologic lesion. Ischemic lesions will
not show direct signs on CT scanning until 12–24 hours
after stroke; sometimes the occluded artery may result in
a hyperdense image even if calcified vessels may cause
false positive findings. Even large ischemic strokes are
not evident on CT scanning in the first hours; 60% of
cerebral infarctions will be evident on CT scanning 
24 hours after symptom presentation, while 100% of
cerebral infarctions are evident 7 days after presentation.
The mass effect associated with large ischemic lesions is
promptly evident on CT scanning even when the direct
signs of ischemia are not present. If the initial CT scanning
is negative and in the case of neurologic deterioration
CT scanning should be repeated after 24 hours until 
7 days after clinical presentation. The early finding of
either hypodensity or mass effect has a negative prog-
nostic value. The diagnostic benefit resulting from 
contrast enhancement in the early phase of stroke is 
controversial, while it is widely accepted for the later
assessment of stabilized strokes. CT scanning is the first
choice among neuroimaging techniques for the early
diagnostic workup of patients with stroke because it is
widely diffused, easy to read, and not very expensive.
NMR could give good diagnostic information especially
in anterior lesions but it may be difficult to perform in
the early phase of stroke because of the instability of the
patient’s condition.
Besides neuroimaging, the early diagnostic workup
for patients with stroke should include electro-
cardiogram and eventually echocardiogram in order to
identify an eventual cardiogenic cause of stroke.
Laboratory examinations should include complete blood
count, glycemia, coagulation tests, electrolytes, blood
gases, and indexes of renal and hepatic function.
Doppler examination of the anterior and vertebrobasilar
circulations may be useful as well as transcranial Doppler.
Electroencephalogram may be useful to demonstrate
seizure activity. Lumbar puncture should be performed
if subarachnoid hemorrhage is suspected with a negative
CT scanning. Radiographic examination of the chest
should also be performed, while X-rays of the cervical
spine should be reserved for patients who are uncon-
scious or with cervical pain or lesions (Box 19-8).
Box 19-8 Diagnostic Workup for
Ischemic Stroke
● CT scan of the head
● Electrocardiogram
● Chest x-rays
● X-rays of the cervical spine (in case of loss of 
consciousness or neck pain)
● Complete blood count
● Coagulation tests
● Electrolytes
● Glycemia
● Blood gas analysis
● Liver and kidney function tests
● Lumbar puncture (in case of suspected subarach-
noid hemorrhage with negative CT scan)
● Electroencephalography
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INTENSIVE CARE UNIT CARE
The target of the treatment of stroke is to limit neu-
ronal damage in order to allow the best neurologic
recovery that is possible for each patient. Clear experi-
mental evidence has focused on the time elapsing from
symptom presentation and treatment initiation. If this
time is short, therapy is more likely to succeed. A “brain
attack” approach that considers stroke as an emergency
has been developed because the time window that
allows a successful treatment is limited to 3–6 hours 
for anterior circulation ischemia and 6–12 hours for 
posterior circulation ischemia. When time becomes the
key of a successful treatment, organizational and educa-
tional aspects of the health system become important.
The diagnostic suspicion of stroke should be met by 
an emergency department able to face stroke with the
same effectiveness as myocardial infarction. Diagnostic
and therapeutic protocols are useful tools in this intent
(Box 19-9).
ICUs dedicated to stroke termed “stroke units” are
growing everywhere and are demonstrated to reduce
mortality and neurologic outcome after stroke. ICU care
for patients with stroke includes specific therapies like
thrombolytic, anticoagulant, and triple H therapy, and
a careful general care (Box 19-10).
SPECIFIC THERAPY
Thrombolytic Therapy
The dissolution of the thrombus occluding the cere-
bral vessel would restore the patency of the vessel
occluded and cerebral perfusion to the ischemic areas.
Several thrombolytic agents like streptokinase, uro-
kinase, and recombinant tissue plasminogen activator
(rt-PA) have been used with success in the treatment of
myocardial infarction. Myocardial vessels have a thicker
wall containing a larger number of smooth muscle cells
while cerebral vessels have a thin wall with few smooth
muscle cells that make them susceptible to break under
reperfusion. Thrombolytic agents activate plasminogen
resulting in fibrine dissolution. They can be used sys-
temically with an intravenous infusion or locally with
intra-arterial instillation. Thrombolytic therapy can be
used if the time elapsed from symptom presentation is
less than 3–6 hours for anterior circulation ischemia or
12 hours for posterior circulation ischemia.
Absolute and relative contraindications must also be
excluded before thrombolytic therapy. Acute bleeding
and cerebrovascular disease or surgery in the last two
months are absolute contraindications. Other contraindi-
cations include severe recent trauma, uncontrolled 
arterial hypertension, mild or severe neurologic impair-
ments, major infarction on CT scan, coagulation defects,
postpartum period, and cardiopulmonary resuscitation
complicated by rib fractures.
Several controlled trials evaluated the effectiveness of
thrombolytic therapy in stroke. While streptokinase has
shown increased mortality resulting from hemorrhagic
complications, intravenous rt-PA has shown improve-
ments in functional outcome without any significant
CLINICAL CAVEAT
Thrombolytic therapy is indicated if the time
elapsed from clinical onset is:
● Less than 3–6 hours for anterior circulation ischemia
● Less than 12 hours for posterior circulation ischemia
Box 19-9 Indications for Intensive Care
Unit Admission After Ischemic
Stroke
● Progressing symptoms
● Unstable hemodynamic parameters
● Embolic occlusion of intracranial carotid or of the
middle cerebral artery
● Multiple embolisms
● Unstable endocarditis
● Intracranial hypertension
● Arterial dissection
● Thrombolytic or hypervolemic therapy
● Comorbidities
● Severe arrhythmias
● Concomitant myocardial infarction
● Hypertensive bursts
● Severe hypotension
● Sepsis
● Severe dehydration
● Renal failure
● Electrolytic abnormalities
● Endocrine abnormalities
Box 19-10 Specific Intensive Care 
Unit Therapy
This includes:
● Thrombolytic
● Anticoagulant
● “Triple H”
increase in mortality in European and North American
trials, although with an increase in hemorrhagic compli-
cations. The dose of rt-PA is usually 0.9 mg/kg (maxi-
mum 90 mg) given over 1 hour. The American Heart
Association, the American Academy of Neurology, and
the Canadian Stroke Consortium recommend rt-PA in
patients with stroke within 3 hours of symptom presen-
tation. Any suspicion of intracranial hemorrhage as well
as any precipitating condition contraindicates thrombo-
lytic therapy. rt-Pa can be used in patients treated with
aspirin. Even if heparin, antithrombotic, and antiaggregant
drugs are not recommended when thrombolytic therapy is
used, good results in patients with posterior circulation
ischemia treated with rt-PA followed by the infusion of
heparin have been obtained. Intra-arterial thrombolytic
therapy is an attractive alternative to systemic thrombo-
lysis even if it requires cerebral angiography. Technical
difficulties could therefore limit its use. Intra-arterial
thrombolysis can probably be safely used within 6 hours
regarding anterior circulation strokes and within 12 hours
regarding posterior circulation strokes. Basilar artery
occlusion carries a mortality of 90% if untreated.
Nonrandomized studies have shown reduced mortality
and morbidity with intra-arterial basilar thrombolysis.
Organizational limits remain a major barrier to the wide
use of thrombolysis in patients with stroke because of its
short therapeutic time window.
Anticoagulant Therapy
Theoretically heparin would be useful when large
arterial vessels are occluded to prevent distal embolism
and in patients with embolic strokes provided that hem-
orrhagic lesions have been excluded. However, heparin
either unfractionated or of low molecular weight
resulted in no significant reductions in death or disability
after stroke when it was used within 24–48 hours after
stroke onset, even in subgroups of patients with atrial
fibrillation. While heparin reduces the incidence of
recurrent ischemic stroke and venous thromboembolism,
it increases the incidence of intracranial bleeding.
Probably the safety of heparin may be improved by care-
fully monitoring coagulation indices. Deferred use of
heparin for thromboembolism prevention is widely
practiced in immobile patients.
Antiplatelet Drugs
Several clinical trials advocate the use of aspirin
150–300 mg within 48 hours after stroke onset. Aspirin
prevents early recurrent ischemic stroke, reduces death
and disability at 3–6 months, and increases the probability
of full functional recovery. Aspirin causes an increase of
as small as 0.2% in the risk of intracranial hemorrhage.
The beneficial effects of aspirin have no significant het-
erogeneity across any subgroup including patients with
intracranial hemorrhage. The modest benefit associated
with aspirin shows no time dependency within 48 hours
and it reflects early secondary prevention rather than
any influence over the acute pathophysiology of stroke.
Triple H Therapy
A therapeutic strategy based on hypervolemia, hyper-
tension, and hemodilution has been advocated for sub-
archnoid hemorrhage but may be useful also in the
treatment of ischemic stroke. This therapy is based on
the fact that cerebral blood flow is dependent on
systemic arterial pressure and blood viscosity when
autoregulation is impaired. Large amount of colloids and
crystalloids are used to achieve hypervolemia and hemo-
dilution that reduce blood viscosity improving cerebral
blood flow. Inotropes such as dopamine are used to
maintain a supranormal systemic arterial pressure result-
ing in a high cerebral perfusion pressure. Triple H ther-
apy requires a careful monitoring of cardiovascular
performance especially in patients with heart disease
(Box 19-11).
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CLINICAL CAVEAT
Contraindications for rt-PA after ischemic stroke:
● Therapy with oral anticoagulants or INR > 1.7
● Therapy with heparin in the past 48 hours or
prolonged aPTT
● Platelets count < 100,000/mm3
● Stroke or head trauma in the past 3 months
● Surgery in the past 14 days
● Systolic pressure > 185 mmHg or diastolic 
pressure > 110 mmHg
● Rapid improvement of clinical examination
● Mild neurologic deficits
● Previous intracranial hemorrhage
● Glycemia > 400 mg/dl or <50 mg/dl
● Seizures
● Gastrointestinal or urinary tract bleeding in the 
past 21 days
● Recent myocardial infarction
Box 19-11 Triple H Therapy
This usually requires:
● Colloids (50–1500 ml)
● Crystalloids (5000–10,000 ml)
● Blood transfusions (if necessary)
● Dopamine or dobutamine (10–30 μg/kg/minute)
GENERAL CARE
The aspects of general ICU care as regards ischemic
stroke are summarized in Box 19-12.
Electrolytes and Fluid Management
An appropriate fluid management is very important
for patients with stroke because the quality and the
quantity of administered fluids may influence cerebral
metabolism and perfusion and intracranial volumes.
Physiologically cerebral perfusion is coupled to cerebral
metabolism and it is not dependent on systemic hemo-
dynamic changes because of cerebral autoregulation.
When the brain is injured cerebral autoregulation is
altered and systemic arterial pressure becomes a funda-
mental factor in determining cerebral blood flow.
Therefore, regarding quantity, fluid management should
be addressed to euvolemia in order to avoid hemo-
dynamic instability that may decrease cerebral blood
flow. Physiologically endothelium of cerebral vessels has
peculiar permeability features that characterize the
blood–brain barrier. In particular, cerebral endothelium
is selectively permeable to small molecules. During brain
injury a disruption of the blood–brain barrier causes an
increase in extravascular fluid. Fluid osmolarity is the
major determinant of water flux across the blood–brain
barrier. Therefore, regarding quality, fluid management
in patients with stroke should be based on isohypertonic
fluids such as normal saline. The use of hypotonic fluids
such as glucose 5% in water should be avoided and
restricted to hyperosmolar states. No definite results
support the use of either colloids or crystalloids.
HyperHaes is a mixture of a 7% NaCl solution with col-
loidal fluids that mobilizes quickly free water into the
vascular compartment and could be useful in reducing
cerebral edema and intracranial hypertension.
Nutritional Support
Patients with stroke have a hypercatabolic state that
requires a careful nutritional support. Even if the patient
is conscious, spontaneous nutrition is not recommended
because the risk of inhalation is high in patients with
stroke. Early enteral nutrition should be initiated as soon as
possible. Enteral nutrition should provide 25–30 kcal/kg
and 1.5 g/kg of proteins every day. A nasogastric tube,
even in tracheal intubated patients, does not exclude
inhalation and percutaneous gastrostomy or jejunostomy
should be considered.
Glycemic Control
Either hyper- or hypoglycemia may be deleterious for
the central nervous system, and a strict glycemic control
is therefore necessary. Hyperglycemia may increase 
lactate production that worsens neuronal acidosis and 
brain damage. Therefore insulin should be used to keep
glycemia in the normal range when hyperglycemia occurs.
Temperature Control
Hyperthermia increases the extension of ischemic
lesions and worsens outcome. Hyperthermia-related dam-
age may depend on the increased production of oxygen
free radicals and neuromediators. Hyperthermia alters
the blood–brain barrier and exacerbates excitotoxicity
in perilesional areas. Therefore hyperthermia should be
promptly controlled using physical and pharmacologic
methods. Deliberate therapeutic hypothermia is still
controversial.
Prevention and Management of
Complications
Ischemic stroke may be associated with seizures,
infectious complications, deep venous thrombosis, and
pulmonary embolism (Box 19-13).
Seizures. Stroke is a frequent cause of seizures and
the most common cause of status epilepticus in adults.
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Box 19-12 General Intensive Care Unit
Care in Ischemic Stroke
Important aspects of general ICU care in ischemic
stroke include:
● Electrolytes and fluid management
● Nutritional support
● Glycemic control
● Temperature control
● Prevention and management of seizures
● Prevention and management of infectious 
complications
● Prevention and management of thromboembolism
CLINICAL CAVEAT
Strategies for fluid management in ischemic stroke:
● Quantity of fluids: the goal is euvolemia
● Quality of fluids: isohyperosmolar fluids
● No definite results support the use of either colloids
or crystalloids
● A mixture of hyperosmolar crystalloids and colloids
may reduce cerebral edema and intracranial
hypertension
Early seizures occur in the first week after the onset of
stroke; late seizures occur later. Seizures are the expres-
sion of ischemic damage. They can aggravate brain injury.
Therefore seizures should be aggressively treated using
benzodiazepines and phenitoine.
Infectious complications are frequent and directly
related to outcome. The cause of death in 15–25% of
patients with stroke is bacterial pneumonia resulting
from inhalation. Urinary tract infections are very frequent
as well because of bladder catheterization. Head-up tilt is
useful for the prevention of pneumonia in patients with
stroke. Inhalation should be promptly identified. Antibiotic
administration may start on an empirical base and then
be turned to a specific strategy when the cultural results
are available.
Deep venous thrombosis and pulmonary embolism.
Pulmonary embolism is the cause of death in 25% of
patients with stroke. Deep venous thrombosis is the main
cause of pulmonary embolism and therefore should 
be appropriately prevented in immobilized patients.
Unfractionated or low-molecular-weight heparin is effec-
tive in the prevention of deep venous thrombosis and
pulmonary embolism and should always be considered
in immobilized patients. Mechanical methods to improve
venous return from the inferior limbs, such as elastic
stockings, may be also useful.
SURGICAL THERAPY
Acute carotid endarterectomy. Carotid endarterectomy
is the treatment of choice for stenotic atherosclerotic
lesion of the carotid artery. Its use in ischemic stroke is
controversial because of the risk of hemorrhagic progres-
sion of stroke. Acute ischemic stroke caused by carotid
occlusion occurring inside the hospital either sponta-
neously or following angiography or elective carotid sur-
gery may be an indication for surgical revascularization.
Acute carotid endarterectomy may be used also in severe
stenosis of the carotid artery with a floating thrombus if
the patient has progressing neurologic symptoms.
NEURORADIOLOGIC PROCEDURES
Angioplasty and stenting. Intravascular treatment of
symptomatic lesions of the cerebral circulation is an
attractive alternative to surgery. These procedures are
reserved to patients with high perioperative risk or with
inoperable lesions. Stenting may be a useful complement to
angioplasty in order to keep the vessel patent. Angioplasty
and stenting are invasive techniques with several possible
complications including microembolism, artery dissec-
tion, thrombosis, intracranial hemorrhage, and hemor-
rhagic progression of the ischemic stroke.
SPONTANEOUS INTRAPARENCHYMAL
HEMORRHAGE
Definition, Etiology, and Pathophysiology
Intraparenchymal hemorrhage accounts for 8–13% of
strokes. Its incidence is decreasing probably because of
the earlier and stricter control of hypertension; in any
case it is still associated with high mortality rates.
The causes of spontaneous intraparenchymal hemor-
rhage include arterial hypertension, vascular abnormalities,
coagulopathies, neoplasia, vasculopathies, drugs, hemor-
rhagic progression of ischemic stroke, postoperative and
post-traumatic hemorrhages, pregnancy, neonatal intra-
ventricular hemorrhage, and other causes (Box 19-14).
204 CRITICAL CARE: THE REQUISITES IN ANESTHESIOLOGY
Box 19-13 Common Complications 
of Ischemic Stroke
● Neurological:
● Cerebral edema
● Hydrocephalus
● Hemorrhagic transformation
● Seizures
● Medical:
● Pulmonary inhalation
● Hypoventilation
● Pneumonia
● Myocardial ischemia
● Arrhythmias
● Thromboembolism
● Urinary tract infections
● Malnutrition
● Anchylosis
Box 19-14 Causes of Intraparenchymal
Hemorrhage
● Chronic arterial hypertension
● Vascular abnormalities
● Coagulopathies
● Neoplasia
● Vasculopathies (amyloid angiopathy, vasculitis,
moya-moya disease)
● Drugs (sympathomimetics, anticoagulants, 
fibrinolytics)
● Postoperative hemorrhages
● Hemorrhagic transformation of ischemic stroke
● Post-traumatic hemorrhage
● Pregnancy
● Other causes
Chronic arterial hypertension is the most common
cause of spontaneous intraparenchymal hemorrhage,
although this etiologic role has decreased during recent
decades because of antihypertensive therapy. Arterial
hypertension results in alterations of cerebral vessels
especially perforating arteries and small subcortical
arteries. Lipids accumulate in the subintimal layer also
damaging the muscularis layer of the media. These abnor-
malities weaken the vessel wall resulting in the small
aneurysms of Charcot Bouchard. Perforating arteries are
terminal branches departing perpendicularly from cere-
bral vessels. Therefore they are exposed to high hemo-
dynamic stress especially at high arterial pressures that
may precipitate the rupture of these weak vessels. Given
the distribution of perforating and subcortical arteries,
intraparenchymal hemorrhages caused by hypertension
occurs usually in basal nuclei, thalamus, cerebellum, and
pons, while they are less common in the hemispheres.
Vascular abnormalities resulting in intraparenchymal
hemorrhage include intracranial aneurysms and vascular
malformations. Although the rupture of an intracranial
aneurysm usually results in subarachnoid hemorrhage, it
can also cause intraparenchymal hemorrhage especially
in case of rebleeding. Intraparenchymal and subarachnoid
hemorrhage can be associated. Intracranial aneurysms are
more common at the bifurcation of the mean cerebral
artery, in the posterior communicant artery, at the bifur-
cation of the internal carotid artery, and in the anterior
cerebral artery. Therefore in these cases intraparenchy-
mal hemorrhage occurs in frontal and temporal lobes.
Aneurysms are generally congenital but they may be 
also post-traumatic. In the latter case they can bleed for
weeks, months, and even years after the initial trauma. 
It is also possible that septic embolism from the heart
results in micotic aneurysms.
Vascular malformations include arterial-venous malfor-
mations, capillary telangiectasis, cavernous angiomas, and
venous angiomas. Arterial-venous malformations are char-
acterized by a direct communication between the arterial
and venous systems without interposed capillaries: this
results in increased pressures in the venous portion with
dilation and high risk of rupture. They usually occur in the
cerebral hemispheres involving branches of the cerebral
mean artery. The rupture of arterial-venous malformations
is more common in patients aged between the second
and the fourth decade. Capillary teleangiectases are capil-
laries abnormally dilated. They are usually localized in the
pons or in the floor of the fourth ventricle and may result
in spontaneous bleedings. Cavernous angiomas are vascu-
lar dilations localized especially over the cerebral hemi-
spheres. They rarely cause massive bleedings; usually they
determine headache, seizures, and neurologic focal signs.
Venous angiomas are abnormal radial veins confluent
toward a central vein. They occur in the frontal and parietal
lobes and rarely bleed (Box 19-15).
Intracranial tumors are a frequent cause of intra-
parenchymal hemorrhages because they have a large and
fragile vascular tissue and large areas of necrosis. They
may be metastatic lesions or malignant glyomas; benign
tumors rarely bleed. Intracranial neoplasia should be sus-
pected if subcortical clotting, abnormal tissue surround-
ing the hematoma, edema with mass effect, and multiple
lesions appear on CT scanning. Either congenital or
acquired coagulopathies may result in intraparenchymal
hemorrhage especially if the platelet count is below
10,000/μl or the activity of a coagulation factor is decreased
below 1%. Intraparenchymal hemorrhage may be a dra-
matic complication of anticoagulant and thrombolytic
treatments. Anticoagulants increase 8–12 times the risk
of intracranial hemorrhage that in these cases is localized
in the hemispheric white matter and in the cerebellum.
Thrombolytic drugs may cause multiple hemispheric
hemorrhages.
Vasculitis is another important cause of intraparenchy-
mal hemorrhages. Sympathomimetic drugs may cause
hypertension resulting in intraparenchymal hemorrhages.
Moya Moya disease is a progressive vascular disease
involving the internal carotid artery and sometimes the
vertebral arteries. It results in the occlusion of the vessels
involved with ischemic or hemorrhagic symptoms.
Clinical Symptoms and Signs
The clinical pattern of spontaneous intraparenchymal
hemorrhage is characterized by an acute onset without
warning signs and by a rapid evolution in minutes or
hours, rarely in days. The incidence of alterations of con-
sciousness in intraparenchymal hemorrhage is 60% and
coma occurs in two-thirds of these patients. Systemic
hypertension is common also in nonhypertensive
patients and represents a reflex response to the intra-
cranial hypertension caused by the mass effect of the
hematoma (Cushing reflex). The goal of this hyperten-
sive response is to maintain cerebral perfusion pressure,
but persistent systemic hypertension may result in 
vasogenic edema and rebleeding. On the other hand,
hypotension must be avoided because it precipitates
Nontraumatic Brain Injury 205
Box 19-15 Vascular Abnormalities
Resulting in Intraparenchymal
Hemorrhage
● Intracranial aneurysms
● Vascular malformations
● Arterial-venous malformations
● Capillary telangiectasis
● Cavernous angiomas
● Venous angiomas
ischemic lesions in perilesional areas, given the alter-
ations of cerebral autoregulation. Therefore systemic
arterial pressure should be maintained in the normal
range. Headache occurs at the onset in 30% of patients
and later in 60% of cases. Vomiting is more common in
hemorrhagic strokes than in ischemic ones. Seizures are
common especially in hemispheric hemorrhages. They
are usually present at the onset or occur early; late
seizures are rare. The clinical pattern is dependent on
the site and the size of the hemorrhage.
Supratentorial Hemorrhage
Intraparenchymal hemorrhages occurring in the
supratentorial area may involve the cerebral cortex, the
cerebral hemispheres, and basal nuclei. Cortical hemor-
rhages are usually multiple and produce neurologic signs
dependent on the site of injury (alterations of mobility or
sensitivity); seizures are common. Hemispheric hemor-
rhages are caused by hypertension in 31% of cases.
Changes of consciousness are rare, although coma may
occur if the hemorrhage is large. If the frontal lobe is
involved, contralateral motility is altered (the superior
limb is more frequently involved than the inferior limb
or the face) and headache, abulia, and disorientation in
time and space may occur. Patients with hemorrhage 
of the parietal lobe present headache and deficit in the
contralateral sensitivity. If the dominant hemisphere 
is involved the patient may have difficulty in naming,
writing, reading, and calculating, while if the nondomi-
nant hemisphere is involved neglect syndrome occurs.
Hemorrhages in the dominant temporal lobe cause sen-
sitive dysphasia with difficulties in the comprehension
but not in the repetition of words. Ear pain may occur.
Hemorrhage in the occipital lobe produces hemianopia
and pain in the homolateral eye, and sometimes halluci-
nations with bright colors may occur.
Intraparenchymal hemorrhage involving putamen
headache is rare, while alterations in motility are common.
Large hemorrhages in this area cause contralateral flaccid
hemiplegia and hemianesthesia, deviation of the eyes
toward the injured side, and hemianopia. Dysphasia or
motor aphasia occur if the dominant hemisphere is
involved, neglect syndrome if the nondominant hemi-
sphere is involved. Very large hemorrhages disconnect
diencephalons from the reticular system and cause stupor
or coma associated with mydriasis and positive Babinski’s
reflex.
Hemorrhages involving the caudate are rare. Confusion,
vomiting, and headache are common in these cases. If the
intraparenchymal hemorrhage involves the thalamus,
there is a contralateral alteration of the sensitivity of the
head, the face, the superior limb, and the chest. If the
injury extends to subthalamic areas, ocular signs (devia-
tion of the eyes, nystagmus) are common, while the
involvement of the internal capsule results in alterations
in motility. Thalamic lesions of the dominant hemisphere
cause aphasia, while those of the nondominant hemi-
sphere produce unilateral neglect syndrome.
Infratentorial Hemorrhage
Intraparenchymal hemorrhages of the mesencephalon
are rare. Sometimes they may cause an important mass
effect, but usually they are benign. The third and fourth
cranial nerves are typically involved. If intraparenchymal
hemorrhage involves the highest portion of the mesen-
cephalon, Parinaud syndrome may occur with paralysis
in looking up, mydriasis, intact convergence movements,
and eyelid movements.
Intraparenchymal hemorrhages involving the pons
may have devastating consequences. Even small hemor-
rhages result in loss of consciousness and tetraplegia
with positive plantar reflex, miosis, and absence of 
horizontal eye movements after oculocephalic and
oculovestibular reflex elicitation. Ocular bobbing, a 
sudden down-deviation of the eyes followed by a slow
return to the resting position, is pathognomonic. Severe
alterations in the respiratory pattern are always present
while an abnormal deglutition facilitates inhalation.
Thermoregulation is often impaired with severe hyper-
thermia and shivers so intense that they may be con-
fused with seizures. Survival is often limited to the first
24 hours, but some patients progress to a vegetative
state or, if injury is limited, to locked in syndrome.
Bulbar hemorrhages are rare. They cause dizziness
and headache followed by hemiparesis. They may be
associated with nystagmus, abnormal deglutition, weak-
ness of the limbs, and cerebellar ataxia.
Cerebellar Hemorrhage
The clinical pattern associated with intraparenchymal
hemorrhages involving the cerebellum is variable: small
hemorrhages may give mild neurologic signs, but if com-
pression of the brain stem occurs consciousness and
vegetative functions become impaired and obstructive
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CLINICAL CAVEAT
Clinical symptoms and signs of intraparenchymal
hemorrhage:
● Alterations of consciousness
● Coma
● Systemic hypertension
● Headache
● Vomiting
● Seizures
hydrocephalus may develop resulting from the com-
pression of the ventricular system. When compressive
complications occur, immediate surgical evacuation of
the hematoma is necessary. The onset of cerebellar hem-
orrhage in conscious patients is usually associated with
headache, dizziness, dysarthria, and difficulties in walking
and standing upright. Less common findings are ataxia,
positive plantar reflex, paralysis of the facial nerve, paral-
ysis of eye movement, and nystagmus. When nausea and
vomiting are severe, the most useful sign of cerebellar
involvement is the difficulty in walking and standing
upright. When the brain stem is involved, consciousness
is invariably altered.
Diagnostic Workup
CT scanning is fundamental for the diagnosis of 
spontaneous intraparenchymal hemorrhage. It allows the
identifications of even small hemorrhages because of the
spontaneous enhancement of the proteic components of
hemoglobin. With CT scanning it is possible to identify
the site of the intraparenchymal hemorrhage and the
eventual presence of mass effect and brain shift.
Ventricular or subarachnoid extension and secondary
hydrocephalus associated with intraparenchymal hem-
orrhage are also evident on the CT scan (Box 19-16).
Brain shift is very important because it correlates 
with the level of consciousness and with the develop-
ment of cerebral herniations. CT scanning also allows 
a rapid calculation of the size of the hematoma using
simple formulas such as the ABC/2 formula of Kothary
(Box 19-17).
NMR is particularly useful in the diagnosis of vascular
malformations and cerebral tumors, although CT scan-
ning is more sensitive for the identification of hemor-
rhages occurring in the last 12 hours because the blood
is isointense on NMR in the early phase of hemorrhages.
Acute and Intensive Care Unit Management
Acute treatment of patients with intraparenchymal
hemorrhage has the goal of obtaining stable vital param-
eters. Ventilation is abnormal in many patients with head
injury and the reflexes for airway protection are often
ineffective. Therefore tracheal intubation and mechani-
cal ventilation are often necessary. In patients with an
effective spontaneous ventilation supplemental oxygen
is recommended to reduce the risk of cerebral hypoxia
(Box 19-18).
Usually patients with intraparenchymal hemorrhage
have systemic arterial hypertension in the early phase
after hemorrhage. This is probably a reflex response to
maintain cerebral perfusion pressure. Although persist-
ent systemic hypertension may result in vasogenic
edema and rebleeding, hypotension must be avoided
because it precipitates ischemic lesions in perilesional
areas. Therefore sudden decreases in systemic arterial
pressure should be avoided. A systolic arterial pressure
of around 160 mmHg has been advocated in conscious
patients and around 180 mmHg in comatose patients;
these values should be even higher, although below 
210 mmHg, in patients with chronic arterial hyper-
tension. Another important target is to obtain stable 
values of arterial pressure; treatment with labetalol,
nitrates, esmolol, and angiotensin converting enzyme
(ACE) inhibitors is useful for the prevention of paroxys-
mal hypertension that may contribute to rebleeding.
Precipitating causes of hypertension should be avoided
also providing appropriate sedation and analgesia.
Coagulation deficits increase the risk of intraparenchy-
mal hemorrhage and should be treated immediately 
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Box 19-16 CT Scanning in Intra-
parenchymal Hemorrhage
This shows:
● The site of the hemorrhage
● The extent of brain shift
● The subarachnoid extension (if present)
● Secondary hydrocephalus (if present)
Box 19-17 ABC/2 Formula of Kothary
Volume of hematoma = (A × B × C)/2
● A = the maximum diameter of the hematoma in a
single scan
● B = the maximum diameter perpendicular to A
● C = the number of scans that show the hematoma
times the thickness of each scan
Box 19-18 Goals of Acute and Intensive
Care Unit Management of
Intraparenchymal Hemorrhage
● Restoration of an appropriate ventilation
● Arterial pressure control
● Treatment of coagulation deficits
● Intracranial pressure monitoring
● Prevention and treatment of seizures
● Surgical treatment if the medical treatment fails to
control intracranial hypertension and to prevent 
neurological deterioration
discontinuing anticoagulant or thrombolytic drugs,
administering plasma, coagulation factors, or protamine.
Intracranial pressure monitoring is useful to guide medical
treatment of patients with intraparenchymal hemorrhage
and to identify early the cases requiring surgical treat-
ment. When there is intracranial hypertension a head-up
tilt of 20–30° improves venous return and mannitol
administrations at a bolus dose of 1–1.5 g/kg followed by
doses of 0.5 g/kg every 4–6 hours should be considered.
Mechanically ventilated patients may be treated with
temporary hyperventilation. Intraventricular catheters may
be used to drain cerebrospinal fluid in the attempt to
reduce intracranial hypertension.
Antiepileptic drugs are administered to all patients
with intraparenchymal hemorrhage even if conclusive
data for the doses and the duration of the antiepileptic
therapy are lacking.
Corticosteroids are not recommended because they
cause many complications and no demonstrable benefi-
cial effect.
When medical treatment fails to control intracranial
hypertension and to prevent neurologic deterioration,
surgical treatment is indicated. Surgery is usually not nec-
essary in conscious patients, while it is advisable when
massive intraparenchymal hemorrhages are associated
with severe neurologic impairments involving the func-
tion of the brainstem. Stereotaxic drainage is an alternative
to open ceiling drainage. Recently, surgical evacuation of
the hematoma has been associated with fibrinolytic drugs
that have been used to obtain dissolution of the clotting.
Outcome
The clinical pattern that characterizes the onset and
the early phase of the intraparenchymal hemorrhage is
the most important prognostic factor. Outcome is signif-
icantly worse in comatose patients. Other negative prog-
nostic factors include a volume of hemorrhage above 
60 ml, the localization in deep structures, brain shift, and
the age of the patient.
SUBARACHNOID HEMORRHAGE
Definition, Etiology, and Pathophysiology
Subarachnoid hemorrhage accounts for 6–8% of cere-
bral strokes. It is defined as a collection of blood in the
subarachnoid space between pia mater and arachnoid
involving the base cisterns and the hemispheric and
interhemispheric fissures. In the most severe cases blood
may reach cerebral ventricles, and in 30% of cases sub-
arachnoid hemorrhage is associated with intraparenchymal
hemorrhage.
The annual incidence of subarachnoid hemorrhage is
15–20 per 100,000 population, and it is higher in women
than in men (1.7:1). The incidence of subarachnoid hem-
orrhage shows a peak in the sixth decade. The mortality
from subarachnoid hemorrhage is high, even if during
recent years it has decreased. Mortalities after 30 days
and after one year are equivalent, so subarachnoid 
hemorrhage causes death mostly within the first month.
One-half of patients with subarachnoid hemorrhage
either die or have severe inability, while one-third sur-
vive with a good functional recovery. Among strokes,
subarachnoid hemorrhage shows the best response to
surgical and medical intensive care.
The cause of subarachnoid hemorrhage may be the
rupture of intracranial aneurysms (75–80%), the rupture
of vascular malformations (4–5%), arteriopathies, infec-
tions (meningitides and meningoencephalitis), intoxica-
tions (alcohol, carbon monoxide, cocaine, epinephrine,
amphetamines, monoamine oxidative inhibitors, opioids),
traumas (head trauma, electrocution, seizures, burns,
strangulations), cancer (ependimoma, glyoma, melanoma,
metastasis), venous thrombosis and blood disorders (sickle
cell anemia, leukemia, lymphoma, anticoagulants, aspirin,
disseminated intravascular coagulation) (Box 19-19).
Intracranial aneurysms have an incidence of 2–5%
and, according to Carmichael’s hypothesis, degenerative
factors acting on a congenitally abnormal vessel con-
tribute to their formation. Risk factors for intracranial
aneurysms are smoking, hypertension, alcohol, contra-
ceptives, and hormonal changes associated with the
menopause. Intracranial aneurysms may be saccular
(berry), fusiform, or dissecting (Box 19-20).
Saccular (berry) aneurysms are the most frequent and
represent the most common cause of subarachnoid hem-
orrhage. They are often associated with type III collagen
deficiency related to congenital diseases including aortic
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Box 19-19 Causes of Subarachnoid
Hemorrhage
● Rupture of intracranial aneurysms
● Rupture of vascular malformations
● Arteriopathies
● Infections (meningitides and meningoencephalitis)
● Intoxications (alcohol, carbon monoxide, cocaine,
epinephrine, amphetamines, monoamine oxidative
inhibitors, opioids)
● Traumas (head trauma, electrocution, seizures,
burns, strangulations)
● Neoplasias (ependimoma, glyoma, melanoma, 
metastasis)
● Venous thrombosis
● Blood disorders (sickle cell anemia, leukemia, 
lymphoma, anticoagulants, aspirin, disseminated
intravascular coagulation)
coarctation, polycystic kidney disease, Marfan’s syndrome,
Ehlers–Danlos syndrome, and fibromuscular dysplasia of
the renal arteries. Saccular aneurysms occur at the bifur-
cation of cerebral arteries, more frequently in the ante-
rior circulation (anterior communicant artery, posterior
communicant artery, middle cerebral artery, carotid
artery). These aneurysms may rarely compress closed
structures causing symptoms before their rupture.
Thrombosis may occur inside the aneurysm causing
acute headache, stiff neck, and inflammatory cells in the
cerebrospinal fluid. The annual rupture risk for saccular
aneurysms is 1.4–3% and it is not related to the aneurysm
size or site.
Fusiform aneurysms are associated with atheroscle-
rotic alterations involving the media and elastica of the
arterial wall. The preferred sites are the basilar artery and
the intracranial segment of the carotid artery. The rup-
ture of fusiform aneurysms is rare, while thrombosis may
occur inside the aneurysm causing embolism. Fusiform
aneurysms may compress the brainstem and structures
inside the sinus carvenosum such as the second, third,
fourth, fifth, and sixth cranial nerves.
Dissecting aneurysms are an infrequent cause of sub-
arachnoid hemorrhage. They can cause ischemic symp-
toms derived from thromboembolism.
Clinical Symptoms and Signs
The typical clinical presentation of subarachnoid
hemorrhage includes acute and severe headache with
stiff neck often associated with photophobia, nausea,
and vomiting. An initial loss of consciousness is very fre-
quent; sometimes it recedes, other times it persists.
Patients with perimesencephalic subarachnoid hemor-
rhage usually present a subacute headache (progressing
over minutes) not associated with alterations of con-
sciousness. Before the rupture of the aneurysm, clinical
symptoms like headache, nausea, neck ache, chest, back
and leg pain, photophobia, and lethargy may be the con-
sequence of minor bleedings or warning leaks. Ischemic
symptoms like dizziness, focal sensory or motor changes,
and speech and cognitive abnormalities may derive from
thromboembolism. Aneurysmal enlargement may result in
the compression of surrounding structures such as cranial
nerves or brain parenchyma. In these cases symptoms
like visual field deficits, eye movement alterations, eye,
ear, or face pain, and seizures may occur. Between 30%
and 60% of patients with intracranial aneurysm will have
warning signs prior to the rupture of the aneurysm; how-
ever, they will be often misinterpreted as hemicranias,
hypertensive encephalopathy, cerebral cancer, meningi-
tides, sinusitis, and cervical spine pathology.
Classification
Several clinical classifications of subarachnoid hemor-
rhage have been proposed to assess objectively the clin-
ical progression of each patient and to achieve an early
outcome determination. The most common classifica-
tions are the Hunt and Hess grading system (Box 19-21)
and the World Federation of Neurologic Surgeons grad-
ing system (Box 19-22). The latter uses the Glasgow
Coma Scale and is more objective, while the Hunt and
Hess grading system uses a more subjective evaluation of
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Box 19-20 Intracranial Aneurysms
These may be:
● Saccular (berry)
● Fusiform
● Dissecting
CLINICAL CAVEAT
Clinical symptoms and signs of subarachnoid
hemorrhage:
● Acute and severe headache
● Stiff neck
● Photophobia
● Nausea
● Vomiting
● Loss of consciousness
Before the rupture of the aneurysm minor bleedings
may cause:
● Headache
● Neck ache
● Chest pain
● Back pain
● Leg pain
● Photophobia
● Lethargy
Box 19-21 Hunt and Hess Grading System
● Grade I – normal neurologic examination, mild head
ache, and slightly stiff neck
● Grade II – moderate to severe headache and stiff
neck; no confusion or neurologic deficit except for
cranial nerve palsy
● Grade III – persistent confusion and/or focal 
neurologic deficit
● Grade IV – persistent stupor; moderate to severe
neurological deficit
● Grade V – coma with moribund appearance
the clinical state. Another classification based on the
Glasgow Coma Scale has been proposed from John
Hopkins University (Box 19-23).
Diagnostic Workup
The suspicion of subarachnoid hemorrhage must be
confirmed by an appropriate diagnostic workup includ-
ing CT scanning. NMR has a limited utility in the acute
phase. When CT scanning is performed in the first hours
following the onset of subarachnoid hemorrhage it has a
sensitivity of 95%. False negatives rise to 10% after 3
days, and to 50% after 7 days. The blood may be drained
from the subarachnoid space within 24 hours in 2–5% of
cases while the blood in the cerebral parenchyma or in
the cerebral ventricles persists longer. The identification
of the aneurysm location is easier if intraparenchymal
blood is present. Intraventricular blood is a sign of
severe hemorrhage.
When CT scanning is negative, lumbar puncture is
necessary. After aneurysmal rupture the blood appears
in the cerebrospinal fluid within a few minutes and dis-
appears within 7–10 days. Oxyhemoglobin is present in
the supernatant of the cerebrospinal fluid 2–4 hours
after the aneurysmal rupture and persists for 4 weeks.
Xanthochromia makes the difference between a positive
lumbar puncture and traumatic bleeding during lumbar
puncture.
If CT scanning or lumbar puncture are positive for
subarachnoid hemorrhage the angiography of the cere-
bral vessels should be performed to identify the site of
bleeding, while it is not indicated if both CT scanning
and lumbar puncture are negative and less than 2 weeks
have elapsed from the clinical onset. Early angiography
should be performed also in patients with severe clinical
symptoms eligible for endovascular treatment; late angiog-
raphy is less reliable because of vasospasm. If angiography
fails to identify the site of bleeding it should be repeated
after a few days: a previously unidentified aneurysm will
be diagnosed in 10% of these cases. Cerebral angiography
poses the risk of nephro- and neurotoxicity. Intravenous
fluids reduce nephrotoxicity that is most common in
patients treated with ACE inhibitors and nonsteroidal
anti-inflammatory drugs (NSAIDs). Neurotoxicity may
cause confusion, abnormal speech, and changes of con-
sciousness. Whenever angiography is not possible, NMR
or CT scanning with contrast enhancement should be
performed (Box 19-24).
Management of Neurologic Complications
Neurological complications following subarachnoid
hemorrhage include vasospasm, rebleeding, intracranial
hematoma, hydrocephalus, persistent intracranial hyper-
tension, and seizures (Box 19-25).
Vasospasm
In around 60% of patients with subarachnoid hemor-
rhage vasospasm of the major cerebral arteries is evident
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Box 19-22 World Federation of
Neurologic Surgeons 
Grading System
● Grade I – GCS 15 without motor deficit
● Grade II – GCS 13–14 without motor deficit
● Grade III – GCS 13–14 with motor deficit
● Grade IV – GCS 7–12 with or without motor deficit
● Grade V – GCS 3–6 with or without motor deficit
Box 19-23 Johns Hopkins University Scale
● Grade I – GCS 15
● Grade II – GCS 14–12
● Grade III – GCS 11–9
● Grade IV – GCS 8–6
● Grade V – GCS 5–3
Box 19-24 Diagnostic Workup for
Subarachnoid Hemorrhage
● CT scanning in the first hours after clinical onset
● Lumbar puncture if CT scanning is negative and 
the clinical suspicion of subarachnoid hemorrhage
still exists
● Angiography of the cerebral vessels if CT scanning 
or lumbar puncture are positive for subarachnoid
hemorrhage
Box 19-25 Neurological Complications 
of Subarachnoid Hemorrhage
● Vasospasm
● Rebleeding
● Intracranial hematoma
● Hydrocephalus
● Persistent intracranial hypertension
● Seizures
angiographically, and half of patients with vasospasm
will present delayed ischemic deficits that may progress
to cause death. Acute vasospasm occurs a few hours
after hemorrhage, while chronic vasospasm occurs 3–4
days after hemorrhage and recedes after 14 days. The
term vasospasm is misleading because it is not a spasm
of the muscularis layer of the vessels but a proliferative
arteriopathy resulting in the obstruction of the vessels
and in the alteration of the cerebral autoregulation. This
arteriopathy seems to be induced by the presence of
hemoglobin in the subarachnoid space which results in
a peroxidative damage involving free radicals. The quan-
tity of blood in the subarachnoid space seen on CT scan-
ning is predictive of vasospasm. Delayed ischemic deficit
causes an alteration in consciousness progressing over
minutes or hours; focal deficits are less frequent. Serial
transcranial Doppler is an effective monitor of cerebral
blood flow in these instances and should be associated
with clinical assessment. Vasospasm may be treated with
calcium antagonists, triple H therapy, or angioplasty.
While other calcium antagonists are less useful,
nimodipine is effective in the prevention of delayed
ischemic deficits. Nimodipine prevents cytotoxicity
blocking calcium channels over neuronal membranes,
and, although it does not reduce the incidence of symp-
tomatic vasospasm, nimodipine improves cerebral blood
flow through collateral branches resulting in a better
functional outcome. Nimodipine may be used at a dose
of 60 mg through a nasogastric tube every 4 hours for 21
days or by a continuous intravenous infusion of 2 mg per
hour for 14 days. Collateral effects are usually mild,
including: hypotension, flushing, edema, headache,
increases in pulmonary shunting, and decreases in gastro-
intestinal motility. Hypotension should be treated to
prevent negative effects on cerebral perfusion. Several
authors advocated triple H therapy to decrease ischemic
lesions from vasospasm. Triple H therapy is based on
deliberate hypertension, hypervolemia, and hemodilu-
tion. The rationale for this therapy is that vasospasm
impairs cerebral autoregulation and makes cerebral
blood flow dependent on systemic arterial pressure and
hematic viscosity. It is still a matter of controversy as to
which is the most important among the three targets;
however, triple H therapy is largely accepted. An appro-
priate fluid management is fundamental in order to
obtain hypertension and hypervolemia. Conclusive data
about the kind of fluid to be used are lacking. The long-
lasting controversy between colloids and crystalloids has
still not produced an evidence-based endpoint. Usually
colloids and crystalloids are used together in a dose ratio
of 1:3. Isotonic fluids with an adequate amount of sodium
are necessary given the dangers of hyponatremia in these
patients. Once provided a hypervolemic state, hyper-
tension may require inotrope or vasopressor drugs.
Hypertension is associated with an important cardiovas-
cular risk and careful hemodynamic monitoring should
be used to obtain a pulmonary capillary wedge pressure
(PCWP) equal to 15–18 mmHg. Transcranial Doppler may
be useful in patients with subarachnoid hemorrhage to
identify when deliberate hypertension is necessary to
ensure an appropriate cerebral blood flow. The use of
transcranial Doppler to guide deliberate hypertension
may be especially beneficial in patients with cardiovas-
cular disease in whom long-lasting hypertension is detri-
mental. Transluminal angioplasty is able to limit ischemic
damage associated with vasospasm. When it is used
within 6–12 hours after the onset of ischemic deficit,
angioplasty is especially useful in patients not responsive
to triple H therapy. Timing is important because when
the vasospasm-related morphological changes of the cere-
bral vessels have occurred, angioplasty is less effective
(Box 19-26).
During neuroradiologic procedures it is possible to
administer intra-arterially papaverine, which in several
cases seems to be useful.
Tirilazilad is a free radical scavenger that has been
used in the treatment of the vasospasm from subarach-
noid hemorrhage. Results seem to be better in males than
females, probably because of a shorter half-life in women.
Phenitoine may also reduce the half-life of tirilazilad.
Rebleeding
Rebleeding occurs in 20% of cases of subarachnoid
hemorrhage and is associated with high mortality (70%).
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CLINICAL CAVEAT
Treatments of vasospasm associated with
subarachnoid hemorrhage:
● Calcium antagonists
● Triple H therapy
● Angioplasty
Box 19-26 Angioplasty
This is indicated if:
● The neurologic deficit has no other possible cause
than vasospasm
● The ischemic deficit is not responsive to 
triple H therapy
● The vasospasm is angiographically evident in an 
accessible area
● A recent infarction is absent
The risk for rebleeding is higher during the 24–48 hours
after the first hemorrhage. Clinically the level of con-
sciousness declines acutely and headache suddenly wors-
ens associating with confusion. If the patient is already
comatose, mydriasis and seizures occur, respiratory 
pattern changes, and apnoea may result. The control of
hypertension has an important role in the prevention of
rebleeding after subarachnoid hemorrhage, although the
treatment of systemic hypertension is complex and con-
troversial. Cerebral ischemia is more likely if patients
receive antihypertensive treatment, but the incidence of
rebleeding is higher if systolic arterial pressure is higher
than 160 mmHg. Patients with a stable mean arterial
pressure higher than 130 mmHg that is not related to
pain, anxiety, or discomfort from mechanical ventilation
should receive an antihypertensive treatment based on
labetalol or esmolol. Surgical repair of the aneurysm is
the best way to prevent rebleeding.
Intracranial Hematoma
Among patients with subarachnoid hemorrhage,
around 15–20% also present with intracranial hematoma.
Immediate surgical drainage is necessary if signs of brain
compression occur, otherwise intracranial hematoma is
drained when aneurysm is repaired.
Hydrocephalus
The incidence of hydrocephalus in patients with sub-
arachnoid hemorrhage is 20%. It may be acute, subacute,
or late. Acute hydrocephalus is evident on the first CT
scanning and is usually associated with intraventricular
hemorrhage. The treatment of acute hydrocephalus is
based on immediate ventricular drainage avoiding a sud-
den decrease in cerebrospinal fluid that may precipitate
rebleeding, while lumbar puncture should be avoided.
Subacute hydrocephalus occurs during the first week after
the onset of subarachnoid hemorrhage. Usually subacute
hydrocephalus is communicant and is not associated with
neurologic impairment. While subacute hydrocephalus
should be monitored with serial examinations, its treat-
ment is reserved for the cases associated with neurologic
signs because it usually resolves spontaneously. Late
hydrocephalus occurs weeks to months after the first
bleeding and it is usually associated with a typical clinical
triad: ataxia, dementia, and incontinence. A permanent
ventricular shunting should be considered.
Persistent Intracranial Hypertension
Subarachnoid hemorrhage is usually associated with 
a sudden increase in intracranial pressure that may
become higher than arterial pressure resulting in the
transient loss of consciousness usually present in the
acute phase. This may be a defensive mechanism that
would limit bleeding. If the amount of blood in the 
subarachnoid space is high enough it may cause persist-
ent intracranial hypertension resulting in cerebral death.
Seizures
The incidence of seizures in the acute phase of sub-
arachnoid hemorrhage is 10–15%. If seizures occur after
the acute phase, rebleeding should be excluded with
appropriate examinations because seizures may be the
sign of rebleeding. Seizures are usually associated with
severe acute hypertension that may be the cause of
rebleeding and should be prevented.
Medical Complications
Arrhythmias (QT tract alterations, atrial flutter and 
fibrillation, supraventricular tachycardia, and ectopic
beats) and electrocardiographic alterations like T wave
inversion and ST-T tract changes are associated with 50%
of the cases of subarachnoid hemorrhage. Ischemic
myocardial lesions including necrosis have been
observed with an incidence around 1%. Acute pulmonary
edema occurs in 2% of cases. Probably cardiovascular
complications result from the high plasmatic levels of
catecholamines observed in patients with subarachnoid
hemorrhage. Cardiac and pulmonary complications may
be precipitated by triple H therapy. Another common
medical complication associated with 4–30% of cases is
hyponatremia. This has been considered the result of
inappropriate secretion of ADH, but it is usually caused
by a cerebral salt wasting syndrome often associated
with subarachnoid hemorrhage. Alterations in the pro-
duction of vasopressin, atrial, and cerebral natriuretic
hormone contribute to this salt wasting syndrome.
Hyponatremia and hypovolemia are associated with
delayed ischemic deficit while hyponatremia and hyper-
volemia are associated with cerebral edema and intra-
cranial hypertension. Other medical complications often
associated with subarachnoid hemorrhage are stress
ulcers and deep venous thrombosis (Box 19-27).
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Box 19-27 Medical Complications of
Subarachnoid Hemorrhage
● Arrhythmias
● Electrocardiographic alterations
● Ischemic myocardial lesions
● Acute pulmonary edema
● Hyponatremia
● Hypovolemia
● Hypervolemia
● Stress ulcers
● Thromboembolism
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EPIDEMIOLOGY
Traumatic brain injury (TBI) is considered a “silent
global epidemic” because the incidence of TBI is
between 180 and 250 per 100,000 population per year
(in the USA) and it may be even higher in Europe. Each
year TBI causes more than 50,000 deaths for a rate of
20.6 per 100,000 population, more than 33% of all
injury-related deaths. Moreover, neuropsychologic
impairments and other disabilities requiring extensive
rehabilitation services and long-term care are common
among survivors. Groups at high risk for TBI include
males, especially adolescents and young adults, and
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individuals living in regions with socioeconomic depriva-
tion. The age-specific TBI incidence curve shows a bipha-
sic pattern with a peak in the second and third decades
and another one over the seventh decade. Mortality rate
from TBI is higher among persons aged over 75 years and
among males. Causes of TBI may be motor vehicle-
related, fall-related, or firearm-related. Industrial acci-
dents, non-motor vehicle-related trauma, and assaults are
other possible causes. The pattern of TBI shows marked
variations across the world. For example, in western
Europe vehicular-related TBIs are decreasing because of
preventive strategies (mandatory helmets, speed control,
etc.). The highest motor vehicle-related TBI death rates
are among persons aged 15–19 and 20–24 years. Among
persons aged over 75 years, falls are the leading cause of
fatal TBIs. Death rates among persons with these injuries
are considerably higher among males than females.
CLASSIFICATION
TBI is a clinical entity caused by a direct and/or indi-
rect mechanical insult, characterized by signs of diffuse
or localized brain dysfunction which may occur early 
or late after the mechanical insult. From an anatomic/
pathologic perspective TBI may be classified according
to the associated lesions of the skull and the brain
parenchyma (Box 20-1).
From a clinical point of view TBI may be classified
according to the Glasgow Coma Scale (GCS) (Box 20-2).
Recently, the modified Head Injury Severity Score
(HISS) has been proposed. This system classifies TBI as:
● minimal if GCS is equal to 15 and TBI has not been
associated with loss of consciousness;
● mild if GCS is equal to 14 or 15 and if TBI has been
associated with brief (<5 minutes) loss of conscious-
ness or amnesia;
● moderate if GCS is between 9 and 13 and loss of con-
sciousness has lasted more then 5 minutes or a focal
neurologic deficit is present; and
● severe if GCS is below 8.
PATHOPHYSIOLOGY
The pathophysiology of TBI depends on three differ-
ent pathologic instances: the brain damage at the time of
injury (primary damage), the insults the brain receives
during the postinjury phase (secondary damage), and
the extracranial lesions. All these move together to cere-
bral tissue hypoxia and ischemia which are the leading
causes of brain death.
Primary Damage
Primary damage is the brain injury that occurs at the
time of the initial mechanical insult. This is a major
determinant of outcome from TBI, but, unless it consists
of a surgically evacuable mass lesion, it is usually irre-
versible. Primary damage includes scalp lacerations and
skull fractures, brain contusion and lacerations, intra-
cranial traumatic hemorrhage (extradural, subdural,
and intracerebral hematoma), and diffuse axonal injury
(Box 20-3).
Box 20-1 Anatomic/Pathologic
Classification of Traumatic
Brain Injury
● Skull vault fracture
● Skull base fracture
● Other skull fractures
● Multiple fractures involving skull or face with other
bones
● Concussion
● Cerebral laceration and contusion
● Subdural, subarachnoid, and extradural hemorrhage
after injury
● Other unspecified intracranial hemorrhage after injury
● Intracranial injury, not otherwise specified
● Late effects of fracture of the skull and face
● Late effects of intracranial injury without skull fracture
● Other open wound to the head
Box 20-2 Glasgow Coma Scale
BEST EYES OPEN SCORE
Spontaneously, 4
On command, 3
To pain, 2
No response, 1
BEST VERBAL RESPONSE
Orientated, 5
Confused, 4
Inappropriate words, 3
Incomprehensible, 2
No response, 1
BEST MOTOR RESPONSE
Obeys to command, 6
Localized pain, 5
Flexion withdrawal, 4
Abnormal flexion, 3
Extension, 2
No response, 1
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Scalp Lacerations and Skull Fractures
Because of the scalp’s rich vascularization, scalp lac-
erations may be associated with underestimated blood
loss. The site and the size of skull fractures depend on
the impact site and the speed and the shape of the dam-
aging agent. Skull fractures may be categorized as blunt
(if the skin is intact) or penetrating (if the skull vault
appears through the scalp laceration) or, according to
their site, as skull vault fractures and skull base fractures.
Skull vault fractures may radiate to the base and may be
linear or depressed.
Skull base fractures may involve the anterior, medial, or
posterior cranial fossa. If the skull base fracture is associ-
ated with a dural lesion cerebrospinal fluid may drain to
the nose or ear producing oto- or rhinoliquorrhea that may
be complicated by meningitides requiring sometimes a sur-
gical treatment. If the anterior cranial fossa is fractured,
lesions of the first, second, third, and fifth cranial nerves
may occur (sphenoidal fissura syndrome); an ecchymosis
over the eyelid, the orbitary, and the subconjunctival
region appears usually 2–3 days after the trauma. When the
medial cranial fossa is fractured, the internal auditory 
meatus and the middle ear are often involved with otor-
rhagia and otorrhoea if the tympanic membrane is injured.
Lesions to the fifth, seventh (peripheral paralysis of the
facial nerve), and eighth cranial nerves may occur. Sinum
cavernosum may be involved resulting in carotid injuries
and fistula between carotid artery and sinum cavernosum.
When there is a posterior cranial fossa fracture, lesions to
the ninth, tenth, eleventh, and twelfth cranial nerves may
occur with phonation and deglutition problems. Growing
fractures are skull fractures associated with dural and
arachnoid lesions; a pulsatile tender mass usually develops
in a few weeks (Box 20-4).
Brain Contusions and Lacerations
Brain contusions and lacerations are traumatic lesions
to the brain parenchyma, usually in the frontal and tem-
poral lobes. Brain contusion is characterized by the
breakage of cortical capillaries and pia mater resulting in
a little hemorrhage and ecchymosis over the brain. Brain
laceration instead is characterized by a macroscopic
lesion to the brain parenchyma that appears necrotic
and mixed to blood clots. Brain laceration may be either
limited to a subcortical area or extended to a cerebral
lobe and cerebral ventricles. Intra- or extraparenchymal
hemorrhages, cerebral edema, and necrosis are often
associated with these lesions.
Extradural Hematoma
Extradural hematoma is a mass of blood between dura
mater and the skull bone. Extradural hematomas are
localized mostly in the temporal and parietal areas
because they are very exposed to traumatic injuries and
because meningeal artery branches run through this
region. More than 50% of extradural hematomas are
arterial in origin, deriving usually from the medial
meningeal artery. They also may be venous either from
bone or dura mater vessels. Usually they are associated
with skull fractures and, in around 40% of cases, with
brain contusions and lacerations or intraparenchymal
hematomas. Clinically extradural hematoma results in
consciousness alterations often stable or progressing
to coma. The classic pattern of loss of consciousness,
symptom-free interval (minutes to days), and coma is not
the most frequent clinical pattern. Usually extradural
hematomas also present site-related signs like contra-
lateral hemiparesis, hemiplegy, Babinski, and homolateral
mydriasis with anisocoria (in 60% of cases). Signs related
to cerebral herniation may present sooner or later after
trauma. Urgent surgical treatment is the primary therapy
for extradural hematoma because outcome is determined
by the size of the blood mass, and also by the extent to
which the secondary distortion of the brain stem has pro-
gressed before surgery has been undertaken (Box 20-5).
Box 20-3 Primary Damage
Primary damage includes:
● Scalp lacerations
● Skull fractures
● Brain contusion and lacerations
● Intracranial traumatic hemorrhages (extradural, 
subdural, and intracerebral)
● Diffuse axonal injury
Box 20-4 Skull Base Fractures
Skull base fractures may involve:
● Anterior cranial fossa with lesions of the first, 
second, third, and fourth cranial nerves and 
ecchymosis over the orbitary region
● Medial cranial fossa with lesions of the fifth, seventh,
and eighth cranial nerves, otorrhagia and otorrhoea
● Posterior cranial fossa with lesions of the ninth,
tenth, eleventh, and twelfth cranial nerves
Box 20-5 Clinical Signs of Extradural
Hematoma
Clinical signs of extradural hematoma include:
● Alterations of consciousness
● Contralateral hemiparesis
● Contralateral Babinski
● Homolateral mydriasis with anisocoria
● Signs of cerebral herniation
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Subdural Hematoma
Subdural hematoma is a blood mass between dura
mater and arachnoides. Usually it is associated with a hem-
orrhagic brain laceration; extradural or intraparenchymal
hematomas may coexist. It is more frequent in the elderly.
It is localized usually in the interhemispheric scissure,
expanding to the frontal, parietal, and temporal lobes.
Brain atrophy may allow the brain to move according to
the trauma-related accelerations and decelerations; this
movement would stretch the “bridge veins” between
dura mater and cerebral parenchyma making them bleed.
The blood may also originate from cerebral cortex arter-
ies and veins. Subdural hematoma is rarely alone and
acute; usually it is associated with brain contusions and
lacerations that may take part in the hematoma devel-
opment. Disorders of consciousness are often early and
severe. A minor disorder of mentation is not unusual,
although it often progresses to coma. Homolateral mydri-
asis and contralateral hemiparesis may often be present
in association with signs of brainstem lesions like decer-
ebration. Neurovegetative signs including hyperthermia,
hypertension, and electrocardiographic abnormalities are
also common. Surgical treatment is the therapy of choice
for subdural hematoma.
Intracerebral Hematoma
Intracerebral hematoma is a blood mass totally inside
the brain parenchyma, without extension to the brain
surface. At the moment of traumatic impact a breakage
of intracerebral vessels results in intracerebral hemor-
rhages. Intracerebral hematoma derives from these mul-
tiple intracerebral traumatic hemorrhages. Frontal and
temporal lobes are the most frequent locations although
even deeper areas such as basal nuclei may be involved.
Usually intracerebral hematomas are associated with
brain lacerations and contusions as well as diffuse axonal
injury. The clinical picture usually includes disorders 
of consciousness, hemiplegy, anisocoria, and brain-
stem involvement. A surgical approach to intracere-
bral hematoma is not always possible and outcome is
usually poor.
Diffuse Axonal Injury
Diffuse axonal injury is a diffuse injury to the white
cerebral matter. Damaged axons display injuries pro-
gressing to axonal disconnection. Time allows a glial
reaction with myelin degeneration. Probably stretching
stress during the acceleration–deceleration phases of
traumatic impact causes axonal breakage and a focal
influx of Ca2+ promoting proteolytic processes involving
cysteine proteases, calpain, and caspase that modify the
axonal cytoskeleton, causing irreversible damage. The
clinical picture of diffuse axonal injury is a severe neu-
rologic failure with post-traumatic coma evolving into 
a persistent vegetative state without macroscopic
encephalic lesions. Surgical treatment is impossible, and
medical treatment gives frustrating results and outcome
is poor. Inhibition of proteolytic processes may be a
therapeutic strategy in the future.
Secondary Damage
Secondary damage includes the insults that the brain
receives in the postinjury phase of trauma. Every clinical
complication that reduces cerebral nutrients and oxygen
delivery (hypotension, hypoxia, anemia, hypoglycemia,
hypocapnia, etc.) or increases cerebral oxygen consump-
tion (hyperthermia, seizures) contributes to secondary
damage. Secondary brain damage includes cerebral edema,
ischemic brain damage, brain shift and herniation, and
hydrocephalus (Box 20-6).
Cerebral Edema
Brain swelling is a very dangerous secondary damage
because it may progress to brain ischemia and herniation
given that the nervous parenchyma is embedded in the
noncompliant box of the skull. The brain is particularly
susceptible to edema because it is not supplied with a
lymphatic system to drain extraneous fluid in the inter-
stitial compartment. Ion and water movement between
the vessels and the brain occurs across the blood–brain
barrier which depends on the capillaries of the brain.
Here endothelium has tight junctions and few endocytotic
vesicles. This kind of endothelial differentiation derives
from the cross-talk with astrocytes. Cerebral edema may
be vasogenic, cytotoxic, and interstitial (Box 20-7).
Box 20-6 Secondary Damage
Secondary damage includes:
● Cerebral edema
● Ischemic brain damage
● Brain shift and herniation
● Hydrocephalus
Box 20-7 Cerebral Edemas
Cerebral edemas include:
● Vasogenic edema resulting from fluid spilling across
the vessels to the extracellular compartment
● Cytotoxic edema resulting from an increase in the
intracellular water caused by ischemia
● Interstitial edema occurring in some kinds of 
hydrocephalus because of fluid accumulation in
periventricular areas
● Vasogenic edema is the result of fluid spilling across
the vessels to the extracellular compartment. Usually
the vessels producing vasogenic edema show an
abnormal barrier function. Brain contusions and lac-
erations usually are surrounded by injured vessels
with poor barrier function. Moreover ischemia may
alter endothelial barrier function resulting in vaso-
genic edema that increases intracranial pressure and
ischemia with a negative closed loop mechanism.
Vasogenic edema affects preferentially white cere-
bral matter that appears swollen.
● Cytotoxic edema results from an increase in the intra-
cellular water. Cerebral gray matter is usually more
susceptible to cytotoxic edema as consequence of
either ischemia or hypo-osmolarity. Ischemia impairs
neuronal metabolism and membrane ionic pump
function. Hypo-osmolarity shifts water into neuronal
cells that appear swollen.
● Interstitial edema occurs in some kinds of hydro-
cephalus when fluids cross ependimal cells and accu-
mulate in the periventricular areas.
Ischemic Brain Damage
Ischemic brain damage is one of the most important
factors precipitating TBI. Most ischemic brain damage is
secondary to brain swelling, brain shift, and brain herni-
ation, rather than the direct effect of the primary damage
upon the brain.
TBI is strongly linked to ischemic brain damage.
Ischemic brain damage results from pathogenetic mech-
anisms associated also with TBI, including excitotoxicity,
inflammation, free radicals, and apoptosis. Production of
heat shock proteins and endogenous antioxidants are
defensive mechanisms triggered by cerebral ischemia
and TBI (Box 20-8).
Phospholipase stimulation may cause alterations in
membrane phospholipids compromising the ability to
accumulate excitotoxic amino acids. Inhibitors of both
cyclooxygenase and lipoxygenase pathways have been
shown to reduce cerebral deficits following ischemia and
trauma. Excitotoxicity is considered to be caused mainly
by the inappropriate release of glutamate. Multiple human
clinical trials focused on glutamate antagonists for the
treatment of TBI and ischemia. Even nonneuronal cells
(brain glia and lymphocytes) can release substances that
bind to glutamate receptors. Excitotoxicity may be ongo-
ing for several days, rather than just in the initial phase
of TBI. Hence arresting excitotoxic processes may mod-
ulate progressive brain injury in the initial days after TBI.
Ischemic brain injury associated with TBI causes neuronal
apoptotic death. A calcium-binding peptide produced by
astrocytes may be implicated in neuronal apoptosis.
Ischemic brain damage adversely affects outcome mor-
bidity, and the difficulty in preventing ischemic damage
in cases with marked brain shift leads to poor outcome in
patients with TBI.
Brain Shift and Herniation
Intracranial hypertension is often associated with TBI
because blood masses may evolve in brain shift and 
herniation. Cerebral masses move areas of cerebral
parenchyma across dural folds resulting in brain shift
and herniation. If one hemisphere expands the cingulate
gyrus may herniate below the falx cerebri or the tempo-
ral lobe may herniate between the tentorium cerebelli
and the brainstem. The latter herniation may injure the
third cranial nerve with anisocoria and homolateral
mydriasis. Moreover the contralateral cerebral pedicle
may be compressed against tentorium cerebelli deter-
mining paralysis homolateral to the cerebral lesion
(Kernoan Woltman syndrome). Even if initially the res-
piratory pattern is not affected by this kind of herniation,
later pathologic respiratory patterns like Cheine–Stokes
breath may occur. Cerebellum may herniate into the
foramen magnum with a coning mechanism impairing
respiration and other brainstem functions. Brainstem
compression resulting from cerebellum herniation may
be fatal. Cerebral parenchyma may also herniate across
skull defects. Brain shift compresses superficial cerebral
arteries against dural folds determining occlusion and
cerebral ischemia (Box 20-9).
Hydrocephalus
Hydrocephalus is a dilatation of the cerebral ventricles
with increased cerebrospinal fluid. TBI may obstruct
cerebrospinal fluid flow. When this obstruction occurs
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Box 20-8 Ischemic Brain Damage
Ischemic brain damage results from:
● Excitotoxicity
● Inflammation
● Free radicals
● Apoptosis
Heat shock proteins and endogenous antioxidants
are defensive mechanisms.
Box 20-9 Brain Herniation
Brain herniation includes:
● Herniation of the cingulate gyrus below falx cerebri
● Herniation of the temporal lobe between tentorium
cerebelli and the brainstem
● Herniation of the cerebellum into the foramen 
magnum
● Herniation of the cerebral parenchyma through
skull defects
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in the intraencephalic liquoral spaces, hydrocephalus is
noncommunicant. If obstruction occurs in the subarach-
noid space, hydrocephalus is communicant. Ventricular
dilatation secondary to severe hydrocephalus may pro-
duce cerebrospinal fluid spillage in periventricular brain
parenchyma resulting in interstitial cerebral edema.
Extracranial Lesions
TBI is often associated with extracranial lesions that
may contribute to outcome. Thoracic lesions should
always be considered and are particularly dangerous in
association with TBI because they cause by themselves
hypoxia and hypercapnia. Moreover hypertensive pneu-
mothorax determines a decrease in cardiac output and
an increase in intracranial pressure resulting in severe
brain hypoperfusion. Abdominal traumas may be associ-
ated with significant blood loss that causes anemia and
hypotension, factors contributing to secondary damage
after TBI. Extremity fractures are also associated with
underestimated hypovolemia that may impair brain per-
fusion after TBI (Box 20-10).
PATHOPHYSIOLOGY OF 
CEREBRAL BLOOD FLOW
TBI is always associated with alterations in cerebral
blood flow because the physical injury and the con-
sequent inflammatory response impair the normal func-
tions of cerebral vessels and neurons. In particular, a
hypoperfusion phase is usually followed by a hyper-
emic or vasospastic phase. The first 72 hours following
TBI are usually characterized by a reduction in cerebral
blood flow resulting from intracranial and extracranial
mechanisms. This hypoperfusion phase produces ischemic
brain damage with cytotoxic cerebral edema and
increased intracranial pressure. Following this hypoper-
fusion phase 25–30% of patients experience a hyper-
emic phase with an increased cerebral blood flow that
persists during 7–10 days after TBI. Probably it is associ-
ated with a recovery of autoregulatory mechanisms.
Intracranial inflammation and the consequent impair-
ment of the blood–brain barrier lead to patients being at
risk for vasogenic cerebral edema in this hyperemic
phase. The hypoperfusion phase may be followed in
10–15% of patients by a persistent vasospastic phase
with cerebral hypoperfusion due to arterial vasospasm
(Box 20-11).
Autoregulation of Cerebral Blood Flow
If the cerebral perfusion pressure ranges between 50
and 150 mmHg, the cerebral vessels maintain a constant
cerebral blood flow according to the actual cerebral
metabolism. This property of cerebral blood flow is
known as cerebral blood flow autoregulation. In hyper-
tensive patients the pressure range of autoregulation is
higher for morphologic and functional changes in the
arterial walls. In TBI autoregulation is altered particularly
during the early hypoperfusion phase when cerebral per-
fusion pressure is directly dependent on systemic blood
pressure and probably should be higher than 60–70 mmHg
to guarantee an appropriate cerebral blood flow. During
the later hyperemic phase, autoregulation starts to
recover but high cerebral perfusion pressure may result
in vasogenic edema and increased intracranial pressure
so a lower range of cerebral perfusion pressure between
50 and 70 mmHg is safe. Mechanical, metabolic, and
neurogenic factors influence normal autoregulation. The
mechanical factor is the automatic and myogenic adapta-
tion of arteriolar resistances to transmural pressure
changes. Transmural pressure is the difference between
pressures inside and outside the vessel; the pressure
inside the vessels is considered the medium arterial pres-
sure and the pressure outside the vessels is considered
the intracranial pressure. If transmural pressure
increases, vessels constrict; if it decreases, vessels vasodi-
late. When vessels change their caliber intracranial blood
volume also changes. If intracranial arterial blood vol-
ume increases, cerebrospinal fluid shifts compressing
intracranial veins and reducing intracranial venous blood
volume. The metabolic factor is the coupling between
cerebral blood flow and cerebral metabolism that guaran-
tees appropriate substrate delivery for cerebral metabolism
(Box 20-12).
Box 20-10 Extracranial Lesions
Extracranial lesions that may complicate traumatic
brain injury:
● Thoracic lesions
● Abdominal traumas
● Extremity fractures
Box 20-11 Pathophysiology of Cerebral
Blood Flow in Traumatic 
Brain Injuries
The pathophysiology of cerebral blood flow in 
traumatic brain injuries includes:
● Hypoperfusion phase, usually characterizes the first
72 hours after trauma
● Hyperaemic phase, occurs in 25–30% of patients
after the hypoperfusion phase, persists for
7–10 days after trauma
● Vasospastic phase, occurs in 10–15% of patients 
following the hypoperfusion phase
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Carbon dioxide is the most important substance acting
on the metabolic factor of autoregulation because it
crosses the blood–brain barrier rapidly influencing extra-
cellular pH that influences vessel caliber. If PaCO2
increases by 1 mmHg, cerebral blood flow increases 4%
and intracranial vascular volume increases 0.04 ml/100 g.
TBI is often characterized by an uncoupling between
cerebral metabolism and cerebral blood flow. In acute
traumatic injury often there is a reduction in cerebral
metabolism sometimes associated with an increase in
cerebral blood flow because of an abnormal autoregula-
tion. TBI is associated also with an impaired hypocapnic
vasoconstriction localized more in injured areas than 
all over the brain. Hypercapnia will determine an “intra-
cranial steal phenomenon” because the vasodilatation of
healthy areas steals blood from the injured areas. Instead,
hypocapnia may cause an “inverse steal phenomenon”
causing a redistribution of blood flow to the injured
areas. This is the rationale for therapeutic hypocapnia in
TBI. In any case hypocapnia may cause ischemia in pre-
viously healthy areas especially during the early hypo-
perfusion phase, so appropriate neuromonitoring is
necessary when hyperventilation is used.
Intracranial Pressure and Cerebral
Perfusion Pressure
The skull is a rigid box with an incompressible 
content including cerebral parenchyma (80%), cere-
brospinal fluid (10%), and blood vessels (10%). The
incompressibility of the content and the rigidity of the
container is the basis of the Monro–Kelly law stating that
the sum of cerebral parenchyma volume, cerebrospinal
fluid volume, and blood vessel volume is constant. If one
of the three contents increases in volume, initially the
others decrease, then, when the total content volume
increases, intracranial pressure also increases. Cerebral
perfusion pressure, a major determinant of cerebral blood
flow, is highly influenced by intracranial pressure. Cerebral
perfusion pressure, in fact, is the difference between the
arterial pressure in the feeding arteries as they enter the
subarachnoid space and the pressure in the draining
veins before they enter dural sinuses. These pressures
are difficult to measure, so cerebral perfusion pressure
(CPP) is considered the difference between the systemic
mean arterial pressure (MAP) and the intracranial pres-
sure (ICP), taken as an estimate of tissue pressure: CPP =
MAP − ICP (Box 20-13).
Simultaneous measurement of both invasive arterial
pressure and intracranial pressure has therefore become
a useful monitoring technique in patients with TBI to
determine the cerebral perfusion pressure.
Given that an estimation of the cerebral perfusion
pressure based on intracranial pressure is misleading if
the intracranial pressure is low, recently it has been pro-
posed to measure the critical closing pressure. The cere-
bral critical closing pressure may be determined in a
minimally invasive way using transcranial Doppler flow
tracings and invasive arterial pressure. In up to 50% of
patients with TBI intracranial pressure may lead to an
overestimation of the cerebral perfusion pressure when
compared to critical closing pressure.
Vasodilatation and Vasoconstriction
Cascades
The physiologic concept of vasodilatation and vaso-
constriction cascades is the base for a recent therapeutic
strategy for TBI. The vasodilatation cascade depends on
a reduction in cerebral perfusion pressure that has an
autoperpetuating trend. In fact, if the cerebral perfusion
pressure decreases, cerebral vessels dilate in an attempt
to maintain cerebral blood flow as a result of normal
autoregulation. This vasodilation results in an increased
cerebral blood volume that increases intracranial pres-
sure and finally reduces the cerebral perfusion pressure.
This vasodilatation vicious circle may be interrupted
triggering the vasoconstriction cascade by increasing
arterial blood pressure. The increase in arterial blood
pressure leads to an increase in cerebral perfusion pres-
sure resulting, according to normal autoregulation,
Box 20-13 Intracranial Pressure and
Cerebral Perfusion Pressure:
The Relationship
● According to the Monroe–Kelly law, the sum of 
cerebral parenchyma volume, cerebrospinal fluid 
volume, and blood vessel volume is constant.
● If one of these three contents of the skull increases
in volume, intracranial pressure also increases.
● The cerebral perfusion pressure (CPP) is considered
the difference between the systemic mean arterial
pressure (MAP) and the intracranial pressure (ICP):
CPP = MAP − ICP
Box 20-12 Autoregulation of Cerebral
Blood Flow
Autoregulation of cerebral blood flow is influenced by:
● Mechanical factor – the automatic and myogenic
adaptation of arteriolar resistances to transmural
pressure changes
● Metabolic factor – the coupling between cerebral
blood flow and cerebral metabolism
● Neurogenic factor
in vasoconstriction of cerebral vessels. This vasocon-
striction reduces cerebral blood volume and then
intracranial pressure resulting finally in an increase in
cerebral perfusion pressure (Box 20-14).
MANAGEMENT OF TRAUMATIC 
BRAIN INJURY
Prehospital and Emergency Room Care
Prehospital and emergency room care of TBI should be
directed by the Advanced Trauma Life Support (ATLS)
guidelines for the early management of trauma. Prehospital
care of TBI includes airway management and treatment of
hypoxia, hypotension, and fluid resuscitation and neuro-
logic assessment only after cardiorespiratory stability has
been guaranteed. Emergency room care includes car-
diorespiratory stability optimization, considerations related
to the multiple trauma patient, neurologic assessment fol-
lowed by brain-specific therapies, and early diagnostic
workup with indications for surgery (Box 20-15).
Hypoxia and Airway Management
Orotracheal intubation is the gold standard for airway
management and hypoxia treatment of patients with
severe traumatic brain injury (GCS < 9), marked agitation,
or severe extracranial trauma. Nasotracheal intubation is
contraindicated in suspected fractures of the skull base
because the lesion of the cribriform plate could create a
communication with intracranial structures. Orotracheal
intubation should be performed using a rapid sequence
induction with cricoid pressure (Sellick maneuver) and
in-line immobilization of the cervical spine. All patients
with TBI are assumed to have a potential cervical spine
injury and should be immobilized in a rigid collar until a
cervical spine fracture is definitely excluded by appro-
priate radiologic imaging examination. After appropriate
orotracheal intubation TBI patients should be ventilated
in 100% oxygen to maintain PaO2 above 100 mmHg; ven-
tilation should be adjusted to maintain a normal PaCO2
of 35–40 mmHg. Hyperventilation in early resuscita-
tion is not indicated, the priorities being appropriate
oxygenation and hemodynamic stability.
Hypotension and Fluid Resuscitation
In TBI hypotension may be a dangerous trigger of sec-
ondary damage. Concomitant multiple system trauma is
often associated with TBI resulting in significant blood
loss, hemodynamic instability, and shock. Prompt restora-
tion of circulating blood volume to prevent secondary
damage deriving from cerebral hypoperfusion is a
widely recognized priority. Fluid resuscitation in TBI has
been the focus of much discussion because of the possi-
ble development of cerebral edema after administration
of large volumes of resuscitative fluids. The goal of fluid
resuscitation in TBI should always be euvolemia to opti-
mize cerebral perfusion pressure without contributing
to cerebral edema. The blood–brain barrier has peculiar
features being freely permeable to water, but nearly
impermeable to larger, colloid-sized molecules, and 
minimally permeable to most ions. The osmotic gradient
between blood and brain regulates water flux across the
blood–brain barrier. The colloid osmotic pressure does
not influence greatly fluid flux across the blood–brain
barrier because plasma colloids account for a small
fraction of the total number of particles in solution.
Serum osmolality is the major determinant of fluid flux
across the normal blood–brain barrier. However, TBI
and hemorrhagic shock are associated with proinflam-
matory mediator production that alters capillary perme-
ability in the brain. If the blood–brain barrier becomes
permeable to ions but not to larger colloid particles,
choice of fluid for resuscitation in TBI could be impor-
tant. If the blood–brain barrier is disrupted, however, per-
meability to both ions and colloidal particles may occur,
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Box 20-14 Vasodilatation Cascade
The vasodilatation cascade:
● Reduction in cerebral perfusion pressure
● Vasodilatation of cerebral vessels
● Increased cerebral blood volume
● Increased intracranial pressure
● Reduction in cerebral perfusion pressure
The vasoconstriction cascade:
● Increased arterial blood pressure
● Increased cerebral perfusion pressure
● Vasoconstriction of cerebral vessels
● Decreased cerebral blood volume
● Decreased intracranial pressare
● Increased cerebral perfusion pressure
Box 20-15 Prehospital Care of
Traumatic Brain Injury
Prehospital care of traumatic brain injury includes:
● Airway management
● Treatment of hypoxia
● Treatment of hypotension
● Neurologic assessment after cardiorespiratory
stability
Emergency room care includes:
● Cardiorespiratory stability optimization
● Neurologic assessment
● Eventual brain-specific therapies
● Early diagnostic workup
so fluid selection would be inconsequential. Patient with
TBI not associated with hemodynamic instability may 
be treated with fluid restriction and brain dehydrating
agents, but whenever traumatic shock occurs, large
volumes of fluids are necessary to restore hemodynamic
stability. There is a lack of evidence so far as to the
choice of fluid in this scenario. Serum osmolarity has an
established importance in the development of cerebral
edema, and hypertonic crystalloids alone or in combina-
tion with colloids have theoretic advantages in terms of
small-volume resuscitation with beneficial effects on
cerebral blood flow and cerebral edema. Although inva-
sive monitoring must not delay volume resuscitation,
early invasive blood pressure monitoring and central
venous pressure monitoring may guide more objectively
hypotension treatment and fluid resuscitation. Especially
when sedatives or opioids are used, inotropes like epi-
nephrine or norepinephrine and vasopressors like
metaraminol and phenylephrine may be necessary to
control hypotension while fluid resuscitation is under
way or complete.
Neurologic Evaluation
When cardiorespiratory stability has been achieved an
assessment of neurologic function is important to deter-
mine the severity of TBI. An initial evaluation during
resuscitation, as suggested by the ATLS guidelines, is
based on response to stimulation: the patient may be
awake, may respond to verbal or painful stimuli, or may
be unresponsive. The neurologic evaluation in TBI is
based on the GCS. GCS should be applied only after 
cardiopulmonary resuscitation and prior to surgical inter-
vention. Neurologic evaluation should always assign the
patient to one of the HISS categories that will guide the
following management of TBI. Pupil size and reactivity
should also be assessed in the initial neurologic evalua-
tion, particularly prior to the administration of opioids,
sedatives, and muscle relaxants. Anisocoria associated
with unilateral mydriasis may be associated with a homo-
lateral intracranial mass indicating compression of the
third cranial nerve and impending herniation. Sometimes
paralysis homolateral to the cerebral lesion is also pres-
ent (Kernoan Woltman syndrome). A motor function
examination deeper than that included in the GCS is
suggested to find out hemiparesis, lateralizing signs,
Babinski sign, and paraparesis and quadriparesis (from
spinal injuries) (Box 20-16).
The Multiple Trauma Patient
TBI is often associated with other potentially fatal
lesions that make the TBI patient a multiple trauma
patient. Once the initial assessment is complete, a care-
ful survey with a top to toe approach is mandatory.
To exclude important lesions every multiple trauma
patient should receive x-rays of the chest, pelvis, and
cervical spine and baseline blood tests. In fact, the mul-
tiple trauma patient may have extracranial causes of
hypoxia like hemo- or pneumothorax that need prompt,
life-saving treatment. Hemorrhages from major vascular
disruption or visceral injuries necessitate aggressive
treatment because of life-threatening cardiovascular
instability. In TBI hypotension may trigger secondary
damage so a target mean arterial pressure equal to the
patient’s usual blood pressure must be reached even
with inotropes or vasopressors. Fractures and lacera-
tions may also cause significant blood loss that must be
interrupted. Diagnosis and treatment of these problems
minimize secondary damage.
Early Management of Intracranial
Hypertension
The early treatment of intracranial hypertension
based on hyperventilation and osmotherapy requires a
CLINICAL CAVEAT
Every multiple trauma patient should receive:
● X-rays of the chest
● X-rays of the pelvis
● X-rays of the cervical spine
● Baseline blood test
Any doubt of lesion, particularly in the cervical
spine, should be clarified using CT scan.
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Box 20-16 Neurologic Evaluation
● GCS
● HISS
● Pupils examination before administration of opioids
● Motor function examination before administration
of sedatives or muscle relaxants
CLINICAL CAVEAT
Hyperventilation and Intracranial Pressure
● Hyperventilation is the most potent nonsurgical way
to reduce intracranial pressure
● The reduction in cerebral blood flow associated
with hyperventilation may precipitate cerebral
ischemia
● Hyperventilation is reserved for patients with
unequivocal signs of increased intracranial pressure
associated with impending herniation (mydriasis,
anisocoria, lateralizing signs)
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diagnosis of intracranial hypertension because they may
have negative side effects aggravating secondary damage.
Hyperventilation is the most potent nonsurgical way of
reducing intracranial pressure.
The other option used in the medical treatment of
intracranial hypertension is mannitol (0.25–1 g/kg) that
is an osmotically active agent administered to increase
plasma osmolality. Hypertonic saline (3%) increases
plasma osmolality and expands plasma volume restoring
systemic and cerebral perfusion in the acute phase of TBI.
Hypertonic saline has fewer side effects than mannitol.
It does not induce any osmolal gap so it allows an easier
titration. Hypertonic saline is the intracranial pressure-
reducing agent of choice in the early phase of TBI because
it reduces intracranial pressure and increases cerebral
blood flow in the early hypoperfusion phase.
Early Diagnostic Workup
Every multiple trauma patient receives x-rays of the
chest, pelvis, and cervical spine. Any doubt of lesion,
particularly in the cervical spine, should be clarified
using computed tomography (CT) scan. TBI guidelines
define the role of CT scan according to the severity of
TBI. In severe TBI a CT scan should be obtained as soon
as cardiovascular and respiratory stability has been
achieved. The patient will be then admitted to an inten-
sive care unit (ICU). In minimal injuries the risk of com-
plications is low and hospital admission is not necessary.
The patient may be discharged with an instruction form
including symptoms (severe headache, repeated vomit-
ing, confusion, reduced level of consciousness) that
should lead the patient to contact a physician. Additional
risk factors in TBI are therapeutic anticoagulation, hemo-
philia, radiographically demonstrated skull fracture, 
clinical signs of depressed skull fracture or skull base
fracture, post-traumatic seizures, shunt-treated hydro-
cephalus, and multiple injuries (Box 20-17).
If one of these risk factors is present CT scanning
should be performed even in minimal TBI and the
patient should be admitted to the hospital for observa-
tion. In mild TBI CT scanning should be performed and,
if it is normal and additional risk factors are absent, the
patient may be discharged with a copy of the instruction
form. If CT scan is not normal or an additional risk factor
is present the patient should be admitted to the hospital
for observation. In moderate TBI the patient should
always receive CT scanning and hospital admission for
observation. In-hospital observation has a sensitivity for
detection of intracranial hematoma lower than early CT
scan and is dependent on strict observation including
assessment of GCS, pupillary responses, motor responses,
blood pressure, and heart rate. This assessment should
occur every 15 minutes for the first 2 hours after admis-
sion and thereafter every hour until at least 12 hours after
injury. If admitted patients deteriorate during observa-
tion developing focal neurological deficits or a reduction
of the GCS of ≥2 points, urgent CT scan should be per-
formed. CT scanning is the most useful radiologic evalu-
ation in TBI. It allows a prompt detection of mass lesions
such as extradural or subdural hematomas. CT scanning
should be performed, using both parenchymal and bone
windows, with 5 mm thick axial slices from the foramen
magnum through the sella, followed by 10 mm thick
slices through the supratentorial region. Combative
patients may require orotracheal intubation, sedation,
and ventilation to facilitate CT scanning.
The degree of TBI may be quantified by radiologic
criteria useful for comparison with subsequent scans,
CLINICAL CAVEAT
Early Diagnostic Workup
● In severe TBI perform CT scan as soon as
cardiopulmonary stability has been achieved
● In moderate TBI perform CT scan and admit the
patient for observation
● In mild TBI perform CT scan and admit the patient
if it is abnormal or there are additional risk factors;
otherwise discharge the patient with an instruction
form
● In minimal TBI with additional risk factors perform
CT scan and admit the patient for observation
● In minimal TBI without additional risk factors
discharge the patient with an instruction form
CLINICAL CAVEAT
Osmotic Therapy and Intracranial Hypertension
● Mannitol treatment prior to imaging is reserved for
cases with unequivocal intracranial hypertension
● Hypertonic saline increases plasma osmolality and
expands plasma volume with fewer side effects than
mannitol in the acute phase of TBI
Box 20-17 Additional Risk Factors
in Traumatic Brain Injury
● Therapeutic anticoagulation
● Hemophilia
● Radiographically demonstrated skull fracture
● Clinical signs of depressed skull fracture or skull
base fracture
● Post-traumatic seizures
● Shunt-treated hydrocephalus
● Multiple injuries
for intracranial pressure monitoring decisions, and for
prognosis. The classification listed in Box 20-18 of CT
scan appearance following TBI is the most popular.
TBI may be associated with a vascular injury like
carotid artery dissection. In these cases cerebral angiog-
raphy may be considered. The suspicion of carotid artery
dissection may rise from an abnormal CT scan or from a
discrepancy between the patient’s clinical condition and
CT scan findings. Although NMR can detect small hem-
orrhagic collections and contusions, usually it does not
provide information significantly better than that deriving
from CT scan. Limitations in placement and monitoring
an acute trauma patient in an NMR scanner raise an addi-
tional risk that advises against its use in these cases.
Indications for Surgery
In TBI several primary damages may necessitate 
surgical treatment. Urgent surgical evacuation is the pri-
mary therapy for extradural hematoma; in these cases
surgery is urgent. Surgical treatment is also the therapy
of choice for subdural hematoma even if the chances of
good outcome decrease when subdural hematoma is
associated with a large brain laceration. A surgical
approach to intracerebral hematoma is not always possi-
ble. Brain contusion and lacerations may be submitted to
surgical treatment, but after evaluation of the clinical
and CT scan evolution of the lesions. Among skull frac-
tures, depressed vault fractures and growing fractures
may be surgically treated (Box 20-19).
Anesthesia for the Head-Injured Patient
Anesthesia for TBI is necessary whenever indication
for surgery is present. In these cases anesthesia should
follow the general principles of maintaining good 
cerebral oxygenation and appropriate cerebral perfusion
pressure and controlling intracranial hypertension.
Appropriate monitoring includes invasive blood pres-
sure monitoring besides the other standard monitors.
PaO2 should always be maintained above 100 mmHg.
While high FIO2 may be necessary to achieve this target,
the value of positive end-expiratory pressure (PEEP)
should remain below 10 cmH2O. The use of a higher
PEEP is discouraged because of the possibility of
decreases in blood arterial pressure in hypovolemic
patients and of compromised cerebral venous return
resulting in increased intracranial pressure. Appropriate
cerebral perfusion pressure requires a systemic blood
pressure maintained to the preinjury level for every
patient. Elderly and hypertensive patients may require a
higher systemic blood pressure to obtain an appropriate
cerebral perfusion pressure. The restoration of the euv-
olemic state is critical to maintain arterial blood pressure
during anesthesia. Overhydration should be avoided.
Adjusting the depth of anesthesia to the surgical stimu-
lation usually ensures a good cerebral perfusion pres-
sure; sometimes it may be necessary to administer
vasopressors or inotropes. The target of appropriate
arterial pressure should always be achieved (Box 20-20).
Anesthetic agent choice should be based on the
effects on cerebral physiology. Intravenous anesthetic
agents cause parallel alterations in cerebral metabolic
rate and cerebral blood flow reducing both. Ketamine is
the exception increasing both cerebral metabolism and
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Box 20-18 Marshall’s Classification of
CT Scans after Traumatic
Brain Injury
● Diffuse injury (DI) I – no intracranial pathology
visible on CT scan
● DI II – cisterns present a midline shift of 0–5 mm,
lesion densities present high or mixed density
<25 mm
● DI III – cisterns are compressed or absent with
midline shift of 0–5 mm, high or mixed densities
<25 mm
● DI IV – midline shift >5 mm, high or mixed densities
<25 mm
● Nonevacuated mass lesion – high or mixed density
lesion >25 mm not surgically evacuated
● Evacuated mass lesion – any lesion surgically
evacuated
Box 20-19 Indications for Surgery
● Extradural hematoma
● Subdural hematoma
● Some kinds of intracerebral hematoma
● Some kinds of brain contusions and lacerations
● Depressed vault fractures
● Growing fractures
Box 20-20 Targets of Anesthesia for the
Head-Injured Patient
● Avoidance of hypoxia
● Maintenance of cerebral perfusion pressure
● Control of intracranial hypertension
These targets require:
● Appropriate FIO2
● PEEP up to 10 cmH2O
● Maintenance of systemic arterial pressure to the
preinjury level
cerebral blood flow. Probably intravenous anesthetic
agents preserve the coupling between cerebral meta-
bolic rate and cerebral blood flow. The cerebral meta-
bolic rate/cerebral blood flow ratio is different using
different intravenous agents so these drugs may have
direct effects on cerebral vessels. Propofol preserves
autoregulation and CO2 responsiveness. Opioids have
relatively little effect on cerebral blood flow and cerebral
metabolism causing modest reductions of both. Inhaled
anesthetics increase cerebral blood flow/cerebral meta-
bolic rate ratio reducing cerebral metabolism more than
cerebral blood flow. This may result in increased
intracranial pressure. Halothane has more vasodilating
potency than isoflurane and sevoflurane and can pro-
duce reversible toxicity when administered in very high
concentrations interfering with oxidative phosphoryla-
tion in the brain. Halothane should be avoided in anes-
thesia for TBI because other inhaled anesthetics show a
better profile. Enflurane is potentially epileptogenic and
should also be avoided. Isoflurane and sevoflurane can
be safely used. They may increase cerebral blood flow 
in relation to cerebral metabolism, but a moderate
hypocapnia prevents or even reverses this alteration in
cerebral blood flow resulting in an unchanged intra-
cranial pressure. Nitrous oxide increases cerebral blood
flow, cerebral metabolic rate, and intracranial pressure,
and so it should be avoided. Nitrous oxide effects on
cerebral physiology are blunted by intravenous agents
such as opioids and benzodiazepines. The most popular
anesthetic technique for anesthesia in the head-injured
patient is probably a balanced technique using opioids
and newer inhaled anesthetics (sevoflurane, isoflurane)
or intravenous agents (propofol). Sometimes the head-
injured patient is placed in the sitting position for
surgery. In these cases attention to the cardiovascular
effects of this position and careful survey for early detec-
tion of venous air embolism are mandatory. Nitrous
oxide is deleterious in case of venous air embolism
(Box 20-21).
INTENSIVE CARE UNIT CARE
The intensive care for TBI still presents controversies
deriving from the progressive change in the pathophysi-
ology of brain injury over the time following trauma.
Controversies about the targets of intensive care in brain
injury still exist. These targets may be cerebral oxygena-
tion, intracranial pressure, cerebral perfusion pressure,
or transcapillary filtration factors. It is possible that
intensive care for TBI should have different targets at
different points of development of its pathophysiology.
If this is the case neuromonitoring methods are the way
to direct therapy against the pathophysiologic target of
choice. The use of neuromonitoring should be encouraged
whenever doubts exist about intracranial pressure, cere-
bral blood flow, and cerebral oxygenation (Box 20-22).
Neuromonitoring
Following TBI the most accurate monitor of brain
function is a complete neurologic clinical examination
performed in the absence of the effects of sedatives or
muscle relaxants. This is not always possible. In any case
the ICU care of TBI should include the regular assess-
ment of GCS and pupillary and motor responses. This
clinical assessment should occur every hour initially.
When the patient becomes more stable a less frequent
assessment may be sufficient. A deterioration in clinical
assessment requires prompt CT scan. Besides this clini-
cal evaluation, there are a lot of neuromonitoring tools
that provide information about intracranial pressure,
intracranial pressure/volume relationship, cerebral per-
fusion, and cerebral function.
Intracranial Pressure Monitoring
TBI is often associated with intracranial hypertension
that reduces cerebral perfusion pressure and cerebral
blood flow resulting in cerebral ischemia. Hence
intracranial pressure monitoring is very important.
According to the Brain Trauma Foundation guidelines,
intracranial pressure should be monitored in severe
brain injury associated with an abnormal CT scan (diffuse
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Box 20-22 Targets of Intensive Care
Unit Care for Traumatic
Brain Injury
● Cerebral oxygenation
● Cerebral perfusion pressure
● Intracranial pressure
● Transcapillary filtration factors
Box 20-21 Anesthetic Agents for the
Head-Injured Patient
Among anesthetic agents:
● Ketamine increases intracranial pressure
● Propofol preserves autoregulation and CO2
responsiveness
● Opioids have little effect on intracranial pressure
● Inhaled anesthetics increase cerebral blood
flow/cerebral metabolic rate ratio
● Halothane and enflurane should be avoided
● Nitrous oxide should be avoided when intracranial
hypertension is a concern
injury II–IV or high–mixed density lesions larger than 
25 mm), with age greater than 40 years, with unilateral 
or bilateral motor posturing, or with extracranial trauma
with hypotension. Intracranial pressure may be monitored
using fluid-coupled intraventricular catheters, fluid-
coupled surface devices, or solid-state devices. Intra-
ventricular catheterization with fluid-couple catheters
allows the most accurate measures of intracranial pressure
and can also be used therapeutically to drain cerebrospinal
fluid in the case of intracranial hypertension. They require
to be zeroed at a reference point represented by the exter-
nal auditory meatus or the Lundberg point (1.5 cm below
the uppermost part of the head). Air, blood, and debris can
interfere with fluid-coupled catheter function. Fluid-
coupled surface devices measure intracranial pressure at
the surface of the hemisphere. Pressure gradients between
intracranial compartments result in inaccurate monitoring
of intracranial pressure and should be considered if the
patient’s clinical condition does not agree with intracranial
pressure measurements. Blood, debris, and brain swelling
may also interfere with fluid-coupled surface devices. Solid-
state devices include fiber optic and strain-gauge-tipped
catheters. They are devoid of fluid coupling for pressure
transduction, resulting in fewer artifacts. The transducer is
not zeroed once it has been inserted, but a baseline drift
requiring transducer replacement occurs after a few days
(Box 20-23).
Complications of intracranial pressure monitoring
include infection, parenchymal hemorrhage, and sub-
dural hemorrhage subsequent to catheter placement
(Box 20-24). Infections such as meningitis are more fre-
quent with the irrigation of the catheter or the drainage
system and with prolonged catheter insertion (>5 days).
Solid-state devices seem to be associated with fewer
complications. Coagulopathy is the main contraindi-
cation to intracranial pressure monitoring because of
the risk of parenchymal and subdural hemorrhage.
Intracranial pressure monitoring allows the calculation
of cerebral perfusion pressure resulting from mean arte-
rial blood pressure minus intracranial pressure. For this
calculation both pressures should be referenced to the
external auditory meatus. Usually intracranial pressure
monitoring is stopped when cerebral edema is resolved
on CT scan or when intracranial pressure stability below
25 cmH2O occurs. Intracranial pressure monitoring for
periods longer than 7 days is often associated with base-
line drift (solid-state devices), infection (intraventricular
fluid-coupled devices), or occlusion (fluid-coupled sur-
face devices). Intracranial pressure monitoring may pro-
vide information about brain elastance if the relationship
between intracranial volume and intracranial pressure 
is explored. Pressure–volume index is the response in
intracranial pressure following the injection of fluid into
an intraventricular catheter over 1 second. If intracranial
pressure increases more than 3 mmHg for each milliliter
of fluid injected intracranial elastance is considered
reduced and surgical decompression should be considered.
Cerebral Blood Flow Monitoring
Methods to monitor directly cerebral blood flow are
lacking. Laser Doppler flowmetry, thermal diffusion flow
measurement, and the use of labeled xenon to estimate
cerebral blood flow under CT are methods resulting
in an intermittent evaluation of cerebral blood flow.
An indirect evaluation is more practical and actually is a
useful parameter to guide therapy in association with
intracranial pressure monitoring and CT scanning.
Jugular Oxygen Saturation Monitoring
Cerebral blood flow may be indirectly assessed by
monitoring oxygen saturation in the jugular bulb. The
brain should have homogeneity in perfusion and metab-
olism for the jugular oxygen saturation to monitor use-
fully the relationship between cerebral oxygen delivery
and cerebral oxygen demand. Unfortunately TBI is asso-
ciated with heterogeneity in perfusion and metabolism
and in this case jugular oxygen saturation will represent
the global average between the lower oxygen satura-
tions derived from areas where oxygen metabolism out-
strips oxygen demand and the higher oxygen saturations
derived from areas with poor metabolism but high per-
fusion. Jugular oxygen saturation monitoring requires
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Box 20-24 Complications of
Intracranial Pressure
Monitoring
● Infection
● Parenchymal hemorrhage
● Subdural hemorrhage
Box 20-23 Indications for Intracranial
Pressure Monitoring
Indications for intracranial pressure monitoring
include severe TBI associated with:
● Diffuse injury II–IV on CT scan
● High–mixed density lesions larger than 25 mm on
CT scan
● Age greater than 40 years
● Unilateral or bilateral motor posturing
● Extracranial trauma with hypotension
Methods for intracranial pressure monitoring:
● Fluid-coupled intraventricular catheters
● Fluid-coupled surface devices
● Solid-state devices
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retrograde placement of a fiber optic catheter into the
jugular bulb that should be confirmed by radiologic
imaging. If cerebral metabolic rate remains stable, an
increase in cerebral blood flow results in an increased
jugular oxygen saturation. If jugular oxygen saturation
decreases below 55%, cerebral hypoperfusion is under
way because of intracranial hypertension, hypocapnia,
or systemic hypoperfusion. Decreased jugular oxygen
saturation may occur independently of increases in
intracranial pressure. Cerebral hyperemia or depressed
neuronal metabolism may cause a jugular oxygen satura-
tion higher than 85%. Both jugular oxygen saturations
above 85% and below 55% are associated with poor
outcome. Jugular oxygen saturation monitoring is useful
if hemodynamic instability poses the patient at risk of
cerebral hypoperfusion. In this case vasopressor infu-
sion may be titrated with a target jugular oxygen satura-
tion above 55%. Jugular oxygen saturation monitoring
should be considered also to titrate other therapeutic
strategies such as hyperventilation, hypothermia, and
barbiturate coma, always aiming to a jugular oxygen 
saturation of between 55% and 85%.
Tissue Oxygen Monitoring
Tissue oxymetry probes allow one to monitor directly
brain tissue oxygen content. The insertion technique
for tissue oximetry probes is similar to that for intra-
parenchymal pressure monitoring. These probes mea-
sure brain tissue oxygen content in a small volume of
tissue. These results may be extrapolated to apply
at least regionally. Tissue oximetry probes provide con-
tinuous, real-time measurements of brain tissue oxygen
saturation. These data are very useful to titrate cerebral
perfusion pressure manipulation, hyperventilation, and
intracranial hypertension management.
Transcranial Doppler
Blood flow through large cerebral vessels may be
evaluated with transcranial Doppler ultrasonography.
This is a noninvasive method that provides an inter-
mittent evaluation. The transtemporal area is a natural
acoustic window that allows the pulsed Doppler probe
to assess the anterior, middle, and posterior cerebral
arteries and anterior and posterior communicating
arteries. Systolic, mean, and diastolic flow velocities are
usually considered indices of flow. Hyperemic, normal,
vasospastic, and absent flow may be differentiated using
derived indices such as the Gosling pulsatility index and
the Lindegaard ratio. Transcranial Doppler should be
used in association with other techniques because it
provides intermittent measures.
Near Infrared Spectroscopy
Near infrared spectroscopy monitors regional oxygen
saturation in the brain. A scalp sensor emits light of
wavelengths in the range near to infrared and measures
the light reflected to the sensor. It measures arterial,
venous, and capillary blood oxygen saturation. The 
average oxygen saturation of all regional microvascular
hemoglobin is evaluated by near infrared spectroscopy
and should be around 70%. Extracranial signals may
interfere with near infrared spectroscopy. Although it is
a noninvasive monitor of regional oxygen saturation,
jugular oxygen saturation is superior as an indirect 
monitor of cerebral blood flow.
Electrophysiologic Monitoring
Electrophysiologic monitoring includes passive moni-
toring methods such as electroencephalography and
active monitoring methods such as somatosensory
evoked potentials. In ICUs monitors and ventilators may
interfere with electroencephalography. It has been used
to titrate barbiturate therapy and to assess seizures that
may contribute to brain injury. Bispectral index cannot be
recommended for barbiturate therapy titration, although
its role in TBI is the object of studies. Somatosensory
evoked potentials assess sensorial and motor pathways
and may provide diagnostic and prognostic information.
Initial bilaterally absent cortical somatosensory evoked
potentials indicate high probability of death, while 
normal evoked potentials predict good outcome.
Electrophysiologic recovery often precedes clinical
recovery.
Temperature Monitoring
TBI may be associated with hyperthermia secondary
to the damage of thermoregulatory centers. Lesions to
the brain are worsened by hyperthermia, which is a
cause of secondary damage in TBI. Core temperature
monitoring may underestimate brain temperature by
1–2°C, but it is a useful method for temperature moni-
toring. Every effort should be made to maintain core
temperature below 37.5°C.
TREATMENT OF INTRACRANIAL
HYPERTENSION
TBI has been traditionally treated with early surgical
treatment of intracranial mass lesions and careful critical
care treatment to avoid secondary damage and minimize
intracranial hypertension. When intracranial pressure is
monitored a stair-step approach is used to treat intracra-
nial hypertension. Methods to reduce intracranial pres-
sure are added considering the complications associated
with each therapy. Usually the first step is sedation, anal-
gesia, and neuromuscular block; then cerebrospinal fluid
drainage may be added if intracranial hypertension is
poorly controlled. If these treatments still fail to control
intracranial hypertension, osmotic agents may be added,
while barbiturate coma should be reserved for intra-
cranial hypertension refractory to all the previous treat-
ments in patients hemodynamically stable. Body position
is also a determinant of intracranial pressure: a 30–45°
head elevation with the head kept in the neutral position
facilitates venous flow and intracranial pressure control.
Sedation, Analgesia, and
Neuromuscular Block
In TBI sedation and analgesia should be titrated
according to hemodynamic stability, intracranial pres-
sure, and the trauma-related disorder of consciousness.
A general rule is to maintain a level of sedation deep
enough to facilitate mechanical ventilation and light
enough to allow frequent clinical neurologic evalua-
tions. During the initial hypoperfusion phase sedation
should be carefully titrated in order to avoid systemic
arterial hypotension. For this purpose short-acting
opioids are useful because they ensure cardiovascular
stability and blunt sympathetic discharge. However
pupillary examination should be performed before
opioids are administered. Prolonged administrations of
benzodiazepines may delay the return of consciousness
because these drugs tend to accumulate. Benzodiazepines
may also cause an emergence delirium state. Among opi-
oids, sufentanyl and especially remifentanyl should prob-
ably be preferred for prolonged administrations because
they have a good profile of the context-sensitive half-life
curve. Propofol has attractive properties for sedation in
TBI. Even used as the sole sedating agent, it ensures
deep levels of sedation resulting in the control of
intracranial hypertension and sympathetic discharges.
Propofol has a short context-sensitive half-life. This prop-
erty allows frequent clinical neurologic evaluations that
are so important to monitor neurologic function in TBI.
Propofol has the advantage that it does not interfere
with pupillary responses and the disadvantage that it has
a higher cardiovascular impact because of its negative
inotrope effect. Therefore, even if propofol remains an
option in hemodynamically unstable patients, it requires
careful titration in these cases. Vasopressors or inotropes
may be necessary to maintain an appropriate systemic
arterial pressure, which is a primary target in TBI.
Ventricular Drainage
Intracranial hypertension may be treated by draining
cerebrospinal fluid through a fluid-coupled intraventric-
ular catheter placed for intracranial pressure monitoring.
The catheter may be placed 5–10 cm above the head and
opened every 2–4 hours. Although ventricular drainage
may increase transcapillary filtration of fluid, this method
is effective in the treatment of intracranial pressure and
should be used if appropriate sedation and analgesia,
eventually associated with muscle relaxation, fail to reduce
intracranial hypertension.
Osmotic Diuresis: Mannitol
If appropriate sedation and analgesia associated with
intermittent ventricular drainage fail to control intra-
cranial hypertension, osmotic diuresis using mannitol can
be used. Mannitol (0.25–1 g/kg) is an osmotically active
agent administered to increase plasma osmolality causing
an efflux of fluid from edematous areas of the brain that
results in the reduction of intracranial pressure (if the
blood–brain barrier is intact enough to be still impermeable
to mannitol). Mannitol also causes a plasma expanding
effect that increases cerebral blood flow. This may con-
tribute to the reduction of intracranial pressure. Mannitol
increases diuresis with an osmotic mechanism. Hypertonic
saline (3%) increases plasma osmolality and expands
plasma volume restoring systemic and cerebral perfusion.
Hypertonic saline has fewer side effects than mannitol,
and it does not induce any osmolal gap so it allows an
easier titration. Hypertonic saline is particularly benefi-
cial in the early hypoperfusion phase because it improves
cerebral blood flow. However, mannitol and hypertonic
saline should be used in patients with unequivocal intra-
cranial hypertension unresponsive to appropriate sedation
and ventricular drainage. Hemodynamic instability and
hypovolemia contraindicate osmotic diuresis as does a
serum osmolality greater than 320 mosm/l.
Hyperventilation
Hyperventilation decreases intracranial pressure
because a reduction in PaCO2 determines cerebral alka-
losis that results in cerebral vasoconstriction with a
decrease in cerebral blood flow and cerebral blood
volume. The effect of hyperventilation on cerebral blood
flow is transient because readjustment of brain pH occurs
within 6–24 hours and thereafter the normalization of
CLINICAL CAVEAT
Stair-step approach for the treatment of intracranial
hypertension:
● Appropriate body position with 30–45° head
elevation with the head in the neutral position
● Sedation and analgesia
● Neuromuscular block in patients competing with
mechanical ventilation
● Cerebrospinal fluid drainage
● Osmotic agents
● Barbiturate coma
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PaCO2 can dramatically increase intracranial pressure.
Thus it does not make sense to use prophylactic hyper-
ventilation resulting in a PaCO2 below 35 mmHg, 
especially in the first 24 hours after brain injury, when
cerebral blood flow is already reduced as much as 50%
(hypoperfusion phase). Prolonged hyperventilation ther-
apy resulting in a PaCO2 below 25 mmHg should be
avoided in the absence of elevated intracranial pressure.
Although hyperventilation still has a role in the treat-
ment of intracranial hypertension unresponsive to con-
ventional intracranial pressure-lowering therapies, its
use requires an appropriate cerebral oxygenation moni-
tor such as jugular oxygen saturation monitoring or 
tissue oxygen monitoring because hyperventilation may
precipitate cerebral ischemia. Ischemia related to hyper-
ventilation may aggravate the pre-existing brain injury.
Cerebral vasoreactivity after TBI increases over time. In
particular cerebral vessels show a decreased responsive-
ness the first day after injury, and a progressive increase
in PaCO2 reactivity between the second and the fifth day
after injury. Intracranial hypertension is often difficult to
treat just three to five days after injury. Therefore hyper-
ventilation therapy is likely to be performed just when
cerebral vessels are more sensitive to hypocapnia and
the brain is more susceptible to the hyperventilation-
related ischemia. When jugular oxygen saturation
demonstrates that cerebral oxygen delivery significantly
outstrips cerebral oxygen demand, hyperventilation may
be beneficial in decreasing cerebral blood volume and
intracranial pressure without inducing ischemia.
Cerebral Perfusion Pressure
Manipulation (Vasoconstriction
and Vasodilatation Cascades)
In the early hypoperfusion phase of TBI the mainte-
nance of a high cerebral perfusion pressure could trigger
a vasoconstriction cascade leading to a reduction in
intracranial hypertension. The target for cerebral per-
fusion pressure should be 60 mmHg, although some-
times cerebral perfusion pressure should be higher than
70–80 mmHg to remain in the autoregulatory range. If
cerebral perfusion pressure management may be useful
to treat intracranial hypertension in the early hypoperfu-
sion phase, it could be less effective or even deleterious
in the late hyperaemic phase.
High-Dose Barbiturate Therapy
In intracranial hypertension unresponsive to tradi-
tional therapies high-dose barbiturate may be useful.
Barbiturates at high doses reduce cerebral metabolic rate
and intracranial pressure. Barbiturate dose should be
titrated using electroencephalography. The target
should be burst suppression. At the high doses used for
intracranial hypertension treatment barbiturates may
cause reductions in systemic arterial blood pressure and
cerebral blood flow. This could be deleterious in the
hypoperfusion phase of TBI when cerebral blood flow is
already reduced. In this case the use of vasopressors
should be considered. The use of barbiturates impairs 
a frequent clinical neurologic evaluation and delays
awakening of patients.
Hypothermia
In TBI the lesions to the brain are temperature
dependent. Fever may worsen TBI, and an aggressive
treatment of fever is mandatory. Hypothermia reduces
cerebral metabolism and may have a beneficial effect
on intracranial hypertension. In several experiments
hypothermia resulted in a decreased intracranial hyper-
tension when used immediately after brain injury. Some
clinical trials failed to demonstrate an improvement in
outcome with the use of hypothermia in TBI. Hypothermia
to temperatures of 30–33°C prolongs ventilation and
increases the risk of nosocomial infections. These side
effects could lead to increased morbidity and mortality
in TBI, even though hypothermia shows beneficial effects
on cerebral metabolic rate and intracranial hypertension.
Steroids
Glucocorticoids may reduce intracranial inflamma-
tion. Inflammatory mechanisms underlie blood–brain
barrier alterations resulting in vasogenic cerebral edema
and may be involved in excitotoxicity that may contribute
to cytotoxic edema. Although steroids at high doses for
24 hours are useful in the treatment of acute spinal cord
injury if treatment is initiated within eight hours, they
have shown no beneficial effect in the outcome of TBI.
Moreover, steroids increase the risk of infection.
Cranial Decompression
When intracranial hypertension is unresponsive to 
all therapies wide bilateral frontoparietal craniectomies
may result in a dramatic reduction of intracranial hyper-
tension. Preemptive decompressive craniectomy may
have a role in high-risk patients.
Current Controversies
There are still several controversies regarding the
treatment of TBI. In this setting the strategies proposed
are essentially three: intracranial pressure-directed 
therapy, cerebral perfusion pressure-directed therapy,
and the Lund approach.
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Intracranial pressure-directed therapy includes intra-
cranial pressure monitoring and a stair-step approach to
treat intracranial hypertension.
Cerebral perfusion pressure-directed therapy aims at
an appropriately high mean arterial pressure to trigger
the vasoconstriction cascade.
The goals of the Lund approach are to preserve a
normal colloid osmotic pressure in cerebral vessels with
infusion of albumin and erythrocytes, to reduce cerebral
capillary hydrostatic pressures by reducing arterial blood
pressure, and to reduce cerebral blood volume by vaso-
constriction of precapillary resistance vessels achieved with
low-dose thiopental or dihydroergotamine (Box 20-25).
The Lund approach discourages treatments that could
result in an increased transcapillary filtration of fluids
including cerebrospinal fluid drainage, high-dose barbi-
turates, osmotic diuresis, and high cerebral perfusion
pressures.
GENERAL CARE
General intensive care is fundamental in TBI. It
includes electrolytes and fluid management, nutritional
support, prevention and treatment of post-traumatic
seizures, prevention and treatment of deep venous
thrombosis and pulmonary embolism, and prevention
and treatment of gastrointestinal bleeding (Box 20-26).
Electrolytes and Fluid Management
Primary targets of electrolytes and fluid management
in TBI are the maintenance of euvolemia and of a rela-
tively high serum osmolality (Box 20-27).
Since hypervolemia may be implicated in increases in
cerebral edema and hypovolemia may reduce cerebral
blood flow, euvolemia should be maintained to allow an
appropriate cerebral blood flow without increasing cere-
bral edema. The volume of fluids administered should be
titrated considering pulse rate, mean arterial pressure,
central venous pressure, and urine output. A hematocrit
of 30% offers the best rheology to cerebral circulation;
therefore red cell transfusions should be used in case of
active bleeding to keep a hemoglobin concentration
around 10 g/dl. Regarding the quality of fluids adminis-
tered in TBI, no evidence supports the use of either 
colloids or crystalloids. The osmotic gradient between
blood and brain regulates water flux across the
blood–brain barrier. Serum osmolality is the major deter-
minant of fluid flux across the normal blood–brain
barrier. However, TBI is associated with alterations of the
blood–brain barrier. If it becomes permeable to ions but
not to larger colloid particles, the choice between col-
loids and crystalloids could be important. If the blood–
brain barrier is disrupted, however, permeability to both
ions and colloidal particles may occur and fluid selection
is inconsequential. Serum osmolarity has an established
importance in the development of cerebral edema and
should be kept at the higher values of normality. In this
regard the use of hypo-osmolar solutions such as 5%
dextrose in water is discouraged and may be required
only if patients become hyperosmolar (>320 mosm/l).
Normal saline has an osmolarity slightly higher than
plasma and is the preferred fluid in TBI. When using nor-
mal saline for fluid management, also other ions such as
potassium, magnesium, and calcium should be adminis-
tered to maintain normal electrolyte homeostasis.
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CURRENT CONTROVERSY
Controversy in the treatment of TBI includes:
● Intracranial pressure-directed therapy
● Cerebral perfusion pressure-directed therapy
● The Lund approach
Box 20-25 Goals of the Lund Approach
● To preserve a normal osmotic pressure in cerebral
vessels using infusions of albumin and erythrocytes
● To reduce cerebral capillary hydrostatic pressures
reducing arterial blood pressure
● To reduce cerebral blood volume by vasoconstric-
tion of precapillary vessels achieved with low-dose
thiopental or dihydroergotamine
Box 20-26 General Care of TBI
General care of TBI includes:
● Electrolytes and fluid management
● Nutritional support
● Prevention and treatment of post-traumatic seizures
● Prevention and treatment of infectious complications
● Prevention and treatment of deep venous thrombosis
and pulmonary embolism
● Prevention and treatment of gastrointestinal bleeding
Box 20-27 Targets of Electrolyte and
Fluid Management in
Traumatic Brain Injury
● Euvolemia
● Relatively high serum osmolality
Fluid management may be particularly challenging in
head-injured patients because TBI is often associated
with the syndrome of inappropriate antidiuretic hormone
secretion and with diabetes insipidus. Sometimes even
when fluid management has achieved euvolemia, cerebral
perfusion pressure is still inadequate. Particularly if these
cases occur in the early hypoperfusion phase of TBI, vaso-
pressors and inotropes should be used because cerebral
perfusion pressure is the major determinant of cerebral
blood flow and is the priority when cerebral hypoperfu-
sion is underway.
Nutritional Support
In TBI early enteral nutrition should be performed to
meet the caloric needs of head-injured patients. Nutritional
support should provide calories corresponding to 140% of
the resting energy expenditure in nonparalyzed patients
and 100% of the resting energy expenditure in paralyzed
patients. At least 15% of calories should derive from pro-
teins. Orogastric or oroenteral tubes are inserted in TBI
because of the possible fracture of the cribriform plate. In
any case once cribriform plate fracture has been excluded,
nasopostpyloric tubes are used because TBI may be asso-
ciated with gastroparesis. Hyperglycemia may complicate
nutritional support. Glycemia should be strictly maintained
in the normal range because either hyperglycemia or hypo-
glycemia may induce secondary damage to the brain.
Insulin is very useful in the case of hyperglycemia.
Prevention and Treatment 
of Post-traumatic Seizures
Short-term prophylactic use of anticonvulsants does
not prevent late post-traumatic seizures. TBI is rarely
associated with seizures that usually are present at the
time of injury. When seizures occur, benzodiazepines
and other anticonvulsants are used. Prophylaxis with
phenytoin may be useful only in patients with significant
parenchymal lesions evident on CT scan and should be
prolonged for ten days after injury.
Prevention and Treatment of Infectious
Complications
TBI patients who receive prolonged mechanical ven-
tilation show an increased risk of nosocomial pneumo-
nia that is associated with an increased mortality. Stress
ulcer prophylaxis, hypothermia, and barbiturates
increase the risk further. Penetrating injuries and intra-
cranial pressure monitoring, especially using fluid-
coupled devices, increase the risk of meningitides and
other neurologic infections. The risk is low if intracranial
pressure monitoring lasts less than 5–7 days. The fre-
quent use of intravascular catheters for arterial pressure
monitoring, central venous pressure monitoring, jugular
oxygen saturation monitoring, and fluid and drug infu-
sions increases the risk of bloodstream infections. The
frequent use of bladder catheters put the head-injured
patient at risk of urinary tract infection. The use of
antibiotics should follow the accepted microbiological
principles. Cultures of cerebrospinal fluid, blood, fluid
from BAL, and urine should guide antibiotic therapy.
Prevention and Treatment of 
Deep Venous Thrombosis and
Pulmonary Embolism
Brain-injured patients who require prolonged immo-
bility are at increased risk of thromboembolism. Prevention
of deep venous thrombosis and pulmonary embolism is
particularly challenging in TBI patients because antico-
agulants such as fractionated and low molecular weight
heparins are contraindicated because of intracranial
hemorrhage. Until CT scan demonstrates resolution of
intracranial hemorrhages and significant brain lesions
anticoagulants should be avoided. Therefore prevention
of deep venous thrombosis and pulmonary embolism in
TBI patients is entrusted to nonpharmacologic methods
such as elastic stockings, pneumatic calf compressors,
and physiotherapy. If pelvic fractures increase the
patient’s risk of deep venous thrombosis, frequent
Doppler ultrasound of the iliofemoral veins is recom-
mended. If brain-injured patients develop a deep vein
thrombosis and anticoagulants are contraindicated by an
intracranial hemorrhage, inferior vena caval filters are
useful to prevent pulmonary embolism. If pulmonary
embolism occurs in TBI patients the use of anticoagu-
lants should be considered if there is a real risk of death.
CLINICAL CAVEAT
TBI is often associated with:
● Syndrome of inappropriate antidiuretic hormone
secretion (SIADH)
● Diabetes insipidus
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What Fluid in Traumatic Brain Injury?
● Normal saline has an osmolarity slightly higher than
plasma and is the preferred fluid in TBI
● Other ions such as potassium, magnesium, and
calcium should be administered to maintain normal
electrolyte homeostasis
● 5% dextrose in water is discouraged and may be
required only if patients become hyperosmolar
(>320 mosm/l)
Prevention and Treatment of 
Gastrointestinal Bleeding
An appropriate resuscitation and an early enteral feed-
ing are the best methods for gastrointestinal bleeding
prevention. Sucralphate, H2 antagonists, and proton
pump inhibitors are useful to prevent gastrointestinal
bleeding and are usually administered during the whole
ICU stay, although they may be avoided once enteral
feeding starts at least in patients without a previous 
history of peptic ulceration.
OUTCOME
Outcome from TBI is influenced by the severity of
primary and secondary damages. Patient-related factors
such as age, comorbidities, and sex also influence out-
come. In particular, age greater than 60 years worsens
outcome. Time may result in significant neurological
improvements and outcome is difficult to predict. The
extended Glasgow Outcome Scale is a very useful tool to
quantify objectively functional outcome after TBI and
should be used 6 and 12 months after injury (Box 20-28).
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Box 20-28 Extended Glasgow
Outcome Scale
Score 6: Death
Score 7: Persistent vegetative state
Score 8: Severe disability
Score 9: Moderate disability
Score 10: Good recovery
Neurologic Examination
Intracranial Pressure
Electroencephalogram and Bispectral Analysis
Conclusion
Assessing a patient’s neurologic status is an important
component of critical care. Clearly patients with brain or
spinal cord pathology require their neurologic status to
be monitored in order to determine the progression of
the pathologic process. Decisions about further evalua-
tion and treatment are dependent upon this assessment.
Critically ill patients with a variety of problems are prone
to neurologic abnormalities. These include ischemic 
and hemorrhagic strokes, traumatic brain and spinal
cord injuries, central nervous system (CNS) tumors, neu-
ropathies, and CNS infections. This chapter focuses on
the methods to assess a patient’s neurologic status in the
intensive care unit (ICU). The neurologic examination is
the mainstay of neurologic monitoring. Intracranial pres-
sure monitoring is the next most common tool for fol-
lowing a patient’s status. The electroencephalogram (EEG)
is used for patients with suspected seizures and to assess
cortical function. In addition, many institutions are using
the Bispectral Index Scale (BIS) monitor to assess patients’
level of sedation in the operating room. The use of the BIS
to monitor progression of neurologic disease in the ICU is
less clear.
NEUROLOGIC EXAMINATION
The neurologic examination is an important compo-
nent in the daily assessment of the critically ill patient.
Many patients are sedated and some are chemically par-
alyzed. This should be noted in the patient’s evaluation.
Ideally, the patient’s sedation should be titrated, so that
they are comfortable but easily arousable and as inter-
active as possible.
The neurologic examination has several components.
These include the mental status examination, cranial
nerve examination, motor examination, sensory exami-
nation, cerebellar examination, and assessing reflexes.
The examination of the critically ill patient is less detailed
than a neurologist’s formal examination but should be
detailed enough to diagnose significant abnormalities 
and assess changes in the patient’s neurologic status. The
mental status examination includes orientation (to person,
place, and time), speech, ability to follow commands, and
the ability to interact appropriately. Purposeful movement
indicates the presence of some cortical function.
Examination of the cranial nerves includes pupil exami-
nation (size and reactivity), presence or absence of con-
jugate gaze, facial symmetry, and gag reflex. These tests
evaluate CN II, III, IV, VI, VII, IX, and X, and thus a signif-
icant portion of the brainstem. On motor examination,
symmetry of extremity movement and, if possible, indi-
vidual muscle group strength should be assessed. The
sensory examination should include response to stimuli
at each extremity. The cerebellar examination would
mainly be significant for patients with cerebellar lesions
and includes evaluation for ataxia (finger to nose test 
and heel-shin test). The gait examination is rarely practi-
cal in the ICU. Deep tendon reflexes should be assessed
in patients with suspected spinal cord lesions. The
examination described can be accomplished rapidly 
and provide quick assessment of the patient’s neurologic
status.
A neurologic scoring system often used for trauma
patients in the ICU is the Glasgow Coma Scale (GCS).
Patients are assigned a score, based on three compo-
nents. The responses assessed are verbal response, eye
opening, and motor response. The responses are scored
as follows:
Verbal response. Oriented speech (5), confused
conversation (4), inappropriate speech (3),
incomprehensible speech (2), and no speech (1).
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Eye opening. Spontaneous (4), response to verbal
stimuli (3), response to noxious stimuli (2), and 
no eye opening (1).
Motor response. Follows commands (6), localizes to
noxious stimuli (5), withdraws to noxious
stimuli/normal flexion (4), abnormal
flexion/decorticate posturing (3), abnormal
extension/decerebrate posturing (2), and no
movement to noxious stimuli (1).
The GCS is a useful, rapid screen of head injury 
severity. Mild head injury usually produces a score of 
13 to 15, moderate head injury produces a score of 9 to 12,
and severe head injury generally carries a score of 8 or
less. If the patient is intubated, the score is qualified with
an “I.”
The GCS is a useful screening tool for the initial assess-
ment but is less reliable for assessing subtle changes in a
patient’s status while in the ICU. A detailed neurologic
examination should be done for the initial presentation
followed by more focused examinations concentrating
on known deficits for subsequent evaluations.
INTRACRANIAL PRESSURE
Intracranial pressure (ICP) monitors are used prima-
rily for patients with known or suspected intracranial
hypertension, and those with head injuries where a neu-
rologic examination is not possible. Patients who cannot
be followed with a neurologic examination include those
under general anesthesia, or those who are chemically
paralyzed or heavily sedated in the ICU. The use of an
ICP monitor alerts the clinician to an elevation of ICP,
which can then be treated.
An understanding of ICP is important when making
decisions about treatment. The intracranial vault can be
considered a fixed volume, which is about 1500 ml in
the adult. The intracranial vault contains three broad 
categories of substances. These are the brain and its 
support structures, cerebrospinal fluid (CSF), and blood.
The brain and its supporting structures account for
about 85% of the volume. CSF and blood account for
10% and 5%, respectively, of the remainder. If any one of
these components is increased, intracranial hyperten-
sion can result. Processes that increase the volume of the
brain and its support structures include brain edema
(cytotoxic edema due to ischemic strokes and vasogenic
edema around tumors and abscesses) and the mass of
tumors. Elevated volumes of CSF occur in various clini-
cal scenarios and is known as hydrocephalus. Elevated
volumes of intracranial blood can occur either extravas-
cularly or intravascularly. Intracranial hemorrhages (such
as epidural hematomas, subdural hematomas, and intra-
cerebral hematomas) can lead to critical elevations of ICP.
Etiologies of increased intravascular blood volume
include hypercarbia, hypoxia, and volatile anesthetics.
Studies looking at the relationship between intracra-
nial volume and pressure have been performed by grad-
ually increasing the volume of an intracranial balloon in
animals. The ICP increases at a relatively slow rate with
increased balloon volume. At a certain point (at an ICP
of approximately 20 torr) the ICP increases dramatically
with small increases in balloon volume. At this point the
system changes from a relatively compliant system to a
relatively noncompliant system. Because small changes
in volume can lead to large increases of ICP and then
cerebral herniation at this pressure, an ICP of 20 torr and
above is considered to be intracranial hypertension.
Another important physiologic parameter is cerebral
perfusion pressure (CPP). This can be calculated by sub-
tracting the ICP from the mean arterial pressure (CPP =
MAP – ICP). Most authorities advocate maintaining a CPP
of 50 torr or greater. This ensures adequate cerebral
blood flow (CBF). Insufficient CBF results in brain
ischemia and cerebral injury. Therefore, it is important
to know the CPP and ICP in critically ill patients with
neurologic injury. The MAP is best measured using an
intra-arterial catheter. This allows continuous assess-
ment of the MAP, which is not possible with noninvasive
blood pressure monitoring. If the patient is felt to have
elevated ICP (usually predicted by evaluation of the head
computed tomography (CT) scan), an ICP monitor should
be placed.
ICP monitors include ventricular catheters connected
to an external strain gauge transducer or catheter-tip
pressure transducer devices, parenchymal catheter-tip
pressure transducer devices, subarachnoid or subdural
fluid-coupled devices, and epidural devices. External
strain gauge transducers are located at the bedside and
are coupled to the patient’s intracranial space through
fluid-filled lines. The catheter-tip transducers are either
strain gauges or fiberoptic technologies and are placed
intracranially.
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CLINICAL CAVEAT
CPP = MAP − ICP
Maintain ICP < 20 torr, CPP > 50 torr
Intraventricular catheters:
● Most reliable means of measuring ICP
● Allows drainage of CSF in order to lower ICP
● More prone to complications
Intraparenchymal, subdural, and epidural monitors:
● More easily placed
● Less associated complications
● Less reliable ICP measurement
The fluid-filled lines connected to the external strain
gauges can become obstructed or have an air bubble 
in the line, which can lead to inaccurate pressures. The
external devices can be recalibrated after insertion.
The transducer has to be positioned at the level of the
patient’s head and therefore has to be moved if the
height of the patient’s bed is moved. Intracranial trans-
ducers are calibrated prior to insertion and cannot be
recalibrated once in place. Therefore, there is the poten-
tial for measurement drift. The intracranial transducer
devices give ICP measurements that are independent of
head elevation.
The ICP monitors can be placed in the epidural space,
subdural space, subarachnoid space, brain parenchyma,
or intraventricular space. Intraventricular catheters have
been used as the reference standard for ICP measure-
ment. Intraventricular catheters can be used to treat
intracranial hypertension by draining CSF. The intra-
ventricular catheters are usually connected to an external
strain gauge transducer, but some incorporate intra-
cranial, fiberoptic transducers. This allows simultaneous
drainage and ICP measurement. When using the external
transducer, ICP measurements cannot be obtained while
CSF is drained. There is potential for significant compli-
cations when using intraventricular catheters. These
devices are usually placed through the nondominant
hemisphere away from the motor strip and the sagittal
sinus. The catheter has to travel through a significant
amount of brain parenchyma to reach the lateral ventricle.
There is the potential for bleeding, CNS injury, infection,
catheter misplacement, and obstruction.
The other devices (parenchymal, subarachnoid, sub-
dural, and epidural catheters) are less likely to cause a
complication. The parenchymal catheters are placed a
short distance into the parenchyma. These devices can-
not be used therapeutically to drain CSF. Many studies
support the accuracy of these devices for measuring 
ICP. However, other studies have shown significant dis-
crepancies when compared to ventricular ICP. The deci-
sion as to which device to use is multifactorial. Clearly,
if the head CT shows significant fluid in the ventricles,
drainage via an intraventricular catheter would be bene-
ficial. Patients who are coagulopathic are at increased
risk for developing intracerebral hemorrhage as a 
complication of intraventricular catheter placement.
Patients with fulminant hepatic failure and high-grade
encephalopathy have a high mortality often as a result of
uncal and tonsillar herniation. A retrospective study by
Blei and colleagues showed fewer complications with
epidural catheters (3.8%) compared to subdural (20%)
and intraparenchymal (22%) catheters. The intra-
parenchymal catheters included intraventricular catheters.
In fact, fatal hemorrhage occurred with 5% of the subdural
catheters and 4% of the intraparenchymal catheters.
Fatal hemorrhage occurred in 1% of the patients with
epidural catheters.
Occasionally, lumbar subarachnoid catheters (lumbar
drains) are used in the ICU. These drains are used for
some neurosurgical procedures (primarily cerebrovascu-
lar procedures) in order to “decompress” the brain and
facilitate the surgical dissection. They are also used for
some vascular surgery procedures (such as thoraco-
abdominal aneurysm resections). In these cases, there is
a significant risk of spinal cord ischemia due to resection
of anterior spinal arteries (most significantly the artery of
Adamkeiwicz). The catheters are used to drain CSF and
thus lower the ICP. This optimizes spinal cord perfusion
and, theoretically, minimizes the risk of cord ischemia.
Postoperatively, ICP is not measured directly, but the
catheters are drained at a predetermined level (highest
point of catheter) above the supine patient. Generally,
the catheter height is placed at approximately 10 cm 
(10 cmH2O/CSF) above the patient. This will be the ICP
as long as the catheter drains freely. It is important not
to “overdrain” the catheter by placing it at or below the
level of the patient. This could lead to complications. The
most severe complication is a subdural hematoma.
Typically, the time patients are most at risk for overdrain-
ing is during transport. It is suggested that the catheter
be clamped during these periods. The ICP will rise only
minimally if the catheter is clamped for a short period
(i.e., less than 30 minutes).
ICP can be measured using a variety of devices. The
intraventricular catheters are probably the most accurate
and can be used therapeutically. Unfortunately, these
catheters have the highest risk for complications. The
decision about which device to use should be made in
conjunction with the neurosurgical team and should be
based on the patient’s comorbidities.
ELECTROENCEPHALOGRAM 
AND BISPECTRAL ANALYSIS
The EEG is another neurologic monitor of some use in
the ICU. A complex discussion of the EEG is well beyond
the scope of this chapter. Briefly, neurons generate electric
fields when ions move between the intra- and extracellular
spaces. Neurotransmitter interactions with postsynaptic
receptors affect ion channel permeability of the neuron,
which allows movement of the ions. This results in
changes in its transmembrane voltage. This is known as
the postsynaptic potential (PSP). If the membrane poten-
tial of a neuron is depolarized beyond its threshold value,
an action potential (AP) is generated which then propa-
gates rapidly along the neuron’s membrane. The electric
fields generated by the neurons result in electrical poten-
tial differences at the skin’s surface. Electrodes at the
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skin’s surface act as transducers, which convert the
physiologic current at the skin to an electrical current
which is then processed by the EEG monitor. This prin-
ciple applies to the electrocardiogram where the syn-
chronous depolarization of all cells of the atria followed
by depolarization and repolarization of all cells of the
ventricles produce the classic normal EKG with its P waves,
QRS complex, and T waves.
Under normal circumstances the PSPs and APs gener-
ated by neurons are not synchronous. The normal EEG
signal has no obvious repetitive pattern or any morphol-
ogy that correlates with underlying neurologic function.
Indeed, “spikes” or “sharp waves” due to synchronous
neuronal activity is diagnostic of seizure activity. Due to
its complexity, interpreting raw EEG data is extremely
difficult. Methods to compress and simplify the raw EEG
data require complex and intensive mathematical compu-
tations. These processed EEGs are used in the operating
room to detect cerebral ischemia (e.g., during carotid
surgery) and to determine if drug therapy causes burst
suppression (e.g., during aneurysm surgery). Examples
of processed EEGs include the compressed spectral
array (CSA) and the density spectral array (DSA). The pri-
mary use of the EEG in the ICU is to make the diagnosis
of status epilepticus in the patient suspected of this dis-
order. Sometimes, the diagnosis is not obvious on obser-
vation of the patient. The EEG is also used in the ICU 
as a confirmatory test when brain death is suspected.
Beyond these indications, there is not much use for the
EEG in the ICU. Certainly, it is not a very useful monitor
for following the patient’s neurologic status and correct-
ing abnormalities. In the operating room there has been
much work to use the EEG to determine depth of anes-
thesia. Similarly, in the ICU it would be desirable to have
a measure of sedation. Often this is difficult to determine.
For example, it is very difficult to assess the adequacy of
sedation of patients who are chemically paralyzed or
extremely edematous. Often, the patient’s eyes are
swollen shut. They are weak and unable to move their
extremities well. The desire to obtain useful information
about anesthetic and sedation depth has led to the devel-
opment of the bispectral index.
Bispectral analysis represents a different type of mathe-
matical analysis of the raw EEG data from the analysis
performed by the processed EEG. The analysis is
extremely complex and only became possible with the
advent of fast microprocessors. The bispectral index
monitor is a device manufactured by Aspect Medical
Systems. It uses one- or two-channel EEG signal acquisi-
tion. The analysis creates a dimensionless number
known as the Bispectral Index Scale (BIS). The number
is scaled from 100 to 0 with 100 indicating an awake
EEG and 0 representing complete electrical silence. 
BIS values are then correlated against clinical endpoints
to sedation (movement to noxious stimuli, hemody-
namic response to stimuli, level of consciousness, etc.).
The BIS has been through multiple versions with
improved clinical correlation in each. In the operating
room the BIS indicates the potential for awareness and
hypnotic overdose. It cannot determine exactly when
consciousness returns. It does not predict unconscious-
ness when ketamine or nitrous oxide is used.
It would be desirable to use the BIS to monitor the
level of sedation in the ICU. This could ensure patient
comfort and prevent oversedation. It is not clear that
conclusions about BIS values obtained from healthy
patients undergoing anesthesia/sedation would be appli-
cable to critically ill patients in the ICU. Studies to
address this issue are problematic, since it is difficult to
determine awareness and recall in ICU patients. In addi-
tion, the electrical environment of the ICU can interfere
with the monitor. Studies in the ICU are ongoing. More
studies are needed.
CONCLUSION
Neurologic monitoring is an important part of the
care of patients in the ICU. While patients with known
CNS pathology clearly require this monitoring, a large
number of ICU patients are at risk to develop neurologic
injury. The neurologic examination, performed by physi-
cians and nurses, is the main component of this moni-
toring. When indicated, monitoring ICP directly with
either a ventriculostomy or other intracranial device can
be very useful in diagnosing and treating intracranial
hypertension. The EEG is an important tool in diagnos-
ing seizures and brain death. The role of the BIS monitor
to measure the level of sedation of critically ill patients is
yet to be determined.
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Summary
Endocrine dysfunction in the critically ill patient poses
frequent and challenging situations for the clinician.
They are as pervasive as glycemic control, and as relatively
rare as pheochromocytoma. In this chapter several
pathologies are reviewed, their clinical manifestations 
discussed, and approaches established to managing them.
THYROID DYSFUNCTION
The thyroid gland is responsible for the production of
thyroxine (T4) which is converted peripherally to the
more potent triiodothyronine (T3). Thyrotropin-releasing
hormone (TRH) from the hypothalamus stimulates the
release of thyroid-stimulating hormone (TSH) from 
the anterior pituitary. TSH then stimulates the release 
of T4 by the thyroid. A negative feedback loop involving
T4 then helps modulate the release of TSH from the 
pituitary gland. Both T3 and T4 are bound reversibly to
plasma proteins, primarily thyroxine binding globulin
(TBG). It is the free fraction of T3 and T4 that produces
the biological effect. They are responsible for maintain-
ing metabolism in tissues at an optimal level. They alter
the rate of cellular metabolism, oxygen consumption,
and heat production, and facilitate mobilization of free
fatty acids. Alterations in the production of T4 and its
subsequent conversion to T3 are responsible for many of
the clinical syndromes we see.
Hypothyroidism
Hypothyroidism results from a decrease in the pro-
duction of T4 and T3. The symptoms and signs are due
chiefly to a decrease in metabolism. Etiologies include
Hashimoto’s thyroiditis which is the most common cause
in adults, thyroidectomy, radioactive iodine, antithyroid
medications, amiodarone, iodine insufficiency, and 
secondary hypothyroidism. The signs can be subtle. 
The patient may complain of weight gain, cold intoler-
ance, muscle fatigue, or lethargy. Physical examination
may reveal dull facial expression, depression, and
hypoactive reflexes. In the elderly subclinical disease
may be present and difficult to identify. A high TSH level
establishes the diagnosis of primary hypothyroidism
when TSH > 20 μU/ml. When levels are moderately 
elevated, but < 20 μU/ml, a low plasma free T4 is used to
confirm the diagnosis. This is the case with secondary
hypothyroidism (Box 22-1).
Myxedema
Myxedema is a severe, potentially life-threatening
form of hypothyroidism. It tends to occur more com-
monly in the elderly and women. Patients often have
preexisting moderate or unrecognized hypothyroidism. It
is typically associated with a precipitant such as infection,
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trauma, surgery, sedative, gastrointestinal bleed, and
hypothermia.
The clinical manifestations are more severe. Signs and
symptoms include those seen in hypothyroidism and also
nonpitting edema, loss of eyebrow and scalp hair,
hypothermia, severe lethargy leading to coma, macro-
glossia with possible airway obstruction, hypotension,
and cardiac and respiratory failure. The presence of
coma associated with bradycardia, hypoventilation, and
hypothermia is life threatening. Associated findings on
laboratory workup include hypoxemia, hypercapnia, 
and respiratory failure. The chest x-ray may disclose a
large cardiac silhouette, pericardial effusion, or pleural
effusion. The EKG may show bradycardia with low voltage.
Although an elevated TSH level greater than 60 μU/ml
establishes the diagnosis, high-dose glucocorticoids or
high-dose dopamine may blunt the level of TSH seen in
the critically ill hypothyroid patient. Additional thyroid
function tests including a free T4 may be useful. The 
clinical picture as in all thyroid illnesses still remains 
the most useful diagnostic tool (Box 22-2).
Mild hypothyroidism is treated with T4, in single daily
doses of 50 to 200 μg. The treatment of myxedema typi-
cally is started, however, with T3 because of the decreased
conversion of T4 to T3 in the critically ill patient. A treat-
ment regimen is 12.5 to 25 μg q 6 h IV for the first 24 hours
followed by 25 to 50 μg/day. As the patient improves T3
is replaced with T4. T4, and especially T3, stimulates
metabolism and increase in oxygen consumption so care
must be taken with the elderly and patients with coro-
nary artery disease. In these patients, half a starting dose
is typically instituted and increased gradually. If angina
occurs while on T4 it must be considered as unstable
since the half-life of T4 is greater than 1 week. The half-
life of T3 on the other hand is approximately one day.
Replacement of hormone takes time and so there is no
indication for frequent TSH or free T4 or T3 levels. One
does not check levels more frequently than once a week.
Clinical status is a more reliable gauge of response to
therapy.
Adrenalitis with decreased cortisol production may
occur in myxedema. Treatment of myxedema may there-
fore unmask adrenal insufficiency and result in hypo-
tension. The pituitary axis should be checked upon the
diagnosis of myxedema and consideration should be
given to starting dexamethasone until the diagnosis of
adrenal insufficiency is excluded or continuing with
hydrocortisone if it is not.
Supportive care during this time may include correct-
ing the core temperature by warming the patient; con-
sidering mechanical ventilation if mental status,
hypoventilation, or acidosis are at a critical stage; and
searching for precipitating causes. Myxedema can be
fatal and hypercapnia and hypothermia are poor prog-
nosticators. However, early recognition, hormone
replacement, evaluation of pituitary–adrenal axis, and
supportive care will improve outcome.
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Box 22-1 Diagnosing Hypothyroidism
● Cold intolerance, lethargy, weight gain, hypoactive
reflexes, and dull facial expression
● TSH is best test
● TSH > 20 μU/ml, primary hypothyroidism
● TSH < 20 μU/ml, low free T4, secondary 
hypothyroidism
Box 22-2 Diagnosing Myxedema
● Severe lethargy, loss of eyebrow hair, nonpitting
edema, macroglossia, hypothermia, bradycardia, 
and hypercapnia
● Typically TSH > 60 μU/ml
● But lower with high-dose steroids or dopamine
● May need free T4 level
DRUG INTERACTIONS
T4 and T3
● T4 and especially T3 may precipitate ischemia in
patients with CAD
● In CAD start with half the dose and monitor closely
● T3 should be reserved for severe myxedema due to
its cardiac effects
● T4, however, has a longer half-life therefore 
continues to be a problem longer
CLINICAL CAVEAT
Myxedema and Adrenal Insufficiency
● Adrenalitis with decreased cortisol production 
may occur
● Treatment with T4 or T3 may unmask adrenal 
insufficiency
● Consider dexamethasone replacement while 
pituitary–adrenal axis is checked
● If diagnosis confirmed begin hydrocortisone at 
100 mg q 8 hours
Hyperthyroidism
Hyperthyroidism results from an excess of T4 and T3
production. Graves’ disease is the most common cause
followed by toxic multinodular goiter, thyroiditis, TSH-
secreting pituitary tumors, thyroid adenomas, excess
hormone replacement, and amiodarone. The symptoms
are the result of a hypermetabolic state. The patient may
present with weight loss, heat intolerance, muscle weak-
ness, diarrhea, and nervousness. Signs may include tachy-
cardia, atrial fibrillation, tremor, hyperactive reflexes,
goiter, and exophthalmos. The diagnosis is confirmed by
high free T4 and free T3 and low TSH. Total T4 and T3 levels
may not be helpful in critical illness (Box 22-3).
Thyroid Storm
Thyroid storm is an extreme form of hyperthyroidism
in long-standing uncontrolled or poorly controlled
hyperthyroidism. It may be related with a precipitating
illness or event such as thyroid surgery, infection,
trauma, acute abdominal problem, or anesthesia. Along
with the hypermetabolic crisis there is a breakdown in
the body’s thermoregulatory mechanism resulting in 
hyperthermia. Signs and symptoms include tachycardia and
atrial fibrillation; tremor, agitation, confusion, psychosis,
and even coma; congestive heart failure (CHF), hypo-
tension, and shock; nausea, vomiting, diarrhea, weight
loss, and cachexia; moist, warm, flushed, velvety skin;
and goiter in patients with Graves’ disease. The clinical
diagnosis is confirmed by a high total and free T4 and T3
and reduced TSH, but T3 and T4 may be distorted acutely
(Box 22-4).
Urgent treatment is necessary in the presence of fever,
delirium, exacerbation of CHF, and coronary artery
disease (CAD). Cardiovascular resuscitation with volume
repletion is an immediate priority in the treatment.
Reduction of thyroid hormone synthesis is then under-
taken. Thyroid hormone synthesis is reduced with
propylthiouracil (PTU) with a loading dose of 600 to
1200 mg PO, followed by 200–300 mg PO q 6. Two hours
after PTU is initiated, potassium iodide, SSKI, 5 drops q
6 hours can be started. To control heart rate and help
prevent T4 to T3 conversion, propranolol 40 mg PO q
6 hours (or 1–2 IV q 15 minutes to a total dose of 10 mg)
or esmolol IV drip can be started. Glucocorticoids
(dexamethasone 4 mg IV q 6 hours or hydrocortisone
100 mg IV q 8 hours) which also prevent T4 to T3 con-
version are given due to the relative adrenal insufficiency
which occurs due to the physiologic stress and increased
glucocorticoid metabolism caused by the hypermetabolic
state. Supportive measures include the treatment of hyper-
pyrexia with acetaminophen, fluid and electrolyte
replacement as needed, and identifying and treating the
underlying cause. These patients require observation and
treatment in a monitored setting such as an intensive care
unit (ICU). Left untreated survival is poor.
Sick Euthyroid Syndrome
Many illnesses and conditions alter thyroid studies
without being due to thyroid disease. Patients with star-
vation, mild illnesses, surgery, and trauma can have a
decrease in peripheral conversion of T4 to T3 resulting in
a low total T3 level. They typically will have a normal
TSH level. In more acutely ill patients there may be a
central suppression in the thyroid axis and T4 may also
fall to low levels. The TSH levels will thus be low despite
the low serum hormone levels. These conditions are
referred to as the sick euthyroid syndrome. It is
believed not to represent true thyroid illness, as these
patients do not manifest clinical signs of hypothy-
roidism. However, there are some who believe this may
more accurately represent a form of hypothyroidism and
use the term nonthyroidal illness syndrome. While the
critical illness gets worse and T4 becomes involved
there is the development of a more complex syndrome.
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Box 22-3 Diagnosing Hyperthyroidism
● Weight loss, heat intolerance, nervousness, tachycar-
dia, hyperactive reflexes, goiter, and exophthalmos
● High free T3 and free T4, low TSH
● Total T4 and T3 may be normal
Box 22-4 Diagnosing Thyroid Storm
● Tachycardia, atrial fibrillation, agitation, psychosis,
coma; if left untreated vascular collapse and shock
● High free T3 and free T4, low TSH
● Total T3 and T4 may be distorted acutely
CLINICAL CAVEAT
Treatment of Thyroid Storm
● Volume resuscitation 
● PTU and SSKI to decrease thyroid hormone 
synthesis
● Propranolol or other beta-blockade for tachycardia
and to decrease T4 to T3 conversion
● Glucocorticoids to decrease T4 to T3 conversion 
and for relative adrenal insufficiency
● Acetaminophen for fever
● Aggressive supportive care
As T4 serum levels decrease below 4 μg/dl the probability
of death increases in these patients. A T4 level < 2 μg/dl
is in fact associated with an 80% mortality. Whether this
represents a treatable condition or a marker for severe
illness is unclear. Some clinicians advocate the use of T3
replacement in the setting of significant cardiac depres-
sion. However, the use of T3 or T4 in these patients has
not been associated with improved outcomes.
PARATHYROID DYSFUNCTION
The four parathyroid glands produce parathyroid hor-
mone (PTH). PTH along with vitamin D (1,25-dihydroxy-
vitamin D) are responsible for the regulation of ionized
calcium in serum. Ionized calcium is the physiologically
active form of calcium; total serum calcium as com-
monly measured is not. Total serum calcium is depend-
ent on albumin level, acid–base status, and chelators.
A low total serum calcium which commonly occurs in
critically ill patients due to a low albumin is generally
associated with a normal ionized calcium level. These
patients are not truly hypocalcemic. An ionized calcium
level should be measured instead. The clinical manifes-
tations of hypo- and hyperparathyroidism are therefore
due to a decrease or increase in ionized calcium level.
The diagnoses of these conditions are made by evaluat-
ing ionized calcium and PTH level. The etiologies and
clinical manifestations are discussed below but the man-
agement of both hypo- and hyperparathyroidism are
covered elsewhere in this text.
Hypoparathyroidism
Hypoparathyroidism can occur postoperatively follow-
ing surgery on the parathyroid glands and on the thyroid
gland if all four parathyroid glands are removed. Other
conditions that result in hypoparathyroidism are severe
and acute hyperphosphatemia, hypomagnesemia, and
sepsis. The symptoms and signs associated with hypocal-
cemia are paresthesia, weakness, spasm, tetany, laryngo-
spasm, apnea; anxiety, irritability, confusion, depression;
hypotension, bradycardia, QT prolongation, arrhyth-
mias, and cardiac arrest. On clinical examination hyper-
reflexia and Chvostek’s and Trousseau’s signs may be
elicited.
Hyperparathyroidism
Primary hyperparathyroidism is the most common
cause of hypercalcemia in the outpatient setting. Solitary
adenoma accounts for 80% to 85% of cases, followed
by hyperplasia of all four glands, parathyroid cancer, and
multiple adenomas. Multiple endocrine neoplasia (MEN)
types I and II represent a particularly important subgroup
due to their associated endocrinopathies. Secondary
hyperparathyroidism is due to a compensation in PTH
secretion because of chronic low serum calcium. Chronic
renal failure accounts for most of this group, followed by
malabsorption, rickets, and osteomalacia. Tertiary hyper-
parathyroidism occurs when hypercalcemia develops in
secondary hyperparathyroidism. The symptoms of hyper-
parathyroidism and its resultant hypercalcemia are often
described by the constellation of symptoms referred to
as “bones, stones, psychic moans, and abdominal groans.”
The symptoms and signs include weakness, hypotonia,
and hyporeflexia; confusion, psychosis, coma, and seizures;
constipation, polyuria, and anorexia; fractures, osteopenia,
and ectopic calcification; and QT shortening, cardiac
arrhythmias, hypertension, and heart block.
ADRENAL DYSFUNCTION
The adrenal gland is responsible for the production
of glucocorticoids, mineralocorticoids, sex hormones,
and catecholamines. The adrenocorticotropic hormone
(ACTH) secreted by the anterior pituitary stimulates the
release of cortisol, the principal glucocorticoid pro-
duced by the adrenal cortex. This is done in a diurnal
pattern and is increased during periods of stress. Cortisol
has effects on protein, fat, and carbohydrate metabolism.
It is essential for proper carbohydrate–protein metabolism,
norepinephrine to epinephrine conversion in the adre-
nal medulla, adrenergic receptors function, cardiac
contractility, vascular tone, endothelial integrity,
immune function, and numerous other functions.
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CURRENT CONTROVERSY
Sick Euthyroid Syndrome
● Occurs in critically ill patients
● Low T3, normal TSH; the more acutely ill have low
T4, low TSH
● Many believe it does not represent thyroid disease
● However, low levels of T4 associated with high 
mortality
● Some clinicians recommend T3 replacement in
severely ill patients
● But no evidence of improved outcomes with T3 use
CLINICAL CAVEAT
Calcium Level
● Ionized calcium is the physiologically active form 
of calcium
● Ionized calcium is altered by albumin level,
acid–base status, and chelators
Deficiency of cortisol has various clinical manifestations
which depend on the extent and acuteness of onset.
Acute Adrenal Insufficiency
Adrenal insufficiency can result from primary, sec-
ondary, or tertiary causes. Primary adrenal insufficiency,
or Addison’s disease, is due to the destruction of the
adrenal cortex. Autoimmune diseases account for a large
percentage of cases. Other causes include chronic infec-
tions besides tuberculosis like AIDS-related infections such
as cytomegalovirus (CMV), or fungal infections; Gram-
negative bacterial infections; invasion of the adrenal by
cancer cells that have spread from another part of the
body, especially the breast; rarely, hemorrhage into the
adrenals during shock; abdominal trauma; and the surgical
removal of both adrenals. Drugs such as ketoconazole
and etomidate have also been implicated. It can be
chronic, but can develop into acute addisonian crisis
during periods of stress. The signs and symptoms are of
both mineralocorticoid deficiency – hyperpigmentation,
vitiligo, hyperkalemia, hyponatremia, and hypovolemia –
and glucocorticoid deficiency – weakness, fatigue, hypo-
glycemia, and hypotension.
Secondary adrenal insufficiency is most commonly
due to previous glucocorticoid use which suppresses
the pituitary–adrenal axis. The subsequent ability of the
adrenal gland to increase cortisol production in periods
of stress is decreased. In fact adrenal recovery may take
9 to 12 months following the discontinuation of steroid
use. These patients should be considered to be at risk for
secondary adrenal insufficiency. Other causes are post-
partum pituitary necrosis, pituitary tumors, pituitary 
surgery, brain tumors, head trauma, radiation therapy,
and anoxic encephalopathy. Some clinicians believe that
sepsis itself may suppress adrenal function, which returns
once sepsis resolves. Patients typically manifest signs and
symptoms of glucocorticoid deficiency.
Tertiary adrenal insufficiency refers to tissue gluco-
corticoid deficiency typically from sepsis or multiple
organ dysfunction. These patients in effect have relative
tissue resistance to cortisol. These patients may have
high levels of circulating cortisol, which may make 
the diagnosis of adrenal insufficiency difficult to make.
The diagnosis can be made by demonstrating a decreased
clearance of cortisol.
Acute adrenal insufficiency results from either addi-
sonian crisis due to acute hemorrhage into the adrenal
cortex or during periods of stress in patients with 
secondary and tertiary adrenal insufficiency. This is 
usually associated with a concurrent illness such as sepsis,
trauma, or surgery. Along with the signs of glucocorti-
coid and mineralocorticoid deficiency, signs of cardio-
vascular collapse are pronounced. Hypotension, relatively
unresponsive to volume resuscitation, will predominate.
It can progress to cardiovascular collapse and death.
Hyperpigmentation seen in primary adrenal insuffi-
ciency is not seen in secondary adrenal insufficiency.
Diagnosis (Box 22-5) requires a high index of suspi-
cion. While an insulin tolerance test would be the most
sensitive diagnostic test it is not practical in the critically
ill patient. A random cortisol level is obtained instead.
Normal patients with an intact hypothalamic–pituitary–
adrenal (HPA) axis during periods of stress will have 
a random cortisol >18 μg/dl and generally >25 μg/dl.
However, a low random cortisol level does not make the
diagnosis of adrenal insufficiency. The HPA axis needs 
to be checked. Traditional diagnosis requires a 250 μg
bolus of cosyntropin (ACTH). By convention this dose is
thought to exclude adrenal insufficiency if the post-
stimulation level at 60 minutes increases the cortisol
level by >8 μg/dl or if the level is >18 μg/dl. However,
the precise diagnostic criteria for adrenal suppression
are unclear. We know that levels of up to 25 μg/dl may
represent an inadequate response. Moreover, the standard
test dose of 250 μg of ACTH is in fact several hundred-fold
greater than the stress ACTH response. This supraphysio-
logic dose may in fact cause the adrenal to respond
when it would not otherwise. One may therefore fail to
diagnose patients with partial or relative adrenal insuffi-
ciency. Many clinicians are concerned that the standard
testing is not sensitive enough. Therefore a lower dose
cosyntropin test of 1 μg is advocated by some. Under a
protocol advocated by Marik and Zaloga, a hypotensive
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CLINICAL CAVEAT
AIDS and Adrenal Insufficiency
● AIDS has a high association with primary adrenal
insufficiency
● Infections, especially CMV and fungal, are 
implicated
● Consider acute adrenal insufficiency in the 
hypotensive, critically ill AIDS patient
Box 22-5 Diagnosing Acute Adrenal
Insufficiency
● Mineralocorticoid deficiency – vitiligo, hyperkalemia,
hyponatremia, and hypovolemia
● Hyperpigmentation only in primary adrenal 
insufficiency
● Glucocorticoid deficiency – weakness, fatigue, 
hypoglycemia, and hypotension
● Hypotension with cardiovascular collapse; 
unresponsive to fluids and pressors
● Cortisol assay
patient with a random cortisol of <25 μg/dl undergoes a
1 μg ACTH stimulation test. An appropriate response is
considered to be a subsequent cortisol level >25 μg/dl at
30 minutes. They follow this up with a 250 μg dose to
differentiate between primary adrenal failure, HPA axis
failure, and ACTH resistance. More experience, how-
ever, is needed before conclusions can be made. We are
currently assessing the use of a 1 μg dose of ACTH fol-
lowed by a 250 μg dose which is injected at the time the
60 minute sample is obtained. When in doubt we treat
with a short course of steroids and observe.
Treatment is with stress doses of hydrocortisone IV
at 100 mg q 8 hours in patients with an established diag-
nosis. In patients with a possible diagnosis, emergent
treatment can be started with dexamethasone IV 4 mg q
6 hours. Dexamethasone does not interfere with the 
cortisol assay. Treatment can therefore be started while
testing is in progress. However, it has no mineralocorti-
coid activity so it should be changed to hydrocortisone
once the cosyntropin test is complete or diagnosis is
made. Emergent treatment should also include D5NS to
treat the associated hypoglycemia and volume depletion.
Perioperative stress dose steroid replacement has tradi-
tionally required full replacement of hydrocortisone IV at
100 mg q 8 initiated at the time of surgery and subsequent
tapering over the next several days. This was regardless of
the planned surgery in any patient who has received
steroids over the last 9 to 12 months. The normal basal pro-
duction of cortisol, however, is 30 mg/day. A more tem-
pered approach appears to be gradually developing
assessing the type of surgery planned and the preoperative
steroid dose. Generally those patients who are on a low-
dose prednisone ≤5 mg/day or are getting minor or periph-
eral surgery receive that dose. This is tailored upwards with
full replacement reserved for patients on a high preopera-
tive regimen or those scheduled to receive major surgery.
DIABETES INSIPIDUS
Diabetes insipidus (DI) is a disorder of water imbal-
ance due to a lack of production of or response to anti-
diuretic hormone (ADH). ADH is secreted by the pituitary
and is responsible for the absorption of water in the col-
lecting tubules. There are neurogenic and nephrogenic
causes. Neurogenic (central) DI may be idiopathic in one-
third of cases or caused by the destruction of hypophysis
due to trauma, surgery, granulomatous disease, vascular
accidents, neoplasms, or infections. Nephrogenic DI 
can be caused by drugs, amphotericin B, democycline,
and lithium; renal failure including correction of post-
obstructive uropathy, systemic diseases such as amyloid-
osis, multiple myeloma, and sarcoidosis; and pregnancy.
Central DI tends to be more severe. These patients 
present with polyuria, polydipsia if alert, hypernatremia
with high serum osmolarity and low urine osmolarity 
<300 mOsm/kg. In the ICU these patients can have very
large urine outputs of ~1 l/hour up to 20 l/day. They will be
hypovolemic and may even be in shock. While a water dep-
rivation test and desmopressin challenge test may be useful
in differentiating a central from nephrogenic cause of DI,
the most useful test in the critically ill patient is urine spe-
cific gravity. A urine specific gravity of <1.004, or a urine
osmolarity <300 mOsm/kg, in the face of hypernatremia
and large urine output is diagnostic for DI (Box 22-6).
Treatment for central DI is with the use of desmopressin
(DDAVP) IV or SC at 1–4 μg q 6 to 24 hours depending on
severity or intranasally at 5–20 μg q 12 hours if mild. Free
water deficits must be calculated and replaced (Box 22-7).
Initial fluids may include normal saline (NS) for volume
expansion but is soon switched to D5W and PO replace-
ments. Potassium, magnesium, and phosphorus losses
are replaced simultaneously. In severe nephrogenic DI,
thiazide diuretics are administered. DI may be masked 
in patients with adrenal insufficiency, so care must be
taken when initiating steroid treatment.
242 CRITICAL CARE: THE REQUISITES IN ANESTHESIOLOGY
CURRENT CONTROVERSY
ACTH Stimulation Test
● Precise diagnostic criteria for acute adrenal
insufficiency using cortisol assays are unavailable
● Standard ACTH stimulation test with 250 μg is
supraphysiologic
● May mask partial or relative adrenal insufficiency
● Low dose with 1 μg is advocated by some
● What cortisol level to use is still unclear
DRUG INTERACTIONS
Dexamethasone
● Dexamethasone does not interfere with cortisol assay
● Little mineralocorticoid activity
● Switch to hydrocortisone once diagnosis is made
● If must continue dexamethasone add flucortisone
Box 22-6 Diagnosing Central Diabetes
Insipidus
● Polyuria, polydipsia if alert; hypernatremia
● Urine specific gravity < 1.004
● Urine osmolarity <300 mOsm/kg
GLYCEMIC DYSFUNCTION
Disorders of glycemic control are extremely common
in the ICU.
Hypoglycemia
Hypoglycemia as defined by Whipple’s triad is a serum
glucose < 50 mg/dl, associated with central nervous
system symptoms, which resolves with glucose adminis-
tration. Initial symptoms and signs include nervousness,
diaphoresis, blurred vision, and tachycardia. Failure to
treat hypoglycemia can lead to lethargy, seizures, coma,
and irreversible brain damage. In the critically ill patients
symptoms can be easily masked by the underlying disease
process and by sedation. Therefore the clinician needs to
have a high index of suspicion and monitor serum glucose
closely in at-risk patients. Conditions associated with
hypoglycemia are liver disease, alcoholism, adrenal failure,
myxedema, insulinomas, and medications such as insulin,
sulfonylureas, and pentamidine. Iatrogenic causes account
for most cases in the hospitalized patient. They include
excessive insulin, decreased caloric intake, and treatment
of hyperkalemia with insulin; conditions such as sepsis,
shock, acute renal failure, and acute fulminant hepatic
failure can result in hypoglycemia. The treatment is with
50 cm3 IV D50W. If hypoglycemia is particularly resistant
to treatment continuous infusions can be used. Glucagon
0.5 to 1.0 mg IV, PO or SC, can also be used if hypo-
glycemia is persistent or there is no IV access. Those
patients who are alcoholic or malnourished should get
100 mg IV thiamine before the administration of glucose to
prevent the onset of Wernicke’s encephalopathy. Specific
treatment with steroid for acute adrenal insufficiency, 
thyroxine for myxedema, and activated charcoal for over-
doses of oral hypoglycemic agents should be given.
Hyperglycemia
Stress-induced hyperglycemia is common in critically
ill patients. This occurs not only in patients with known
diabetes, but can also occur in patients with no previous
history. There are various etiologies aside from insulin
deficiency and resistance. Stress itself with the release
of cytokines, and hormones such as catecholamines,
cortisol, and growth hormone can play a role. Dextrose-
containing IV fluids, total parenteral nutrition (TPN), and
drugs such as steroids can also contribute.
Hyperglycemia in critically ill patients is known to be
associated with an increased morbidity especially due to
infections in surgical patients. The control of glucose has
subsequently been shown to decrease the infection rate.
Traditionally hyperglycemia is handled with either sub-
cutaneous insulin or an IV insulin drip when the glucose
level is more difficult to manage. The goal had been to
maintain a blood glucose < 180–200 mg/dl. Tighter con-
trol was avoided by many because of its perceived unclear
efficacy and concern for hypoglycemia. This is in spite 
of various studies suggesting continued improvement 
in morbidity as the blood glucose target level was
decreased. Recently a study showed an almost 50%
reduction in mortality in patients who were on mechan-
ical ventilation more than 5 days when their blood glu-
cose levels were kept between 80 and 110 mg/dl vs.
traditional goals of <180–200 mg/dl. While these patients
had a slightly higher number of hypoglycemic episodes
it was neither statistically significant nor was it associ-
ated with any residual effects. Although we await further
confirmation from other centers we insist on the same
tight control with close monitoring.
Diabetic Ketoacidosis
Diabetic ketoacidosis (DKA) is a potentially fatal con-
sequence of uncontrolled diabetes occurring almost
exclusively in type I diabetes mellitus (DM). It commonly
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CLINICAL CAVEAT
Treatment of Hypoglycemia
● D50W 50 cm3 IV
● D10W 100 IV 100 to 200 cm3/hour
● Glucagon 0.5 mg to 1.0 mg IV, PO or SC
● Steroids if adrenal insufficiency, thyroxine for
myxedema, and activated charcoal for oral 
hypoglycemic agents
Box 22-7 Calculating Free Water Deficit
Water deficit = 0.6 × (wt in kg) × (([Na] − 140)/140)
CURRENT CONTROVERSY
Blood Glucose Target
● Traditional goal is <180 mg/dl to 200 mg/dl
● Concerns about further efficacy and hypoglycemia
with tighter control
● Evidence, however, that further decreases improve
morbidity
● Evidence that a goal of 80 mg/dl to 110 mg/dl
decreases mortality
● No significant hypoglycemic effects
● Our goal is 80 mg/dl to 110 mg/dl
occurs in children and young adults due to new-onset
diabetes, noncompliance of insulin therapy, or concur-
rent conditions such as infections, trauma, myocardial
ischemia, and emotional stress. On rare occasions it
occurs in severely stressed older patients with type II DM.
Its pathogenesis is due to a complete or relative defi-
ciency of insulin during periods of stress. This, coupled
with a secondary counter regulatory hormone excess
of glucagon and catecholamines, results in the over-
production and underutilization of glucose and lipolysis.
The clinical picture is due to these metabolic disturbances.
In DKA hyperglycemia results typically with a blood
glucose of 400–800 mg/dl. This is accompanied by an
osmotic diuresis, an anion gap metabolic acidosis due 
to the increased production of acetoacetic acid and 
β-hydroxybutyric acid, and the accumulation of ketones
due to acetone and acetoacetic acid. Patients may pres-
ent with polyuria, mild dyspnea, nausea, vomiting, vague
abdominal discomfort, lethargy, and occasionally an
altered mental status. Findings on physical examination
may include tachypnea, tachycardia, and a weak thready
pulse consistent with hypotension. The diagnosis is
established in a hyperglycemic patient by a serum sample
revealing an anion gap metabolic acidosis and positive
for ketones. Urine for ketones which can be analyzed
rapidly at the bedside may also be useful. Hyperkalemia
due to lack of insulin and acidosis is typically present 
in spite of large potassium deficits due to the osmotic
diuresis. The diuresis may also cause hypomagnesemia
and hypophosphatemia. Free water loss at the expense of
sodium occurs readily. However, a low or normal sodium
is often seen on laboratory tests. This is due to the dilu-
tional effect of hyperglycemia and hypertriglyceridemia
on serum sodium concentrations. This “psuedohypona-
tremia” underestimates the true total body sodium level.
A correction formula adding 1.6 mg/dl Na+ to the mea-
sured Na+ concentration for every 100 mg/dl of glucose
over 100 mg/dl is generally used (Box 22-8). True total
sodium levels may actually be normal or high. The
osmotic diuresis causes volume depletion and dehydra-
tion as evidenced by the increased urea nitrogen, creati-
nine, and osmolarity. Increased plasma amylase without
evidence of pancreatits and hypertriglyceridemia can
also be seen.
Insulin, volume resuscitation, and electrolyte replace-
ment are crucial in the treatment of DKA. Insulin is needed
to decrease hepatic production of glucose and ketones
and to increase glucose utilization and ketone clearance.
A bolus of insulin is given at 0.1 units/kg and a drip is
started at 0.1–0.2 units/kg/hour. Blood glucose should
be monitored q 1 hour at first and a reasonable goal
should be a decrease of 100–150 mg/dl/hour initially.
Fluid deficits, typically of the order of 5–8 liters, are
replaced aggressively with NS. Although patients may
actually be hypernatremic, the correction of volume sta-
tus initially with NS is more important than the risk of
increasing sodium content. Infusion of 500 to 1000
cm3/hour for the first 1 to 2 hours is followed by 250 to
500 cm3/hour for the next 2 to 4 hours depending on
the extent of dehydration. Although care should be
taken in patients with cardiac dysfunction, volume resus-
citation should be started early and continued until after
the resolution of ketoacidosis. When blood glucose
approaches 250 mg/dl the fluid is changed to D5W or
D5W1/2NS in order to prevent hypoglycemia while con-
tinuing to give insulin. Insulin is maintained until the
ketoacidosis resolves. Potassium replacement must be
initiated early. In fact patients with normal and espe-
cially with low potassium should have their potassium
replacement begun prior to insulin administration.
Magnesium and phosphate replacement will also need to
be addressed. Although a pH < 7.2 or even < 7.1 with a
serum HCO3 < 10 is not uncommon, the use of NaHCO3
should be avoided. We reserve its use for a persistent 
pH < 7.0 after several hours of treatment. Underlying
precipitants are searched for and treated.
Nonketotic Hyperosmolar
Syndrome
Nonketotic hyperosmolar syndrome (NKHS) is a con-
dition that occurs in older, type II diabetics and rarely in
type I diabetics. These patients typically secrete enough
insulin to prevent lipolysis and ketogenesis and the sub-
sequent DKA from occurring, but not enough to prevent
hyperglycemia. An altered mental status along with renal
insufficiency or prerenal azotemia appear to be impor-
tant in the development of the hyperglycemia. Typical
precipitating factors are infections, stroke, myocardial
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Box 22-8 Correction of Serum Sodium
Concentration
Corrected [Na+] = 1.6 × [([Glucose]−100)/
100] mg/dl + [Na+]
CLINICAL CAVEAT
Treatment of Diabetic Ketoacidosis
● Volume – NS at 500 to 1000 cm3/hour then D5W 
or D5W1/2NS
● Insulin drip – continue <250 mg/dl until ketoacidosis
resolves
● Potassium, magnesium, and phosphorus 
replacements early
● Treat precipitating illness
ischemia, and noncompliance. The clinical picture is
due mostly to hyperglycemia and dehydration.
As in DKA, polyuria and polydipsia (if the patient 
is able) are common, but a more severely depressed
mental status occurs. Hyperglycemia is generally in the
800 to 1200 mg/dl range, and severe dehydration and
lack of significant acidosis tends to be the rule. Although
ketosis and even mild ketoacidosis are sometimes seen,
typically acidosis when present is from lactic acidosis or
renal insufficiency. Electrolyte loss due to osmotic diure-
sis is present, especially potassium and magnesium, 
but the pseudohyponatremia that occurs is more pro-
nounced than in DKA owing to the greater hyper-
glycemia. Other evidence of dehydration is also found in
laboratory tests.
The treatment approach to NKHS is similar to that 
of DKA. Volume resuscitation, insulin, and electrolyte
replacement are also crucial but with a greater emphasis
on volume replacement. Fluid deficits are greater and 
in the range 5–10 liters. Initial replacement is with NS at
1000 cm3/hour for the first 1 to 2 hours and subse-
quently 250 to 500 cm3/hour for the next 2 to 4 hours.
After the initial resuscitation to restore intravascular 
volume, consideration can be given to using a less hypo-
tonic fluid such as 1/2NS, LR, or D5W in cases of severe
hypernatremia. D5W is started when the blood glucose
approaches 250 mg/dl. Although blood glucose rapidly
decreases just by the dilution effect of the initial resusci-
tation, insulin, however, remains a crucial part of the
treatment. A bolus of insulin is given at 0.1 units/kg and
a drip is started at 0.1 to 0.2 units/kg/hour. Blood glucose
should be monitored q 1 hour at first. Once the blood
glucose is around 250 mg/dl the drip can be decreased
to 1 to 2 units/hour. Hypokalemia and hypomagnesemia
are addressed shortly after initiation of volume resuscita-
tion. As in DKA, an aggressive search and treatment of all
precipitating causes is undertaken.
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CLINICAL CAVEAT
Diabetic Ketoacidosis vs. Nonketotic
Hyperosmolar Syndrome
● Age: typically younger vs. typically older
● BG: 400 mg/dl to 800 mg/dl vs. 800 mg/dl to 
1200 mg/dl
● Acidosis: ketoacidosis vs. none but lactic or renal
insufficiency occurs
● Volume loss: 5 to 8 liters vs. 5 to 10 liters
● DKA associated with symptoms and signs 
of acidosis
● NKHS associated with altered mental status and 
renal insufficiency
● Both need aggressive insulin administration
● Both need aggressive electrolyte replacement
CLINICAL CAVEAT
Diagnosing Pheochromocytoma
● Classic triad of headaches, palpitations, and
diaphoresis in the presence of severe hypertension
has a 91% sensitivity
● Testing is difficult in the critically ill due to assay
interference
● Definitive diagnosis often awaits resolution of 
critical illness
● Imaging studies locate tumor once diagnosis is made
PHEOCHROMOCYTOMA
Pheochromocytomas are usually benign tumors of the
adrenal medulla with unregulated growth and secretion
of catecholamines. The adrenal medullae account for
90% of presentations. The rest are extra-adrenal with the
organ of Zuckerkandl at the aortic bifurcation being a
common intra-abdominal site. Associations with MEN IIA
and IIB and Von Recklinghausen syndrome do occur.
The signs and symptoms are related to catecholamine
excess. Pheochromocytomas account for 0.1% of all cases
of hypertension. Paroxysmal changes in blood pressure, a
“hallmark” of pheochromocytomas, occur in only a third
of patients, and sustained hypertension occurs in about
half. Patients classically experience spells characterized 
by headaches, palpitations, and diaphoresis in association
with severe hypertension. These four characteristics
together have a sensitivity of 91% and are strongly sugges-
tive of pheochromocytoma. Other signs and symptoms
include anxiety, cutaneous flushing, chest pain, abdominal
pain, orthostatic pressure fluctuations, CHF, and changes
related to chronic hypertension. Paroxysmal changes can
be precipitated by trauma, induction of anesthesia, sur-
gery, and certain medications such as opioids, histamine,
beta-blockers, glucagon, and dopamine antagonists.
The diagnosis requires a high index of suspicion which
may be supported in the ICU by hypertension poorly
responsive to therapy. It is made by measuring an increase
in 24-hour urinary collection of catecholamines and their
byproducts such as metanephrines and vanillymandelic
acid (VMA). Plasma catecholamines which are more diffi-
cult to measure can help with borderline cases. However,
there are acute physiologic changes that occur in the criti-
cally ill that may make it difficult to differentiate them from
patients with pheochromocytomas. Provocative testing
such as the clonidine suppression test can also be used but
has little role in ICU patients. The definitive diagnosis
therefore often awaits resolution of the acute illness. Once
the diagnosis is made, localizing the tumor is done by com-
puted tomography (CT) or preferably magnetic resonance
imaging (MRI). A scan with iodine-131 (131I)-labeled meta
iodobenzylguanidine (MIBG) is used when CT scan or MRI
fails to localize the tumor.
Alpha-adrenergic blockade is the cornerstone of hyper-
tension control in these patients, and in fact needs to
occur before beta-blockade is introduced. Beta-blockade
without adequate alpha-blockade can result in unop-
posed alpha-mediated vasoconstriction and severe
hypertension. Labetolol because of its combined alpha-
and beta-blockade has been promoted as a first-line
agent. However, there are reports of worsening hyper-
tension in some patients presumably due to inadequate
alpha-blockade.
Acute hypertensive episodes requiring immediate
management can be treated with phentolamine a short-
acting alpha-adrenergic blocker at 2–5 mg IV q 5 minutes
until the blood pressure is controlled. Prazosin, another
alpha-blocker, can also be used at a starting dose of 
1–2 mg PO q 6 hours. A nitroprusside infusion may be
useful during the acute management of the hypertensive
episode. Definitive treatment is with surgical removal of
the tumor. However, prior to surgery, adrenergic block-
ade, blood pressure control, and volume resuscitation
need to take place. Phenoxybenzamine, a noncompeti-
tive alpha-adrenergic receptor blocker, is started at a dose
of 10 mg PO q 12 hours for 7 to 10 days before surgery.
Expansion of intravascular volume is also undertaken
during this time. Subsequent to adequate alpha-blockade,
beta-blockers are sometimes used for the management 
of tachyarrhythmias. Nitroprusside, phentalomine, and
beta-blockers are sometimes needed intraoperatively.
Immediately postoperatively a short course of phenyl-
ephrine may be needed to maintain vascular tone. If
both adrenals are removed steroid replacement therapy
must be started.
SUMMARY
Endocrinopathies have an impact on the critically ill
patient in many ways. These conditions can be as rare as
pheochromocytoma or as ubiquitous as hyperglycemia.
The apparent affects may be extraordinary and life
threatening or subtle and seemingly trivial. While
the need to have approaches to diagnosing and aggres-
sively managing the more serious complications are well
appreciated, those subtle and trivial effects warrant
careful consideration. Recent data for instance support-
ing the concept of partial or incomplete adrenal insuffi-
ciency and that tight blood glucose control improves
mortality in mechanically ventilated patients forces us
to view these “subtle or trivial” effects in a new light.
So while we must manage life-threatening situations
without delay, we cannot forget that other abnormalities
which are thought to be minor may have a detrimental
impact on our patients.
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DRUG INTERACTIONS
Beta-Blockade and Pheochromocytomas
● Beta-blockade before adequate alpha-blockade
results in unopposed alpha-mediated vasoconstriction
and hypertension
● Labetolol may not provide adequate alpha-blockade
CASE STUDY
A 47-year-old female with a history of poorly
controlled hypertension and a recent diagnosis of
medullary carcinoma of the thyroid is admitted to the
ICU for uncontrolled hypertension immediately
postoperatively after a thyroidectomy. Examination in
the ICU reveals an extubated, thin, anxious diaphoretic
female. Her blood pressure is 176/94, heart rate is 
142 regular, respiratory rate is 22, and temperature 
is 38.2°C. Her examination other than the dressing 
on her neck which is clean and dry is otherwise
unremarkable. She is noted to be on nitroprusside 
drip at 3.5 μg/kg/minute.
QUESTIONS
1. What is your differential diagnosis?
2. How can you explain her presentation?
3. What other abnormalities may be present?
4. What medications would you use for her blood
pressure control?
5. How would you make the diagnosis?
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PHYSIOLOGY
Intensive care of the pregnant patient involves the
simultaneous care of two individual patients. Critical
decisions made for maternal well-being can profoundly
affect the fetus. A basic understanding of the physiologic
changes associated with pregnancy is necessary to pro-
vide proper care to the critically ill gravida. The following
is a brief review of the major physiologic changes seen
in pregnancy (Box 23-1).
Cardiorespiratory Systems
The following increase significantly during pregnancy:
respiratory rate, oxygen consumption, minute ventilation,
tidal volume, and PaO2. Functional residual capacity 
and PaCO2 decrease but there is also a compensatory
decrease in plasma bicarbonate concentration thereby
avoiding a marked respiratory alkalosis. As the uterus
enlarges, the diaphragm is elevated and thoracic breath-
ing is favored over abdominal breathing. During periods
of apnea, there is rapid oxygen desaturation due to a
decreased functional residual capacity and increased
oxygen consumption. It is especially important to 
presaturate pregnant patients to avoid hypoxemia dur-
ing induction of general anesthesia. Maintaining a mater-
nal PO2 above 60 mmHg will help ensure adequate fetal
oxygenation. Uptake of inhalation agents is accelerated
due to the increase in minute ventilation. Respiratory
mucosa becomes engorged and prone to bleeding due 
to hormonal changes so special care must be rendered 
during intubation.
Maternal blood volume increases by up to 50% at
term. Cardiac output increases significantly to accom-
modate the increased maternal and fetal demands by
an increase in both heart rate and stroke volume. Cardiac
output is greatest during delivery and immediately
thereafter. There is generally about a 400 cm3 and
800 cm3 blood loss during vaginal and cesarean deliveries,
respectively, but this is usually well accommodated by
the increased blood volume. Blood volume as well as 
cardiac output generally return to normal one to two
weeks postpartum.
The supine position causes decreases in cardiac out-
put due to compression of the great vessels. This aorto-
caval compression is a significant and easily correctable
cause of fetal distress due to the hypotension causing a
significant uterine hypoperfusion. Gravidas in the third
trimester especially should be placed in a tilt if they need
to lie down in order to displace the enlarged uterus. It is
also important to note that during the second trimester,
there is a decrease in systemic vascular resistance low-
ering the maternal blood pressure, which gradually rises
back to normal at term. Maternal systolic blood pressure
should be maintained at 90 mmHg to ensure adequate
placental perfusion.
EKG changes are common including a left axis devia-
tion and chest x-rays can give the appearance of an
enlarged heart due to elevation of the diaphragm. Finally,
systolic flow murmurs are commonly appreciated due to
increased blood volume.
Renal and Gastrointestinal Systems
Glomerular filtration rate increases significantly in
pregnancy by as much as 50% causing decreases in
blood urea nitrogen (BUN) as well as creatinine. There is
a decrease in renal tubular threshold for both glucose
and amino acids causing glycosuria as well as protein-
uria (less than 300 mg/dl). Disease processes such as
preeclampsia can affect the renal system significantly
causing profound proteinuria and even renal failure.
Gastroesophageal reflux and delayed emptying of 
the stomach are significant causes of maternal morbidity
and mortality. This is due to a combination of factors
including progesterone effect as well as upward dis-
placement of the stomach by the gravid uterus. There is
generally hypersecretion of gastric acid causing a gastric
pH under 2.5 placing gravidas at risk for severe aspira-
tion pneumonitis.
Hematologic
Pregnancy is considered a hypercoagulable state that
increases the risk for deep venous thrombosis (DVT) and
pulmonary embolism but is protective against maternal
hemorrhage. Mild leukocytosis and a 20% decrease 
in platelet count are also seen. Finally, a physiologic 
anemia caused by a nonconcordant increase in red blood
cell mass versus plasma volume is seen commonly.
BASIC FETAL MONITORING
When a pregnant patient is admitted to the intensive
care unit, a team approach will optimize outcomes. 
A qualified obstetrician should be consulted at the 
onset of care due to the necessity of providing 
proper monitoring of not only the mother but also
the fetus.
The most commonly used modalities in fetal monitor-
ing include ultrasound, the nonstress test (NST), the con-
traction stress test (CST), and the biophysical profile.
Ultrasound can be used to assess fetal viability, position,
placenta location and possible abruption status, amni-
otic fluid volume, and uterine artery blood flow, all of
which are helpful in assessing fetal well-being. The NST
is used to assess fetal heart rate variability and accelera-
tions in relation to fetal movement as well as uterine
activity. In term pregnancies, an NST is considered 
reactive when the fetal heart rate rises for 15 beats over
a 15-second time period. In preterm pregnancies, a 10 by
10 criterion is sometimes used. When an NST is deter-
mined to be nonreactive, further testing is usually war-
ranted, either by a CST or a biophysical profile. The CST
is used to determine fetal tolerance of the intrauterine
environment. Contractions are induced generally with
the use of oxytocin and the fetal heart rate response 
is assessed. If there are three late decelerations within a
10-minute period, the test is considered positive and
intervention needs to be considered. Fetal heart rate
decelerations are important to identify as they have dif-
ferent physiologic meanings. Briefly, early decelerations
signify head compression, essentially a brief vagal
response to uterine contractions. Variable decelerations
signify cord compression and are generally benign unless
they start to show atypical signs. Late decelerations are
generally considered a sign of uteroplacental insuffi-
ciency and warrant prompt attention. It is important to
consider the maternal condition when interpreting fetal
tracing prior to intervening, as some maternal conditions
such as hypotension and hypoxemia can sometimes 
be quickly corrected with a subsequent improvement 
in the fetal testing results. The biophysical profile is
another useful test to assess fetal well-being. This test
involves factors such as fetal movement, fetal tone, fetal
breathing, as well as amniotic fluid measurement and
results of NSTs. Each category is given 0 or 2 points.
A score of 8 or 10 is generally reassuring. Anything below
that requires either additional testing or intervention based
on the circumstances.
OBSTETRIC COMPLICATIONS
Pregnancy can result in serious complications requir-
ing the expertise of an intensive care team. The most
common problems generally stem from massive blood
loss, hypertensive diseases of pregnancy, and amniotic
fluid/pulmonary embolus.
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Box 23-1 Physiologic Changes 
of Pregnancy
● Increased oxygen consumption
● Increased minute ventilation
● Increased respiratory rate
● Increased PaO2
● Decreased functional residual capacity
● Decreased PaCO2
● Increased maternal blood volume
● Increased cardiac output
● Left axis deviation of EKG
● Increased glomerular filtration rate
● Decreased BUN and creatinine
● Increased gastroesophageal reflux
● Hypersecretion of gastric acid
● Delayed gastric emptying
● Hypercoagulable state: increased risk of DVT
Massive Blood Loss
Obstetric hemorrhage is the leading cause of maternal
death worldwide. It is generally caused by uterine atony,
although other causes include retained placental frag-
ments, abnormal placentation (placenta previa, accreta,
percreta, increta), placental abruption, genital lacera-
tions, uterine inversion, uterine rupture, coagulopathy,
and hematoma. Postpartum hemorrhage is defined as
more than 500 cm3 and 1000 cm3 losses during vaginal 
and cesarean deliveries, respectively; a decrease in
hematocrit by more than 10%; or a need for transfusion
after delivery secondary to blood loss. Management of
hypovolemic shock includes maintaining systolic blood
pressure above 90 mmHg, maintaining urine output above
25 ml/hour, and maintaining normal mental status.
Volume replacement is especially important, but overag-
gressive replacement may contribute to the development
of pulmonary edema.
Hypertensive Disorders
Pregnancy-induced hypertension (PIH), preeclamp-
sia, eclampsia, and HELLP (hemolysis, elevated liver
enzymes, and low platelets) syndrome are all part of a
spectrum of hypertensive diseases of pregnancy. There
can be pathophysiologic changes seen in the cardiovascu-
lar, hematological, renal, hepatic, and neurologic systems.
Hallmarks of preeclampsia and its related diseases include
hypertension (generally readings of 140/90), proteinuria
(generally >300 mg/dl), and edema (although this may
be absent). When present, the edema is commonly seen
in the periorbital region. Eclampsia is the addition of tonic-
clonic seizures with preeclampsia. There are several varia-
tions of HELLP syndrome, which can manifest with
hepatic involvement without thrombocytopenia. Other
serious sequelae of hepatic involvement can include
acute fatty liver of pregnancy as well as development of
a subscapular hematoma of the liver leading to rupture
of the liver. Delivery is the only known cure although
there have been reports of preeclampsia developing 
up to two weeks postpartum. Management can often 
be difficult especially in the face of prematurity as deliv-
ery may be devastating for the fetus while beneficial 
for the mother. There is a fine balance needed to obtain
the best outcome, and with proper surveillance delivery
can often be delayed to allow the fetus to become 
more mature without undo harm to the mother. The
hallmarks of management involve early identification,
consideration of delivery, prevention of seizures with the
use of magnesium sulfate (4–7 mEq/l), management of
hypertension (hydralazine, labetolol, nicardipine), man-
agement of oliguria, prevention of renal failure, and pre-
vention of the serious sequelae of hepatic involvement
(Box 23-2).
Amniotic Fluid Embolus
Amniotic fluid embolus (AFE) is a devastating compli-
cation of pregnancy with mortality rates as high as 80%. It
is rare, unpredictable, and unpreventable. In the USA this
in combination with pulmonary embolus are the leading
causes of maternal mortality. AFE results from entry of
amniotic fluid into the maternal circulation and results in
sudden onset of severe dyspnea, tachypnea, and profound
hypoxia. In addition, there is abrupt onset of disseminated
intravascular coagulation as well as complete cardiovas-
cular collapse. The differential of AFE includes pulmonary
embolism, air embolism, aspirations of gastric contents,
acute heart failure, and hemorrhagic shock with its asso-
ciated causes. Management involves supportive measures
including cardiopulmonary resuscitation, volume replace-
ment, and correction of coagulopathy.
Pulmonary Embolus
There is a wide range of reported incidence of throm-
botic events during pregnancy. Incidence of DVT ranges
from 0.18% to 0.25%. In patients with untreated DVT,
15–25% develop pulmonary emboli versus 5% in treated
patients. Etiologies for DVT are vessel wall trauma, venous
stasis, and alterations in coagulation (Virchow’s triad).
Risk factors include advanced maternal age and increased
parity, obesity, prolonged bedrest, and antithrombin III
deficiency. Presenting signs for DVT include pain, ten-
derness, edema, change in limb color, and/or a palpable
cord in the back of the leg. Diagnosis can be confirmed
with Doppler ultrasound, ascending venography, and/or
magnetic resonance imaging (when pelvic or ovarian vein
thrombosis is suspected). Treatment involves the use of
heparin and careful monitoring.
Pulmonary embolus (PE) is defined as an occlusion of a
pulmonary vessel secondary to an intravascular clot from
another location of the body. Signs of PE include dyspnea,
tachypnea, and pleuritic chest pain. Diagnosis is made from
clinical presentation, arterial blood gases, EKG, chest x-ray,
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Box 23-2 Criteria for Severe
Preeclampsia
● Blood pressure greater than 160/110
● Greater than 5 g/24 hours proteinuria
● Oliguria
● Cerebral changes such as altered mentation, blurred
vision, seizure activity
● Severe right upper quadrant or epigastric pain
(hepatic involvement)
● Thrombocytopenia (nonhematologic such as ITP)
● Fetal growth restriction
V/Q scan, spiral computed tomography, and/or pulmonary
arteriography. Pulmonary arteriography is generally
reserved for patients in whom lung scanning results are
indeterminate or do not coincide with a patient’s clinical
symptoms or when heparin therapy is considered high risk.
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CLINICAL CAVEAT
Pulmonary Embolus in Pregnancy
Pulmonary embolus is a common complication in
pregnancy and needs close monitoring and prevention
in the critically ill pregnant patient.
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Summary
Host defense mechanisms are either nonspecific,
nonimmune-mediated or specific, immune-mediated.
Intact physical barriers are in part responsible for the
nonimmune-mediated defense mechanism. Conversely,
the various immune components with their complex
interrelationships provide the immune-mediated response.
The immune-compromised host can be defective in any
part of the host defense system, while the immune-
suppressed host refers only to the immune defective
group.
NONSPECIFIC HOST DEFENSES
The skin and mucosal surfaces are responsible for the
primary defense due to physical barriers. The break-
down of skin and mucosa due to trauma, either inadver-
tently or iatrogenically, results in the introduction of
pathogens. Infections at the various sites are due to
pathogens that either normally colonize the site or are
introduced by contamination. Instrumentation with IV
lines, dialysis catheters, and surgical procedures are
common insults. The introduction of an endotracheal
tube for mechanical ventilation will result in both the
loss of protective airway mechanisms and allow a direct
conduit for pathogens to the lungs. Obstruction or injury
to the genitourinary mucosa due to instrumentation,
calculi, and cytotoxic agents may result in infections.
Breakdown of the gastrointestinal mucosal barrier
commonly results from cytotoxic agents during treatment
for malignancies. The neutropenic patient may have a
subtle, not easily apparent gastrointestinal source, or
may present with an acutely ill fulminant picture. These
patients often have polymicrobial infections. A high
index of suspicion is necessary.
The normal flora should be considered as a host defense
mechanism. It competes with nonindigenous pathogens
that are introduced, and generally inhibits their growth.
Disruption of normal flora may allow the propagation of
nonindigenous pathogens. Patients who have been insti-
tutionalized, have received broad-spectrum antibiotics,
or who are neutropenic have altered flora.
Other nonspecific defense mechanisms include the
normal flow of secretions from either drainage, as in the
biliary tract, or the ciliary action of the respiratory mucosa;
and the gastric acidity of the stomach, which kills bacteria.
Adequate nutritional status is crucial in providing sub-
strates for metabolic needs and protein synthesis.
SPECIFIC HOST DEFENSES
Specific host defenses are immune-mediated, and are
categorized into four different components. They are the
polymorphonuclear leukocytes (PMNs), cell-mediated,
humoral, and complement arms of the immune
response. The immune-suppressed host is susceptible 
to indigenous, common community-acquired and noso-
comial pathogens, along with unusual or opportunistic
ones. Community-acquired and nosocomial infections
that typically occur in hosts with intact immune systems
present in a more virulent and fulminant fashion.
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Unusual or opportunistic organisms, not generally viru-
lent, or otherwise found as normal flora or as inconse-
quential colonizers, may result in severe, life-threatening
infections. The initial presentation of these infections
may be subtle and atypical. A delay in recognition, diag-
nosis, and treatment is therefore more likely. Although
there is significant interrelationship between the immune
components, the different types of immune deficiency
are associated with characteristic infections. An under-
standing of the pathology associated with the specific
immune deficiency will allow the clinician to more accu-
rately diagnose, and choose aggressive, targeted therapy.
Polymorphonuclear Leukocytes
PMNs are also called neutrophils or granulocytes, and
are responsible for phagocytosis and killing of extra-
cellular microbes. The microbes are phagocytozed by
PMNs subsequent to being opsonized by antibodies and
complement. PMNs can be defective due to both con-
genital deficiencies and qualitative defects towards
chemotaxis and killing. Chediak–Higashi syndrome is an
example of a congenital defect to chemotaxis. The most
common causes of impaired PMN dysfunction, however,
are related to acquired deficiencies. Neutropenia defined
by an absolute neutrophil count (ANC) < 500 cells/mm3
is associated with a significant increase in bacterial infec-
tions. Counts below 100 cells/mm3 have an even higher
risk and are associated with the most severe infections.
Neutropenia is most commonly associated with malig-
nant diseases and their treatment with cytotoxic agents.
Bone marrow infiltration by hematologic malignancies
and lymphomas may result in bone marrow failure.
Treatment with cancer chemotherapy (adriamycin, ARA-C,
and cyclophosphamide) along with affecting bone marrow
activity also results in damage to mucosal membranes
and therefore significantly increases the risk to infec-
tions. Other causes of neutropenia include total body
radiation, aplastic anemia, β-lactam antibiotics, and idio-
pathic drug reactions (Box 24-1).
Neutropenic patients most often develop infections
from endogenous bacteria and fungal flora. Traditionally
infections were due to Gram-negative aerobic bacteria
such as Escherichia coli, Klebsiella pneumoniae, and
Pseudomonas aeruginosa with occasional Gram-positive
bacteria from the staphylococcal and streptococcal species.
More recently, Gram-positive bacteria have become the
most commonly isolated pathogens. Although the most
severe infections are still Gram-negative infections, severe
life-threatening α-hemolytic streptococcal (Streptococcus
viridans) infections have emerged. Nosocomial infec-
tions clearly play a role and occur in a significant pro-
portion of neutropenic patients. They tend to be associated
with prolonged duration of neutropenia and physical
exposure to these organisms. Fever with neutropenia of
less than 1 week is associated with Gram-positive cocci,
between 1 and 2 weeks with Gram-negative bacilli, and
greater than 3 weeks with opportunistic infections, espe-
cially with Candida spp. and Aspergillus spp.
Different sites are associated with specific pathogens.
Pneumonias may be due to enteric Gram-negative bacilli
P. aeruginosa, Staphylococcus aureus, and Aspergillus
fumigatus. Central nervous system (CNS) infections
include enteric Gram-negative bacilli Aspergillus spp. and
Mucormycosis spp. Skin and line infections may result
from S. epidermis, S. aureus, P. aeruginosa, Bacillus
spp., Corynebacterium jeikeium, and fungal pathogens.
Perirectal infections result in P. aeruginosa and polymi-
crobial infections. Typhilitis may be due to P. aeruginosa,
Bacteroides fragilis, and Clostridium septicum. Severe
life-threatening infections associated with septic shock
are associated with enteric Gram-negative bacilli
P. aeruginosa, S. aureus, Candida spp., Aspergillus spp.,
and α-hemolytic streptococcus.
A febrile (temperature > 38.5°C) neutropenic patient
may have a subtle, atypical infection. Although a source
may be apparent, a definitive site is not found in 60–70%
of patients. In fact, microbiological identification of
pathogen occurs in only 30% of cases. There is the poten-
tial for a delay in determining whether an infection is truly
present and initiating treatment. The use of empiric ther-
apy has fortunately been shown to decrease mortality
during neutropenic fever. Therefore, the use of empiric
antibiotic therapy is the key to treating these patients.
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Box 24-1 Characteristics of
Polymorphonuclear
Leukocyte Dysfunction
● Associated with malignant diseases and their
treatment with cytotoxic agents
● Decreases phagocytosis and killing of extracellular
organisms
● Neutropenia
● ANC < 500 cells/mm3 has an increase in infections
● ANC < 100 cells/mm3 higher risk and more
severe
● Typically from endogenous bacteria and fungal flora
CLINICAL CAVEAT
Neutropenic Fever
● ANC < 500 cells/mm3 and temperature > 38.5°C
● Subtle, atypical infections may progress to
life-threatening ones
● No site identified in up to 60–70%, or organism in
30% of patients
● Empiric therapy, however, decreases mortality
Empiric broad-spectrum therapy should be chosen
with an understanding of the local microbiological flora.
Local sensitivity patterns of likely infections may alter
the specific choices. Treatment will include coverage
against Gram-negative bacteria including P. aeruginosa
and Gram-positive organisms. In noncritically ill patients
monotherapy with imipenem-cilastatin, or an anti-
pseudomonal third-generation cephalosporin may be
sufficient. In critically ill patients combination therapy 
is used. Coverage against nosocomial antibiotic-resistant
organisms and Serratia, Citrobacter, and Enterobacter
spp., which become rapidly resistant to β-lactams, is essen-
tial. Possible combinations include an antipseudomonal
third-generation cephalosporin or an antipseudomonal
penicillin plus an aminoglycoside or a fluoroquinolone
(especially ciprofloxacin). Vancomycin can be added if
a Gram-positive infection due to methicillin-resistant
S. aureus (MRSA) is suspected, or if patients become
hemodynamically unstable. If fever persists after 4 to
7 days, or there is rapid clinical deterioration, empiric cov-
erage for fungal infections with amphotericin B should
be started. The broad-spectrum antibiotics should be
continued for a minimum of 10 to 14 days or longer until
the ANC is >500 cells/mm3.
Cell-Mediated Immunity
The components of cell-mediated immunity are
macrophages and T-lymphocytes. Macrophages perform
phagocytosis, while T-lymphocytes are important in the
initiation of the immune response and include CD4
helper lymphocytes and CD8 suppressor lymphocytes.
T-lymphocytes also include the “natural killer cells.”
Cell-mediated immunity is responsible for eliminating
obligate intracellular pathogens, virus-infected cells, and
malignant cells. Acquired defects are the most common
while congenital ones are rare. Human immunodefi-
ciency virus (HIV) infections, lymphoreticular malignan-
cies, and cytotoxic and immunosuppressive chemotherapy
with azathioprine, vincristine, bleomycin, cyclosporine,
tacrolimus, OKT3, and high-dose corticosteroids result
in the majority of acquired cell-mediated deficiencies in
the developed world. HIV and severe protein malnutri-
tion are the most common cause in developing nations.
Defects in cell-mediated immunity are associated with
infections due to bacteria, fungi, viruses, and protozoa.
These infections can be indigenous, community
acquired, or nosocomial in origin. Unusual infections
due to cell-mediated infections may occur in various
organs. Lungs can develop pneumonias due to
Pneumocystis carinii, Legionella pneumophilia,
cytomegalovirus (CMV), herpes simplex virus (HSV), vari-
cella zoster virus (VZV), adenovirus, coccidiomycosis,
and Cryptococcus neoformans. The CNS can be infected
with C. neoformans, Toxoplasma gondii, and Listeria
monocytogenes. Mucocutaneous infections can occur due
to Candida spp., HSV, VZV, and CMV. Unusual dissemi-
nated infections with Mycobacterium avium intracellulare
(MAI), CMV, and VZV can occur (Box 24-2).
Factors determining the pathogen and site of infec-
tion include the CD4 count, which reflects the progres-
sive decline of cell-mediated immune function; the
duration of immune suppression; and, if an organ was
transplanted, the time since the transplant and the organ
transplanted. As the CD4 site decreases opportunistic
infections particularly Pneumocystis carinii and CMV
become more prevalent. As time progresses from 0 to
6 months from organ transplantation, typical postsurgical
or nosocomial infections are replaced by opportunistic
infections. After 6 months the infections depend on level
of immune suppression and environmental factors. They
are similar to those in immune-competent individuals.
The treatment which is individualized on the basis of the
CLINICAL CAVEAT
Empiric Neutropenic Therapy
● Noncritically ill – monotherapy may be sufficient
● Imipenem-cilastatin, or an antipseudomonal third-
generation cephalosporin
● Critically ill – combination therapy is needed
● Antipseudomonal third-generation cephalosporin
or an antipseudomonal penicillin plus an
aminoglycoside or a fluoroquinolone
● Add vancomycin if MRSA or hemodynamically
unstable
● Add amphotericin B if fever > 4 to 7 days or
decompensates
● Know local microbiological sensitivities
● Continue for 10 to 14 days or until
ANC > 500 cells/mm3
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Box 24-2 Characteristics of Cellular-
Mediated Dysfunction
● HIV, lymphoreticular malignancies, chemotherapy,
and malnutrition are causes
● Macrophage and T lymphocytes (along with CD4
and CD8) function poorly
● Affects phagocytosis and initiation of the immune
response
● Poor removal of obligate intracellular organisms,
virus-infected cells, and malignant cells
● CD4 count is useful in predicting the organism and
the site affected
nature of the immune defect and the above factors, is
discussed elsewhere in this chapter.
Humoral Immunity
Humoral immunity is mediated through antibodies
(immunoglobulins) produced by B lymphocytes.
Immunoglobulins generally assume one of two roles.
They may act as plasma membrane-bound antigen recep-
tors on the surface of a B-cell or as antibodies free in
cellular fluids functioning to intercept and eliminate anti-
genic determinants. These antibodies activate comple-
ment and go on to destroy microorganisms by promoting
phagocytosis via opsonization, toxin neutralization, and
lysis of susceptible organisms. Similar to complement
immunity, humoral immunity is responsible for the clear-
ance of extracellular bacteria. For practical purposes
humoral and complement deficiencies can be considered
together. Multiple myeloma (MM), chronic lymphatic
leukemia (CLL), and Waldenström’s macroglobulinemia
are common causes of disease states associated with
impaired humoral defects. Several cytotoxic chemo-
therapeutic agents, including azathioprine, cyclophos-
phamide, and methotrexate, suppress humoral function
along with other effects on the immune system (Box 24-3).
Pathogens frequently found include encapsulated
pyogenic bacteria such as Streptococcus pneumoniae,
Haemophilus influenzae, and rarely Neisseria menin-
gitidis. Pneumonias tend to predominate with S. pneu-
moniae, Haemophilus influenzae, and occasionally
K. pneumoniae. CNS infections include S. pneumoniae,
H. influenzae, and N. meningitidis. Overwhelming sepsis
can occur with S. pneumoniae, H. influenzae, and
N. meningitidis. CNS infections are predominantly
caused by these organisms.
Asplenia, either anatomic or functional, results in
immune defects which have properties of both humoral
and complement deficiencies. The spleen contains many
antibody-producing B-lymphocytes, and is involved in
T-cell independent immune responses. Specific comple-
ment deficiencies also result if asplenia occurs. The spleen
is therefore important in the clearance of nonopsonized
and opsonized bacteria. Overwhelming septicemia may
occur in asplenic patients. Streptococcus pneumoniae
and Haemophilus influenzae infections predominate,
although Neisseria meningitidis has been described.
Mortality approaches 80%; and multiple amputations are
frequent in survivors. Due to the rapid progression of ill-
ness, febrile, splenectomized patients require treatment
with high-dose antipneumococcal antibiotics. The 
incidence of penicillin-resistant S. pneumoniae has been
increasing, and so initial therapy with ceftriaxone and
vancomycin is wise. All splenectomized patients require
immunization with pneumococcal, meningococcal A and
C, and haemophilus influenza B vaccines. Uncommon
infections with intraerythrocyte protozoa such as
Plasmodium malariae and Babesia can also occur in
splenectomized patients.
Complement System
The complement cascade is involved in regulating the
immune response. Complement are proteins, C3 and C5
being the most crucial, which form complexes that
interact with specific cell receptors or directly with
cell membranes. They facilitate phagocytosis, may
independently kill extracellular organisms, and mediate
acute inflammatory reactions. Acquired deficiencies in
complement are the most common and occur in systemic
lupus erythematosus (SLE) and MM, while congenital
deficiencies are rare.
The pathogens are similar to those present during
humoral defects, and can present with overwhelming
infections due to encapsulated organisms. Infections
with Neisseria meningitidis, Streptococcus pneumoniae,
and less commonly N. gonorrheae occur. Infections of
the CNS and joints may occur along life-threatening
disseminated infections (Box 24-4).
CLINICAL CAVEAT
Asplenia
● Has both humoral and complement deficiencies
● Loss of both antibody-producing B-lymphocytes and
complement proteins
● Overwhelming sepsis can occur, mortality
approaches 80%
● Encapsulated organisms: S. pneumoniae,
H. influenzae, and N. meningitidis
● Immunization crucial, acutely treat with
antipneumococcal antibiotics
The Immune-Compromised Host and the HIV Patient 255
Box 24-3 Characteristics of Humoral
Dysfunction
● MM, CLL, Waldenström’s macroglobulinemia, and
cytotoxic agents are causes
● Immunoglobulin function and activation of
complement is decreased
● Poor phagocytosis by opsonization, toxin
neutralization, and lysis of organisms
● Failure to clear extracellular organisms and
encapsulated pyogenic bacteria
● Humoral and complement deficiencies are
considered together
IMMUNOSUPPRESSION AND
TRANSPLANT PATIENTS
Solid Organ Transplant Patients
These patients are primarily faced with the immune-
related complications of allograft rejection and infec-
tions. The need to prevent rejection is juxtaposed with
the infectious consequences of immunosuppression.
Rejection is defined as an acute deterioration of func-
tion associated with specific pathologic changes. Allograft
rejection is common in transplant patients. It occurs in
up to 30% of kidney transplants, 50–80% of heart trans-
plants, and 60% of liver transplants. Most episodes occur
in the first 6 months. Allograft rejection is classified as
hyperacute rejection, accelerated acute rejection, acute
rejection, and chronic rejection.
Hyperacute rejection is due to cytotoxic antibodies,
anti-HLA, antivascular endothelium, and isohemagglutinins
against ABO antigens. These antibodies cause platelets and
fibrin to aggregate, and result in thrombosis of the graft.
Onset is within 48 hours of transplant, and can occur
immediately after unclamping of vessels. Diagnosis is made
by ultrasound, which reveals thrombosis of the graft.
Kidney and heart transplants are often involved.
Accelerated acute rejection occurs within 7–10 days.
Cellular and humoral-mediated components play a role.
There is both antibody involvement with anti-HLA and
increased T-lymphocyte activity due to previous sensiti-
zation. The rate of allograft loss is high.
Acute rejection generally occurs between 7 and 90 days
after transplant. It can be seen, however, any time after
discontinuing immunosuppression. Both humoral and
cellular mechanisms are involved with antibodies and
T-lymphocytes playing a role. There are common symp-
toms and signs such as graft pain, swelling, warmth,
fever, malaise, and fatigue. However, there are specific
abnormalities dependent on the organ transplanted.
Renal transplant patients will have hypertension, edema,
and weight gain. Liver transplant patients have ascites,
hepatosplenomegaly, and elevated transaminases.
Cardiac transplant patients may complain of dyspnea, be
hypotensive, and develop arrhythmias. Diagnosis is by
ultrasound and biopsy; severity is graded on the basis
of specific histopathologic findings. Treatment for acute
rejections is generally directed by the transplant team
but options include corticosteroids, monoclonal anti-
T-cell antibody (OKT3), antithymocyte globulin, and
plasmapheresis.
Chronic rejection is a slowly progressive decline in
function of the allograft and occurs months to years after
transplant. The etiology is controversial, but it is charac-
terized by gradual vascular and ductal obliteration,
parenchymal atrophy, and interstitial fibrosis. Clinical
presentation depends on the organ involved. Kidney
transplant patients have hypertension, proteinuria, and
elevated creatinine. Lung transplant patients will present
with dyspnea, hypoxemia, and abnormal PFTs. Chronic
rejection of the liver is associated with jaundice and
hyperbilirubinemia. Pancreatic rejection will reveal
decreased urinary amylase and hyperglycemia on labora-
tory studies. Diagnosis is again made by biopsy. There is
no effective treatment for chronic rejection.
The improvement in success rate of organ transplant
has been possible through the use of cytotoxic
chemotherapeutic agents. Many of these primarily
induce defects in cell-mediated immunity. Although cell-
mediated immunity is responsible for eliminating intra-
cellular pathogens including viruses, these patients are
also at risk for a variety of infections from normal flora,
community-acquired, and nosocomial organisms. Dividing
solid organ transplant on the basis of time since trans-
plant allows us to better predict the pathogens involved.
Susceptibility to life-threatening infections is greatest
in the first 6 months after the transplant. During the first
month infections are due to bacteria and fungi that typi-
cally cause infections in the immunocompetent post-
surgical patient. They may be secondary to perioperative
illness, IV catheters, endotracheal tube, and infections
originating at the surgical site. They tend to be noso-
comial, and reflect local sensitivity patterns. Reactiva-
tion of latent or subclinical infections of HSV and
M. tuberculosis can also occur. Between 1 and 6 months
pathogens specific to cell-mediated defects play a large
role. Viral and opportunistic infections are most common.
CMV, EBV, Pneumocystis carinii, aspergillosis, Listeria
monocytogenes, Toxoplasma gondii, Cryptococcus
spp., and others may occur. After 6 months the infec-
tions tend to reflect the immunosuppressant state. Those
patients on minimal immunosuppression develop infec-
tions similar to immunocompetent patients. Those
who remain on high-dose immunosuppression continue
to be at risk for opportunistic infections. P. carinii,
L. monocytogenes, aspergillosis, Cryptococcus neoformans,
and various viral infections may play a role (Box 24-5).
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Box 24-4 Characteristics of
Complement Dysfunction
● Acquired deficiencies most common, SLE, MM
● Congenital deficiencies rare
● C3 and C5 the most crucial
● Affects phagocytosis, extracellular killing, and
inflammatory response
● Encapsulated organisms: S. pneumoniae,
H. influenzae, and N. meningitidis
● Humoral and complement deficiencies are
considered together
Treatment strategies consider possible site of infec-
tion, pathogen if identified, local sensitivity patterns, and
time since transplant. Signs and symptoms of infections
should be pursued aggressively. Prevention of viral infec-
tions through the use of pretransplant immunization
with pneumococcal and hepatitis, and yearly influenza A
vaccines should be done. Prophylaxis against oppor-
tunistic infections with trimethoprim-sulfamethoxazole
(TMP/SMX) for P. carinii and nocardia, acyclovir for
HSV, ganciclovir for CMV, and flucanazole or ketocana-
zole for fungal infections is also performed.
CMV infections pose a very common problem in
transplant patients. It typically occurs from reactivation
of CMV in a seropositive patient, but can be due to a new
infection from a CMV-positive organ. It is the most com-
mon cause of fever in the post-transplant patient. CMV
infections can cause isolated fever, hypotension, hepatitis,
pneumonitis, encephalitis, enterocolitis, and glomerulo-
nephritis. Involvement of the transplanted organ occurs
frequently. The diagnosis is difficult. Shell vial culture of
the buffy coat is useful when prepared less than 24 hours
after obtaining a sample. Intranuclear inclusion bodies in
cells from biopsied tissue are useful if seen. New tech-
niques using polymerase chain reaction (PCR) are
becoming more common. Treatment is with ganciclovir.
When organ involvement occurs hyperimmune globulin
is often used. Foscarnet is reserved for the sickest
patients because of its nephrotoxicity.
Bone Marrow Transplant Patients
Bone marrow transplants are performed for acute and
chronic leukemias, lymphomas, solid tumors, multiple
myeloma, and severe aplastic anemia. These patients
have a combined alteration in immune function due to
both early ablative chemotherapy with its severe neu-
tropenia, and the depression in cell-mediated and
humoral immunity mostly from immunosuppressive
therapy. After a preparative regimen with ablative
chemotherapy and possibly radiation therapy, a pro-
found pancytopenia, ANC < 100 cells/mm3, for 7–10 days
occurs in all patients. The granulocytopenia generally
resolves within 30 days, although some phagocytic 
dysfunction remains. At this point, cell-mediated and
humoral dysfunction becomes important. The pattern of
infectious complications reflects the sequence and is
characterized by three broad time periods (Box 24-6).
The preengraftment period lasts from bone marrow
ablation until 30 days post-transplant. It is characterized
by ongoing neutropenia and mucositis. Bacterial, fungal,
and viral infections similar to other neutropenic patients
are common. Treatment is aggressive, with empiric
broad-spectrum antibiotic regiments similar to those
used for other febrile neutropenic patients. Nearly all
patients experience fever during this period, and require
empiric antibiotic coverage. Prophylaxis with acyclovir,
for HSV and VZV, along with TMP/SMX, for P. carinii, is
given during this time.
The postengraftment period lasts from 30 to 100 days
post-transplant. Neutropenia has recovered, and infec-
tions are due mostly to cell-mediated and, to a lesser
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Box 24-5 Pattern of Infections in Solid
Organ Transplants
● First 30 days – infections typical of the immuno-
competent patient
● Nosocomial, and reflect local sensitivity patterns
● 30 to 180 days – infections from cell-mediated
deficiency play a larger role
● Viral and opportunistic infections are most
common
● After 180 days – reflect immunosuppressant state
● If on high-dose immunosuppressants then
opportunistic infections
CLINICAL CAVEAT
Cytomegalovirus Infection
● Most common cause of fever in the post-transplant
patient
● Also may have hypotension, hepatitis, pneumonitis,
encephalitis, enterocolitis, and glomerulonephritis
● Involvement of transplanted organ frequent
● Diagnose with buffy coat, intranuclear inclusion
bodies on biopsy or PCR
● Treat with ganciclovir, occasionally hyperimmune
globulin and foscarnet
Box 24-6 Pattern of Infectious
Complications in Bone
Marrow Transplant Patients
● Preengraftment period – 0 to 30 days: neutropenia
and mucositis
● Bacterial, fungal, and viral – similar to other
neutropenic patients
● Postengraftment period – 30 to 100 days: cellular
and humoral dysfunction
● Become susceptible to viral, especially CMV,
opportunistic infections
● Late post-transplant period – more than 100 days:
persistent cellular and waning humoral dysfunction
● VZV reactivation and viral respiratory tract
infections
● Susceptibility to encapsulated pathogens remains
degree, humoral defects resulting from the antirejection
immunosuppressive therapy. Patients become susceptible
to viral infections, especially CMV, other opportunistic
infections such as P. carinii, T. gondii, and aspergillosis,
along with other bacterial infections. Treatment requires
an aggressive search for a pathogen while broad empiric
coverage, including opportunistic coverage, is instituted.
The late post-transplant period occurs after 100 days.
Cellular-mediated immune dysfunction is present and
late infections due to VZV reactivation and viral respira-
tory tract infections such as respiratory syncytial virus
(RSV), and parainfluenza virus may occur. A humoral
defect characterized by a decrease in opsonizing anti-
bodies also persists for years, and predisposes patients to
infections with encapsulated pathogens.
Graft versus host disease (GVHD) is an immunologic
response by the donor to recipient antigens, and is the
major complication of allogenic bone marrow transplants.
Acute GVHD occurs within the first 100 days and results
in a skin rash that appears first in the hands, feet, and face;
large amounts of watery or bloody diarrhea; and liver dys-
function. Chronic GVHD occurs more than 100 days after
transplantation and resembles an autoimmune disorder. A
dry, itchy rash of the skin with involvement of the face
with the mouth and eyes is common. Chronic GVHD sub-
stantially increases susceptibility to infections.
Human Immunodeficiency Virus Patients
It is estimated that as of 2002 about 42 million people
worldwide and over 1 million people in the USA are
infected with HIV. Although the median incubation period
appears to be around 10 years, the progression from HIV
infection to acquired immunodeficiency syndrome
(AIDS) can vary from months to years. Fortunately since
the implementation of highly active antiretroviral ther-
apy (HAART) in the USA in 1996, the number of persons
diagnosed with AIDS and the number of deaths among
persons with AIDS have declined substantially. Not only
has the progression of disease been altered, but the mor-
tality of AIDS patients admitted to the intensive care unit
(ICU) has also improved. During the early phases of the
AIDS epidemic, admission to the ICU for patients with
AIDS was associated with very high mortality approach-
ing 90%. Over the years this has improved significantly,
with recent survival rates of better than 50%. This
improvement in ICU mortality appears to be due to the
improved and aggressive use of antiretroviral therapy,
prophylaxis, and treatment of opportunistic infections
and malignancies and supportive care.
HIV infections and AIDS are caused by the human
retrovirus HIV type I. HIV type I infects lymphocytes and
other cells carrying the CD4 surface protein. Screening is
performed with an enzyme-linked immunosorbent assay
(ELISA). A positive test is then confirmed by a repeat
positive ELISA and a Western blot test. Once a patient 
is infected with the virus, through either parenteral or
sexual transmission, viral replication soon begins. If viral
replication is not suppressed, it progressively results in
lymphopenia and CD4 T-cell reduction with impaired
cell-mediated immunity. The cell-mediated defects
result in the classic picture of opportunistic infections
and malignancies. HIV infections, however, may also
cause a reduction in immunoglobulin production by
B-lymphocytes and cause humoral immune defects.
These humoral defects lead to an increased susceptibility
to encapsulated organisms such as S. pneumoniae and 
H. influenzae. AIDS can subsequently result if the HIV
infection advances. AIDS is defined as the presence of an
opportunistic infection, malignancy, HIV-related syn-
drome, or depletion of CD4 counts (<200 cells/mm3 or
<14% total) in a patient with evidence of HIV infection.
The CD4 count correlates well with type and site of
infections and malignancies found in patients with HIV.
PCR assays for HIV type I RNA viral load are also useful
to assess clinically the degree of immunosuppression,
but are less frequently used. Normal CD4 count has
a wide range, typically considered to be from 500 to 1500
cells/mm3. In general, the CD4 count goes down as
HIV disease progresses. However, any single CD4 count
value may differ from the last one even though the
health status has not changed. Patients with a CD4 count
> 500 cells/mm3 will have infections from community-
acquired organisms. On close examination these patients
may have a generalized lymphadenopathy. An increase
in the incidence of tuberculosis has also been reported.
As the CD4 count decreases below 500 cells/mm3 oppor-
tunistic infections with esophageal candidiasis, reactivation
of HSV and VZV, and bacterial pneumonias such as
S. pneumoniae appear along with a wasting syndrome
comprising of low-grade fever associated with unexplained
weight loss. When the count goes below 200 cells/mm3
the likelihood of P. carinii pneumonia (PCP) increases
significantly, along with the reactivation of coccidioido-
mycosis and histoplasmosis leading to disseminated
infections. At 50–100 cells/mm3 CNS infections from
C. neoformans and T. gondii and disseminated M. tuber-
culosis occur. Lymphomas, primarily non-Hodgkin’s
lymphomas (NHL), can be anticipated as the CD4 counts
decrease and primary CNS lymphomas are increasingly
more common as the count decreases to less then
100 cells/mm3. With CD4 counts below 50 cells/mm3,
disseminated infections with M. avium intracellulare,
CMV, cryptosporidia, microsporidia, isospora, and pro-
gressive multifocal leukoencephalopathy (PML) from the
Jakob Creutzfeldt virus (JCV) can occur.
Pulmonary and CNS infections comprise two of the
most common causes of ICU admissions. Pneumonias with
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S. pneumoniae are common in HIV-positive patients.
Opportunistic infections with M. tuberculosis, histo-
plasmosis, coccidioidomycosis, CMV (with CD4 count
< 50 cells/mm3), and P. carinii in particular become
increasingly common as the CD4 decreases. PCP is the
leading cause of death in AIDS patients. As a result pro-
phylaxis typically with TMP/SMX or pentamidine for
PCP is instituted when the CD4 count is <200 cells/mm3.
Progressive respiratory failure with fever, hypoxemia,
and diffuse pulmonary infiltrates requires an aggressive
assessment. Induced sputum has a 70–90% sensitivity for
P. carinii. A bronchiolar lavage (BAL) is indicated if a
sample does not yield a diagnosis. Empiric antibiotic 
coverage on the basis of a CD4 count should be started.
Treatment with TMP/SMX with pentamidine as an alter-
native is indicated for 21 days. Prednisone or an equiva-
lent should be started at 40 mg bid and tapered over the
21 days of treatment in patients with PaO2 < 70 mmHg or
a PAO2–PaO2 gradient > 35 mmHg. This regimen has been
shown to improve survival in patients with severe PCP.
The lung can also be affected by lymphoid interstitial pneu-
monitis which is believed to be due to direct HIV infection
to the lung. It is a nonspecific interstitial pneumonitis 
that resembles PCP, but the CD4 is between 200 and 
500 cells/mm3 and the BAL is negative for PCP. Treatment
is with HAART and steroids are added by many if symptoms
progress. Some patients become oxygen dependent.
CNS infections such as brain abscess, meningitis, and
encephalitis along with primary CNS lymphomas and
NHL involvement of the brain may result in admission to
the ICU. Patients at risk or known to have HIV disease who
present with altered mental status require an aggressive
evaluation including computed tomography (CT) scan
or magnetic resonance imaging (MRI) of the brain, and
lumbar puncture for cerebrospinal fluid analysis.
Empiric antibiotic coverage is initiated on the basis of the
clinical picture while awaiting results. C. neoformans
will require amphotericin B, T. gondii is treated with
sulfadiazine/pyrimethamine along with leucovorin (to
prevent hematologic toxicity), and M. tuberculosis is
treated with various evolving regimens. PML from the
JCV can occur, and results in a clinical picture of mental
status changes, weakness, and disorders of gait. A char-
acteristic picture of white matter lesions is present on
MRI. Antiretroviral therapy has improved the outcome
of PML. CNS lymphomas are treated with chemotherapy
and radiation therapy. Although not the cause of ICU
admissions, CMV retinitis occurs in 85% of AIDS patients
and can lead to significant morbidity. It is treated with
ganciclovir which may lead to neutropenia. Other drugs
such as AZT may similarly be myelotoxic. Treatment
with neupogen (G-CSF) may be beneficial.
There are several other organs that may be involved
with HIV/AIDS that may have an impact on the care of
the critically ill patient. While some of these are a direct
result of secondary opportunistic infections, the mecha-
nisms for others are not known. Cardiomyopathy is well
described and in fact 8% of HIV patients have a dilated
cardiomyopathy on echocardiogram. Subclinical cardiac
abnormalities are common and correlate with the degree
of immune suppression. Treatment with angiotensin
converting enzyme (ACE) inhibitors is often prescribed
DRUG INTERACTIONS
Gancyclovir
● Commonly used in AIDS patients
● Causes neutropenia which exacerbates that caused
by AZT and HIV itself
● Treat with neupogen to maintain ANC of
1000–2000/mm3
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CLINICAL CAVEAT
CD4 Count
● Correlates with type and site of infection in
HIV/AIDS patients
● Normal 500 to 1500, although individual variations
exist
● As CD4 < 500 – opportunistic infections
● Esophageal candidiasis, reactivation of HSV, VZV
● S. pneumoniae
● Wasting syndrome
● As CD4 < 200
● PCP increases significantly
● Reactivation of coccidioidomycosis and
histoplasmosis
● As CD4 < 50 disseminated infections
● MAI, CMV, cryptosporidia, microsporidia,
isospora
● PML from JCV
CLINICAL CAVEAT
Pneumocystis carinii Pneumonia
● Most common infection and the leading cause of
death in AIDS
● Progressive, nonproductive cough with dyspnea and
hypoxemia
● Interstitial pneumonia and CD4 < 200 cells/mm3
● Induced sputum or BAL
● Treatment:
● TMP/SMX or pentamidine
● Steroids with PaO2 < 70 mmHg or a PAO2–PaO2
gradient > 35 mmHg; steroids improve survival
● Aggressive supportive care
and diuretics and digitalis can be added for symptomatic
left ventricular disease. Nephropathy can occur and is
commonly characterized on biopsy as a focal segmental
glomerulosclerosis. Patients present with nephrosis and
can have a rapid course to end-stage renal disease in 1 to
4 months. Response to antiretroviral therapy HAART has
been reported by clinical and biopsy data. ACE inhibitors
are useful and the response to steroids is variable. Adrenal
gland involvement appears to occur commonly. It has
been documented in up to two-thirds of HIV patients on
postmortem studies with CMV infection found in up to
80% of cases. The frequent incidence of adrenal gland
involvement is reinforced by studies examining the
hypothalamus–pituitary–adrenal (HPA) axis in HIV/AIDS
patients. Although many of these patients are typically
asymptomatic, unexplained hypotension or hypotension
out of proportion to the clinical picture should warrant
an examination of the HPA axis. Treatment with supple-
mental or replacement steroids during periods of stress
may be warranted. Some of the other organs involved
include the gastrointestinal tract with mouth ulcers, 
gingivitis, esophagitis, anorexia, nausea/vomiting, and
profuse diarrhea; hepatobiliary tract with papillary 
strictures, papillary stenosis, pancreatitis, and hepatitis B 
and C; hematologic system with anemia, neutropenia,
idiopathic thrombocytopenic purpura (ITP), and throm-
botic thrombocytopenic purpura (TTP); and the nervous
system with peripheral neuropathy, myopathy, and 
HIV-associated dementia.
SUMMARY
An understanding of the pathophysiology involved in
the immune-compromised patient is crucial in not only
anticipating the clinical course of the disease process
but also in diagnosing infections and noninfectious
complications and choosing appropriate therapy. These
patients may present with subtle, atypical signs and
symptoms which may progress rapidly to life-threaten-
ing situations. Yet there are patterns related to the
specific deficiency, the time since onset, the time since
transplant, and even specific “markers” such as ANC and
CD4 count which gives the clinician information to better
choose treatment. By understanding these diseases with
their particular patterns we may thus be able to choose
timely, aggressive treatment and improve outcome.
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CASE STUDY
A 51-year-old patient is referred to you for
management and admission to the ICU because of
hypotension unresponsive to volume resuscitation.
The patient is now 11 days post a stem cell transplant
for acute myeloid leukemia. The patient previously 
had undergone induction chemotherapy with ara-c 
and daunorubicin and was in remission prior 
to the transplant. On examination the patient is
anxious, diaphoretic, febrile to 39.9°C, tachycardic
with a heart rate of 130 regular, and a hypotensive 
at 83/49. Physical examination aside from disclosing
mild cachexia and mucositis with mouth ulcers is
otherwise unremarkable.
QUESTIONS
1. What laboratory workup would you 
request?
2. What would you expect to find?
3. What are the possible causes of hypotension in this
patient?
4. How likely are you to find the organism and
definitive site of infection?
5. What antibiotic coverage would you chose?
Physiology and Development of the Coagulation
Pathophysiology of Disseminated
Intravascular Coagulation
Congenital Hypocoagulable States
Acquired Hypocoagulable States
Increased Risk for Thrombosis
Clinical Findings in Coagulopathy
Laboratory Findings in Coagulopathy
Key Laboratory Findings in Disseminated
Intravascular Coagulation
Diagnosis of Disseminated Intravascular 
Coagulation
Treatment of Coagulopathy and Disseminated
Intravascular Coagulation
PHYSIOLOGY AND DEVELOPMENT 
OF THE COAGULATION
Hemostasis is achieved through a three-phase process:
primary hemostasis (minutes) where activated platelets
form a platelet plug, secondary hemostasis (hours)
reinforces the frail platelet plug with fibrin strands, and
fibrinolysis (days) dissolves the clot after vascular wall
repair. This system is volume controlled by several mod-
ulators such as antithrombin (AT), the thrombomodulin
(TM)/protein C (PC) and protein S (PS) system, and tissue
factor pathway inhibitor (TFPI).
In the last ten years a revised coagulation concept,
based on new understanding of secondary hemostasis 
and its modulation, has replaced the in vitro-based “coag-
ulation cascade” concept presented in 1964 by Davie,
Ratnoff, and MacFarlane. These new insights include the
regulatory role of the vascular endothelium as well as 
the links between inflammation and coagulation. Loss of
the normal modulation of the coagulation in, for example,
sepsis, is now believed to contribute to multisystem organ
failure (MSOF), the most common cause of death in the
intensive care unit (ICU).
Endothelial cells are normally antiadhesive (by release
of nitric oxide (NO), prostacycline (PGI2), adenosine,
and interleukin-10 (IL-10)), antithrombotic (due to
expression of TM, heparans, and TFPI), and fibrinolytic
(by secretion of tissue plasminogen activator (tPA)). The
underlying smooth muscle tone is predominantly relaxed
due to release of vasodilators such as NO and PGI2 oppos-
ing endothelin (ET-1), a polypeptide that is predominantly
vasoconstrictive. The damaged endothelium exhibits the
opposite characteristics. Vasoconstriction by serotonin
(5-HT) and thromboxane (TxA2) from activated platelets
serves to limit local blood loss after trauma. Primary
hemostasis is primed due to release of von Willebrand
factor (vWF), activation of platelet-activating factor (PAF),
and release of IL-8 and P-selectins. Secondary hemostasis
is promoted by release of tissue factor (TF) and by expo-
sure of phosphatidylserine (from lipids in cell membranes),
which can mimic the activated platelet surface (platelet
factor 3, PF3). Endothelium released plasminogen acti-
vator inhibitor (PAI-1) will inhibit tPA, which promotes
deposits of fibrin. The activated endothelium allows
adhesion molecules to bind and activated white blood cells
(WBCs), attracted by inflammatory mediators, migrate
out into the tissues and eventually set the stage for tissue
repair. It has become clear that the endothelium itself is
a crucial regulator of the different stages of hemostasis,
and also that inflammation is a necessary component of
tissue repair.
The primary hemostasis is initiated by activation of
platelets that undergo a conformational change from dis-
coid shape to irregular shape with multiple pseudopods,
release of secretions (containing vWF, FV, FVIII, Ca2+, 5-HT,
fibrinogen, ADP, TxA2) from granules, and extrusion of
several types of domains with glycoprotein receptors, as
the Ib (GPIb) and IIb/IIIa (GPIIb/IIIa) receptors. ADP as
well as TxA2 promote platelet activation. Other strong
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activators are thrombin, PAF, and immune complexes.
Exposed collagen permits the platelet to attach to the
site of injury using its GPIb receptor and an intermediary
vWF molecule that allows binding to the site of injury.
Activated platelets form a three-dimensional plug using
their GPIIb/IIIa receptors and intermediary fibrinogen
molecules. The activated platelets expose a phospholipid
surface, PF3, which will become the catalytic center for
the secondary hemostasis.
The secondary hemostasis is most commonly triggered
by appearance of TF in the blood, normally a membrane-
bound small protein not in direct contact with blood,
that when combined with circulating FVIIa can activate
FIX and FX in the extrinsic tenase complex, enough to
form a small amount of thrombin. This initial thrombin
formation serves to activate the platelet, but is too small
for substantial fibrin formation. On the activated platelets,
the prothrombinase complex is the catalytic center
where FXa and FVa generate the first thrombin. Further
thrombin feedback by activation of FVIII, FIX, and FXI
in the intrinsic tenase complex serves to produce larger
amounts of thrombin required for fibrin production.
It appears that a substantial “thrombin burst” is required
to form enough fibrin to stabilize the platelet clot, the
more thrombin the more stable the clot. Formed fibrin
is then cross-linked by FXIII, increasing clot strength.
In this process the activated FVIII sheds its carrier protein
vWF that is used in the initial platelet adhesion.
The major new understanding is the role of thrombin,
which, once formed, maintains its own production for
the prothrombinase complex, and the extrinsic tenase
complex is no longer needed. Note that calcium is needed
as a bridge to anchor the activated prothrombinase com-
plex and intrinsic tenase complex to the PF3 surface in
order to reach critical concentration of activated factors
for reactions to occur. In patients treated with Coumadine,
the calcium-binding site is no longer exposed on factors II,
VII, IX, and X, so calcium cannot anchor these factors to
the catalytic site. Secondly, phospholipid membranes are
necessary for these catalytic reactions to take place, either
normally on activated platelets (PF3) or after endothelial
injury as phosphatidylserine sites appear on cell
membranes of damaged endothelial cells.
Several important modulating systems control sec-
ondary hemostasis. First, TFPI rapidly inactivates the
extrinsic tenase complex after it activates FX. In dissem-
inated intravascular coagulation (DIC), however, this
does not appear to be an effective pathway to neutralize
large amounts of TF. New data indicate that heparin stim-
ulates the release of TFPI and that a significant part (1/3)
of the heparin effect is mediated through this pathway.
The second important modulator is AT, formerly called
ATIII, which inactivates thrombin as well as FXa, FIXa, and
FXIa. Heparan, a naturally occurring glucosaminoglycan,
is the physiologic stimulant of this system, increasing the
speed of inactivation. The third modulating system is the
PC system, activated by the large cell surface-bound 
molecule TM after TM is activated by thrombin. PC then
together with its cofactor PS inactivate FVa and FVIIIa.
Deficiencies in any of these three modulating systems, as
by consumption in DIC, or as a genetic predisposition,
can contribute to prothrombotic states of varying severity.
Fibrinolysis occurs normally several hours to days
later by activation of plasminogen to plasmin by tPA.
Plasmin then degrades fibrin (and fibrinogen) to fibrin
split products (FSP), also known as FDP. Plasmin’s phys-
iologic modulator is alpha2-antiplasmin with high affinity
for its catalytic site (when not occupied by fibrin). PAI-1
inactivates tPA and thereby controls the degree of acti-
vation of fibrinolysis. A distinction is sometimes made
between normal (secondary) plasma-activated fibrinolysis
(by tPA) and abnormal (primary) clot-activated fibri-
nolysis that may appear after burns and prostate and
neurosurgery, and after streptokinase or urokinase therapy.
When plasmin lyses a clot with cross-linked fibrin, small
segments that can be analyzed with the D-dimer test 
are formed. Of historical interest is that activation of the
contact system with FXII will also induce fibrinolysis
through activation of pre-kallikrein to kallikrein and even-
tually plasminogen to plasmin.
The development of the coagulation system in verte-
brates has occurred over the last 1.5 billion years. In pre-
vertebrates there was only an antibacterial system where
intruders were marked for phagocytosis by coagulation
of an early version of fibrinogen on their surface. With
the development of a closed vascular system in the first
vertebrates, separate immune and coagulant systems
eventually developed, initially the contact system with
FXII. Studies have revealed that genes coding for coagu-
lation factors are derived from cytokine genes. With the
development of vertebrates, three main families of serine
proteases have undergone 10–12 generations of change,
the last 8 generations in vertebrates. The first family was
the ancestors to FXII, TPA, PC, thrombin, TF, and the
complement system. The second family was factors VII,
IX, X, XI, and kallikrein. The third family stems from the
development of an ancestor to ceruloplasmin that led
to FVIII and FV. The clinical interest this has today is
that it explains the commonly observed problem of
cross-activation of systems such that many mediators of
inflammation cause activation of the coagulation and
vice versa.
PATHOPHYSIOLOGY OF DISSEMINATED
INTRAVASCULAR COAGULATION
In DIC increased TF exposure will induce a prothrom-
botic state with initially normal fibrinogen and platelet
levels, sometimes referred to as compensated DIC.
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Increased fibrinolysis lyzes the increased fibrin clot load
until increasing levels of PAI-1 inhibits plasmin. If the speed
of consumption of coagulation products progresses beyond
liver (coagulation products) and bone marrow (platelets)
production capacity, the patient becomes hypocoagulable,
sometimes referred to as decompensated DIC. Platelet
counts and fibrinogen levels are then decreased below 
normal levels. It is believed that large deposition of fibrin 
in the microvasculature leads to local hypoperfusion
(patchy ischemia), MSOF, and, ultimately, organ failure and
death. DIC can present with differing speed varying from
explosive (acute) to slow (chronic) onset.
One of the most common causes for acute DIC is sep-
sis, where it occurs in 30–50% of patients, regardless of the
cause for sepsis (Box 25-1). Delayed resuscitation from
shock can lead to endothelial cell injury making the patient
procoagulant. In extensive crush injury, particularly in
head injury with release of thromboplastin, and in fat
embolism 50–70% can be shown to have DIC. Acute
leukemias (particularly acute promyelocytic leukemia)
and metastatic prostatic carcinomas are frequently (15%)
associated with DIC development. In abruptio placenta,
abortion, amniotic fluid embolism, hemorrhage, and
shocked obstetric patients 50% develop DIC. In contrast,
only 7% of preeclamptic patients have DIC. Many immuno-
logic disorders develop DIC, including thrombotic
thrombocytopenic purpura (TTP), HELLP (hemolysis,
elevated liver enzymes, and low platelets) syndrome,
and transfusion and transplant reactions. In newborns
with a congenital homozygous PC deficiency, purpura
fulminans with DIC can be life-threatening. Reactions to
toxins, either drugs or snake or spider bites, can lead to
DIC. Prothrombin complex solutions formerly used in
life-threatening emergencies to stop a catastrophic
bleeding can induce DIC, as opposed to rVIIa.
In contrast, chronic DIC occurs predominantly in some
types of cancer, aortic aneurysms, and giant cavernous
hemangiomas (Kasabach–Merritt syndrome), dead fetus
in utero, and in chronic infections such as tuberculosis,
abscess, and osteomyelitis. Chronic DIC can be asymp-
tomatic or present as prothrombotic state with deep
venous thrombosis (DVT) and pulmonary embolism (PE).
Chronic inflammatory bowel disease such as Crohn’s dis-
ease and ulcerative colitis can be associated with slow-onset
DIC. Cancers can express either TF or a direct activator
of FX (Box 25-2).
In sepsis and systemic inflammatory response syn-
drome (SIRS) release of IL-6 has been shown to up-regulate
TF while release of tumor necrosis factor-α (TNF-α) down-
regulates TM as well as up-regulates PAI-1. This produces
a procoagulant state while at the same time the modula-
tors through the PC/PS system are down-regulated and
fibrinolysis is suppressed through release of PAI-1. This
common inflammatory response pattern produces the
compensated DIC state described above. Several prospec-
tive studies have shown that DIC with sepsis or trauma
doubles the risk of death.
CONGENITAL HYPOCOAGULABLE STATES
The most common congenital hypocoagulable state
(1% of the population, autosomal dominant) is von
Willebrand’s disease (vWD), of which three major types
exist. Type I, present in >70%, has a quantitative decrease
in normally shaped vWF molecules. Many patients are
unaware of their mild disease until trauma or surgery. The
levels of vWF are sensitive to the estrogen level, and some
female patients present with perimenopausal bleeding
problems. Complicating genetic workup in these patients
is the variability of the disease penetrance. Type II has 
several subtypes with variable structural abnormalities of
the vWF, e.g., type 2N resembles type II with low FVIII
levels. Type III is much rarer but severe with undetectable
levels of vWF in plasma. Since vWF is the carrier protein
for FVIII, this group of patients may clinically appear to
have hemophilia A and are usually detected earlier in
life. Detection is usually by long BT, workup is with
FVIII levels, vW antigen, Ristocetin cofactor activity, while
immunoelectropheresis helps subtype vWD (Box 25-3).
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Box 25-1 Key Etiologies in Acute
Disseminated Intravascular
Coagulation
● Sepsis
● Delayed shock resuscitation
● Trauma
● Certain cancers
● Obstetric complications
● Preeclampsia
● Immunologic disorders
● Extensive burns
● Vasculitis
● Certain blood products
● Newborn purpura fulminans
● Toxins
Box 25-2 Key Etiologies in Chronic
Disseminated Intravascular
Coagulation
● Cancer
● Vascular
● Obstetric
● Chronic infections
● Inflammatory bowel disease
Treatment modalities vary by type. In pregnancy, levels
of vWF increase dramatically, and type I patients do
not require therapy at delivery. In general, 1-deamino-8-
D-arginine vasopressin (DDAVP) (0.3 μg/kg over 30 min-
utes) is the mainstay therapy for Type I. Most of the
Type IIs and Type III require FVIII (virally inactivated
Humate-P), based on FVIII levels.
Patients with hemophilia A, B, and C have a variable
deficiency in FVIII, FIX, and FXI, respectively. Of the
hemophiliac types, 85% are type A, 14% type B, and 1%
type C. Mild deficiency is present when the patient has fac-
tor levels above 5%, moderate at 1–5%, and severe at <1%.
Hemophilia A and B are X chromosome-linked diseases
that affect 1 in 10,000 males, while C is an autosomal
recessive disease. These problems are usually detected
early in life. Activated partial thromboplastin time (APTT)
is typically prolonged while prothrombin time (PT) and
thrombin time (TT) are normal. Diagnosis is established
by measuring plasma levels of factors VIII, IX, or XI.
Properative treatment of hemophilia A consists of
FVIII level-driven replacement every 12 hours (levels
kept >50% first postoperative week), hemophilia B
requires FIX concentrate every 24 hours, and hemophilia
C requires fresh frozen plasma (FFP). Approximately
10% of hemophilia A patients have developed antibodies
to FVIII, and may require rFVIIa that bypasses the FVIII
step on the activated platelet. Mild hemophilia A may
also respond well to DDAVP. Recombinant FVIII
decreases the risk for viral transmission to these patients,
but is more expensive at this time. A significant number
of these patients have contracted hepatitis B and/or
C and/or HIV from repeated transfusions in the past.
Two congenital forms of thrombocytopathy are
Bernard–Soulier syndrome (defective GPIb receptor)
and Glanzmann’s thrombasthenia (defective GPIIb/IIIa
receptor). They are both uncommon and can be identi-
fied by platelet aggregation studies. Some of these
patients respond to DDAVP, and may require platelets
for ongoing bleeding.
Other rare inherited types include other inborn
platelet abnormalities conferring platelet dysfunction
(but normal numbers) or congenital thrombocytopenia
with large, small, or normally sized platelets. Isolated 
factor deficiencies as well as alpha2-antiplasmin deficiency
are also rare. Dysfibrinogenemias may be hereditary or
acquired, and can be associated with either a bleeding
or a thrombotic propensity.
ACQUIRED HYPOCOAGULABLE STATES
Continuous activation of coagulation and/or down-
regulation of its modulation or fibrinolysis can lead to a
hypocoagulable state. Acquired states are more common
in the older population (Box 25-4).
Acquired thrombocytopenia (<150,000/μl) can be
the result of impaired production, increased destruc-
tion (immune or nonimmune causes), or sequestration.
Impaired production is found in aplastic and myeloprolif-
erative disorders, as a result of drugs or toxins (chemother-
apy, radiation), in viral illness (HIV, AIDS), and also in
vitamin B12 and folate deficiency. Increased destruction
from immune causes includes TTP and hemolytic-uremic
syndrome (TTP-HUS; lack of protease activity cleaving
large vWF multimers, producing fever, schistocytes, tissue
ischemia, anemia, ARF, fluctuating mental state), idio-
pathic thrombocytopenic purpura (ITP; afebrile, autoAb
to GPIIb/IIIa receptor), isoantibodies in post-transfusion
purpura (in women sensitized during pregnancy, lacking
the PL-A1 Ag), other immune complex disorders (sys-
temic lupus erythematosus, SLE), as well as in drug-
induced thrombocytopenia (heparin: 3% heparin-induced
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Box 25-3 Congenital Hypocoagulable
States
● vWD (types I, II, and III)
● Hemophilia A, B, and C
● Bernard–Soulier syndrome and Glanzmann’s 
thrombasthenia
● Inborn platelet abnormalities
● Isolated coagulation factor deficiency
● Dysfibrinogenemias
● Alpha2-antiplasmin deficiency
Box 25-4 Acquired Hypocoagulable
States
● DIC
● Acquired thrombocytopenia
● Acquired platelet dysfunction
● Drug induced
● Uremia
● Hepatic dysfunction
● Massive transfusion
● Transfusion reaction
● Cardiopulmonary bypass
● Vitamin K deficiency
● Hypocalcemia
● Inhibitors to clotting factors (II, V, VII, VIII, X)
● Lupus-type inhibitors
● Primary fibrinolysis
● Hypothermia
● Dilutional
● Leukemia
● Polycythemia vera
thrombocytopenia (HIT)/1% HIT with thrombosis (HITT);
quinidine, cimetidine, ranitidine, sulfa, vancomycin).
Nonimmune-related mechanisms occur in DIC, cardio-
pulmonary bypass, and hypersplenism.
Massive transfusion (>10 U/24 hours) can lead to
thrombocytopenia from blood loss and failure to replace
platelets as well as from dilution (platelets and coagula-
tion factors) associated with massive fluid resuscitation.
Thrombocytopenia in acquired thrombocytopenia
can be treated with platelet infusions if there is a bleed-
ing problem except in the contraindicated states of TTP-
HUS, HIT/HITT, and the presence of platelet antibodies.
Drugs known to induce thrombocytopenia should be
discontinued.
Dysfunctional platelets (thrombocytopathy) are less
common than low platelet count but may be present
with normal platelet count or with thrombocytopenia.
Acquired forms are uremia, postcardiopulmonary bypass,
malignant paraproteinemia (Waldenstrom, multiple
myeloma), hypothermia, after antiplatelet therapy (ticlo-
pidine, clopidogrel, abciximab, tirofiban, eptifibatide),
or after other drugs (COX and TxA2 inhibitors, CCB, 
H2-receptor antagonists, PCN, cephalosporin, dextran,
starch, gelatins, NTP, NTG). Treatment is to identify and
deal with the underlying condition or drug. DDAVP may
be helpful. Platelet transfusion into a toxic environment
may make the platelets rapidly dysfunctional.
Drug-induced hypocoagulable states can be found in
patients on various types of anticoagulants, after rat 
poison intoxication, and in patients on fibrinolytic drugs.
See also under acquired thrombocytopenia and thrombo-
cytopathy for drug-induced problems. The drug should be
stopped, and correction carried out with blood products
and high doses of vitamin K in the case of rat poison
intoxication.
In liver failure variable impairment of the production
of coagulation factors is often associated with hyper-
splenism, low platelet counts, and decreased clearing 
of FDPs and PAI leading to platelet dysfunction and
impaired fibrinolysis. Fibrinogen production is usually
well maintained until end-stage liver disease. FFP may be
required, and vitamin K should always be given. Anemia
may be present when bleeding varices. When exposed to
trauma or extensive surgery, massive transfusion scenarios
often ensue. Release of thromboplastin can cause DIC.
One should plan for good venous access and frequent 
laboratory findings to guide replacement therapy.
The patient with renal failure may have associated bone
marrow failure leading to thrombocytopenia, and this type
of patient often additionally has a chronic anemia. Uremia
confers a platelet dysfunction that is reversible with dialy-
sis. Acute renal failure frequently has a component of asso-
ciated low-grade DIC. Heparin overdosing is common for
dialysis patients, and heparin may need to be neutralized
with protamine or with FFP. DDAVP can temporarily (day)
improve platelet function by release of vWF. Conjugated
estrogens (dose 0.6 mg/kg for 5 days) have a longer dura-
tion of action (weeks) but the response comes slower than
after DDAVP. Erythropoietin is frequently used to raise
hemoglobin in this type of patient.
Massive transfusion is defined as transfusion of
>10 U blood/24 hours. Coagulation problems are usually
rare with loss of less than one blood volume unless the
patient has a preexisting coagulation problem. After loss
of more than one blood volume thrombocytopenia and
coagulation factor deficiencies are common. Risks
include hypothermia, under-resuscitation leads to hypo-
volemia, while over-resuscitation may lead to dilution of
coagulation factors and platelets. Hypocalcemia results
from chelation by ACD (citrate) in blood bags. Blood
products replacement must be based on frequent labo-
ratory findings, possibly thromboelastograph (TEG). All
fluids except platelets should go through high-capacity
fluid warmers. The blood bank should be contacted
early. Damage control is an alternative procedure for the
patient where surgical hemostasis is difficult or impossible.
In hypothermia a reversible platelet dysfunction occurs
due to decreased TxA2 and other platelet enzymatic
activities. Hypothermia is also associated with enhanced
fibrinolytic activity. Acidosis depresses platelet aggrega-
tion, fibrinogen levels fall, and FDP increases. The triad
of hypothermia, coagulopathy, and acidosis has been
called “the triangle of death.” All these changes are
reversible with correction of hypothermia. The patient
should be warmed actively with a warmed air convec-
tion blanket, in addition to fluid warmers.
In cardiopulmonary bypass platelet dysfunction from
degranulation, loss of GP receptors, hypothermia, and
heparin- and protamin-induced malfunction add to con-
sumptive dysfunction of primary and secondary hemo-
stasis. Additionally, cytokine-activated TF expression and
increased primary fibrinolysis and decreased alpha2-
antiplasmin add to the scenario to create a complex state.
Basically, all three steps of the hemostatic response are
affected. This may explain why 29% of patients on car-
diopulmonary bypass bleed excessively, part of which is
due to platelet dysfunction. In addition to perioperative
heparinization there is sometimes need for inhibition of
a primary fibrinolysis as well as for fresh platelets. This is
particularly indicated when risk for bleeding is higher as
in repeat cardiac surgery, underlying coagulation abnor-
mality, or after aspirin ingestion the last week.
Antifibrinolytic therapy may be required in a variety of
situations including cardiopulmonary bypass, and after
tonsillectomy and gynecological and prostate surgery.
Both FDP and D-dimers will be high, while other labora-
tory findings depend on the extent of the bleeding. Two
groups of fibrinolytics are available. The lysine derivates
(aminocaproic acid 5 g bolus followed by a 1 g/hour
infusion; tranexamic acid 10–15 mg/kg every 8 hours)
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prevent plasminogen binding to fibrin(ogen) at the lysine
site and activation to plasmin. They have been shown to
reduce postoperative blood loss after prostate surgery,
after dental extraction in hemophiliacs and anticoagu-
lated patients, and reduce blood loss in cardiopulmonary
bypass by 30–40%. Aminocaproic acid has also been
shown to reduce blood loss in liver transplantation. The
main complication with this type of drug is thrombosis.
Aminocaproic acid is also US FDA approved for heredi-
tary angioneurotic edema.
The second group of antifibrinolytics is the serine
protease inhibitor aprotinin which inhibits TF, FXII, and
kallikrein, in addition to plasmin. In high dose the con-
cern has been that it may also inhibit PC and make the
patient hypercoagulable. Aprotinin (low dose 1 million KIU
bolus plus 1 million in pump prime and 250,000 KIU/
hour) has been shown to be more effective in reducing
blood loss (than lysine derivates) in coronary artery
bypass grafting, valves, endocarditis, and heart trans-
plantation, as well as in patients who took aspirin before
surgery. Extracted from bovine lung, there has been
some concern in Italy of transmission of bovine spongi-
form encephalopathy and Creutzfeldt–Jakob disease to
humans.
INCREASED RISK FOR THROMBOSIS
(THROMBOPHILIA)
This is a larger problem from a hospital perspective
than bleeding since it affects a large part of the patient
population and the consequences are longstanding and
expensive. A patient with a DVT or PE may be on war-
farin medication for 6 months.
There are a number of both acquired and inherited
states that increase the risk for DVT and PE. The most
common inherited disorders include PC deficiency, PS
deficiency, AT deficiency, FV Leiden, prothrombin
mutation, dysfibrinogenemia, and elevated homocystein
levels. The most common acquired hypercoagulable states
are extensive trauma (particularly the first 24 hours), head
trauma, surgery and immobilization, vasculitis (SLE), lupus
anticoagulants, DIC (sepsis), cancer, TTP-HUS, drugs (anti-
fibrinolytics, iatrogenic hyperfibrinogenemia, heparin
(HIT/HITT), warfarin (if PC/PS deficient), oral contracep-
tives, chemotherapy) (Box 25-5).
Immune-type HIT occurs in 3% of heparin-treated
patients, and one-third of these patients go on to develop
HITT, sometimes with life-threatening consequences.
This has been shown to be caused by the formation of an
IgG type antibody (some patients have IgA or IgM anti-
bodies) against a heparin–platelet factor 4 complex. There
is a small cross-reactivity with low molecular weight heparin
(LMWH), which should not be used in these patients.
Direct thrombin antagonists like hirudin (0.4 mg/bolus,
infusion 0.15 mg/kg/hour), recombinant hirudin (lepirudin
dose 0.4 mg/kg max. 44 mg then 0.15 mg/kg/hour
max. 16.5 mg/hour), or synthetic AT (argatroban dose 
2 μg/kg/minute) appear to be effective and safe but
should be managed by a hematologist. Dosing is usually
checked by APTT.
Antiphospholipid antibody (APLA) syndrome consists
of the presence of antibodies against certain phospho-
lipids associated with a hypercoagulable state, some-
times thrombocytopenia, repeated fetal loss, stroke, and
dementia. A detailed knowledge of the underlying
pathology is lacking. Primary APLA syndrome is the diag-
nosis when SLE is not a patient diagnosis, otherwise called
lupus anticoagulant or lupus inhibitor. Chlorpromazine,
dilantin, and quinidine are also known to induce APLA.
They can develop both venous and arterial thrombosis
already at young age. These patients have an elevated
APTT and sometimes PT. Heparin treatment appears
more effective than warfarin. Anticoagulation with
heparin or LMWH is necessary for surgery, problematic
after trauma.
Practice guidelines for management of these patients
have been published recently (see Selected Reading).
Management options include sequential compression
devices, aspirin, LMWH (prophylaxis: enoxaparin 30 mg
q 12 hours; therapeutically 1 mg/kg q 12 hours: 
anti-Xa 0.3–0.6), heparin (prophylaxis: 5000 sq q 8
hours; therapeutically 80 U/kg bolus and then infusion
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Box 25-5 Inherited and Acquired States
that Increase the Risk for DVT
and PE
CONGENITAL HYPERCOAGULABLE STATE
● Factor V Leiden
● PC deficiency
● PS deficiency
● AT deficiency
● Prothrombin mutation
● Dysfribrinogenemia
● Elevated homocystein level
ACQUIRED HYPERCOAGULABLE STATE
● Trauma
● Surgery
● Immobilization
● Vasculitis
● APLA syndrome
● Sepsis with DIC
● Cancer
● TTP-HUS
● Drugs
to keep APTT 1.5–2.5 times normal), and warfarin 
(prophylaxis: 1–5 mg po qd; therapeutically 5–10
mg/day: international normalized ratio (INR) 2–3 use
heparin initially), as well as inferior vena cava (IVC) fil-
ter for those patients where anticoagulation is perceived
as too high of a risk. IVC filter may actually increase the
risk for DVT (if no anticoagulation) but should decrease
the risk for PE from lower parts of the body.
Thrombolytic therapy may be indicated in patients
experiencing DVT, hemodynamically unstable PE, acute
myocardial infarction (MI), peripheral arterial occlusion,
and ischemic stroke. The alternatives include tPA (bolus
plus infusion: dose by indication), streptokinase (250,000 U
for 24–72 hours by indication), and urokinase (4400 U/kg
loading plus 4400 U/kg/hour for 12 hours) all followed
by heparin. Contraindications for their use are recent
surgery, head trauma, hemorrhagic stroke, and active
bleeding. A major complication is bleeding, particularly
intracranial bleeding.
CLINICAL FINDINGS IN COAGULOPATHY
Petechia on skin and mucous membranes or sponta-
neous gingival or epistaxial bleeding suggest an abnor-
mal primary hemostasis, most commonly due to low
platelet number or abnormal platelet function. It can
also be associated with hypofibrinogenemia due to slow
platelet plug formation. Patients with Type I vWD typi-
cally present with these symptoms, or with a large post-
operative hematoma. Type II and III may present with a
hemophiliac-type bleeding.
Overt bleeding as in hematochezia, melena,
hematemesis, blood in NGT, bleeding from previously dry
surgical incisions or wounds, hematuria, hemoptysis,
bleeding from vascular catheter sites, hemarthrosis, and
muscle, brain, or subcutaneous bleeding suggest a defect
in the secondary hemostasis. Hemophiliacs typically
present with hemarthrosis and muscle or brain bleeding.
Acute DIC patients bleed from multiple sites, display
skin and mucous membrane ecchymoses, and signs of
tissue ischemia. Petechia are commonly seen in throm-
bocytopenia accompanying decompensated DIC, the
first usually found under the blood pressure cuff. The
dead fetus situation in chronic DIC may show the signs
of acute DIC.
Commonly, occult bleeding manifests with hemody-
namic instability and falling hematocrit, such as in
retroperitoneal bleeding, postoperative bleeding with
clotted drains, hemothorax, intra-abdominal bleeding,
and pelvic or femoral hemorrhage.
Fibrinolysis-associated bleeding occurs mostly in spe-
cific settings (see above), but also in liver failure. See also
under DIC.
Trousseau described the association between cancer
and DVT, but half of his patients also had tuberculosis.
Chronic DIC patients usually present with DVT, PE, or
arterial embolism, sometimes recurring and in multiple
locations.
LABORATORY FINDINGS 
IN COAGULOPATHY
A particular laboratory may have established refer-
ence values that may be slightly different from the values
cited below. The reference values of a local laboratory
should be used when in doubt. In general a laboratory
should be able to provide a complete blood count
(including a platelet count), PT INR, partial thrombo-
plastin time (PTT), and fibrinogen within 20–30 minutes.
Table 25-1 lists some common causes of abnormal coag-
ulation parameters and typical patterns of associated
coagulation abnormalities.
Low platelet count (normal 150,000–400,000) is
more common than platelet dysfunction. Bleeding is rare
when the count is >50,000, unless the platelets are dys-
functional. High platelet counts in polycythemia vera or
essential thrombocythemia are associated with throm-
bosis or bleeding. A number of commonly used drugs
are associated with thrombocytopenia, including amio-
darone, diltiazem, heparin, quinidine, cimetidine, raniti-
dine, sulfa, gentamycin, and vancomycin. Three percent
of all heparin-treated patients develop HIT and a third
of them go on to develop HITT, also known as white
clot syndrome. This immune type of thrombocytopenia
develops typically after 5–7 days of heparin therapy and is
different from the nonimmune transient drop in platelet
counts commonly seen after heparin initiation. Platelet
count should therefore always be checked twice a week
for all heparinized patients.
Bleeding time (BT): a function test (Ivy 3–6 minutes).
In GPIb receptor failure (postcardiopulmonary bypass,
old bank platelets), blockage by dextran, and congenital
absence (Bernard–Soulier syndrome) platelets cannot
bind to vWF. BT is also prolonged in vWD and certain
connective tissue diseases (scurvy, Ehler–Danlos) where
collagen has abnormal structure and vWF cannot bind
normally. Inhibition of cyclooxygenase (COX) by ASA
(irreversibly) prevents normal activation of the GPIIb/IIIa
receptor by TxA2. Other drugs like nonsteroidal anti-
inflammatory drugs (NSAIDs), carbenicillin, ampicillin,
piperacillin, heparin, nitroprusside, and dextran can also
affect platelet metabolic function but usually less pro-
nounced than ASA. Patients with severe anemia, myeloma,
and uremia also may have prolonged BT.
PFA-100 (Platelet Function Analyser-100): an 
“in vitro bleeding time” that has replaced the BT at 
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many institutions. Citrated whole blood is forced under
high shear over a grid impregnated with the platelet 
agonist pairs collagen/epinephrine or collagen/EDTA,
with the readout being time to occlusion of flow
through tubing on the other side of the grid. Prolonged
closure times (range for each agonist pair is institution
specific) indicate platelet dysfunction. Prolongation to
collagen/epinephrine alone is highly characteristic of
drug effects (ASA, NSAIDs). Like the BT, the PFA-100 will
also become abnormal if the platelet count is <80,000 or
if the hematocrit is low (<28). Because platelet adhesion
to collagen under high shear conditions is dependent on
vWF, the PFA-100 is often abnormal (closure times pro-
longed) in patients with vWD, although normal values
do not absolutely exclude this diagnosis.
PT (normal 11–13 seconds) has largely been replaced
by INR due to quality variability in the tissue phospho-
lipid used to activate the extrinsic tenase complex in the
PT test. The INR test uses human brain thromboplastin
as a reference substance that permits calculation of an
International Sensitivity Index (ISI). The local ISI value
permits calculation of the INR: INR = PT(ISI), a logarithmic
relationship. INR is the recommended way to monitor
warfarin anticoagulation therapy with recommended
range 2–3 for all conditions except bileaflet prosthetic
valves and recent MI (2.5–3.5).
APTT (normal 21–35 seconds): kaolin is used to surface
activate FXII as well as FXI in the intrinsic tenase complex.
As it is sensitive even to lower factor levels, a normal
APTT does not rule out mild factor deficiency. In sys-
temic heparin therapy (DVT, PE) the target APTT is
60–85 seconds.
1:1 mixing studies. These may be done for the PT or
the PTT and can be helpful in distinguishing whether a
prolonged PT or PTT is due to factor deficiency or due
to the presence of a circulating inhibitor (either to a
factor called an “acquired inhibitor” or to phospholipids
in the test system called the “lupus anticoagulant” or “lupus
inhibitor”). In the 1:1 mix patient plasma is mixed in
equal proportion with normal plasma (assuring at least
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Table 25-1 Coagulation Findings in Conditions Commonly Seen in Clinical Practice
Platelet Count PT INR PTT Fibrinogen Comment
Vitamin K Normal Prolonged (major Prolonged Normal PTT normally not prolonged at
deficiency/ prolongation in (severe therapeutic doses of OACs
OACs severe deficiency) deficiency)
SH Normal Mildly prolonged Prolonged Normal PT INR usually not prolonged at
(massive doses) therapeutic SH doses
LMWH Normal Normal Normal Normal PTT cannot be used to monitor
(or slightly anticoagulation on LMWHs.
prolonged) Routine monitoring is usually
unnecessary. If assessment of
coagulation is necessary do a
heparin level
Acute DIC Decreased Prolonged Prolonged Decreased
Chronic DIC Decreased Prolonged Prolonged (rarely Decreased 
or normal (rarely normal) normal) or normal
Liver disease Mildly to More prolonged Prolonged Normal In early liver disease the PT INR
moderately (decreased will be prolonged and the
decreased in end-stage PTT normal, reflecting the
liver disease) short half-life of FVII
Circulating Normal Normal or Prolonged Normal 1:1 mix that does not correct is
anticoagulant prolonged supportive of diagnosis. 
“acquired Clinical problem is excess
factor bleeding. Lupus inhibitor 
inhibitor” should be excluded
LAC Normal Normal or Often prolonged Normal 1:1 mix that does not correct is
(sometimes prolonged (depends on supportive of diagnosis. 
decreased reagent Clinical problem is excess
if antiphospho- sensitivity) thrombosis. Specific LAC
lipid syndrome) testing indicated
DIC, disseminated intravascular coagulation; INR, international normalized ratio; LAC, “lupus anticoagulent/lupus inhibitor”; LMWH, low molecular weight heparin;
OAC, oral anticoagulant; PT, prothrombin time; PTT, partial thromboplastin time; SH, standard heparin.
50% of any given factor is present) and the test is
repeated. Full correction is seen in factor deficiencies, as
even with sensitive reagents, the PT and PTT do not
begin to “pull out” unless factor levels are <40%. Lack of
correction suggests the presence of either an acquired
inhibitor (most commonly anti-FVIII or anti-vWF – these
patients have a bleeding diathesis) or a lupus anti-
coagulant (these patients have a thrombotic propensity).
Distinction between these two is often suggested by
the clinical presentation but can be clarified by a lupus
inhibitor panel (see below). It is important, especially in
the case of acquired factor inhibitors, to look not only for
immediate correction of the test in question, but also for
correction at 60 minutes after mixing, as many antifactor
antibodies show complex kinetics and the mix may only
be abnormal at 60 minutes.
Lupus inhibitor panel and anticardiolipin antibodies.
There is no single “gold standard” test for the lupus 
anticoagulant/lupus inhibitor. In accordance with inter-
national standards most laboratories do three different
tests (such as a sensitive PTT, dilute Russell’s viper venom
time, hexagonal PTT, dilute PT, or other tests). Presence
of a lupus inhibitor is suggested by prolongation of a clot-
based assay and its correction with the addition of phos-
pholipids. Making this diagnosis implies the patient has
a thrombotic propensity. Anticardiolipin antibodies are
another part of the “antiphospholipid” spectrum. These
antibodies do not prolong clot-based assays but are
detected by separate enzyme-linked immunosorbent assay
(ELISA) testing. Their presence also implies a thrombotic
propensity.
Reptilase is a thrombin-like enzyme that is not sensitive
to heparin (unlike APTT), and is used to diagnose heparin
effect.
TT (normal 7–12 seconds) monitors fibrinogen trans-
formation to fibrin after addition of thrombin, a qualitative
test (as opposed to fibrinogen level, a quantitative test).
TT is prolonged in fibrinolysis and at low fibrinogen levels
(<90 mg/100 cm3). It is sometimes used in DIC diagnosis,
as well as to monitor heparin or thrombolytic therapy.
Activated clotting time (ACT; normal 94–120 seconds,
therapeutic level 400–600 seconds) is used for monitoring
of intraoperative heparinization. Activation of the intrinsic
tenase complex is achieved by using celite (diatomaceous
earth) to activate FXII. Platelet quantity, quality, hemo-
dilution, as well as hypothermia all affect the ACT. When
there is discrepancy between the clinical status and the
ACT result, it usually means the patient is hypothermic,
since the test cuvette is heated to 37°C. It is insensitive to
coagulation abnormalities. It does not correlate well with
microvascular bleeding after cardiopulmonary bypass.
Fibrinogen level (normal 175–350 mg/100 ml) is usu-
ally low in consumptive processes such as DIC, in severe
liver disease, or in massive transfusion by consumption
and/or dilution. The most common reason for elevated
PT/INR and PTT is hypofibrinogenemia. Required level
is 50–100% for effective hemostasis. It is common prac-
tice to give cryoprecipitate to the bleeding patient if the
fibrinogen level is below normal range, while this is not
true for a stable nonbleeding patient. Iatrogenic hyper-
fibrinogenemia should be avoided, which can trigger
thrombotic events.
Factor assays are sometimes measured in hemophilia
patients to guide replacement therapy before or after
surgery. In hemophilia A a FVIII level > 50% is recom-
mended, and since the half-life is 6–12 hours replenish-
ment twice daily is required. In massive transfusions, FV
and FVIII drop off quickly (“labile factors”) since their
activity is lost rapidly in stored blood. DDAVP will induce
transient release of vWF and also of FVIII, since vWF is
the carrying molecule for FVIII. LMWH in higher dosage is
sometimes monitored by anti-Xa activity assays according
to patient weight.
AT (also known as ATIII; normal 70–130%) is usually
low in DIC by consumption in the thrombin inactivation
as well as breakdown by elastase (from polymorpho-
nuclear leukocytes). Congenital AT deficiency is more
uncommon. AT inhibits thrombin, FIXa, FXa, and FXIa
but its activity is enhanced 100 times by heparin, or
physiologically heparan. Low AT levels are responsible
for “heparin resistance.” Since it is produced by the liver,
advanced liver disease may lead to deficiency. Children
with nephritic syndrome may also exhibit low AT levels
and heparin resistance. Rapid consumption of AT in DIC
and sepsis may lead to low AT levels. Low AT levels in
DIC make patients heparin resistant.
Calcium (normal 8.9–10.1 mg/100 ml) is required 
to hold coagulation factors down to catalytic centers 
on platelets via a calcium bridge. Calcium activity is 
better monitored with ionized (or free) calcium (normal
1–1.25 mmol/l) since it is protein bound in the normal
state. Excess ACD in massive transfusion can rapidly 
produce hypocalcemia, which needs to be corrected in
massive transfusion scenarios.
Magnesium level can affect coagulation in that sub-
stituting subnormal magnesium levels will improve the
clotting ability of FIX.
D-dimers (normal < 250 μg/ml) and FSPs (or FDPs)
(normal < 10 μg/ml) are both indicative of plasmin activity
on fibrin, but the presence of D-dimers is specific for cross-
linked fibrin. FSPs are elevated in both primary and sec-
ondary fibrinolysis, whereas elevated D-dimer implies that
there has been clot formation with secondary fibrinolysis.
Moderately to strongly positive D-dimers are present in
DIC. Elevated D-dimers are also seen in DVT and PE as well
as in any clinical setting where there is widespread sec-
ondary fibrinolysis (postoperative major surgery, trauma).
Weakly positive D-dimers are frequent in line draws and in
sick hospitalized patients. FSPs are normally cleared by the
reticuloendothelial system (normal half-life 9 hours), as
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are other activated coagulation products. High FSP titers
inhibit thrombin, prevent cross-linking of fibrin, and 
disrupt platelet function. High FSP levels (>100 μg/ml)
are also seen in active renal disease and renal transplant
rejection.
Fibrinopeptide A is a breakdown product of fibrino-
gen by thrombin, elevated in DIC.
Euglobulin lysis time (normal >2 hours at 37°C) is 
elevated in states with high circulating plasmin levels,
but normal in clot-bound fibrinolysis.
High PAI-1 levels (normal < 50 ng/ml) can be seen in
sepsis and DIC, and indicate a suppressed fibrinolysis.
The patient is at risk for microthrombi and MSOF.
Schistocytes (fragmented red blood cells) are high in
microangiopathic hemolytic anemia (MHA) but may also
be present in DIC from other causes.
Thromboelastograph (TEG) is a whole blood, in vitro
point-of-care system, for assessment of the tensile strength
of the developing clot, as well as for disappearing clot
strength in fibrinolysis. It can give directions in blood
component therapy and also test drugs in vitro before
administration to the patient. It has been shown to save
blood products in massive bleeding scenarios and liver
transplantation. Additionally, it is very useful in evalua-
tions for hypercoagulability.
HIT test: ELISA platelet aggregation test or serotonin
release test (not available everywhere). Laboratory test-
ing for HIT can be frustrating and HIT is still largely a
clinical diagnosis. ELISA tests are sensitive but often
falsely positive. Functional HIT tests (aggregation, sero-
tonin release) are less sensitive but more specific.
KEY LABORATORY FINDINGS 
IN DISSEMINATED INTRAVASCULAR
COAGULATION
Traditionally, in acute DIC serial assays of platelet count
(90%), fibrinogen (sensitivity < 50% but high specificity of
80%), APTT (sensitivity 50%), PT/INR (sensitivity 68%),
FDP (sensitivity 87%), and D-dimers (sensitivity 95%)
have been used. More recently, thrombin–AT complex
(TAT; sensitivity 98%), plasmin–plasmin inhibitor com-
plex (PPIC; sensitivity 95% but low specificity of 35%),
and soluble fibrin monomer (sFM; sensitivity 81%) have
been shown to be more specific for DIC but are not used
in routine clinical practice yet. There is not a single param-
eter but a group of markers that accurately predict DIC and
these are a combination of TAT, PPIC, and sFM. High
plasma TM levels are common in DIC patients with organ
failure indicating endothelial injury. AT levels fall with
rapid consumption. IL-6 and TNF-α levels are both high.
In chronic DIC FDP is usually increased, but the other
laboratory diagnostics discussed above are unreliable. 
A shortened APTT is sometimes seen in chronic DIC.
DIAGNOSIS OF DISSEMINATED
INTRAVASCULAR COAGULATION
The combination of test results (low platelet count or
its rapid decline; prolonged PT/APTT; elevated FDP or
D-dimers; low AT or/and PC) and the presence of a clin-
ical condition known to be associated with DIC will be
required for diagnosis. If uncertainty remains, soluble
fibrin monomer or TAT complexes should be measured
in a specialty laboratory (Box 25-6).
TREATMENT OF COAGULOPATHY 
AND DISSEMINATED INTRAVASCULAR
COAGULATION
It is very important to move the patient to an ICU
where monitoring of vital signs as well as frequent blood
draws can enable the team to follow the course and the
effect of treatment. Depending on the situation, the
most common approach is to reverse coagulopathy
with blood products prior to insertion of devices for
central monitoring. In massive transfusions, all fluids
except platelets are given through a fluid warmer.
Normal blood volume is maintained as guided with
central monitoring and urine output using LR, saline,
and colloids. Hematology consult will be particularly
helpful when speed of bleeding high (can expedite
transfer of blood products from blood bank) particularly
in a massive transfusion situation, and when the patient
does not stop bleeding with standard therapy.
Red blood cells should be replaced to restore oxygen
carrying capacity. In overt bleeding if hematocrit < 30,
otherwise if hematocrit < 23 in a young and otherwise
healthy patient. It is advisable to keep hematocrit = 30 in
patients with coronary artery disease and with age over 70.
FFP: if INR > 2.0 or PTT > 1.5 times normal and fib-
rinogen is normal. Also consider FFP in hemodynamic
instability if coagulation results are not immediately avail-
able. 4 FFP is a common initial dose.
Cryoprecipitate: in a bleeding patient with fibrinogen
lower than 125 g/dl; avoid hyperfibrinogenemia. A 5 pack
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Box 25-6 Differential Diagnosis to
Disseminated Intravascular
Coagulation
● Severe liver failure
● Vitamin K deficiency
● Primary fibrinolysis
● HITT
● Idiopathic purpura fulminans
will raise a moderately decreased fibrinogen level into
the lower normal range.
Platelets should be transfused in a bleeding patient if
<50,000. In stable patients not due for surgery, transfusion
is not recommended unless platelet count is <10,000.
Transfusion should be started when necessary with
platelets from five donors, or alternatively pheresis
platelets from one donor. Platelet transfusion is contra-
indicated in TTP, HIT/HITT, and in the case of platelet
autoantibodies. ITP: prednisone, immunoglobulin, 
possible splenectomy; TTP: prednisone, plasma exchange
5 days; HIT/HITT: discontinue heparin and heparin-coated
central venous catheters, and if anticoagulation is
required argatroban or recombinant hirudin (leprudin)
should be used, not LMWH. Post-transfusion purpura
patients may require immunoglobulin, plasmapheresis, and
corticosteroids.
Dysfunctional platelets: drug list should be checked
(penicillins, cephalosporins, H2 receptor antagonists,
dextran, hetastarch, heparin, warfarin, antiplatelet drugs,
NSAIDs) if abnormal PFA-100 or prolonged bleeding time
and platelet count in normal range. Central core tempera-
ture should be kept above 36°C. Keeping the hematocrit
around 30 probably facilitates platelet adhesion. DDAVP
(0.3 μg/kg) or conjugated estrogens (0.6 mg/kg/day for
1–5 days) are recommended for uremic platelets.
Pathologic primary fibrinolysis can occur in the post-
operative cardiac bypass patient (aprotinin), after tonsil-
lectomy, in obstetric or gynecological bleeding, and
after prostate surgery. Antifibrinolytic therapy (drug and
dose) should be considered.
Surgical hemostasis should be considered in post-
operative patients if bleeding is from drains or surgical
sites only. If perioperative uncontrolled diffuse bleeding
and coagulopathy is present, packing the patient should
be considered, and they should be taken to an ICU for cor-
rection of coagulopathy and later second look (“damage
control”). Small series of trauma patients with uncontrol-
lable bleeding have received rFVIIa (Novo7®: 90 μg/kg q
2 hours) with rapid cessation of bleeding, but the expense
limits its use. Also used successfully in patients on warfarin
after head trauma, it stops bleeding rapidly. If surgical
hemostasis not possible, angiographic localization and
embolization should be considered.
DIC. Identification and elimination of the underlying
factor(s) is the essential part. If the triggering factor can
be dealt with the DIC state gradually subsides over the
next few days. Acute DIC is usually treated with blood
components (platelets, FFP, cryoprecipitate, PRBC) that
control bleeding if necessary. Prophylactic administration
of FFP or other blood products have not been shown to
confer advantage to these patients. The heparin dose is
300–500 U/hour as infusion. LMWH can also be used as
an alternative to heparin. Direct inhibitors of thrombin
(AT independent) have not undergone controlled trials
for DIC yet, but are known to be associated with a
higher risk of bleeding and cannot be reversed. Heparin
is most frequently used for DIC associated with thrombo-
embolism (Box 25-7).
AT concentrates have in trials been shown to reduce
mortality slightly (but not statistically significantly) in
sepsis. A meta-analysis showed a mortality reduction
from 56 to 44%, but the costs are substantial. A recent
large multicenter trial of more than 2300 patients failed
to show survival advantage at 28, 56, or 90 days. TFPI
has failed in large multicenter trials to show survival 
benefit in sepsis-induced DIC.
While antifibrinolytics may be effective in some bleed-
ing patients, they are contraindicated in DIC, except if
the bleeding can be shown to result from hyperfibrino-
lysis, as in promyelocytic leukemia.
Activated PC has been shown to decrease sepsis-
induced mortality in patients with the highest Apache II
scores, but has been associated with bleeding in patients
with lower Apache scores. It has not been tested for DIC
associated with conditions other than severe sepsis.
Site-inactivated rFVIIai may theoretically be an attractive
way to block increased TF activity known to precipitate
DIC, but no human trials support this approach yet.
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Box 25-7 Drug Side Effects
● Heparin: HIT/HITT; osteoporosis, hyperlipidemia
from lipase release, PLA2 stimulation causes
cytokine release
● LMWH: small risk for cross-reaction in HIT patients
● Hirudin-type anticoagulants: no reversal
● Warfarin: if heparin is not used initially, certain 
categories with inborn PC or PS deficiency or PC
resistance (FV Leiden) may become hypercoagulable
before they become fully anticoagulated. Warfarin-
induced skin necrosis
● Thrombolytics: bleeding
● Antifibrinolytics: DVT and PE
● DDAVP: transient hypotension, tachyphylaxis;
hyponatremia
CURRENT CONTROVERSIES
When is it safe to use heparin in DIC? Even though
controlled trials have not shown benefit for hepariniza-
tion, it appears reasonable to anticoagulate DIC patients
with heparin if there are signs of ischemia from gut, or
acral ischemia (fingertips, nose, ears). On the other hand,
heparin does not appear to increase the risk for bleeding
in the DIC patient. In chronic DIC long-term therapy with
LMWH appears to be a reasonable choice until the
underlying factor is brought under control. Warfarin
therapy is often ineffective for long-term control.
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PREPARATION AND COMPOSITION 
OF BLOOD AND BLOOD COMPONENTS
AND DERIVATIVES
Blood products in North America are normally
donated by volunteers, either as whole blood or by
apheresis. Over 11 million units of whole blood are col-
lected annually in the USA. In whole blood donation a
450 ml unit (U) is collected into citrate-based anticoagu-
lant. Autologous units (donated by a person for their
own later use) are stored as whole blood. Other whole
blood units are separated into two or three components:
into 1 U of red blood cells (RBCs), 1 U of plasma, and
sometimes into 1 U of “random donor” platelets. The
plasma may be further separated into 1 U of cryoprecip-
itate (a small-volume product rich in fibrinogen) and 1 U
of cryosupernatant plasma. Platelets are most commonly
not made from whole blood but are collected by aphere-
sis harvest of donor platelet-rich plasma. One apheresis
platelet unit is equivalent to 5–6 “random donor” platelet
units. Apheresis can also be used to harvest RBCs and
plasma, although these products are not yet available in
most areas of North America. Plasma derivatives (albumin,
plasma-derived clotting factor concentrates, intravenous
gammaglobulin, etc.) are made by subfractionation of
pooled plasma or cryopsupernatant plasma from large
numbers of donors (up to 20,000). Also, specialized hyper-
immune gammaglobulins (rhesus (Rh)-immune globulin,
cytomegalovirus (CMV)-immune globulin, etc.) can be
made from plasma of special donors with high titers of
the desired antibody. The composition, shelf life, and
postissue storage conditions for red cells, plasma, cryo-
precipitate, and platelets are given in Table 26-1. Note
that most RBC units currently have an additive solution
added to them, which improves viability and increases
their shelf life. All blood components should be admin-
istered through a standard blood filter (“170–260 micron”)
to remove any aggregates that may have formed during
storage.
SPECIAL TRANSFUSION NEEDS:
LEUKOREDUCTION, “CMV SAFE,”
IRRADIATION, WASHING
Contaminating leukocytes in whole blood preparations
in North America partition about 80% into the red cell
component. Leukoreduction of red cells and platelets can
remove 3–4 log of these leukocytes. This is usually done
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by filtration or by sophisticated apheresis technology at
the blood center at the time of collection (prestorage
leukoreduction). It may also be done using special leuko-
reduction filters in the hospital transfusion service or at
the bedside. Leukoreduced products are more costly but
are less likely to cause febrile transfusion reactions and
human leukocyte antigen (HLA) alloimmunization. They
are also considered by the American Association of Blood
Banks to be the equivalent of “CMV seronegative” units in
being “CMV safe,” and many hospitals no longer specifi-
cally provide “CMV negative” products. Leukoreduced
products are routinely given to hematology/oncology
patients, solid organ transplant candidates/recipients,
neonates, and patients who have had previous febrile
reactions. Flow rates for bedside leukoreduction are often
slow and for surgery prestorage leukoreduced products
are preferred.
Irradiation of red cells and platelets with 2500 centigrays
abrogates blastogenesis of contaminating lymphocytes and
prevents transfusion-associated graft versus host disease
(TA-GVHD). Frozen plasma and cryoprecipitate do not
need irradiation. Prestorage leukoreduction alone is
inadequate to prevent TA-GVHD. Irradiated products are
needed by patients who have undergone bone marrow
transplant, who have congenital immunodeficiency, or
who are receiving directed donations from a blood rela-
tive. In addition irradiated products are given to many
patients with hematologic malignancy and to some solid
tumor patients. Solid organ transplant patients and AIDS
patients do not require irradiated products. Irradiation
increases potassium leak from RBCs and should ideally
be done at the time of product issue from the hospital
transfusion service.
Washing of RBCs and platelets is rarely needed. It is
used in prevention of recurrent refractory major allergic
reactions, to remove potassium (K+) where K+ toxicity is
an issue (RBCs < 5 days old may be substituted in most
cases), and to prepare frozen deglycerolized RBCs (rare
blood groups). Washing of RBCs normally takes 1–2 hours,
and washing of platelets 2–3 hours. Once washed the
RBCs must be used within 24 hours and platelets within
4 hours.
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Table 26-1 Blood Products, Contents, and Storage
Blood Approx. 
Component Contents Volume Shelf Life Comments
Whole blood RBCs and plasma. 450 ml blood 520 ml 35 days at 4°C. WBCs and platelets not viable
(autologous and 63 ml CPDA-1 anticoagulant. Transfuse within 4 hours after 24 hours. Factors V
predonation) Hct ~ 35 at room temperature and VIII significantly
decreased after 2 days
Red cell concentrate RBCs with about 25 ml plasma and 340 ml 42 days at 4°C. “Packed cells” (Hct 70) lack
(additive solution 100 ml of additive solution (saline, Transfuse within 4 hours the additive solution and
red cells – AS-1, adenine, dextrose). Hct 55–60 at room temperature are not usually provided
AS-3, AS-5)
Platelet Platelets (5.5 × 1010); some WBCs; 50 ml 5 days at 20°C with Refrigeration results in
“random donor” 50 ml plasma; few RBCs agitation echinocytic transformation
(Hct < 0.005) and dysfunction
Platelet “apheresis” Platelets (3.5 × 1011); fewer 300 ml 5 days at 20°C with 1 apheresis U = 5−6 “random
WBCs and RBCs than agitation donors.” Do not refrigerate
“randoms”; 300 ml plasma
FFP; FP Normal levels all coagulation factors, 250 ml 1 year frozen at −18°C; ~30 minutes to thaw.
natural inhibitors (AT, protein C, post-thaw: 4°C × 24 hours Post-thaw: major decreases
protein S) and plasma proteins. in factors V and VIII
No significant difference after 24 hours
between FFP and FP
Solvent detergent All coagulation factors. Plasma 200 ml 1 year frozen at −18°C; ~30 minutes to thaw. Storage at
plasma proteins. Significant decreases post-thaw: room 4°C may activate factor VII.
in proteins C and S vs. FFP and FP temperature × 24 hours Possibly prothrombotic vs.
FFP and FP
Cryoprecipitate ~150 mg fibrinogen, at least 80 U 15 ml/U. 1 year frozen at −18°C; ~15 minutes to thaw. 
factor VIII, von Willebrand Note: also post-thaw: room Refrigeration may
factor, factor XIII comes in temperature × 4 hours re-precipitate proteins – warm
5 U pools to room temperature
AS-1, AS-3, AS-5, RBC additive solutions; AT, antithrombin III; CPDA-1, citrate phosphate dextrose-1 anticoagulant; FFP, fresh frozen plasma; FP, frozen plasma;
Hct, hematocrit; RBC, red blood cell; WBC, white blood cell.
COMPATIBILITY ISSUES
ABO Compatibility
ABO compatibility of donor and recipient is critically
important for RBCs and plasma. There are four basic
blood groups: O, A, B, and AB. The A and B genes code
for glycosyltransferases that add A or B substance onto a
base H substance on all red cells. Anyone who lacks A or
B on their red cells always has the corresponding natu-
rally occurring antibody in their plasma. Anti-A and anti-B
are complement-fixing antibodies that are active at body
temperature and cause nasty or fatal acute intravascular
hemolytic reactions (Box 26-1).
Basic donor/recipient ABO compatibility of RBCs and
plasma can be found in Table 26-2. When in doubt one
should use O red cells and AB plasma (O red cells can be
used for all blood groups because there is very little 
O plasma in red cells).
Replacement of the Total Blood Volume 
of an Adult
The total blood volume (TBV) of an adult is about 
70 cm3/kg, or for a 70 kg individual about 5 liters. If the
hematocrit is 0.40, about 2 liters of this TBV is red cells,
and about 3 liters is plasma. Using the product volumes
and composition in Table 26-1 one can calculate that,
roughly, to replace the TBV of a 70 kg person would
require about 10 U of red cells, 10–12 U of plasma, and
10–12 U “random donor” platelets = 2 U apheresis
platelets. Keeping this in mind one can roughly estimate
the number of units of a particular product needed to
correct a given level of deficiency (Box 26-2).
RED BLOOD CELLS AND ANEMIA
More than 11 million red cell units are transfused
annually in the USA to more than 3 million recipients.
Physiologic Response to Acute
and Chronic Anemia
Normal physiologic response to anemia consists of 
cardiac and peripheral tissue adaptations as well as
changes in RBC 2,3-diphosphoglycerate (2,3-DPG).
Cardiac output is increased by increasing heart rate or
stroke volume. As the heart normally extracts ~80% of
O2 delivered, increased cardiac O2 extraction is largely
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Table 26-2 Recipient and Donor ABO Groups and RBC and Plasma Compatibilities
Donor RBC Donor Plasma
Recipient Blood Group Antigens on RBCs Antibodies in Plasma Compatibility Compatibility
O None Anti-A and anti-B O only O, A, B, AB
A A Anti-B A, O A, AB
B B Anti-A B, O B, AB
AB A and B None AB, A, B, O AB only
Unknown or undeterminable Unknown Unknown O AB
Box 26-1 ABO Incompatibility
ABO incompatibility is the leading cause of preventable
transfusion fatalities.
● Meticulous attention to specimen and recipient
identification would have prevented most of 
these deaths
CLINICAL CAVEAT
Blood Component Compatibility with Solutions
and Drugs
● Compatible with isotonic crystalloid and with 5%
albumin
● Do not mix with drugs (acidic pH, protein binding),
calcium-containing solutions (may clot), or
hypotonic solutions (lysis of RBCs and platelets)
Box 26-2 Basic Principles of Blood
Component Therapy
● Replace what is needed – red cells for anemia,
platelets for thrombocytopenia, plasma for 
coagulopathies, etc.
● Transfuse only if the defect is clinically significant.
● Weigh the risks, benefits, and alternatives to 
transfusion
achieved by increasing coronary artery flow by coronary
artery vasodilatation. As demand escalates in excess of
compensatory increases in heart rate and vasodilatation,
the heart shifts from aerobic to anaerobic metabolism
and blood flow is shifted from the subendocardium to
the epicardium, placing the subendocardium at ischemic
risk. Clearly patients with impaired ability to increase their
heart rate (intrinsic disease, pharmacologic blockade) or to
increase coronary flow through vasodilatation (stenotic
lesions) are at increased risk for ischemia. Animal studies
suggest the lower limit of cardiac tolerance for anemia in
the presence of a normal cardiovascular system is a hemo-
globin (Hb) of ~3–5 g/dl, and in the presence of coronary
stenosis is in the range 7–10 g/dl.
Peripheral tissue compensation for anemia is to
increase O2 delivery by increasing blood flow through
vascular beds, to recruit more capillaries, or in the case of
supply-dependent tissues to increase oxygen extraction.
However, these compensatory mechanisms may be 
limited and dependent on circulating intravascular volume
as well as on red cell mass in the case of the splanchnic
bed, muscles, and skin. With chronic anemia, RBC intra-
cellular 2,3-DPG concentrations also increase, shifting the
oxyhemoglobin dissociation curve to the right, thereby
facilitating tissue off-loading of O2 (Box 26-3).
Serologic Safety of Uncrossmatched 
Red Blood Cells
Once a blood sample reaches the hospital transfusion
service it takes about 10 minutes to do an ABO and
Rh type, about 30 minutes to do an antibody screen, and
about 45 minutes to issue crossmatched RBCs if no irreg-
ular antibodies are identified (in most hospitals 2–5% of
patients will have such antibodies). If RBC transfusion is
needed more urgently than this, uncrossmatched O or
group-specific uncrossmatched RBCs may be issued on
request of appropriate personnel. Statistically, if a unit of
RBCs is randomly selected with no effort to ensure sero-
logic compatibility with the recipient (ABO, Rh, or other
clinically significant anti-RBC antibodies) it will serendip-
itously be compatible ~64% of the time. This is fortunate
as available data show ~1 in 30,000 to 1 in 40,000 patients
get the wrong blood! If ABO compatibility is assured (as it
can be by giving group O RBCs) serologic safety rises to
99.4%; for ABO and Rh compatibility to 99.8%; and for ABO
and Rh compatibility with a negative antibody screen to
99.94%. Also even if irregular antibodies are present titers
are often low, and the clinical sequelae are usually not
immediate but delayed in the form of a delayed hemolytic
transfusion reaction. Therefore, when faced with an exsan-
guinating patient the clinical risk/benefit is usually over-
whelmingly in favor of using uncrossmatched blood.
Choice of the Perioperative Red Blood
Cell “Transfusion Trigger”
There is little to justify a specific Hb or hematocrit,
such as the former “10/30” Hb/hematocrit rule, in making
decisions regarding perioperative RBC transfusion, and
withholding transfusion unless a patient is symptomatic
has been advocated by some expert groups. Adults with 
Hb of <7 g/dl are more likely to manifest hemodynamic
symptoms than are children, who more often become
dyspneic or show impaired levels of consciousness.
However, multiple studies indicate that signs and symp-
toms of anemia are unreliable especially in the surgical
setting, and that myocardial ischemia is often silent, par-
ticularly postoperatively. Complicating this is the fact that
estimates of intraoperative blood loss are often difficult,
and estimates of intraoperative blood volume indirect
(inferred from arterial, central venous, and pulmonary
capillary wedge pressures). Even when invasive moni-
toring is used to measure whole-body O2 consumption,
or O2 extraction ratios, such measurements are global and
have not been verified as predictive of ischemia. The real
issue of interest is the adequacy of O2 delivery to specific
organs and regions within these organs, and unfortunately
it is not possible to measure this directly in the routine clin-
ical setting. The dynamic nature of surgical hemorrhage
and the anticipation of major blood loss are also frequent
factors in the decision to transfuse intraoperatively.
It should also be noted that a Hb/hematocrit that is
adequate in the stable intraoperative setting (where the
patient is paralyzed and the ventilation and FIO2 con-
trolled) may no longer be adequate in the same patient
in the postoperative setting, breathing room air and with
exertional demands for increased O2 delivery. A recent
study in Jehovah’s Witnesses indicates that postopera-
tive morbidity and mortality begin to rise when the Hb 
is <5 g/dl in patients without cardiovascular compromise
and when it is <6 g/dl in patients with cardiovascular
compromise (Box 26-4).
Choice of “Transfusion Trigger” in the
Critical Care Setting
One recent randomized trial in which adult patients
were randomized to a hemoglobin (Hb) of 7–9 g/dl vs. a Hb
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Box 26-3 Increment Expected per 
RBC Unit Transfused in
Nonbleeding Patients
● In an adult 1 U RBCs will increase the hematocrit 
by ~3 % and the hemoglobin by ~1 g/dl
● In the pediatric patient the roughly equivalent dose
is 10–15 ml RBCs/kg
of 10–12 g/dl suggested a trend to decreased 30-day mor-
tality in the former group. Subgroup analysis showed
younger (age < 55 years), less critically ill patients (Acute
Physiology and Chronic Health Evaluation II score ≤ 20)
were half as likely to die in the Hb 7–9 g/dl group as in
the 10–12 g/dl group. Conversely a large retrospective
study showed that in patients with myocardial infarc-
tion, anemia below a hematocrit of 33 was associated
with increased mortality in patients over the age of 65.
PLASMA, CRYOPRECIPITATE, 
AND COAGULOPATHY
More than 2 million U of plasma and almost 1 million
U of cryoprecipitate are transfused annually in the USA.
The basic composition, volume, shelf life, and postissue
storage conditions for plasma and cryoprecipitate are
given in Table 26-1. Specific coagulation factor charac-
teristics of plasma are given in Table 26-3.
Clinically, spontaneous bleeding is rare in isolated 
factor deficiencies unless levels are below 5% of normal.
Under conditions of stress (surgery, invasive procedures)
bleeding often occurs when factor levels are below 30%,
particularly in the case of multifactorial coagulopathies.
Monitoring of individual factor levels (except for fibrin-
ogen) is not feasible in routine clinical settings, and
more global measures of coagulation (prothrombin time
international normalized ratio (PT INR), partial throm-
boplastin time (PTT)) are normally used for clinical
assessment (see Chapter 25). Although sensitivity to 
factor deficiencies is reagent specific, in general the
PT INR and PTT do not prolong until factors are <40% of
normal.
Plasma
The major indications for plasma use are given in 
Box 26-5 and the usual dosing in Box 26-6.
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Box 26-4 Recommended Perisurgical
Red Blood Cell “Transfusion
Trigger”
● None firm – need for transfusion needs to be 
individualized for any given patient in any given
clinical setting
● Transfusion is frequently indicated when the 
hemoglobin/hematocrit are <6 g/dl/18% and rarely
indicated when they are >10 g/dl/30% (exception is
acute blood loss)
● Postoperatively hemoglobins <5 g/dl in patients
without cardiovascular compromise and <6 g/dl in
patients with cardiovascular compromise appear to
carry increased morbidity and mortality
CURRENT CONTROVERSY
Red Blood Cell “Transfusion Trigger” 
in the Critical Care Setting
Optimal hemoglobin/hematocrit in the critical 
care setting is unclear and likely dependent on clinical
setting, patient age, and underlying cardiovascular status.
Table 26-3 Coagulation Factor Characteristics 
in Plasma
Coagulation Factor t1/2 Postinfusion (hours)*
Fibrinogen 96
II 60
V 24
VII 4–6
VIII 11–12
IX 22
X 35
XI 60
XIII 144
vWF 8–12
* t1/2 = half-disappearance time of the clotting factor in the absence of
accelerated consumption.
Box 26-5 Major Indications for Use 
of Plasma
● Urgent clinical correction of a multifactorial coagu-
lopathy (vitamin K deficiency, warfarin reversal,
severe liver disease, DIC, dilutional coagulopathy)
when the PT INR is >1.5*or the PTT is >1.5 times
normal
● Factor replacement for known factor deficiencies
for which specific plasma-derived or recombinant
factor concentrates are unavailable (factor II, V,
VII**, X, XI**, and XIII** deficiencies; protein C** 
and protein S deficiencies)
● Correction of microvascular bleeding when the 
PT INR is >1.5 or the PTT is >1.5 times normal 
(or when the PT and PTT are not available in a
timely fashion)
● Plasmapheresis or plasma infusion in TTP
* The choice of a PT INR of >1.5 as predictive of clinical bleeding is quite 
conservative. Some groups have in fact argued that the literature does not
really support this and that a PT INR of >2.0 is more appropriate.
** Specific replacement products available in some geographical areas.
Plasma should not be used as a volume expander, as 
a nutritional supplement, or for nonurgent correction 
of vitamin K deficiency (pharmaceutic preparations 
of vitamin K will usually reverse this in 6–12 hours).
Hypofibrinoginemia (massive transfusion, disseminated
intravascular coagulation (DIC)) is best corrected with
cryoprecipitate (see below).
Although plasma is frequently used to correct mild pro-
longations of the PT INR (1.2–1.5) and the PTT (<1.5 times
normal) prior to invasive procedures (line placements,
biopsies, paracentesis), there is little evidence to support
this, practice and the skill of the operator doing the proce-
dure is more predictive of bleeding. It should also be noted
that increasing coagulation factor levels by 10% will have a
significant effect on the PT and PTT when they are pro-
longed more than twice mid-range normal but will have
only a minimal effect on more modest prolongations. It is
difficult or impossible to correct the coagulopathy of severe
liver disease with plasma because the short half-life of 
factor VII (4–6 hours) makes it difficult to infuse the prod-
uct fast enough. In this setting 1-deamino-8-D-arginine vaso-
pressin (DDAVP) (for the platelet function defect), plasma
exchange (to correct the factor defect), and more recently
recombinant factor VIIa (if available) may be helpful.
Cryoprecipitate
Cryoprecipitate (cryo) is supplied as individual “bags”
or units (each made from 1 U of plasma) or as 5 U pools.
The major plasma proteins contained in cryoprecipitate are
given in Table 26-4 and dosing guidelines in Table 26-5.
Cryo is used in congenital and acquired hypofibrino-
genemia (fibrinogen < 100 mg/dl – DIC, obstetrical catas-
trophe, fulminant hepatic failure). It is also used in
dysfibrinogenemias with microvascular bleeding. Although
used in the past for treatment of both hemophilia A
and von Willebrand’s disease (vWD), cryo is no longer
the first-line treatment for either as factor concentrates 
(now treated to inactivate viruses or made by recombi-
nant technology) and DDAVP (which carries no risk of
transfusion-transmitted disease) carry less risk. Cryo is
suitable for treatment of vWD unresponsive to DDAVP
if von Willebrand concentrates are unavailable, as well
as for treatment of moderate to severe factor VIII defi-
ciency where DDAVP is ineffective and factor concen-
trates are unavailable. Factor XIII deficiency is usually
treated with plasma, although cryo can also be used.
Other uses for cryo, although not confirmed by random-
ized clinical trials, include treatment of platelet dysfunc-
tion unresponsive to DDAVP (uremia, drug-induced).
Cryo is ineffective and contraindicated for treatment of
multiple organ failure.
Cryo can also be used as a source of fibrinogen in
making “homemade” fibrin glue, where it is mixed with
a source of thrombin (usually bovine) at the time of use.
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Box 26-6 Plasma Dosing
● ~20/ml/kg will achieve coagulation factor 
concentrations of ~30% of normal in nonbleeding,
otherwise stable adults and children
● A minimum of 2–4 U (500–1000 ml) is generally
required to have an impact on a clinically significant
coagulopathy in an adult
Table 26-4 Major Plasma Proteins in a Single 
10–15 ml Bag (U) of Cryo
Constituent Amount per Bag Half-life (hours)
Fibrinogen 150–250 mg 100–150
Von Willebrand factor 100–150 U 12
(normal multimeric  (40–70% of 
pattern) original plasma)
Factor VIII 80–150 U 12
Factor XIII 50–75 U 150–300
Table 26-5 Dosing Guidelines for Cryo
Clinical Condition Usual Dose Minimal Hemostatic Level
Fibrinogen replacement Adult: 10 U (two 5-pools); child: 1 U/10 kg Fibrinogen of 75–100 mg/dl (measure postinfusion – dosing
(will increase fibrinogen by 60–100 mg/dl) frequency can vary from hours in active DIC to days)
Von Willebrand’s Adult: 10–12 U q 12 hours; This dose will usually ensure hemostasis
disease (second-line child:1 U/6 kg q 12 hours
therapy – see text)
Hemophilia A (factor VIII Assume 1 U contains 100 U factor VIII; Factor VIII levels of 35–100% depending on clinical setting
deficiency) (second-line 1 U/6 kg will usually give a factor VIII
therapy – see text) level of ~35%
Factor XIII deficiency 1 U/10 kg q 7–14 days 2–3% levels of factor XIII are hemostatic
Fibrin glue is used most commonly in cardiothoracic and
vascular surgery, neurosurgery, and maxillofacial surgery
to provide local control of slow venous bleeding, diffuse
ooze, and lymphatic leaks. Commercial fibrin sealant
preparations, which use human thrombin, may be pre-
ferred as bovine thrombin may rarely be associated with
formation of antifactor V antibodies.
PLASMA DERIVATIVES
Albumin
Albumin, unlike other blood products, comes in glass
bottles and must be vented for IV administration. The 5%
solution is isotonic and the 25% solution hypertonic.
Albumin and other colloids are often used to restore
intravascular volume in patients with hypovolemia.
Rhesus Immune Globulin
Rh immune globulin (RhIg) is used to prevent forma-
tion of anti-D anti-RBC antibodies by Rh-negative women
(about 15% of Caucasians) exposed to Rh-positive blood.
If anti-D is formed, hemolytic disease of the newborn
may result. The source of the sensitizing Rh-positive
blood is usually exposure to fetal red cells as the result
of abdominal trauma or invasive procedures, or during
delivery. Usual preventative dose is 300 μg, best given
within three days of exposure.
Other Plasma Derivatives
A detailed discussion of the use of plasma derivatives,
including the use of specialized plasma-derived and
recombinant factors for treating hemophilia (factor VIII
and IX concentrates, prothrombin complex concen-
trates, FEIBA, recombinant factor VIIa), as well as the use
of specialized plasma derivatives (intravenous gamma-
globulin, hyperimmune globulins, antithrombin concen-
trates, C1 esterase inhibitor, etc.), is beyond the scope of
this chapter. In dealing with the perioperative manage-
ment of patients with hemophilia (particularly those with
inhibitors), vWD, and complex coagulopathies including
congenital and acquired prothrombotic disorders such
as antithrombin (AT, formerly antithrombin III) defi-
ciency hematological consultation should be sought. If
at all possible patients with hemophilia should not be
taken to surgery without being tested for the presence of
inhibitors and without a trial infusion of factor to assess
adequacy of factor recovery. Likewise patients with
vWD should have the subtype of their vWD defined
prior to surgery and a DDAVP trial, if appropriate.
Patients with mild to moderate Type I vWD (where the
defect is in endothelial cell release of normal von
Willebrand factor (vWF)) will often respond to DDAVP.
In other types of vWD an abnormal vWF is made and
DDAVP should not normally be used. Table 26-6 provides
some basic guidelines and caveats regarding perioperative
treatment of hemophilia and vWD (and of patients with AT
deficiency). Antifibrinolytic therapy (epsilon aminocaproic
acid, tranexamic acid) can be a useful adjunct for oral
surgery in patients with underlying coagulation disorders.
PLATELETS AND THROMBOCYTOPENIA
The basic composition, volume, shelf life, and storage
conditions for “random donor” and apheresis platelets
are given in Table 26-1. Platelets are given both prophyl-
actically, to prevent bleeding, and therapeutically, to
treat active bleeding or to ensure effective hemostasis
during surgery or other invasive procedures (biopsies,
thoracentesis, paracentesis). Spontaneous bleeding is rare
at platelet counts of >10 × 109/l providing platelet func-
tion is normal and there is no coincident coagulation or
hemostatic defect, and this is the usual prophylactic
“transfusion trigger.” In the absence of accelerated con-
sumption, splenic sequestration, etc., approximately 80%
of the transfused platelets will still be circulating 24 hours
later. Perisurgically, as well as for invasive procedures,
platelet counts of 40−50 × 109/l functional platelets, in the
absence of other coagulation defects, are usually enough
to ensure hemostasis. For central nervous system and
life- or limb-threatening bleeding higher target platelet
counts (75−100 × 109/l) are often used. Platelets may also
be used to treat thrombocytopathy (postcardiopulmonary
bypass, drug-induced, etc.). The normal dose in this sit-
uation is sufficient to raise the platelet count by 40−50 ×
109/l, as normal platelets will recruit dysfunctional
platelets into the hemostatic plug. Nontransfusion treat-
ments for platelet dysfunction may be useful as alterna-
tives or adjuncts to platelet transfusion. These include
intravenous or intranasal DDAVP, keeping the hematocrit
around 30, and use of conjugated estrogens (in uremia)
or antifibrinolytic agents (oral bleeding).
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CURRENT CONTROVERSY
Albumin (Colloid) vs. Crystalloid in Acute
Resuscitation
● Two controversial recent meta-analyses of
randomized trials comparing albumin and
nonalbumin volume expanders with crystalloid 
for resuscitation found a 4–6% excess of deaths 
in the colloid group
● Caution may be warranted in the use of albumin 
and other colloids for acute resuscitation
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Table 26-6 Use of Plasma Derivatives
Condition Clinical Setting Agent and Dose Caveats
Hemophilia A Surgery or trauma Factor VIII concentrate: • Severe hemophiliacs (<1% factor VIII) and 
(factor VIII • Usual goal is FVIII level of 100% initially, moderate hemophiliacs (2–5%) require 
deficiency): then 50% until wound healing begins, factor VIII concentrates. Mild hemophilia A
no inhibitor then 30% until healing complete may be responsive to ddAVP 0.3 mg/kg – 
(usually 7–14 days) preoperative trial infusion recommended
• 1 unit/kg usually ↑s FVIII level by 2% • Neurosurgery goal: 100% initial then 
• Usual dose: 50 U/kg initially then 50–100% × 10–14 days or until complete healing
25 U/kg q 8–12 hours (or by • Factor levels should be monitored 
continuous infusion) perioperatively
Hemophilia B Surgery or trauma Factor IX concentrate: • ddAVP is ineffective in Factor IX deficiency
(factor IX • Usual goal is FVIII level of 100% initially, • Neurosurgery goal: 100% initial then 
deficiency): then 50% until wound healing begins, 50–100% × 10–14 days or until complete healing
no inhibitor then 30% until healing complete • Factor levels should be monitored
(usually 7–14 days) perioperatively
• 1 unit/kg usually ↑s FIX level by 1%
• Usual dose: 100 U/kg initially, then
50 U/kg q 8–12 hours 
(or by continuous infusion)
Hemophilia A Surgery or trauma • Activated prothrombin complex • Perisurgical management of hemophiliacs 
or B with concentrates (aPCCs): 75 U/kg or with inhibitors can be very challenging.
inhibitors • Porcine factor VIII (if available and no Elective surgery should not be done on
antibody cross reactivity; VIII inhibitor patients without consultation 
inhibitors only): 100–150 U/kg or with a hematologist
• Recombinant factor VIIa (rVIIa): • aPCCs prothrombotic especially with repetitive 
90 μg/kg – repeat at 2–3 hour intervals doses in older patients or patients with 
(usually at least 2–3 doses  needed) liver disease
• rVIIa: issues of cost, availability, and possible 
thrombogenicity
Factor XI Surgery or trauma • Plasma infusion q 12–24 hours to • Poor correlation of hemostatic control with 
deficiency maintain factor levels of 40–60% either PTT or measured factor levels – often 
(t1/2 ≈ 45–60 hours) a management challenge. Hematologic 
• Factor XI concentrate unavailable in consultation advised
North America and thrombogenic
• rVIIa (experimental): 90 μg/kg – repeat
at 2–3 hour intervals (usually at least 
2–3 doses needed)
Von Willebrand’s Surgery or trauma • Mild–moderate Type I vWD may respond • ddAVP is first-line treatment only for 
disease (vWD) to ddAVP IV 0.3 μg/kg – usual rise in mild–moderate Type I vWD. Other treatment 
factor VIII and vWF is 3–5 fold modalities should normally be used in the 
• Other forms of vWD should be treated different Type II subtypes and in Type III
with von Willebrand concentrates • Plasma factor levels of vWF required 
(Humate-P®): 50–60 U/kg will usually perioperatively are similar to those required 
↑ plasma level in severe (Type III) for FVIII hemophiliacs
vWD to 100% • Hematological consultation is advised in treating 
vWD patients
Antithrombin Surgery or trauma Antithrombin concentrates (Thrombate®) • In sick or pregnant patients higher doses (50 U/kg)
(AT) deficiency • 1 U/kg will ↑ AT by ~2% (t1/2 ~ 60 hours) should be used and t1/2 may be significantly less, 
• Dose in patients with heterozygous AT so daily dosing may be necessary
deficiency needing surgery (heparin: • Hematological consultation is advised in treating 
↑ hemorrhagic risk): 25 U/kg AT deficient patients perioperatively and 
(should ↑ baseline levels by 50%) during pregnancy
Dosages are rough guidelines for use in the perioperative setting. Hematologic consultation should normally be sought in managing patients with the above-mentioned
conditions preoperatively, intraoperatively, and perioperatively.
Relative contraindications to platelet transfusion
include idiopathic thrombocytopenic purpura (ITP)
unless there is life-threatening bleeding (half-life of trans-
fused platelets in ITP is only ~15 minutes). There is also
fairly good evidence that platelet transfusion in heparin-
induced thrombocytopenia (HIT) and in thrombotic
thrombocytopenic purpura/hemolytic uremic syndrome
(TTP-HUS) may precipitate thrombosis, and in these sit-
uations platelet transfusion is contraindicated except in
the presence of active bleeding (Box 26-7).
Refractoriness may be defined as the failure to achieve
a 15 minute to 1 hour postplatelet increase of at least
10 × 109/l. Insufficient platelet dose should be excluded.
The differential diagnosis of refractoriness includes clini-
cal factors (accelerated consumption, sepsis, DIC, bleeding,
splenic sequestration), infusion of a suboptimal platelet
product (ABO mismatch, especially A platelets trans-
fused to a group O recipient; product more than 48 hours
old), and alloimmunization. Alloimmunization is most
frequent (~75–80%) to HLA class I antigens (shared by
platelets and leukocytes) but may also be to platelet-
specific antigen systems. Use of leukodepleted red cell
and platelet products will minimize HLA alloimmuniza-
tion risk in multiply transfused patients. Approaches to
diagnosing and treating alloimmunization vary from insti-
tution to institution. At the authors’ institution the first
intervention is to try as fresh as possible ABO-matched
platelet products and to measure the 15 minute to 1 hour
postplatelet count. If there is a reasonable but suboptimal
rise in the platelet count and a higher count is needed,
dose and/or frequency of transfusion are increased. If there
is no significant rise, patient plasma is tested for the pres-
ence of anti-HLA and antiplatelet-specific antibodies and
either platelet-crossmatched or HLA-matched apheresis
platelet products provided as appropriate.
TRIGGERS FOR TRANSFUSION:
CONSENSUS STATEMENTS
We have tried to provide a short discussion for each
blood product highlighting the issue of the “transfusion
trigger” indicating where there are new data, where clini-
cal judgment is necessary, and where controversy exists.
In fact there have been significant discrepancies in rec-
ommendations for blood component therapy as set forth
by different expert groups within North America, among
them the National Institutes of Health consensus confer-
ences in the late 1980s, the American College of Physicians
in 1992, the American Society of Anesthesiology in 1996,
and the Canadian Medical Association in 1997. The inter-
ested reader is referred to these sources, which are refer-
enced in the Selected Reading.
MASSIVE TRANSFUSION
Massive transfusion is defined as replacement of the
entire circulating blood volume within a 24-hour period.
As a rule in an adult this occurs when ≥10 U of RBCs
have been transfused. Massive transfusion occurs most
often in the setting of major trauma and surgery,
although gastrointestinal bleeding, especially in liver dis-
ease, is another frequent cause. The coagulopathy that
occurs in massively transfused patients is multifactorial
and not normally due to “dilution” of factors and platelets
by large volumes of crystalloid, colloid, and transfused
RBCs alone. There is no simple correlation between the
amount of blood lost and replaced and the incidence of
coagulopathy; rather coagulopathy is strongly correlated
with the incidence and duration of hypotension. In gen-
eral patients with no or only brief hypotension do not
develop coagulopathy despite massive transfusion, those
with hypotension for more than 1 hour develop severe
coagulopathy, and those with intermediate levels of
hypotension develop moderate coagulopathy. Other fac-
tors that will influence the development of coagulopathy
in the massive transfusion setting are the following:
● Presence of preexisting clinically evident or subclinical
coagulation defects (congenital, disease-related, drug-
related). For example, patients with liver disease will
“pull out” dilutionally very rapidly and patients with
uremia or who are on antiplatelet agents will be partic-
ularly sensitive to thrombocytopenia.
● Presence of significant tissue injury (especially crush
injury and head trauma) or overwhelming sepsis,
which release large amounts of tissue factor and
result in a systemic procoagulant drive.
● Administration of large volumes of hetastarch (more
than a liter may cause acquired vWD) or dextrans
(platelet dysfunction).
Formula replacement of blood components (“give
2–4 units of plasma and 1 apheresis platelet per 10 U RBCs
transfused”) is wasteful and may be harmful. Decision to
transfuse should be guided by clinical considerations
including the presence of microvascular bleeding and by
serial monitoring of the hemoglobin/hematocrit, platelet
count, PT INR, PTT, and fibrinogen (see Table 26-6).
Given the time required to thaw plasma (~30 minutes),
if the presence of coagulopathy is clinically likely, 4 U of
plasma should be thawed “on spec.” If the initial dose
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Box 26-7 Platelet Dosing
One apheresis unit in an adult (or 1 U random donor
platelets/10 kg) should raise the 15 minute to 1 hour
postplatelet count by 40–50 × 109/l.
chosen of a particular component does not satisfactorily
correct the target coagulation parameter, and bleeding is
ongoing, the next dose should be doubled.
Rapid transfusion of cold citrated blood products can
also result in metabolic derangements. Hypothermia (body
temperature 35°C) in particular is associated with platelet
dysfunction and diffuse microvascular bleeding in addition
to being synergistic with hypocalcemia (Ca2+ chelation by
citrate) in potentiating arrhythmia. Table 26-7 summarizes
some of the special problems surrounding massive trans-
fusion and suggested management of these.
TRANSFUSION REACTIONS 
AND COMPLICATIONS
Although public preoccupation has been with viral
transfusion-transmitted diseases (TTDs) such as HIV and
hepatitis, viral TTD is actually a very uncommon cause of
transfusion-related morbidity and mortality. Blood prod-
ucts in the USA are currently tested for HIV 1 and 2, for
hepatitis B (HBV) and C (HCV), for human lymphotrophic
virus I and II, for syphilis, and from the summer of 2003 for
West Nile virus. In the case of HIV and HCV nucleic ampli-
fication testing is used and residual risk is estimated at ~1
in 2 million to 1 in 4 million per unit transfused for HIV and
at ~1 in 1 million to 1 in 2 million for HCV, with some geo-
graphical variability. Many patients receive multiple blood
products and overall average patient risk of TTD has been
estimated as ~1 in 100,000. Although surveillance data
from the United Kingdom indicate possible transfusion
transmission of spongiform encephalopathy (“mad cow
disease,” variant Creutzfeldt-Jakob disease) in man in two
cases, this appears to be very rare. Transfusion recipients
are actually much more likely to have serious adverse
effects from other transfusion complications, and the cur-
rent leading causes of transfusion-related fatalities come as
a surprise to most people (Box 26-8).
Some common and clinically important transfusion
reactions, including their approximate frequency, clini-
cal presentation, cause, prevention, and treatment, can
be found in Table 26-8. All suspected transfusion reac-
tions should be reported to the hospital transfusion 
service; post-transfusion blood (and sometimes urine)
samples should be sent to the transfusion service along
with the implicated product bag and any remaining
product. An area of major controversy in transfusion
medicine currently is whether blood transfusion is
immunomodulatory, whether this effect is clinically sig-
nificant in humans as regards postoperative infections
and tumor progression, and whether leukodepletion will
abrogate this effect if present. Some practitioners have
gone so far as to advocate a policy of universal leuko-
reduction to prevent the putative significant immuno-
modulatory effects of transfusion. However, at present
data are conflicting, the majority of transfusion medicine
specialists are opposed to such a policy due to lack of
firm evidence of benefit and cost/benefit, and major US
blood suppliers are still supplying both leukoreduced
and nonleukoreduced red cell and platelet products.
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Table 26-7 Special Issues in Massive Transfusion
Issue Cause Suggested management
Coagulopathy Multifactorial (see text) • Obtain baseline complete blood count (hemoglobin, hematocrit, platelet count), 
PT INR, PTT, and fibrinogen and continue to monitor these as clinically indicated 
(in major bleeding every 45–60 minutes)
• Transfuse RBCs to maintain a Hct > 24, platelets to keep platelet count > 50–80, plasma 
to keep PT INR < 1.5–2.0, and cryoprecipitate to keep fibrinogen > 100
Hypothermia Transfusion of cold Use of a validated blood warmer is helpful in massive transfusion settings and most 
blood; clinical causes rapid infusion devices have blood warmers. Platelets should not be given through 
(trauma, etc.) blood warmers
Hypocalcemia Infusion of citrate • Check Ca2+ after transfusion of about 10 U RBCs in an adult and give Ca2+ as necessary to
correct the Ca2+. Formula administration may be harmful and should be avoided
• In truly massive transfusion (>2 blood volumes) Mg2+ should also be checked
Hyperkalemia K+ load in RBCs • Depending on their age RBCs may contain from 10 to 60 mEq/l of K+. This is usually not 
a problem in adults, but rarely may be in neonates and small children receiving large 
volumes of RBCs rapidly, especially in the presence of renal failure and acidosis
• K+ should be monitored and if necessary RBCs < 5 days old or washed RBCs used
Box 26-8 The Three Leading Causes of
Transfusion-Related Fatalities
● Acute hemolytic transfusion reactions 
(most due to ABO incompatibility)
● Bacterial sepsis (4–5 day old platelets)
● Transfusion-related acute lung injury (TRALI)
ALTERNATIVES TO BLOOD 
COMPONENT THERAPY
Alternatives to blood component therapy are numer-
ous, and a number have been touched upon in the dis-
cussions above on plasma, cryo, and coagulopathy and
platelets. Unfortunately, for many of these alternatives
the risks, benefits, and cost-effectiveness are unclear, and
there may also be associated reimbursement issues. General
blood conservation measures include minimizing blood
draws, use of pediatric tubes, stopping aspirin at least
four days prior to surgery, correction of coagulopathies
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Table 26-8 Transfusion Reactions
Reaction Usual Approximate Signs and Treatment and
Type Urgency incidence Symptoms Cause Prevention
Acute +++++ 1:12,000–1:35,000; Fever, rigors, IV site Serological Meticulous specimen/
hemolytic ~50–75% of fatalities pain, hypotension, incompatibility recipient identification 
(1:100,000–1:600,000) hematuria, renal (ABO) due to is preventative. 
failure, DIC specimen/recipient Maintain blood pressure,
misidentification treat DIC and metabolic
derangements
Delayed + 1:1000–1:12,000; Fever, jaundice Recipient has No treatment usually
hemolytic severe symptomatic 2–3 days to antibody to antigen required. Antigen 
hemolysis: 1:250,000; 2–3 weeks on donor RBCs negative RBCs needed for
death rare post-transfusion subsequent transfusion
Febrile non- +/− to ++ 0.5–1.4%, 15% recur; Temp. rise of >1°C Contaminating If recurrent reactions use
hemolytic 43–75% of reactions leukocytes; cytokines leukoreduced RBCs and 
generated during platelets and premedicate 
product storage with acetaminophen
Allergic • Minor (rash, urticaria) – 1–3% Idiosyncratic Diphendyramine (minor);
• Generalized (confluent urticaria, bronchospasm, IgA-mediated hemodynamic and
anaphylactoid) – 1:1000–1:5000 reaction respiratory support,
• Anaphylactic: 1:20,000–1:50,000 to a plasma corticosteroids (major).
component If severe rule out IgA
deficiency. Premedication with
benadryl +/− corticosteroids
+/− H1 and H2 blockers
Bacterial ++++ Platelets: 1:54,000; Fever, rigors, Gram-positive or Culture patient and blood bag.
sepsis RBCs: 1:1.4 million hypotension Gram-negative Treat shock. Provide “on spec”
contamination Gram-positive and Gram-
negative antibiotic coverage
Volume + − ++++ ? 1:100 Congestive heart Excess volume Treat pulmonary edema
overload failure, pulmonary administration for 
edema. cardiopulmonary 
reserve
Transfusion- +++ − ? 1:5000; likely Acute respiratory Passive transfer of Provide respiratory support as 
related ++++ under-recognized compromise; antileukocyte needed. With antibody-mediated 
acute lung noncardiogenic antibodies in donor TRALI risk of recurrence is 
injury pulmonary edema. plasma; neutrophil- very low. With neutrophil-
(TRALI) Fever and priming activity priming TRALI recurrence rate 
hypotension generated during is higher and use of prestorage
may occur storage of RBCs leukoreduced RBCs and 
and platelets apheresis and fresh-as-possible 
platelets may prevent 
recurrence
and nutritional anemias (iron, folate, B12) preoperatively,
and use of an experienced surgeon and anesthesiologist. 
If the estimated blood loss is >750–1000 ml and/or the
hemoglobin is <14 g/dl consideration should be given to
increasing the preoperative hemoglobin with erythro-
poietin (see below). Autologous predonation (donation
of whole blood by a patient for their own later use –
donations are generally given 1 week apart beginning 
3 weeks prior to surgery) avoids TTD but has other risks:
it results in preoperative anemia and increases overall
chance of transfusion; the risks of patient/specimen
misidentification, volume overload, and bacterial contam-
ination remain; and it is significantly more costly than
allogeneic blood due to nonutilization of collected units.
In addition about 1 in 17,000 standard risk donors are
hospitalized as a direct result of complications of the
autologous donation. Autologous predonation of high-risk
patients (stable cardiac disease, on pharmacologic agents
that block compensatory response) should be done only
under conditions of close monitoring and isovolemic fluid
replacement.
Isovolemic hemodilution appears to be safe and effec-
tive, and considerably more cost-effective than autologous
predonation in selected surgeries (radical prostatectomy).
However, the technique is poorly standardized, data are
conflicting, operating room time may be necessary, and
meticulous attention to volume is crucial in borderline
cases. Intraoperative blood salvage (cell saver, etc.) is 
suitable for high-volume “clean” losses (vascular surgery).
If large-volume (>500–1000 ml) salvage is done, the device
should “wash” the salvaged blood and return only the
RBCs to the patient. Postoperative blood salvage (medi-
astinal drainage, knee and hip drains) is more contro-
versial. In general such salvage is costly and little blood
is salvaged; there may also be issues of sterility and of
inducing coagulopathy. In selected surgical settings and
patients, particularly in bloodless medicine and surgery
programs, hypotensive anesthesia may be used.
A variety of pharmacologic agents can be useful as
adjuncts or alternatives to blood products. Erythropoietin
can be useful to increase the hematocrit preopera-
tively (see above) and is approved for this purpose in 
noncardiovascular surgery. The dose is 600 U/kg/week 
for 3 weeks prior to surgery (days –21, –14, and –7) or
300 U/kg given 10 consecutive days before surgery and
4 days postoperatively. It usually takes a minimum of
10–14 days to get any meaningful increase in hematocrit.
Adequate iron repletion should be ensured. Postoperatively
there is resistance to the action of erythropoietin and it
is less effective. DDAVP is first-line therapy in treatment
of mild to moderate hemophilia A and mild to moderate
Type I vWD and may be given both IV and intranasally.
IV dose is 0.3 μg/kg. A preoperative trial is recommended
to ensure hemostatic levels. DDAVP may also be useful in
correction of platelet dysfunction (uremia, drug-induced).
Fibrinolytic inhibitors (aprotinin, tranexamic acid,
epsilon aminocaproic acid) can be useful in attenuating
blood loss in cardiac surgery (especially reoperative
surgery) and in oral surgery and perhaps in other set-
tings. Dose optimization is unclear, cost can be an issue,
and there are questions regarding possible prothrom-
botic risk. Fibrin glues have been discussed above.
Recombinant factor VIIa is a new pharmacologic hemo-
static agent whose therapeutic role is evolving. It is
extremely costly and not readily available. It is probably
now the established first-line therapeutic agent in con-
genital hemophiliacs with inhibitors and in acquired
hemophilia. Its role and cost/benefit in correction of
other hemostatic abnormalities (urgent warfarin reversal,
refractory coagulopathy of hepatic dysfunction, severe
congenital platelet abnormalities, microvascular bleeding
in trauma, etc.) remains to be established.
There are currently no “red cell substitutes” licensed
in North America, although a bovine hemoglobin-based
O2 carrier (HBOC), Hemopure, was recently licensed in
South Africa. Three HBOCs have now completed or are
undergoing US FDA phase 3 trials in the USA: Hemopure
(bovine hemoglobin glutamer, Biopure Corp.), PolyHeme
(human pyridoxilated polymerized hemoglobin, Northfield
Laboratories), and Hemolink (human hemoglobin raf-
fimer, Hemosol Inc., although this trial was halted pre-
maturely). The products are being investigated primarily
in the perioperative setting, although acute resuscitation
studies are planned. An earlier human diasporin-linked
HBOC (Hemassist, Baxter) has been discontinued. All
the HBOCs have short plasma half-lives (days), and it
is not clear that they are equivalent in efficacy or side
effects. Their clinical roles remain to be established, and
rather than “red cell substitutes” discussion is now turn-
ing to their potential broader role in “oxygen therapeu-
tics.” Their presence in the plasma may also interfere
with certain laboratory tests (including optically based
tests of coagulation and O2 determination by pulse
oximetry). Perfluorocarbon solutions are also capable of
carrying O2 dissolved in solution, although like HBOCs
they have short plasma half-lives and a variety of side
effects reported. One of them, Perflubron (Alliance
Pharmaceuticals), was being used in a phase 3 trial in
perioperative hemodilution, but this was recently
halted. Potential platelet substitutes are being developed
(infusible platelet membranes, fibrinogen-coated albumin
microspheres).
Jehovah’s Witnesses refuse whole blood and all of its
primary components (RBCs, platelets, and plasma) and
pose special challenges in the perioperative setting.
However, plasma derivatives (cryo, albumin, fibrin glues)
are considered “matters of conscience” and are accepted
by some Jehovah’s Witnesses but not others. Autologous
predonation is unacceptable to Jehovah’s Witnesses but
perioperative hemodilution and intraoperative salvage
procedures where the blood is kept in a continuous 
circuit with the body are “matters of conscience.”
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CURRENT CONTROVERSY
Autologous Predonation
Once considered the “standard of care” for some
surgeries (orthopedic) recent studies have suggested
that, with declining transmissible disease risks, the risks
of autologous predonation in many cases appear to
outweigh the benefits.
Erythropoietin (stabilized with traces of albumin) is
acceptable to most Jehovah’s Witnesses, as are all phar-
macologic blood-sparing agents. HBOCs, when available,
will be “matters of conscience.” The Jehovah’s Witness
community has a hospital liaison network which can
provide information and put practitioners in contact
with physicians experienced in managing Jehovah’s
Witness patients who can provide advice.
SELECTED READING
Expert Group Recommendations
American College of Physicians: Practice strategies for elective
red blood cell transfusion. Ann Int Med 116:403–406, 1992.
Expert Working Group: Guidelines for red blood cell and
plasma transfusions for adults and children. Can Med Assoc
J 156(Suppl 11):S1–S25, 1997.
Practice guidelines for blood component therapy: a report by
the American Society of Anesthesiologists Task Force on
Blood Component Therapy. Anesthesiology 84:732–747,
1996.
General
Carson JL, Noveck H, Berlin J, Gould SA: Mortality and mor-
bidity in patients with very low postoperative Hb levels
who decline transfusion. Transfusion 42:812–818, 2002.
DeLoughery TG: Hemostasis and Thrombosis, Austin, TX:
Landes Bioscience, 1999.
Dzik S: The use of blood components prior to invasive bedside
procedures: a critical appraisal. In Mintz PD, editor:
Transfusion Therapy: Clinical Principles and Practice,
Bethesda, MD: AABB Press, 1999, pp 151–169.
Goodnight SH Jr, Hathaway WE, editors: Disorders of Hemostasis
and Thrombosis: A Clinical Guide, ed 2, McGraw-Hill: 
New York, 2001.
Goodnough LT, Bach RG: Anemia, transfusion and mortality
[editorial]. New Engl J Med 345:1272–1274, 2001.
Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP:
Transfusion medicine: I. Blood transfusion. New Engl J Med
340:438–447, 1999.
Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP:
Transfusion medicine: II. Blood conservation. New Engl J Med
340:525–533, 1999.
Hebert PC, Wells G, Blajchman MA, Marshall J et al; Transfusion
Requirements in Critical Care Investigators for the Canadian
Critical Care Trials Group: A multicenter, randomized con-
trolled clinical trial of transfusion requirements in critical
care. New Engl J Med 340:409–417, 1999.
Jahr JS, Nesargi SB, Lewis K, Johnson C: Blood substitutes 
and oxygen therapeutics: an overview and current status.
Am J Therapeut 9:437–443, 2002.
Spence RK, Jeter EK, Mintz PD: Transfusion in surgery and
trauma. In Mintz PD, editor: Transfusion Therapy: Clinical
Principles and Practice, Bethesda, MD: AABB Press, 1999,
pp 171–197.
Blood and Blood Component Therapy 285
286
Etiology
Classification of Severity of Cirrhosis and
Fulminant Hepatic Failure
Cirrhosis
Fulminant Hepatic Failure
Diagnostic Studies
Laboratory Testing
Imaging Studies
Clinical Manifestations of Cirrhosis and
Fulminant Hepatic Failure
Encephalopathy
Cardiovascular Manifestations
Pulmonary Manifestations
Gastrointestinal Manifestations
Renal Manifestations
Coagulation Manifestations
Immunologic Manifestations
Liver Transplantation
Alternatives to Orthotopic Liver Transplantation
Artificial Liver
Cirrhosis is an irreversible process of fibrosis and
nodular regeneration that occurs throughout the liver.
This represents the end stage of hepatocellular injury in
which viable hepatocytes are replaced primarily by con-
nective tissue due to a chronic disease process, e.g.,
longstanding alcohol use or chronic viral infection, usu-
ally occurring over decades. Cirrhosis can be classified
histologically as micro- or macronodular depending on
the stage of liver disease, and its natural history can also
be divided into compensated and decompensated states.
Decompensation is characterized by the development of
jaundice, ascites, gastrointestinal (GI) bleeding, or
hepatic encephalopathy.
Fulminant hepatic failure (FHF) is defined as develop-
ment of hepatic encephalopathy within eight weeks of
the clinical onset of acute hepatic disease without a pre-
vious history of liver disease. This hepatic dysfunction is
due to either massive hepatocellular necrosis or, less
commonly, replacement of hepatocytes with malignant
tissue.
ETIOLOGY
The causes of cirrhosis can be broadly divided into
two major categories: (1) parenchymal liver disease and
(2) cholestasis with or without extrahepatic biliary
obstruction. The pathophysiology of cholestatic liver dis-
ease is thought to be secondary to bile acid accumula-
tion in viable hepatocytes that leads to apoptosis in these
cells. Most cirrhotic patients in the USA today are likely
to have multiple parenchymal hepatic insults, most com-
monly chronic hepatitis C, alcohol abuse, and fatty liver
of obesity, also known as nonalcoholic steatohepatitis
(NASH). The presence of any two of these three etiolo-
gies has been shown to be synergistic in causing cirrhosis.
Since 1990, when obesity was convincingly shown to
be a causative factor for cirrhosis, the diagnosis of 
cryptogenic cirrhosis has decreased dramatically. The
pathophysiology of NASH has been linked to coexisting
insulin resistance with subsequent development of 
dysfunctional fatty acid metabolism. This is thought to
result in excess free fatty acids that lead to oxidative
CURRENT CONTROVERSY
New classifications of FHF have been proposed by
many clinicians. One modification suggests that the
term FHF be reserved for encephalopathy that occurs
within 2 weeks of the onset of acute liver disease, and
that the term subfulminant hepatic failure be used
when encephalopathy occurs between 2 weeks and
3 months after the onset of jaundice or other clinically
apparent liver disease, i.e., coagulopathy or jaundice.
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stress and direct hepatotoxicity. The etiologies for
cirrhosis are shown in Table 27-1.
The etiologies for FHF are listed in Table 27-2.
Hepatitis A and B (HAV and HBV) are the two most com-
mon viral etiologies for FHF. Although hepatitis C (HCV)
is also a rare cause of FHF, recent studies have shown
that patients with chronic HCV are particularly prone to
develop FHF when superinfected with HAV. Hepatitis D
is an uncommon etiology unless present concomitantly
with HBV. Hepatitis E has been associated with cases of
FHF outside of the USA. Of note, chronic viral infection
with either hepatitis B or C can predispose to the devel-
opment of hepatocellular carcinoma.
There are multiple potential mechanisms for 
drug-induced FHF. They are listed in Table 27-3.
Acetaminophen-induced FHF involves a dose-related
mechanism. It is initially metabolized via glucuronide
and sulfate conjugation, and at higher doses this pathway
becomes saturated. The metabolism is then shifted to an
alternative cytochrome p450 system that is dependent
on glutathione. With excessive dosing, glutathione
stores become depleted. This results in an accumulation
of the hepatotoxic metabolite N-acetyl-p-benzoquinone.
N-acetylcysteine, a glutathione donor, is commonly used
in the setting of acetaminophen overdose to prevent fur-
ther hepatotoxicity. The risk for acetaminophen toxicity
has been shown to be higher in chronic alcoholics
wherein lower doses can result in FHF. The associated
morbidity and mortality of acetaminophen-related FHF is
also higher in this patient population. Halothane hepatitis
is an example of an immunoallergic drug reaction.
Metabolites of halothane, an inhalational anesthetic agent,
are recognized as antigenic, and an autoimmune response
occurs that results in cross-reactivity with hepatic tissue.
This is a rare but severe reaction. More commonly, mild
postoperative increases in hepatic transaminases can be
seen with the use of halothane and other inhaled agents
such as isoflurane. This reaction is less severe, self-limited,
and is the result of indirect toxicity due to decreased
hepatic blood flow that occurs with inhaled anesthetics.
Isoniazid and tricyclic antidepressants are classic exam-
ples of drugs whose metabolites are hepatotoxic. They are
potentially dangerous to administer in combination with
drugs that induce the cytochrome p450 system.
CLINICAL CAVEAT
Acetaminophen serum levels do not reliably indicate
the degree or severity of hepatotoxicity. If an overdose
is suspected, N-acetylcysteine should be administered
immediately.
Table 27-1 Etiologies of Cirrhosis
Parenchymal Disease Cholestatic Disease
Chronic hepatitis C* Primary biliary cirrhosis
Ethanol or Leannec’s cirrhosis* Primary sclerosing cholangitis
Nonalcoholic steatohepatitis Neoplasm of bile ducts or
(NASH)* pancreas
Chronic hepatitis B Chronic biliary obstruction
Other drugs or toxins, e.g., due to stone/stricture
methotrexate and isoniazid Cystic fibrosis
Hemochromatosis
Wilson’s disease
Alpha-1-antitrypsin deficiency
Chronic congestive heart failure
or pericarditis with hepatic
venous congestion
Cryptogenic
Autoimmune
Polycystic liver disease
* These three etiologies comprise 80% of all causes of cirrhosis.
Table 27-2 Etiologies of Fulminant Hepatic Failure
Predominant Causes* Other Causes
Viral hepatitis Acute fatty liver of pregnancy Reye’s syndrome
Acetaminophen toxicity Autoimmune hepatitis (initial Primary graft nonfunction following liver
(attempted suicide, intentional/ presentation) transplantation
unintentional overdose) Vascular abnormalities (Budd Chiari or Other infectious cause (other viruses,
Other drug reactions/toxicities other hepatic veno-occlusive disease) tuberculosis)
Cardiac failure; eclampsia; ischemia Toxins: Amanita phylloides, organic solvents,
(hypotension, heat stroke) herbal medications (ginseng,
Lecithin-cholesterol acyl transferase deficiency pennyroyal oil), bacterial toxins
Malignant infiltration (primary or metastatic) (B. cereus, cyanobacteria), Ecstasy
Wilson’s disease (initial presentation) (methyldioxymethamphetamine), cocaine
* Approximately 15–20% of causes are indeterminate.
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The list of drugs that can result in hepatotoxicity is an
exhaustive one that will not be covered here. There are,
however, certain clinical indicators that are helpful to
consider when assessing whether or not drug toxicity is
the etiology of hepatic failure. These include the presence
of an acute process (drug toxicity is rarely chronic in
nature), ruling out other etiologies of liver disease and
specific chronological parameters. The time interval
between use of the drug and the onset of hepatic toxicity
is generally 1 week to 3 months. Resolution or improve-
ment of liver disease after withdrawal of the suspected
agent or worsening of disease after accidental use of the
drug are also suggestive chronologic markers. Table 27-4
lists the remainder of commonly observed positive clini-
cal criteria associated with drug-induced hepatotoxicity.
CLASSIFICATION OF SEVERITY OF
CIRRHOSIS AND FULMINANT HEPATIC
FAILURE
Cirrhosis
The Child-Pugh score (CPS) is the most commonly
used classification scale for cirrhotic patients. Survival
has been shown to be inversely related to the CPS.
Patients with 10 points usually require frequent medical
checkups. Patients with 12 points regularly require 
hospitalization for management of decompensated liver
disease. Patients with 13–14 points generally require
management in the intensive care unit (see Table 27-5).
The Model End Stage Liver Disease or MELD score has
currently been adopted by the United Network for
Organ Sharing (UNOS) as an alternative to the CPS sys-
tem. UNOS is the national organization that assigns list-
ing status for organ allocation to recipients based on
disease severity. The MELD is calculated using a formula
with three primary variables which include serum crea-
tinine, total bilirubin, and international normalized ratio
(INR). The formula for the MELD score and its correla-
tion with the former CPS-based UNOS listing criteria are
shown in Table 27-6.
Fulminant Hepatic Failure
Table 27-7 shows prognostic indicators that are asso-
ciated with adverse outcomes in patients with FHF.
These variables were obtained from King’s College
Hospital in London, UK, and since their introduction in
1989 they are the most widely utilized FHF criteria. In
patients with acetaminophen toxicity the presence of a
single indicator is associated with a mortality rate of
at least 55%. The presence of severe acidosis in aceta-
minophen patients carries a mortality rate of 95%. The
presence of a single indicator in nonacetaminophen
patients is associated with an 80% mortality rate, and the
presence of three indicators carries a mortality rate of
greater than 95%. All of these respective mortality rates,
however, vastly exceed perioperative mortality rates
associated with liver transplantation.
DRUG INTERACTION
● Isoniazid and rifampin: rifampin is a potent p450
induction agent and greatly increases the quantity of
hepatotoxic metabolites generated by isoniazid.
● Barbiturates and tricyclic antidepressants (TCAs),
e.g., Amitryptilline: barbiturates such as sodium
thiopental are potent inducers of cytochrome p450
and greatly increase the metabolism of TCAs with a
subsequent increase in hepatotoxic TCA
metabolites.
Table 27-3 Mechanisms of Drug Toxicity*
Direct toxicity (dose related)
Drug metabolite toxicity
Immunoallergic
Idiosyncratic reactions (sporadic and not dose related)
* Idiosyncratic reactions are most common.
Table 27-4 Positive Clinical Criteria for
Drug-Induced Hepatotoxicity
Age > 50 years
Polypharmacy
Use of known hepatotoxic drugs or toxins
Drug serum levels (e.g., acetaminophen)
Specific serum autoantibodies
Specific liver biopsy findings (e.g., drug deposits, eosinophilic
infiltration)
Table 27-5 Child-Pugh Scoring System
1 Point 2 Points 3 Points
Serum albumin >3.5 2.8–3.5 <2.8
(g/dl)
INR <1.7 1.7–2.3 >2.3
Ascites None Slight or diuretic Moderate or
controlled severe
Encephalopathy None Mild or moderate Severe
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DIAGNOSTIC STUDIES
Laboratory Testing
Specific laboratory tests are ordered routinely for
patients with suspected or documented cirrhosis and/or
FHF. Certain results can detect treatable chronic liver
disease before significant decompensation occurs. These
tests also facilitate care of FHF patients and help rule out
specific FHF etiologies. A complete blood count can
reveal anemia secondary to splenic sequestration, GI
hemorrhage, or decreased erythropoietin production in
the setting of hepatorenal syndrome. Thrombocytopenia
may present secondary to splenic sequestration, bone
marrow suppression, disseminated intravascular coagu-
lation, or massive hemorrhage. Elevated white blood cell
count (WBC) can present with infectious processes such
as spontaneous bacterial peritonitis (SBP). A full liver
panel is routinely obtained with subsequent serial meas-
urements. It is important to note that serum AST and
ALT levels may not be elevated in cirrhotic patients due
to extensive hepatocyte destruction and subsequent
decrease of transaminase production. Prolonged pro-
thrombin time (PT)/INR and partial thromboplastin time
(PTT) generally result from decreased synthesis of clot-
ting factors by the liver. Poor absorption of fat-soluble
vitamin K due to altered bilirubin excretion and poor
nutritional intake of vitamin K are other factors to con-
sider when evaluating for a coagulopathy. The degree of
PTT abnormalities tends to parallel PT/INR abnormalities
in patients with acute or chronic liver disease.
Serologic testing for viral hepatitis is routine for
patients with evidence of chronic or acute hepatic dis-
ease. Quantitative DNA and RNA tests for hepatitis B and
C, respectively, are now commonly obtained if antigen
or antibody tests are positive. Hepatitis B quantitative
DNA testing has largely replaced the e antigen test. Serial
measurements of serum electrolytes and glucose levels
are also routinely obtained. Cirrhotic patients may pres-
ent with decreased serum potassium and magnesium lev-
els secondary to chronic diuresis. Hypocalcemia may be
present with advanced renal dysfunction due to hepa-
torenal syndrome or in the setting of citrate toxicity sec-
ondary to blood product administration. Hypoglycemia
can occur with malnourishment or with impaired gluco-
neogenesis and glycogenolysis at the hepatocyte level.
Hyperglycemia can be seen in patients with cirrhosis
secondary to NASH who often exhibit insulin resistance.
Hyponatremia is a common clinical entity in cirrhotic
patients due to either chronic diuresis or an overall total
body hypervolemic state. Table 27-8 outlines the remain-
der of standard laboratory screening tests obtained in the
setting of acute or chronic liver disease.
CLINICAL CAVEAT
Chronically cirrhotic patients are unlikely to
respond to vitamin K administration for the treatment
of coagulopathy secondary to nonfunctioning
hepatocytes with impaired synthetic ability.
CURRENT CONTROVERSY
Some clinicians advocate the use of CT-guided
hepatic volumetry and liver histology, i.e., parenchymal
necrosis of greater than 50% as prognostic indicators
for FHF. The practicality of these measures has been
questioned due to bleeding risk with hepatic biopsy
and the difficulty of transporting critically ill patients
for CT evaluation.
Table 27-6 MELD Score and UNOS Status
UNOS
MELD* Status Comments
< 24 3 CPS > 7 and requires continuous medical
surveillance
24–29 2b CPS > 10 or CPS > 7 with at least one of the
following criteria: significant variceal
hemorrhage, hepatorenal syndrome, SBP, or
refractory ascites
> 30 2a End-stage chronic liver disease with CPS > 10
and life expectancy < 7 days
1 FHF with life expectancy < 7 days, primary
nonfunction of liver transplant within
7 days, hepatic artery thrombosis within
7 days of liver transplant
* Maximum MELD score is 40. MELD score formula: 10[0.957(Cr) + 0.378(Tbili)
+ 1.12(INR) + 0.643].
Table 27-7 King’s College Hospital Criteria
Acetaminophen Nonacetaminophen 
Patients Patients
pH < 7.30 Age <10 years or >40 years
INR > 6.50 INR > 3.5
Serum creatinine > 3.4 mg/dl Etiology: non-A and non-B 
in patients with stage 3 or hepatitis, halothane hepatitis,
4 encephalopathy drug/toxin mediated
Duration of jaundice > 1 week
before the development of 
encephalopathy
Serum bilirubin > 18 mg/dl
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Imaging Studies
Ultrasonography is the least invasive, least expensive,
and most widely utilized imaging modality in the man-
agement of acute and chronic liver disease. Assessing the
size of both the spleen and portal vein and the presence
of ascites or tumor are the primary concerns when per-
forming abdominal ultrasonography. Maximum spleen
dimension greater than 12 cm or a portal vein diameter
greater than 13 mm are suggestive of portal hyperten-
sion. Doppler scanning is also used to observe vascular
flow and can detect thromboses. Although cholelithiasis
is detected in approximately one-third of cirrhotic
patients, they are generally asymptomatic.
Computed tomography (CT) scans are also commonly
obtained for cirrhotic patients. This modality involves
radiation and usually the addition of an intravenous con-
trast agent. It is also more expensive. Spiral CT is cur-
rently the preferred method due to its superior scanning
speed and decreased artifact.
Esophagogastroduodenoscopy (EGD) is used as both
a diagnostic tool and treatment modality in the manage-
ment of esophageal varices. This is discussed in more
detail later in this chapter. Colonoscopy is commonly
performed as a part of the pretransplantation evaluation.
It is generally not performed in nontransplantation
candidates.
Imaging-guided liver biopsy can be performed to doc-
ument the presence of cirrhosis, to assess the etiology of
hepatic disease, and to evaluate the severity of hepatic
injury. Percutaneous approaches are associated with
higher morbidity in the setting of ascites or coagulo-
pathy. Transjugular biopsy can be performed if the biopsy
is required, and the patient is in a high-risk category.
CLINICAL MANIFESTATIONS 
OF CIRRHOSIS AND FULMINANT
HEPATIC FAILURE
Encephalopathy
Hepatic encephalopathy or portasystemic
encephalopathy (PSE) is the second most common com-
plication of cirrhosis, developing in approximately 28%
of patients within 10 years after the diagnosis of decom-
pensated disease. It can also be present in FHF and
becomes clinically apparent as liver function progres-
sively worsens. Encephalopathy is due primarily to
shunting of toxins past the liver and into the systemic
circulation. In the setting of FHF, however, the greater
concern is that many patients develop cerebral edema
with the potential for increased intracranial pressure,
cerebral herniation, and subsequent brain death. The
pathogenesis of this cerebral edema has not been
completely elucidated, but both vasogenic and cytokine-
mediated mechanisms have been proposed. In general,
vasogenic edema results from a breakdown in the
CURRENT CONTROVERSY
The practice of performing colonoscopy in hepatic
transplant candidates is controversial and not
supported by some data. Polypectomy in the presence
of ascites can lead to an increased risk of colonic
perforation.
CLINICAL CAVEAT
Cholecystectomy is to be avoided in cirrhotic
patients. Mortality rates associated with this procedure
in the cirrhotic patient population have been reported
as high as 80% in some studies.
CLINICAL CAVEAT
Some degree of hyponatremia should be tolerated in
cirrhotic patients. Aggressive replacement of sodium
with excessive fluids can precipitate central pontine
myelinolysis or volume overload with pulmonary edema.
Table 27-8 Laboratory Screening Tests
Laboratory Test Etiology
Serum iron, ferritin, Elevated with hemachromatosis
iron saturation
Antinuclear and smooth Present with autoimmune
muscle antibodies hepatic disease
Antimitochondrial Present with primary biliary
antibodies cirrhosis
Ceruloplasmin levels Elevated with Wilson’s disease
Alpha-1-antitrypsin Present with alpha-1-antitrypsin
phenotype deficiency
Alpha-fetoprotein Increased with hepatocellular
carcinoma
CLINICAL CAVEAT
The use of a contrast agent should be avoided if the
serum creatinine is 2 mg/dl or greater.
blood–brain barrier that allows passage of plasma con-
tents into the brain parenchyma.
The grades of hepatic encephalopathy are listed in
Table 27-9. Grades I and II have a better prognosis com-
pared to grades III and IV with respect to progression to
cerebral edema, especially in patients with FHF. Elective
intubation and mechanical ventilation is often per-
formed in patients who progress to grade III
encephalopathy.
In cirrhotic patients encephalopathy can develop
spontaneously as liver disease progressively worsens or
it can be unmasked by certain medications such as seda-
tives or narcotics, polysubstance abuse, or other precip-
itating factors. These factors include infections (e.g.,
spontaneous bacterial peritonitis), GI bleeding, dehydra-
tion, or hypokalemia. The treatment of these underlying
disturbances or the removal of the offending factor usu-
ally rapidly reverses PSE symptoms.
The primary therapy for PSE is lactulose.
Approximately 90% of patients with PSE will respond to
lactulose in combination with the correction of a coex-
isting precipitating factor. Patients who are refractory to
lactulose therapy can be treated with oral neomycin in
combination with lactulose. Serial serum ammonia levels
and dietary protein restriction are also commonly initi-
ated in the treatment of PSE.
As stated previously, patients with grades III and IV
encephalopathy, especially those with FHF, are at higher
risk for the development of cerebral edema. A prolonged
intracranial pressure (ICP) greater than 40 mmHg or a
prolonged cerebral perfusion pressure (CPP) less than
50 mmHg have been associated with poor neurological
recovery.
Treatment of elevated ICP is managed primarily with
mannitol, although no single agent has been shown to
benefit all patients. Corticosteroids have not been
shown to have clinical efficacy. N-acetylcysteine has
been shown to improve neurological outcome in
patients with acetaminophen toxicity. Some clinicians
advocate the use of pentobarbital with continuous EEG
monitoring for burst suppression. However, the use of
this agent is controversial due to the risk of barbiturate-
induced leukocyte suppression and hypotension.
CURRENT CONTROVERSY
Some clinicians consider a CPP below 40 mmHg for
longer than 1 hour a contraindication for liver
transplantation. However, there have been multiple
case reports of patients making full neurologic
recoveries following prolonged episodes (24–38 hours)
of severely impaired CPP.
CURRENT CONTROVERSY
Recent literature has shown that cirrhotic patients
are at times inappropriately hospitalized or experience
longer hospital stays due to asymptomatic elevated
serum ammonia levels. Other clinicians have shown
that protein restriction can actually worsen PSE
symptoms due to aggravation of malnutrition in
cirrhotic patients.
CLINICAL CAVEAT
Overdosing of lactulose via oral route, nasogastric
tube, or enema can lead to complications such as
hypernatremia, central nervous system demyelination
with rapid increases in serum sodium levels, or
permanent coma. It is important for clinicians to be
patient in assessing response to lactulose
administration.
CLINICAL CAVEAT
Sedatives and/or narcotics should be specifically
avoided or minimized in cirrhotic patients with the
exception of advanced hepatocellular carcinoma or the
perioperative setting.
CLINICAL CAVEAT
Although cerebral edema has been implicated
primarily in FHF, there have been a significant number
of reports concerning cerebral edema in cirrhotic
patients with severe PSE.
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Table 27-9 Grades of Portasystemic
Encephalopathy
Grade Mental Status
I Restless, mild confusion
II Lethargic, inappropriate behavior
III Somnolent but rousable, incoherent speech
IV Comatose
Propofol has been proposed as an alternative to barbi-
turates, but there has been associated hypotension,
increased cost, and no discernible clinical advantage
with this agent. Hyperventilation is in general currently
avoided due to critical decreases in cerebral blood flow
seen with this intervention. There are also now new data
to support the institution of mild hypothermia (35°C) in
this patient population. Mild hypothermia significantly
decreases cerebral metabolic rate and can be utilized 
as a bridge to transplantation or in the intraoperative
transplant setting to improve neurological outcome.
Hyperthermia and hyperglycemia should be specifically
avoided because of poorer neurological outcomes asso-
ciated with these specific clinical factors.
Cardiovascular Manifestations
A hyperdynamic circulation with elevated cardiac
output and decreased systemic vascular resistance (SVR)
develops in 30–60% of all patients with cirrhosis. A sim-
ilar circulatory disturbance with concomitant hypoten-
sion is also common in the setting of FHF. Ultimately,
this circulatory state makes hemodynamic parameters
difficult to evaluate. Elevated levels of circulating vaso-
pressors and vasodilators with the balance in favor of
vasodilation is thought to be the mechanism of the
hyperdynamic circulation and pressor resistance seen 
in both the cirrhotic and FHF population. Cirrhotic
patients tend to have impaired contractility in response
to physiologic stress, and those with ascites have been
shown to manifest small degrees of diastolic dysfunc-
tion. Cardiac dysrhythmias, decreases in tissue oxygen
uptake, and development of arteriovenous shunts may
also develop. Intravascular volume depletion is also a
common finding in both chronic and acute liver disease
due to GI hemorrhage, production and replacement of
protein-rich ascites, and/or chronic diuresis.
Pulmonary Manifestations
Pulmonary dysfunction is common in the setting of
FHF and cirrhosis. Pneumonia and acute respiratory 
distress syndrome (ARDS) are the most common pul-
monary manifestations in the FHF population. Some
studies have reported rates of ARDS as high as 33% in
cases of acetaminophen toxicity. The development of
ARDS in the setting of FHF is also associated with high
mortality rates. Chronically debilitated cirrhotic patients
are prone to pulmonary dysfunction due to atelectasis,
obstructive airway disease, aspiration, and pleural effu-
sions. In addition, severe ascites with abdominal disten-
tion predisposes these patients to early airway closure
and a restrictive pattern of lung disease. Cirrhotic
patients also manifest vascular pulmonary disease in the
form of intrapulmonary vasodilations (IPVDs), true
shunting, and potentially portopulmonary hypertension.
Hepatopulmonary syndrome is defined as hypoxemia
that is caused by IPVDs or intrapulmonary shunts. This
hypoxemia is often the result of impaired diffusion of
oxygen across the significantly dilated capillary. Oxygen
does not effectively penetrate this widened stream of
blood, and thus part of the stream circulates through
deoxygenated and is essentially shunted. True anatomic
shunts are much less common and are usually porto-
pulmonary. Treatment with 100% oxygen increases the
driving force of oxygen through the capillary bed and
usually is effective therapy. The supine position is also
surprisingly helpful due to the shifting of blood to the
apices where IPVDs and shunting are less common. The
pathophysiology of hepatopulmonary syndrome is
thought to be due to vasodilatory vasoactive mediators,
most likely nitric oxide and endothelin, which are
shunted into the systemic circulation secondary to portal
hypertension.
Portopulmonary hypertension secondary to or in con-
junction with hepatopulmonary syndrome is a concern-
ing condition in patients with end-stage liver disease.
This population experiences much higher perioperative
mortality rates when undergoing hepatic transplanta-
tion. Pulmonary hypertension is defined as a mean pul-
monary artery pressure of 25 mmHg or greater with a
pulmonary capillary wedge pressure less than 15 mmHg
or, as an alternative, a pulmonary vascular resistance (PVR)
CURRENT CONTROVERSY
Monitoring of ICP in the setting of advanced
encephalopathy is controversial, although many
clinicians advocate its use. Identifying patients with
severely elevated ICP and decreased CPP allows the
rejection of transplant candidates who are higher risk
of intraoperative brain death. The use of CT scanning
and clinical signs such as papilledema are also much
less sensitive for detecting increased ICP in this patient
population. Some clinicians avoid ICP monitoring due
to the increased risk of intracranial hemorrhage,
especially with ventriculostomies.
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CLINICAL CAVEAT
The incidence of coronary artery disease in
transplant recipient patients older than 50 years has
been shown to be in the range 5–27%. These patients
require aggressive initial and subsequent continued
cardiac evaluation.
of greater than 120 dynes/cm/s5. In general, transplant
candidates with mean pulmonary arterial pressures
greater than 35–50 mmHg are rejected on the basis of
significantly increased risk of perioperative death.
Gastrointestinal Manifestations
Ascites is a common GI manifestation of cirrhosis, and
it occurs secondary to elevated portal pressures and vol-
ume overload with subsequent leakage of excess fluid
across the liver capsule. The two-year survival rate in 
cirrhotic patients who develop ascites is approximately
50%. The cornerstones of treatment are dietary sodium
restriction and diuresis. Diuretics increase urine sodium
excretion which is generally reduced in cirrhotic
patients. A combination of potassium sparing and wast-
ing diuretics is often chosen to maintain normokalemia.
In addition, cirrhotic patients usually have significantly
elevated aldosterone levels, and spironolactone is gener-
ally thought of as the single best diuretic in this popula-
tion because of its antialdosterone activity. If ascites
becomes diuretic resistant, the patient is often given a
diagnosis of prehepatorenal syndrome which carries a
mortality rate of approximately 50% within 6 months of
onset.
If ascites is diuretic resistant, large-volume paracentesis
is generally performed. Many studies have now demon-
strated the safety of this technique, and it can generally be
performed every 2 weeks. It should, however, be reserved
for those patients who are truly diuretic resistant.
The transjugular intrahepatic portosystemic shunt
(TIPS) is also utilized in the management of intractable
ascites. This procedure is performed by an interven-
tional radiologist and is generally indicated for diuretic-
resistant ascites, variceal bleeding not responsive to
other forms of therapy, and hepatorenal syndrome.
CURRENT CONTROVERSY
Some clinicians advocate albumin infusions
following large-volume paracentesis due to removal of
proteins that cannot be easily synthesized and replaced
by the cirrhotic liver. Many studies, however, have not
shown a difference in mortality rates with this
approach. Other studies that show a benefit have been
criticized as regards their design.
CURRENT CONTROVERSY
Some clinicians argue that patients with mean
pulmonary artery pressures in the range 35–50 mmHg
should be risk stratified between PVR values of greater
or less than 250 dynes. There are data to support
proceeding with transplantation in patients who have
resistance of less 250 dynes in this population. Certain
clinicians also advocate a pharmacologic challenge in
this setting with agents such as nitric oxide or
prostaglandin E1 to assess responsiveness of the
pulmonary vasculature. A decrease in mean pressure or
PVR by 20% or greater is cited as a favorable response.
Patients with mean pulmonary arterial pressures of
greater than 50 mmHg and a PVR of greater than 250
dynes are usually not accepted as hepatic transplant
candidates.
There is also debate regarding whether or not
portopulmonary syndrome and hepatopulmonary
syndrome are completely separate entities. Some
clinicians argue that pulmonary hypertension develops
as a result of chronic hypoxemia in the setting of
hepatopulmonary syndrome. Others claim that
portopulmonary hypertension develops independently
due to a pulmonary vasoconstrictive process, whereas
hepatopulmonary syndrome is exclusively a pulmonary
vasodilatory phenomenon.
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DRUG INTERACTION
Due to the intravascular volume depletion seen with
these agents, diuretics can often potentiate
hypotension that occurs with the use of both inhaled
and intravenous anesthetic agents, e.g., isoflurane and
propofol. Hyperkalemia can also be seen with the use
of spironolactone, and serum potassium levels should
be checked prior to administration of succinylcholine.
The transient increase of serum potassium seen with
succinylcholine use may be dangerously high with this
drug combination.
CURRENT CONTROVERSY
TIPS has been criticized by some clinicians because
of poorer survival rates shown to be associated with
this intervention. Although it is less invasive than an
open surgical shunt, there is also a relatively high risk
of complications with the procedure. These include
hemorrhage, shunt obstruction, and a 25% incidence of
encephalopathy. The mortality rate directly related to
this procedure has also been quoted as high as 10%.
TIPS is, however, preferred by some clinicians who
utilize it as a bridge to liver transplantation, and some
studies have shown that TIPS improves outcomes in
decompensated cirrhotic patients who undergo
nontransplant surgical procedures. New stent grafts
have also been used with lower complication rates in
some studies.
Variceal bleeding is the third most common compli-
cation of cirrhosis, and the distal esophagus is the usual
site of variceal hemorrhage. Interestingly, more than
50% of patients with known liver disease develop hem-
orrhage from lesions other than varices such as portal
hypertensive gastropathy. Variceal bleeding carries a
high mortality rate and emergency treatment is crucial.
Fluid resuscitation with crystalloid and blood products is
essential for initial treatment; however, over-transfusion,
i.e., hemoglobin greater than 10 g/dl or excessive use of
plasma expanders may increase portal pressures and
exacerbate variceal bleeding and/or ascites. Orogastric
lavage is also performed to confirm GI source of bleed-
ing and to clear clots and frank blood in preparation for
endoscopy. Endoscopic management of variceal hemor-
rhage is now done primarily with band ligation, and this
approach has been shown to be superior to sclerotherapy.
Balloon tamponade is usually reserved for massive bleed-
ing that cannot be seen well enough to treat directly.
Reducing portal pressure with agents such as octreotide
and somatostatin is also routinely carried out. These agents
are generally used in combination with endoscopic
therapy because of high re-hemorrhage rates when they
are used as sole therapy.
In contrast to cirrhotic patients, GI bleeding in the
setting of FHF is due primarily to stress ulceration and
coagulopathy. H2 antagonists are commonly adminis-
tered to prevent and treat this clinical entity.
Somatostatin and octreotide are usually avoided in this
setting to prevent additional decrease in portal blood
flow to the acutely failing liver. Pancreatitis can also
occur with FHF but is not generally a contraindication to
transplantation unless there is a necrotizing component.
Approximately 50% of cirrhotic patients who present
with variceal bleeding will experience a repeat hemor-
rhage. Secondary prevention of rebleeding involves
weekly endoscopic banding until varices are obliterated.
Surveillance endoscopy is then performed every 3 months.
As noted earlier, TIPS is utilized by some clinicians for
the management of variceal hemorrhage that is refractory
to endoscopic treatment. This again is a controversial
procedure primarily because of its relatively high com-
plication rate. Newer shunts are being investigated for
this indication.
SBP is a common and potentially fatal complication of
cirrhosis. It is defined as the abrupt onset of bacterial
peritonitis without any external or intra-abdominal
source of infection. Colonization is thought to be pre-
cipitated by decreased immune-mediated opsonization
of organisms in the ascitic fluid or by bacterial transloca-
tion across the intestinal wall. Cirrhotic patients with GI
bleeding, FHF, recent history of invasive procedure, or
severely elevated bilirubin concentrations have been
shown to be at a higher risk for this condition. SBP pres-
ents without abdominal symptoms in approximately
one-third of patients. GI bleeding, encephalopathy, and
DRUG INTERACTION
Beta-blockers can potentiate the cardiovascular
instability seen with most anesthetic agents, especially
in the relatively hypotensive and vasodilated cirrhotic
patient. Beta-blockade can also compromise
hemodynamic compensatory mechanisms that are
critical for patients undergoing liver transplantation.
CURRENT CONTROVERSY
Beta-blockers, with their ability to reduce portal
hypertension, have been convincingly shown to
prevent a first bleeding episode in patients who have
documented varices. Their use in rebleeding
prevention is controversial. Although these medications
have been shown to reduce repeat hemorrhage,
compliance with these drugs is an issue due to
exacerbation of fatigue and hypotension seen in
cirrhotic patients. There are also data to suggest that
beta-blockade does not reduce overall mortality rates in
patients at risk for rebleeding. New studies looking at
rebleed rates have shown that certain subsets of
patients may respond to combination drug therapy
consisting of beta-blockade and isosorbide mononitrate.
These responders were identified by significant
reductions in hepatic venous pressure gradients while
taking combination therapy.
CLINICAL CAVEAT
Placement of an orogastric tube may initially worsen
variceal bleeding or rupture additional varices with
passage through the esophagus. These tubes should
generally be softened with warm water and lubricated
to minimize this risk. If the tube is placed through the
nose, a vasoconstrictive agent should also be added
through the nares to minimize potential trauma and
additional hemorrhage.
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CLINICAL CAVEAT
Nonsteroidal anti-inflammatory drugs should be
strictly avoided in cirrhotic patients. Even a single
aspirin can trigger a fatal GI bleed in this patient
population. Many clinicians advocate the use of
acetaminophen as long as the total daily dose does not
exceed 3000 mg.
worsening renal insufficiency may be the only symptoms
present. Diagnosis of SBP is confirmed by an ascitic fluid
cell count of greater than 250 PMN/mm3 or a pure
growth positive bacterial culture. Cultures are positive
in approximately 50–75% of patients. The most common
organisms (70%) are aerobic Gram negatives with E. coli
and klebsiella predominating. The remaining 30% are
Gram-positive cocci with S. pneumonia predominating.
The recommended treatment is appropriate intravenous
antibiotic therapy.
Renal Manifestations
Hepatorenal syndrome (HRS) is the most common
manifestation of renal disease in cirrhotic patients and
can also be seen in the setting of FHF. Other etiologies
of renal dysfunction can also be seen in both chronic
and acute liver disease. Simultaneous hepatic and renal
damage can occur due to systemic conditions such as
collagen vascular disease or amyloidosis. Acute tubular
necrosis can be seen with acetaminophen toxicity and in
the setting of FHF. Prerenal azotemia is common in cir-
rhotic patients secondary to chronic diuresis or multiple
large-volume peritoneal taps. Intrinsic renal disorders
can also be seen with certain liver diseases such as the
association between IgA nephropathy and alcohol-
induced cirrhosis and the link between glomerulo-
nephritis and hepatitis B and C.
HRS is a diagnosis of exclusion and other clinical enti-
ties including GI bleed, SBP, nephrotoxic agents, and
hypovolemia must be ruled out before assigning the
diagnosis. There are two distinct clinical patterns of HRS
that are generally recognized. Type 1 HRS is usually seen
in the FHF population or in cirrhotic patients who
acutely decompensate. It is characterized by a doubling
of the initial serum creatinine to a level greater than
2.5 mg/dl or a 50% reduction in the 24-hour creatinine
clearance to a level lower than 20 ml/minute in less than
2 weeks. Type 2 HRS is recognized as the more chronic
form of the disease and occurs in relatively compensated
patients with refractory ascites. Renal function generally
worsens over months. Urinary parameters of HRS
include urine volume of less than 500 cm3/day and urine
sodium of less than 10 mEq/day. However, there are well-
documented cases of nonoliguric forms of HRS and cases
with significantly increased urine sodium excretion.
Although the pathophysiology of HRS is complex and
controversial, it is generally thought to be due to renal
vasoconstriction that occurs in response to splanchnic
vasodilation and increased intra-abdominal pressure from
ascites. Activation of the renin–angiotensin–aldosterone
system with simultaneous decreases in renal prostaglandin
production results in the observed renal vasoconstric-
tion. Some clinicians have hypothesized a hepatorenal
sympathetic reflex that occurs secondary to portal
hypertension as the initiating factor. The mechanism of
systemic and splanchnic vasodilation has multiple
hypotheses that include increased levels of nitric oxide
(NO), endotoxins, and bilirubin, and elevated levels of
cytokines such as tumor necrosis factor and interleukin
(IL)-1 and IL-6. Others have proposed the hypothesis of
elevated NO levels in the splanchnic circulation with
concomitantly low levels of NO present in the portal 
circulation.
Treatment of HRS focuses initially on treatment of
refractory ascites, especially in type 2. This can be done
by large-volume paracentesis, although smaller volumes
have been advocated due to potential intravascular vol-
ume depletion. The use of selective renal prostaglandins
has shown no direct benefit. The use of vasopressin ana-
logues such as ornipressin for splanchnic vasoconstric-
tion with or without intravascular volume loading has
shown some positive results when used over a period of
time greater than 1 week. A TIPS procedure is advocated
by some clinicians, but, as noted previously, this inter-
vention is controversial and has a significant compli-
cation rate. Hemodialysis or continuous veno-veno hemo-
filtration (CVVH) can be used as a bridge to transplant.
CVVH offers more hemodynamic stability in this setting
and also has been shown to reduce vasopressor require-
ments. Liver transplantation is the definitive therapy 
for HRS. The diagnosis of HRS, however, carries with it
a significant increase in perioperative hepatic transplant
mortality rates, especially in patients with a serum 
creatinine > 2 mg/dl. Renal function may not return to 
normal after transplantation in the setting of HRS, espe-
cially with the use of nephrotoxic immunosuppressive
medications in the postoperative setting.
CLINICAL CAVEAT
Nonsteroidal anti-inflammatory drugs should be
strictly avoided in any patient with acute or chronic
liver disease due to concerns of impaired renal
function. These medications can decrease already
significantly reduced levels of vasodilating
prostaglandins and promote additional renal
vasoconstriction.
CLINICAL CAVEAT
Although the Gram stain of ascitic fluid is positive
in 30% of cases, the result of the Gram stain does not
correlate with culture growth in about one-third of
those cases.
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Coagulation Manifestations
There are multiple mechanisms of coagulopathy in
the setting of acute and chronic liver disease.
Thrombocytopenia can occur due to blood loss, seques-
tration in liver and spleen, disseminated intravascular
coagulation (DIC), or autoimmune destruction. Platelet
dysfunction is also common. Vitamin K-dependent 
factors are often depleted secondary to malnutrition,
decreased synthesis, impaired fat absorption, or blood
loss. Essentially all of the factors, both pro- and anti-
coagulant, involved in the clotting cascade are produced
by the liver with the exception of factor VIII and tissue
plasminogen activator (TpA). Because the liver is also
the primary site of TpA metabolism, some degree of fib-
rinolysis is always present in this patient population and
does contribute to coagulopathy.
Immunologic Manifestations
Infectious processes other than SBP are common in
patients with cirrhosis and FHF due to immunosuppres-
sion. The source of infections in both groups is most
commonly the respiratory or urinary tract. These infec-
tions predominate in FHF patients with one study find-
ing an 80% incidence. Bacteremia is also more common
in the FHF population and has been cited as high as 20%.
Defects in both humoral and cell-mediated immunity
have been seen in both populations. There is often
decreased complement production by liver in advanced
disease which results in impaired opsonization of bacte-
ria. These patients demonstrate decreased IgM activity
against Gram-negative organisms, and also develop 
reticuloendothelial dysfunction. The macrophages in the
reticuloendothelial system represent a critical filtering
mechanism for blood-borne pathogens that becomes
compromised. Bacterial translocation of viable bacteria
and endotoxins into mesenteric lymph nodes also
occurs in the setting of splanchnic hypoperfusion. This
is thought to initiate the release of multiple inflammatory
mediators.
LIVER TRANSPLANTATION
Orthotopic liver transplantation (OLT) has evolved
from an experimental treatment to the standard of care
for patients with end-stage liver disease and FHF. The
mortality rate of FHF, for example, approaches 80% for
cases in which liver transplant is not available. The
UNOS listing criteria for transplant recipients was noted
earlier in this chapter. Contraindications for liver trans-
plantation are listed in Table 27-10.
Recognized factors have emerged that are associated
with increased graft failure rates and increased recipient
mortality rates in the setting of OLT. Increasing patient
age, elevated serum creatinine, worsening UNOS status,
and female gender of the donor have all been shown to
be associated with lower recipient survival rates.
Prolonged warm ischemic times, poor clinical status of
the recipient, and female gender of the donor have been
shown to be independent risk factors for graft failure 
following transplantation.
OLT is commonly divided into three intraoperative
phases, which include the preanhepatic phase, the
anhepatic phase, and the postreperfusion or neohepatic
phase. The preanhepatic phase involves induction and
maintenance of anesthesia, endotracheal intubation with
mechanical ventilation, line placement, and ultimately
surgical dissection of the liver with removal of the organ.
Anesthetic induction generally involves a rapid-sequence
induction and intubation. Barbiturates or propofol can
be used as induction agents unless gross hemodynamic
instability is evident, and succinylcholine is also used
regularly. Despite the potential for significant decreases
in pseudocholinesterase synthesis in the setting of
advanced liver disease, metabolism of succinylcholine
has not been shown to be affected clinically with a sin-
gle intubating dose. Inhaled agents such as isoflurane or
desflurane, narcotics, and intermediate- to long-acting
muscle relaxants are the standard maintenance anes-
thetic agents of choice. Muscle relaxants that require
renal excretion are generally avoided in the setting of HRS.
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Table 27-10 Contraindications for Orthotopic
Liver Transplantation
1. Advanced cardiac or pulmonary disease including severe
pulmonary hypertension
2. Well-compensated cirrhosis without complications such as
ascites or variceal hemorrhage
3. Alcohol use in previous six months
4. Illicit drug use in previous six months
5. Extrahepatic malignancy other than skin cancer
6. Uncontrolled systemic sepsis
7. HIV positive status (controversial)
CURRENT CONTROVERSY
The presence of severely elevated ICP with
prolonged episodes of decreased CPP is a relative
contraindication to orthotopic liver transplantation. In
the past, HIV positive status represented an absolute
contraindication to liver transplantation. However, with
the increasing acceptance of HIV infection as a chronic
disease state, some transplant centers will consider
these patients as potential organ recipients.
Nitrous oxide is avoided due to associated bowel expan-
sion and the risk of potentiating air embolic events that
can occur in the setting of veno-veno bypass or vena
cava manipulation. Line placement generally consists of
at least one arterial line, pulmonary artery catheter, and
multiple large-bore access sites including a central
venous access port.
Adequate venous access is critical for all portions of the
case due to the potential for large fluid shifts, large shifts
in SVR, acute blood loss, and augmentation of preload
with surgical caval manipulation. Immediate availability of
blood products is standard throughout the procedure.
Serial arterial blood gases are monitored throughout
the case to assess acid–base and pulmonary status.
Serial complete blood counts, PT/INR, PTT, fibrinogen
levels, glucose levels, and electrolyte levels, including
calcium and magnesium, are also routinely obtained.
Thromboelastography (TEG) is variably utilized in 
transplant centers and is advocated by some clinicians.
Continuous cardiac output pulmonary artery catheters
with SvO2 capability are also commonly used for man-
agement in this patient population.
The use of transesophageal echocardiography (TEE)
is used variably in transplant centers. Many practitioners
avoid this monitor due to the potential presence and
rupture of esophageal varices.
Removal of the organ in the preanhepatic phase can
be facilitated by veno-veno bypass (VVB) or by partial
caval clamping near the hepatic vein(s) insertions also
known as “piggy backing.” There have been no data to
support the use of either technique, and this is an area
of controversy. VVB is generally performed initially from
the femoral vein to the axillary vein with subsequent
addition of the portal vein circulation. The liver is then
completely removed. VVB is not routinely performed by
some clinicians because of a higher risk of vascular
injury, hemorrhage, thrombotic complications, and air
embolus. If the partial caval clamping technique is cho-
sen, a test clamp is generally performed first to assess if
hemodynamics can be corrected with volume loading
and vasopressor support. If this test is successful, many
surgeons will proceed with “piggy backing” and remove
the liver without the use of VVB. A perfusion team,
however, is always immediately available throughout the
preanhepatic and anhepatic phases whether or not VVB
is utilized.
The anhepatic phase consists of surgical vascular anas-
tamoses of the hepatic veins to the vena cava and the
portal vein anastomosis. The primary anesthetic goals of
this period in preparation for reperfusion of the graft are
the optimization of serum potassium levels, ensuring
adequate intravascular volume, administering immuno-
suppressives, and correction of acid–base disturbances.
Serum potassium should preferably be below 4.0 mEq/l
at reperfusion because of the significant rise in serum K+
that occurs at this point in the procedure. Sodium bicar-
bonate, insulin, hyperventilation, calcium chloride, and
potassium wasting diuretics are all commonly used to
decrease serum K+ to favorable levels. Patients with
renal compromise are at particularly high risk of devel-
oping hyperkalemic complications. CVVH or dialysis can
be utilized for potassium clearance prior to graft reper-
fusion if necessary. “Venting” through the graft prior to
reperfusion has shown to decrease the degree of potas-
sium elevation in some studies, and is practiced in some
centers. This involves allowing approximately 500 cm3
of portal blood to reperfuse the liver. This blood is then
discarded.
The neohepatic phase begins with reperfusion of the
portal circulation through the liver, hepatic veins, and
vena cava. Management is focused on treatment of
postreperfusion syndrome (PRS) and any significant
hyperkalemic response. PRS is generally defined as a
mean arterial pressure that decreases greater than 30%
from baseline or that is less than 60 mmHg. This lasts
greater than 1 minute and occurs within the first 5 min-
utes of reperfusion. The pathophysiology of PRS is due
to multiple factors including a significant decrease in
SVR, relative hypovolemia, potential dysrhythmias, and
acute metabolic acidosis with subsequent pulmonary
hypertension and right and left ventricular depression.
Treatment consists of hyperventilation with 100%
inspired oxygen, volume resuscitation, and vasopressor
support. Anastamoses of the hepatic artery and the biliary
drainage procedure (Roux-en-y choledochojejunostomy
versus choledochocholedochostomy) are the remaining
surgical goals of the neohepatic phase. Anesthetic man-
agement at this point focuses on treatment of coagulo-
pathy and monitoring for signs of function of the new
graft. There are multiple mechanisms for impaired hemo-
stasis at this juncture. These include hypothermia,
hypocalcemia, metabolic acidosis, platelet consumption,
hepatic dysfunction following graft reperfusion, release
of heparin and heparin-like substances from the new
graft, and enhanced fibrinolysis secondary to increased
TpA activity with additional factor consumption.
CURRENT CONTROVERSY
There have been some data to suggest that
desflurane is associated with a lesser decrease in
splanchnic and hepatic blood flow compared to
isoflurane. Certain clinicians who advocate extubation
in the operating room at the conclusion of the case
also note that emergence time from anesthesia is
shortened with desflurane use.
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Treatment is focused on product administration (fresh
frozen plasma, packed red blood cells, platelets, cryo-
precipitate), calcium replacement, correction of
hypothermia, treatment of acidosis, and surgical hemo-
stasis. Serial measurements of platelet counts, PT/INR,
PTT fibrinogen levels, TEG (if utilized), and clinical
reports of clot or subjective coagulopathy by the surgi-
cal team are followed. Appropriate cardiopulmonary
support is provided throughout the postreperfusion phase.
Continued vasopressor administration may be necessary
due to delayed graft function or due to hypovolemia
seen with continued blood loss. Some degree of pul-
monary edema may also be present secondary to volume
overload or secondary to lung injury that can occur with
graft reperfusion and/or blood product administration.
This pulmonary injury, when it occurs, is usually tran-
sient in nature, is often associated with an exudative
edema, and generally presents within 1–2 hours after
reperfusion.
Clinical functioning of the new graft is assessed by
multiple parameters including improvement of coagu-
lopathy, decreasing vasopressor requirements, bile pro-
duction, resolution of acidosis, improved calcium and
magnesium homeostasis secondary to improved citrate
metabolism by the new graft, and decreasing levels of
serum lactate. Lactate is primarily metabolized in the
liver, and lactate levels are used as a marker of graft func-
tion in some facilities. Delayed graft function may be
seen in the setting of reperfusion injury with hepatic
congestion. Diuresis and/or nitroglycerin have been
used routinely in some centers to reduce central venous
pressures and subsequently relieve congestion of the
new graft.
Alternatives to Orthotopic Liver
Transplantation
Adult live donor liver transplantation (aLDLT) is cur-
rently being performed in certain North American trans-
plant centers. The number of adult recipients awaiting
liver transplantation has increased significantly over the
past decade. The number of adult cadaveric livers, how-
ever, has not increased proportionately, and, as a result,
waiting list times and mortality rates in this adult popula-
tion of recipients have risen dramatically. This procedure
is being offered in response to this relative organ shortage.
The use of live donor organ donation (right hepatic
lobectomy) is controversial. aLDLT does offer the advan-
tage of decreased warm and cold ischemic times for the
donated graft, and it also ensures an optimally screened,
healthy donor. However, the complex nature of the 
surgery and the potential risk to an otherwise healthy
patient bring up many clinical and ethical concerns
regarding live donation.
The size of the graft is crucial when performing
aLDLT. This is calculated by either the graft-to-recipient
weight ratio (GRWR) or the graft-to-recipient standard
liver volume ratio (GSLV). It is now generally accepted
that a GRWR of at least 1% and a GSLV of at least 50% are
safe concerning the development of a “small for size” syn-
drome. However, graft congestion in the postreperfusion
period can precipitate this syndrome despite adequate
size, especially since the right hepatic lobe has been
shown to be very susceptible to venous congestion.
There have been a significant number of biliary tract
complications in the recipient population with the
aLDLT procedure. These have been reported as high as
28–34% in some studies. Hepatic arterial thrombosis may
also be higher in this population due to the fact that
smaller vessels are used in the anastamosis. Postoperative
care of these patients should involve frequent monitor-
ing for signs of potential bile leaks or graft dysfunction
and frequent Doppler examinations of the hepatic artery
to ensure patency.
Artificial Liver
The use of bioartificial hybrid devices for the treat-
ment of liver disease as a bridge to transplant has shown
limited usefulness in randomized trials. Some studies
using plasma exchange as the primary modality have
shown increased survival times and this intervention
may have some utility as a bridge to transplantation in
critically ill patients.
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Summary
Acute gastrointestinal (GI) bleeding accounts for
300,000 hospital admissions every year in the USA alone.
Additionally, 5% of all patients admitted to the intensive
care unit (ICU) will experience clinically significant upper
GI bleeding as a complication of their primary illness.
Despite advances in care and prevention, overall hos-
pital mortality remains at 9% for those who present with
bleeding as their primary complaint and over 50% for
those whose bleeding complicates their primary diagnosis
in the ICU.
Early recognition and diagnosis, adequate resuscitation,
and proper treatment are essential in the management
of acute GI hemorrhage. Prophylactic acid suppressive
therapy in the ICU, in attempts to limit stress-related
mucosal disease, is essential in certain subsets of patients.
However, such therapy is probably being over-utilized
and represents a significant cause of morbidity and cost.
In this chapter we review the causes and presentations
of both upper and lower GI bleeding, the diagnostic and
therapeutic modalities available, and the role of acid sup-
pression therapy to prevent stress-related bleeding or
recurrent bleeding in the ICU.
DEFINITIONS
Upper gastrointestinal (UGI) bleeding is defined as
bleeding from a GI source proximal to the ligament of
Treitz – a band of muscular/fibrous tissue between the
fourth portion of the duodenum and the jejunum. UGI
bleeding remains a significant cause of morbidity and
mortality in adults despite improved practices of stress
ulcer prophylaxis and treatment of H. pylori associated
with peptic ulcer disease (PUD).
Lower GI bleeding occurs anywhere distal to the liga-
ment of Treitz to include most of the small bowel, the
colon, and anorectal area. Bleeding can present briskly
with cardiovascular compromise or slowly and intermit-
tently. Brisk bleeding typically presents with hematochezia
but it is important to note that UGI bleeding remains the
main cause of hematochezia and bleeding in the small
bowel often presents as melena.
RESUSCITATION
Resuscitation is the first priority in treating those
patients with significant GI bleeding from any source. The
degree of blood loss can be assessed as per the American
College of Surgeons classification scheme. Blood loss is
classified into four levels of severity determined by the
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clinical parameters of blood pressure, urine output, and
heart rate. Shock requiring aggressive hydration and blood
replacement corresponds to levels II and III depending
on the patient and presentation. Reversal of shock should
be accomplished with rapid infusion of IV fluids. This
may include blood and blood products but resuscitation
should not be delayed for their arrival and crystalloid
infusion should commence immediately, through a
large-bore IV, ideally before hospital admission. Once
admitted, consideration for placement of an introducer
catheter into a central vein should be made in the event
rapid large-volume fluid infusion becomes necessary.
Monitoring of central venous pressure and mixed venous
pO2 can also be helpful. Adequate urine output, resolution
of orthostatic blood pressure changes, pulse rate < 100,
supine blood pressure > 90, and level of consciousness can
all be used to assess recovery from shock (Table 28-1).
When blood is to be replaced, transfusion with packed
red blood cells is preferred. Whole blood transfusion with
O negative blood is rarely used and should be reserved for
those patients with massive blood loss who cannot be
cross-matched rapidly. Patients requiring greater than 10
units of packed red blood cells should undergo a massive
transfusion protocol and should receive fresh-frozen
plasma, platelets, and cryoprecipitate as needed. Timing
of transfusion and goal hemoglobin, platelet counts, fib-
rinogen, and international normalized ratio (INR) vary
with the presentation but generally hemoglobin should be
kept above 8 g/dl, except in heart disease where it should
be kept above 10 g/d, fibrinogen above 100 mg/dl, and
INR less than 1.3–1.5. A blood warmer should be used if a
patient is to receive more than 3 liters of fluid.
HISTORY AND PHYSICAL
A thorough history and physical examination can aid
in determining the source of GI bleeding and its etiology.
Drugs, particularly nonsteroidal anti-inflammatory drugs
(NSAIDs), and alcohol are associated with PUD and gas-
tritis. NSAIDs are associated with a two-fold increase in
the risk of bleeding and are felt to contribute to the devel-
opment of 5–25% of all gastric ulcers. Cigarette smoking
has been associated with a higher recurrence rate of PUD. 
A recent history of retching or vomiting prior to bleeding
may be indicative of a Mallory–Weiss tear. Stigmata of liver
disease and portal hypertension such as spider nevi,
palmer erythema, hepatomegaly, jaundice, asterixis, or
ascites should be looked for on examination with concern
for a variceal source of bleeding if found. Drug-induced
coagulopathies with coumadin and low-molecular-weight
heparin should be evaluated for and a history of such med-
ications sought. Recent weight loss or a change in bowel
habits may be indicative of colorectal cancer. A history of
diverticular disease, prior malignancy, inflammatory
bowel disease, or significant vascular disease can aid in
determining a diagnosis in lower GI bleeding. Crampy
abdominal pain out of proportion to examination findings
occurring after meals followed by hematochezia may indi-
cate mesenteric ischemia.
UPPER GASTROINTESTINAL BLEEDING
UGI bleeding is defined as bleeding from a GI source
proximal to the ligament of Treitz. It is more common than
lower GI bleeding, accounting for 1–2% of all hospital
admissions in the USA per year. Despite improvements in
care and prevention, mortality and morbidity statistics have
not improved in the last 20 years. The increased use of
NSAIDs has probably contributed to an increase in the
number of patients presenting with UGI bleeds, though
their use has not been associated with worsening outcome.
UGI bleeding is often encountered in the critically ill
complicating other primary diseases. Clinically impor-
tant stress-related UGI bleeding is seen in only 1–4% of
the critically ill; however, the death rate exceeds 50% in
this group. Within 24 hours of admission to the ICU,
75–100% of patients will demonstrate endoscopic evi-
dence of mucosal damage and most will have at least
occult bleeding making prophylactic acid suppression a
necessary part of ICU therapy. Studies have shown, how-
ever, that there is benefit with acid suppressive therapy
only in patients who are mechanically ventilated for pro-
longed periods, have coagulopathies, recent prior bleed-
ing from PUD, major head trauma, or significant burns.
Thus acid suppressive therapy should be reserved for
these subsets of patients only.
Diagnoses and Management
Presentation of Bleeding
Patients with upper GI bleeding typically present
with hematemesis and melena. Nasogastric tube (NGT)
Table 28-1 Classification of Hemorrhage Based
on Extent of Blood Loss
Parameter Class I Class II Class III Class IV
Loss of blood <15 15–30 30–40 >40
volume (%)
Pulse rate <100 >100 >120 >140
Supine blood Normal Normal Decreased Decreased
pressure
Urine output >30 20–30 5–15 <5
(ml/hour)
Mental status Anxious Agitated Confused Lethargic
Committee on Trauma: Advanced Trauma Life Support Student Manual,
Chicago: American College of Surgeons, 1989, p 57.
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aspiration often shows “coffee-ground” material or
bright red blood. If reflux through the pylorus is absent
gastric aspiration can be negative, despite significant
bleeding in the duodenum. Patients with massive UGI
bleeding can also present with hematochezia, given the
speed blood can transit the GI tract.
During the initial assessment defining factors that
have prognostic value is important. Factors that predict
mortality include age greater than 65 years, comorbid
conditions, the presence of shock, and endoscopic find-
ings. Comorbid conditions such as renal failure, liver failure,
and metastatic malignancy have a very poor prognosis.
Patients who develop significant overt bleeding as a com-
plication of another illness while in the ICU have a greater
than 50% mortality – probably indicative of overall disease
severity and not necessarily attributable to the bleeding
itself. Finally rebleeding carries a mortality rate ten times
that of the initial cause of bleeding (Box 28-1).
Management
After adequate resuscitation has been accomplished,
as described above, empiric acid neutralization should be
done with high-dose IV proton pump inhibitors. In those
UGI bleeds suspected to be of a variceal origin infusion of
IV octreotide can also be begun. Endoscopy is then
undertaken once cardiovascular stability has been achieved.
Typically endoscopy can be done electively but should be
done within 24 hours of admission. If endoscopy cannot
identify the source of blood, and bleeding continues,
angiography with or without embolization can then be
attempted. A technetium-labeled red blood cell scan can be
done for gross localization of bleeding for both upper and
lower GI sources but active bleeding at rates greater than
0.05 to 0.1 ml/minute is necessary at the time of the exam-
ination – and results can be difficult to interpret.
Treatment
Drugs
An algorithm for the treatment of acute UGI bleeding
is shown in Figure 28-1.
For nonvariceal bleeding IV proton pump inhibitors
have been shown to reduce rebleeding and the need for
surgery. Patients infected with H. pylori should undergo
eradication with triple antibiotic therapy, although this
therapy has not been shown to reduce rebleeding during
initial hospitalization.
If variceal bleeding is suspected, octreotide should be
begun. Although rarely used, if bleeding does not stop
and surgery and endoscopy are not immediately avail-
able, a Sengstaken-Blakemore (Minnesota) tube may be
inserted to control massive bleeding until definitive
therapy is available.
Endoscopic Therapy
Nonvariceal bleeding can be treated with a wide range
and combination of therapies. However, injection with 
a vasoconstricting agent combined with cautery may be
the best.
With regards to variceal bleeding, band ligation stops
bleeding and obliterates varices with the fewest compli-
cations, but can be difficult to do in actively bleeding
patients.
Angiography
Attempts at localizing bleeding and subsequent
embolization can be attempted if endoscopy is unsuc-
cessful at locating the source and stopping the bleeding.
A transjugular intrahepatic portosystemic shunt (TIPS)
procedure can be attempted in bleeding caused from
portal hypertension – and has been highly successful at
stopping variceal bleeding in the acute setting.
CLINICAL CAVEAT
Octreotide for Esophageal Varices
● Infusion: 50 μg × 1 then 25–50 μg/hour IV gtt
● Caution: impaired renal function, liver function,
cardiac disease, thyroid disease, diabetes mellitus
● Interaction with beta-blockers, calcium channel
blockers may cause hypotension, bradycardia, 
and conduction abnormalities
● Pancreatic hormone effects may cause 
hyper-/hypoglycemia
CLINICAL CAVEAT
Nonsteroidal Anti-inflammatory Drugs and
Gastrointestinal Bleeding
● Cyclooxygenase II inhibitors offer lower risk for GI
bleeding as compared to nonselective NSAIDs but
significant risk for UGI bleeding while taking these
medications still exists
● 3–5 times increase in relative risk of UGI ulceration,
twice the risk of significant bleeding with NSAIDs
● Incidence of NSAID-induced gastric ulcers not
reduced by concomitant proton pump inhibitor, 
H2 blockade – has been reduced by misoprostol
Box 28-1 Poor Prognostic Indicators 
for Acute Upper
Gastrointestinal Bleed
● Age > 65 years
● Shock on admittance: pulse > 100, SBP < 100
● Comorbidity – renal failure, liver failure, metastatic
cancer
● Endoscopic findings: active, pulsatile hemorrhage,
visible vessel, large arterial defect > 1 mm, ulcer
> 2 cm, adherent clot
● Rebleeding
● GI malignancy
● Bleeding complicating other critical illness
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Figure 28-1 Algorithm for the
treatment of acute upper GI bleeding.
Box 28-2 Differential Diagnosis 
of Upper Gastrointestinal
Bleeding
Esophageal
● Mallory–Weiss tear
● Varices
● Esophagitis
● Malignancy
Gastric
● PUD
● Zollinger–Ellison syndrome
● Gastritis or stress ulcer
● Varices
● Malignancy
Duodenal
● PUD
● Malignancy
Other
● Angiodysplasia
● Coagulopathy
● Ischemia
Surgery
Surgical treatment is, for the most part, reserved for
cases in which endoscopy, angiography, and/or TIPPS
have failed (Box 28-2).
CURRENT CONTROVERSY
Acid Suppression Therapy in the Intensive 
Care Unit
● Probably only effective in patients with prolonged
mechanical ventilation (MV), coagulopathy, and
head trauma, burn victims, or to prevent rebleeding
in known PUD
● H2 antagonist Rx as effective in MV patients as
proton pump inhibitor Rx
● Continuous IV proton pump inhibitor better to
prevent UGI rebleed from PUD than intermittent
bolus proton pump inhibitor and IV H2 blockers
● Suppressive therapy may be associated with
increased risk of aspiration pneumonia
● Suppressive therapy may be associated with higher
incidence of bacterial translocation from the gut
to the blood in the critically ill
LOWER GASTROINTESTINAL BLEEDING
Lower GI bleeding is defined as bleeding from a GI
source distal to the ligament of Treitz. Bleeding typically
occurs in the colorectal area but can occur in the small
bowel. Despite significant advances in diagnostic meth-
ods over the last 20 years, localizing the source of bleed-
ing can be difficult. As many as 8–12% of patients with
lower GI bleeding fail to have their source identified
prior to surgery. While not as prevalent as UGI bleeding,
the annual incident rate of lower GI bleeding in the USA
exceeds 20.5/100,000 with a mortality rate of 2.4% for
those who present with bleeding and 23.1% for those
whose bleeding complicates other critical illness. The
most common diagnoses for massive lower GI bleeding
in patients older than 50 years of age are diverticulosis,
which accounts for 30–40% of all cases, followed by
colorectal cancer, ischemic colitis, and angiodysplasias.
For those patients younger than 50 years the most com-
mon causes are infectious colitis, anorectal disease, and
inflammatory bowel disease.
Diagnoses and Management
Presentation of Bleeding
Bleeding can be occult, slow, moderate, or massive
and life threatening. Episodic bleeding is more common
in the lower GI tract than in the UGI tract. Bleeding 
typically presents as hematochezia but it is important to
note that small bowel bleeding can present as melena,
and massive UGI bleeding is the most common cause of
hematochezia. Thus localization of bleeding to the lower
GI tract begins with placement of an NGT (Box 28-3;
Figure 28-2).
Specific Causes
Diverticulosis
Diverticulosis is responsible for 30–40% of all cases of
lower GI bleeding and is the leading cause in patients
over 50 years. Colonic diverticuli occur where major
branches of the vasa recta penetrate the colonic wall.
These points of penetration occur through connective
tissue between sections of muscle and represent rela-
tively weak areas in the colon wall. With increased pres-
sure colonic tissue may herniate through these areas and
may then over time erode into the arteries resulting in
bleeding. The bleeding can be large volume and is usually
painless, presenting typically as hematochezia, but can
present as melena. This is due to the fact that whereas
diverticuli occur more frequently in the left colon, bleed-
ing from diverticuli occurs more often in the right colon.
Frequent recurrent bleeding or massive life-threatening
bleeding from diverticuli is an indication for hemicolec-
tomy, which is curative.
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Box 28-3 Differential Diagnosis of Lower
Gastrointestinal Bleeding
UGI source
Small intestine
● Angiodysplasia
● Malignancy
● Inflammatory bowel disease
● Ischemia
● Trauma
● Meckel’s diverticulum
Colon
● TICs
● Inflammatory bowel disease
● Neoplasm
● Infectious colitis
● Ischemia
● Angiodysplasia
● Radiation
● Trauma
Rectal
● Hemorrhoids
● Fissures
● Malignancy
● Trauma
 	




  
 
   
 
  
  !"  



! 


# 
$#
#
%
	
%
 

# 
&'

# 


# 
 (#
)*+)+
)*+
)*+
)*+
)+
)+
)+
Figure 28-2 Algorithm for the treatment of hematochezia.
Ischemic Colitis
The second leading cause of lower GI bleeding in
patients over 50 years is ischemic colitis. It typically pres-
ents as crampy abdominal pain out of proportion to exam-
ination findings followed by bleeding for one to two days.
It can occur anytime but is often precipitated by meals. The
bleeding is usually mild and self-limiting but occasionally
can present as massive bleeding. Over 90% of patients with
mesenteric ischemia have underlying atherosclerotic dis-
ease. Ischemia is felt to be caused by a relatively low flow
state through diseased blood vessels supplying the bowel.
Abdominal angina is a term sometimes used to describe the
pain experienced after meals when demand for blood
exceeds available supply due to atherosclerotic lesions.
Colorectal Cancer
Malignancies in the lower GI tract rarely present with
massive bleeding but when they do there is a very poor
prognosis. Therapy is surgical resection to control bleeding.
Angiodysplasias
Vascular malformations and anomalies in the lower GI
tract are typically located in the cecum and right colon.
Their cause is unclear but it is felt that most of these are
acquired with age. Bleeding is usually intermittent and
small volume presenting with signs and symptoms of
blood loss anemia, but they can present with brisk
bleeding. They are usually easily seen on endoscopy and
are amenable to cautery. If refractory to endoscopic
and/or medical therapy, surgery is then indicated.
Inflammatory Bowel Disease
Inflammatory bowel disease to include Crohn’s disease
and ulcerative colitis are the most common causes of lower
GI bleeding in patients less than 50 years. It rarely presents
with life-threatening hemorrhage, instead usually present-
ing with moderate bleeding, with blood mixed with stool
and associated with crampy abdominal pain and sometimes
fever. Occasionally an ulcer can erode into a major vessel
and these patients will present with massive bleeding.
Infectious Colitis
Invasive infectious pathogens can cause a hemorrhagic
colitis and present as hematochezia. Salmonella, yersinia,
shigella, Campylobacter jejuni, Clostridium difficile,
Escherichia coli, Vibrio parahaemolyticus, Entamoeba 
histolytica, and schistosomatidae are the most common
of the pathogens responsible. Fever, diarrhea, crampy
abdominal pain, recent travel, and recent contact or 
family illness are important clues in a patient’s history
pointing to an infectious etiology.
Meckel’s Diverticulum
Meckel’s diverticulum is a congenital abnormality in
the terminal ileum. The diverticulum is lined with
ectopic gastric cells and acid secreted from these cells
can cause ulceration into the adjacent bowel wall and
blood vessels supplying the bowel. It typically presents
in childhood or early adult as painless hematochezia or
melena, and can cause massive bleeding.
SUMMARY
GI bleeding remains a significant cause of morbidity
and mortality, especially in those patients who develop
bleeding while in hospital. Early recognition and prompt
resuscitation is essential in the management of these
patients to minimize complications associated with
shock and anemia. Prompt therapy guided by early diag-
nostic evaluation aimed at determining the site and cause
of bleeding should follow a formulation of a differential
diagnoses based on bleeding characteristics, patient age,
history and physical examination, and laboratory results.
Early referral to gastroenterology should be made.
H2 blockers have no role in the acute management of
UGI bleeding, whereas proton pump inhibitors reduce
rebleeding in PUD and gastritis. Empiric use of octreotide
for suspected portal hypertension related bleeding
should be done.
Stress ulcer prophylaxis in the ICU is important in
select patients but indiscriminant use of such therapy
with either H2 blockers or proton pump inhibitors should
be avoided.
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CASE STUDY
A 63-year-old male is admitted to the ICU with
community-acquired pneumonia. Medical history is
significant for type II diabetes and moderate
emphysema with ongoing tobacco use. Chest x-ray
reveals an area of dense consolidation in the left upper
lobe superimposed with changes consistent on chronic
obstructive pulmonary disease. Examination reveals
mild distress on 4 liters nasal oxygen, a blood pressure
of 115/65, a respiratory rate of 24 with mild accessory
muscle use, febrile to 38.7°C, and decreased breath
sounds were appreciated on the left with rare
expiratory wheezes in all lung fields. Patient was only
taking minimal PO fluids, refusing to eat.
QUESTIONS
1. Should acid suppression therapy be initiated at 
this time?
2. What are the risks/benefits associated with acid
suppression?
Patient’s respiratory status deteriorated and he was
subsequently intubated. Shortly thereafter he became
septic requiring vasopressors despite aggressive
hydration with IV crystalloid and colloid.
QUESTIONS
1. Should acid suppression therapy be initiated if not
already done?
2. If yes which agent/s would you use? And why?
The next day the patient’s nurse notices a large
volume of bright red blood in his orogastric tube
aspirate and a short time later he develops melena. 
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CASE STUDY—cont’d
Aggressive resuscitation with IV crystalloid and 4 units
of packed red blood cells enacted cardiovascular stability.
QUESTIONS
1. What are the next steps in evaluating and treating
this patient’s bleeding?
2. What are the likely causes of his bleeding, and
what therapies could be employed to control
bleeding caused by them?
3. If not on acid suppression therapy would you now
start? If on therapy would you change therapy given
this new bleeding? Which treatment would you use?
4. What is this patient’s estimated mortality based
solely on his bleeding episode in the ICU?
Assessment of Renal Function
Diagnosis and Clinical Classification
Hepatorenal Syndrome
Rhabdomyolysis-Associated Acute Renal Failure
Pathogenesis of Acute Renal Failure
Clinical Picture
Preventing Acute Renal Failure
Radiocontrast Nephropathy
Diagnostic Investigations
Managing Acute Renal Failure
Renal Replacement Therapy
Continuous Renal Replacement Therapy
Anticoagulation During Continuous Renal Replacement Therapy
Intermittent Hemodialysis
Plasmapheresis or Plasma Exchange
Blood Purification Technology for
Nonacute Renal Failure Indications
Drug Prescription During Dialytic Therapy
Conclusions
Acute renal failure (ARF) remains one of the major
therapeutic challenges for the critical care physician.
The term describes a syndrome characterized by a rapid
(hours to days) decrease in the kidney’s ability to elimi-
nate waste products. Such loss of excretory function is
clinically manifested by the accumulation of end prod-
ucts of nitrogen metabolism (urea and creatinine) which
are routinely measured in intensive care unit (ICU)
patients. Other typical clinical manifestations include
decreased urine output (not always present), accumula-
tion of nonvolatile acids, and an increased potassium
concentration.
Depending on the criteria used to define its presence,
ARF has been reported to occur in 15–20% of ICU
patients. Acute renal injury (albuminuria, loss of small
tubular proteins, inability to excrete a water load or a
sodium load or amino acid load) is almost ubiquitous in
critically ill patients. There is some evidence, however,
that, when dialysis becomes necessary, mortality is
increased. The incidence of such severe ARF has been
recently reported at approximately 11 cases/100,000
people/year. It is important to realize that, unlike acute
respiratory distress syndrome (ARDS) or sepsis, there is
no consensus definition of ARF. Although such a defini-
tion has been suggested, the matter remains controver-
sial. The lack of a consensus definition is holding back
research in the area when compared to ARDS and sepsis.
There is limited evidence that another frequently
used term, “acute tubular necrosis”(ATN), has any clini-
cal implications or that it describes the histopathology of
what is now seen in a modern ICU. The term ATN comes
from animal models that poorly reflect clinical situations
and from old biopsy data. Even in such cases, tubular
“necrosis” is patchy and mostly isolated to the thick
ascending loop of Henle. Furthermore, cells found in the
urinary “tubular casts” of such patients are viable on stain-
ing studies, thus partly invalidating the term “necrosis.”
ASSESSMENT OF RENAL FUNCTION
Renal function is complex (control of calcium and
phosphate, acid–base balance, water balance, erythro-
poiesis. etc.). In the clinical context monitoring of renal
function is reduced to assessment of glomerular filtration
rate (GFR) by the measurement of urea and creatinine in
blood. These waste products are insensitive markers of
GFR and are heavily modified by nutrition, the use of
steroids, the presence of gastrointestinal blood, or 
muscle injury. Furthermore, they become abnormal only
when more than 50% of GFR is lost, they do not reflect
dynamic changes in GFR, and are grossly modified by
aggressive fluid resuscitation. The use of creatinine clear-
ance (2 or 4 hour collections) or of calculated clearance
by means of formulae increases accuracy but rarely if
ever changes clinical management. The use of more
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sophisticated radionuclide-based tests is cumbersome in
the ICU and only useful for research purposes.
DIAGNOSIS AND CLINICAL
CLASSIFICATION
The most practically useful approach to the etiologic
diagnosis of ARF is to divide its causes according to the
probable source of renal injury: prerenal, renal
(parenchymal), and postrenal.
So-called prerenal ARF is by far the most common in
ICU. The term indicates that the kidney malfunctions
predominantly because of systemic factors that diminish
renal blood flow and decrease GFR or alter intra-
glomerular hemodynamics and thereby also decrease
GFR. Renal blood flow can be diminished because of
decreased cardiac output, hypotension, or raised intra-
abdominal pressure. Such raised intra-abdominal pres-
sure can be suspected on clinical grounds and confirmed
by measuring bladder pressure with a urinary catheter.
A pressure of >25–30 mmHg above the pubis should
prompt consideration of decompression.
If the systemic cause of renal failure is rapidly
removed or corrected, renal function improves and rela-
tively rapidly returns to near normal levels. However, if
intervention is delayed or unsuccessful, renal injury
becomes established and several days or weeks are then
necessary for recovery. Several tests have been used to
help clinicians identify the development of such “estab-
lished” ARF (Table 29-1). The clinical utility of these tests
in ICU patients who receive vasopressors, massive fluid
resuscitation, and, increasingly, loop diuretic infusions is
untested and questionable. Furthermore, it is important
to observe that prerenal ARF and established ARF are
part of a continuum, and their separation has limited
clinical implications. The treatment is the same: treatment
of the cause while promptly resuscitating the patient
using invasive hemodynamic monitoring to guide therapy.
The term parenchymal renal failure is used to define
a syndrome where the principal source of damage is
within the kidney and where typical structural changes
can be seen on microscopy. Disorders that affect the
glomerulus or the tubule can be responsible (Box 29-1).
Among these, nephrotoxins are particularly impor-
tant, especially in hospitalized patients. The most com-
mon nephrotoxic drugs affecting ICU patients are listed
in Box 29-2. Many cases of drug-induced ARF rapidly
improve upon removal of the offending agent. Accordingly,
a careful history of drug administration is mandatory in
all patients with ARF. In some cases of parenchymal ARF
a correct working diagnosis can be obtained from his-
tory, physical examination, and radiological and labora-
tory investigations. In such patients one can proceed to
a therapeutic trial without the need to resort to renal
biopsy. However, prior to aggressive immunosuppres-
sive therapy, renal biopsy is recommended to allow 
histological confirmation of the etiology of ARF. Renal
biopsy in ventilated patients under ultrasound guidance
does not carry additional risks compared to standard
conditions.
More than a third of patients who develop ARF have
chronic renal dysfunction due to factors such as age-
related changes, long-standing hypertension, diabetes,
or atheromatous disease of the renal vessels. They may
have a raised serum creatinine. However, this is not
always the case. Often, what may seem to the clinician
to be a relatively trivial insult, which does not fully
explain the onset of ARF in a normal patient, is sufficient
to unmask lack of renal functional reserve in another.
CLINICAL CAVEAT
Intra-abdominal Hypertension
● If intra-abdominal hypertension is suspected, such
pressure must be measured
● If intra-abdominal hypertension is not relieved, there
is no hope of restoring renal function
308 CRITICAL CARE: THE REQUISITES IN ANESTHESIOLOGY
Table 29-1 Laboratory Tests Used to Help Diagnose
“Established” Acute Renal Failure
Prerenal Established 
Test ARF ARF
Urine microscopy Normal Epithelial casts
Specific gravity High: >1.020 Low: <1.020
Urine sodium Low High
U/P creatinine ratio High: >40 Low: <10
P urea/creatinine ratio High Normal
U, urine; P, plasma.
Box 29-1 Causes of Parenchymal Acute
Renal Failure
● Glomerulonephritis
● Vasculitis
● Interstitial nephropathy
● Malignant hypertension
● Pelvicaliceal infection
● Bilateral cortical necrosis
● Amyloidosis
Hepatorenal Syndrome
This condition is a form of ARF, which occurs in the
setting of severe liver dysfunction in the absence of
other known causes of ARF. Typically, it presents as
progressive oliguria with a very low urinary sodium con-
centration (<10 mmol/l). Its pathogenesis is not well
understood but appears to involve severe renal vasocon-
striction. However, in patients with severe liver disease
other causes of ARF are much more common. They
include sepsis, paracentesis-induced hypovolemia, raised
intra-abdominal pressure due to tense ascites, diuretic-
induced hypovolemia, lactulose-induced hypovolemia,
alcoholic cardiomyopathy, and any combination of these.
The avoidance of hypovolemia by albumin adminis-
tration in patients with spontaneous bacterial peritonitis
has been shown to decrease the incidence of renal
failure in a recent randomized controlled trial. These
causes must be looked for and promptly treated. Recent
uncontrolled studies suggest that vasopressin derivatives
(orinipressin) may improve GFR in this condition.
The use of such agents remains controversial.
Rhabdomyolysis-Associated Acute
Renal Failure
This condition accounts for close to 5–10% of cases of
ARF in ICUs depending on the setting. Its pathogenesis
involves prerenal, renal, and postrenal factors. It is now
typically seen following major trauma, drug overdose
with narcotics, vascular embolism, and in response to a
variety of agents that can induce major muscle injury.
The principles of treatment are based on retrospective
data, small series, and multivariate logistic regression
analysis, because no randomized controlled trials have
been conducted. Treatment includes prompt and aggres-
sive fluid resuscitation, elimination of causative agents,
and correction of compartment syndromes.
Obstruction to urine outflow causes so-called post-
renal renal failure, which is the most common cause of
functional renal impairment in the community. Typical
causes of obstructive ARF include bladder neck obstruc-
tion from an enlarged prostate, ureteric obstruction
from pelvic tumors or retroperitoneal fibrosis, papillary
necrosis, or large calculi. The clinical presentation of
obstruction may be acute or acute-on-chronic in patients
with longstanding renal calculi. It may not always be
associated with oliguria. If obstruction is suspected,
ultrasonography can be easily performed at the bedside.
However, not all cases of acute obstruction have an
abnormal ultrasound and, in many cases, obstruction
occurs in conjunction with other renal insults (e.g.,
staghorn calculi and severe sepsis of renal origin).
PATHOGENESIS OF ACUTE
RENAL FAILURE
The pathogenesis of obstructive ARF involves several
humoral responses as well as mechanical factors.
CURRENT CONTROVERSY
Role of Bicarbonate and Mannitol
in Rhabdomyolysis
● The alkalinization of urine (pH > 6.5) with
bicarbonate is not sustained by controlled studies.
Neither is the maintenance of polyuria (>300 ml/hour)
● However, both are relatively easy to perform and
are safe when done with invasive hemodynamic
monitoring
● The role of mannitol is untested, but unlikely to
cause harm
CLINICAL CAVEAT
Hepatorenal Syndrome
● Hepatorenal syndrome is a diagnosis of exclusion
● A low urinary sodium may simply reflect sodium
retention caused by inadequate intravascular volume
● Fluid resuscitation must take place under invasive
monitoring and other causes of renal failure must be
excluded
● Primary bacterial peritonitis must always be
suspected. The clinical signs of such infection may
be completely absent and an ascitic tap is needed to
make the diagnosis
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Box 29-2 Drugs That May Cause Acute
Renal Failure in the Intensive
Care Unit or Operating Room
● Radiocontrast agents
● Aminoglycosides
● Amphotericin
● Nonsteroidal anti-inflammatory drugs
● β-Lactam antibiotics (interstitial nephropathy)
● Methotrexate
● Cisplatin
● Cyclosporin A
● FK-506 (Tacrolimus)
The pathogenesis of parenchymal renal failure is typi-
cally immunologic. It varies from vasculitis to interstitial
nephropathy and involves an extraordinary complexity
of immunologic mechanisms. The pathogenesis of pre-
renal ARF is of greater direct relevance to the intensivist.
Several mechanisms appear to play a major role in the
development of renal injury:
● Ischemia of outer medulla with activation of the
tubuloglomerular feedback
● Tubular obstruction from casts of exfoliated cells
● Interstitial edema secondary to back diffusion of fluid
● Humorally mediated afferent arteriolar renal
vasoconstriction
● Inflammatory response to cell injury and local release
of mediators
● Disruption of normal cellular adhesion to the
basement membrane
● Radical oxygen species-induced apoptosis
● Phospholipase A2-induced cell membrane injury
In septic patients with hyperdynamic circulations
there may be adequate global blood flow to the kidney
but intrarenal shunting away from the medulla causing
medullary ischemia or efferent arteriolar vasodilatation
causing decreased intraglomerular pressure and thus
decreased GFR.
CLINICAL PICTURE
The most common clinical picture of ARF is that of
a patient who has sustained a major systemic insult.
When the patient arrives in the operating room or ICU
resuscitation is well under way. Despite such efforts, the
patient is often anuric or profoundly oliguric, the serum
creatinine is rising, and metabolic acidosis is devel-
oping. Potassium and phosphate levels may also be 
rapidly rising. Accompanying multiple organ dysfunction
(mechanical ventilation and need for vasoactive drugs)
is common. Fluid resuscitation is typically undertaken
under the guidance of invasive hemodynamic moni-
toring. Vasoactive drugs are often used to restore mean
arterial pressure (MAP) to “acceptable” levels (typically
>70–75 mmHg). The patient may improve over time and
urine output may return with or without the assistance
of diuretic agents. If urine output does not return,
however, renal replacement therapy needs to be rapidly
considered.
If the cause of ARF has been removed and the patient
has become physiologically stable, slow recovery occurs
(from 4 to 5 days to 3 or 4 weeks). In some cases, urine
output can be above normal for several days. If the cause
of ARF has not been adequately remedied, the patient
remains gravely ill, the kidneys do not recover, and
death from multiple organ failure occurs.
PREVENTING ACUTE RENAL FAILURE
The fundamental principle of ARF prevention is to
treat its cause. If prerenal factors contribute, these must
be identified, and hemodynamic resuscitation quickly
instituted. Intravascular volume must be maintained or
rapidly restored, and this is often best done using inva-
sive hemodynamic monitoring (central venous catheter,
arterial cannula, and pulmonary artery catheter in some
cases). Oxygenation must be maintained. An adequate
hemoglobin concentration (at least 80 g/l) must be main-
tained or immediately restored. Once intravascular
volume has been restored, some patients remain
hypotensive (MAP < 75 mmHg). In these patients
autoregulation of renal blood flow may be lost.
Restoration of MAP to near normal levels is likely to
increase GFR. Such elevations in MAP require the addi-
tion of vasopressor drugs. In patients with hypertension
or renovascular disease a MAP of 75–80 mmHg may still
be inadequate. The nephroprotective role of additional
fluid therapy in a patient with a normal or increased car-
diac output and blood pressure is questionable. Despite
these measures renal failure may still develop if cardiac
output is inadequate. This may require a variety of inter-
ventions from the use of inotropic drugs to the applica-
tion of ventricular assist devices.
Following hemodynamic resuscitation and removal of
nephrotoxins, it is unclear whether the use of additional
pharmacologic measures is of further benefit to the
kidneys. Renal dose dopamine is still frequently used.
Evidence of the efficacy of its administration in critically
ill patients is lacking. However, this agent is a tubular
diuretic and occasionally increases urine output. This
may be incorrectly interpreted as an increase in GFR.
In a patient with a low cardiac output, however, the
administration of beta-dose dopamine (as would dobuta-
mine or milrinone) may increase cardiac output, renal
blood flow, and GFR. A biologic rationale exists for the
use of mannitol, as is the case for dopamine. Animal
experiments offer some encouraging findings. However,
no controlled human data exist to support its clinical
use. The effect of mannitol as a renal protective agent
remains questionable. Loop diuretics may protect the
CURRENT CONTROVERSY
Role of Low-Dose Dopamine
All recent studies involving low-dose dopamine
have been meta-analyzed and a large double-blind
randomized controlled study has been completed.
Low-dose dopamine is not different from placebo in its
effects on GFR.
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loop of Henle from ischemia by decreasing its transport-
related workload. Animal data are encouraging, as are
ex vivo experiments. There are no double-blind ran-
domized controlled studies of suitable size to prove that
these agents reduce the incidence of renal failure.
However, there are several studies that support the view
that loop diuretics may decrease the need for dialysis in
patients with developing ARF. They appear to achieve
this by inducing polyuria, which results in the preven-
tion or easier control of volume overload, acidosis, and
hyperkalemia, the three major triggers for renal replace-
ment therapy in the ICU. Because avoiding dialysis sim-
plifies treatment and reduces cost of care, loop diuretics
may be useful in patients with renal dysfunction espe-
cially in the form of continuous infusion. Other agents
such as theophylline, urodilatin, and anaritide (a syn-
thetic atrial natriuretic factor) have also been proposed.
Studies so far, however, have been experimental, too
small, or have shown no beneficial effect.
Radiocontrast Nephropathy
In patients receiving radiocontrast a randomized con-
trolled trial (RCT) suggested that half-isotonic saline infu-
sion to maintain intravascular fluid expansion is superior
to the addition of mannitol or furosemide. A more recent
RCT of similar patients demonstrated a beneficial effect
of N-acetylcysteine treatment before and after radio-
contrast administration. A further study of 1620 patients
recently demonstrated that isotonic saline is superior to
half-isotonic saline. Since these preventive interventions
have minimal toxicity they should be considered when-
ever a patient is scheduled for the administration of intra-
venous radiocontrast either in or outside the operating
room.
DIAGNOSTIC INVESTIGATIONS
An etiological diagnosis of ARF must always be estab-
lished. Such diagnosis may be obvious on clinical
grounds. However, in many patients it is best to consider
all possibilities and exclude common treatable causes by
simple investigations. Such investigations include the
examination of urinary sediment and exclusion of a uri-
nary tract infection (most if not all patients), the exclu-
sion of obstruction when appropriate (some patients)
and the careful exclusion of nephrotoxins (all patients).
In specific situations, other investigations are neces-
sary to establish the diagnosis, such as creatine kinase
and free myoglobin for possible rhabdomyolysis. A chest
radiograph, a blood film, the measurement of non-
specific inflammatory markers, and the measurement of
specific antibodies (anti-GBM, antineutrophil cytoplasm,
anti-DNA, antismooth muscle, etc.) are extremely useful
screening tests to help support the diagnosis of vasculi-
tis or of certain types of collagen disease or glomerulo-
nephritis. If thrombotic thrombocytopenic purpura
(TTP) is suspected, the additional measurement of lactic
dehydrogenase, haptoglobin, unconjugated bilirubin,
and free hemoglobin is needed. In some patients specific
findings (cryoglobulins, Bence-Jones proteins) are almost
diagnostic. In a few rare patients a renal biopsy becomes
necessary.
MANAGING ACUTE RENAL FAILURE
The principles of management of established ARF are
the treatment or removal of its cause and the mainte-
nance of physiologic homeostasis while recovery takes
place. Complications such as encephalopathy, pericarditis,
myopathy, neuropathy, electrolyte disturbances, or
other major electrolyte, fluid, or metabolic derangement
should never occur in a modern ICU. Their prevention
may include several measures, which vary in complexity
from fluid restriction to the initiation of extracorporeal
renal replacement therapy.
Nutritional support must be started early and must
contain adequate calories (30–35 kcal/kg/day) as a mix-
ture of carbohydrates and lipids. Adequate protein
(about 1–2 g/kg/day) must be administered. There is no
evidence that specific renal nutritional solutions are
useful. Vitamins and trace elements should be adminis-
tered at least according to their recommended daily
allowance. The role of newer immunonutritional solu-
tions remains controversial. The enteral route is pre-
ferred to the use of parenteral nutrition.
Hyperkalemia (>6 mmol/l) must be promptly treated
with insulin and dextrose administration (exclude spuri-
ous hyperkalemia secondary to hemolysis, thrombocyto-
sis, and a very high white cell count), the infusion of
bicarbonate if acidosis is present, the administration of
nebulized salbutamol, or all of these together. If the
“true” serum potassium is >7 mmol/l or electrocardio-
graphic signs of hyperkalemia appear, calcium gluconate
(10 ml of 10% solution IV) should also be administered.
The above measures are temporizing actions, while renal
replacement therapy is being set up. The presence of
hyperkalemia is a major indication for the immediate
institution of renal replacement therapy.
Metabolic acidosis is almost always present but rarely
requires treatment per se. Anemia requires correction to
maintain a hemoglobin level > 70 g/l. More aggressive
transfusion needs individual patient assessment. Drug
therapy must be adjusted to take into account the effect
of the decreased clearances associated with loss of renal
function. Stress ulcer prophylaxis is advisable and
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should be based on H2-receptor antagonists or proton
pump inhibitors in selected cases. Assiduous attention
should be paid to the prevention of infection.
Fluid overload can be prevented by the use of loop
diuretics in polyuric patients. However, if the patient is
oliguric, the only way to avoid fluid overload is to insti-
tute renal replacement therapy at an early stage (see
below). Marked azotemia ([urea] > 40 mmol/l or [creati-
nine] > 400 mmol/l) is undesirable and should probably
be treated with renal replacement therapy unless 
recovery is imminent or already under way and a return
toward normal values is expected within 24 hours. It is
recognized, however, that no RCTs exist to define the
ideal time for intervention with artificial renal support.
Renal Replacement Therapy
When ARF is severe, resolution can take several days
or weeks. In these patients extracorporeal techniques of
blood purification must be applied to prevent complica-
tions. Such techniques, broadly named renal replace-
ment therapy (RRT), include continuous hemofiltration,
intermittent hemodialysis (IHD), and peritoneal dialysis
(PD), each with its technical variations. All of these tech-
niques rely on the principle of removing unwanted
solutes and water through a semipermeable membrane.
Such a membrane is either biologic (peritoneum) or arti-
ficial (hemodialysis or hemofiltration membranes) and
offers several advantages, disadvantages, and limitations.
In the critically ill patient RRT should be initiated
early, prior to the development of complications. Fear of
early dialysis stems from the adverse effects of conven-
tional IHD with cuprophane membranes, especially
hemodynamic instability, and from the risks and limita-
tions of continuous or intermittent PD. However, con-
tinuous renal replacement therapy (CRRT) or slow
extended IHD minimize these effects. The criteria for
the initiation of RRT in patients with chronic renal 
failure may be inappropriate in the critically ill. A set of
modern criteria for the initiation of RRT in the ICU is
presented in Box 29-3.
With either IHD or CRRT there are limited data on
what is “adequate” intensity of dialysis. However, this
should include maintenance of homeostasis at all levels,
and better uremic control may translate into better
survival. An appropriate target urea is 15–25 mmol/l, with
a protein intake around 1.5 g/kg/day. This can be easily
achieved using CRRT at urea clearances of 30–40 l/day
depending on patient size and catabolic rate. If IHD is
used, daily treatment and extended treatment become
desirable.
There is a great deal of controversy as to which mode
of RRT is “best” in the ICU, due to the lack of RCTs
comparing different techniques. Trials of sufficient
statistical power are difficult to conduct and may never
be performed. In their absence, techniques of RRT may
be judged on the basis of the following criteria:
● Hemodynamic side effects
● Ability to control fluid status
● Biocompatibility
● Risk of infection
● Uremic control
● Avoidance of cerebral edema
● Ability to allow full nutritional support
● Ability to control acidosis
● Absence of specific side effects
● Cost
CRRT and slow low-efficiency extended dialysis
(SLED) offer many advantages over PD and conventional
IHD (3–4 hours/day, 3–4 times/week), and while CRRT is
almost exclusively used in Europe, Japan, and Australia, a
minority of American ICU patients receive CRRT. Some
salient aspects of CRRT and IHD require discussion.
Continuous Renal Replacement Therapy
CRRT was initially performed as an arteriovenous
therapy (continuous arteriovenous hemofiltration,
CAVH) where blood flow through the hemofilter was
driven by the patient’s blood pressure. The need to can-
nulate an artery, however, is associated with 15–20%
morbidity. Accordingly, double-lumen catheters and
peristaltic blood pumps have come into use (continuous
venovenous hemofiltration, CVVH) with or without con-
trol of ultrafiltration rate.
In a venovenous system dialysate can also be deliv-
ered countercurrent to blood flow (continuous veno-
venous hemodialysis/hemodiafiltration) to achieve either
almost pure diffusive clearance or a mixture of diffusive
and convective clearance.
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Box 29-3 Modern Criteria for the
Initiation of Renal
Replacement Therapy in the
Intensive Care Unit*
● Oliguria (urine output < 200 ml/12 hours)
● [Blood urea nitrogen] > 80 mg/dl
● [Creatinine] > 3 mg/l
● [K+] > 6.5 mmol/l or rapidly rising
● Pulmonary edema unresponsive to diuretics
● Uncompensated metabolic acidosis (pH < 7.1)
● Temperature > 40°C
● Uremic complications
(encephalopathy/myopathy/neuropathy/pericarditis)
● Overdose with a dialyzable toxin (e.g., lithium)
* If one criterion is present, RRT should be considered. If two criteria are
simultaneously present, RRT is strongly recommended.
No matter what technique is used, the following
outcomes are predictable:
● Continuous control of fluid status
● Hemodynamic stability
● Control of acid–base status
● Ability to provide protein-rich nutrition while
achieving uremic control
● Control of electrolyte balance, including phosphate
and calcium balance
● Prevention of swings in intracerebral water
● Minimal risk of infection
● High level of biocompatibility
However, CRRT mandates the presence of specifi-
cally trained nursing and medical staff 24 hours a day.
Small ICUs often cannot provide such level of support. If
CRRT is only used 5–10 times a year, the cost of training
may be unjustified and expertise may be hard to main-
tain. Furthermore, depending on the organization of
patient care, CRRT may be more expensive that IHD.
Finally, the issues of continuous circuit anticoagulation
and the potential risk of bleeding have been a major
concern.
Anticoagulation During Continuous
Renal Replacement Therapy
Anticoagulants are frequently used during CRRT.
However, circuit anticoagulation increases risk of
bleeding. Therefore, the risks and benefits of more or
less intense anticoagulation and alternative strategies
(Box 29-4) must be considered.
In the vast majority of patients low-dose heparin
(< 500 IU/hour) is sufficient to achieve adequate filter
life, is easy and cheap to administer, and has almost no
effect on the patient’s coagulation tests. In some patients
a higher dose is necessary. In others (pulmonary
embolism, myocardial ischemia) full heparinization may
actually be concomitantly indicated. Regional citrate
anticoagulation is very effective but requires a special
dialysate or replacement fluid. Regional heparin/protamine
anticoagulation is also somewhat complex but may be
useful if frequent filter clotting occurs and further anti-
coagulation of the patient is considered dangerous.
Low-molecular-weight heparin is also easy to give but
more expensive. Its dose must be adjusted for the loss of
renal function. This is difficult to monitor. Heparinoids
and prostacyclin may be useful if the patient has devel-
oped heparin-induced thrombocytopenia and thrombosis.
Finally, in perhaps 10–20% of patients anticoagulation is
best avoided because of endogenous coagulopathy or
recent surgery. In such patients mean filter lives of >24
hours can be achieved provided that blood flow is kept 
at about 200 ml/minute and vascular access is reliable.
Particular attention needs to be paid to the ade-
quacy/ease of flow through the double-lumen catheter.
Smaller (11.5 Fr) catheters in the subclavian position are
a particular problem. Larger catheters (13.5 Fr) in the
femoral position appear to function more reliably.
CLINICAL CAVEAT
Anticoagulation During Continuous Renal
Replacement Therapy
● Anticoagulants should not be used during CRRT
within 24 hours of surgery. They are unnecessary
and dangerous
● Adequate filter life can be achieved without any
anticoagulation if vascular access is adequate and
blood flow is kept at 200 ml/minute or above
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Box 29-4 Strategies for Circuit
Anticoagulation During
Continuous Renal
Replacement Therapy
● No anticoagulation
● Low-dose prefilter heparin (<500 IU/hour)
● Medium-dose prefilter heparin (500–1000 IU/hour)
● Full heparinization
● Regional heparin/protamine anticoagulation
● Regional citrate anticoagulation
● Low-molecular-weight heparin
● Prostacyclin
● Heparinoids
CASE STUDY
Continuous Renal Replacement Therapy after
Cardiac Surgery
A 46-year-old man undergoes pericardectomy for
constrictive pericarditis. He has a renal transplant with
chronic rejection, and a BUN of 70 mg/dl. The
operation is complicated by severe intraoperative
bleeding from the pericardial bed. Such oozing
continues postoperatively at a rate of 300 ml/minute.
Despite 5 units of fresh frozen plasma, 3 units of blood,
and 5 units of platelets intraoperatively, his INR is
2.5, APTT is 56 seconds, HB is 7 g/dl, and platelet
count is 56,000/mm3. The surgeon does not want to
take him back to the operating room because attempts
at intraoperative hemostasis have already failed.
A normal clotting profile must be urgently restored.
However, the patient has a pulmonary artery occlusion
pressure of 20 mmHg, pulmonary congestion (revealed
on chest x-ray), a urine output of 20 ml/hour on a
frusemide infusion at 30 mg/hour, and a PaO2 of
67 mmHg on 70% FIO2.
Continued
The choice of membrane is also a matter of contro-
versy. There are several biosynthetic membranes on the
market, which have excellent biocompatibility (AN69,
polyamide, polysulfone, cellulose triacetate). There are
no controlled studies to show that one of them confers
a clinical advantage over the others.
Intermittent Hemodialysis
Vascular access is typically by double-lumen catheter
as CRRT. The circuit is also the same, with venovenous
blood flow driven by a peristaltic pump. Countercurrent
dialysate flow is used as in CVVHD. The major differ-
ences are that standard IHD uses high dialysate flows
(300–400 ml/minute), generates dialysate using purified
water and concentrate, and is applied for short periods
of time (3–4 hours). These differences have important
implications. Firstly, volume has to be removed over a
short period of time and this may be poorly tolerated
by critically ill patients, with a high incidence of hypo-
tension. Repeated hypotensive episodes may delay renal
recovery. Secondly, solute removal is episodic. This
translates into inferior uremic control, and acid–base
control. Limited fluid and uremic control imposes unnec-
essary limitations on nutritional support. Furthermore,
rapid solute shifts increase brain water content and raise
intracranial pressure. Finally, much controversy has
surrounded the issue of membrane bioincompati-
bility. Standard low-flux dialyzing membranes made of
cuprophane are known to trigger the activation of several
inflammatory pathways when compared to high-flux
synthetic membranes (also used for continuous hemo-
filtration). It is possible that such proinflammatory
effect contributes to further renal damage and delays
recovery or even affects mortality. The matter remains
unresolved.
The limitations of applying “standard” IHD to the
treatment of ARF has led to the development of new
approaches (so-called “hybrid techniques”) such as SLED
and intermittent extended hemofiltration. These tech-
niques seek to adapt IHD to the clinical circumstance
and there by increase its tolerance and its clearances.
The technique of peritoneal dialysis is now uncom-
monly used in the treatment of adult ARF in developed
countries. However, it may be an adequate technique in
developing countries or in children where alternatives
are considered too expensive, too invasive, or are not
available.
Plasmapheresis or Plasma Exchange
This technique might be applied to some critically ill
patients. Plasma is removed from the patient and
exchanged with fresh frozen plasma (FFP) and a mixture
of colloid and crystalloid solutions. This technique can
also be performed in an ICU familiar with CRRT tech-
niques. A plasmafilter (a filter that allows the passage of
molecules up to 500 kD) instead of a hemofilter is
inserted in the CVVH circuit, and the filtrate (plasma)
discarded. Plasmapheresis can also be performed with
special machines using the principles of centrifugation.
The differences, if any, between centrifugation and fil-
tration technology are unclear. Replacement (postfilter)
will occur as in CVVH using, for example, a 50/50 com-
bination of FFP and albumin. Plasmapheresis has been
shown to be effective treatment for TTP and for several
diseases mediated by abnormal antibodies (Guillain–
Barré syndrome, cryoglobulinemia, myasthenia gravis,
Goodpasture’s syndrome, etc.) in which antibody
removal appears desirable. Its role in the treatment of
sepsis remains uncertain.
CURRENT CONTROVERSY
How Often Should Dialysis Be Done?
● A randomized controlled trial has shown that daily
dialysis increases survival and improves the rate of
renal recovery in ICU patients
● Second daily conventional dialysis is inadequate
therapy for critically ill patients
314 CRITICAL CARE: THE REQUISITES IN ANESTHESIOLOGY
CASE STUDY—Cont’d
CLINICAL NEED
Fluid must be removed and clotting factors and
blood must be given simultaneously while avoiding
further pulmonary edema.
RESPONSE
Double-lumen catheter is inserted, and CVVH
started without anticoagulation. Blood flow is 200 ml/
minute, net fluid removal at 1000 ml/hour. Fresh
frozen plasma (10 units), cryoprecipitate (10 units),
platelets (20 units), and red cells (6 units) are given
over 4 hours. CVVH is continued at 1000 ml/hour for
4 hours. Net fluid removal was decreased to 300 ml/hour.
Filter clotted at 12 hours. Bleeding stopped at 4 hours.
Gas exchange was markedly better at 12 hours.
Second filter started without anticoagulation for another
16 hours. Patient was extubated at 28 hours after ICU
admission and discharged from ICU at 38 hours.
CONCLUSION
CRRT without anticoagulation is safe and effective
after surgery and can help save lives.
Blood Purification Technology for
Nonacute Renal Failure Indications
There is growing interest in the possibility that blood
purification may provide a clinically significant benefit in
patients with severe sepsis/septic shock by removing cir-
culating “mediators.” A variety of techniques including
plasmapheresis, high-volume hemofiltration, very-high-
volume hemofiltration, and coupled plasma filtration
adsorption are being studied in animals and in phase I/II
studies in humans. Initial experiments support the need
to continue exploring this therapeutic option. However,
no suitably powered RCTs have yet been reported. Also,
blood purification technology in combination with
bioreactors containing either human or porcine liver
cells is under active investigations as a form of artificial
liver support for patients with fulminant liver failure or
for patients with acute-on-chronic liver failure. Such
complex technology is beginning to show some promis-
ing results.
Drug Prescription During Dialytic Therapy
ARF and RRT profoundly affect drug clearance. A
comprehensive description of changes in drug dosage
according to the technique of RRT, residual creatinine
clearance, and other determinants of pharmacodynamics
is beyond the scope of this chapter and can be found in
specialist texts. Table 29-2 provides general guidelines
for the prescription of drugs that are commonly used in
the ICU.
CONCLUSIONS
The areas of ARF and of RRT have undergone remark-
able changes over the last five years. Major advances
have been made in the prevention of radiocontrast
nephropathy. No drugs, however, have been found to
help in patients with ARF from other causes. CRRT is
now firmly established throughout the world as perhaps
the most commonly used form of RRT. Conventional
dialysis, however, which was slowly losing ground, is
reappearing in the form of extended, slow, low-efficiency
treatment. In the meanwhile the uses of novel membranes,
of sorbents, and of different intensities of treatment are
being explored in the area of sepsis management and liver
support. Anesthesiologists need to keep abreast of this
rapid evolution if they are to offer their patients the best
of care.
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Table 29-2 Drug Dosage During Dialytic Therapy
Drug CRRT IHD
Aminoglycosides Normal dose q 36 hours 50% normal dose q 48 hours – 2/3 redose after IHD
Cefotaxime or ceftazidime 1 g q 8–12 hours 1 g q 12–24 hours after IHD
Imipenem 500 mg q 8 hours 250 mg q 8 hours and after IHD
Meropenem 500 mg q 8 hours 250 mg q 8 hours and after IHD
Metronidazole 500 mg q 8 hours 250 mg q 8 hours and after IHD
Co-trimoxazole Normal dose q 18 hours Normal dose q 24 hours after IHD
Amoxycillin 500 mg q 8 hours 500 mg daily and after IHD
Vancomycin 1 g q 24 hours 1 g q 96–120 hours
Piperacillin 3–4 g q 6 hours 3–4 g q 8 hours and after IHD
Ticarcillin 1–2 g q 8 hours 1–2 g q 12 hours and after IHD
Ciprofloxacin 200 mg q 12 hours 200 mg q 24 hours and after IHD
Fluconazole 200 mg q 24 hours 200 mg q 48 hours and after IHD
Acyclovir 3.5 mg/kg q 24 hours 2.5 mg/kg/day and after IHD
Gancyclovir 5 mg/kg/day 5 mg/kg/48 hours and after IHD
Amphotericin B Normal dose Normal dose
Liposomal amphotericin Normal dose Normal dose
Ceftriaxone Normal dose Normal dose
Erythomycin Normal dose Normal dose
The values represent approximations and should be used as a general guide only. Critically ill patients have markedly abnormal volumes of distribution for these agents
which will affect dosage. CRRT is conducted at variable levels of intensity in different units also requiring adjustment. The values reported here relate to CVVH at
2 l/hour of ultrafiltration. Vancomycin is poorly removed by CVVHD. IHD may also differ from unit to unit. The values reported relate to standard IHD with low-flux
membranes for 3–4 hours every second day.
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Urologic Procedures
Urethral Catheterization
Equipment and Technique
Cystourethroscopy
Suprapubic Cystotomy Catheter
Equipment and Technique
Percutaneous Nephrostomy Catheter
Management of Upper Urinary Tract Obstruction
Nonoperative Management of Genitourinary Trauma
Renal
Physical Examination
Imaging and Radiographic Staging
Nonoperative Management
Bladder
Physical Examination and Radiologic Imaging
Nonoperative Management
Urethra
Physical Examination and Radiologic Imaging
Nonoperative Management
The intensive care unit (ICU) represents a meeting
point between the most critically ill patients receiving
aggressive therapies and many specialties of medicine
and surgery. Changing concepts of disease management,
with more aggressive therapies being offered to the 
elderly patient with multiple comorbid conditions, has
increased the need for urologic care in the ICU setting.
Therefore the urologist’s primary role in treating
patients in the ICU is to expeditiously recognize and rap-
idly institute the appropriate medical and surgical inter-
vention needed in coordination with the ICU team. This
chapter focuses on techniques needed to treat patients
with urologic problems in the ICU, diagnosis and man-
agement of emergent upper urinary tract obstruction,
and nonoperative management of patients with genito-
urinary trauma in the ICU. Other important issues 
involving the genital tract such as phimosis and paraphi-
mosis, epididymoorchitis, and pelvic abscesses can also
be present in ICU patients but will not be discussed in
this chapter.
UROLOGIC PROCEDURES
Instrumentation of the upper and lower urinary tract
is routinely performed in the ICU setting for diagnosis
and treatment of urologic diseases. An understanding of
the available instruments and procedures, and their indi-
cations, is essential for safe and successful manipulation
of the urinary tract. The techniques routinely needed in
patients in an ICU include:
● Urethral catheterization
● Cystourethroscopy
● Suprapubic cystotomy
● Percutaneous nephrostomy
Urethral Catheterization
Catheterization of the male and female urethra is rou-
tinely performed in the ICU for both diagnosis and therapy
of urologic and medical diseases. There are numerous
types of urethral catheters available for catheterization of
the male and female urinary bladder (Figure 30-1). The
choice of which specific catheter is to be used depends
on the underlying reason for catheterization. Table 30-1
reviews the indications for urethral catheterization for
diagnostic and therapeutic purposes. Common indications
include collection of urine for culture, measurement of
postvoid residual urine volume, and instillation of contrast
agents and antibiotics into the bladder in order to diagnose
and treat lower urinary tract pathologies. Therapeutic
causes for urethral catheterization includes relief and
management of acute urinary retention and infravesical
obstruction, clot evacuation, accurate monitoring of urine
output, and the need for bladder decompression after
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surgical procedures. Contraindications for urethral
catheterization include patients with acute prostatitis,
blood at the urethral meatus or suspicion of urethral injury,
and patients with severe urethral strictures, and fistulas.
Equipment and Technique
Urethral catheterization is an invasive procedure 
and the patient should be informed of the reason 
for catheterization. It is important to prepare and drape
the urethra in a sterile fashion in order to decrease intro-
duction of skin and genital flora into the urinary tract. 
In conscious males, it is helpful to insert 2% lidocaine
jelly to anesthetize and lubricate the long urethra. The
equipment needed for urethral catheterization includes
a urethral catheter, povidone-iodine solution (or a simi-
lar antiseptic solution in a patient with a known iodine
allergy), lubricating or lidocaine jelly, urinary drainage bag,
10 ml syringe, sterile gloves and drapes, and normal saline
(Box 30-1).
Although intubating the urethra seems relatively sim-
ple, this procedure nevertheless can cause significant
morbidity in an already ailing patient. The most common
complications from urethral catheterizations include 
creation of a urethral perforation (false passage) and
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Figure 30-1 Various types of urethral catheters. A, Conical tip
urethral catheter, one eye. B, Robinson urethral catheter. 
C, Whistle-tip urethral catheter. D, Coudé hollow olive-tip catheter.
E, Malecot self-retaining four-wing urethral catheter. F, Malecot
self-retaining two-wing catheter. G, Pezzer self-retaining drain open-
ended head, used for cystotomy drainage. H, Foley-type balloon
catheter, one limb of distal end for balloon inflation (i), one for
drainage (ii). I, Foley-type three-way balloon catheter, one limb of
distal end for balloon inflation (i), one for drainage (ii), and one to
infuse irrigating solution to prevent clot retention within the bladder
(iii). (From Carter HB: Basic instrumentation and cystoscopy. In
Walsh PC, Retik AB, Vaughan D, Wein AJ, editors: Campbell’s
Urology, ed 8, Philadelphia: WB Saunders, 2002, pp 111–121.)
Table 30-1 Indications for Urethral Catheterization
Diagnostic Therapeutic
Collection of urine for culture Acute or chronic urinary retention
Measurement of postvoid Urinary output measurement
residual urine Management of hematuria and 
Urodynamic studies clot evacuation
Measurement of intra- Intravesical chemotherapy
abdominal compartment Bladder decompression after 
Retrograde instillation of surgical procedures
contrast agents for cystograms
or cystourethrography
Box 30-1 Technique for Urethral
Catheterization
● Start the procedure with positioning the patient.
Men can be catheterized in the supine position with
the penis stretched perpendicular to the body; in
females it is very helpful to place the patient in the
frog-leg position (Figures 30-2 and 30-3). Alternatively,
elderly women or women with recent orthopedic
surgery who are unable to abduct the thighs can be
flexed at the hips to provide direct access to the
urethra (often an assistant should help maintain this
position in women who are incapable of assisting).
● Swab the urethra with povidone-iodine.
● In men it is critical to retract the foreskin and clean
the glans penis thoroughly. In addition it is easier to
inject 10 ml of 2% lidocaine jelly into the urethra in
order to facilitate catheter passage through the long
urethra.
● After the urethra is prepped and draped grasp the
catheter with the dominant hand after lubricating it
with lubricating jelly.
● Using steady and gentle pressure advance the
catheter into the urethra.
● In females the urethra is short (3–5 cm) and after
the catheter is advanced 8–10 cm through the 
urethral meatus urine will be brought forth. At this
point inflate the balloon with 5–10 cm3 of normal
saline and connect the urethral catheter to a urinary
drainage bag.
● In males, it is critical to advance the catheter up to
the balloon hub and only inflate the balloon when
urine is returned. If urine is not returned irrigate
the catheter to confirm placement in the bladder
before inflating the balloon.
● In males it is also critical to replace the foreskin at
the end of catheterization in order to prevent a
paraphimosis from developing.
hematuria with traumatic catheterizations. If a false pas-
sage is suspected the balloon of the Foley catheter
should never be inflated and the catheterization should
be aborted. Urology should be consulted as this may be
best evaluated by bedside cystoscopy. Hematuria caused
by traumatic Foley catheter placement is caused by the
disruption and damage to the small mucosal vessels of
the urethra and prostate. The treatment of traumatic Foley
catheter placement usually consists of IV fluid hydration,
catheter irrigation, and monitoring. In addition, bleeding
from prostatic origin usually will need continuous bladder
irrigation with a three-way Foley catheter (see Figure 30-1).
Other physiologic complications that can occur after
bladder decompression in patients with acute retention
include hypotension and postobstructive diuresis. Early
hypotension is typically a result of a vasovagal response
to the acute decompression of a distended bladder.
Cystourethroscopy
Cystourethroscopy is the technique that permits
direct visualization of the lower urinary tract through a
cystoscope. In the ICU setting this is easily accomplished
with a flexible cystoscope and can be performed at the
patient’s bedside (Figure 30-4). Often anatomic or func-
tional lower urinary tract pathologies such as benign
prostatic hyperplasia (BPH), anterior or posterior ure-
thral obstruction, urethral strictures, and spasms of the
external urinary sphincter do not allow successful pas-
sage of the catheter into the bladder. If a Coudé catheter-
ization is not successful it is sometimes possible to
negotiate the obstruction with a flexible cystoscope.
The advantages of a flexible cystoscope over the con-
ventional rigid cystoscope include greater comfort for
the patient, ability to perform the procedure while the
patient is supine or bedridden, ease of passing the
instrument over an elevated bladder neck or through an
enlarged prostate with minimal bleeding, and the capac-
ity to inspect many angles of the urethra and bladder
with deflection of the tip of the instrument. The flexible
CLINICAL CAVEAT
Urethral Catheterizations
● Catheter size is usually referred to using the French
scale (1 Fr = 0.33 mm in diameter). Therefore an 
18 F catheter is approximately 6 mm in diameter.
● Usually an 18 F Foley is recommended for male
patients and a 16 F Foley is recommended for
female patients.
● A large 22 or 24 F three-way Foley should be placed
for patients who have gross hematuria and are at risk
from obstructing clots resulting in the need for manual
clot evacuation or continuous bladder irrigation.
● Coudé or curved tip catheters are specifically
designed to help bypass areas of the male urethra
that are difficult to negotiate such as the prostatic
urethra in a patient with prostatic enlargement.
● Difficulty in catheterizing the male patient can result
from various causes including BPH or prostatic
adenocarcinoma, urethral strictures (including urethra
meatal stenosis, and bladder neck contractures). 
If the initial attempt for Foley placement has failed
in a patient who has a history of or is suspected of
having one of the above mentioned pathologies,
further attempts at catheterization should be avoided
and urology consulted for urethral evaluation and
placement.
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Figure 30-2 Proper positioning of the hand while trying to
place a urethral catheter into the penis. It is very helpful to keep
the penis stretched and perpendicular to the patient’s body. Using
steady and gentle pressure the catheter is advanced into the urethra.
(Used with permission from Han M: Urological procedures. 
In Chen H, Sonnenday CJ, editors: Manual of Common Surgical
Procedures, ed 2, Philadelphia: Lippincott Williams and Wilkins,
2000, pp 205–236.)
cystoscope can be passed under direct vision into the
bladder or to the level of the obstruction where a guide
wire can be placed through the compromised urethral
lumen into the bladder through the working port of the
cystoscope. After visualizing the wire in the bladder the
flexible cystoscope is withdrawn making sure not to
remove the guide wire simultaneously from the bladder.
A specialized catheter hole puncher is then used to create
a hole at the tip of a straight urethral catheter (Figure 30-5).
The hole punch creates a smooth hole at the tip of the
urethral Foley catheter which is much easier to pass
through a narrowed urethra than the more jagged opening
created by a scissors or scalpel blade. Alternatively, a
Council-tipped catheter, a Foley catheter manufactured
with a smooth edged hole at the tip, can be used if avail-
able. The lubricated catheter is then passed over the
guide wire into the bladder. When urine drains the bal-
loon is inflated and the guide wire is withdrawn. Patient
preparation and equipment is identical to that of urethral
catheterization in addition to the equipment needed for
cystoscopy, which usually includes a flexible cysto-
scope, light source with fiber-optical light, 0.035 or
0.038 F flexible tip guide wire (so that the wire does not
perforate through the bladder wall), 1 liter of normal saline
or sterile water irrigant, and transurethral resection
(“TUR”) tubing. If the obstruction is caused by a tight
urethral stricture or bladder neck contracture, urethral
dilation may be needed prior to insertion of the Foley
catheter of sufficient luminal size to drain a bladder par-
ticularly if bleeding and clots are anticipated. Dilation is
performed with Heyman serial dilators that are more
rigid than a rubber or latex catheter but still flexible
enough to negotiate urethral curves and bends. Serial
dilations in the bladder (so there is a return of urine) are
done starting at 8 F and increasing by 2 F sizes until a
dilator 2 F sizes larger than the catheter to be placed is
passed. This ensures smooth catheter passage.
If the patient is receiving anticoagulation (e.g., full-
dose heparin) urethral dilation can induce significant
bleeding and should be avoided and alternative access
should be sought. It is important to ensure that the
patient does not have an active urinary tract infection as
urethral instrumentation can worsen the infection and
make the patient bacteremic and/or uroseptic. If cysto-
urethroscopy is needed, the patient should receive
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Figure 30-3 Proper positioning of a female patient in the frog-leg position for urethral catheterization. (Used with permission from Han M:
Urological procedures. In Chen H, Sonnenday CJ, editors: Manual of Common Surgical Procedures, ed 2, Philadelphia: Lippincott Williams
and Wilkins, 2000, pp 205–236.)
Figure 30-4 Flexible cystoscope with an attached light source
and a deflectable tip. (From Carter HB: Basic instrumentation and
cystoscopy. In Walsh PC, Retik AB, Vaughan D, Wein AJ, editors:
Campbell’s Urology, ed 8, Philadelphia: WB Saunders, 2002, 
pp 111–121.)
antibiotics (preferably before as well as after instrumen-
tation) making sure to adequately cover Gram-negative
microbes.
Suprapubic Cystotomy Catheter
When it is not possible to bypass bladder outlet obstruc-
tion secondary to an enlarged prostate, bladder neck
contracture, nonpassable urethral strictures, or proximal
urethral disruption by using the above mentioned pro-
cedures, placement of a percutaneous suprapubic cysto-
tomy catheter is recommended and preferable to
repeated attempts at urethral catheterizations in order to
avoid urethral trauma. Furthermore, repeated attempts
at urethral catheterizations can cause the creation of false
passages which can make subsequent catheterizations
impossible and lead to urethral stricture disease or even
fistula. Table 30-2 lists the indications and contraindica-
tions for performing this procedure. Currently there are
two common commercial available types of percutaneous
catheters: the Bonanno percutaneous suprapubic catheter
set (Becton-Dickinson and Co., Franklin Lakes, NJ) and the
Stamey percutaneous suprapubic catheter set in 10 F, 12 F,
or 14 F (Cook Urological, Spencer, IA).
The basic approach of this technique involves percu-
taneous puncture of the bladder through the anterior
abdominal wall with an obturator and catheter together.
Upon entering the bladder, the obturator is withdrawn
leaving the draining catheter in the bladder.
Equipment and Technique
As with all bedside or surgical procedures consent
should be attained for placement of a suprapubic catheter.
The equipment needed includes a percutaneous supra-
pubic catheter, as mentioned above (Figure 30-6), sterile
prep solution, drapes and gloves, an 18–24 gauge 3-inch
spinal needle, injectable 1% lidocaine, needle driver with
0 or 2-0 permanent (e.g., silk) suture, scalpel, and a urinary
drainage bag (Box 30-2).
Before one places a suprapubic catheter it is critical
that coagulation profiles are normalized and the patient’s
platelet count is adequate. If there has been prior abdom-
inal or pelvic surgery, past trauma to the lower abdomen,
pelvic irradiation, and an empty bladder it is helpful to
use ultrasound for bladder localization. Complications of
suprapubic catheter placement include bowel injury,
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Figure 30-5 Left, Council catheter with end-hole passed over a
guide wire. Right, Creation of an end-hole in a Foley-type catheter
with a catheter hole puncher. (From Carter HB: Basic instrumen-
tation and cystoscopy. In Walsh PC, Retik AB, Vaughan D, Wein AJ,
editors: Campbell’s Urology, ed 8, Philadelphia: WB Saunders, 2002,
pp 111–121.)
Table 30-2 Indications and Contraindications 
for Percutaneous Suprapubic 
Cystotomy Catheter
Indications Contraindications
Urethral strictures Prior midline infraumbilical incision*
False passage Nondistended bladder*
Repeated catheterizations Coagulopathy
with inability to pass Pregnancy
urethral catheters Carcinoma of the bladder
Acute prostatitis Pelvic irradiation*
Traumatic urethral disruption
Periurethral abscess
* If an ultrasound machine is available then a suprapubic cystotomy can be
placed under ultrasound guidance in these situations with extreme caution.
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Figure 30-6 Stamey percutaneous cystotomy set with obturator and catheter. (From Carter HB: Basic instrumentation and cystoscopy.
In Walsh PC, Retik AB, Vaughan D, Wein AJ, editors: Campbell’s Urology, ed 8, Philadelphia: WB Saunders, 2002, pp 111–121.)
Box 30-2 Technique for Percutaneous Suprapubic Cystostomy Catheter
● Start the procedure with positioning and prepping the patient. The patient is placed in the supine position and the
suprapubic area is percussed in order to confirm an adequately distended bladder. If the bladder is not distended the
patient’s bladder can be filled by injecting normal saline through the urethra until the bladder is filled. Using a catheter
tip syringe gently close the distal urethra around the tip to prevent escape of the solution through the urethral meatus.
Alternatively, if available an ultrasound can be used to localize the bladder. This is especially useful in patients who have
had previous abdominal surgery or pelvic irradiation.
● The suprapubic area is shaved, prepped with povidone-iodine solution, and draped in a sterile fashion.
● The percutaneous tract and the surrounding area (2–3 cm above the superior margin of the pubic symphysis in the 
midline with a 2 cm radius) should be anesthetized with 1% lidocaine (Figure 30-7). Infiltration of local anesthetic
should reach to the anterior rectus abdominus fascia.
● The catheter of choice (Bonanno or Stamey) is assembled
● For the Bonanno catheter: the disposable catheter sleeve is advanced over the radiopaque catheter thereby straightening
the J of the distal catheter. After the catheter is straightened the 18-gauge needle is inserted into the catheter. Once the
bevel of the needle is seen extending from the end of the catheter, the disposable catheter sleeve is removed.
● For the Stamey catheter: the needle obturator is guided into the catheter tip to stretch and straighten the self-retaining
mechanism of the Malecot catheter. The catheter is then locked in place by turning the Luer lock thereby closing the
Malecot wings.
● An 18–24-guage 5-inch spinal needle with a 10 ml syringe is then inserted perpendicular to the anesthetized skin and
advanced while withdrawing on the syringe (see Figures 30-7 and 30-8). Correct placement is usually 4 cm above the
pubic symphysis in the midline. The needle is usually directed using a 45–60° angle (Figure 30-8). Correct placement of
the needle is confirmed by withdrawing urine into the syringe.
● Some people find it useful to leave the spinal needle in place as a guide.
● The catheter is then placed in the same tract or adjacent to the spinal needle if left in and is inserted into the bladder.
The suprapubic catheter is then advanced until the bladder is punctured and urine will be seen emerging from the
catheter. Once urine is brought forth, the catheter can be advanced another 1–2 cm.
● The next step involves the disengagement of the suprapubic catheter from the obturator and final advancement of the
catheter into the bladder.
● For the Bonanno catheter: the needle is stabilized while the catheter is advanced over it. The catheter should be
advanced until the suture disk lies flush with the skin.
● For the Stamey catheter: the catheter is stabilized and the white hub of the needle obturator is rotated counterclockwise
opening the Malecot wings. The catheter is then fully advanced as with the Bonanno tube. The catheter is then slowly
withdrawn until the Malecot wings meet resistance of the bladder wall.
● Aspirate as needed to confirm correct intraluminal placement (Figure 30-8). The catheter is then secured to the skin
with permanent suture (2-0 silk or nylon suture can be used). The tube is then attached to the urinary drainage bag 
utilizing a gentle curve so that it is not kinked. Abdominal fixation in multiple sites may be necessary to avoid kinking.
transient hematuria, and leakage around the catheter
site. Bowel injury is the most feared complication. If
bowel is entered, one may exchange the needle and
continue with the procedure. In order to minimize
bowel injury, the bladder should be adequately 
distended with the patient placed in the Trendelenburg
position thereby displacing any loops of bowel that
encroach on the dome of the bladder. Ultrasound guid-
ance is also helpful in preventing injury to the bowel.
Transient hematuria is also common with suprapubic
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Figure 30-7 Localization of the bladder with a spinal needle placed percutaneously above the pubic bone (left). Placement of a percuta-
neous cystotomy catheter with obturator (right). (From Carter HB: Basic instrumentation and cystoscopy. In Walsh PC, Retik AB, Vaughan D,
Wein AJ, editors: Campbell’s Urology, ed 8, Philadelphia: WB Saunders, 2002, pp 111–121.)
Figure 30-8 Correct position and placement of a
suprapubic cystotomy catheter. (Used with permis-
sion from Han M: Urological procedures. In Chen H,
Sonnenday CJ, editors: Manual of Common Surgical
Procedures, ed 2, Philadelphia: Lippincott Williams
and Wilkins, 2000, pp 205–236.)
catheter placement. If the bladder is filled with clots
there is a possibility for the smaller catheters to become
obstructed. This can usually be relieved with gentle irri-
gation of the catheter with normal saline. Leakage around
the catheter may indicate catheter damage or plugging,
obstruction, bladder spasms, or that the tube has become
partially dislodged where some holes are in the bladder
and others are intramucosally located, or even outside
the wall of the bladder. Administration of antimuscarinic
agents such as oxybutynin or tolterodine can assist with
reducing bladder spasms.
Percutaneous Nephrostomy Catheter
A percutaneous nephrostomy tube is an alternative
method of gaining access to and diverting urine away
from (or simply draining) the urinary system. Originally,
percutaneous tube placement was considered to be a
substitute for surgical nephrostomy in critically ill
patients or as a temporizing measure prior to definitive
surgery. With advancement of percutaneous experience
and instruments and improved radiographic imaging,
the clinical benefits of percutaneous access to the renal
collecting system have been expanded (Table 30-3).
Frequently in the ICU setting patients have postrenal fail-
ure and develop hydronephrosis secondary to supravesical
ureteral obstruction. Moreover, patients in the ICU who
have multiple medical comorbidities can develop
supravesical obstruction with primary or superimposed
renal infection, leading to urosepsis, which requires 
emergent percutaneous drainage. Under semi-urgent and
elective tube placement the following contraindications
for percutaneous nephrostomy tube placement exist:
uncorrected coagulopathy, hyperkalemia (>7 mEq/l),
urothelial neoplasms, and anatomical variations that may
preclude the procedure. However, there are many times
when urgent tube placement is performed in light of
these relative contraindications as in the situation in
which drainage may be necessary to reverse intravascu-
lar coagulopathy arising from urosepsis.
In most centers, percutaneous nephrostomy tube
placement is performed in an interventional radiology
suite. Patients must be hemodynamically stable enough
to lie prone for roughly one hour. In ICU patients this
often requires nursing and respiratory staff to accompany
them for the procedure. Under conscious sedation, fluo-
roscopic or computed tomography (CT) guidance is used
with the administration of intravenous contrast to visualize
the opacified collecting system. Alternatively, ultrasound
guidance can also be used in patients with contrast allergy,
pregnant women, or patients with high-grade obstruction
necessitating urgent decompression. Usually an 8 to 10 F
catheter is placed for urgent decompression with larger
tubes reserved for drainage of thick, purulent, or bloody
material. The technique is performed by placing a needle
or catheter-sheathed needle into the pelvicaliceal system
via a translumbar approach (Figure 30-9). The needle
should not go directly into the renal pelvis, but instead go
first through the renal cortex, because the decompressed
renal pelvis is often too flimsy in its own right to permit
the somewhat firm tube in place. After radiographic
(fluoroscopic) confirmation of needle placement is
obtained, a J-shaped guide wire is then passed through
the needle into the renal pelvis and the needle or sheath
is pulled out, leaving the guide wire in place. The tract
is then serially dilated with a 6 to 10 F Teflon fascial dila-
tor and a pigtailed 8 F catheter is passed through the dila-
tor into the renal pelvis. Because this provides direct
access to the upper collecting system, urine for culture
and/or cytology can be obtained simultaneously. The
tube is then locked in place causing the tube to curl or
pigtail in the renal pelvis, and is then sutured to the skin
(Figure 30-10). Urinary drainage is ensured by the multi-
ple side holes in the pigtail portion of the nephrostomy
tube which resides within the renal pelvis.
Complications of nephrostomy tube placement include
bleeding, worsening or development of urosepsis, pneu-
mothorax or hemothorax, and bowel, vascular (e.g., infe-
rior vena cava or major renal vessels), or visceral injury. If
access to the necessary calyx is over the twelfth rib there
is an increased chance of lung and splenic injury, pneu-
mothorax, and hemothorax. As with all other surgical
procedures any coagulopathy must be corrected and an
adequate platelet count is needed prior to percutaneous
tube placement.
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Table 30-3 Indications and Applications of
Percutaneous Nephrostomy Tube
Obstruction
Pyonephrosis
Acute and obstructive pyelonephritis
Renal or ureteral calculi
Fungus ball or sloughed papillae
Renal abscess, urinoma, lymphocele
Obstructing neoplasms
Diversion
Urinomas
Fistula and fibrosis
Infection and abscesses
Functional assessment
Oliguria and azotemia
Renal salvage
Collecting system access
Stricture dilation
Culture, biopsy, and cytology
Stent placement
Calculus therapy
Drug instillation
Nephroscopy
Intrarenal surgery
Figure 30-9 Typical patient position during percutaneous nephrotomy placement in an interventional radiology suite. (From McDougall EM,
Liatsikos E, Dinlenc CZ, Smith AD: Percutaneous approaches to the upper urinary tract. In Walsh PC, Retik AB, Vaughan D, Wein AJ, editors:
Campbell’s Urology, ed 8, Philadelphia: WB Saunders, 2002, pp 3320–3360.)
Figure 30-10 Self-retaining nephrostomy tube in place. A, Diagram of a standard self-retaining nephrostomy tube in place with the tip coiled
in the renal pelvis. This catheter has a string that forces it to maintain its pigtail configuration. B, Radiograph demonstrating the typical radio-
graphic appearance of a standard self-retaining percutaneous nephrostomy catheter. (From Zagoria RJ, Tung GA: Interventional genitourinary
radiology. In Zagoria RJ, Tung GA, editors: Genitourinary Radiology – The Requisites, ed 1, St. Louis: Mosby-Year Book, 1997, pp 371–399.)
MANAGEMENT OF UPPER URINARY
TRACT OBSTRUCTION
Bacteremia and sepsis from urologic origin in patients
in the ICU may occur in a variety of settings. Therefore,
appropriate imaging is essential when excluding urinary
obstruction and intrarenal or perinephric abscesses as the
cause. Subsequently if a source is found, prompt elimina-
tion is critical for full recovery of the septic episode.
Lower urinary tract obstruction, as may occur in
patients with complicated urinary tract infections and/or
bladder outlet obstruction, can usually be relieved with
successful placement of a Foley urethral catheter (either
by direct urethral catheterization or by flexible cysto-
urethroscopy; see above) or by percutaneous supra-
pubic cystotomy catheter. In the setting of upper urinary
tract obstruction and sepsis it is critical to decompress
urgently the upper urinary tract and relieve the obstruc-
tion. Upper urinary tract obstruction is usually diag-
nosed by an elevation in serum creatinine and with
subsequent imaging (usually ultrasound or CT scan)
revealing hydronephrosis with a possible etiology such
as an obstructing calculus or extrinsic compression of
the ureter. Table 30-4 lists common causes of upper tract
obstruction in patients in the ICU.
Obstructive pyelonephritis is a true urologic emer-
gency that warrants immediate decompression of the
collecting system to prevent life-threatening sepsis. If
the obstructed collecting system is not decompressed,
the process can progress to pyonephrosis which carries
a high risk of renal scarring and mortality. Other indica-
tions for upper tract drainage include prevention or treat-
ment of urinary extravasation, management of urinary
tract fistulae and perforation, extrinsic compression from
nonurinary malignancies (e.g., ovarian, cervical, colonic,
lymphomatous, pancreatic, and gastric cancers), and
relief of intractable pain. In addition, there are certain
urologic pathologies that can cause rapidly progressive
bacteremia and life-threatening sepsis if they are not
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Table 30-4 Causes of Upper Urinary Tract
Obstruction
Obstructive pyelonephritis and pyonephrosis
Impacted proximal ureteral stone or staghorn calculi
Ureteral stricture or fistula
Lower urinary tract obstruction
Emphysematous pyelonephritis
Acute papillary necrosis
Intrinsic obstruction by ureteral or renal pelvis carcinoma
Extrinsic compression of the ureter
Neoplastic processes (usually nongenitourinary malignancy)
Retroperitoneal hematoma
expeditiously managed. Emphysematous pyelonephritis,
which is commonly caused by aerobic and facultative
anaerobic coliform microorganisms, causes life-threatening
sepsis in poorly controlled diabetics. Acute papillary
necrosis, also routinely seen in the diabetic among other
populations, can cause significant upper tract obstruc-
tion as the papillae slough off and occlude the renal
pelvis and ureter. It is critical to remember that the
absence of pyuria or bacteruria in bladder urine does not
entirely exclude upper tract obstruction as complete
obstruction may render the urine in the bladder free
from bacteria or white blood cells.
In the setting of upper urinary tract obstruction, effec-
tive and emergent urinary drainage can be accomplished
by either percutaneous nephrostomy or retrograde
ureteral stent placement. The selection of nephrostomy
tube placement versus ureteral stent placement depends
on various factors including rapidity of access and avail-
ability to a cystoscopy or interventional radiology suite,
expertise available, availability of anesthesia, or the pres-
ence of a coagulopathic state which may preclude the
procedure from occurring. Both are widely used and
accepted methods for decompression of the upper uri-
nary tract. Although urinary drainage and decompression
is of paramount importance, the question that remains is –
Are all types of drainage equal? The optimal choice (assum-
ing both procedures are readily available) for upper tract
drainage is controversial. Proponents of percutaneous
drainage claim that placement of large-caliber tubes dur-
ing percutaneous nephrostomy allows for better drainage
of the thick and viscous purulent fluid. These larger-caliber
tubes (12 to 14 F tubes as compared to 6 to 8 F internal
ureteral stents) are less likely to become occluded by the
viscous material and subsequently will allow for a rapid
resolution of the infection. Another advantage of per-
cutaneous nephrostomy tube placement includes the
ability to assess accurately and monitor the drainage from
the affected kidney. By close monitoring of the affected 
kidney, the adequacy of drainage and recovery can be
assessed. Alternatively, because most ureteral stents are
internalized, an accurate assessment of drainage from the
pathologic kidney is not possible. Furthermore, the
development of pyonephrosis usually occurs secondary
to ureteral obstruction. Therefore, ureteral stenting is
often difficult or impossible. Attempted passage of a
ureteral stent through an obstructed ureter increases the
risk of worsening sepsis and/or ureteral perforation.
Finally, placement of a percutaneous tube allows for the
possibility for a delayed nephrostogram with identifica-
tion of the site of obstruction thereby facilitating planning
of definitive treatment. Advocates for ureteral stenting
argue the greater comfort and decreased morbidity of 
an internal tube, thereby reducing the need for urgent
definitive management. In addition, placement of the
ureteral stent usually is faster and requires less radiation
than nephrostomy tube placement. Moreover, they cite
the decreased risk of major complications such as hemor-
rhage, pneumothorax, and visceral injury that exists with
percutaneous nephrostomy tube placement. Table 30-5
reviews the advantages and disadvantages of ureteral stent
versus percutaneous nephrostomy for drainage of an
obstructed upper urinary tract.
As seen from Table 30-5, the choice for drainage is
controversial since each procedure has significant
advantages and disadvantages. Despite strong arguments
on both sides of the controversy, only two prospective,
randomized studies have directly compared the efficacy
of both drainage procedures for decompression of an
obstructed, infected urinary system. The first trial was
performed by Pearle and colleagues, who randomized 
42 patients presenting with acute urinary tract obstruc-
tion with signs and symptoms of infection due to ureteral
calculi to either percutaneous nephrostomy placement
or cystoscopic ureteral stent placement. There was one
treatment failure in the percutaneous nephrostomy arm,
which was salvaged by ureteral stent placement. Neither
treatment modality demonstrated superiority in promoting
a more rapid recovery from acute obstruction after
drainage. The two treatment arms were comparable with
regard to time to clinical improvement including nor-
malization of temperature, time to normal white blood
cell count, and length of hospital stay. Procedure and 
fluoroscopic time were significantly shorter in the stent
group, while cost analysis demonstrated an advantage to
the percutaneous nephrostomy group, which was half as
costly as stent placement. As expected, this was largely
due to the higher costs of anesthesia, the operating
room, and its staff. Patient satisfaction was also evaluated
using a visual analog pain scale. Flank pain was noted to
be greater in the nephrostomy tube arm with the need for
a significantly increased amount of parenteral narcotics.
This result was probably confounded by the general anes-
thesia and pain medication received in the operating
room in the stent group. Finally, there was no significant
difference between the duration of pain medication
needed after the procedure between the two groups.
The authors concluded that the choice of drainage can
be individualized according to the patients and institu-
tional characteristics.
The second study was performed by Mokhmalji and
associates who randomized 40 patients with stone-
induced hydronephrosis to either percutaneous nephros-
tomy tube or ureteral stent placement. Unlike the Pearle
study, only 65% of the patients had signs and symptoms
of infection. The rest of the patients had a procedure
done for other reasons including persistent renal colic,
elevated creatinine, and the presence of large obstruct-
ing calculi. In this study all patients in the nephrostomy
group had successful nephrostomy tube placement, while
only 80% of the stent patients randomized to stent place-
ment were able to be successfully stented. Percutaneous
tube placement was associated with a significant
decrease in indwelling tube drainage time, with over
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Table 30-5 Advantages and Disadvantages of Ureteral Stent versus Percutaneous Nephrostomy Tube
Placement for Upper Urinary Tract Decompression
Procedure Advantages Disadvantages
Percutaneous Large-caliber tubes (with no size limitation) Morbidity of an external drain
nephrostomy for external drainage Need for mandatory care of an external tube
External access allows for accurate measurement of drain output Risk of hemorrhage
Access to the catheter allows for irrigation and possible Risk of pneumothorax
management of clotted off tubes Greater risk for injury to the surrounding organs
Can be performed with local anesthesia or IV sedation Radiologist-driven
Avoids manipulation of the ureter and possibility for Impossibility to perform this procedure in a 
worsening sepsis coagulopathic patient
No irritative bladder symptoms 
Possibility for access to the nephrostomy tract for 
subsequent definitive treatment
Ureteral stent No external collection device Irritative voiding symptoms
Low risk of injury Incontinence or reflux
Can be performed in coagulopathic state Suprapubic and/or flank pain
Less urgency to perform a definitive procedure High failure rate for extrinsic compression
Unable to monitor urinary drainage from affected kidney
No way to manually unobstruct the stent
Can require the possibility to manipulate an obstructed
ureter causing bacteremia and sepsis
Ureteral erosion or fistulization
High chance for stent encrustation
half of the stented patients and only 20% of the nephros-
tomy patients requiring an indwelling tube for 
4 weeks. In addition, the duration of antibiotic use was
longer in the stented group, although the difference did
not reach statistical significance. Unlike the Pearle study,
a trend for a reduction in the quality of life was seen in
the patients with stents compared to those who under-
went percutaneous nephrotomy tube placement. This
was most pronounced for male patients and patients
younger than 40 years of age. Other trends seen were a
shorter x-ray exposure time and decreased analgesic use
in the percutaneous nephrostomy tube arm. Based on
the findings that the nephrostomy tube arm had a
shorter indwelling tube time and antibiotic usage as well
as a marginally higher quality of life score, the authors
concluded that percutaneous nephrostomy tube place-
ment was favored over cystoscopic stent placement for
drainage of an obstructed upper tract.
In our opinion, the optimal choice for drainage of an
obstructed, infected upper urinary tract remains a matter
of controversy, as the current prospective trials fail to
show a clear-cut advantage of either procedure. Currently,
the choice for which procedure we use depends on 
multiple factors including patient preference, availability
of a skilled endoscopist or interventional radiologist,
patient clinical parameters (which may preclude anes-
thesia), and availability of an operating room. Larger
prospective, randomized trials with adequate patient
numbers and ability to perform subgroup analyses are
awaited.
NONOPERATIVE MANAGEMENT 
OF GENITOURINARY TRAUMA
Although recent developments of trauma systems and
centers have contributed to the declining rates of mortal-
ity from major traumatic injuries, the best care provided
to a patient with polytrauma comes from the organized
team of specialists including members of the trauma
ICU. As trauma to the genitourinary tract occurs in 10%
of all serious traumatic injuries the urologist is a critical
member of this team. In the majority of cases traumatic
injury to the genitourinary tract when encountered in an
ICU setting will be managed nonoperatively. The follow-
ing sections discuss the nonoperative management of
renal, bladder, and urethral injury. Injuries to the ureter,
testicles, and penis are not included as in the majority of
cases they are operatively managed.
Renal
Out of all injuries to the genitourinary tract, renal
injuries are the most common. It has been estimated that
renal trauma occurs in 1–3% of all trauma patients and
up to 5% in patients with abdominal trauma. Renal injury
management has evolved over time as a result of the
increased use of CT scans in the trauma setting. This has
allowed for better radiologic staging of renal trauma
thereby permitting the vast majority of these injuries to
be managed nonoperatively. Nonetheless, certain injuries
will require surgical management. Overall, the main objec-
tive in dealing with patients with renal trauma is to prevent
significant hemorrhage while retaining as much kidney
function as possible in order to avoid end-stage renal 
failure.
The approach to any patient with renal trauma
involves assessing whether the cause of the injury is due
to penetrating or blunt trauma. This is extremely impor-
tant, as the management of the injury will be quite 
different. Ninety percent of real injuries occur from blunt
trauma including falling from heights, motor vehicle acci-
dents, and violent assaults. Most renal injuries occurring
from blunt trauma are minor and rarely, if ever, require
surgical intervention. Alternatively, penetrating trauma,
which compromises 10% of patients with renal trauma,
requires surgical exploration unless there is definitive
clinical and radiographic evidence establishing the
extent of injury. In one study of a level III trauma center,
only 2% of renal injuries resulting from blunt trauma
required surgical intervention. Therefore, nonoperative
management of renal trauma has been espoused by 
multiple level III trauma centers that have significant
experience managing kidney injuries.
Physical Examination
Initial work-up of renal trauma follows the same
assessment and resuscitation algorithms as established by
the American College of Surgeons Trauma Life Support
program (ATLS). After assessing for adequate airway,
breathing, circulation, disability, and exposure, as out-
lined by the well-known mnemonic “ABCs of trauma,” a
more detailed physical examination to assess for renal
trauma can be performed. External evaluation of the
abdomen, back, and chest should be performed as
abdominal and flank tenderness, contusions and abdom-
inal and flank ecchymosis, lower rib fractures, and pen-
etrating wounds of the upper abdomen, flank, and lower
thorax have all been associated with renal trauma. A
palpable flank mass should cause the evaluating exam-
iner to suspect retroperitoneal and renal injury.
Urinalysis should be quickly performed in patients
suspected of having renal injury. Hematuria (macro- and
microscopic) is the most common sign of penetrating
and blunt renal trauma. It has been estimated that dip-
stick urinalysis can detect the presence or absence of
hematuria in over 97% of cases. A key point to remem-
ber is that the presence and amount of hematuria does
not correlate with the degree of renal trauma. Moreover,
the absence of hematuria does not preclude renal injury
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as its absence has been reported in 25–36% of patients
with thrombosis of the renal artery and in 33% of
patients with ureteropelvic junction injury. If urine is
microscopically analyzed the presence of greater than 
5 red blood cells per high-powered field indicates the
possibility for renal trauma. The presence of hematuria
in patients presenting to a trauma center usually signifies
a significant renal injury with estimated rates of grade IV
and V injuries around 25%.
Imaging and Radiographic Staging
Patients that have hematuria and are stable enough to
undergo imaging can safely be staged with a radiographic
procedure. The different imaging modalities that have been
used to assess the extent of renal injury include contrast-
enhanced CT scan, intravenous pyelography, angiography,
retrograde pyelography, ultrasonography, radionuclide
scintigraphy, and magnetic resonance imaging (MRI). With
the advance of CT scanners, CT scan is the procedure of
choice to detect renal injury in the trauma setting. CT
scans are noninvasive, readily available in most trauma
centers, and can rapidly and accurately detect the sever-
ity and depth of renal injuries, the presence of urinary
extravasation and perirenal hemorrhage, and determine
the status of the renal vascular pedicle. Furthermore, they
provide information about the contralateral kidney and
the extent of devitalized renal parenchyma, and the state
of neighboring viscera which are important factors needed
when a management plan is being formulated. Thus, CT
scans have replaced intravenous pyelography as the 
primary modality for the assessment of renal injuries.
Indications for radiographic imaging in patients with
abdominal trauma include:
● All patients with penetrating injuries to the flank,
abdomen, and lower back
● Blunt trauma associated with gross hematuria
● Microscopic hematuria with and without shock or a
positive diagnostic peritoneal lavage
The advances of current CT scanners have con-
tributed to the highly accurate organ injury grading scale
of renal injuries developed by the American Association
for Surgery of Trauma (AAST). The scale classifies renal
injuries into five grades which correlate with patient out-
come and permit selective management to be undertaken
(Figure 30-11). Moreover, the scale has been prospec-
tively validated and found to correlate directly with the
need for surgical intervention. Table 30-6 reviews the
renal injury scale. Overall, grade I injuries are subcapsular
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Figure 30-11 Classification of renal injuries by grade based on the organ injury scale of the American Association for the Surgery of
Trauma. (From McAninch JW, Santucci RA: Genitourinary trauma. In Walsh PC, Retik AB, Vaughan D, Wein AJ, editors: Campbell’s Urology,
ed 8, Philadelphia: WB Saunders, 2002, pp 3707–3744.)
hematomas and renal contusions, while grade II injuries
are small parenchymal lacerations into the renal cortex.
Grade III injuries are parenchymal lacerations that extend
through the corticomedullary junction, and grade IV
injuries are those that involve the collecting system and/or
vascular injuries with contained hemorrhage. Grade V
injuries are completed shattered kidneys and pedicle
avulsions of the great vessels.
Nonoperative Management
Fortunately, the vast majority of renal injuries are con-
tusions or minor lacerations which are now adequately
staged with the increased use of CT scanners in the
trauma setting. Significant injuries (grades II–V) have
been estimated to occur in only 5.4% of renal trauma
cases. Most trauma surgeons and urologists would agree
that grades I and II renal trauma are managed nonopera-
tively and only require conservative management.
Extensive perirenal and large subcapsular hematomas
rarely require surgery. These hematomas become organ-
ized and eventually reabsorb in a 2–3 month period.
Periodic CT scan with frequent creatinine evaluations on
an outpatient basis can ensure the hematoma is resolving
with no damage occurring to the affected kidney. With
appropriate and radiologically confirmed staging of
grades III–V renal trauma there is controversy as to what
is the most appropriate method of management. The only
absolute indication for surgical exploration is massive life-
threatening hemorrhage from a macerated and severely
injured kidney (grade V renal trauma). Consequently,
there are multiple reports from many trauma centers that
show appropriately staged blunt and penetrating renal
injuries can undergo selective nonoperative manage-
ment, including major lacerations and some collecting
system injuries.
The nonoperative course of a ruptured (grade III or IV)
kidney requires strict hemodynamic monitoring and 
diligent follow-up with routine hematocrit or hemoglo-
bin checks (e.g., hemoglobin checks every 6 hours for
48 hours while vital signs are stable, which can then be
tapered to every 12 hours and then once a day) and a
repeat CT scan 3–7 days after the injury to evaluate for
size of the hematoma, urinary extravasation, and perfu-
sion of the kidney laceration or fragment. It is also criti-
cal to obtain delayed images in order to ensure that the
contrast can be seen flowing through the renal pelvis
and down the ureter. Between 3 and 7 days after the
original insult, marginally perfused kidney lacerations
and fragments that can recover will appear as recovering
while devitalized tissue will become more apparent.
Furthermore, minor urinary extravasation will disappear
by this time, while larger leaks will become more readily
identified. These can be controlled either by percuta-
neous nephrostomy tube placement or internal ureteral
stent placement. It is also important to realize that
expectant management does not invariably lead to non-
surgical management and active monitoring can indicate
when conservative management has failed. Therefore
the urologist should be actively involved with the ICU
team in the patient’s progress and the possibility for sur-
gical intervention. Indications for deferred open surgical
treatment are recurring or persisting related bleeding
particularly with hemodynamic instability despite ade-
quate fluid resuscitation, and secondarily infected
hematomas that have to be evacuated and surgically
drained. A summary algorithm for initial nonoperative
management of renal trauma is shown in Figure 30-12.
Bladder
Bladder injuries in trauma patients usually occur from
a blow to the abdomen when the bladder is distended
(mostly from motor vehicle accidents, crushing injuries,
falls, or violent blows to the lower abdomen) or in 
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Table 30-6 Renal Injury Scale of the American Association for Surgery of Trauma
Grade Injury Description
I Contusion: Microscopic or gross hematuria with normal findings of imaging studies
Hematoma: Subcapsular, nonexpanding hematoma without parenchymal laceration
II Hematoma: Nonexpanding perirenal hematoma confined to renal retroperitoneum
Laceration: Cortical (superficial) laceration <1 cm parenchymal depth of renal cortex without 
extension into the collecting system
III Laceration: Deep, >1 cm parenchymal depth of renal cortex without extension into the 
collecting system or urinary extravasation
IV Laceration: Laceration extending through the renal cortex, medulla, and collecting system 
with or without a devascularized segment
Vascular: Main or segmental renal artery or vein injury and/or thrombosis with contained hemorrhage
V Laceration: Completed shattered kidney
Vascular: Avulsion of the renal hilum and pedicle
M
ic
ro
sc
op
ic 
he
m
at
ur
ia
 w
ith
 n
o 
sh
oc
k
R
en
al
 im
ag
in
g 
un
ne
ce
ss
ar
y
if 
m
in
or
 in
jur
ie
s 
pr
es
en
t
CT
 s
ca
n 
fo
r 
pa
tie
nt
s 
wi
th
 
m
u
lti
pl
e 
as
so
cia
te
d 
in
jur
ie
s 
or
de
ce
le
ra
tio
n 
in
jur
ie
s
O
bs
er
va
tio
n 
fo
r 
a
ll 
ty
re
s 
of
 re
na
l in
jur
ie
s
Pr
oc
ee
d 
to
 O
R
Pr
oc
ee
d 
to
 O
R
G
ra
de
 I-
II 
re
na
l in
jur
y
As
so
ci
at
ed
 in
jur
ie
s 
re
qu
iri
ng
 la
pa
ro
to
m
y
N
o 
as
so
ci
at
ed
 in
jur
ie
s 
w
ith
 
a
de
qu
at
e 
ra
di
og
ra
ph
ic
 
st
ag
in
g 
of
 re
na
l in
jur
y
G
ra
de
 II
I-V
 re
na
l in
jur
y
O
bs
er
ve
O
bs
er
va
tio
n
 
w
ith
 s
el
ec
tiv
e
re
n
a
l e
xp
lo
ra
tio
n
Un
st
ab
le
St
ab
le
Ab
do
m
in
al
 C
T 
sc
an
Su
sp
ec
te
d 
re
na
l 
tra
u
m
a
G
ro
ss
 h
em
at
ur
ia
 o
r m
ic
ro
sc
op
ic
 
he
m
at
ur
ia
 w
ith
 s
ho
ck
F
ig
u
re
 3
0
-1
2
D
ec
is
io
n
-m
ak
in
g 
al
go
ri
th
m
 f
o
r 
ad
u
lt
 p
at
ie
n
ts
 w
it
h
 r
en
al
 i
n
ju
ri
es
.
combination with pelvic fractures. In these cases the
normal protective barrier of the pelvic ring is lost and
the shearing forces of the injury may tear the bladder
from its attachments. It has been estimated that in
greater than 80% of patients with bladder injuries there
is an associated pelvic fracture. Although rare, penetrat-
ing and blast injuries can injure the bladder during gun-
shot wounds to the lower abdomen.
Physical Examination and Radiologic Imaging
Gross hematuria (95%) is the hallmark finding in blad-
der injury. In addition the patient may also complain of
suprapubic tenderness. If there is a concomitant urethral
injury (see below) there may be blood at the urethral
meatus or a history of an inability to urinate. Definitive
diagnosis of a bladder laceration can be obtained by con-
ventional cystography or CT cystography. Conventional
cystography uses conventional x-rays or fluoroscopy,
while CT cystography can be performed during the
abdominal and pelvic CT scan performed for evaluation
of other organ injuries. We routinely perform CT cysto-
graphy in our center as it is quick and does not need an
additional trip to the radiology suite after CT scans are
obtained for nonurologic reasons. It is important to
remember that the bladder needs to be distended ade-
quately in order to show bladder leakage; an inadequately
distended bladder can cause a false negative result. The
procedure is usually done by using retrograde filling of
the bladder with a minimum of 350 cm3 of diluted con-
trast (5%) and axial images are obtained through the
pelvis. If urethral injury is suspected a retrograde ure-
throgram should first be performed to rule out urethral
damage. It is crucial that even with CT scans, images also
be obtained after the bladder is completely drained to
make sure that no extravesical pooling of contrast is
identified. With conventional cystography, oblique and
lateral images during filling and after drainage are also
mandatory. The adequacy of cystography for the diagno-
sis of traumatic bladder injury has varied in different
studies from 85 to 100%. To achieve a high degree of
accuracy careful attention to proper technique must be
performed. Radiologically, bladder injuries can be classi-
fied as being extra- or intraperitoneal depending if the
rupture is in the peritoneum or not. Intraperitoneal rup-
tures account for one-third of major bladder injuries,
while two-thirds are extraperitoneal or combined.
Nonoperative Management
Extraperitoneal bladder ruptures are the most fre-
quent type of bladder injury and can usually be conserv-
atively managed by urinary catheter drainage. These
injuries are usually handled by placing a Foley catheter
(see Box 30-1 and Figures 30-1–30-3) for 10–21 days
allowing the bladder to heal. Afterwards a cystogram is
performed in order to ensure that any leakage has ceased
and the bladder is well healed. If the bleeding does not
clear during this three-week time period or if multiple
clots are formed not allowing for adequate urinary
drainage, conservative management should be aborted
and surgical correction undertaken. In general, all
intraperitoneal and penetrating wounds to the bladder
need to undergo prompt surgical correction. A summary
algorithm for nonoperative management of bladder and
urethral trauma is shown in Figure 30-13.
Urethra
Traumatic injuries to the urethra resulting from exter-
nal trauma are the most devastating and debilitating
injuries of the lower urinary tract. The potential compli-
cations of urethral trauma are associated with consider-
able long-term morbidity including incontinence,
impotence, strictures, and fistula formation. The reported
incidence of urethral injury with pelvic fracture in the
world literature ranges from 1.6 to 25% (mean 10%) 
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Figure 30-13 Decision-making algorithm for patients with
pelvic fracture and suspected bladder or urethral injury, or both.
(From McAninch JW, Santucci RA: Genitourinary trauma. In 
Walsh PC, Retik AB, Vaughan D, Wein AJ, editors: Campbell’s
Urology, ed 8, Philadelphia: WB Saunders, 2002, pp 3707–3744.)
with 66% of them being complete posterior urethral 
ruptures. The primary aim in the management of posterior
urethral disruption is the re-establishment of a continuous
urinary tract while minimizing the incidence of long-term
complications. Double vertical fractures, fractures and dis-
locations involving the pubic symphysis, and Malgaigne’s
fractures (fracture through the ipsilateral ischiopubic
rami or pubic symphysis and usually associated with mas-
sive posterior disruption through the sacrum or ilium)
are among the fractures associated with highest incidence
of urethral trauma.
Physical Examination and Radiologic Imaging
Clinically, urethral disruption is suspected by the
triad of blood at the urethral meatus, inability to urinate
with a palpable full bladder, and a high-riding prostate
on digital rectal examination. When blood at the meatus
is discovered or these clinical symptoms suggest urethral
disruption it is mandatory to perform a retrograde ure-
throgram to rule out urethral disruption. If the contrast
does not leak and makes its way into the bladder in a 
retrograde manner without evidence of extravasation, a
urethral catheter can be placed. If urethral disruption is
suspected, a urethral catheter is not inserted to avoid
converting a partial rupture into a complete one and a
suprapubic cystotomy catheter is placed as mentioned
above (Box 30-2 and Figures 30-6–30-8).
Nonoperative Management
The treatment of traumatic urethral disruptions is
controversial and still remains unresolved, mainly due to
the complications that may arise during the initial treat-
ment. Some urologists advocate primary urethral align-
ment while others favor initial suprapubic cystotomy
and delayed urethroplasty. The various series reported in
the literature along with recent advances in endoscopic
and radiologic procedures has fueled the controversy even
further. Currently, the most widely accepted approach in
the management of posterior urethral disruption, and
the approach we use in our center, is delayed repair in
order to re-establish urethral continuity under controlled
circumstances. A suprapubic cystotomy tube is quickly
placed in the trauma bay and the injury conservatively
managed. After three months the patient is re-evaluated
and scheduled for delayed urethroplasty. A summary
algorithm for nonoperative management of bladder and
urethral trauma is shown in Figure 30-13.
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CLINICAL CAVEAT
Nonoperative Management of Genitourinary
Trauma
● Fortunately, the vast majority of renal injuries are
contusions or minor lacerations which are now
adequately staged with the increased use of CT
scanners in the trauma setting.
● Most renal injuries are conservatively managed with
serial hemoglobin or hematocrit checks and delayed
reimaging.
● Extraperitoneal bladder ruptures are the most
frequent type of bladder injury and can be
conservatively managed by urinary catheter drainage
for 10–21 days. Afterwards a cystogram is
performed in order to ensure that any leakage has
ceased and the bladder is well healed.
● Traumatic injuries to the urethra resulting from
external trauma are the most devastating and
debilitating injuries of the lower urinary tract.
● Clinically, urethral disruption is suspected by the
triad of blood at the urethral meatus, inability to
urinate with a palpable full bladder, and a high-
riding prostate.
● Currently, the most widely accepted approach in
the management of posterior urethral disruption is
initial immediate placement of suprapubic catheter
and delayed repair in order to re-establish urethral
continuity under controlled circumstances.
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The Golden Hour
Primary Survey
Secondary Survey
Tertiary Survey
Ancillary Studies
Resuscitation
Monitoring
The Elderly Trauma Victim
The field of trauma, or injury, is continuously evolv-
ing as knowledge is gained into therapeutic manage-
ment. Currently trauma is the leading cause of death in
the USA of individuals under 44 years of age and the
fourth leading cause of death overall. Of the approxi-
mately 60 million injuries annually occurring in the USA,
half, or 30 million, require some form of medical care.
About 12% of these injured patients, or 3.6 million, require
hospitalization, with many of these patients residing in
the intensive care unit (ICU). Approximately 9 million of
these injuries lead to various types of disabilities, with
450,000 being serious and permanent, such as paraplegia.
In the USA 150,000 victims die as a result of their injury;
thus there is a 3:1 ratio of permanent disability to death.
Fifty one percent of all injury deaths are a result of motor
vehicle crashes in the USA. The annual cost related to
trauma is over $400 billion annually and is in part
accounted for by medical expenses, lost wages, insurance-
related costs, property damage, fire loss, employer costs,
and indirect loss from work-related injuries.
There is a trimodal distribution of death due to
trauma. Early or immediate death (45%) occurs at the
scene of the incident and is related to a devastating and
catastrophic injury such as cerebral herniation, aortic
transection, or cardiac rupture. Other than preventive
measures, there is little medically that can be done.
Although rapid transport from the scene has allowed
some of these patients to arrive in extremis in the
emergency room, lethality is uniform. The second group
(35%) are those that arrive in the emergency department
(ED) and require aggressive evaluation and therapy.
These patients will be discussed as part of the term
“golden hour” below. The third mode of death (20%)
occurs days or weeks after admission in patients who
usually reside in the ICU. These patients progress to
severe sepsis, hypotension, and even multiple organ fail-
ure before succumbing to death. In the following sec-
tions on trauma assessment and resuscitation, methods
of care are discussed so as to prevent the progression to
this most serious of clinical conditions.
THE GOLDEN HOUR
When the term “golden hour” was first utilized and
popularized by R. Adams Cowley, one of the founders of
MIEMS, the Maryland Institute of Emergency Medical
Services, in Baltimore in 1963, the approach to the
trauma patient was relatively straightforward, with a
limited number of diagnostic tests available as part of the
initial evaluation. Most trauma centers try to adhere to
this concept; however, frequently those seriously ill
CLINICAL CAVEAT
The Golden Hour
● Try to be thorough but expeditious
● Do not spend too much time in the radiology
department
● Hemodynamically labile patients need
expeditiously to have determined the etiology
of hypotension and have it treated. This may
involve moving the patient to the operating
room, ICU, or interventional radiology
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require other types of procedures, generally radiographic,
to be performed and this takes the patient out of the ED and
ICU environment. Once a patient arrives, a rapid, though
thorough, examination needs to be completed and disposi-
tion of the patient should be decided. There is certain
information that can be obtained while the patient is in
the ED to help with decision-making.
The advanced trauma life support (ATLS) course devel-
oped by the American College of Surgeons’ Committee
on Trauma provides an extensive discussion of the algo-
rithm used to approach a multiply and seriously injured
patient. By following the steps outlined below, little will
be missed. Any life-threatening injuries need to be iden-
tified early and addressed, even if out of sequence of the
algorithm. The team in the emergency room must be
assigned before arrival of any injured patient to certain
responsibilities. If staffing levels allow, nursing should be
responsible for charting, obtaining equipment, obtaining
vital signs, and beginning two large-bore cannulas, initially
in the antecubital fossa if possible.
The fact that many prehospital support systems now
are “scooping and running” to the ED prior to IV access
being established has allowed critical savings of time at
the scene, and in urban areas is being seen more fre-
quently with transported critically injured patients.
Once the vein is cannulated, it is imperative that a
trauma panel be obtained, including a complete blood
count, electrolytes, blood urea nitrogen, creatinine,
blood sugar, type, and cross for 4–6 units of packed
cells, prothrombin time (international normalized ratio),
partial thromboplastin time, amylase for blunt trauma,
and drug and alcohol screen when appropriate.
However, the role of clinical laboratory values in assist-
ing in the management of patients early on in their resus-
citation may be misleading. Even though the hematocrit
may be normal early on after the injury, it may be ele-
vated due to dehydration from the environment or as a
result of polyuria from an intoxicated patient. The hema-
tocrit may also be low due to the effects of dilution from
the resuscitation. However, a low hematocrit in the
acute setting implies that there is blood loss and blood
should be given. The white blood cell count is also ele-
vated after injury due to the demargination of leukocytes
from the effects of cortisol, glucagon, and epinephrine.
The inability to normalize elevated lactate, correct a sig-
nificant base deficit, or correct a metabolic acidosis is a
poor prognostic sign. An arterial blood gas can be bene-
ficial, although this requires another puncture. Once the
laboratory values are obtained, fluids, as discussed
below, can be given.
The role of gastric tonometry to guide resuscitation
remains unfounded due to its limitations to distinguish
between intramucosal carbon dioxide and that residing
within the gastric lumen. There also remains debate as to
whether the mucosal bicarbonate level is equal to the
easily measured arterial level. Tissue oximetry, which
allows for the direct measurement of tissue PO2, remains
strictly a research tool.
Primary Survey
Beginning with the primary survey upon arrival, a
rapid glance over of the entire patient is performed as
well as trying to obtain as complete a history from the
prehospital support personnel as rapidly as possible.
Identification of the following life-threatening conditions
requires urgent intervention:
● Tension pneumothorax
● Pericardial tamponade
● Respiratory insufficiency
● Hemorrhage
● Shock
● Massive hemothorax
The algorithm “ABCDE” has been used for the pri-
mary survey. Coincident with the drawing of laboratory
studies, the airway of the patient needs to be assessed.
If there is evidence of respiratory insufficiency or hypox-
emia, an airway needs to be established. Acutely a
nasopharyngeal or oral airway may not be enough to
allow the patient to maintain a patent airway or to clear
secretions and endotracheal intubation is necessary.
Although the prehospital support population is begin-
ning to get away from rapid sequence intubation (RSI),
it is still popular in the emergency room. Box 31-1 pres-
ents one formula used with preoxygenation on 100%
oxygen.
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Box 31-1 Rapid Sequence Intubation
● Lidocaine – 1 mg/kg
● Norcuronium – 0.01 mg/kg
● Versed – 0.05 mg/kg or etomidate 0.3 mg/kg
● Succinylcholine – 1–2 mg/kg
CLINICAL CAVEAT
Primary Survey and the ABCs
● Airway with cervical spine control
● Breathing
● Circulation with hemorrhage control and cardiac care
● Disability with rapid neurologic evaluation
● Exposure of the patient without inducing hypothermia
● Resuscitate, draw serum chemistries, place a gastric
and bladder drainage tube if no contraindication
Under emergent conditions an orotracheal tube
should be placed. This route should also be used for 
any trauma victim with a head injury or maxillofacial
injuries. If these conditions and findings are not present
and the intubation is semi-elective, the nasal route can
be considered. In situations where the anatomic land-
marks are indistinct, or oral intubation is not possible to
be accomplished for whatever reason, a surgical airway
should be created. A large needle/catheter cricothy-
roidotomy can be performed, ventilating the patient
with small tidal volumes and a rapid rate. A cricothy-
roidotomy can also be performed with a small tra-
cheostomy or endotracheal tube. A CO2 device can be
used to confirm correct position of the airway access
in addition to pulse oximetry, auscultation, end tidal
CO2 if available, and bronchoscopy, if the tube size will
allow.
Once the airway has been established, breathing, or
ventilation, must be instituted. Although the neurologic
examination is lost with narcotic sedation or chemical
paralysis, these agents may need to be administered in
order to ventilate adequately the patient. Manual venti-
lation should ensure that there is minimal resistance and
that oxygenation can be accomplished. If this is not
feasible then a checklist of possible problems includes
malposition of the tube, a pneumothorax, hemothorax,
or an occluded tube.
Circulation involves two aspects to be addressed.
If the patient is hemorrhaging, the bleeding needs to be
controlled. Pelvic fractures with lateral displacement
can be tamponaded by using a bed sheet folded and
placed around the anterior and posterior superior and
inferior iliac crest. A beanbag molding the pelvis, manu-
ally reduced, may also work. Otherwise external fixa-
tion, internal fixation, or even angiography to try to
identify and embolize the bleeding may be helpful. If
there is major bleeding coming from a transected
extremity vessel due to a penetrating injury or from a
large scalp injury, pressure should be applied to control
the bleeding while operative intervention is being
arranged. One study which looked at hypovolemic
resuscitation for penetrating torso trauma demonstrated
that until the bleeding is controlled, if the patient gets
over resuscitated and even hypertensive, bleeding
may be further exacerbated, leading more rapidly to
hypothermia and coagulopathy.
The other “C” in the algorithm is cardiac. If the
intravascular volume is low, the cardiac output will be
compromised. If myocardial contractility is compromised,
such as in a patient who had an MI and this led to a the
motor vehicle crash, then a cardiac work-up is in order,
possibly including coronary angiography. However, anti-
coagulation may be contraindicated if there is also an
intracranial bleed or an injury that has a major bleeding
tendency with anticoagulation, such as a pelvic fracture
or hepatic laceration.
Disability is a rapid neurologic examination which
consists of talking to the patient to see how they
respond, checking the pupil reactivity and size, evaluat-
ing for evidence of otorrhea or rhinorrhea, and tabulat-
ing a Glasgow Coma Scale (GCS) which ranges from a
worst possible score of 3 to a best possible score of 15
in evaluating the three categories of Box 31-2.
The Brain Trauma Foundation in collaboration with
the Joint Section on Neurotrauma in Critical Care of the
American Association of Neurological Surgeons and the
Congress of Neurological Surgeons performed an evi-
dence-based review of the literature and of the 13 clini-
cal recommendations found three that they considered
to achieve the level of standards. (See Clinical Caveats:
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CURRENT CONTROVERSY
Rapid Sequence Intubation
● There are many thoughts on whether RSI is
necessary. Various centers uses various methods of
RSI
● Some centers do not use a nondepolarizing
neuromuscular blocking agent
● Succinlycholine can cause an increase in ICP,
intragastric pressure, and intraocular pressure and is
avoided generally in burn patients due to potassium
mobilization
Box 31-2 Glasgow Coma Scale
EYE OPENING
Spontaneous: 4
To speech: 3
To pain: 2
None: 1
BEST MOTOR RESPONSE
Obeys commands: 6
Localizes pain: 5
Normal flexion (withdrawal): 4
Abnormal flexion (decorticate): 3
Extension (decerebrate): 2
None (flaccid): 1
VERBAL RESPONSE
Oriented: 5
Confused conversation: 4
Inappropriate words: 3
Incomprehensible sounds: 2
None: 1
Neurologic Evidence-Based Recommendations box.)
Other recommendations included:
● Intracranial pressure (ICP) monitoring in severe head
injury with a GCS of 3–8
● Initiation of therapy at an ICP of 20–25
● Avoidance of hypotension
● Avoidance of hypoxia
● Maintenance of cerebral perfusion pressure
> 70 mmHg
● Providing 140% of resting-metabolism caloric support
in nonparalyzed, brain-injured patients (100% in
chemically paralyzed patients), using feedings that
contain ≥15% of calories as protein, by the seventh
day after injury
● Consideration of high-dose barbiturate therapy in
hemodynamically acceptable, salvageable head-injury
patients with refractory intracranial hypertension
● Use of mannitol in intermittent boluses for control
of intracranial hypertension
The National Acute Spinal Cord Injury Study found
that in traumatic patients a 30 mg/kg bolus of methyl
prednisolone followed by 5.4 mg/kg for 24 hours, and for
another 24 hours in those having treatment initiated at
3–8 hours after injury, had an improved functional outcome
although there was an increased incidence of pneumonia
and severe sepsis with the 48-hour administration.
The “E” in the algorithm is for exposure, in that the
patient must be examined front to back and top to bottom
and in order to do that the anatomy must be available.
Hypothermia is a real concern, however, and patients
should remain covered to prevent a loss in temperature.
Coincident with resuscitation should be gastric
decompression and bladder decompression. Only after
the patient has had a rectal examination, and in the male
there is no evidence of a scrotal hematoma, a high-riding
prostate, or blood at the urethral meatus, should a Foley
catheter be inserted. If there are any of these findings, a
urethrogram should be performed and, if normal, a Foley
can be placed, followed by a cystogram. Although ure-
thral injuries in females are rare due to the short length, a
pelvic examination should be performed and if abnormal
blood is present at the meatus or there is concern due
to a severe pelvic fracture a urethrogram should be per-
formed. If normal, a Foley catheter can be placed and a
cystogram should be performed.
Secondary Survey
By convention, the secondary survey, which is a more
in-depth evaluation of the entire patient from top to
bottom and front to back, may then be accomplished,
while the patient is in the emergency room. If any life-
threatening injuries are identified, they should be
treated. Limb-threatening injuries should also have an
action plan by this point.
Tertiary Survey
This process identifies and catalogues all injuries
within 24 hours. Some injuries are identified as a result
of repeated examinations, clinical suspicions confirmed
by radiography, or other diagnostic modalities. As patients
begin to normalize after resuscitation, they may have
new complaints or distracting injuries become less dis-
tracting. Additional lacerations and possibly underlying
bony injuries may be discovered. The oral cavity may
reveal loose teeth, which could possibly be aspirated if
dislodged. A mandible fracture may be palpated. Seat
belt marks may become more obvious, raising suspicion
of hollow viscous injury, blunt cervical carotid, or
brachial plexus injury. As many of these patients arrive
in the ICU still with a cervical collar in place, laryngeal
fracture as well as clearing of the cervical spine should
be accomplished. Figure 31-1 shows one method to try
to clear the cervical spine early. Occasionally fractures of
the digits, ankles, or even fibula are found at this point.
The hemodynamically labile patient may not be able
to be transported safely out of the ICU. Thus high-quality
radiographs, computed tomography (CT) scanning, and
multiplanar angiography may have to be delayed or alter-
native studies, such as portable radiographs, fluoroscopic
on-table angiograms, ultrasound, or even diagnostic
peritoneal lavage, will have to be performed as bedside
procedures.
Depending on the need for neuromuscular blocking
agents, anxiolytics and analgesics will also alter the 
ability to perform a complete neurologic examination. The
level of sedation or somnolence can also be assessed
through such methods as the Ramsay Scale, allowing for the
CLINICAL CAVEAT
Secondary Survey
Examine the patient head to toe and front to back,
repeating the primary survey as you go along.
CLINICAL CAVEAT
Neurologic Evidence-Based Recommendations
● Recommendation against the use of prophylactic
antiseizure medications to prevent LATE post-
traumatic seizures
● Avoid chronic, prolonged hyperventilation in the
absence of increased ICP
● Avoid glucocorticoids in the treatment of severe head
injury
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titration of these medications. There are also some short-
acting, although more expensive, agents such as diprovan,
which has a short half-life; however, as a fat emulsion it
can precipitate pancreatitis and has been associated with
elevated ICP in patients with intracranial bleeding. In
addition stress gastritis prophylaxis should be instituted
early as well as lower extremity compression devices for
deep venous thrombosis (DVT) prophylaxis. Chemical
antithrombotic prophylaxis should also be started if the
patient is nonbleeding or has no other injuries or clinical
conditions that would preclude its use.
Ancillary Studies
In addition to the serum laboratory tests obtained as
the intravenous catheters are being placed and in addition
to the cardiac monitor and pulse oximetry, an abdominal
ultrasound, the focused assessment with sonography for
trauma (FAST), can be performed. This rapidly looks at
four areas: the pericardium, the pubic region, Morison’s
pouch which is the right hepatorenal space, and the left
splenorenal space, looking for blood in the abdomen or
around the heart. For the most part the FAST examina-
tion has replaced diagnostic peritoneal lavage (DPL) in
the ED to evaluate for unexplained hypotension due to
blood loss or pericardial tamponade. In addition a
portable chest radiograph is also performed to look for a
pnemothorax, hemothorax, mediastinal widening, or
other pathology. The pelvic radiograph looks again for
occult bleeding since a patient may lose up to half of
their intravascular volume from a closed pelvic fracture.
The third portable plain film obtained early on in the ED
CLINICAL CAVEAT
Tertiary Survey
● This more leisurely review of systems may lead to
delayed recognition of injuries
● Do not jeopardize resuscitation by sending the patient
prematurely out of the ICU where monitoring is less
than ideal
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Figure 31-1 Protocol for clearing blunt trauma C-spines.
Remove cervical collar maintaining spine immobilization
Examine, record findings and replace collar
Alert, awake, reliable Unreliable history
Stable
Stable
StableUnstable
No neck pain Neck pain No neck pain Neck pain
May remove
collar
X-rays in dept
Lat, dens, A/P
swimmers if needed
Suspicious
Suspicious Suspicious
SuspiciousCT C-spine
Spine consult
(flexion-extension)
No C-spine No C-spine
Keep collar on
Keep
collar on
Re-examine
Follow stable
protocol
Unstable
ED Lat C-spine
if possible
Needs head
or body CT
Does not
need CT
CT C-spine or
keep collar on
Keep collar on until stable
then follow stable protocol
Needs head
or body CT
Does not need
head CT
ED Lat C-spine ED Lat C-spine
+ swimmers
CT C-spine or
Dept A/P, dens Dept A/P, dens,
Lat C-spine
   swimmers
No
suspicion
No
suspicion
SuspiciousNo suspicion
Spine
consult
Spine
consult
May remove
collar
May remove
collar
May remove
collar
CT
C-spine
is the lateral cervical spine, looking for misalignment.
Spinal cord injury can rapidly lead to profound vaso-
dilatation and shock, necessitating aggressive volume
resuscitation.
Although these studies in general can be obtained
quickly, further studies may delay a critically injured
patient from going to the ICU. Thus the so-called golden
hour can become four hours or longer and may not be in
the patient’s best interest to adhere to in some situa-
tions. The dynamic helical CT scan is rapid and capable
of evaluating the entire body in relatively short order. In
addition as a screen, the dynamic chest CT with contrast
injection screens for aortic injury and has supplanted
conventional angiography to large measure. However,
interventional angiography with embolization, coiling,
and stent graft placement has opened windows for non-
operative approaches to vascular lesions.
RESUSCITATION
In general adult victims of serious trauma who are in
shock require aggressive resuscitation. By administering
fluids rapidly it appears the incidence of end-stage organ
dysfunction and ischemia can be ameliorated, if not
halted. Access to the circulation is crucial and although
routinely two large-bore antecubital vein lines are
sought, rapid access and administration via nine French
introducer sheaths placed in the femoral, subclavian, 
or internal jugular veins provides this access. Using a
pressure infuser for two large-bore central cannulas, up
to 5 liters of crystalloid can be given warmed to core
temperature in 2 minutes or 5 liters of blood warmed to
core temperature in 21/2 minutes. Initially 2 liters of crys-
talloid is given rapidly and if the hemodynamics do not
return to the patient’s baseline, a further 2 liters are
given as blood is being requested.
The crystalloids of choice are either lactated Ringer’s
(LR) solution or normal saline. The author’s personal pref-
erence is LR due to the fact that there may be a theoretical,
although not scientifically proven, advantage. When com-
pared to normal saline the pH of LR is one log higher 
(pH = 6), sodium and chloride concentration is closer to
that of serum, and the lactate gets converted by a function-
ing liver to bicarbonate. Both solutions cost the hospital
under a dollar per liter. In a hypotensive trauma victim
these fluids should be administered wide open and if after
4 liters the patient still is tachycardic, blood should be
given. Typed and cross-matched blood is preferred, but this
takes at least 30 minutes to process and that lag time may
not be acceptable. Type-specific blood takes about 15 min-
utes to obtain, leaving O-negative blood that most com-
monly given urgently. Its administration should be given
under pressure and warmed, given as rapidly as possible,
and as much as needed. In the meantime bleeding sites
should be sought and attempts to control them initiated.
Although the arterial blood gas may give the hemoglobin
value, this may not be reliable, and transfusion should be
based in the initial period on the clinical condition.
Other blood components may also have to be admin-
istered, such as fresh frozen plasma if the number of
units of packed cells exceeds 10 or there is on-going
nonsurgical bleeding, platelets for profound thrombo-
cytopenia, in the vicinity of 50,000, and cryoprecipitate
for patients with factor deficiencies. This aggressive
CLINICAL CAVEAT
Resuscitation
● Use two large-bore cannulas
● Warm the fluids and give the fluids rapidly
● In general 4 liters of crystalloid are given, followed
by blood
● Begin blood immediately if actively bleeding
● Surgical bleeding belongs in general in the
operating room
CLINICAL CAVEAT
Ancillary Studies
● The FAST (focused assessment with sonography for
trauma) examination is a rapid screening for
pericardial fluid and intra-abdominal fluid and is
replacing diagnostic peritoneal lavage
● CT scan remains the gold standard for intra-
abdominal evaluation in the trauma setting, short of
surgery
● The radiology department is not a substitute for the
ICU and as such attention to and provision of care is
difficult to match in radiology. Beware of
hemodynamic lability in a patient in which there is
limited access, such as with angiography
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CURRENT CONTROVERSY
Resuscitation
● The literature in general recommends crystalloids
initially, although there is interest in hypertonic
saline. Currently this is not the fluid of choice
● There is very little difference between LR and normal
saline, although LR has some theoretical advantages
● Factor VIIa has been successful only anecdotally and
is not a substitute for operatively correcting surgical
bleeding
● Blood substitutes, although attractive, are still under
investigation
resuscitation should continue in the ICU and should
include crystalloids and blood early on. The use of albu-
min and hydroxyethylstarch as colloid volume is usually
initiated in the ICU. These more expensive agents than
crystalloids have not been shown to have an advantage
early on in the trauma patient.
Other agents that have been used with limited suc-
cess with nonsurgical coagulopathic bleeding is factor
VIIa, which is given in the dose of up to 90 units/kg.
It works temporarily for a couple of hours, which might
be enough to warm and further resuscitate the patient
and allow assessment of whatever might be bleeding.
As a procoagulant factor VIIa may also cause vascular
thrombosis, but in combat situations has been found to
stop, albeit temporarily, bleeding.
A human and a bovine blood substitute are currently
undergoing investigation in the trauma setting. One
thought is to give these compounds in the prehospital
setting so as to begin resuscitation with a compound
providing oxygen-carrying capacity early and to cut
down on the number of allogeneic blood transfusions.
Monitoring
Once the patient has been placed in the ICU, moni-
toring is crucial. There are advantages to getting trauma
victims quickly from the ED to the ICU for continued,
aggressive resuscitation. Patients with labile blood pres-
sures may have to bypass departmental radiology studies
such as CT scans or plain films. The latter can be done in
the ICU, but foremost is to try to return the patients’ vital
signs to their normal physiologic level. Warm fluids rap-
idly given are continued. Pulse oximetry and EKG moni-
toring are routine as is frequent vital sign recordings.
End tidal CO2 monitoring may also be useful if available.
An arterial line should be placed after ascertaining the
best location. The radial artery is a common choice if the
Allen’s test reveals a patent palmer arch. The femoral
artery can also be used. Arterial access allows for con-
tinuous blood pressure monitoring and access for blood
gasses and serum chemistries. However, it has been
shown that the presence of an arterial cannula leads to
increased phlebotomy, so serum chemistries should be
drawn judiciously with as little blood as possible.
Central venous pressure (CVP) may provide a crude
measure of central pressure. The pulmonary artery
catheter is helpful when used early, although its popu-
larity, even in trauma patients, has diminished. The vol-
umetric pulmonary artery catheter calculates right
ventricular end diastolic volume as a reflection of pre-
load. It correlates fairly well with cardiac index and our
practice is a goal of 120–150 ml/m2. In addition these
catheters can provide information used to calculate
oxygen delivery and consumption index with goals 
of 150 and 600 ml/minute/m2, respectively. These
catheters are placed in the operating room or the ICU.
If there is no concern of esophageal injury, trans-
esophageal cardiac monitoring can be utilized, providing
information on filling pressures and cardiac perform-
ance. Transthoracic or transesophageal echocardiogra-
phy can assess preload by evaluating end-diastole cardiac
chamber size. However, in most institutions it requires
specialists to perform the test, and is operator depend-
ent, is variable in reproducibility, must be repeated for
further evaluations, and is expensive. Esophageal
Doppler sonography, in which an ultrasound probe is
placed within the esophagus and positioned at the level
of the descending thoracic aorta, measures blood flow
velocity to calculate flow. This allows cardiac index
determinations on a continuous basis and can help in
goal-directed therapy.
Thoracic bioelectric impedance using surface electrodes
is still being investigated in the ICU setting.
The Elderly Trauma Victim
The elderly represent the fastest growing segment of
the population. As one ages there is a decrease in fixed
expiratory volumes over 1 second (FEV1), functional vital
capacity (FVC), FEV1/FVC, and peak expiratory flow rate
(PEFR). These changes all lead to a predictable decrease
CURRENT CONTROVERSY
Pulmonary Artery Catheter
Although there are studies showing that right
ventricular end-diastolic pressure index correlates well
with cardiac index, others still use pulmonary artery
wedge pressure, oxygen delivery, or oxygen
consumption to guide goal-directed therapy.
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CLINICAL CAVEAT
Monitoring
● EKG and pulse oximetry monitoring should be done
in the ED
● An arterial line can be useful for blood pressure
monitoring; however, beware of over-
phlebotomization
● A CVP is a poor method to monitor preload in the
trauma setting
● Less invasive methods of cardiac monitoring such as
esophageal Doppler can be used successfully as the
use of the pulmonary artery catheter is decreasing
● The utility of bioimpedance is still being evaluated
in arterial oxygen tension with age which may be
expressed as PaO2 = 103.7 − 0.24 (Age) ± 7.9 mmHg.
As one ages there is also a decrease in cardiac reserve
with a limited ability to compensate for shock or respira-
tory failure. Pulse rate decreases with age as does cardiac
index. Although these patients are aggressively resusci-
tated, the amount needed may have to be decreased to
avoid congestive heart failure and pulmonary edema.
Once the volume status has been judged to be adequate,
vasopressors may need to be instituted. A low threshold
for noninvasive and invasive monitoring, including a pul-
monary artery catheter, should be kept in mind and in
addition to myocardial performance and other vital signs,
lactate levels may be useful. If the lactate is clearing, then
coupled with clinical history and examination, the
patient should be improving. Due to other comorbidities
in the elderly even what may be considered minor
injuries can have devastating consequences. This alone
frequently necessitates an ICU admission (Box 31-3).
Although ethical issues are important for all patients,
all health care providers must be aware whether the
trauma victim has an advanced directive. Many elderly
have voiced concerns on the level of heroics and thus have
limited the scope of care provided. If this information is
available, it should be followed, if possible. In all other
circumstances aggressive care continues unless there is
an indication to limit this aggressive care, such as a
patient with a neurologically devastating injury or inability
to be resuscitated.
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CLINICAL CAVEAT
Elderly Trauma Victim
Although the elderly have diminished pulmonary
function and increased comorbidities, evaluation and
resuscitation should be aggressive.
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Box 31-3 Risk Factors for Mortality
Following Significant Blunt Trauma in
the Elderly
● Pedestrian hit by a motor vehicle
● Initial systolic blood pressure < 130 mmHg
● Acidosis (pH < 7.35)
● Multiple long bone fractures
● Head injury
Assessment of Depth of Injury
Pathophysiology of Burn Shock and 
Smoke Inhalation
Initial Management Priorities
Stop the Burning Process
Airway/Breathing
Circulation
Burn Wound Care
Other Considerations
Systemic Wound Management
Pain Control
Nutritional Support
Conclusions
Thermal injury is a major cause of morbidity and mor-
tality in the USA. The USA has the fourth-highest fire
death rate of all industrialized countries with 75–85% of
all fire deaths related to residential fires. Approximately
2 million fires occur annually resulting in 1.4 million
injuries. Burn injuries result in about 54,000 hospital
admissions and 5000 deaths each year. Fires related to
smoking are the leading cause of fire-related deaths, and
flame injury is the predominant type of injury seen in
patients admitted to burn centers. Most fire-related
deaths, however, are due to inhalation of smoke and
toxic gases with only about 25% due to the actual burn.
Initial resuscitation of the burn patient, therefore,
requires a high index of suspicion for inhalation injury
and airway compromise.
Although the more severe burns are likely referred to
a regional burn center, half of the admissions for thermal
injuries are to hospitals without burn care facilities. It is
therefore essential that physicians caring for these
patients have some expertise in the initial management
of thermal injury. Also, it is necessary to understand
when referral to a regional burn center is appropriate.
ASSESSMENT OF DEPTH OF INJURY
Thermal injury causes coagulation necrosis of cuta-
neous tissue to variable depths. The degree to which tissue
injury occurs depends on the temperature to which the 
tissue is exposed, the duration of contact, and the thickness
of the exposed skin. The depth of the burn correlates
with its clinical behavior and burns are often classified as
first, second, third, and fourth degree. First- and second-
degree burns are also classified as partial-thickness while
third- and fourth-degree burns are classified as full-thickness
injuries. Partial-thickness burns affect the epidermis and
dermis and heal by migration of epithelial cells from pre-
served dermal appendages such as sebaceous glands,
sweat glands, and hair follicles. Full-thickness burns affect
the epidermis, entire dermis, and, in cases of fourth-degree
burns, deeper tissues, destroying the dermal appendages
and thus requiring skin grafting for closure. Deep partial-
thickness burns may also require skin grafting for closure
to avoid the development of a hypertrophic scar. 
Table 32-1 lists distinguishing characteristics of partial- and
full-thickness burns.
The depth of the burn is usually established at the
time of the injury. There are certain physiologic changes
in the burn wound, however, that can result in the burn
becoming deeper after the offending agent has been
removed. Since the skin is frequently the first organ com-
promised in shock, failure to resuscitate a burn victim
can result in ischemia of the burned skin, therefore causing
a deeper burn wound. Furthermore, thromboxane A2, a
potent vasoconstrictor, is released by platelets in the
burned skin. This, too, causes vasoconstriction of dermal
vessels, impairing the oxygenation of burned tissue and
expanding the zone of thermal injury. The temporary
vasoconstriction caused by thomboxane A2 also results
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in a reperfusion injury within the burn. This results in
the formation of oxygen free radicals which can further
potentiate the tissue injury.
PATHOPHYSIOLOGY OF BURN 
SHOCK AND SMOKE INHALATION
In addition to the local tissue injury, burns also have
systemic effects. Burns with a percent total body surface
area (%TBSA) greater than 20% can result in hypovolemic
shock or burn shock. There are two main losses of intra-
vascular volume in thermal injury victims. First, the
direct thermal injury to the tissue causes changes in 
dermal collagen resulting in a hydrostratic vacuum in the
burned skin. This effectively draws fluid into the inter-
stitial space at a significant rate. Obviously, the larger
surface area burned results in a greater loss of fluid into
the wound.
The second etiology of burn shock is the increase in
microvascular permeability to albumin. In burns with a
%TBSA > 20% this increase in permeability occurs through-
out the body in burned and nonburned tissue. An increase
in microvascular permeability is observed due to the
direct effects of heat as well as the release of factors such
as histamine, thromboxane A2, leukotrienes, bradykinin,
serotonin, and cytokines such as interleukin (IL)-1, IL-6,
and IL-8. These result in a net loss of fluid and protein from
the intravascular to the extravascular space, thus causing
the edema that occurs in the areas of thermal injury (as
well as the edema that develops in unburned tissue as the
resuscitation of large burns proceeds).
It is the combination of both hydrostatic forces and
increases in microvascular permeability that produces the
hypovolemic shock observed in thermal injury victims.
Patients with larger burns will have more significant
shock due to the large loss of intravascular volume into
the interstitium. This is the reason resuscitation formulas
have been developed to estimate the fluid needs of a burn
victim based on their weight and the %TBSA burned.
Smoke inhalation injury is present in approximately
20% of burn admissions and increases the mortality asso-
ciated with burns of any size. Inhalation injury is due to
the inhalation of the chemical products of combustion.
There are three main components contributing to the
pathophysiology of smoke inhalation. The first of these is
carbon monoxide (CO) toxicity. Carbon monoxide causes
a functional anemia, as hemoglobin will preferentially
bind CO rather than oxygen (by a factor of 250-fold).
The carboxyhemoglobin (COHb) that is formed will shift
the oxyhemoglobin dissociation curve to the left, thus
decreasing oxygen delivery to the tissues. Patients can
therefore be severely hypoxemic, manifested by a low
oxygen saturation (SaO2), while maintaining a normal
arterial oxygen tension (PaO2).
Cyanide toxicity may also be present. Inhalation of
hydrocyanide, produced when synthetic materials such
as plastics are burned, leads to rapid systemic absorption
and binding of the mitochondrial cytochrome a-a3 system,
thus impairing ATP production and forcing cellular anaer-
obic metabolism. Cyanide toxicity should be suspected in
a patient with a persistent metabolic acidosis despite ade-
quate resuscitation and adequate urine output.
Finally, acrolein and aldehyde gases dissolved within
the smoke are directly toxic to the airway epithelium.
When these compounds come into contact with the air-
way, the pseudostratified ciliated epithelial cells literally
fall off the trachea and bronchi, leaving a raw basement
membrane. This raw surface then secretes a proteina-
ceous material which solidifies and forms obstructing
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Table 32-1 Characteristics of Burn Wounds
Depth of Injury Appearance Sensation Healing
PARTIAL THICKNESS
First degree Epidermis Hyperemic Painful/hypersensitive Scarless within 7 days
Second degree
Superficial Superficial dermis Moist, blistering, blanching Painful/hypersensitive Minimal scarring 
hyperemia with rapid capillary refill within 2 weeks
Deep Deep dermis Pale pink or dark red, nonblanching Decreased pinprick Hypertrophic scarring 
hyperemia or with delayed sensation, intact in many weeks
capillary refill pressure sensation
FULL THICKNESS
Third degree Entire dermis Dry, pearly-white or leathery Insensate By contracture
Fourth degree Deep tissues Necrotic, with thrombosed vessels Insensate Requires debridement
or amputation
airway casts if not removed. Unlike the immediate effects
of carbon monoxide and hydrogen cyanide, the airway
damage from acrolein and aldehyde persists until the 
airway epithelium heals (which can take several weeks).
Also, acrolein and aldehyde set off an inflammatory 
cascade in the airway circulation which affects the lung
parenchyma. This results in the development of acute
respiratory dysfunction syndrome (ARDS).
INITIAL MANAGEMENT PRIORITIES
Stop the Burning Process
The approach to the evaluation and treatment of a burn
patient is similar to that of a trauma patient and, in fact,
the patient should be assessed for concomitant trauma.
The initial goal should be to stop the burning process. The
patient’s clothing should be removed and the burn
wounds should be irrigated with cool water. The use of ice
or ice water can cause vasoconstriction and can poten-
tially cause ischemia to the burned skin, thus making the
burn deeper. Acid burns cause a coagulation necrosis
and should be irrigated for at least 30 minutes. Alkali
burns cause liquefaction necrosis and are therefore more
destructive. These types of burns should be irrigated for
60 minutes. Powdered chemicals should be brushed off
and not irrigated. If a powdered chemical goes into solu-
tion, the surface area of skin damaged will be signifi-
cantly increased. Eye burns require continuous irrigation
with normal saline for up to 1 or 2 hours.
Burn patients are at great risk for developing hypother-
mia. The damaged skin has limited ability to regulate blood
flow and therefore the convective loss of heat from a
thermal injury victim is great. Since the majority of the
above-mentioned techniques require wetting the patient,
every effort should be made to insulate the patient and to
increase the ambient temperature of the environment to
minimize the risk of hypothermia.
Airway/Breathing
The airway should be initially assessed to ensure
patency. The presence of stridor is an immediate indica-
tion for endotracheal intubation. Burns to the face are
not at immediate risk for airway compromise; however,
subsequent edema formation in addition to resuscitation
fluids can make securing an airway more difficult later. It
is therefore recommended that patients with facial burns
be prophylactically intubated with a 7.5 mm internal
diameter (i.d.) endotracheal tube or larger. This caliber
of endotracheal tube will permit flexible bronchoscopy
for diagnosis and therapeutic lavage if needed.
Patients burned in an enclosed space or found uncon-
scious in a burning structure should be suspected of having
smoke inhalation. Smoke inhalation is highly unlikely in
patients injured outdoors since the smoke dissipates
quickly. Findings that may be associated with inhalation
include a history of hoarseness, wheezing, facial burns,
singeing of facial hair, carbon deposits in the oropharynx,
or carbonaceous sputum. Patients with significant smoke
inhalation will have a COHb level of >10%. Chest radio-
graphy is useless in diagnosing inhalation injury. It is typi-
cally obtained to exclude underlying pulmonary pathology
or evidence of thoracic trauma and therefore should 
be obtained. A definitive diagnosis of inhalation injury is
made by bronchoscopy; if positive, carbonaceous deposits,
hyperemia, edema, superficial sloughing, and/or ulcera-
tion of the mucosa will be seen below the level of the
vocal cords.
If there is a suspected CO exposure, 100% oxygen
should be administered. Patients with COHb levels <15%
are frequently asymptomatic and smokers can have
COHb levels of 5–7%. The classic cherry-red skin color is
rare and can be difficult to evaluate if the skin is burned.
A baseline COHb level and arterial blood gas should be
obtained if CO exposure is suspected. Table 32-2 gives
symptoms associated with varying levels of COHb.
If, despite adequate resuscitation, the patient has a
progressive metabolic acidosis, cyanide toxicity should
be expected. Blood cyanide levels of >0.1 mg/l should be
immediately treated. The antidote for cyanide poisoning
requires two interventions. First, sodium thiosulfate
(125–250 mg/kg) is administered to transfer sulfur to the
cyanide ion. Next, hydroxycobalamin (4 g) is given to
chelate the cyanide to permit excretion.
Large surface area burns also require intubation and
ventilatory support. Patients with large burns become
hypercatabolic and produce large amounts of carbon
dioxide. If the patient is unable to increase and maintain
an adequate minute ventilation, hypercapnia ensues.
Patients with underlying pulmonary pathology associ-
ated with an increase in physiologic dead space are more
prone to this complication.
Circumferential third-degree torso burns can restrict
respiratory excursion due to the constricting effects of
the burned skin. This restriction is not usually present
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Table 32-2 Carbon Monoxide Effects
COHb (%) Signs and Symptoms
0–10 None
10–30 Headache
30–50 Dizziness, weakness, presyncope
50–70 Syncope, coma, cardiovascular depression
70–80 Further cardiovascular depression
80–100 Death
initially, but becomes more problematic during fluid
resuscitation. Progressive tissue edema below the burned
skin decreases total thoracic compliance and eventually
impairs ventilation. This is manifest by a gradual increase
in peak airway pressures and worsening respiratory 
acidosis. The treatment is a chest wall escharotomy; a cut
into the burned chest skin along the right and left anterior
axillary lines and joined horizontally across the costal
margin. This will improve respiratory excursion and
therefore improve compliance. Figure 32-1 illustrates the
placement of escharotomy incisions along the anterior 
axillary lines connected by a subcostal incision. An escharo-
tomy should only be performed by a knowledgeable
surgeon.
Anticipation and treatment of pulmonary complications
is necessary in order to decrease the morbidity and mor-
tality associated with large burns (with or without smoke
inhalation injury). Patients with smoke inhalation injury
are at risk for pneumonia, ARDS, bronchiectasis, tracheo-
malacia, and subglottic stenosis. Humidified oxygen,
encouraging the patient to cough, and chest physiotherapy
assist in the clearing of airway secretions. Bronchodilators
may be helpful to relieve bronchospasm. Mechanical
ventilation may be required. Ventilator management
strategies in patients with smoke inhalation injury include
a pressure mode of ventilation with longer inspiratory
times at lower peak pressures and positive end-expiratory
pressure (PEEP) to improve compliance, recruit alveoli,
and maintain an adequate functional residual capacity.
Permissive hypercapnia may also be necessary to limit
airway pressures.
Circulation
Since burned tissue swells, all constricting clothing
and jewelry should be removed to prevent circulatory
compromise. Finger rings should be removed as soon as
possible since swelling of the digits may make removal
later more difficult. Earrings should also be removed
since increasing edema of burned ears could lead to
pressure necrosis.
Burns with %TBSA greater than 20% will require
resuscitation. It is necessary, in these patients, to secure
adequate intravenous (IV) access. Large-bore (at least 
16-gauge) IV catheters should be placed, preferentially
through unburned skin, although this is not always 
possible. Catheters can be placed through burned skin,
but since adhesive tape will not adhere to the burn, they
should be secured with sutures. Central venous catheters
provide more definitive venous access. Due to the high
incidence of catheter colonization and infection, antibiotic-
impregnated central venous catheters should be used if
available. An indwelling urethral catheter should be placed
to monitor urine output during resuscitation.
Resuscitation formulas have become the standard for
initiating and conducting the treatment for burn shock.
The most commonly used formula is the Parkland (or
Baxter) formula. Correct application of this formula
requires an estimation of the second- and third-degree
%TBSA involvement and the patient’s weight. The extent
of the burn can be approximated using the “Rule of
Nines” (Figure 32-2), a guide to estimating %TBSA burned
based upon dividing the adult body into 11 regions each
corresponding to 9%TBSA. The head and each upper
extremity represent 9% of the TBSA; the anterior torso,
posterior torso, and each lower extremity represent 18%
of the TBSA. Children under 30 kg require a slightly dif-
ferent approximation of %TBSA due a disproportionately
larger head; a child’s head represents 18% of the TBSA and
each lower extremity represents 14% of the TBSA. A rough
estimate for irregular burns is that the patient’s palm (not
including the fingers) represents about 1% of the TBSA. 
A computerized estimation of the %TBSA burned may be
generated at the website www.sagediagram.com.
Fluid resuscitation with lactated Ringer’s (LR) solution
should be guided by the Parkland formula which directs
CLINICAL CAVEAT
Acute increases in peak airway pressures in patients
with circumferential torso burns should first be evaluated
for airway obstruction, right main stem intubation, or
pneumothorax prior to considering chest wall
escharotomy.
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Figure 32-1 Correct placement of esharotomy incisions.
that a fluid volume of 4 ml/kg/%TBSA burned be admin-
istered over the first 24 hours following the time of
injury; half of this volume should be administered over
the first 8 hours and the other half administered over the
next 16 hours. Although this is the classic teaching of
the application of the Parkland formula, it is impractical.
Reducing the IV fluid rate to half after an arbitrary 
8 hours does not estimate the physiologic need for fluid
after being burned. Most burn centers use the Parkland
formula to calculate the initial IV fluid rate. Then, physi-
ologic parameters are used to titrate the IV fluid down
over the next 24 hours. Practically speaking, this calcu-
lation provides a starting rate for IV fluid administration;
this rate is then titrated up or down to maintain a urine
output of at least 0.5 ml/kg/hour. The fluid is titrated
down to a maintenance rate at 24 hours from the time of
injury.
The presence of a smoke inhalation injury will increase
IV fluid resuscitation requirements by anywhere from 40%
to 75%. Other factors that may contribute to increased IV
fluid requirements include large burns (>50% TBSA),
alcohol intoxication, hepatic insufficiency, electrical
injuries, and a history of chronic diuretic use. At 24 hours
postinjury, adequate resuscitation will allow the patient
to be treated with IV fluids at a maintenance rate 
(30 ml/kg/day) plus 1 ml/kg/%TBSA burned to account
for evaporative losses through the open burned wound.
In large surface area burns this estimate of insensible loss
can be quite significant.
If the above resuscitation strategy is unsuccessful by
12 hours postinjury and the patient remains hypotensive
(mean arterial pressure < 80 mmHg), tachycardic (heart
rate > 120 beats per minute), or oliguric (urine output 
< 0.5 ml/kg/hour) despite increasing the rate of IV fluid
administration, colloid should be administered. A variety
of colloid solutions can be used; commonly used solutions
include 5% albumin (0.3–0.5 ml/kg/%TBSA burned over
18 hours), 6% dextran-70 (0.5–1.0 ml/kg/%TBSA burned,
not exceeding 33 ml/kg over any 24 hour period), and
6% hetastarch (0.5–1.0 ml/kg/%TBSA burned).
Electrical burns often require more extensive IV fluid
resuscitation than calculated by the Parkland formula
because the extent of subcutaneous and deep tissue
involvement is usually underestimated by the apparent
cutaneous injury. In addition, rhabdomyolysis may occur
as a result of muscle necrosis, leading to myoglobinuria.
Patients with myoglobinuria should be treated with LR at
a rate of at least 1000 ml/hour to prevent acute tubular
necrosis and ensure a urine output of at least 100 ml/hour.
A sample of the patient’s urine should be obtained ini-
tially and kept with the patient for comparison to subse-
quent samples to assess clearing of the pigment. Patients
who sustain electrical injuries should be monitored with
telemetry for at least 24 hours due to an increased risk
for cardiac arrhythmias. Patients with electrical burns must
also be assessed for neurologic injuries and concomitant
musculoskeletal, especially spine, trauma, as these injuries
are commonly associated with electrical injuries.
After appropriate wound care, extremity burns
should be elevated and splinted in a position of function.
Peripheral circulation should be monitored using a Doppler
ultrasonic flow meter as circumferential full-thickness
extremity burns may compromise distal perfusion and
require escharotomy. Patients who sustain electrical
injuries are at risk for the development of a compartment
syndrome and may require fasciotomy to decompress 
tissue compartments. Doppler flow should be monitored
on an hourly basis at the most distal aspects of the extrem-
ities, i.e., the palmar arch and digital vessels of the hands
CLINICAL CAVEAT
The rate of IV fluid administration should be
calculated from the time of injury. For example, if a
patient sustains a burn 3 hours prior to instituting IV
fluids, half of the calculated 24-hour fluid requirement
should be administered within the first 5 hours.
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Figure 32-2 The “Rule of Nines,” a guide to estimating the per-
cent of the total body surface area (%TBSA) burned based upon
dividing the adult body into 11 regions each corresponding to
9%TBSA.
and the pedal vessels of the feet. One should not await
the presence of neurologic signs such as paresthesias,
pain, or paralysis to make the diagnosis of impaired distal
perfusion. Figure 32-1 illustrates placement of escharo-
tomy incisions along the lateral and medial aspects of the
extremities and over the dorsal aspect of the hand. A lat-
eral incision is made first; if no improvement in Doppler
flow is detected within 5–10 minutes, the medial incision
is then made. It is important that the escharotomy inci-
sion is made along the entire length of the full-thickness
burn and that it crosses the joints.
BURN WOUND CARE
Basic principles of burn wound care involve keeping
the wounds clean, moist, and protected. It is essential
that the patient be kept in a warm environment above
30°C. Burns should be cleansed with a warm chlorhexi-
dine solution. First-degree burns may be treated with any
moisturizing cream. Superficial or deep partial-thickness
burns to the face or neck should be treated with petro-
latum. This should be reapplied several times per day to
maintain moisture. Burns to the ears should be treated
with mafenide acetate (Sulfamylon) cream if cartilage 
is exposed. Large blisters, especially those located over
the palms or the soles should be evacuated but left intact
and dressed with a moisturizing ointment and gauze 
dressing.
Superficial partial-thickness burns elsewhere on the
body may be treated with petrolatum or temporary skin
substitutes such as xenografts, cadaveric allografts, Apligraf
(collagen/fibroblast matrix with overlying keratinocytes),
Biobrane (collagen/nylon mesh with an outer silicone
film), or Trancyte (human newborn fibroblasts cultured
on the nylon mesh of Biobrane). These temporary skin
substitutes promote reepithelialization and reduce wound
pain, evaporative losses, and edema, and are left in place
to adhere to the wound bed until healing occurs.
Deep partial-thickness and full-thickness burn wounds
should be treated with a topical antimicrobial agent to
decrease the risk of developing an invasive burn wound
infection. Table 32-3 lists distinguishing characteristics 
of four commonly used topical antimicrobial agents. 
One effective treatment strategy is to treat deep partial-
thickness or full-thickness wounds with silver sulfadiazine
(Silvadene) or Acticoat (an ionic silver-coated polyethylene
fabric). Wounds treated with silver sulfadiazine should be
cleansed once or twice daily and the cream reapplied.
Wounds treated with Acticoat need to be moistened
with water (not saline, as this will cause the dressing to
dry out) several times a day and the dressing changed
every 3–4 days.
Infected full-thickness burns should be treated with
mafenide acetate, as this is the only agent that can 
penetrate the eschar, and the dressings changed twice
daily. Note that mafenide acetate is a strong carbonic
anhydrase inhibitor and can cause a hyperchloremic
metabolic acidosis.
OTHER CONSIDERATIONS
Systemic Wound Management
Ibuprofen should be administered on a scheduled
basis (1200 mg loading dose followed by 800 mg every 
8 hours) for the first 72 hours after a burn injury occurs
to decrease thromboxane A2 production and the result-
ant dermal vasoconstriction.
Tetatus toxoid should be administered if the patient’s
last immunization was more than 5 years previously.
There is no role for the administration of prophylactic
systemic antibiotics.
Pain Control
Partial-thickness burns are associated with a signifi-
cant amount of pain due to the exposure of pain fibers
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Table 32-3 Characteristics of Topical Antimicrobial Agents Used in the Treatment of Deep 
Partial- and Full-Thickness Burns
Agent Spectrum of Activity Eschar Penetration Disadvantages/Side Effects
Silver sulfadiazine, Gram positive, Poor Transient leukopenia in 5–15%; some Gram-negative 
1% cream (Silvadene) Gram negative, yeast organisms, e.g., clostridia, are resistant
Ionic silver fabric Gram positive, Poor None
dressing (Acticoat) Gram negative, yeast
Mafenide acetate, Gram positive, Good Painful; carbonic anhydrase inhibitor causing acidosis
11.1% cream (Sulfamylon) Gram negative
Silver nitrate, 0.5% solution Gram positive, Poor Can cause hyponatremia, hypokalemia, hypochloremia, 
Gram negative, yeast hypocalcemia, and met-hemoglobinemia; stains 
environment, equipment, and personnel
in the dermis; adequate analgesia is essential and can 
usually be achieved by the intermittent administration of
small amounts of IV narcotics. Patients requiring mechan-
ical ventilation are commonly treated with a continuous
infusion of IV narcotics. Patients with full-thickness burns
usually have decreased narcotic requirements as these
burns have destroyed the pain fibers in the dermis.
Nutritional Support
Patients with extensive thermal injury will experi-
ence a hypermetabolic state with increased oxygen con-
sumption and catabolism resulting in the wasting of lean
body mass. Patients with burns of >20%TBSA will have a
resting energy expenditure (REE) 1.5 to 2 times normal
and will require supplemental nutritional support. One
formula for calculating the REE (in kcal/m2/hour) in a
burn patient, developed at the US Army Institute of
Surgical Research, is:
REE = BEE × [0.89 + (0.014 × %TBSA burned)]
where BEE is the basal energy expenditure and can be
calculated from the Harris–Benedict equation:
for males, BEE = 66 + (13.7 × wt) + (5 × ht) − (6.8 × age)
for females, BEE = 65 + (9.6 × wt) + (1.8 × ht) − (4.7 × age)
where wt is weight in kilograms and ht is height in 
centimeters. Protein requirements may be in the range
2.5–3 g/kg/day.
Enteral feeds represent the optimal route of caloric
support; however, patients with a >20%TBSA burn may
have an ileus in the early postburn period and will not
tolerate enteral feeds. These patients often require naso-
gastric tube decompression until the ileus resolves; 
gastrointestinal motility usually returns by the third to
fifth day postinjury. Serum glucose levels should be mon-
itored every four hours once feeds begin as burn patients
will experience some degree of peripheral insulin resis-
tance. Continuous insulin infusions may be necessary 
to control hyperglycemia. These patients are also at risk 
for the development of stress gastritis and should be 
prophylactically treated with antacids, H2 receptor
antagonists, or proton pump inhibitors.
CONCLUSIONS
The USA has one of the highest rates of fire-related
deaths. The successful management of a burn patient
requires an understanding of the pathophysiology asso-
ciated with thermal injury and a high index of suspicion
for smoke inhalation injury. Continued assessment of the
airway, adequate IV fluid resuscitation, pain control,
nutritional support, and appropriate wound care are
essential components of the care of patients with ther-
mal, chemical, or electrical burns. The anticipation and
treatment of complications associated with different
burn injuries play an equally important role in the man-
agement of these complex patients.
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The probability that civilian physicians will treat civilian
casualties within the USA due to biological, chemical, and
nuclear exposure continues to increase daily. The likeli-
hood of such an attack outweighs that of conventional
weapons in the civilian arena primarily because of accel-
erated terrorist activities. The impact of these agents 
is fourfold. The first is mortality and incapacitation of
directly exposed individuals, the second is the psychology
of mass panic and hysteria, thirdly civil disruption is super-
seded by post-traumatic stress disorders, and finally there
are the lingering effects of agents on chronic health and
genetic mutation in survivors. The key to effective response
is based in education, index of suspicion (situational
awareness), and response planning (standard operating
procedures).
Physicians and other health care providers in civilian
practice settings do not presently have sufficient training
to participate in the frontline management of environmen-
tal threat scenarios. Physicians practicing in life-support
specialties such as anesthesiology, emergency medicine,
and critical care have a key role in the immediate and
long-term public health response.
The general principles for the management of environ-
mental threat are similar to the management principles for
natural disasters, industrial accidents, or epidemics. Since
these principles can be learned, education is fundamental
to public policy initiatives regarding preparation of the
health care system.
TYPES OF ENVIRONMENTAL THREAT
● Artificial versus natural. For example, a biological
agent released either during or as a terrorist act
versus natural epidemic of either an established or
emerging biological organism.
● Point source versus line source. For example,
release of an agent at a particular location versus
multiple releases simultaneously or in sequence.
● Immediate versus sustained release.
● Human target versus infrastructure target. Humans
as targets of environmental threat versus food
sources or technology.
● Direct effect versus indirect effects. The immediate or
discernible effect of environmental threat on humans
versus insidious contamination, genetic effects, or
vector-mediated diseases.
Toxins are biological substances produced by animals,
plants, or microbes. Toxins are more difficult to manufac-
ture on a large scale than are synthetic chemical weapons.
Mass casualty biological weapons (MCBWs) are toxins capa-
ble of being used in attacks against the civilian or military
infrastructure. The method of dispersion (e.g., aerosol, gas,
ingestion) differentiates agents based on method of 
delivery. Inhalation, ingestion, and dermal activity differen-
tiates agents based on the method of introduction.
LD50 refers to the dose required to cause death in 50%
of patients, or the dose that results in a 50% chance of
survival or death in a person receiving it. LD50 is a measure
of toxity and also defines the practical applicability of
agents as potential MCBWs.
The effects of agents must be considered. Lethality is
only one index of effect; short-term and long-term inca-
pacitation and public panic and anxiety are also important.
GENERAL PRINCIPLES OF CONTAINMENT
The first priority of disaster medicine is the prevention
of secondary casualties. Caregivers who are inexperienced
in disaster or military medicine are especially vulnerable.
The disaster plan is an operations blueprint that defines the
policies and procedures to be implemented in the event of
an emergency. The plan must include every conceivable
aspect of mass casualty care including a contact hierarchy
and contact information, personnel assignments, internal
and external communication protocols, decontamination
procedures and equipment, quarantine and lockdown,
evacuation plans, and supply management. The effective-
ness of any disaster plan will depend on the weakest link.
The chain of command is the hierarchy for various
professionals involved in the response. Responsibilities
are based on training and experience. Although health
care providers are experienced in providing medical care
in general, they lack the specialized training required to
manage disasters. Inexperienced providers risk becoming
casualties.
Law enforcement, the fire department, emergency
medical systems, environmental agencies, public health
organizations, and the military are included in the com-
mand structure.
The first principle of management is containment with
a perimeter. Multiple circumferential perimeters are
defined by threat levels. Quarantine may be necessary to
prevent continued spread of offensive agents. Quarantine
refers to a compulsory physical separation of affected
persons and the definition further extends to a restriction
of movement and to segregation as an affected group.
Isolation is less restrictive and refers to separation and
confinement of affected individuals known or suspected
to be affected with an infectious agent. Disaster manage-
ment assistance teams (DMATs) are disaster relief per-
sonnel usually deployed within 24–48 hours.
A variety of command posts may need to be established
for various services and teams or locations. Command
posts report to a command center which has operational
control over disaster management personnel. Individual
command centers report to a tactical command center
which coordinates the allocation of personnel and
resources. A strategic command center, usually geo-
graphically removed from the immediate disaster area,
usually coordinates government agency activities.
Communications are critical and likely to be extremely
vulnerable. Communications may be targeted. Landline
telephone communications may be physically compro-
mised or overwhelmed by excessive use. Efficient com-
munication requires prioritization and organization.
Access overload control for cellular radio telephones
(ACCOLC) assigns priority to cellular phones used by
emergency personnel during periods of circuit overload.
Cellular, radio (UHF and VHF), and internet communica-
tions provide redundancy. A system of couriers can be
locally effective in the setting of a total communications
breakdown. External communication is also necessary
with local, state, and federal agencies; with the media;
and with families.
Methods for cataloging the injured must be in place.
Principles of disaster response form the basis for a dis-
aster plan. Disaster plans exist at the institutional, com-
munity, state, regional, and federal levels. Knowledge of
the plan and repetitive rehearsal are important to the
plan’s success. Preparation activities increase organiza-
tional capacity in the event of a disaster. Preparation
includes resources (material and personnel) inventories,
prearranged agreements with suppliers and personnel,
staff orientation and training, and drills. Response activi-
ties control the situation when it occurs. The first level is
organizational and requires internal leadership and coor-
dination with local and regional agencies. The second is
a coordinated and dedicated staff response.
GENERAL PRINCIPLES OF MEDICAL
MANAGEMENT
Natural Disasters
A “disaster” is defined as a “situation or event which
overwhelms local capacity, necessitating a request to
PEARLS
Principles of Response
Situational awareness:
● Index of suspicion
● Education and familiarity with potential problems
● Communication
Response deployment:
● Coordination and leadership
● Chain of command
Source control:
● Perimeter establishment
● Quarantine and isolation
● Disinfection and decontamination
● Antidotes and antibiotics
● Supportive critical care
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national or international levels for external assistance” or
a sudden event which “causes great damage, destruction,
and human suffering.” Natural disasters can include hur-
ricanes, tornadoes, volcanoes, earthquakes, flood, fire, 
or drought. Natural disasters can have both initial and
secondary impact. Initial impact is the result of trauma or
environmental exposure. Secondary injuries may occur as
a result of impact on technological infrastructure, damage
to nuclear, toxic chemical, or biologic facilities with leak-
age of hazardous materials, the precipitation of dangerous
conditions, loss of power, and spread of disease. Initial
priorities will include evacuation, evaluation and resus-
citation, and containment of casualties.
Public health issues include the availability of basic
services (water supply, food supply, electricity, sanitation
and waste disposal, housing and shelter, and disposition
of human and animal remains). Medical care ranges from
trauma resuscitation to vaccination and treatment of
secondary illnesses. Psychological support may be nec-
essary to minimize post-traumatic stress disorder (PTSD)
or crisis incidence stress disorder (CISD) and long-term
psychological impact of the disaster. The purpose of 
psychiatric intervention is twofold: to provide immediate
relief and early return to normal activities, and to prevent
the development of chronic syndromes.
Vector control may be necessary to prevent spread of
disease by mosquitoes, flies, and rodents.
Conventional Weapons
Explosives remain the most likely mass casualty cause
in the USA and elsewhere. Explosives directly cause blast,
burn, and penetrating trauma. Additionally, explosive
devices will indirectly cause other injuries and fatalities
depending on the arena in which the explosives are
deployed: buildings, subways, airplanes, industrial com-
plexes, for example. Since the US health care system is
currently functioning near or at capacity, special plans
must be in place for the care of large numbers of acute
casualties.
Biologic Agents
Overview
Throughout history epidemics have killed countless
millions, eliminated cultures, defeated empires and their
armies, and thereby irrevocably altered the course of civ-
ilization. That the power of infectious agents could be
strategically and tactically directed for political and mili-
tary purposes is a logical extrapolation. Bacteria, viruses,
fungi, and their biological toxins, as well as newer chem-
ical toxins could be deployed to kill or disable combat-
ants or cripple the civilian or agricultural infrastructure
of enemies.
The key advantages of such agents are that they are
relatively inexpensive to produce, allow for the preserva-
tion of structural integrity following attack, and allow for
selective immunization, barrier protective, or antidotal
defensive measures. In addition, such agents can be easily
deployed, are difficult to detect, and it can be difficult to
trace temporal, spatial, and causal origins when used for
terrorist purposes. The key disadvantage remains epidemi-
ological unpredictability.
A key function of health care providers will be the
rapid diagnosis of index cases and communication with
public health authorities. A key dilemma for public health
authorities will be the differentiation of the presenting
symptoms of the pathogens listed below from other dis-
eases with similar symptoms, especially in the flu season,
and to differentiate isolated endemic cases from index cases
of potential epidemics. Biologic agents can be categorized
as either infectious agents per se or biological toxins.
Infectious Agents
Infectious biologic agents used in biologic warfare or
bioterrorism can include bacterial, viral, and atypical
organisms. Almost any agent that incapacitates troops 
can be employed in the battlefield. The most effective 
terrorism agents are those which incite panic. Bacterial
agents which have been successfully weaponized include
anthrax (Bacillus anthracis), plague (Yersinia pestis), and
tularemia (Francisella tularensis) (Boxes 33-1 and 33-2).
Anthrax is a spore-forming gram-positive bacillus that is
endemic worldwide. Occupationally, cutaneous anthrax is
contracted by individuals working with contaminated 
animal fibers such as goat hair. Gastrointestinal anthrax is
enzootic in Third World countries with domestic ungulate
herds. The use of anthrax as a germ-warfare agent requires
that anthrax spores be concentrated, electrostatically 
stabilized, and disseminated at a target. An outbreak of 
● A sudden or increased incidence of a stable 
endemic disease
● A similar genetic type of organism isolated from
different times or locations
● A simultaneous cluster of outbreaks in
noncontiguous geographic areasx
PEARLS
Clues Signaling a Biologic/Chemical/
Toxicologic Event
● Large numbers of patients with a similar syndrome
● Large numbers of patients with an unusual disease
or syndrome
● A higher morbidity or mortality than expected with
common disease
● A single case of a very uncommon disease
● An unusual clinical presentation of a known disease
● An unusual geographic or seasonal distribution
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respiratory anthrax should be presumed to be a result of a
threat until proven otherwise. The symptomatology of 
respiratory anthrax follows a biphasic clinical pattern; ini-
tially, there is nonspecific syndrome consisting of malaise,
fatigue, myalgia, fever, nonproductive cough, and occa-
sionally a sense of precordial fullness. Frequently, this pro-
drome is followed by signs of improvement after 2–4 days.
The second phase of respiratory anthrax is characterized
by the acute onset of hypoxia, dyspnea, and severe respi-
ratory failure. Radiographic studies may reveal mediastinal
widening and pleural effusion. Septicemia, septic shock,
with or without meningitis, then usually develops within
24 hours. The pathophysiology of anthrax-related sepsis is
due to toxins produced by the germinating spores.
Vaccines, not completely effective, target the exotoxin
components. Inhalational anthrax is very difficult to diag-
nose in its early, treatable stages. Paradoxically, antibiotic
therapy must be initiated rapidly, and often empirically,
with penicillin or fluoroquinolones such as ciprofloxacin.
Spores are extremely tenacious and vigorous decontami-
nation at the site of spore release is necessary.
Plague (bubonic plague, the “black death”) eradicated
a significant segment of the world’s population during a
series of pandemics in the Middle Ages. Y. pestis is a gram-
negative bipolar-staining bacillus which belongs to the
Enterobacteriaceae family. Plague is presently endemic
worldwide and is also notably endemic in the south-
western United States. Plague is an enzoonotic infection
which is transmitted from natural animal reservoirs to
humans by either contaminated tissues or insect vectors.
Bubonic plague is characterized by bacterial proliferation
in regional lymph nodes. Massive regional lymphadeno-
pathy (“buboe”) typically occurs 2–8 days following the
bite of an infected flea. The groin is the most common site
of buboes. The lymphadenopathy is typically followed by
sepsis with high-density bacteremia, diffuse purpuric skin
lesions, hemorrhage, and necrosis. Weaponized plague is
most likely to be pneumonic plague which is spread by the
intentional release of aerosolized bacteria, or by person-to-
person droplet-mediated transmission. The incubation
period for pneumonic plague is 1–6 days, and is mani-
fested by progressive diffuse lymphadenopathy, hemopty-
sis, patchy bronchopneumonia or confluent consolidation,
purulent sputum, septic shock, and respiratory failure. The
mortality rate from pneumonic plague is extremely high. A
formalin-killed vaccine is no longer commercially available.
Early aggressive treatment with intravenous  streptomycin,
penicillin, or gentamicin may be effective; postexposure
prophylaxis with doxycycline or ciprofloxacin is also 
recommended. The psychological effect of a widespread
urban outbreak of plague  is likely to be devastating.
Tularemia is a gram-negative coccobacillus, enzootic
primarily in animals, and endemic worldwide, primarily
within the northern hemisphere. Tularemia continues to
be responsible for significant human morbidity and 
mortality, and is regionally referred to as either “rabbit
fever,” “water-rat trapper’s disease,” or “deerfly fever.”
The human host in tularemia is generally accidental, occur-
ring through insect vectors. Tularemia can be typhoidal,
pneumonic, or ulcero-glandular. The incubation period
ranges from 1–21 days but usually starts abruptly with
acute onset of fever, chills, headache, malaise, anorexia,
and fatigue. Additional prominent symptoms include
cough, chest discomfort, emesis, diarrhea, and dysphagia.
Pneumonic tularemia occurs in only 7–20% of all
tularemia cases, and therefore, a regional outbreak of pul-
monary tularemia should suggest a threat. Approximately
25–30% of patients with pulmonary tularemia will not
manifest the radiographic infiltrates or other clinical find-
ings for pneumonia. Pulmonary tularemia is characterized
by a dry cough, minimal sputum production, pleuritic
chest pain, substernal tightness, and only occasional respi-
ratory failure requiring mechanical ventilation. Tularemia
is more likely to be incapacitating than lethal. However,
severe disease may be complicated by disseminated intra-
vascular regulation, rhabdomyolysis, hepatitis, meningitis,
and renal failure. The diagnosis is basically one based in a
high index of suspicion. The drug of first choice for all forms
of tularemia except meningitis is streptomycin, but gentam-
icin is an acceptable substitute. A vaccine for tularemia 
is currently under review by the FDA. Person-to-person
transmission of tularemia is unlikely.
Smallpox, caused by the Variola major virus, is 
probably the most feared viral bioterrorism agent.
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Box 33-1 Categorization of Agents
● The Center for Disease Control (CDC) categorizes
agents as A–C based on ease of dissemination,
impact, and defensibility.
● A-type agents receive the highest priority because 
of ease of dissemination, person-to-person transmis-
sion, and high morbidity and mortality. These
agents include anthrax, botulism, plague, smallpox,
tularemia, and viral hemorrhagic fevers.
Box 33-2 Anthrax
● Anthrax can present in three different forms:
inhalational, cutaneous, and gastrointestinal.
Inhalation anthrax is the most lethal form spread 
by inhalation of anthrax spores.
● Inhalation anthrax has incubation period of 1–7 days
and affects the mediastinal lymphatic system causing
death by hemorrhagic mediastinitis. There is no 
respiratory transmission between persons.
● Treatment of inhalation anthrax is with intravenous
ciprofloxacin or doxycycline based on sensitivities.
Because smallpox is considered to have been eradicated
worldwide since 1977, even a single case of smallpox
would likely indicate a terrorist attack. Smallpox has an
incubation period ranging from 7 to 17 days, with an aver-
age of 12 days; the illness typically follows a brief prodromal
period of 2–4 days during which the virus can be isolated
from the blood. The prodromal symptoms are flu-like and
include fever, myalgias, nausea, and vomiting. The disease
typically begins with a centrifugal rash which progresses in
a uniform pattern from maculopapules to vesicles to pus-
tules and scabs over a 1–2 week period. It is important to
note that the centrifugal distribution and the homogeneity
of the rash are key differential diagnostic points: in chick-
enpox, lesions are distributed evenly over the body begin-
ning on the trunk and in chickenpox, individual lesions
form and scab over at different times. In its most prominent
form, death may occur before the rash becomes manifest,
and in its most discreet form, the disease may follow its full
course to recovery. The mortality in the past has ranged
from 25–50%; however, those statistics reflect mortality
within a partially immunized population. Vaccination has
been shown to be effective up to four days after exposure.
Treatment is supportive. Notably, monkeypox is another
Orthopoxvirus disease caused by a variola virus. It is
endemic in African monkeys and can rarely be spread to
humans. 
Viral hemorrhagic fevers include Marburg and Ebola,
which belong to the Filovirus class. The incubation
period for filovirus fevers ranges from 2 to 19 days and
symptoms begin with the abrupt onset of fever, myalgia,
and headache. Progression of symptoms to gastroenteritis,
pneumonitis, pancreatitis, pharyngitis, and encephalitis is
common. With further progression, petechiae, diffuse
hemorrhage, and a truncal maculopapular rash may
become evident. Typically, in the second week, the
patient will either defervesce and improve rapidly, or
will die in shock from multiorgan failure. The mortality
of Marburg at the present time is approximately 25%.
Ebola has higher mortality depending on the subtype of
virus: Sudan subtype has mortality of 50%, and Zaire 
subtype has a much higher mortality of 90%. There 
are no vaccines or similar preventive measures; antiviral
chemotherapy such as Ribavirin may be effective as
treatment. Management is supportive and extensive
quarantine precautions are indicated. These viruses can
be weaponized for aerosolized dissemination.
The viral encephalitides include a variety of agents
such as the Togavirus subclass of alphaviruses (Eastern
equine, Western equine, Venezuelan equine); the flavi-
viruses (West Nile, Dengue, St. Louis); the Bunyaviruses
(Rift Valley); the Arenaviruses (Lassa, Junin, and Machupo).
Patients with viral encephalitis tend to have signs and
symptoms of meningeal inflammation but, in addition to
headache, fever, and nuchal rigidity, the patients with
encephalitis also have alterations in consciousness.
Infections may be acute, subacute or chronic. Treatment is
generally symptomatic unless the cause is otherwise iden-
tified to not be viral, in which case specific therapy is usu-
ally available and should be instituted as soon as possible.
Q fever, caused by Coxiella burnetii, is an enzootic ill-
ness in ungulates with worldwide distribution. Humans
are infected by inhalation of contaminated aerosols 
or by insect vectors. C. burnetii is a pleomorphic cocco-
bacillus with a gram-negative cell wall which possibly
enters host cells. Person-to-person transmission is poss-
ible, especially in the pneumonic form of the disease.
The incubation period for Q fever is 14–40 days and
once again, the prodrome and clinical illness are non-
specific. Clinical manifestations range from pneumonia,
to endocarditis, hepatitis, osteomyelitis, encephalitis,
and meningitis. The radiographic appearance of Q fever
pneumonia is variable; however nonsegmental and seg-
mental pleural-based opacities are common findings. 
A pleural effusion is found in approximately 35% of
cases. The pneumonia is rarely fatal. The treatment of
choice is doxycycline or tetracycline, which can also be
used for postexposure prophylaxis. An investigational
vaccine is currently under development.
Community surveillance and centralized reporting
form the basis for a bioterrorism response. Potential indi-
cations for intentional release of a bioweapon include
unusual temporal or geographic presentations, unusual
severity, and rapid epidemiologic spread.
Rapid diagnosis can be achieved using either immuno-
logic testing or electron micrography for many agents.
Containment and prevention of secondary spread are
vital. Access to the National Pharmaceutical Stockpile for
treatment will be managed by the Center for Disease
Control in the armed forces. Rapid immunization or dis-
pensation of prophylactic medication will help contain
centers of outbreak.
Toxins and Chemical Agents
A disaster that involves the release of toxic chemicals
and widespread toxic exposure of a population can
occur in two different scenarios: first, the intentional
release of a chemical warfare agent directed against the
population; and second, the accidental or intentional
spillage of stored or transported toxic chemicals in a
populated area. A third potential scenario is chemical
terrorism directed at the food supply chain, a scenario of
which is discussed below.
Broadly speaking, a chemical attack could occur
through the use of either toxins or synthetic chemical
agents. The toxins represent a category of agents related
to biological agents and also chemical agents. The toxins
are products of biological processes or organisms which
must be concentrated and weaponized prior to deploy-
ment. In general, toxins are proteins with high affinity 
to cellular binding sites. The toxins represent chemicals
that include some of the most potent and deadly 
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compounds known. Similar to chemical agents, toxins
can be inhaled, ingested, or dermally absorbed.
Toxins
Botulinum toxin is the most potent toxin known 
(Box 33-3). It is a naturally occurring product of
Clostridium botulinum and is comprised of seven differ-
ent molecular toxins. The LD50 is 0.001 μg/kg. The
mechanism of action of botulinum toxin is through bind-
ing to the neuronal cell membrane at the nerve termi-
nus, followed by endocytosis, then the light chain of
botulinum toxin cleaves specific sites on SNARE proteins
preventing assembly of the symmetric fusion complex
and blocking the release of acetylcholine. The intensive
care unit (ICU) at Unity Health System in Rochester,
New York, recently cared for a patient exposed to 
botulinum toxin who was in the ICU for almost a year.
Botulinum toxin produces a flaccid paralysis. A pentava-
lent antidote available from the US Department of Defense
must be administered early.
Clostridium tetanii produces tetanus toxin. The LD50
is 0.002 μg/kg. Tetanus produces a rigid, tetanic paralysis.
Ricin is a protein byproduct of castor bean processing
in the production of castor oil. Ricin is a toxic byproduct
of castor oil fermentation and affects cellular protein syn-
thesis. Inhalation exposure produces symptoms within
4–8 hours manifested by pulmonary edema and respira-
tory tract necrosis. Treatment is supportive. Processing
yields 3–5% ricin by weight and there is thus a large
amount of ricin available. The LD50 is 3.0 μg/kg. Inhalation
causes acute respiratory distress with pulmonary lesions;
ingestion causes gastrointestinal hemorrhage with necrosis
of the liver, spleen and kidneys; intramuscular injection
causes localized pain, and muscle and regional lymph node
necrosis.
Staphylococcal enterotoxin B is a seven-component
pyrogenic protein toxin isolated from S. aureus. The toxin
classes and subclasses stimulate T-cells and cause fever
and myalgia, nonproductive cough and interstitial
edema, headache, and gastrointestinal complaints. The
LD50 is 0.02 μg/kg.
Chemical Agents
Chemical agents are classified as vesicants, nerve
agents, toxic inhalants, cyanogens, or riot control agents.
Vesicants
Vesicants include the mustards (HD, HT, HN),
Lewisite (L), and phosgene (CX) and are defined to be
agents that produce blisters or vesicles. These agents
have been available since World War I. The mustards
enter the body through the mucous membranes or the
skin and react with proteins and nucleic acids. DNA repli-
cation is inhibited. There are no immediate signs or
symptoms on contact, inhalation, or ingestion, unless
direct exposure to concentrate occurs. Odor is variable.
Symptoms occur 2–24 hours after exposure and include
destruction of the spleen and bone marrow. The eyes are
extremely sensitive to mustard gas. Mucosal sloughing of
the lower respiratory tract followed by pneumonia and
pulmonary edema result from heavy exposure. The 
mustards are also teratogenic.
Lewisite inhibits multiple enzymes by reacting with
either glutathione or sulfhydryl groups. Lewisite contains
arsenic and reacts with enzymes to cause pulmonary
edema, diarrhea, fever, and lethargy. Lewisite causes
immediate pain and irritation on contact, with erythema
and blistering. Although Lewisite also inhibits DNA repli-
cation, it generally spares the bone marrow. It causes
more severe tissue destruction. Death is usually from 
respiratory failure, bronchospasm, or pneumonia. The
clinical effects are similar to mustard gas exposure and
include profound shock from plasma leakage. Lewisite
has an odor similar to that of geraniums. The specific
antidote is Dimercapterol (2,3-dimercaptopropanol),
otherwise known as British Anti-Lewisite (BAL), and
aggressive intravenous fluid management. Iodophors
and topical antibiotics may limit skin damage. Lewisite,
like the mustards, is teratogenic.
Phosgene is commonly grouped with the blister agents
and is a urticant causing extreme irritation of tissues.
Phosgene has not been previously used in warfare. Like
the vesicants it also inhibits DNA replication. Epithelial
sloughing occurs from the skin and the respiratory, gas-
trointestinal, and genitourinary tracts. It is a potent pul-
monary irritant. There is immediate pain on contact and
ocular exposure results in conjunctivitis and keratitis.
The main lesion is pulmonary edema with necrotizing
bronchiolitis and thrombosis of pulmonary vessels.
There is no laboratory test or antidote. Rapid topical
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Box 33-3 Botulism
● Botulism results from the ingestion of botulinum
toxin types A–G which are produced by C. botulinum
and two other clostridial species. Botulinum toxin is
the most potent neurotoxin known and affects the
presynaptic releases of the acetylcholine, blocking
neuromuscular transmission. The onset of botulinum
toxin is generally slow and incapacitation is progres-
sive ending in respiratory fatigue and generalized
paralysis in 24–72 hours. Specific antitoxin therapy
is available.
● The onset of botulism ranges from 24 hours to 
several days depending on the dose ingested.
Person-to-person transmission is not generally an
issue. Botulism can be treated using an equine 
polyvalent antitoxin if administered early. In the 
setting of established botulism, long-term mechani-
cal ventilatory support and routine critical care
management are necessary.
decontamination is essential. An effective decontami-
nant is 0.5% sodium hypochlorate if immediately avail-
able; otherwise copious water irrigation should be used.
Iodophors may limit toxicity. Treatment is decontamina-
tion and supportive care.
Nerve Agents
Nerve agents include Tabun (GA), Sarin (GB), Soman
(GD), and VX. The effects of nerve agents occur in seconds
to minutes depending on the concentration of vapor.
Biotoxicity is a function of acetylcholinesterase inhibition
in the plasma, on red blood cells, and at the synapses.
Accumulation of acetylcholine causes symptoms within
minutes. Symptoms are therefore both nicotinic and
muscarinic, being due to both nicotinic and muscarinic
overactivity and include bronchorrhea, rhinorrhea, and
bronchoconstriction; miosis; bradyarrhythmias; nausea,
vomiting, and diarrhea; muscle fasciculations; and loss of
consciousness and apnea. GB and VX are odorless, and GA
and GD smell fruity. Sarin has an LD50 that is 26 times less
than cyanide gas. Antidotes include atropine (6 mg IV/IM),
diazepam, and pralidoxime hydrochloride (2-PAM).
MARK and nerve agent antidote kits (NAAKs) contain
these antidotes.
Toxic Inhalants
Toxic inhalants include phosgene (CX, CG), diphos-
gene (DP), chloropicrin (PS), and chlorine (Cl). The toxic
inhalants/pulmonary agents specifically attack the lung
tissue and cause pulmonary edema; their specificity dif-
ferentiates these agents from the vesicants, which inciden-
tally involve the respiratory tract. CG and DP are colorless
and have the odor of green corn or freshly mown hay.
These agents have a latent period of several hours.
Pulmonary edema occurs due to an acetylation reaction
which precipitates acute leakage at the alveolar–capillary
membrane. Treatment is supportive and often requires
airway maintenance, fluids/vasopressors, theophylline,
and methylprednisolone.
Cyanogens
Cyanogens are variants of cyanide and include hydro-
gen cyanide (AC) and cyanogen chloride (CK). These com-
pounds combine with the iron molecule of cytochrome a3
and precipitate anaerobic glycolysis and lactic acidosis
due to cellular hypoxia. Cyanogens may have the odor of
bitter almonds. The onset of effect is within 15–30 seconds
and includes vomiting, convulsions, and respiratory fail-
ure. Antidotes consist of thiosulfate and sodium nitrite
which form thiocyanate and methemoglobin, binding
cyanide.
Riot Control Agents
Riot control agents are used by police departments
and include lacrimants and irritants. Riot control agents
include chloroacetophenone (CN), ortho-chlorobenzyl-
idene-malononitrile (CS), dibenz(b,f)-1,4-oxazepine
(CR), and Adamsite (DM). The riot control agents are lac-
rimants, skin irritants, and vomiting agents. Effects occur
immediately on exposure and usually last 15–30 min-
utes. Treatment is supportive; however, asthmatics may
require bronchodilator therapy and persistent ocular 
irritation may require ophthalmology consultation.
Agent 15 is a nonlethal psychotomimetic agent which
causes incapacitation from delirium. It can be ingested,
inhaled, or absorbed. Symptoms are anticholinergic (delir-
ium, temperature, dry mouth, and papillary dilatation).
Physostigmine is an antidote.
Other Chemicals
A large variety of hazardous materials are stored near
populated areas and are transported on public roads
every day. These include hydrocarbons, corrosive
agents, oxidizing agents, compressed gases, insecticides,
and heavy metals. Examples include ammonia, pentabo-
rane, potassium cyanide, sodium superoxide, and vana-
dium tetrachloride.
General Principles of Chemical/Toxic Response
The critical points regarding the medical response are
(a) that medical personnel typically do not have the
training or experience to become involved at “ground
zero” and that the best of intentions may have disastrous
effects, (b) that in any chemical or biological disaster
there will be some patients who present without decon-
tamination or treatment, (c) that the medical response
must be prepared to triage, continue supportive care,
specifically identify the threat, and institute antidotal
therapy, and (d) the leadership of the hospital-based care
team (Box 33-4).
Protective containment actions are (a) the initial 
isolation zone: surrounds the incident and includes
upwind and downwind areas; and (b) the protective
actions zone: areas downwind from the incident. These
areas are considered perimeters. The key purposes of 
a perimeter are minimization of secondary injury and
spread of the toxin. Protective actions also include the
use of protective gear including the battledress overgar-
ment (BDO) and the mission-oriented protective posture
(MOPP) suits. In some circumstances protective action
can also include prophylactic administration of antidotes
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Box 33-4 Management
● Continued medical education is fundamental to an
effective and concerted disaster response and
national security.
● Mass simultaneous casualties in a concentrated area
with the same or similar presenting symptoms raise
immediate suspicion for chemical or toxin exposure.
● General management principles include decontami-
nation, ventilation, antidote administration, and 
supportive therapies.
to chemical agents prior to entry into an “event” zone.
Protective containment also requires an understanding
of prevailing and forecast meteorologic conditions.
Evacuation requires the movement of people from a
threatened area to a safer place. This may include decon-
taminated survivors. Meteorologic conditions are impor-
tant to dispersal and containment. Wind influences
dispersal whereas rain can remove toxin particles from
the air. Shelter in place should be considered when the
risk of evacuating exposed patients could pose greater
public harm than keeping them in place and treating
them when they are. This can include isolation and/or
quarantine.
The fundamental principle of decontamination after
chemical or toxic exposure is dilution. Dilution can be
accomplished by copious irrigation with water but can
also include using soap and dilute solutions of sodium
hydrochlorite (bleach). Decontamination procedures are
essential and relatively easy consisting of the removal of
residual agents from clothing and skin. Dry decontami-
nation employs absorbant powder, whereas wet decont-
amination works by dilution. Mild soap or bleach
solutions can increase the effectiveness of wet deconta-
mination. It is important to remember that those per-
forming decontamination must protect themselves from
exposure to toxic agents. Decontamination logistics
must also include the decontamination facility, water
supply, personnel and protective gear, and potentially
drainage control (Box 33-5).
Nuclear Threat
Although nuclear attack in the form of warfare remains
an ever-present possibility, the indiscriminate global rami-
fications have made retaliation a sound mutually accepted
deterrent strategy. Nuclear casualties are most likely to
arise from a reactor mishap, inadvertent spillage of con-
tained nuclear waste, or a terrorist attack (Box 33-6).
Nuclear radiation refers to ionizing radiation and includes
alpha, beta, and gamma radiation, and neutrons. Ionizing
radiation directly interacts with cellular water to produce
highly reactive free radicals and with nucleic acids to
affect cell replication and tissue regeneration.
The unit for exposure is the roentgen, symbol R, equal
to 2.58 × 10−4 coulombs/kg of air. The unit for absorption
is the rad, which is equal to 100 ergs per gram of energy
deposited. The unit for tissue effects is the dose equiva-
lent, which is equal to absorbed dose × quality factor.
Clinical acute radiation syndrome follows the acute
absorption of 2000–4000 rad, has immediate onset, and
is usually rapidly lethal. An absorption of 70–2000 rad
equates with a fair chance of survival and is manifested
by severe nausea, vomiting, bloody diarrhea, severe cap-
illary leak, and hypovolemia. Lower doses cause bleed-
ing, immunosuppression, vomiting, and severe fatigue.
Potassium iodide (KI) can protect the thyroid if it is
administered within 3–4 hours of radiation exposure.
Paradoxically, KI administered after radioactive iodine
has become concentrated in the thyroid will actually
block the elimination of radioactive iodine and worsen
its effects. Decontamination is with soap and water and
requires protective gear.
PEARLS
● Contaminated clothing must be removed since it is a
source of continued exposure
● Antidotes may need to be administered immediately
on exposure
● Survivors of the initial exposure can then be
managed to minimize injury
● Decontamination by dilution with large quantities of
water is the first line of therapy
● The spread of agents will be largely determined by
environmental conditions
● Evacuation is in the downwind direction
● Approach to the affected area is from upwind
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Box 33-5 Intensive Care Unit Care
Following decontamination provisions for intensive
cardiovascular support for mass casualties will be neces-
sary. The doses of atropine required to treat nerve agent
exposure are massive. Immediate treatment with specific
antidotes can be lifesaving. In the case of nerve agents
and cyanogens, antidotes are available. The understand-
ing of symptoms and their management is also important.
Since ventilators are not likely to be available for all casu-
alties, AMBU ventilation via endotracheal tubes may be
necessary. Mouth-to-mouth resuscitation can be dangerous
and expose rescuers to residual nerve agents, especially
VX. Anesthesiologists possess specialized knowledge
regarding airway management, chemical ventilation, fluid
management, hemodynamic support, and assessment of
central nervous system and neuromuscular function.
Additional supportive care may include topical applica-
tion of Betadine to limit the effects of vesicants, burn
and wound care, and antibiotics where indicated.
Box 33-6 Dirty Bomb
The “dirty” bomb is a high-yield conventional explosive
contaminated with radioactive material such as uranium,
cobalt-60, cesium-137, plutonium, or thorium.
Food and Water Supply
Food and water supplies are vulnerable to contamina-
tion by chemical, biologic, and nuclear agents. Dilution
naturally protects the water supply to some extent.
Diversity of ingredients and diverse food sources make
large-scale food contamination difficult. Specific con-
tamination of a point food source such as a salad bar has
occurred (i.e., the Dalles, Oregon). Such contaminations
are similar to other “outbreaks” of food poisoning 
and are differentiated by the intent behind the occur-
rence. Contamination of fertilizers or the introduction 
of pathogens such as hoof-and-mouth disease or s
pongiform encephalopathy (“wasting disease”) are 
possible, but logistically difficult, easily detectable, and
can be intercepted early. A high index of suspicion,
communication, and situational awareness is always 
necessary.
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Conclusion
Patients suffering from either intentional or accidental
poisoning frequently require an admission to the intensive
care unit (ICU). Poisoning may also be associated with
traumas, such as carbon monoxide with burns, and illegal
drugs with motor vehicle accidents. Resuscitation and
stabilization should be the first priority when treating the
poisoning victim. It is then important to limit absorption
of the toxin, identify the toxin, and initiate specific ther-
apy. This chapter focuses on these points and examines
the identification and treatment of specific agents. A dis-
cussion of the treatment of patients exposed to chemical
weapons completes the chapter.
RESUSCITATION AND STABILIZATION
Identifying the toxic agent should never delay the
resuscitation of the patient. Using basic life support guide-
lines, the patient’s airway, breathing, and circulation
should be assessed and problems treated. Many agents can
cause respiratory insufficiency and therefore supplemental
oxygen should be administered. In some cases tracheal
intubation and mechanical ventilation are required. If a
patient is at risk for aspiration, due to a depressed level of
consciousness, the airway should be protected. In most
cases this would be accomplished with a rapid sequence
induction and oral intubation. Next, attention is turned
to the cardiovascular system. Many agents can cause
hypotension (usually by increases in venous capacitance).
Therefore, hypotensive patients should have IV access
established and be treated with isotonic crystalloid solu-
tions to correct intravascular volume deficiencies. Certain
agents are associated with life-threatening tachycardia
and hypertension, which would require pharmacologic
intervention. When the patient is hemodynamically stable
with adequate oxygenation and ventilation, attention
should be turned toward identifying the toxic agent and
the extent of the exposure. In addition, a patient pre-
senting with an unexplained depression of level of con-
sciousness should receive intravenous thiamine (100 mg),
intravenous dextrose (ampule of D50), and intravenous
naloxone (0.4–2 mg).
DIAGNOSIS
After the initial resuscitation, attention should be turned
toward determining the responsible toxin(s). When pos-
sible, the administered substance (ingestion, injection,
inhalation) and extent of exposure (quantity, timing, and
chronicity) should be determined. Sources for this infor-
mation include the patient, family members, and friends.
Next, a physical examination should be performed, which
could supply useful information, since many toxins pro-
duce predictable physiologic changes (see Tables 34-1
and 34-2). In addition, there are constellations of symp-
toms that characterize certain poisoning syndromes. These
are known as “toxidromes” (Table 34-3).
Laboratory examinations may be of benefit in the eval-
uation and treatment of patients suffering from poison-
ing. These examinations include an arterial blood gas,
qualitative toxicology screens, quantitative analyses,
and, perhaps, an EKG. An arterial blood gas is useful for
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several reasons. Determining hypoxia, hypercarbia, and
anion gaps may be useful in determining the offending
agent. In addition, the information gained may prompt
emergent treatment such as securing the airway and
providing mechanical ventilation. Qualitative toxicology
screens are performed on urine samples and report only
the presence or absence of a substance. They are limited
to the particular tests performed at individual institu-
tions. The “tox screen” is often of limited utility, since it
rarely changes therapy and many toxins are not
detectable. Quantitative serum levels are useful in the
treatment of acetaminophen and salicylate overdoses.
Other potentially useful quantitative levels include car-
boxyhemoglobin, ethanol, methanol, ethylene glycol,
theophylline, phenytoin, lithium, barbiturates, digoxin,
cyclic antidepressants, lead, mercury, and arsenic.
TREATMENT
After the initial stabilization of the patient, efforts are
turned toward decreasing the exposure to the agent
through gastrointestinal (GI) decontamination and/or
enhanced elimination. During this time it is important to
continue efforts to support the airway and ventilation
and to maintain hemodynamic stability.
GI decontamination can be accomplished through
several modalities. This includes gastric emptying proce-
dures, adsorption of drugs, and increasing transit through
the GI tract. Gastric emptying procedures include ipecac-
induced emesis and gastric lavage. Ipecac-induced emesis
has very limited utility. It is not used when managing
adult poisoning victims. It is contraindicated in patients
with depressed level of consciousness or when corrosive
substances or hydrocarbons are ingested. Complications
of induced emesis include aspiration pneumonitis,
esophageal rupture, and Mallory–Weiss tear (upper GI
hemorrhage). Gastric lavage with a large-bore (36–40 F)
orogastric tube has been used. It is contraindicated in
caustic and hydrocarbon ingestions, in patients at risk of
GI perforation, in combative patients, and in patients
Table 34-2 Clues to Diagnosis in Poisoning:
Neurologic Findings
Pinpoint Pupils (Miotic) Dilated Pupils (Mydratic)
Cholinergics Alcohol
Narcotics Anticholinergics
Organophosphates Antihistamines
Phenothiazine Phenytoin
Phencyclidine (PCP) Sympathomimetics
Reproduced with permission of the Society of Critical Care Medicine from
Zimmerman JL: Poisoning/overdose. In Dries DJ, editor: 5th Critical Care
Refresher Course, ed 5, Des Plaines, IL: Society of Critical Care Medicine, 2001,
pp 123–136.
Table 34-3 Toxidromes
Drug Class Symptoms
Cholinergics Salivation, lacrimation, urination, 
defecation, GI upset, emesis 
(SLUDGE); also, bradycardia, 
fasciculations, confusion, meiosis
Anticholinergics Dry skin, hyperthermia, mydriasis, 
delirium, thirst
Sympathomimetics Hypertension, tachycardia, seizures, 
CNS excitation, mydriasis
Narcotics Miosis, respiratory depression, depressed 
level of consciousness
Sedatives/hypnotics Depressed level of consciousness, 
respiratory depression, hyporeflexia
Reproduced with permission of the Society of Critical Care Medicine from
Zimmerman JL: Poisoning/overdose. In Dries DJ, editor: 5th Critical Care
Refresher Course, ed 5, Des Plaines, IL: Society of Critical Care Medicine, 2001,
pp 123–136.
Table 34-1 Clues to Diagnosis in Poisoning: 
Vital Signs
Vital sign Increased Decreased
Blood Amphetamines Antihypertensives
pressure Cocaine Cyclic antidepressants
Anticholinergics Narcotics
Sympathomimetics Organophosphates
Sedatives/hypnotics
Heart Amphetamines Barbiturates
rate Cocaine Beta-blockers
Anticholinergics Cholinergics
Ethanol Digoxin
Sympathomimetics Sedatives/hypnotics
Theophylline
Respiratory Amphetamines Alcohol
rate Anticholinergics Barbiturates
Carbon monoxide Narcotics
Hydrocarbons Sedatives/hypnotics
Organophosphates Gamma-hydroxy-
Salicylates butyrate (GHB)
Temperature Amphetamines Sedatives/hypnotics
Cocaine Barbiturates
Anticholinergics Carbon monoxide
Beta-blockers Ethanol
Cyclic antidepressants Hypoglycemics
Salicylates Narcotics
Sympathomimetics Sedatives/hypnotics
Gamma-hydroxy-
butyrate (GHB)
Reproduced with permission of the Society of Critical Care Medicine from
Zimmerman JL: Poisoning/overdose. In Dries DJ, editor: 5th Critical Care
Refresher Course, ed 5, Des Plaines, IL: Society of Critical Care Medicine, 2001,
pp 123–136.
with severe coagulopathies. The current recommenda-
tion is that gastric lavage only be used for life-threatening
quantities of poison when the therapy can be instituted
within 60 minutes of the ingestion. There is no good
evidence showing the benefit of gastric lavage (although
the highest risk patients are often excluded from the
studies). The decision to perform gastric lavage must be
made on a case-by-case basis. Its use is limited.
Single-dose activated charcoal is the most common
technique used for GI decontamination. The activated
charcoal adsorbs the toxin in the GI tract thus limiting
systemic absorption. The usual dose is 1 g/kg. Activated
charcoal is not effective in adsorbing iron, lithium,
cyanide, strong acids and bases, alcohols, and some
hydrocarbons. Activated charcoal is contraindicated in
patients with depressed levels of consciousness who do
not have airway protection, or if a GI perforation is
known or suspected. Studies suggest that the maximum
benefit of activated charcoal is obtained when it is
administered within one hour of the ingestion.
Cathartics and whole bowel irrigation have been used
in poisonings. It is felt that limiting the contact time with
the GI tract may be of some benefit in limiting absorp-
tion. There is no clinical evidence showing the benefit of
either technique.
The other major treatment category for managing toxic
exposures is enhanced elimination. Enhanced elimination
can be achieved with multiple-dose activated charcoal
(MDAC), urinary alkalinization, and renal replacement
therapies.
MDAC is used to adsorb agents that are initially
absorbed but then reenter the GI tract. Toxins (or their
metabolites) reenter the GI tract either through the
enterohepatic circulation (present in bile) or through
active secretion or passive diffusion distal to the stom-
ach. There is no strong evidence demonstrating the effi-
cacy of MDAC. However, it has been recommended that
MDAC be used in the cases of life-threatening ingestion
of carbamazepine, dapsone, phenobarbital, quinine, or
theophylline. MDAC is administered either as bolus
doses (0.5–1.0 g/kg every 4 hours) or a continuous infu-
sion (0.25–0.5 g/kg/hour, not less than 12.5 g/hour).
Urinary alkalinization has been of proven benefit in
poisoning involving weak acids such as salicylates, phe-
nobarbital, and primidone. The weak acids are ionized in
the alkaline urine where they are trapped in the renal
tubules, and then cleared. Urinary alkalinization is
achieved by administering a sodium bicarbonate drip.
The drip can be made in multiple ways including adding
three ampules of sodium bicarbonate to 1 liter of sterile
water or varying amounts of sodium bicarbonate (e.g.,
75 mEq) in D5W. The drip rate is then adjusted to
achieve a urinary pH of 7.5–8.5. Electrolytes should be
monitored and corrected as needed.
Renal replacement techniques used to enhance elimi-
nation include intermittent hemodialysis, intermittent
hemoperfusion, continuous hemofiltration (CVVH), and
continuous hemodialysis (CVVHD). Hemodialysis should
be used early in the treatment of toxicities involving
methanol, ethylene glycol, salicylates, lithium, boric acid,
and thallium. Hemoperfusion involves passing whole
blood through an adsorbent containing (charcoal) car-
tridge. Charcoal hemoperfusion is the preferred method
for eliminating carbamazepine, phenobarbital, phenytoin,
and theophylline. Continuous renal replacement tech-
niques are of primary benefit for patients who are not
hemodynamically stable enough to tolerate intermittent
techniques.
SPECIFIC TOXICITIES
Clearly there is a large variety of substances that can
cause toxicities. An exhaustive discussion of many dif-
ferent agents is beyond the scope of this chapter. This
chapter examines substances that are more likely to be
associated with critically ill patients in the ICU. Although
not yet seen in the West, a terrorist attack using nerve
agents is a distinct possibility. These agents will be briefly
discussed.
Acetaminophen
Acetaminophen (N-acetyl-p-aminophenol (APAP))
toxicity is commonly seen. The reason for this is multi-
factorial. Clearly, it is easily available to individuals wish-
ing to harm themselves. In addition, it is present in a large
number of medications, which may not be known to
many patients. For example, patients taking percocet for
pain may supplement themselves with acetaminophen
and easily achieve toxic doses. Many lay people are
unaware of the potential toxicity of APAP. APAP can lead
to hepatotoxicity and potential mortality that is prevent-
able. APAP toxicity is the second leading cause of acute
liver failure in the USA and is the leading cause in the
UK. APAP is metabolized in the liver to the toxic metabo-
lite N-acetyl-p-benzoquinoneimine, which results in liver
cell injury and death. Maximal hepatic cell injury occurs
at 72–96 hours postingestion. Initial symptoms include
right upper quadrant pain and abnormal liver function
tests. The severity of symptoms is somewhat variable
and depends on the quantity of ingestion. Toxicity may
occur when 7.5–10 g are ingested over 8 hours. Fatalities
are rare for doses less than 15 g. Symptoms may progress
to encephalopathy, coagulopathy, jaundice, and renal
failure. When patients develop encephalopathy (fulmi-
nant hepatic failure), they have a mortality approaching
80%. At this point, liver transplant may be their only
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option (60–80% survival). The treatment for APAP toxicity
beyond the supportive measures described earlier is to
administer N-acetylcysteine (NAC (mucomyst)). For acute,
single ingestions an APAP level is obtained at 4 hours after
ingestion (or immediately on admission if the time of the
ingestion is unknown). The Rumack–Matthew nomo-
gram is used to determine whether or not to institute
NAC therapy. The initial dose of mucomyst is 140 mg/kg
administered orally (PO or NG) followed by 70 mg/kg
doses every 4 hours for 17 doses. The treatment duration
and dosing should be coordinated with the local poison
control service.
Salicylates
Salicylate toxicity should be suspected if a metabolic
acidosis with an anion gap is present on blood gas analysis.
Initial symptoms include tinnitus and nausea/vomiting.
Tachypnea, respiratory alkalosis, and hyperthermia are
seen. Symptoms may progress to include depressed level of
consciousness, coma, seizures, coagulopathy, transient
hepatotoxicity, and hypoglycemia. Treatment includes
alkalization of the urine and administering activated char-
coal. In severe cases hemodialysis may be required.
Carbon Monoxide
Carbon monoxide (CO) poisoning is common and
could be the result of accidental exposure (car/structure
fires, poorly ventilated heaters, poorly ventilated genera-
tors, etc.) or intentional exposure. CO binds to hemoglo-
bin with an affinity 200–250 times greater than oxygen.
This results in poor oxygen delivery to the tissues which
leads to cell hypoxia and possibly cell death. Clinical
manifestations are nonspecific and may be confused
with other illnesses unless the exposure is known or sus-
pected. Common symptoms include headache, nausea,
and vomiting. Other signs and symptoms include con-
fusion, arrhythmias, angina, syncope, seizures, tachycar-
dia, and tachypnea. Clearly, death can be the result of
severe exposures. Of those that recover from acute CO
exposure, 10–30% have delayed neuropsychiatric seque-
lae. Many may have a permanent neurologic injury.
Quantitative CO levels should be obtained on either arte-
rial or venous blood gases. Management includes admin-
istering 100% oxygen until CO levels return to normal
and treating clinical abnormalities (cardiac ischemia,
arrhythmias, acid–base disorders, etc.). In severe cases
hyperbaric oxygen therapy may be instituted. This can
decrease the half-life of carboxyhemoglobin from 40 to
80 minutes (with isobaric 100% oxygen) to 15 to 30 min-
utes. Hyperbaric oxygen therapy is not widely available,
which limits its use. Furthermore, outcome studies have
not shown a benefit of hyperbaric oxygen therapy on
the long-term sequelae and mortality associated with CO
poisoning.
Cocaine and Amphetamines/
Metamphetamines
These drugs are widely used and abused in the USA
and may be seen in patients presenting to the ICU.
Clearly use of these agents may lead to severe trauma,
which would then complicate the treatment of the
patient’s injuries. Adverse sequelae of the use of these
drugs have complicated the course of routine surgical
procedures. The most severe sequelae include cardio-
vascular complications (severe hypertension, arrhyth-
mias, myocardial ischemia, and aortic dissection) and
neurovascular complications (seizures, cerebral infarction,
and intracranial hemorrhage). The management of these
complications is largely supportive (managing hyper-
tension, cardiac ischemia, arrhythmias, seizures, etc.).
Beta-blockers and Calcium 
Channel Blockers
Occasionally, overdoses of beta-blockers and calcium
channel blockers are seen. The most common manifes-
tations include bradycardia, hypotension, and atrio-
ventricular conduction abnormalities. Central nervous
system (CNS) abnormalities, such as lethargy, confusion,
and coma, are sometimes seen. The cardiovascular abnor-
malities are difficult to manage with traditional inotropes
and vasopressors. Initial management includes isotonic
intravenous fluid, atropine, and glucagon. Glucagon stim-
ulates cyclic adenosine monophosphate (cAMP) thus
bypassing the adrenergic receptors. In some cases high-
dose vasopressors/inotropes may be required.
Other Agents
Other agents that may be seen in toxic levels in the
ICU include benzodiazepines, opioids, digoxin, etc.
Benzodiazepines and opioids are commonly used in the
hospital for sedation and analgesia. Patients may receive
excessive dosages of these agents. Treatment primarily
involves respiratory support until serum levels decrease.
Occasionally, a benzodiazepine antagonist (flumazenil)
or narcotic antagonist (naloxone) may be used to treat
overdoses. Caution should be used with both. Flumazenil
use has been associated with seizures. Complete block of
narcotic receptors in the setting of severe injury or sur-
gery will result in severe pain with possible hypertension,
tachycardia, and pulmonary edema. If naloxone is used,
small doses should be administered until the respiratory
status improves while maintaining adequate pain control.
Toxic digoxin levels are occasionally seen in the ICU
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especially in patients on chronic doses who develop
renal insufficiency. Manifestations include a large variety
of cardiac arrhythmias, anorexia, nausea/vomiting, and
hyperkalemia. The standard of care for life-threatening
digoxin toxicity is to administer digoxin-specific anti-
body fragments (digibind). There are many other agents
that can cause toxicity in the ICU. When unexpected
symptoms are encountered, an investigation of agents
used/exposed to should be undertaken and treatment
initiated. This often involves consultation with the local
poison control service.
CHEMICAL WARFARE AGENTS
In the current world situation a major chemical attack
in a large populated area is a distinct possibility. There
were 27,000 casualties due to the use of chemical weapons
(including mustard gas and tabun nerve agent) by the
Iraqis during the Iran–Iraq war. Even more concerning,
there were several fatalities and hundreds of casualties
when the Aum Shinrikyo cult released sarin nerve gas in
a Tokyo subway. These agents could be used in a terrorist
attack in the future. It is therefore reasonable for physi-
cians managing ICUs to have knowledge of the identifi-
cation and treatment of these agents.
There are several classes of chemical weapons that may
be employed. These include the nerve agents (sarin, tabun,
soman, VX), blistering agents (mustard gas, Lewisite),
choking agents (chlorine, phosgene, chloropicrin), blood
agents (hydrogen cyanide and cyanogen chloride), and
toxins (saxitoxin, ricin, and botulinum toxin). It is beyond
the scope of this chapter to discuss all of the agents. This
chapter briefly discusses the more likely agents, namely
the nerve agents and blistering agents.
Nerve agents are irreversible anticholinesterases of
high potency and are chemically related to organophos-
phate insecticides. They inactivate acetylcholinesterase
(AChE), which causes accumulation of acetylcholine at
muscarinic, nicotinic, and CNS synapses. The muscarinic
effects include miosis, glandular hypersecretion (sali-
vary, bronchial, and lacrimal), sweating, bradycardia,
atrioventricular block, QT prolongation, bronchocon-
striction, diarrhea, and incontinence of urine/stool. The
effects on the nicotinic receptors progress from fascicu-
lations to skeletal muscle weakness to paralysis. AChE
inactivation in the CNS results in irritability, giddiness,
ataxia, fatigue, amnesia, hypothermia, lethargy, seizures,
coma, and respiratory depression. Death can occur
through a variety of mechanisms. Treatment must be
instituted rapidly if there is going to be any chance of
survival.
Like other poisonings, attention to basic resuscitation
(intubation, controlled ventilation, etc.) must be made.
Atropine and oximes are effective antidotes but need to
be administered early (i.e., in the field). If the patient sur-
vives to the ICU, continued treatment will probably be
necessary. Atropine antagonizes the muscarinic and CNS
effects. It is preferable to glycopyrrolate, which does not
cross the blood–brain barrier. The initial dose of atropine
is 2 mg IV and should be repeated every 5–10 minutes
until pupillary dilation occurs and heart rate rises above
80 beats/minute. An atropine infusion (0.02–0.08 mg/
kg/hour, up to 1000 mg/day) may be required for per-
sistent bradycardia. The oximes (pralidoxime) reverse
nicotinic receptor dysfunction and thus reduce or
reverse skeletal muscle weakness. They reactivate AChE
by cleavage of phosphorylated active sites, detoxify
unbonded nerve agent molecules by direct action, and
have an endogenous anticholinergic effect. Irreversible
bonds between the nerve agents and AChE form after 
2 minutes of exposure to soman, after 5 hours for sarin,
after 13 hours for tabun, and after 48 hours for VX gas.
This gives time to administer the pralidoxime for most of
the agents. Other potential treatments include diazepam
(control seizures and limit long-term neurologic sequelae),
clonidine to control CNS cholinergic symptoms, and
magnesium to reduce presynaptic ACh release.
Mustard gas is the most likely used vesicant. It causes
NAD+ depletion, which disrupts glycolysis and causes
the release of destructive proteases. There is a latency
period between exposure and the development of symp-
toms. Therefore, close observation is required for all 
suspected exposures. The clinical symptoms include
cutaneous manifestations, ocular symptoms, respiratory
complications, and bone marrow suppression. The cuta-
neous manifestations are universal and range from first-
degree chemical burns to severe edema, vesication, and
necrosis. Management includes decontamination, burn
care, fluid resuscitation following burn protocols, pain
control, and perhaps antibiotic therapy. Ocular symptoms
(85% of victims) include pain, blurred vision, lacrimation,
corneal edema, and vesication. Management includes
copious irrigation and standard corneal abrasion treat-
ment. Respiratory compromise occurs in over 70% of the
victims ranging from tracheobronchitis to pulmonary
hemorrhage and pulmonary edema. Management is pri-
marily supportive with endotracheal intubation and
mechanical ventilation. The lung injury may be perma-
nent. Bone marrow suppression occurs with severe
exposure and may result in immunosuppression and
increased bleeding risk. Bone marrow suppression is a
poor prognostic sign.
It is hoped that the ICU physician will not have to
deal with mass casualties from a terrorist chemical
attack. This is not an exhaustive discussion, but covers
the more likely agents. For both nerve agents and mus-
tard gas it is important to be aware of potential provider
exposure to these agents. Decontamination should be
accomplished prior to ICU admission.
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CONCLUSION
Poisoning and toxicity problems are common prob-
lems in the ICU. As in all cases, attention to the basics of
resuscitation (airway, breathing, and circulation) should
be the clinician’s first priority. After stabilization, atten-
tion should be turned toward agent identification, limit-
ing absorption, and administering antidotes. Early and
aggressive treatment in the ICU can limit morbidity and
mortality.
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An appreciation for medical ethics arms the inten-
sivist with the ability to dissect the frequent dilemmas
that arise in the intensive care unit (ICU). The ICU is
replete with controversy and situations that require a
formal understanding of the basic principles used to
guide us through the quagmire that often arises when
life and death hang in the balance.
From a practical standpoint, medical ethics is the art
of resolving conflicts that arise around treatment and
treatment decisions. The conflict may involve the patient,
family, caregivers, or society. An approach to these con-
flicts is as necessary as, say, an approach to hypotension
or oliguria. Without an approach we would be ignoring
the mechanisms that led to the conflict or problem in
the first place. A little preparation will allow one to be
more comfortable when confronting these situations,
making responses more likely to be useful (and less
likely to make things worse).
There are four basic principles of medical ethics that
give us the tools to begin to resolve some of these con-
flicts: autonomy, beneficence, nonmaleficence, and
justice. The weight we give each of these four different
principles is often determined by our individual and 
societal morals (Box 35-1).
PRINCIPLES OF MEDICAL ETHICS
Autonomy
Autonomy is the principle that most often supersedes
the other principles in the USA. Whether or not this fact
is justified depends on one’s moral beliefs and how con-
sistent they are with the majority. It is based on the
belief that, if at all possible, we should let each individ-
ual determine his or her own destiny.
Capacity is presumed in an adult and one does not
need a psychiatrist to make this determination. In addi-
tion, a patient may have capacity for one decision and
not for another, so understanding the complexity of a
decision is extraordinarily important. Thus patients may
still be able to communicate a choice of health care
agent, even when they cannot make a medical decision.
In the ICU, however, we often work through a surro-
gate to determine the patient’s wishes when capacity is
not present. Ideally the surrogate is chosen by the
patient and becomes their health care agent. In that case
a living will is a document that directs the health care
agent. The documents together, the appointment of a
health care agent and the living will, comprise the health
care proxy. It is important to realize that it is in the
CHAPTER
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Box 35-1 Principles of Medical Ethics
● Autonomy
● Beneficence
● Nonmaleficence
● Justice
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province of the health care agent to interpret the living
will. Although it is important for physicians to guide
patients and their surrogates through this difficult
process, it is also important to accept the authority of
the health care agent over the living will should the
physician believe they are in conflict.
If no health care agent is selected, most intensivists
will rely on a next-of-kin to help direct care. It is impor-
tant to know that, although this is a widely accepted
practice, it is justified by the ethical assumption that the
next-of-kin can represent the patient’s wishes. If there is
someone who knows the patient well, but is not a
“blood relative,” and the family are all distant (or worse,
estranged), then this same assumption would justify 
letting the close friend make decisions.
The health care agent is supposed to pattern their deci-
sions after the choice the patient would have made if they
had capacity. Unfortunately, this is often not the reality.
Many people are unable or unwilling to stop treatment for
someone else even when they know the person would
have stopped it himself or herself. Sometimes they are
unwilling to accept the burden of the decision and some-
times they are unwilling to accept the reality that contin-
ued treatment is approaching medical futility. Someone
tried to put a humorous spin on this once by saying that,
unfortunately, patients often choose for their agent the
one person who cannot live without them.
In situations where one has reason to believe a health
care agent or other surrogate is not following the
patient’s wishes, the best recourse is time: one should
put aside as much time to talk to the surrogate as the sur-
rogate needs, and ask them to think about which of the
available options the patient would choose, if the patient
could sit up and talk for one moment of clarity. They
should be given some time to think about it, and time set
to meet again to make a decision. If possible, they should
be given some signs to look for which would make their
decision easier, such as the improvement or worsening
of blood pressure or oxygenation. (There have been rare
cases of agents being removed from power even though
they were chosen by the patient, but only when it was
painfully obvious that their decisions were totally con-
trary to the patient’s wishes. In general this should be
viewed as an unneccessarily adversarial move, not to
mention one likely to fail in court.)
The doctors the family will remember kindly in such
a personal crisis are the ones who show they understand
why the family is having a difficult time, and help them
to deal with it. Communication skills, trustworthiness
(including honesty and patience, and just being on
time), and compassion are the personal qualities that are
needed to become an exemplary intensivist. In modern
medicine it is very often only after arriving in the ICU
that the family gets this chance to establish a relationship
with a physician.
Beneficence and Nonmaleficence
Beneficence is the concept that we will treat the
patient to try to benefit them. This principle is the most
subject to interpretation of all the principles because
benefit may be defined differently for the same patient
by different physicians. Nonmaleficence is the concept
in medicine that physicians should attempt to not cause
any harm. This approach often means that nothing should
be done unless the potential benefits outweigh the risks
of a treatment. Together these principles represent the
traditional ethics of the Hippocratic Oath (which gave no
weight to patient autonomy).
Often beneficence and nonmaleficence are in direct
conflict. Suppose a patient, without capacity or a surro-
gate, has marginal renal function and requires a study
with intravenous contrast. If the physician believes the
benefits outweigh the risks the physician will make the
beneficence argument and proceed with the study. If,
on the other hand, the physician believes the risks out-
weigh the benefits, the physician will make the non-
maleficence argument and not perform the study. There
may be much clinical judgment involved in this decision.
The lesson to keep in mind here is that it is not always
best to “do everything.” Indeed, that term is one that
should never be used with patients or surrogates,
because it is so vague. It is better to think that one can
aggressively try to “cure” a patient, or just as aggressively
try to “care” for a patient, and those may require different
interventions (so one cannot do both, i.e., “everything”).
It should be remembered that the words “intensive care”
have hints of both possible goals of treatment. Many
patients die in the ICU, and ethical practice would require
clinicians to be skilled in the care of those patients as well
as those who live. (For similar reasons, one should never
say, “There’s nothing more we can do,” or suggest that
one will “withdraw care.” There are things that can be
done that show one still cares about the patient right
through pronouncing death and care delivered to the
body until the person is taken to the morgue.)
Justice
The concept of justice incorporates the greater good of
society into the ethical equation. This principle is difficult
to accept if applied to the individual patient at the bedside
rather than to a group of patients. Is it fair for one inten-
sivist to deny admission to the ICU for a patient in a per-
sistent vegetative state and yet another intensivist accepts
the patient in to another ICU? Ideally, society as a whole
should make justice decisions and we should not leave
this principle solely in the hands of a single physician.
Intensivists are often faced with an expensive new
therapy and need to decide who should receive this 
therapy. For example, activated protein C was recently
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approved for the treatment of septic shock and costs
between $6000 and $10,000 for a course of therapy.
Should the price play a role in our decision to use this
novel new drug? Do we give activated protein C to
someone who is 100 years old and suffering from severe
septic shock and, we believe, is unlikely to survive more
than a couple of hours? Do we give it to someone who
is young and who is suffering from very mild septic
shock and is very likely to survive with standard therapy?
Tackling justice at the bedside is a prickly path that, if
taken, must be done consciously and cautiously. It can
be very tempting to use one’s authority to impose one’s
own value judgment, and it is important to remember
that not everyone has the same values.
Arguments
These four principles serve a very practical function.
They allow the clinician to view an ethical dilemma from
different perspectives. They are not meant to provide a
simple solution to problems, so much as helping in
understanding the source of the problem. The four prin-
ciples are independent, meaning there is no reason to
expect them to lead to a single answer to a dilemma.
Once a problem is analyzed using this scheme the con-
flicting positions in a dilemma are better appreciated.
Even if the dispute continues after the analysis, at least
the problem can be understood from more than one per-
spective. This appreciation for other perspectives may
lead to softening of firmly held positions and make an
eventual compromise easier, even if it does not lead to
an immediate resolution.
An argument in philosophy means a conclusion with
premises that provide support, like evidence for a scien-
tific theory. A dilemma is when there are arguments for
two incompatible conclusions. The goal of analyzing ethi-
cal dilemmas is not to prove only one view is right, but to
show persons holding each position that the other position
is also reasonable. Which course to follow may be decided
by which argument has better support, or by which person
has more at stake or more authority to make the decision or
will suffer the consequences of the decision.
Case Studies
There are many unique ethical situations that arise in
the ICU that deserve mention. Three situations, however,
bring out special features of this environment and are
particularly illustrative. We will use them to investigate
the different view obtained from the vantage point of the
four basic principles of medical ethics discussed above.
The Jehovah’s Witness
A 58-year-old woman who is a Jehovah’s Witness pres-
ents to the ICU after a skiing accident that led to a splenic
laceration. Given the fact that she would not accept a
transfusion at a presenting hemoglobin of 6.0 g/dl a
splenectomy was performed with her consent rather
than observation. Postoperatively she had unexpected
bleeding and her hemoglobin dropped to 2.3 g/dl. At
this point she developed a lactate level of 3.5 mmol/l and
a delirium. Her husband, who is not a Jehovah’s Witness,
demands that a blood transfusion be given. She has not
filled out a health care proxy.
This case, like many in the ICU, does not have an
obvious answer. The principle of autonomy would dic-
tate that we follow her initial wishes but we cannot be
sure that she would not choose a transfusion if she was
so morbidly anemic. We could even speculate that by
not appointing a proxy, she knew her husband would be
asked to decide, and she preferred it that way.
The principle of beneficence could also be inter-
preted in different ways. Should we say that it is in her
best interests to have a blood transfusion or is it in her
best interests not to have a blood transfusion because it
goes against her religious beliefs? It is most important
when facing this situation to realize that many Jehovah’s
Witnesses never change their mind, and accept death
over transfusion, but that some do change their mind
(and even make subtle provisions to enable that to hap-
pen). The tone of the family meeting should be a quiet
enquiry into which of these scenarios is the more likely,
without calling into doubt the scientific validity of the
metaphysical beliefs of the faithful.
The Transplant
A 23-year-old woman presents to the emergency
department and is transferred to the ICU following an
overdose of acetaminophen. This is her third suicide
attempt. Despite appropriate therapy, she develops
fulminant hepatic failure. A liver is identified and she is
scheduled for a transplant. She has hepatic encephalopa-
thy and does not presently have capacity. The anesthesia
resident on rotation asks why a patient that has tried to
commit suicide is scheduled for a transplant when
donated livers are such a limited resource.
The issue of justice is woven into every transplant deci-
sion. Since organs are a limited resource, for each person
who receives a vital organ somebody else must be denied
the organ who will die as a result. Ranking systems are
attempts to remove justice from bedside decision-making
and, appropriately, place them in the hands of society.
Since this patient does not have capacity we would turn to
her health care agent or, more likely if she did not a have
a health care proxy, her next-of-kin to make a decision.
Since it was a suicide attempt the agent would be invoking
the principle of beneficence over autonomy since she may
very likely refuse a transplant if she had capacity.
A waiting list for livers may include many patients
who have potential contraindications: an active alcoholic
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with cirrhosis, a person with a genetic disease that
would eventually destroy the transplanted liver, a pris-
oner, or a patient with viral hepatitis that may recur. The
best reason to have a centralized rating system such as
the United Network for Organ Sharing (UNOS) is to pre-
vent these decisions being made according to random
variations in social biases.
Brain Death
A 20-year-old woman presents following a gunshot
wound to the head and is pronounced dead by brain 
criteria following appropriate examinations and confir-
matory tests. Her family is informed and they do not
accept these criteria. They believe as long as there is 
a heartbeat she is alive and that they will consult a
lawyer if an attempt is made to disconnect her from the
ventilator.
Death by brain criteria (as opposed to cardiorespira-
tory criteria) is an accepted method of declaring death in
the USA. As a society we have been unable to define life
to everyone’s satisfaction so it should be no surprise that
we have been unable to define death without some con-
troversy. Indeed, it is amazing that the criteria for brain
death have not been steeped in more controversy. In
this situation the interpretation of the principles of
autonomy, beneficence, nonmaleficence, and justice
depends entirely on whether or not one accepts this def-
inition of death. If it is believed she is dead there can be
no issue of autonomy, beneficence, or nonmaleficence
unless one believes it is harming her not to fulfill any
known wishes regarding her death she is believed to
have held while alive. Justice and the use of resources
for someone who is dead is the only active principle that
can be invoked. While it would be justified to stop all
interventions as soon as the diagnosis of death is made,
in the case of brain death it is common to allow the fam-
ily to visit with the patient before discontinuing treat-
ment. This may give them some comfort, but it should
not be done in a way that makes them think that the
patient is still alive, or it may lead to resistance to with-
drawal of treatment.
It is very important to be careful with the terms that
the staff uses in the ICU. Even some very experienced
doctors and nurses will occasionally say “brain dead”
when they mean “irreversibly and profoundly brain dam-
aged, with no hope of a significant recovery” or “per-
sistent vegetative state” (PVS). If families confuse these
various concepts, the differences should be explained to
them. PVS patients have eye movements, sleep–wake
cycles, and can be kept alive for months, years, and
sometimes even decades with little more than good
nursing care and occasional antibiotics for infections.
The decision of whether to continue or discontinue life-
sustaining treatment for PVS patients is left to the
patient’s surrogate.
General Comments
There are other ways to approach medical ethics
besides using these four basic principles. Some experts
have advocated learning ethics from case studies alone.
This is known as casuistry. As might be imagined, it is
often criticized as relying too heavily on the ethical
equivalent of anecdotal evidence. Other experts have
advocated what is called virtue theory, emulating per-
sons we recognize as role models in order to hone our
insight and judgment in ethically complex cases. This too
has its critics, who are concerned that it will weigh tra-
ditional values too heavily, and not allow room for moral
progress. As in other fields in medicine, these different
methods are models that allow us to move closer to the
truth, but we are still looking at shadows. Each model
may help to understand medical ethics, and none should
be ignored. However, from a practical perspective the
four principles do help determine why well-meaning
people disagree, and that may be why they have been the
most commonly used model for the past 30 years.
CAPACITY
When determining capacity the physician must take
into account the patient as well as the proposed deci-
sion. Patients may have capacity for one decision and
not another. The most important element of capacity is
whether the patient understands the consequences of
the choice they make, whether that choice is to accept
or refuse a treatment option that has been offered (or
even recommended).
Additionally, a patient may not be able to make a deci-
sion but would understand a decision that has been
made. In this situation the patient should be informed of
the decision. The patient’s response may help one solid-
ify or rethink the determination in the first place.
Telling a patient that he or she has been made DNR
may feel impossible to do, but with experience it can be
done. It should always be remembered that capacity is
presumed in an adult. Hence, while the right of physi-
cians unilaterally to “lift” a DNR order agreed to by a
patient is ethically questionable, the right of a patient to
refuse DNR status is not. Here, as above, communication
and honesty are all important. DNR does not mean stop-
ping anything currently being provided – it means not
escalating the level of interventions should there be a
sudden turn for the worse. And the justification for DNR
is that cardiopulmonary resuscitation would not work in
this situation, or would be likely to leave the patient in a
worse condition. Every intensivist should be familiar
with the literature around success rates of DNR for vari-
ous classes of patients.
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CHOICE OF A HEALTH CARE AGENT
Most people choose a health care agent who is 
closest to them. It seems appropriate to choose a wife or
adult child for such a potentially momentous task. The
theory, however, is that this person will make the
patient’s own decision should they be without capacity.
Many agents know that the patient would not want their
present and future life but are afraid to make a decision
to withdraw or limit treatment or are afraid to continue
their own life without this person, and so choose to
keep the person alive. Perhaps it would make more
sense to suggest to patients that they choose someone
who knows them well but can live without them.
The ideal surrogate exists in textbooks but rarely in
real life. It is not realistic to expect a surrogate to come
to the table free of any of their own agendas. The edu-
cation of the patient’s family is an important role for the
intensivist. Surrogates must be frequently but gently
reminded that they are making their loved one’s deci-
sion rather that making a decision for their loved one.
FUTILITY
Futility is a word frequently evoked in the ICU but
rarely defined. We tend to use the word as if it were a
mathematical absolute rather than a statistical prob-
ability. Many experienced intensivists have had the expe-
rience of telling the family of a patient that continued
treatment was “futile,” only to have the patient improve
and survive to a quality life. Besides, it is often unclear
what we mean by futility. Are we implying that the
patient is so moribund that death is imminent? Are we
implying that the patient will not survive the ICU admis-
sion? Or are we implying that if the patient does survive
his or her quality of life will be very limited?
It is probably best to avoid the term futility and focus
on providing the family with more descriptive and indi-
vidualized terms. An in-depth discussion with time to
answer questions will be more beneficial than using
terms that are confusing and possibly misleading.
Sometimes “futility” needs to be determined during a
code. Some physicians believe that attempts at resusci-
tation need to be attempted for a specified period of
time. The truth is that some judgment is involved and
there is no magic period of time or duration of a partic-
ular rhythm that is defining.
Recently there has been discussion about whether
the family should be allowed to be present during a
resuscitation attempt. The traditional rule that the family
is asked to leave has a paternalistic air, and can create
suspicion in the mind of the family if the attempt fails.
There is increasing acceptance of allowing the family to
remain in the room if they request to do so, assuming
there is enough room and they are not likely to interfere
with the process. Many families do not want to watch
their loved one in this situation, but for some others this
will provide them with the conviction that death was
inevitable.
INFORMED CONSENT
Ideally all patients and their surrogates should be
informed about the potential risks and benefits for all
procedures performed and all medications given.
Increasingly, this includes blood transfusions. Here,
once again, judgment must be used given the sheer num-
ber of procedures and medications ordered in the ICU.
It is also important to remember that one’s responsibil-
ity is to offer only reasonable alternatives, and that fami-
lies should not be asked to micromanage or allowed to
make unreasonable choices, such as accepting high-risk
interventions while refusing low-risk ones with equal or
better efficacy.
PHARMACEUTICAL CONNECTION
The pharmaceutical industry frequently buys gifts for
physicians, claiming they are interested in dialogue and
education. It must always be remembered that drug
companies are for-profit businesses and they must, 
ultimately, answer to their shareholders and not care
givers. They know the gifts they buy influence prescrip-
tion patterns, whether the recipients believe it or not.
Research by independent agencies shows that drug 
companies now spend more money on detailers and
advertising than on research and development, totaling
about $9000 per physician per year. Many physicians
falsely believe their colleagues are susceptible to this
kind of influence, but not them. The only way to be 
certain one is not being influenced is to realize there is
no “free lunch.”
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Physicians subscribe to the Hippocratic Oath and
strive to provide the highest quality of medical care to
their patients; a professional atmosphere of caring,
respect, and trust within the physician–patient relation-
ship; and are therefore patient advocates of the highest
order. Health care accounts for approximately 14% of
the US gross domestic product (GDP) and yet paradoxi-
cally almost 50% of Americans have limited access to
health care because they either do not have health insur-
ance or have coverage limitations. Critical care medicine
(CCM) alone accounts for approximately 0.5% of the
GDP, 13% of hospital costs, 4.2% of national health
expenditures; furthermore, most of these costs are
accrued within the last year of patients’ lives.
Since physicians have traditionally placed paramount
importance on their fiduciary responsibilities to patients,
they have been slow to accept health care costs as meas-
ures of quality. However, medical care, especially CCM,
represents a significant cost to society and there is thus a
reasonable request for social accountability. Increasingly,
individual providers and health care systems are being
held accountable for the quality they provide in return for
health care dollars spent. The trend is one of increasing
scrutiny. In all areas of medicine, incremental measures of
value added will be used to justify incremental costs.
The outcome of health care can be assessed retro-
spectively using any one of a myriad of measures ranging
from crude mortality to more complex quality-of-life
indices. Measures of outcome must be risk-adjusted
(e.g., comorbidities, severity of illness) and account for
variables such as functional status at discharge, quality of
life, and cost of care. Although vitally important to the
medical education and continuing medical education
process, medical quality assurance in the form of mor-
bidity and mortality rounds has largely failed in itself to
provide either minimum quality standards or a means for
system-wide performance improvement.
Individual provider or departmental performance
becomes meaningful only when it is aggregated in data-
bases that provide for longitudinal trending, risk adjust-
ment, statistical analysis, and external comparisons.
External comparisons are especially important to differ-
entiate reliably “best practices” which potentially form
the basis for outcomes-based standards of care which
can be published, disseminated, and thereafter continu-
ally improved upon. Guidelines and practice parameters,
and protocols and pathways are examples of standards
of care. These tools are developed and disseminated by
medical societies and colleges, regulatory organizations,
lawmakers, and developers of health policy.
The topics of safety, quality, severity of illness and case
mix, and risk management and medical liability are closely
related and inter-related. An understanding of safety,
process improvement, and legal requirements not only
improves clinical patient care but also optimizes team-
work and communication in the health care setting and
minimizes risk exposure. Physicians must be “citizens” of
the institutions and systems in which they practice.
Involvement or leadership requires an understanding of
the support systems, processes, and the vocabulary of
teamwork.
SAFETY
Heightened societal awareness regarding the incidence
and impact of errors in medicine resulted in the wide-
spread focus on a “culture of safety.” Error management
focuses on the principles of prevention, recognition, and
mitigation-of-effect. Prevention is best accomplished via
multiple tiers of decision-support and verification. General
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systems theory suggests that the use of algorithms, check-
lists, and team-based practice creates a more optimal envi-
ronment for error prevention. Decision-support systems
also include the availability of information at the point of
prescribing, such as PDAs, intranet and internet access,
and reference texts. Multiple levels of verification include
nurses, pharmacy, and colleagues. According to the
Agency for Health Care Research and Quality, adverse
drug events (ADEs) cause approximately 777,000 injuries
and deaths annually and cost $1.5 million to $5.6 million
annually per hospital depending on hospital size. In addi-
tion, ADEs increase hospital length of stay by 8–12 days
per patient affected and increase hospitalization cost by up
to $24,000 per event. Medication dosage errors account
for 28% of all hospital-related errors. The Institute of
Medicine has highlighted the problem and proposed
changes. Hospitals that do not proactively implement
plans to reduce medical error will risk losing market share
and increase their medical–legal liability. Examples of prac-
tical implementations of safety measures include resident
work hours and supervision requirements, computerized
position order entry and point-of-care decision support sys-
tems, and communication facilitation models such as crew
resource management. Medical errors are also common in
CCM, perhaps as a result of the intensity of care. The team
model of critical care practice is a key component of the
“culture of safety” and encourages collaboration and input.
Computerized physician order entry (CPOE) is a com-
puterized order entry system whereby physicians and
other licensed providers enter medication and plan-of-
care orders directly into a computer terminal. CPOE has
an impact on patient safety by eliminating transcription
errors, and automatically crosschecking for patient drug
allergies and sensitivities, end-organ dysfunction and dos-
ing, and drug interactions. Electronic medical records can
potentially increase patient safety by delivering accurate
and legible medical information to many health care
providers simultaneously at any point of care. Decision
support systems (DSSs) include digitalized reference mate-
rials, formularies, internet access to search engines, and
guidelines and protocols available at the point of care
through digital area networks. DSSs can also automatically
initiate physical/occupational therapy evaluations, social
work consultations, and discharge planning, for example.
Crew resource management (CRM), originally called
cockpit resource management, is a model of active team
participation at all levels of decision-making. In essence,
based on the safety practices of airlines, “any crew mem-
ber can question or stop takeoff.” CRM is based on the
concepts of situational awareness, interpersonal com-
munications, and standard operating procedures, and
debriefing to optimize operational integrity and safety.
Fully trained and credentialed providers and appropriate
staffing ratios are important to outcomes.
Leadership defines the culture. The impact of leader-
ship style, attitude, commitment, and willingness to
adhere to the team model of critical care is fundamental
to nurturing a culture of safety and quality. Continuous
learning is essential. Medicine and especially critical care
is a field where significant changes and advances occur
frequently. Distillation of information and a dedication
to education in both academia and private practice alike
is a key component of safety and quality.
Data also reveal that patient safety varies in the same
institution between days, nights, and weekends. There 
is a significantly higher incidence of errors, slower
response to critical incidents, and poorer outcomes dur-
ing “off-shifts.” Fatigue impairs data assimilation and
decision-making ability. Although standard operating
procedures and other support systems can mitigate the
effects of fatigue, the imposition of mandatory rest times
is becoming uniform practice.
QUALITY
A precise definition of “quality” is elusive but may be
best defined as an error rate, although both frequency and
magnitude of errors must be considered. Maximization of
quality may be considered to represent minimization of
the variation from an accepted standard. Health care
reform of any nature must be based in a delivery system
based in data and information. The challenge is to deter-
mine what is sufficiently important to be measured 
and how best to measure it. Measurement is the basis 
for any systematic safety or quality program; thus, there
is an overlap between the concepts of safety and 
PEARLS
Examples of Patient Safety Improvement
Opportunities
● Adverse drug reactions (ADRs)
● Venous thromboembolism (VTE)
● Stress-related gastrointestinal bleeding
● Unplanned extubations
● Ventilator weaning protocols
● Sedation and pain management protocols
● Falls, restraints, and related injuries
● Failure to honor patient DNR preferences
● Communication issues
● Wrong surgery/site
● Informed consent
● Abnormal laboratory or radiology results
● Nosocomial infections
● Ventilator-associated pneumonia (VAP)
● Central venous catheter-related infections
● Surgical site infections
● Contrast-induced nephropathy
● Malnutrition and related complications
● Unanticipated mortality
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quality management. The public is increasingly aware of
safety and quality issues and will be a driving force for
changes in this arena (Box 36-1).
Peer review is a legislatively mandated review of
adverse clinical events and outcomes. Morbidity and
mortality (M&M) conferences represent a type of peer
review. Peer review is subject to legislation such as
confidentiality, privilege, and antitrust.
Intensive care unit (ICU) staffing may also have an
impact on quality, as reflected in patient outcome. ICU
staffing by a dedicated full-time intensivist has been
shown to improve significantly clinical care and patient
outcomes, measured as the efficiency of resource uti-
lization, mortality, morbidity, or patients’ and staff satis-
faction. Nursing staff-to-patient ratios are important to
both quality and safety initiatives. The State of California
enacted mandatory nursing staffing ratios in an effort to
improve patient safety and quality of care.
Credentialing of providers ensures that minimum edu-
cational, training, and certification requirements have
been met. Advanced cardiac life support (ACLS) and 
fundamental critical care support (FCCS) are examples
of advanced credentialing. Continuing medical educa-
tion (CME) is also an important basis for continued 
credentialing. Credentialing is also regulated by state 
legislation and hospital bylaws (Box 36-2).
Publication of a guideline, protocol, or pathway pre-
supposes a certain level of consensus within the scientific
community regarding its validity. Guidelines are state-
ments from specialty societies that define practice param-
eters based on extensive literature review by experts.
Guidelines are published and become important “stan-
dards” but are not absolutely binding.
The American College of Cardiology/American Heart
Association guidelines on perioperative cardiovascular
evaluation for noncardiac surgery is one example of a
comprehensive clinical guideline that has been widely
accepted and adopted. Protocols are statements-of-
care plans that are based on best practices. Protocols
and pathways reduce variation and increase the cost-
effectiveness of clinical care.
Systematic expert analysis of published medical liter-
ature is necessary because the medical literature is
replete with published studies of questionable scientific
validity. Sophisticated critical appraisal is necessary to
Box 36-1 Quality Management
● Quality management refers to any one of a number
of terminologies for a system of quality
maximization. These terms include quality
improvement (QI), quality assurance (QA),
continuous quality improvement (CQI), total quality
management (TQM), and performance improvement
(PI), among others.
● Quality measurement and improvement has its basis
in clinical epidemiology.
● The purpose of quality management in medicine is
to clarify the implications of variations in medical
practice and suggest improvements based on data.
PEARLS
Underlying Root Causes of Adverse Events
● Human
● Fatigue
● Training
● Communication
● Technical
● Equipment failure
● Systemic
● Workplace ergonomics
● Decision support systems and backup
● Production pressure
● Lack of policies and procedures
● Organizational culture
Box 36-2 Root Cause Analysis
● Root cause analysis (RCA) is a method of incident
analysis and quality improvement which focuses on
identifying the causes of adverse events. The RCA
employs the scientific method, verbal and visual
dialogue, and systems attempting to identify cause
and effect relationships.
● The RCA has become the prevalent model of
incident analysis for both quality and risk
management activities.
● The importance of RCA is that it focuses not on a
single event or person as a root cause of an adverse
event, but upon the systems and processes that were
absent or failed to detect an unsafe situation, provide
appropriate backup, or mitigate the extent of injuries.
PEARLS
Continuous Quality Improvement Process
Data
↓
Practice pattern measurement
↓
Benchmarking
↓
Dissemination of information
↓
Protocol and pathway development
↓
Interventions
↓
Ongoing practice pattern monitoring
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determine the relevancy and applicability of the studies
to clinical situations.
INTENSIVE CARE UNIT SCORING
SYSTEMS
Scoring systems have been developed in response to
a need for comparative analysis of patient outcomes
within a single institution over time and to assess the
impact of continuous quality improvement (CQI), and
for inter-institutional analysis to identify best practices.
Scoring systems are also used to estimate prognosis and
outcome, to justify triage decisions, and to optimize
resource allocation.
Many commonly accepted medical practices have
been implemented which had not been subjected to rig-
orous scientific clinical investigation. The lack of con-
vincing evidence supporting the efficacy of interventions
or medical therapies has resulted in diverse individual
practitioner beliefs or practices with large variations in
clinical outcome. Increasingly, these beliefs are being
questioned and challenged in large prospective random-
ized multicenter clinical trials resulting in accepted 
evidence-based standards. Theoretically, each and every
intervention used in intensive care should be subjected
to randomized controlled trials to determine its clinical
effectiveness.
Data-driven evidence-based practices are supplanting
traditional teachings. ICU scoring systems allow fairly
accurate predictions regarding clinical outcomes in pop-
ulations of patients but cannot accurately and reliably
predict the probability of individual survival.
A scoring system describes the association between an
independent variable such as case mix or severity of illness
and a dependent variable such as survival or functional
status. A scoring system is developed using retrospective
outcome data from large populations of patients and is a
mathematical model capable of being prospectively applied
to new populations to predict outcome. Development of
the scoring system is accomplished through multiple
logistic regression analyses which describe the strength
of the association between combinations of independent
variables while simultaneously accounting for the effects
of other independent variables in the system.
Scoring systems are most commonly used for research
studies and for general inter-institutional comparisons.
The use of scoring systems for inter-institutional out-
come and performance comparisons is very controversial
both because of the unknown underlying assumptions in
the statistical modeling and because outcomes other
than survival and mortality are important. Descriptors of
outcomes include measures such as mortality, morbidity,
functional status, quality of life, and cost.
A scoring system must function independently of
treatment, be disease specific and yet function over a
range of diseases, be clinically credible, be capable of
measuring severity at multiple points along the care con-
tinuum, be relatively easy to implement, and provide
statistically valid information. All predictive indices cur-
rently in use have a false classification rate of 10–15%.
Therefore, 10–15% of patients predicted to survive will
die, and vice versa.
Data can be quantitative, quantal, or qualitative.
Quantitative data refers to measured quantities. Quantal
data refers to attributes that may be classified.
A distribution curve is a frequency distribution of the
incidence of specific values. A normal or Gaussian curve
has values evenly distributed around the mode; a multi-
modal curve is a frequency distribution curve with more
than one mode. Many populations are normally distrib-
uted but many critical care populations cannot be
described using a normal distribution curve.
However, the fundamental issue regarding mortality
and survival is the appropriate time interval (30 days,
6 months, 5 years, etc.) at which the endpoint represents
a valid quality indicator.
Applications of scoring systems include comparative
audit, evaluative research, development of standards,
and clinical care. Limitations of scoring systems include
data accuracy, population sampling, data interpretation,
and clinical applicability.
Examples of critical care scoring systems include
organ-specific measures (Box 36-3) and general severity-
of-illness scoring measures.
The Glasgow Coma Scale (GCS) is an example of a sim-
ple scoring system used for the assessment of the extent of
coma in patients based on eye opening (4), verbal
response (5), and motor response (6). The scale is
weighted in favor of motor response. The total GCS is the
sum of each category and ranges from a minimum of 3 to
a maximum of 15. GCS applications include prehospital
triage and assessment of clinical change based on serial
examinations. The GCS is an example of a descriptive scor-
ing system which later evolved into a correlate of out-
come. The GCS is incorporated into most contemporary
general severity scoring systems including Acute
Physiology and Chronic Health Evaluation (APACHE) II
and III, Simplified Acute Physiology Score (SAPS) II, and
Mortality Probability Model (MPM) II (Box 36-4).
Box 36-3 Examples of Organ-Specific
Measures
● Glasgow Coma Scale (GCS) for central nervous
system injuries
● Child–Pugh Score for cirrhosis
● Ranson’s Criteria for pancreatitis
● Lung Injury Score (LIS) for respiratory failure
Trauma Increased Severity Score (TRISS) was devel-
oped in 1983 and combined elements from the Trauma
Score and the Injury Severity Score (ISS). The Trauma
Score was replaced by the Revised Trauma Score which
is used in the current model along with the ISS, age, and
type of injury. APACHE I was the first version of the
APACHE system developed between 1979 and 1981 to
measure the severity of illness in ICU patients and con-
sisted of two parts: (a) an acute physiology score reflect-
ing the extent of 34 potential variables and (b) chronic
health evaluation questionnaire which classified patients
according to prior health status. This model correlated
directly with hospital mortality but did not include prob-
ability calculations.
APACHE II is the second version of APACHE intro-
duced in 1985 with several important changes: (a) the
number of physiologic variables is reduced to 12, (b)
acute renal failure receives double weighting, (c) the
cost of coma scale is given greater weight, (d) a score is
assigned to reflect the prognostic impact of emergency
surgery, and (e) the chronic health questionnaire is
dropped and scores are assigned to reflect diminished
physiologic reserves related to aging, immune deficiency,
and chronic cardiac, pulmonary, renal, and liver disease.
APACHE II scores range from 0 to 71. APACHE III allows
for (a) individual evaluative scoring and (b) predictive
modeling to estimate the probability of death for indi-
vidual patients at different times during their ICU stay.
The scoring system is based on 17 physiologic variables,
a coma scale, age, and comorbid conditions. APACHE III
scores range from 0 to 299.
APACHE is expensive to implement and use. APACHE
scores do not correlate well with resource utilization.
APACHE scores may penalize patients with good end-
organ reserve and good ward care, since they may not
accumulate sufficient points to warrant ICU admission.
The MPM was developed by Lemeshow in 1985 and
subsequently revised as MPM II in 1993. MPM incorpo-
rates a large number of variables: 137 at admission and
75 at 24 hours. Therefore, the MPM has a unique versa-
tility in being applicable at admission and also 24 hours
later. The MPM modeling population also excludes
patients admitted with burns, cardiac surgery and coro-
nary care patients, and patients less than 18 years old.
SAPS II was created in 1992. The model excludes
patients who are admitted for burns, coronary care, and
cardiac surgery. SAPS II uses 17 variables: 12 physiologic
variables, age, type of admission (scheduled surgical,
unscheduled surgical, medical), and three variables
related to underlying disease (hematologic malignancy,
AIDS, and metastatic cancer).
The Therapeutic Intervention Scoring System (TISS)
was developed in 1989 and was originally proposed as a
method for the quantitation of resource utilization in
critically ill patients. The premise was that more seri-
ously ill patients would require more therapeutic inter-
ventions independent of specific diagnoses. Therefore,
the severity of illness could be determined from the
number and complexity of monitoring needs and inter-
ventions. TISS has remained a method of analysis of
expenditures and outcome. An advantage of TISS is its
inherent simplicity.
MEDICOLEGAL ISSUES
Medicolegal matters of concern to critical care practi-
tioners extend from medical malpractice to increasingly
complex regulatory legislative law. The threat of legal
liability based on a malpractice claim of negligence is an
important concern and may drive defensive medicine
practices as well as increasing health care costs. The
trend is one of increasing judicial awards, increasing
societal awareness of litigation as a forum for recovery of
awards, and increasing malpractice insurance premiums.
Adverse outcomes can range from dissatisfaction of
patients and/or family to iatrogenic mortality. However,
regulatory legislation is an important source of legal risk
to both individual practitioners and institutions. For exam-
ple, guidelines for documentation of services and coding
and billing are associated with the risk of fraud in both
teaching institutions and in private practice. Additionally,
legislation intended to ensure patients’ privacy protection
will have significant impact on electronic medical records
and databases, and the transmission of electronic informa-
tion between providers. Trends such as the development
of telemedicine and electronic mail communications with
patients will continue to challenge the medical–legal 
relationship. The following should not be strictly con-
strued as legal advice, since laws regarding medical prac-
tice vary by individual state. In general, patients may have
legal recourse against physicians, hospital staff, hospitals,
and payers individually or in combinations.
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Box 36-4 Examples of Generalized
Severity-of-Illness Scoring
Systems
● Trauma Increased Severity Score (TRISS)
● Sequential Organ Failure Assessment (SOFA)
● Acute Physiology and Chronic Health Evaluation
(APACHE I–III)
● Mortality Probability Model (MPM I and II)
● Simplified Acute Physiology Score (SAPS I and II)
● Therapeutic Intervention Scoring System (TISS)
● Multiple Organ Dysfunction Score (MODS)
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Negligence and Professional Malpractice
Medical malpractice is a type of negligence. Under civil
liability the tort of negligence requires that the plaintiff
demonstrate four elements: duty, breach of duty, causa-
tion, and damages. In addition, the causation relationship
must satisfy the proximate cause requirement whereby a
breach of duty proximately caused either an injury or 
a lost opportunity for clinical recovery. Negligence is 
generally treated as a civil cause of action; however, under
some rare circumstances, negligence in medical treatment
law may rise to a level of criminal action.
Negligence is defined based on deviations from
accepted medical practices but not errors of judgment.
Duty is the primary element of the negligence theory of
liability. Duty is created by the physician–patient rela-
tionship and requires that a physician act in accordance
with the specific norms or standards established by the
medical profession. Medical malpractice specifically
refers to a medical care which represents a deviation
from that care which would normally be rendered in the
same or similar situation. Medical malpractice is not
defined by a less than optimal outcome, unless the care
rendered was otherwise substandard. Therefore, expert
testimony is required to demonstrate medical malprac-
tice by defining an appropriate standard of care. The
standard of medical care is that which a prudent physi-
cian with similar qualifications would have rendered in
the same or similar situation. The standard of medical
care is determined from expert testimony. Breach of
duty must be proved by the plaintiff. The plaintiff must
demonstrate that the defendant-physician did not act in
accordance with the standard of care required as a duty
stemming from the physician–patient relationship.
Causation refers to the reasonably close causal connec-
tion between the act and the injury. Causation is closely
related to “legal cause” and “proximate cause.”
Damages is a term that refers to the actual loss, injury,
or harm suffered by the patient as a result of the physi-
cian’s breach of standard of care. The purpose of award-
ing damages in a tort action is “to make whole again” the
injured party and return him or her to a position or
condition similar to that which existed before the tort. The
damages awarded may be either compensatory or puni-
tive. Compensatory damages may be special or general.
General damages include noneconomic losses such as
“pain and suffering.” Punitive or exemplary damages
awarded in addition to actual losses to make an example
of the egregious actions. Special damages compensate the
plaintiff for hospital and long-term care costs, for example.
Consent for Treatment
Consent is a key element of the physician and patient
relationship and may be considered as a type of contract
which requires that there be an element of consideration
(informed) and acceptance of a plan of care. Therefore,
consent obtained under fraudulent pretenses or under
duress, for example, may not be valid. Informed consent
presupposes that patients must agree to be examined
and/or treated; without such an agreement, there is
potentially an invasion of privacy and possibly a tort of
battery. The physician must disclose to patient informa-
tion that is sufficient to enable the patient to make an
“informed” decision about a potential treatment or pro-
cedure. In order for such an agreement to constitute
informed consent there must be a clear documentation
of the risks, benefits, and alternatives to the proposed
intervention. Implied consent is consent that may be
tacit, or implied, which is based in the situational con-
text of the patient presenting for care. Implied consent
is most often used to justify treatment interventions in
the context of emergency and critical care. Whenever
possible consent should be informed and express. The
documentation of the basis on which consent was
obtained is fundamental. Express consent is best docu-
mented in written form. However, documentation of a
verbal discussion may be adequate under some circum-
stances. In order for consent to be informed and valid
the consenter must have both capacity and competence.
Both terms refer to the cognitive ability of the patient to
understand the ramifications of his/her decision.
Capacity is generally considered to be contextual and
situational and not fixed. For example, a patient who has
received psychoactive medication may temporarily lack
the capacity to form an informed decision. Competence
is generally a fixed characteristic of the patient such as a
cognitive limitation or an age of minority without eman-
cipation or other potential modifiers.
Patients may also refuse treatment. Competent
patients have the right to refuse particular elements of
medical therapy (surgery, blood or blood product trans-
fusions, other specific interventions) or all and any med-
ical care. Refusal of one therapeutic intervention does
not in itself constitute refusal of other alternatives.
Patients who make an informed decision to refuse
all interventions may request to be discharged AMA or
“against medical advice.” A discharge AMA does not
necessarily relieve practitioners of their obligations.
PEARLS
Liability – Risk Minimization Strategies
● Communication
● Documentation
● Dissemination of accepted guidelines and protocols
● Adherence to policy
378 CRITICAL CARE: THE REQUISITES IN ANESTHESIOLOGY
Abandonment constitutes a breach of the duty to provide
continuity of care once the physician–patient relation-
ship has been established. Abandonment can become an
issue where a discharge AMA does not well document the
exact circumstances and does not provide for follow-up if
needed.
Advance Directives and Do Not Resuscitate
Advance directives are requests made by capable and
competent persons which become important when
patients can no longer communicate. Examples of issues
involving advance directives include living wills and
health care proxies, and do not resuscitate (DNR) status.
In the absence of a written designation of a health care
proxy state laws often delineate the order in which rela-
tives and decision-making authority occurs (Box 36-5).
Autonomy refers to an individual’s right to decision-
making regarding his or her own personal self-deter-
mination. Beneficence refers to the fiduciary duty of
physicians to act in the best interests of their patients.
Fiduciary duty is a special responsibility with which
physicians are entrusted to act as agents on their
patients’ behalf. The word “duty” has both ethical and
legal ramifications. Thus, physicians must balance the
duty of care against the respect for individual autonomy.
This means that it may be ethically more acceptable to
err in resuscitating a patient who may have not desired
it, rather than to erroneously assume the patient is DNR
and inappropriately withhold life-sustaining treatment. It
also means that the communication between physician,
patient, and families regarding life support decisions
must be clear, complete, and absolutely unambiguous. It
is unfair to focus on issues of pain, discomfort, and dig-
nity without clearly revealing that the alternative to life
support is “death.” Nonmaleficence expresses the guid-
ing principle which underlines the fiduciary duty of
medical care: primum non nocere; meaning “above all
else, do no harm.” Notably, harm can be defined either by
omission or commission of acts which inflict emotional,
psychological, or physical injury. Paternalism refers to
the desire of health-care providers to make decisions on
behalf of their patients. Where instinctive paternalism
drives physicians to withhold information or disclose
information selectively, it is inappropriate, and probably
illegal, since consent to treatment or a refusal of treat-
ment are not based on “informed consent.” Thus, a DNR
order, is essentially an informed consent document. In
order to be truly valid, consent must equally disclose
risks, benefits, and alternatives; and it must be obtained
after full disclosure to a patient who is competent, with-
out any duress or coercion. Documentation of a mental
status examination has significant legal, medical, and
ethical value where DNR discussions take place with
patients whose capacity to understand and consent may
later be questioned.
DNR orders are generally classified into three or more
general categories reflecting specific levels of treatment
that the patient consents to: (1) limited critical care, sug-
gesting full life support but limiting CPR; (2) conservative
care, suggesting full medical care short of mechanical
ventilation and CPR; and (3) comfort care, suggesting
treatment to maximize comfort only. However, these cat-
egories vary in their interpretation between providers
and between institutions. Therefore, additional docu-
mentation, aside from simply “checking a box on a form”
is usually required. Additionally, the DNR form should
always be accompanied by a written note in the body of
the chart reflecting the basis of the decision, the alter-
natives discussed, and the patient’s level of comprehen-
sion. Perhaps most importantly, it is necessary to realize
that Do Not Resuscitate never means “do not treat.”
Additionally, withdrawal of life support never means
“withdrawal of care”.
The administration of medication with the intent of
treating pain and anxiety within the comfort care context
is not generally considered to be synonymous with either
euthanasia or physician-assisted suicide. Medication doses
are generally based on individual clinical effect and not
absolute numerical values.
Withdrawal of life support usually requires either a
determination of medical futility, brain death, or a change
Box 36-5 Do Not Resuscitate
● “Do not resuscitate” (DNR) is also referred to as “do
not attempt resuscitation” (DNAR) and is a type of
informed refusal of treatment. Given the complexity
of the term “resuscitation,” a blanket DNR may be
subject to scrutiny.
● DNR is no longer generally considered to be an
absolute specification; it is necessary that it be
further categorized and subclassified in order to
best represent an individual patient’s precise
directives.
● Limited critical care DNR may allow mechanical
ventilation and hemodynamic monitoring and
support but may limit the use of cardiopulmonary
resuscitation, defibrillation, or dialysis, for example.
● Conservative care DNR may allow dialysis and
hemodynamic support but preclude intubation and
mechanical ventilation, for example.
● Comfort care may restrict interventions to those
measures maximizing comfort. It is important to
realize that DNR is a type of consent that requires
careful documentation. Additionally, DNR never
means “do not treat” and even comfort care DNR
patients require maximization of comfort and
dignity.
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in DNR status to comfort care DNR. Brain death is a statu-
torily defined definition of death. The Uniform Brain
Death Act (1978), the Uniform Determination of Death
Act (1980), state legislation, and case law are all important
considerations to the development of policy. Since state
laws regarding brain death determination are not uniform,
policy should be developed with the advice of counsel.
Triage and Rationing of Services
Triage refers to the prioritization of resource alloca-
tion to the individuals most acutely in need. Where
scarce resources preclude an appropriate level of care to
a critically ill patient, considerations for an appropriate
transfer must be made. Triage in the ICU is common-
place and is often based on a subjective assessment of
severity of illness and requirements for therapeutics and
monitoring. Triage should probably be accompanied by
an objective measure of severity of illness if possible.
The Health Insurance Portability and
Accountability Act: HIPAA
Respect for the privacy and confidentiality of
patients’ medical information is a well-established prin-
ciple of both medical ethics and health law. A respect for
each patient’s individual rights and dignity is essential to
ensure trust and to promote the integrity and the com-
pleteness of health information disclosure within the
scope of the physician–patient relationship. A  “fiduciary
duty” is one which a professional owes to a patient ben-
eficiary, by virtue of knowledge, training, and experi-
ence. Fiduciary principles impose a heightened duty of
loyalty, integrity, and devotion upon professionals. The
physician’s duty of confidentiality dates from the
Hippocratic Oath, is codified within the Principles of
Medical Ethics of the American Medical Association, and
has been reiterated in legislative statutes such as the
Federal Privacy Act of 1974, in the Guiding Principles of
the Joint Commission for the Accreditation of Health
Care Organizations (JCAHO), and, most recently within
HIPAA. Multiple levels of law govern the privacy of
health-care information and existing civil causes of
action can include breach of privacy, breach of confi-
dentiality, breach of contract, breach of loyalty, and
other statutory violations.
The broad goals of HIPAA are to: (1) increase the effi-
ciency of electronic health-care transactions; (2) ensure
the continuity of an employee’s health insurance cover-
age during the process of changing jobs; and (3) man-
date widespread privacy protection measures for
ensuring the security of individually identifiable health
information. HIPAA is increasingly necessary as “elec-
tronic data interchange” (EDI) is used to transmit per-
sonal health information via electronic and digital media.
Additionally, digitally stored information is vulnerable to
threats such as worms, viruses, and Trojan horses which
can eradicate digital data or compromise their security.
HIPAA is characterized by three intra-related parts: (1)
the administrative simplification provisions; (2) the pri-
vacy rule, which sets security standards and policies; and
(3) the security rule which governs relationships
between health-care business associates. HIPAA
increases the level of control that individual patients
have over their personal health information (PHI) by
requiring notice regarding the proposed uses of their
personal information, allowing patients the right to
inspect, amend, and copy medical records, receive an
accounting of disclosures of their PHI, and also restrict
the use of their information. HIPAA privacy regulations
protect only that health information which is indivi-
dually identifiable. De-identified data, on the other 
hand, can be used or shared, generally without restric-
tions, for research, organizational strategic planning, and
teaching.
The penalties for violation of HIPAA provisions are
strict. The Office of Civil Rights has the authority to
receive and investigate complaints, and the United States
Department of Justice imposes penalties at $100 per 
violation to a maximum of $25,000 per year for each 
violation. Intentional or malicious disclosures which fall
under the category of criminal violations range from
$50,000 to $100,000 and up to five years in prison for
false pretenses; and $250,000 and 10 years in prison if
the information is sold for commercial advantage, per-
sonal gain, or malicious harm.
Billing, Coding, the False Claims Act
The economic realities of practice management
require not only the highest possible level of quality in
patient care, but also an analysis of costs and reimburse-
ment to achieve an optimum balance between revenue
and expenses without compromising quality. Critical
care is defined by the U.S. Health Care Financing
Administration (HCFA) to be the direct delivery by physi-
cians of medical care for a critically ill or critically
injured patient. Critical illness or injury acutely impairs
the function of one or more vital organ systems such that
there is a high probability of a sudden and clinically sig-
nificant deterioration by which survival of the patient is
jeopardized. A high level of professional preparedness is
necessary to intervene urgently. Critical care also involves
frequent assessment, and high complexity decision-mak-
ing to assess, manipulate, and support vital organ func-
tions. ICU admission in itself is insufficient justification for
claiming reimbursement for critical care services unless
other explicit criteria of medical necessity, physician
attendance, and therapeutic complexity are met as well
as documented. Additionally, the standard for procedural
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supervision is such that the attending physician must be
physically present and immediately available in the case
of difficulty. Although otherwise credentialed residents
may be sufficiently technically proficient to perform
independently, the requirements for procedural billing
are more stringent. Misrepresentation of patient care
rendered in a teaching hospital setting as ‘supervised’
when in fact it was not closely supervised, represents
fraudulent billing and is subject to civil and/or criminal
penalties. Since hospitals are reimbursed independently
by the Centers for Medicare and Medicaid Services
(CMS) for resident teaching, hospitals and providers may
not bill for services provided independently by residents
alone. Also, time spent teaching residents cannot be
claimed toward critical care time unless the physician
and residents are together directly engaged in patient
care. Billing for critical care services requires diagnostic
codes which must match the verbiage documented
within the medical record. Thus, documentation is the
key to accurate and timely claims review and payment
by insurers, defensibility in the event of a bad outcome,
and a pivotal tenet to billing compliance standards. The
submission of claims for any component of critical care,
procedure, or other evaluation and management for
which the attending physician was not directly present
may constitute fraud and abuse under the False Claims
Act. Submission of a bill for services at a level of service
greater than that which was actually provided represents
“up-coding;” whereas, submission of a claim a level of 
service lower than that actually provided represents
“down-coding.” Both up-coding and down-coding repre-
sent mis-coding and are both illegal. Although, the False
Claims Act has traditionally been enforced by the 
government against hospitals and providers in the set-
ting of inappropriate billing for services rendered to
Medicare patients, there is an increasing trend towards
monitoring for billing fraud, and enforcement action, by
private insurers.
Other issues within the scope of health-care fraud and
abuse include restrictions on self-referral under the Stark
Law, and the relationships between physicians and hos-
pitals under the “anti-kickback” statute.
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Summary
Critical care consumes a disproportionate share of
hospital resources. While intensive care unit (ICU) beds
comprise between 5 and 10% of total hospital beds, criti-
cal care accounts for as much as 25–34% of total hospital
costs. Quality and cost of care are emerging as growing
concerns among health care buyers, policy makers, regu-
lators, and the public at large. As a result there is increased
scrutiny and pressure to improve ICU care processes and
outcomes. Critical care, by virtue of its high cost, high
complexity, and high mortality, lends itself to measure-
ment of ICU performance and quality of care. Given the
relatively high mortality in ICU patients, death is a sensitive
and meaningful measure of outcome. Therefore, mortality
still remains a “gold standard” as an outcome measure for
critically ill patients. Scoring systems have been developed
in response to an increasing emphasis on the evaluation
and monitoring of critical care services.
ROLE OF SCORING SYSTEMS
The purpose of scoring systems in ICUs is to take into
account the characteristics of patients that could affect
their risk of a particular outcome and account for factors
that are outside the control of those providing the care.
Various patient-related factors associated with an
increase in risk of death in ICUs include increasing age,
greater severity of illness, emergency surgery, and
presence of concurrent severe medical conditions.
Accounting for such patient characteristics or “case
mix” is essential for proper comparisons of outcome.
Outcome is usually measured as death before discharge
from hospital after critical care. The role of scoring sys-
tems is based on the quantification of case mix and the
development of mathematical models to estimate proba-
bilities of outcome for ICU patients. The association
between the independent variables (case mix) and the
dependent variable (death) is described in the form of a
multiple logistic regression model. Applying the model,
the probability of death before discharge from hospital
after critical care can be estimated for each patient and
summed for all patients to yield the expected hospital
death rate for the group of patients. The expected hos-
pital death rate can then be compared with the actual
hospital death rate. Standardized mortality ratio (SMR) is
the ratio of actual to expected deaths. SMR can be used
as a measure of quality of different providers or ICUs.
An SMR greater than 1.0 may reflect poor care and an
SMR of less than 1.0 may reflect good care.
The major roles of ICU scoring systems include the
following:
● Perform comparative audits. As mentioned above,
the use of case-mix-adjusted outcomes as a measure
of clinical effectiveness of ICUs assumes that an
SMR of >1.0 may reflect poor care and an SMR of
<1.0 may reflect good care. Local clinical audits
must be performed to explain the reasons for any
unexpected results. Severity models (Box 37-1) have
been widely used as the basis for public report
cards. Managed care organizations and group
practices are keenly interested in outcomes
reporting.
● Perform evaluative research. Scoring systems have
been used to aid risk stratification in randomized
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controlled trials. Given the heterogeneity of ICU
patients, it is proposed that stratification of using an
accurate, objective estimate of the risk of hospital
death might create a more homogeneous subset of
patients to isolate better the effects of the
intervention on the outcome. Therefore, in clinical
trials severity scores may provide a number of
functions including a way to evaluate entry or
exclusion criteria, randomization balance, and 
risk-adjusted efficacy outcome measure.
● Individual patient management. Scoring systems
have been used as a common, standard terminology
to convey information rapidly about a patient and
classify patients according to severity of illness. It is
believed that an accurate, objective estimate of the
risk of hospital death can provide an additional
piece of information to help make clinical decisions
about treatment plans for individual patients. It is
important to mention that no model is accurate
enough to predict that a given patient will certainly
either survive or die, so the use of scoring system
alone to direct therapy is not recommended.
● Quality improvement, like research, requires a
severity-adjusted method to control for differences in
the presenting characteristics of patients when one is
assessing outcome. Resource utilization, cost varia-
tion, and reimbursement strategies can also be 
analyzed using a severity adjustment approach. In
various quality improvement and/or cost strategies
severity scoring systems can provide a benchmark
for new initiatives.
TYPES OF SCORING SYSTEMS
Scoring Systems based on Resource
Utilization
Severity of illness can be ranked based on resource uti-
lization, on the assumption that more severely ill patients
will need more ICU resources (nursing, monitoring, and
therapeutic interventions). The Therapeutic Intervention
Scoring System (TISS) quantifies the number of inter-
ventions to estimate severity of illness. The original TISS
scored 57 therapeutic interventions with point values of
1 to 4, and patients at highest risk had scores of more
than 40 points. Variations on TISS include the intermedi-
ate TISS, designed for step-down areas, and a simplified
TISS-28, which reduces the number of variables. Because
interventions can be driven by local practices, TISS scores
generally are not used for prognosis or quality assessment.
Scoring Systems based on Physiologic
Derangement
There are three major ICU scoring systems based on
physiology. These models are all based on the assumption
that more critically ill patients have values that deviate
more from physiologic normal for a variety of common
variables such as heart rate, blood pressure, and neuro-
logic status, and that they also have altered physiologic
reserve with advanced age and chronic illness.
Acute Physiology and Chronic Health Evaluation
In the early 1980s Knaus and colleagues first devel-
oped Acute Physiology and Chronic Health Evaluation
(APACHE I) as a general ICU outcomes model. Initially,
34 physiologic variables thought to have an effect on out-
come were selected. These were then reduced to 12 more
commonly measured variables in APACHE II. The values
that represent the greatest deviation from normal for the
physiologic variables are collected during the first 24 hours
after admission to the ICU. The final APACHE II score
(Table 37-1) is the sum of the points assigned to each of
the three components and range from 0 to 71, with an
increasing score representing a greater severity of illness.
In addition, coefficients are assigned to 42 specific disease
designations that are considered to represent the majority
of patients admitted to most ICUs. The patient’s probabil-
ity of dying is calculated with a logit equation that takes
into account the APACHE II score and a disease coefficient
with a weight added for emergent surgery. APACHE II
represents a reduction in variables and an improvement
in performance over the original APACHE based on 
multivariate regression analysis. Pediatric, burns, and
coronary bypass patients are excluded from APACHE II.
The relationship between APACHE II scores and hospital
mortality differs for surgical and nonsurgical patients.
APACHE II does not control for pre-ICU management.
Admission source predicts hospital death irrespective of
the APACHE II score.
APACHE III is the most recent version of the APACHE
system. It addresses the limitations of APACHE II, specif-
ically the impact of treatment location before ICU
admission. This commercially available model includes
CLINICAL CAVEAT
None of the ICU prediction models is accurate
enough to predict that a given patient will certainly
either survive or die, so the use of a scoring system
alone to direct therapy is not recommended.
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Box 37-1 Severity Models
Severity models present a “point estimate” of proba-
bility of hospital mortality.
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Table 37-1 APACHE II Score Form
Physiologic Variable High Abnormal Range Low Abnormal Range
+4 +3 +2 +1 0 +1 +2 +3 +4
1. Temperature, rectal (°C) ≥41 39–40.9 38.5–38.9 36.0–38.4 34–35.9 32–33.9 30–31.9 ≤29.9
2. Mean arterial pressure = ≥160 130–159 110–129 70–109 50–69 ≤49
(2 × diastolic + systolic)/3
3. Heart rate (ventricular response) ≥180 140–179 110–139 70–109 55–69 40–54 ≤39
4. Respiratory rate (nonventilated ≥50 35–49 25–34 12–24 10–11 6–9 <5
or ventilated)
5. Oxygenation, A-aDO2 or 
PaO2 (mmHg)
(a) FIO2 > 0.5: record A-aDO2 ≥500 350–499 200–349 <200
(b) FIO2 < 0.5: record PaO2 >70 61–70 55–60 <55
6. Arterial pH (if no ABGs record ≥7.7 7.6–7.69 7.5–7.59 7.33–7.49 7.25–7.32 7.15–7.24 <7.15
serum HCO3 below*)
7. Serum sodium ≥180 160–179 155–159 150–154 130–139 120–129 111–119 ≤110
8. Serum potassium ≥7 6–6.9 5.6–5.9 3.5–5.4 3–3.4 2.5–2.9 <2.5
9. Serum creatinine (mg/dl); double ≥3.5 2–3.4 1.5–1.9 0.6–1.4 <0.6
point for acute renal failure
10. Hematocrit (%) ≥60 50–59.9 46–49.9 30–45.9 20–29.9 <20
11. White blood cell count ≥40 20–39.9 15–19.9 3–14.9 1–2.9 <1
12. Glasgow Coma Scale 15 – GCS
(score = 15 − actual GCS)
A. Total acute physiology Sum of the 12 individual variable points = 
score (APS)
*Serum HCO3 (venous, mmol/l); <52 41–51.9 32–40.9 22–31.9 18–21.9 15–17.9 <15
not preferred, use if no ABGs
Glasgow Coma Scale (circle
appropriate response) B: Age Points C: Chronic Health Points APACHE II Score
Eyes open Verbal – nonintubated Age Points If any of the 5 CHE categories A + B + C (A = APS points,
is answered with “yes” give + B = age points, C = chronic
5 points for nonoperative or health points)
emergency postoperative 
patients
Liver                Cirrhosis with Total APACHE II Score =
PHT or 
encephalopathy
Cardiovascular Class IV angina or 
at rest with 
minimal self-care 
activities
Pulmonary       Chronic hypoxemia 
or hypercapnia or 
polycythemia of 
PHT > 40 mmHg
Kidney            Chronic peritoneal 
or hemodialysis
Immune           Immune 
compromised host
Age points = Chronic health points =
4 – spontaneously 5 – oriented and <44 0
3 – to verbal stimulus converses 45–54 2
2 – to painful stimulus 4 – disoriented 55–64 3
1 – no response and talks 65–74 5
3 – inappropriate >75 6
words
2 – incomprehensible
sounds
Motor response 1 – no response
6 – to verbal command
Verbal – intubated
5 – localizes to pain
5 – seems able to talk
4 – withdraws to pain
3 – questionable
3 – decorticate
ability to talk
2 – decerebrate
1 – generally
1 – no response
unresponsive
17 physiologic variables that were determined to con-
tribute independently to outcome. Five new variables
(blood urea nitrogen, urine output, serum albumin,
bilirubin, and glucose) were added, and serum potas-
sium and bicarbonate were deleted from the score. The
final APACHE III score is determined by the sum of the
physiologic points together with age and chronic health
points. The final APACHE III score can vary between 0
and 300, and a 5-point increase represents a significant
increase risk of hospital death. The APACHE III scoring
system has not been widely accepted or used.
Simplified Acute Physiology Score
The Simplified Acute Physiology Score (SAPS) I uses a
subset of the original APACHE variables. SAPS is the
European equivalent of APACHE. Like the APACHE sys-
tem, SAPS uses the worst values collected during the first
24 hours after ICU admission, and excludes burn
patients and cardiac surgery patients. The outcome
measure for SAPS II is vital status for hospital discharge.
This model includes 17 variables, including 12 physio-
logic variables, age, type of admission, and three under-
lying diagnoses (AIDS, metastatic cancer, and hematologic
malignancies).
Mortality Probability Models
Mortality probability models (MPMs), like APACHE
and SAPS, exclude pediatric, burn, and cardiac surgery
patients and estimate hospital mortality risk based partly
on physiologic derangement, but consider a smaller
number of variables. MPM II uses data obtained at ICU
admission (MPM0) and at the end of the first 24 hours
(MPM24). The admission model contains 15 variables and
the 24-hour model uses five of the 15 MPM0 variables
plus 8 additional ones. Age and chronic health status are
included in both MPM0 and MPM24. MPM directly calcu-
lates a probability of survival from the available data. The
final result for MPM II is expressed as a probability of
death with a range from 0 to 1. The most important 
difference between MPMs and other systems is that 
the MPM0, with the exception of information related to
cardiopulmonary resuscitation, produces a probability
estimate that is available at ICU admission and is inde-
pendent of ICU treatment. MPM does not require speci-
fying a diagnosis (Table 37-2).
Trauma Scoring Systems
The general scoring systems such as APACHE II, SAPS
II, and MPM II perform poorly on trauma patients. The
revised trauma score (RTS) consists of Glasgow coma
scale (GCS), systolic blood pressure, and respiratory
rate. The most abnormal value is recorded, and the RTS
is the sum of the coded values multiplied by the weight
for each of the variables. The injury severity score (ISS)
is an index of the severity and extent of anatomic injury.
The trauma–injury severity score (TRISS) combines the
RTS and the ISS, a classification of the type of injury
(penetrating vs. blunt), and the patient’s age. TRISS has
become the most widely used and accepted scoring sys-
tem for trauma outcome assessment. In patients with
acute head trauma GCS still remains the most applicable
severity scoring system.
Morbidity Scores
A number of studies have raised the concern about
mortality rate as a sensitive outcome measure. There is
growing interest in using morbidity as an outcome
measure. In critically ill patients the development of one
or more organ system dysfunctions represents the most
important morbid event. Multiple organ dysfunction syn-
drome (MODS) represents a major cause of ICU and hos-
pital mortality. The two most commonly used morbidity
scores are the Multiple Organ Dysfunction (MOD) score
(Table 37-3) and the Sequential Organ Failure
Assessment (SOFA) score. Both are based on serial meas-
urement of easily available parameters of organ dysfunc-
tion. The MOD score has the advantage of being
relatively independent of any particular treatment prac-
tices. The maximal MOD score (the sum of the highest
score achieved in each organ system during the patient’s
ICU stay) gives an estimate of cumulative organ dysfunc-
tion. The change in MOD score is thought to reflect the
development of additional organ failure. There is fairly
good correlation between the change in MOD score and
ICU mortality. The method of scoring for SOFA is similar
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Table 37-2 Mortality Probability Model at Intensive
Care Unit Presentation (MPM0)
Physiology
Coma/deep stupor
Heart rate > 150/minute
Systolic blood pressure < 90 mmHg
Chronic diagnoses
Chronic renal disease
Cirrhosis
Metastatic neoplasm
Acute diagnoses
Acute renal failure
Cardiac dysrhythmias
Cerebrovascular incident
Gastrointestinal bleeding
Intracranial mass effect
Other
Cardiopulmonary resuscitation before ICU admission
Mechanical ventilation
Medical or unscheduled surgery
Age
to the MOD scores in most organs, except for cardiovas-
cular dysfunction. The SOFA score utilizes a combina-
tion of hypotension and requirement for specific
vasoactive drugs (Table 37-4).
SHORTCOMINGS IN SELECTING
A SCORING SYSTEM
APACHE II remains the most widely used and recog-
nized scoring system. The URL http://www.sfar.org/
scores2/apache22.html can be used to download APACHE
II. The criteria for selection of a scoring system should
be based on the accuracy (validity and reliability) and
goodness-of-fit (calibration and discrimination) of the
mathematical model used to estimate outcome.
Discrimination, or the ability of a model to distinguish
between a patient who will die and one who will live, 
is usually measured by the area under the measured
receiver operator characteristic (ROC) curve. The total
area under the curve is a good summary measure of pre-
dictive ability. Calibration compares the observed mor-
tality with that predicted by the model within severity
strata. Validity is the ability of the score to measure fully
what it is intended to measure, and includes construct,
content, and criterion validity. There is no “gold standard”
to use as the basis for establishing the validity of scoring
systems. Reproducibility is the ability of the score to be
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Table 37-3 Multiple Organ Dysfunction (MOD) Score
Score
Organ System 0 1 2 3 4
Respiratory* (PO2/FIO2 ratio) >300 226–300 151–225 76–150 ≤75
Renal† (serum creatinine) ≤100 101–200 201–350 351–500 >500
Hepatic‡ (serum bilirubin) ≤20 21–60 61–120 121–240 >240
Cardiovascular§ (PAR) ≤10.0 10.1–15.0 15.1–20.0 20.1–30.0 >30.0
Hematologic¶ (platelet count) >120 81–120 51–80 21–50 ≤20
Neurologic** (Glasgow Coma Score) 15 13–14 10–12 7–9 ≤6
* The PO2/FIO2 ratio is calculated without reference to the use or mode of mechanical ventilation, and without reference to the use or level of positive end-expiratory
pressure.
† The serum creatinine concentration is measured in μmol/l without reference to the use of dialysis.
‡ The serum bilirubin concentration is measured in μmol/l.
§ The pressure-adjusted heart rate (PAR) is calculated as the product of the heart rate (HR) and the ratio of the right atrial (central venous) pressure (RAP) to the mean
arterial pressure (MAP): PAR = HR × RAP/MAP.
¶ The platelet count is measured in platelets/ml × 10−3.
** The Glasgow Coma Score is preferably calculated by the patient’s nurse, and is scored conservatively (for the patient receiving sedation or muscle relaxants, normal
function is assumed, unless there is evidence of intrinsically altered mentation).
Table 37-4 Sequential Organ Failure Assessment (SOFA) Score
SOFA Score
Variable 0 1 2 3 4
Respiratory (PaO2/FIO2, mmHg) >400 ≤400 ≤300 ≤200* ≤100*
Coagulation (platelets × 103/μl) >150 ≤150 ≤100 ≤50 ≤20
Liver (bilirubin, mg/dl)† <1.2 1.2–1.9 2.0–5.9 6.0–11.9 >12.0
Cardiovascular (hypotension)‡ No hypotension MAP < 70 mmHg Dop ≤ 5 or Dob Dop > 5, Epi ≤ 0.1, Dop > 15, Epi > 0.1, 
(any dose)§ or Norepi ≤ 0.1§ or Norepi > 0.1§
Central nervous system 15 13–14 10–12 6–9 <6
(Glasgow Coma Score)
Renal (creatinine, mg/dl; or <1.2 1.2–1.9 2.0–3.4 3.5–4.9 or <500 >5.0 or <200
urine output, ml/dl)¶
* Values are with respiratory support.
† To convert bilirubin from mg/dl to μmol/l, multiply by 17.1.
‡ Dob, dobutamine; Dop, dopamine; Epi, epinephrine; MAP, mean arterial pressure; Norepi, norepinephrine.
§ Adrenergic agents administered for at least 1 hour (doses given are in μg/kg/minute).
¶ To convert creatinine from mg/dl to μmol/l, multiply by 88.4.
repeated with similar results in differing situations. A
responsive score is one in which a change in the score
correlates with a clinically important change in the gold
standard. In general, APACHE II and III, SAPS II, and
MPM II demonstrate good discrimination (ROC 0.83),
but have poor calibration.
It is important to note that while scoring systems
may apply to groups of patients they do not accurately
predict death in an individual patient or the external
data sets. This is due to the inability of a single model
adequately to adjust risk for all case mixes across a
long time period during which quality of care has
changed.
SUMMARY
The ICU scoring systems provide us with the best
available measures of “quality.” The scoring systems can
play a role in identifying the processes of care associated
with best outcomes. Before an ICU scoring system is
implemented, there must be an institution’s cultural
desire to change and an organizational commitment to
measure processes and outcomes, and a commitment to
standardized care. The scoring systems of the future are
likely to be disease-specific, not generic, and be applica-
ble to a more homogeneous population.
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SELF-ASSESSMENT
QUESTION
The most appropriate use of a severity-of-illness
model represents which one of the following?
A. As a screening tool for ICU admissions
B. To decide when “near” futile care should be
stopped
C. Quality of care comparisons
D. To determine nurse staffing ratio
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The anesthesiologists’ goal following surgery is to
return their patients to normal physiologic states with
minimal side effects. The transfer of patients from the
operating room (OR) to the postanesthesia care unit
(PACU) entails many challenges, including treatment of
pain, nausea/vomiting, hypoxia, temperature distur-
bances, confusion, and hemodynamic instability. These
PACU problems often lead to delays in discharge. The
potential for complications following even the most
benign anesthetics is 20–30%. This chapter reviews
many common PACU complications and examines 
new strategies and therapeutic measures available for
the recovery room practitioner. Hemodynamic compli-
cations in the postoperative patient are described in
Chapter 40.
PAIN
Pain control in the perioperative period is always 
a high priority for anesthesiologists and patients.
Postoperative pain is most common after orthopedic
surgery (especially shoulder surgery) and surgery of more
than 2 hours’ duration. Inadequate pain relief can pre-
dispose a patient to a variety of postoperative complica-
tions, including increased sympathetic nervous system
responses, nausea and vomiting, atelectasis, pneumonia,
and deep vein thrombosis. Postoperative pain manage-
ment begins with review of a patient’s preoperative pain
state and any treatments provided prior to surgery.
Patients with longstanding pain associated with chronic
medication use will have developed a tolerance espe-
cially notable in the perioperative period. The provider
must consider not only the type and amount of preoper-
ative pain medication, but also the level of pain control
prior to surgery. Those patients without adequate pain
control prior to surgery will be difficult to manage espe-
cially in the immediate postoperative period. Patients tak-
ing chronic opioid therapy should continue their regimen
through the day of surgery and, if possible, throughout
the postoperative period to assist with developed toler-
ance. Patients that received preemptive analgesia with
analgesics or by regional or neuraxial blockade may have
reduced postoperative pain; preemptive analgesia pre-
vents the establishment of central sensitization caused
by incisional and inflammatory injuries.
Before prescribing analgesics, the PACU practitioner
must consider the type of the surgery and the intensity
of pain expected. A patient’s physical and psychologic
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state and cultural background may influence subjective
perception of pain. Therefore, the provider must assess
the patient in order to determine the severity of pain and
course of treatment. Numeric pain scales and Visual
Analog Pain scales (VAS; 0 being no pain and 10 being
the worst pain ever noted) can assist in the treatment of
pain by helping patients quantify their pain.
In addition to incisional pain, a patient may complain
of nonsurgical pain, which must be elucidated before
aggressive treatment is initiated. A headache, sore throat
from airway instrumentation, and limb or back pain from
prolonged positioning may distract the provider from
adequate incisional pain relief.
Narcotics
Opioids are considered the mainstay for treatment for
early postoperative pain. Opioids are potent analgesics
that control moderate to severe postoperative pain.
Binding to mu, kappa, and delta receptors spinally and
supraspinally, opioids may cause respiratory depression,
pruritis, nausea and vomiting, over-sedation, urinary
retention, and prolongation of postoperative ileus.
Opioids such as fentanyl (12.5 to 50 μg), hydromor-
phone (0.125 to 0.5 mg), meperidine (10 to 25 mg), or
morphine (1 to 4 mg) may be cautiously intravenously
titrated at five-minute intervals until an adequate anal-
gesic level is reached or respirations are 10 or less per
minute. Although fentanyl has a quick onset (1 to 2 min-
utes) and rapid peak effect (3 to 5 minutes), its short
duration of action compared with morphine results in
higher pain scores and more need for oral analgesia
when patients recover in phase II. In the face of residual
postoperative sedation, PACU nurses should be acutely
aware of respiratory depression and titrate opioid therapy
carefully for patient comfort. Preoperative neuraxial
morphine may last up to 24 hours (0.1 to 0.4 mg
intrathecal, 3 to 5 mg epidural) and delivers good pain
control in the recovery room. Pruritis and nausea are
common side effects with opioid therapy and can be
treated with nalbuphine and antiemetics, respectively.
Intrathecal water-soluble opioids such as morphine may
cause respiratory depression in the late postoperative
period. Recently, more research has demonstrated good
pain control with intra-articular opioids placed by sur-
geons at the completion of their procedures, with or
without local anesthetics. Patient-controlled analgesia
(PCA) most commonly involves a preprogrammed sys-
tem of continuous and/or incremental dosage of opioids
with a set lockout interval. PCA is often started in the
PACU, where nurses can evaluate and initiate loading
doses. PCA increases patient satisfaction and decreases
opioid requirement compared to scheduled regimens.
Morphine and meperidine should be avoided in patients
with renal insufficiency due to the accumulation of
active metabolites. PCA can be used with epidural infu-
sions with combination techniques of local anesthetics
and opioids or with local and opioid infusions inde-
pendently. Naloxone 40 μg IV may be repeated as
needed to reverse respiratory depression; care should be
taken, as rapid reversal has been associated with cate-
cholamine release and pulmonary edema.
Nonsteroidal Anti-inflammatory Drugs
The role of nonsteroidal anti-inflammatory drugs
(NSAIDs) has changed as more anesthesiologists pursue
regimens that can supplement or replace opioids, and
thus decrease the incidence of opioid side effects.
Effective as an analgesic, NSAID inhibition of cyclo-
oxygenase (COX) expression has been associated with
reduction of inflammatory mediators on peripheral noci-
ceptors to promote preemptive analgesia. The use of
NSAIDs has increased recently as studies have found
equal efficacy between doses of NSAIDs and opioids
without many of the deleterious central effects.
Unfortunately, unlike opioids, there is a ceiling effect
with NSAIDs. Contraindications to NSAID use include
history of allergy, renal insufficiency, peptic ulcer dis-
ease, and platelet dysfunction. There has been great
concern over the COX2 inhibitor agents over the last
year. The majority have been withdrawn from use.
There may be increased risk for cardiovascular events.
We therefore recommend that they not be used until 
further evaluation and risk benefit studies by the FDA.
Local Anesthetics
Local anesthetics block sodium channels and prevent
the transmission of electrical nerve impulses and are
widely recognized as effective agents in perioperative
and postoperative pain management. Local anesthetics
can be utilized at various sites for analgesia. In addition
to nerve blocks performed by the anesthesiology team,
intraoperative infiltration of incisions and joints by
surgeons can reduce postoperative pain. Those at high
risk for potential pulmonary complications can benefit
from intercostal nerve blocks with local anesthetic seen
commonly in thoracic and upper abdominal procedures.
Extremity nerve blocks (e.g., interscalene, axillary, supra-
clavicular, and sciatic) provide excellent pain control
that will last many hours beyond the patient’s time in the
PACU. Many patients without adequate pain control may
be offered a nerve block in the PACU. Ultrasound guided
blocks can be performed accurately and efficiently, with
a lower incidence of complications. The toxicity of local
anesthetics is reflected in the central nervous and cardio-
vascular systems. With careful management and vigilant
390 CRITICAL CARE: THE REQUISITES IN ANESTHESIOLOGY
dosing of local anesthetics, especially in the pediatric
and geriatric populations, seizures and cardiac arrhyth-
mias can be minimized. These potential toxicities are
generally due to intravascular or inadvertent intrathecal
injection. Neuraxial anesthesia involving the placement
of local anesthesia into intrathecal, epidural, or caudal
space can be performed throughout the perioperative
period to help manage postoperative pain. Side effects
include hypotension secondary to sympathectomy 
and difficulty ambulating due to motor blockade and 
loss of proprioception. Analgesia is enhanced when 
narcotics are added to local anesthetics in neuraxial
blockade. Safety with caudal anesthesia with the pedi-
atric population has been well documented in the one-shot
bolus or continual infusion, with close observance to 
dosing.
NAUSEA AND VOMITING
Postoperative nausea and vomiting (PONV) remains
the most common complication in the immediate post-
operative period. Many patients acknowledge that
PONV is the most distressing complication involved
with the surgical experience, often more distressing
than postoperative pain. The incidence of PONV has
been found to be as high as 30–50% in the first 24 hours
following surgery. As the number of ambulatory surgery
centers and outpatient procedures continue to rise, the
management of PONV becomes increasingly more
important to both patients and the health care system.
Delays in discharge, risk of pulmonary aspiration,
increased cost of nursing and medical care, and the
potential for unanticipated hospital admission following
ambulatory surgery erode the cost savings of outpatient
surgery. The debate continues regarding the timing and
the efficacy of the many modalities for the prevention
and treatment of PONV.
Nausea involves the subjective sensation of discom-
fort often associated with vomiting, but may occur inde-
pendently caused by impulses from the gastrointestinal
tract or from the cerebellum with motion sickness.
The physiology of vomiting involves an intricate com-
munications network centering on the emetic center
located in the lateral reticular formation in the medulla.
Afferent inputs involve chemical mediators from the
chemoreceptor trigger zone, solitary tract nucleus,
vestibular apparatus, cerebellum, and higher cortical
areas, as well as input from the gastrointestinal system.
Efferent impulses are transmitted through the vagus,
phrenic, and spinal nerves and coordinate the diaphragm
and abdominal musculature in the act of vomiting. The
central chemical receptors involved include dopamin-
ergic, muscarinic, serotoninergic, histaminic, and opioid.
The blockade of these receptors is the mainstay in the
treatment of PONV.
Risk Factors
The risk factors involved in PONV can be subdivided
into three areas: patient, surgery, and anesthesia. Patient-
related factors include female gender, nonsmoking
status, and previous history of PONV or motion sickness.
School-age children have a higher incidence than adults,
whereas younger infants have a lower incidence.
The type and duration of surgery are associated with
the rate of PONV. Surgery with an increased incidence
of PONV includes craniotomy; ear, nose, and throat pro-
cedures including tonsillectomies and adenoidectomies;
ophthalmic, including strabismus surgery; major breast;
laparoscopic, especially gynecologic; laparotomies; and
orthopedic/shoulder operations. There is a 60% increase
in the incidence of PONV for each 30-minute increase in
surgical duration.
Anesthetic-related factors can be divided into pre-
operative, intraoperative, and postoperative management.
Perioperative opioids have been associated with two to
four times the incidence of PONV. However, inadequate
analgesia in the perioperative period can cause increased
PONV. Intraoperatively, the use of nitrous oxide has
been shown to increase PONV, especially in the later
postoperative period. The diffusion of nitrous oxide to
the middle ear and bowel, stimulating the vestibular
apparatus and bowel distention, activates the dopamin-
ergic receptors in the cortical medullary system and
endogenous cerebrospinal opioids from bowel disten-
tion. Modern volatile anesthetics increase the incidence
of PONV, although less than previously used ether and
cyclopropane. When propofol is used as an induction
and maintenance agent, it reduces PONV in the early
postoperative period with less benefit approximately 
6 hours postoperatively. Propofol in low bolus doses 
(20 mg IV) in the PACU has been shown to assist in 
the treatment of PONV. Reversal of neuromuscular
blocking drugs (NMBDs) with anticholinesterases, such
as neostigmine and edrophonium, increases gastric
motility and may increase PONV. PONV is more common
at doses greater than 2.5 mg of neostigmine. Because 
anticholinergic medications are routinely given with
anticholinesterases to reduce their muscarinic actions,
there are reports that the use of tertiary agents like
atropine, which cross the blood–brain barrier, may cause
less PONV than those that do not (glycopyrrolate).
Recent research has found that oxygen at 80% during
and possibly two hours following laparoscopic gyneco-
logic surgery results in a twofold reduction in nausea
and vomiting compared to 30% oxygen. It is thought that
hyperoxia decreases dopamine release by the carotid
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bodies and decreases serotonin release by the intestines
in periods of ischemia.
Although not conclusive, administration of intra-
venous fluids above maintenance rates (20 ml/kg) to
ensure proper hydration reduces PONV. Dehydration,
orthostatic hypotension, and dizziness can all promote
postoperative emesis.
Postoperatively, there are numerous stimuli that 
may cause PONV. Following a general anesthetic, the
vestibular apparatus may become sensitized by diffusion
of nitrous oxide into the middle ear, causing emesis.
Movement of those individuals by stretcher, wheelchair,
or ambulation may cause PONV, especially in those indi-
viduals that received opioids. Environmental factors can
reduce the incidence of PONV, especially those with a
history of previous PONV or motion sickness. A quiet
environment with minimal activity may prevent and
reduce emesis.
Agents
There are a number of agents available in the preven-
tion and treatment of PONV. There are opposing views
regarding treatment of PONV prophylactically or with
rescue medication. The cost effectiveness, side effect
profile, and patient satisfaction must be considered,
especially as newer and more expensive antiemetic
agents are being developed and used regularly.
Pretreating patients at low risk for nausea and vomiting
is not cost effective; however, many providers agree that
high-risk patients undergoing operations with a high
likelihood of emesis should be treated aggressively with
multiple agents. We will focus on each medication as a
treatment for emesis and/or nausea, and the potential for
effective combination therapy.
Dopamine Antagonists
Metoclopramide antagonizes central dopamine recep-
tors and at high doses antagonizes 5-HT3 receptors.
Although it is not recommended to treat or prevent
PONV because of its minimal antiemetic effect, meto-
clopramide increases lower esophageal sphincter tone
and motility through interactions of dopaminergic and
cholinergic receptors. Droperidol interacts though
heterocyclic, neuroleptic central dopaminergic receptors
and is known to cause adverse effects similar to meto-
clopramide, including sedation, lethargy, agitation and
extrapyramidal symptoms. These effects can be mini-
mized by the use of lower dosing (0.625–1.25 mg) in
adults; its low cost and high efficacy make it an attractive
agent. Droperidol is contraindicated in patients with
Parkinson’s disease. Droperidol can be effectively dosed
at 50–75 μg/kg in children. Droperidol has been much
discussed with regards to the “black box” warning that
was provided recently by the US Food and Drug
Administration, due to anecdotal reports that found the
prolongation of QTc interval and fatal arrhythmias; one
should consider alternatives in patients with a prolonged
QT interval or at high risk of arrhythmias.
Promethazine and prochlorperazine are direct-acting
dopamergic antagonists that work directly on the CTZ.
Even at low doses, they appear to be very effective for
PONV but are associated with sedation and extra-
pyramidal side effects.
Histamine H1 Antagonists
Commonly used in regimens for chemotheraputic-
induced nausea and vomiting, the histamine H1 receptor
antagonists are weakly antiemetic. Due to their low cost,
H1 blockers have found resurgence in interest as
antiemetic medication. Common side effects include seda-
tion that may not be suitable for the postoperative period.
Muscarinic Antagonists
Receptors in the vestibular apparatus include mus-
carinic and histaminic receptors. Although many studies
extrapolate the use of anticholinergics from the premed-
ication period, atropine can cause irritable behavior, dry
mouth, and blurred vision. Transdermal scopolamine, 
if placed well before the preoperative period, has 
been shown to lessen PONV, especially in patients
receiving epidural opioids as well as children using a
morphine PCA.
Serotonin Antagonists
Ondansetron is the prototypical serotonin antagonist
and although it has structure similar to metoclopramide,
it has no affinity at the dopamine receptor. Multiple
studies have shown that ondansetron used to treat
PONV is effective at a 1 mg dose and is effective in the
prevention of PONV at a 4 mg dose. Many believe that
ondansetron is more consistently an antiemetic than an
antinausea agent. Side effects include headache, light-
headedness, dizziness, increased liver enzymes, and con-
stipation. Ondansetron has been noted to be effective in
children at a dose of 50 μg/kg. Although increasingly
expensive, other agents in this class include granisetron
40 μg/kg and dolasetron 12.5–50 mg.
Corticosteroids
Although its exact mechanism of action is unknown,
dexamethasone is an effective antiemetic at a dose
150 μg/kg for children and 8–10 mg for adults if
given prior to incision. There is no proven benefit of
dexamethasone in the PACU.
Postanesthesia Care Unit Regimens
After receiving a patient in the PACU with PONV, the
care provider must examine the patient at the bedside and
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determine if there is a disease process causing PONV which
needs immediate treatment such as cardiac ischemia,
hypotension, hypoxia, abdominal obstruction, a nasogas-
tric tube causing irritation, or residual blood or sputum in
the airway. Next, it should be determined whether or not
prophylaxis was given prior to completion of surgery. For
patients who did not receive prophylaxis or only received
dexamethasone, a 5HT3 receptor antagonist such as
ondansetron 1.0 mg should be administered. If prophylaxis
with 5HT or droperidol was attempted, it should not be
repeated within the first 6 hours after surgery; propofol 
20 mg or phenergan 12.5 mg are acceptable alternatives.
RESPIRATORY COMPLICATIONS
Postoperative hypoxemia is of great concern for anes-
thesiologists and the incidence of it ranges from 3 to
50%. Risk factors involved in predicting postoperative
hypoxemia include increased ASA class, preoperative
oxygen saturation, increased age, male gender, obesity,
smoking history, coexisting lung disease, surgical site,
and duration of surgery. Transferring patients emerging
from general anesthesia to the PACU carries a significant
risk of postoperative hypoxia if transferred without oxy-
gen; approximately 30% of pediatric and adult inpatients
will develop hypoxemia.
Diffusion hypoxia is most often seen in the first minutes
following cessation of nitrous oxide. This most commonly
occurs when a patient receiving nitrous oxide is switched
directly to room air. Nitrous oxide is 30 times as diffusible
as nitrogen and the inspired air is diluted with nitrous oxide
and PAO2 lowered. This can be prevented by routinely pro-
viding patients with supplemental oxygen following dis-
continuation of nitrous oxide. Although the differential
diagnosis of hypoxia and/or hypercarbia in PACU patients
is broad, a directed history and physical examination usu-
ally leads to the correct etiology and treatment (Table 38-1).
Hypoventilation
Following general anesthesia and early in the PACU,
many studies have shown the need for ASA 1 and 2 patients
to require supplemental oxygen therapy. It is estimated
that approximately 50% of patients without supple-
mental oxygen will have an episode of postoperative
hypoxemia within three hours after surgery.
Residual potent inhalational agents and narcotics
given in the perioperative period may cause hypoventi-
lation in the postoperative patient, especially in patients
with underlying lung disease, such as chronic obstruc-
tive pulmonary disease (COPD). These drugs will
depress ventilatory drive mainly at central locations and
depress the body’s normal response to hypoxemia 
and hypercarbia. Low levels of isoflurane and halothane 
(0.1 MAC) severely reduce hypoxic drive. Respiratory
depression caused by opioids will present with a slow
respiratory rate. Although sedation may be present, the
patient is arousable and will follow commands. Normal
oxygenation does not rule out significant hypoventila-
tion, as high inspired oxygen concentrations may allow
patients to remain adequately oxygenated with progres-
sive hypercarbia.
Airway obstruction in the early postoperative period is
commonly caused by decreased upper airway tone and
possibly increased airway edema. Pharyngeal obstruction
is commonly due to the tongue. Pharyngeal dilator muscle
contraction activity is decreased due to residual medica-
tions in the semiconscious patient. Laryngeal obstruction
may also occur secondary to laryngeal spasm or direct air-
way injury. Prolonged procedures, traumatic intubations,
excessive bucking, and coughing during emergence may
result in laryngeal edema. Hematomas are common causes
for external compression of the trachea, following head
and neck procedures, including surgery on the carotid
artery and thyroid. Patients with history of obstructive
sleep apnea are at increased risk of airway obstruction
especially with sedation. Bilateral injury to the recurrent
laryngeal nerve (e.g., during thyroidectomy) will result in
unopposed vocal cord tension and stridor. Postoperative 
stridor may also be caused by acute hypocalcemia after
unintentional removal of parathyroid glands, although this
often presents after leaving the PACU. Laryngospasm may
occur in a sedated patient due to secretions.
Recurarization, or residual neuromuscular blockade,
is more common with long-acting neuromuscular block-
ade, such as pancuronium, although residual paralysis 
is common even two hours after administration of an 
intermediate-acting agent. Patients will have shallow
breathing patterns and generally be tachypneic in the PACU.
Many modalities have assisted with the monitoring of
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Table 38-1 Respiratory Complications in the
Postanesthesia Care Unit
Hypoventilation Residual medications
Airway obstruction
Residual neuromuscular blockade
Pain with breathing
Increased shunt Atelectasis
Mucus plugging
Preexisting anatomic shunts
Increased dead space Pulmonary edema
Aspiration
Pulmonary embolism – thrombus, air, fat
Pneumothorax
Bronchospasm
Decreased cardiac output
Acute respiratory distress syndrome
blockade including train-of-four ratio, sustained tetanus,
and sustained head lift for 5 seconds. The ideal train-of-
four ratio of >0.7 is not practical in the operating suite.
Due to increased use of shorter-acting neuromuscular
agents and more commonplace use of nerve stimulators,
adequate reversal is more reliable and less postoperative
residual blockade and upper airway obstruction is
observed in the PACU.
Incisional thoracic and abdominal pain results in 
shallow rapid breathing and may result in a decrease in
the forced vital capacity/vital capacity (FVC/VC) ratio
postoperatively. Upper abdominal surgery will reduce
diaphragm excursion musculature and decrease abdom-
inal assistance to breathing, converting the work of
breathing to the intercostals musculature. Pain can also
prevent the coughing and deep breathing that 
is required to clear secretions and open closed airways.
V/Q Mismatch
Ventilation/perfusion mismatch may cause hypoxia
or hypercarbia in the PACU. Shunt (low ventilation
relative to perfusion) will cause a more significant
hypoxemia, whereas deadspace (high ventilation relative
to perfusion) may additionally cause hypercarbia.
Intraoperatively, patient positioning will potentially
worsen V/Q mismatch prior to surgical intervention.
Nondependent areas of lung will be well ventilated but
poorly perfused, while dependent areas will have better
perfusion. These changes will linger into the early post-
operative period and may cause hypoxemia.
Postoperative atelectasis can occur from bronchial
obstruction due to secretions or blood in the airway, or
poor inspiratory effort. This can occur in a segmental or
diffuse pattern. Right to left intrapulmonary shunting
will occur and the patient will develop a decreased func-
tional residual capacity and smaller airway volumes, which
increase airway collapse. Upper abdominal and thoracic
procedures will commonly cause significant postoperative
atelectasis. Following thoracic cases with endobronchial
intubation, collapse of a patient’s lung is a source of major
atelectasis and if not corrected intraoperatively will be
difficult to manage in the PACU without positive pressure
ventilation to open up the collapsed airways.
Pulmonary edema may cause hypoxia in the PACU.
Pulmonary edema is most common in patients with a
decreased left ventricular ejection fraction, severe valvular
disease, or myocardial ischemia, especially in the setting
of acute rises in afterload or heart rate. Healthy patients
with airway obstruction and hypoxia after extubation
can develop negative pressure pulmonary edema from
the sustained reduction in interstitial hydrostatic pres-
sure. Pulmonary edema may also be due to increased
capillary permeability after pulmonary injury, including
aspiration, trauma, massive transfusion, sepsis, and acute
respiratory distress syndrome.
Pulmonary embolus would be suspected in a patient
with pleuritic chest pain, dyspnea, tachypnea, and
decreases in PaO2. Pulmonary hypertension, right-sided
heart strain on ECG, elevated central venous pressures,
and systemic hypotension may be apparent in those
patients with a large pulmonary embolus. Patients at
high risk include those who have been on prolonged
bed rest prior to surgery. Petechiae may be present in
patients with fat emboli, which may occur after long
bone fractures.
Pneumothorax should be high on the differential
diagnosis of hypoxemia in cases following central line
placement, brachial plexus blockade, intercostal nerve
blocks, trauma including rib fractures and chest tube
placement, procedures which involve the head and
neck, and diaphragm, especially in the retroperoneum.
In addition to rarely causing a pneumothorax, upper
extremity blocks may cause hypoxia from phrenic nerve
paralysis.
Evaluation
Hypoxemia may present as hypertension, hypotension,
tachycardia, bradycardia, agitation, or cardiac dysrhyth-
mias. These signs and symptoms are nonspecific and may
be subtle; thus, the pulse oximeter should be continued
throughout the PACU period. Pulse oximeters are accu-
rate in the range 70–100%, although they require pul-
satile blood flow for differentiation of oxygenated and
deoxygenated blood and are unreliable in periods of
hypovolemia, hypothermia, and peripheral vasoconstric-
tion. Pulse oximeters are poor monitors of other clini-
cally important species of hemoglobin (Hb), including
Met-Hb and carboxy-Hb, which may cause unreliable
readings. If in doubt, the clinician should draw an arte-
rial blood gas and measure the partial pressure of oxygen
directly. The arterial blood gas will reveal the patient’s
oxygenation and ventilation status. In addition to careful
lung auscultation, a chest x-ray will help define the
etiology of a patient with suboptimal oxygenation
despite supplemental oxygen and a reasonable respira-
tory rate and tidal volume.
Treatment
Many of the above diagnoses can be treated quickly
with supplemental oxygenation. Concentrations of
30–60% generally will correct mild to moderate hypox-
emia. Although this may help correct arterial hypoxemia
temporarily, the practitioner must evaluate the patient
and treat the underlying cause of hypoxemia.
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Airway obstruction requires expeditious correction.
Loud snoring and/or inspiratory stridor characterize partial
obstruction. Total obstruction is characterized by lack of air
exchange and loss of breath sounds. The patient will com-
monly attempt to use all respiratory musculature to assist in
respirations. Nasal flaring, retractions of the substernal
notch as well as intercostal muscles, and increased
diaphragmatic/abdominal excursions, which may perform
paradoxically to chest movement, may occur. These
patients should receive supplemental oxygen while correct-
ing the obstruction. The patient’s head should be extended
and jaw thrust forward to assist in pulling the tongue for-
ward from the posterior pharynx. If needed, an oropharyn-
geal or nasopharyngeal airway should be placed to ensure a
patent airway down to the vocal cords. The nasal airway
may be better tolerated in the lightly sedated patient.
Continuous positive airway pressure may be successful in
some patients. If the obstruction is not relieved, one must
then consider problems with the larynx. Laryngospasm is
treated with the head tilt and jaw thrust maneuver, as well
as manual pressure at the angle of the mandible and posi-
tive pressure ventilation with a tight fitting bag and face-
mask with 100% oxygen. Suction if secretions or blood is
suspected. If the laryngospasm does not resolve, a small
amount of IV succinylcholine (10–20 mg) should be
administered to assist in the relaxation of the cords. If
unsuccessful, endotracheal intubation may be necessary to
reestablish adequate ventilation. While intubating, one
should observe the vocal cords closely for edema or
trauma. Laryngeal edema may be treated with humidified
inspired gases and nebulized racemic epinephrine.
Although not of immediate relief, dexamethasone 0.5 mg/kg
IV can be given in cases of laryngeal edema.
Residual opioid effects can be treated by the adminis-
tration of naloxone. Naloxone 40 μg every 2 minutes will
allow the practitioner to titrate the opioid reversal to ade-
quate ventilation without completely antagonizing the
analgesic effects following surgery. Poor titration will not
only cause pain but activate the sympathetic nervous sys-
tem, including hypertension, nausea and vomiting, pul-
monary edema, and myocardial ischemia. Naloxone has a
much shorter half-life than most narcotic medications
provided for analgesia; therefore, patients must be moni-
tored closely following dosing for renarcotization.
The evaluation of a patient with suspected neuromus-
cular blockade should include a sustained head lift for 
5 seconds, vigorous hand grasping, and adequate vital
capacity. Double vision and difficulty swallowing may also
occur. Neuromuscular blockade can be evaluated in a
moderately sedated patient with a nerve stimulator by test-
ing for acceptable response with no fade to a sustained
tetanus. There are generally four reasons for residual neuro-
muscular blocking drugs. First, conditions that poten-
tiate neuromuscular blockers include aminoglycoside
antibiotics or magnesium therapy as well as hypokalemia
or metabolic acidosis. Second, altered pharmacokinetics
with hypothermia and liver or renal failure will cause
delayed metabolism or excretion of certain neuromuscular
agents. Third, pharmacologic reversal of the neuromus-
cular blockade may have been inadequate, causing pro-
longed paralysis in the PACU. Fourth, the patient may
inadvertently receive a neuromuscular block bolus in the
PACU when a previously obstructed IV line is cleared.
Patients with residual neuromuscular blockade must be
quickly treated with supplemental oxygenation, additional
antagonist, if indicated, and ventilatory support as needed.
Wheezing, rales, diminished bronchial sounds, and
rhonchi may be present in many forms of ventiliation/
perfusion defects. Increased inspired oxygen concentra-
tion will overcome many of these defects, especially in
patients with known preoperative obstructive or restric-
tive lung disease. Bronchospasm should be treated with
nebulized inhaled beta agonists or through metered dose
inhalers for intubated patients. Right to left shunting,
including atelectasis, may not significantly improve with
increased oxygen concentration. In intubated patients
simple atelectasis without potentially catastrophic com-
plications (i.e., lobar collapse, mainstem intubation, pul-
monary edema, aspiration) may easily be corrected with
simple maneuvers performed in the PACU. Humidified
gases, lung opening procedures, and administration of
continuous airway pressures and positive end-expiratory
pressure may be necessary to reinflate closed lung units.
Pulmonary edema of cardiac and noncardiac origin may
be treated with diuretics, vasodiliators, and dialysis, if
necessary, in renal failure patients. Positive pressure ven-
tilation may be indicated in cases of unresponsive severe
hypoxemia or respiratory acidosis. Intubation and venti-
lation with positive pressure ventilation will improve
oxygenation by expanding lung volumes. Continued
ventilatory support may be necessary until definitive
treatment is identified.
Following aspiration, gastric contents must be quickly
removed from the airway in the orophayrnx with thor-
ough suctioning. To protect the patient’s airway, a rapid
sequence intubation with cricoid pressure will prevent
further aspiration. The newly placed endotracheal 
tube should be quickly suctioned to prevent passing of
foreign material to the distal airways. 100% oxygen and
positive pressure ventilation should be started as soon
as possible following the above maneuvers to avoid
transient hypoxia.
TEMPERATURE ABNORMALITIES
Patients that arrive in the PACU with a temperature less
than 35°C are associated with a 30% increase in PACU 
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duration. Factors involved in heat loss include radiation,
convection, cutanous vasodilation, evaporative loss from
the surgical field, and sweating. In addition, infusion of
room temperature intravenous fluids or cold blood prod-
ucts will contribute to heat loss. Although cool room
temperature greatly contributes to hypothermia, anes-
thetic-induced reduction in thermoregulatory control of
a patient will add to postoperative hypothermia. Mild
hypothermia is generally defined as 34–36°C.
Complications with hypothermia have been exten-
sively studied. Notable are myocardial ischemia, coagu-
lopathy, wound infection/healing, prolonged drug
effects, increased recovery times, and thermal discom-
fort. Upon emergence of general anesthesia, shivering
may cause a large increase in oxygen demand. This may
not directly cause hypoxia, but with an increased shunt
fraction, the patient will likely become hypoxemic. As
the patient attempts to regain thermostatic equilibrium
following a procedure, oxygen consumption will
increase and cause cardiac output and CO2 production
to increase. Oxygen consumption may increase as much
as 400–500% above baseline cardiac consumption, caus-
ing a significant decrease in mixed venous oxygen satu-
ration. Postoperative cold-induced hypertension in the
elderly is associated with a threefold increase in nor-
epinephrine concentrations, which could lead to myo-
cardial ischemia.
Elderly patients with prolonged surgery have an
increased likelihood of being transferred to the PACU
hypothermic. These patients are three times more likely to
have hypothermic-related myocardial ischemia or ven-
tricular arrhythmias. Platelet function, clotting factor
enzyme function, and fibrinolytic activity are three general
mechanisms that may cause hypothermia-induced coagu-
lopathy. Platelet numbers are not affected by hypothermia
directly; however, platelet function is seriously impaired.
Coagulation tests are completed at 37°C even if the
patient’s temperature is much lower; therefore, prothrom-
bin and partial thromboplastin times will not be prolonged
by hypothermia. Fibrinolysis appears to remain normal in
mild hypothermia; however, the inability adequately to
form clot may be the cause of coagulopathy.
Wound infections have been a concern for both 
surgeons and anesthesiologists. Hypothermia can cause
complications related to poor healing in two ways.
First, hypothermia causes thermoregulatory vasocon-
striction. Vasoconstriction markedly decreases oxygen
tension to subcutaneous tissues, which directly correlates
with wound infections. Second, mild hypothermia impairs
normal immune function, especially T-cell-mediated anti-
body and neutrophil oxidative bactericidal activities.
Reduced free oxygen radicals, which are oxygen depend-
ent, is notable in areas of vasoconstriction and hypoxia.
The pharmacokinetics of many anesthetic-related
drugs are retarded in hypothermia. Many enzymes that
metabolize drugs are temperature sensitive and will be
affected by hypothermia. These medications include
muscle relaxants and volatile and intravenous agents.
The duration of vecuronium is nearly doubled in patients
with a reduction of 2°C of core temperature, and
atracurium at 3°C below core temperature will have an
increase in duration of about 60%. Tissue solubility of
volatile agents increases with hypothermia. This will cause
greater uptake by the body at lower temperatures, and,
therefore, longer exhalation times to recover. Intravenous
propofol and fentanyl will have concentrations approxi-
mately 10% and 5% greater, respectively, for every 1°C
drop in temperature. These factors are related to the delay
in discharge of patients from recovery units.
Thermal discomfort is notable for patients with mild
hypothermia. Many patients in the recovery room will
complain more about feeling cold than pain. Other con-
cerns with hypothermia include hypokalemia and unre-
liable pulse oxygenation due to vasoconstriction.
Many PACUs will not discharge patients until their
temperature reaches 36°C. Treatment involves an envi-
ronment that provides a source of warming and prevents
heat loss. Warming intravenous fluids will not actively
warm patients, but rather sustain normothermia for a
patient. Active cutaneous insulation and a forced air
warming system will provide adequate warming. Most
forced air systems include a powered heat blowing unit
as well as a cover. These disposable covers warm patients
through convection and radiant heat. Convection loss is
common in the operative suite and is the most common
source of heat loss, as cold air passing over skin will pro-
mote loss, as seen with wind chill. A warming blanket
passing warm air over skin will increase heat gain. Radiant
heat loss will be reduced, as the warm covering will
replace the cool surfaces of the operating suite and PACU.
Hyperthermia
Iatrogenic hyperthermia is usually due to vigorous
warming without monitoring by the anesthesiologist.
The differential diagnosis of hyperthermia includes
sepsis, inflammation, endocrine abnormalities, central
nervous system abnormalities, drug effects, and ineffec-
tive heat loss.
Sepsis may cause hypotension and systemic vasodila-
tion in a febrile patient. Inflammation mediated through
cytokines will cause a systemic inflammatory reaction
that will present with hyperthermia. Transfusion reac-
tions related to immune reactions of incompatible blood
products will cause a febrile reaction, hemolysis, and a
leukoagglutinin reaction.
Endocrine abnormalities include catecholamine
excess, such as pheochromocytoma, thyroid storm,
Addisonian crisis, and cocaine or amphetamine use.
There are several central nervous system sources of
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hyperthermia, including trauma, in which hypothalamic
injury can result in an elevated thermoregulatory set
point, intoxication, or postoperative delirium (resulting
in agitation and uncontrolled muscular exertion) and
status epilepticus.
Anticholinergics and medications with similar actions
including antihistamines and antidepressants will dimin-
ish sweating, classically seen in heat stroke, as well as a
delirium. Serotonin syndrome is caused when a combi-
nation of meperidine or dextromethorphan is given to 
a patient on a monoamine oxidative inhibitor (MAOI).
Other combinations include a selective serotonin reup-
take inhibitor or tricyclic antidepressant and MAOIs or
lithium. Patients on ecstasy (3,4-methylenedioxymetham-
phetamine, MDMA) or other hallucinogenic ampheta-
mines react similarly. The syndrome is characterized by
altered mental status, myoclonus, shivering, hyperthermia,
and muscle injury. Treatments involve supportive meas-
ures, including antipyretics, antihypertensive agents,
sedatives, and steroids.
Malignant hyperthermia (MH) is a rare but deadly myo-
pathic disorder triggered by volatile inhalational anes-
thetics or succinylcholine. Although MH usually occurs
during administration of triggering agents, MH may begin
to manifest in the PACU or several hours later. MH is an
autosomal dominant of variable penetrance characterized
by an increase of metabolism and sympathetic hyper-
activity resulting in increased production of heat, carbon
dioxide, and lactic acid resulting in a respiratory and meta-
bolic acidosis. Hyperthermia is a late sign. The involved
defect is found in sarcoplasmic reticulum, which has lost
the ability to reuptake calcium causing an intracellular
buildup of calcium and uncontrolled skeletal muscle con-
traction and metabolism. MH is a diagnosis of exclusion and
may be confused with sepsis, thyroid storm, neuroleptic
malignant syndrome (NMS), and pheochromocytoma,
although a severe uncontrollable respiratory acidosis
responsive to dantrolene is most consistent with MH.
Possible complications from MH include cardiac arrest,
cerebral or pulmonary edema, renal failure, and dissemi-
nated intravascular coagulopathy.
In most cases, the onset, diagnosis, and treatment of
MH will begin in the operating room and continue in the
PACU. Treatment includes:
● Stopping surgery and triggering agents.
● Hyperventilation with 100% oxygen to correct severe
respiratory acidosis.
● Titration of dantrolene 2 mg/kg every 5 minutes up
to total of 10 mg/kg.
● Bicarbonate approximately 2–4 mEq/kg if needed to
assist with the buildup of lactate created by the
increased metabolism.
● Treatment of hyperthermia by cooling measures,
including iced fluids, core temperature cooling,
cooling blankets.
● Treatment of hyperkalemia if needed, e.g., insulin
(10 units regular IV and glucose 50 ml D50).
● Monitoring urine to ensure adequate output, with
examination for myogloninuria.
● Consideration of arterial and central venous access.
● Monitoring for arrhythmias, electrolytes, arterial
blood gases.
The treatment of MH will follow in the ICU with close
observation for 48–72 hours. The PACU practitioner
must be acutely aware of these patients and the many
possible complications with treatment and resolution of
the acute crisis.
NMS is associated with medications that antagonize
the effects of dopamine, notably phenothiazides and buty-
rophenones. Signs and symptoms include altered mental
status, myoclonus, sweating, rigidity, hyperthermia, rhab-
domyolysis, and autonomic instability. Although NMS
and MH appear to have similar signs and symptoms, the
mechanism of action is different and does not appear to
have a genetic basis, nor does NMS have an increased
susceptibility to MH. There is no completely effective
therapy for NMS. Bromocriptine and dantrolene have
been variably successful in combination with cooling
and supportive measures.
DELAYED AROUSAL
Emerging patients brought into the PACU often
exhibit delayed responses and disorientation, confusion,
agitation, and uncooperativeness. These patients must
be immediately evaluated for hypoxia (pulse oximeter)
and hypercarbia (adequate respiratory rate and tidal vol-
ume). Agitation may be due to pain in a patient not fully
arousable. This may manifest as increased sympathetic
tone that can cause hypertension and tachycardia, dan-
gerous in patients with cardiac disease. The most com-
mon cause of delayed arousal is residual medication
effects; however, one must also consider metabolic
abnormalities and neurologic injury.
Residual Drug Effects
Residual drug effects are seen most frequently in the
elderly and patients with hepatic or renal failure.
Reviewing the anesthesia record for preoperative and
intraoperative medications may assist in the diagnosis
and treatment of delayed emergence. Inhalational
agents, especially in long cases, may be the reason for
delayed emergence. Although inhalational agents are
eliminated mainly though the lungs, many of the inhala-
tional agents can accumulate in body fat. Following
emergence, decreased stimulation in addition to pro-
longed excretion out of the body fat of inhalational
agents can depress mental status. Age, pregnancy, and
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hypothermia will reduce minimum alveolar concentra-
tion in those patients.
Narcotics and benzodiazepines may be reversed with
nalaxone and flumazenil (0.2 mg IV every minute, up to
1 mg total), respectively, but barbiturates, anticholiner-
gics, psychotropic drugs, and alcohol have no specific
antagonists. Physostigmine (1.25 mg IV) has been used
with variable success as a nonspecific treatment of
delayed arousal.
Metabolic Abnormalities
Many metabolic and electrolyte abnormalities in the
anesthetized patient will not become apparent until
emergence from general anesthesia, presenting as
decreased mental status or delayed emergence. Hypo-
glycemia, hyponatremia, and hypocalcemia are common
disturbances that necessitate evaluation in the PACU.
A notable substrate for the brain to metabolize is glu-
cose, and it is well known that hypoglycemia will cause
confusion and potentially coma. Those patients at high-
est risk for abnormalities include patients with diabetes
mellitus who take insulin or oral hypoglycemics, patients
with hepatic dysfunction (low glycogen stores), and
patients who have endocrine dysfunction including
hypothyroidism, hypopituitarism, and insulinomas.
Glucose test strips can quickly evaluate for hypoglycemia,
which can be easily treated with intravenous 50% dex-
trose. Severe hyperglycemia may cause decreased arousal;
however, nonketotic hyperosmolar hyperglycemic
coma takes days to develop and would rarely present in
the PACU, unless in patients who were debilitated prior
to presenting for surgery.
Hyponatremia can be seen related to multiple events,
including free water absorption following transurethral
resection of the prostate (TURP), hysteroscopy, and 
syndrome of inappropriate antidiuretic hormone release
(SIADH). Pulmonary carcinomas commonly secrete
antidiuretic hormone (ADH). Positive pressure ventila-
tion and stress following a surgical procedure also 
cause SIADH. Neurologic evaluation of patients with
TURP procedures performed under spinal anesthesia
can be easily observed; however, the free water absorp-
tion of glycine-based irrigating solution during general
anesthesia is more difficult to evaluate. Depending on the
degree of hyponatremia, confusion, seizures, dysrhyth-
mias, and coma can occur. Acute, severe hyponatremia
may be treated quickly with infusion of hypertonic saline,
but minimally symptomatic hyponatremia may be cor-
rected slowly with normal saline and furosemide. Chronic
hyponatremia should not be rapidly corrected due to the
risk of central pontine myelinolysis.
Hypocalcemia may occur following thyroidectomy 
or parathyroidectomy and in patients with pancreatic
insufficiency and malnutrition. Rapid infusion of blood
products decreases ionized calcium due to binding with
citrate. Hypocalcemia is exaggerated by alkalosis, such
as in a patient hyperventilating due to pain. Signs and
symptoms include confusion, seizures, and coma.
Dysrhythmias including QT prolongation and decreased
cardiac contractility are commonly seen. Tetanus may
also occur as well as laryngeal and diffuse muscle spasm.
Treatment includes IV fluid hydration, correction of
respiratory alkalosis, and replacement with intravenous
calcium.
Neurologic Events
Postoperative confusion may occur from intraopera-
tive neurologic events such as cerebral ischemia,
seizures, and embolic or thrombotic events. Prolonged
hypotension during anesthesia will have deleterious
effects on perfusion and cerebral blood flow. Although
the brain autoregulates to maintain constant perfusion 
at a mean arterial pressure range of 50–150 mmHg,
patients who are above and below these values will have
cerebral perfusion that is pressure dependent. This
curve is shifted to the right in patients with hypertension
and cerebral hypoperfusion may occur without signifi-
cant hypotension. Patients with existing cerebrovascular
disease have even less tolerance to hypotensive events,
as stenotic areas decrease perfusion to already suscepti-
ble areas of the brain.
Embolic phenomena may occur during carotid
endarterectomy, sitting craniotomy (paradoxical emboli
if patent foramen ovale), or in patients with longstand-
ing atrial fibrillation. Those with localized motor deficits
on examination indicating a possible ischemic or hem-
orrhagic event must be evaluated appropriately with
imaging and/or neurologic evaluation.
Any neurosurgical procedure will have the potential for
seizure activity, as foci are potentially created with manip-
ulation of the brain. Generally, those being treated for
seizures will already have a depressed mental status due to
the disease itself or seizure medications. Many anesthetic
agents are indicated in the treatment of seizures including
benzodiazepines and barbiturates; however, certain
intravenous agents have the potential for lowering
seizure thresholds, including methohexatol and keta-
mine. The postictal state can be treated conservatively
including protection of the airway, maintenance of
hemodynamic stability, and treatment with phenytoin.
Although muscle relaxants will stop physical muscle
activity, brain metabolic activity will continue and must
be treated accordingly.
If the above diagnoses are ruled out, and postopera-
tive delirium continues, sedation and/or psychotropic
agents may be needed to manage the uncooperative
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patient. Benzodiazepines, barbiturates, and haloperidol
are agents of choice. Both benzodiazepines and barbitu-
rates have sedative effects and may potentially interfere
with further examination of the patient; however,
haloperidol is a butyrophenone neuroleptic agent and
can be used in cases of extreme delirium, agitation, and
disorientation. Haloperidol is a dopamine antagonist
with minimal amounts of sedation and cardiac depres-
sive effects and can be given 5.0 mg IM or 2.5 mg IV prn.
Side effects include dysrhythmias, acute dystonic reac-
tions, extrapyramidal symptoms reversed by diphen-
hydramine, tarditave dyskinesias, and NMS.
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CASE STUDY
The case is a 78-year-old male, with longstanding
diabetes mellitus, hypertension, s/p TURP under spinal
anesthesia. The patient is somnolent upon arrival in the
PACU and the report received by the anesthesiology
resident is that the patient received a bupivicane spinal,
3 liters LR and a propofol infusion because the patient
“did not want to hear anything.” As the anesthetist
prepares to leave for the next patient it is quickly
stated that the propofol infusion was discontinued
approximately 5 minutes prior to the completion of the
procedure and the patient has been “sleepy” since.
Notable on preoperative evaluation is that the patient
does not remember if he had taken his insulin at night
or in the morning, but finger stick blood glucose on
the morning of surgery was 92. Your evaluation finds
an elderly gentleman, somnolent, unarousable, BP
100/45 P 98, RR 10 SpO2 99% on 3L NC. How would
you evaluate this patient?
This is an elderly patient with multiple medical
problems presenting to the PACU with prolonged
somnolence. His preoperative history appears unreliable
and his baseline mental status may not be completely
normal. Even so, following his procedure under spinal
anesthesia and propofol, the patient should be more
arousable. His vital signs, oxygenation, and ventilation
appear stable. After evaluating the airway, if the patient
continues to be unarousable, check for iatrogenic causes
including residual propofol in the intravenous line, agents
given to the patient for nausea, or anxiolysis prior to the
short procedure. Blood glucose should be checked and
electrolytes drawn and evaluated. Hypoglycemia should
immediately be corrected with D50 and monitored
closely. Hyponatremia can cause central nervous system
(CNS) depression following a TURP, which can be
corrected with normal saline. Another CNS abnormality
which may be evaluated if indicated from the
anesthesiologist’s record of the procedure is a prolonged
hypotensive period following the spinal and an ischemic
event in a patient with hypertension and diabetes and
most likely cerebrovascular disease. Neurologic
evaluation and imaging studies would then be indicated
in this case, especially if the patient exhibited localizing
motor deficits.
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Summary
With the advent of new techniques and technology,
there has been a tremendous growth in pulmonary sur-
gery in the last two decades. The emergence of video-
assisted thoracic surgery (VATS) and recent advances in
anesthetic management, including routine use of intra-
operative flexible brochoscopy, has allowed pulmonary
surgery to be performed with less stress and lower risk
of intraoperative hypoxemia, thereby resulting in faster
convalescence and improved outcomes. The patient for
pulmonary surgery presents with unique challenges as
compared with the patient for cardiac and vascular
surgery. Inherent with the nature of the disease pathology
and pulmonary surgery, the major cause of postopera-
tive morbidity and mortality in this group of patients is
pulmonary complications. Just as in cardiac and vascular
surgery, the issues for pulmonary risk are complex, but
there are no universally agreed on algorithms. However,
many factors can be identified in the preoperative assess-
ment of these patients for risk stratification purpose and
identification of the high-risk patient. Advances in surgi-
cal techniques, anesthetic preoperative assessment and
intraoperative management, and mechanical ventilation
have decreased postoperative (post-op) complications
and improved the outcomes after pulmonary surgery.
This chapter presents a review of post-op care of pul-
monary surgery patients. In addition to the routine post-op
care of the pulmonary surgery patient, identification of the
high-risk patient and management of post-op complications
are discussed. Special scenarios such as lung transplantation
and thoracic trauma are also addressed.
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THE HIGH-RISK PULMONARY 
SURGERY PATIENT
Recent advances in surgical techniques and periopera-
tive management have expanded the scope of pulmonary
surgery. As a result, surgical procedures, especially mini-
mally invasive and palliative, are being offered to patients
previously considered “inoperable.” Respiratory compli-
cations such as atelactasis, pneumonia, and respiratory
failure requiring mechanical ventilation represent risks
specific to pulmonary surgery. In the high-risk pulmonary
surgery patient, measures can be taken preoperatively to
pre-optimize respiratory function as much as possible,
prevent complications, and improve outcome.
Assessment of Respiratory System
Impairment
Impairment in the patient’s quality of life, physical
activity, and exercise capacity closely correlates with 
the degree of impairment in the respiratory function. A
detailed history is extremely important to determine
which patients will require pulmonary testing. There is
no single test of pulmonary function that can predict
outcomes for all patients having pulmonary surgery.
Assessment of respiratory system mechanics, gas
exchange, and heart–lung interaction provides the
“three-pronged” approach (Box 39-1) on which to base
“operability” of a patient with “resectable” lung cancer.
Respiratory Mechanics
The most valid test to predict post-thoracotomy pul-
monary complications is the predicted postoperative
(ppo) forced expiratory volume in 1 second (FEV1%)
expressed as a percentage of predicted volumes for age,
sex, and height. It is calculated as:
FEV1(ppo) % = preoperative FEV1% (1 − % functional lung 
tissue removed/100)
The majority of post-op respiratory complications
occur in patients who are left with ppoFEV1 of less than
40%. In the patient with borderline ppoFEV1 (30–40%)
postresection pulmonary function can be further
defined using ventilation perfusion scintigraphy (V/Q
scan). If the lung region to be resected is nonfunctioning
or minimally functioning on V/Q scan, the ppoFEV1 can
be modified accordingly.
The right lung has 22 subsegments (6 in right upper,
4 right middle, and 12 in right lower lobe) and the left
lung has 20 (10 in left upper and 10 in left lower lobe).
For example, if a patient is having left lower lobe
resected the ppoFEV1 decrease will be 10/42 or 28%.
Gas Exchange
Diffusion capacity of carbon monoxide (DLCO) cor-
relates well with the efficiency and total surface area of
alveolar–capillary units. A ppoDLCO (using the same cal-
culation as for the FEV1) of less than 40% predicted cor-
relates with a high probability of developing post-op
respiratory as well as cardiac complications. The tradi-
tional criteria of gas exchange, with an arterial partial pres-
sure of oxygen (PaO2) less than 60 mmHg or an arterial
partial pressure of carbon dioxide (PaCO2) of greater than
45 mmHg remain as useful warning signals of increased
post-op risk.
Heart–Lung Interaction
The maximal oxygen consumption (VO2 max) with
exercise is a very useful predictor of post-op respiratory
complications. A VO2 max of less than 15 ml/kg/minute is
consistent with increased risk of post-op complications.
VO2 max less than 10 ml/kg/minute carries extremely high
mortality following pulmonary surgery. The ability of the
heart and lungs to interact physiologically in response to
exercise can also be evaluated by two simple and reliable
tests: 6-minute walk test (6MWT) and exercise pulse
oximetry. A 6MWT of less than 2000 feet correlates to a
VO2 max of less than 15 ml/kg/minute as well as a fall in
oxygen saturation (SpO2) during exercise. Patients with a
decrease of SpO2 greater than 4% during exercise are at
increased risk of post-op morbidity and mortality following
pulmonary surgery.
Using echocardiography, evaluation of the right ventric-
ular function at rest and with exercise can provide clues to
the hemodynamic tolerance of pulmonary resection.
Coexisting Medical Conditions
Cardiac Disease
Second only to respiratory complications, cardiac 
complications are a common cause of post-op morbidity
and mortality following pulmonary surgery. Coronary
artery disease risk factors must be elicited in the patient
having pulmonary surgery. Elective pulmonary surgery
is generally considered as an “intermediate risk” with
respect to perioperative cardiac ischemia. Atrial fibrillation
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Box 39-1 The “Three-Pronged” Approach
The “three-pronged” approach to evaluate
respiratory system impairment includes assessment
of respiratory mechanics (FEV1), efficiency of gas
exchange (DLCO), and heart–lung interaction 
(VO2 max).
is a well-recognized complication of pulmonary surgery.
Continuing beta-blockers or calcium channel blockers
(diltiazem) through the perioperative period may be pro-
tective against development of such dysrhythmia. Risk of
post-op atrial fibrillation increases with the amount of
lung tissue resected, age, intraoperative blood loss, and
dissection of pericardium.
Renal Dysfunction
Renal dysfunction after pulmonary surgery is associ-
ated with increased post-op mortality. Factors associated
with an increased risk of post-thoracotomy renal dys-
function include previous history of renal insufficiency,
diuretic therapy, pneumonectomy, infection, and blood
transfusion.
Age
In general, risk of respiratory complications and cardiac
arrhythmias is greater in the older than in the younger
population.
Chronic Obstructive Pulmonary Disease
Patients with chronic obstructive pulmonary disease
(COPD) are more likely to retain PaCO2, have right ven-
tricular dysfunction, and develop nocturnal hypoxemia.
The presence of these factors in a post-thoracotomy
COPD patient is associated with increased risk of respi-
ratory complications. Cessation of smoking, optimiza-
tion of bronchospasm and heart failure, and education in
chest physiotherapy in this group of patients will help
minimize post-op complications.
Table 39-1 summarizes the risk factors in a high-risk
pulmonary surgery patient.
ROUTINE POSTOPERATIVE CARE
The vast majority of patients who undergo pulmonary
surgery are extubated in the operating room and have 
at least one chest tube. One of the most outstanding
problems encountered in the post-op pulmonary surgery
patient is impaired gas exchange. Most post-op pulmonary
surgery patients can be cared for on a specialized ward
with nurses and other ancillary personnel trained to
address the unique needs of these patients. A few patients,
especially if kept intubated, are brought to the intensive
care unit (ICU). When the patient has been settled into
the postanesthesia care unit (PACU) or ICU, a complete
assessment is done to establish a baseline and a verbal
report is given to the PACU or ICU nurse and staff out-
lining operative procedure, the patient’s intraoperative
course, patient’s condition, and expected post-op course.
Typical post-op orders include routine orders, ventilator
setting (if the patient is intubated), fluid orders, pain control
orders, and a portable chest radiograph.
Monitoring
The level of monitoring is determined by the severity
of impairment in cardiopulmonary function. Close clini-
cal supervision of pulmonary surgery patients allows
early institution of therapy and prevention of cardiopul-
monary catastrophe. In general, most pulmonary surgery
patients can be safely cared for on the hospital ward.
A pulse oximeter is commonly utilized to monitor
closely peripheral arterial saturation and response to
oxygen therapy. Thoracic surgical patients are vulnera-
ble to hypothermia. Hypothermia and shivering can
increase oxygen consumption tremendously and result
in metabolic acidosis, pulmonary arterial hypertension,
and increased risk for bleeding. Therefore, hypothermia
must be avoided in pulmonary surgery patients.
Telemetry can be used for patients considered at high
risk for cardiac arrhythmia. All patients with unstable
blood pressure (BP), refractory hypoxemia, relative 
narcotic overdose, and mechanical ventilation must be
transferred to the ICU. An intra-arterial and a central
venous catheter are used for BP monitoring, drawing
arterial blood gases, and measuring central venous filling
pressure to guide fluid therapy. A pulmonary artery
catheter is rarely required in a post-op pulmonary surgery
patient.
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Table 39-1 Characteristics of a High-Risk Thoracic
Surgery Patient
1. History
Advanced age
COPD (hypercarbia, hypoxemia, heart failure)
Impaired quality of life (poor functional capacity, limited 
exercise tolerance)
Renal impairment
Presence of dysrhythmia and multiple coronary artery 
disease risk factors
2. Pulmonary functions
ppoFEV1 < 40%
ppoDLCO < 40%
VO2 max < 15 ml/kg/minute
Decline in exercise SpO2 > 4%
3. Amount of pulmonary tissue removed and laterality
Pneumonectomy
Right-sided surgery
4. Recent history of radiation or chemotherapy
COPD, chronic obstructive pulmonary disease; ppoFEV1, predicted 
postoperative FEV1; ppoDLCO, predicted postoperative diffusing capacity 
of carbon monoxide; VO2 max, maximum oxygen consumption; SpO2, 
peripheral oxygen saturation.
Fluid Management
The goal of fluid management in post-op pulmonary
surgery patients is to infuse the minimum amount of
fluid that will maintain adequate end-organ perfusion
and electrolyte balance. For hypotension not due to
acute blood loss, vasoactive agents may be used. Liberal
fluid replacement may be associated with hypoxemia
due to increased pulmonary arterial hydrostatic pres-
sure, especially when post-op increased pulmonary 
capillary permeability is present. In most patients with
normal BP, a urinary output of 0.5 ml/kg is considered
adequate.
Care of the Chest Tube
The chest tube and drainage system must be func-
tioning properly, unclamped, and applied to water seal
before transport. In many circumstances two chest
tubes may be placed to drain both air and fluid from the
pleural space. A chest radiograph is ordered to confirm
proper chest tube position and identify kinks or residual
pneumothorax. Modern chest tube drainage systems
have three compartments as shown in Figure 39-1. The
first compartment is a simple graduated collection cham-
ber where the amount of blood and fluid can be meas-
ured. The second compartment is an underwater seal
that serves as a simple, reliable one-way valve, which
allows air to escape from pleural space, but not to enter
the pleural space during the next inspiration. The third
compartment controls, via an atmospheric vent, the
amount of negative pressure that can be developed by
the chest tube drainage system suction. Two factors
determine the level of suction. First, the height of under-
water depth of the central movable tube; and second,
actual suction pump capable of generating low pressure
(−15 to 20 cmH2O and 10–15 l/minute flow) or high
pressure (up to −60 cmH2O with flows > 20 l/minute).
A blood loss up to 200 ml/hour via a chest tube is 
considered acceptable in the immediate post-op or post-
trauma period. It should decrease with time. Persistent
large-volume blood loss from the chest tube warrants re-
exploration in the post-thoracotomy and trauma patient.
Chest Radiographs
Chest radiographs constitute an important part of the ini-
tial evaluation of the post-op pulmonary surgery or trauma
patient. The following points are carefully evaluated.
Endotracheal Tube
The tip of the endotracheal tube (ETT) must be at
least 3–4 cm above the carina. Too high or too low an ETT
tip may risk accidental extubation and mainstem intuba-
tion, respectively. A double-lumen endobronchial tube,
if left in place postoperatively, should be withdrawn
until the tip is 3 cm above the carina. This will reduce
the risk of coughing and tracheobronchial injury.
Pneumothorax
A small pneumothorax in the presence of a chest tube
may be cleared by application of suction to the chest
tube. However, continued pneumothorax may indicate a
malfunctioning chest tube or the need for an additional
tube due to bronchopleural fistula.
Mediastinal Shift
After lung resection, the mediastinum shifts toward
the resected side and the diaphragm moves upward.
Unusual shift may indicate atelactasis. After pneumonec-
tomy, the mediastinum should be as near the center as
possible. Too much air in the pneumonectomy space
may compress the remaining lung and shift the medi-
astinum to the opposite side, making ventilation difficult
(Figure 39-2). Aspirating air with a large-bore catheter,
syringe, and stopcock can relieve too much tension in
the pneumonectomy space. Combination of acute medi-
astinal shift and acute gastric dilatation can cause acute
respiratory embarrassment.
Pulmonary Surgery Postoperative Care 403
 
	

 

	 	 
	
	
 	
Figure 39-1 Chest tube drainage system showing three
chambers for fluid collection, water seal, and suction control.
CLINICAL CAVEAT
The combination of acute mediastinal shift and
gastric dilatation in a postpneumonectomy patient
represents impending respiratory failure and must be
recognized and relieved immediately.
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Chest Physiotherapy
Thoracotomy surgically traumatizes the intercostal 
muscles and chest wall leading to ventilation/perfusion mis-
matching and hypoventilation from “inspiratory splinting.”
The most common post-op pulmonary complication
is atelactasis. Surgical factors, general anesthesia and
paralysis, and the underlying medical condition of the
patient all contribute to development of atelactasis. The
functional residual capacity (FRC) declines by 35% after
thoracotomy. Closing volume (CV), defined as the vol-
ume at which the flow from the dependent portions of
the lung stops during exhalation during airway closure,
increases in the post-op period due to a variety of fac-
tors, including fluid overload, advanced age, obesity,
smoking, bronchospasm, and airway secretions. As the
FRC declines and the CV increases, the lung is subject to
airway collapse and atelactasis. In the low-risk patient,
lung re-expansion can be achieved with nursing inter-
vention such as coughing, deep breathing exercises, and
ambulation. In higher-risk patients various devices such
as incentive spirometry and intermittent positive pres-
sure breathing are effective and cheap. Proper posi-
tioning of the patient helps to improve diaphragmatic
excursion and postural drainage of secretions. Chest
physiotherapy should ideally begin in the preoperative
period with smoking cessation education, optimization
of bronchospasm, teaching deep breathing, and coughing.
Table 39-2 summarizes commonly used agents in post-op
pulmonary care.
Mechanical Ventilation
The need for mechanical ventilation may arise due to
acute or chronic PaCO2 retention, excessive fluid or blood
product administration, incomplete reversal of neuro-
muscular blockade, and excessive sedation. Ventilator
settings, whether in volume- or pressure-limited mode,
must limit peak pressure to less than 35 cmH2O and
plateau airway pressure to less than 25 cmH2O. Settings
resulting in high peak airway pressures or excessive 
positive end-expiratory pressure (PEEP) can produce
barotrauma and result in disruption of bronchial anas-
tomosis and bronchopleural fistula. COPD patients have
a tendency to develop intrinsic PEEP, which can be min-
imized by using lower tidal volumes (6–8 ml/kg) and
lower respiratory rates, high flow rates, and prolonged
exhalation times. The patients must be appropriately
sedated. Early extubation is always desired in a post-
thoracotomy patient, especially after lung volume resec-
tion, pneumonectomy, or in the presence of a broncho-
pleural fistula.
Post-thoracotomy Analgesia
Pain control is integral to the care of patients having
pulmonary surgery. When compared to open thoraco-
tomy procedures, it is associated with significantly
reduced post-op pain. Post-thoracotomy pain is transmit-
ted via intercostal, phrenic, and vagus nerves. Effective
post-thoracotomy analgesia may decrease perioperative
A B
Figure 39-2 A chest radiograph taken immediately after right pneumonectomy. Panel A shows mediastinal shift to left. Panel B shows
mediastinum returned to midline after aspiration of 1 liter of air from the right hemithorax (postpneumonectomy space).
stress, reduce post-op pulmonary complications, and
limit chronic post-thoracotomy pain syndrome. Post-
thoracotomy analgesia begins with a thorough discussion
of post-op events and course and analgesia choices.
Typically, a multimodal analgesia regimen provides supe-
rior pain control compared to any single technique.
Intercostal Nerve Block
Before thoracotomy is closed, intercostal nerve
blocks with 0.25% bupivacaine with epinephrine can
reduce post-op pain and opioid requirement.
Systemic Opioids
Systemic opioids are generally given as part of a mul-
timodal analgesia regimen, including nerve block and
nonopioid analgesics. Patient-controlled analgesia pro-
vides better patient satisfaction. The benefit of analgesia
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Table 11-4 Commonly Used Agents in Postoperative Pulmonary Care
Agent Dosage Route Formulation Comment
INHALED β-ADRENERGIC AGENTS
Albuterol 2.5 mg (0.5 ml) in 3 ml Nebulized 0.5% solution Predominant β2, watch for hypokalemia
NaCl q 4–6 h with repeated doses
4 puffs q 4–6 h MDI 90 μg/MDI dose
Terbutaline 1–2 puffs q 2–6 h MDI 200 μg Watch for hypokalemia, pulmonary 
edema, SVT
0.25 mg Subcutaneous injection 1 mg/ml
Racemic epinephrine 0.5 mg in 3 ml NaCl Nebulized 2.25% solution Localized vasoconstriction reduces
q 1–4 h PRN airway swelling
ANTICHOLINERGIC AGENTS
Atropine sulfate 2.5–5 mg in 3 ml Nebulized 1 mg/ml
NaCl q 4–6 h
Glycopyrrolate 0.2 mg in 3 ml NaCl Nebulized 0.2 mg/ml
q 6 h
Ipratropium bromide 0.5 mg in 3 ml NaCl Nebulized 0.02% solution
q 4–6 h
2–4 puffs q 4–6 h MDI 18 μg/MDI dose
CORTICOSTEROIDS
Hydrocortisone 2 mg/kg or IV 50 mg/ml
2 mg/kg then IV
0.5 mg/kg/h Continuous 
infusion
Methylprednisolone 60–125 mg q 6–8 h IV/PO 40, 62.5 mg/ml
Dexamethasone 4 mg q 6–8 h IV/PO 4 mg/ml Prophylactic for airway swelling
MUCOLYTIC AGENTS
N-acetylcysteine 3 ml of 20% solution Nebulized 10, 20% solution Use after nebulized β-agonist
q 6–8 h
Guaifenesin 100–400 mg q 6 h PO 100 mg/5 ml
NONSPECIFIC AGENTS
Helium/oxygen 70/30, 80/20 mixture Face mask Decreases turbulence of airflow via
mixture inhalation narrow airway
MDI, metered dose inhaler; SVT, supraventricular tachycardia; IV, intravenous; PO, oral; h, hours.
must be carefully balanced against the risk of sedation,
hypoventilation, and cough inhibition.
Nonsteroidal Anti-inflammatory Drugs
Nonsteroidal anti-inflammatory drugs (NSAIDs) block
the synthesis of prostaglandins by inhibiting the enzyme
cyclooxygenase. NSAIDs may be used for controlling
ipsilateral shoulder pain after thoracotomy in patients
with epidural analgesia. Gastrointestinal bleeding and
decreased creatinine clearance are potentially serious
side effects of NSAIDs. These drugs must be avoided 
in elderly patients and patients with preexisting renal
disease, hypovolemia, and congestive heart failure.
Paravertebral Block
Paravertebral block can be established by a catheter
placed surgically, at the time of thoracotomy, into the
paravertebral space. Analgesia is usually supplemented
with systemic opioids and NSAIDs. In spite of its sim-
plicity, paravertebral block carries a failure rate of
approximately 10%.
Interpleural Analgesia
After thoracotomy, dilution of local anesthetic with
blood and loss of local of local anesthetic into the chest
tube reduces the efficacy of interpleural block.
Epidural Analgesia
A thoracic epidural catheter provides effective and
reliable post-thoracotomy analgesia and has been shown
to be associated with decreased risk of post-thoracotomy
respiratory complications and potentially improved
outcome. The optimal site of insertion of the thoracic
epidural catheter should be at the level of surgical incision.
We use a mixture of 0.1% bupivacaine and 4 μg per ml fen-
tanyl for epidural infusion at 6–10 ml per hour. A properly
functioning thoracic epidural catheter is extremely valu-
able for post-thoracotomy analgesia in patients having
lung volume reduction surgery or pneumonectomy.
Epidural opioids may potentially cause urinary retention
and delayed gastric emptying. One of the common con-
cerns among surgeons of epidural analgesia is that it can
potentially cause hypotension requiring excessive fluid
administration.
Whether thoracic epidural analgesia reduces post-
thoracotomy mortality is still a controversial topic. Current
evidence, however, suggests that epidural analgesia 
can reduce post-op respiratory complications, decrease 
perioperative myocardial infarction, and reduce the 
incidence of thromboembolic events.
Management of Arrhythmia
Atrial tachyarrhythmias are common in a post-
thoracotomy patient, with incidence ranging from 9 to
33%. The major arrhythmia in this population is atrial fib-
rillation (AF), followed by paroxysmal supraventricular
tachycardia (PSVT), atrial flutter (A-Flutter), and multi-
form atrial tachycardia (MAT). The incidence of nonsus-
tained ventricular tachycardia is approximately 15%.
The incidence of AF increases with amount of lung
tissue removed (12–25% after lobectomy, 20–30% after
pneumonectomy, and up to 40% after resection of malig-
nant pleural mesothelioma) and advanced age (60 years
or older). The onset of AF is greatest 2–3 days after 
thoracic surgery, with the majority reverting to sinus
rhythm with appropriate therapy. Common clinical pre-
sentations of AF include dyspnea, palpitation, dizziness,
and shortness of breath. With respect to the development
of hypotension, younger patients tend to tolerate AF better
than older patients. The proposed mechanisms of peri-
operative AF include preexisting atrial pathology (valvular
heart disease, congestive heart failure, advanced age), pres-
ence of triggering factors (atrial extrasystoles, increased
sympathetic stimulation, acute atrial stretch), and surgical
factors (atrial trauma, heightened sympathetic tone,
inflammatory response).
A variety of drugs have been used to prevent post-op
AF. Routine use of digoxin should be discouraged due to
its lack of proven efficacy to prevent post-op AF. In a
recent double-blind, placebo-controlled trial, Amar
showed that diltiazem was effective in reducing AF by
50% in thoracic surgery patients. The rate of AF remains
high despite extensive use of prophylactic beta-blockers.
The routine use of amiodarone is not recommended due
to its high cost and concern about pulmonary toxicity
in thoracic surgery patients. The treatment of post-
thoracotomy arrhythmias must begin with correction of
reversible factors such as respiratory failure and hypox-
emia, pain, and electrolyte imbalance. The initial goal is
to establish hemodynamic stability, obtain a 12-lead ECG
for diagnosis, and control the ventricular response.
Patients with severe hypotension or signs of organ
hypoperfusion must be emergently electrically car-
dioverted using synchronized DC cardioversion.
Adenosine is used to treat PSVT and delineate the under-
lying arrhythmia. Recent evidence from cardiac surgery
suggests that rate-controlling strategy may be superior to
rhythm control. Beta-blockers (esmolol and metoprolol)
or calcium channel blockers (verapamil and diltiazem)
are commonly used rate-controlling drugs. Calcium
channel blockers are avoided in patients with pre-
excitation arrhythmia (Wolff-Parkinson-White syndrome).
Caution should be exercised with beta-blockers in
patients with known ventricular dysfunction and severe
COPD. Pharmacologic conversion to sinus rhythm, if
considered, must be used within 48 hours of AF due to
the risk of developing left atrial thrombus with persistent
AF and potential embolic complication with restoration
of sinus rhythm. The examples of converting drugs include
ibutilide, amiodarone, flecainide, and propafenone.
Prophylactic magnesium administration before using any
of these drugs will reduce the risk of torsades de pointes.
The potential for thromboembolic complications increases
if AF persists beyond 48 hours. Anticoagulation, using
aspirin, heparin, or warfarin, is considered after weighing
the risk of post-op bleeding.
MANAGEMENT OF SPECIAL CONDITIONS
Postpneumonectomy Pulmonary Edema
The syndrome of postpneumonectomy pulmonary
edema (PPPE) refers to the development of an acute
lung injury (ALI) or acute respiratory distress syndrome
(ARDS) characterized by severe and often fatal pulmonary
406 CRITICAL CARE: THE REQUISITES IN ANESTHESIOLOGY
edema of unknown etiology. In spite of an increased
awareness over the last two decades, a precise definition
and pathogenesis of PPPE is lacking. The reported inci-
dence of PPPE ranges from 2.5% to 14%. The incidence
is greater after right pneumonectomy. It is universally
fatal if unrecognized. It accounts for the majority of in-
hospital mortality following lung resections. PPPE
remains an equally challenging clinical problem for sur-
geons, anesthesiologists, and intensivists alike.
The diagnosis of PPPE is based on high index of
suspicion and exclusion of factors known to cause
ALI/ARDS. Among several conditions, the differential
diagnoses include aspiration pneumonitis, pneumonia,
cardiogenic pulmonary edema, pulmonary embolism,
extrapulmonary sepsis, and drugs (amiodarone) and blood
transfusions. The onset of symptoms usually occurs
between post-op day 2 and 4, although radiologic findings
may be seen earlier. Among many factors involved in the
pathophysiology of PPPE, volume overload still remains
an important topic of controversy between surgeons and
anesthesiologists and has led to the dictum “Don’t drown
the down lung.” The probable etiologies involved in the
pathophysiology of PPPE include fluid overload, lung lym-
phatic injury, endothelial damage, increased pulmonary
capillary pressure, hyperinflation of the lung, and right
ventricular dysfunction. The role of oxygen toxicity and
cytokines in PPPE is unclear.
The most important management strategy for PPPE is
its prevention. The anesthesiologist and surgeon work-
ing together can take measures that will hopefully pre-
vent the occurrence of PPPE in the post-op period.
Among many considerations for the anesthesiologist
include careful attention to perioperative fluid adminis-
tration (not to exceed 20 ml/kg in the first 24 hours) and
ventilation of the residual lung (limiting peak airway
pressure to less than 35 cmH2O and plateau pressure
under 25 cmH2O), use of vasopressors (instead of fluids)
in the treatment of nonhemorrhagic hypotension, and
minimizing the risk of hypotension due to epidural anal-
gesia. Similarly, considerations for the surgeon include
expeditious and hemostatic surgery and preventing resid-
ual lung compression or hyperinflation by establishing
mediastinal centricity by aspirating excess air or fluid
from the pneumonectomy space or using a balanced
drainage system. Other supportive treatments include
aggressive pain control measures using a multimodal
approach, supplemental oxygen to prevent hypoxemia
during rest, sleep, and exercise, avoiding long periods
with the residual lung in the dependent position, and
lung protective ventilation with or without inhaled 
nitric oxide in patients requiring intubation. High-dose
steroids may be considered in patients with a recent
history of radiation or chemotherapy.
Bronchopleural Fistula
Air leak via a chest tube is initially common after
lobectomy or segmental resection due to transection of
small airways. With proper drainage via chest tube(s),
moderate suction (20–30 cmH2O), physiotherapy, and
ambulation, the initial air leak normally subsides over
3–4 days. The development of a bronchopleural fistula
(BPF) due to bronchial-stump disruption after pul-
monary surgery is a serious complication. The etiologies
of BPF include surgical reasons (poor suturing or sta-
pling techniques or bronchial ischemia due to poor dis-
section) or post-op necrosis due to infection or tumor in
the stump. Prompt re-operation and closure of the fistula
are recommended for early bronchial-stump disruption.
High-frequency jet ventilation (HFJV) or one-lung venti-
lation using a double-lumen tube may be required to
facilitate healing and maintain adequate oxygenation and
ventilation.
Lung Torsion or Infarction
Following lobectomy, torsion or infarction of the lung
is possible if the blood vessels are twisted as the lung 
re-expands. Torsion usually occurs within the first 48 hours
postoperatively. Venous engorgement may lead to tissue
infarction. The middle lobe and lingua are more suscep-
tible to torsion. Diagnostic findings include enlarging
density on serial chest radiographs, hemoptysis, dyspnea,
fever, and tachycardia. Bronchoscopy shows a distorted
compressed bronchus. Immediate exploration and possi-
ble further excision of nonviable lung is required.
Cardiac Herniation
Cardiac herniation is a rare complication of pul-
monary resection requiring wide surgical excision of the
pericardium. Herniation occurs after chest closure in the
early post-op period and may be related to differential
pressures in two hemithoraces pushing (or pulling) the
heart through the defect. Symptoms and signs may be
sudden in onset and dramatic (cardiovascular collapse,
hypotension, dysrhythmias, and myocardial infarction).
Signs and symptoms are more profound with right-
sided herniation due to the ease of superior vena caval
obstruction. Immediate re-operation with correction of
herniation and pericardial patching should be done.
CURRENT CONTROVERSY
In postpneumonectomy pulmonary edema volume
overload still remains an important topic of controversy
between surgeons and anesthesiologists and has led to
the dictum “Don’t drown the down lung.”
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Temporizing measures include discontinuing suction,
placing the patient in the lateral decubitus position with
the operative hemithorax uppermost, and minimizing
PEEP and airway pressures in intubated patients.
Lung Transplantation
The major concerns relating to the post-op care of
lung transplant recipients are hemodynamic and fluid
management, respiratory management, management of
renal function, ischemia reperfusion injury, allograft
rejection, nutrition, and sepsis.
Respiratory Management and 
Mechanical Ventilation
After lung transplant, recipients have impaired cough
reflexes due to the disruption of afferent nerve fibers
and thus have difficulty mobilizing respiratory secre-
tions. Aggressive pulmonary toilet is crucial. Frequent
airway suctioning and inhaled bronchodilators are uti-
lized in patients on or off the ventilator. After extuba-
tion, early ambulation, cough and deep breathing
maneuvers, and bronchodilators help mobilize secre-
tions and prevent atelactasis.
In uncomplicated cases most lung recipients can be
extubated 24–36 hours after surgery. Adequate oxy-
genation is assured with supplemental oxygen and PEEP
and PaCO2 and pH adjusted based on minute ventilation.
In general, during mechanical ventilation, lung pro-
tective ventilation using small tidal volumes (6 ml/kg
adjusted body weight) and PEEP with close attention
to prevent dynamic hyperinflation (auto-PEEP) is used.
Recipients who were hypercapnic before remain so
until medullary respiratory center readjusts over several
weeks. At times, hyperinflation of a more compliant lung
in a single-lung recipient with conventional ventilation
necessitates differential lung ventilation utilizing a double-
lumen endobronchial tube. Unrecognized hyperinflation
can result in mediastinal shift and hemodynamic com-
promise. Weaning from the mechanical ventilator is
initiated when the patient is warm, hemodynamically
stable, and arterial blood gases show adequate oxygena-
tion and ventilation using inspired oxygen 0.4 or less.
A short trial of spontaneous breathing is performed
using pressure support ventilation and pulmonary
mechanics (negative inspiratory force and vital capacity)
are measures prior to extubation. Weaning may be ham-
pered by emergence of infection, phrenic nerve injury
secondary to surgical procedure, ischemia reperfusion
injury, and preexisting nutrition deficiency.
Hemodynamic and Fluid Management
The goals of hemodynamic and fluid management in a
lung transplant recipient are to ensure adequate organ per-
fusion and prevent pulmonary edema. Vasoactive agents
are added when appropriate, to maintain mean arterial
pressure. Inotropic agents are needed to support cardiac
output in recipients with preexisting right ventricular dys-
function. Vasodilators such as prostaglandin E1 are used to
control elevated pulmonary artery pressure, especially if it
was being used preoperatively. Because of alterations in
pulmonary capillary permeability, disordered fluid clear-
ance related to disruption of pulmonary lymphatics, and
therefore propensity to develop pulmonary edema, fluid
administration is generally kept to a minimum. Blood and
blood component replacement is undertaken as necessary.
Echocardiography is useful in evaluating cardiac function
and pericardial tamponade in an unstable patient.
Ischemia Reperfusion Injury 
and Allograft Rejection
The release of superoxide anions and oxygen free rad-
icals and subsequent activation of neutrophils following
reperfusion of the ischemic lung ultimately leads to
increased capillary permeability, interstitial alveolar
edema, altered vascular tone, and dysfunction of type-II
pneumocytes. Clinically, lung injury induced by
ischemia-reperfusion is characterized by nonspecific
alveolar damage, pulmonary edema, and progressive
hypoxemia within 72 hours of lung transplantation.
Signs of resolution are usually apparent by day 4 and
complete resolution is usually seen by day 14. If severe
enough, it can lead to primary graft failure. Treatment is
generally supportive and includes lung protective venti-
lation both during and immediately after surgery to pro-
tect the injured lung and prevent further worsening of
acute lung injury and diuretics. Inhaled nitric oxide may
be useful in the treatment of ischemia reperfusion injury
by improving ventilation-perfusion mismatch without
affecting systemic vascular resistance.
Acute rejection usually presents on days 4–5 following
surgery and presents as worsening gas exchange, pul-
monary infiltrates, and pulmonary hypertension. A trans-
bronchial or open lung biopsy is required for definitive
diagnosis. Current immunosuppressive regimens are based
on the use of cyclosporine, azathioprine, and prednisone
as the mainstay of therapy after lung transplantation.
Immunosuppressive agents are continued and inhaled
nitric oxide is used to decrease pulmonary vascular resist-
ance without altering systemic resistance. Primary graft
failure from ischemia-reperfusion may be so severe that
it necessitates extracorporeal membrane oxygenation
(ECMO) to support the patient until injury improves.
Management of Renal Function
Fluid restriction and diuretic and vasopressor use in
conjunction with the use of nephrotoxic immunosup-
pressive and antimicrobial medications can lead to the
development of acute renal failure in the post-op period.
Dosing of all medications must be based on alteration in
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creatinine clearance. Low-dose nicardipine has been
shown to be reno-protective in transplant recipients 
taking immunosuppressive agents. Some degree of renal
insufficiency persists in these patients.
Nutrition
Stress ulcer prophylaxis is routinely used. Nutrition is
a very important issue in lung transplant recipients. In
general, enteral nutrition is desired. Metoclopramide can
be used to treat gastroparesis, which is quite common in
lung transplant recipients. Laxatives are used for regulation
of bowel function.
Sepsis
Sepsis can be another problem in these patients.
Prophylactic antimicrobials are important in preventing
post-op infections. Common infections that are likely
include bacterial pneumonia around day 2–3, acute
rejection around day 4–6, and cytomegalovirus pneu-
monitis at week 4 following the surgery. Bacterial, viral,
and fungal prophylaxis is based on culture data from the
donor lung. After 1 month, trimethoprim-sulfamethoxazole
is given as a prophylaxis against Pneumocystis carinii
and acyclovir against herpes simplex virus.
Thoracic Trauma
Thoracic trauma accounts for 25% of all trauma
deaths in the USA. With blunt or penetrating injury the
basic principles of resuscitation are rapid restoration of
airway, supplemental oxygen, needle decompression of
a suspected tension pneumothorax, and coverage of an
open pneumothorax wound.
Diagnosis
The initial evaluation is directed at diagnosing and
treating life-threatening injuries related to the airway and
cardiopulmonary system. A secondary survey should be
rapidly done to search for other injuries. A combination
of radiologic and clinical procedures is usually required
to clearly define the nature and extent of thoracic injury.
Despite its limitations, the initial chest radiograph repre-
sents the most important diagnostic tool in patients with
thoracic trauma. Presence of pneumothorax, hemothorax,
and rib fractures may be identified. A wide mediastinum
on chest radiograph may indicate traumatic aortic injury.
A computerized tomography scan of the chest is useful in
diagnosing mediastinal hemorrhage, pulmonary contusion,
and aortic rupture. Transesophageal performed intra-
operatively may help in diagnosing traumatic aortic
injury, traumatic rupture of the ventricular septum, car-
diac tamponade, or wall motion abnormality seen with
myocardial contusion in a hemodynamically unstable
patient. A 12-lead ECG is required in monitoring all
trauma patients. Unexplained arrhythmia may be an
initial clue to the presence of myocardial contusion.
Aortography remains the “gold standard” for diagnosis of
traumatic aortic injury in a hemodynamically stable
patient. Bronchoscopy is the diagnostic test of choice in
tracheobrochial trauma. The role of videothoracoscopy
in the treatment and management of thoracic trauma
patients has been expanding. The current indications
for videothoracoscopy include evaluation of suspected
diaphragmatic and mediastinal injuries, removal of foreign
bodies, evaluation and treatment of persistent leaks and
bleeding, and evacuation of a retained hematoma.
Management
Rib Fractures and Flail Chest
Simple rib fractures can be successfully treated with
analgesics. Intercostal, interpleural, or epidural analgesia
can be used in a high-risk patient. A flail chest occurs when
the fracture of ribs at multiple locations produces discon-
tinuity of a segment of thoracic wall and paradoxical
motion with respiration. This results in increased work of
breathing, decreased vital capacity, and hypoxemia due to
V/Q mismatch. Invariably there is underlying pulmonary
contusion in patients with flail chest. It is the underlying
pulmonary contusion that plays the greater role in the
patient’s inability to oxygenate and ventilate. Key in the
management of flail chest is pain relief. Conservative man-
agement including supplemental oxygen, epidural analge-
sia, and pulmonary physiotherapy may be used in patients
with mild flail chest. Arterial blood gases may be drawn to
monitor gas exchange. The patient with severe flail chest
and pulmonary contusion requires mechanical ventilator
support using lung protective ventilation strategy, along
with adequate pain control, sedation, and careful attention
to fluids. Pulmonary contusions are common after blunt
thoracic trauma and may progress to full-blown ARDS.
Cardiac Contusion
Patients sustaining massive blunt chest trauma, with
ECG abnormalities, and with a positive “steering wheel
sign” on the anterior chest should be investigated for car-
diac contusion. Patients with normal ECG can be man-
aged on the regular ward. Stable patients with abnormal
ECG should be admitted to a telemetry ward. All patients
with unstable hemodynamic status must be admitted to
the ICU. Antiarrhythmic and inotropic support is used for
the treatment of arrhythmias and cardiogenic shock.
Tracheobronchial Injuries
Tracheobronchial injuries may be suspected in
patients with thoracic trauma who develop massive sub-
cutaneous and mediastinal emphysema or continuous air
leak via chest tube. Laryngeal and tracheal injuries can
be managed by endotracheal intubation with the cuff
below the level of injury. HFJV can be used in to mini-
mize airway pressure and inspiratory peak pressures to
decrease the likelihood of suture line dehiscence after
repair of distal tracheobronchial injury.
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SUMMARY
The optimum post-op care of pulmonary surgery
patients is challenging. Respiratory complications repre-
sent the major cause of post-op morbidity and mortality
in this group of patients. Preoperative teaching in smoking
cessation and pulmonary physiotherapy goes a long way
in the prevention of post-op respiratory complications.
Integral to routine post-op care of pulmonary surgery
patients is good pain control. PPPE is universally fatal if
unrecognized. The post-op period in patients with pul-
monary trauma and transplant equally presents with
unique challenges.
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Conclusion
Hemodynamic instability is frequently encountered in
the recovery room. Early recognition and treatment of
hemodynamic instability in the recovering patient may
prevent postoperative morbidity and mortality. For
example, postoperative cardiac complications are the
leading cause of postoperative death, and it may be in
part due to the surgical stress hormone response that
peaks in the recovery room. In patients with risk factors
for coronary artery disease the estimated incidence of
postoperative cardiac ischemia is 30–40% and is associ-
ated with increased mortality. Postoperative myocardial
infarction results in a death rate of 30–70%. Other cardiac
morbidities include heart failure and serious dysrhyth-
mias. To prevent or minimize these potential complica-
tions it is essential to monitor vigilantly the patient with
particular focus on the hemodynamics, followed by
prompt treatment if indicated.
It is hoped that morbidity and mortality will improve
with the advancement of surgical techniques and med-
ical management, such as the perioperative use of beta-
blockers to prevent coronary artery plaque rupture. This
may be offset by surgical and medical advances that lead
to patients with multiple severe medical problems, who
were previously considered to be nonsurgical candi-
dates, now receiving surgery, and, therefore, anesthesia.
In addition, as longevity increases, the age of surgical
patients may increase.
General and regional anesthesia can cause cardiovas-
cular instability. The anesthesiologist is required to resus-
citate continually the surgical patient, while concomitantly
giving hemodynamically destabilizing anesthetic agents.
Resuscitation extends into the postoperative care period
when the residual effects of anesthetics are enhanced by
the lack of surgical stimulation. Residual anesthesia can
also mask the signs and symptoms of cardiovascular
instability and attenuate or ablate the physiologic com-
pensatory reflexes. The postoperative patient, therefore,
needs to be closely and continually monitored in the
recovery unit for the early prevention or detection and
treatment of complications.
This chapter discusses the following cardiovascular
complications encountered postoperatively: hypoten-
sion, hypertension, bradycardia, tachycardia, and tachy-
arrhythmias. Effective evaluation and treatment requires
an organized and systematic approach. This begins
with history gathering, consisting of reviewing the
patient’s preoperative evaluation (to determine the
patient’s baseline) and intraoperative course (to identify
any complication or hemodynamic instability already
encountered and the treatment). This is followed by an
assessment of the patient’s vital signs, a careful perform-
ance of a targeted physical examination, and a review
of the patient’s available laboratory data to formulate a
differential diagnosis and determine an appropriate treat-
ment. At times, the acuity of the instability requires
immediate treatment to stabilize the patient while an
etiology is sought.
HYPOTENSION
Hypotension is a frequently encountered complica-
tion in the postoperative setting. Hypotension is often
defined as systolic blood pressure lower than 90 mmHg,
or a decrease of 40% or greater from the patient’s base-
line blood pressure. If untreated, hypoperfusion of vital
organs may lead to tissue ischemia or infarction. Some
patients are at higher risk for developing hypotensive
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complications, such as patients with chronic hyperten-
sion, atherosclerotic disease of the coronary or carotid
arteries, stenotic valvular disease, or increased intra-
cranial pressure. Compensatory mechanisms act to pre-
serve perfusion to vital organs; signs or symptoms of
end-organ hypoperfusion, such as altered mental status,
indicate the compensatory mechanisms are inadequate
to overcome the degree of hypotension. Tissue hypoxia
results in anaerobic metabolism and a lactic acid-induced
metabolic acidosis and electrolyte derangements. If not
treated, vital organ dysfunction can result, and a cycle of
decompensation may ensue.
Determinants of Blood Pressure
To understand and control blood pressure one needs
to understand the underlying physiology. Blood pressure
(BP) is related to cardiac output (CO) and systemic vas-
cular resistance (SVR) by the following equation:
BP = CO × SVR (40-1)
This relationship is derived from rearranging the basic
flow equation:
Q = ΔP/R or ΔP = Q × R (40-2)
where ΔP is the pressure difference between two points
(mmHg), Q is the flow rate (volume/time), and R is the
resistance to flow (mmHg × time/volume). This equation
is a variant of Ohm’s law. When applied to human 
circulation, ΔP represents blood pressure, Q describes
cardiac output, and R is analogous to systemic vascular
resistance. Equation 40-1 demonstrates that a decrease in
blood pressure must be caused by either a decrease in
cardiac output or a decrease in SVR.
The output of the left ventricle may be measured by
themodilution using a pulmonary artery catheter, which
approximates right ventricular output and when aver-
aged over a period of time must be equal to left ventric-
ular output. Cardiac output is directly related to heart
rate (HR) and stroke volume (SV):
CO = HR × SV (40-3)
Normal resting heart rate in the adult is 60–100 beats
per minute. In patients with noncompliant ventricles
(e.g., neonates or patients with left ventricular hypertro-
phy) HR is the primary determinant of cardiac output.
Heart rate is regulated by the autonomic nervous system
and influenced by hormones, such as thyroid hormone.
A slow heart rate is desirable in patients with coronary
artery disease, but significant bradycardia may result 
in a low cardiac output. A rapid heart rate increases myo-
cardial oxygen demand and decreases diastolic time, and,
thus, perfusion of the myocardium (the left ventricle
receives most of its perfusion during diastole). Decreased
diastolic time also may prevent adequate ventricular 
filling, resulting in a reduced stroke volume and cardiac
output.
Stroke volume is defined as the end-diastolic volume
minus the end-systolic volume, or the volume of blood
ejected with each ventricular contraction. Stroke vol-
ume is reduced if there is a decrease in preload or con-
tractility. Preload is the myocardial tension at the end of
diastole and may be estimated using multiple tech-
niques. Ventilation-induced systolic pressure variation of
greater than 15 mmHg accurately diagnoses low preload.
Pressure in the left ventricle can be indirectly measured
by the central venous pressure (CVP) or pulmonary cap-
illary wedge pressure (PCWP). However, these pressure
measurements may not accurately reflect left ventricular
volume due to valvular heart disease or decreased left
ventricular compliance. The right ventricular ejection
fraction catheter uses a rapid thermistor and electro-
cardiogram electrodes to calculate end-diastolic volume
without interference from ventricular hypertrophy or
valvular disease. Preload is more accurately assessed
using echocardiography, where the ventricular filling
volume is directly visualized.
The amount of venous blood return to the ventricle
and the venous vascular tone determine preload. The
most common cause of inadequate preload is hypo-
volemia due to blood loss or inadequate fluid resuscitation.
Impaired venous return can also be due to mechanical
impedance such as positive pressure ventilation, diastolic
dysfunction, inadequate ventricular filling time, stenotic
valvular disease, abdominal compartment syndrome,
pulmonary embolus, tension pneumothorax, or cardiac
tamponade.
Contractility is the peak isometric tension that a 
cardiac muscle can generate for a fixed fiber length. The
heart contracts more vigorously when the end-diastolic
volume increases. This relationship is known as the
Frank–Starling law of the heart. Contractility is affected
by cardiac ischemia, the sympathetic tone, viable muscle
mass of the ventricle, and inotropic drugs (e.g., dopamine,
dobutamine, epinephrine, milrinone).
Blood pressure is also directly related to the SVR as
shown in Equation 40-1. The factors that determine the
resistance to fluid flow are described by Poiseuille’s
equation:
R = 8Lη/πr4 (40-4)
where L is the length of the tubing, η is the viscosity of
the fluid, and r is the radius of the tubing. Poiseuille
initially described this relationship for the flow of liquids
through a glass tube. This relationship is applicable to the
flow of blood in the circulatory system. The length of the
vascular tubing can be considered to be a fixed variable.
The viscosity of the blood, although it can be altered
by hemoconcentration or hemodilution, is not regulated
by the body on a minute-to-minute basis. Changing the
radius through vasoconstriction or vasodilation is the
primary means by which the body regulates vascular
resistance, and, therefore, blood pressure. One can see
from Equation 40-4 that if the radius is decreased 
by one-half, the resistance increases sixteen fold. This
relationship holds for lamellar flow, where the maxi-
mum velocity of the fluid is at the center and zero at 
the walls. When there is a narrowing of the tubing such
that lamellar flow becomes turbulent, the resistance to
flow is even higher than that predicted by Poiseuille’s
equation. One can therefore appreciate that small changes
in the vessel diameter can have significant impact on
resistance.
Afterload is the ventricular wall tension during systole
caused by the forces that oppose muscle fiber short-
ening. Afterload is proportional to arterial blood pres-
sure and the chamber dimension, shape, and wall
thickness. SVR can be readily altered and approximates
afterload. The pulmonary artery catheter can be used to
calculate SVR:
(40-5)
where MAP is mean arterial pressure; the units for SVR
are dyns/cm5.
SVR is regulated by the autonomic nervous system
and affected by inflammatory processes and tempera-
ture. A decreased sympathetic tone can be due to vaso-
dilating properties of some medications or direct spinal
cord inhibition of sympathetic nerves from intrathecal
or epidural local anesthetics. Neurogenic shock, liver
failure, spinal cord injury, carotid sinus dysfunction (S/P
carotid endarterectomy), and adrenal insufficiency can
also result in a low SVR. Systemic inflammation, such as
sepsis or anaphylaxis, involves circulating factors that
cause vasodilation. Bacteremia from urogenital procedures
has caused fever and hypotension in the recovery room.
Hyperthermia from excessive warming or malignant
hyperthermia results in temperature-related vasodilation.
Treatment is geared toward correcting the underlying
cause and, if needed, instituting pharmacologic agents 
that augment vascular tone. Alpha-agonists are successful
at increasing SVR and blood pressure, but the vasocon-
striction may lead to decreased perfusion of vital organs.
Management of Hypotension
The management of hypotension begins with the
elimination of erroneous blood pressure measurements,
such as those caused by too large a cuff or calibration of
a transducer above the level of the heart. An overdamped
waveform can result in a falsely low systolic blood pres-
sure; the MAP should be used in guiding therapy. It may
be wise to check the blood pressure in the other upper
extremity, particularly in patients with peripheral vascu-
lar disease that may have occlusions proximal to the cuff
or arterial line. A careful review of the patient’s history
and intraoperative course will help determine if additional
monitoring is needed prior to treatment.
The most common cause of postoperative hypoten-
sion is decreased preload from hypovolemia. Causes
include inadequate replacement of intraoperative blood
loss, postoperative bleeding, urinary losses, and third
spacing of fluid. A simple test for hypovolemia is to use
positional maneuvers that utilize gravity to augment
venous return to the heart. Placing a patient in the
Trendelenburg position can autotransfuse up to two
units of blood volume. A rise in blood pressure suggests
hypovolemia. Another useful test is to administer rapidly
250 ml of a crystalloid solution. If invasive monitoring 
is present, a rise in blood pressure with only a small
increase in CVP or PCWP is suggestive of a hypovolemic
state. This is followed by further fluid resuscitation as
indicated. Vasopressors and positive inotropic agents are
not indicated in this setting, except as a temporary
means of treatment until intravascular volume can be
adequately restored. Hypotension because of obstruc-
tion to venous return (e.g., cardiac tamponade) will
often respond to fluid therapy, but the definitive treat-
ment is eliminating the impedance.
If a fluid challenge results in rapidly rising filling pres-
sures without much improvement in blood pressure,
then the heart may be failing and further administration
of fluids may be of little benefit. The pulmonary artery
catheter (PAC) will indicate an elevated PCWP and SVR
with a low cardiac output. Causes of cardiac dysfunction
include hypocalcemia and myocardial infarction.
Hypocalcemia should be suspected in any patient that
received a large amount of blood products, especially in
patients with liver dysfunction who will not efficiently
metabolize citrate. If the ionized calcium level is low,
intravenous calcium may correct the hypotension. Acute
ST elevation indicates coronary artery occlusion and
requires immediate and aggressive treatment (see Case
Study box) including supporting blood pressure with
inotropic agents in hypotensive patients. In contrast to
ST elevation, new ST depression on the EKG may indi-
cate cardiac ischemia secondary to the hypotension and
the diastolic pressure should be raised (using phenyle-
phrine) rather than employing the usual steps to maxi-
mize oxygen supply/demand (using beta-blockers and
nitroglycerin). Other reversible causes of myocardial
depression include acidosis and hypothermia.
A failure of hypotension to respond to a volume load
may also be due to a significantly reduced SVR (Table 40-1).
The PAC helps differentiate low SVR conditions from
patients with decreased preload or decreased contractility.
SVR
MAP CVP
CO
=
−
× 80
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Common pharmacologic agents used to treat hypoten-
sion are listed in Table 40-2.
HYPERTENSION
Postoperative hypertension is common and must be
considered in the context of the patient’s preoperative
and intraoperative blood pressure range. Treatment is
indicated to prevent myocardial ischemia or infarction,
left ventricular failure, or bleeding. However, treatment of
hypertension must be balanced against the risk of over-
treatment and the potential for end-organ hypoperfusion,
as in patients with carotid artery disease or chronic
uncontrolled hypertension, when blood pressures higher
than normal may be required to maintain organ perfusion.
Prior to treatment, erroneous measurements must be
ruled out; the size of the blood pressure cuff should be
checked (a small cuff will give a falsely high reading) and
if present the arterial line tracing should be observed for
signs of an underdamped waveform. The most common
causes of postoperative hypertension are heightened
sympathetic activity, hypervolemia, and preexisting
hypertension (Table 40-3).
Treatment is geared toward correcting the underlying
cause prior to giving antihypertensive agents (Table 40-4).
Hypoxia and hypercarbia can immediately be deter-
mined with the pulse oximeter and physical examina-
tion and treated as indicated. There are many modalities
available to treat postoperative pain, including narcotics,
intravenous ketorolac, and nerve blocks. Hypervolemia
is typically due to aggressive fluid administration, exces-
sive fluid absorption of irrigation fluids (e.g., transurethral
resection of the prostate (TURP) syndrome), or renal
failure. Clinical signs include jugular venous distention,
pulmonary rales, and dilute urine. Treatment involves
fluid restriction and use of diuretics; coexisting electrolyte
abnormalities should be corrected.
Preexisting hypertension predisposes patients to
postoperative hypertension. Patients that did not take
their medications the day of surgery or loss of residual
Table 40-1 Causes of Low Systemic Vascular
Resistance
Septicemia
Regional anesthesia
Medications
Histamine releasers (e.g., morphine)
Vasodilators
Angiotensin receptor blockers
Impaired sympathetic nervous system regulation
Adrenal insufficiency
Anaphylaxis – blood products, medications (antibiotics)
Baroreceptor dysfunction s/p CEA
Table 40-2 Common Pharmacologic Agents Used to Treat Hypotension
Agent Therapeutic Category Usual IV Dosage Comment
Phenylephrine Alpha-adrenergic agonist Children: 1–30 μg/kg/dose every 10–15 minutes; May see reflex bradycardia
0.1–0.5 μg/kg/minute infusion.
Adults: 100–500 μg/dose every 10–15 minutes; 
100–180 μg/minute initial infusion rate, followed 
by 40–60 μg/minute maintenance rate
Ephedrine Releases tissue stores  Children: 0.1–0.3 mg/kg/dose Longer acting, but less potent
of epinephrine Adults: 5–25 mg/dose than epinephrine
Epinephrine Alpha- and beta- Children: 0.05–0.1 μg/kg/minute infusion; titrate 
adrenergic agonist as needed
Adults: 1–10 μg/minute infusion
Norepinephrine Alpha- and beta- Children: 0.05–0.1 μg/kg/minute infusion; Requires cautious monitoring
adrenergic agonist titrate as needed for extravasation
Adults: 1–10 μg/minute infusion
Dopamine Dopaminergic and 1–20 μg/kg/minute, up to 50 μg/kg/minute; Hemodynamic effects are
adrenergic agonist titrate as needed dose-dependent
Vasopressin Antidiuretic hormone Children: 0.002–0.005 units/kg/minute; Water intoxication requires
analog titrate as needed discontinuation of the drug
Adults: 0.2–0.4 units/minute; titrate as needed
Calcium chloride Electrolyte supplement Children: 10–20 mg/kg/dose Used in hypocalcemic
Adults: 500–1000 mg/dose states to improve 
myocardial contractions
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effects of medications already taken is not uncommon.
The ideal agents for treating hypertension in the
postanesthesia care unit (PACU) are agents that can be
given with repeated intravenous boluses; continuous intra-
venous infusions will necessitate increased monitoring
postoperatively. Beta-blockers have been proven to
reduce perioperative morbidity and mortality and they
should be used to treat postoperative hypertension
unless there is a contraindication (uncontrolled conges-
tive heart failure, advanced heart block, bradycardia, or
history of significant bronchospasm). Other good
options that will not need postoperative monitoring
include nitropaste (1–2 inches topically), angiotensin
converting enzyme (ACE) inhibitors (vasotec is available
in intravenous form), labetolol (combined alpha and
beta effects), and hydralazine. Short-acting antihyper-
tensive infusions, such as nitroglycerine or nitroprusside,
require arterial line monitoring and admission to an
intensive care unit (ICU) or monitored care unit to
continue their use.
The benefits and potential complications of each drug
must be considered. Beta-blockers may precipitate
bronchospasm in patients with reactive airway disease.
Vasodilating agents may cause reflex tachycardia. ACE
inhibitors decrease glomerular filtration and may
depress renal function in the postoperative setting.
Alpha-2 agonists may result in excessive sedation, par-
ticularly when used in the elderly or when combined
with analgesics or anxiolytics. The choice of antihyper-
tensive agent is considered in the context of the
patient’s underlying disease, comorbidities, and periop-
erative needs (e.g., same-day discharge, or ICU admis-
sion if continuous intravenous therapy is used).
Table 40-3 Causes of Hypertension
Preexisting hypertension
Heightened sympathetic activity due to
Pain
Anxiety
Restlessness
Surgical stress
Distended bladder
Hypothermia
Hypoxia
Hypercarbia
Endocrine abnormalities
Thyrotoxicosis
Pheochromocytoma
Cushing’s disease
Hyperaldosteronism
Hypervolemia
Disorder of blood pressure regulation
Postcarotid endarterectomy baroreceptors dysfunction
Increased intracranial pressure
Exogenous causes
Cocaine
Medication or medication withdrawal
Table 40-4 Common Pharmacologic Agents Used to Treat Hypertension
Agent Therapeutic Category Usual IV Dosage Comment
Esmolol Beta-adrenergic Children: limited information Short acting. All beta-blockers must be used 
blocker Adults: 500 μg/kg over 1 minute loading cautiously in patients with bronchospastic 
dose; 50–200 μg/kg/minute maintenance disease or acute congestive heart failure
Metoprolol Beta-adrenergic Adults: 5 mg/dose every 2 minutes, Beta-blockers can mask the signs and 
blocker up to 3 doses symptoms of hypoglycemia
Labetalol Beta-adrenergic Adults: 0.25 mg/kg/dose; 2 mg/minute Blocks alpha- and beta-adrenergic 
blocker infusion, titrate as needed receptor sites
Diltiazem Calcium channel Adults: 0.25 mg/kg over 2 minutes loading Use cautiously in hepatic/renal impairment
blocker dose; 5–15 mg/hour maintenance
Hydralazine Arteriole vasodilator Children: 0.1–0.2 mg/kg/dose Half-life is prolonged in renal disease
Adults: 10–20 mg/dose
Enalaprilat Angiotensin converting 1.25 mg/dose May impair renal function
enzyme inhibitor
Nitroprusside Vasodilator Children: 0.1–2 μg/kg/minute; High dose or prolonged administration 
maximum 5 μg/kg/minute can lead to cyanide toxicity
Adults: 0.3–10 μg/kg/minute
Nitroglycerin Vasodilator, Children: 0.25–0.5 μg/kg/minute; Commonly causes headaches
anti-anginal maximum 5 μg/kg/minute
Adults: 5–200 μg/minute, 1/2–2 inch ointment
Furosemide Loop diuretic Children: 1 mg/kg/dose Check serum potassium
Adults: 20–40 mg/dose
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BRADYCARDIA
Bradycardia, sinus or ventricular escape rhythms, may
be the result of hypoxia, hypercarbia, hypothermia,
myocardial ischemia, or medications. High spinal anes-
thetics or residual anticholinesterases from muscle relax-
ation reversal also result in an increased parasympathetic
tone. Triggers of vagal tone include ocular pressure,
carotid pressure, and Valsalva’s maneuver. A patient
after neurosurgery with bradycardia and hypertension
may have increased intracranial pressure.
Bradycardia should only be treated if the patient is
symptomatic or exhibits advanced heart block. Hypo-
tension is initially treated with atropine 0.5 to 1.0 mg
followed by dopamine (5 to 20 μg/kg/minute) or epi-
nephrine (2 to 10 μg/minute) if needed. Cardiac pacing is
indicated in high-grade AV nodal blocks, and may be effec-
tive if pharmacologic interventions do not adequately treat
bradycardia and hypotension. Glucagon (0.15 mg/kg fol-
lowed by 0.05–0.10 mg/kg/hour) has been demonstrated
to counter effectively beta-blocker-induced bradycardia.
TACHYCARDIA/TACHYARRHYTHMIAS
In the postoperative period patients are predisposed
to a variety of arrhythmias, especially in the presence of
a heightened catecholamine state; the surgical stress
response results in increased epinephrine levels that
usually peak in the PACU. The commonly encountered
dysrhythmias are sinus tachycardia, premature ventri-
cular contractions, supraventricular tachycardia, and
ventricular tachycardia. Tachycardia at a rate < 150 beats
per minute is generally well tolerated except in patients
with coronary artery disease or stenotic heart valves.
Hemodynamic compromise associated with tachycardia
is due to diminished stroke volume or decreased con-
tractility from cardiac ischemia. Decreased stroke volume
is a result of the shortened diastolic filling time. If a
patient has coronary artery disease, decreased coronary
artery perfusion coupled with increased oxygen con-
sumption may result in myocardial ischemia and infarc-
tion if prolonged. Prompt diagnosis and correction of
the underlying causes are essential in the recovery period.
Sinus tachycardia has many triggers and is also a
compensatory mechanism for decreased oxygen deliv-
ery such as hypovolemia or severe anemia. Therapy
should be aimed at treating the etiology of the sinus
tachycardia (Table 40-5).
Tachyarrhythmias may present in the PACU, especially
in patients with cardiomyopathies or history of arrhyth-
mias. Cardioversion is indicated in patients exhibiting vital
signs deterioration or symptoms associated with end-
organ hypoperfusion. It is essential to identify correctly
an arrhythmia and assess its hemodynamic consequence
in order to determine the appropriate intervention and
its urgency. If a diagnosis cannot be made by bedside
telemetry, a 12-lead EKG, free of artifacts, may facilitate
identification of the rhythm.
The causes of arrhythmias are variable. In the recovery
period they commonly include preexisting heart disease,
hypoxia, acid–base disturbances, myocardial ischemia,
drugs, hypothermia, electrolyte abnormalities (potassium,
calcium, and magnesium), and increased sympathetic
tone. These physiologic disturbances increase myocardial
excitability and irritability. General anesthesia lowers the
threshold for dysrhythmias, and the recovering patient
often has residual circulating anesthetics.
Inhalational anesthetics sensitize the myocardium to
circulation catecholamines and premature ventricular
contractions (PVCs) may be seen. Electrolyte abnormali-
ties, acid–base disturbances, and hypoxia also cause PVCs.
PVCs alone typically do not cause hemodynamic insta-
bility and management involves correcting any underlying
cause listed above. PVCs generally resolve once residual
anesthetics have worn off and do not require treatment
with an antiarrhythmic.
Atrial flutter and fibrillation are the most common
postoperative supraventricular tachyarrhythmias. Any
physiologic alteration can precipitate atrial flutter or
atrial fibrillation, even in the absence of underlying heart
disease. This rhythm disturbance can result in a rapid
ventricular response and hypotension. The loss of the
atrial “kick” further decreases ventricular filling, particu-
larly in patients with left ventricular hypertrophy (e.g.,
patients with aortic stenosis). In the stable patient treat-
ment is first geared toward correcting reversible causes.
Atrial fibrillation can be seen in the tachypneic patient
with respiratory alkalosis and hypoxemia. Treating the
hypoxemia and respiratory alkalosis will usually correct
Table 40-5 Causes of Sinus Tachycardia
Hypoxia
Hypercarbia
Pain
Anxiety
Hyperthermia
Infection
Hypotension
Acidosis
Medications – e.g., anticholinergics given with muscle 
relaxant reversal
Beta-blocker withdrawal
Alcohol withdrawal
Pulmonary embolus
Congestive heart failure
Thyrotoxicosis
Malignant hyperthermia
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the dysrhythmia. If the rhythm is not corrected with
treating reversible causes, attempts to convert atrial
fibrillation or atrial flutter to normal sinus rhythm with
amiodarone may be successful. To control the ventricu-
lar rate, pharmacologic intervention involves slowing the
AV node with beta-blockers, calcium channel blockers, or
digoxin. These medications should be avoided in patients
with Wolf-Parkinson-White syndrome and digoxin should
be used cautiously in patients with hypokalemia.
Ventricular tachycardia and fibrillation are commonly
caused by acute myocardial infarction or ischemia. These
rhythms are managed and treated as outlined in the
advanced cardiac life support guidelines. Ventricular
tachycardia that is unstable should be treated immedi-
ately with cardioversion, followed by drug therapy.
Electrolyte and metabolic derangements should be
promptly sought and corrected. Those without significant
symptoms or hemodynamic instability may be treated
with antiarrhythmic agents (amiodarone, lidocaine, or
procainamide) and correction of underlying triggers.
Patients with recurring ventricular tachyarrhythmias
may develop cardiac death. Recurrence can be pre-
vented by continuous infusion of an effective anti-
arrhythmic agent.
CONCLUSION
Hemodynamic instability is commonly encountered
in the postanesthesia period. Vigilance in patient moni-
toring during this time is essential. Early identification of
possible causes and institution of appropriate therapy
may prevent the development of complications or death.
A good understanding of the pathophysiology coupled
with astute clinical skills are required to provide effec-
tive care for the recovering patient.
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CASE STUDY
A 68-year-old woman with a history of hypertension
and diverticulosis was admitted to the emergency room
with abdominal pain and nausea with vomiting of one
day duration. Work-up revealed an elevated white
blood cell count of 14.6 and a perforated diverticulum
in the sigmoid colon. Her remaining preoperative
laboratory data showed hematocrit 36, potassium 3.8,
and creatinine 1.2. EKG showed normal sinus rhythm
at a rate of 92 beats per minute, and left ventricular
hypertrophy by voltage criteria. She normally takes
amlodipine for hypertension. She had an uneventful
rapid-sequence induction, and her intraoperative
course was uncomplicated. Estimated blood loss was
300 ml, and she received 3000 ml of crystalloid. 
She was extubated at the end of the case, and was
transferred to the PACU in stable condition.
After 35 minutes in the PACU she complained of
chest pressure and dyspnea. Her vital signs were 
BP 145/86, HR 102, RR 24, O2 sat 92% on room air.
Telemetry revealed ST segment elevation. Physical
examination revealed a woman in moderate discomfort.
Lung examination was notable for new bibasilar
crackles. Heart examination was notable only for
tachycardia. A repeat 12-lead EKG showed sinus
tachycardia with 2 mm ST segment elevation in 
leads II, III, and aVF consistent with an acute inferior
myocardial infarction. Treatment was immediately
initiated while cardiology was consulted. She was given
4 liters/minute of oxygen via nasal canula and her pulse
oxymetry improved to 100%. She was also given
nitroglycerin 0.3 mg × 3 sublingually with mild
improvement in her chest pressure. This was followed
by morphine 4 mg IV × 2 with good pain relief. Aspirin
325 mg PO and metoprolol 5 mg IV × 3 were
administered. Stat labs for hematocrit, electrolytes, 
and cardiac enzymes were sent. Chest x-ray was clear.
Heparin and thrombolytics were not administered 
due to concerns about bleeding. She was taken
emergently to the cardiac catheterization lab where 
she successfully underwent angioplasty of her right
coronary artery.
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Conclusions
The transport from the operating room to the inten-
sive care unit (ICU) is a crucial time in the critically ill
patient’s care. In the operating room patients are man-
aged one-to-one by an anesthesia care provider with full
monitors. There is rapid access to emergency drugs, air-
way management equipment, IV infusion equipment, etc.
In the ICU, the ICU team with 1:1 or 1:2 nursing coverage
manages patients. During transport from the operating
room to the ICU, these conditions may not exist. Optimal
management of these patients during transport requires
excellent communication between the operating room
and ICU. In addition, conditions must be established that
will provide for the safest possible transfer from the
operating room to the ICU.
Before any discussion of transfer, clearly the need for
a critical care bed must be established. This is not a trivial
point. We all desire the optimal care for our patients.
Unfortunately, ICU beds are often in short supply. Often
the intensivist is faced with discharging a patient who
would benefit from more time in the ICU in order to
admit a new patient. The decision to admit a patient to
the ICU should be made jointly between the surgical and
anesthesiology teams. Clearly, a patient who requires
more than a few hours of postoperative ventilatory sup-
port will need an ICU bed. These include those with
large blood losses, evolving sepsis, long procedures with
associated airway edema, etc. Patients who are extubated
but have very marginal pulmonary function, are at high
risk for respiratory failure and will need an ICU bed.
There are patients who require intensive neurologic or
vascular monitoring that can only be accomplished in an
ICU. As soon as the need for an ICU bed is established,
the critical care team should be contacted, so that prepa-
rations for the patient’s arrival can be initiated.
COMMUNICATION
Communication between the surgical team and criti-
cal care team is one of the most important aspects of
postoperative transport of the patient. Whether the
patient is expected in the ICU after surgery or the need
develops intraoperatively, contact with the ICU team
should be made well in advance of patient transport.
Issues discussed should include the surgical procedure,
past medical history, blood loss, volume/product/vaso-
pressor requirements, IV access, any significant intraoper-
ative events, and special monitors (arterial line, Swan-Ganz
catheter, etc.). In addition, anticipated postoperative
ventilator requirements should be discussed. Ideally, the
communication between the operating room and ICU
should be physician to physician. However, it is impor-
tant that the ICU physician communicate with the ICU
nursing staff about the patient.
EQUIPMENT NEEDS FOR TRANSPORT
JACHO requirements for the ICU include having 
uniform monitor requirements for all ICUs for patient
transport. At our institution, the monitors include EKG
monitoring, pulse oximetry, and blood pressure moni-
toring. A defibrillator must be available. Since the patient
transporting to the ICU from the operating room is an
ICU patient, transport should be accomplished at a min-
imum with the above monitors. If patient requirements
exceed the minimum required (such as pulmonary artery
pressure monitoring, intracranial pressure monitoring,
etc.), then they should be used. Beyond monitors, the
physician transporting the patient should be prepared to
CHAPTER
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manage any foreseeable problems the patient may
develop en route to the ICU. This should include having
a laryngoscope, endotracheal tube, stylette, AMBU bag,
oxygen tank, IV fluid, and emergency drugs (including
induction drugs, neuromuscular blockers, and vasopres-
sors). Some patients present with or develop severe lung
injury intraoperatively. These patients may have high
oxygen and positive end-expiratory pressure (PEEP)
requirements in order to oxygenate adequately. They may
be very difficult to ventilate. Transport of these patients
with an AMBU bag, with or without a PEEP valve, may be
very unsafe. In these cases, transport should be accom-
plished using a ventilator.
THE TRANSFER
The transfer begins on the operating room table and
ends in the ICU. Monitoring should not be interrupted
during transfer of the patient from the operating room
table to the ICU bed. Use of the transport monitor can
start either before or after the patient is moved to the ICU
bed. Care must be taken to protect the airway, IV access,
and other implements (such as ventricular drains, epidural
catheter, chest tubes, and Foley catheter) during the
move from operating room table to ICU bed. At this point,
the patient is ready to move. Before leaving the operating
room, a final check for suitability for transfer should be
made. The patient should be hemodynamically stable and
adequately sedated for the period of transfer. Emergency
equipment and drugs should be on the patient’s bed.
Lastly, the ICU should be contacted to ensure that it is
ready to accept the patient. If the route to the ICU includes
an elevator, this should be readied prior to leaving the
room. Personnel for the transfer should include at least
two individuals (one to monitor and treat the patient and
one to move the bed). Upon arrival in the ICU, a detailed
sign out should be given to the ICU staff.
DETOURS
Frequently, patients cannot be transferred directly to
the ICU. The most common reason is the need for an
admission to the postanesthesia care unit (PACU). This
may include the need for postextubation respiratory
monitoring, vascular monitoring, or neurologic monitor-
ing. In this case, a detailed sign out should be given both
to the PACU staff and telephonically to the ICU staff. It is
important to establish the time when care will be trans-
ferred from the anesthesiology team to the ICU team.
Confusion on the part of the PACU staff as to who is man-
aging the patient could result in adverse outcomes.
Another common detour is to the radiology suite for
a radiologic study or procedure. In this case the anes-
thesiologist should either continue to monitor and care
for the patient or arrange for ICU personnel to care for
the patient. Transfer of care to a member of the surgical
team or the radiology staff during the study is strongly
discouraged. These individuals are either not qualified to
care for critically ill patients or unlikely to be familiar
with anesthesiology equipment (monitors, infusion
pumps, etc.) to make this a safe practice.
CONCLUSIONS
Communication is the most import factor in providing
excellent continuity of care for patients leaving the oper-
ating room. At the University of Rochester, New York,
we have established ICU transfer guidelines which are
specific to our institution (see Box 41-1). These recom-
mendations were agreed to by anesthesiologists and ICU
directors (physicians and nurses). It is strongly recom-
mended that institutions establish their own guidelines
in order to facilitate the transfer of patients from the
operating room to the ICU.
Box 41-1 SMH Department of Anesthesiology Guidelines for the Transfer of Intensive
Care Unit Patients to and from the Operating Room
TRANSFER FROM THE ICU TO THE OPERATING ROOM
A. Patients will not be transferred until the anesthesia team responsible for the patient in the operating room gives direct
approval to the operating room desk to send for the patient.
B. Patients will be accompanied from the ICU by a critical care nurse, who will remain with the patient until care is 
transferred to an anesthesia care provider (attending, resident, or CRNA). At times, the anesthesia team cannot 
immediately take over completely because of ongoing preparations for all aspects of anesthesia care.
C. The patient will be fully monitored (minimum EKG and pulse oximetry; add blood pressure for adults) and 
appropriately ventilated. Transfer equipment will include a defibrillator.
Continued
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Box 41-1 SMH Department of Anesthesiology Guidelines for the Transfer of Intensive
Care Unit Patients to and from the Operating Room—Cont’d
INTRAOPERATIVE
A. When it becomes clear that an ICU admission will be required, contact one of the following individuals to arrange for a bed.
1. Adult, noncardiac: critical care fellow on call.
2. Pediatric: PICU attending.
3. Neonates: NICU attending.
B. Make sure that an ICU bed with monitor and defibrillator is available for the end of the procedure.
POSTOPERATIVE
A. Direct transfer to the ICU.
1. Anesthesia care provider to contact ICU immediately prior to leaving the operating room.
2. Anesthesia care provider will accompany the patient to the ICU.
3. Full monitors and defibrillator for transfer.
4. Direct sign out by anesthesia care provider to ICU team member detailing the operative course.
B. PACU admission prior to ICU admission.
1. Certain situations dictate admission to PACU first (vascular checks, neurologic examinations, etc.).
2. Anesthesia care provider will accompany the patient to the PACU and give sign out to the PACU nurse.
3. Anesthesia care provider will contact the ICU physician to give sign out and transfer care as soon as feasible.
4. For transfer to the ICU, a PACU nurse will accompany the patient with full monitors and defibrillator.
5. Direct sign out to ICU team member detailing the perioperative course.
C. Indirect transfer to the ICU.
1. Certain situations require procedures/studies outside of the operating room prior to transfer to the ICU (e.g., CT,
MRI, angiography).
2. Unless continued anesthesia is required, the anesthetist will not accompany the patient to an “off site” location.
3. As soon as the need for the study/procedure is known, the ICU attending should be contacted to arrange for 
critical care nursing coverage during the procedure and thereafter. The ICU attending, in collaboration with the
ICU and/or PACU nurses will arrange for coverage of the patient during the procedure.
4. The place where care will be transferred will be arranged by mutual agreement between the anesthesia and 
critical care teams.
5. If no ICU or PACU nurse is available, remain in the operating room.
D. ICU patients boarding in the PACU.
1. When an ICU bed in not available, the patient will be boarded in the PACU.
2. The critical care attending and ICU team will be responsible for the patient’s care.
E. Nursing coverage in either the ICU or PACU is not available. The patient will remain in the operating room under the
care of the anesthesiology team.
Department of Anesthesiology, University of Rochester, Rochester, New York.
421
A
ABC/2 formula of Kothary 207
ABCDE algorithm 328, 338
abdomen
intra-abdominal hypertension 308
pain, hypoventilation and 393
trauma 219, 341
“abdominal angina” 305
abdominal ultrasound, trauma assessment 341
ABO blood groups 275, 275t
abscess, brain
in congenital heart disease (adult) 154
in HIV/AIDS 259
accelerated acute rejection 256
acetaminophen poisoning 363–364, 369
fulminant hepatic failure 287
classification 288, 289t
hepatorenal syndrome 295
N-acetylcysteine (NAC; mucomyst) 287,
291, 364
acetazolamide
alkalosis treatment 68
hyperphosphatemia treatment 54
acetone, catheter insertion 119
acetylcholinesterase inhibitors
anticholinergic syndrome treatment 57
PONV and 391
acid
burns 347
definition 38
total weak acid concentration 40
acid–base physiology 37–46, 67–68 
see also electrolytes
biochemistry 39–40, 68
anion gap 42
chloride ions 41–42
lactate role 42–43, 44–45
controversies/background 38–39, 41
definitions 38
disorders of 40–45 see also acidosis;
alkalosis 
anions causing 41–43
cardiac arrhythmias and 68, 76
case study 46
iatrogenic 46
proteinaceous 45–46
acid–base physiology (Continued)
quantification 40–41
renal replacement therapy 44–45
treatment 43–44
in liver transplantation 297
plasma proteins 45–46
the Stewart approach 37–38
acidemia 43–44 see also acidosis
acidosis 67–68
acute renal failure 311
case study 46
chloride ions and 41
clinical features 67
dilutional 41–42
hyperkalemia and 67
hyperphosphatemia and 54
iatrogenic 46
metabolic see metabolic acidosis 
potassium ions and 64
proteinaceous 45–46
pseudoacidosis 67
relative 67
respiratory see respiratory acidosis 
tissue oxygen relationship 35
treatment 43–44, 68, 395
Acinetobacter spp. infections 168
acquired immunodeficiency syndrome (AIDS)
see HIV/AIDS
acrolein gas 346–347
Acticoat (ionic silver fabric dressing) 350, 350t
action potentials
cardiac 74, 74f
neuronal 235–236
activated charcoal 363
activated clotting time (ACT) 269
activated partial thromboplastin time 
(APTT) 268
activated protein C
coagulopathy/DIC management 271
ethical issues 368–369
acute fatty liver of pregnancy 250
acute lung injury (ALI) 176, 177 see also acute
respiratory distress syndrome (ARDS)
management 178
pathology 177, 178
postpneumonectomy 406
ventilatory weaning 194
Acute physiology and Chronic Health
Evaluation see APACHE scores
acute quadriparetic myopathy syndrome
(AQMS) 133, 134
acute renal failure (ARF) 307–316
assessment 307–308
clinical features 310
anemia 311
hyperkalemia 311
hyponatremia 48
metabolic acidosis 311
complications 311
definition 307
diagnosis/classification 308–309, 311
intra-abdominal hypertension 308
laboratory findings 308t
drug-induced 309
etiology 295, 308, 309, 311
hepatorenal syndrome 295, 309
hypertension and 139
lung transplantation and 408–409
occurrence 307
parenchymal 308, 310
pathogenesis 309–310
postrenal renal failure 309
prerenal 308, 310
radiocontrast nephropathy 311
rhabdomyolysis-associated 309
trauma and 110
treatment 309, 311–315 see also specific
treatments
acid–base balance 311
diuretics 310–311, 312
low-dose dopamine 310
nutritional support 113, 311
plasma exchange 314
preventative 310–311
renal replacement 311, 312–315
resuscitation 309, 310
stress ulcer prophylaxis 311–312
vasoactive drugs 309, 310
acute respiratory distress syndrome (ARDS)
176–180 see also acute lung injury (ALI)
case study 179
clinical features 176–177
infection 165, 176, 179
definition 176, 177
Index
Please note as the subject of this book is critical care, all entries refer to this unless otherwise stated. Entries followed by “f” and “t” denote figures
and tables respectively.
acute respiratory distress syndrome (ARDS)
(Continued)
in hepatic disease 292
hypercapnic respiratory failure 14
management 178–179
mortality 178
open lung concept 178–179
pathology 177
postpneumonectomy 406
risk factors 176, 177
thermal injury/smoke inhalation 348
ventilation and 176, 178, 185–186
Acute Respiratory Distress Syndrome Network
(ARDS-NET) 178, 187
acute respiratory failure (ARF) 11–15,
181–182 see also hypercapnia;
hypoxemia
hypercapnic (type 2) 11, 14–15, 182t
hypoxemic (type 1) 11–14, 182t
infection in 111, 112, 165
management see also ventilatory support 
hypercapnia 14–15
hypoxia 12–14, 14t
nutritional support 110–112
acute tubular necrosis (ATN) 295, 307 
see also acute renal failure (ARF)
acyanotic heart defects 150–152, 151t
atrial septal defect 151
critical care in 155
patent ductus arteriosus 151–152
ventricular septal defect 150–151
acyclovir
dialysis and 315t
pneumonia management 174
Adamsite 358
Addisonian crisis 241
adenosine
multifocal atrial tachycardia 82
paroxysmal supraventricular tachycardia 83
pulmonary surgery and 406
adenovirus infection 254
adrenal gland
functions 240–241
hemorrhage 241
insufficiency 241–242
diagnosis 241–242
in HIV/AIDS 241
presentation 64
primary, secondary and tertiary 241
treatment 242
tumors 245–246
adrenaline see epinephrine
adrenalitis, in myxedema 238
adrenergic receptors
α-2 agonists see alpha-2 agonists 
α-blockers see alpha-blockers 
beta-adrenergic agents
arrhythmia induction 77
β-agonists 77, 173
β-blockers see beta-blockers 
pneumonia management 173
postoperative pulmonary care 405t
adrenocorticotropic hormone (ACTH) 240
resistance 242
stimulation tests 241–242
adult live donor liver transplantation (aLDLT)
298
Advanced Cardiac Life Support Protocol 27
credentialing 374
advance directives 367, 378–379
Advanced Trauma Life Support (ATLS) course
328, 338
traumatic brain injury 222
adverse events, root cause analysis 374
afterload (outflow resistance) 30, 31f, 413
measures 32
“against medical advice” (AMA) 377
Agent 15 358
agitation see also sedation/sedatives
drug-related 124, 124t
evaluation 123–124
scales 125, 125t
AIDS see HIV/AIDS
airway
assessment, primary survey 338, 339–340
disease, pneumonia management in 173
increasing mean pressure in 12–14 
see also ventilatory support 
management
ABCDE algorithm 328, 338
ischemic stroke 198
postanesthetic 395
traumatic brain injury 221
obstruction
chronic disease see COPD 
hypercapnia 14
hypoventilation 393
management 395
thermal injury/smoke inhalation 347–348
trauma 409
airway pressure-release ventilation (APRV) 186
alarm systems 16
albumin
anion gap and 42
blood products 279
burn pathophysiology 346
oncotic pressure and 69
trauma management 343
thermal injury 349
albuterol
pneumonia management 173
postoperative pulmonary care 405t
alcohol/alcoholism
cirrhosis pathophysiology 286 see also
cirrhosis 
hypoglycemia 243
poisoning 362t
aldehyde gas 346–347
aldosterone, hypertension pathogenesis 138
ALI see acute lung injury (ALI)
alkali, burns 347
alkalosis 68
chloride ions and 41, 68
hyperkalemic 46
hypoalbuminemic 45
ionized hypocalcemia 66
metabolic 41, 68
proteinaceous 45–46
relative 67
respiratory 40
cardiac arrhythmias 416
metabolic acidosis compensation 67
treatment 68
Allen test 24
allergies/allergic reactions
epinephrine in 93
latex allergy 22–23
transfusion-related reaction 283t
allograft rejection 256
lung 408
alloimunization, platelet transfusion 281
alpha-2 agonists 131
hypertension management 140, 198–199,
415
myocardial ischemia prevention 146
stroke management 198–199
alpha-blockers 140
drug interactions 148
pheochromocytoma treatment 246
stroke management 199
alphaviruses 356
aluminum hydroxide 54
alveolar–capillary unit
hypoxemia and 11–12, 13f
ventilation–perfusion 33
alveolus
ARDS pathology 177
oxygen tension gradient 11–12, 13f
physiology 188f
pressure in (PA) 33
type I cells 177
amantadine 56
American Academy of Neurology, rt-PA use in
stroke 202
American Association for Surgery of Trauma
(AAST), renal trauma classification
329–330, 329f, 330t
American College of Cardiology (ACC),
myocardial ischemia evaluation 143
American College of Surgeons, advanced
trauma life support (ATLS) course 222,
328, 338
American–European Consensus Conference,
ALI/ARDS definitions 77, 176
American Heart Association (AHA)
Advanced Cardiac Life Support 
Protocol 27
myocardial ischemia evaluation 143
rt-PA use in stroke 202
American Medical Association, principles of
Medical Ethics 379
amino acids
immunonutrition 115
nutritional requirements 107–108
in renal failure 113
in sepsis 112
aminocaproic acid 266
aminoglycoside antibiotics
dialysis and 315t
pneumonia management 172–173
amiodarone
multifocal atrial tachycardia 82
pulmonary surgery and 406
Torsade de pointes 84
ventricular fibrillation 79
Wolff–Parkinson–White syndrome 81
ammonia, serum levels in cirrhosis 291
amniotic fluid embolus (AFE) 250
amoxycillin, dialysis and 315t
amphetamines, poisoning 362t, 364
amphotericin B, dialysis and 315t
amphotericin, liposomal, dialysis and 315t
analgesia see also anesthesia; sedation/
sedatives; specific drugs
agitation and anxiety 123, 124t
angina treatment 147
burn care 350–351
ICP reduction 199, 228
inadequate 123
ketamine 130–131
NSAIDs see nonsteroidal anti-inflammatory
drugs (NSAIDs) 
opioid see opioids 
patient-controlled 390
postoperative 389–391
post-thoracotomy 404–406
tolerance 389
in traumatic brain injury 228
during vascular access 20–21
422 INDEX
anaphylaxis 31
catheter-induced 120
epinephrine in 93
muscle relaxant-induced 132
anastomoses, hepatic artery 297
anemia
acute renal failure 311
blood transfusion 69, 275–277
diagnosis 69
physiological response 275–276
anerobic metabolism
DO2–VO2 relationship 34–35, 35f
lactic acidosis and 45
anesthesia see also analgesia; postanesthesia
care unit (PACU)
atenolol interactions 140
cardiac surgery 146
complications see also specific
complications
cardiac arrhythmia 75, 77, 391
case study 399
delayed arousal 397–399
hypotension 398
metabolic anomalies 398
nausea and vomiting 391–393
neurological 398–399
residual drug effects 397–398
respiratory 393–395, 393t
thermal 55, 57, 395–397
congenital heart defects (adult) and
155–156
goals 389
in hypertensive patients 139–140
ketamine-induced 131
liver transplantation 296–297
local
postoperative analgesia 390–391
during vascular access 20–21
neuraxial 391
stress of 139
in traumatic brain injury 224–225
aneurysm(s)
aortic 140, 141
cerebral
anesthesia and 140
intraparenchymal hemorrhage 205
subarachnoid hemorrhage 208–209
hypertensive crisis 141
angina
hypertension and 139
preoperative, treatment 147–148
angiodysplasias, gastrointestinal bleeding 305
angiography
gastrointestinal bleeding 302
subarachnoid hemorrhage 210
angiomas, intraparenchymal hemorrhage 205
angioplasty
stroke management 204
in subarachnoid hemorrhage 211
angiotensin converting enzyme (ACE)
inhibitors 141
adverse effects 102
angina treatment 147
drug interactions 148
intravenous 102
postoperative hypertension management
415, 415t
in renovascular hypertension 138
angiotensin I and II, hypertension
pathogenesis 138
anion gap 42, 68
anisocoria, in traumatic brain injury 222
antacids, gastrointestinal bleeding and 301, 303
anterior cerebral artery, occlusion 196, 197
anthrax 164, 354–355
anthropometric evaluation, nutritional status
106, 112
antiarrhythmic drugs 79t, 417 see also
specific agents
atrial fibrillation/flutter 81, 82t
congenital heart defect management 156
pulmonary surgery and 406
Torsade de pointes 84
ventricular fibrillation 79
Wolff–Parkinson–White syndrome 81
“antibiotic lock” 120
antibiotics see also specific drugs/infections
agitation and anxiety 124t
anthrax 355
catheter-related infection management
121–122
in HIV/AIDS-related infection 259
plague 355
pneumonia management 162–171
community-acquired pneumonia 163
hospital-acquired pneumonia 167
inhaled antibiotics 173
Pneumocystis carnii pneumonia 171
principles 172–173
prophylactic
catheter-related infection 
prevention 120
organ transplantation 257
resistance 118, 120, 162, 168, 254
mechanisms 173
antibodies see immunoglobulins
anticholinergic drugs
complications 56–57
hyperthermia and 397
pneumonia management 173
poisoning 362t
PONV prevention/treatment 392
postoperative pulmonary care 405t
anticholinergic syndrome 56–57
anticholinesterases
anticholinergic syndrome treatment 57
PONV and 391
anticoagulation
atrial fibrillation and 81
catheter insertion and 120
cystourethroscopy and 320
hypocoagulable states 265
ischemic stroke management 202
renal replacement therapy and 313–314
thrombophilic states 266–267
in traumatic brain injury 231
vascular access and 20, 24
anticonvulsants
agitation and anxiety 124t
in hemorrhagic stroke 208
in traumatic brain injury (TBI) 231
antidepressants
hepatotoxicity 287
hyperthermia and 397
poisoning 362t
antidiuretic hormone (ADH; vasopressin) 
see vasopressin
antidotes, chemical/toxic response 
358–359
antiemetics
PONV prevention/treatment 392
propofol 129
antifibrinolytic therapy
coagulopathy/DIC management 271
hypocoagulable states 265–266
in liver transplantation 298
antihistamines
hyperthermia and 397
pneumonia management 173
PONV prevention/treatment 392
antihypertensive drugs 101, 140–141,
414–415, 415t see also specific drugs
anesthesia and 139–140
poisoning 362t
in stroke management 198–199
anti-inflammatory cytokines 7
Anti-Kickback statute 380
antimicrobial therapy
antibiotics see antibiotics 
catheter-related infection management
121–122
neutropenic infections 254
topical, burns 350, 350t
antioxidants, ARDS management 179
antiphospholipid syndrome
laboratory findings 268t, 269
thrombosis risk 266
antipsychotic drugs
neuroleptic malignant syndrome 55–56,
130, 397
in postoperative delirium 399
antiseptics, catheter placement 119
antithrombin
coagulopathy/DIC management 271
deficiency 266, 280t
laboratory assay 269
sepsis pathophysiology 7
anxiety
evaluation 123–124
management see sedation/sedatives 
aorta
aneurysm
anesthesia and 140
hypertensive crisis 141
coarctation 153–154
dissection
labetolol actions 100
vasodilator drug choice 103
thoracic trauma 409
aortic regurgitation, ventral septal 
defects 151
aortography, thoracic trauma 409
APACHE scores 375–376, 382–384
APACHE I 380
APACHE II 380, 381t
problems 385
APACHE III 380–381
aphasia, stroke and 196
apheresis 273, 279
Apligraf, burns care 350
apnea
pregnancy 248
sleep, postoperative hypoventilation 393
aprotinin 284
fibrinolysis 266
aqueous solutions, biochemistry 40
ARDS see acute respiratory distress syndrome
(ARDS)
Arenaviruses 356
ARF see acute respiratory failure (ARF)
arginine, immunonutrition 115
arm, vascular anatomy 27f
arousal, postoperative 397–399
arrhythmias see cardiac arrhythmias
arteries see also specific vessels
cannulation 24–26
blood pressure monitoring 24
insertion technique 24–25, 25f
in myocardial ischemia 146
Index 423
arteries (Continued)
pulmonary see pulmonary artery catheter
(PAC) 
sites 24
cerebral 196–197
occlusion see ischemic stroke 
oxygen content 71
transposition of great 152–153
arteriopathy, subarachnoid hemorrhage 211
arteriovenous malformations, intraparenchymal
hemorrhage 205
artificial liver 298, 315
ascites, in hepatic disease 293
aseptic technique, catheter insertion 
119–120
Aspergillus infection
hospital-acquired pneumonia 167
neutropenia 253
pneumonia 160
transplantation and 256
aspiration pneumonia 159
aspiration pneumonitis 158, 158f
postpneumonectomy pulmonary edema 
vs. 406
aspirin
ischemic stroke management 202
myocardial ischemia prevention 147, 148
asplenia, humoral immunity and 255
assessment see also scoring systems
burns, depth of injury 345–346
motor activity 125, 125t
neurological 233
sequential organ failure 5, 6t
trauma see trauma, assessment 
assist-control ventilation 183–184, 183t
asthma, pneumonia management in 173
asystole 80, 80f
atelectasis
evaluation/treatment 395
mechanical ventilation and 187–188
postoperative V/Q mismatch 394
prevention in lung transplantation 408
radiography 403
thoracic surgery complication 404
atenolol
anesthesia and 139
drug interactions 140
atherosclerosis
hypertension pathogenesis 138
stroke pathophysiology 196
atracurium 133
properties 133t
atrial fibrillation 80–81, 80f
antiarrhythmic drugs 81, 82t, 406
anticoagulation 81
atrial septal defects 151
multiple wavelet theory 80
postoperative 416–417
pulmonary surgery 401–402, 406
risk factors 75
stroke risk 154
atrial flutter 80–81, 80f
atrial septal defects 151
postoperative 416–417
pulmonary surgery and 406
atrial septal defect (ASD) 151
stroke risk 154
atrial tachycardia see also specific
abnormalities
multifocal 82, 82f
pulmonary surgery and 406
atrioventricular node 74
blockers 81
atropine
nerve gas antidote 358, 359, 365
PONV prevention/treatment 392
in postoperative bradycardia 416
postoperative pulmonary care 405t
Atrovent, pneumonia management 173
audit, scoring systems 381
auscultation, blood pressure monitoring 19
autologous blood transfusion 273, 
283–284
autonomic dysfunction, neuroleptic malignant
syndrome 55–56
autonomy 367–368, 369
advance directives and 378
auto-PEEP 183, 187, 408
minimization 188
axonal injury 217
azithromycin, pneumonia management 
172, 173
B
Bacillus spp. infections
atypical pneumonia 164
neutropenia 253
bacteremia, hospital-acquired 
pneumonia 167
bacterial infection(s) see also pneumonia;
sepsis; specific organisms/infections
drug treatment see antibiotics 
pneumonia 158t
sepsis pathophysiology 5
bacterial products, sepsis pathophysiology 5
Bacteroides fragilis infections, 
neutropenia 253
barbiturates
intracranial hypertension reduction
in hepatic encephalopathy 292
in stroke 200
in traumatic brain injury 229
poisoning 362t
treatment 363
in postoperative delirium 399
seizure management 398
barotrauma, mechanical ventilation 184
basal ganglia, hemorrhage 206
base excess (BE)
concept 39
standard (SBE) 40–41
basilic vein 27f
Beer–Lambert law 17, 17f
beneficence 368, 369
advance directives and 378
benzodiazepines 128–131 see also specific
drugs
actions 128
pharmacology 128
poisoning 364
treatment 363
in postoperative delirium 399
reversal of actions 129, 398
seizure management 398
serotonin syndrome treatment 56
sympathomimetic poisoning syndrome
treatment 56
in traumatic brain injury 228
Bernard–Soulier syndrome 264
berry aneurysms, hemorrhage 208–209
best practice 372
beta-2 agonists
arrhythmia induction 77
pneumonia management 173
beta-adrenergic agents
beta-2 agonists 77, 173
beta-blockers see beta-blockers 
postoperative pulmonary care 405t
beta-blockers
arrhythmia induction 77
arrhythmia management
atrial fibrillation 81
multifocal atrial tachycardia 82
cirrhosis-associated gastrointestinal 
bleeding 294
contraindications/precautions 100
drug interactions 148, 246
hypertension management 140, 415, 415t
in stroke 198
myocardial ischemia 144, 148
angina 147
perioperative prevention 146
pheochromocytoma treatment 246
poisoning 362t, 364
pulmonary surgery and 406
beta-lactamase antibiotics
pneumonia management 172
ventilator-associated pneumonia 168
bicarbonate see sodium bicarbonate
biliary disease, cirrhosis and 286
biliary drainage, liver transplantation 297
billing 379–380
Biobrane, burns care 350
bioimpedence, noninvasive hemodynamic
monitoring 35
biological incidents 354–356
identifying 354
infectious agents 354–356
biopsy
liver 290
lung 169
bioterrorism 354–356
biphasic airway pressure (BiPAP) 186
in hypercapnic respiratory failure 15
biphosphonates, hypercalcemia treatment 52
Bispectal index (BIS) 125
bispectral analysis 125, 236
“black death” (bubonic plague) 355
bladder
decompression 340
suprapubic catheterization 321–324, 323f
trauma 330, 332
examination 332
nonoperative management 332, 332f
Blalock–Taussig shunt, tetralogy of Fallot 152
Blastomyces dermatitidis, pneumonia 165, 166f
bleeding see also hemorrhage
coagulopathies 267
gastrointestinal see gastrointestinal bleeding 
scalp 216
bleeding time 267
blood 273–285
body water 60
catheter-related infection(s) 117–122
conservation 283
gases see blood gas analysis 
groups 275, 275t
pregnancy physiology 249
products see blood products 
storage 274t
substitutes 343
total volume (adult) 275
transfusion see blood transfusion 
blood–brain barrier
in liver disease 291
in stroke 203
in traumatic brain injury 221
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blood count, hepatic disease 289
blood gas analysis see also carbon dioxide;
oxygen
acceptable values 182
capnography 17, 18–19
postanesthetic 394
pulse oximetry 17–18, 17f
blood glucose
disturbance 62, 243–245 see also
hyperglycemia; hypoglycemia 
target level 243
blood pressure
arterial waveform 25
determinants 412–413
elevated see hypertension 
“fallacy of” 26f
low see hypotension 
massive blood transfusion and 281
mean arterial see mean arterial pressure
(MAP)
monitoring
invasive 24–26
noninvasive 17, 19
poisoning 362t
pulse pressure 26
blood products 72, 273–285 see also blood
transfusion
alternatives 283–285
clotting factors 273, 277t
coagulopathy and DIC management 270–271
contents 274t, 278t
cryoprecipitate 72, 273, 278–279
dosing guidelines 278t
protein contents 278t
donation 273
fresh frozen plasma 72, 273, 277–278
dosing 278t
indications 277t
immunoglobulins 273, 279
irradiation 274
leukoreduction 273–274
plasma derivatives 273, 279, 280t
platelets 72, 273, 279, 281
storage 274t, 279
trauma management 342–343
use in liver transplantation 298
blood purification, renal failure 315
blood salvage 284
bloodstream infections (BSIs), catheter-related
see catheter-related infection
blood substitutes 343
blood tests
hepatic disease 289
myocardial ischemia 147
blood transfusion 69, 71–72, 273–285 
see also blood products
ABO compatibility 275, 275t, 276
anemia 69, 275–277
autologous 273, 283–284
choice of “trigger”
consensus statements 281
critical care 276–277
perioperative 276, 277t
coagulopathy management 270–271
complications 71–72, 282, 283t
alloimmunization 281
coagulopathy 264, 265, 281
febrile 396
graft versus host reactions 71, 283t
hemolysis 72, 276, 283t
hypothermia 72, 282
infectious 72, 159, 282
leukoreduction and 274, 282
blood transfusion (Continued)
donation 273
fatality 282
gastrointestinal bleeding 
management 301
hypocalcemia and 51
informed consent 71, 371
Jehovah’s Witnesses 276, 284–285
massive 281–282
coagulopathy and 265
special issues 282t
total blood volume replacement 275
optimal hematocrit 71
special transfusion needs 273–274
trauma management 342
uncrossmatched RBCs, safety 276
blood urea nitrogen (BUN), pregnancy
changes 249
“blue bloaters” 111
blunt trauma
in the elderly 344
renal 328
B lymphocytes 255
body fluid 59–60 see also electrolytes; water;
specific components
balance 61
cardiac output and 59–60, 59f
compartments 60, 60f
hypovolemia see hypovolemia 
loss/redistribution
normal 61
in pathology 61–67
maintenance see fluid management 
normal 60–61, 60f
osmotic pressure 61
body temperature
anesthesia effects 55, 57, 395–397
circadian 54
hyperthermia see hyperthermia 
hypothalamus and 397
hypothermia see hypothermia 
normal 54
poisoning 362t
stroke patients 203
in traumatic brain injury
manipulating 229
monitoring 227
Bonanno catheter 321
bone marrow transplantation 257–258
case study 260
patterns of infection 257
bones
assessment 340 see also radiography 
fractures see fractures 
botulinum toxin 365
environmental threat 357
botulism 357
bowel see also intestines
injury, suprapubic cystostomy 323
irrigation, poisoning treatment 363
bradyarrhythmias 77t, 84–85
postoperative 416
brain see also entries beginning
cerebral/cerebro-; specific regions
abscess(es)
in congenital heart disease (adult) 154
in HIV/AIDS 259
in congenital heart disease (adult) 154
edema/swelling see cerebral edema 
herniation 207, 218
hypertension effects 139
ICP monitor placement 235
nontraumatic injury see stroke 
brain (Continued)
traumatic injury see traumatic brain 
injury (TBI) 
tumors 205
brain death
criteria 370
ethical issues 370
legal issues 379
brainstem, hemorrhage 206
Brain Trauma Foundation 339
brain tumors, intraparenchymal 
hemorrhage 205
Brater’s syndrome 68
breathing see also entries beginning
respiration/respiratory; lung
assessment 339
Cheine–Stokes respiration 218
postanesthetic complications 393–395, 393t
hypoventilation 393–394
pregnancy 248
rate, poisoning 362t
respiratory muscles 111, 190, 401
spontaneous 111–112
thermal injury/smoke inhalation 347–348
thoracic trauma and 409
“breath stacking” 183, 184
bretylium, in hypothermia 57
British Anti-Lewisite (BAL) 357
bromocryptine, neuroleptic malignant
syndrome treatment 56
bronchiectasis, thermal injury/smoke
inhalation 348
bronchoalveolar lavage, ventilator-associated
pneumonia diagnosis 169
bronchodilators see also specific drugs
pneumonia management 173
ventilator weaning and 191
bronchopleural fistula
pulmonary surgery complications 407
radiography 403
bronchopneumonia 160, 161f
bronchoscopy
thermal injury/smoke inhalation 347
thoracic trauma 409
ventilator-associated pneumonia 
diagnosis 169
bronchospasm, evaluation/treatment 395
Brønsted–Lowry acid definition 38
bubonic plague 355
buffers, definition 38
burns see thermal injury
C
caffeine–halothane contracture test 55
calcitonin, hypercalcemia treatment 52
calcium 51–52, 66
cardiac arrhythmias and 66, 76
coagulopathy 269
drug interactions 51
homeostasis 51
hormonal regulation 240
in hyperalbuminemia 67
low see hypocalcemia 
normal plasma levels 51
raised see hypercalcemia 
calcium channel blockers 101
angina treatment 147
atrial fibrillation 81, 82t
hypertension management 140–141, 
415, 415t
multifocal atrial tachycardia 82
Index 425
calcium channel blockers (Continued)
poisoning 364
pulmonary surgery and 406
stroke management 199
subarachnoid hemorrhage and 211
calcium chloride
hyperkalemia treatment 65
hypocalcemia treatment 66
hypotension management 414t
calcium gluconate
hyperkalemia treatment 50, 65
hypermagnesemia treatment 53
hypocalcemia treatment 66
caliculi, renal 309
calorimetry 112
Campylobacter jejuni infections, 
GI bleeding 305
Canadian Stroke Consortium, rt-PA use in
stroke 202
cancer see malignancy
Candida infections
catheter-related 118, 121
cell-mediated immunity and 254
neutropenia 253
capacity 367, 370
consent and 377
capnography 17, 18–19
carbamazepine, poisoning 363
Carbicarb 42, 43
carbohydrates, nutritional requirements 107
carbon dioxide
and acid–base balance 40
monitoring 17, 18–19
partial pressure (PaCO2)
cerebral autoregulation and 220
cyanotic heart defects 156
manipulation see hyperventilation,
manipulation of PaCO2
respiratory failure 11–12
carbon monoxide
diffusion capacity (DLCO) 401
poisoning 18, 364
effects of 347
hyperbaric oxygen therapy 364
pulse oximetry 18
smoke inhalation 346, 347
vital signs 362t
carboxyhemoglobin 18
smoke inhalation 346
cardiac abnormalities
in HIV/AIDS 259–260
postoperative 413
cardiac action potential 74, 74f
cardiac arrest arrhythmias 77t, 78–80
cardiac arrhythmias 73–88 see also specific
arrhythmias
abnormal automaticity 75
bradyarrhythmias 77t, 84–85, 416
cardiac arrest 77t, 78–80
classification 77, 77t
congenital defects 156
atrial septal defects 151
tetralogy of Fallot 152
tricuspid atresia/single ventricle 153
diagnosis 78
droperidol contraindications 392
drug-induced 66, 76–77, 77t, 91, 130
electrophysiology 74–75, 74f
in hepatic disease 292
hypothermia-induced 57, 396
management 406
basic principles 78
cardioversion 79, 81, 83, 84
cardiac arrhythmias (Continued)
defibrillation 79
drugs see antiarrhythmic drugs 
implantable devices 85–88, 87f
metabolic disturbances 75t, 76
acid–base 68, 76
calcium 66, 76
implantable devices and 86, 88
magnesium 65, 76
potassium 50, 76
postoperative 416–417
pulmonary surgery 401–402, 406
reentry 74, 83
risk factors 75–77, 75t
structural heart disease 75t, 76
in subarachnoid hemorrhage 212
supraventricular 77t, 80–83
thermal injury 349
thoracic trauma 409
triggered activity 75
ventricular 77t, 83–84
cardiac assessment, preoperative 145f
cardiac complications
postoperative 413
pulmonary surgery 401–402, 406,
407–408
in subarachnoid hemorrhage 212
cardiac contractility 30, 412
electrophysiology 74, 74f
measures 32
cardiac contusions 409
cardiac cycle 74, 74f
cardiac drugs see also specific types
agitation and anxiety 124t
antiarrhythmic see antiarrhythmic drugs 
drug interactions 148
cardiac ejection fraction, TEE 36
cardiac failure see heart failure
cardiac filling volume 59
cardiac herniation, post-pulmonary surgery
407–408
cardiac index (CI) 32
cardiac monitoring see also hemodynamic
monitoring
ECG see electrocardiography (ECG) 
trauma 343
cardiac output 29
in anemia 275–276
determinants 30, 30f, 31f, 412
fluid administration and 59–60, 59f
measurement 31–35, 33f
pregnancy 248
cardiac pacing 85–86
clinical management 86–88, 87f
permanent 85–86
third-degree heart block 85
transcutaneous pacing 85
transvenous pacing 85
cardiac reserve, elderly patients 344
cardiac risk assessment 143–144
cardiac surgery
anesthesia 146
blood loss 284
CRRT after 313–314
ischemia/infarction risk 143–144, 148
medication and 144, 146
preoperative assessment 145f
preoperative preparation 144–146
sedation in 146
cardiac tamponade 31, 34
cardiogenic pulmonary edema 406
cardiogenic shock 30–31
vasopressin 97
cardiomyopathy
blood transfusion in 71
hypertensive 139
cardiopulmonary bypass, platelet 
dysfunction 265
cardiopulmonary resuscitation (CPR), cardiac
arrhythmias 80
cardiopulmonary support, in liver
transplantation 298
cardiopulmonary system 137–194 see also
circulation; heart; lung
anemia and 275–276
ARDS 176–180
ARF 11–16
congenital heart disease 150–156
in hepatic disease 292–293
in HIV/AIDS 259–260
hypertension effects 138–139
ischemic heart disease see myocardial
ischemia/infarction 
mechanical ventilation see mechanical
ventilation 
monitoring 17 see also hemodynamic
monitoring 
pneumonia see pneumonia 
in pregnancy 248
in subarachnoid hemorrhage 212
trauma, primary assessment 339
cardioversion 79
atrial fibrillation 81
external, implantable devices and 88
implantable cardioverter 
defibrillator 86
paroxysmal supraventricular 
tachycardia 83
Torsade de pointes 84
Wolff–Parkinson–White syndrome 81
carotid endarterectomy 204
case mix 381
casuistry 370
catecholamines 89–97 see also individual
amines
adrenal secretion 240
arrhythmia induction 77, 91
drug interactions 97
pheochromocytoma production 245
safety 94
in sepsis/septic shock 89–97
comparative studies 95–96t
drug choice 94–97
cathartics, poisoning treatment 363
catheter-related infection 21–22, 117–122 
see also specific infections/organisms
clinical factors 118
diagnosis 121
management 121–122
microbiology/common organisms 118
pathogenesis 117–118
prevention strategies 118–121
antibiotic/antiseptic impregnation
120–121
anticoagulation 120
aseptic technique 119–120
catheter care 121
insertion site 118–119
prophylactic antibiotics 120
site dressing 120
site preparation 119
specialized teams 121
rate 22
risk factors 118
tip infection vs. colonization 22, 22t
in traumatic brain injury 231
426 INDEX
catheters see also specific types
anaphylaxis induction 120
care 121
central venous see central venous catheters
(CVCs) 
cystourethroscopy 319, 320, 321f
fluid flow through 27–28, 69, 71
French size 28, 319
ICP monitors 235
impregnation of 120–121
infection see catheter-related infection 
pulmonary see pulmonary artery 
catheter (PAC) 
radiological verification 23–24
suprapubic cystostomy 321, 322f
placement 322, 323f
thrombosis induction 24
urethral 317, 318f
urinary 332
cation exchange, hyperkalemia treatment 50
cations, definition 61
caudate, hemorrhage 206
cavernous angiomas, hemorrhage 205
cavitation, pneumonia 160
CD4 cell counts 254
HIV/AIDS 258, 259
CD8 cells 254
CD14 cells, sepsis pathophysiology 5
cefotaxime, dialysis and 315t
ceftazidime, dialysis and 315t
ceftriaxone
dialysis and 315t
hospital-acquired pneumonia 167
cefuroxime, hospital-acquired pneumonia 167
cell-mediated immunity 254–255
in HIV/AIDS 258
Centers for Disease Control (CDC),
pneumonia definition 157
Centers for Medicare and Medicaid Services
(CMS) 380
central (neurogenic) diabetes insipidus 242
central nervous system (CNS) see also brain;
entries beginning neural/neuro-
hypertension effects 139
hypomagnesemia effects 52–53
infection
complement deficiencies 255
in HIV/AIDS 258, 259
humoral defects 255
monitoring 233–236
nontraumatic injury 195–213
postoperative events 398–399
traumatic injury
brain see traumatic brain injury (TBI) 
spinal cord 340, 341f, 342
central pontine demyelination 48, 64
central venous catheters (CVCs) 19, 26–30
complications
DVT 119
infections see catheter-related infection 
pneumothorax 23, 29, 109
CVP monitoring 29–30, 30f
fluid flow through 27–28, 69, 71
French size 28
insertion 27, 27f
in myocardial ischemia 146
parenteral nutrition 109
peripherally inserted (PICC lines) 27
positioning/placement 21, 28–29, 118–119
approaches 28, 28f, 119
infection prevention 118–120
malpositioning 23
radiological verification 23–24
central venous catheters (CVCs) (Continued)
Seldinger technique 28, 29
site preparation 119
ultrasound use 28–29
preparation 20
site dressing 120
uses/importance 26–28
central venous pressure (CVP) 28, 412
monitoring 29–30
trauma, monitoring 343
waveform 29, 30f
cephalic vein 27f
cephalosporin, hospital-acquired 
pneumonia 167
cerebellum
hemorrhage 206–207
herniation 218
infarction 197
neurological assessment 233
cerebral aneurysms
anesthesia and 140
intraparenchymal hemorrhage 205
subarachnoid hemorrhage 208–209
cerebral angiography 210
cerebral arteries
anterior circulation 196–197
occlusion see ischemic stroke 
cerebral blood flow
anesthesia and 398
anterior circulation 196–197
autoregulation 219–220
carbon dioxide 220
factors affecting 219, 220
stroke and 203
cerebral perfusion pressure see cerebral
perfusion pressure (CPP) 
intracranial pressure see intracranial
pressure (ICP) 
obstruction/occlusion see ischemic stroke 
in trauma 219–221, 229
anesthesia and 224
hyperemia 219
hypoperfusion 219
monitoring 226–227
vasospacticity 219
vasoconstriction cascade 221
vasodilation cascade 220–221
cerebral edema 217–218 see also intracranial
hypertension
cytotoxic 217, 218
glucose administration and 62
hyponatremia 47
interstitial 217, 218
vasogenic 217, 218
cerebral embolization
in congenital heart disease (adult) 154
postoperative 398
cerebral hemorrhage 195, 204–212
classification 196
congenital heart disease and 154
intraparenchymal see intraparenchymal
hemorrhage 
neurologic monitoring complication 235
subarachnoid see subarachnoid 
hemorrhage 
cerebral ischemia see ischemic stroke
cerebral perfusion pressure (CPP) 199, 220,
224, 229, 234
in hepatic encephalopathy 291
cerebral salt wasting syndrome 212
cerebrospinal fluid (CSF)
analysis in HIV/AIDS 259
drainage 228, 235
cerebrospinal fluid (CSF) (Continued)
elevated ICP 234
hydrocephalus 218–219
cerebrovascular disease 195–213
stroke see stroke 
cervical spine, assessment 340, 341f
Charcot Bouchard aneurysms, hemorrhage 205
Chediak–Higashi syndrome 253
Cheine–Stokes respiration 218
chemical incidents/weapons 354, 356–359
agents 357–358, 365
antidotes 358, 359, 365
burns 347
management principles 358–359, 365
chemotherapy, neutropenia 253
chest drainage 403, 403f
chest physiotherapy, post-pulmonary 
surgery 404
chest radiography
ARDS 177
pneumonia diagnosis 160–161, 160f, 171
“ground glass” appearance 171f
“honeycomb” appearance 172f
interpretation 174–175
post-pulmonary surgery 403, 404f
thermal injury/smoke inhalation 347
thoracic trauma 409
chickenpox, smallpox vs. 356
Child–Pugh score (CPS) 288, 288t
children, sedation in 130, 131
chlorhexidine
catheter impregnation 120
catheter insertion 119
chloride ions 65
acid–base physiology 41–42, 68, 69
hyperkalemia treatment 65
chlorine gas 358, 365
chloroacetophenone 358
chloropicrin 358, 365
cholecystectomy, avoidance in cirrhosis 290
choledochocholedochostomy 297
cholestasis, cirrhosis and 286, 287t
chronic lymphatic leukemia (CLL), humoral
defects 255
chronic obstructive pulmonary disease 
see COPD
Chvostek’s sign 66
cingulate gyrus, herniation 218
ciprofloxacin
anthrax 355
dialysis and 315t
Y. pestis infection 355
circadian rhythm, body temperature 54
circulation
assessment 339
failure (shock) see shock 
hepatic disease and 292
ketamine-induced hyperdynamic 
response 131
cirrhosis 286–299 see also fulminant hepatic
failure (FHF)
cholecystectomy avoidance 290
classification 286, 288, 288t, 289t
clinical manifestations 290–296
cardiovascular 292
coagulopathy 289, 296
encephalopathy 290–292, 291t
gastrointestinal 293–295
immunologic 296
pulmonary 292–293
renal 295
definition 286
diagnostic studies 289–290, 290t
Index 427
cirrhosis (Continued)
etiology 286–287, 287t
hyponatremia 48
liver transplant in see liver transplantation 
NSAID avoidance in 294
cisatracurium 133, 133t
citrate anticoagulation, in CRRT 313
Citrobacter spp. infections, ventilator-
associated pneumonia 168
clarithromycin, pneumonia management 172
clindamycin, pneumonia management 172
clinical audit, scoring systems 381
clinical guidelines
cryoprecipitate dosing 278t
pneumonia treatment 157–158
community-acquired 163, 164t
quality and 374
sedation 126, 129
transport to and from ICU 419–420
clinical pulmonary infection score 
(CPIS; Pugin score) 170
clonidine 140
myocardial ischemia prevention 146
stroke management 198–199
closing volume (CV), post-thoracic surgery 404
Clostridium botulinum 357
Clostridium difficile infection
enteral nutrition and 108, 109
gastrointestinal bleeding 305
Clostridium septicum infections, 
neutropenia 253
Clostridium tetanii 357
clotting factors see also specific factors
blood products 273, 277t
coagulation cascade 261, 262
coagulation role 262
deficiency 72, 266, 278
laboratory assays 269
trauma management 343
coagulase-negative staphylococci, 
catheter-related infections 118
coagulation 261–272 see also hemostasis;
specific components
congenital heart defects (adult) and 155
dysfunction see coagulopathies 
evolution 262
physiology 261–262
sepsis pathophysiology 7
coagulopathies 261–272, 277 see also specific
conditions
blood transfusion-induced 264, 281, 282t
cerebral hemorrhage 207–208, 235
clinical findings 267
hepatic disease 289, 296
hypercoagulopathy 266–267 see also
thromboembolism; thrombosis 
hypocoagulopathy
acquired 264–266
congenital/inherited 263–264
hypothermia-induced 396
laboratory findings 267–269, 268t, 
in liver transplantation 298
management see also thrombolysis 
anticoagulants see anticoagulation 
blood products 72, 277–279, 277t
sepsis pathophysiology 7
vascular access and 20
coarctation of the aorta 153–154
cocaine, poisoning 362t, 364
Coccidioides immitis, pneumonia 
165–166, 166f
coccidiomycosis, cell-mediated immunity 
and 254
cockpit resource management 373
coding 379–380
colitis gastrointestinal bleeding 305
collagen disease, acute renal failure 
and 311
colloids 69
composition 71t
crystalloids vs. 279
pneumonia management 172
sepsis management 8
stroke management 202
thermal injury 349
traumatic brain injury management 230
colon, gastrointestinal bleeding 301, 
304–305
colonoscopy, liver disease 290
colorectal cancer, gastrointestinal bleeding
301, 305
color-flow mapping 36
coma
diffuse axonal injury 217
extradural hematoma 216
postoperative hyperglycemic 398
command posts, disaster management 353
communication
postoperative transport and 418
skills 368
community-acquired pneumonia (CAP)
162–164
atypical 163–164
risk 162, 163t
treatment
antibiotics 163
guidelines 163, 164t
typical 162–163
compartment syndrome, electrical burns
349–350
compassion 368
competence, consent and 377
complement system 255–256
deficiencies 255, 296
compressed spectral array (CSA) 236
computed tomography (CT)
ARDS 177
brain hemorrhage
intraparenchymal 207
subarachnoid 210
liver disease 290
stroke 200
trauma assessment 342
bladder trauma 332
indications 223
renal trauma 329
traumatic brain injury 223–224
computerized physician order entry 
(CPOE) 373
Confusion Assessment Method for the ICU
(CAM-ICU) 125–126
confusion, postoperative 398
congenital heart defects (CHD) see also
specific defects
in adults 150–156
management 155–156
arrhythmia and 151, 152, 153, 156
classification 150–154, 151t
acyanotic 150–152, 151t, 155
cyanotic 151t, 152–153, 155–156
obstructive 151t, 153–154, 156
noncardiac complications 154–155
hematologic 154–155
neurologic 154
pulmonary 154
renal 155
congestive heart failure
coarctation of the aorta 153
enalaprilat 102
hyponatremia 48
consciousness see also coma
brain shift and 207
extradural hematoma effects 216
intracranial hypertension 212
intraparenchymal hemorrhage 205, 207
scale see Glasgow Coma Scale (GCS) 
subarachnoid hemorrhage 209, 212
consent 377–378
informed see informed consent 
constrictive pericarditis, CVP 30
containment 353, 358
continuing medical education (CME) 374
continuous hemofiltration
acute renal failure 312–313
veno-venous (CVVH) 312–313
in hepatorenal syndrome 295
continuous positive airway pressure (CPAP)
186, 187
hypoxic respiratory failure 13
postanesthetic 395
continuous quality improvement (CQI)
process 374
scoring systems 375
continuous renal replacement therapy 
(CRRT) 312
acute renal failure 312–314
anticoagulation during 313–314
case study 313–314
drug prescription and 315t
outcomes 313
continuous veno-venous hemofiltration
(CVVH) 295, 312–313
contraction stress test (CST), 
fetal monitoring 249
controlled mechanical ventilation (CMV) 
183, 183t
contusions
brain 216
heart 409
lung 409
conversion of mass 40
cooling techniques 54
controversy 55
Coomb’s test 72
COPD
blood transfusion in 71
“blue bloaters” 111
“pink puffers” 111
pneumonia management in 173
postoperative hypoventilation 393
pulmonary surgery and 402
radiography difficulties 160
respiratory failure
hypercapnic 14, 15
nutritional support 111–112
ventilatory support 111–112
Cori cycle, lactic acidosis 45
coronary artery bypass graft 144
coronary steal syndrome
hydralazine-induced 100
sodium nitroprusside-induced 98
corticosteroid-binding globulin 110
corticosteroids see also individual steroids
agitation and anxiety 124t
ARDS management 179
in intraparenchymal hemorrhage 208
lung transplantation 408
neuromuscular blockade and 132
pneumonia management 173
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corticosteroids (Continued)
PONV prevention/treatment 392
postoperative pulmonary care 405t
preoperative, adrenal insufficiency 242
sepsis management 9
spinal cord injury 340
thyroid storm management 239
cortisol 240
Corynebacterium jeikeium infections,
neutropenia 253
co-trimoxazole, dialysis and 315t
Coudé catheter 319
Council-tipped catheters 320, 321f
Coxiella burnetii 356
atypical pneumonia 164
cranial nerves, neurological assessment 233
craniectomy, decompressive 200, 229
creatine clearance, glomerular filtration rate
307–308
credentialing 19–20, 374
Creutzfeldt–Jakob disease (CJD)
needlestick injuries 23
transfusion-related 72, 282
crew (cockpit) resource management 373
cricothyroidotomy 339
crisis incident stress disorder (CISD), natural
disasters 354
critical care, HCFA definition 379
critically ill patients
erythropoietin deficiency 69
fever 162
neurological status 233
Crohn’s disease, gastrointestinal bleeding 305
cryoprecipitate 72, 273, 278–279
coagulopathy and DIC management
270–271
dosing guidelines 278t
plasma proteins 278t
storage 274t
trauma management 342–343
Cryptococcus neoformans infection
cell-mediated immunity and 254
in HIV/AIDS 258
in the immune-compromised 170, 171f
transplantation and 256
crystalloids 68–69
colloids vs. 279
composition 70t
hypotension management 413
sepsis management 8
stroke management 202
trauma management 342
traumatic brain injury 222, 230
CS gas 358
curare 132
Cushing reflex, intraparenchymal hemorrhage
and 205
Cushing’s syndrome
alkalosis and 68
hypertension 138
hypokalemia and 65
cyanide toxicity/poisoning 365
metabolic acidosis 346
smoke inhalation 346, 347
sodium nitroprusside-induced 98–99
cyanogens 358
cyanotic heart defects 151t, 152–153
critical care in 155–156
tetralogy of Fallot 152
transposition of great arteries 152–153
tricuspid atresia/single ventricle 153
cyclooygenase enzymes, NSAIDs and 128, 390
cyclopropane, PONV and 391
cyclosporine, lung transplantation 408
cyproheptadine, serotonin syndrome 56
cystography, bladder trauma 332
cystoscope 319, 320f
cystourethroscopy 319–321
anticoagulation and 320
catheters 319, 320, 321f
cystoscope 319, 320f
urinary tract infection and 320–321
cytokines
burns pathophysiology 346
sepsis pathophysiology 7
cytomegalovirus (CMV) infection
cell-mediated immunity and 254
in HIV/AIDS 260
in the immune-compromised 170
lung transplantation and 409
needlestick injuries 23
transfusion-related 72
transplantation and 256, 257
cytotoxic cerebral edema 217, 218
D
damage(s), legal definition 377
Dantrolene sodium
malignant hyperthermia treatment 
55, 397
neuroleptic malignant syndrome 
treatment 56
dapsone, poisoning, treatment 363
DDAVP see 1-deamino-8-D-arginine
vasopressin (DDAVP)
D-dimer test 262, 269–270
deadspace ventilation 14
1-deamino-8-D-arginine vasopressin 
(DDAVP) 265
diabetes insipidus treatment 242
hemophilia A treatment 278, 284
hypernatremia treatment 63
platelet dysfunction treatment 279
von Willebrand’s disease treatment 278,
280t, 284
decision-support systems 373
decompressive craniectomy 200, 229
decontamination 359
deep vein thrombosis (DVT)
central line placement 119
hypercoagulable states 266–267
in malignancy 267
in pregnancy 249, 250–251
in stroke 204
thrombolysis 267
trauma-induced, prophylaxis 341
in traumatic brain injury 231
“deerfly fever” 355
defibrillation
external, implantable devices and 88
in hypothermia 57
implantable cardioverter defibrillator 86
ventricular fibrillation 79
delirium, postoperative 398–399
density spectral array (DSA) 236
deoxyhemoglobin 17
Department of Justice, HIPPA violation
penalty 379
depolarizing drugs 132–133
desflurane, in liver transplantation 297
desmopressin see 1-deamino-8-D-arginine
vasopressin (DDAVP)
device for noninvasive automatic mean
arterial blood pressure (DINAMAP) 19
dexamethasone
adrenal insufficiency 242
PONV prevention/treatment 392
postoperative pulmonary care 405t
dexmetomidine 131
hypertension management 140
myocardial ischemia prevention 146
during vascular access 21
dextrans
massive blood transfusion and 281
in thermal injury/smoke inhalation 349
dextrose, hyperkalemia treatment 311
diabetes insipidus 242
hypernatremia 49, 63
diabetes mellitus
acute papillary necrosis 326
emphysematous pyelonephritis 326
hypertension and 139, 141
postoperative complications 398
type II, nonketotic hyperosmolar syndrome
244–245
type I, ketoacidosis 42, 50, 243–244
diabetic ketoacidosis (DKA) 243–244
hypokalemia 50, 244
management 42, 244
nonketotic hyperosmolar syndrome 
vs. 245
diagnostic peritoneal lavage, trauma
assessment 341
dialysis see also hemodialysis
acute renal failure 311, 312, 314, 315
drug prescription and 315, 315t
membranes 314
peritoneal 312, 314
diarrhea, enteral nutrition and 108, 109
diazepam 128
dibenz(b,f)-1,4-oxazepine 358
dichloroacetate, acidosis treatment 43
diffuse axonal injury 217
diffusion capacity of carbon monoxide
(DLCO) 401
diffusion limitation hypoxemia 11, 12
digibind, in digoxin poisoning 365
digoxin
atrial fibrillation 81, 82t
poisoning 364–365
pulmonary surgery and 406
dihydropyridines 101
diltiazem
atrial fibrillation 82t
hypertension management 140–141, 415t
multifocal atrial tachycardia 82
pulmonary surgery and 406
dilutional acidosis 41–42
Dimercapterol 357
DINAMAP (device for noninvasive automatic
mean arterial blood pressure) 19
diphosgene 358
“dirty” bombs 359
disability
trauma, primary assessment 339
traumatic brain injury 214
disaster, definition 353–354
disaster management assistance teams
(DMATs) 353
disaster medicine 352–360 see also
environmental threat; specific threats
containment 353, 358
decontamination 359
management principles 353–360
biological weapons 354–356
conventional weapons 354
natural disasters 353–354
Index 429
disaster medicine (Continued)
nuclear incidents 359
toxins/chemicals 356–359
disaster plans 353
discharge, against medical advice 377
dissecting aneurysms, subarachnoid
hemorrhage 209
disseminated intravascular coagulation (DIC)
261–272
acute 262, 268t
amniotic fluid embolus 250
chronic 262, 268t
compensated 262
diagnosis/differential diagnosis 270
in hepatic disease 296
laboratory findings 268t, 270
pathophysiology 262–263
sepsis and 7
treatment 270–271
“dissociative state,” ketamine-induced 131
distribution curves, scoring systems 375
diuresis
drugs see diuretics 
hypernatremia 49
osmotic 49, 62, 199, 223, 228
diuretics
acute renal failure and 310–311, 312
drug interactions 293
in heart failure, nesiritide vs. 103
in hepatic disease 293
hypercalcemia treatment 52
hypertension management 141, 415, 415t
anesthesia and 140
hypo-osmolar hyponatremia 48
diverticulosis
gastrointestinal bleeding 304
hemodynamic instability 417
dobutamine 97
acute renal failure and 310
heart failure, nesiritide vs. 103
norepinephrine combination 92
dolasetron, PONV prevention/treatment 392
do-not-resuscitate (DNR) orders 370, 
378–379
classification 378
dopamine 90–91
acute renal failure and 310
adverse effects 91
dosage 90
hypotension management 414t
in hypothermia 57
in postoperative bradycardia 416
in sepsis/septic shock 8, 90–91, 90t,
95–96t, 97
stroke management 202
dopamine agonists 101
in neuroleptic malignant syndrome 56
dopamine antagonists, PONV
prevention/treatment 392
Doppler principle, blood pressure 
monitoring 19
Doppler ultrasound
hemodynamic monitoring 35–36
stroke 200
dorsalis pedis artery, cannulation 24
doxycycline
Coxiella burnetii infection 356
Y. pestis infection 355
dreams, ketamine-induced 131
droperidol, PONV prevention/treatment 392
drotrecogin-alfa (activated), sepsis
management 8–9
contraindications/cautions 9t
drug-induced conditions
acute renal failure 309
cardiac arrhythmias 75t, 76–77, 91
haloperidol 130
hypocalcemia treatment 66
hepatic failure 287–288, 288t, 363–364, 369
hyperthermia 54, 55–57
anticholinergic syndrome 56–57
malignant hyperthermia 55, 397
neuroleptic malignant syndrome 55–56
serotonin syndrome 56
sympathomimetic poisoning syndrome 56
hypoglycemia 62
neuroleptic malignant syndrome 55–56,
130, 397
platelet dysfunction 270
thrombocytopenia 24, 72, 264–265, 281, 313
drug interactions
agitation and anxiety 124, 124t
atenolol 140
beta-blockers 148, 246
calcium ions 51
catecholamines 97
dexamethasone 242
diuretics 293
gancyclovir 259
hepatotoxicity 288
neuromuscular blockers 134
potassium ions 50
thyroxine and triiodothyronine 238
drug prescription, during dialysis 315, 315t
drug tolerance
analgesics 389
neuromuscular blockade 132
nitroglycerin 99
dura mater, lesion 216, 217
dynamic hyperventilation 183
E
Ebola virus 356
echocardiography 35–36
congenital heart defects (adult) 155
myocardial ischemia 146–147
stroke 200
trauma 343
eclampsia 250
economics 372
trauma 337
edema
cerebral see cerebral edema 
hyponatremia 47, 48
laryngeal, postanesthetic 395
pregnancy 250
pulmonary see pulmonary edema 
“third space” loss 62
edrophonium, PONV and 391
Eisenmenger’s disease 150, 154
elderly patients
postoperative hypothermia 396
pulmonary surgery and 402
residual anesthesia effects 397
trauma resuscitation 343–344
electrical burns 349–350
electrocardiography (ECG) 17
cardiac arrhythmias
asystole 80, 80f
atrial fibrillation 80, 80f
atrial flutter 80, 80f
diagnosis 78
heart block 84, 84f, 85
junctional tachycardia 83
electrocardiography (ECG) (Continued)
multifocal atrial tachycardia 82, 82f
paroxysmal supraventricular tachycardia
82f, 83
pulseless electrical activity 79, 80f
Torsade de pointes 83, 83f
ventricular fibrillation 79, 79f
Wolff–Parkinson–White syndrome 81, 82f
cardiac cycle 74, 74f
implantable cardiac devices 86
myocardial ischemia diagnosis 146
in stroke 200
in subarachnoid hemorrhage 212
electrocautery, implantable cardiac devices 86
electrocoagulation, implantable cardiac
devices 86
electroencephalography (EEG) 235–236
bispectral analysis 227, 236
somatosensory evoked potentials 227
in stroke 200
in traumatic brain injury 227, 229
waveforms 236
electrolytes see also acid–base physiology;
fluid management; specific electrolytes
average body content 60t
cardiac arrhythmias and 50, 65, 66, 68, 
75t, 76
implantable devices 86, 88
chloride ions 41–42
colloids 71t
crystalloids 68–69, 70t
definitions 61
diabetic ketoacidosis 244
distribution 61
disturbance 51–54, 62–67
neuromuscular blockade and 134
nonketotic hyperosmolar syndrome 245
regulation/homeostasis 59–60
stroke and 203
traumatic brain injury and 230–231
electroneutrality 40
electronic data interchange (EDI) 379
electronic medical records 373, 379
elevated white blood cell count, 
hepatic disease 289
emphysema, hypoxemia 12
emphysematous pyelonephritis 326
enalaprilat 102, 141
characteristics 104t
hypertension management 415t
encephalitides 356
encephalitis, in HIV/AIDS 259
encephalopathy, hepatic see portosystemic
encephalopathy (PSE)
endocarditis, ventral septal defects and 150
endocrine dysfunction 237–247 see also
specific conditions
case study 246
in the critical patient 237, 246
hypertension and 138
hyperthermia and 396–397
parenteral nutrition and 110
endoscopy, GI bleeding 294, 302
endothelial cells, coagulation role 261
endotoxin, sepsis pathophysiology 5
endotracheal intubation see intubation
energy balance 106–107
energy expenditure 106–107
acute respiratory failure 111
total (TEE) 112
enflurane, in traumatic brain injury 225
Entamoeba histolytica, gastrointestinal
bleeding 305
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enteral nutrition 108–109
parenteral and 110
total (TEN) 110
in traumatic brain injury 231
enteric feeding, pneumonia 
management 172
enteric Gram-negative bacteria (EGNB)
hospital-acquired pneumonia 167
ventilator-associated pneumonia 168
Enterobacteriaceae infections
catheter-related 118
ventilator-associated pneumonia 168
Enterococcus spp. infections, catheter-related
22, 118
environmental threat 352–360 see also
disaster medicine; specific threats
biological 354–356
containment 353, 358
conventional weapons 354
decontamination 359
food and water supplies 360
identification of 354
natural disasters 353–354
nuclear 359
toxins/chemicals 356–359
types 352–353
enzyme-linked immunosorbent assay 
(ELISA)
HIT test 270
HIV diagnosis 258
pneumonia diagnosis 163
ephedrine, hypotension management 414t
epidural analgesia, post-thoracotomy 406
epidural space, ICP monitors 235
epilepsy see seizures
epinephrine 92–93
adverse effects 93
asystole 80
effects on MAP 92
hypotension management 414t
in postoperative bradycardia 416
postoperative pulmonary care 405t
in sepsis/septic shock 92–93, 95–96t
during vascular access 20
ventricular fibrillation 79
epithelial damage, pneumonia risk 159
epsilon aminocaproic acid 284
Epstein–Barr virus (EBV), transplantation 
and 256
error management 372
erythrocytes see red blood cells
erythromycin
dialysis and 315t
pneumonia management 173
erythropoietin
deficiency, critically ill patients 69
Jehovah’s Witnesses 285
preoperative use 284
escharotomy, chest burns 348, 348f
Escherichia coli infections
catheter-related 118
gastrointestinal bleeding 305
neutropenia 253
ventilator-associated pneumonia 168
esmolol 140
anesthesia and 139
atrial fibrillation 82t
hypertension management 415t
pulmonary surgery and 406
esophagogastroduodenoscopy (EGD), liver
disease 290
esophagus
diverticuli, pneumonia risk 159
esophagus (Continued)
ultrasound, hemodynamic monitoring 35
see also transesophageal
echocardiography (TEE) 
varices, octreotide 302
ether, PONV and 391
ethical issues 367–380 see also legal issues;
quality issues
adult live donor liver transplantation
(aLDLT) 298
brain death 370
capacity 367, 370
casuistry 370
consent see consent 
elderly trauma victims 344
ethical principles 367–370
arguments 369
autonomy 367–368, 369
beneficence/nonmaleficence 
368, 369
case studies 369–370
justice 368–369
futility 371
health care agents, choice 371
informed consent 20, 71, 371
Jehovah’s Witnesses 369
living wills 367
patient safety 372–373
pharmaceutical industry and 371
principles 367–370
arguments 369
autonomy 367–368, 369
beneficence/nonmaleficence 368, 369
case studies 369–370
confidentiality 379
justice 368–369
quality of care 373–375
scoring systems 375–376, 381–386
transplantation 369–370
etidronate disodium, hypercalcemia 
treatment 52
etomidate 131
during vascular access 21
euglobulin lysis time 270
euthanasia (physician-assisted) 378
evidence-based medicine
quality issues 374–375
scoring systems 375
excitotoxicity, cerebral ischemia 218
exercise tests 401
expectorants, pneumonia management 173
explosives 354
express consent 377
Extended Glasgow Outcome Scale 232
extended-spectrum beta-lactamases (ESBL),
ventilator-associated pneumonia 168
external jugular vein, cannulation 28
extracellular fluid (ECF) 60
hypernatremia and 49
hyponatremia and 47–48
loss 61
osmolality 47, 48t
spaces 62
extracorporeal membrane oxygenation
(ECMO), lung transplantation 408
extradural hematoma 216
extrapulmonary sepsis, pulmonary 
edema vs. 406
extubation, stress 139, 140
eye
burns 347
opening, GCS scoring 234
pupillary responses, poisoning 362t
F
factor II deficiency 72
factor IX
assay 269
coagulation role 262
deficiency 72
factor IXa, assay 269
factor V
assay 269
deficiency 72, 266
Leiden variant 266
factor Va, coagulation role 262
factor VIIa
coagulation role 262
recombinant 271, 284
trauma management 343
factor VII deficiency 72
factor VIII
assay 269
coagulation role 262
deficiency 72, 278
factor X
coagulation role 262
deficiency 72
factor Xa
assay 269
coagulation role 262
factor XI
coagulation role 262
deficiency 72, 280t
factor XIa, assay 269
factor XIII
coagulation role 262
deficiency 72, 278
False Claims Act 379–380
famotidine, pneumonia management 173
fat embolism 263
fatty acids
immunonutrition 114–115
nutritional support in sepsis 112
stress response 114
fatty liver of obesity 286
fatty liver of pregnancy, acute 250
febrile conditions see fever
Federal Privacy Act (1974) 379
feeding solutions, enteral nutrition 108
feeding tubes, enteral nutrition 108
femoral vein, catheterization 28, 29
fenoldopam 101–102
characteristics 104t
fentanyl 127
postoperative pain management 390
during vascular access 21
fetal monitoring 249
fever 54, 396 see also hyperthermia
in the critically ill patient 162
neutropenic 253
fibrin, coagulation role 261
fibrin glue 278–279
fibrinogen
assay 268t, 269
gastrointestinal bleeding and 301
fibrinolysis 261
coagulation role 262
disseminated intravascular coagulation 263
hypocoagulable states 265–266
inhibitors 284
laboratory tests 268t, 267–269
postoperative 271
fibrinopeptide A assay 270
fibrin split products, coagulation role 262
fibronectin loss, pneumonia risk 159
Index 431
Fick principle 32
fiduciary duty
advance directives and 378
HIPPA 379
filovirus fevers 356
flail chest 409
flaviviruses 356
flecainide
pulmonary surgery and arrhythmia 406
Wolff–Parkinson–White syndrome 81
fluconazole, dialysis and 315t
fluid balance 61
fluid challenge 413
sepsis 8, 8t
fluid management 59–72 see also blood
products; blood transfusion; electrolytes;
water
acute renal failure 310
hepatorenal syndrome 309
cardiac output and 59–60, 59f
colloids see colloids 
colloid vs. crystalloid controversy 279
crystalloids see crystalloids 
diabetic ketoacidosis 244
nonketotic hyperosmolar syndrome 245
pneumonia treatment 171–172
in pulmonary surgery 403
lung transplants 408
purpose 59
in sepsis 7–8, 8t
stroke management 203, 211
triple-H therapy 202, 211
trauma 342–343
brain injury 221–222, 230–231
thermal injuries 348–350
flumazenil 129, 398
in benzodiazepine poisoning 364
fluoroquinolones
anthrax 355
pneumonia management 173
focused assessment with sonography for
trauma 341, 342
Foley catheter 318f, 326, 332, 340
urethral trauma due to 319
Fontan procedures 153, 154, 156
food, environmental threat and 360
forced expiratory volume in 1sec (FEV1) 401
fractures
assessment 340
pelvis 332
skull 216
thoracic 409
traumatic brain injury and 216, 219
Francisella tularensis, atypical pneumonia
164
Frank–Starling law 412
fraud 379–380
“free water”
contraindications 62, 69
deficit 49, 49t, 243
glucose effects 62
French size 28, 319
fresh frozen plasma (FFP) 72, 273, 277–278
in acute renal failure 314
coagulopathy and DIC management 270
storage 274t
trauma management 342
fulminant hepatic failure (FHF) 286–299 
see also cirrhosis
classification 286, 288, 289t
clinical manifestations 290–296
cardiovascular 292
coagulopathy 289, 296
fulminant hepatic failure (FHF) (Continued)
encephalopathy 290–292, 291t, 363, 369
gastrointestinal 293–295
immunologic 296
pulmonary 292–293
renal 295
definition 286
diagnostic studies 290t
etiology 287–288, 287t
drug toxicity see hepatotoxic drugs 
liver transplant in see liver transplantation 
mortality 296
functional residual capacity (FRC), 
post-thoracic surgery 404
fundamental critical care support,
credentialing 374
fungal infection(s) see also specific
organisms/infections
pneumonia 158t, 165–166, 166f
furosemide
hypercalcemia treatment 52
hypertension management 415t
fusiform aneurysms, hemorrhage 209
futility 371
G
GABA receptors, benzodiazepine 
effects 128
gallstones, congenital heart defects (adult) 
and 155
gamma-hydroxybutyrate (GHB), 
poisoning 362t
gamma irradiation, blood products 274
gancyclovir
dialysis and 315t
drug interactions 259
gases
blood see blood gas analysis 
smoke inhalation 346–347
gas exchange, assessment 401
gastric decompression 340
gastric emptying, poisoning treatment 362
gastric lavage, poisoning treatment 362–363
gastric tonometry, trauma patients 338
gastric ulcers, NSAIDs and 301
gastritis, stress
burns 351
prophylaxis in trauma 341
gastroesophageal reflux, in pregnancy 249
gastrointestinal bleeding 300–306
case study 305
cirrhosis-associated 294
definitions 300
history 301
lower 300, 304–305
causes 301, 304–305
differential diagnosis 304
management algorithm 304f
presentation 304
NSAIDs and 301, 302
physical examination 301
presentation 300
resuscitation 300–301
severity classification 300–301, 301t
trauma-related 232
upper 300, 301–303
differential diagnosis 303
management/treatment 302–303, 303f
presentation 301–302
prognosis 302
gastrointestinal mucosa, host defense 252
gastrointestinal system 286–334 see also
specific components
bleeding see gastrointestinal bleeding 
enteral nutrition and 108
in hepatic disease 293–295
host defense role 252
in pregnancy 249
general systems theory 372–373
genetic polymorphism
pneumonia pathogenesis 158
sepsis predisposition 4
genitourinary trauma 328–333
bladder 330, 332
renal 328–330
urethral 332–333
gentamicin
magnesuria 65
Y. pestis infection 355
Glanzmann’s thrombasthenia 264
Glasgow Coma Scale (GCS) 215, 222,
233–234, 339, 375, 383t
subarachnoid hemorrhage grading systems
209, 210
Glasgow Outcome Scale (extended) 232
glomerular filtration
fenoldopam effects 101–102
rate assessment 307–308
glomerular nephritis, acute renal failure 
and 311
glucagon, in postoperative bradycardia 416
glucocorticoids 240
thyroid storm management 239
in traumatic brain injury management 229
glucose
blood level disturbance 62, 243–245
diabetic ketoacidosis 243–244
hyperglycemia see hyperglycemia 
hypoglycemia see hypoglycemia 
nonketotic hyperosmolar syndrome
244–245
glycosuria in pregnancy 249
hyperkalemia treatment 50, 65
metabolism
in acute pancreatitis 114
in stroke patients 203
nutritional requirements 107
sepsis pathophysiology 112
glutamine, immunonutrition 115
glycogen 107
glycolysis, lactic acidosis 45
glycoprotein receptors, coagulation role
261–262, 262
glycopyrrolate, nerve gas antidote 365
glycopyrrolate, postoperative pulmonary care
405t
glycosuria, pregnancy 249
goiter 239
“golden hour” 337–342
graft-to-recipient standard liver volume ratio
(GSLV) 298
graft-to-recipient weight ratio (GRWR), liver
transplantation 298
graft versus host reactions
blood transfusions 71, 283t
reduction 274
bone marrow transplantation 258
Gram stain 161
granisetron, PONV prevention/treatment 392
granulocyte colony-stimulating factor (GCSF),
pneumonia management 173
granulocytes see polymorphonuclear
leukocytes
Grave’s disease 239
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guaifenesin, postoperative pulmonary 
care 405t
gut motor hypothesis 160
catheter-related sepsis 21–22
gynecologic surgery, PONV and 391
H
Haemophilus influenzae infection
bronchopneumonia 160
community-acquired pneumonia 162, 163
in HIV/AIDS 258
humoral defects 255
ventilator-associated pneumonia 168
Haldol, neuroleptic malignant syndrome 55
haloperidol 130
in postoperative delirium 399
halothane
hepatotoxicity 287
postoperative hypoventilation 393
in traumatic brain injury 225
Hamburger shift 45
hand hygiene, catheter insertion 119–120
Harris–Benedict equation 106, 351
Hashimoto’s thyroiditis 237
headache
intraparenchymal hemorrhage and 205
subarachnoid hemorrhage 209
head injury see traumatic brain injury (TBI)
Head Injury Severity Score (HISS) 215, 222
Health Care Financing Administration 
(HCFA) 379
health care rationing 379
Health Insurance Portability and 
Accountability Act (HIPPA) 379
heart see also entries beginning
cardiac/cardio-
abnormalities
congenital see congenital heart defects
(CHD) 
in HIV/AIDS 259–260
catheterization see central venous catheters
(CVCs) 
contractility 30, 412
disease see heart disease 
electrophysiology 74, 74f
failure see heart failure 
functional measures 32
hyperkalemia effects 65
hypertension effects 138–139
ischemia see myocardial ischemia/infarction 
rate 30, 412
poisoning 362t
trauma 409
valves see heart valves 
heart block 84–85
ECG 84, 84f, 85
first-degree 84, 84f
hyperphosphatemia 54
PAC use 33
second-degree 84–85, 84f
third-degree 84f, 85
ventral septal defects 151
heart disease
arrhythmias and 75t, 76
congenital see congenital heart defects
(CHD) 
ischemic see myocardial ischemia/infarction 
pulmonary surgery and 401–402
heart failure
congestive
coarctation of the aorta 153
heart failure (Continued)
enalaprilat 102
hyponatremia 48
hypertension and 139, 141
hyponatremia 48
nesiritide 102–103
sodium nitroprusside 98
vasodilator drug choice 103
ventricular function curve 30f
heart–lung interaction assessment 401
heart valves
bicuspid defects 153
pulmonary stenosis 153
in tetralogy of Fallot 152
tricuspid agenesis 13
in ventricular septal defects 151
heat stroke 54–55
Helicobacter pylori, gastrointestinal bleeding
302
helium/oxygen mixture, postoperative
pulmonary care 405t
HELLP syndrome 250
hematemesis, coagulopathies 267
hematochezia
coagulopathies 267
gastrointestinal bleeding 300, 302, 
304, 305
hematocrit
congenital heart defects (adult) and
154–155
gastrointestinal bleeding and 301
optimal in ICU patients 71
transfusion “trigger” 276
trauma patients 338
hematologic system 252–285 see also blood
coagulation 261–272
congenital heart defects (adult) and
154–155
immune-compromised host 252–260
pregnancy physiology 249
hematoma(s)
extradural 216
renal 330
subarachnoid hemorrhage 212
subdural 217
hematuria
bladder trauma 332
renal trauma 328–329
suprapubic cystostomy 323–324
urethral catheterization 319
hemicolectomy, diverticulosis management 304
hemodialysis
acute renal failure 312, 314
drug prescription and 315t
lactate metabolism 44–45
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surgical 271
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artificial liver 315
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fulminant see fulminant hepatic failure (FHF)
protein intake in 108, 291
residual anesthesia effects 397
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diagnosis 289
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transfusion-related 72, 282
hepatopulmonary syndrome 292
hepatorenal syndrome 295
acute renal failure 309
hepatotoxic drugs 287–288
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drug interactions 288
mechanisms of action 288t
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herpes simplex virus (HSV) infection
cell-mediated immunity and 254
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histamine antagonists
hyperthermia and 397
pneumonia management 173
PONV prevention/treatment 392
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HIV/AIDS 258–260
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ICU mortality 258
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258–259
organ involvement 259–260
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in HIV/AIDS 258
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cerebellar hemorrhage 207
subarachnoid hemorrhage and 212
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hydrocortisone
adrenal insufficiency 242
hypercalcemia treatment 52
postoperative pulmonary care 405t
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regulation 39–40
hydromorphone, postoperative pain
management 390
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sepsis management 8
trauma management 343
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hyperacute rejection 256
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hypercalcemia 51–52, 66
cardiac arrhythmias and 76
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case study 15
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definition 11
management 14–15
monitoring 17
physiology 14
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thermal injury/smoke inhalation 347
traumatic brain injury and 219
ventilator weaning and 191
hypercarbia, postoperative V/Q mismatch 394
hyperchloremic metabolic acidosis 41
hypercoagulopathy 266–267
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hyperglycemia 62, 243
diabetic ketoacidosis 244
epinephrine-induced 93
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nonketotic hyperosmolar syndrome 245
norepinephrine-induced 92
postoperative 398
sepsis 112
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alkalosis 46, 68
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contraindication 324
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in renal failure 311
transfusion-related 282t
treatment 65, 311
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treatment 63
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diabetes mellitus and 139
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malignant hyperthermia 55, 397
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hypo-osmolar hyponatremia 47–48
hypoparathyroidism 240
hyperphosphatemia and 54
hypophosphatemia 53–54, 66–67
diabetic ketoacidosis 244
hypoprolactinemia, dopamine-induced 91
hypotension
definition 411
hemodialysis and 314
management 413–414
crystalloid 413
pharmacological agents 92, 94, 414t
Trendelenburg position 413
massive blood transfusion and 281
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poisoning 361
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in HIV/AIDS 260
hypothalamus, body temperature 397
hypothermia 57
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postpartum hemorrhage 250
preload (venous return) and 412, 413
pulse pressure 26
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TEE 36
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postpartum hemorrhage 250
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traumatic brain injury 221
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stroke 200
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implantable cardioverter defibrillator (ICD) 86
clinical management 86–88, 87f
implied consent 377
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infection 
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host defense mechanisms
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in stroke 204
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inflammation
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surgery-induced 109
inflammatory bowel disease, gastrointestinal
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ARDS and ALI pathology 177, 178
disseminated intravascular coagulation 262
sepsis pathophysiology 5, 7
surgery-induced 109
influenza virus infection, pneumonia 164, 164f
informed consent 371, 377
advance directives and 378
blood transfusions 71, 371
vascular access and 20
infratentorial hemorrhage 206
inhaled anesthetics
tachycardia and 416
in traumatic brain injury 224–225
injury see trauma
insulin
deficiency 243
hyperglycemia treatment 243, 244
hyperkalemia treatment 65, 311
hypoglycemia-induction 243
nonketotic hyperosmolar syndrome 245
resistance 62, 243
response to glucose infusion 107
intensive care unit (ICU)
cardiac devices 86–88
chemical/toxic incidents 359
congenital heart defects (adult) and 155–156
credentialing 19–20, 374
hemorrhagic stroke 207–208
HIV/AIDS mortality 258
ischemic stroke 201–204
anticoagulation 202
general care 203–204
indications 201
stroke units 201
thrombolysis 201–202
triple-H therapy 202
monitoring see monitoring 
nutrition see nutrition 
pharmacological principles 89–105
postanesthesia care unit see postanesthesia
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pregnancy and 248–251
radiography 23–24
scoring systems see scoring systems 
sedation see sedation/sedatives 
specialized IV teams 121
staff-to-patient ratios 374
standards of care 16–17
transport issues see transport issues 
traumatic brain injury 225–227
urological concerns 317–334
vascular access see vascular access 
intercostal nerve block, post-thoracotomy
analgesia 405
interleukin-1 (IL-1)
burn pathophysiology 346
sepsis pathophysiology 7
surgery-induced changes 109
interleukin-6 (IL-6)
burn pathophysiology 346
sepsis pathophysiology 7
surgery-induced changes 109
interleukin-8 (IL-8)
burn pathophysiology 346
coagulation role 261
sepsis pathophysiology 7
intermittent hemodialysis
acute renal failure 312, 314
drug prescription and 315t
intermittent mandatory ventilation (IMV) 184
weaning 193
intermittent positive pressure ventilation
(IPPV), post-thoracic surgery 404
internal jugular vein, cannulation 28, 119
interstitial cerebral edema 217, 218
interstitial fluid (ISF) 60
interstitial pneumonia (peribronchovascular
infiltrates) 160, 161f
intestines
bleeding 300, 304–305
injury, suprapubic cystostomy 323
ischemia 301
intra-abdominal hypertension 308
intracellular fluid (ICF) 60
intracerebral hematoma 212, 217
intracerebral hemorrhage see cerebral
hemorrhage
intracranial aneurysms
anesthesia and 140
intraparenchymal hemorrhage 205
subarachnoid hemorrhage 208–209
intracranial hypertension 234 see also
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autoregulation in 219
in hepatic encephalopathy 291–292
management 291–292, 340
analgesia 199, 228
barbiturates 200, 229, 292
cerebral perfusion pressure 220–221, 229
cranial decompression 200, 229
head position 199
hemorrhagic stroke 208
hyperventilation 182, 199–200, 222,
228–229, 292
hypothermia 200, 229, 292
osmotic therapy 199, 223, 228
sedation 199, 228
stair-step approach 228
steroids 229
in stroke 199–200
in traumatic brain injury 222–223, 227–230
ventricular drainage 228, 235
monitoring 225–226, 234–235, 292
sodium nitroprusside-induced 99
subarachnoid hemorrhage and 212
traumatic 218, 220, 222–223, 225–226,
227–228
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cerebral perfusion pressure and 199, 
220, 234
monitoring 225–226, 234–235
complications 226
indications 226
PaCO2 effects 182, 199–200, 222, 228–229
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intraoperative blood salvage 284
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intraparenchymal hemorrhage 204–208
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etiology 204–205
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ICP monitoring 208
ICU management 207–208
infratentorial 206
outcome 208
pathophysiology 204–205
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in hepatic disease 292
intravascular replacement therapy, 
in pneumonia management 172
intravenous pyelography, renal trauma 329
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intubation
agitation and 124
ischemic stroke 198
radiography 403
rapid sequence in trauma 338, 339
stress 139, 140
thermal injury/smoke inhalation 347
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respiratory failure 13
“inverse steal syndrome” 220
iodine
catheter dressings 120
catheter insertion 119
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care 350, 350t
ionized hypocalcemia 66
ipratropium bromide, postoperative
pulmonary care 405t
irradiation, blood products 274
irritants 358
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cerebral see ischemic stroke 
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lung transplantation 408
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ischemic stroke 139, 196–200
anterior circulation 196–197
classification 196
complications 203–204
neurological vs. medical 204
congenital heart disease and 154
definition 195, 196
diagnosis 200
hypertension and 139, 198–199
crisis 141
lacunar infarcts 196, 197
management
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anticoagulation 202
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intracranial pressure 199–200
neuroradiological 204
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K-phos, hypophosphatemia treatment 67
L
labetolol 100–101, 140, 415t
actions 100
adverse effects 100–101
characteristics 104t
stroke management 198
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trauma management 342
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malignancies
chemotherapy, neutropenia 253
deep vein thrombosis risk 267
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mesenteric ischemia 301
metabolic acidosis 67–68
acute renal failure 311
chloride ions and 41, 65, 69
cyanide toxicity 346
diabetic ketoacidosis 42, 243–244, 244
hypokalemia and 50
lactic see lactic acidosis 
mixed disorders 45
metabolic alkalosis 68
chloride ions and 41
metabolic derangements 47–58 see also
acid–base physiology; body temperature;
specific conditions
arrhythmias and 50, 65, 66, 68, 75t, 76
implantable devices 86, 88
consequences 57–58
electrolytes 51–54
postoperative 398
respiratory failure relationship 111
surgery-induced changes 109
thermal 54–58
thyroid storm/hyperthyroidism 239
metamphetamines, poisoning 364
methemoglobinemia
nitroglycerin-induced 99
pulse oximetry 18
438 INDEX
methicillin-resistant Staphylococcus aureus
(MRSA) 118, 254
hospital-acquired pneumonia 167
ventilator-associated pneumonia 168
methohexatol, seizure association 398
methylprednisolone, postoperative pulmonary
care 405t
methysergide, serotonin syndrome 
treatment 56
metoclopramide, PONV prevention/
treatment 392
metoprolol
atrial fibrillation 82t
hypertension management 415t
pulmonary surgery and 406
metronidazole, dialysis and 315t
microbiology see also infection(s)
catheter-related infection 118
pneumonia diagnosis 161–162, 162t, 163
micronodular cirrhosis 286
microvascular thrombosis 7
midazolam 128, 129
middle cerebral artery occlusion 196–197
miliary tuberculosis 170, 171f
milrinone, acute renal failure and 310
mineralocorticoids 240
minimum inhibitory concentration (MIC) 173
Minnesota (Sengstaken-Blakemore) tube 302
minocycline, catheter impregnation 120
minute ventilation, ventilatory weaning
criteria 192
miotic pupils, poisoning 362t
misrepresentation, patient care 380
mithramycin (Plicamycin), hypercalcemia
treatment 52
Mobitz type I (Wenkebach) heart block 84
Mobitz type II heart block 84–85
Model End Stage Liver Disease (MELD) 
score 289t
molarity, definition 61
mole, definition 61
monitoring see also specific methods
alarm systems 16
blood gases 17–19, 17f
blood pressure 17, 19
in coagulopathy 270
complications of 16
credentialing 19–20
fetal 249
general principles 19–24
hemodynamic see hemodynamic
monitoring 
implantable cardiac devices 86
justification 20
in liver transplantation 297
neurological see neurologic monitoring 
postoperative 394
pulmonary surgery 402
standards of care 16–17
during transport 419
in trauma 343
monoamine oxidase inhibitors, serotonin
syndrome 56
Moraxella catarrhalis, community-acquired
pneumonia 163
morbidity
quality of care and 374
scoring systems 384–385
morphine sulfate 127
postoperative pain management 390
mortality
acute respiratory distress syndrome 178
blood transfusion 282
mortality (Continued)
fulminant hepatic failure 296
HIV/AIDS 258
Mortality Probability Models (MPMs) 375,
384, 384t
quality of care and 374
standardized mortality ratio (SMR) 381
subarachnoid hemorrhage 211
trauma 337
blunt trauma in the elderly 344
Mortality Probability Models (MPMs) 375, 
384, 384t
Motor Activity Assessment Scale (MAAS) 
125, 125t
motor aphasia, stroke and 196, 197
motor function
GCS scoring 234
Motor Activity Assessment Scale (MAAS)
125, 125t
neurological assessment 233
motor neuropathy, neuromuscular blockade
and 132
Moya Moya disease, intraparenchymal
hemorrhage 205
MRSA see methicillin-resistant Staphylococcus
aureus (MRSA)
mucolytic agents
pneumonia management 173
postoperative pulmonary care 405t
Mucomyst see N-acetylcysteine 
(NAC; Mucomyst)
mucosa, host defense mechanism 252
multifocal atrial tachycardia 82, 82f
multiple-dose activated charcoal (MDAC) 363
multiple logistic regression model 381
multiple myeloma, humoral defects 255
multiple organ dysfunction syndrome (MODS)
nutritional support 114
scoring 384, 385t
sepsis pathophysiology 7
ventilation and 178
multiple wavelet theory, atrial fibrillation 80
muscarinic antagonists, PONV
prevention/treatment 392
muscle relaxants 132–134 see also
neuromuscular blockade; specific agents
depolarizing agents 132–133
drug interactions 134
nondepolarizing agents 133
properties 133t
muscle weakness, weaning failure and 190
mustard gas 357, 365
Mustard procedure 152, 156
Mycobacterial infection
cell-mediated immunity and 254
in HIV/AIDS 258
in the immune-compromised 170, 171f
risk factors 163
Mycoplasma pneumoniae infection 160, 161f
community-acquired pneumonia 163
Mycostatin, pneumonia management 173
mydratic pupils, poisoning 362t
myocardial ischemia/infarction 143–149
angina 139, 147–148
blood transfusion in 71, 276, 277
cardiac arrhythmias and 76
clinical features 143, 144
diagnosis 146–147
hydralazine-induced 100
hypertension and 139
hypothermia-induced 396
intraoperative 148
pathophysiology 143, 144
myocardial ischemia/infarction (Continued)
postoperative 148, 411, 413
preoperative assessment 145f
prevention
postoperative 148
preoperative/perioperative 144–146, 148
risk 143–144
sodium nitroprusside-induced 98
treatment 147–148
vasodilator drugs in 103
myoclonus, etomidate-induced 131
myoglobinuria, electrical burns 349
myopathic syndrome, neuromuscular
blockade and 132
myxedema 237–238
N
N-3 fatty acid, immunonutrition 114–115
N-acetylcysteine (NAC; Mucomyst)
acetaminophen poisoning 287, 291, 364
postoperative pulmonary care 405t
naloxone
opioid reversal 127, 395, 398
in opioid poisoning 364
postoperative pain management 390
narcotics see opioids
nasojejunal tube 114
total enteral nutrition 110
National Acute Spinal Cord Injury Study 340
National Nosocomial Infections Surveillance
System, catheter-related infections 118
natural disasters 353–354
natural killer cells 254
nausea, postoperative see postoperative
nausea and vomiting (PONV)
near infrared spectroscopy, in traumatic brain
injury 227
needlestick injuries, vascular access and 23
neglect syndromes 196, 206
negligence 376, 377
Neisseria meningitidis infection 255
neoplasia see malignancy
neostigmine, PONV and 391
nephrogenic diabetes insipidus 242
nephropathy, in HIV/AIDS 260
nephrostomy, percutaneous 324, 324t, 
325f, 326
renal trauma 330
ureteral stent vs. 326–328, 327t
nephrostomy tubes 324, 325f
nephrotic syndrome
congenital heart defects (adult) and 155
hyponatremia 48
nephrotoxic drugs 309
nerve agents 358, 359, 365
nerve block, post-thoracotomy analgesia
405–406
nervous system, in congenital heart disease
(adult) 154
nesiritide 102–103
neuraxial anesthesia 391
neuroendocrine system 195–251 see also
central nervous system (CNS); endocrine
dysfunction
cardiac arrhythmias and 76
neurogenic diabetes insipidus 242
neuroleptic malignant syndrome (NMS)
55–56, 130, 397
neurological complications
congenital heart disease (adult) 154
postoperative 398–399
Index 439
neurological examination 233–234
poisoning 362t
trauma assessment 339, 340–341
in traumatic brain injury 222
neurological status 233, 339
neurologic monitoring 233–236
body temperature 227
cerebral blood flow 226–227
cerebral perfusion pressure 234
complications 226, 235
electrophysiology 227, 235–236
examination 233–234, 339
intracranial pressure 199, 225–226,
234–235, 292
indications 226
in stroke 199
in traumatic brain injury 225–227
neuromuscular blockade 132–134 see also
specific agents
clinical use
indications 132
neuroleptic malignant syndrome 56
sympathomimetic poisoning 56
complications 132, 133–134
respiratory 393, 395
depolarizing drugs 132–133
drug interactions 134
drug properties 133t
evaluation/treatment 395
nondepolarizing drugs 133
tolerance 132
in traumatic brain injury 228
neurovegetative signs, subdural hematoma 217
Neutra-Phos
hypercalcemia treatment 52
hypophosphatemia treatment 53, 67
neutropenia
antimicrobial therapy in 254
definition 253
neutropenic fever 253
neutrophils see polymorphonuclear leukocytes
next-of-kin 368
nicardipine 101, 140–141
nifedipine
hypertension management 140–141
stroke management 199
nimodipine, subarachnoid hemorrhage and 211
nitrates 140
hydralazine 99–100, 104t, 140
nitroglycerin see nitroglycerin 
sodium nitroprusside see sodium
nitroprusside 
stroke management 199
nitric oxide
ARDS management 179
arginine and 115
lung transplantation and 408
pneumonia management 174
nitrogen balance 106
in renal failure 113
nitroglycerin 99, 140
characteristics 104t
heart failure, nesiritide vs. 103
hypertension management 415t
intraoperative ischemia management 148
stroke management 199
nitroprusside see sodium nitroprusside
nitrous oxide
PONV association 391
postanesthetic hypoxia 393
in traumatic brain injury 225
nodules, pneumonia 160
noninvasive blood pressure monitoring 19
noninvasive ventilatory support 13, 14t, 15, 15t
nonketotic hyperosmolar syndrome (NKHS)
244–245
diabetic ketoacidosis vs. 245
nonmaleficence 368
advance directives and 378
nonsteroidal anti-inflammatory drugs (NSAIDs)
burn care 350
gastric ulcers and 301
gastrointestinal bleeding and 301, 302
liver disease and 294, 295
mechanisms of action 128, 390
postoperative analgesia 390
post-thoracotomy analgesia 405
sedation and 128
nonstress test (NST), fetal monitoring 249
nonthyroidal illness syndrome 239–240
noradrenaline see norepinephrine
norepinephrine 91–92
adverse effects 92
hypotension management 92, 414t
in sepsis/septic shock 8, 90t, 91–92, 97
comparative studies 95–96t
drug of choice 94
tachycardia induction 91, 97
normal saline (NS) 68–69
in traumatic brain injury 230
normo-osmolar hyponatremia 48
nosocomial pneumonia 166–170
hospital-acquired 166–167
infectious disease (ID) services 167
pathogens 168t
ventilator-associated 167–170
NSAIDs see nonsteroidal anti-inflammatory
drugs (NSAIDs)
nuclear incidents 359
nuclear magnetic resonance (NMR)
intraparenchymal hemorrhage 207
subarachnoid hemorrhage 210
in traumatic brain injury 224
nuclear medicine, ventilation perfusion
scintigraphy 401
nucleotides, immunonutrition 115
nutrition see also malnutrition
amino acids 107–108
carbohydrates 107
energy/energy balance 106–107
in ICU 106–116
acute pancreatitis 113–114
burns patients 351
enteral route 108–109, 110
immunonutrition 110, 114–115
lung transplants 409
parenteral route see parenteral nutrition 
perioperative 109–110
pneumonia 172
renal failure 113, 311
respiratory failure 110–112
septic patients 112–113
stroke patients 203
trauma patients 110, 231
lipids 107
status evaluation 106
nutritional status 106
nutrition risk index (NRI) 106
O
obesity, cirrhosis pathophysiology 286
obstetric complications 249–251
disseminated intravascular coagulation 263
hemorrhage 250
obstetric complications (Continued)
hypertensive 250
thrombotic 250–251
obstructive heart defects 151t, 153–154
coarctation of the aorta 153–154
critical care in 156
pulmonary stenosis 153
obstructive pyelonephritis 326
obstructive sleep apnea, postoperative
hypoventilation 393
obturators, suprapubic cystostomy 
322f, 323
occipital lobe, hemorrhage 206
occult bleeding, coagulopathies 267
ocular bobbing 206
Ohm’s law 412
oliguria 60, 61
definition 62
thermal injury 349
oncotic pressure 69
definition 61
ondansetron, PONV prevention/treatment 392
open lung biopsy, in ventilator-associated
pneumonia 169
open lung concept 178–179
opioids 126–128 see also individual opioids
adverse effects 128
management 127, 395
PONV association 391
respiratory depression 390
agitation and anxiety 124t
in cirrhotic patients 291
inadequate analgesia 123
patient-controlled analgesia 390
pharmacology 126t
poisoning 362t, 364
postoperative pain management 390
post-thoracotomy analgesia 405
reversal of effects 127, 395, 398
in traumatic brain injury 225, 228
oral care agents, pneumonia management
173–174
oral surgery, blood loss 284
organic brain syndrome, neuroleptic
malignant syndrome 55
organ of Zuckerkandl, tumors 245
organophosphates, poisoning 362t
organ-specific scoring systems 375
organ systems 135–334 see also individual
organs/systems
in HIV/AIDS 259–260
sepsis and 4t, 5
organ transplantation 256–257
antibiotic prophylaxis 257
cell-mediated immunity dysfunction 254
ethical issues 369–370
immunosuppression 408
infection following 254, 256–257
patterns of 257
liver see liver transplantation 
lung 408–409
rejection 256, 408
success rates 256
orogastric tubes, cirrhosis-associated 
GI bleeding 294
orotracheal tubes 339
ortho-chlorobenzylidene-malononitrile 
(CS gas) 358
orthopedic surgery, postoperative pain 389
orthoptic liver transplantation (OLT) 296–298
oscillating ventilation, in hypoxemic
respiratory failure 13–14
oscillometry 19
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osmolality
calculation 48t
serum 60
osmolarity pressure, definition 61
osmole, definition 61
osmotic diuresis 62
hypernatremia 49
ICP reduction
in stroke management 199
in traumatic brain injury management
223, 228
osmotic pressure 61
outcome measures 372, 381
in traumatic brain injury 232
oxacillin-resistant Staphylococcus aureus
(ORSA) 167
ventilator-associated pneumonia 168
oximes, nerve gas antidote 365
oxygen
administration see also ventilatory support 
hyperbaric, CO poisoning 364
PONV and 391–392
postoperative transport 419
thermal injury/smoke inhalation 347
alveolar-arterial (A-a PO2) tension,
hypoxemia 11–12
arterial tension (PaO2) 71
elderly trauma victims 344
in stroke 198
in traumatic brain injury 221, 224
delivery (DO2) 30, 30f, 71
cardiac output and 59
dopamine effects 91
lactic acidosis relationship 35
phenylephrine effects 93–94
pregnancy 248
uptake (DO2–VO2) relationship 34–35, 35f
demand, myocardial 144
hypoxemic respiratory failure 11–12
saturation (SaO2)
jugular oxygen monitoring 226–227
near infrared spectroscopy 227
pulse oximetry (SpO2) 17–18
tissue oximetry 227
uptake (VO2)
assessment 401
delivery (DO2–VO2) relationship 34–35
dopamine effects 91
maximal (VO2max) 401
phenylephrine effects 93–94
oxygen extraction ratio (O2 ER) 34
oxyhemoglobin 17, 18
P
pacemaker cells 74
pacemakers see cardiac pacing
pain
abdominal 393
burns 350–351
control see analgesia 
postoperative 389–391
hypoventilation and 393
post-thoracotomy 404–406
scales 390
palmar arch 27f
pamidronate, hypercalcemia treatment 52
pancreatitis
acute
nutritional support 113–114
sepsis 114
hypocalcemia 66
pancuronium 132, 133
postoperative hypoventilation 393
properties 133t
papillary necrosis, acute 326
paracentesis, cirrhosis-associated ascites 293
paracetamol see acetaminophen
parapneumonic infiltrates 160–161, 161f
parathyroid gland
dysfunction
hyperparathyroidism 52, 240
hypoparathyroidism 54, 240
hormones 51, 66, 240
surgery, hypocalcemia 398
parathyroid hormone (PTH)
calcium regulation 240
hypocalcemia and 51, 66
paravertebral block, post-thoracotomy
analgesia 405–406
parenchymal acute renal failure 308
pathogenesis 310
parenchymal liver disease 286, 287t
parenteral nutrition 109–110
acute pancreatitis 114
total (TPN) 110
catheter-related infection 118
parietal lobe, hemorrhage 206
Parkland formula, thermal injuries 348–349
paroxysmal supraventricular tachycardia
82–83, 82f
partial thromboplastin time (PTT) 268t, 
268, 277
1:1 mixing studies 268–269
hepatic disease 289
patent ductus arteriosus (PDA) 151–152
patient(s)
capacity 367, 370, 377
comfort, during vascular access 20–21
competence 377
confidentiality/privacy laws 379
consent issues see consent 
elderly see elderly patients 
management, scoring systems role 382
safety 372–373
staff ratios 374
treatment refusal 377
wishes, ethical issues 368
patient care
individual 382
misrepresentation 380
patient positioning
catheter insertion 21
urethral 318, 320f
hypotension management 413
percutaneous nephrostomy 325f
stroke management 199
suprapubic cystostomy 323
in ventilator-associated pneumonia 170
ventilator weaning and 192
pediatric medicine, sedation in 130, 131
pelvis
examination 340
fracture 332
trauma assessment 341–342
penetrating trauma, renal 328
penicillin
anthrax 355
Y. pestis infection 355
penicillin-resistant Streptococcus pneumoniae
(PRSP) 162
pentamidine, Pneumocystis carnii infection 171
peptidoglycan, sepsis pathophysiology 5
percutaneous gastronomy, enteral nutrition
and 108
percutaneous nephrostomy 324, 324t, 325f, 326
renal trauma 330
ureteral stent vs. 326–328, 327t
percutaneous suprapubic cystostomy
catheterization 321–324, 321t, 326
percutaneous transluminal coronary
angioplasty (PTCA) 144
Perflubron 284
perfluorocarbon solutions 284
peribronchovascular infiltrates (interstitial
pneumonia) 160, 161f
pericardial tamponade, trauma assessment 341
perioperative complications
hypothermia 57
myocardial ischemia/infarction 143–149
perioperative nutrition 109–110
peripherally inserted central catheters 
(PICC lines) 27
peritoneal dialysis, acute renal failure 312, 314
peritoneal lavage, trauma assessment 341
peritonitis, bacterial 289, 296
cirrhosis 294–295
hepatorenal syndrome 309
permanent pacemaker (PPM) 85–86
persistent vegetative state (PVS)
diffuse axonal injury 217
ethical issues 370
petrolatum, burns care 350
phagocytosis, polymorphonuclear 
leukocytes 253
pharmaceutical industry, ethical issues 371
pharyngeal obstruction, postoperative
hypoventilation 393
pH, definition 38
phenobarbital, poisoning 363
phenoxybenzamine 246
phentolamine 246
phenylephrine 93–94
adverse effects 94
hypotension management 94, 414t
intraoperative ischemia management 148
pheochromocytoma 245–246
diagnosis 245
hypertension 138, 245
treatment 140, 246
phlebitis, catheter-related 22
phlebostatic axis 29
phlebotomy 71
phosgene 357–358, 365
phosphate ions 53–54, 66–67
acid–base balance 43
hypercalcemia treatment 52
hyperphosphatemia 51, 54, 67
hypophosphatemia 53–54, 66–67, 244
metabolic functions 53, 66
physiotherapy, post-pulmonary surgery 404
physostigmine, anticholinergic syndrome
treatment 57
PICC lines (peripherally inserted central
catheters) 27
“pink puffers” 111
piperacillin, dialysis and 315t
PIRO system 4–5, 4t
pituitary hormones, TSH 237
plague 355
plasma
exchange (plasmapheresis), ARF 314
proteins, acid–base physiology 45–46
transfusion 72, 273, 277–278
derivatives 273, 279, 280t
indications for use 277t
storage 274t
volume 60, 62
Index 441
plasmapheresis (plasma exchange), 
acute renal failure 314
plasminogen activator inhibitor (PAI-1)
assay 270
coagulation role 261
plasminogen activator inhibitor 1 (PAI-1),
sepsis 7
plasminogen, coagulation role 261, 262
platelet-activating factor (PAF), coagulation
role 261, 262
platelet function analyzer-100 (PFA-100)
267–268
platelets
activation 261–262
counts 267, 268t
dysfunction
cardiopulmonary bypass 265
drug-induced 270
in hepatic disease 296
hypothermia 265
inherited abnormalities 264
storage 274t, 279
substitutes 284
transfusion 72, 273, 279, 281
coagulopathy/DIC management 271
dosing 281
trauma 342
washing 274
plethysmography 17, 18
pleural effusion
in congenital heart disease (adult) 154
parapneumonic infiltrates 160–161, 161f
ventilator-associated pneumonia 170
Plicamycin (mithramycin), hypercalcemia
treatment 52
Pneumocystis carnii infection 170–171, 
171f, 172f
cell-mediated immunity and 254
in HIV/AIDS 170–171, 258, 259
interstitial pneumonia 160
transplantation and 256
treatment 171
pneumocytes type II 177
pneumonectomy 403, 404f
pulmonary edema 406–407
pneumonia
in adults 157–175
ARDS and 165, 176, 179
ARF and 111, 112, 165
bronchopneumonia 160, 161f
causative organisms 157, 158t, 168t see
also specific organisms/infections
cavitation 160
CDC definition 157
cell-mediated immunity and 254
classification 162–171
community-acquired 162–164
atypical 158t, 163–164
typical 158t, 162–163
diagnosis 160–162
nonradiologic 161–162, 162t, 163
radiography 160–161, 160f, 161f, 171,
171f, 172f, 174–175
ventilator-associated pneumonia 169
differential diagnosis 158, 406
fungal 158t, 165–166, 166f
in hepatic disease 292
in HIV/AIDS 258–259
in the immune-compromised 170–171, 171f
interstitial (peribronchovascular) 160, 161f
lobular 160, 160f
lung transplantation and 409
nodular infiltrates 160
pneumonia (Continued)
nosocomial 166–170, 168t
hospital-acquired 166–167
ventilator-associated 159, 167–170
parapneumonic infiltrates 160–161, 
161f, 170
pathogenesis 159–160
genetics 158
gut motor hypothesis 160
presentation 158
risk factors 159–160, 162, 163t
thermal injury/smoke inhalation 348
treatment 162–171
adjunctive/supportive 171–174
antibiotics see antibiotics 
Fine prediction rule/criteria 163t
guidelines 157–158, 163, 164t
nonantibiotic drugs 173–174
viral 158t, 164–165, 164f, 174
pneumonic tularemia 355
pneumonitis, pneumonia vs. 158, 158f
pneumothorax
catheter-induced 23, 29
postoperative V/Q mismatch 394
radiography 23, 403
Poiseuille–Hagen formula 27, 69, 71
Poiseuille’s equation 412
poisoning 361–366 see also specific 
toxicities
diagnosis 361–362
neurological signs 362t
“toxidromes” 361, 362t
resuscitation/stabilization 361
treatment 362–363
polycythemia, congenital heart defects (adult)
and 154, 156
polydipsia 64
nonketotic hyperosmolar syndrome 245
PolyHeme 284
polymorphic ventricular tachycardia 83–84,
83f see also Torsade de Pointes
polymorphonuclear leukocytes 253–254
dysfunction (neutropenia)
antimicrobial therapy in 254
characteristics 253
fever 253
infections associated 253
polystyrene sulfonate, hyperkalemia 
treatment 50, 65
polyurethane dressings 120
polyuria, nonketotic hyperosmolar 
syndrome 245
portopulmonary hypertension, 
hepatic disease 292
portosystemic encephalopathy 
(PSE) 290–292
acetaminophen poisoning 363, 369
grades 291, 291t
lactulose therapy 291
raised ICP and 291–292
positive end expiratory pressure (PEEP)
auto-PEEP 183, 187, 188, 408
in hypoxemic respiratory failure 13
indications 188
key effects 187
in lung transplantation 408
postoperative, pulmonary surgery 404
postoperative transport 419
thermal injury/smoke inhalation 348
titration 187, 187f
in traumatic brain injury 224
ventilation–perfusion zone 
vulnerability 34
postanesthesia care unit (PACU) 389–420 
see also anesthesia
case study 399
common problems 389–399 see also
specific complications
arousal 397–399
nausea and vomiting 391–393
pain 389–391
respiratory 393–395
thermal 395–397
hemodynamic instability 411–417
postoperative transport 418–420
pulmonary surgery 400–410 see also
pulmonary surgery 
post-hypercapnic syndrome 68
postoperative blood salvage 284
postoperative nausea and vomiting (PONV)
391–393
incidence 391
prevention/treatment
agents 392
PACU regimens 392–393
risk factors 391–392
postoperative pain 389–391
hypoventilation and 393
post-thoracotomy 404–406
postoperative transport see transport issues
postpartum hemorrhage 250
postpneumonectomy pulmonary edema
(PPPE) 406
postreperfusion syndrome (PRS), 
liver transplantation 297
postsynaptic potential (PSP) 235–236
post-thoracotomy pain syndrome 405
posttraumatic stress disorder (PTSD)
natural disasters 354
sedation and 123
potassium iodide, radioactive iodine 
exposure 359
potassium ions 49–51, 64–65
cardiac arrhythmias and 50, 76
deficiency see hypokalemia 
drug interactions 50
excess see hyperkalemia 
functions 49
potassium phosphate, hypophosphatemia
treatment 53, 67
potassium-sparing diuretics, hypertension
management 141
Potts shunt, tetralogy of Fallot 152
pralidoxime, nerve gas antidote 365
predicted postoperative forced expiratory
volume in 1sec (ppoFEV1) 401
prednisolone, lung transplantation 408
preeclampsia 249, 250
disseminated intravascular coagulation 263
pregnancy 248–251
disseminated intravascular coagulation 263
fetal monitoring 249
obstetric complications 249–251
hemorrhage 250
hypertension 250
thromboembolism 249, 250–251
physiological issues 248–249
cardiorespiratory 248
hematologic 249
renal/gastointestinal 249
von Willebrand’s disease 264
pregnancy-induced hypertension (PIH) 250
preload (venous return) 30, 412
definition 29
fluid administration and 59, 59f
hypovolemia and 412
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preload (Continued)
measures 32
Starling curves 32, 60
prerenal acute renal failure 308
pathogenesis 310
pressure-controlled inverse ratio ventilation
(PCIRV) 185–186
pressure-control ventilation (PVC) 185
pressure-regulated volume control (PRVC)
185
pressure support ventilation (PSV) 185
weaning 193
primidone, poisoning, treatment 363
primum atrial defects 151
primum non nocere, advance directives 
and 378
prion disease, transfusion-related 72, 282
procainamide
ventricular fibrillation 79
Wolff–Parkinson–White syndrome 81
prochlorperazine, PONV prevention/
treatment 392
proinflammatory cytokines, sepsis 7
promethazine, PONV 392
propafenone
pulmonary surgery and arrhythmia 406
Wolff–Parkinson–White syndrome 81
propanolol, atrial fibrillation 82t
propofol 129–130
in hepatic encephalopathy 292
PONV and 391
in traumatic brain injury 225, 228
propylthiouracil 239
prostacyclin, pneumonia management 174
protamine anticoagulation, in CRRT 313
protein(s)
catabolism, acute pancreatitis 114
nutritional requirements 107–108
in hepatic failure 108, 291
in renal failure 113
in urine, pregnancy and 249, 250
visceral, status 106
protein C
activated, coagulopathy/DIC 
management 271
deficiency 266
sepsis pathophysiology 7
protein S, deficiency 266
protein status, visceral 106
proteinuria, pregnancy 249, 250
Proteus spp. infections, ventilator-associated
pneumonia 168
prothrombinase complex, coagulation 
role 262
prothrombin time (PT) 268t, 268, 277
1:1 mixing studies 268–269
hepatic disease 289
proton pump inhibitors
gastrointestinal bleeding 302
pneumonia management 173
P-selectins, coagulation role 261
pseudoacidosis 67
pseudohyperkalemia 50, 64
pseudohypocarbia 67
pseudohyponatremia 48, 64
pseudohypoparathyroidism 66
pseudohypoxemia 67
Pseudomonas aeruginosa infections
catheter-related 118
neutropenia 253
ventilator-associated pneumonia 168
Wegener’s granulomatosis 160
“pseudo-wedging” 31–32
psychiatric intervention, natural disasters 354
psychological considerations, ventilator
weaning 191–192
Pugin score (clinical pulmonary infection
score; CPIS) 170
pulmonary artery
catheterization see pulmonary artery
catheter (PAC) 
rupture 33
pulmonary artery catheter (PAC) 30–35
anatomy 31f
complications 32–33
effectiveness 34
information obtained 32
insertion 31
mechanical ventilation and 34
in myocardial ischemia 146
“pseudo-wedging” 31–32
in pulmonary surgery 402
trauma 343
ventilation–perfusion pressures 33–34, 33f
waveforms 31f
pulmonary artery occlusion pressure (PAOP) 32
pulmonary capillary pressure (Pc) 33
pulmonary catheter wedge pressure (PCWP)
31f, 32, 34, 34f, 412
pulmonary complications see also specific
conditions
congenital heart disease (adult) 154
in hepatic disease 292–293
postoperative 393–395
evaluation 394
hypoventilation 393–394
post-thoracic surgery 404, 406–407
in subarachnoid hemorrhage 212
thermal injury/smoke inhalation 348
treatment 394–395
V/Q mismatch see ventilation/perfusion
(V/Q) mismatch 
pulmonary contusion 409
pulmonary edema
cardiogenic 406
evaluation/treatment 395
in liver transplantation 298
postoperative V/Q mismatch 394
postpneumonectomy 406–407
pulmonary embolism
circulatory shock 31
definition 250
hypercoagulable states 266
postoperative V/Q mismatch 394
postpneumonectomy pulmonary edema 
vs. 406
in pregnancy 249, 250–251
in stroke 204
in traumatic brain injury 231
pulmonary Hantavirus syndrome 164
pulmonary histoplasmosis 165, 166f
pulmonary hypertension
congenital heart defects (adult) 155
patent ductus arteriosus 151
tetralogy of Fallot 152
crisis 155
definition 292
hepatic disease 292–293
management 155
pulmonary stenosis 153
pulmonary surgery
complications 404
bronchopleural fistula 407
cardiac arrhythmia 401–402, 406
cardiac herniation 407–408
lung torsion/infarction 407
pulmonary surgery (Continued)
pulmonary edema 406–407
high-risk patients 401–402, 402t
coexisting medical conditions 401–402
respiratory assessment 401
lung opening procedure (LOP) 178–179
lung transplantation 408–409
postanesthesia care 400–410
analgesia 404–406
arrhythmia management 406
chest drainage 403, 403f
chest radiography 403, 404f
commonly used agents 405t
fluid management 403, 408
lung transplants 408–409
monitoring 402
physiotherapy 404
routine 402–406
specific conditions 406–409
ventilatory support 404
thoracic trauma 409
video-assisted 400
pulmonary tularemia 355
pulse alternans 26
pulseless electrical activity 79–80, 80f
pulseless ventricular tachycardia 78–79
pulse oximetry
physiology 17–18, 17f
postanesthetic 394
pulse pressure 26
pupillary responses
poisoning 362t
traumatic brain injury 222
purine bases, immunonutrition 115
purpura
post-transfusion 264
thrombocytopenic 264, 281, 311
putamen, hemorrhage 206
P wave 74, 74f, 78
pyelography, renal trauma 329
pyelonephritis
emphysematous 326
obstructive 326
pyrexia see fever
pyrimidine bases, immunonutrition 115
Q
Q fever 356
atypical pneumonia 164
QRS complex 74, 74f, 78
QT interval 74, 74f
prolongation 75
drug-induced arrhythmia 77
drugs causing 77t
Torsade de pointes 83, 83f, 84
qualitative data 375
quality issues 367, 373–375
scoring systems role 382
quantitative data 375
quarantine, disaster management 353
quinine, poisoning, treatment 363
quinolones, pneumonia management 172
R
“rabbit fever” 355
radial artery 27f
cannulation 24, 25f
radiation syndrome 359
radioactivity, exposure 359
radiocontrast nephropathy 311
Index 443
radiography
ARDS 177
bladder trauma 332
chest see chest radiography 
renal trauma 329–330
stroke 200
transport to radiology suite 419
trauma assessment 341
urethral trauma 333
vascular access verification 23–24
Ramsey sedation scale 124–125, 125t, 340–341
rapid sequence intubation (RSI) 338, 339
rapid shallow breathing index, ventilatory
weaning criteria 193
Rashkind balloon septostomy, transposition of
great arteries 152–153
receiver operator characteristic (ROC) 
curve 385
recombinant factor VIIa 271, 284
recombinant tissue plasminogen activator 
(rt-PA) 201–202
recovery room see postanesthesia care unit
(PACU)
red blood cells
storage 274t
substitutes 284
transfusion see blood transfusion 
reentry arrhythmias 74
reflexes, neurological assessment 233
rejection, solid organ 256
remifentanil 127
renal blood flow, fenoldopam effects 101–102
renal caliculi, acute renal failure 309
renal dysfunction
congenital heart defects (adult) and 155
hypertension in 138
lung transplantation and 408–409
pulmonary surgery and 402
vasodilator drug choice 103
renal failure
acute see acute renal failure (ARF) 
assessment 307–308
blood purification techniques 315
chronic 308
coagulopathy 265
hyperkalemia 311
hypermagnesemia 53, 65
hyperphosphatemia 54
management
blood purification techniques 315
renal replacement see renal replacement
therapy (RRT) 
nitrogen balance 113
nutritional support 113, 311
postoperative, hypertensive diabetics 139
residual anesthesia effects 397
renal replacement therapy (RRT) see also
individual techniques
acute renal failure 311, 312–315
blood purification 315
case study 313–314
CRRT 312–314
hemodialysis 312, 314
hemofiltration 312
initiation criteria 311
peritoneal dialysis 312
plasma exchange 314
anticoagulation during 313–314
continuous see continuous renal
replacement therapy (CRRT) 
drug prescription and 315, 315t
hemodialysis see hemodialysis 
hemofiltration see hemofiltration 
renal replacement therapy (RRT) (Continued)
lactate metabolism and 44–45
peritoneal dialysis 312, 314
plasmapheresis (plasma exchange) 314
poisoning treatment 363
renal stenosis, ACE inhibitors and 138
renal system see also kidney; urological
procedures
function assessment 307–308
in pregnancy 249
renal trauma 328–330
blunt vs. penetrating 328
classification 329–330, 329f, 330t
imaging studies 329–330
nonoperative management 330, 331f
occurrence 328
physical examination 328–329
renin, hypertension pathogenesis 138
renovascular hypertension 138
reptilase 269
resource utilization, scoring systems 382
respiration see breathing
respiration rate, poisoning 362t
respiratory acidosis 40, 46
chronic 68
treatment 395
respiratory alkalosis 40
atrial flutter/fibrillation 416
metabolic acidosis compensation 67
respiratory assessment 401
respiratory depression, opioid-induced 
128, 390
respiratory dysfunction
assessment 401
poisoning 362t
postanesthetic 393–395, 393t
evaluation 394
hypoventilation 393–394
treatment 394–395
V/Q mismatch 394
sodium nitroprusside-induced 99
thermal injury/smoke inhalation 347–348
respiratory failure 11–16 see also
hypercapnia; hypoxemia
acute see acute respiratory failure 
chronic 11
classification 181, 182t
clinical parameters 182t
management see ventilatory support 
respiratory mechanics 401
respiratory muscles
assessment 401
weaning failure and 111, 190
respiratory tract, microorganisms found in 168
resting energy expenditure (REE), burns
patients 351
resuscitation 59–72
controversy 342
ethics 370
fluids see fluid management 
gastrointestinal bleeding 300–301
poisoning 361
postoperative 411
trauma 342–344
elderly patients 343–344
monitoring 343
“rule of nines” 348, 349f
thermal injury 348–350
rhabdomyolysis
acute renal failure and 309
electrical burns 349
hyperphosphatemia and 54
hypocalcemia and 51
rhabdomyolysis (Continued)
hypokalemia and 65
management 309
rhesus immune globulin 279
rib fractures 409
ricin 365
terrorism threat 357
rifampin, catheter impregnation 120
Riker Sedation–Agitation Scale (SAS) 125, 125t
Ringer’s solution, lactated 42, 342, 348–349
riot control agents 358
risk-benefit analysis 20
risk stratification 381–382
myocardial ischemia 143–144
Riva–Rocci method, blood pressure
monitoring 19
rocuronium 133
properties 133t
roentgen 359
Romazicon (flumazenil) 129, 364, 398
root cause analysis 374
Roux-en-y choledochojejunostomy 297
“rule of nines” 348, 349f
S
saccular (berry) aneurysms, hemorrhage
208–209
safety issues 372–373
salicylate poisoning 362t, 364
treatment 363
saline
hypertonic 223, 228
normal 68–69, 230
in traumatic brain injury 223, 228, 230
Sarin 358, 365
SARS (severe acute respiratory distress
syndrome) 179
saxitoxin 365
scalp laceration 216
schistocytes 270
schistosomatidae, gastrointestinal 
bleeding 305
scopolamine, PONV prevention/treatment 392
scoring systems 375–376, 381–386 see also
individual systems
case mix 381
data/data handling 375, 381
ethics 375–376
transplantation 369, 370
liver disease 288–289
neurologic 233–234
organ-specific 375
pain scales 390
problems 385–386
roles 381–382
sepsis 3, 4–5, 4t, 6t
types 382–385
morbidity-based 384–385
physiology-based 382–384
resource-based 382
trauma-based 384
validity 385–386
second hit hypothesis, catheter-related 
sepsis 22
secundum atrial defects 151
sedation/sedatives 123–134 see also
analgesia; specific sedative agents
in cardiac surgery 146
in cirrhotic patients 291
common agents 126–134
benzodiazepines see benzodiazepines 
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sedation/sedatives (Continued)
muscle relaxants 132–134
nonopioid analgesics 128
opioids see opioids 
evaluation and titration of drugs 124
guidelines/protocols 126, 129
ICP reduction 199, 228
mechanical ventilation 182–183, 191
neurological assessment and 233
pediatric 130, 131
poisoning 362t
scale(s) 124–126, 125t, 340–341
trauma assessment and 340–341
in traumatic brain injury 228
during vascular access 21
segmental wall motion defects (SWMAs), 
TEE 36
seizures see also anticonvulsants
postoperative 398
in stroke
hemorrhagic 208, 212
ischemic 203–204
in traumatic brain injury 231
Seldinger technique, CVC placement 28, 29
selective serotonin reuptake inhibitors (SSRIs),
serotonin syndrome 56
Sellick maneuver 221
semipermeable polyurethane dressings 120
Sengstaken–Blakemore (Minnesota) tube 302
Senning procedure 152, 156
sensory aphasia, stroke and 197
sensory function, neurological assessment 233
sepsis 3–10 see also anaphylaxis; septic
shock; specific infections
acid–base balance 45
acute pancreatitis 114
acute renal failure 309, 310
acute respiratory distress syndrome 176
catheter-related 21–22, 22t see also
catheter-related infection 
definitions 3–4
diagnosis 3–5
ACCP/SCCM classification 3
criteria 4t
PIRO system 4–5, 4t
SOFA assessment 5, 6t
disseminated intravascular 
coagulation 262
hospital-acquired pneumonia 167
humoral defects and 255
hyperthermia vs. 396
immune response 4–5, 4t, 5f
incidence 3
insult 4, 4t
lung transplants and 409
management 7–9
blood purification techniques 315
catecholamines see catecholamines 
catheter-related infection 121–122
hemodynamic stabilization 7–8, 8t, 90t
immunomodulation 8–9, 9t
nutritional support 112–113
massive blood transfusion and 281
organ dysfunction 4t, 5, 6t, 7
pathophysiology 5–7
coagulation 7
glucose production 112
inflammatory mediators 5, 7
predisposition 4, 4t
SIRS see systemic inflammatory response
syndrome (SIRS) 
transfusion-related reaction 283t
urinary tract 324, 326
Sepsis Occurrence in Acutely Ill Patients
(SOAP) 3
septic shock 31 see also anaphylaxis; sepsis
gut motor hypothesis 21–22
hyperdynamic 91
lactic acidosis 45
management, blood purification 
techniques 315
pulse oximetry 18
refractory 90, 94
second hit hypothesis 22
vasoconstrictive drugs 89–97, 90t see also
individual drugs
choice of 94–97
comparative studies 95–96t
septic thrombosis, catheter-related 22
sequential multichannel analyzer (SMA) 67
Sequential Organ Failure Assessment (SOFA)
5, 6t, 384–385, 385t
serotonin antagonists, PONV prevention/
treatment 392
serotonin syndrome 56, 397
Serratia spp. infections, ventilator-associated
pneumonia 168
severe acute respiratory distress syndrome
(SARS) 179
severity models 381, 382
sevoflurane, in traumatic brain injury 225
sex hormones 240
shock 60
acute respiratory distress syndrome 176
cardiogenic 30–31
definition 30
drug treatment see vasopressors 
gastrointestinal bleeding 301
hypovolemic 30, 61
lactic acidosis 35, 35f
resuscitation 301, 342–344
septic see septic shock 
thermal injury (burn shock) 346
shunt hypoxemia, physiology 11, 12, 13f
sick euthyroid syndrome 239
sick sinus syndrome, atrial septal defects 
and 151
Silvadene 350, 350t
silver, catheter impregnation 120–121
silver nitrate, burns care 350t
silver sulfadiazine 350, 350t
catheter impregnation 120
Simplified Acute Physiology Score (SAPS)
375, 376, 384
single ventricle defects 153
Sin Nombre virus, pneumonia 164
sinoatrial (S-A) node 74
sinum cavernosum, injury 216
sinus bradycardia 84, 416
sinus rhythm 78
congenital defects 153
postoperative arrhythmia 416
sinus tachycardia 416, 416t
sinus venosus atrial defects 151
Site-Rite® 28
6-minute walk test (6MWT) 401
skeletal hypertonus, remifentanil-
induced 127
skin
burns see thermal injury 
host defense mechanism 252
substitutes 350
skull fracture 216
sleep apnea, postoperative 
hypoventilation 393
smallpox 355–356
smoke inhalation see also thermal injury
management principles
airway/breathing 347–348
fluid resuscitation and 349
pathophysiology 346–347
respiratory dysfunction 347–348
smoking, pneumonia risk 159
“sneaky PEEP” 13
Society of Critical Care Medicine (SCCM)
Practice Parameters for Hemodynamic
Support of Sepsis in Adult Patients 89
sedation guidelines 129
sodium bicarbonate
acidosis management 42–43
acute renal failure treatment 311
hyperkalemia treatment 51
malignant hyperthermia treatment 397
rhabdomyolysis management 309
sodium ions 47–49, 62–63
deficiency see hyponatremia 
excess see hypernatremia 
fractional excretion 60
sodium nitroprusside 98–99
adverse effects 98
characteristics 104t
hypertension management 140, 415t
mechanism of action 98
pheochromocytoma treatment 246
stroke management 199
in sympathomimetic poisoning syndrome 56
sodium phosphate, hypophosphatemia
treatment 53, 67
sodium pump (Na+,K+ ATPase), hypokalemia
and 50
sodium thiosulfate, thermal injury/smoke
inhalation 347
Soman 358
somatosensory evoked potentials, in traumatic
brain injury 227
sorbitol, hyperkalemia treatment 50
sotalol, Wolff–Parkinson–White syndrome 81
sphygmomanometer 19
spinal cord injury, assessment 340, 341f, 342
spirometry, post-thoracic surgery 404
spironolactone, hypertension management 141
splanchnic perfusion, dopamine effects 91
spleen
community-acquired pneumonia and 163
humoral immunity and 255
liver disease and 290
splenectomy, community-acquired 
pneumonia 163
spontaneous bacterial peritonitis (SBP),
hepatic disease 289, 294–295, 296
spontaneous breathing trials 193
sputum, pneumonia diagnosis 161–162
stable monomorphic ventricular tachycardia
83, 83f
staff-to-patient ratios 374
Stamy catheter set 321, 322f
standard base excess (SBE) 40–41
standardized mortality ratio (SMR) 381
standards of care 16–17
staphylococcal enterotoxin B, terrorism 
threat 357
Staphylococcus aureus infections
bronchopneumonia 160
catheter-related 21, 22, 118, 121
hospital-acquired pneumonia 167
management 121
methicillin-resistant (MRSA) 118, 167, 
168, 254
neutropenia 253
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Staphylococcus aureus infections (Continued)
oxacillin-resistant (ORSA) 167
staphylococcal enterotoxin B 357
vancomycin-resistant (VRSA) 168
ventilator-associated pneumonia 168
Staphylococcus epidermis infections
catheter-related sepsis 21
neutropenia 253
Stark Law 380
Starling curves 32, 60
Starling–Landis equation 60, 69t
statins, angina treatment 147
status epilepticus, in stroke 203
“steering wheel sign” 409
stenting
stroke management 204
ureteral 326–327, 327t
sterile technique, vascular access 21
steroids see also specific drugs
corticosteroids see corticosteroids 
glucocorticoids see glucocorticoids 
sex hormones 240
in traumatic brain injury 229
Stewart, Peter 37, 39
stomach see also entries beginning
gastric/gastro-
“pumping” in poisoning 362
ulcers, NSAIDs and 301
Streptococcus pneumoniae infection
community-acquired pneumonia 162, 163
complement deficiencies 255
in HIV/AIDS 258, 259
hospital-acquired pneumonia 167
humoral defects 255
lobular pneumonia 160
penicillin-resistant (PRSP) 162
ventilator-associated pneumonia 168
Streptococcus viridans infection, 
neutropenia 253
streptokinase, stroke management 201
streptomycin, Y. pestis infection 355
stress
adrenal insufficiency 241–242
of anesthesia 139
cardiac arrhythmias and 76
fatty acid metabolism 114
gastrointestinal bleeding 301
hyperglycemia 243
stress gastritis
burns 351
prophylaxis in trauma 341
stress tests, adrenal insufficiency 241–242
stress ulcers
in fulminant hepatic failure 294
prophylaxis
acute renal failure management 311–312
lung transplantation 409
pneumonia management 173
stroke 195–213
classification 196
congenital heart disease and 154
definition 195
epidemiology 195–196
hemorrhagic 195, 204–212
classification 196
congenital heart disease and 154
intraparenchymal see intraparenchymal
hemorrhage 
subarachnoid see subarachnoid
hemorrhage 
hypertension and 139
crisis 141
hemorrhage 205, 207
stroke (Continued)
ischemia 198
ischemic see ischemic stroke 
stroke units 201
stroke volume 412
strong ion difference (SID) 40, 45
strong ion gap (SIG) 45
structural heart disease, arrhythmias and 75t, 76
ST segment 74, 74f
ST-T complex 74, 74f
subacute bacterial endocarditis (SBE) 151
subarachnoid hemorrhage 208–212
classification/grading systems 209–210
clinical symptoms/signs 209
definition 208
diagnostic workup 210
etiology/pathophysiology 208–209
incidence 208
management 210–212
medical complications 212
neurologic complications 210–212
outcomes 211
subarachnoid space
hemorrhage into see subarachnoid
hemorrhage 
ICP monitors 235
subclavian artery steal syndrome 197
subclavian vein, cannulation 28, 29, 119
subdural hematoma 217
subdural space, ICP monitors 235
subglottic stenosis, thermal injury/smoke
inhalation 348
succinylcholine 132–133
complications 133
malignant hyperthermia 55
laryngospasm treatment 395
malignant hyperthermia 397
properties 133t
sudden death, tetralogy of Fallot and 152
suicide
attempted, ethical issues 369–370
physician-assisted 378
Sulfamylon (mafenide acetate), burns care
350, 350t
suprapubic cystostomy catheterization
321–324, 326
complications 321, 323–324
equipment 321, 322f
indications/contraindications 321t
technique 322, 323f
urethral trauma examination 333
supratentorial hemorrhage 206
supraventricular arrhythmias 77t, 80–83
atrial septal defects and 151
pulmonary surgery and 406
surfactant 178
ARDS pathology 177
replacement therapy 179
surgery see also specific types
nutritional requirements during 109–110
PONV incidence 391
stress response 416
Swan–Ganz catheter see pulmonary artery
catheter (PAC)
swelling see edema
sympathomimetic poisoning syndrome 56
sympathomimetics, poisoning 56, 362t
synchronized intermittent mandatory
ventilation (SIMV) 184
syndrome of inappropriate ADH secretion
(SIADH) 48, 64
postoperative 398
in subarachnoid hemorrhage 212
systemic inflammatory response 3–10
sepsis and 4–5
systemic inflammatory response syndrome
(SIRS)
acute respiratory distress syndrome 176
definition 3
disseminated intravascular coagulation 262
pneumonia 158
predisposing factors 4
systemic lupus erythematosus (SLE),
laboratory findings 268t, 269
systemic vascular resistance (SVR) 412, 413
calculation 32
in hepatic disease 292
low, causes 414t
T
Tabun 358, 365
tachyarrhythmias
atrial fibrillation see atrial fibrillation 
atrial flutter see atrial flutter 
causes 416t
hypovolemia-induced 32
junctional 83
norepinephrine-induced 91, 97
paroxysmal supraventricular 82–83, 82f
in pneumonia management 172
polymorphic ventricular 83–84, 83f see
also Torsade de pointes 
postoperative 416–417
stable monomorphic ventricular 83, 83f
thermal injury 349
ventricular (pulseless) 78–79
ventricular fibrillation 78–79, 79f
telangiectasis, intraparenchymal 
hemorrhage 205
telemetry, postoperative monitoring 402
temporal lobe, herniation 218
terbutaline, postoperative pulmonary care 405t
terrorism 352 see also environmental threat
bioterrorism 354–356
explosives 354
nuclear 359
toxins/chemicals 356–359
tetanus toxin 357
tetracycline
Coxiella burnetii 356
pneumonia management 172
tetralogy of Fallot (TOF) 152
thalamus, hemorrhage 206
theophylline, poisoning 362t, 363
Therapeutic Intervention Scoring System
(TISS) 376, 382
thermal injury 345–351 see also smoke
inhalation
assessment 345–346
classification 345
electrical burns 349–350
epidemiology 345
hypovolemic shock 346
management principles
airway/breathing 347–348
analgesia 350–351
circulation 348–350
escharotomy 348, 348f
neutralization 347
nutritional support 351
“rule of nines” 348, 349f
topical agents 350, 350t
wound care 350
pain 350–351
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thermal injury (Continued)
partial vs. full-thickness 345, 346t
pathophysiology 346–347
thermodilution measures 32, 33f
Thiazide diuretics, hypertension 
management 141
“third space” loss 62, 69
thoracic bioimpedence, noninvasive
hemodynamic monitoring 35
thoracic trauma 409
traumatic brain injury and 219
thrombin
coagulation role 262
sepsis pathophysiology 7
thrombin activatable fibrinolysis inhibitor
(TAFI), sepsis pathophysiology 7
thrombin time (TT) 269
thrombocytopathy, inherited 264
thrombocytopenia
acquired 264–265
heparin and 24, 72, 264–265, 281, 313
causes 72
hepatic disease 289
platelet transfusion 72, 279, 281
thrombocytopenic purpura
acute renal failure and 311
idiopathic 264
thromboelastograph (TEG) 270
thromboembolism
atrial fibrillation risk 81
atrial septal defects and 151
in congenital heart disease (adult) 154
hypercoagulable states 266–267
in pregnancy 249, 250–251
prevention in trauma 231, 341
pulmonary see pulmonary embolism 
in stroke 204
in traumatic brain injury 231
thrombolysis see also individual
thrombolytic therapies
ischemic stroke management 201–202, 204
indications 201
thrombophilic states 267
thrombomodulin and endothelial protein C
receptor (EPCR) 7
thrombophilia 266–267
thromboprophylaxis, trauma 231, 341
thrombosis
catheter-induced 24
embolization see thromboembolism 
heparin-induced 313
hypercoagulable states 266–267
neuromuscular blockade and 134
in pregnancy 249, 250–251
septic
catheter-related 22
pathophysiology 7
subarachnoid hemorrhage 208
in traumatic brain injury 231
thromboxane A2
burn care 350
thermal injuries 345–346
thyroid gland
dysfunction 237–240
hyperthyroidism and thyroid storm 239
hypothyroidism and myxedema 237–238
sick euthyroid syndrome 239–240
hormone production 237
surgery, hypocalcemia 398
thyroid-stimulating hormone (TSH) 237
in hyperthyroidism 239
in hypothyroidism 238
in sick euthyroid syndrome 239
thyroid storm 239
thyrotropin-releasing hormone (TRH) 237
thyroxine (T4) 237
drug interactions 238
excess 239
in hyperthyroidism 239
in hypothyroidism 238
in sick euthyroid syndrome 239
thyroxine-binding globulin (TBG) 237
parenteral nutrition and 110
ticarcillin, dialysis and 315t
tidal volume 187
ventilatory weaning criteria 192, 193
tirilazilad, in subarachnoid 
hemorrhage 211
tissue factor (TF), coagulation role 
261, 262
tissue factor pathway inhibitor (TFPI),
coagulation role 261, 262
tissue oximetry
trauma patients 338
in traumatic brain injury 227
tissue plasminogen activator (tPA)
coagulation role 261, 262
recombinant (rt-PA) 201–202
T-lymphocytes 254–255
Togavirus 356
Toll-like receptors (TLRs) 4, 5
Torsade de pointes 83–84
drug-induced 77
ECG 83, 83f
pulmonary surgery risks 406
treatment 65, 84
triggered activity 75
total energy expenditure (TEE) 112
total enteral nutrition (TEN), trauma 110
total parenteral nutrition (TPN), trauma 110
toxic inhalants 358
toxicology screens 362
“toxidromes” 361, 362t
toxins 365
environmental threat 352, 354, 356, 357
hepatic failure 287t
management principles 358–359, 365
Toxoplasma gondii infection
cell-mediated immunity and 254
in HIV/AIDS 258
in the immune-compromised 170
transplantation and 256
T-piece trials 193–194
trachea, injury 409
tracheobronchial injuries 409
tracheomalacia, thermal injury/smoke
inhalation 348
tracheostomy, dressings 120
train-of-four (TOF) stimulation tests 132
Trancyte, burns care 350
tranexamic acid 284
transcapillary fluid flux 69t
transcranial Doppler
subarachnoid hemorrhage 211
in traumatic brain injury 227
transcutaneous pacing (TCP) 85
transesophageal echocardiography (TEE)
35–36
congenital heart defects (adult) 155
in liver transplantation 297
myocardial ischemia 146–147
trauma 343
transfusion-related acute lung injury 
(TRALI) 283t
transient ischemic attack (TAI) 196
congenital heart disease and 154
transjugular intrahepatic portosystemic 
shunt (TIPS)
cirrhosis-associated ascites 293
gastrointestinal bleeding 294, 302
hepatorenal syndrome 295
transluminal angioplasty, in subarachnoid
hemorrhage 211
transplantation
bone marrow 257–258
ethical issues 369–370
solid organ see organ transplantation 
transport issues 418–420
communication issues 418
detours 419
equipment needs 418–419
guidelines 419–420
monitoring 419
transposition of great arteries (TGA) 
152–153
transthoracic echocardiography (TTE)
congenital heart defects (adult) 155
trauma 343
transvenous pacing (TVP) 85
trauma 337–366 see also specific injuries
acute renal failure in 110, 113
assessment 337–342
ancillary studies 341–342
bladder trauma 332
primary survey 338–340
renal trauma 328–329
scoring systems 233–234, 339, 384
secondary survey 340
tertiary survey 340–341, 341f
thoracic trauma 409
urethra trauma 333
blunt 328, 344
burns see thermal injury 
causes 337
coagulopathy 266
DIC 263
disasters 352–360
economics 337
genitourinary 328–333
bladder 330, 332
kidney 328–330
urethra 332–333
“golden hour” 337–342
head injury see traumatic brain injury (TBI) 
hyperphosphatemia 54
hypothermia 340
life support 338
mortality 337
risk factors in elderly 344
multiple 222
nutritional support 110, 231
penetrating 328
poisoning see poisoning 
rapid sequence intubation 338
resuscitation 342–344
elderly patients 343–344
fluid management 221–222, 342–343
monitoring 343
smoke inhalation see smoke inhalation 
thoracic 409
ventilatory support see ventilatory support 
traumatic brain injury (TBI) 214–232
assessment/diagnosis
early workup 223–224
imaging 222, 223–224
neurological evaluation 222
primary survey 339–340
risk factors/warning signs 223
tertiary survey 340–341
Index 447
traumatic brain injury (TBI) (Continued)
classification 215
Marshall’s 224
disability and 214
disseminated intravascular coagulation 263
epidemiology 214–215
evidence-based recommendations 340
free water administration and 62, 69
hyperthermia in 227, 229
intracranial hypertension 340
management 221–225
airway 221
analgesia 228
anesthesia in 224–225
antithrombotic 231
approaches, controversy 229–230
electrolyte management 230–231
emergency room 221
fluid management 62, 69, 221–222,
230–231
gastrointestinal bleeding 232
general care 230–232
hypothermia 229
ICU 225–227
of infections 231
intracranial hypertension 222–223,
227–230
multiple trauma 222
neuromuscular block 228
nutritional support 231
prehospital 221
sedation 228
seizures 231
surgery, indications for 224
neurologic monitoring 225–227
cerebral blood flow 226–227
ICP 225–226
jugular oxygen saturation 226–227
near infrared spectroscopy 227
tissue oxygen 227
transcranial Doppler 227
outcome 232
oxygen saturation and 227
primary damage and 215, 217
pathophysiology
cerebral blood flow 219–221
primary and secondary damage 215–219
primary damage 215–217
brain contusion/laceration 216, 217
diffuse axonal injury 217
extradural hematoma 216
intracerebral hematoma 217
scalp laceration 216
skull fracture 216
subdural hematoma 217
scoring systems 222, 233–234, 339, 384
anatomic/pathologic 215
Glasgow Coma Scale 215, 233–234, 339
Head Injury Severity Score 215
secondary damage 217–219
brain shift/herniation 218
cerebral edema 217–218
extracranial lesions 219
hydrocephalus 218–219
ischemia 218
vasodilator drug choice 103
Trendelenburg position
catheter insertion 21
hypotension management 413
suprapubic cystostomy 323
triage 379
tricuspid atresia 153
tricylic antidepressants, hepatotoxicity 287
triiodothyronine (T3) 237
drug interactions 238
excess 239
in hyperthyroidism 239
in hypothyroidism 238
in sick euthyroid syndrome 239
trimethoprim-sulfamethoxazole (TMP-SMX)
Pneumocystis carnii infection 171
pneumonia management 172
triple-H therapy
ischemic stroke management 202
subarachnoid hemorrhage and 211
tris-hydroxymethyl aminomethane (THAM),
acidosis treatment 43, 68
Trousseau’s sign 66
T-tubes 193
tuberculosis
in HIV/AIDS 258, 259
in the immune-compromised 170, 171f
transplantation and 256
tubular necrosis, acute (ATN) 307
tularemia 355
atypical pneumonia 164
tumor lysis syndrome
hyperphosphatemia and 54
hypocalcemia and 51
tumor necrosis factor (TNF)
sepsis pathophysiology 7
sepsis predisposition 4
surgery-induced changes 109
tumors see also malignancy; specific tumors
adrenal 245–246
cerebral 205
organ of Zuckerkandl 245
pneumonia risk 160
tumor lysis syndrome 51, 54
T wave 74, 74f
typhilitis, neutropenia 253
U
ulcerative colitis, gastrointestinal 
bleeding 305
ulnar artery 27f
ultrasound see also specific techniques
CVC placement 28–29
fetal monitoring 249
hemodynamic monitoring 35–36
liver disease 290
stroke 200
trauma assessment 341, 342
trauma monitoring 343
United Network for Organ Sharing (UNOS)
liver status 288, 289t
United States Department of Justice, HIPPA
violation penalty 379
United States Health Care Financing
Administration (HCFA) 379
upper urinary tract obstruction 326–328
urapidil, stroke management 199
ureteral stent placement, percutaneous
nephrostomy vs. 326–328, 327t
urethra
catheterization 317–319
catheters 317, 318f
complications 318–319
indications 317, 318t
patient position 318, 320f
technique 318–319, 319f
dilatation, cysturethroscopy 320
trauma 332–333
management 332f, 333
urethroplasty 333
urinalysis, renal trauma 328
urinary catheters 332
urinary tract see also specific regions
infection 324, 326
cysturethroscopy and 320–321
percutaneous nephrostomy 324
in stroke 204
lower, obstruction 326
upper, obstruction
causes 326, 326t
management 326–328
urine
alkalization, poisoning treatment 363
analysis, renal trauma 328
in diabetic ketoacidosis 244
flow obstruction, postrenal renal failure 309
output monitoring 16–17
urokinase, stroke management 201
urological procedures 317–324, 317–334 
see also individual techniques
cystourethroscopy 319–321, 320f, 321f
nonoperative 328–333
bladder 332, 332f
renal trauma 330, 331f
urethra 332f, 333
percutaneous nephrostomy 324, 324t,
325f, 326–328, 330
suprapubic cystostomy 321–324, 321t,
322f, 326
upper urinary tract obstruction 326–328
ureteral stenting 326–327, 327t
urethral catheterization 317–319, 318f,
318t, 319f
urosepsis 324
V
vagal maneuver, paroxysmal supraventricular
tachycardia 83
vagal stimulation, multifocal atrial 
tachycardia 82
Valsalva’s maneuver 416
vancomycin
catheter-related infection prevention 120
dialysis and 315t
hospital-acquired pneumonia 167
resistance 168–169
in ventilator-associated pneumonia 168
vancomycin-resistant enterococcus (VRE)
168–169
vancomycin-resistant Staphylococcus aureus
(VRSA) infections 168
variceal bleeding, cirrhosis-associated 294
varicella zoster virus (VZV) infection
cell-mediated immunity and 254
pneumonia 164
Variola major virus 355–356
vascular abnormalities/malformations
gastrointestinal bleeding 305
intraparenchymal hemorrhage 205
subarachnoid hemorrhage 208
vascular access see also catheters; specific
sites
analgesia/sedation 20–21
arterial see arteries, cannulation 
central venous see central venous catheters
(CVCs) 
complications
infectious see catheter-related infection 
thrombotic 24
credentialing 19–20
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vascular access (Continued)
general principles 19–24
informed consent 20
justification 20
latex allergy and 22–23
in liver transplantation 297
needlestick injuries 23
preparation 20
procedural positioning 21
radiological verification 23–24
sterile technique 21
thermal injury and 348
wound dressing/care 22
vascular pulmonary disease, in hepatic 
disease 292
vasculitis
acute renal failure and 311
intraparenchymal hemorrhage 205
vasoactive drugs 89–105 see also specific
drugs/drug types
in acute renal failure 309, 310
infusion 27
sepsis management 8
vasoconstrictive see vasopressors 
vasodilational see vasodilators 
vasoconstriction
cerebral blood flow 221, 229
drugs inducing see vasopressors 
hypocapnic 220
subarachnoid hemorrhage and 210–211
vasoconstrictive drugs see vasopressors
vasodilation
cerebral blood flow 220–221, 229
drugs inducing see vasodilators 
vasodilators 97–103 see also specific drugs
characteristics 104t
choice 103
indications 97
lung transplantation 408
pulmonary 155
sites of activity 98t
vasogenic cerebral edema 217, 218
vasopressin 97
asystole 80
in cardiogenic shock 97
DDAVP see 1-deamino-8-D-arginine
vasopressin (DDAVP) 
diabetes insipidus 242
in hepatorenal syndrome 309
hypotension management 414t
in sepsis/septic shock 9, 97
ventricular fibrillation 79
vasopressors 89–97 see also
specific drugs
catecholamines see catecholamines 
elderly trauma victims 344
hyperthermia contraindication 54
in pneumonia management 172
sepsis management 8, 89–97, 90t
vasopressin see vasopressin 
vasospasm, subarachnoid hemorrhage and
210–211
vecuronium 132, 133
hypothermia effects 396
properties 133t
venous air embolism (VAE), catheter 
insertion 21
venous angiomas, intraparenchymal
hemorrhage 205
venous cannulation
central see central venous 
catheters (CVCs) 
femoral vein 28, 29
venous thrombosis
DVT see deep vein thrombosis (DVT) 
subarachnoid hemorrhage 208
veno-veno bypass (VVB), in liver
transplantation 297
ventilate, infuse and pump (VIP) principle,
sepsis 7–8
ventilation
alveolar-arterial oxygen 11–12, 13f
assessment 339, 401
assisted see ventilatory support 
deadspace 14
sustainable 14
voluntary 14
weaning criteria 192
ventilation/perfusion (V/Q) mismatch 394
assessment 401
physiology 11, 12, 13f
postoperative 394
thoracic surgery 404
sodium nitroprusside-induced 99
ventilation–perfusion scintigraphy 401
ventilation–perfusion zones 33–34, 33f
ventilator-associated pneumonia 159, 167–170
diagnosis 169
pathogens 168t
treatment, controversy 169
ventilator desynchronization, agitation and 124
ventilator-induced lung injury (VILI) 176, 178,
184, 185
ventilatory support see also specific methods
agitation and 124
in ARDS/ALI 176, 178, 185–186
case study 188
indications 181–182
lung injury due to 176, 178, 184, 185
lung recruitment 187–188, 188f
mechanical see mechanical ventilation 
monitoring 17
noninvasive 12–13, 15
clinical caveat 14t
controversy 15t
pneumonia and 159, 167–170
postoperative, pulmonary surgery 404
respiratory failure
hypercapnic 15
hypoxic 12–14
ventricles (cerebral)
dilatation 218–219
drainage 228
ventricles (heart)
arrhythmias see ventricular arrhythmias 
function curves 30, 30f, 32
septal defects 150–151
single 153
ventricular arrhythmias 77t, 83–84
postoperative 416
tachycardia (pulseless) 78–79
tetralogy of Fallot 152
ventricular fibrillation 78–79, 79f
ventricular function curve 30, 30f, 32
ventricular septal defect (VSD) 150–151
ventricular tachycardia (pulseless) 78–79
verapamil
atrial fibrillation 82t
hypertension management 140–141
pulmonary surgery and 406
verbal responses, GCS scoring 233
vertebral artery dissection 197
vertebrobasilar ischemia 197
vesicants 357–358
Vibrio parahaemolyticus infection,
gastrointestinal bleeding 305
video-assisted thoracic surgery (VATS) 400
videothoracoscopy, thoracic trauma 409
viral encephalitides 356
viral hemorrhagic fevers 356
viral infection(s) see also specific
organisms/infections
cell-mediated immunity and 254
encephalitides 356
hemorrhagic fevers 356
hepatic disease 289
pneumonia 158t, 164–165, 164f, 174
transplantation and 256
“viral priming” 159
Virchow’s triad 250
virtue theory 370
Visual Analog Pain Scale (VAS) 390
vital capacity, ventilatory weaning criteria 192
vital signs
in coagulopathy 270
poisoning diagnosis 362t
vitamin D
calcium regulation 240
deficiency 66
vitamin K deficiency
hepatic disease 289, 296
laboratory findings 268t
plasma transfusion and 278
volatile anesthetics
arrhythmia induction 77
hypothermia effects 396
malignant hyperthermia 397
PONV and 391
volume overload, postpneumonectomy
pulmonary edema 406
volume-targeted assist-control ventilation
183–184
vomiting
hypo-osmolar hyponatremia 48
intraparenchymal hemorrhage and 205
poisoning treatment 362
postoperative see postoperative nausea and
vomiting (PONV) 
von Willebrand’s disease 72, 263–264
management 278, 279, 280t, 284
von Willebrand’s factor
assay 269
coagulation role 261
VX 358
W
Waldström’s macroglobulinemia, humoral
defects 255
Wallenberg syndrome 197
warfarin, catheter insertion 120
water 62–63
deficit
calculation 49t, 243
diabetes insipidus 242
hypernatremia 49, 63, 64
environmental threat and 360
“free”
contraindications 62, 69
deficit 49, 49t, 243
glucose effects 62
glucose administration and 62
total body 60, 60f
male vs. female 63
“water-rat trapper’s disease” 355
watershed infarcts 196, 197
Waterstone shunt, tetralogy of Fallot 152
Wegener’s granulomatosis 160
Index 449
Wenkebach (Mobitz type I) heart block
85–86
West zones 33–34, 33f
Whipple’s triad 243
white blood cell count, hepatic disease 289
“white coat” hypertension 137
Wolff–Parkinson–White syndrome 81, 82f, 417
pulmonary surgery and 406
World Federation of Neurologic Surgeons,
subarachnoid hemorrhage grading system
209, 210
wound dressing/care
catheter-related infection and 120
thermal injury 350
vascular access 22
wound infections, hypothermia 
effects 396
X
X-rays see radiography
Y
Yersinia pestis 354
atypical pneumonia 164
Z
Zenker’s diverticuli, pneumonia risk 159
Zyvox (linezolid)
hospital-acquired pneumonia 167
ventilator-associated pneumonia 169
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